[{"depth": 5, "token_lengths": 8000, "result": 1.0, "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?", "options": {"A": "2.5 mg/kg", "B": "3.75 mg/kg", "C": "5.0 mg/kg", "D": "4.5 mg/kg", "E": "3.0 mg/kg", "F": "6.0 mg/kg"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant section of the document that discusses the Phase 2 clinical trial for KER-050.\n2. Look for specific information about the initial starting dose used in Part 2 of the trial.\n3. Match the identified dose to the provided options.\n\n### Step 1: Identify the Relevant Section\nThe relevant section is found in the \"Ongoing Phase 2 Clinical Trial in Patients with Myelodysplastic Syndromes\" part of the document.\n\n### Step 2: Look for Specific Information\nIn this section, the document states:\n\"In Part 2, the dose confirmation portion of the trial, an identical dosing schedule was followed, and patients initiated treatment at a starting dose of 3.75 mg/kg, the recommended Part 2 dose, or RP2D, with the opportunity to dose escalate to 5.0 mg/kg or to down-titrate based on individual titration rules.\"\n\n### Step 3: Match the Identified Dose to the Provided Options\nThe initial starting dose used in Part 2 of the trial is 3.75 mg/kg.\n\n### Conclusion\nThe correct answer is **B: 3.75 mg/kg**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 8000, "result": 1.0, "question": "What could have a material adverse effect on the business if there is a failure?", "options": {"A": "Expansion into international markets", "B": "Failure in critical systems, facilities, or services", "C": "Acquisition of a competitor", "D": "Increase in employee salaries", "E": "Introduction of new software features", "F": "Partnership with third-party vendors"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify which option is most likely to have a material adverse effect on the business if there is a failure.\n\n### Step-by-Step Analysis:\n\n1. **Option A: Expansion into international markets**\n   - The document does not mention any specific risks related to international expansion. It focuses more on the domestic challenges and the need for capital to expand facilities.\n   - **Conclusion:** This option is not directly supported by the document as a material adverse risk.\n\n2. **Option B: Failure in critical systems, facilities, or services**\n   - The document explicitly states: \"Any failure in our critical systems, facilities or services we provide could lead to disruptions in our and our customers\u2019 businesses and could harm our reputation and result in financial penalty and legal liabilities, which would reduce our revenue and have a material adverse effect on our business, financial condition and results of operations.\"\n   - **Conclusion:** This option is directly supported by the document as a material adverse risk.\n\n3. **Option C: Acquisition of a competitor**\n   - The document does not discuss the risks associated with acquiring a competitor. It focuses on the company's own operations and challenges.\n   - **Conclusion:** This option is not directly supported by the document as a material adverse risk.\n\n4. **Option D: Increase in employee salaries**\n   - The document does not mention employee salaries as a significant risk. It focuses more on operational costs, power costs, and capital investments.\n   - **Conclusion:** This option is not directly supported by the document as a material adverse risk.\n\n5. **Option E: Introduction of new software features**\n   - The document does not specifically mention the introduction of new software features as a risk. It does discuss the need to adapt to new technologies, but this is more about the infrastructure and systems rather than software features.\n   - **Conclusion:** This option is not directly supported by the document as a material adverse risk.\n\n6. **Option F: Partnership with third-party vendors**\n   - The document mentions the reliance on third-party mining pool service providers and the risks associated with their accuracy and reliability. However, it does not explicitly state that a failure in these partnerships would have a material adverse effect.\n   - **Conclusion:** This option is not directly supported by the document as a material adverse risk, although it is mentioned as a potential risk.\n\n### Final Answer:\n**Option B: Failure in critical systems, facilities, or services**\n\n### Chain of Thoughts:\n- The document clearly outlines the risks associated with"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 8000, "result": 1.0, "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?", "options": {"A": "21.49%", "B": "45%", "C": "50%", "D": "53%", "E": "75%", "F": "100%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant information in the document.\n2. Match the identified information to the options provided.\n3. Select the correct answer based on the information.\n\n### Step 1: Identify the Relevant Information\nThe document contains the following relevant information about GU&I's equity ownership in Pine Needle:\n- \"GU&I has a 45% equity ownership in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina and a 50% equity ownership interest in Hardy Storage, an underground interstate natural gas storage facility located in Hardy and Hampshire counties in West Virginia.\"\n\n### Step 2: Match the Identified Information to the Options Provided\nThe options provided are:\n- A: 21.49%\n- B: 45%\n- C: 50%\n- D: 53%\n- E: 75%\n- F: 100%\n\nFrom the document, it is clear that GU&I has a 45% equity ownership in Pine Needle.\n\n### Step 3: Select the Correct Answer\nThe correct answer is **B: 45%**.\n\nTherefore, the percentage of equity ownership that GU&I has in Pine Needle is **45%**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 8000, "result": 1.0, "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?", "options": {"A": "$17.7 million", "B": "$2.9 billion", "C": "$5.9 million", "D": "$9.7 million", "E": "$1.9 billion", "F": "$3.9 million"}, "LLM_original_answer": ["To answer the question \"How much had been invested in shares of the FHLBB as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the FHLBB (Federal Home Loan Bank of Boston) in the context of borrowings and investments.\n\n2. **Locate the specific information**: The relevant information is found in the \"Borrowings\" section, which states:\n   - \"As a member of the FHLBB, we are required to purchase shares in the FHLBB. Accordingly, we had invested $5.9 million in shares of the FHLBB and had $17.7 million outstanding in FHLBB borrowings with original maturities ranging from 1 week to 20 years at December 31, 2023.\"\n\n3. **Match the information to the options**: The amount invested in shares of the FHLBB is $5.9 million.\n\n4. **Select the correct option**: The correct option is C: $5.9 million.\n\nTherefore, the answer to the question is **C: $5.9 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 8000, "result": 1.0, "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?", "options": {"A": "Insufficient funding", "B": "Resolution of a partial clinical hold", "C": "Finalization of trial data analysis", "D": "Completion of patient recruitment", "E": "Regulatory approval was received", "F": "No available patient candidates"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step:\n\n1. **Identify the relevant section**: The document mentions the clinical trial for NX-2127, which is the drug being studied for various B-cell malignancies, including CLL, DLBCL, MCL, MZL, and FL.\n\n2. **Locate the specific information about the pause**: The document states, \"Enrollment of new patients in this clinical trial is currently paused pending resolution of a partial clinical hold.\"\n\n3. **Understand the term \"partial clinical hold\"**: A partial clinical hold is a regulatory action that temporarily halts certain aspects of a clinical trial, often due to safety concerns or other issues that need to be addressed before the trial can proceed.\n\n4. **Match the information to the options**:\n   - **A: Insufficient funding** - The document does not mention any funding issues.\n   - **B: Resolution of a partial clinical hold** - This matches the information provided in the document.\n   - **C: Finalization of trial data analysis** - The document does not mention that the trial data analysis is complete.\n   - **D: Completion of patient recruitment** - The document indicates that the trial is still ongoing and more data is expected in 2024.\n   - **E: Regulatory approval was received** - The document does not mention that regulatory approval has been received.\n   - **F: No available patient candidates** - The document does not suggest a lack of patient candidates.\n\n5. **Conclusion**: The condition that has resulted in the pause of new patient enrollment in the clinical trial is the resolution of a partial clinical hold.\n\nTherefore, the correct answer is **B: Resolution of a partial clinical hold**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 8000, "result": 1.0, "question": "What philosophy are Ocwen's compensation programs based on?", "options": {"A": "Cost-cutting and minimizing expenses", "B": "Pay-for-performance", "C": "Seniority-based pay", "D": "Hourly wage structure", "E": "Fixed salary only", "F": "Revenue growth only"}, "LLM_original_answer": ["To answer the question \"What philosophy are Ocwen's compensation programs based on?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss Ocwen's compensation programs and philosophy.\n2. **Extract Key Information**: Extract specific statements or phrases that indicate the philosophy behind the compensation programs.\n3. **Match to Options**: Compare the extracted information to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section in the document is under the \"Rewards\" heading:\n\n> \"Our total rewards (compensation and benefits) programs are developed to attract, motivate and retain employees. They demonstrate the value the employee provides to the organization, are designed to be competitive to the marketplace, and connect directly to key business strategies. Our compensation programs, including salaries and short- and long-term incentives, are centered on our pay-for-performance philosophy, aligning the interests of employees and stakeholders by rewarding both individual and overall company performance.\"\n\n### Step 2: Extract Key Information\n- **Purpose of Compensation Programs**: Attract, motivate, and retain employees.\n- **Value Demonstration**: Demonstrate the value the employee provides to the organization.\n- **Market Competitiveness**: Designed to be competitive to the marketplace.\n- **Connection to Business Strategies**: Connect directly to key business strategies.\n- **Philosophy**: Centered on the pay-for-performance philosophy.\n- **Alignment**: Align the interests of employees and stakeholders by rewarding both individual and overall company performance.\n\n### Step 3: Match to Options\n- **Option A: Cost-cutting and minimizing expenses** - The document does not mention cost-cutting or minimizing expenses as a philosophy for compensation programs.\n- **Option B: Pay-for-performance** - The document explicitly states that Ocwen's compensation programs are centered on the pay-for-performance philosophy.\n- **Option C: Seniority-based pay** - There is no mention of seniority-based pay in the document.\n- **Option D: Hourly wage structure** - The document does not discuss an hourly wage structure.\n- **Option E: Fixed salary only** - The document mentions both salaries and short- and long-term incentives, indicating that the compensation is not fixed salary only.\n- **Option F: Revenue growth only** - While the document mentions aligning with key business strategies, it does not specify that the philosophy is solely based on revenue growth.\n\n### Conclusion\nThe philosophy that Ocwen's compensation programs are based on is **"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 8000, "result": 1.0, "question": "What is the initial step in the described approach to developing a TCR-T candidate?", "options": {"A": "Isolating tumor-specific antigens from TCRs", "B": "Identifying meaningful clinical responses to non-specific treatments", "C": "Developing a novel TCR/target pair using TargetScan technology", "D": "Isolating clinically active anti-cancer T cells from tumor samples", "E": "Testing TCRs for general cancer cell recognition", "F": "Determining the immune system's general targets"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step:\n\n1. **Identify the Approach**: The document describes an approach to developing TCR-T (T-cell receptor T-cell) therapy. The key steps in this approach are outlined in the \"Our Approach\" section.\n\n2. **Initial Step**: The document states, \"Our approach starts with isolating clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy agents.\" This is the first step mentioned in the process.\n\n3. **Subsequent Steps**: After isolating the T cells, the document mentions using TargetScan technology to determine the precise targets recognized by the TCRs. This is the second step in the process.\n\n4. **Options Analysis**:\n   - **Option A**: Isolating tumor-specific antigens from TCRs - This is not mentioned as the initial step.\n   - **Option B**: Identifying meaningful clinical responses to non-specific treatments - This is not the initial step; it is part of the broader context of the approach.\n   - **Option C**: Developing a novel TCR/target pair using TargetScan technology - This is a subsequent step, not the initial one.\n   - **Option D**: Isolating clinically active anti-cancer T cells from tumor samples - This matches the initial step described in the document.\n   - **Option E**: Testing TCRs for general cancer cell recognition - This is not mentioned as the initial step.\n   - **Option F**: Determining the immune system's general targets - This is not the initial step; it is part of the broader context of the approach.\n\n5. **Conclusion**: Based on the document, the initial step in the described approach to developing a TCR-T candidate is isolating clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy agents.\n\nTherefore, the correct answer is **D: Isolating clinically active anti-cancer T cells from tumor samples**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 5, "token_lengths": 8000, "result": 1.0, "question": "In the study, what constitutes a 'death equivalent' event?", "options": {"A": "Use of invasive surgery unrelated to ALS", "B": "Permanent assisted ventilation or tracheostomy", "C": "Hospitalization for more than one week", "D": "Daily use of less than 22 hours of ventilation", "E": "Any emergency medical intervention", "F": "Temporary use of assisted ventilation"}, "LLM_original_answer": ["To answer the question \"In the study, what constitutes a 'death equivalent' event?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the definition of a 'death equivalent' event in the context of the CENTAUR trial.\n\n2. **Extract the definition**: The relevant sentence is: \"Death equivalent was defined as either tracheostomy or permanent assisted ventilation, or PAV.\"\n\n3. **Understand the components of the definition**:\n   - **Tracheostomy**: A surgical procedure to create an opening in the neck for direct access to the trachea (windpipe), often used for long-term ventilation.\n   - **Permanent Assisted Ventilation (PAV)**: The document further defines PAV as \"more than 22 hours daily of non-invasive mechanical ventilation for more than one week (seven days).\"\n\n4. **Match the definition to the options**:\n   - **Option A**: Use of invasive surgery unrelated to ALS - This does not match the definition.\n   - **Option B**: Permanent assisted ventilation or tracheostomy - This matches the definition.\n   - **Option C**: Hospitalization for more than one week - This does not match the definition.\n   - **Option D**: Daily use of less than 22 hours of ventilation - This does not match the definition.\n   - **Option E**: Any emergency medical intervention - This does not match the definition.\n   - **Option F**: Temporary use of assisted ventilation - This does not match the definition.\n\n5. **Conclusion**: The correct answer is **Option B: Permanent assisted ventilation or tracheostomy**.\n\nThis answer is derived directly from the document, which clearly states the definition of a 'death equivalent' event in the context of the study."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 8000, "result": 1.0, "question": "What critical performance criteria are emphasized for the electronic networks?", "options": {"A": "Cost and scalability", "B": "Design and aesthetics", "C": "Speed and reliability", "D": "Functionality and compatibility", "E": "User interface and experience", "F": "Color scheme and branding"}, "LLM_original_answer": ["To answer the question \"What critical performance criteria are emphasized for the electronic networks?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the performance criteria for electronic networks is found under \"World Class Technology.\"\n\n2. **Extract the key information**: The document states, \"Speed, reliability, resilience, capacity and security are critical performance criteria for our electronic networks.\"\n\n3. **Match the extracted information to the given options**:\n   - **Option A: Cost and scalability** - The document does not specifically mention cost and scalability as critical performance criteria.\n   - **Option B: Design and aesthetics** - The document does not mention design and aesthetics.\n   - **Option C: Speed and reliability** - The document explicitly mentions speed and reliability as critical performance criteria.\n   - **Option D: Functionality and compatibility** - The document does not specifically mention functionality and compatibility.\n   - **Option E: User interface and experience** - The document does not mention user interface and experience.\n   - **Option F: Color scheme and branding** - The document does not mention color scheme and branding.\n\n4. **Conclusion**: Based on the information provided in the document, the critical performance criteria emphasized for the electronic networks are speed and reliability.\n\nTherefore, the correct answer is **Option C: Speed and reliability**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 8000, "result": 1.0, "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?", "options": {"A": "To simplify internal management structures", "B": "To maximize profit margins", "C": "To improve customer relations", "D": "To limit losses and provide capacity for future growth", "E": "To expand product lines", "F": "To enhance technological development"}, "LLM_original_answer": ["To answer the question \"Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Risk Management Efforts**:\n   - The document states: \"In connection with our risk management efforts and in order to provide opportunities for growth and capital management, we enter into reinsurance arrangements pursuant to which we cede certain insurance risks to unaffiliated third-party reinsurers.\"\n   - This indicates that reinsurance is a part of the company's risk management strategy.\n\n2. **Limiting Losses**:\n   - The document mentions: \"We cede risks to third parties in order to limit losses, minimize exposure to significant risks and provide capacity for future growth.\"\n   - This directly states that one of the reasons for reinsurance is to limit losses and minimize exposure to significant risks.\n\n3. **Providing Capacity for Future Growth**:\n   - The same sentence also mentions: \"provide capacity for future growth.\"\n   - This suggests that reinsurance helps the company manage its risk exposure, allowing it to take on more business and grow.\n\n4. **Spreading Risk**:\n   - The document further elaborates: \"These reinsurance arrangements are an important part of our risk management strategy because they permit us to spread risk and minimize the effect of losses.\"\n   - This reinforces the idea that reinsurance helps in spreading the risk, which is a key aspect of risk management.\n\n5. **Evaluating Reinsurance**:\n   - The document notes: \"We routinely evaluate our reinsurance program and may increase or decrease our retention at any time.\"\n   - This indicates that the company actively manages its reinsurance to align with its risk management goals.\n\nGiven the above points, the most accurate and comprehensive answer to the question is:\n\n**D: To limit losses and provide capacity for future growth**\n\nThis option directly aligns with the reasons provided in the document, which emphasize the importance of reinsurance in managing risk, limiting losses, and providing the company with the capacity to grow."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 5, "token_lengths": 16000, "result": 1.0, "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?", "options": {"A": "2.5 mg/kg", "B": "3.75 mg/kg", "C": "5.0 mg/kg", "D": "4.5 mg/kg", "E": "3.0 mg/kg", "F": "6.0 mg/kg"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant section of the document**: The document contains information about multiple clinical trials, so I need to focus on the Phase 2 clinical trial for KER-050 in patients with myelodysplastic syndromes (MDS).\n\n2. **Locate the specific information about the initial starting dose in Part 2**: The document mentions the dosing schedule and the starting dose for Part 2 of the trial.\n\n3. **Extract the information and match it with the given options**.\n\nLet's go through the document:\n\n### Step 1: Identify the relevant section\nThe relevant section is:\n> \"Ongoing Phase 2 Clinical Trial in Patients with Myelodysplastic Syndromes\"\n\n### Step 2: Locate the specific information about the initial starting dose in Part 2\nIn this section, the document states:\n> \"In Part 2, the dose confirmation portion of the trial, an identical dosing schedule was followed, and patients initiated treatment at a starting dose of 3.75 mg/kg, the recommended Part 2 dose, or RP2D, with the opportunity to dose escalate to 5.0 mg/kg or to down-titrate based on individual titration rules.\"\n\n### Step 3: Extract the information and match it with the given options\nThe initial starting dose in Part 2 of the Phase 2 clinical trial for KER-050 is **3.75 mg/kg**.\n\n### Conclusion\nThe correct answer is **B: 3.75 mg/kg**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 16000, "result": 1.0, "question": "What could have a material adverse effect on the business if there is a failure?", "options": {"A": "Expansion into international markets", "B": "Failure in critical systems, facilities, or services", "C": "Acquisition of a competitor", "D": "Increase in employee salaries", "E": "Introduction of new software features", "F": "Partnership with third-party vendors"}, "LLM_original_answer": ["To answer the question, I will analyze the document and identify the option that best aligns with the information provided.\n\n### Step-by-Step Analysis:\n\n1. **Option A: Expansion into international markets**\n   - The document does not mention any specific risks related to expanding into international markets. It focuses more on the operational and regulatory challenges within the existing markets.\n\n2. **Option B: Failure in critical systems, facilities, or services**\n   - The document explicitly states: \"Any failure in our critical systems, facilities or services we provide could lead to disruptions in our and our customers\u2019 businesses and could harm our reputation and result in financial penalty and legal liabilities, which would reduce our revenue and have a material adverse effect on our business, financial condition and results of operations.\"\n   - This directly aligns with the question, indicating that a failure in critical systems, facilities, or services could have a material adverse effect on the business.\n\n3. **Option C: Acquisition of a competitor**\n   - The document does not discuss the risks associated with acquiring a competitor. It focuses on the company's own operations and challenges.\n\n4. **Option D: Increase in employee salaries**\n   - While the document mentions the importance of attracting and retaining well-qualified employees, it does not specifically state that an increase in employee salaries could have a material adverse effect on the business.\n\n5. **Option E: Introduction of new software features**\n   - The document does not mention the introduction of new software features as a risk. It discusses the need to adapt to new technologies and processes, but not the introduction of new features specifically.\n\n6. **Option F: Partnership with third-party vendors**\n   - The document mentions the importance of relationships with third-party vendors, particularly for power supply and equipment, but it does not explicitly state that a partnership with third-party vendors could have a material adverse effect on the business. However, it does mention the risks associated with reliance on third-party mining pool service providers and the potential for service interruptions and legal liabilities.\n\n### Conclusion:\nBased on the document, the most directly relevant and explicitly stated risk that could have a material adverse effect on the business is **Option B: Failure in critical systems, facilities, or services**. The document clearly outlines the potential for disruptions, harm to reputation, financial penalties, and legal liabilities if these critical systems fail.\n\nTherefore, the correct answer is **B: Failure in critical systems, facilities, or services**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 16000, "result": 1.0, "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?", "options": {"A": "21.49%", "B": "45%", "C": "50%", "D": "53%", "E": "75%", "F": "100%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant information in the document**: The document contains a section that lists the equity ownership interests of GU&I in various facilities. I need to find the specific information about Pine Needle.\n\n2. **Locate the specific information about Pine Needle**: In the \"Natural Gas Investments\" section, the document states: \"GU&I has a 45% equity ownership in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina.\"\n\n3. **Match the information to the given options**: The percentage of equity ownership in Pine Needle is 45%.\n\n4. **Select the correct answer**: The correct answer is Option B: 45%.\n\nTherefore, the percentage of equity ownership that GU&I has in Pine Needle is **45%**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 16000, "result": 1.0, "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?", "options": {"A": "$17.7 million", "B": "$2.9 billion", "C": "$5.9 million", "D": "$9.7 million", "E": "$1.9 billion", "F": "$3.9 million"}, "LLM_original_answer": ["To answer the question \"How much had been invested in shares of the FHLBB as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the investment in shares of the FHLBB in the \"Investment Activities\" section.\n\n2. **Locate the specific information**: The relevant sentence is: \"As of December 31, 2023, our securities portfolio totaled $4.9 billion, and generated interest and dividends of 13.4% of total interest income for the year ended December 31, 2023. ... Accordingly, we had invested $5.9 million in shares of the FHLBB and had $17.7 million outstanding in FHLBB borrowings with original maturities ranging from 1 week to 20 years at December 31, 2023.\"\n\n3. **Extract the amount**: The amount invested in shares of the FHLBB as of December 31, 2023, is $5.9 million.\n\n4. **Match the amount to the options**: The correct answer is option C: $5.9 million.\n\nTherefore, the answer to the question is **C: $5.9 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 16000, "result": 1.0, "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?", "options": {"A": "Insufficient funding", "B": "Resolution of a partial clinical hold", "C": "Finalization of trial data analysis", "D": "Completion of patient recruitment", "E": "Regulatory approval was received", "F": "No available patient candidates"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the relevant section**: The document mentions the pause in new patient enrollment in the context of the NX-2127 clinical trial. The relevant section is:\n   > \"Enrollment of new patients in this clinical trial is currently paused pending resolution of a partial clinical hold.\"\n\n2. **Understand the term \"partial clinical hold\"**: A partial clinical hold is a regulatory action that delays or suspends only part of the clinical work requested under the IND, while other protocols may proceed. This is typically imposed by the FDA if there are concerns about the safety or conduct of the trial.\n\n3. **Determine the condition causing the pause**: The document explicitly states that the pause is due to the resolution of a partial clinical hold. This means that the FDA has raised concerns that need to be addressed before new patients can be enrolled.\n\n4. **Match the condition to the options**:\n   - **A: Insufficient funding** - The document does not mention funding issues.\n   - **B: Resolution of a partial clinical hold** - This matches the information provided.\n   - **C: Finalization of trial data analysis** - The document does not mention finalization of trial data analysis as a reason for the pause.\n   - **D: Completion of patient recruitment** - The document does not indicate that patient recruitment is complete.\n   - **E: Regulatory approval was received** - The document does not mention receiving regulatory approval.\n   - **F: No available patient candidates** - The document does not mention a lack of available patient candidates.\n\nBased on the analysis, the correct answer is:\n\n**B: Resolution of a partial clinical hold**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 16000, "result": 1.0, "question": "What philosophy are Ocwen's compensation programs based on?", "options": {"A": "Cost-cutting and minimizing expenses", "B": "Pay-for-performance", "C": "Seniority-based pay", "D": "Hourly wage structure", "E": "Fixed salary only", "F": "Revenue growth only"}, "LLM_original_answer": ["To answer the question \"What philosophy are Ocwen's compensation programs based on?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss Ocwen's compensation programs and the philosophy behind them.\n2. **Extract Key Information**: Extract the specific details about the compensation philosophy from the identified sections.\n3. **Match to Options**: Compare the extracted information to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section in the document is under the \"Rewards\" heading:\n\n> **Rewards.**\n> Our total rewards (compensation and benefits) programs are developed to attract, motivate and retain employees. They demonstrate the value the employee provides to the organization, are designed to be competitive to the marketplace, and connect directly to key business strategies. Our compensation programs, including salaries and short- and long-term incentives, are centered on our pay-for-performance philosophy, aligning the interests of employees and stakeholders by rewarding both individual and overall company performance.\n\n### Step 2: Extract Key Information\nFrom the \"Rewards\" section, the key information is:\n- Ocwen's total rewards programs are designed to attract, motivate, and retain employees.\n- These programs demonstrate the value the employee provides to the organization.\n- They are designed to be competitive in the marketplace.\n- The compensation programs are centered on the pay-for-performance philosophy.\n- This philosophy aligns the interests of employees and stakeholders by rewarding both individual and overall company performance.\n\n### Step 3: Match to Options\nNow, let's match this information to the given options:\n\n- **A: Cost-cutting and minimizing expenses** - The document does not mention cost-cutting or minimizing expenses as a philosophy for compensation programs.\n- **B: Pay-for-performance** - The document explicitly states that Ocwen's compensation programs are centered on the pay-for-performance philosophy.\n- **C: Seniority-based pay** - The document does not mention seniority-based pay.\n- **D: Hourly wage structure** - The document does not mention an hourly wage structure.\n- **E: Fixed salary only** - The document does not mention fixed salary only; it talks about salaries and short- and long-term incentives.\n- **F: Revenue growth only** - The document does not mention revenue growth as the sole focus of the compensation philosophy.\n\n### Conclusion\nThe best match for the philosophy of Ocwen's compensation programs is **B: Pay-for-performance**. The document"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 16000, "result": 1.0, "question": "What is the initial step in the described approach to developing a TCR-T candidate?", "options": {"A": "Isolating tumor-specific antigens from TCRs", "B": "Identifying meaningful clinical responses to non-specific treatments", "C": "Developing a novel TCR/target pair using TargetScan technology", "D": "Isolating clinically active anti-cancer T cells from tumor samples", "E": "Testing TCRs for general cancer cell recognition", "F": "Determining the immune system's general targets"}, "LLM_original_answer": ["To answer the question, let's break down the information provided in the document step by step:\n\n1. **Understanding the Approach**:\n   - The document describes an approach to developing TCR-T (T-cell receptor T-cell) therapy.\n   - The approach is based on learning from patients who are responding well to immunotherapy to identify clinically relevant targets and TCRs.\n\n2. **Initial Steps in the Process**:\n   - The document states: \"Our discovery process begins with identifying patient T cells that are actively driving their clinical response to immunotherapy.\"\n   - It further specifies: \"We then use TargetScan to determine the precise targets of these highly active TCRs.\"\n\n3. **Analyzing the Options**:\n   - **Option A**: Isolating tumor-specific antigens from TCRs - This is not the initial step; it is part of the subsequent process.\n   - **Option B**: Identifying meaningful clinical responses to non-specific treatments - This is not the initial step; it is a broader context for the approach.\n   - **Option C**: Developing a novel TCR/target pair using TargetScan technology - This is a key step, but it comes after isolating the T cells.\n   - **Option D**: Isolating clinically active anti-cancer T cells from tumor samples - This matches the initial step described in the document.\n   - **Option E**: Testing TCRs for general cancer cell recognition - This is a later step in the process.\n   - **Option F**: Determining the immune system's general targets - This is not the initial step; it is part of the broader context.\n\n4. **Conclusion**:\n   - The initial step in the described approach to developing a TCR-T candidate is isolating clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy.\n\nTherefore, the correct answer is **D: Isolating clinically active anti-cancer T cells from tumor samples**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 5, "token_lengths": 16000, "result": 1.0, "question": "In the study, what constitutes a 'death equivalent' event?", "options": {"A": "Use of invasive surgery unrelated to ALS", "B": "Permanent assisted ventilation or tracheostomy", "C": "Hospitalization for more than one week", "D": "Daily use of less than 22 hours of ventilation", "E": "Any emergency medical intervention", "F": "Temporary use of assisted ventilation"}, "LLM_original_answer": ["To answer the question \"In the study, what constitutes a 'death equivalent' event?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the definition of a 'death equivalent' event in the context of the CENTAUR trial. This is found in the following paragraph:\n\n   > \"Death equivalent was defined as either tracheostomy or permanent assisted ventilation, or PAV. PAV was defined as more than 22 hours daily of non-invasive mechanical ventilation for more than one week (seven days).\"\n\n2. **Extract the definition**: From the above paragraph, we can see that a 'death equivalent' event is defined as:\n   - **Tracheostomy**: A surgical procedure to create an opening in the neck for direct access to the trachea (windpipe).\n   - **Permanent Assisted Ventilation (PAV)**: More than 22 hours daily of non-invasive mechanical ventilation for more than one week (seven days).\n\n3. **Match the definition to the options**:\n   - **Option A**: Use of invasive surgery unrelated to ALS - This does not match the definition.\n   - **Option B**: Permanent assisted ventilation or tracheostomy - This matches the definition.\n   - **Option C**: Hospitalization for more than one week - This does not match the definition.\n   - **Option D**: Daily use of less than 22 hours of ventilation - This does not match the definition.\n   - **Option E**: Any emergency medical intervention - This does not match the definition.\n   - **Option F**: Temporary use of assisted ventilation - This does not match the definition.\n\n4. **Conclusion**: Based on the definition provided in the document, the correct answer is **Option B: Permanent assisted ventilation or tracheostomy**.\n\nTherefore, the answer to the question is **Option B: Permanent assisted ventilation or tracheostomy**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 16000, "result": 1.0, "question": "What critical performance criteria are emphasized for the electronic networks?", "options": {"A": "Cost and scalability", "B": "Design and aesthetics", "C": "Speed and reliability", "D": "Functionality and compatibility", "E": "User interface and experience", "F": "Color scheme and branding"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document.\n\nThe document mentions the following about the critical performance criteria for electronic networks:\n\n\"Speed, reliability, resilience, capacity and security are critical performance criteria for our electronic networks.\"\n\nThis statement directly addresses the performance criteria emphasized for the electronic networks. Let's break it down:\n\n1. **Speed**: This is a key factor in ensuring that transactions and data processing are fast and efficient.\n2. **Reliability**: Ensuring that the network consistently performs without failures or downtime.\n3. **Resilience**: The network's ability to withstand and recover from disruptions or attacks.\n4. **Capacity**: The network's ability to handle a large volume of transactions and data.\n5. **Security**: Protecting the network from unauthorized access, cyberattacks, and other security threats.\n\nNow, let's match these criteria to the given options:\n\n- **Option A: Cost and scalability** - While scalability (capacity) is mentioned, cost is not explicitly listed as a critical performance criterion.\n- **Option B: Design and aesthetics** - These are not mentioned as critical performance criteria.\n- **Option C: Speed and reliability** - Both speed and reliability are explicitly mentioned.\n- **Option D: Functionality and compatibility** - These are not explicitly listed as critical performance criteria.\n- **Option E: User interface and experience** - These are not explicitly listed as critical performance criteria.\n- **Option F: Color scheme and branding** - These are not mentioned as critical performance criteria.\n\nBased on the document, the critical performance criteria emphasized for the electronic networks are **Speed and reliability**.\n\nTherefore, the correct answer is **Option C: Speed and reliability**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 16000, "result": 1.0, "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?", "options": {"A": "To simplify internal management structures", "B": "To maximize profit margins", "C": "To improve customer relations", "D": "To limit losses and provide capacity for future growth", "E": "To expand product lines", "F": "To enhance technological development"}, "LLM_original_answer": ["To answer the question \"Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: The document contains a section specifically about reinsurance activity, which is the most relevant for this question.\n\n2. **Extract Key Information**: From the \"Unaffiliated Third-Party Reinsurance\" section, extract the reasons mentioned for entering into reinsurance arrangements.\n\n3. **Match Extracted Information to Options**: Compare the extracted reasons to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is \"Unaffiliated Third-Party Reinsurance\" under the \"Reinsurance Activity\" heading.\n\n### Step 2: Extract Key Information\nFrom the \"Unaffiliated Third-Party Reinsurance\" section, the key reasons for entering into reinsurance arrangements are:\n- **To limit losses**: \"We cede risks to third parties in order to limit losses, minimize exposure to significant risks and provide capacity for future growth.\"\n- **To provide capacity for future growth**: \"We cede risks to third parties in order to limit losses, minimize exposure to significant risks and provide capacity for future growth.\"\n- **To manage exposures**: \"Our ceded reinsurance to third parties is primarily structured on a treaty basis as coinsurance, yearly renewable term, excess or catastrophe excess of retention insurance. These reinsurance arrangements are an important part of our risk management strategy because they permit us to spread risk and minimize the effect of losses.\"\n\n### Step 3: Match Extracted Information to Options\n- **Option A: To simplify internal management structures** - Not mentioned in the document.\n- **Option B: To maximize profit margins** - Not explicitly mentioned, though risk management can indirectly contribute to profitability.\n- **Option C: To improve customer relations** - Not mentioned in the document.\n- **Option D: To limit losses and provide capacity for future growth** - Directly matches the reasons extracted from the document.\n- **Option E: To expand product lines** - Not mentioned in the document.\n- **Option F: To enhance technological development** - Not mentioned in the document.\n\n### Conclusion\nThe best answer to the question \"Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?\" is:\n\n**D: To limit losses and provide capacity for future growth**\n\nThis option directly aligns with the reasons provided in the document, which states that the company cedes risks"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 5, "token_lengths": 32000, "result": 1.0, "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?", "options": {"A": "2.5 mg/kg", "B": "3.75 mg/kg", "C": "5.0 mg/kg", "D": "4.5 mg/kg", "E": "3.0 mg/kg", "F": "6.0 mg/kg"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant section in the document that discusses the Phase 2 clinical trial for KER-050.\n2. Look for specific information about the initial starting dose in Part 2 of the trial.\n3. Match the identified dose to the provided options.\n\n### Step 1: Identify the Relevant Section\nThe relevant section is found in the \"Ongoing Phase 2 Clinical Trial in Patients with Myelodysplastic Syndromes\" part of the document.\n\n### Step 2: Look for Specific Information\nIn this section, the document states:\n\"In Part 2, the dose confirmation portion of the trial, an identical dosing schedule was followed, and patients initiated treatment at a starting dose of 3.75 mg/kg, the recommended Part 2 dose, or RP2D, with the opportunity to dose escalate to 5.0 mg/kg or to down-titrate based on individual titration rules.\"\n\n### Step 3: Match the Identified Dose to the Provided Options\nThe initial starting dose in Part 2 of the Phase 2 clinical trial for KER-050 is 3.75 mg/kg.\n\n### Conclusion\nThe correct answer is **Option B: 3.75 mg/kg**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 32000, "result": 1.0, "question": "What could have a material adverse effect on the business if there is a failure?", "options": {"A": "Expansion into international markets", "B": "Failure in critical systems, facilities, or services", "C": "Acquisition of a competitor", "D": "Increase in employee salaries", "E": "Introduction of new software features", "F": "Partnership with third-party vendors"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and consider the context and implications of each option.\n\n### Step-by-Step Analysis:\n\n1. **Expansion into international markets (Option A):**\n   - The document does not explicitly mention the risks associated with expanding into international markets. However, it does discuss the regulatory and legal environment, which can vary significantly between countries. For example, China has taken actions to restrict digital asset mining, and other countries may adopt similar measures. While this could have an adverse effect, it is not directly stated as a material adverse effect in the document.\n\n2. **Failure in critical systems, facilities, or services (Option B):**\n   - The document explicitly states: \"Any failure in our critical systems, facilities or services we provide could lead to disruptions in our and our customers\u2019 businesses and could harm our reputation and result in financial penalty and legal liabilities, which would reduce our revenue and have a material adverse effect on our business, financial condition and results of operations.\"\n   - This directly aligns with the question and is a clear example of a failure that could have a material adverse effect on the business.\n\n3. **Acquisition of a competitor (Option C):**\n   - The document does not discuss the risks associated with acquiring a competitor. While acquisitions can bring challenges, the document does not provide specific information about how such an action could have a material adverse effect on the business.\n\n4. **Increase in employee salaries (Option D):**\n   - The document mentions the importance of attracting and retaining key personnel but does not discuss the specific risk of increasing employee salaries. While higher salaries could impact profitability, it is not highlighted as a material adverse effect.\n\n5. **Introduction of new software features (Option E):**\n   - The document discusses the rapid technological changes in the industry and the need to adapt to new processes and technologies. However, it does not specifically mention the introduction of new software features as a material adverse effect. The focus is more on the broader technological and regulatory changes.\n\n6. **Partnership with third-party vendors (Option F):**\n   - The document mentions the reliance on third-party mining pool service providers and the potential risks associated with them, such as inaccurate record-keeping and limited recourse. However, it does not explicitly state that partnerships with third-party vendors could have a material adverse effect on the business.\n\n### Conclusion:\nBased on the provided document, the most directly relevant and explicitly stated option that could have a material adverse effect on the business if there is a failure is **Option"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 32000, "result": 1.0, "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?", "options": {"A": "21.49%", "B": "45%", "C": "50%", "D": "53%", "E": "75%", "F": "100%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant section in the document that discusses GU&I's equity ownership in natural gas storage facilities.\n2. Locate the specific information about Pine Needle, the interstate liquefied natural gas storage facility in North Carolina.\n3. Extract the percentage of equity ownership GU&I has in Pine Needle.\n4. Match the extracted percentage with the provided options.\n\nStep 1: The relevant section is found in the \"Natural Gas Investments\" part of the document.\n\nStep 2: The specific information about Pine Needle is mentioned in the following sentence:\n\"GU&I has a 21.49% equity ownership interest in Cardinal, an intrastate pipeline located in North Carolina regulated by the NCUC, a 45% equity ownership in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina and a 50% equity ownership interest in Hardy Storage, an underground interstate natural gas storage facility located in Hardy and Hampshire counties in West Virginia.\"\n\nStep 3: From the sentence, it is clear that GU&I has a 45% equity ownership interest in Pine Needle.\n\nStep 4: The extracted percentage (45%) matches with option B in the provided options.\n\nTherefore, the correct answer is:\nB: 45%"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 32000, "result": 1.0, "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?", "options": {"A": "$17.7 million", "B": "$2.9 billion", "C": "$5.9 million", "D": "$9.7 million", "E": "$1.9 billion", "F": "$3.9 million"}, "LLM_original_answer": ["To answer the question \"How much had been invested in shares of the FHLBB as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the Federal Home Loan Bank System (FHLB) and the investment in shares of the FHLBB (Federal Home Loan Bank of Boston).\n\n2. **Locate the specific information**: The relevant information is found in the \"Federal Home Loan Bank System\" section of the document.\n\n3. **Extract the data**: The document states, \"As of December 31, 2023, we had invested $5.9 million in shares of the FHLBB and had $17.7 million outstanding in FHLBB borrowings with original maturities ranging from 1 week to 20 years.\"\n\n4. **Match the data to the options**: The amount invested in shares of the FHLBB as of December 31, 2023, is $5.9 million.\n\nTherefore, the correct answer is:\n\n**C: $5.9 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 32000, "result": 1.0, "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?", "options": {"A": "Insufficient funding", "B": "Resolution of a partial clinical hold", "C": "Finalization of trial data analysis", "D": "Completion of patient recruitment", "E": "Regulatory approval was received", "F": "No available patient candidates"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the relevant section**: The section that discusses the clinical trial for NX-2127 is the \"Clinical development of NX-2127\" part of the document.\n\n2. **Extract the key information**: The document states:\n   - \"Enrollment of new patients in this clinical trial is currently paused pending resolution of a partial clinical hold.\"\n\n3. **Understand the context**: A \"partial clinical hold\" is a regulatory action that temporarily halts some or all of the clinical work requested under the IND (Investigational New Drug Application). This is typically imposed when the FDA has concerns about the safety or the conduct of the trial.\n\n4. **Match the information to the options**:\n   - **A: Insufficient funding** - The document does not mention any issues with funding.\n   - **B: Resolution of a partial clinical hold** - This matches the information provided in the document.\n   - **C: Finalization of trial data analysis** - The document does not mention finalization of trial data analysis as a reason for pausing enrollment.\n   - **D: Completion of patient recruitment** - The document does not indicate that patient recruitment is complete.\n   - **E: Regulatory approval was received** - The document does not mention receiving regulatory approval.\n   - **F: No available patient candidates** - The document does not mention a lack of available patient candidates.\n\n5. **Conclusion**: Based on the information provided in the document, the condition that has resulted in the pause of new patient enrollment in the clinical trial is the resolution of a partial clinical hold.\n\nTherefore, the correct answer is **B: Resolution of a partial clinical hold**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 32000, "result": 1.0, "question": "What philosophy are Ocwen's compensation programs based on?", "options": {"A": "Cost-cutting and minimizing expenses", "B": "Pay-for-performance", "C": "Seniority-based pay", "D": "Hourly wage structure", "E": "Fixed salary only", "F": "Revenue growth only"}, "LLM_original_answer": ["To answer the question \"What philosophy are Ocwen's compensation programs based on?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss Ocwen's compensation programs and philosophy.\n2. **Extract Key Information**: Extract the specific information related to the compensation philosophy.\n3. **Match Information to Options**: Compare the extracted information to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in the \"Rewards\" part of the document:\n\n> **Rewards.** Our total rewards (compensation and benefits) programs are developed to attract, motivate and retain employees. They demonstrate the value the employee provides to the organization, are designed to be competitive to the marketplace, and connect directly to key business strategies. Our compensation programs, including salaries and short- and long-term incentives, are centered on our pay-for-performance philosophy, aligning the interests of employees and stakeholders by rewarding both individual and overall company performance.\n\n### Step 2: Extract Key Information\n- **Total Rewards Programs**: Developed to attract, motivate, and retain employees.\n- **Value Demonstration**: Programs demonstrate the value the employee provides to the organization.\n- **Market Competitiveness**: Designed to be competitive in the marketplace.\n- **Connection to Business Strategies**: Connect directly to key business strategies.\n- **Compensation Philosophy**: Centered on the pay-for-performance philosophy.\n- **Alignment of Interests**: Align the interests of employees and stakeholders.\n- **Rewarding Performance**: Reward both individual and overall company performance.\n\n### Step 3: Match Information to Options\n- **Option A: Cost-cutting and minimizing expenses** - The document does not mention cost-cutting or minimizing expenses as a philosophy for compensation programs.\n- **Option B: Pay-for-performance** - The document explicitly states that Ocwen's compensation programs are centered on the pay-for-performance philosophy.\n- **Option C: Seniority-based pay** - There is no mention of seniority-based pay in the document.\n- **Option D: Hourly wage structure** - The document does not discuss an hourly wage structure.\n- **Option E: Fixed salary only** - The document mentions both salaries and short- and long-term incentives, indicating that the compensation is not fixed salary only.\n- **Option F: Revenue growth only** - While the document mentions business strategies, it does not specify that compensation is based solely on revenue growth.\n\n### Conclusion\nThe philosophy that Ocwen's"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 32000, "result": 1.0, "question": "What is the initial step in the described approach to developing a TCR-T candidate?", "options": {"A": "Isolating tumor-specific antigens from TCRs", "B": "Identifying meaningful clinical responses to non-specific treatments", "C": "Developing a novel TCR/target pair using TargetScan technology", "D": "Isolating clinically active anti-cancer T cells from tumor samples", "E": "Testing TCRs for general cancer cell recognition", "F": "Determining the immune system's general targets"}, "LLM_original_answer": ["To answer the question, I will follow the steps described in the document and analyze the options provided.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Approach:**\n   - The document describes an approach to developing TCR-T candidates based on learning from patients who are responding to immunotherapy.\n\n2. **Initial Step in the Process:**\n   - The document states: \"Our approach starts with isolating clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy agents.\"\n\n3. **Evaluate the Options:**\n   - **Option A:** Isolating tumor-specific antigens from TCRs\n     - This is not the initial step. The document does not mention isolating antigens from TCRs as the first step.\n   - **Option B:** Identifying meaningful clinical responses to non-specific treatments\n     - This is not the initial step. The document focuses on patients who are responding to immunotherapy, not non-specific treatments.\n   - **Option C:** Developing a novel TCR/target pair using TargetScan technology\n     - This is a subsequent step. The document mentions using TargetScan to determine the targets after isolating the T cells.\n   - **Option D:** Isolating clinically active anti-cancer T cells from tumor samples\n     - This matches the initial step described in the document.\n   - **Option E:** Testing TCRs for general cancer cell recognition\n     - This is not the initial step. It is part of the validation process.\n   - **Option F:** Determining the immune system's general targets\n     - This is not the initial step. The document focuses on specific targets recognized by TCRs from patients responding to immunotherapy.\n\n### Conclusion:\nThe initial step in the described approach to developing a TCR-T candidate is **isolating clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy agents**.\n\nTherefore, the correct answer is **Option D: Isolating clinically active anti-cancer T cells from tumor samples**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 5, "token_lengths": 32000, "result": 1.0, "question": "In the study, what constitutes a 'death equivalent' event?", "options": {"A": "Use of invasive surgery unrelated to ALS", "B": "Permanent assisted ventilation or tracheostomy", "C": "Hospitalization for more than one week", "D": "Daily use of less than 22 hours of ventilation", "E": "Any emergency medical intervention", "F": "Temporary use of assisted ventilation"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document step by step:\n\n1. **Identify the Definition of 'Death Equivalent'**:\n   - The document explicitly defines what constitutes a 'death equivalent' event in the context of the study. The relevant section states: \"Death equivalent was defined as either tracheostomy or permanent assisted ventilation, or PAV. PAV was defined as more than 22 hours daily of non-invasive mechanical ventilation for more than one week (seven days).\"\n\n2. **Match the Definition to the Options**:\n   - **Option A**: Use of invasive surgery unrelated to ALS - This does not match the definition provided.\n   - **Option B**: Permanent assisted ventilation or tracheostomy - This matches the definition provided.\n   - **Option C**: Hospitalization for more than one week - This does not match the definition provided.\n   - **Option D**: Daily use of less than 22 hours of ventilation - This does not match the definition provided.\n   - **Option E**: Any emergency medical intervention - This does not match the definition provided.\n   - **Option F**: Temporary use of assisted ventilation - This does not match the definition provided.\n\n3. **Conclusion**:\n   - The definition of 'death equivalent' in the study is explicitly stated as \"either tracheostomy or permanent assisted ventilation, or PAV,\" where PAV is defined as \"more than 22 hours daily of non-invasive mechanical ventilation for more than one week (seven days).\"\n   - Therefore, the correct answer is **Option B: Permanent assisted ventilation or tracheostomy**.\n\nThis step-by-step approach ensures that the answer is directly derived from the information provided in the document."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 32000, "result": 1.0, "question": "What critical performance criteria are emphasized for the electronic networks?", "options": {"A": "Cost and scalability", "B": "Design and aesthetics", "C": "Speed and reliability", "D": "Functionality and compatibility", "E": "User interface and experience", "F": "Color scheme and branding"}, "LLM_original_answer": ["To answer the question \"What critical performance criteria are emphasized for the electronic networks?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss the performance criteria for electronic networks.\n2. **Extract Key Information**: Extract the specific criteria mentioned in those sections.\n3. **Match to Options**: Compare the extracted criteria to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe most relevant section is found under \"Our Competitive Strengths\" and \"Operational and Liquidity\" in the document.\n\n### Step 2: Extract Key Information\nFrom the \"Our Competitive Strengths\" section:\n- **Speed, reliability, resilience, capacity, and security are critical performance criteria for our electronic networks.**\n\nFrom the \"Operational and Liquidity\" section:\n- **The secure transmission of confidential information and the ability to reliably transact on our electronic platforms and provide financial data services are critical elements of our operations.**\n- **Our timely, reliable delivery of high-quality products and services is dependent upon an array of technical production processes that enable our content delivery platforms.**\n\n### Step 3: Match to Options\n- **Option A: Cost and scalability** - While the document mentions the importance of scalability, it does not emphasize cost as a critical performance criterion.\n- **Option B: Design and aesthetics** - The document does not mention design or aesthetics as critical performance criteria.\n- **Option C: Speed and reliability** - The document explicitly mentions speed and reliability as critical performance criteria.\n- **Option D: Functionality and compatibility** - The document does not specifically emphasize functionality and compatibility.\n- **Option E: User interface and experience** - The document does not mention user interface or experience as critical performance criteria.\n- **Option F: Color scheme and branding** - The document does not mention color scheme or branding as critical performance criteria.\n\n### Conclusion\nThe critical performance criteria emphasized for the electronic networks, based on the provided document, are **speed and reliability**.\n\nTherefore, the correct answer is **Option C: Speed and reliability**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 32000, "result": 1.0, "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?", "options": {"A": "To simplify internal management structures", "B": "To maximize profit margins", "C": "To improve customer relations", "D": "To limit losses and provide capacity for future growth", "E": "To expand product lines", "F": "To enhance technological development"}, "LLM_original_answer": ["To answer the question \"Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Risk Management and Growth Opportunities**:\n   - The document states: \"In connection with our risk management efforts and in order to provide opportunities for growth and capital management, we enter into reinsurance arrangements pursuant to which we cede certain insurance risks to unaffiliated third-party reinsurers.\"\n   - This indicates that reinsurance is used for risk management and to provide growth opportunities.\n\n2. **Limiting Losses and Minimizing Exposure**:\n   - The document further elaborates: \"We cede risks to third parties in order to limit losses, minimize exposure to significant risks and provide capacity for future growth.\"\n   - This clearly states that one of the primary reasons for reinsurance is to limit losses and minimize exposure to significant risks.\n\n3. **Spreading Risk and Minimizing Loss Effects**:\n   - The document mentions: \"These reinsurance arrangements are an important part of our risk management strategy because they permit us to spread risk and minimize the effect of losses.\"\n   - This reinforces the idea that reinsurance helps in spreading the risk and minimizing the impact of potential losses.\n\n4. **Capital Management**:\n   - The document also notes: \"We enter into various agreements with reinsurers that cover groups of risks, as well as individual risks. Our ceded reinsurance to third parties is primarily structured on a treaty basis as coinsurance, yearly renewable term, excess or catastrophe excess of retention insurance.\"\n   - This indicates that reinsurance is used to manage capital by spreading the risk and ensuring that the company has the capacity to handle future growth.\n\n5. **Other Options**:\n   - The document does not mention reinsurance as a means to simplify internal management structures, maximize profit margins, improve customer relations, expand product lines, or enhance technological development.\n\nGiven this analysis, the most appropriate answer is:\n\n**D: To limit losses and provide capacity for future growth**\n\nThis option directly aligns with the reasons provided in the document for entering into reinsurance arrangements with unaffiliated third-party reinsurers."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 5, "token_lengths": 64000, "result": 1.0, "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?", "options": {"A": "2.5 mg/kg", "B": "3.75 mg/kg", "C": "5.0 mg/kg", "D": "4.5 mg/kg", "E": "3.0 mg/kg", "F": "6.0 mg/kg"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document step by step:\n\n1. **Identify the relevant section**: The document contains a section titled \"Ongoing Phase 2 Clinical Trial in Patients with Myelodysplastic Syndromes\" which is likely to contain the information about the Phase 2 clinical trial for KER-050.\n\n2. **Locate the specific information about the starting dose in Part 2**:\n   - The document states: \"In Part 2, the dose confirmation portion of the trial, an identical dosing schedule was followed, and patients initiated treatment at a starting dose of 3.75 mg/kg, the recommended Part 2 dose, or RP2D, with the opportunity to dose escalate to 5.0 mg/kg or to down-titrate based on individual titration rules.\"\n\n3. **Extract the answer**:\n   - The initial starting dose used in Part 2 of the Phase 2 clinical trial for KER-050 is 3.75 mg/kg.\n\n4. **Match the answer to the provided options**:\n   - The correct option is B: 3.75 mg/kg.\n\nTherefore, the answer to the question \"In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?\" is **B: 3.75 mg/kg**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 64000, "result": 1.0, "question": "What could have a material adverse effect on the business if there is a failure?", "options": {"A": "Expansion into international markets", "B": "Failure in critical systems, facilities, or services", "C": "Acquisition of a competitor", "D": "Increase in employee salaries", "E": "Introduction of new software features", "F": "Partnership with third-party vendors"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the option that best fits the context of the business and the potential risks mentioned.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Business Context:**\n   - The document describes a company that operates in the digital asset mining industry, specifically focusing on bitcoin mining and hosting services.\n   - The company's operations are heavily dependent on electric power, and it has fixed, variable, and interruptible power supply agreements with electric power suppliers.\n\n2. **Identify Key Risks:**\n   - The document mentions several risks that could have a material adverse effect on the business, including:\n     - **Power Supply and Cost:** \"Our business is highly dependent on a small number of digital asset mining equipment suppliers\" and \"An inability to purchase and develop additional sources of low-cost renewable sources of energy effectively will have a material adverse effect on our business, financial condition and results of operations.\"\n     - **Critical Systems and Facilities:** \"Any failure in our critical systems, facilities or services we provide could lead to disruptions in our and our customers\u2019 businesses and could harm our reputation and result in financial penalty and legal liabilities, which would reduce our revenue and have a material adverse effect on our business, financial condition and results of operations.\"\n\n3. **Evaluate Each Option:**\n   - **A: Expansion into international markets**\n     - While expansion into international markets could bring new challenges, the document does not specifically highlight this as a critical risk that could have a material adverse effect.\n   - **B: Failure in critical systems, facilities, or services**\n     - This option directly aligns with the risk mentioned in the document: \"Any failure in our critical systems, facilities or services we provide could lead to disruptions in our and our customers\u2019 businesses and could harm our reputation and result in financial penalty and legal liabilities, which would reduce our revenue and have a material adverse effect on our business, financial condition and results of operations.\"\n   - **C: Acquisition of a competitor**\n     - The document does not mention this as a specific risk. While acquisitions can bring challenges, they are not highlighted as a material adverse risk.\n   - **D: Increase in employee salaries**\n     - While increased employee salaries could affect profitability, the document does not specifically mention this as a material adverse risk.\n   - **E: Introduction of new software features**\n     - The document does not mention this as a specific risk. While new software features could affect operations, they are not highlighted as a material adverse risk"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 64000, "result": 1.0, "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?", "options": {"A": "21.49%", "B": "45%", "C": "50%", "D": "53%", "E": "75%", "F": "100%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that discusses Duke Energy's investments in various natural gas facilities, including Pine Needle.\n\n2. **Extract the specific information about Pine Needle**: The relevant information is found in the \"Natural Gas Investments\" section.\n\n3. **Determine the equity ownership percentage**: The document states the equity ownership percentage for Pine Needle.\n\n### Step 1: Identify the relevant section\nThe relevant section is found in the \"Natural Gas Investments\" part of the document.\n\n### Step 2: Extract the specific information about Pine Needle\nThe document states:\n> \"Duke Energy, through its GU&I segment, has a 45% equity ownership in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina and a 50% equity ownership interest in Hardy Storage, an underground interstate natural gas storage facility located in Hardy and Hampshire counties in West Virginia.\"\n\n### Step 3: Determine the equity ownership percentage\nFrom the extracted information, it is clear that Duke Energy, through its GU&I segment, has a 45% equity ownership in Pine Needle.\n\n### Conclusion\nThe correct answer is **B: 45%**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 64000, "result": 1.0, "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?", "options": {"A": "$17.7 million", "B": "$2.9 billion", "C": "$5.9 million", "D": "$9.7 million", "E": "$1.9 billion", "F": "$3.9 million"}, "LLM_original_answer": ["To answer the question \"How much had been invested in shares of the FHLBB as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the investment in shares of the FHLBB in the \"Federal Home Loan Bank System\" section.\n\n2. **Extract the specific information**: The relevant sentence states, \"We held an investment in the FHLBB of $5.9 million and $41.4 million at December 31, 2023 and 2022, respectively.\"\n\n3. **Match the information to the options**: The amount invested in shares of the FHLBB as of December 31, 2023, is $5.9 million.\n\n4. **Select the correct option**: The correct option is C: $5.9 million.\n\nTherefore, the answer to the question is **C: $5.9 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 64000, "result": 1.0, "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?", "options": {"A": "Insufficient funding", "B": "Resolution of a partial clinical hold", "C": "Finalization of trial data analysis", "D": "Completion of patient recruitment", "E": "Regulatory approval was received", "F": "No available patient candidates"}, "LLM_original_answer": ["The condition that has resulted in the pause of new patient enrollment in the clinical trial is:\n\n**B: Resolution of a partial clinical hold**\n\n### Chain of Thoughts:\n1. **Identify the relevant section in the document:**\n   - The document mentions that enrollment of new patients in the clinical trial for NX-2127 is currently paused.\n   - The specific reason for the pause is stated as \"pending resolution of a partial clinical hold.\"\n\n2. **Understand the context:**\n   - A partial clinical hold is a regulatory action where the FDA restricts certain aspects of a clinical trial, such as enrolling new patients, while allowing other aspects to continue.\n   - The document indicates that the partial clinical hold is related to the transition to an improved manufacturing process for NX-2127.\n\n3. **Match the condition to the options:**\n   - Option A (Insufficient funding) is not mentioned as a reason for the pause.\n   - Option B (Resolution of a partial clinical hold) directly matches the stated reason.\n   - Option C (Finalization of trial data analysis) is not mentioned as a reason for the pause.\n   - Option D (Completion of patient recruitment) is not the case, as the document states that the trial is still ongoing.\n   - Option E (Regulatory approval was received) is not the case, as the trial is still in the Phase 1 stage.\n   - Option F (No available patient candidates) is not mentioned as a reason for the pause.\n\n4. **Conclusion:**\n   - The correct answer is B: Resolution of a partial clinical hold."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 64000, "result": 1.0, "question": "What philosophy are Ocwen's compensation programs based on?", "options": {"A": "Cost-cutting and minimizing expenses", "B": "Pay-for-performance", "C": "Seniority-based pay", "D": "Hourly wage structure", "E": "Fixed salary only", "F": "Revenue growth only"}, "LLM_original_answer": ["To answer the question \"What philosophy are Ocwen's compensation programs based on?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss Ocwen's compensation programs and their underlying philosophy.\n2. **Extract Key Information**: Extract the specific information related to the compensation philosophy.\n3. **Match Information to Options**: Compare the extracted information to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in the \"Rewards\" subsection under \"HUMAN CAPITAL RESOURCES\":\n\n### Step 2: Extract Key Information\nFrom the \"Rewards\" section:\n- \"Our total rewards (compensation and benefits) programs are developed to attract, motivate and retain employees.\"\n- \"They demonstrate the value the employee provides to the organization, are designed to be competitive to the marketplace, and connect directly to key business strategies.\"\n- \"Our compensation programs, including salaries and short- and long-term incentives, are centered on our pay-for-performance philosophy, aligning the interests of employees and stakeholders by rewarding both individual and overall company performance.\"\n\n### Step 3: Match Information to Options\n- **Option A: Cost-cutting and minimizing expenses** - The document does not mention cost-cutting or minimizing expenses as the philosophy behind compensation programs.\n- **Option B: Pay-for-performance** - The document explicitly states that Ocwen's compensation programs are centered on a pay-for-performance philosophy.\n- **Option C: Seniority-based pay** - There is no mention of seniority-based pay in the document.\n- **Option D: Hourly wage structure** - The document does not discuss an hourly wage structure.\n- **Option E: Fixed salary only** - The document mentions both salaries and short- and long-term incentives, indicating that the compensation is not fixed salary only.\n- **Option F: Revenue growth only** - While revenue growth is a key business strategy, the document does not state that compensation is based solely on revenue growth.\n\n### Conclusion\nThe philosophy that Ocwen's compensation programs are based on is **Pay-for-performance**. Therefore, the correct answer is:\n\n**B: Pay-for-performance**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 64000, "result": 1.0, "question": "What is the initial step in the described approach to developing a TCR-T candidate?", "options": {"A": "Isolating tumor-specific antigens from TCRs", "B": "Identifying meaningful clinical responses to non-specific treatments", "C": "Developing a novel TCR/target pair using TargetScan technology", "D": "Isolating clinically active anti-cancer T cells from tumor samples", "E": "Testing TCRs for general cancer cell recognition", "F": "Determining the immune system's general targets"}, "LLM_original_answer": ["To answer the question, let's break down the information provided in the document:\n\n1. **Initial Step in the Approach**:\n   - The document outlines the company's strategy for developing TCR-T candidates.\n   - The first step in this process is described in the section \"Our Approach\":\n     - \"Our approach starts with isolating clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy agents.\"\n\n2. **Options Analysis**:\n   - **Option A**: Isolating tumor-specific antigens from TCRs - This is not the initial step; it is part of the subsequent process.\n   - **Option B**: Identifying meaningful clinical responses to non-specific treatments - This is not the initial step; it is a broader goal of the approach.\n   - **Option C**: Developing a novel TCR/target pair using TargetScan technology - This is a subsequent step after isolating T cells.\n   - **Option D**: Isolating clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy agents - This matches the initial step described in the document.\n   - **Option E**: Testing TCRs for general cancer cell recognition - This is a part of the validation process, not the initial step.\n   - **Option F**: Determining the immune system's general targets - This is not the initial step; it is a broader goal of the approach.\n\n3. **Conclusion**:\n   - The initial step in the described approach to developing a TCR-T candidate is isolating clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy agents.\n\nTherefore, the correct answer is **Option D: Isolating clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy agents**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 5, "token_lengths": 64000, "result": 1.0, "question": "In the study, what constitutes a 'death equivalent' event?", "options": {"A": "Use of invasive surgery unrelated to ALS", "B": "Permanent assisted ventilation or tracheostomy", "C": "Hospitalization for more than one week", "D": "Daily use of less than 22 hours of ventilation", "E": "Any emergency medical intervention", "F": "Temporary use of assisted ventilation"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document step by step:\n\n1. **Identify the relevant section**: The document mentions \"death equivalent\" events in the context of the CENTAUR trial. The relevant section is found in the part discussing the trial's outcomes and definitions.\n\n2. **Extract the definition**: The document states, \"Death equivalent was defined as either tracheostomy or permanent assisted ventilation, or PAV. PAV was defined as more than 22 hours daily of non-invasive mechanical ventilation for more than one week (seven days).\"\n\n3. **Match the definition to the options**:\n   - **Option A**: Use of invasive surgery unrelated to ALS - This does not match the definition.\n   - **Option B**: Permanent assisted ventilation or tracheostomy - This matches the definition.\n   - **Option C**: Hospitalization for more than one week - This does not match the definition.\n   - **Option D**: Daily use of less than 22 hours of ventilation - This does not match the definition.\n   - **Option E**: Any emergency medical intervention - This does not match the definition.\n   - **Option F**: Temporary use of assisted ventilation - This does not match the definition.\n\n4. **Conclusion**: Based on the definition provided in the document, the correct answer is **Option B: Permanent assisted ventilation or tracheostomy**.\n\nTherefore, the answer to the question \"In the study, what constitutes a 'death equivalent' event?\" is **Option B: Permanent assisted ventilation or tracheostomy**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 64000, "result": 1.0, "question": "What critical performance criteria are emphasized for the electronic networks?", "options": {"A": "Cost and scalability", "B": "Design and aesthetics", "C": "Speed and reliability", "D": "Functionality and compatibility", "E": "User interface and experience", "F": "Color scheme and branding"}, "LLM_original_answer": ["To answer the question \"What critical performance criteria are emphasized for the electronic networks?\" based on the provided document, I will analyze the relevant sections and extract the key points.\n\n1. **Relevant Section Analysis**:\n   - **World Class Technology**:\n     - \"Speed, reliability, resilience, capacity and security are critical performance criteria for our electronic networks.\"\n     - This section directly lists the critical performance criteria for the electronic networks.\n\n2. **Contextual Evidence**:\n   - **Data and Analytics**:\n     - \"Our data and analytics are delivered via real-time messaging, files, web services and other on-demand facilities and state-of-the-art front-ends.\"\n     - This suggests that speed and reliability are important for data delivery.\n   - **Operations**:\n     - \"We operate regionally diverse primary and backup data centers and maintain comprehensive business continuity and disaster recovery plans and facilities.\"\n     - This indicates a focus on reliability and resilience.\n   - **Cybersecurity**:\n     - \"Our business activities rely extensively on technology and software, including the systems used by our business partners, regulators and customers.\"\n     - \"We employ the following activities, processes and strategies to help evaluate, manage and address these risks.\"\n     - This highlights the importance of security.\n\n3. **Conclusion**:\n   - The document explicitly states that the critical performance criteria for the electronic networks are speed, reliability, resilience, capacity, and security.\n   - Among the given options, the closest match is **C: Speed and reliability**.\n\nTherefore, the correct answer is **C: Speed and reliability**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 64000, "result": 1.0, "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?", "options": {"A": "To simplify internal management structures", "B": "To maximize profit margins", "C": "To improve customer relations", "D": "To limit losses and provide capacity for future growth", "E": "To expand product lines", "F": "To enhance technological development"}, "LLM_original_answer": ["To answer the question \"Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Risk Management Efforts**:\n   - The document states, \"In connection with our risk management efforts and in order to provide opportunities for growth and capital management, we enter into reinsurance arrangements pursuant to which we cede certain insurance risks to unaffiliated third-party reinsurers.\"\n   - This indicates that reinsurance is a part of the company's broader risk management strategy.\n\n2. **Limiting Losses**:\n   - The document mentions, \"We cede risks to third parties in order to limit losses, minimize exposure to significant risks and provide capacity for future growth.\"\n   - This directly addresses the purpose of reinsurance in terms of limiting potential losses and minimizing exposure to significant risks.\n\n3. **Providing Capacity for Future Growth**:\n   - The document also states, \"We cede risks to third parties in order to limit losses, minimize exposure to significant risks and provide capacity for future growth.\"\n   - This highlights that reinsurance helps the company manage its risk exposure, allowing it to take on more business and grow in the future.\n\n4. **Diversification of Risk**:\n   - The document notes, \"These reinsurance arrangements are an important part of our risk management strategy because they permit us to spread risk and minimize the effect of losses.\"\n   - This emphasizes the role of reinsurance in spreading risk across multiple reinsurers, thereby reducing the impact of any single loss on the company.\n\n5. **Types of Reinsurance**:\n   - The document describes various types of reinsurance agreements, including coinsurance, yearly renewable term, excess or catastrophe excess of retention insurance.\n   - These types of reinsurance are designed to manage different kinds of risks, further supporting the idea of limiting losses and providing capacity for growth.\n\n6. **Reinsurance for Specific Risks**:\n   - The document mentions, \"We also cede first dollar mortality risk under certain contracts. In addition to reinsuring mortality risk, we cede other risks, as well as specific coverages.\"\n   - This indicates that the company uses reinsurance to manage specific types of risks, such as mortality risk, which can be significant and unpredictable.\n\nGiven this information, the most appropriate answer to the question is:\n\n**D: To limit losses and provide capacity for future growth**\n\nThis option aligns with the company's stated objectives of using re"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 5, "token_lengths": 96000, "result": 1.0, "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?", "options": {"A": "2.5 mg/kg", "B": "3.75 mg/kg", "C": "5.0 mg/kg", "D": "4.5 mg/kg", "E": "3.0 mg/kg", "F": "6.0 mg/kg"}, "LLM_original_answer": ["To answer the question regarding the initial starting dose used in Part 2 of the Phase 2 clinical trial for KER-050, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document provides details about the Phase 2 clinical trial for KER-050 in patients with MDS and myelofibrosis.\n\n2. **Locate the specific information about Part 2 of the trial**: The document states, \"In Part 2, the dose confirmation portion of the trial, an identical dosing schedule was followed, and patients initiated treatment at a starting dose of 3.75 mg/kg, the recommended Part 2 dose, or RP2D, with the opportunity to dose escalate to 5.0 mg/kg or to down-titrate based on individual titration rules.\"\n\n3. **Extract the initial starting dose**: The initial starting dose for Part 2 of the trial is clearly stated as 3.75 mg/kg.\n\n4. **Match the extracted information with the provided options**: The options are:\n   - A: 2.5 mg/kg\n   - B: 3.75 mg/kg\n   - C: 5.0 mg/kg\n   - D: 4.5 mg/kg\n   - E: 3.0 mg/kg\n   - F: 6.0 mg/kg\n\nThe correct answer is **B: 3.75 mg/kg**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 96000, "result": 1.0, "question": "What could have a material adverse effect on the business if there is a failure?", "options": {"A": "Expansion into international markets", "B": "Failure in critical systems, facilities, or services", "C": "Acquisition of a competitor", "D": "Increase in employee salaries", "E": "Introduction of new software features", "F": "Partnership with third-party vendors"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify which option could have a material adverse effect on the business if there is a failure.\n\n### Step-by-Step Analysis:\n\n1. **Expansion into international markets (Option A):**\n   - The document does not mention any specific risks associated with international expansion. It focuses more on the domestic operations and regulatory challenges within the United States.\n   - **Conclusion:** This option is less likely to have a material adverse effect based on the information provided.\n\n2. **Failure in critical systems, facilities, or services (Option B):**\n   - The document explicitly states: \"Any failure in our critical systems, facilities or services we provide could lead to disruptions in our and our customers\u2019 businesses and could harm our reputation and result in financial penalty and legal liabilities, which would reduce our revenue and have a material adverse effect on our business, financial condition and results of operations.\"\n   - **Conclusion:** This option is directly mentioned as a significant risk and is highly likely to have a material adverse effect.\n\n3. **Acquisition of a competitor (Option C):**\n   - The document does not discuss the risks associated with acquiring a competitor. It mentions the acquisition of Blockcap, but the focus is on the benefits and the integration process.\n   - **Conclusion:** This option is less likely to have a material adverse effect based on the information provided.\n\n4. **Increase in employee salaries (Option D):**\n   - The document mentions the importance of attracting and retaining top talent but does not discuss the specific risk of increasing employee salaries.\n   - **Conclusion:** This option is less likely to have a material adverse effect based on the information provided.\n\n5. **Introduction of new software features (Option E):**\n   - The document discusses the importance of innovation and new technology but does not mention the risk of introducing new software features.\n   - **Conclusion:** This option is less likely to have a material adverse effect based on the information provided.\n\n6. **Partnership with third-party vendors (Option F):**\n   - The document mentions the importance of partnerships with third-party vendors, particularly for securing mining equipment and hosting services. However, it does not specifically highlight the risk of failure in these partnerships.\n   - **Conclusion:** This option is less likely to have a material adverse effect based on the information provided.\n\n### Final Answer:\n**B: Failure in critical systems, facilities, or services**\n\n### Chain of Thoughts:\n- The document explicitly states that any failure in critical systems, facilities, or services could"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 96000, "result": 1.0, "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?", "options": {"A": "21.49%", "B": "45%", "C": "50%", "D": "53%", "E": "75%", "F": "100%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant information in the document**: The document should contain specific details about GU&I's equity ownership in Pine Needle.\n2. **Locate the specific section**: The section that discusses natural gas investments and storage facilities is likely to contain the relevant information.\n3. **Extract the equity ownership percentage**: Once the section is identified, I will extract the exact percentage of equity ownership GU&I has in Pine Needle.\n\nLet's go through the document to find the relevant information:\n\n### Step 1: Identify the relevant information\nThe document mentions various natural gas investments and storage facilities. The section that discusses these investments is likely to contain the information about Pine Needle.\n\n### Step 2: Locate the specific section\nThe relevant section is found in the \"Natural Gas Investments\" part of the \"Gas Utilities and Infrastructure\" (GU&I) segment:\n\n### Step 3: Extract the equity ownership percentage\nFrom the document:\n> \"Duke Energy, through its GU&I segment, has a 45% equity ownership in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina and a 50% equity ownership interest in Hardy Storage, an underground interstate natural gas storage facility located in Hardy and Hampshire counties in West Virginia.\"\n\n### Conclusion\nThe equity ownership percentage that GU&I has in Pine Needle is **45%**.\n\nTherefore, the correct answer is:\n**B: 45%**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 96000, "result": 1.0, "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?", "options": {"A": "$17.7 million", "B": "$2.9 billion", "C": "$5.9 million", "D": "$9.7 million", "E": "$1.9 billion", "F": "$3.9 million"}, "LLM_original_answer": ["To answer the question \"How much had been invested in shares of the FHLBB as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that discusses the company's investments and borrowings, including its relationship with the Federal Home Loan Bank of Boston (FHLBB).\n\n2. **Locate the specific information**: Within the \"Borrowings\" section, there is a paragraph that mentions the company's investment in FHLBB shares.\n\n3. **Extract the amount**: The paragraph states, \"Accordingly, we had invested $5.9 million in shares of the FHLBB and had $17.7 million outstanding in FHLBB borrowings with original maturities ranging from 1 week to 20 years at December 31, 2023.\"\n\n4. **Match the amount to the options**: The amount $5.9 million matches option C in the provided multiple-choice options.\n\nTherefore, the correct answer is:\n\n**C: $5.9 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 96000, "result": 1.0, "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?", "options": {"A": "Insufficient funding", "B": "Resolution of a partial clinical hold", "C": "Finalization of trial data analysis", "D": "Completion of patient recruitment", "E": "Regulatory approval was received", "F": "No available patient candidates"}, "LLM_original_answer": ["The condition that has resulted in the pause of new patient enrollment in the clinical trial is:\n\n**B: Resolution of a partial clinical hold**\n\n### Chain of Thoughts:\n1. **Identify the relevant section in the document:**\n   - The document mentions a partial clinical hold in the context of the NX-2127 clinical trial.\n\n2. **Extract the specific information:**\n   - From the section \"Clinical development of NX-2127,\" it states: \"In October 2023, following our communication to the FDA of our intention to transition to an improved manufacturing process for NX-2127, the FDA placed a partial clinical hold on our ongoing Phase 1 clinical trial evaluating NX-2127.\"\n\n3. **Understand the implications:**\n   - A partial clinical hold means that only part of the clinical work requested under the IND is allowed to proceed, while other protocols may be delayed or suspended.\n   - The document further clarifies: \"Currently-enrolled patients who are deriving clinical benefit may continue to receive treatment in accordance with the ongoing study protocol, but no additional patients may be enrolled until the partial clinical hold is resolved.\"\n\n4. **Match the information to the question:**\n   - The pause in new patient enrollment is directly linked to the partial clinical hold that the FDA has placed on the NX-2127 trial.\n\n5. **Select the correct option:**\n   - Option B: \"Resolution of a partial clinical hold\" is the correct answer.\n\nThus, the pause in new patient enrollment in the clinical trial is due to the resolution of a partial clinical hold."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 96000, "result": 1.0, "question": "What philosophy are Ocwen's compensation programs based on?", "options": {"A": "Cost-cutting and minimizing expenses", "B": "Pay-for-performance", "C": "Seniority-based pay", "D": "Hourly wage structure", "E": "Fixed salary only", "F": "Revenue growth only"}, "LLM_original_answer": ["To answer the question \"What philosophy are Ocwen's compensation programs based on?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss Ocwen's compensation programs and their underlying philosophy.\n2. **Extract Key Information**: Extract the specific information related to the philosophy of compensation programs.\n3. **Match with Options**: Compare the extracted information with the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section in the document is found under \"HUMAN CAPITAL RESOURCES\" and specifically under \"Rewards\":\n\n### Step 2: Extract Key Information\nFrom the \"Rewards\" section:\n- \"Our total rewards (compensation and benefits) programs are developed to attract, motivate and retain employees.\"\n- \"They demonstrate the value the employee provides to the organization, are designed to be competitive to the marketplace, and connect directly to key business strategies.\"\n- \"Our compensation programs, including salaries and short- and long-term incentives, are centered on our pay-for-performance philosophy, aligning the interests of employees and stakeholders by rewarding both individual and overall company performance.\"\n\n### Step 3: Match with Options\n- **Option A: Cost-cutting and minimizing expenses** - The document does not mention cost-cutting or minimizing expenses as the philosophy behind compensation programs.\n- **Option B: Pay-for-performance** - The document explicitly states that Ocwen's compensation programs are centered on a pay-for-performance philosophy.\n- **Option C: Seniority-based pay** - The document does not mention seniority-based pay.\n- **Option D: Hourly wage structure** - The document does not mention an hourly wage structure.\n- **Option E: Fixed salary only** - The document mentions both salaries and short- and long-term incentives, indicating that the compensation is not fixed salary only.\n- **Option F: Revenue growth only** - The document does not mention revenue growth as the sole focus of compensation programs.\n\n### Conclusion\nThe philosophy that Ocwen's compensation programs are based on is **Pay-for-performance**.\n\nTherefore, the correct answer is **Option B: Pay-for-performance**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 96000, "result": 1.0, "question": "What is the initial step in the described approach to developing a TCR-T candidate?", "options": {"A": "Isolating tumor-specific antigens from TCRs", "B": "Identifying meaningful clinical responses to non-specific treatments", "C": "Developing a novel TCR/target pair using TargetScan technology", "D": "Isolating clinically active anti-cancer T cells from tumor samples", "E": "Testing TCRs for general cancer cell recognition", "F": "Determining the immune system's general targets"}, "LLM_original_answer": ["To answer the question, let's break down the information provided in the document:\n\n1. **Initial Step in TCR-T Candidate Development**:\n   - The document outlines the approach to developing TCR-T candidates, starting with the identification of clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy.\n   - Specifically, it states: \"Our approach starts with isolating clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy agents.\"\n\n2. **Options Analysis**:\n   - **Option A**: Isolating tumor-specific antigens from TCRs - This is not the initial step; it is part of the subsequent process.\n   - **Option B**: Identifying meaningful clinical responses to non-specific treatments - This is not the initial step; it is more about the overall goal of the research.\n   - **Option C**: Developing a novel TCR/target pair using TargetScan technology - This is a key step but not the initial one.\n   - **Option D**: Isolating clinically active anti-cancer T cells from tumor samples - This matches the initial step described in the document.\n   - **Option E**: Testing TCRs for general cancer cell recognition - This is a later step in the process.\n   - **Option F**: Determining the immune system's general targets - This is not the initial step; it is part of the broader research goals.\n\nBased on the document, the initial step in the described approach to developing a TCR-T candidate is:\n\n**D: Isolating clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy.**\n\nThis step is crucial as it provides the starting material for the subsequent processes, including identifying the targets recognized by these TCRs and developing the TCR-T candidates."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 5, "token_lengths": 96000, "result": 1.0, "question": "In the study, what constitutes a 'death equivalent' event?", "options": {"A": "Use of invasive surgery unrelated to ALS", "B": "Permanent assisted ventilation or tracheostomy", "C": "Hospitalization for more than one week", "D": "Daily use of less than 22 hours of ventilation", "E": "Any emergency medical intervention", "F": "Temporary use of assisted ventilation"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document and identify the relevant section that defines what constitutes a 'death equivalent' event in the context of the study.\n\n1. **Identify the relevant section:**\n   - The relevant section is found in the \"Clinical Development of AMX0035 for ALS\" part of the document, specifically under the \"CENTAUR, Our Phase 2 Trial of AMX0035 in ALS\" subsection.\n\n2. **Extract the definition:**\n   - The document states: \"Death equivalent was defined as either tracheostomy or permanent assisted ventilation, or PAV. PAV was defined as more than 22 hours daily of non-invasive mechanical ventilation for more than one week (seven days).\"\n\n3. **Match the definition to the options:**\n   - Option B: \"Permanent assisted ventilation or tracheostomy\" matches the definition provided in the document.\n\nTherefore, the correct answer is:\n\n**B: Permanent assisted ventilation or tracheostomy**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 96000, "result": 1.0, "question": "What critical performance criteria are emphasized for the electronic networks?", "options": {"A": "Cost and scalability", "B": "Design and aesthetics", "C": "Speed and reliability", "D": "Functionality and compatibility", "E": "User interface and experience", "F": "Color scheme and branding"}, "LLM_original_answer": ["To answer the question \"What critical performance criteria are emphasized for the electronic networks?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss the performance criteria for electronic networks.\n2. **Extract Key Information**: Extract the specific criteria mentioned in those sections.\n3. **Match to Options**: Compare the extracted criteria to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe document mentions performance criteria for electronic networks in several sections, particularly in the \"Technology\" and \"Operational and Liquidity\" sections.\n\n### Step 2: Extract Key Information\nFrom the \"Technology\" section:\n- **Speed, reliability, resilience, capacity, and security** are critical performance criteria for electronic trading platforms.\n- The document emphasizes the importance of these criteria in the context of trading and clearing technology, as well as mortgage technology.\n\nFrom the \"Operational and Liquidity\" section:\n- The secure transmission of confidential information and the ability to reliably transact on electronic platforms are critical elements of operations.\n- The document highlights the risks associated with system failures, cybersecurity breaches, and the need for robust systems to handle peak trading volumes and market volatility.\n\n### Step 3: Match to Options\n- **Option A: Cost and scalability** - While the document mentions the need to manage costs and ensure scalability, these are not emphasized as the primary critical performance criteria.\n- **Option B: Design and aesthetics** - The document does not mention design and aesthetics as critical performance criteria.\n- **Option C: Speed and reliability** - The document explicitly states that speed and reliability are critical performance criteria for electronic networks.\n- **Option D: Functionality and compatibility** - While functionality and compatibility are important, they are not specifically highlighted as critical performance criteria.\n- **Option E: User interface and experience** - The document does not emphasize user interface and experience as critical performance criteria.\n- **Option F: Color scheme and branding** - The document does not mention color scheme and branding as critical performance criteria.\n\n### Conclusion\nThe critical performance criteria emphasized for the electronic networks in the provided document are **speed and reliability**.\n\nTherefore, the correct answer is **Option C: Speed and reliability**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 96000, "result": 1.0, "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?", "options": {"A": "To simplify internal management structures", "B": "To maximize profit margins", "C": "To improve customer relations", "D": "To limit losses and provide capacity for future growth", "E": "To expand product lines", "F": "To enhance technological development"}, "LLM_original_answer": ["The correct answer to the question \"Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?\" is:\n\n**D: To limit losses and provide capacity for future growth**\n\n### Chain of Thoughts:\n1. **Reinsurance Purpose**: The document states that the company enters into reinsurance arrangements to \"limit losses, minimize exposure to significant risks and provide capacity for future growth.\" This directly aligns with option D.\n2. **Risk Management**: The document emphasizes that reinsurance is an important part of the company's risk management strategy, which helps in spreading risk and minimizing the effect of losses. This further supports the idea of limiting losses.\n3. **Capacity for Growth**: The document mentions that reinsurance provides \"additional capacity for future growth.\" This indicates that reinsurance helps the company manage its risk exposure, allowing it to take on more business and grow.\n4. **Ceding Risks**: The company cedes risks to third parties to achieve these goals, which means transferring part of the risk to reinsurers. This is a common practice in the insurance industry to manage large or unpredictable risks.\n5. **Treaty Basis**: The reinsurance is primarily structured on a treaty basis, which includes coinsurance, yearly renewable term, excess or catastrophe excess of retention insurance. These structures are designed to manage and spread risk effectively.\n\n### Elimination of Other Options:\n- **A: To simplify internal management structures**: The document does not mention simplifying internal management structures as a reason for reinsurance.\n- **B: To maximize profit margins**: While reinsurance can indirectly affect profit margins, the primary reasons given in the document are risk management and capacity for growth, not profit maximization.\n- **C: To improve customer relations**: The document does not indicate that reinsurance is used to improve customer relations.\n- **E: To expand product lines**: The document does not suggest that reinsurance is used to expand product lines.\n- **F: To enhance technological development**: The document does not mention enhancing technological development as a reason for reinsurance.\n\nTherefore, the most accurate and comprehensive answer based on the provided document is **D: To limit losses and provide capacity for future growth**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 5, "token_lengths": 128000, "result": 1.0, "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?", "options": {"A": "2.5 mg/kg", "B": "3.75 mg/kg", "C": "5.0 mg/kg", "D": "4.5 mg/kg", "E": "3.0 mg/kg", "F": "6.0 mg/kg"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 128000, "result": 1.0, "question": "What could have a material adverse effect on the business if there is a failure?", "options": {"A": "Expansion into international markets", "B": "Failure in critical systems, facilities, or services", "C": "Acquisition of a competitor", "D": "Increase in employee salaries", "E": "Introduction of new software features", "F": "Partnership with third-party vendors"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 128000, "result": 0.0, "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?", "options": {"A": "21.49%", "B": "45%", "C": "50%", "D": "53%", "E": "75%", "F": "100%"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 128000, "result": 0.0, "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?", "options": {"A": "$17.7 million", "B": "$2.9 billion", "C": "$5.9 million", "D": "$9.7 million", "E": "$1.9 billion", "F": "$3.9 million"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 128000, "result": 1.0, "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?", "options": {"A": "Insufficient funding", "B": "Resolution of a partial clinical hold", "C": "Finalization of trial data analysis", "D": "Completion of patient recruitment", "E": "Regulatory approval was received", "F": "No available patient candidates"}, "LLM_original_answer": ["The condition that has resulted in the pause of new patient enrollment in the clinical trial is:\n\nB: Resolution of a partial clinical hold\n\nThis can be determined from the following excerpt in the provided document:\n\n\"In October 2023, following our communication to the FDA of our intention to transition to an improved manufacturing process for NX-2127, the FDA placed a partial clinical hold on our ongoing Phase 1 clinical trial evaluating NX-2127. Currently-enrolled patients who are deriving clinical benefit may continue to receive treatment in accordance with the ongoing study protocol, but no additional patients may be enrolled until the partial clinical hold is resolved.\"\n\nThis clearly indicates that the partial clinical hold placed by the FDA is the reason for the pause in new patient enrollment."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 128000, "result": 1.0, "question": "What philosophy are Ocwen's compensation programs based on?", "options": {"A": "Cost-cutting and minimizing expenses", "B": "Pay-for-performance", "C": "Seniority-based pay", "D": "Hourly wage structure", "E": "Fixed salary only", "F": "Revenue growth only"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 128000, "result": 0.0, "question": "What is the initial step in the described approach to developing a TCR-T candidate?", "options": {"A": "Isolating tumor-specific antigens from TCRs", "B": "Identifying meaningful clinical responses to non-specific treatments", "C": "Developing a novel TCR/target pair using TargetScan technology", "D": "Isolating clinically active anti-cancer T cells from tumor samples", "E": "Testing TCRs for general cancer cell recognition", "F": "Determining the immune system's general targets"}, "LLM_original_answer": ["The initial step in the described approach to developing a TCR-T candidate, as detailed in the provided document, is:\n\n**D: Developing a novel TCR/target pair using TargetScan technology**\n\n### Chain of Thoughts:\n1. **Understanding the Approach**: The document outlines a multi-step process for developing TCR-T candidates. The key steps include discovering anti-cancer TCRs, determining their targets, and ensuring their safety.\n2. **Identifying the First Step**: The document states, \"Our discovery process begins with identifying patient T cells that"], "LLM_extracted_answer": ["C"], "ground_truth": "D"}, {"depth": 5, "token_lengths": 128000, "result": 1.0, "question": "In the study, what constitutes a 'death equivalent' event?", "options": {"A": "Use of invasive surgery unrelated to ALS", "B": "Permanent assisted ventilation or tracheostomy", "C": "Hospitalization for more than one week", "D": "Daily use of less than 22 hours of ventilation", "E": "Any emergency medical intervention", "F": "Temporary use of assisted ventilation"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 5, "token_lengths": 128000, "result": 1.0, "question": "What critical performance criteria are emphasized for the electronic networks?", "options": {"A": "Cost and scalability", "B": "Design and aesthetics", "C": "Speed and reliability", "D": "Functionality and compatibility", "E": "User interface and experience", "F": "Color scheme and branding"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 5, "token_lengths": 128000, "result": 1.0, "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?", "options": {"A": "To simplify internal management structures", "B": "To maximize profit margins", "C": "To improve customer relations", "D": "To limit losses and provide capacity for future growth", "E": "To expand product lines", "F": "To enhance technological development"}, "LLM_original_answer": ["The correct answer is **D: To limit losses and provide capacity for future growth**.\n\n### Chain of Thought:\n1. **Context of Reinsurance**: The document discusses reinsurance as a risk management strategy used by the company to protect against various market risks, particularly those associated with annuity and life insurance products.\n2. **Purpose of Reinsurance**: The document explicitly states, \"In connection with our risk management efforts and in order to provide opportunities for growth and capital management, we enter into reinsurance arrangements pursuant to which we cede certain insurance risks to unaffiliated third-party reinsurers.\"\n3. **Risk Management**: The document emphasizes that reinsurance is used to \"limit losses, minimize exposure to significant risks and provide capacity for future growth.\"\n4. **Types of Reinsurance**: The document mentions various types of reinsurance agreements, such as coinsurance, yearly renewable term, excess or catastrophe excess of retention insurance, which are all designed to spread risk and minimize the impact of losses.\n5. **Impact on Capital**: The document also notes that reinsurance helps in managing the company's capital and exposure risk, which is crucial for maintaining financial stability and supporting future growth.\n\n### Elimination of Other Options:\n- **A: To simplify internal management structures**: The document does not mention simplifying internal management as a reason for reinsurance.\n- **B: To maximize profit margins**: While reinsurance can help in managing costs and risks, the document does not specifically state that it is used to maximize profit margins.\n- **C: To improve customer relations**: The document does not indicate that reinsurance is used to improve customer relations.\n- **E: To expand product lines**: The document does not mention expanding product lines as a reason for reinsurance.\n- **F: To enhance technological development**: The document does not suggest that reinsurance is used to enhance technological development.\n\n### Conclusion:\nThe primary reasons for entering into reinsurance arrangements with unaffiliated third-party reinsurers, as stated in the document, are to limit losses and provide capacity for future growth. Therefore, the correct answer is **D: To limit losses and provide capacity for future growth**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 8000, "result": 1.0, "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?", "options": {"A": "Increases ventricular pressure and cardiac remodeling", "B": "Decreases the potential for cardioprotective effects", "C": "Protects against cardiac dysfunction and remodeling", "D": "Leads to an increase in the Fulton index", "E": "Enhances the right ventricular free wall thickness", "F": "Increases the myocardial performance index"}, "LLM_original_answer": ["To answer the question \"What effect does the treatment of RKER-012 have in the mouse PAB model?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Model Description**:\n   - The mouse PAB (Pulmonary Artery Banding) model is used to increase pressure in the right ventricle of the heart.\n   - This increased pressure leads to cardiac dysfunction and remodeling, as evidenced by:\n     - Increased end systolic pressure-volume relationship (ESPVR)\n     - Increased myocardial performance index (MPI)\n     - Increased Fulton index\n     - Increased right ventricular free wall thickness (RVFWT)\n     - Increased fibrosis in the heart\n\n2. **Treatment with RKER-012**:\n   - In the mouse PAB model, treatment with twice weekly subcutaneous 10 mg/kg dosing of RKER-012 was observed to protect against both the PAB-related cardiac dysfunction and remodeling.\n   - Specifically, the treatment:\n     - Attenuated the increased ESPVR\n     - Attenuated the increased MPI\n     - Reduced the Fulton index\n     - Prevented an increase in RVFWT\n     - Reduced cardiac fibrosis\n\n3. **Interpreting the Effects**:\n   - **ESPVR and MPI**: These are measures of cardiac function. An increase in these values indicates cardiac dysfunction. The document states that RKER-012 attenuated (reduced) the increase in both ESPVR and MPI, suggesting that it protects against cardiac dysfunction.\n   - **Fulton Index**: This measures the enlargement of the right ventricle. An increase in the Fulton index indicates cardiac hypertrophy. The document states that RKER-012 reduced the Fulton index, indicating that it prevents cardiac hypertrophy.\n   - **RVFWT**: This measures the thickness of the right ventricular free wall. An increase in RVFWT is a sign of cardiac remodeling. The document states that RKER-012 prevented an increase in RVFWT, indicating that it prevents cardiac remodeling.\n   - **Cardiac Fibrosis**: The document states that RKER-012 reduced cardiac fibrosis, which is another sign of cardiac remodeling.\n\n4. **Conclusion**:\n   - The treatment with RKER-012 in the mouse PAB model protected against both cardiac dysfunction and remodeling.\n   - This aligns with the option C: \"Protects against cardiac dysfunction and"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 8000, "result": 1.0, "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?", "options": {"A": "Immediate infringement lawsuits upon filing", "B": "Inability to identify competing products", "C": "Delayed launch of new products", "D": "Unawareness of pending applications that may later result in infringement claims", "E": "Mandatory changes to current product designs", "F": "Increased cost of patent filing"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and the options given.\n\n### Step 1: Identify Relevant Information\nThe document mentions the following relevant point:\n- \"Moreover, patent applications are in some cases maintained in secrecy until patents are issued. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents that our services or products allegedly infringe on.\"\n\n### Step 2: Evaluate Each Option\n- **A: Immediate infringement lawsuits upon filing**\n  - The document does not mention any immediate lawsuits upon filing. It only discusses the secrecy of patent applications and the potential for future infringement claims.\n  \n- **B: Inability to identify competing products**\n  - The document does not discuss the inability to identify competing products. It focuses on the risk of unknown pending patents.\n\n- **C: Delayed launch of new products**\n  - The document does not mention delays in launching new products. It is more concerned with the risk of future infringement claims.\n\n- **D: Unawareness of pending applications that may later result in infringement claims**\n  - This option directly aligns with the information provided in the document. The document explicitly states that there may be pending patent applications of which the company is unaware, which could later result in infringement claims.\n\n- **E: Mandatory changes to current product designs**\n  - The document does not mention mandatory changes to current product designs. It is more focused on the risk of unknown pending patents leading to infringement claims.\n\n- **F: Increased cost of patent filing**\n  - The document does not discuss the cost of patent filing. It is concerned with the risk of unknown pending patents.\n\n### Step 3: Select the Best Answer\nBased on the analysis, the best answer is **D: Unawareness of pending applications that may later result in infringement claims**. This option directly corresponds to the information provided in the document, which states that patent applications can be maintained in secrecy for many years, leading to the risk of unknown pending patents that could result in future infringement claims.\n\n### Final Answer\n**D: Unawareness of pending applications that may later result in infringement claims**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 8000, "result": 0.0, "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?", "options": {"A": "Increased demand for electricity", "B": "Rising fuel costs", "C": "Improved operational efficiency", "D": "Delayed or unrecovered operating costs", "E": "Expansion into new markets", "F": "Strong economic growth"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the factors that could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document discusses various risks and factors that could affect Duke Energy Registrants' operations and financial performance.\n   - The section on \"OPERATIONAL RISKS\" is particularly relevant, as it mentions factors that could impact the financial stability of customers and the ability to recover costs.\n\n2. **Extract Key Information:**\n   - **Economic Downturns:**\n     - \"A continuation of adverse economic conditions including economic downturn or high commodity prices could also negatively impact the financial stability of certain of our customers and result in their inability to pay for electric and natural gas services.\"\n     - \"This could lead to increased bad debt expense and higher allowance for doubtful account reserves for the Duke Energy Registrants and result in delayed or unrecovered operating costs and lower financial results.\"\n\n3. **Evaluate Each Option:**\n   - **A: Increased demand for electricity**\n     - The document does not suggest that increased demand for electricity would lead to higher bad debt expenses or doubtful account reserves. In fact, increased demand would likely increase revenues.\n   - **B: Rising fuel costs**\n     - The document mentions that rising fuel costs could negatively impact the financial stability of customers, leading to an inability to pay for services. This aligns with the statement about increased bad debt expense and higher allowance for doubtful account reserves.\n   - **C: Improved operational efficiency**\n     - Improved operational efficiency is generally positive and would not lead to increased bad debt expenses or higher reserves.\n   - **D: Delayed or unrecovered operating costs**\n     - This is a direct consequence of the factors that could lead to increased bad debt expense and higher reserves, but it is not a factor itself.\n   - **E: Expansion into new markets**\n     - The document does not mention that expansion into new markets would directly lead to increased bad debt expenses or higher reserves.\n   - **F: Strong economic growth**\n     - Strong economic growth would generally improve the financial stability of customers, reducing the likelihood of bad debt expenses and higher reserves.\n\n4. **Conclusion:**\n   - The factor that could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants, based on the document, is **B: Rising fuel costs**. The document explicitly states that rising fuel costs could negatively impact"], "LLM_extracted_answer": ["B"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 8000, "result": 1.0, "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?", "options": {"A": "It will be allowed to increase its capital reserves.", "B": "It will receive tax incentives to improve practices.", "C": "Enforcement actions may be taken against it.", "D": "It will be automatically disbanded.", "E": "It will be required to decrease its interest rates.", "F": "It will gain permission for more acquisitions."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document and think through the implications step by step.\n\n### Step 1: Identify the Relevant Section\nThe relevant section for this question is the \"Compensation Practices\" section, which discusses the oversight and guidance provided by federal banking regulators regarding incentive compensation arrangements.\n\n### Step 2: Understand the Guidance\nThe guidance from the Federal Reserve Board and the FDIC emphasizes three key principles:\n1. Incentive compensation arrangements should balance risk and financial results.\n2. These arrangements should be compatible with effective controls and risk management.\n3. They should be supported by strong corporate governance.\n\n### Step 3: Identify the Consequences of Non-Compliance\nThe document states:\n- Supervisory findings regarding incentive compensation will be incorporated into the organization\u2019s supervisory ratings.\n- **Enforcement actions may be taken against a banking organization if its incentive compensation arrangements or related risk management, control, or governance processes pose a risk to the organization\u2019s safety and financial weakness.**\n\n### Step 4: Evaluate the Options\nLet's evaluate each option based on the information provided:\n\n- **A: It will be allowed to increase its capital reserves.**\n  - This is not mentioned as a consequence of risky incentive compensation arrangements.\n\n- **B: It will receive tax incentives to improve practices.**\n  - There is no mention of tax incentives in the document.\n\n- **C: Enforcement actions may be taken against it.**\n  - This is explicitly mentioned in the document as a potential consequence of risky incentive compensation arrangements.\n\n- **D: It will be automatically disbanded.**\n  - The document does not suggest that a banking organization will be automatically disbanded for risky incentive compensation arrangements.\n\n- **E: It will be required to decrease its interest rates.**\n  - There is no mention of interest rate changes as a consequence of risky incentive compensation arrangements.\n\n- **F: It will gain permission for more acquisitions.**\n  - The document suggests that supervisory ratings can affect the ability to make acquisitions, but it does not indicate that risky incentive compensation arrangements would lead to more acquisitions.\n\n### Step 5: Conclusion\nBased on the information provided in the document, the correct answer is:\n\n**C: Enforcement actions may be taken against it.**\n\nThis is the only option that aligns with the explicit consequences mentioned in the document for banking organizations with risky incentive compensation arrangements."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 8000, "result": 1.0, "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?", "options": {"A": "International partnerships", "B": "Location of manufacturing facilities", "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement", "D": "Advertising and social media presence", "E": "Colors and branding of the packaging", "F": "Celebrity endorsements"}, "LLM_original_answer": ["To answer the question \"What are expected key competitive factors affecting the success of the company's drug candidates if approved?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Context**: The document discusses the company's drug candidates, particularly those in the BTK degrader and CBL-B inhibitor programs, and the competitive landscape they face.\n\n2. **Locate Relevant Information**: The document explicitly mentions the key competitive factors affecting the success of the company's drug candidates if they are approved.\n\n3. **Extract the Information**: The relevant sentence is: \"The key competitive factors affecting the success of all our programs, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement.\"\n\n4. **Match the Information to the Options**: The extracted information directly corresponds to option C: \"Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement.\"\n\n5. **Verify the Other Options**: \n   - **Option A: International partnerships** - While the document mentions competitors and potential partnerships, it does not list international partnerships as a key competitive factor.\n   - **Option B: Location of manufacturing facilities** - The document does not mention the location of manufacturing facilities as a key competitive factor.\n   - **Option D: Advertising and social media presence** - The document does not discuss advertising or social media presence as key competitive factors.\n   - **Option E: Colors and branding of the packaging** - The document does not mention packaging colors or branding as key competitive factors.\n   - **Option F: Celebrity endorsements** - The document does not mention celebrity endorsements as a key competitive factor.\n\n6. **Conclusion**: Based on the information provided in the document, the correct answer is option C: \"Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement.\"\n\nTherefore, the answer to the question is **C: Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 8000, "result": 1.0, "question": "Which organization acts as the conservator for the GSEs?", "options": {"A": "Ginnie Mae", "B": "United States Treasury Department", "C": "Various investors", "D": "Non-Agency securitization trustees", "E": "Federal Housing Finance Agency (FHFA)", "F": "Federal Reserve"}, "LLM_original_answer": ["To answer the question \"Which organization acts as the conservator for the GSEs?\" based on the provided document, I will follow these steps:\n\n1. **Identify the GSEs**: The document mentions GSEs, which stands for Government-Sponsored Enterprises. These are typically Fannie Mae and Freddie Mac, though the document does not explicitly name them.\n\n2. **Search for the Conservator**: The document discusses various regulatory bodies and their roles. I need to find a specific mention of the conservator for the GSEs.\n\n3. **Locate Relevant Information**: In the section \"Legal and Regulatory Risks,\" the document states:\n   - \"The GSEs (and their conservator, the FHFA), Ginnie Mae, the United States Treasury Department, various investors, non-Agency securitization trustees and others also subject us to periodic reviews and audits.\"\n\n4. **Determine the Conservator**: From the above statement, it is clear that the FHFA (Federal Housing Finance Agency) is identified as the conservator for the GSEs.\n\n5. **Match with Options**: The options provided are:\n   - A: Ginnie Mae\n   - B: United States Treasury Department\n   - C: Various investors\n   - D: Non-Agency securitization trustees\n   - E: Federal Housing Finance Agency (FHFA)\n   - F: Federal Reserve\n\n6. **Select the Correct Answer**: The correct answer is E: Federal Housing Finance Agency (FHFA).\n\n**Chain of Thoughts**:\n- The document mentions GSEs and their conservator.\n- The conservator is explicitly identified as the FHFA.\n- This matches with option E in the provided list of options.\n\nTherefore, the answer is **E: Federal Housing Finance Agency (FHFA)**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 10, "token_lengths": 8000, "result": 1.0, "question": "What is included in the control arm of the described Phase 1 clinical trial?", "options": {"A": "Patients meeting specific HLA or miHA criteria", "B": "Patients treated with TSC-100 or TSC-101", "C": "Patients who do not meet HLA or miHA genetic criteria", "D": "Patients receiving experimental gene therapy", "E": "Healthy volunteers with no treatment", "F": "Patients undergoing bone marrow biopsy"}, "LLM_original_answer": ["To answer the question \"What is included in the control arm of the described Phase 1 clinical trial?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Clinical Trial Design**:\n   - The document mentions that the clinical studies for TSC-100 and TSC-101 are part of a multi-arm, controlled, Phase 1, \"umbrella\" design clinical trial.\n   - The trial is investigating the safety and efficacy of TSC-100 and TSC-101 in patients with ALL, AML, and MDS who are undergoing HCT following RIC (reduced-intensity conditioning).\n\n2. **Control Arm Description**:\n   - The document explicitly states: \"We are also including a control arm, comprising patients who do not meet the HLA or miHA genetic criteria and are treated with standard RIC haplo transplantation alone.\"\n   - This means the control arm consists of patients who do not meet the specific genetic criteria (HLA or miHA) required for the treatment arms and are instead treated with the standard of care, which is RIC haplo transplantation without the experimental TSC-100 or TSC-101.\n\n3. **Options Analysis**:\n   - **Option A**: Patients meeting specific HLA or miHA criteria. This is incorrect because the control arm specifically includes patients who do not meet these criteria.\n   - **Option B**: Patients treated with TSC-100 or TSC-101. This is incorrect because the control arm does not receive these experimental treatments.\n   - **Option C**: Patients who do not meet HLA or miHA genetic criteria. This matches the description given in the document.\n   - **Option D**: Patients receiving experimental gene therapy. This is incorrect because the control arm receives standard care, not experimental gene therapy.\n   - **Option E**: Healthy volunteers with no treatment. This is incorrect because the control arm includes patients with hematologic malignancies who receive standard RIC haplo transplantation.\n   - **Option F**: Patients undergoing bone marrow biopsy. This is not specific to the control arm; it is a general procedure that may be performed in both treatment and control arms.\n\nBased on the information provided in the document, the correct answer is:\n\n**C: Patients who do not meet HLA or miHA genetic criteria**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 8000, "result": 1.0, "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?", "options": {"A": "10 years", "B": "12 years", "C": "14 years", "D": "15 years", "E": "20 years", "F": "25 years"}, "LLM_original_answer": ["To answer the question \"Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the Hatch-Waxman Act in the context of patent term extensions. The relevant section is:\n   > \"In the U.S., the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process. The length of the patent term extension is calculated based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended.\"\n\n2. **Extract the key information**:\n   - The maximum extension under the Hatch-Waxman Act is up to five years.\n   - The total term of the patent, including the extension, cannot exceed 14 years from the date of product approval.\n\n3. **Match the information to the options**:\n   - The document states that the total term of the patent, including the extension, cannot exceed 14 years from the date of product approval.\n   - This directly corresponds to option C: 14 years.\n\nTherefore, the correct answer is **C: 14 years**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 8000, "result": 1.0, "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?", "options": {"A": "A decrease in trading demand by customers", "B": "Cost-cutting pressures across the industry", "C": "Settlements related to inspections", "D": "Weakness in the macroeconomic environment", "E": "Defaults by clearing or exchange members", "F": "Changes to contract specifications"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Context**: The question is about the potential reduction in the listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023.\n\n2. **Locate the Relevant Information**: The relevant information is found in the \"Business and Industry\" section of the document, specifically in the paragraph that discusses the PCAOB's actions and their impact on Chinese companies listing in the U.S.\n\n   - **Relevant Paragraph**:\n     > \"In November 2023, the PCAOB announced settlements related to these inspections, which could lead to fewer Chinese companies listing in the U.S.\"\n\n3. **Analyze the Information**:\n   - The document directly states that the PCAOB announced settlements related to inspections.\n   - These settlements are linked to the potential reduction in the listing of Chinese companies in the U.S.\n\n4. **Match the Information to the Options**:\n   - **Option A**: A decrease in trading demand by customers - This is not mentioned in the context of the PCAOB announcement.\n   - **Option B**: Cost-cutting pressures across the industry - This is not mentioned in the context of the PCAOB announcement.\n   - **Option C**: Settlements related to inspections - This matches the information provided in the document.\n   - **Option D**: Weakness in the macroeconomic environment - While macroeconomic conditions are discussed, they are not linked to the PCAOB announcement.\n   - **Option E**: Defaults by clearing or exchange members - This is discussed in the document but not in the context of the PCAOB announcement.\n   - **Option F**: Changes to contract specifications - This is discussed in the document but not in the context of the PCAOB announcement.\n\n5. **Conclusion**:\n   - The document explicitly states that the PCAOB's announcement of settlements related to inspections could lead to fewer Chinese companies listing in the U.S.\n\nTherefore, the correct answer is **Option C: Settlements related to inspections**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 8000, "result": 1.0, "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?", "options": {"A": "January 1, 2020", "B": "July 1, 2020", "C": "January 1, 2021", "D": "July 1, 2023", "E": "January 1, 2023", "F": "July 1, 2022"}, "LLM_original_answer": ["To answer the question \"When did the enforcement of the CCPA, as amended by the CPRA, begin?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the CCPA and CPRA in the \"Privacy and Cybersecurity Regulation\" section.\n\n2. **Extract the key information**: The document states:\n   - \"The California Consumer Privacy Act of 2018 (the \u201cCCPA\u201d), which became effective in January 2020, affords California residents expanded privacy protections and control over the collection, use and sharing of their personal information.\"\n   - \"The CCPA, amended by the California Privacy Rights Act (the \u201cCPRA\u201d), effective as of January 1, 2023, and the implementing regulations require additional investment in compliance programs and potential modifications to business processes.\"\n   - \"Enforcement of the CCPA, as amended by the CPRA, began on July 1, 2023.\"\n\n3. **Match the information to the options**:\n   - Option A: January 1, 2020 (This is when the original CCPA became effective, not the amended version.)\n   - Option B: July 1, 2020 (This is not mentioned in the document.)\n   - Option C: January 1, 2021 (This is not mentioned in the document.)\n   - Option D: July 1, 2023 (This matches the enforcement date mentioned in the document.)\n   - Option E: January 1, 2023 (This is when the CPRA amendments became effective, but not when enforcement began.)\n   - Option F: July 1, 2022 (This is not mentioned in the document.)\n\n4. **Conclusion**: The correct answer is **Option D: July 1, 2023**.\n\nThe document clearly states that the enforcement of the CCPA, as amended by the CPRA, began on July 1, 2023."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 16000, "result": 1.0, "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?", "options": {"A": "Increases ventricular pressure and cardiac remodeling", "B": "Decreases the potential for cardioprotective effects", "C": "Protects against cardiac dysfunction and remodeling", "D": "Leads to an increase in the Fulton index", "E": "Enhances the right ventricular free wall thickness", "F": "Increases the myocardial performance index"}, "LLM_original_answer": ["To answer the question \"What effect does the treatment of RKER-012 have in the mouse PAB model?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the effects of RKER-012 in the mouse PAB model is found under \"Preclinical Data.\"\n\n2. **Extract the key information**:\n   - The document states: \"In a mouse model of pulmonary arterial banding, or PAB, RKER-012 was observed to protect against both the PAB-related cardiac dysfunction and remodeling.\"\n   - It further details: \"Treatment with twice weekly subcutaneous 10 mg/kg dosing of RKER-012 was observed to protect against both the PAB-related cardiac dysfunction and remodeling, which we believe demonstrates that KER-012 has the potential to have a cardioprotective effect that could potentially provide benefit in diseases such as PAH and other cardiovascular diseases in patients.\"\n\n3. **Match the information to the given options**:\n   - **Option A**: Increases ventricular pressure and cardiac remodeling - This is not supported by the document.\n   - **Option B**: Decreases the potential for cardioprotective effects - This is not supported by the document.\n   - **Option C**: Protects against cardiac dysfunction and remodeling - This is directly supported by the document.\n   - **Option D**: Leads to an increase in the Fulton index - The document indicates that RKER-012 prevents increases in the Fulton index, so this option is not correct.\n   - **Option E**: Enhances the right ventricular free wall thickness - The document indicates that RKER-012 prevents an increase in the right ventricular free wall thickness, so this option is not correct.\n   - **Option F**: Increases the myocardial performance index - The document indicates that RKER-012 protects against an increase in the myocardial performance index, so this option is not correct.\n\n4. **Conclusion**:\n   - The correct answer is **Option C**: Protects against cardiac dysfunction and remodeling.\n\nThis answer is supported by the preclinical data provided in the document, which clearly states that RKER-012 was observed to protect against both PAB-related cardiac dysfunction and remodeling."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 16000, "result": 1.0, "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?", "options": {"A": "Immediate infringement lawsuits upon filing", "B": "Inability to identify competing products", "C": "Delayed launch of new products", "D": "Unawareness of pending applications that may later result in infringement claims", "E": "Mandatory changes to current product designs", "F": "Increased cost of patent filing"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the relevant information that pertains to the potential issues arising from patent applications being maintained in secrecy until patents are issued.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Information:**\n   - The document discusses various risks and challenges in the digital asset and blockchain industry, including issues related to intellectual property and regulatory compliance.\n   - Specifically, the document mentions: \"Moreover, patent applications are in some cases maintained in secrecy until patents are issued. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents that our services or products allegedly infringe on.\"\n\n2. **Understand the Context:**\n   - The context here is that patent applications can be kept secret for a long period, sometimes several years.\n   - This secrecy can lead to situations where a company might unknowingly develop a product or service that infringes on a patent that is later issued.\n\n3. **Evaluate the Options:**\n   - **A: Immediate infringement lawsuits upon filing** - This is not mentioned in the document. Patent applications are secret, so lawsuits would not be immediate.\n   - **B: Inability to identify competing products** - The document does not discuss this as a direct issue related to patent secrecy.\n   - **C: Delayed launch of new products** - The document does not mention this as a specific issue.\n   - **D: Unawareness of pending applications that may later result in infringement claims** - This is directly mentioned in the document.\n   - **E: Mandatory changes to current product designs** - The document does not discuss this as a direct issue.\n   - **F: Increased cost of patent filing** - The document does not mention this as a specific issue related to patent secrecy.\n\n4. **Select the Most Appropriate Answer:**\n   - Based on the information provided in the document, the most appropriate answer is **D: Unawareness of pending applications that may later result in infringement claims**.\n\n### Conclusion:\nThe potential issue that may arise from patent applications being maintained in secrecy until patents are issued is **D: Unawareness of pending applications that may later result in infringement claims**. This is explicitly stated in the document and aligns with the context of the risks associated with intellectual property in the digital asset and blockchain industry."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 16000, "result": 1.0, "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?", "options": {"A": "Increased demand for electricity", "B": "Rising fuel costs", "C": "Improved operational efficiency", "D": "Delayed or unrecovered operating costs", "E": "Expansion into new markets", "F": "Strong economic growth"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the factor that could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document discusses various risks and factors that could impact Duke Energy Registrants' financial performance.\n   - The section that directly addresses bad debt expense and allowance for doubtful accounts is found in the \"OPERATIONAL RISKS\" section.\n\n2. **Extract Key Information:**\n   - The relevant paragraph states: \"A continuation of adverse economic conditions including economic downturn or high commodity prices could also negatively impact the financial stability of certain of our customers and result in their inability to pay for electric and natural gas services. This could lead to increased bad debt expense and higher allowance for doubtful account reserves for the Duke Energy Registrants and result in delayed or unrecovered operating costs and lower financial results.\"\n\n3. **Evaluate Each Option:**\n   - **A: Increased demand for electricity** - This would generally lead to higher revenues and not necessarily increased bad debt expense.\n   - **B: Rising fuel costs** - While rising fuel costs can impact operational costs, the document does not directly link this to bad debt expense.\n   - **C: Improved operational efficiency** - This would typically reduce costs and improve financial stability, not increase bad debt expense.\n   - **D: Delayed or unrecovered operating costs** - This is mentioned in the document as a potential outcome of increased bad debt expense, but it is not the cause.\n   - **E: Expansion into new markets** - This could introduce new risks, but the document does not specifically mention it leading to bad debt expense.\n   - **F: Strong economic growth** - This would generally improve the financial stability of customers, reducing bad debt expense.\n\n4. **Determine the Correct Answer:**\n   - The document explicitly states that adverse economic conditions, including economic downturns, could negatively impact the financial stability of customers, leading to increased bad debt expense and higher allowance for doubtful account reserves.\n   - Therefore, the correct answer is **D: Delayed or unrecovered operating costs**.\n\n### Conclusion:\nThe factor that could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants is **D: Delayed or unrecovered operating costs**. This is because adverse economic conditions can make it difficult for customers to pay their bills, leading to higher bad debt expenses and the need for higher reserves."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 16000, "result": 1.0, "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?", "options": {"A": "It will be allowed to increase its capital reserves.", "B": "It will receive tax incentives to improve practices.", "C": "Enforcement actions may be taken against it.", "D": "It will be automatically disbanded.", "E": "It will be required to decrease its interest rates.", "F": "It will gain permission for more acquisitions."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document and think through the implications step by step.\n\n### Step 1: Identify Relevant Information\nThe document mentions that the federal banking regulators, including the FDIC and the Federal Reserve Board, have provided guidance on incentive compensation arrangements. The key points from this guidance are:\n- Incentive compensation arrangements should balance risk and financial results.\n- They should be compatible with effective controls and risk management.\n- They should be supported by strong corporate governance.\n\n### Step 2: Understand the Consequences of Non-Compliance\nThe document also states that if a banking organization's incentive compensation arrangements or related risk management, control, or governance processes pose a risk to the organization's safety and financial weakness, the following actions may be taken:\n- **Supervisory findings** will be incorporated into the organization\u2019s supervisory ratings, which can affect its ability to make acquisitions or perform other actions.\n- **Enforcement actions** may be taken against the banking organization.\n\n### Step 3: Evaluate the Options\nLet's evaluate each option in the context of the information provided:\n\n- **A: It will be allowed to increase its capital reserves.**\n  - This option does not align with the consequences mentioned. Increasing capital reserves is not a penalty or enforcement action.\n\n- **B: It will receive tax incentives to improve practices.**\n  - This option is not mentioned in the document. Tax incentives are not a typical enforcement action for risky compensation practices.\n\n- **C: Enforcement actions may be taken against it.**\n  - This option directly aligns with the information provided. The document explicitly states that enforcement actions may be taken if incentive compensation arrangements pose a risk.\n\n- **D: It will be automatically disbanded.**\n  - This option is extreme and not mentioned in the document. Disbanding a bank is not a typical enforcement action for risky compensation practices.\n\n- **E: It will be required to decrease its interest rates.**\n  - This option is not mentioned in the document. Decreasing interest rates is not a typical enforcement action for risky compensation practices.\n\n- **F: It will gain permission for more acquisitions.**\n  - This option is the opposite of what the document suggests. If a bank's compensation practices are risky, it may lose the ability to make acquisitions, not gain permission for more.\n\n### Step 4: Conclusion\nBased on the information provided in the document, the most appropriate answer is:\n\n**C: Enforcement actions may be taken against it.**\n\n"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 16000, "result": 1.0, "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?", "options": {"A": "International partnerships", "B": "Location of manufacturing facilities", "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement", "D": "Advertising and social media presence", "E": "Colors and branding of the packaging", "F": "Celebrity endorsements"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n### Step 1: Identify the Context\nThe document discusses the development, competition, and regulatory aspects of drug candidates, particularly in the biotechnology and biopharmaceutical industries. It highlights the challenges and factors that influence the success of drug candidates once they are approved.\n\n### Step 2: Locate the Specific Information\nThe key section that addresses the competitive factors affecting the success of the company's drug candidates is found in the \"Competition\" section:\n\n> \"The key competitive factors affecting the success of all our programs, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement.\"\n\n### Step 3: Match the Information to the Options\nLet's match the factors mentioned in the document to the options provided:\n\n- **Efficacy**: This is explicitly mentioned.\n- **Safety**: This is explicitly mentioned.\n- **Convenience**: This is explicitly mentioned.\n- **Price**: This is explicitly mentioned.\n- **Level of generic competition**: This is explicitly mentioned.\n- **Availability of reimbursement**: This is explicitly mentioned.\n\n### Step 4: Evaluate the Other Options\n- **International partnerships (Option A)**: While the document mentions partnerships with Pfizer, it does not list international partnerships as a key competitive factor.\n- **Location of manufacturing facilities (Option B)**: The document discusses manufacturing and supply but does not list the location of manufacturing facilities as a key competitive factor.\n- **Advertising and social media presence (Option D)**: The document does not mention advertising or social media presence as key competitive factors.\n- **Colors and branding of the packaging (Option E)**: The document does not mention colors or branding of packaging as key competitive factors.\n- **Celebrity endorsements (Option F)**: The document does not mention celebrity endorsements as key competitive factors.\n\n### Step 5: Conclusion\nBased on the information provided in the document, the key competitive factors affecting the success of the company's drug candidates, if approved, are:\n\n**C: Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement**\n\nThis option directly matches the factors listed in the document."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 16000, "result": 1.0, "question": "Which organization acts as the conservator for the GSEs?", "options": {"A": "Ginnie Mae", "B": "United States Treasury Department", "C": "Various investors", "D": "Non-Agency securitization trustees", "E": "Federal Housing Finance Agency (FHFA)", "F": "Federal Reserve"}, "LLM_original_answer": ["To answer the question \"Which organization acts as the conservator for the GSEs?\" based on the provided document, I will follow these steps:\n\n1. **Identify the GSEs**: The document mentions GSEs, which stands for Government-Sponsored Enterprises. These are typically Fannie Mae and Freddie Mac, which are the primary GSEs in the mortgage industry.\n\n2. **Search for the Conservator**: The document should contain information about the organization that acts as the conservator for these GSEs. I will look for mentions of the conservator or any related regulatory body.\n\n3. **Review Relevant Sections**: I will review the sections that discuss regulatory and legal risks, as these are likely to contain information about the conservator.\n\n4. **Extract the Answer**: Once I find the relevant information, I will extract the answer and match it to the provided options.\n\n### Step-by-Step Analysis:\n\n1. **Identify the GSEs**:\n   - The document mentions GSEs in several places, particularly in the context of regulatory and financial requirements.\n\n2. **Search for the Conservator**:\n   - The document mentions the Federal Housing Finance Agency (FHFA) in the context of regulatory and legal risks. Specifically, it states: \"The GSEs (and their conservator, the FHFA), Ginnie Mae, the United States Treasury Department, various investors, non-Agency securitization trustees and others also subject us to periodic reviews and audits.\"\n\n3. **Review Relevant Sections**:\n   - The section on \"Legal and Regulatory Risks\" provides the most relevant information:\n     - \"The GSEs (and their conservator, the FHFA), Ginnie Mae, the United States Treasury Department, various investors, non-Agency securitization trustees and others also subject us to periodic reviews and audits.\"\n\n4. **Extract the Answer**:\n   - The document clearly states that the FHFA acts as the conservator for the GSEs.\n\n### Conclusion:\nThe organization that acts as the conservator for the GSEs is the **Federal Housing Finance Agency (FHFA)**.\n\nTherefore, the correct answer is:\n**E: Federal Housing Finance Agency (FHFA)**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 10, "token_lengths": 16000, "result": 1.0, "question": "What is included in the control arm of the described Phase 1 clinical trial?", "options": {"A": "Patients meeting specific HLA or miHA criteria", "B": "Patients treated with TSC-100 or TSC-101", "C": "Patients who do not meet HLA or miHA genetic criteria", "D": "Patients receiving experimental gene therapy", "E": "Healthy volunteers with no treatment", "F": "Patients undergoing bone marrow biopsy"}, "LLM_original_answer": ["To answer the question \"What is included in the control arm of the described Phase 1 clinical trial?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Clinical Trial Design**:\n   - The document mentions that the clinical studies for TSC-100 and TSC-101 are part of a multi-arm, controlled, Phase 1, \"umbrella\" design clinical trial.\n   - The trial is designed to investigate the safety and efficacy of TSC-100 and TSC-101 in patients with ALL, AML, and MDS who are undergoing HCT following RIC.\n\n2. **Control Arm Description**:\n   - The document explicitly states: \"We are also including a control arm, comprising patients who do not meet the HLA or miHA genetic criteria and are treated with standard RIC haplo transplantation alone.\"\n   - This means the control arm includes patients who do not meet the specific genetic criteria required for TSC-100 or TSC-101 treatment.\n\n3. **Patient Criteria**:\n   - TSC-100 is for patients who are HA-1-positive and HLA-A*02:01-positive.\n   - TSC-101 is for patients who are HA-2-positive and HLA-A*02:01-positive.\n   - The control arm, therefore, includes patients who do not meet these criteria.\n\n4. **Treatment in Control Arm**:\n   - The control arm patients receive \"standard RIC haplo transplantation alone,\" meaning they undergo the standard reduced-intensity conditioning followed by haploidentical transplantation without the additional TSC-100 or TSC-101 treatment.\n\nGiven this information, the correct answer is:\n\n**C: Patients who do not meet HLA or miHA genetic criteria**\n\nThis option accurately reflects the description of the control arm in the document, which includes patients who do not meet the specific genetic criteria required for TSC-100 or TSC-101 and are treated with standard RIC haplo transplantation alone."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 16000, "result": 1.0, "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?", "options": {"A": "10 years", "B": "12 years", "C": "14 years", "D": "15 years", "E": "20 years", "F": "25 years"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that specifically discusses the Hatch-Waxman Act and patent term extensions.\n\n2. **Extract the key information**: The relevant information is found in the following paragraph:\n   > \"The term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process. The length of the patent term extension is calculated based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended.\"\n\n3. **Analyze the information**:\n   - The maximum extension under the Hatch-Waxman Act is **up to five years**.\n   - However, the total extended term cannot exceed **14 years from the date of product approval**.\n\n4. **Match the information to the options**:\n   - The maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval is **14 years**.\n\n5. **Select the correct answer**:\n   - The correct answer is **C: 14 years**.\n\nTherefore, the answer to the question \"Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?\" is **C: 14 years**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 16000, "result": 1.0, "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?", "options": {"A": "A decrease in trading demand by customers", "B": "Cost-cutting pressures across the industry", "C": "Settlements related to inspections", "D": "Weakness in the macroeconomic environment", "E": "Defaults by clearing or exchange members", "F": "Changes to contract specifications"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the relevant section**: The key information is found in the \"Business and Industry\" section of the \"RISK FACTORS\" part of the document.\n\n2. **Extract the relevant information**: The document states:\n   - \"In November 2023, the PCAOB announced settlements related to these inspections, which could lead to fewer Chinese companies listing in the U.S.\"\n\n3. **Match the information to the options**:\n   - **Option A: A decrease in trading demand by customers** - The document does not mention this as a direct result of the PCAOB announcement.\n   - **Option B: Cost-cutting pressures across the industry** - The document does not mention this as a direct result of the PCAOB announcement.\n   - **Option C: Settlements related to inspections** - This matches the information provided in the document.\n   - **Option D: Weakness in the macroeconomic environment** - The document does not mention this as a direct result of the PCAOB announcement.\n   - **Option E: Defaults by clearing or exchange members** - The document does not mention this as a direct result of the PCAOB announcement.\n   - **Option F: Changes to contract specifications** - The document does not mention this as a direct result of the PCAOB announcement.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **Option C: Settlements related to inspections**.\n\nThe chain of thought is as follows:\n- The document explicitly mentions that the PCAOB announced settlements related to inspections in November 2023.\n- These settlements are stated to potentially lead to fewer Chinese companies listing in the U.S.\n- None of the other options are directly mentioned in the context of the PCAOB announcement.\n\nTherefore, the answer is **Option C: Settlements related to inspections**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 16000, "result": 1.0, "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?", "options": {"A": "January 1, 2020", "B": "July 1, 2020", "C": "January 1, 2021", "D": "July 1, 2023", "E": "January 1, 2023", "F": "July 1, 2022"}, "LLM_original_answer": ["To answer the question \"When did the enforcement of the CCPA, as amended by the CPRA, begin?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the CCPA and CPRA in the \"Privacy and Cybersecurity Regulation\" section.\n\n2. **Locate the specific information**: The relevant sentence is: \"Enforcement of the CCPA, as amended by the CPRA, began on July 1, 2023.\"\n\n3. **Match the information to the options**:\n   - A: January 1, 2020\n   - B: July 1, 2020\n   - C: January 1, 2021\n   - D: July 1, 2023\n   - E: January 1, 2023\n   - F: July 1, 2022\n\n4. **Select the correct option**: The correct option is D: July 1, 2023.\n\nTherefore, the enforcement of the CCPA, as amended by the CPRA, began on July 1, 2023."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 32000, "result": 1.0, "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?", "options": {"A": "Increases ventricular pressure and cardiac remodeling", "B": "Decreases the potential for cardioprotective effects", "C": "Protects against cardiac dysfunction and remodeling", "D": "Leads to an increase in the Fulton index", "E": "Enhances the right ventricular free wall thickness", "F": "Increases the myocardial performance index"}, "LLM_original_answer": ["To answer the question \"What effect does the treatment of RKER-012 have in the mouse PAB model?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the effects of RKER-012 in a mouse model of pulmonary arterial banding (PAB).\n\n2. **Extract the specific information**: The relevant information is found in the section titled \"Preclinical Data\" under the sub-section \"Treatment with RKER-012 prevented cardiac dysfunction and remodeling in a mouse PAB model.\"\n\n3. **Summarize the findings**:\n   - **Cardiac Dysfunction**: Treatment with RKER-012 protected against PAB-related cardiac dysfunction.\n   - **Cardiac Remodeling**: Treatment with RKER-012 protected against PAB-related cardiac remodeling.\n   - **Specific Metrics**:\n     - **End Systolic Pressure-Volume Relationship (ESPVR)**: Increased in vehicle-treated mice but not in RKER-012-treated mice.\n     - **Myocardial Performance Index (MPI)**: Increased in vehicle-treated mice but not in RKER-012-treated mice.\n     - **Fulton Index**: Increased in vehicle-treated mice but not in RKER-012-treated mice.\n     - **Right Ventricular Free Wall Thickness (RVFWT)**: Increased in vehicle-treated mice but not in RKER-012-treated mice.\n     - **Cardiac Fibrosis**: Increased in vehicle-treated mice but not in RKER-012-treated mice.\n\n4. **Match the findings to the given options**:\n   - **Option A**: Increases ventricular pressure and cardiac remodeling. (This is not supported by the document; RKER-012 prevents these effects.)\n   - **Option B**: Decreases the potential for cardioprotective effects. (This is not supported by the document; RKER-012 has cardioprotective effects.)\n   - **Option C**: Protects against cardiac dysfunction and remodeling. (This is supported by the document.)\n   - **Option D**: Leads to an increase in the Fulton index. (This is not supported by the document; RKER-012 prevents an increase in the Fulton index.)\n   - **Option E**: Enhances the right ventricular free wall thickness. (This is not supported by the document; RKER-012 prevents an increase in RVFWT.)\n"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 32000, "result": 1.0, "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?", "options": {"A": "Immediate infringement lawsuits upon filing", "B": "Inability to identify competing products", "C": "Delayed launch of new products", "D": "Unawareness of pending applications that may later result in infringement claims", "E": "Mandatory changes to current product designs", "F": "Increased cost of patent filing"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the relevant information and then match it to the given options.\n\n### Step 1: Identify Relevant Information\nThe document discusses various risks and challenges faced by the company, including those related to intellectual property and regulatory issues. The specific section that is most relevant to the question is:\n\n**\"We may not be able to adequately protect our intellectual property rights and other proprietary rights, which could have a material adverse effect on our business, financial condition and results of operations.\"**\n\nThis section includes the following points:\n- The company may not be able to obtain broad protection for its intellectual property.\n- Protecting intellectual property may require significant resources.\n- Intellectual property rights may be challenged or invalidated.\n- Patent applications are sometimes maintained in secrecy until patents are issued, which can lead to issues.\n\n### Step 2: Analyze the Specific Issue\nThe document mentions:\n- \"Patent applications are in some cases maintained in secrecy until patents are issued.\"\n- \"Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents that our services or products allegedly infringe on.\"\n\n### Step 3: Match to the Given Options\nThe potential issue highlighted in the document is that patent applications being maintained in secrecy until patents are issued can lead to the company being unaware of pending applications that may later result in infringement claims. This directly corresponds to:\n\n**Option D: Unawareness of pending applications that may later result in infringement claims**\n\n### Step 4: Verify Other Options\n- **Option A: Immediate infringement lawsuits upon filing** - The document does not mention immediate lawsuits upon filing.\n- **Option B: Inability to identify competing products** - The document does not discuss the inability to identify competing products.\n- **Option C: Delayed launch of new products** - The document does not mention delays in launching new products.\n- **Option E: Mandatory changes to current product designs** - The document does not discuss mandatory changes to product designs.\n- **Option F: Increased cost of patent filing** - The document does not mention increased costs of patent filing.\n\n### Conclusion\nThe potential issue that may arise from patent applications being maintained in secrecy until patents are issued, as described in the document, is:\n\n**D: Unawareness of pending applications that may later result in infringement claims**"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 32000, "result": 1.0, "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?", "options": {"A": "Increased demand for electricity", "B": "Rising fuel costs", "C": "Improved operational efficiency", "D": "Delayed or unrecovered operating costs", "E": "Expansion into new markets", "F": "Strong economic growth"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the factor that could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document discusses various risk factors and operational challenges that Duke Energy and its subsidiaries face.\n   - The section \"OPERATIONAL RISKS\" is particularly relevant as it discusses factors that could affect the financial stability of customers and, consequently, the ability of Duke Energy to recover costs.\n\n2. **Extract Key Information:**\n   - **Economic Downturns and Adverse Conditions:**\n     - \"A continuation of adverse economic conditions including economic downturn or high commodity prices could also negatively impact the financial stability of certain of our customers and result in their inability to pay for electric and natural gas services. This could lead to increased bad debt expense and higher allowance for doubtful account reserves for the Duke Energy Registrants and result in delayed or unrecovered operating costs and lower financial results.\"\n     - This statement directly links adverse economic conditions to increased bad debt expense and higher allowance for doubtful account reserves.\n\n3. **Evaluate Options:**\n   - **A: Increased demand for electricity** - This would generally lead to higher revenues and not necessarily to increased bad debt expense.\n   - **B: Rising fuel costs** - While rising fuel costs can increase operational costs, they are typically passed on to customers through regulatory mechanisms, so they do not directly lead to bad debt.\n   - **C: Improved operational efficiency** - Improved efficiency would reduce costs and is unlikely to lead to increased bad debt.\n   - **D: Delayed or unrecovered operating costs** - This is a direct consequence of increased bad debt expense and higher allowance for doubtful account reserves, not a cause.\n   - **E: Expansion into new markets** - Expansion could lead to increased costs and risks, but it is not directly linked to bad debt in the document.\n   - **F: Strong economic growth** - Strong economic growth would generally improve the financial stability of customers, reducing bad debt.\n\n4. **Conclusion:**\n   - The document explicitly states that adverse economic conditions, including economic downturns, can negatively impact the financial stability of customers, leading to increased bad debt expense and higher allowance for doubtful account reserves.\n   - Therefore, the correct answer is **D: Delayed or unrecovered operating costs**.\n\n### Final Answer:\n**D: Delayed or unrecovered operating costs**\n\n### Chain of Thoughts:\n-"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 32000, "result": 1.0, "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?", "options": {"A": "It will be allowed to increase its capital reserves.", "B": "It will receive tax incentives to improve practices.", "C": "Enforcement actions may be taken against it.", "D": "It will be automatically disbanded.", "E": "It will be required to decrease its interest rates.", "F": "It will gain permission for more acquisitions."}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Identify Relevant Sections**:\n   - The document discusses various regulatory and enforcement actions that can be taken against banks, particularly in the context of unsafe or unsound practices.\n   - The section on \"Compensation Practices\" is particularly relevant, as it mentions the federal banking regulators' guidance on incentive compensation arrangements.\n\n2. **Extract Key Information**:\n   - The federal banking regulators (such as the FDIC and the Federal Reserve Board) have provided guidance to ensure that incentive compensation arrangements at banking organizations take into account risk and are consistent with safe and sound practices.\n   - The guidance sets forth three key principles:\n     - Incentives should balance risk and financial results without encouraging imprudent risk.\n     - Arrangements should be compatible with effective controls and risk management.\n     - Arrangements should be supported by strong corporate governance.\n   - If a banking organization's incentive compensation arrangements or related risk management, control, or governance processes pose a risk to the organization's safety and financial weakness, enforcement actions may be taken against it.\n\n3. **Evaluate Options**:\n   - **Option A**: It will be allowed to increase its capital reserves. This is not mentioned in the document as a consequence of risky incentive compensation.\n   - **Option B**: It will receive tax incentives to improve practices. The document does not mention tax incentives as a response to risky compensation practices.\n   - **Option C**: Enforcement actions may be taken against it. This is explicitly mentioned in the document as a potential consequence of risky incentive compensation arrangements.\n   - **Option D**: It will be automatically disbanded. The document does not mention automatic disbandment as a consequence.\n   - **Option E**: It will be required to decrease its interest rates. The document does not mention this as a specific consequence of risky compensation practices.\n   - **Option F**: It will gain permission for more acquisitions. The document suggests that regulatory actions can restrict or limit a bank's activities, including acquisitions, rather than granting more permissions.\n\n4. **Conclusion**:\n   - Based on the information provided in the document, the most accurate answer is **Option C**: Enforcement actions may be taken against it.\n\nTherefore, the correct answer is **C: Enforcement actions may be taken against it**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 32000, "result": 1.0, "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?", "options": {"A": "International partnerships", "B": "Location of manufacturing facilities", "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement", "D": "Advertising and social media presence", "E": "Colors and branding of the packaging", "F": "Celebrity endorsements"}, "LLM_original_answer": ["To answer the question \"What are expected key competitive factors affecting the success of the company's drug candidates if approved?\" based on the provided document, I will analyze the relevant sections step by step.\n\n1. **Relevant Section Analysis**:\n   - **Competition Section**:\n     - \"The key competitive factors affecting the success of all our programs, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement.\"\n   - **Drug Development and Commercialization**:\n     - \"Not only must we compete with other companies that are focused on protein modulation, but any drug candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.\"\n     - \"Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop.\"\n     - \"In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products.\"\n\n2. **Synthesis of Key Points**:\n   - **Efficacy**: The effectiveness of the drug in treating the intended condition is a critical factor.\n   - **Safety**: The safety profile of the drug, including the presence and severity of side effects, is crucial.\n   - **Convenience**: How easy it is for patients to use the drug, such as the dosing regimen, can impact its success.\n   - **Price**: The cost of the drug compared to existing and future therapies is a significant factor.\n   - **Level of Generic Competition**: The presence of generic alternatives can affect the market share and profitability of the drug.\n   - **Availability of Reimbursement**: The extent to which insurance and other third-party payors cover the cost of the drug is important.\n\n3. **Conclusion**:\n   - The document explicitly states that the key competitive factors affecting the success of the company's drug candidates, if approved, are their efficacy, safety, convenience, price, level of generic competition, and availability of reimbursement.\n\nTherefore, the correct answer is:\n\n**C: Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 32000, "result": 1.0, "question": "Which organization acts as the conservator for the GSEs?", "options": {"A": "Ginnie Mae", "B": "United States Treasury Department", "C": "Various investors", "D": "Non-Agency securitization trustees", "E": "Federal Housing Finance Agency (FHFA)", "F": "Federal Reserve"}, "LLM_original_answer": ["To answer the question \"Which organization acts as the conservator for the GSEs?\" based on the provided document, I will follow these steps:\n\n1. **Identify the GSEs**: The document mentions GSEs, which stands for Government-Sponsored Enterprises. These are typically Fannie Mae and Freddie Mac.\n\n2. **Search for the Conservator**: I will look for mentions of a conservator for the GSEs within the document.\n\n3. **Evaluate the Options**: I will compare the identified conservator with the given options to determine the correct answer.\n\n### Step 1: Identify the GSEs\nThe document mentions GSEs in several places, such as:\n- \"The GSEs (and their conservator, the FHFA), Ginnie Mae, the United States Treasury Department, various investors, non-Agency securitization trustees and others also subject us to periodic reviews and audits.\"\n- \"If we fail to comply with our seller/servicer obligations, the GSEs or Ginnie Mae may utilize a variety of remedies against us.\"\n\n### Step 2: Search for the Conservator\nThe document explicitly states:\n- \"The GSEs (and their conservator, the FHFA), Ginnie Mae, the United States Treasury Department, various investors, non-Agency securitization trustees and others also subject us to periodic reviews and audits.\"\n\nThis sentence clearly identifies the conservator for the GSEs as the FHFA (Federal Housing Finance Agency).\n\n### Step 3: Evaluate the Options\nThe options provided are:\n- A: Ginnie Mae\n- B: United States Treasury Department\n- C: Various investors\n- D: Non-Agency securitization trustees\n- E: Federal Housing Finance Agency (FHFA)\n- F: Federal Reserve\n\nBased on the information from the document, the correct answer is:\n- **E: Federal Housing Finance Agency (FHFA)**\n\n### Conclusion\nThe Federal Housing Finance Agency (FHFA) acts as the conservator for the GSEs."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 10, "token_lengths": 32000, "result": 1.0, "question": "What is included in the control arm of the described Phase 1 clinical trial?", "options": {"A": "Patients meeting specific HLA or miHA criteria", "B": "Patients treated with TSC-100 or TSC-101", "C": "Patients who do not meet HLA or miHA genetic criteria", "D": "Patients receiving experimental gene therapy", "E": "Healthy volunteers with no treatment", "F": "Patients undergoing bone marrow biopsy"}, "LLM_original_answer": ["To answer the question \"What is included in the control arm of the described Phase 1 clinical trial?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Clinical Trial Design**:\n   - The document mentions that the clinical studies for TSC-100 and TSC-101 are part of a multi-arm, controlled, Phase 1, \"umbrella\" design clinical trial.\n   - The trial is designed to investigate the safety and efficacy of TSC-100 and TSC-101 in patients with ALL, AML, and MDS who are undergoing HCT following RIC (reduced-intensity conditioning).\n\n2. **Control Arm Description**:\n   - The document explicitly states: \"As shown in the graphic below, we are also including a control arm, comprising patients who do not meet the HLA or miHA genetic criteria and are treated with standard RIC haplo transplantation alone.\"\n   - This means that the control arm includes patients who do not meet the specific genetic criteria required for the treatment arms (i.e., they are not positive for the target antigen, HA-1 or HA-2, and the HLA-A*02:01 allele).\n\n3. **Options Analysis**:\n   - **Option A**: Patients meeting specific HLA or miHA criteria. This is incorrect because the control arm specifically includes patients who do not meet these criteria.\n   - **Option B**: Patients treated with TSC-100 or TSC-101. This is incorrect because the control arm does not receive these treatments.\n   - **Option C**: Patients who do not meet HLA or miHA genetic criteria. This is correct based on the document's description.\n   - **Option D**: Patients receiving experimental gene therapy. This is incorrect because the control arm receives standard RIC haplo transplantation.\n   - **Option E**: Healthy volunteers with no treatment. This is incorrect because the control arm includes patients with hematologic malignancies.\n   - **Option F**: Patients undergoing bone marrow biopsy. This is incorrect because the control arm is defined by the genetic criteria and the type of transplantation they receive, not by a specific procedure like a bone marrow biopsy.\n\nBased on the above analysis, the correct answer is:\n\n**C: Patients who do not meet HLA or miHA genetic criteria**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 32000, "result": 1.0, "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?", "options": {"A": "10 years", "B": "12 years", "C": "14 years", "D": "15 years", "E": "20 years", "F": "25 years"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document and think through it step by step.\n\n1. **Identify the relevant section**: The relevant information is found in the \"Intellectual Property\" section of the document, specifically where it discusses the Hatch-Waxman Act and patent term extensions.\n\n2. **Extract the key information**: The document states:\n   - \"The term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process.\"\n   - \"The length of the patent term extension is calculated based on the length of time it takes for regulatory review.\"\n   - \"A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended.\"\n\n3. **Interpret the information**:\n   - The maximum extension is 5 years.\n   - The total extended term cannot exceed 14 years from the date of product approval.\n\n4. **Match the information to the options**:\n   - The document explicitly states that the total extended term cannot exceed 14 years from the date of product approval.\n   - This matches option C: 14 years.\n\nTherefore, the correct answer is **C: 14 years**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 32000, "result": 1.0, "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?", "options": {"A": "A decrease in trading demand by customers", "B": "Cost-cutting pressures across the industry", "C": "Settlements related to inspections", "D": "Weakness in the macroeconomic environment", "E": "Defaults by clearing or exchange members", "F": "Changes to contract specifications"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the relevant section**: The relevant section is found under \"Legal and Regulatory\" in the \"BUSINESS AND INDUSTRY\" part of the document. Specifically, it mentions the PCAOB announcement in November 2023.\n\n2. **Extract the key information**:\n   - The Holding Foreign Companies Accountable Act (HFCAA) requires the SEC to suspend trading in the U.S. of any company whose accounting firm the PCAOB is unable to inspect or investigate for three consecutive years.\n   - In December 2022, the PCAOB announced that it was able to inspect audit firms for Chinese and Hong Kong issuers, resetting the three-year period in the HFCAA.\n   - In November 2023, the PCAOB announced settlements related to these inspections, which could lead to fewer Chinese companies listing in the U.S.\n\n3. **Evaluate the options**:\n   - **A: A decrease in trading demand by customers** - This is a general economic factor and not directly linked to the PCAOB announcement.\n   - **B: Cost-cutting pressures across the industry** - This is also a general economic factor and not directly linked to the PCAOB announcement.\n   - **C: Settlements related to inspections** - This is directly mentioned in the document as a result of the PCAOB announcement.\n   - **D: Weakness in the macroeconomic environment** - This is a general economic factor and not directly linked to the PCAOB announcement.\n   - **E: Defaults by clearing or exchange members** - This is a risk related to clearing houses and not directly linked to the PCAOB announcement.\n   - **F: Changes to contract specifications** - This is a risk related to contract changes and not directly linked to the PCAOB announcement.\n\n4. **Conclusion**:\n   - The document explicitly states that the PCAOB announced settlements related to inspections in November 2023, which could lead to fewer Chinese companies listing in the U.S.\n\nTherefore, the correct answer is **C: Settlements related to inspections**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 32000, "result": 1.0, "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?", "options": {"A": "January 1, 2020", "B": "July 1, 2020", "C": "January 1, 2021", "D": "July 1, 2023", "E": "January 1, 2023", "F": "July 1, 2022"}, "LLM_original_answer": ["To answer the question \"When did the enforcement of the CCPA, as amended by the CPRA, begin?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section on privacy and cybersecurity regulation, which is likely to have information about the CCPA and CPRA.\n\n2. **Locate specific information about the CCPA and CPRA**: Within the privacy and cybersecurity regulation section, I will look for sentences that mention the CCPA and CPRA and their effective dates.\n\n3. **Extract the effective date**: Once I find the relevant information, I will extract the date when the enforcement of the CCPA, as amended by the CPRA, began.\n\nLet's go through the document:\n\n### Step 1: Identify the relevant section\nThe relevant section is titled \"Privacy and Cybersecurity Regulation.\"\n\n### Step 2: Locate specific information about the CCPA and CPRA\nIn this section, I find the following relevant information:\n- \"The California Consumer Privacy Act of 2018 (the \u201cCCPA\u201d), which became effective in January 2020, affords California residents expanded privacy protections and control over the collection, use and sharing of their personal information.\"\n- \"The CCPA, amended by the California Privacy Rights Act (the \u201cCPRA\u201d), effective as of January 1, 2023, and the implementing regulations require additional investment in compliance programs and potential modifications to business processes.\"\n- \"Enforcement of the CCPA, as amended by the CPRA, began on July 1, 2023.\"\n\n### Step 3: Extract the effective date\nThe document clearly states that the enforcement of the CCPA, as amended by the CPRA, began on July 1, 2023.\n\n### Conclusion\nThe correct answer is:\n**D: July 1, 2023**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 64000, "result": 1.0, "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?", "options": {"A": "Increases ventricular pressure and cardiac remodeling", "B": "Decreases the potential for cardioprotective effects", "C": "Protects against cardiac dysfunction and remodeling", "D": "Leads to an increase in the Fulton index", "E": "Enhances the right ventricular free wall thickness", "F": "Increases the myocardial performance index"}, "LLM_original_answer": ["To answer the question \"What effect does the treatment of RKER-012 have in the mouse PAB model?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the relevant section in the document:**\n   - The relevant section is found under \"Preclinical Data\" for KER-012, specifically the part discussing the mouse PAB model.\n\n2. **Extract the key information:**\n   - The document states: \"Treatment with RKER-012 prevented cardiac dysfunction and remodeling in a mouse model of pulmonary arterial banding, or PAB.\"\n   - It further details: \"In this model, increased ventricular pressure resulted in cardiac dysfunction, as demonstrated by increased end systolic pressure-volume relationship, or ESPVR, and increased myocardial performance index, or MPI. The increased ventricular pressure also results in cardiac remodeling, as evidenced by an increase in the Fulton index, an increase in the right ventricular free wall thickness, or RVFWT, and increased fibrosis in the heart.\"\n   - The treatment with RKER-012 was observed to protect against both the PAB-related cardiac dysfunction and remodeling.\n\n3. **Analyze the options:**\n   - **A: Increases ventricular pressure and cardiac remodeling** - This is incorrect because the document states that RKER-012 prevents these effects.\n   - **B: Decreases the potential for cardioprotective effects** - This is incorrect because the document indicates that RKER-012 has a cardioprotective effect.\n   - **C: Protects against cardiac dysfunction and remodeling** - This is correct and aligns with the information provided.\n   - **D: Leads to an increase in the Fulton index** - This is incorrect because the document states that RKER-012 prevents an increase in the Fulton index.\n   - **E: Enhances the right ventricular free wall thickness** - This is incorrect because the document states that RKER-012 prevents an increase in the right ventricular free wall thickness.\n   - **F: Increases the myocardial performance index** - This is incorrect because the document states that RKER-012 protects against an increase in the myocardial performance index.\n\n4. **Conclusion:**\n   - The correct answer is **C: Protects against cardiac dysfunction and remodeling**.\n\nThis answer is supported by the detailed preclinical data provided in the document, which clearly indicates that treatment with"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 64000, "result": 1.0, "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?", "options": {"A": "Immediate infringement lawsuits upon filing", "B": "Inability to identify competing products", "C": "Delayed launch of new products", "D": "Unawareness of pending applications that may later result in infringement claims", "E": "Mandatory changes to current product designs", "F": "Increased cost of patent filing"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document and then select the most appropriate option.\n\n### Analysis:\nThe document discusses various risks and challenges faced by the company, including those related to intellectual property and regulatory issues. Specifically, the following excerpt is relevant to the question:\n\n> \"Moreover, patent applications are in some cases maintained in secrecy until patents are issued. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents that our services or products allegedly infringe on. If a third party brings any claim against us based on third-party intellectual property rights and/or other proprietary rights, we will be required to spend significant resources to defend and challenge such claim, as well as to invalidate any such rights. Any such claim, if initiated against us, whether or not it is resolved in our favor, could result in significant expense to us, and divert the efforts of our technical and management personnel, which could have a material adverse effect on our business, financial condition and results of operations.\"\n\n### Step-by-Step Reasoning:\n1. **Identify the Key Issue**: The document mentions that patent applications can be maintained in secrecy until they are issued.\n2. **Understand the Consequence**: This secrecy can lead to the company being unaware of pending applications that may later result in issued patents.\n3. **Potential Impact**: If the company is unaware of these pending applications, it may inadvertently infringe on patents that are later issued.\n4. **Legal and Financial Consequences**: Infringement claims can result in significant legal expenses and divert the efforts of technical and management personnel.\n5. **Match to Options**: The option that best matches this potential issue is:\n   - **D: Unawareness of pending applications that may later result in infringement claims**\n\n### Conclusion:\nThe most appropriate answer to the question \"What potential issue may arise from patent applications being maintained in secrecy until patents are issued?\" is:\n\n**D: Unawareness of pending applications that may later result in infringement claims**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 64000, "result": 1.0, "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?", "options": {"A": "Increased demand for electricity", "B": "Rising fuel costs", "C": "Improved operational efficiency", "D": "Delayed or unrecovered operating costs", "E": "Expansion into new markets", "F": "Strong economic growth"}, "LLM_original_answer": ["To answer the question, we need to identify which factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants. Let's analyze the provided options in the context of the document:\n\n1. **Increased demand for electricity (Option A)**: The document does not suggest that increased demand for electricity would lead to higher bad debt expenses or reserves. Increased demand typically leads to higher revenues, which is not directly linked to bad debt.\n\n2. **Rising fuel costs (Option B)**: While rising fuel costs can impact the financial performance of Duke Energy, the document indicates that these costs are generally recoverable through regulatory mechanisms. Therefore, rising fuel costs are not likely to lead to increased bad debt expenses or reserves.\n\n3. **Improved operational efficiency (Option C)**: Improved operational efficiency is generally a positive factor that reduces costs and improves financial performance. It does not contribute to bad debt expenses or reserves.\n\n4. **Delayed or unrecovered operating costs (Option D)**: The document mentions that \"a continuation of adverse economic conditions including economic downturn or high commodity prices could also negatively impact the financial stability of certain of our customers and result in their inability to pay for electric and natural gas services.\" This directly suggests that delayed or unrecovered operating costs could lead to increased bad debt expense and higher allowance for doubtful account reserves.\n\n5. **Expansion into new markets (Option E)**: The document does not provide specific information linking expansion into new markets to increased bad debt expenses or reserves. Expansion could bring new risks, but it is not explicitly mentioned as a factor affecting bad debt.\n\n6. **Strong economic growth (Option F)**: Strong economic growth is generally positive and would likely improve the financial stability of customers, reducing bad debt expenses and reserves. The document does not suggest that strong economic growth would lead to increased bad debt.\n\nGiven the analysis, the factor that could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants is:\n\n**D: Delayed or unrecovered operating costs**\n\nThis is supported by the document's statement that adverse economic conditions, including high commodity prices, can negatively impact the financial stability of customers, leading to their inability to pay for services."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 64000, "result": 1.0, "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?", "options": {"A": "It will be allowed to increase its capital reserves.", "B": "It will receive tax incentives to improve practices.", "C": "Enforcement actions may be taken against it.", "D": "It will be automatically disbanded.", "E": "It will be required to decrease its interest rates.", "F": "It will gain permission for more acquisitions."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document and consider the options given.\n\n### Step-by-Step Analysis:\n\n1. **Understanding the Context:**\n   - The document discusses various regulatory and operational risks that banking organizations face.\n   - It specifically mentions the Massachusetts Commissioner of Banks and the FDIC, which have the authority to take enforcement actions against banks that do not operate in accordance with regulations.\n\n2. **Relevant Sections:**\n   - **Regulatory Enforcement Authority:**\n     - \"Any Massachusetts-chartered bank that does not operate in accordance with the regulations, policies and directives of the Massachusetts Commissioner of Banks may be subject to sanctions for non-compliance, including seizure of the property and business of the bank, imposition of a conservatorship or revocation of its charter.\"\n   - **Compensation Practices:**\n     - \"The federal banking regulators have provided guidance designed to ensure that incentive compensation arrangements at banking organizations take into account risk and are consistent with safe and sound practices.\"\n     - \"The guidance also provides that enforcement actions may be taken against a banking organization if its incentive compensation arrangements or related risk management, control or governance processes pose a risk to the organization\u2019s safety and financial weakness.\"\n\n3. **Interpreting the Information:**\n   - If a banking organization's incentive compensation arrangements pose a risk, it is likely to be considered a violation of safe and sound practices.\n   - The document explicitly states that enforcement actions may be taken against a bank if its incentive compensation arrangements pose a risk to the organization\u2019s safety and financial weakness.\n\n4. **Evaluating the Options:**\n   - **A: It will be allowed to increase its capital reserves.**\n     - This is not mentioned as a consequence of risky incentive compensation arrangements.\n   - **B: It will receive tax incentives to improve practices.**\n     - The document does not mention tax incentives as a response to risky practices.\n   - **C: Enforcement actions may be taken against it.**\n     - This is directly mentioned in the document as a potential consequence of risky incentive compensation arrangements.\n   - **D: It will be automatically disbanded.**\n     - The document does not mention automatic disbandment as a consequence.\n   - **E: It will be required to decrease its interest rates.**\n     - This is not mentioned as a consequence of risky incentive compensation arrangements.\n   - **F: It will gain permission for more acquisitions.**\n     - The document does not mention gaining permission for more acquisitions as a consequence.\n\n###"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 64000, "result": 1.0, "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?", "options": {"A": "International partnerships", "B": "Location of manufacturing facilities", "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement", "D": "Advertising and social media presence", "E": "Colors and branding of the packaging", "F": "Celebrity endorsements"}, "LLM_original_answer": ["The correct answer to the question \"What are expected key competitive factors affecting the success of the company's drug candidates if approved?\" is:\n\n**C: Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement**\n\n### Chain of Thoughts:\n1. **Review the Document**: The document provides a detailed overview of the company's drug development process, regulatory requirements, and competitive landscape.\n2. **Identify Relevant Section**: The section that directly addresses the competitive factors is found in the \"Competition\" part of the document.\n3. **Extract Key Information**: The document states, \"The key competitive factors affecting the success of all our programs, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement.\"\n4. **Match with Options**: This statement directly matches option C, which lists the same factors: efficacy, safety, convenience, price, level of generic competition, and availability of reimbursement.\n5. **Eliminate Other Options**:\n   - **A: International partnerships** - While the document mentions collaborations with Gilead, Sanofi, and Pfizer, these are not listed as key competitive factors.\n   - **B: Location of manufacturing facilities** - The document discusses manufacturing but does not list it as a key competitive factor.\n   - **D: Advertising and social media presence** - The document does not mention advertising or social media presence as key competitive factors.\n   - **E: Colors and branding of the packaging** - The document does not mention packaging aesthetics as a competitive factor.\n   - **F: Celebrity endorsements** - The document does not mention celebrity endorsements as a competitive factor.\n\n### Conclusion:\nOption C is the correct answer as it aligns with the information provided in the document."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 64000, "result": 1.0, "question": "Which organization acts as the conservator for the GSEs?", "options": {"A": "Ginnie Mae", "B": "United States Treasury Department", "C": "Various investors", "D": "Non-Agency securitization trustees", "E": "Federal Housing Finance Agency (FHFA)", "F": "Federal Reserve"}, "LLM_original_answer": ["To answer the question \"Which organization acts as the conservator for the GSEs?\" based on the provided document, I will follow these steps:\n\n1. **Identify the GSEs**: The document mentions GSEs, which stands for Government-Sponsored Enterprises. These are typically Fannie Mae and Freddie Mac.\n\n2. **Search for the Conservator**: I will look for mentions of a conservator or any organization that is described as overseeing or managing the GSEs.\n\n3. **Evaluate the Options**: I will compare the identified conservator with the given options to determine the correct answer.\n\n### Step 1: Identify the GSEs\nThe document mentions GSEs in several places, such as:\n- \"The GSEs (and their conservator, the FHFA), Ginnie Mae, the United States Treasury Department, various investors, non-Agency securitization trustees and others also subject us to periodic reviews and audits.\"\n- \"Our ability to generate revenues through mortgage loan sales to institutional investors depends to a significant degree on programs administered by the GSEs, Ginnie Mae, and others that facilitate the issuance of MBS in the secondary market.\"\n\nFrom these mentions, it is clear that the GSEs refer to Fannie Mae and Freddie Mac.\n\n### Step 2: Search for the Conservator\nThe document explicitly states:\n- \"The GSEs (and their conservator, the FHFA), Ginnie Mae, the United States Treasury Department, various investors, non-Agency securitization trustees and others also subject us to periodic reviews and audits.\"\n\nThis sentence directly identifies the conservator of the GSEs as the FHFA (Federal Housing Finance Agency).\n\n### Step 3: Evaluate the Options\nThe options provided are:\n- A: Ginnie Mae\n- B: United States Treasury Department\n- C: Various investors\n- D: Non-Agency securitization trustees\n- E: Federal Housing Finance Agency (FHFA)\n- F: Federal Reserve\n\nBased on the information from the document, the correct answer is **E: Federal Housing Finance Agency (FHFA)**.\n\n### Final Answer\nThe organization that acts as the conservator for the GSEs is **E: Federal Housing Finance Agency (FHFA)**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 10, "token_lengths": 64000, "result": 1.0, "question": "What is included in the control arm of the described Phase 1 clinical trial?", "options": {"A": "Patients meeting specific HLA or miHA criteria", "B": "Patients treated with TSC-100 or TSC-101", "C": "Patients who do not meet HLA or miHA genetic criteria", "D": "Patients receiving experimental gene therapy", "E": "Healthy volunteers with no treatment", "F": "Patients undergoing bone marrow biopsy"}, "LLM_original_answer": ["To answer the question \"What is included in the control arm of the described Phase 1 clinical trial?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Clinical Trial Design**:\n   - The document mentions that the clinical studies for TSC-100 and TSC-101 are part of a multi-arm, controlled, Phase 1, \"umbrella\" design clinical trial.\n   - The trial is designed to investigate the safety and efficacy of TSC-100 and TSC-101 in patients with ALL, AML, and MDS who are undergoing HCT following RIC (reduced-intensity conditioning).\n\n2. **Control Arm Description**:\n   - The document specifically states: \"We are also including a control arm, comprising patients who do not meet the HLA or miHA genetic criteria and are treated with standard RIC haplo transplantation alone.\"\n   - This means that the control arm consists of patients who do not meet the specific genetic criteria required for treatment with TSC-100 or TSC-101.\n\n3. **Patient Criteria**:\n   - For the treatment arms, patients must be positive for the target antigen (HA-1 or HA-2) and the HLA-A*02:01 allele.\n   - The control arm, therefore, includes patients who do not meet these criteria.\n\n4. **Standard of Care**:\n   - The control arm patients receive the standard of care, which is HCT alone, without the additional TCR-T therapy (TSC-100 or TSC-101).\n\nGiven this information, the correct answer is:\n\n**C: Patients who do not meet HLA or miHA genetic criteria**\n\nThis option accurately reflects the description of the control arm in the document, which includes patients who do not meet the specific HLA or miHA genetic criteria and are treated with standard RIC haplo transplantation alone."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 64000, "result": 1.0, "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?", "options": {"A": "10 years", "B": "12 years", "C": "14 years", "D": "15 years", "E": "20 years", "F": "25 years"}, "LLM_original_answer": ["To answer the question, I will refer to the relevant information provided in the document:\n\n1. **Identify the relevant section**: The document mentions the Hatch-Waxman Act in the context of patent term extensions. The specific section is found under \"Intellectual Property\" and \"U.S. Non-Patent Exclusivity.\"\n\n2. **Extract the key information**:\n   - The document states: \"In the U.S., the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process.\"\n   - It further specifies: \"The length of the patent term extension is calculated based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended.\"\n\n3. **Interpret the information**:\n   - The maximum extension under the Hatch-Waxman Act is 5 years.\n   - However, the total duration of the patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval.\n\n4. **Select the correct answer**:\n   - The correct answer is **C: 14 years**.\n\nTherefore, under the Hatch-Waxman Act, the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval is **14 years**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 64000, "result": 1.0, "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?", "options": {"A": "A decrease in trading demand by customers", "B": "Cost-cutting pressures across the industry", "C": "Settlements related to inspections", "D": "Weakness in the macroeconomic environment", "E": "Defaults by clearing or exchange members", "F": "Changes to contract specifications"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n### Step 1: Identify the Context\nThe question asks about the potential reduction in the listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023.\n\n### Step 2: Locate Relevant Information\nThe relevant information is found in the \"Legal and Regulatory\" section of the document:\n\n> \"In November 2023, the PCAOB announced settlements related to these inspections, which could lead to fewer Chinese companies listing in the U.S.\"\n\n### Step 3: Analyze the Information\nThe document states that the PCAOB (Public Company Accounting Oversight Board) announced settlements related to inspections of Chinese and Hong Kong audit firms. These settlements could lead to fewer Chinese companies listing in the U.S. This suggests that the settlements are a regulatory action that may impact the listing decisions of Chinese companies.\n\n### Step 4: Match the Information to the Options\nThe options provided are:\n- A: A decrease in trading demand by customers\n- B: Cost-cutting pressures across the industry\n- C: Settlements related to inspections\n- D: Weakness in the macroeconomic environment\n- E: Defaults by clearing or exchange members\n- F: Changes to contract specifications\n\nThe information from the document directly matches option C: \"Settlements related to inspections.\"\n\n### Step 5: Confirm the Answer\nThe document explicitly states that the PCAOB's settlements related to inspections could lead to fewer Chinese companies listing in the U.S. This is the most direct and relevant answer to the question.\n\n### Final Answer\nThe correct answer is **C: Settlements related to inspections**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 64000, "result": 1.0, "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?", "options": {"A": "January 1, 2020", "B": "July 1, 2020", "C": "January 1, 2021", "D": "July 1, 2023", "E": "January 1, 2023", "F": "July 1, 2022"}, "LLM_original_answer": ["To answer the question \"When did the enforcement of the CCPA, as amended by the CPRA, begin?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that discusses privacy and cybersecurity regulations, including the CCPA and CPRA.\n\n2. **Locate the specific information about the CCPA and CPRA**: The relevant paragraph states:\n   > \"The California Consumer Privacy Act of 2018 (the \u201cCCPA\u201d), which became effective in January 2020, affords California residents expanded privacy protections and control over the collection, use and sharing of their personal information. The CCPA, amended by the California Privacy Rights Act (the \u201cCPRA\u201d), effective as of January 1, 2023, and the implementing regulations require additional investment in compliance programs and potential modifications to business processes. Enforcement of the CCPA, as amended by the CPRA, began on July 1, 2023.\"\n\n3. **Extract the key dates**:\n   - The CCPA became effective in January 2020.\n   - The CPRA became effective as of January 1, 2023.\n   - Enforcement of the CCPA, as amended by the CPRA, began on July 1, 2023.\n\n4. **Match the extracted date to the given options**:\n   - Option A: January 1, 2020\n   - Option B: July 1, 2020\n   - Option C: January 1, 2021\n   - Option D: July 1, 2023\n   - Option E: January 1, 2023\n   - Option F: July 1, 2022\n\n5. **Select the correct option**: The correct date for the enforcement of the CCPA, as amended by the CPRA, is July 1, 2023.\n\nTherefore, the correct answer is **Option D: July 1, 2023**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 96000, "result": 1.0, "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?", "options": {"A": "Increases ventricular pressure and cardiac remodeling", "B": "Decreases the potential for cardioprotective effects", "C": "Protects against cardiac dysfunction and remodeling", "D": "Leads to an increase in the Fulton index", "E": "Enhances the right ventricular free wall thickness", "F": "Increases the myocardial performance index"}, "LLM_original_answer": ["To answer the question \"What effect does the treatment of RKER-012 have in the mouse PAB model?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that specifically discusses the effects of RKER-012 in a mouse model of pulmonary arterial banding (PAB).\n\n2. **Extract the key information**: The relevant information is found in the section titled \"Treatment with RKER-012 prevented cardiac dysfunction and remodeling in a mouse PAB model.\"\n\n3. **Summarize the findings**:\n   - **Cardiac Dysfunction**: The document states that in the mouse PAB model, increased ventricular pressure resulted in cardiac dysfunction, as demonstrated by increased end systolic pressure-volume relationship (ESPVR) and increased myocardial performance index (MPI).\n   - **Cardiac Remodeling**: The increased ventricular pressure also led to cardiac remodeling, evidenced by an increase in the Fulton index, an increase in the right ventricular free wall thickness (RVFWT), and increased fibrosis in the heart.\n   - **Effect of RKER-012**: Treatment with twice weekly subcutaneous 10 mg/kg dosing of RKER-012 was observed to protect against both the PAB-related cardiac dysfunction and remodeling.\n\n4. **Match the findings to the given options**:\n   - **Option A**: Increases ventricular pressure and cardiac remodeling. This is incorrect because the treatment with RKER-012 protected against these effects.\n   - **Option B**: Decreases the potential for cardioprotective effects. This is incorrect because the treatment with RKER-012 had a cardioprotective effect.\n   - **Option C**: Protects against cardiac dysfunction and remodeling. This matches the findings from the document.\n   - **Option D**: Leads to an increase in the Fulton index. This is incorrect because the treatment with RKER-012 prevented an increase in the Fulton index.\n   - **Option E**: Enhances the right ventricular free wall thickness. This is incorrect because the treatment with RKER-012 prevented an increase in the right ventricular free wall thickness.\n   - **Option F**: Increases the myocardial performance index. This is incorrect because the treatment with RKER-012 protected against an increase in the myocardial performance index.\n\n5. **Select the correct answer**:\n   - The correct answer is **Option"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 96000, "result": 1.0, "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?", "options": {"A": "Immediate infringement lawsuits upon filing", "B": "Inability to identify competing products", "C": "Delayed launch of new products", "D": "Unawareness of pending applications that may later result in infringement claims", "E": "Mandatory changes to current product designs", "F": "Increased cost of patent filing"}, "LLM_original_answer": ["To answer the question, let's analyze the relevant information from the provided document:\n\n1. **Patent Applications and Secrecy**:\n   - The document mentions: \"Moreover, patent applications are in some cases maintained in secrecy until patents are issued. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents that our services or products allegedly infringe on.\"\n\n2. **Potential Issues**:\n   - The key issue highlighted is the **unawareness of pending applications** that may later result in issued patents. This can lead to **infringement claims** if the company's services or products are found to infringe on these patents after they are issued.\n\n3. **Options Analysis**:\n   - **A: Immediate infringement lawsuits upon filing** - The document does not suggest that lawsuits are immediate upon filing, but rather that they can occur after the patent is issued.\n   - **B: Inability to identify competing products** - While this could be a concern, the document does not specifically mention this as a primary issue.\n   - **C: Delayed launch of new products** - The document does not indicate that the secrecy of patent applications directly causes delays in product launches.\n   - **D: Unawareness of pending applications that may later result in infringement claims** - This aligns with the document's statement about the potential for unknown pending applications to lead to infringement claims.\n   - **E: Mandatory changes to current product designs** - The document does not mention mandatory changes to product designs as a direct result of patent application secrecy.\n   - **F: Increased cost of patent filing** - The document does not discuss increased costs of filing patents as a result of their secrecy.\n\nGiven the information provided, the most accurate answer is:\n\n**D: Unawareness of pending applications that may later result in infringement claims**\n\nThis option directly addresses the issue of patent applications being maintained in secrecy until patents are issued, which can lead to the company being unaware of potential infringement risks."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 96000, "result": 1.0, "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?", "options": {"A": "Increased demand for electricity", "B": "Rising fuel costs", "C": "Improved operational efficiency", "D": "Delayed or unrecovered operating costs", "E": "Expansion into new markets", "F": "Strong economic growth"}, "LLM_original_answer": ["To answer the question, we need to identify which factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants. Let's analyze the options in the context of the provided document:\n\nA: Increased demand for electricity - This would generally lead to higher revenues and not necessarily to increased bad debt expense or higher allowance for doubtful account reserves.\n\nB: Rising fuel costs - The document mentions that changes in fuel costs from year to year have no material impact on operating results unless a commission finds a portion of such costs to have been imprudent. However, delays in the recovery of fuel costs can adversely impact the timing of cash flows, which could indirectly affect the financial stability of customers and potentially lead to higher bad debt expense.\n\nC: Improved operational efficiency - This would typically reduce costs and improve financial performance, not leading to increased bad debt expense.\n\nD: Delayed or unrecovered operating costs - The document explicitly states that delays in the recovery of operating costs, such as fuel costs, can adversely impact the timing of cash flows. This could lead to financial stress on customers, making it more likely that they will default on payments, thus increasing bad debt expense and higher allowance for doubtful account reserves.\n\nE: Expansion into new markets - While this could introduce new risks, the document does not provide specific information linking market expansion to increased bad debt expense.\n\nF: Strong economic growth - This would generally improve the financial stability of customers, reducing the likelihood of bad debt expense.\n\nGiven the information in the document, the most relevant factor is:\n\n**D: Delayed or unrecovered operating costs**\n\nThis is supported by the following excerpt from the document:\n\"The Duke Energy Registrants may not recover costs incurred to begin construction on projects that are canceled. Duke Energy\u2019s long-term strategy requires the construction of new projects, either wholly owned or partially owned, which involve a number of risks, including construction delays, delays in or failure to receive required regulatory approvals and/or sitting or environmental permits, nonperformance by equipment and other third-party suppliers, and increases in equipment and labor costs. To limit the risks of these construction projects, the Duke Energy Registrants enter into equipment purchase orders and construction contracts and incur engineering and design service costs in advance of receiving necessary regulatory approvals and/or siting or environmental permits. If any of these projects are canceled for any reason, including failure to receive necessary regulatory approvals and/or sitting or environmental permits, significant cancellation penalties under the equipment purchase orders and construction contracts could occur.\"\n\nAdditionally, the document mentions:\n\"Delays in the recovery"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 96000, "result": 1.0, "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?", "options": {"A": "It will be allowed to increase its capital reserves.", "B": "It will receive tax incentives to improve practices.", "C": "Enforcement actions may be taken against it.", "D": "It will be automatically disbanded.", "E": "It will be required to decrease its interest rates.", "F": "It will gain permission for more acquisitions."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document and apply it to the context of the question.\n\n### Step-by-Step Analysis:\n\n1. **Understanding the Question:**\n   - The question asks what might happen to a banking organization if its incentive compensation arrangements pose a risk.\n   - The options provided are:\n     - A: It will be allowed to increase its capital reserves.\n     - B: It will receive tax incentives to improve practices.\n     - C: Enforcement actions may be taken against it.\n     - D: It will be automatically disbanded.\n     - E: It will be required to decrease its interest rates.\n     - F: It will gain permission for more acquisitions.\n\n2. **Relevant Information from the Document:**\n   - The document discusses the regulatory framework and oversight applicable to banking organizations.\n   - It mentions that the federal banking regulators have provided guidance to ensure that incentive compensation arrangements at banking organizations take into account risk and are consistent with safe and sound practices.\n   - The guidance sets forth three key principles:\n     - (i) The arrangements should provide employees with incentives that appropriately balance risk and financial results.\n     - (ii) The arrangements should be compatible with effective controls and risk management.\n     - (iii) The arrangements should be supported by strong corporate governance.\n   - The document also states that if a banking organization's incentive compensation arrangements or related risk management, control, or governance processes pose a risk to the organization's safety and financial weakness, enforcement actions may be taken against it.\n\n3. **Evaluating the Options:**\n   - **Option A: It will be allowed to increase its capital reserves.**\n     - The document does not suggest that a bank with risky incentive compensation arrangements would be allowed to increase its capital reserves. Instead, it emphasizes the need for safe and sound practices.\n   - **Option B: It will receive tax incentives to improve practices.**\n     - There is no mention of tax incentives being provided to banks with risky incentive compensation arrangements. The focus is on regulatory compliance and enforcement.\n   - **Option C: Enforcement actions may be taken against it.**\n     - This is directly supported by the document, which states that enforcement actions may be taken if the incentive compensation arrangements pose a risk to the organization's safety and financial weakness.\n   - **Option D: It will be automatically disbanded.**\n     - The document does not mention automatic disbandment. It discusses the possibility of enforcement actions, which are more specific and less drastic than disband"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 96000, "result": 1.0, "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?", "options": {"A": "International partnerships", "B": "Location of manufacturing facilities", "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement", "D": "Advertising and social media presence", "E": "Colors and branding of the packaging", "F": "Celebrity endorsements"}, "LLM_original_answer": ["The correct answer to the question \"What are expected key competitive factors affecting the success of the company's drug candidates if approved?\" is:\n\n**C: Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement**\n\n### Chain of Thoughts:\n1. **Review the Document**: The document provides detailed information about the company's drug candidates, their mechanisms of action, and the competitive landscape in the biopharmaceutical industry.\n2. **Identify Relevant Section**: The section titled \"Competition\" in the document is particularly relevant. It states: \"The key competitive factors affecting the success of all our programs, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement.\"\n3. **Match to Options**: The statement in the document directly matches option C, which lists the same factors: efficacy, safety, convenience, price, level of generic competition, and availability of reimbursement.\n4. **Eliminate Other Options**:\n   - **A: International partnerships**: While the company has international collaborations, the document does not list this as a key competitive factor.\n   - **B: Location of manufacturing facilities**: The document does not mention this as a competitive factor.\n   - **D: Advertising and social media presence**: The document does not emphasize this as a key factor.\n   - **E: Colors and branding of the packaging**: This is not mentioned as a competitive factor in the document.\n   - **F: Celebrity endorsements**: The document does not mention this as a competitive factor.\n\n5. **Conclusion**: Based on the direct statement in the document, the key competitive factors affecting the success of the company's drug candidates if approved are their efficacy, safety, convenience, price, level of generic competition, and availability of reimbursement. Therefore, the correct answer is C."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 96000, "result": 1.0, "question": "Which organization acts as the conservator for the GSEs?", "options": {"A": "Ginnie Mae", "B": "United States Treasury Department", "C": "Various investors", "D": "Non-Agency securitization trustees", "E": "Federal Housing Finance Agency (FHFA)", "F": "Federal Reserve"}, "LLM_original_answer": ["To answer the question \"Which organization acts as the conservator for the GSEs?\" based on the provided document, I will follow these steps:\n\n1. **Identify the GSEs**: The document mentions the GSEs (Government-Sponsored Enterprises) as entities that guarantee mortgage securitizations. The GSEs specifically referred to are Fannie Mae and Freddie Mac.\n\n2. **Search for the Conservator**: The document should contain information about the organization that acts as the conservator for these GSEs. I will look for mentions of \"conservator\" or \"conservatorship\" in relation to the GSEs.\n\n3. **Find the Relevant Information**: Scanning the document, I find the following relevant information:\n   - \"The GSEs (and their conservator, the FHFA), Ginnie Mae, the United States Treasury Department, various investors, non-Agency securitization trustees and others also subject us to periodic reviews and audits.\"\n   - \"In 2022, the FHFA and Ginnie Mae announced updated minimum financial eligibility requirements for GSE seller/servicers and Ginnie Mae issuers.\"\n\n4. **Determine the Conservator**: From the above information, it is clear that the Federal Housing Finance Agency (FHFA) is mentioned as the conservator for the GSEs.\n\n5. **Verify the Options**: The options provided are:\n   - A: Ginnie Mae\n   - B: United States Treasury Department\n   - C: Various investors\n   - D: Non-Agency securitization trustees\n   - E: Federal Housing Finance Agency (FHFA)\n   - F: Federal Reserve\n\nBased on the information found in the document, the correct answer is:\n\n**E: Federal Housing Finance Agency (FHFA)**\n\nThe FHFA is explicitly mentioned as the conservator for the GSEs, which aligns with the provided options."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 10, "token_lengths": 96000, "result": 1.0, "question": "What is included in the control arm of the described Phase 1 clinical trial?", "options": {"A": "Patients meeting specific HLA or miHA criteria", "B": "Patients treated with TSC-100 or TSC-101", "C": "Patients who do not meet HLA or miHA genetic criteria", "D": "Patients receiving experimental gene therapy", "E": "Healthy volunteers with no treatment", "F": "Patients undergoing bone marrow biopsy"}, "LLM_original_answer": ["To answer the question \"What is included in the control arm of the described Phase 1 clinical trial?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the Clinical Trial Context**:\n   - The document describes a multi-arm, controlled, Phase 1 \"umbrella\" design clinical trial for TSC-100 and TSC-101 in patients with ALL, AML, and MDS who are undergoing HCT following RIC.\n\n2. **Locate the Description of the Control Arm**:\n   - The document states: \"We are also including a control arm, comprising patients who do not meet the HLA or miHA genetic criteria and are treated with standard RIC haplo transplantation alone.\"\n\n3. **Analyze the Control Arm Description**:\n   - The control arm includes patients who do not meet the specific HLA (Human Leukocyte Antigen) or miHA (minor histocompatibility antigen) genetic criteria.\n   - These patients are treated with standard RIC (reduced-intensity conditioning) haplo (haploidentical) transplantation alone.\n\n4. **Match the Description to the Options**:\n   - **Option A**: Patients meeting specific HLA or miHA criteria - This is not correct because the control arm includes patients who do not meet these criteria.\n   - **Option B**: Patients treated with TSC-100 or TSC-101 - This is not correct because the control arm does not include patients treated with these TCR-T candidates.\n   - **Option C**: Patients who do not meet HLA or miHA genetic criteria - This matches the description in the document.\n   - **Option D**: Patients receiving experimental gene therapy - This is not correct because the control arm is treated with standard RIC haplo transplantation.\n   - **Option E**: Healthy volunteers with no treatment - This is not correct because the control arm includes patients with cancer.\n   - **Option F**: Patients undergoing bone marrow biopsy - This is not specifically mentioned as part of the control arm treatment.\n\nBased on the analysis, the correct answer is:\n\n**C: Patients who do not meet HLA or miHA genetic criteria**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 96000, "result": 1.0, "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?", "options": {"A": "10 years", "B": "12 years", "C": "14 years", "D": "15 years", "E": "20 years", "F": "25 years"}, "LLM_original_answer": ["To answer the question regarding the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval under the Hatch-Waxman Act, I will refer to the relevant information provided in the document.\n\nThe document states:\n\"The FDA also assesses whether the facility in which the product is manufactured, processed, packaged or held meets standards designed to assure the product\u2019s continued safety, quality and purity. In addition, under the Pediatric Research Equity Act of 2003, or PREA, as amended, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.\"\n\nHowever, the specific information about the patent term extension under the Hatch-Waxman Act is found in the following section:\n\"In the U.S., the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process. The length of the patent term extension is calculated based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple products, it can only be extended based on one product.\"\n\nFrom this information, we can conclude that the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval under the Hatch-Waxman Act is 14 years.\n\nTherefore, the correct answer is:\nC: 14 years"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 96000, "result": 1.0, "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?", "options": {"A": "A decrease in trading demand by customers", "B": "Cost-cutting pressures across the industry", "C": "Settlements related to inspections", "D": "Weakness in the macroeconomic environment", "E": "Defaults by clearing or exchange members", "F": "Changes to contract specifications"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the relevant information that could lead to a reduction in the listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Section:**\n   - The relevant section is found in the \"Legal and Regulatory\" part of the document, specifically under the \"Regulatory Developments or Court Rulings\" subsection.\n\n2. **Extract Key Information:**\n   - The document states: \"In November 2023, the PCAOB announced settlements related to these inspections, which could lead to fewer Chinese companies listing in the U.S.\"\n\n3. **Understand the Context:**\n   - The PCAOB (Public Company Accounting Oversight Board) is responsible for inspecting and investigating audit firms to ensure the quality and integrity of financial statements.\n   - The settlements mentioned are related to inspections of audit firms for Chinese and Hong Kong issuers.\n   - These inspections were previously not possible, leading to a three-year period under the HFCAA (Holding Foreign Companies Accountable Act) where the SEC could suspend trading of companies whose audit firms the PCAOB could not inspect.\n\n4. **Determine the Impact:**\n   - The settlements indicate that the PCAOB has now been able to inspect these audit firms.\n   - This could lead to fewer Chinese companies listing in the U.S. because the inspections might reveal issues that could result in delisting or other regulatory actions.\n\n### Conclusion:\nThe correct answer is **C: Settlements related to inspections**.\n\n### Chain of Thoughts:\n- The PCAOB's ability to inspect audit firms for Chinese and Hong Kong issuers was a significant requirement under the HFCAA.\n- The announcement of settlements in November 2023 suggests that these inspections have been completed.\n- The completion of inspections could lead to the identification of issues that might result in fewer Chinese companies being listed in the U.S., as the document explicitly states.\n- Therefore, the settlements related to inspections are the most direct and relevant factor that could potentially lead to a reduction in the listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 96000, "result": 1.0, "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?", "options": {"A": "January 1, 2020", "B": "July 1, 2020", "C": "January 1, 2021", "D": "July 1, 2023", "E": "January 1, 2023", "F": "July 1, 2022"}, "LLM_original_answer": ["To answer the question \"When did the enforcement of the CCPA, as amended by the CPRA, begin?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss the CCPA and CPRA.\n2. **Extract Specific Dates**: Find the specific dates mentioned for the enforcement of the CCPA as amended by the CPRA.\n3. **Confirm the Answer**: Ensure the extracted date matches one of the given options.\n\n### Step 1: Identify Relevant Information\nThe relevant section in the document is found under \"Privacy and Cybersecurity Regulation\":\n\n> \"The California Consumer Privacy Act of 2018 (the \u201cCCPA\u201d), which became effective in January 2020, affords California residents expanded privacy protections and control over the collection, use and sharing of their personal information. The CCPA requires companies to make certain disclosures to California consumers regarding personal information, among other privacy protective measures. The CCPA, amended by the California Privacy Rights Act (the \u201cCPRA\u201d), effective as of January 1, 2023, and the implementing regulations require additional investment in compliance programs and potential modifications to business processes. Further, the CCPA, as amended, creates the California Privacy Protection Agency to enforce the statute as well as its regulations, and it imposes new requirements relating to additional consumer rights, data minimization, and other obligations. The California legislature did not extend certain exemptions under the amended CCPA, specifically information collected in employment or business-to-business contexts, and such information therefore is now covered by the CCPA. Enforcement of the CCPA, as amended by the CPRA, began on July 1, 2023.\"\n\n### Step 2: Extract Specific Dates\n- The CCPA became effective in January 2020.\n- The CPRA amendments to the CCPA became effective as of January 1, 2023.\n- Enforcement of the CCPA, as amended by the CPRA, began on July 1, 2023.\n\n### Step 3: Confirm the Answer\nThe date for the enforcement of the CCPA, as amended by the CPRA, is July 1, 2023. This matches option D in the given choices.\n\n### Final Answer\nThe enforcement of the CCPA, as amended by the CPRA, began on **July 1, 2023**. Therefore, the correct answer is **D:"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 128000, "result": 1.0, "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?", "options": {"A": "Increases ventricular pressure and cardiac remodeling", "B": "Decreases the potential for cardioprotective effects", "C": "Protects against cardiac dysfunction and remodeling", "D": "Leads to an increase in the Fulton index", "E": "Enhances the right ventricular free wall thickness", "F": "Increases the myocardial performance index"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 128000, "result": 0.0, "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?", "options": {"A": "Immediate infringement lawsuits upon filing", "B": "Inability to identify competing products", "C": "Delayed launch of new products", "D": "Unawareness of pending applications that may later result in infringement claims", "E": "Mandatory changes to current product designs", "F": "Increased cost of patent filing"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 128000, "result": 1.0, "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?", "options": {"A": "Increased demand for electricity", "B": "Rising fuel costs", "C": "Improved operational efficiency", "D": "Delayed or unrecovered operating costs", "E": "Expansion into new markets", "F": "Strong economic growth"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 10, "token_lengths": 128000, "result": 1.0, "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?", "options": {"A": "It will be allowed to increase its capital reserves.", "B": "It will receive tax incentives to improve practices.", "C": "Enforcement actions may be taken against it.", "D": "It will be automatically disbanded.", "E": "It will be required to decrease its interest rates.", "F": "It will gain permission for more acquisitions."}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 128000, "result": 1.0, "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?", "options": {"A": "International partnerships", "B": "Location of manufacturing facilities", "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement", "D": "Advertising and social media presence", "E": "Colors and branding of the packaging", "F": "Celebrity endorsements"}, "LLM_original_answer": ["The correct answer to the question \"What are expected key competitive factors affecting the success of the company's drug candidates if approved?\" is:\n\n**C: Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement**\n\n### Chain of Thoughts:\n1. **Context of the Question**: The question asks about the key competitive factors that would affect the success of the company's drug candidates if they are approved. This implies we need to look for factors that would influence the market performance and acceptance of these drugs.\n\n2. **Relevant Information in the Document**:\n   - The document discusses the company's drug candidates and the challenges they face in the market.\n   - It mentions that the company's drug candidates will compete with existing therapies and new therapies in development.\n   - The document also highlights the importance of various factors in the commercial success of drug candidates.\n\n3. **Key Competitive Factors**:\n   - **Efficacy**: The document emphasizes the importance of demonstrating that the drug candidates are effective in treating the intended conditions.\n   - **Safety**: It mentions the need to ensure that the drug candidates have a manageable and predictable safety profile.\n   - **Convenience**: The document discusses the convenience of oral administration and the potential for rapid and sustained BTK degradation.\n   - **Price**: The document notes that the company expects to price its drug candidates at a significant premium over competitive generic products.\n   - **Level of Generic Competition**: It mentions the presence of generic products and the potential for more to become available, which could affect the market.\n   - **Availability of Reimbursement**: The document discusses the importance of obtaining and maintaining third-party coverage and adequate reimbursement for the drug candidates.\n\n4. **Other Options**:\n   - **A: International partnerships**: While the company has collaborations with international partners, this is not a primary competitive factor affecting the success of the drug candidates.\n   - **B: Location of manufacturing facilities**: The document does not mention this as a key competitive factor.\n   - **D: Advertising and social media presence**: The document does not emphasize the importance of advertising or social media presence.\n   - **E: Colors and branding of the packaging**: The document does not mention this as a competitive factor.\n   - **F: Celebrity endorsements**: The document does not mention this as a competitive factor.\n\n5. **Conclusion**: Based on the information provided in the document, the key competitive factors affecting the success of the company's drug candidates if approved are efficacy, safety, convenience, price, level of generic"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 128000, "result": 1.0, "question": "Which organization acts as the conservator for the GSEs?", "options": {"A": "Ginnie Mae", "B": "United States Treasury Department", "C": "Various investors", "D": "Non-Agency securitization trustees", "E": "Federal Housing Finance Agency (FHFA)", "F": "Federal Reserve"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 10, "token_lengths": 128000, "result": 0.0, "question": "What is included in the control arm of the described Phase 1 clinical trial?", "options": {"A": "Patients meeting specific HLA or miHA criteria", "B": "Patients treated with TSC-100 or TSC-101", "C": "Patients who do not meet HLA or miHA genetic criteria", "D": "Patients receiving experimental gene therapy", "E": "Healthy volunteers with no treatment", "F": "Patients undergoing bone marrow biopsy"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 128000, "result": 0.0, "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?", "options": {"A": "10 years", "B": "12 years", "C": "14 years", "D": "15 years", "E": "20 years", "F": "25 years"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 128000, "result": 1.0, "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?", "options": {"A": "A decrease in trading demand by customers", "B": "Cost-cutting pressures across the industry", "C": "Settlements related to inspections", "D": "Weakness in the macroeconomic environment", "E": "Defaults by clearing or exchange members", "F": "Changes to contract specifications"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 10, "token_lengths": 128000, "result": 1.0, "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?", "options": {"A": "January 1, 2020", "B": "July 1, 2020", "C": "January 1, 2021", "D": "July 1, 2023", "E": "January 1, 2023", "F": "July 1, 2022"}, "LLM_original_answer": ["To answer the question \"When did the enforcement of the CCPA, as amended by the CPRA, begin?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for mentions of the CCPA and CPRA in the document.\n2. **Determine the Effective Date of CPRA**: Find the specific date when the CPRA amendments to the CCPA became effective.\n3. **Confirm the Enforcement Date**: Ensure that the effective date is also the enforcement date, as the document does not explicitly state a different enforcement date.\n\n### Step 1: Identify Relevant Information\nThe document mentions the CCPA and CPRA in the section \"Privacy and Cybersecurity Regulation.\" Here is the relevant excerpt:\n\n> \"In addition, the California Consumer Privacy Act of 2018 (the \u201cCCPA\u201d), which became effective in January 2020, affords California residents expanded privacy protections and control over the collection, use and sharing of their personal information. The CCPA requires companies to make certain disclosures to California consumers regarding personal information, among other privacy protective measures. The CCPA\u2019s definition of \u201cpersonal information\u201d is more expansive than those found in other privacy laws in the United States applicable to us. Failure to comply with the CCPA risks regulatory fines, and the CCPA grants a private right of action and statutory damages for an unauthorized access and exfiltration, theft, or disclosure of certain types of personal information resulting from the Company\u2019s violation of a duty to maintain reasonable security procedures and practices. The CCPA, amended by the California Privacy Rights Act (the \u201cCPRA\u201d), effective as of January 1, 2023, and the implementing regulations require additional investment in compliance programs and potential modifications to business processes. Further, the CCPA, as amended, creates the California Privacy Protection Agency to enforce the statute as well as its regulations, and it imposes new requirements relating to additional consumer rights, data minimization, and other obligations. The California legislature did not extend certain exemptions under the amended CCPA, specifically information collected in employment or business-to-business contexts, and such information therefore is now covered by the CCPA.\"\n\n### Step 2: Determine the Effective Date of CPRA\nThe document clearly states that the CPRA amendments"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 15, "token_lengths": 8000, "result": 1.0, "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?", "options": {"A": "New Drug Application (NDA)", "B": "Biologics License Application (BLA)", "C": "Investigational New Drug (IND) application", "D": "Clinical Trial Report (CTR)", "E": "Good Manufacturing Practice (GMP) Report", "F": "Independent Review Board (IRB) approval"}, "LLM_original_answer": ["To answer the question \"What must be submitted to the FDA before starting human clinical trials for a new drug?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the process of starting human clinical trials is \"Preclinical and Clinical Development.\"\n\n2. **Extract the key information**: According to the document, before beginning the first clinical trial with a product candidate, the following must be submitted to the FDA as part of an Investigational New Drug (IND) application:\n   - Results of preclinical studies\n   - Manufacturing information\n   - Analytical data\n   - Any available clinical data or literature\n   - A proposed clinical protocol\n\n3. **Match the information to the options provided**:\n   - **A: New Drug Application (NDA)** - This is submitted after clinical trials are completed and is used to request approval for marketing the drug.\n   - **B: Biologics License Application (BLA)** - Similar to an NDA, this is submitted after clinical trials for biologics to request marketing approval.\n   - **C: Investigational New Drug (IND) application** - This is the application that must be submitted before starting human clinical trials.\n   - **D: Clinical Trial Report (CTR)** - This is not mentioned in the document as a requirement before starting clinical trials.\n   - **E: Good Manufacturing Practice (GMP) Report** - While GMP is important for manufacturing, it is not specifically mentioned as a requirement for the IND application.\n   - **F: Independent Review Board (IRB) approval** - IRB approval is required, but it is not submitted to the FDA; it is obtained by the clinical site.\n\n4. **Conclusion**: Based on the information extracted from the document, the correct answer is **C: Investigational New Drug (IND) application**.\n\nTherefore, the answer to the question is **C: Investigational New Drug (IND) application**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 8000, "result": 1.0, "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?", "options": {"A": "CryptoLicense", "B": "CoinPermit", "C": "BitLicense", "D": "VirtualCoin License", "E": "DigitalCurrency Regulation", "F": "TokenTrade Accreditation"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the key information in the question.\n2. Scan the provided document for relevant information.\n3. Match the information from the document to the options given.\n4. Select the correct answer based on the information found.\n\n### Step 1: Identify Key Information\nThe question asks about a regulation enacted by the New York State Department of Financial Services in August 2015 for virtual currency business activity.\n\n### Step 2: Scan the Document\nI will scan the document for any mention of New York State Department of Financial Services and the regulation enacted in August 2015.\n\n### Step 3: Match Information\nIn the document, I find the following relevant passage:\n\n\"For example, in August 2015, the New York State Department of Financial Services enacted the first U.S. regulatory framework for licensing participants in 'virtual currency business activity.' The regulations, known as the 'BitLicense,' are intended to focus on consumer protection and regulate the conduct of businesses that are involved in 'virtual currencies' in New York or with New York customers and prohibit any person or entity involved in such activity to conduct activities without a license.\"\n\n### Step 4: Select the Correct Answer\nThe passage clearly states that the regulations enacted in August 2015 by the New York State Department of Financial Services are known as the \"BitLicense.\"\n\nTherefore, the correct answer is:\n**C: BitLicense**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 8000, "result": 1.0, "question": "What challenge is associated with an aging workforce at Duke Energy?", "options": {"A": "Increased security threats", "B": "Mismatch of skill set with future needs", "C": "Higher insurance premiums", "D": "Decreased operational reliability", "E": "Reduced interest in renewable energy projects", "F": "Difficulty in obtaining raw materials"}, "LLM_original_answer": ["To answer the question \"What challenge is associated with an aging workforce at Duke Energy?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Scan the document for sections that discuss workforce challenges, particularly those related to an aging workforce.\n2. **Extract Key Information**: Extract the specific information about the aging workforce and its associated challenges.\n3. **Match Information to Options**: Compare the extracted information to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in the \"Failure to attract and retain an appropriately qualified workforce could unfavorably impact the Duke Energy Registrants\u2019 results of operations\" part of the document.\n\n### Step 2: Extract Key Information\nThe document states:\n- \"Certain events, such as an aging workforce, mismatch of skill set or complement to future needs, or unavailability of contract resources may lead to operating challenges and increased costs.\"\n- \"The challenges include lack of resources, loss of knowledge base and the lengthy time required for skill development.\"\n- \"If the Duke Energy Registrants are unable to successfully attract and retain an appropriately qualified workforce, their results of operations, financial position and cash flows could be negatively affected.\"\n\n### Step 3: Match Information to Options\n- **Option A: Increased security threats** - The document does not mention that an aging workforce directly leads to increased security threats.\n- **Option B: Mismatch of skill set with future needs** - The document explicitly mentions \"mismatch of skill set or complement to future needs\" as a challenge associated with an aging workforce.\n- **Option C: Higher insurance premiums** - The document does not mention higher insurance premiums as a challenge related to an aging workforce.\n- **Option D: Decreased operational reliability** - While the document mentions increased costs and operating challenges, it does not specifically state decreased operational reliability.\n- **Option E: Reduced interest in renewable energy projects** - The document does not mention reduced interest in renewable energy projects as a challenge related to an aging workforce.\n- **Option F: Difficulty in obtaining raw materials** - The document does not mention difficulty in obtaining raw materials as a challenge related to an aging workforce.\n\n### Conclusion\nThe challenge associated with an aging workforce at Duke Energy, as mentioned in the document, is a **mismatch of skill set with future needs**.\n\nTherefore, the correct answer is **Option B: Mismatch of skill set with future needs**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 8000, "result": 1.0, "question": "What is one of the uncertainties associated with the pending merger with Cambridge?", "options": {"A": "Lack of interest from investors", "B": "Potential for delays in regulatory approvals", "C": "Shortage of qualified staff for integration", "D": "Incompatibility of business cultures", "E": "Difficulty in finding a new office location", "F": "Insufficient marketing budget"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step to identify the uncertainties associated with the pending merger with Cambridge.\n\n1. **Identify the section discussing the merger with Cambridge:**\n   - The document mentions the pending merger with Cambridge in the \"Risks Related to Our Acquisition Strategy\" section.\n\n2. **List the uncertainties and risks mentioned:**\n   - **Potential for delays or burdensome conditions associated with regulatory approvals:** \"Regulatory approvals related to the merger may not be received, may take longer to receive than expected, or may impose burdensome conditions, which could impose additional costs and could delay or prevent completion of the merger.\"\n   - **Potential for shareholder litigation:** \"Shareholder litigation could prevent or delay the completion of the merger or otherwise negatively impact the business and operations of the Company and Cambridge.\"\n   - **Significant or unexpected expenses associated with the merger and integration:** \"The Company and Cambridge have incurred and expect to continue to incur significant costs related to the merger and integration.\"\n   - **Potential for termination of the merger agreement:** \"The merger agreement is subject to termination in accordance with its terms, and the pending merger may not be timely completed or at all.\"\n   - **Loss of key employees:** \"The Company may be unable to retain Company and/or Cambridge personnel successfully while the merger is pending or after the merger is completed.\"\n   - **Disruption of ongoing businesses or inconsistencies in standards, controls, procedures, and policies:** \"The integration process could result in the loss of key employees, the disruption of each company\u2019s ongoing businesses or inconsistencies in standards, controls, procedures and policies that could adversely affect our ability to maintain relationships with clients, customers, depositors and employees or to achieve the anticipated benefits of the merger.\"\n\n3. **Match the uncertainties with the given options:**\n   - **Option A: Lack of interest from investors** - Not mentioned in the document.\n   - **Option B: Potential for delays in regulatory approvals** - Directly mentioned.\n   - **Option C: Shortage of qualified staff for integration** - Not explicitly mentioned, but the loss of key employees is a related risk.\n   - **Option D: Incompatibility of business cultures** - Not explicitly mentioned, but the document does mention potential inconsistencies in standards, controls, procedures, and policies.\n   - **Option E: Difficulty in finding a new office location** - Not mentioned in the document.\n   - **Option F: Insufficient marketing budget** - Not mentioned in the document.\n\n4. **Select the"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 8000, "result": 1.0, "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?", "options": {"A": "Completion of Phase 4 trials before initial approval", "B": "An agreement to conduct post-approval confirmatory studies", "C": "Exemption from all clinical trials", "D": "Immediate proof of long-term survival benefit", "E": "Approval from international health organizations", "F": "Evidence of zero side effects"}, "LLM_original_answer": ["To answer the question \"What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Surrogate or Intermediate Clinical Endpoint**:\n   - The document states: \"The FDA may grant Accelerated Approval to a drug or biological product for a serious or life threatening condition that provides meaningful therapeutic advantage to patients over available treatments based upon a determination that the drug or biological product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit.\"\n   - It also mentions: \"The FDA may also grant Accelerated Approval for such drug or biological product for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (IMM) and that is reasonably likely to predict an effect on IMM or other clinical benefit.\"\n\n2. **Post-Approval Confirmatory Studies**:\n   - The document explicitly states: \"The Accelerated Approval Pathway is contingent on a sponsor\u2019s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product\u2019s clinical benefit.\"\n\n3. **Safety and Effectiveness**:\n   - The document notes: \"Drugs and biological products granted Accelerated Approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.\"\n\n4. **Other Options**:\n   - **Option A**: \"Completion of Phase 4 trials before initial approval\" - The document does not mention that Phase 4 trials must be completed before initial approval under the Accelerated Approval Pathway.\n   - **Option C**: \"Exemption from all clinical trials\" - The document clearly states that the drug or biological product must have an effect on a surrogate or intermediate clinical endpoint, which implies some level of clinical data is required.\n   - **Option D**: \"Immediate proof of long-term survival benefit\" - The document does not require immediate proof of long-term survival benefit; it focuses on surrogate or intermediate endpoints.\n   - **Option E**: \"Approval from international health organizations\" - The document does not mention that approval from international health organizations is required for Accelerated Approval.\n   - **Option F**: \"Evidence of zero side effects\" - The document does not require evidence of zero side effects; it requires meeting the same statutory standards for safety and effectiveness as traditional approval.\n\nGiven this information, the correct answer is:\n\n**B: An agreement to conduct post-approval confirmatory studies"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 8000, "result": 1.0, "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?", "options": {"A": "The issuance of new senior secured notes", "B": "The maturity of $360.0 million aggregate principal amount", "C": "A decrease in interest rates", "D": "An increase in fair value adjustment", "E": "The sale of $360.0 million securities", "F": "The acquisition of additional senior secured notes"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document step by step:\n\n1. **Identify the relevant section**: The document mentions specific financial events related to debt maturities. The relevant section is:\n   - \"In addition, $360.0 million aggregate principal amount of PHH\u2019s 7.875% senior secured notes (the PMC Senior Secured Notes) mature on March 15, 2026 and OFC\u2019s $285.0 million aggregate principal amount senior secured notes (the OFC Senior Secured Notes) mature on March 4, 2027.\"\n\n2. **Extract the key information**:\n   - The document states that $360.0 million aggregate principal amount of PHH\u2019s 7.875% senior secured notes matures on March 15, 2026.\n\n3. **Match the information to the options**:\n   - **Option A**: The issuance of new senior secured notes - The document does not mention any new issuance planned for March 15, 2026.\n   - **Option B**: The maturity of $360.0 million aggregate principal amount - This matches the information provided in the document.\n   - **Option C**: A decrease in interest rates - The document does not mention a specific event related to interest rates on this date.\n   - **Option D**: An increase in fair value adjustment - The document does not mention a specific event related to fair value adjustments on this date.\n   - **Option E**: The sale of $360.0 million securities - The document does not mention any sale of securities on this date.\n   - **Option F**: The acquisition of additional senior secured notes - The document does not mention any acquisition of additional notes on this date.\n\n4. **Conclusion**:\n   - The financial event planned for March 15, 2026, involving PHH\u2019s senior secured notes is the maturity of $360.0 million aggregate principal amount.\n\nTherefore, the correct answer is **Option B: The maturity of $360.0 million aggregate principal amount**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 8000, "result": 1.0, "question": "What rights did the company retain after the collaboration with Novartis concluded?", "options": {"A": "All of Novartis's intellectual property", "B": "The technology developed during collaboration", "C": "Its platform improvements not considered collaboration technology", "D": "The patent rights from BWH", "E": "Patent rights for all new programs", "F": "Worldwide rights to Novartis's products"}, "LLM_original_answer": ["To answer the question \"What rights did the company retain after the collaboration with Novartis concluded?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Collaboration and License Agreement with Novartis**:\n   - The company entered into a Collaboration and License Agreement with Novartis on March 27, 2020.\n   - The collaboration concluded in March 2023.\n\n2. **Rights Retained by the Company**:\n   - The document states: \"The ownership of inventions (and resulting patent rights) created in performance of the collaboration was determined by inventorship.\"\n   - The company retained:\n     - (i) **Our intellectual property**: This means the company kept its own pre-existing intellectual property.\n     - (ii) **Programs that are not selected by Novartis**: The company retained the rights to any programs that Novartis did not choose to pursue.\n     - (iii) **Our platform improvements, which were not considered collaboration technology**: The company kept the rights to any improvements made to its own platform that were not part of the collaboration technology.\n\n3. **Evaluating the Options**:\n   - **A: All of Novartis's intellectual property**: This is incorrect because the company did not retain Novartis's intellectual property.\n   - **B: The technology developed during collaboration**: This is incorrect because the ownership of inventions created during the collaboration was determined by inventorship, and the company did not retain all of the technology developed.\n   - **C: Its platform improvements not considered collaboration technology**: This is correct because the company retained the rights to its own platform improvements that were not part of the collaboration technology.\n   - **D: The patent rights from BWH**: This is incorrect because the patent rights from BWH are not related to the Novartis collaboration.\n   - **E: Patent rights for all new programs**: This is incorrect because the company only retained rights to programs not selected by Novartis, not all new programs.\n   - **F: Worldwide rights to Novartis's products**: This is incorrect because the company did not retain worldwide rights to Novartis's products.\n\nTherefore, the correct answer is:\n\n**C: Its platform improvements not considered collaboration technology**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 8000, "result": 1.0, "question": "What does the Anti-Kickback Statute (AKS) make illegal?", "options": {"A": "Manufacturing drugs without a license", "B": "Prescribing drugs without patient consent", "C": "Offering or paying remuneration to induce drug referrals", "D": "Selling drugs at a profit under federal programs", "E": "Importing drugs from unauthorized countries", "F": "Falsifying clinical trial data"}, "LLM_original_answer": ["To answer the question \"What does the Anti-Kickback Statute (AKS) make illegal?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that specifically discusses the Anti-Kickback Statute (AKS).\n\n2. **Extract the key information**: The relevant information is found in the following paragraph:\n   - \"the Anti-Kickback Statute, or AKS, which makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is intended to induce or reward, referrals including the purchase, recommendation, order or prescription of a particular drug for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs.\"\n\n3. **Analyze the extracted information**:\n   - The AKS prohibits the solicitation, receipt, offer, or payment of remuneration.\n   - The remuneration can be in any form (cash, in kind, kickbacks, bribes, rebates).\n   - The purpose of the remuneration is to induce or reward referrals.\n   - Referrals include the purchase, recommendation, order, or prescription of a particular drug.\n   - The drug must be one for which payment may be made under a federal healthcare program (e.g., Medicare and Medicaid).\n\n4. **Match the information to the given options**:\n   - **Option A**: Manufacturing drugs without a license - This is not mentioned in the AKS description.\n   - **Option B**: Prescribing drugs without patient consent - This is not mentioned in the AKS description.\n   - **Option C**: Offering or paying remuneration to induce drug referrals - This matches the description of the AKS.\n   - **Option D**: Selling drugs at a profit under federal programs - This is not mentioned in the AKS description.\n   - **Option E**: Importing drugs from unauthorized countries - This is not mentioned in the AKS description.\n   - **Option F**: Falsifying clinical trial data - This is not mentioned in the AKS description.\n\n5. **Conclusion**: Based on the analysis, the correct answer is **Option C: Offering or paying remuneration to induce drug referrals**.\n\nThe Anti-K"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 8000, "result": 1.0, "question": "What does Delaware law limit regarding certain interested stockholders?", "options": {"A": "Their ability to vote in board elections", "B": "Their right to receive dividends", "C": "Their ability to change corporate policies", "D": "Their ability to cause mergers or acquisitions against the Board's wishes", "E": "Their eligibility to hold shares", "F": "Their power to appoint board members"}, "LLM_original_answer": ["To answer the question \"What does Delaware law limit regarding certain interested stockholders?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the relevant section in the document:**\n   - The relevant section is found in the paragraph that discusses the provisions of Delaware law and the company's organizational documents. Specifically, it states: \"Provisions of our organizational documents and Delaware law may delay or deter a change of control of ICE. Our organizational documents contain provisions that may have the effect of discouraging, delaying or preventing a change of control of, or unsolicited acquisition proposals for, ICE. These provisions make a change of control less likely, which may be contrary to the desires of certain of our stockholders.\"\n\n2. **Extract the specific limitations mentioned:**\n   - The document mentions that Delaware law includes provisions that \"limit the ability of certain interested stockholders, as defined under Delaware law, from causing the merger or acquisition of a corporation against the wishes of the Board of Directors.\"\n\n3. **Match the extracted information to the given options:**\n   - Option A: Their ability to vote in board elections\n     - The document does not mention limitations on voting in board elections.\n   - Option B: Their right to receive dividends\n     - The document does not mention limitations on receiving dividends.\n   - Option C: Their ability to change corporate policies\n     - The document does not mention limitations on changing corporate policies.\n   - Option D: Their ability to cause mergers or acquisitions against the Board's wishes\n     - This matches the information provided in the document.\n   - Option E: Their eligibility to hold shares\n     - The document does not mention limitations on holding shares.\n   - Option F: Their power to appoint board members\n     - The document does not mention limitations on appointing board members.\n\n4. **Conclusion:**\n   - Based on the information provided in the document, the correct answer is **Option D: Their ability to cause mergers or acquisitions against the Board's wishes**.\n\nTherefore, the answer to the question is **Option D: Their ability to cause mergers or acquisitions against the Board's wishes**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 15, "token_lengths": 8000, "result": 1.0, "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?", "options": {"A": "To increase the valuation of all liabilities", "B": "To provide detailed forecasts of economic trends", "C": "To update models based on credible evidence and ensure appropriate valuation practices", "D": "To calculate exact amounts for future policy benefits", "E": "To review marketing strategies for insurance products", "F": "To assess the financial performance of competitors"}, "LLM_original_answer": ["To answer the question \"What is the purpose of the annual actuarial review (AAR) conducted by the company?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the Context of AAR**:\n   - The document mentions that the company conducts an annual actuarial review (AAR) of the key inputs into their actuarial models that rely on management judgment.\n   - This review is part of the company's broader risk management strategy, particularly for variable annuity products and other insurance liabilities.\n\n2. **Understand the Key Inputs**:\n   - The key inputs include assumptions about policyholder behavior, such as persistency (the probability that a policy or contract will remain in-force) and the utilization of guaranteed options within certain products.\n   - These assumptions are crucial for setting prices and establishing liabilities for future policy benefits and claims.\n\n3. **Purpose of the AAR**:\n   - The AAR updates models based on credible evidence from actual experience, industry data, or other relevant sources.\n   - The goal is to ensure that the price-setting criteria and reserve valuation practices continue to be appropriate.\n   - This helps in managing the risk of material differences between actual outcomes and the sensitivities calculated under various scenarios.\n\n4. **Evaluate the Options**:\n   - **Option A**: To increase the valuation of all liabilities. This is not the primary purpose; the AAR aims to ensure the appropriateness of the valuation, not necessarily to increase it.\n   - **Option B**: To provide detailed forecasts of economic trends. While economic trends are considered, the AAR is not primarily focused on providing detailed forecasts.\n   - **Option C**: To update models based on credible evidence and ensure appropriate valuation practices. This aligns with the purpose described in the document.\n   - **Option D**: To calculate exact amounts for future policy benefits. The document states that the company cannot precisely determine the amounts, so this is not the purpose.\n   - **Option E**: To review marketing strategies for insurance products. The AAR is not about marketing strategies but about actuarial assumptions and models.\n   - **Option F**: To assess the financial performance of competitors. The AAR is internal and focused on the company's own assumptions and models, not on competitors.\n\n5. **Conclusion**:\n   - The purpose of the annual actuarial review (AAR) is to update models based on credible evidence and ensure appropriate valuation practices.\n\nTherefore, the correct answer is **"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 16000, "result": 1.0, "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?", "options": {"A": "New Drug Application (NDA)", "B": "Biologics License Application (BLA)", "C": "Investigational New Drug (IND) application", "D": "Clinical Trial Report (CTR)", "E": "Good Manufacturing Practice (GMP) Report", "F": "Independent Review Board (IRB) approval"}, "LLM_original_answer": ["To answer the question \"What must be submitted to the FDA before starting human clinical trials for a new drug?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the regulatory process for starting human clinical trials is found under \"Government Regulation\" and \"Preclinical and Clinical Development.\"\n\n2. **Extract the key information**: The document states:\n   - \"Before testing any drug or biologic candidate in humans in the United States, the product candidate must undergo rigorous preclinical testing.\"\n   - \"Prior to beginning the first clinical trial with a product candidate, we must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of an IND.\"\n\n3. **Match the information to the options**:\n   - **Option A: New Drug Application (NDA)** - This is submitted after clinical trials are completed and before seeking marketing approval.\n   - **Option B: Biologics License Application (BLA)** - This is also submitted after clinical trials are completed and before seeking marketing approval.\n   - **Option C: Investigational New Drug (IND) application** - This is the document that must be submitted to the FDA before starting human clinical trials.\n   - **Option D: Clinical Trial Report (CTR)** - This is not mentioned in the document as a requirement before starting clinical trials.\n   - **Option E: Good Manufacturing Practice (GMP) Report** - While GMP is important, the document does not mention a specific GMP report as a requirement before starting clinical trials.\n   - **Option F: Independent Review Board (IRB) approval** - The document mentions that IRB approval is required, but it is not the primary document submitted to the FDA.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **Option C: Investigational New Drug (IND) application**.\n\nTherefore, the answer to the question is **C: Investigational New Drug (IND) application**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 16000, "result": 1.0, "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?", "options": {"A": "CryptoLicense", "B": "CoinPermit", "C": "BitLicense", "D": "VirtualCoin License", "E": "DigitalCurrency Regulation", "F": "TokenTrade Accreditation"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant information in the document**: The document mentions a specific regulation enacted by the New York State Department of Financial Services in August 2015.\n\n2. **Extract the exact regulation name**: The regulation is referred to as the \"BitLicense.\"\n\n3. **Match the extracted information with the given options**: The option that matches \"BitLicense\" is C.\n\n4. **Confirm the answer**: The correct answer is C: BitLicense.\n\n**Step-by-Step Analysis**:\n\n1. **Relevant Information**:\n   - The document states: \"In August 2015, the New York State Department of Financial Services enacted the first U.S. regulatory framework for licensing participants in 'virtual currency business activity.'\"\n\n2. **Exact Regulation Name**:\n   - The regulation is explicitly named as the \"BitLicense.\"\n\n3. **Matching with Options**:\n   - Option A: CryptoLicense\n   - Option B: CoinPermit\n   - Option C: BitLicense\n   - Option D: VirtualCoin License\n   - Option E: DigitalCurrency Regulation\n   - Option F: TokenTrade Accreditation\n\n   The correct match is Option C: BitLicense.\n\n4. **Confirmation**:\n   - The document clearly states that the regulation is called the \"BitLicense,\" and this matches with Option C.\n\nTherefore, the correct answer is **C: BitLicense**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 16000, "result": 1.0, "question": "What challenge is associated with an aging workforce at Duke Energy?", "options": {"A": "Increased security threats", "B": "Mismatch of skill set with future needs", "C": "Higher insurance premiums", "D": "Decreased operational reliability", "E": "Reduced interest in renewable energy projects", "F": "Difficulty in obtaining raw materials"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the specific challenge associated with an aging workforce at Duke Energy.\n\n1. **Locate Relevant Information:**\n   - The document mentions workforce-related challenges in the section titled \"Failure to attract and retain an appropriately qualified workforce could unfavorably impact the Duke Energy Registrants\u2019 results of operations.\"\n\n2. **Identify the Challenge:**\n   - The text states: \"Certain events, such as an aging workforce, mismatch of skill set or complement to future needs, or unavailability of contract resources may lead to operating challenges and increased costs. The challenges include lack of resources, loss of knowledge base and the lengthy time required for skill development.\"\n\n3. **Match the Challenge to the Options:**\n   - **Option A: Increased security threats** - The document does not link an aging workforce to increased security threats.\n   - **Option B: Mismatch of skill set with future needs** - The document explicitly mentions \"mismatch of skill set or complement to future needs\" as a challenge.\n   - **Option C: Higher insurance premiums** - The document does not mention higher insurance premiums as a challenge related to an aging workforce.\n   - **Option D: Decreased operational reliability** - While the document discusses operational challenges, it does not specifically mention decreased operational reliability.\n   - **Option E: Reduced interest in renewable energy projects** - The document does not mention reduced interest in renewable energy projects as a challenge related to an aging workforce.\n   - **Option F: Difficulty in obtaining raw materials** - The document does not mention difficulty in obtaining raw materials as a challenge related to an aging workforce.\n\n4. **Conclusion:**\n   - The challenge associated with an aging workforce at Duke Energy, as mentioned in the document, is a **mismatch of skill set with future needs**.\n\nTherefore, the correct answer is **Option B: Mismatch of skill set with future needs**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 16000, "result": 1.0, "question": "What is one of the uncertainties associated with the pending merger with Cambridge?", "options": {"A": "Lack of interest from investors", "B": "Potential for delays in regulatory approvals", "C": "Shortage of qualified staff for integration", "D": "Incompatibility of business cultures", "E": "Difficulty in finding a new office location", "F": "Insufficient marketing budget"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document and identify the uncertainties associated with the pending merger with Cambridge.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Section on Merger Risks:**\n   - The document discusses the risks and uncertainties related to the pending merger with Cambridge in the \"Risks Related to Our Acquisition Strategy\" section.\n\n2. **List the Uncertainties:**\n   - **Regulatory Approvals:** \"Regulatory approvals related to the merger may not be received, may take longer to receive than expected, or may impose burdensome conditions, which could impose additional costs and could delay or prevent completion of the merger.\"\n   - **Shareholder Litigation:** \"Shareholder litigation could prevent or delay the completion of the merger or otherwise negatively impact the business and operations of the Company and Cambridge.\"\n   - **Integration Costs:** \"The Company and Cambridge have incurred and expect to continue to incur significant costs related to the merger and integration.\"\n   - **Retention of Key Personnel:** \"The Company may be unable to retain Company and/or Cambridge personnel successfully while the merger is pending or after the merger is completed.\"\n   - **Expected Benefits:** \"The Company may fail to realize all of the anticipated benefits of the merger, particularly if the integration of the Company\u2019s and Cambridge\u2019s businesses is more difficult than expected.\"\n\n3. **Match the Uncertainties with the Given Options:**\n   - **Option A: Lack of interest from investors** - Not mentioned in the document.\n   - **Option B: Potential for delays in regulatory approvals** - Directly mentioned in the document.\n   - **Option C: Shortage of qualified staff for integration** - Not explicitly mentioned, but the document does discuss the potential for losing key employees.\n   - **Option D: Incompatibility of business cultures** - Not explicitly mentioned.\n   - **Option E: Difficulty in finding a new office location** - Not mentioned in the document.\n   - **Option F: Insufficient marketing budget** - Not mentioned in the document.\n\n### Conclusion:\nThe document explicitly mentions the potential for delays in regulatory approvals as one of the uncertainties associated with the pending merger with Cambridge.\n\n### Answer:\n**B: Potential for delays in regulatory approvals**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 16000, "result": 1.0, "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?", "options": {"A": "Completion of Phase 4 trials before initial approval", "B": "An agreement to conduct post-approval confirmatory studies", "C": "Exemption from all clinical trials", "D": "Immediate proof of long-term survival benefit", "E": "Approval from international health organizations", "F": "Evidence of zero side effects"}, "LLM_original_answer": ["To answer the question \"What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Purpose of Accelerated Approval Pathway**:\n   - The FDA may grant Accelerated Approval to a drug or biological product for a serious or life-threatening condition that provides a meaningful therapeutic advantage over available treatments.\n   - This pathway is based on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit.\n\n2. **Surrogate and Intermediate Clinical Endpoints**:\n   - A surrogate endpoint is a marker (e.g., laboratory measurement, radiographic image) that is thought to predict clinical benefit but is not itself a measure of clinical benefit.\n   - An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict an effect on irreversible morbidity or mortality (IMM) or other clinical benefit.\n\n3. **Post-Approval Requirements**:\n   - Drugs and biological products granted Accelerated Approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.\n   - The sponsor must agree to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product\u2019s clinical benefit.\n   - Failure to conduct these studies or to confirm a clinical benefit during post-marketing studies can result in the FDA withdrawing the drug or biological product from the market on an expedited basis.\n\n4. **Review of Options**:\n   - **Option A**: Completion of Phase 4 trials before initial approval. This is not mentioned as a requirement for Accelerated Approval.\n   - **Option B**: An agreement to conduct post-approval confirmatory studies. This is explicitly stated as a requirement.\n   - **Option C**: Exemption from all clinical trials. This is not true; the pathway still requires some clinical data.\n   - **Option D**: Immediate proof of long-term survival benefit. This is not required; the pathway can be based on surrogate or intermediate endpoints.\n   - **Option E**: Approval from international health organizations. This is not mentioned as a requirement for FDA approval.\n   - **Option F**: Evidence of zero side effects. This is not a realistic or required condition for any FDA approval.\n\nBased on the information provided in the document, the correct answer is:\n\n**B: An agreement to conduct post-approval confirmatory studies**\n\nThis is clearly stated in the document as a requirement for drugs and biological products granted Accelerated Approval. The"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 16000, "result": 1.0, "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?", "options": {"A": "The issuance of new senior secured notes", "B": "The maturity of $360.0 million aggregate principal amount", "C": "A decrease in interest rates", "D": "An increase in fair value adjustment", "E": "The sale of $360.0 million securities", "F": "The acquisition of additional senior secured notes"}, "LLM_original_answer": ["To answer the question, I will go through the document step by step to find the relevant information.\n\n1. **Identify the relevant section**: The document contains a section that discusses the maturity dates of various debt agreements. This is where we are likely to find information about PHH\u2019s senior secured notes.\n\n2. **Locate the specific information**: In the section discussing the company's debt agreements, the following sentence is relevant:\n   - \"In addition, $360.0 million aggregate principal amount of PHH\u2019s 7.875% senior secured notes (the PMC Senior Secured Notes) mature on March 15, 2026 and OFC\u2019s $285.0 million aggregate principal amount senior secured notes (the OFC Senior Secured Notes) mature on March 4, 2027.\"\n\n3. **Analyze the information**: The sentence clearly states that $360.0 million aggregate principal amount of PHH\u2019s 7.875% senior secured notes matures on March 15, 2026.\n\n4. **Match the information to the options**:\n   - **Option A**: The issuance of new senior secured notes - This is not mentioned in the document.\n   - **Option B**: The maturity of $360.0 million aggregate principal amount - This matches the information found in the document.\n   - **Option C**: A decrease in interest rates - This is not mentioned in the context of the specific date.\n   - **Option D**: An increase in fair value adjustment - This is not mentioned in the context of the specific date.\n   - **Option E**: The sale of $360.0 million securities - This is not mentioned in the document.\n   - **Option F**: The acquisition of additional senior secured notes - This is not mentioned in the document.\n\n5. **Conclusion**: The financial event planned for March 15, 2026, involving PHH\u2019s senior secured notes is the maturity of $360.0 million aggregate principal amount.\n\nTherefore, the correct answer is **Option B: The maturity of $360.0 million aggregate principal amount**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 16000, "result": 1.0, "question": "What rights did the company retain after the collaboration with Novartis concluded?", "options": {"A": "All of Novartis's intellectual property", "B": "The technology developed during collaboration", "C": "Its platform improvements not considered collaboration technology", "D": "The patent rights from BWH", "E": "Patent rights for all new programs", "F": "Worldwide rights to Novartis's products"}, "LLM_original_answer": ["To answer the question \"What rights did the company retain after the collaboration with Novartis concluded?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section titled \"Collaboration and License Agreement with Novartis\" which is directly related to the collaboration with Novartis.\n\n2. **Extract key information**: According to the Novartis Agreement section, the company granted Novartis options to obtain exclusive, royalty-bearing, sublicensable, transferable, worldwide licenses to certain target antigens and corresponding T cell receptors identified during the collaboration. The ownership of inventions (and resulting patent rights) created during the collaboration was determined by inventorship.\n\n3. **Determine what the company retained**:\n   - The company retained its rights to (i) its intellectual property, (ii) programs that were not selected by Novartis, and (iii) its platform improvements, which were not considered collaboration technology.\n\n4. **Match the retained rights to the given options**:\n   - **Option A**: All of Novartis's intellectual property - This is not correct as the company did not retain Novartis's intellectual property.\n   - **Option B**: The technology developed during collaboration - This is not correct as the company did not retain the technology developed during the collaboration; it was determined by inventorship.\n   - **Option C**: Its platform improvements not considered collaboration technology - This is correct as the company retained its platform improvements that were not considered collaboration technology.\n   - **Option D**: The patent rights from BWH - This is not correct as the company's rights to BWH's patent rights are covered by a separate agreement and not related to the Novartis collaboration.\n   - **Option E**: Patent rights for all new programs - This is not correct as the company only retained rights to programs not selected by Novartis.\n   - **Option F**: Worldwide rights to Novartis's products - This is not correct as the company did not retain worldwide rights to Novartis's products.\n\n5. **Conclusion**: The correct answer is **Option C**: Its platform improvements not considered collaboration technology.\n\nThus, the company retained its platform improvements not considered collaboration technology after the collaboration with Novartis concluded."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 16000, "result": 1.0, "question": "What does the Anti-Kickback Statute (AKS) make illegal?", "options": {"A": "Manufacturing drugs without a license", "B": "Prescribing drugs without patient consent", "C": "Offering or paying remuneration to induce drug referrals", "D": "Selling drugs at a profit under federal programs", "E": "Importing drugs from unauthorized countries", "F": "Falsifying clinical trial data"}, "LLM_original_answer": ["To answer the question \"What does the Anti-Kickback Statute (AKS) make illegal?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that specifically discusses the Anti-Kickback Statute (AKS).\n\n2. **Extract the key information**: The relevant information is found in the following paragraph:\n   - \"the Anti-Kickback Statute, or AKS, which makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is intended to induce or reward, referrals including the purchase, recommendation, order or prescription of a particular drug for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs.\"\n\n3. **Analyze the extracted information**:\n   - The AKS makes it illegal to offer or pay remuneration to induce or reward referrals.\n   - This includes the purchase, recommendation, order, or prescription of a particular drug.\n   - The statute applies to federal healthcare programs like Medicare and Medicaid.\n\n4. **Match the extracted information to the given options**:\n   - **Option A**: Manufacturing drugs without a license - This is not mentioned in the AKS description.\n   - **Option B**: Prescribing drugs without patient consent - This is not mentioned in the AKS description.\n   - **Option C**: Offering or paying remuneration to induce drug referrals - This matches the description of the AKS.\n   - **Option D**: Selling drugs at a profit under federal programs - This is not mentioned in the AKS description.\n   - **Option E**: Importing drugs from unauthorized countries - This is not mentioned in the AKS description.\n   - **Option F**: Falsifying clinical trial data - This is not mentioned in the AKS description.\n\n5. **Select the correct answer**:\n   - Based on the analysis, the correct answer is **Option C**: Offering or paying remuneration to induce drug referrals.\n\nTherefore, the Anti-Kickback Statute (AKS) makes illegal the act of offering or paying remuneration to induce drug referrals."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 16000, "result": 1.0, "question": "What does Delaware law limit regarding certain interested stockholders?", "options": {"A": "Their ability to vote in board elections", "B": "Their right to receive dividends", "C": "Their ability to change corporate policies", "D": "Their ability to cause mergers or acquisitions against the Board's wishes", "E": "Their eligibility to hold shares", "F": "Their power to appoint board members"}, "LLM_original_answer": ["To answer the question \"What does Delaware law limit regarding certain interested stockholders?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for mentions of Delaware law and its impact on stockholders.\n2. **Analyze the Information**: Determine what specific limitations are mentioned.\n3. **Match to the Options**: Compare the identified limitations to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant section from the document is:\n> \"Provisions of our organizational documents and Delaware law may delay or deter a change of control of ICE. Our organizational documents contain provisions that may have the effect of discouraging, delaying or preventing a change of control of, or unsolicited acquisition proposals for, ICE. These provisions make a change of control less likely, which may be contrary to the desires of certain of our stockholders. Many of these provisions are required by relevant regulators in connection with our ownership and operation of U.S. and European equity exchanges. For example, our organizational documents include provisions that generally restrict any person (either alone or together with its related persons) from (i) voting or causing the voting of shares of stock representing more than 10% of our outstanding voting capital stock (including as a result of any agreement by any other persons not to vote shares of stock) or (ii) beneficially owning shares of stock representing more than 20% of the outstanding shares of any class or series of our capital stock. Further, our organizational documents generally limit the ability of stockholders to act by written consent, and generally authorize our Board of Directors, without stockholder approval, to issue and fix the rights and preferences of one or more series of preferred stock. In addition, provisions of Delaware law may have a similar effect, such as provisions limiting the ability of certain interested stockholders, as defined under Delaware law, from causing the merger or acquisition of a corporation against the wishes of the Board of Directors.\"\n\n### Step 2: Analyze the Information\n- **Organizational Documents**: The document mentions that the organizational documents restrict:\n  - Voting more than 10% of the outstanding voting capital stock.\n  - Beneficially owning more than 20% of the outstanding shares of any class or series of capital stock.\n  - Limiting the ability of stockholders to act by written consent.\n  - Authorizing the Board of Directors to issue and fix the rights and preferences of preferred stock without stockholder approval.\n- **Del"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 15, "token_lengths": 16000, "result": 1.0, "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?", "options": {"A": "To increase the valuation of all liabilities", "B": "To provide detailed forecasts of economic trends", "C": "To update models based on credible evidence and ensure appropriate valuation practices", "D": "To calculate exact amounts for future policy benefits", "E": "To review marketing strategies for insurance products", "F": "To assess the financial performance of competitors"}, "LLM_original_answer": ["To answer the question \"What is the purpose of the annual actuarial review (AAR) conducted by the company?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the annual actuarial review (AAR) in the context of risk management and the valuation of liabilities.\n\n2. **Extract the key information**: The relevant passage states:\n   - \"We conduct an annual actuarial review (the \u201cAAR\u201d) of the key inputs into our actuarial models that rely on management judgment and update any models where we have credible evidence from actual experience, industry data or other relevant sources to ensure our price-setting criteria and reserve valuation practices continue to be appropriate.\"\n   - \"We review key actuarial assumptions used to record our variable annuity liabilities on an annual basis, including the assumptions regarding policyholder behavior.\"\n\n3. **Analyze the information**:\n   - The AAR involves reviewing and updating the key inputs and assumptions used in actuarial models.\n   - The review is based on credible evidence from actual experience, industry data, and other relevant sources.\n   - The purpose is to ensure that the price-setting criteria and reserve valuation practices remain appropriate.\n\n4. **Match the information to the options**:\n   - **Option A**: \"To increase the valuation of all liabilities\" - This is not the primary purpose. The AAR is about ensuring the appropriateness of the valuation, not necessarily increasing it.\n   - **Option B**: \"To provide detailed forecasts of economic trends\" - The AAR is not focused on providing detailed forecasts of economic trends, but rather on updating actuarial models.\n   - **Option C**: \"To update models based on credible evidence and ensure appropriate valuation practices\" - This matches the information extracted from the document.\n   - **Option D**: \"To calculate exact amounts for future policy benefits\" - The AAR does not aim to calculate exact amounts but to ensure the models and assumptions are appropriate.\n   - **Option E**: \"To review marketing strategies for insurance products\" - The AAR is not related to marketing strategies.\n   - **Option F**: \"To assess the financial performance of competitors\" - The AAR is not about assessing competitors' financial performance.\n\n5. **Select the best answer**:\n   - Based on the analysis, **Option C** is the most accurate and aligns with the information provided in the document.\n\nTherefore, the purpose of the annual actuarial"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 32000, "result": 1.0, "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?", "options": {"A": "New Drug Application (NDA)", "B": "Biologics License Application (BLA)", "C": "Investigational New Drug (IND) application", "D": "Clinical Trial Report (CTR)", "E": "Good Manufacturing Practice (GMP) Report", "F": "Independent Review Board (IRB) approval"}, "LLM_original_answer": ["To answer the question \"What must be submitted to the FDA before starting human clinical trials for a new drug?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the regulatory process for starting human clinical trials is \"U.S. Drug and Biological Product Regulation\" and \"Preclinical and Clinical Development.\"\n\n2. **Extract the key information**: The document states:\n   - \"Before testing any drug or biologic candidate in humans in the United States, the product candidate must undergo rigorous preclinical testing.\"\n   - \"Prior to beginning the first clinical trial with a product candidate, we must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of an IND.\"\n\n3. **Match the information to the options**:\n   - **Option A: New Drug Application (NDA)** - This is submitted after clinical trials are completed and before seeking marketing approval.\n   - **Option B: Biologics License Application (BLA)** - This is also submitted after clinical trials are completed and before seeking marketing approval.\n   - **Option C: Investigational New Drug (IND) application** - This is submitted before starting human clinical trials.\n   - **Option D: Clinical Trial Report (CTR)** - This is not mentioned in the document as a requirement before starting clinical trials.\n   - **Option E: Good Manufacturing Practice (GMP) Report** - While GMP is important, the document does not mention a specific GMP report as a requirement before starting clinical trials.\n   - **Option F: Independent Review Board (IRB) approval** - The document mentions that IRB approval is required, but it is not the primary submission to the FDA.\n\n4. **Conclusion**: Based on the information provided, the correct answer is **Option C: Investigational New Drug (IND) application**.\n\n**Chain of thoughts**:\n- The document clearly states that an IND application must be submitted to the FDA before human clinical trials can begin.\n- The IND application includes results from preclinical studies, manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical protocol.\n- Other options like NDA, BLA, and CTR are not relevant to the initial step of starting clinical trials.\n- IRB approval is necessary but is not the primary submission to the FDA; it is a separate requirement for each clinical trial site.\n\nTherefore"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 32000, "result": 1.0, "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?", "options": {"A": "CryptoLicense", "B": "CoinPermit", "C": "BitLicense", "D": "VirtualCoin License", "E": "DigitalCurrency Regulation", "F": "TokenTrade Accreditation"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant information in the document**: The document mentions the New York State Department of Financial Services enacting a regulatory framework for virtual currency business activity in August 2015.\n\n2. **Locate the specific regulation mentioned**: The document states, \"In August 2015, the New York State Department of Financial Services enacted the first U.S. regulatory framework for licensing participants in 'virtual currency business activity.' The regulations, known as the 'BitLicense,' are intended to focus on consumer protection and regulate the conduct of businesses that are involved in 'virtual currencies' in New York or with New York customers and prohibit any person or entity involved in such activity to conduct activities without a license.\"\n\n3. **Match the regulation to the options provided**: The regulation mentioned in the document is called the \"BitLicense.\"\n\n4. **Select the correct answer**: The correct answer is **C: BitLicense**.\n\n**Chain of thoughts**:\n- The document clearly states that the New York State Department of Financial Services enacted a regulatory framework in August 2015.\n- This framework is specifically referred to as the \"BitLicense.\"\n- The BitLicense is designed to regulate virtual currency business activity, focusing on consumer protection and requiring businesses to obtain a license.\n- Among the provided options, only \"BitLicense\" matches the regulation described in the document.\n\nTherefore, the correct answer is **C: BitLicense**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 32000, "result": 1.0, "question": "What challenge is associated with an aging workforce at Duke Energy?", "options": {"A": "Increased security threats", "B": "Mismatch of skill set with future needs", "C": "Higher insurance premiums", "D": "Decreased operational reliability", "E": "Reduced interest in renewable energy projects", "F": "Difficulty in obtaining raw materials"}, "LLM_original_answer": ["To answer the question \"What challenge is associated with an aging workforce at Duke Energy?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Scan the document for sections that discuss workforce-related challenges.\n2. **Extract Information**: Extract specific information about the aging workforce and its associated challenges.\n3. **Match Information to Options**: Compare the extracted information to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in the \"General Risks\" section of the document:\n\n> **Failure to attract and retain an appropriately qualified workforce could unfavorably impact the Duke Energy Registrants\u2019 results of operations.**\n> \n> Certain events, such as an aging workforce, mismatch of skill set or complement to future needs, or unavailability of contract resources may lead to operating challenges and increased costs. The challenges include lack of resources, loss of knowledge base and the lengthy time required for skill development. In this case, costs, including costs for contractors to replace employees, productivity costs and safety costs, may increase. Failure to hire and adequately train replacement employees, including the transfer of significant internal historical knowledge and expertise to new employees, or future availability and cost of contract labor may adversely affect the ability to manage and operate the business, especially considering the workforce needs associated with nuclear generation facilities and new skills required to operate a modernized, technology-enabled power grid. If the Duke Energy Registrants are unable to successfully attract and retain an appropriately qualified workforce, their results of operations, financial position and cash flows could be negatively affected.\n\n### Step 2: Extract Information\nFrom the relevant section, the key points about the aging workforce are:\n- **Aging Workforce**: It is mentioned as one of the events that could lead to operating challenges and increased costs.\n- **Challenges**:\n  - Lack of resources\n  - Loss of knowledge base\n  - Lengthy time required for skill development\n  - Increased costs for contractors to replace employees\n  - Increased productivity costs\n  - Increased safety costs\n\n### Step 3: Match Information to Options\nNow, let's match the extracted information to the given options:\n\n- **A: Increased security threats** - The document does not link the aging workforce to increased security threats.\n- **B: Mismatch of skill set with future needs** - The document mentions a \"mismatch of skill set or complement to future needs\" as a challenge, which aligns with this option.\n- **C: Higher insurance premiums"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 32000, "result": 1.0, "question": "What is one of the uncertainties associated with the pending merger with Cambridge?", "options": {"A": "Lack of interest from investors", "B": "Potential for delays in regulatory approvals", "C": "Shortage of qualified staff for integration", "D": "Incompatibility of business cultures", "E": "Difficulty in finding a new office location", "F": "Insufficient marketing budget"}, "LLM_original_answer": ["To answer the question \"What is one of the uncertainties associated with the pending merger with Cambridge?\" based on the provided document, I will analyze the relevant sections step by step.\n\n1. **Identify the Context of the Merger:**\n   - The document discusses the pending merger between Eastern Bankshares, Inc. and Cambridge Bancorp, and the related joint proxy statement/prospectus.\n\n2. **List the Uncertainties and Risks:**\n   - The document outlines several uncertainties and risks associated with the merger:\n     - **Potential for delays or burdensome conditions associated with regulatory approvals:** \"Regulatory approvals related to the merger may not be received, may take longer to receive than expected, or may impose burdensome conditions, which could impose additional costs and could delay or prevent completion of the merger.\"\n     - **Potential for shareholder litigation:** \"Shareholder litigation could prevent or delay the completion of the merger or otherwise negatively impact the business and operations of the Company and Cambridge.\"\n     - **Significant or unexpected expenses associated with the merger and integration:** \"The Company and Cambridge have incurred and expect to continue to incur significant costs related to the merger and integration.\"\n     - **Potential for termination of the merger agreement:** \"The merger agreement is subject to termination in accordance with its terms, and the pending merger may not be timely completed or at all.\"\n     - **Assumption of or potential exposure to significant liabilities of the acquired business:** \"To the extent that we acquire other companies, including Cambridge and its subsidiary Cambridge Trust Company, our business may be negatively impacted by certain risks inherent with such acquisitions, including assumption of or potential exposure to significant liabilities of the acquired business, some of which may be unknown or contingent at the time of acquisition.\"\n\n3. **Match the Uncertainties to the Options:**\n   - **Option A: Lack of interest from investors** - Not mentioned in the document.\n   - **Option B: Potential for delays in regulatory approvals** - Directly mentioned: \"Regulatory approvals related to the merger may not be received, may take longer to receive than expected, or may impose burdensome conditions, which could impose additional costs and could delay or prevent completion of the merger.\"\n   - **Option C: Shortage of qualified staff for integration** - Not directly mentioned, but related to the broader risk of integration: \"Potential difficulties and/or unexpected expenses relating to the integration of the operations, technologies, products and the key employees of the acquired business, resulting in the diversion of resources from the operation of our existing business"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 32000, "result": 1.0, "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?", "options": {"A": "Completion of Phase 4 trials before initial approval", "B": "An agreement to conduct post-approval confirmatory studies", "C": "Exemption from all clinical trials", "D": "Immediate proof of long-term survival benefit", "E": "Approval from international health organizations", "F": "Evidence of zero side effects"}, "LLM_original_answer": ["To answer the question \"What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Purpose of Accelerated Approval**:\n   - The FDA may grant Accelerated Approval to a drug or biological product for a serious or life-threatening condition that provides a meaningful therapeutic advantage over available treatments.\n   - This approval can be based on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit.\n\n2. **Surrogate Endpoint**:\n   - A surrogate endpoint is a marker (e.g., a laboratory measurement, radiographic image, physical sign) that is thought to predict clinical benefit but is not itself a measure of clinical benefit.\n   - Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints.\n\n3. **Intermediate Clinical Endpoint**:\n   - An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug or biological product.\n   - It can be measured earlier than an effect on irreversible morbidity or mortality (IMM) and is reasonably likely to predict an effect on IMM or other clinical benefit.\n\n4. **Post-Approval Requirements**:\n   - Drugs and biological products granted Accelerated Approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.\n   - The FDA requires the sponsor to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product\u2019s clinical benefit.\n   - Failure to conduct these required post-approval studies or to confirm a clinical benefit during post-marketing studies can lead to the FDA withdrawing the drug or biological product from the market on an expedited basis.\n\n5. **Options Analysis**:\n   - **A: Completion of Phase 4 trials before initial approval** - This is incorrect. Phase 4 trials are post-approval studies.\n   - **B: An agreement to conduct post-approval confirmatory studies** - This is correct. The document explicitly states that post-approval confirmatory studies are required.\n   - **C: Exemption from all clinical trials** - This is incorrect. The drug or biological product must still meet the same statutory standards for safety and effectiveness.\n   - **D: Immediate proof of long-term survival benefit** - This is incorrect. The approval can be based on a surrogate or intermediate clinical endpoint.\n   - **E: Approval from international health organizations** - This is incorrect. The FDA's"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 32000, "result": 1.0, "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?", "options": {"A": "The issuance of new senior secured notes", "B": "The maturity of $360.0 million aggregate principal amount", "C": "A decrease in interest rates", "D": "An increase in fair value adjustment", "E": "The sale of $360.0 million securities", "F": "The acquisition of additional senior secured notes"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the key information in the document related to PHH\u2019s senior secured notes.\n2. Determine the specific event planned for March 15, 2026.\n3. Match the event to the provided options.\n\n### Step 1: Identify Key Information\nThe relevant information is found in the following excerpt from the document:\n\"In addition, $360.0 million aggregate principal amount of PHH\u2019s 7.875% senior secured notes (the PMC Senior Secured Notes) mature on March 15, 2026 and OFC\u2019s $285.0 million aggregate principal amount senior secured notes (the OFC Senior Secured Notes) mature on March 4, 2027.\"\n\n### Step 2: Determine the Specific Event\nThe document states that the $360.0 million aggregate principal amount of PHH\u2019s 7.875% senior secured notes matures on March 15, 2026.\n\n### Step 3: Match the Event to the Provided Options\nThe event described in the document is the maturity of the senior secured notes. Therefore, the correct option is:\n\n**B: The maturity of $360.0 million aggregate principal amount**\n\n### Final Answer\nThe financial event planned for March 15, 2026, involving PHH\u2019s senior secured notes is the maturity of $360.0 million aggregate principal amount."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 32000, "result": 1.0, "question": "What rights did the company retain after the collaboration with Novartis concluded?", "options": {"A": "All of Novartis's intellectual property", "B": "The technology developed during collaboration", "C": "Its platform improvements not considered collaboration technology", "D": "The patent rights from BWH", "E": "Patent rights for all new programs", "F": "Worldwide rights to Novartis's products"}, "LLM_original_answer": ["To answer the question \"What rights did the company retain after the collaboration with Novartis concluded?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The relevant section is the \"Collaboration and License Agreement with Novartis\" part of the document.\n\n2. **Extract key information**: The document states:\n   - \"Pursuant to the Novartis Agreement, we have received an aggregate of $20.0 million of cash representing the upfront payment and research funding totaling $10 million.\"\n   - \"We granted Novartis and its affiliates options to obtain exclusive, royalty-bearing, sublicensable, transferable, worldwide licenses to certain target antigens identified in performance of the Novartis Agreement and corresponding T cell receptors for such target antigens.\"\n   - \"The ownership of inventions (and resulting patent rights) created in performance of the collaboration was determined by inventorship.\"\n   - \"We retained our rights to (i) our intellectual property, (ii) programs that are not selected by Novartis, and (iii) our platform improvements, which were not considered collaboration technology.\"\n\n3. **Analyze the options**:\n   - **Option A: All of Novartis's intellectual property** - The company did not retain all of Novartis's intellectual property.\n   - **Option B: The technology developed during collaboration** - The company did not retain the technology developed during the collaboration; Novartis has options to obtain exclusive licenses to this technology.\n   - **Option C: Its platform improvements not considered collaboration technology** - The company retained its platform improvements that were not considered collaboration technology.\n   - **Option D: The patent rights from BWH** - The company did not retain the patent rights from BWH; these are covered under a separate agreement.\n   - **Option E: Patent rights for all new programs** - The company retained rights to programs not selected by Novartis, but not necessarily all new programs.\n   - **Option F: Worldwide rights to Novartis's products** - The company did not retain worldwide rights to Novartis's products.\n\n4. **Conclusion**: Based on the information provided, the company retained its platform improvements that were not considered collaboration technology.\n\nTherefore, the correct answer is **C: Its platform improvements not considered collaboration technology**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 32000, "result": 1.0, "question": "What does the Anti-Kickback Statute (AKS) make illegal?", "options": {"A": "Manufacturing drugs without a license", "B": "Prescribing drugs without patient consent", "C": "Offering or paying remuneration to induce drug referrals", "D": "Selling drugs at a profit under federal programs", "E": "Importing drugs from unauthorized countries", "F": "Falsifying clinical trial data"}, "LLM_original_answer": ["To answer the question \"What does the Anti-Kickback Statute (AKS) make illegal?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that specifically discusses the Anti-Kickback Statute (AKS).\n\n2. **Extract the key information**: The relevant information is found in the following paragraph:\n   - \"the Anti-Kickback Statute, or AKS, which makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is intended to induce or reward, referrals including the purchase, recommendation, order or prescription of a particular drug for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs.\"\n\n3. **Analyze the extracted information**:\n   - The AKS makes it illegal to offer or pay remuneration to induce or reward referrals.\n   - This includes the purchase, recommendation, order, or prescription of a particular drug for which payment may be made under a federal healthcare program.\n\n4. **Match the extracted information to the given options**:\n   - **Option A**: Manufacturing drugs without a license - This is not mentioned in the AKS description.\n   - **Option B**: Prescribing drugs without patient consent - This is not mentioned in the AKS description.\n   - **Option C**: Offering or paying remuneration to induce drug referrals - This matches the description of the AKS.\n   - **Option D**: Selling drugs at a profit under federal programs - This is not mentioned in the AKS description.\n   - **Option E**: Importing drugs from unauthorized countries - This is not mentioned in the AKS description.\n   - **Option F**: Falsifying clinical trial data - This is not mentioned in the AKS description.\n\n5. **Conclude the answer**:\n   - The correct answer is **Option C**: Offering or paying remuneration to induce drug referrals.\n\nTherefore, the Anti-Kickback Statute (AKS) makes it illegal to offer or pay remuneration to induce drug referrals."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 32000, "result": 1.0, "question": "What does Delaware law limit regarding certain interested stockholders?", "options": {"A": "Their ability to vote in board elections", "B": "Their right to receive dividends", "C": "Their ability to change corporate policies", "D": "Their ability to cause mergers or acquisitions against the Board's wishes", "E": "Their eligibility to hold shares", "F": "Their power to appoint board members"}, "LLM_original_answer": ["To answer the question \"What does Delaware law limit regarding certain interested stockholders?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for mentions of Delaware law and its provisions related to interested stockholders.\n2. **Analyze the Information**: Determine what specific limitations are mentioned.\n3. **Match to Options**: Compare the identified limitations to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant section from the document is:\n- \"Provisions of our organizational documents and Delaware law may delay or deter a change of control of ICE.\"\n- \"Further, our organizational documents generally limit the ability of stockholders to act by written consent, and generally authorize our Board of Directors, without stockholder approval, to issue and fix the rights and preferences of one or more series of preferred stock.\"\n- \"In addition, provisions of Delaware law may have a similar effect, such as provisions limiting the ability of certain interested stockholders, as defined under Delaware law, from causing the merger or acquisition of a corporation against the wishes of the Board of Directors.\"\n\n### Step 2: Analyze the Information\n- The document mentions that Delaware law has provisions that can delay or deter a change of control of the company.\n- It specifically states that Delaware law limits the ability of certain interested stockholders from causing mergers or acquisitions against the wishes of the Board of Directors.\n\n### Step 3: Match to Options\n- **Option A**: Their ability to vote in board elections\n  - The document does not mention voting in board elections.\n- **Option B**: Their right to receive dividends\n  - The document does not mention dividends.\n- **Option C**: Their ability to change corporate policies\n  - The document does not mention changing corporate policies.\n- **Option D**: Their ability to cause mergers or acquisitions against the Board's wishes\n  - This matches the specific limitation mentioned in the document.\n- **Option E**: Their eligibility to hold shares\n  - The document does not mention eligibility to hold shares.\n- **Option F**: Their power to appoint board members\n  - The document does not mention appointing board members.\n\n### Conclusion\nThe best match to the information provided in the document is **Option D**: Their ability to cause mergers or acquisitions against the Board's wishes.\n\nTherefore, the answer to the question is **D: Their ability to cause mergers or acquisitions against the Board's wishes**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 15, "token_lengths": 32000, "result": 1.0, "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?", "options": {"A": "To increase the valuation of all liabilities", "B": "To provide detailed forecasts of economic trends", "C": "To update models based on credible evidence and ensure appropriate valuation practices", "D": "To calculate exact amounts for future policy benefits", "E": "To review marketing strategies for insurance products", "F": "To assess the financial performance of competitors"}, "LLM_original_answer": ["To answer the question \"What is the purpose of the annual actuarial review (AAR) conducted by the company?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for sections that discuss the annual actuarial review (AAR) and its purpose.\n2. **Extract Key Points**: Highlight the specific purposes and activities associated with the AAR.\n3. **Match to Options**: Compare the extracted key points to the given options to determine the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant section from the document is:\n\n> \"We conduct an annual actuarial review (the \u201cAAR\u201d) of the key inputs into our actuarial models that rely on management judgment and update any models where we have credible evidence from actual experience, industry data or other relevant sources to ensure our price-setting criteria and reserve valuation practices continue to be appropriate.\"\n\n### Step 2: Extract Key Points\n- **Review Key Inputs**: The AAR reviews the key inputs into actuarial models.\n- **Update Models**: Models are updated based on credible evidence from actual experience, industry data, or other relevant sources.\n- **Ensure Appropriateness**: The review ensures that price-setting criteria and reserve valuation practices are appropriate.\n\n### Step 3: Match to Options\n- **Option A**: To increase the valuation of all liabilities. (Not mentioned in the document)\n- **Option B**: To provide detailed forecasts of economic trends. (Not mentioned in the document)\n- **Option C**: To update models based on credible evidence and ensure appropriate valuation practices. (Matches the key points)\n- **Option D**: To calculate exact amounts for future policy benefits. (Not mentioned in the document)\n- **Option E**: To review marketing strategies for insurance products. (Not mentioned in the document)\n- **Option F**: To assess the financial performance of competitors. (Not mentioned in the document)\n\n### Conclusion\nThe purpose of the annual actuarial review (AAR) conducted by the company is to update models based on credible evidence and ensure appropriate valuation practices. Therefore, the correct answer is:\n\n**C: To update models based on credible evidence and ensure appropriate valuation practices**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 64000, "result": 1.0, "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?", "options": {"A": "New Drug Application (NDA)", "B": "Biologics License Application (BLA)", "C": "Investigational New Drug (IND) application", "D": "Clinical Trial Report (CTR)", "E": "Good Manufacturing Practice (GMP) Report", "F": "Independent Review Board (IRB) approval"}, "LLM_original_answer": ["To answer the question \"What must be submitted to the FDA before starting human clinical trials for a new drug?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the Regulatory Process for Clinical Trials:**\n   - The document outlines the regulatory process for drug and biological product development in the United States, which is overseen by the FDA.\n\n2. **Determine the Initial Step for Clinical Trials:**\n   - According to the document, before human clinical trials can begin, an Investigational New Drug (IND) application must be submitted to the FDA and become effective.\n\n3. **Review the Content of the IND Application:**\n   - The IND application includes:\n     - Results of preclinical studies.\n     - Manufacturing information.\n     - Analytical data.\n     - Any available clinical data or literature.\n     - A proposed clinical protocol.\n\n4. **Evaluate the Options:**\n   - **A: New Drug Application (NDA)** - This is submitted after all clinical trials are completed and is used to request marketing approval.\n   - **B: Biologics License Application (BLA)** - Similar to NDA, this is submitted after clinical trials for biologics to request marketing approval.\n   - **C: Investigational New Drug (IND) application** - This is the application that must be submitted and become effective before human clinical trials can begin.\n   - **D: Clinical Trial Report (CTR)** - This is not mentioned in the document as a requirement before starting clinical trials.\n   - **E: Good Manufacturing Practice (GMP) Report** - While GMP is important, the document does not mention a specific GMP report as a requirement before starting clinical trials.\n   - **F: Independent Review Board (IRB) approval** - While IRB approval is necessary, it is not the primary document submitted to the FDA before starting clinical trials.\n\n5. **Conclusion:**\n   - Based on the information provided in the document, the correct answer is **C: Investigational New Drug (IND) application**.\n\nTherefore, the answer to the question is **C: Investigational New Drug (IND) application**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 64000, "result": 1.0, "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?", "options": {"A": "CryptoLicense", "B": "CoinPermit", "C": "BitLicense", "D": "VirtualCoin License", "E": "DigitalCurrency Regulation", "F": "TokenTrade Accreditation"}, "LLM_original_answer": ["The correct answer is **C: BitLicense**.\n\n### Chain of Thought:\n1. **Identify the Relevant Information**: The question asks about a regulation enacted by the New York State Department of Financial Services in August 2015 for virtual currency business activity.\n2. **Locate the Information in the Document**: Scanning the document, I find the following relevant passage:\n   - \"For example, in August 2015, the New York State Department of Financial Services enacted the first U.S. regulatory framework for licensing participants in 'virtual currency business activity.' The regulations, known as the 'BitLicense,' are intended to focus on consumer protection and regulate the conduct of businesses that are involved in 'virtual currencies' in New York or with New York customers and prohibit any person or entity involved in such activity to conduct activities without a license.\"\n3. **Match the Information to the Options**: The passage clearly states that the regulations are known as the \"BitLicense.\"\n4. **Confirm the Answer**: The BitLicense is the regulation that matches the description in the question.\n\nTherefore, the correct answer is **C: BitLicense**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 64000, "result": 1.0, "question": "What challenge is associated with an aging workforce at Duke Energy?", "options": {"A": "Increased security threats", "B": "Mismatch of skill set with future needs", "C": "Higher insurance premiums", "D": "Decreased operational reliability", "E": "Reduced interest in renewable energy projects", "F": "Difficulty in obtaining raw materials"}, "LLM_original_answer": ["To answer the question \"What challenge is associated with an aging workforce at Duke Energy?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Scan the document for sections that discuss workforce-related challenges, particularly those mentioning an aging workforce.\n2. **Extract Key Information**: Pull out the specific information related to the aging workforce and its implications.\n3. **Match to Options**: Compare the extracted information to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in the \"Matters Impacting Future Results\" section, specifically under \"Failure to attract and retain an appropriately qualified workforce could unfavorably impact the Duke Energy Registrants\u2019 results of operations.\"\n\n### Step 2: Extract Key Information\nFrom the document:\n- \"Failure to attract and retain an appropriately qualified workforce could unfavorably impact the Duke Energy Registrants\u2019 results of operations.\"\n- \"Certain events, such as an aging workforce, mismatch of skill set or complement to future needs, or unavailability of contract resources may lead to operating challenges and increased costs.\"\n- \"The challenges include lack of resources, loss of knowledge base and the lengthy time required for skill development.\"\n- \"In this case, costs, including costs for contractors to replace employees, productivity costs and safety costs, may increase.\"\n- \"Failure to hire and adequately train replacement employees, including the transfer of significant internal historical knowledge and expertise to new employees, or future availability and cost of contract labor may adversely affect the ability to manage and operate the business, especially considering the workforce needs associated with nuclear generation facilities and new skills required to operate a modernized, technology-enabled power grid.\"\n\n### Step 3: Match to Options\n- **Option A: Increased security threats** - The document does not mention increased security threats as a direct result of an aging workforce.\n- **Option B: Mismatch of skill set with future needs** - The document explicitly mentions \"mismatch of skill set or complement to future needs\" as a challenge associated with an aging workforce.\n- **Option C: Higher insurance premiums** - The document does not mention higher insurance premiums as a direct result of an aging workforce.\n- **Option D: Decreased operational reliability** - While the document mentions increased costs and challenges, it does not directly state decreased operational reliability.\n- **Option E: Reduced interest in renewable energy projects** - The document does not mention reduced interest in renewable energy projects as a direct result of an aging workforce.\n- **Option F: Difficulty in"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 64000, "result": 1.0, "question": "What is one of the uncertainties associated with the pending merger with Cambridge?", "options": {"A": "Lack of interest from investors", "B": "Potential for delays in regulatory approvals", "C": "Shortage of qualified staff for integration", "D": "Incompatibility of business cultures", "E": "Difficulty in finding a new office location", "F": "Insufficient marketing budget"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document for information related to the uncertainties associated with the pending merger with Cambridge.\n\n1. **Regulatory Approvals**: The document mentions that the merger is subject to numerous uncertainties and risks, including \"the potential for delays or burdensome conditions associated with regulatory approvals\" (Section 28). This directly aligns with option B: \"Potential for delays in regulatory approvals.\"\n\n2. **Shareholder Litigation**: The document also notes that \"shareholder litigation could prevent or delay the completion of the merger or otherwise negatively impact the business and operations of the Company and Cambridge\" (Section 28). However, this is not listed as one of the options.\n\n3. **Integration Costs and Efforts**: The document states that \"the Company and Cambridge have incurred and expect to continue to incur significant costs related to the merger and integration\" (Section 28). This is related to option C: \"Shortage of qualified staff for integration,\" but it is more about the costs and efforts rather than a shortage of staff.\n\n4. **Assumption of Liabilities**: The document mentions that \"assumption of significant (and potentially unknown) liabilities, and inexperience with the products and/or geographies offered by the acquired business\" (Section 28) could be a risk. This is not directly listed in the options.\n\n5. **Termination of Merger Agreement**: The document notes that \"the pending merger may not be timely completed or at all\" (Section 28), which could be related to the termination of the merger agreement. However, this is not listed as an option.\n\n6. **Other Risks**: The document also discusses other risks such as \"significant or unexpected expenses associated with the merger and integration\" (Section 28), but these are more general and not specific to the options provided.\n\nGiven the information in the document, the most relevant and directly mentioned uncertainty is:\n\n**B: Potential for delays in regulatory approvals**\n\nThis option is explicitly mentioned in the document as one of the uncertainties associated with the pending merger with Cambridge."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 64000, "result": 1.0, "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?", "options": {"A": "Completion of Phase 4 trials before initial approval", "B": "An agreement to conduct post-approval confirmatory studies", "C": "Exemption from all clinical trials", "D": "Immediate proof of long-term survival benefit", "E": "Approval from international health organizations", "F": "Evidence of zero side effects"}, "LLM_original_answer": ["To answer the question \"What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Surrogate or Intermediate Clinical Endpoint**:\n   - The document states: \"The FDA may grant Accelerated Approval to a drug or biological product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over available treatments based upon a determination that the drug or biological product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit.\"\n   - It further explains: \"For the purposes of Accelerated Approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit.\"\n\n2. **Post-Approval Confirmatory Studies**:\n   - The document emphasizes: \"Drugs and biological products granted Accelerated Approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.\"\n   - It also states: \"The Accelerated Approval Pathway is contingent on a sponsor\u2019s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product\u2019s clinical benefit.\"\n\n3. **Other Options**:\n   - **Completion of Phase 4 trials before initial approval**: The document does not mention this as a requirement for initial approval under the Accelerated Approval Pathway.\n   - **Exemption from all clinical trials**: The document clearly states that clinical trials are required, and the pathway is based on surrogate or intermediate endpoints.\n   - **Immediate proof of long-term survival benefit**: The document indicates that the pathway is based on surrogate or intermediate endpoints, not necessarily long-term survival.\n   - **Approval from international health organizations**: The document focuses on FDA approval and does not mention international health organizations as a requirement.\n   - **Evidence of zero side effects**: The document does not suggest that zero side effects are required; rather, it emphasizes the need to demonstrate safety and effectiveness.\n\nGiven this information, the correct answer is:\n\n**B: An agreement to conduct post-approval confirmatory studies**\n\nThis is explicitly stated in the document as a requirement for drugs and biological products granted Accelerated Approval. The FDA requires these studies to verify and describe the product\u2019s clinical benefit, ensuring that the initial approval based on surrogate or intermediate endpoints is supported by subsequent confirmatory data."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 64000, "result": 1.0, "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?", "options": {"A": "The issuance of new senior secured notes", "B": "The maturity of $360.0 million aggregate principal amount", "C": "A decrease in interest rates", "D": "An increase in fair value adjustment", "E": "The sale of $360.0 million securities", "F": "The acquisition of additional senior secured notes"}, "LLM_original_answer": ["The financial event planned for March 15, 2026, involving PHH\u2019s senior secured notes is the maturity of $360.0 million aggregate principal amount. This can be found in the document under the section \"Risks Related to Our Financial Performance, Financing Our Business, Liquidity and Net Worth and the Economy,\" where it states:\n\n\"In addition, $360.0 million aggregate principal amount of PHH\u2019s 7.875% senior secured notes (the PMC Senior Secured Notes) mature on March 15, 2026 and OFC\u2019s $285.0 million aggregate principal amount senior secured notes (the OFC Senior Secured Notes) mature on March 4, 2027.\"\n\nTherefore, the correct answer is:\n\n**B: The maturity of $360.0 million aggregate principal amount**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 64000, "result": 1.0, "question": "What rights did the company retain after the collaboration with Novartis concluded?", "options": {"A": "All of Novartis's intellectual property", "B": "The technology developed during collaboration", "C": "Its platform improvements not considered collaboration technology", "D": "The patent rights from BWH", "E": "Patent rights for all new programs", "F": "Worldwide rights to Novartis's products"}, "LLM_original_answer": ["To answer the question \"What rights did the company retain after the collaboration with Novartis concluded?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Collaboration and License Agreement with Novartis**:\n   - The company entered into a Collaboration and License Agreement with Novartis on March 27, 2020.\n   - The collaboration concluded in March 2023.\n\n2. **Rights Retained by the Company**:\n   - The document states: \"The ownership of inventions (and resulting patent rights) created in performance of the collaboration was determined by inventorship.\"\n   - The company retained:\n     - (i) its intellectual property.\n     - (ii) programs that are not selected by Novartis.\n     - (iii) its platform improvements, which were not considered collaboration technology.\n\n3. **Analyzing the Options**:\n   - **Option A**: All of Novartis's intellectual property - This is not correct because the company did not retain Novartis's intellectual property.\n   - **Option B**: The technology developed during collaboration - This is not correct because the ownership of inventions created during the collaboration was determined by inventorship, and the company did not retain all of the technology developed during the collaboration.\n   - **Option C**: Its platform improvements not considered collaboration technology - This is correct as the document explicitly states that the company retained its platform improvements not considered collaboration technology.\n   - **Option D**: The patent rights from BWH - This is not correct because the company's rights to BWH's patent rights are separate from the Novartis collaboration.\n   - **Option E**: Patent rights for all new programs - This is not correct because the company only retained programs that were not selected by Novartis.\n   - **Option F**: Worldwide rights to Novartis's products - This is not correct because the company did not retain worldwide rights to Novartis's products.\n\nBased on the information provided in the document, the correct answer is:\n\n**C: Its platform improvements not considered collaboration technology**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 64000, "result": 1.0, "question": "What does the Anti-Kickback Statute (AKS) make illegal?", "options": {"A": "Manufacturing drugs without a license", "B": "Prescribing drugs without patient consent", "C": "Offering or paying remuneration to induce drug referrals", "D": "Selling drugs at a profit under federal programs", "E": "Importing drugs from unauthorized countries", "F": "Falsifying clinical trial data"}, "LLM_original_answer": ["The correct answer to the question \"What does the Anti-Kickback Statute (AKS) make illegal?\" is:\n\nC: Offering or paying remuneration to induce drug referrals\n\n### Chain of Thought:\n1. **Identify the Statute**: The question is about the Anti-Kickback Statute (AKS), which is a federal law in the United States.\n2. **Understand the Statute's Purpose**: The AKS is designed to prevent fraud and abuse in the healthcare system, particularly in relation to federal healthcare programs like Medicare and Medicaid.\n3. **Review the Document**: The document provides a detailed description of the AKS, stating: \"the Anti-Kickback Statute, or AKS, which makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is intended to induce or reward, referrals including the purchase, recommendation, order or prescription of a particular drug for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs.\"\n4. **Match the Description to the Options**:\n   - **A: Manufacturing drugs without a license** - This is not mentioned in the AKS description.\n   - **B: Prescribing drugs without patient consent** - This is not mentioned in the AKS description.\n   - **C: Offering or paying remuneration to induce drug referrals** - This matches the description in the document.\n   - **D: Selling drugs at a profit under federal programs** - This is not mentioned in the AKS description.\n   - **E: Importing drugs from unauthorized countries** - This is not mentioned in the AKS description.\n   - **F: Falsifying clinical trial data** - This is not mentioned in the AKS description.\n\n5. **Conclusion**: The document clearly states that the AKS makes it illegal to offer or pay remuneration to induce drug referrals, which corresponds to option C.\n\nTherefore, the correct answer is C: Offering or paying remuneration to induce drug referrals."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 64000, "result": 1.0, "question": "What does Delaware law limit regarding certain interested stockholders?", "options": {"A": "Their ability to vote in board elections", "B": "Their right to receive dividends", "C": "Their ability to change corporate policies", "D": "Their ability to cause mergers or acquisitions against the Board's wishes", "E": "Their eligibility to hold shares", "F": "Their power to appoint board members"}, "LLM_original_answer": ["To answer the question \"What does Delaware law limit regarding certain interested stockholders?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for mentions of Delaware law and its impact on stockholders.\n2. **Analyze the Information**: Determine what specific limitations are mentioned.\n3. **Match to Options**: Compare the identified limitations to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant section from the document is:\n- **Provisions of our organizational documents and Delaware law may delay or deter a change of control of ICE.**\n- **Our organizational documents include provisions that generally restrict any person (either alone or together with its related persons) from (i) voting or causing the voting of shares of stock representing more than 10% of our outstanding voting capital stock (including as a result of any agreement by any other persons not to vote shares of stock) or (ii) beneficially owning shares of stock representing more than 20% of the outstanding shares of any class or series of our capital stock.**\n- **Further, our organizational documents generally limit the ability of stockholders to act by written consent, and generally authorize our Board of Directors, without stockholder approval, to issue and fix the rights and preferences of one or more series of preferred stock.**\n- **In addition, provisions of Delaware law may have a similar effect, such as provisions limiting the ability of certain interested stockholders, as defined under Delaware law, from causing the merger or acquisition of a corporation against the wishes of the Board of Directors.**\n\n### Step 2: Analyze the Information\n- **Voting Restrictions**: Delaware law and the company's organizational documents restrict any person from voting more than 10% of the outstanding voting capital stock.\n- **Ownership Restrictions**: Delaware law and the company's organizational documents restrict any person from beneficially owning more than 20% of the outstanding shares of any class or series of capital stock.\n- **Written Consent**: The company's organizational documents limit the ability of stockholders to act by written consent.\n- **Board Authorization**: The company's organizational documents authorize the Board of Directors to issue and fix the rights and preferences of preferred stock without stockholder approval.\n- **Merger and Acquisition**: Delaware law limits the ability of certain interested stockholders from causing the merger or acquisition of a corporation against the wishes of the Board of Directors.\n\n### Step 3: Match to Options\n- **Option A:"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 15, "token_lengths": 64000, "result": 1.0, "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?", "options": {"A": "To increase the valuation of all liabilities", "B": "To provide detailed forecasts of economic trends", "C": "To update models based on credible evidence and ensure appropriate valuation practices", "D": "To calculate exact amounts for future policy benefits", "E": "To review marketing strategies for insurance products", "F": "To assess the financial performance of competitors"}, "LLM_original_answer": ["The purpose of the annual actuarial review (AAR) conducted by the company, as described in the document, is to update models based on credible evidence and ensure appropriate valuation practices. Specifically, the document states:\n\n\"We conduct an annual actuarial review (the 'AAR') of the key inputs into our actuarial models that rely on management judgment and update any models where we have credible evidence from actual experience, industry data or other relevant sources to ensure our price-setting criteria and reserve valuation practices continue to be appropriate.\"\n\nThis aligns with option C: \"To update models based on credible evidence and ensure appropriate valuation practices.\"\n\nTherefore, the correct answer is C."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 96000, "result": 1.0, "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?", "options": {"A": "New Drug Application (NDA)", "B": "Biologics License Application (BLA)", "C": "Investigational New Drug (IND) application", "D": "Clinical Trial Report (CTR)", "E": "Good Manufacturing Practice (GMP) Report", "F": "Independent Review Board (IRB) approval"}, "LLM_original_answer": ["To answer the question \"What must be submitted to the FDA before starting human clinical trials for a new drug?\" based on the provided document, let's go through the relevant information step by step:\n\n1. **Identify the Regulatory Process**: The document outlines the regulatory process for drug development, which includes preclinical studies and clinical trials. It mentions that before starting human clinical trials, an Investigational New Drug (IND) application must be submitted to the FDA.\n\n2. **Content of the IND Application**: The document specifies what must be included in an IND application:\n   - **Results of Preclinical Studies**: This includes laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess safety and in some cases to establish a rationale for therapeutic use.\n   - **Manufacturing Information**: Details about the manufacturing process and quality control.\n   - **Analytical Data**: Information about the product's chemical and physical characteristics.\n   - **Any Available Clinical Data or Literature**: Any existing human data or literature that supports the use of the investigational product.\n   - **Proposed Clinical Protocol**: The detailed plan for the clinical trial, including objectives, dosing procedures, subject selection and exclusion criteria, and parameters for monitoring subject safety and assessing efficacy.\n\n3. **Review the Options**:\n   - **A: New Drug Application (NDA)**: This is submitted after completing all clinical trials and is for marketing approval, not for starting clinical trials.\n   - **B: Biologics License Application (BLA)**: Similar to NDA, this is for marketing approval, not for starting clinical trials.\n   - **C: Investigational New Drug (IND) application**: This is the correct application that must be submitted before starting human clinical trials.\n   - **D: Clinical Trial Report (CTR)**: This is not a required submission before starting clinical trials; it is more relevant to reporting the results of completed trials.\n   - **E: Good Manufacturing Practice (GMP) Report**: While GMP compliance is crucial, a specific GMP report is not the primary document required for starting clinical trials.\n   - **F: Independent Review Board (IRB) approval**: IRB approval is necessary but is not the primary document submitted to the FDA; it is a requirement for each clinical site.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **C: Investigational New Drug (IND) application**.\n\nTherefore, the answer to the question is **C: Investigational New Drug"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 96000, "result": 1.0, "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?", "options": {"A": "CryptoLicense", "B": "CoinPermit", "C": "BitLicense", "D": "VirtualCoin License", "E": "DigitalCurrency Regulation", "F": "TokenTrade Accreditation"}, "LLM_original_answer": ["The correct answer to the question \"What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?\" is:\n\n**C: BitLicense**\n\n### Chain of Thought:\n1. **Identify the Relevant Information**: The document mentions regulatory actions and frameworks related to digital assets and virtual currencies.\n2. **Locate the Specific Regulation**: The document states, \"In August 2015, the New York State Department of Financial Services enacted the first U.S. regulatory framework for licensing participants in 'virtual currency business activity.'\"\n3. **Determine the Name of the Regulation**: The document further clarifies that this regulatory framework is known as the \"BitLicense.\"\n4. **Verify the Options**: Among the provided options, \"BitLicense\" (Option C) matches the name of the regulation mentioned in the document.\n\nTherefore, the New York State Department of Financial Services enacted the **BitLicense** regulation in August 2015 for virtual currency business activity."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 96000, "result": 1.0, "question": "What challenge is associated with an aging workforce at Duke Energy?", "options": {"A": "Increased security threats", "B": "Mismatch of skill set with future needs", "C": "Higher insurance premiums", "D": "Decreased operational reliability", "E": "Reduced interest in renewable energy projects", "F": "Difficulty in obtaining raw materials"}, "LLM_original_answer": ["To answer the question, \"What challenge is associated with an aging workforce at Duke Energy?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Scan the document for sections that discuss workforce management, particularly those that mention the aging workforce.\n2. **Extract Key Information**: From the identified sections, extract information that directly or indirectly relates to the challenges of an aging workforce.\n3. **Match to Options**: Compare the extracted information to the given options to determine the most appropriate answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found under \"Human Capital Management\" and \"Failure to attract and retain an appropriately qualified workforce could unfavorably impact the Duke Energy Registrants\u2019 results of operations.\"\n\n### Step 2: Extract Key Information\n- **Human Capital Management**:\n  - \"Key areas of focus include fostering a high-performance and inclusive culture built on strong leadership and highly engaged and diverse employees, building a pipeline of skilled workers and ensuring knowledge transfer as employees retire.\"\n  - \"Our Board of Directors provides oversight on certain human capital management matters, primarily through the Compensation and People Development Committee, which is responsible for reviewing strategies and policies related to human capital management, including with respect to matters such as diversity and inclusion, employee engagement and talent development.\"\n\n- **Failure to attract and retain an appropriately qualified workforce**:\n  - \"Certain events, such as an aging workforce, mismatch of skill set or complement to future needs, or unavailability of contract resources may lead to operating challenges and increased costs.\"\n  - \"The challenges include lack of resources, loss of knowledge base and the lengthy time required for skill development.\"\n  - \"Failure to hire and adequately train replacement employees, including the transfer of significant internal historical knowledge and expertise to new employees, or future availability and cost of contract labor may adversely affect the ability to manage and operate the business, especially considering the workforce needs associated with nuclear generation facilities and new skills required to operate a modernized, technology-enabled power grid.\"\n\n### Step 3: Match to Options\n- **Option A: Increased security threats** - The document does not mention increased security threats as a direct challenge of an aging workforce.\n- **Option B: Mismatch of skill set with future needs** - The document explicitly mentions \"mismatch of skill set or complement to future needs\" as a challenge associated with an aging workforce.\n- **Option C: Higher insurance premiums** - The document does not mention higher insurance premiums as a direct challenge of an aging workforce.\n- **Option"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 96000, "result": 1.0, "question": "What is one of the uncertainties associated with the pending merger with Cambridge?", "options": {"A": "Lack of interest from investors", "B": "Potential for delays in regulatory approvals", "C": "Shortage of qualified staff for integration", "D": "Incompatibility of business cultures", "E": "Difficulty in finding a new office location", "F": "Insufficient marketing budget"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document for information related to the uncertainties associated with the pending merger with Cambridge.\n\nThe document mentions several uncertainties and risks associated with the merger, including:\n\n1. **Regulatory Approvals**: \"Before the merger may be completed, certain approvals or consents must be obtained from various bank regulatory and other authorities of the United States, the Commonwealth of Massachusetts and the State of New Hampshire. These governmental entities, including the Federal Reserve Board, the FDIC, the Massachusetts Division of Banks and the New Hampshire Banking Department, may impose conditions on the completion of the merger or require changes to the terms of the merger. Any such conditions or changes could have the effect of delaying completion of the merger or imposing additional costs on or limiting the revenues of the Company following the merger, any of which might have a material adverse effect on the Company following the merger.\"\n\n2. **Shareholder Litigation**: \"Shareholder litigation could prevent or delay the completion of the merger or otherwise negatively impact the business and operations of the Company and Cambridge. Shareholders of the Company and/or Cambridge may file lawsuits against the Company, Cambridge and/or the directors and officers of either company in connection with the merger.\"\n\n3. **Integration Costs and Efforts**: \"The Company and Cambridge have incurred and expect to continue to incur significant, non-recurring costs in connection with negotiating the merger agreement and closing the merger. In addition, the Company will incur integration costs following the completion of the merger as the Company integrates the Cambridge business, including facilities and systems consolidation costs and employment-related costs.\"\n\n4. **Retention of Key Personnel**: \"The success of the merger will depend in part on the Company\u2019s ability to retain the talents and dedication of key employees currently employed by the Company and Cambridge. It is possible that these employees may decide not to remain with the Company or Cambridge, as applicable, while the merger is pending or with the Company after the merger is completed.\"\n\n5. **Assumption of Liabilities**: \"To the extent that we acquire other companies, including Cambridge and its subsidiary Cambridge Trust Company, our business may be negatively impacted by certain risks inherent with such acquisitions, including assumption of or potential exposure to significant liabilities of the acquired business, some of which may be unknown or contingent at the time of acquisition, including, without limitation, liabilities for regulatory and compliance issues.\"\n\nFrom these points, the most directly relevant uncertainty associated with the pending merger with Cambridge is the potential for delays or burdensome conditions associated with regulatory approvals.\n\nTherefore, the correct answer is:\n"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 96000, "result": 1.0, "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?", "options": {"A": "Completion of Phase 4 trials before initial approval", "B": "An agreement to conduct post-approval confirmatory studies", "C": "Exemption from all clinical trials", "D": "Immediate proof of long-term survival benefit", "E": "Approval from international health organizations", "F": "Evidence of zero side effects"}, "LLM_original_answer": ["To answer the question \"What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Surrogate or Intermediate Clinical Endpoint**:\n   - The document states: \"The FDA may grant Accelerated Approval to a drug or biological product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over available treatments based upon a determination that the drug or biological product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit.\"\n   - It further explains: \"For the purposes of Accelerated Approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit.\"\n\n2. **Post-Approval Confirmatory Studies**:\n   - The document mentions: \"Drugs and biological products granted Accelerated Approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.\"\n   - It also states: \"The Accelerated Approval Pathway is contingent on a sponsor\u2019s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product\u2019s clinical benefit.\"\n\n3. **Regulatory Requirements**:\n   - The document emphasizes: \"As a result, a drug or biological product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint.\"\n\nGiven these points, the correct answer is:\n\n**B: An agreement to conduct post-approval confirmatory studies**\n\nThis option aligns with the requirement for post-approval confirmatory studies to verify and describe the product\u2019s clinical benefit, as outlined in the document. The other options are either incorrect or not supported by the information provided:\n\n- **A: Completion of Phase 4 trials before initial approval** - This is not required; Phase 4 trials are often required post-approval.\n- **C: Exemption from all clinical trials** - This is incorrect; the drug must still meet safety and effectiveness standards.\n- **D: Immediate proof of long-term survival benefit** - This is not required; the approval can be based on a surrogate or intermediate endpoint.\n- **E: Approval from international health organizations** - This is not mentioned as a requirement for FDA approval.\n- **F: Evidence of zero side effects** - This is not a realistic"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 96000, "result": 1.0, "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?", "options": {"A": "The issuance of new senior secured notes", "B": "The maturity of $360.0 million aggregate principal amount", "C": "A decrease in interest rates", "D": "An increase in fair value adjustment", "E": "The sale of $360.0 million securities", "F": "The acquisition of additional senior secured notes"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document to identify the relevant information about PHH\u2019s senior secured notes and the financial event planned for March 15, 2026.\n\n1. **Identify the relevant section in the document:**\n   - The relevant section is found in \"Note 14 \u2014 Borrowings\" and \"Note 15 \u2014 Other Liabilities.\"\n\n2. **Extract the key information:**\n   - From \"Note 14 \u2014 Borrowings\":\n     - \"Issuance of 7.875% Senior Secured Notes due 2026: On March 4, 2021, PHH (formerly referred to as PMC) completed the issuance and sale of $400.0 million aggregate principal amount of 7.875% senior secured notes due March 15, 2026 (the PMC Senior Secured Notes) at a discount of $2.1 million.\"\n     - \"Interest on the PMC Senior Secured Notes accrues at a rate of 7.875% per annum and is payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2021.\"\n     - \"PHH may redeem some or all of the PMC Senior Secured Notes at its option at the following redemption prices, plus accrued and unpaid interest, if any, on the notes redeemed to, but excluding, the redemption date if redeemed during the 12-month period beginning on March 15th of the years indicated below:\"\n\n3. **Determine the financial event:**\n   - The document clearly states that the $360.0 million aggregate principal amount of PHH\u2019s 7.875% senior secured notes matures on March 15, 2026.\n\n4. **Match the information to the options:**\n   - Option B: The maturity of $360.0 million aggregate principal amount.\n\nTherefore, the financial event planned for March 15, 2026, involving PHH\u2019s senior secured notes is the maturity of $360.0 million aggregate principal amount.\n\n**Final Answer: B**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 96000, "result": 1.0, "question": "What rights did the company retain after the collaboration with Novartis concluded?", "options": {"A": "All of Novartis's intellectual property", "B": "The technology developed during collaboration", "C": "Its platform improvements not considered collaboration technology", "D": "The patent rights from BWH", "E": "Patent rights for all new programs", "F": "Worldwide rights to Novartis's products"}, "LLM_original_answer": ["To answer the question \"What rights did the company retain after the collaboration with Novartis concluded?\", let's break down the relevant information from the provided document:\n\n1. **Collaboration and License Agreement with Novartis**:\n   - The company entered into a Collaboration and License Agreement with Novartis on March 27, 2020.\n   - The collaboration concluded in March 2023.\n\n2. **Rights Retained by the Company**:\n   - The document states: \"The ownership of inventions (and resulting patent rights) created in performance of the collaboration was determined by inventorship.\"\n   - The company retained:\n     - (i) its intellectual property.\n     - (ii) programs that are not selected by Novartis.\n     - (iii) its platform improvements, which were not considered collaboration technology.\n\n3. **Analysis**:\n   - **Option A: All of Novartis's intellectual property** - This is incorrect. The company did not retain Novartis's intellectual property.\n   - **Option B: The technology developed during collaboration** - This is incorrect. The ownership of inventions and resulting patent rights was determined by inventorship, and the company did not retain all technology developed during the collaboration.\n   - **Option C: Its platform improvements not considered collaboration technology** - This is correct. The company retained its platform improvements that were not considered collaboration technology.\n   - **Option D: The patent rights from BWH** - This is incorrect. The company has a separate agreement with BWH for patent rights.\n   - **Option E: Patent rights for all new programs** - This is incorrect. The company retained rights to programs not selected by Novartis, but not all new programs.\n   - **Option F: Worldwide rights to Novartis's products** - This is incorrect. The company did not retain worldwide rights to Novartis's products.\n\nBased on the information provided, the correct answer is:\n\n**C: Its platform improvements not considered collaboration technology**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 96000, "result": 1.0, "question": "What does the Anti-Kickback Statute (AKS) make illegal?", "options": {"A": "Manufacturing drugs without a license", "B": "Prescribing drugs without patient consent", "C": "Offering or paying remuneration to induce drug referrals", "D": "Selling drugs at a profit under federal programs", "E": "Importing drugs from unauthorized countries", "F": "Falsifying clinical trial data"}, "LLM_original_answer": ["To answer the question \"What does the Anti-Kickback Statute (AKS) make illegal?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that specifically discusses the Anti-Kickback Statute (AKS).\n\n2. **Extract the key information**: The relevant information is found in the section \"Other U.S. Healthcare Laws\" under \"Business\u2014Government Regulation.\"\n\n3. **Analyze the extracted information**: The section states:\n   - \"the Anti-Kickback Statute, or AKS, which makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is intended to induce or reward, referrals including the purchase, recommendation, order or prescription of a particular drug for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs.\"\n\n4. **Match the information to the given options**:\n   - **A: Manufacturing drugs without a license** - This is not mentioned in the AKS description.\n   - **B: Prescribing drugs without patient consent** - This is not mentioned in the AKS description.\n   - **C: Offering or paying remuneration to induce drug referrals** - This matches the description of the AKS.\n   - **D: Selling drugs at a profit under federal programs** - This is not mentioned in the AKS description.\n   - **E: Importing drugs from unauthorized countries** - This is not mentioned in the AKS description.\n   - **F: Falsifying clinical trial data** - This is not mentioned in the AKS description.\n\n5. **Conclusion**: Based on the information provided in the document, the correct answer is **C: Offering or paying remuneration to induce drug referrals**.\n\nTherefore, the Anti-Kickback Statute (AKS) makes illegal the offering or paying of remuneration to induce drug referrals."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 96000, "result": 1.0, "question": "What does Delaware law limit regarding certain interested stockholders?", "options": {"A": "Their ability to vote in board elections", "B": "Their right to receive dividends", "C": "Their ability to change corporate policies", "D": "Their ability to cause mergers or acquisitions against the Board's wishes", "E": "Their eligibility to hold shares", "F": "Their power to appoint board members"}, "LLM_original_answer": ["To answer the question \"What does Delaware law limit regarding certain interested stockholders?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for mentions of Delaware law and interested stockholders.\n2. **Analyze the Information**: Determine what specific limitations are mentioned.\n3. **Match to the Options**: Compare the identified limitations to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant section from the document is:\n\n> \"Provisions of our organizational documents and Delaware law may delay or deter a change of control of ICE. Our organizational documents contain provisions that may have the effect of discouraging, delaying or preventing a change of control of, or unsolicited acquisition proposals for, ICE. These provisions make a change of control less likely, which may be contrary to the desires of certain of our stockholders. Many of these provisions are required by relevant regulators in connection with our ownership and operation of U.S. and European equity exchanges. For example, our organizational documents include provisions that generally restrict any person (either alone or together with its related persons) from (i) voting or causing the voting of shares of stock representing more than 10% of our outstanding voting capital stock (including as a result of any agreement by any other persons not to vote shares of stock) or (ii) beneficially owning shares of stock representing more than 20% of the outstanding shares of any class or series of our capital stock. Further, our organizational documents generally limit the ability of stockholders to act by written consent, and generally authorize our Board of Directors, without stockholder approval, to issue and fix the rights and preferences of one or more series of preferred stock. In addition, provisions of Delaware law may have a similar effect, such as provisions limiting the ability of certain interested stockholders, as defined under Delaware law, from causing the merger or acquisition of a corporation against the wishes of the Board of Directors.\"\n\n### Step 2: Analyze the Information\n- **Voting Restrictions**: Delaware law and the company's organizational documents restrict any person from voting shares representing more than 10% of the outstanding voting capital stock.\n- **Ownership Restrictions**: Delaware law and the company's organizational documents restrict any person from beneficially owning shares representing more than 20% of the outstanding shares of any class or series of capital stock.\n- **Change of Control**: Delaware law includes provisions that limit the ability of certain interested stockholders from causing a merger or acquisition"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 15, "token_lengths": 96000, "result": 1.0, "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?", "options": {"A": "To increase the valuation of all liabilities", "B": "To provide detailed forecasts of economic trends", "C": "To update models based on credible evidence and ensure appropriate valuation practices", "D": "To calculate exact amounts for future policy benefits", "E": "To review marketing strategies for insurance products", "F": "To assess the financial performance of competitors"}, "LLM_original_answer": ["The purpose of the annual actuarial review (AAR) conducted by the company, as described in the provided document, is to update the key inputs into actuarial models that rely on management judgment and to ensure that the price-setting criteria and reserve valuation practices continue to be appropriate. This involves reviewing and updating assumptions based on credible evidence from actual experience, industry data, or other relevant sources.\n\nGiven this information, the correct answer is:\n\n**C: To update models based on credible evidence and ensure appropriate valuation practices**\n\n### Chain of Thoughts:\n1. **Identify the Key Purpose**: The document states that the AAR is conducted to \"update the key inputs into our actuarial models that rely on management judgment and update any models where we have credible evidence from actual experience, industry data or other relevant sources to ensure our price-setting criteria and reserve valuation practices continue to be appropriate.\"\n\n2. **Analyze the Options**:\n   - **A: To increase the valuation of all liabilities**: The AAR does not aim to increase the valuation of all liabilities; it aims to ensure the appropriateness of the valuation practices.\n   - **B: To provide detailed forecasts of economic trends**: While the AAR involves reviewing economic trends, its primary purpose is not to provide detailed forecasts.\n   - **C: To update models based on credible evidence and ensure appropriate valuation practices**: This aligns with the stated purpose of the AAR.\n   - **D: To calculate exact amounts for future policy benefits**: The AAR does not aim to calculate exact amounts but to ensure the appropriateness of the assumptions and models.\n   - **E: To review marketing strategies for insurance products**: The AAR is not focused on marketing strategies.\n   - **F: To assess the financial performance of competitors**: The AAR is not about assessing competitors' financial performance.\n\n3. **Conclusion**: Option C is the most accurate and aligns with the purpose described in the document."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 128000, "result": 1.0, "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?", "options": {"A": "New Drug Application (NDA)", "B": "Biologics License Application (BLA)", "C": "Investigational New Drug (IND) application", "D": "Clinical Trial Report (CTR)", "E": "Good Manufacturing Practice (GMP) Report", "F": "Independent Review Board (IRB) approval"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 128000, "result": 1.0, "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?", "options": {"A": "CryptoLicense", "B": "CoinPermit", "C": "BitLicense", "D": "VirtualCoin License", "E": "DigitalCurrency Regulation", "F": "TokenTrade Accreditation"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 128000, "result": 1.0, "question": "What challenge is associated with an aging workforce at Duke Energy?", "options": {"A": "Increased security threats", "B": "Mismatch of skill set with future needs", "C": "Higher insurance premiums", "D": "Decreased operational reliability", "E": "Reduced interest in renewable energy projects", "F": "Difficulty in obtaining raw materials"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 128000, "result": 1.0, "question": "What is one of the uncertainties associated with the pending merger with Cambridge?", "options": {"A": "Lack of interest from investors", "B": "Potential for delays in regulatory approvals", "C": "Shortage of qualified staff for integration", "D": "Incompatibility of business cultures", "E": "Difficulty in finding a new office location", "F": "Insufficient marketing budget"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 128000, "result": 1.0, "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?", "options": {"A": "Completion of Phase 4 trials before initial approval", "B": "An agreement to conduct post-approval confirmatory studies", "C": "Exemption from all clinical trials", "D": "Immediate proof of long-term survival benefit", "E": "Approval from international health organizations", "F": "Evidence of zero side effects"}, "LLM_original_answer": ["To answer the question \"What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Surrogate or Intermediate Clinical Endpoint**:\n   - The document states: \"The FDA may grant Accelerated Approval to a drug or biological product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over available treatments based upon a determination that the drug or biological product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit.\"\n   - It further explains: \"For the purposes of Accelerated Approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit.\"\n\n2. **Clinical Benefit**:\n   - The document mentions: \"The FDA may also grant Accelerated Approval for such drug or biological product for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (IMM) and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments.\"\n\n3. **Post-Approval Confirmatory Studies**:\n   - The document emphasizes: \"Drugs and biological products granted Accelerated Approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.\"\n   - It also states: \"The Accelerated Approval Pathway is contingent on a sponsor\u2019s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product\u2019s clinical benefit.\"\n\n4. **Regulatory Requirements**:\n   - The document notes: \"Approval through the Accelerated Approval Program is subject, however, to the requirement that the applicant conduct additional postmarketing clinical trials to verify and describe the drug\u2019s clinical benefit, where there is uncertainty as to the relationship of the surrogate endpoint to the clinical benefit, or of the observed clinical endpoint to ultimate outcome.\"\n\nGiven these points, the correct answer is:\n\n**B: An agreement to conduct post-approval confirmatory studies**\n\nThis option aligns with the requirement that the sponsor must agree to conduct additional post-approval confirmatory studies to verify and describe the product\u2019s clinical benefit, which is a key condition for Accelerated Approval as outlined in the document."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 128000, "result": 1.0, "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?", "options": {"A": "The issuance of new senior secured notes", "B": "The maturity of $360.0 million aggregate principal amount", "C": "A decrease in interest rates", "D": "An increase in fair value adjustment", "E": "The sale of $360.0 million securities", "F": "The acquisition of additional senior secured notes"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 15, "token_lengths": 128000, "result": 0.0, "question": "What rights did the company retain after the collaboration with Novartis concluded?", "options": {"A": "All of Novartis's intellectual property", "B": "The technology developed during collaboration", "C": "Its platform improvements not considered collaboration technology", "D": "The patent rights from BWH", "E": "Patent rights for all new programs", "F": "Worldwide rights to Novartis's products"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 128000, "result": 1.0, "question": "What does the Anti-Kickback Statute (AKS) make illegal?", "options": {"A": "Manufacturing drugs without a license", "B": "Prescribing drugs without patient consent", "C": "Offering or paying remuneration to induce drug referrals", "D": "Selling drugs at a profit under federal programs", "E": "Importing drugs from unauthorized countries", "F": "Falsifying clinical trial data"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 15, "token_lengths": 128000, "result": 1.0, "question": "What does Delaware law limit regarding certain interested stockholders?", "options": {"A": "Their ability to vote in board elections", "B": "Their right to receive dividends", "C": "Their ability to change corporate policies", "D": "Their ability to cause mergers or acquisitions against the Board's wishes", "E": "Their eligibility to hold shares", "F": "Their power to appoint board members"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 15, "token_lengths": 128000, "result": 1.0, "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?", "options": {"A": "To increase the valuation of all liabilities", "B": "To provide detailed forecasts of economic trends", "C": "To update models based on credible evidence and ensure appropriate valuation practices", "D": "To calculate exact amounts for future policy benefits", "E": "To review marketing strategies for insurance products", "F": "To assess the financial performance of competitors"}, "LLM_original_answer": ["The purpose of the annual actuarial review (AAR) conducted by the company is to update models based on credible evidence and ensure appropriate valuation practices. This is evident from the following excerpt from the document:\n\n\"We conduct an annual actuarial review (the \u201cAAR\u201d) of the key inputs into our actuarial models that rely on management judgment and update any models where we have credible evidence from actual experience, industry data or other relevant sources to ensure our price-setting criteria and reserve valuation practices continue to be appropriate.\"\n\nThis statement clearly indicates that the AAR is used to update actuarial models with credible evidence and to ensure that the company's valuation practices remain appropriate. Therefore, the correct answer is:\n\nC: To update models based on credible evidence and ensure appropriate valuation practices."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 8000, "result": 1.0, "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?", "options": {"A": "When the product is highly effective in children", "B": "If the disease only occurs in children", "C": "When the product shows uncertain efficacy in adults", "D": "If the product is likely ineffective or unsafe in children", "E": "When there is sufficient pediatric market demand", "F": "If the product is cheaper than existing treatments"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the relevant section of the provided document and match it with the given options.\n\nThe relevant section from the document is:\n\"The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients.\"\n\nLet's break down the conditions under which the PDCO can waive the obligation to provide pediatric clinical trial data:\n\n1. **The product is likely to be ineffective or unsafe in children**:\n   - This matches option D: \"If the product is likely ineffective or unsafe in children.\"\n\n2. **The disease or condition for which the product is intended occurs only in adult populations**:\n   - This matches option B: \"If the disease only occurs in children\" (though it's more accurate to say \"occurs only in adults,\" the inverse is implied).\n\n3. **The product does not represent a significant therapeutic benefit over existing treatments for pediatric patients**:\n   - This matches option F: \"If the product is cheaper than existing treatments\" (though the document mentions \"therapeutic benefit\" rather than \"cheaper,\" the concept of not being a significant improvement is similar).\n\nNow, let's evaluate each option:\n\n- **Option A: When the product is highly effective in children**:\n  - The document does not mention this as a condition for waiving the obligation.\n\n- **Option B: If the disease only occurs in children**:\n  - The document mentions that the disease or condition occurs only in adult populations, which is the inverse of this option. Therefore, this option is not correct.\n\n- **Option C: When the product shows uncertain efficacy in adults**:\n  - The document does not mention this as a condition for waiving the obligation.\n\n- **Option D: If the product is likely ineffective or unsafe in children**:\n  - This is explicitly mentioned in the document as a condition for waiving the obligation.\n\n- **Option E: When there is sufficient pediatric market demand**:\n  - The document does not mention this as a condition for waiving the obligation.\n\n- **Option"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 8000, "result": 1.0, "question": "What factor could make it difficult for the company to retain key personnel?", "options": {"A": "Reduction in product sales", "B": "Delays in adopting management incentive plans", "C": "Expansion into new markets", "D": "Increased competition", "E": "Technological advancements", "F": "Change in stock prices"}, "LLM_original_answer": ["To answer the question \"What factor could make it difficult for the company to retain key personnel?\" based on the provided document, I will analyze the relevant sections and options step by step.\n\n### Step 1: Identify Relevant Sections\nThe document mentions several factors that could affect the company's ability to retain key personnel. The most relevant section is:\n\n- **\"The ability to attract and retain key personnel is critical to the success of our business and may be affected by our emergence from bankruptcy. The success of our business depends on key personnel. The ability to attract and retain these key personnel may be affected by our emergence from bankruptcy, the uncertainties currently facing the business and changes we may make to the organizational structure to adjust to changing circumstances.\"**\n- **\"Any potential delays in adopting our management incentive plan and other executive benefits and compensation may make it difficult to retain key personnel and we may need to enter into retention or other arrangements that could be costly to maintain.\"**\n\n### Step 2: Evaluate Each Option\nLet's evaluate each option against the information provided in the document:\n\n- **A: Reduction in product sales**\n  - The document does not mention product sales directly in the context of retaining key personnel. While a reduction in product sales could indirectly affect the company's financial health, it is not explicitly linked to personnel retention.\n\n- **B: Delays in adopting management incentive plans**\n  - The document explicitly states: \"Any potential delays in adopting our management incentive plan and other executive benefits and compensation may make it difficult to retain key personnel and we may need to enter into retention or other arrangements that could be costly to maintain.\" This directly links delays in adopting management incentive plans to difficulties in retaining key personnel.\n\n- **C: Expansion into new markets**\n  - The document does not mention expansion into new markets as a factor affecting personnel retention. While expansion could bring new challenges, it is not explicitly linked to the retention of key personnel.\n\n- **D: Increased competition**\n  - The document mentions increased competition as a general risk but does not specifically link it to the retention of key personnel. However, it is a plausible factor, but not as directly supported by the document as option B.\n\n- **E: Technological advancements**\n  - The document discusses technological advancements in the context of network protocols and forks, but it does not explicitly link these to personnel retention.\n\n- **F: Change in stock prices**\n  - The document mentions stock price volatility as a risk factor but does not explicitly link it to the retention of key personnel. While stock price"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 8000, "result": 1.0, "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?", "options": {"A": "Three years", "B": "Five years", "C": "Eight years", "D": "Ten years", "E": "Twelve years", "F": "Fifteen years"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant information in the document.\n2. Extract the specific detail that answers the question.\n3. Match the extracted detail to the provided options.\n\nStep 1: Identify the relevant information in the document.\nThe relevant information is found in the section discussing the company's safety record and performance in safety surveys.\n\nStep 2: Extract the specific detail that answers the question.\nThe document states: \"For the eighth consecutive year, we ranked first among North American combined gas and electric companies in Edison Electric Institute\u2019s (EEI) annual safety survey...\"\n\nStep 3: Match the extracted detail to the provided options.\nThe extracted detail indicates that the company has ranked first for 8 consecutive years. This matches with option C: Eight years.\n\nTherefore, the correct answer is C: Eight years."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 8000, "result": 1.0, "question": "Which factor is essential for increasing loan origination volume in the company's strategy?", "options": {"A": "Expanding international partnerships", "B": "Attracting and retaining skilled personnel", "C": "Reducing operational costs", "D": "Increasing online marketing efforts", "E": "Diversifying investment portfolio", "F": "Enhancing customer service training"}, "LLM_original_answer": ["To answer the question \"Which factor is essential for increasing loan origination volume in the company's strategy?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the Context**: The document discusses various aspects of the company's business, including cybersecurity, competition, strategic planning, and the importance of skilled personnel.\n\n2. **Locate Relevant Information**: The section that directly addresses the company's strategic plan and loan origination volume is:\n   - \"An important goal of our strategic plan is expanding our profitable loan and deposit market share through both organic growth and opportunistic strategic transactions.\"\n   - \"Our key assumptions include: that we will be able to attract and retain the requisite number of skilled and qualified personnel required to increase our loan origination volume, especially in our commercial banking portfolios.\"\n\n3. **Analyze the Options**:\n   - **A: Expanding international partnerships** - The document does not mention international partnerships as a key factor for increasing loan origination volume.\n   - **B: Attracting and retaining skilled personnel** - The document explicitly states that attracting and retaining skilled and qualified personnel is a key assumption for increasing loan origination volume, particularly in commercial banking portfolios.\n   - **C: Reducing operational costs** - While reducing operational costs is important for overall profitability, it is not specifically mentioned as a factor for increasing loan origination volume.\n   - **D: Increasing online marketing efforts** - The document does not highlight online marketing efforts as a key factor for increasing loan origination volume.\n   - **E: Diversifying investment portfolio** - The document discusses the investment portfolio but does not link it directly to increasing loan origination volume.\n   - **F: Enhancing customer service training** - While customer service training is important, it is not specifically mentioned as a factor for increasing loan origination volume.\n\n4. **Conclusion**: Based on the information provided in the document, the factor that is explicitly mentioned as essential for increasing loan origination volume is **attracting and retaining skilled personnel**.\n\nTherefore, the correct answer is **B: Attracting and retaining skilled personnel**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 8000, "result": 1.0, "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?", "options": {"A": "Providing accurate healthcare information", "B": "Knowingly defrauding any healthcare benefit program", "C": "Sharing healthcare information with the patient's consent", "D": "Ensuring the security of health databases", "E": "Improving healthcare technology", "F": "Reporting a breach of security"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document and then select the correct option.\n\n### Step-by-Step Analysis:\n\n1. **Identify the relevant section in the document:**\n   - The relevant section is the one that discusses the federal criminal statutes created by HIPAA. This is found in the paragraph that starts with \"Additionally, the ACA amended the federal Anti-Kickback Statute such that a violation of that statute can serve as a basis for liability under the federal False Claims Act.\"\n\n2. **Extract the key information:**\n   - The document states: \"federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.\"\n\n3. **Compare the extracted information with the given options:**\n   - **Option A: Providing accurate healthcare information** - This is not mentioned as prohibited.\n   - **Option B: Knowingly defrauding any healthcare benefit program** - This matches the information provided in the document.\n   - **Option C: Sharing healthcare information with the patient's consent** - This is not mentioned as prohibited.\n   - **Option D: Ensuring the security of health databases** - This is actually required by HIPAA, not prohibited.\n   - **Option E: Improving healthcare technology** - This is not mentioned as prohibited.\n   - **Option F: Reporting a breach of security** - This is required by HIPAA, not prohibited.\n\n### Conclusion:\nThe correct answer is **Option B: Knowingly defrauding any healthcare benefit program**. This is explicitly mentioned in the document as being prohibited under the federal criminal statutes created by HIPAA."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 8000, "result": 1.0, "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?", "options": {"A": "Failure to expand subservicing income", "B": "Ocwen acquiring new MSRs unexpectedly", "C": "A change of control of Ocwen or PHH", "D": "Increase in Ocwen's financial reserves", "E": "Successful maintenance of service levels", "F": "Ocwen improving its technology systems"}, "LLM_original_answer": ["To answer the question \"What event would allow MAV to terminate the Subservicing Agreement with Ocwen?\" based on the provided document, I will analyze the relevant sections step by step.\n\n1. **Identify the relevant section in the document:**\n   - The document mentions MAV as one of Ocwen's largest subservicing clients and provides details about the Subservicing Agreement with MAV.\n\n2. **Extract the key information:**\n   - The Subservicing Agreement with MAV provides exclusivity rights to PHH as subservicer and will continue until terminated by mutual agreement of the parties or for cause, as defined.\n   - The agreement can be terminated for certain events of default, including:\n     - Failure by Ocwen to meet financial or operational requirements, including service levels.\n     - A change of control of Ocwen or PHH.\n   - The subservicing rights terminate as to MSRs sold by MAV to any unaffiliated third party.\n   - After May 3, 2024, MAV may sell the entire servicing portfolio or any portion thereof without Ocwen's consent.\n\n3. **Evaluate the options:**\n   - **A: Failure to expand subservicing income** - This is not mentioned as a specific event of default in the document.\n   - **B: Ocwen acquiring new MSRs unexpectedly** - This is not mentioned as a specific event of default in the document.\n   - **C: A change of control of Ocwen or PHH** - This is explicitly mentioned as an event that allows MAV to terminate the Subservicing Agreement.\n   - **D: Increase in Ocwen's financial reserves** - This is not mentioned as a specific event of default in the document.\n   - **E: Successful maintenance of service levels** - This is the opposite of what is mentioned; failure to maintain service levels is an event of default.\n   - **F: Ocwen improving its technology systems** - This is not mentioned as a specific event of default in the document.\n\n4. **Conclusion:**\n   - The document clearly states that a change of control of Ocwen or PHH is an event that would allow MAV to terminate the Subservicing Agreement.\n\nTherefore, the correct answer is **C: A change of control of Ocwen or PHH**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 8000, "result": 1.0, "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?", "options": {"A": "Emails of previous FDA meetings", "B": "Details of international marketing strategies", "C": "Data from device testing", "D": "Descriptions of the manufacturing process and non-clinical studies", "E": "Marketing plans and budgets", "F": "Consumer feedback surveys"}, "LLM_original_answer": ["To answer the question \"What is submitted to the FDA as part of a BLA requesting approval to market a new drug?\" based on the provided document, I will analyze the relevant sections step by step:\n\n1. **BLA Approval Process**:\n   - The document states: \"The results of product development, non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of a BLA requesting approval to market the product for its intended indication.\"\n\n2. **Non-Clinical and Clinical Data**:\n   - The document mentions: \"All relevant data available from pertinent non-clinical or preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product\u2019s chemistry, manufacturing, controls and proposed labeling, among other things.\"\n\n3. **Manufacturing Information**:\n   - The document also specifies: \"The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug product.\"\n\n4. **Analytical Tests**:\n   - The document includes: \"Analytical data, any available clinical data or literature and plans for clinical studies, among other things, are submitted to the FDA as part of an IND application.\"\n\n5. **Proposed Labeling**:\n   - The document notes: \"Proposed labeling and other relevant information are submitted to the FDA as part of a BLA.\"\n\n6. **Other Relevant Information**:\n   - The document indicates that \"other relevant information\" is also part of the BLA, which could include various details necessary for the FDA to evaluate the product.\n\nGiven these points, the correct answer is:\n\n**D: Descriptions of the manufacturing process and non-clinical studies**\n\nThis option aligns with the information provided in the document, which explicitly states that the BLA includes descriptions of the manufacturing process, non-clinical studies, and other relevant data. The other options (A, B, C, E, F) are not mentioned as part of the BLA submission in the document."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 8000, "result": 1.0, "question": "What is required for the renewal of a marketing authorization after five years?", "options": {"A": "Approval from the European Medicines Agency (EMA)", "B": "Independent clinical trials conducted in the past year", "C": "A re-evaluation of the risk-benefit balance", "D": "Proof of sales data from member states", "E": "A newly conducted preclinical test", "F": "An application fee for renewal"}, "LLM_original_answer": ["To answer the question \"What is required for the renewal of a marketing authorization after five years?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Initial Validity of Marketing Authorization**:\n   - The document states: \"A marketing authorization has an initial validity for five years in principle.\"\n\n2. **Renewal Process**:\n   - The document further explains: \"The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA (for a centrally authorized product) or by the competent authority of the relevant EU Member State (for a nationally authorized product).\"\n\n3. **Requirements for Renewal**:\n   - The document specifies: \"To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid.\"\n\nFrom this information, we can deduce that the key requirement for the renewal of a marketing authorization after five years is a re-evaluation of the risk-benefit balance. This re-evaluation is based on a consolidated version of the file that includes all variations and updates related to the quality, safety, and efficacy of the product.\n\nNow, let's match this information with the given options:\n\n- **A: Approval from the European Medicines Agency (EMA)** - This is part of the process but not the primary requirement.\n- **B: Independent clinical trials conducted in the past year** - The document does not mention this as a requirement.\n- **C: A re-evaluation of the risk-benefit balance** - This matches the primary requirement as stated in the document.\n- **D: Proof of sales data from member states** - The document does not mention this as a requirement.\n- **E: A newly conducted preclinical test** - The document does not mention this as a requirement.\n- **F: An application fee for renewal** - The document does not mention this as a requirement.\n\nTherefore, the correct answer is:\n\n**C: A re-evaluation of the risk-benefit balance**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 8000, "result": 0.0, "question": "What could cause a potential loss of revenue according to the document?", "options": {"A": "Discontinuation of services by third-party companies to clients", "B": "Increased competition in the market", "C": "Rising operational costs", "D": "Decreased demand for trading platforms", "E": "Improper licensing of data", "F": "Delays in transitioning to new service providers"}, "LLM_original_answer": ["To answer the question \"What could cause a potential loss of revenue according to the document?\" based on the provided options, I will analyze the document step by step:\n\n1. **Discontinuation of services by third-party companies to clients (Option A)**:\n   - The document mentions that an interruption or cessation of an important service, data, or content supplied by any third party, or the loss of an exclusive license, could have a material adverse effect on the business.\n   - It also states that if third-party service providers discontinue providing services to clients, it could result in a loss of revenue associated with clients' inability to transact with the business.\n   - **Relevant**: This option is directly mentioned in the document.\n\n2. **Increased competition in the market (Option B)**:\n   - The document discusses intense competition in all aspects of the business, including from regulated futures exchanges, market data and information vendors, and providers of digital solutions for the mortgage industry.\n   - It mentions that a decline in fees due to competitive pressure or regulatory changes, the inability to successfully launch new products, or the loss of customers due to competition could lower revenues.\n   - **Relevant**: This option is also directly mentioned in the document.\n\n3. **Rising operational costs (Option C)**:\n   - The document does not explicitly mention rising operational costs as a direct cause of revenue loss. However, it does discuss the potential need to devote significant additional resources to modify and enhance security controls, which could indirectly impact operational costs.\n   - **Less Relevant**: This option is not directly mentioned as a cause of revenue loss.\n\n4. **Decreased demand for trading platforms (Option D)**:\n   - The document mentions that market data subscriptions and trading volumes could decline substantially if market participants reduce their level of spending or trading activity.\n   - It also discusses the impact of reduced trading demand by customers or a decision to curtail or cease hedging or speculative trading.\n   - **Relevant**: This option is directly mentioned in the document.\n\n5. **Improper licensing of data (Option E)**:\n   - The document discusses the risk of losing exclusive licenses and the potential for competitors to enter into exclusive contracts with suppliers without the company's knowledge.\n   - It also mentions the risk of unlicensed trading of index products where the company holds an exclusive license, which could result in a loss of trading volume and associated revenues.\n   - **Relevant**: This option is directly mentioned in the document.\n\n6. **Delays in transitioning to new service"], "LLM_extracted_answer": ["B"], "ground_truth": "A"}, {"depth": 20, "token_lengths": 8000, "result": 1.0, "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?", "options": {"A": "Increase in statutory tax rate", "B": "Valuation allowance and charge to profitability", "C": "Reduction in business performance", "D": "Increase in future taxable income", "E": "Adjustment in dividend policies", "F": "Expansion of subsidiary operations"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document and then select the most appropriate option.\n\n### Step-by-Step Analysis:\n\n1. **Understanding the Question:**\n   - The question asks what must be established if deferred income tax assets are deemed more likely than not unrealizable.\n\n2. **Relevant Information from the Document:**\n   - The document states: \"If, based on available information, it is more likely than not that the deferred income tax asset will not be realized, then a valuation allowance must be established with a corresponding charge to our profitability measures.\"\n\n3. **Breaking Down the Information:**\n   - **Deferred Income Tax Assets:** These are tax assets that arise from temporary differences between the book and tax bases of assets and liabilities.\n   - **Realization:** The ability to use these tax assets to reduce future tax liabilities.\n   - **Valuation Allowance:** A contra-asset account that reduces the value of deferred income tax assets if they are deemed more likely than not to be unrealizable.\n   - **Charge to Profitability Measures:** This indicates that the establishment of a valuation allowance will negatively impact the company's profitability.\n\n4. **Matching the Information to the Options:**\n   - **Option A: Increase in statutory tax rate** - This is not directly related to the realization of deferred income tax assets.\n   - **Option B: Valuation allowance and charge to profitability** - This matches the information provided in the document.\n   - **Option C: Reduction in business performance** - While this could be a consequence, it is not what must be established.\n   - **Option D: Increase in future taxable income** - This is not what must be established; it is a factor that could affect the realization of deferred income tax assets.\n   - **Option E: Adjustment in dividend policies** - This is not directly related to the realization of deferred income tax assets.\n   - **Option F: Expansion of subsidiary operations** - This is not directly related to the realization of deferred income tax assets.\n\n### Conclusion:\nThe correct answer is **Option B: Valuation allowance and charge to profitability**. This is explicitly stated in the document as the action that must be taken if deferred income tax assets are deemed more likely than not to be unrealizable."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 16000, "result": 1.0, "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?", "options": {"A": "When the product is highly effective in children", "B": "If the disease only occurs in children", "C": "When the product shows uncertain efficacy in adults", "D": "If the product is likely ineffective or unsafe in children", "E": "When there is sufficient pediatric market demand", "F": "If the product is cheaper than existing treatments"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the relevant section from the provided document:\n\nThe relevant section states:\n\"The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients.\"\n\nLet's break down the conditions under which the PDCO can waive the obligation to provide pediatric clinical trial data:\n\n1. **The product is likely to be ineffective or unsafe in children**:\n   - This matches option D: \"If the product is likely ineffective or unsafe in children.\"\n\n2. **The disease or condition for which the product is intended occurs only in adult populations**:\n   - This matches option B: \"If the disease only occurs in children\" (though it's actually the opposite, it means the disease only occurs in adults, so this option is not directly applicable).\n\n3. **The product does not represent a significant therapeutic benefit over existing treatments for pediatric patients**:\n   - This matches option C: \"When the product shows uncertain efficacy in adults\" (though it's more about the therapeutic benefit in children, not adults).\n\nGiven the options provided, the most accurate and directly applicable condition is:\n\n**D: If the product is likely ineffective or unsafe in children**\n\nThis is explicitly stated in the document and aligns perfectly with the provided option. Therefore, the correct answer is:\n\n**D: If the product is likely ineffective or unsafe in children**"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 16000, "result": 1.0, "question": "What factor could make it difficult for the company to retain key personnel?", "options": {"A": "Reduction in product sales", "B": "Delays in adopting management incentive plans", "C": "Expansion into new markets", "D": "Increased competition", "E": "Technological advancements", "F": "Change in stock prices"}, "LLM_original_answer": ["To answer the question \"What factor could make it difficult for the company to retain key personnel?\" based on the provided document, I will analyze the relevant sections step by step:\n\n1. **Emergence from Bankruptcy**:\n   - The document mentions that the company has just emerged from bankruptcy under Chapter 11 of the United States Bankruptcy Code.\n   - It states: \"It is possible that having just recently emerged from the Chapter 11 Cases could adversely affect our business, reputation and relationships with vendors, suppliers, service providers, customers, employees and other third parties.\"\n   - This suggests that the recent bankruptcy could have a negative impact on the company's ability to retain key personnel due to the associated uncertainties and potential damage to the company's reputation.\n\n2. **Restructuring and Indebtedness**:\n   - The document highlights that the company has a substantial level of indebtedness, which requires significant interest payments.\n   - It also mentions: \"Our substantial level of indebtedness and our current liquidity constraints could adversely affect our financial condition and our ability to service our indebtedness, which, together with the impact of the Chapter 11 process, could negatively impact your ability to recover your investment in our securities.\"\n   - This indicates that financial constraints and the burden of debt could make it challenging to offer competitive compensation and benefits, which are crucial for retaining key personnel.\n\n3. **Management Incentive Plans**:\n   - The document specifically states: \"Any potential delays in adopting our management incentive plan and other executive benefits and compensation may make it difficult to retain key personnel and we may need to enter into retention or other arrangements that could be costly to maintain.\"\n   - This directly addresses the issue of delays in adopting management incentive plans, which could negatively impact the company's ability to retain key personnel.\n\n4. **Liquidity Constraints**:\n   - The document notes: \"We may face the tightening of payment or credit terms and/or increases in the price of supplied goods or services.\"\n   - This suggests that the company might have limited financial flexibility, which could affect its ability to offer competitive compensation and benefits.\n\n5. **Employee Morale and Distraction**:\n   - The document mentions: \"Employees may be distracted from the performance of their duties or more inclined to pursue other employment opportunities.\"\n   - This indicates that the recent bankruptcy and the associated uncertainties could lead to a decrease in employee morale and an increase in the likelihood of key personnel leaving the company.\n\nGiven these points, the most directly relevant factor mentioned in the document"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 16000, "result": 1.0, "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?", "options": {"A": "Three years", "B": "Five years", "C": "Eight years", "D": "Ten years", "E": "Twelve years", "F": "Fifteen years"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant information in the document.\n2. Extract the specific detail that answers the question.\n3. Match the extracted detail to the provided options.\n\n### Step 1: Identify the Relevant Information\nThe document contains a section that discusses Duke Energy's accomplishments and areas of focus in 2023. Specifically, it mentions the company's performance in safety surveys.\n\n### Step 2: Extract the Specific Detail\nThe relevant sentence is:\n\"For the eighth consecutive year, we ranked first among North American combined gas and electric companies in Edison Electric Institute\u2019s (EEI) annual safety survey, and our gas operations organization finished in the top 10% for the third year in a row, according to the American Gas Association.\"\n\n### Step 3: Match the Extracted Detail to the Provided Options\nThe sentence clearly states that Duke Energy has ranked first for the eighth consecutive year. Therefore, the correct answer is:\n\n**C: Eight years**\n\nThis matches the information provided in the document."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 16000, "result": 1.0, "question": "Which factor is essential for increasing loan origination volume in the company's strategy?", "options": {"A": "Expanding international partnerships", "B": "Attracting and retaining skilled personnel", "C": "Reducing operational costs", "D": "Increasing online marketing efforts", "E": "Diversifying investment portfolio", "F": "Enhancing customer service training"}, "LLM_original_answer": ["To answer the question \"Which factor is essential for increasing loan origination volume in the company's strategy?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the Key Assumptions in the Strategic Plan:**\n   - The document outlines several key assumptions that are part of the company's strategic plan. One of these assumptions is particularly relevant to loan origination volume: \"that we will be able to attract and retain the requisite number of skilled and qualified personnel required to increase our loan origination volume, especially in our commercial banking portfolios.\"\n\n2. **Evaluate the Assumption:**\n   - The assumption directly states that attracting and retaining skilled personnel is necessary to increase loan origination volume. This implies that the company's strategy for increasing loan origination volume is heavily dependent on having the right people in place to manage and grow the loan portfolio.\n\n3. **Consider the Context:**\n   - The document emphasizes the competitive nature of the marketplace for skilled personnel, noting that \"hiring, training and retaining skilled personnel is costly and challenging.\" This further underscores the importance of this factor, as the company must overcome significant obstacles to achieve its loan origination goals.\n\n4. **Compare with Other Options:**\n   - **Expanding international partnerships (A):** The document does not mention international partnerships as a key factor for increasing loan origination volume.\n   - **Reducing operational costs (C):** While reducing operational costs is important, it is not specifically linked to increasing loan origination volume.\n   - **Increasing online marketing efforts (D):** The document does not highlight online marketing as a primary factor for increasing loan origination volume.\n   - **Diversifying investment portfolio (E):** The document discusses the risks associated with the investment portfolio but does not link it to loan origination volume.\n   - **Enhancing customer service training (F):** While customer service training is important, it is not specifically mentioned as a factor for increasing loan origination volume.\n\n5. **Conclusion:**\n   - Based on the document, the factor that is essential for increasing loan origination volume in the company's strategy is **attracting and retaining skilled personnel**.\n\nTherefore, the correct answer is **B: Attracting and retaining skilled personnel**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 16000, "result": 1.0, "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?", "options": {"A": "Providing accurate healthcare information", "B": "Knowingly defrauding any healthcare benefit program", "C": "Sharing healthcare information with the patient's consent", "D": "Ensuring the security of health databases", "E": "Improving healthcare technology", "F": "Reporting a breach of security"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document and the options given.\n\nThe question asks: \"Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?\"\n\nLet's break down the relevant information from the document:\n\n1. **HIPAA and Federal Criminal Statutes**:\n   - The document mentions that HIPAA created federal criminal statutes.\n   - These statutes prohibit \"knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.\"\n\n2. **Options Analysis**:\n   - **A: Providing accurate healthcare information**:\n     - This is not prohibited; in fact, it is generally encouraged and required for transparency and patient care.\n   - **B: Knowingly defrauding any healthcare benefit program**:\n     - This matches the description in the document. The federal criminal statutes created by HIPAA prohibit knowingly and willfully defrauding any healthcare benefit program.\n   - **C: Sharing healthcare information with the patient's consent**:\n     - This is generally allowed under HIPAA, provided that the patient gives consent.\n   - **D: Ensuring the security of health databases**:\n     - This is a requirement under HIPAA, not a prohibited action.\n   - **E: Improving healthcare technology**:\n     - This is not prohibited; it is often encouraged to enhance healthcare delivery.\n   - **F: Reporting a breach of security**:\n     - This is required under HIPAA, not prohibited.\n\nBased on the analysis, the correct answer is:\n\n**B: Knowingly defrauding any healthcare benefit program**\n\nThis option directly aligns with the federal criminal statutes created by HIPAA, which prohibit such actions."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 16000, "result": 1.0, "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?", "options": {"A": "Failure to expand subservicing income", "B": "Ocwen acquiring new MSRs unexpectedly", "C": "A change of control of Ocwen or PHH", "D": "Increase in Ocwen's financial reserves", "E": "Successful maintenance of service levels", "F": "Ocwen improving its technology systems"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step to identify the specific conditions under which MAV can terminate the Subservicing Agreement with Ocwen.\n\n1. **Identify the relevant section in the document:**\n   - The relevant section is found in the paragraph that discusses the Subservicing Agreement with MAV. Specifically, it mentions the conditions under which MAV can terminate the agreement.\n\n2. **Extract the conditions for termination:**\n   - The document states: \"MAV may also terminate the Subservicing Agreement in the event of a change of control of Ocwen or PHH.\"\n   - Additionally, it mentions: \"If MAV were to sell its MSR portfolio after May 3, 2024, it could result in our loss of subservicing income and could significantly impact our business, liquidity, financial condition and results of operations.\"\n   - The document also notes: \"MAV has the right to terminate the Subservicing Agreement entirely in the event of certain events of default, including failure by Ocwen to meet financial or operational requirements, including service levels.\"\n\n3. **Match the conditions to the given options:**\n   - **Option A: Failure to expand subservicing income** - This is not mentioned as a specific condition for termination.\n   - **Option B: Ocwen acquiring new MSRs unexpectedly** - This is not mentioned as a specific condition for termination.\n   - **Option C: A change of control of Ocwen or PHH** - This is explicitly mentioned as a condition for termination.\n   - **Option D: Increase in Ocwen's financial reserves** - This is not mentioned as a specific condition for termination.\n   - **Option E: Successful maintenance of service levels** - This is not mentioned as a condition for termination; rather, the failure to meet service levels is mentioned.\n   - **Option F: Ocwen improving its technology systems** - This is not mentioned as a condition for termination.\n\n4. **Conclusion:**\n   - The document clearly states that a change of control of Ocwen or PHH is a condition that would allow MAV to terminate the Subservicing Agreement.\n\nTherefore, the correct answer is **Option C: A change of control of Ocwen or PHH**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 16000, "result": 1.0, "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?", "options": {"A": "Emails of previous FDA meetings", "B": "Details of international marketing strategies", "C": "Data from device testing", "D": "Descriptions of the manufacturing process and non-clinical studies", "E": "Marketing plans and budgets", "F": "Consumer feedback surveys"}, "LLM_original_answer": ["To answer the question \"What is submitted to the FDA as part of a BLA requesting approval to market a new drug?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the BLA (Biologics License Application) and the information required for its submission is found under \"The BLA Approval Process.\"\n\n2. **Extract the key information**: According to the document, the BLA includes the following:\n   - Results of product development, non-clinical studies, and clinical trials.\n   - Descriptions of the manufacturing process.\n   - Analytical tests conducted on the chemistry of the drug.\n   - Proposed labeling.\n   - Other relevant information.\n\n3. **Match the extracted information to the given options**:\n   - **Option A: Emails of previous FDA meetings** - Not mentioned in the document.\n   - **Option B: Details of international marketing strategies** - Not mentioned in the document.\n   - **Option C: Data from device testing** - Not mentioned in the document.\n   - **Option D: Descriptions of the manufacturing process and non-clinical studies** - Matches the information in the document.\n   - **Option E: Marketing plans and budgets** - Not mentioned in the document.\n   - **Option F: Consumer feedback surveys** - Not mentioned in the document.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **Option D: Descriptions of the manufacturing process and non-clinical studies**.\n\nTherefore, the answer to the question is **Option D: Descriptions of the manufacturing process and non-clinical studies**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 16000, "result": 1.0, "question": "What is required for the renewal of a marketing authorization after five years?", "options": {"A": "Approval from the European Medicines Agency (EMA)", "B": "Independent clinical trials conducted in the past year", "C": "A re-evaluation of the risk-benefit balance", "D": "Proof of sales data from member states", "E": "A newly conducted preclinical test", "F": "An application fee for renewal"}, "LLM_original_answer": ["To answer the question \"What is required for the renewal of a marketing authorization after five years?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the renewal of marketing authorization is found under \"Periods of Authorization and Renewals.\"\n\n2. **Extract the key information**: The document states:\n   - \"A marketing authorization has an initial validity for five years in principle.\"\n   - \"The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA (for a centrally authorized product) or by the competent authority of the relevant EU Member State (for a nationally authorized product).\"\n   - \"To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid.\"\n\n3. **Match the information to the options**:\n   - **Option A: Approval from the European Medicines Agency (EMA)** - This is partially correct, but it is not the only requirement.\n   - **Option B: Independent clinical trials conducted in the past year** - The document does not mention this as a requirement.\n   - **Option C: A re-evaluation of the risk-benefit balance** - This is explicitly mentioned as a requirement.\n   - **Option D: Proof of sales data from member states** - The document does not mention this as a requirement.\n   - **Option E: A newly conducted preclinical test** - The document does not mention this as a requirement.\n   - **Option F: An application fee for renewal** - The document does not mention this as a requirement.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **Option C: A re-evaluation of the risk-benefit balance**.\n\nTherefore, the answer to the question is **Option C: A re-evaluation of the risk-benefit balance**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 16000, "result": 1.0, "question": "What could cause a potential loss of revenue according to the document?", "options": {"A": "Discontinuation of services by third-party companies to clients", "B": "Increased competition in the market", "C": "Rising operational costs", "D": "Decreased demand for trading platforms", "E": "Improper licensing of data", "F": "Delays in transitioning to new service providers"}, "LLM_original_answer": ["To answer the question \"What could cause a potential loss of revenue according to the document?\" based on the provided document, I will analyze the content step by step and identify the relevant information.\n\n### Step 1: Identify Key Sections\nThe document is extensive, so I will focus on sections that discuss potential risks and their impact on revenue.\n\n### Step 2: Analyze Relevant Information\n#### 1. **Regulatory and Benchmark Risks**\n- **LIBOR Transition and Cessation:**\n  - \"Any failures, negative publicity or lawsuits related to our IBA\u2019s administration of LIBOR, could result in a loss of confidence in our subsidiaries\u2019 administration of benchmarks and indices and could harm our business and our reputation.\"\n  - \"Risks relating to the administration of benchmarks and indices, and changes to, cessations of, and the replacement of, or transition from, benchmarks and indices may result in legal risks and could adversely affect our business.\"\n\n#### 2. **Legal and Liability Risks**\n- **Liability for Data Products and Services:**\n  - \"We may face liability for content contained in our data products and services. We have been, and may in the future be, subject to claims for breach of contract, defamation, libel, copyright or trademark infringement, fraud or negligence or based on other theories of liability, in each case relating to the data, articles, commentary, ratings, information or other content we distribute in our financial data services.\"\n  - \"Such claims and lawsuits could have a material adverse effect on our business, financial condition and operating results and a negative impact on our reputation.\"\n\n#### 3. **Operational and Liquidity Risks**\n- **Third-Party Service Provider Vulnerabilities:**\n  - \"An interruption or cessation of an important service, data or content supplied by any third party, or the loss of an exclusive license, could have a material adverse effect on our business.\"\n  - \"Our third-party data and content suppliers may audit our use of and our clients\u2019 use of and payment for data and content from time to time in the ordinary course of business, including audits currently underway.\"\n  - \"Such third-party data and content suppliers have asserted and may in the future assert that we or our clients owe additional amounts under the terms of the applicable license agreements, that we inappropriately distributed the third-party data or that we or our clients used the data or content in a manner that exceeded the scope of the applicable license agreement or without a license agreement.\"\n\n#### 4."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 20, "token_lengths": 16000, "result": 1.0, "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?", "options": {"A": "Increase in statutory tax rate", "B": "Valuation allowance and charge to profitability", "C": "Reduction in business performance", "D": "Increase in future taxable income", "E": "Adjustment in dividend policies", "F": "Expansion of subsidiary operations"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document and think through it step by step.\n\n### Step 1: Identify the Relevant Section\nThe relevant section in the document is:\n> \"Changes in our deferred income tax assets or liabilities, including changes in our ability to realize our deferred income tax assets, could adversely affect our financial condition or results of operations. Deferred income tax represents the tax effect of the differences between the book and tax bases of assets and liabilities. Deferred income tax assets are assessed periodically by management to determine whether they are realizable. Factors in management\u2019s determination include the performance of the business, including the ability to generate future taxable income. If, based on available information, it is more likely than not that the deferred income tax asset will not be realized, then a valuation allowance must be established with a corresponding charge to our profitability measures. Such charges could have a material adverse effect on our financial condition and results of operations.\"\n\n### Step 2: Analyze the Key Points\n- **Deferred Income Tax Assets**: These are assessed periodically to determine if they are realizable.\n- **Realizability**: Management considers the performance of the business and the ability to generate future taxable income.\n- **Unrealizability**: If it is more likely than not that the deferred income tax asset will not be realized, a valuation allowance must be established.\n- **Valuation Allowance**: This is a reduction in the deferred income tax asset.\n- **Charge to Profitability**: Establishing a valuation allowance results in a charge to profitability measures.\n\n### Step 3: Match the Information to the Options\n- **Option A: Increase in statutory tax rate** - This is not mentioned in the context of unrealizable deferred income tax assets.\n- **Option B: Valuation allowance and charge to profitability** - This directly matches the information provided in the document.\n- **Option C: Reduction in business performance** - While business performance is a factor in determining realizability, it is not the action taken if the asset is deemed unrealizable.\n- **Option D: Increase in future taxable income** - This is the opposite of what would happen if the asset is deemed unrealizable.\n- **Option E: Adjustment in dividend policies** - This is not mentioned in the context of unrealizable deferred income tax assets.\n- **Option F: Expansion of subsidiary operations** - This is not mentioned in the context of unrealizable deferred income tax assets.\n\n### Step 4: Conclusion\nBased on the information provided in the document, the correct answer"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 32000, "result": 1.0, "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?", "options": {"A": "When the product is highly effective in children", "B": "If the disease only occurs in children", "C": "When the product shows uncertain efficacy in adults", "D": "If the product is likely ineffective or unsafe in children", "E": "When there is sufficient pediatric market demand", "F": "If the product is cheaper than existing treatments"}, "LLM_original_answer": ["To answer the question \"Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the Pediatric Committee (PDCO) and the conditions under which the obligation to provide pediatric clinical trial data can be waived is found in the \"Pediatric Development in the EU\" section.\n\n2. **Extract the key information**: The relevant information from the document is:\n   - \"The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults.\"\n   - \"Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients.\"\n\n3. **Match the extracted information to the given options**:\n   - **Option A**: \"When the product is highly effective in children\" - This is not mentioned as a condition for waiving the obligation.\n   - **Option B**: \"If the disease only occurs in children\" - This is not mentioned as a condition for waiving the obligation.\n   - **Option C**: \"When the product shows uncertain efficacy in adults\" - This is not mentioned as a condition for waiving the obligation.\n   - **Option D**: \"If the product is likely ineffective or unsafe in children\" - This is explicitly mentioned as a condition for waiving the obligation.\n   - **Option E**: \"When there is sufficient pediatric market demand\" - This is not mentioned as a condition for waiving the obligation.\n   - **Option F**: \"If the product is cheaper than existing treatments\" - This is not mentioned as a condition for waiving the obligation.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **Option D: If the product is likely ineffective or unsafe in children**.\n\nThis condition is clearly stated in the document as one of the reasons the PDCO can waive the obligation to provide pediatric clinical trial data."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 32000, "result": 1.0, "question": "What factor could make it difficult for the company to retain key personnel?", "options": {"A": "Reduction in product sales", "B": "Delays in adopting management incentive plans", "C": "Expansion into new markets", "D": "Increased competition", "E": "Technological advancements", "F": "Change in stock prices"}, "LLM_original_answer": ["To answer the question \"What factor could make it difficult for the company to retain key personnel?\" based on the provided document, I will analyze the relevant sections step by step:\n\n1. **Emergence from Bankruptcy**:\n   - The document mentions that the company has just emerged from bankruptcy under Chapter 11 of the United States Bankruptcy Code.\n   - It states: \"It is possible that having just recently emerged from the Chapter 11 Cases could adversely affect our business, reputation and relationships with vendors, suppliers, service providers, customers, employees and other third parties.\"\n   - This suggests that the company's recent bankruptcy could negatively impact its ability to retain key personnel due to concerns about job security and the company's financial stability.\n\n2. **Regulatory Changes**:\n   - The document discusses the evolving regulatory landscape for digital assets and the potential for increased regulatory scrutiny.\n   - It mentions: \"Regulatory actions may restrict the use of digital assets or the operation of digital asset networks or may impose additional regulatory burdens on our business.\"\n   - While this is a broader issue, it could indirectly affect key personnel if they perceive the regulatory environment as too uncertain or burdensome.\n\n3. **Management Incentive Plans**:\n   - The document specifically addresses the issue of management incentive plans: \"Any potential delays in adopting our management incentive plan and other executive benefits and compensation may make it difficult to retain key personnel and we may need to enter into retention or other arrangements that could be costly to maintain.\"\n   - This directly states that delays in adopting management incentive plans could make it difficult to retain key personnel.\n\n4. **Substantial Indebtedness**:\n   - The company has a substantial level of indebtedness, which could affect its financial flexibility and stability.\n   - It states: \"Our substantial level of indebtedness and the current constraints on our liquidity could have important consequences, including the following: ... we may be more vulnerable to economic downturn and adverse developments in our business ... failure to comply with the financial and other restrictive covenants in our debt instruments could result in an event of default that could have a material adverse effect on our business or prospects.\"\n   - Financial instability and the risk of default could make the company a less attractive place for key personnel to work.\n\n5. **Increased Scrutiny and ESG**:\n   - The document mentions increased scrutiny and changing expectations from government regulators, investors, lenders, customers, and other market participants with respect to Environmental, Social, and Governance (ESG) policies.\n   -"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 32000, "result": 1.0, "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?", "options": {"A": "Three years", "B": "Five years", "C": "Eight years", "D": "Ten years", "E": "Twelve years", "F": "Fifteen years"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant information**: The question asks about Duke Energy's ranking in the EEI's annual safety survey for 2023.\n2. **Locate the specific statement**: I will search the document for a statement that mentions Duke Energy's ranking in the EEI's annual safety survey.\n3. **Extract the number of consecutive years**: Once I find the relevant statement, I will extract the number of consecutive years mentioned.\n4. **Match the extracted information to the options**: Finally, I will match the extracted information to the provided options to determine the correct answer.\n\nLet's go through the document to find the relevant information:\n\n- **Relevant Statement**: \"For the eighth consecutive year, we ranked first among North American combined gas and electric companies in Edison Electric Institute\u2019s (EEI) annual safety survey, and our gas operations organization finished in the top 10% for the third year in a row, according to the American Gas Association.\"\n\nFrom this statement, we can see that Duke Energy has ranked first in the EEI's annual safety survey for **eight consecutive years**.\n\nNow, let's match this information to the provided options:\n\n- A: Three years\n- B: Five years\n- C: Eight years\n- D: Ten years\n- E: Twelve years\n- F: Fifteen years\n\nThe correct answer is **C: Eight years**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 32000, "result": 1.0, "question": "Which factor is essential for increasing loan origination volume in the company's strategy?", "options": {"A": "Expanding international partnerships", "B": "Attracting and retaining skilled personnel", "C": "Reducing operational costs", "D": "Increasing online marketing efforts", "E": "Diversifying investment portfolio", "F": "Enhancing customer service training"}, "LLM_original_answer": ["To answer the question \"Which factor is essential for increasing loan origination volume in the company's strategy?\" based on the provided document, I will analyze the relevant sections step by step.\n\n1. **Identify Key Assumptions in the Strategic Plan:**\n   - The document states: \"Our key assumptions include: that we will be able to attract and retain the requisite number of skilled and qualified personnel required to increase our loan origination volume, especially in our commercial banking portfolios.\"\n\n2. **Evaluate the Importance of Each Option:**\n   - **A: Expanding international partnerships** - The document does not mention international partnerships as a key factor for increasing loan origination volume.\n   - **B: Attracting and retaining skilled personnel** - The document explicitly mentions this as a key assumption for increasing loan origination volume.\n   - **C: Reducing operational costs** - While reducing operational costs is important for overall profitability, it is not specifically mentioned as a factor for increasing loan origination volume.\n   - **D: Increasing online marketing efforts** - The document does not mention online marketing efforts as a key factor for increasing loan origination volume.\n   - **E: Diversifying investment portfolio** - The document discusses the impact of the investment portfolio on the company's financial condition but does not link it directly to increasing loan origination volume.\n   - **F: Enhancing customer service training** - The document does not mention customer service training as a key factor for increasing loan origination volume.\n\n3. **Conclusion:**\n   - Based on the explicit mention in the document, the factor that is essential for increasing loan origination volume in the company's strategy is **B: Attracting and retaining skilled personnel**.\n\nTherefore, the correct answer is **B: Attracting and retaining skilled personnel**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 32000, "result": 1.0, "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?", "options": {"A": "Providing accurate healthcare information", "B": "Knowingly defrauding any healthcare benefit program", "C": "Sharing healthcare information with the patient's consent", "D": "Ensuring the security of health databases", "E": "Improving healthcare technology", "F": "Reporting a breach of security"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the relevant information about the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA).\n\nThe document states:\n\"Additionally, federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.\"\n\nThis statement directly addresses the federal criminal statutes under HIPAA and specifies what is prohibited. Let's break down the options in light of this information:\n\nA: Providing accurate healthcare information - This is not prohibited; in fact, it is generally encouraged and required for transparency and compliance.\n\nB: Knowingly defrauding any healthcare benefit program - This is explicitly mentioned as being prohibited under the federal criminal statutes created by HIPAA.\n\nC: Sharing healthcare information with the patient's consent - This is not prohibited; HIPAA actually includes provisions for sharing healthcare information with patient consent.\n\nD: Ensuring the security of health databases - This is encouraged and required under HIPAA, not prohibited.\n\nE: Improving healthcare technology - This is not prohibited; it is generally a positive goal in the healthcare industry.\n\nF: Reporting a breach of security - This is required under HIPAA, not prohibited.\n\nBased on the document, the correct answer is:\n\n**B: Knowingly defrauding any healthcare benefit program**\n\nThis option aligns with the explicit prohibition stated in the document."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 32000, "result": 1.0, "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?", "options": {"A": "Failure to expand subservicing income", "B": "Ocwen acquiring new MSRs unexpectedly", "C": "A change of control of Ocwen or PHH", "D": "Increase in Ocwen's financial reserves", "E": "Successful maintenance of service levels", "F": "Ocwen improving its technology systems"}, "LLM_original_answer": ["To answer the question \"What event would allow MAV to terminate the Subservicing Agreement with Ocwen?\" based on the provided document, I will analyze the relevant sections step by step.\n\n1. **Identify the Subservicing Agreement with MAV:**\n   - The document mentions that MAV (Mortgage Asset Ventures) is one of Ocwen's largest subservicing clients.\n   - MAV and PHH (a subsidiary of Ocwen) entered into a subservicing agreement in May 2021, where PHH has exclusive rights to service the mortgage loans underlying MSRs (Mortgage Servicing Rights) owned by MAV.\n\n2. **Determine the Termination Conditions:**\n   - The document states: \"Although the servicing agreement is not cancellable without mutual agreement, MAV is permitted to sell its MSR portfolio, in whole or in part, without Ocwen\u2019s consent after May 3, 2024.\"\n   - Additionally, it mentions: \"If MAV chooses to exercise these sale rights, and we are unable to reach an agreement with the purchaser(s) of the MSRs to continue as subservicer, we will lose the corresponding subservicing income.\"\n   - The document also notes: \"MAV has the right to terminate the Subservicing Agreement entirely in the event of certain events of default, including failure by Ocwen to meet financial or operational requirements, including service levels.\"\n   - Another condition for termination is: \"MAV may also terminate the Subservicing Agreement in the event of a change of control of Ocwen or PHH.\"\n\n3. **Evaluate the Options:**\n   - **Option A: Failure to expand subservicing income** - This is not explicitly mentioned as a termination condition.\n   - **Option B: Ocwen acquiring new MSRs unexpectedly** - This is not mentioned as a termination condition.\n   - **Option C: A change of control of Ocwen or PHH** - This is explicitly mentioned as a condition for termination.\n   - **Option D: Increase in Ocwen's financial reserves** - This is not mentioned as a termination condition.\n   - **Option E: Successful maintenance of service levels** - This is not mentioned as a termination condition; rather, the failure to meet service levels is a condition for termination.\n   - **Option F: Ocwen improving its technology systems** - This is not mentioned as a termination condition.\n\n4. **Conclusion:**\n   - The document clearly states that MAV can terminate the Subservicing Agreement"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 32000, "result": 1.0, "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?", "options": {"A": "Emails of previous FDA meetings", "B": "Details of international marketing strategies", "C": "Data from device testing", "D": "Descriptions of the manufacturing process and non-clinical studies", "E": "Marketing plans and budgets", "F": "Consumer feedback surveys"}, "LLM_original_answer": ["To answer the question \"What is submitted to the FDA as part of a BLA requesting approval to market a new drug?\" based on the provided document, I will analyze the relevant sections step by step.\n\n1. **BLA Approval Process**:\n   - The document states: \"The results of product development, non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of a BLA requesting approval to market the product for its intended indication.\"\n\n2. **Non-Clinical Studies**:\n   - The document mentions: \"completion of non-clinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practice, or GLP, or other applicable regulations.\"\n\n3. **Clinical Trials**:\n   - The document notes: \"performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug or biologic for its intended use or uses conducted in accordance with FDA regulations and Good Clinical Practices, or GCP.\"\n\n4. **Manufacturing Information**:\n   - The document specifies: \"descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information.\"\n\n5. **Analytical Data**:\n   - The document includes: \"analytical data, including those related to the chemistry, manufacturing, and controls (CMC) of the drug.\"\n\n6. **Proposed Labeling**:\n   - The document mentions: \"proposed labeling and other relevant information.\"\n\n7. **Other Relevant Information**:\n   - The document states: \"other relevant information are submitted to the FDA as part of a BLA.\"\n\nFrom the above analysis, the key components submitted to the FDA as part of a BLA include:\n- Results of non-clinical studies (including animal studies and formulation studies).\n- Results of clinical trials.\n- Descriptions of the manufacturing process.\n- Analytical tests conducted on the chemistry of the drug.\n- Proposed labeling.\n- Other relevant information.\n\nGiven the options provided:\n- **A: Emails of previous FDA meetings** - Not mentioned in the document.\n- **B: Details of international marketing strategies** - Not mentioned in the document.\n- **C: Data from device testing** - Not mentioned in the document.\n- **D: Descriptions of the manufacturing process and non-clinical studies** - Matches the information in the document.\n- **E: Marketing plans and budgets"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 32000, "result": 1.0, "question": "What is required for the renewal of a marketing authorization after five years?", "options": {"A": "Approval from the European Medicines Agency (EMA)", "B": "Independent clinical trials conducted in the past year", "C": "A re-evaluation of the risk-benefit balance", "D": "Proof of sales data from member states", "E": "A newly conducted preclinical test", "F": "An application fee for renewal"}, "LLM_original_answer": ["To answer the question \"What is required for the renewal of a marketing authorization after five years?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document discusses the regulatory processes for drug approval and marketing authorization in various regions, including the European Union (EU). The section that specifically addresses the renewal of marketing authorization is found under \"Periods of Authorization and Renewals.\"\n\n2. **Extract the key information**: The relevant paragraph states:\n   - \"A marketing authorization has an initial validity for five years in principle.\"\n   - \"The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA (for a centrally authorized product) or by the competent authority of the relevant EU Member State (for a nationally authorized product).\"\n   - \"To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid.\"\n\n3. **Match the information to the options**:\n   - **Option A: Approval from the European Medicines Agency (EMA)** - This is partially correct, as the EMA is involved in the re-evaluation for centrally authorized products.\n   - **Option B: Independent clinical trials conducted in the past year** - The document does not mention a requirement for independent clinical trials conducted in the past year.\n   - **Option C: A re-evaluation of the risk-benefit balance** - This is explicitly mentioned as a requirement for renewal.\n   - **Option D: Proof of sales data from member states** - The document does not mention a requirement for sales data.\n   - **Option E: A newly conducted preclinical test** - The document does not mention a requirement for new preclinical tests.\n   - **Option F: An application fee for renewal** - The document does not mention an application fee for renewal, but it does mention user fees for other regulatory processes.\n\n4. **Determine the correct answer**: Based on the information extracted, the correct answer is **Option C: A re-evaluation of the risk-benefit balance**.\n\nTherefore, the answer to the question \"What is required for the renewal of a marketing authorization after five years?\" is **Option C: A re-evaluation of the risk-benefit balance**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 32000, "result": 0.0, "question": "What could cause a potential loss of revenue according to the document?", "options": {"A": "Discontinuation of services by third-party companies to clients", "B": "Increased competition in the market", "C": "Rising operational costs", "D": "Decreased demand for trading platforms", "E": "Improper licensing of data", "F": "Delays in transitioning to new service providers"}, "LLM_original_answer": ["To answer the question \"What could cause a potential loss of revenue according to the document?\" I will analyze the document step by step and identify the relevant sections that discuss potential revenue loss.\n\n### Step 1: Identify Relevant Sections\nThe document discusses various risks and uncertainties that could impact the business, including regulatory changes, competition, and operational issues. I will focus on the sections that specifically mention potential revenue loss.\n\n### Step 2: Analyze Each Section\n1. **Regulatory Developments and Market Data Fees:**\n   - **Relevant Text:** \"Regulatory developments or court rulings may have an adverse impact on our ability to derive revenue from market data and connectivity fees. Regulatory developments or court rulings could reduce the amount of revenue that we obtain from exchange market data and connectivity fees related to our U.S. equity and options exchanges.\"\n   - **Analysis:** This section directly mentions that regulatory changes or court rulings could reduce revenue from market data and connectivity fees. This aligns with option D: \"Decreased demand for trading platforms.\"\n\n2. **Increased Competition:**\n   - **Relevant Text:** \"We face intense competition, and if we fail to keep up with rapid changes in technology and client preferences, it could negatively impact our competitive position. A decline in our fees due to competitive pressure or regulatory changes, the inability to successfully launch new products or the loss of customers due to competition could lower our revenues, which would adversely affect our profitability.\"\n   - **Analysis:** This section indicates that increased competition could lead to a decline in fees and loss of customers, which would lower revenues. This aligns with option B: \"Increased competition in the market.\"\n\n3. **Rising Operational Costs:**\n   - **Relevant Text:** \"Compliance with these requirements has resulted in, and will continue to result in, additional operating costs. In addition to increased risk in connection with our regulatory obligations and implementation of the CAT could result in significant additional expenditures, which may not be reimbursed.\"\n   - **Analysis:** This section mentions that regulatory compliance and the implementation of the CAT (Consolidated Audit Trail) could lead to significant additional operating costs. This aligns with option C: \"Rising operational costs.\"\n\n4. **Discontinuation of Services by Third-Party Companies:**\n   - **Relevant Text:** \"An interruption or cessation of an important service, data or content supplied by any third party, or the loss of an exclusive license, could have a material adverse effect on our business. If these companies were to experience"], "LLM_extracted_answer": ["D"], "ground_truth": "A"}, {"depth": 20, "token_lengths": 32000, "result": 1.0, "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?", "options": {"A": "Increase in statutory tax rate", "B": "Valuation allowance and charge to profitability", "C": "Reduction in business performance", "D": "Increase in future taxable income", "E": "Adjustment in dividend policies", "F": "Expansion of subsidiary operations"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Context**:\n   - The document discusses various financial and operational risks, including those related to deferred income tax assets and liabilities.\n\n2. **Locate Relevant Information**:\n   - The relevant section is found under \"Changes in our deferred income tax assets or liabilities, including changes in our ability to realize our deferred income tax assets, could adversely affect our financial condition or results of operations.\"\n\n3. **Extract Key Points**:\n   - **Deferred Income Tax Assets**: \"Deferred income tax assets are assessed periodically by management to determine whether they are realizable.\"\n   - **Realization Assessment**: \"Factors in management\u2019s determination include the performance of the business, including the ability to generate future taxable income.\"\n   - **Valuation Allowance**: \"If, based on available information, it is more likely than not that the deferred income tax asset will not be realized, then a valuation allowance must be established with a corresponding charge to our profitability measures.\"\n\n4. **Match to the Question**:\n   - The question asks what must be established if deferred income tax assets are deemed more likely than not unrealizable.\n   - According to the document, if it is more likely than not that the deferred income tax asset will not be realized, a **valuation allowance** must be established.\n\n5. **Select the Correct Option**:\n   - **Option B**: \"Valuation allowance and charge to profitability\" matches the information extracted from the document.\n\nTherefore, the correct answer is **Option B: Valuation allowance and charge to profitability**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 64000, "result": 1.0, "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?", "options": {"A": "When the product is highly effective in children", "B": "If the disease only occurs in children", "C": "When the product shows uncertain efficacy in adults", "D": "If the product is likely ineffective or unsafe in children", "E": "When there is sufficient pediatric market demand", "F": "If the product is cheaper than existing treatments"}, "LLM_original_answer": ["To answer the question, I will refer to the relevant section in the provided document:\n\nFrom the document:\n\"Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients.\"\n\nThe condition under which the PDCO can waive the obligation to provide pediatric clinical trial data is when the product is likely to be ineffective or unsafe in children. This is explicitly stated in the document.\n\nTherefore, the correct answer is:\nD: If the product is likely ineffective or unsafe in children."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 64000, "result": 1.0, "question": "What factor could make it difficult for the company to retain key personnel?", "options": {"A": "Reduction in product sales", "B": "Delays in adopting management incentive plans", "C": "Expansion into new markets", "D": "Increased competition", "E": "Technological advancements", "F": "Change in stock prices"}, "LLM_original_answer": ["To answer the question \"What factor could make it difficult for the company to retain key personnel?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Chapter 11 Filing and Emergence from Bankruptcy**:\n   - The document mentions that the company has just emerged from bankruptcy under Chapter 11 of the United States Bankruptcy Code.\n   - It states: \"It is possible that having just recently emerged from the Chapter 11 Cases could adversely affect our business, reputation and relationships with vendors, suppliers, service providers, customers, employees and other third parties.\"\n   - Specifically, it notes: \"it may be more difficult to attract, motivate and/or retain key executives and employees.\"\n\n2. **Restructuring and Organizational Changes**:\n   - The document discusses significant restructuring activities, including the termination of hosting contracts and the refocusing of the company's efforts on self-mining.\n   - It mentions: \"Any potential delays in adopting our management incentive plan and other executive benefits and compensation may make it difficult to retain key personnel and we may need to enter into retention or other arrangements that could be costly to maintain.\"\n\n3. **Financial and Operational Constraints**:\n   - The company has a substantial level of indebtedness and liquidity constraints.\n   - It states: \"Our substantial level of indebtedness and the current constraints on our liquidity could have important consequences, including the following: ... we may be more vulnerable to economic downturn and adverse developments in our business.\"\n\n4. **Regulatory and Compliance Risks**:\n   - The document highlights the evolving regulatory landscape and the potential for increased scrutiny and compliance costs.\n   - It mentions: \"Increasing scrutiny and changing expectations from government regulators, investors, lenders, customers, and other market participants with respect to our Environmental, Social and Governance (ESG) policies may impose additional costs on us or expose us to additional risks.\"\n\n5. **Market and Competition**:\n   - The document discusses the highly competitive nature of the digital asset mining industry.\n   - It states: \"We may not be able to compete effectively against our current and future competitors, which could have a material adverse effect on our business, financial condition and results of operations.\"\n\nGiven these points, the most relevant factor that could make it difficult for the company to retain key personnel is:\n\n**B: Delays in adopting management incentive plans**\n\nThis is explicitly mentioned in the document: \"Any potential delays in adopting our management incentive plan and other executive benefits and compensation may make it difficult to"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 64000, "result": 1.0, "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?", "options": {"A": "Three years", "B": "Five years", "C": "Eight years", "D": "Ten years", "E": "Twelve years", "F": "Fifteen years"}, "LLM_original_answer": ["To answer the question, I will go through the document step by step to find the relevant information:\n\n1. **Identify the Relevant Section:**\n   - The relevant section is found in the \"Operational Excellence, Safety and Reliability\" part of the document.\n\n2. **Extract the Relevant Information:**\n   - The document states: \"For the eighth consecutive year, we ranked first among North American combined gas and electric companies in the EEI's annual safety survey, and our gas operations organization finished in the top 10% for the third year in a row, according to the American Gas Association.\"\n\n3. **Determine the Answer:**\n   - The company has ranked first among North American combined gas and electric companies in the EEI's annual safety survey for the eighth consecutive year.\n\nTherefore, the correct answer is:\n\n**C: Eight years**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 64000, "result": 1.0, "question": "Which factor is essential for increasing loan origination volume in the company's strategy?", "options": {"A": "Expanding international partnerships", "B": "Attracting and retaining skilled personnel", "C": "Reducing operational costs", "D": "Increasing online marketing efforts", "E": "Diversifying investment portfolio", "F": "Enhancing customer service training"}, "LLM_original_answer": ["To answer the question, \"Which factor is essential for increasing loan origination volume in the company's strategy?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Identify Key Assumptions and Strategies**:\n   - The document mentions that a significant component of the company's business strategy is to grow through acquisitions of other financial institutions or business lines.\n   - It also states that the company's strategic plan includes expanding profitable loan and deposit market share through both organic growth and opportunistic strategic transactions.\n\n2. **Examine the Assumptions**:\n   - One of the key assumptions in the strategic plan is that the company will be able to attract and retain the requisite number of skilled and qualified personnel required to increase loan origination volume, especially in commercial banking portfolios.\n   - The document emphasizes the competitive nature of the marketplace for skilled personnel, noting that hiring, training, and retaining skilled personnel is costly and challenging.\n\n3. **Evaluate the Options**:\n   - **A: Expanding international partnerships** - The document does not mention international partnerships as a key factor for increasing loan origination volume.\n   - **B: Attracting and retaining skilled personnel** - This is explicitly mentioned as a key assumption for increasing loan origination volume.\n   - **C: Reducing operational costs** - While reducing operational costs is important, it is not specifically linked to increasing loan origination volume.\n   - **D: Increasing online marketing efforts** - The document does not highlight online marketing as a primary factor for increasing loan origination volume.\n   - **E: Diversifying investment portfolio** - The document discusses the investment portfolio but does not link it directly to loan origination volume.\n   - **F: Enhancing customer service training** - While customer service training is important, it is not specifically mentioned as a factor for increasing loan origination volume.\n\n4. **Conclusion**:\n   - The document clearly states that the company's ability to increase loan origination volume depends on its ability to attract and retain skilled and qualified personnel, particularly in commercial banking portfolios.\n\nTherefore, the essential factor for increasing loan origination volume in the company's strategy is **B: Attracting and retaining skilled personnel**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 64000, "result": 1.0, "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?", "options": {"A": "Providing accurate healthcare information", "B": "Knowingly defrauding any healthcare benefit program", "C": "Sharing healthcare information with the patient's consent", "D": "Ensuring the security of health databases", "E": "Improving healthcare technology", "F": "Reporting a breach of security"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and the options given:\n\nThe question asks: \"Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?\"\n\nLet's review the options and the relevant information from the document:\n\nA: Providing accurate healthcare information\n- The document does not mention any prohibition on providing accurate healthcare information. In fact, HIPAA aims to protect the privacy and security of health information, which implies that accurate information is generally encouraged.\n\nB: Knowingly defrauding any healthcare benefit program\n- The document states: \"federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.\"\n- This directly aligns with the prohibition mentioned in the document.\n\nC: Sharing healthcare information with the patient's consent\n- The document does not mention a prohibition on sharing healthcare information with the patient's consent. In fact, HIPAA includes provisions for patient consent in the sharing of health information.\n\nD: Ensuring the security of health databases\n- Ensuring the security of health databases is a requirement under HIPAA, not a prohibited action. The document mentions that HIPAA imposes obligations to safeguard the privacy, security, and transmission of individually identifiable health information.\n\nE: Improving healthcare technology\n- The document does not mention any prohibition on improving healthcare technology. HIPAA is primarily concerned with the privacy and security of health information, not the development of technology.\n\nF: Reporting a breach of security\n- Reporting a breach of security is actually required under HIPAA, not prohibited. The document mentions that HIPAA requires the reporting of certain breaches of security of individually identifiable health information.\n\nBased on the analysis, the correct answer is:\n\n**B: Knowingly defrauding any healthcare benefit program**\n\nThis is explicitly mentioned as a prohibited action under the federal criminal statutes created by HIPAA."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 64000, "result": 1.0, "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?", "options": {"A": "Failure to expand subservicing income", "B": "Ocwen acquiring new MSRs unexpectedly", "C": "A change of control of Ocwen or PHH", "D": "Increase in Ocwen's financial reserves", "E": "Successful maintenance of service levels", "F": "Ocwen improving its technology systems"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n### Step 1: Identify the Subservicing Agreement with MAV\nThe document mentions that MAV (Mortgage Asset Vehicle) is one of Ocwen's largest subservicing clients. The Subservicing Agreement with MAV is described in the following excerpt:\n> \"MAV is one of our largest subservicing clients, accounting for 19% of the UPB and 15% of the loan count in our servicing and subservicing portfolio as of December 31, 2023. The Subservicing Agreement with MAV provides exclusivity rights to PHH as subservicer and will continue until terminated by mutual agreement of the parties or for cause, as defined.\"\n\n### Step 2: Determine the Conditions for Termination\nThe document outlines the conditions under which MAV can terminate the Subservicing Agreement:\n> \"However, under the terms of our Subservicing Agreement, our subservicing rights terminate as to MSRs sold by MAV to any unaffiliated third party. Prior to May 3, 2024, MAV may sell MSRs, in one or more sales, constituting up to 20% of MAV\u2019s total assets without our consent. After May 3, 2024, MAV may sell the entire servicing portfolio or any portion thereof without our consent (although we have a right of first offer with respect to the full or partial sale of the MAV entity itself).\"\n\n### Step 3: Identify Additional Termination Events\nThe document also mentions other events that could lead to termination:\n> \"If MAV chooses to exercise these sale rights, and we are unable to reach an agreement with the purchaser(s) of the MSRs to continue as subservicer, we will lose the corresponding subservicing income. Further, if the MSRs sold by MAV include MSRs previously sold by PHH, we may recognize additional losses on the associated MSR and Pledged MSR liability reported at fair value on our consolidated balance sheets.\"\n\n### Step 4: Analyze the Options\nNow, let's analyze each option to see if it matches the conditions for termination:\n\n- **A: Failure to expand subservicing income** - This is not mentioned as a specific termination event.\n- **B: Ocwen acquiring new MSRs unexpectedly** - This is not mentioned as a specific termination event.\n- **C: A change of control of Ocwen or PHH**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 64000, "result": 1.0, "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?", "options": {"A": "Emails of previous FDA meetings", "B": "Details of international marketing strategies", "C": "Data from device testing", "D": "Descriptions of the manufacturing process and non-clinical studies", "E": "Marketing plans and budgets", "F": "Consumer feedback surveys"}, "LLM_original_answer": ["To answer the question \"What is submitted to the FDA as part of a BLA requesting approval to market a new drug?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Understanding the BLA Process**:\n   - The document outlines the process required by the FDA before a biologic can be marketed in the U.S. This process involves several steps, including preclinical studies, clinical trials, and the submission of a Biologics License Application (BLA).\n\n2. **Content of the BLA**:\n   - The document states: \"The results of product development, non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of a BLA requesting approval to market the product for its intended indication.\"\n\n3. **Analyzing the Options**:\n   - **A: Emails of previous FDA meetings** - The document does not mention emails of previous FDA meetings as part of the BLA submission.\n   - **B: Details of international marketing strategies** - The document does not mention international marketing strategies as part of the BLA submission.\n   - **C: Data from device testing** - The document does not mention data from device testing as part of the BLA submission.\n   - **D: Descriptions of the manufacturing process and non-clinical studies** - The document explicitly mentions that descriptions of the manufacturing process and non-clinical studies are part of the BLA submission.\n   - **E: Marketing plans and budgets** - The document does not mention marketing plans and budgets as part of the BLA submission.\n   - **F: Consumer feedback surveys** - The document does not mention consumer feedback surveys as part of the BLA submission.\n\n4. **Conclusion**:\n   - Based on the information provided in the document, the correct answer is **D: Descriptions of the manufacturing process and non-clinical studies**.\n\nTherefore, the answer to the question is **D: Descriptions of the manufacturing process and non-clinical studies**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 64000, "result": 1.0, "question": "What is required for the renewal of a marketing authorization after five years?", "options": {"A": "Approval from the European Medicines Agency (EMA)", "B": "Independent clinical trials conducted in the past year", "C": "A re-evaluation of the risk-benefit balance", "D": "Proof of sales data from member states", "E": "A newly conducted preclinical test", "F": "An application fee for renewal"}, "LLM_original_answer": ["To answer the question \"What is required for the renewal of a marketing authorization after five years?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Initial Validity of Marketing Authorization**:\n   - The document states: \"A marketing authorization has an initial validity for five years in principle.\"\n\n2. **Renewal Process**:\n   - The document further explains: \"The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA (for a centrally authorized product) or by the competent authority of the relevant EU Member State (for a nationally authorized product).\"\n\n3. **Requirements for Renewal**:\n   - To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety, and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid.\n\n4. **Annual Review for Exceptional Circumstances**:\n   - The document mentions: \"A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual reassessment procedure.\"\n\n5. **Conclusion**:\n   - The key requirement for the renewal of a marketing authorization after five years is a re-evaluation of the risk-benefit balance.\n\nGiven the options provided:\nA: Approval from the European Medicines Agency (EMA)\nB: Independent clinical trials conducted in the past year\nC: A re-evaluation of the risk-benefit balance\nD: Proof of sales data from member states\nE: A newly conducted preclinical test\nF: An application fee for renewal\n\nThe correct answer is **C: A re-evaluation of the risk-benefit balance**. This is explicitly stated in the document as the basis for renewing the marketing authorization after five years."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 64000, "result": 0.0, "question": "What could cause a potential loss of revenue according to the document?", "options": {"A": "Discontinuation of services by third-party companies to clients", "B": "Increased competition in the market", "C": "Rising operational costs", "D": "Decreased demand for trading platforms", "E": "Improper licensing of data", "F": "Delays in transitioning to new service providers"}, "LLM_original_answer": ["To answer the question \"What could cause a potential loss of revenue according to the document?\" let's analyze the document step by step and identify the relevant sections that discuss potential revenue loss.\n\n1. **Global Economic and Market Conditions:**\n   - The document mentions that adverse macroeconomic conditions, including recessions, inflation, and market volatility, can negatively impact consumer and corporate confidence, leading to reductions in spending. This could result in lower trading volumes and reduced demand for financial data, which would decrease revenues.\n   - Specifically, it states: \"Adverse macroeconomic conditions, including recessions, inflation, supply chain issues, labor shortages, government shutdowns, currency fluctuations, interest rate changes, increased mortgage foreclosure volume, decreased mortgage origination or servicing volume, decreased mortgage servicing volume, geopolitical events or conflicts, election results, international trade disputes, including the imposition of tariffs or other protectionist measures, actual or anticipated large-scale defaults or failures or slowdown of global trade have in the past negatively impacted consumer and corporate confidence and resulted in reductions in consumer, government and corporate spending, and could have such effects in the future, and in turn impact our business.\"\n\n2. **Interest Rates and Inflation:**\n   - Rising interest rates are likely to reduce mortgage loan production volumes and increase loan foreclosures, which could impact transaction-based revenues.\n   - Inflation can increase the cost of capital, leading to a slowdown in the growth of early-stage companies and causing companies to stay private longer. This can reduce demand for trading platforms and other services.\n   - The document notes: \"Rising interest rates are likely to reduce mortgage loan production volumes and increase loan foreclosures, which could potentially impact our transaction-based revenues. In the event that inflation continues to increase, this would likely further increase the cost of capital, resulting in a slowdown of the growth of early stage companies, causing companies to stay private longer.\"\n\n3. **Regulatory Changes:**\n   - Regulatory developments or court rulings could reduce the amount of revenue obtained from exchange market data and connectivity fees.\n   - The document states: \"Regulatory developments or court rulings may have an adverse impact on our ability to derive revenue from market data and connectivity fees. With respect to our U.S. equities and equity options exchanges, our ability to assess fees for market data products and certain connectivity fees are subject to review by the SEC.\"\n\n4. **Climate Change and Transition to Renewable Energy:**\n   - The transition to renewable energy could impact the demand for certain products and services, particularly those related to fossil"], "LLM_extracted_answer": ["D"], "ground_truth": "A"}, {"depth": 20, "token_lengths": 64000, "result": 1.0, "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?", "options": {"A": "Increase in statutory tax rate", "B": "Valuation allowance and charge to profitability", "C": "Reduction in business performance", "D": "Increase in future taxable income", "E": "Adjustment in dividend policies", "F": "Expansion of subsidiary operations"}, "LLM_original_answer": ["To answer the question, we need to identify the relevant information from the provided document. The question is: \"What must be established if deferred income tax assets are deemed more likely than not unrealisable?\"\n\nLet's break down the relevant information:\n\n1. **Deferred Income Tax Assets and Realization**:\n   - The document states: \"Deferred income tax assets are assessed periodically by management to determine whether they are realizable. Factors in management\u2019s determination include the performance of the business, including the ability to generate future taxable income.\"\n   - It further mentions: \"If, based on available information, it is more likely than not that the deferred income tax asset will not be realized, then a valuation allowance must be established with a corresponding charge to our profitability measures.\"\n\n2. **Valuation Allowance**:\n   - The document explicitly states: \"Valuation allowances are established when management determines, based on available information, that it is more likely than not that deferred income tax assets will not be realized.\"\n\n3. **Impact on Profitability**:\n   - The document indicates that the establishment of a valuation allowance results in a charge to profitability measures.\n\nGiven this information, the correct answer is:\n\n**B: Valuation allowance and charge to profitability**\n\nThis is because the document clearly states that if it is more likely than not that deferred income tax assets will not be realized, a valuation allowance must be established, and this establishment results in a charge to profitability measures."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 96000, "result": 1.0, "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?", "options": {"A": "When the product is highly effective in children", "B": "If the disease only occurs in children", "C": "When the product shows uncertain efficacy in adults", "D": "If the product is likely ineffective or unsafe in children", "E": "When there is sufficient pediatric market demand", "F": "If the product is cheaper than existing treatments"}, "LLM_original_answer": ["To answer the question \"Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the Relevant Section**: The document mentions the Pediatric Committee (PDCO) and its role in the European Union (EU) regulatory framework. The relevant section is found under \"Pediatric Development in the EU.\"\n\n2. **Extract the Key Information**: The document states:\n   - \"The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product for which MA is being sought.\"\n   - \"The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults.\"\n   - \"Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients.\"\n\n3. **Analyze the Conditions for Waiver**:\n   - **Ineffective or Unsafe in Children**: The PDCO can waive the obligation if the product is likely to be ineffective or unsafe in children.\n   - **Disease Occurs Only in Adult Populations**: The PDCO can waive the obligation if the disease or condition for which the product is intended occurs only in adult populations.\n   - **No Significant Therapeutic Benefit**: The PDCO can waive the obligation if the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients.\n\n4. **Match the Conditions to the Options**:\n   - **Option A**: \"When the product is highly effective in children\" - This does not match the conditions for waiver.\n   - **Option B**: \"If the disease only occurs in children\" - This does not match the conditions for waiver.\n   - **Option C**: \"When the product shows uncertain efficacy in adults\" - This does not match the conditions for waiver.\n   - **Option D**: \"If the product is likely ineffective or unsafe in children\" - This matches the first condition for waiver.\n   - **Option E**: \"When there is sufficient pediatric market demand\" - This does not match the conditions for waiver.\n   - **Option F**:"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 96000, "result": 1.0, "question": "What factor could make it difficult for the company to retain key personnel?", "options": {"A": "Reduction in product sales", "B": "Delays in adopting management incentive plans", "C": "Expansion into new markets", "D": "Increased competition", "E": "Technological advancements", "F": "Change in stock prices"}, "LLM_original_answer": ["To answer the question \"What factor could make it difficult for the company to retain key personnel?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Identify Key Information**:\n   - The document mentions that the company's success depends on its ability to attract, develop, motivate, and retain highly qualified and skilled management and other employees.\n   - It also states that the company may face challenges in retaining key personnel due to its recent emergence from bankruptcy and the uncertainties currently facing the business.\n   - Specifically, the document notes: \"Any potential delays in adopting our management incentive plan and other executive benefits and compensation may make it difficult to retain key personnel and we may need to enter into retention or other arrangements that could be costly to maintain.\"\n\n2. **Evaluate the Options**:\n   - **A: Reduction in product sales** - The document does not directly link a reduction in product sales to difficulties in retaining key personnel.\n   - **B: Delays in adopting management incentive plans** - The document explicitly mentions that delays in adopting management incentive plans and other executive benefits and compensation could make it difficult to retain key personnel.\n   - **C: Expansion into new markets** - The document does not suggest that expansion into new markets would directly impact the retention of key personnel.\n   - **D: Increased competition** - While the document discusses competition, it does not specifically link increased competition to difficulties in retaining key personnel.\n   - **E: Technological advancements** - The document discusses technological advancements and the need to adapt, but it does not directly link this to difficulties in retaining key personnel.\n   - **F: Change in stock prices** - The document does not directly link changes in stock prices to difficulties in retaining key personnel.\n\n3. **Conclusion**:\n   - The most relevant and directly stated factor in the document that could make it difficult for the company to retain key personnel is **B: Delays in adopting management incentive plans**.\n\nTherefore, the correct answer is **B: Delays in adopting management incentive plans**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 96000, "result": 1.0, "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?", "options": {"A": "Three years", "B": "Five years", "C": "Eight years", "D": "Ten years", "E": "Twelve years", "F": "Fifteen years"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant information**: The question asks about the number of consecutive years Duke Energy ranked first among North American combined gas and electric companies in the EEI's annual safety survey in 2023.\n\n2. **Locate the specific statement**: I will search the provided document for a statement that mentions Duke Energy's ranking in the EEI's annual safety survey.\n\n3. **Extract the relevant data**: Once I find the statement, I will extract the number of consecutive years mentioned.\n\n4. **Match the data to the options**: I will compare the extracted data to the provided options to determine the correct answer.\n\n### Step-by-Step Analysis:\n\n1. **Identify the relevant information**:\n   - The document is extensive, so I need to focus on sections that discuss Duke Energy's performance and achievements.\n\n2. **Locate the specific statement**:\n   - I found the relevant information in the \"Operational Excellence, Safety and Reliability\" section of the document.\n\n3. **Extract the relevant data**:\n   - The specific statement is: \"For the eighth consecutive year, we ranked first among North American combined gas and electric companies in Edison Electric Institute\u2019s (EEI) annual safety survey, and our gas operations organization finished in the top 10% for the third year in a row, according to the American Gas Association.\"\n\n4. **Match the data to the options**:\n   - The statement indicates that Duke Energy has ranked first for 8 consecutive years.\n   - The options provided are:\n     - A: Three years\n     - B: Five years\n     - C: Eight years\n     - D: Ten years\n     - E: Twelve years\n     - F: Fifteen years\n\n### Conclusion:\nThe correct answer is **C: Eight years**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 96000, "result": 1.0, "question": "Which factor is essential for increasing loan origination volume in the company's strategy?", "options": {"A": "Expanding international partnerships", "B": "Attracting and retaining skilled personnel", "C": "Reducing operational costs", "D": "Increasing online marketing efforts", "E": "Diversifying investment portfolio", "F": "Enhancing customer service training"}, "LLM_original_answer": ["To answer the question, \"Which factor is essential for increasing loan origination volume in the company's strategy?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Identify the Context**:\n   - The document discusses various aspects of Eastern Bank's operations, including its loan portfolio, regulatory requirements, and strategic plans.\n   - The focus is on the company's ability to manage and grow its loan origination volume.\n\n2. **Key Assumptions and Strategic Goals**:\n   - The document mentions that one of the key assumptions in the company's strategic plan is the ability to attract and retain skilled and qualified personnel, especially in commercial banking portfolios.\n   - This is stated in the \"Results of Operations\" section under \"Outlook and Trends\":\n     - \"Our key assumptions include: that we will be able to attract and retain the requisite number of skilled and qualified personnel required to increase our loan origination volume, especially in our commercial banking portfolios.\"\n\n3. **Evaluate the Options**:\n   - **A: Expanding international partnerships** - The document does not mention international partnerships as a key factor for increasing loan origination volume.\n   - **B: Attracting and retaining skilled personnel** - This is explicitly mentioned as a key assumption for increasing loan origination volume.\n   - **C: Reducing operational costs** - While reducing operational costs is important for overall profitability, it is not specifically mentioned as a factor for increasing loan origination volume.\n   - **D: Increasing online marketing efforts** - The document does not highlight online marketing efforts as a primary factor for increasing loan origination volume.\n   - **E: Diversifying investment portfolio** - This is more related to investment strategies and not directly to loan origination.\n   - **F: Enhancing customer service training** - While customer service training is important, it is not specifically mentioned as a factor for increasing loan origination volume.\n\n4. **Conclusion**:\n   - Based on the explicit mention in the document, the factor essential for increasing loan origination volume in the company's strategy is **B: Attracting and retaining skilled personnel**.\n\nTherefore, the correct answer is **B: Attracting and retaining skilled personnel**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 96000, "result": 1.0, "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?", "options": {"A": "Providing accurate healthcare information", "B": "Knowingly defrauding any healthcare benefit program", "C": "Sharing healthcare information with the patient's consent", "D": "Ensuring the security of health databases", "E": "Improving healthcare technology", "F": "Reporting a breach of security"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document and the options given.\n\n### Analysis of the Document\nThe document mentions the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) in the section \"Risks Related to Our Intellectual Property.\" Specifically, it states:\n- **Federal criminal statutes created by HIPAA** prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.\n\n### Options Analysis\n1. **A: Providing accurate healthcare information** - This is generally encouraged and not prohibited by HIPAA.\n2. **B: Knowingly defrauding any healthcare benefit program** - This is explicitly prohibited by the federal criminal statutes created by HIPAA.\n3. **C: Sharing healthcare information with the patient's consent** - This is allowed and encouraged under HIPAA, provided it is done with proper consent and in compliance with the regulations.\n4. **D: Ensuring the security of health databases** - This is a requirement under HIPAA, not a prohibited action.\n5. **E: Improving healthcare technology** - This is not prohibited by HIPAA and is generally encouraged.\n6. **F: Reporting a breach of security** - This is required under HIPAA and is not prohibited.\n\n### Conclusion\nBased on the information provided in the document, the correct answer is:\n\n**B: Knowingly defrauding any healthcare benefit program**\n\nThis action is explicitly prohibited by the federal criminal statutes created by HIPAA."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 96000, "result": 1.0, "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?", "options": {"A": "Failure to expand subservicing income", "B": "Ocwen acquiring new MSRs unexpectedly", "C": "A change of control of Ocwen or PHH", "D": "Increase in Ocwen's financial reserves", "E": "Successful maintenance of service levels", "F": "Ocwen improving its technology systems"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identifying Relevant Information:**\n   - The document states: \"MAV has the right to terminate the Subservicing Agreement entirely in the event of certain events of default, including failure by Ocwen to meet financial or operational requirements, including service levels.\"\n   - It also mentions: \"MAV may also terminate the Subservicing Agreement in the event of a change of control of Ocwen or PHH.\"\n\n2. **Evaluating the Options:**\n   - **Option A: Failure to expand subservicing income** - This is not mentioned as a reason for termination.\n   - **Option B: Ocwen acquiring new MSRs unexpectedly** - This is not mentioned as a reason for termination.\n   - **Option C: A change of control of Ocwen or PHH** - This is explicitly mentioned as a reason for termination.\n   - **Option D: Increase in Ocwen's financial reserves** - This is not mentioned as a reason for termination.\n   - **Option E: Successful maintenance of service levels** - This is the opposite of what is mentioned; failure to maintain service levels is a reason for termination.\n   - **Option F: Ocwen improving its technology systems** - This is not mentioned as a reason for termination.\n\n3. **Conclusion:**\n   - The document clearly states that MAV can terminate the Subservicing Agreement if there is a change of control of Ocwen or PHH.\n\nTherefore, the correct answer is **Option C: A change of control of Ocwen or PHH**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 96000, "result": 1.0, "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?", "options": {"A": "Emails of previous FDA meetings", "B": "Details of international marketing strategies", "C": "Data from device testing", "D": "Descriptions of the manufacturing process and non-clinical studies", "E": "Marketing plans and budgets", "F": "Consumer feedback surveys"}, "LLM_original_answer": ["To answer the question \"What is submitted to the FDA as part of a BLA requesting approval to market a new drug?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Understanding the BLA Process**:\n   - The document outlines the process required by the FDA for a Biologics License Application (BLA) to market a new biologic product.\n   - It states that a BLA must include extensive data and information to establish the safety and effectiveness of the proposed drug for its intended use.\n\n2. **Components of the BLA**:\n   - The document specifies that the BLA must include:\n     - **Relevant Data from Non-Clinical and Clinical Testing**: This includes all pertinent non-clinical studies and clinical trials.\n     - **Manufacturing Information**: Detailed information about the product\u2019s chemistry, manufacturing, and controls (CMC).\n     - **Analytical Data**: Data from analytical tests conducted on the drug.\n     - **Proposed Labeling**: Information about how the product will be labeled.\n     - **Other Relevant Information**: Any additional information that supports the application.\n\n3. **Evaluating the Options**:\n   - **Option A: Emails of previous FDA meetings** - The document does not mention emails of previous FDA meetings as part of the BLA.\n   - **Option B: Details of international marketing strategies** - The document does not indicate that international marketing strategies are part of the BLA.\n   - **Option C: Data from device testing** - The document does not mention device testing as part of the BLA for biologics.\n   - **Option D: Descriptions of the manufacturing process and non-clinical studies** - The document explicitly states that the BLA must include detailed information about the product\u2019s chemistry, manufacturing, and controls, as well as non-clinical studies.\n   - **Option E: Marketing plans and budgets** - The document does not mention marketing plans and budgets as part of the BLA.\n   - **Option F: Consumer feedback surveys** - The document does not mention consumer feedback surveys as part of the BLA.\n\n4. **Conclusion**:\n   - Based on the information provided in the document, the correct answer is **Option D: Descriptions of the manufacturing process and non-clinical studies**.\n\nTherefore, the answer to the question is **Option D: Descriptions of the manufacturing process and non-clinical studies**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 96000, "result": 1.0, "question": "What is required for the renewal of a marketing authorization after five years?", "options": {"A": "Approval from the European Medicines Agency (EMA)", "B": "Independent clinical trials conducted in the past year", "C": "A re-evaluation of the risk-benefit balance", "D": "Proof of sales data from member states", "E": "A newly conducted preclinical test", "F": "An application fee for renewal"}, "LLM_original_answer": ["To answer the question \"What is required for the renewal of a marketing authorization after five years?\" based on the provided document, I will analyze the relevant sections and extract the necessary information.\n\n### Relevant Section:\n**Periods of Authorization and Renewals**\n- **Marketing Authorization Renewal:**\n  - \"A marketing authorization has an initial validity for five years in principle.\"\n  - \"The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA (for a centrally authorized product) or by the competent authority of the relevant EU Member State (for a nationally authorized product).\"\n  - \"To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid.\"\n\n### Analysis:\n1. **Initial Validity:**\n   - The marketing authorization is initially valid for five years.\n\n2. **Renewal Basis:**\n   - The renewal is based on a re-evaluation of the risk-benefit balance.\n\n3. **Re-evaluation Process:**\n   - The marketing authorization holder must provide a consolidated version of the file.\n   - This file should include information on quality, safety, and efficacy.\n   - It should also include all variations introduced since the marketing authorization was granted.\n\n4. **Timing:**\n   - The marketing authorization holder must submit this consolidated file at least nine months before the marketing authorization ceases to be valid.\n\n### Conclusion:\nBased on the information provided in the document, the correct answer is:\n\n**C: A re-evaluation of the risk-benefit balance**\n\nThis is explicitly stated as the basis for the renewal of a marketing authorization after five years. The marketing authorization holder must provide a comprehensive and updated file to the EMA or the competent authority, which includes all relevant information on quality, safety, and efficacy, to support this re-evaluation."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 96000, "result": 0.0, "question": "What could cause a potential loss of revenue according to the document?", "options": {"A": "Discontinuation of services by third-party companies to clients", "B": "Increased competition in the market", "C": "Rising operational costs", "D": "Decreased demand for trading platforms", "E": "Improper licensing of data", "F": "Delays in transitioning to new service providers"}, "LLM_original_answer": ["To answer the question \"What could cause a potential loss of revenue according to the document?\" let's analyze the provided document step by step:\n\n1. **Global Economic, Political, and Financial Market Events or Conditions**:\n   - The document mentions that adverse macroeconomic conditions, including recessions, inflation, supply chain issues, labor shortages, government shutdowns, currency fluctuations, interest rate changes, and increased mortgage foreclosure volume, can negatively impact consumer and corporate confidence, leading to reductions in consumer, government, and corporate spending.\n   - **Relevant Options**: B (Increased competition in the market), C (Rising operational costs), D (Decreased demand for trading platforms), E (Improper licensing of data), F (Delays in transitioning to new service providers).\n\n2. **Interest Rate Levels, Inflation, and Financial Markets Volatility**:\n   - Rising interest rates and inflation can reduce mortgage origination volumes and increase mortgage foreclosure volumes, which can negatively impact transaction-based revenues.\n   - **Relevant Options**: C (Rising operational costs), D (Decreased demand for trading platforms).\n\n3. **Regulatory Changes**:\n   - The document discusses various regulatory changes that could impact trading volumes and demand for market data and connectivity fees. For example, the SEC's proposed rule to prohibit securities exchanges from offering volume-based transaction pricing could negatively impact the ability to compete with off-exchange trading venues.\n   - **Relevant Options**: B (Increased competition in the market), D (Decreased demand for trading platforms), E (Improper licensing of data).\n\n4. **Systems Failures and Cybersecurity**:\n   - High-profile system failures and cybersecurity risks can result in a loss of confidence in technology and markets, leading to regulatory investigations, fines, and business activity slowdowns.\n   - **Relevant Options**: F (Delays in transitioning to new service providers).\n\n5. **Mortgage Lending Industry**:\n   - Adverse conditions in the mortgage lending industry, such as a substantial or prolonged decline in mortgage lending volume, can increase costs and have an adverse effect on revenues.\n   - **Relevant Options**: C (Rising operational costs), D (Decreased demand for trading platforms).\n\n6. **Competition**:\n   - Intense competition in the market for derivatives trading and clearing, as well as in the market for cash equity listings, trading, and execution, can impact trading volumes and demand for market data.\n   - **Relevant Options**: B (Increased competition in the market), D (Decre"], "LLM_extracted_answer": ["D"], "ground_truth": "A"}, {"depth": 20, "token_lengths": 96000, "result": 1.0, "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?", "options": {"A": "Increase in statutory tax rate", "B": "Valuation allowance and charge to profitability", "C": "Reduction in business performance", "D": "Increase in future taxable income", "E": "Adjustment in dividend policies", "F": "Expansion of subsidiary operations"}, "LLM_original_answer": ["To answer the question, we need to identify the correct action that must be taken if deferred income tax assets are deemed more likely than not unrealizable. Let's break down the relevant information from the provided document:\n\n1. **Deferred Income Tax Assets and Valuation Allowance**:\n   - The document states: \"Deferred income tax assets are assessed periodically by management to determine whether they are realizable. Factors in management\u2019s determination include the performance of the business, including the ability to generate future taxable income.\"\n   - It further mentions: \"If, based on available information, it is more likely than not that the deferred income tax asset will not be realized, then a valuation allowance must be established with a corresponding charge to our profitability measures.\"\n\n2. **Impact on Financial Condition**:\n   - The document notes: \"Such charges could have a material adverse effect on our financial condition and results of operations.\"\n\nFrom this information, we can deduce the following:\n\n- **Valuation Allowance**: If deferred income tax assets are deemed more likely than not unrealizable, a valuation allowance must be established.\n- **Charge to Profitability**: The establishment of a valuation allowance results in a charge to the company's profitability measures.\n\nTherefore, the correct answer is:\n\n**B: Valuation allowance and charge to profitability**\n\nThis option directly aligns with the requirement to establish a valuation allowance and the corresponding charge to profitability measures as described in the document."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 128000, "result": 1.0, "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?", "options": {"A": "When the product is highly effective in children", "B": "If the disease only occurs in children", "C": "When the product shows uncertain efficacy in adults", "D": "If the product is likely ineffective or unsafe in children", "E": "When there is sufficient pediatric market demand", "F": "If the product is cheaper than existing treatments"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 128000, "result": 1.0, "question": "What factor could make it difficult for the company to retain key personnel?", "options": {"A": "Reduction in product sales", "B": "Delays in adopting management incentive plans", "C": "Expansion into new markets", "D": "Increased competition", "E": "Technological advancements", "F": "Change in stock prices"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 128000, "result": 0.0, "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?", "options": {"A": "Three years", "B": "Five years", "C": "Eight years", "D": "Ten years", "E": "Twelve years", "F": "Fifteen years"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 128000, "result": 1.0, "question": "Which factor is essential for increasing loan origination volume in the company's strategy?", "options": {"A": "Expanding international partnerships", "B": "Attracting and retaining skilled personnel", "C": "Reducing operational costs", "D": "Increasing online marketing efforts", "E": "Diversifying investment portfolio", "F": "Enhancing customer service training"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 128000, "result": 1.0, "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?", "options": {"A": "Providing accurate healthcare information", "B": "Knowingly defrauding any healthcare benefit program", "C": "Sharing healthcare information with the patient's consent", "D": "Ensuring the security of health databases", "E": "Improving healthcare technology", "F": "Reporting a breach of security"}, "LLM_original_answer": ["To answer the question, I will refer to the relevant section of the provided document that discusses the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA).\n\nThe relevant section states:\n\"Federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program, or, in any matter involving a healthcare benefit program, for knowingly and willfully making materially false, fictitious or fraudulent statements in connection with the delivery of or payment for health care benefits, items or services.\"\n\nBased on this information, the correct answer is:\n\n**B: Knowingly defrauding any healthcare benefit program**\n\nThis option directly aligns with the federal criminal statutes mentioned in the document, which prohibit schemes to defraud healthcare benefit programs."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 20, "token_lengths": 128000, "result": 1.0, "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?", "options": {"A": "Failure to expand subservicing income", "B": "Ocwen acquiring new MSRs unexpectedly", "C": "A change of control of Ocwen or PHH", "D": "Increase in Ocwen's financial reserves", "E": "Successful maintenance of service levels", "F": "Ocwen improving its technology systems"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 128000, "result": 1.0, "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?", "options": {"A": "Emails of previous FDA meetings", "B": "Details of international marketing strategies", "C": "Data from device testing", "D": "Descriptions of the manufacturing process and non-clinical studies", "E": "Marketing plans and budgets", "F": "Consumer feedback surveys"}, "LLM_original_answer": ["To answer the question \"What is submitted to the FDA as part of a BLA requesting approval to market a new drug?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Understanding the BLA Process**:\n   - The document states that the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (FDCA) and biologics under the Public Health Service Act.\n   - A Biologics License Application (BLA) is required for a biologic to be legally marketed in the U.S.\n\n2. **Components of a BL"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 20, "token_lengths": 128000, "result": 1.0, "question": "What is required for the renewal of a marketing authorization after five years?", "options": {"A": "Approval from the European Medicines Agency (EMA)", "B": "Independent clinical trials conducted in the past year", "C": "A re-evaluation of the risk-benefit balance", "D": "Proof of sales data from member states", "E": "A newly conducted preclinical test", "F": "An application fee for renewal"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 20, "token_lengths": 128000, "result": 0.0, "question": "What could cause a potential loss of revenue according to the document?", "options": {"A": "Discontinuation of services by third-party companies to clients", "B": "Increased competition in the market", "C": "Rising operational costs", "D": "Decreased demand for trading platforms", "E": "Improper licensing of data", "F": "Delays in transitioning to new service providers"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "A"}, {"depth": 20, "token_lengths": 128000, "result": 1.0, "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?", "options": {"A": "Increase in statutory tax rate", "B": "Valuation allowance and charge to profitability", "C": "Reduction in business performance", "D": "Increase in future taxable income", "E": "Adjustment in dividend policies", "F": "Expansion of subsidiary operations"}, "LLM_original_answer": ["To answer the question, we need to identify the correct action that must be taken if deferred income tax assets are deemed more likely than not unrealisable. Let's break down the relevant information from the provided document:\n\n1. **Deferred Income Tax Assets and Valuation Allowance**:\n   - The document states: \"Deferred income tax assets are assessed periodically by management to determine whether they are realizable. Factors in management\u2019s determination include the performance of the business, including the ability to generate future taxable income. If, based on available information, it is more likely than not that the deferred income tax asset will not be realized, then a valuation allowance must be established with a corresponding charge to our profitability measures. Such charges could have a material adverse effect on our financial condition and results of operations.\"\n\n2. **Key Points**:\n   - **Assessment**: Management periodically assesses the realizability of deferred income tax assets.\n   - **Realizability**: The realizability is determined based on the ability to generate future taxable income.\n   - **Action**: If it is more likely than not that the deferred income tax asset will not be realized, a valuation allowance must be established.\n   - **Impact**: The establishment of a valuation allowance results in a charge to profitability measures.\n\n3. **Options Analysis**:\n   - **A: Increase in statutory tax rate**: This is not directly related to the realizability of deferred income tax assets.\n   - **B: Valuation allowance and charge to profitability**: This matches the document's statement about the action required.\n   - **C: Reduction in business performance**: This is a potential consequence but not the action required.\n   - **D: Increase in future taxable income**: This is a factor in the assessment but not the action required.\n   - **E: Adjustment in dividend policies"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 8000, "result": 1.0, "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?", "options": {"A": "$58.7 million", "B": "$104.7 million", "C": "$153.0 million", "D": "$381.4 million", "E": "$420.5 million", "F": "$275.9 million"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the accumulated deficit reported by the company?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that discusses the company's financial position and the need for additional capital. This section is likely to contain the information about the accumulated deficit.\n\n2. **Locate the specific information**: Within the \"Risks Related to Our Financial Position and Need for Additional Capital\" section, there is a statement that directly addresses the accumulated deficit as of December 31, 2023.\n\n3. **Extract the information**: The relevant statement is: \"As of December 31, 2023, we had an accumulated deficit of $381.4 million.\"\n\n4. **Match the information to the options**: The extracted information matches option D: $381.4 million.\n\nTherefore, the correct answer is **D: $381.4 million**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 25, "token_lengths": 8000, "result": 1.0, "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?", "options": {"A": "The executive summary of the annual report", "B": "The company's market analysis", "C": "The consolidated financial statements and Notes to Financial Statements", "D": "The corporate governance guidelines", "E": "The strategic business plan", "F": "The risk management framework"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document and match it with the options given.\n\n### Step 1: Identify the relevant section in the document\nThe relevant section is found in **Item 7. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations (MD&A)**. The key sentence is:\n\"This MD&A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying Notes to Financial Statements (Part II, Item 8 of this Form 10-K).\"\n\n### Step 2: Understand the context\nThe MD&A is a detailed analysis of the company's financial condition and results of operations. It is meant to provide insights and explanations that are not available in the financial statements alone. The document explicitly states that the MD&A should be read alongside the consolidated financial statements and the Notes to Financial Statements.\n\n### Step 3: Match the information with the options\n- **Option A: The executive summary of the annual report** - This is not mentioned as a document to be read in conjunction with the MD&A.\n- **Option B: The company's market analysis** - This is not mentioned as a document to be read in conjunction with the MD&A.\n- **Option C: The consolidated financial statements and Notes to Financial Statements** - This is explicitly mentioned in the document.\n- **Option D: The corporate governance guidelines** - This is not mentioned as a document to be read in conjunction with the MD&A.\n- **Option E: The strategic business plan** - This is not mentioned as a document to be read in conjunction with the MD&A.\n- **Option F: The risk management framework** - This is not mentioned as a document to be read in conjunction with the MD&A.\n\n### Step 4: Conclusion\nBased on the information provided in the document, the correct answer is **Option C: The consolidated financial statements and Notes to Financial Statements**.\n\n### Final Answer\n**C: The consolidated financial statements and Notes to Financial Statements**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 8000, "result": 1.0, "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?", "options": {"A": "Increase in secondary marketing sales", "B": "Customer growth", "C": "Lower natural gas costs passed through to customers", "D": "Increase in North Carolina IMR", "E": "Tennessee ARM revenue recognition", "F": "Increase in off-system sales"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Identify the relevant section**: The question asks about the decrease in operating revenues for the year ended December 31, 2023, compared to 2022. The relevant section is found under \"DUKE ENERGY OHIO Results of Operations\" and \"Operating Revenues.\"\n\n2. **Extract the key information**: The document states:\n   - \"The variance was driven primarily by: a $585 million decrease due to lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs.\"\n   - \"Partially offset by: a $26 million increase due to customer growth; a $19 million increase due to North Carolina IMR; an $11 million increase due to Tennessee ARM revenue recognition; and a $9 million increase due to secondary marketing sales.\"\n\n3. **Evaluate the options**:\n   - **A: Increase in secondary marketing sales** - The document mentions a $9 million increase in secondary marketing sales, which is a small amount and does not explain the $585 million decrease.\n   - **B: Customer growth** - The document mentions a $26 million increase due to customer growth, which is also a small amount and does not explain the $585 million decrease.\n   - **C: Lower natural gas costs passed through to customers** - The document explicitly states that the primary driver of the $585 million decrease is \"lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs.\"\n   - **D: Increase in North Carolina IMR** - The document mentions a $19 million increase due to North Carolina IMR, which is a small amount and does not explain the $585 million decrease.\n   - **E: Tennessee ARM revenue recognition** - The document mentions an $11 million increase due to Tennessee ARM revenue recognition, which is a small amount and does not explain the $585 million decrease.\n   - **F: Increase in off-system sales** - The document mentions a decrease in off-system sales natural gas costs, which is part of the primary driver but does not stand alone as the primary cause.\n\n4. **Conclusion**: Based on the information provided, the primary cause of the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022,"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 8000, "result": 1.0, "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?", "options": {"A": "Technological advancements", "B": "Climate change", "C": "Economic policies", "D": "Urban development", "E": "Infrastructure improvements", "F": "Regulatory changes"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step to identify the factor mentioned as potentially worsening the severity and impact of future natural disasters.\n\n1. **Identify the relevant section**: The section that discusses natural disasters and their potential impacts is found in the part of the document that mentions \"Climate change, natural disasters, public health crises, geopolitical developments, acts of terrorism and other external events could harm our business.\"\n\n2. **Extract the specific information**: Within this section, the document states:\n   - \"Climate change may worsen the severity and impact of future hurricanes, earthquakes, fires, floods and other extreme weather-related events that could cause disruption to our business and operations.\"\n   - \"Chronic results of climate change such as shifting weather patterns could also cause disruption to our business and operations.\"\n   - \"Rising sea levels projected for the coastal regions of Massachusetts and New Hampshire could adversely affect our business.\"\n\n3. **Evaluate the options**:\n   - **A: Technological advancements** - Not mentioned in the context of worsening natural disasters.\n   - **B: Climate change** - Directly mentioned as a factor that could worsen the severity and impact of natural disasters.\n   - **C: Economic policies** - Not mentioned in the context of worsening natural disasters.\n   - **D: Urban development** - Not mentioned in the context of worsening natural disasters.\n   - **E: Infrastructure improvements** - Not mentioned in the context of worsening natural disasters.\n   - **F: Regulatory changes** - Not mentioned in the context of worsening natural disasters.\n\n4. **Conclusion**: Based on the information provided in the document, the factor mentioned as potentially worsening the severity and impact of future natural disasters is **B: Climate change**.\n\nTherefore, the correct answer is **B: Climate change**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 8000, "result": 1.0, "question": "What is a primary reason for fluctuations in the company's financial results?", "options": {"A": "Successful transition of operations", "B": "Regular market growth", "C": "Factors beyond the company's control", "D": "Consistent product demand", "E": "Reduced operational expenses", "F": "Stable regulatory environment"}, "LLM_original_answer": ["To answer the question \"What is a primary reason for fluctuations in the company's financial results?\" based on the provided document, I will analyze the content step by step:\n\n1. **Review the Document's Context**:\n   - The document is an excerpt from an Annual Report on Form 10-K, which typically discusses the company's financial position, risks, and future plans.\n   - The company is in the early stages of developing drug candidates and has not yet generated revenue from product sales.\n\n2. **Identify Key Financial Factors**:\n   - The company has incurred significant losses since its inception and expects to continue incurring losses for several years.\n   - The company's expenses are expected to increase substantially due to various activities, including clinical trials, regulatory submissions, and commercialization efforts.\n   - The company's financial condition and results of operations are expected to fluctuate significantly from quarter to quarter and year to year.\n\n3. **Analyze the Reasons for Fluctuations**:\n   - **Successful Transition of Operations (A)**: The document does not mention successful transitions as a reason for financial fluctuations. Instead, it emphasizes the challenges and uncertainties in transitioning from a research and development focus to commercial activities.\n   - **Regular Market Growth (B)**: The document does not discuss regular market growth as a factor affecting financial results. It focuses on the uncertainties and risks associated with drug development.\n   - **Factors Beyond the Company's Control (C)**: The document explicitly mentions that many factors affecting the company's financial results are beyond its control. These include regulatory delays, clinical trial outcomes, and market conditions.\n   - **Consistent Product Demand (D)**: The document does not discuss consistent product demand, as the company has not yet commercialized any products.\n   - **Reduced Operational Expenses (E)**: The document indicates that operational expenses are expected to increase, not decrease.\n   - **Stable Regulatory Environment (F)**: The document highlights the uncertainties and potential changes in the regulatory environment, which can impact the company's financial results.\n\n4. **Conclusion**:\n   - The primary reason for fluctuations in the company's financial results, as mentioned in the document, is **factors beyond the company's control**. This includes regulatory delays, clinical trial outcomes, and market conditions, all of which can significantly impact the company's expenses and potential revenue.\n\nTherefore, the correct answer is **C: Factors beyond the company's control**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 8000, "result": 1.0, "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?", "options": {"A": "55 or older", "B": "62 or older", "C": "65 or older", "D": "70 or older", "E": "60 or older", "F": "50 or older"}, "LLM_original_answer": ["To answer the question \"What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that discusses HECM reverse mortgages. This section is likely to contain the information needed to answer the question.\n\n2. **Extract the specific information**: Within the relevant section, I will look for a statement that specifies the age requirement for HECM reverse mortgages.\n\n3. **Match the information to the options**: Once I have the specific age requirement, I will match it to the options provided in the question.\n\n### Step-by-Step Analysis:\n\n1. **Identify the relevant section**:\n   - The relevant section is found in the part of the document that discusses the risks associated with HECM reverse mortgages. Specifically, it states: \"We originate, securitize and service FHA-insured HECM mortgages. The reverse mortgage business is subject to substantial risks, including market, credit, interest rate, liquidity, operational, reputational and legal risks.\"\n\n2. **Extract the specific information**:\n   - The document provides the following detail: \"Generally, a HECM reverse mortgage is a government-insured loan available to seniors aged 62 or older that allows homeowners to borrow money against the value of their home.\"\n\n3. **Match the information to the options**:\n   - The age requirement specified in the document is \"62 or older.\"\n   - This matches option B: \"62 or older.\"\n\n### Conclusion:\nThe correct answer is **B: 62 or older**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 8000, "result": 1.0, "question": "What is one potential consequence of violating the civil False Claims Act?", "options": {"A": "Execution of a scheme without penalty", "B": "Four times the actual damages sustained by the government", "C": "Exclusion from private healthcare programs", "D": "Participation in federal healthcare programs", "E": "Mandatory civil penalties for each false claim", "F": "No penalties for private individuals"}, "LLM_original_answer": ["To answer the question \"What is one potential consequence of violating the civil False Claims Act?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the Context**: The document discusses various healthcare regulatory laws, including the Federal Anti-Kickback Statute and the Federal False Claims Act. It specifically mentions the consequences of violating these laws.\n\n2. **Locate Relevant Information**: The section on the Federal False Claims Act states:\n   - \"Federal false claims and false statement laws, including the civil False Claims Act, prohibits any person or entity from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent.\"\n   - \"Penalties for a civil False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the Federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes.\"\n\n3. **Evaluate the Options**:\n   - **A: Execution of a scheme without penalty** - This is incorrect because the document clearly states that violations are punishable.\n   - **B: Four times the actual damages sustained by the government** - This is incorrect because the document specifies three times the actual damages, not four.\n   - **C: Exclusion from private healthcare programs** - This is incorrect because the document mentions exclusion from federal healthcare programs, not private ones.\n   - **D: Participation in federal healthcare programs** - This is incorrect because the consequence is exclusion, not participation.\n   - **E: Mandatory civil penalties for each false claim** - This is correct because the document explicitly states that mandatory civil penalties are included for each separate false claim.\n   - **F: No penalties for private individuals** - This is incorrect because the document indicates that private individuals can bring actions under the Federal Civil False Claims Act.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **E: Mandatory civil penalties for each false claim**.\n\nThis answer is supported by the document's clear statement that penalties for a civil False Claims Act violation include mandatory civil penalties for each separate false claim."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 25, "token_lengths": 8000, "result": 1.0, "question": "What is a potential risk mentioned regarding the company's financial position?", "options": {"A": "High competition leading to reduced market share", "B": "Inability to generate sufficient revenue to cover expenses", "C": "Government regulations affecting sales", "D": "Incorrect labeling of products", "E": "Issues with supply chain logistics", "F": "Patent expiration affecting product exclusivity"}, "LLM_original_answer": ["To answer the question \"What is a potential risk mentioned regarding the company's financial position?\" based on the provided document, I will analyze the relevant sections step by step:\n\n1. **Identify the relevant section**: The document contains a section titled \"Risks Related to Our Financial Position and Need for Capital\" which is directly related to the company's financial position.\n\n2. **Extract key points**:\n   - The company has incurred significant losses in the past and may incur additional losses if it is unable to generate sufficient revenue from its approved products to cover its expenses.\n   - The company has a limited history of recognizing revenue from product sales and may not be able to achieve or maintain long-term sustainable profitability.\n   - The company's financial results are highly dependent on the successful commercialization of its products, particularly AMX0035 (RELYVRIO in the U.S. and ALBRIOZA in Canada).\n   - The company anticipates continuing to incur significant costs associated with the commercialization of RELYVRIO and ALBRIOZA, and the development of additional product candidates.\n   - The company's financial condition and operating results may fluctuate significantly, making it difficult to predict future performance.\n   - The company may require substantial additional funding to meet its financial needs and pursue its business objectives, and if it cannot raise capital, it may have to delay, reduce, or eliminate its development and commercialization efforts.\n\n3. **Match the key points to the options**:\n   - **Option A: High competition leading to reduced market share** - This is mentioned in the document but is not directly related to the company's financial position.\n   - **Option B: Inability to generate sufficient revenue to cover expenses** - This is explicitly mentioned in the document as a potential risk: \"We have in the past incurred significant losses and may in the future incur additional losses if we are unable to continue to generate sufficient revenue from our approved products to cover our expenses.\"\n   - **Option C: Government regulations affecting sales** - While government regulations are discussed, they are more related to reimbursement and pricing rather than directly affecting the company's financial position.\n   - **Option D: Incorrect labeling of products** - This is not mentioned in the document.\n   - **Option E: Issues with supply chain logistics** - This is not mentioned in the document.\n   - **Option F: Patent expiration affecting product exclusivity** - This is not mentioned in the document.\n\n4. **Conclusion**: The potential risk most directly mentioned regarding the company's"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 8000, "result": 1.0, "question": "What economic factor is likely to reduce mortgage loan production volumes?", "options": {"A": "Decrease in volatility", "B": "Increase in inflation", "C": "Rising interest rates", "D": "Stability in commodity prices", "E": "Reduction in speculative trading", "F": "Growth of early stage companies"}, "LLM_original_answer": ["To answer the question \"What economic factor is likely to reduce mortgage loan production volumes?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Interest Rates and Mortgage Loan Production Volumes**:\n   - The document states: \"In addition, interest rates are a significant factor influencing mortgage loan production volumes and loan foreclosures. Rising interest rates are likely to reduce mortgage loan production volumes and increase loan foreclosures, which could potentially impact our transaction-based revenues.\"\n   - This directly links rising interest rates to a reduction in mortgage loan production volumes.\n\n2. **Inflation**:\n   - The document mentions: \"If inflation continues to increase, this would likely further increase the cost of capital, resulting in a slowdown of the growth of early stage companies, causing companies to stay private longer.\"\n   - While inflation can increase the cost of capital, the document does not explicitly state that it reduces mortgage loan production volumes. Instead, it focuses on the impact on early stage companies and the cost of capital.\n\n3. **Volatility**:\n   - The document discusses: \"Trading volume in our markets and products is largely driven by the degree of volatility - the magnitude and frequency of fluctuations - in prices and levels of the underlying commodities, securities, indices, financial benchmarks or other instruments.\"\n   - It does not mention that a decrease in volatility would reduce mortgage loan production volumes. In fact, it suggests that higher volatility increases trading volumes, which is not directly related to mortgage loan production.\n\n4. **Commodity Prices**:\n   - The document does not provide any information linking stability in commodity prices to mortgage loan production volumes.\n\n5. **Speculative Trading**:\n   - The document does not mention speculative trading as a factor affecting mortgage loan production volumes.\n\n6. **Growth of Early Stage Companies**:\n   - The document states: \"In the event that inflation continues to increase, this would likely further increase the cost of capital, resulting in a slowdown of the growth of early stage companies, causing companies to stay private longer.\"\n   - This is more about the impact of inflation on early stage companies rather than on mortgage loan production volumes.\n\nGiven the information provided, the economic factor that is explicitly mentioned as likely to reduce mortgage loan production volumes is **rising interest rates**.\n\nTherefore, the correct answer is:\n**C: Rising interest rates**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 8000, "result": 1.0, "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?", "options": {"A": "Fluctuations in global oil prices", "B": "Changes in local tax regulations", "C": "Ongoing military actions and threat of terrorism", "D": "Increases in online security breaches", "E": "Cybersecurity threats from internal employees", "F": "Competition from new market entrants"}, "LLM_original_answer": ["To answer the question, I will analyze the document and identify the risks that could adversely affect the company's investment portfolio. The document outlines several types of risks, and I will match these to the provided options.\n\n1. **Credit Spread Risk**:\n   - The document mentions that widening credit spreads can cause unrealized losses and increase borrowing costs. This is a significant risk to the investment portfolio.\n   - **Not directly listed in the options**.\n\n2. **Risks Related to Equity Markets**:\n   - The document discusses the volatility in equity markets and how it can affect the returns and net investment income from leveraged buy-out funds and private equity funds.\n   - **Not directly listed in the options**.\n\n3. **Risks Related to the Valuation of Securities**:\n   - The document highlights the difficulty in valuing securities during market disruptions, which can lead to significant variations in estimated fair values.\n   - **Not directly listed in the options**.\n\n4. **Liquidity Risk**:\n   - The document mentions that certain investments are relatively illiquid, and selling them during market volatility could result in realized losses.\n   - **Not directly listed in the options**.\n\n5. **Real Estate Risk**:\n   - The document discusses the risks associated with mortgage loans on commercial, agricultural, and residential real estate, including default risk and the impact of general economic conditions.\n   - **Not directly listed in the options**.\n\n6. **Derivative Risk**:\n   - The document notes that defaults by derivative counterparties and ratings downgrades can have a material adverse effect on the company's financial condition.\n   - **Not directly listed in the options**.\n\n7. **Other Risks**:\n   - **Ongoing military actions and the continued threat of terrorism**:\n     - The document explicitly states that ongoing military actions and the threat of terrorism can cause significant declines and volatility in global financial markets, affecting the value of the investment portfolio.\n     - **Matches Option C**.\n   - **Climate change and other catastrophic events**:\n     - The document mentions that climate change and other catastrophic events can also adversely affect the investment portfolio.\n     - **Not directly listed in the options**.\n\n8. **Cybersecurity Risks**:\n   - The document discusses the risk of cyber-attacks and the potential for loss or disclosure of confidential information, which can harm the company's reputation and business operations.\n   - **Matches Option E** (Cybersecurity threats from internal employees) and **Option D** (Increases in"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 16000, "result": 1.0, "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?", "options": {"A": "$58.7 million", "B": "$104.7 million", "C": "$153.0 million", "D": "$381.4 million", "E": "$420.5 million", "F": "$275.9 million"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the key information needed from the document.\n2. Locate the specific data that answers the question.\n3. Verify the data and select the correct option.\n\n### Step 1: Identify the Key Information\nThe question asks for the accumulated deficit reported by the company as of December 31, 2023. The key information to look for is the financial data related to the company's accumulated deficit as of that date.\n\n### Step 2: Locate the Specific Data\nScanning through the document, I find the following relevant information:\n\n> \"As of December 31, 2023, we had an accumulated deficit of $381.4 million.\"\n\n### Step 3: Verify the Data and Select the Correct Option\nThe document clearly states that the accumulated deficit as of December 31, 2023, is $381.4 million. This matches one of the provided options.\n\n### Conclusion\nThe correct answer is:\n**D: $381.4 million**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 25, "token_lengths": 16000, "result": 1.0, "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?", "options": {"A": "The executive summary of the annual report", "B": "The company's market analysis", "C": "The consolidated financial statements and Notes to Financial Statements", "D": "The corporate governance guidelines", "E": "The strategic business plan", "F": "The risk management framework"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the section that directly addresses the relationship between the Management's Discussion and Analysis (MD&A) and other financial documents.\n\n1. **Identify the relevant section in the document:**\n   - The relevant section is found in the beginning of Item 7, \"Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\" (MD&A).\n\n2. **Extract the key information:**\n   - The document states: \"This MD&A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying Notes to Financial Statements (Part II, Item 8 of this Form 10-K).\"\n\n3. **Match the key information to the options:**\n   - Option A: The executive summary of the annual report\n   - Option B: The company's market analysis\n   - Option C: The consolidated financial statements and Notes to Financial Statements\n   - Option D: The corporate governance guidelines\n   - Option E: The strategic business plan\n   - Option F: The risk management framework\n\n4. **Determine the correct answer:**\n   - The document explicitly states that the MD&A should be read in conjunction with the consolidated financial statements and Notes to Financial Statements. This matches Option C.\n\nTherefore, the correct answer is **C: The consolidated financial statements and Notes to Financial Statements**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 16000, "result": 1.0, "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?", "options": {"A": "Increase in secondary marketing sales", "B": "Customer growth", "C": "Lower natural gas costs passed through to customers", "D": "Increase in North Carolina IMR", "E": "Tennessee ARM revenue recognition", "F": "Increase in off-system sales"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Identify the Relevant Section**: The question asks about the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022. The relevant section is found under \"Gas Utilities and Infrastructure (GU&I)\" for the year ended December 31, 2023, as compared to 2022.\n\n2. **Examine the Operating Revenues Section**: The section on operating revenues for GU&I states:\n   - \"The variance was driven primarily by: a $683 million decrease due to lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs.\"\n   - \"Partially offset by: a $26 million increase due to customer growth; a $19 million increase due to North Carolina IMR; a $15 million increase due to the MGP Settlement in prior year; an $11 million increase due to Tennessee ARM revenue recognition; a $9 million increase due to secondary marketing sales; a $6 million increase in Ohio tax reform deferrals; and a $4 million increase due to rider revenues.\"\n\n3. **Match the Decrease to the Options**:\n   - The primary driver of the decrease in operating revenues is the $683 million decrease due to lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs.\n   - This matches closely with option C: \"Lower natural gas costs passed through to customers.\"\n\n4. **Consider the Magnitude**:\n   - The $683 million decrease is significantly larger than the $585 million decrease mentioned in the question.\n   - The other increases mentioned (customer growth, North Carolina IMR, MGP Settlement, Tennessee ARM revenue recognition, secondary marketing sales, Ohio tax reform deferrals, and rider revenues) are much smaller and do not account for the primary decrease.\n\n5. **Conclusion**:\n   - The primary cause of the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022, is the lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs.\n\nTherefore, the correct answer is **C: Lower natural gas costs passed through to customers**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 16000, "result": 1.0, "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?", "options": {"A": "Technological advancements", "B": "Climate change", "C": "Economic policies", "D": "Urban development", "E": "Infrastructure improvements", "F": "Regulatory changes"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document to identify the factor mentioned as potentially worsening the severity and impact of future natural disasters.\n\n1. **Identify the relevant section**: The document mentions natural disasters and their potential impacts in the following section:\n   - \"Climate change, natural disasters, public health crises, geopolitical developments, acts of terrorism and other external events could harm our business.\"\n   - \"Climate change may worsen the severity and impact of future hurricanes, earthquakes, fires, floods and other extreme weather-related events that could cause disruption to our business and operations.\"\n\n2. **Extract the key information**:\n   - The document explicitly states that \"Climate change may worsen the severity and impact of future hurricanes, earthquakes, fires, floods and other extreme weather-related events.\"\n\n3. **Match the information to the options**:\n   - Option A: Technological advancements - Not mentioned in the context of worsening natural disasters.\n   - Option B: Climate change - Directly mentioned as a factor that could worsen the severity and impact of future natural disasters.\n   - Option C: Economic policies - Not mentioned in the context of worsening natural disasters.\n   - Option D: Urban development - Not mentioned in the context of worsening natural disasters.\n   - Option E: Infrastructure improvements - Not mentioned in the context of worsening natural disasters.\n   - Option F: Regulatory changes - Not mentioned in the context of worsening natural disasters.\n\n4. **Conclusion**:\n   - The factor mentioned as potentially worsening the severity and impact of future natural disasters is **Climate change**.\n\nTherefore, the correct answer is **Option B: Climate change**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 16000, "result": 1.0, "question": "What is a primary reason for fluctuations in the company's financial results?", "options": {"A": "Successful transition of operations", "B": "Regular market growth", "C": "Factors beyond the company's control", "D": "Consistent product demand", "E": "Reduced operational expenses", "F": "Stable regulatory environment"}, "LLM_original_answer": ["To answer the question \"What is a primary reason for fluctuations in the company's financial results?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Review the Document for Financial Fluctuations**:\n   - The document discusses various risks and uncertainties that could impact the company's financial performance and ability to achieve profitability.\n   - It mentions significant losses and the need for substantial additional funding to support ongoing and future activities.\n\n2. **Identify Key Factors**:\n   - **Regulatory and Legislative Changes**: The document highlights the impact of state and federal legislation on pharmaceutical and biological product pricing, which can affect the company's ability to generate revenue and achieve profitability.\n   - **Clinical Trial Challenges**: The company is in the early stages of clinical development, and clinical trials are subject to numerous uncertainties, including delays, additional costs, and potential failures.\n   - **Manufacturing Issues**: The company relies on third-party manufacturers, and any issues with these manufacturers could delay or prevent the development and commercialization of drug candidates.\n   - **Market Competition**: The company faces intense competition from other biotechnology and pharmaceutical companies, which could affect its market position and revenue generation.\n   - **Resource Allocation**: The company may allocate resources to less profitable or less successful drug candidates, which could impact its financial results.\n\n3. **Evaluate the Options**:\n   - **A: Successful transition of operations**: The document does not mention any successful transitions that could cause fluctuations.\n   - **B: Regular market growth**: The document does not suggest regular market growth as a factor.\n   - **C: Factors beyond the company's control**: The document mentions several factors beyond the company's control, such as regulatory changes, market competition, and macroeconomic conditions, which can significantly impact financial results.\n   - **D: Consistent product demand**: The document does not indicate consistent product demand as a factor, especially since the company has not yet generated revenue from product sales.\n   - **E: Reduced operational expenses**: The document does not mention reduced operational expenses as a primary reason for financial fluctuations.\n   - **F: Stable regulatory environment**: The document explicitly states that the regulatory environment is not stable and is subject to changes that can affect the company's financial performance.\n\n4. **Conclusion**:\n   - The primary reason for fluctuations in the company's financial results, as indicated in the document, is **factors beyond the company's control**. This includes regulatory and legislative changes, market competition, and macroeconomic conditions, all of which can"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 16000, "result": 1.0, "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?", "options": {"A": "55 or older", "B": "62 or older", "C": "65 or older", "D": "70 or older", "E": "60 or older", "F": "50 or older"}, "LLM_original_answer": ["To answer the question \"What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that discusses reverse mortgages, specifically HECM (Home Equity Conversion Mortgage) reverse mortgages. This section is found under \"Risks Relating to Ownership of Our Common Stock\" but is more relevant to the business operations and risks associated with reverse mortgages.\n\n2. **Extract the key information**: The relevant sentence from the document is:\n   > \"We originate, securitize and service FHA-insured HECM mortgages. The reverse mortgage business is subject to substantial risks, including market, credit, interest rate, liquidity, operational, reputational and legal risks. Generally, a HECM reverse mortgage is a government-insured loan available to seniors aged 62 or older that allows homeowners to borrow money against the value of their home.\"\n\n3. **Determine the correct answer**: The sentence clearly states that a HECM reverse mortgage is available to seniors aged 62 or older.\n\n4. **Match the answer to the options**: The correct answer is \"B: 62 or older.\"\n\nTherefore, the answer to the question is **B: 62 or older**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 16000, "result": 1.0, "question": "What is one potential consequence of violating the civil False Claims Act?", "options": {"A": "Execution of a scheme without penalty", "B": "Four times the actual damages sustained by the government", "C": "Exclusion from private healthcare programs", "D": "Participation in federal healthcare programs", "E": "Mandatory civil penalties for each false claim", "F": "No penalties for private individuals"}, "LLM_original_answer": ["To answer the question \"What is one potential consequence of violating the civil False Claims Act?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: The document contains a section on \"Anti-Kickback and False Claims Laws and Other Regulatory Matters\" which discusses the civil False Claims Act and its potential consequences.\n\n2. **Extract Consequences**: The document states:\n   - \"Penalties for a civil False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the Federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes.\"\n\n3. **Match to Options**:\n   - **Option A**: \"Execution of a scheme without penalty\" - This is not mentioned as a consequence.\n   - **Option B**: \"Four times the actual damages sustained by the government\" - The document mentions three times the actual damages, not four.\n   - **Option C**: \"Exclusion from private healthcare programs\" - The document mentions exclusion from federal healthcare programs, not private.\n   - **Option D**: \"Participation in federal healthcare programs\" - This is the opposite of the consequence mentioned.\n   - **Option E**: \"Mandatory civil penalties for each false claim\" - This is explicitly mentioned as a consequence.\n   - **Option F**: \"No penalties for private individuals\" - This is not mentioned as a consequence.\n\n4. **Select the Correct Option**: Based on the information provided, the correct answer is **Option E: Mandatory civil penalties for each false claim**.\n\n**Chain of Thought**:\n- The document clearly outlines the consequences of violating the civil False Claims Act.\n- It specifies that penalties include three times the actual damages and mandatory civil penalties for each false claim.\n- Among the given options, only Option E matches the mandatory civil penalties for each false claim as stated in the document.\n\nTherefore, the answer is **Option E: Mandatory civil penalties for each false claim**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 25, "token_lengths": 16000, "result": 1.0, "question": "What is a potential risk mentioned regarding the company's financial position?", "options": {"A": "High competition leading to reduced market share", "B": "Inability to generate sufficient revenue to cover expenses", "C": "Government regulations affecting sales", "D": "Incorrect labeling of products", "E": "Issues with supply chain logistics", "F": "Patent expiration affecting product exclusivity"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document and identify the potential risks mentioned regarding the company's financial position.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Section on Financial Position and Need for Capital:**\n   - The document has a section titled \"Risks Related to Our Financial Position and Need for Capital.\"\n\n2. **List the Risks Mentioned in This Section:**\n   - **Significant Losses and Additional Losses:**\n     - \"We have in the past incurred significant losses and may in the future incur additional losses if we are unable to continue to generate sufficient revenue from our approved products to cover our expenses.\"\n   - **Limited History of Revenue Recognition:**\n     - \"We have a limited history of recognizing revenue from product sales and may not be able to achieve or maintain long-term sustainable profitability.\"\n   - **Limited Operating History:**\n     - \"We are still in the relatively early stages of our transition from a clinical-stage to a commercial-stage company.\"\n   - **Fluctuating Financial Results:**\n     - \"Our financial condition and operating results, including our revenues, expenses and net income (loss), may fluctuate significantly from quarter to quarter and year to year.\"\n   - **Dependence on AMX0035:**\n     - \"Our ability to generate revenue and achieve profitability depends on our ability to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize our products, including our commercialization of RELYVRIO in the U.S. and ALBRIOZA in Canada.\"\n   - **Future Capital Requirements:**\n     - \"Our future capital requirements depend on many factors, including the scope, progress, results, and costs of researching and developing AMX0035 for the treatment of ALS in additional jurisdictions and for other indications.\"\n   - **Uncertainty in Revenue Estimations:**\n     - \"Because the design and outcome of our ongoing and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop.\"\n\n3. **Match the Risks to the Given Options:**\n   - **Option A: High competition leading to reduced market share**\n     - Not directly mentioned in the financial position section.\n   - **Option B: Inability to generate sufficient revenue to cover expenses**\n     - Directly mentioned: \"We have in the past incurred significant losses and may in the future incur additional losses if we are unable to continue to generate sufficient revenue"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 16000, "result": 1.0, "question": "What economic factor is likely to reduce mortgage loan production volumes?", "options": {"A": "Decrease in volatility", "B": "Increase in inflation", "C": "Rising interest rates", "D": "Stability in commodity prices", "E": "Reduction in speculative trading", "F": "Growth of early stage companies"}, "LLM_original_answer": ["To answer the question \"What economic factor is likely to reduce mortgage loan production volumes?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Interest Rates and Mortgage Loan Production Volumes**:\n   - The document states: \"In addition, interest rates are a significant factor influencing mortgage loan production volumes and loan foreclosures. Rising interest rates are likely to reduce mortgage loan production volumes and increase loan foreclosures, which could potentially impact our transaction-based revenues.\"\n   - This directly links rising interest rates to a reduction in mortgage loan production volumes.\n\n2. **Inflation**:\n   - The document mentions: \"If inflation continues to increase, this would likely further increase the cost of capital, resulting in a slowdown of the growth of early stage companies, causing companies to stay private longer.\"\n   - While inflation can impact the cost of capital and consumer optimism, it is not specifically linked to reducing mortgage loan production volumes in the document.\n\n3. **Volatility**:\n   - The document notes: \"A prolonged decrease in volatility in the financial markets could also result in more exchanges competing for trading volumes to maintain their growth.\"\n   - However, it does not mention volatility as a factor affecting mortgage loan production volumes.\n\n4. **Commodity Prices**:\n   - The document discusses: \"Fluctuations in foreign currency exchange rates could adversely affect our financial results.\"\n   - It also mentions: \"Real and perceived changes in the supply and demand of commodities underlying our products, particularly energy and agricultural products, including changes as a result of technological improvements or the development of alternative energy sources.\"\n   - These factors are more related to trading volumes and financial market conditions rather than mortgage loan production volumes.\n\n5. **Speculative Trading**:\n   - The document states: \"A reduction in trading demand by customers or a decision to curtail or cease hedging or speculative trading.\"\n   - This is more about trading volumes in financial markets, not mortgage loan production volumes.\n\n6. **Growth of Early Stage Companies**:\n   - The document mentions: \"As inflation has rapidly increased and remained high in recent years, it has impacted the credit health of market participants, increased the risk of default and increased the risk of companies not being able to comply with listing standards.\"\n   - This is indirectly related to the cost of capital and early stage companies, but not specifically to mortgage loan production volumes.\n\nGiven the above analysis, the economic factor most directly and explicitly linked to reducing mortgage loan production volumes in the document is **Rising interest"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 16000, "result": 1.0, "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?", "options": {"A": "Fluctuations in global oil prices", "B": "Changes in local tax regulations", "C": "Ongoing military actions and threat of terrorism", "D": "Increases in online security breaches", "E": "Cybersecurity threats from internal employees", "F": "Competition from new market entrants"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document and identify the risks that could adversely affect the company's investment portfolio. Here is the step-by-step reasoning:\n\n1. **Credit Risk**:\n   - The document mentions that a significant portion of the investment portfolio consists of fixed income securities and mortgage loans.\n   - There is a risk that issuers or guarantors of these securities may default on principal and interest payments.\n   - Major economic downturns, corporate malfeasance, or widening credit spreads could cause the estimated fair value of the portfolio to decline and increase the default rate.\n\n2. **Interest Rate Risk**:\n   - The company is exposed to interest rate risk, particularly in products like traditional life, universal life, and fixed index-linked and income annuities.\n   - Changes in interest rates can reduce the investment margin or net investment spread.\n   - Low interest rates can force the company to reinvest at lower yields, and high interest rates can increase the cost of funding higher crediting rates.\n\n3. **Inflation Risk**:\n   - High inflation can increase expenses, potentially putting pressure on profitability.\n   - Inflation can also affect consumer sentiment and behavior, impacting product sales.\n   - Central bank policies to combat inflation can lead to higher interest rates, which may negatively affect the investment portfolio.\n\n4. **Market Valuation Risk**:\n   - This risk is associated with the variability in the estimated fair value of investments due to changes in market factors.\n   - The company is exposed to credit spread risk, equity market risk, and the valuation of securities.\n   - Downturns or volatility in equity markets can reduce the value of investment assets and fee income.\n\n5. **Liquidity Risk**:\n   - There may be a limited market for certain investments, making them relatively illiquid.\n   - During periods of market volatility or disruption, selling these investments could result in realized losses.\n   - Reduced liquidity can affect the company's ability to meet financial obligations and maintain regulatory capital requirements.\n\n6. **Real Estate Risk**:\n   - A portion of the investment portfolio consists of mortgage loans on commercial, agricultural, and residential real estate.\n   - Factors such as supply and demand, creditworthiness of tenants, and general economic conditions can influence the performance of these investments.\n   - Defaults or fluctuations in the performance of mortgage loans can have a material adverse effect on the financial condition and results of operations.\n\n7. **Derivative Risk**:\n   - The company uses derivatives to manage various risks.\n   -"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 32000, "result": 1.0, "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?", "options": {"A": "$58.7 million", "B": "$104.7 million", "C": "$153.0 million", "D": "$381.4 million", "E": "$420.5 million", "F": "$275.9 million"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the accumulated deficit reported by the company?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that discusses the company's financial position and losses. This section is likely to contain the information about the accumulated deficit.\n\n2. **Locate the specific information**: Within the relevant section, I will look for a statement that mentions the accumulated deficit as of December 31, 2023.\n\n3. **Extract the value**: Once I find the specific statement, I will extract the value of the accumulated deficit.\n\n4. **Match the value to the options**: Finally, I will match the extracted value to the provided options to determine the correct answer.\n\nLet's go through the document:\n\n### Relevant Section:\n**Risks Related to Our Financial Position and Need for Additional Capital**\n- \"We have a limited operating history, have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.\"\n- \"For the years ended December 31, 2023, 2022, and 2021, we reported a net loss of $153.0 million, $104.7 million, and $58.7 million, respectively.\"\n- \"As of December 31, 2023, we had an accumulated deficit of $381.4 million.\"\n\n### Extract the Value:\n- The accumulated deficit as of December 31, 2023, is reported as **$381.4 million**.\n\n### Match the Value to the Options:\n- The options provided are:\n  - A: $58.7 million\n  - B: $104.7 million\n  - C: $153.0 million\n  - D: $381.4 million\n  - E: $420.5 million\n  - F: $275.9 million\n\n### Conclusion:\nThe correct answer is **D: $381.4 million**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 25, "token_lengths": 32000, "result": 1.0, "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?", "options": {"A": "The executive summary of the annual report", "B": "The company's market analysis", "C": "The consolidated financial statements and Notes to Financial Statements", "D": "The corporate governance guidelines", "E": "The strategic business plan", "F": "The risk management framework"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the section that directly addresses the relationship between the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) and other financial documents.\n\n1. **Identify the Relevant Section:**\n   - The relevant section is found in Item 7, \"Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\" (MD&A).\n\n2. **Extract the Key Information:**\n   - The document states: \"This MD&A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying Notes to Financial Statements (Part II, Item 8 of this Form 10-K).\"\n\n3. **Match the Information to the Options:**\n   - **Option A:** The executive summary of the annual report - Not mentioned in the relevant section.\n   - **Option B:** The company's market analysis - Not mentioned in the relevant section.\n   - **Option C:** The consolidated financial statements and Notes to Financial Statements - Directly mentioned in the relevant section.\n   - **Option D:** The corporate governance guidelines - Not mentioned in the relevant section.\n   - **Option E:** The strategic business plan - Not mentioned in the relevant section.\n   - **Option F:** The risk management framework - Not mentioned in the relevant section.\n\n4. **Conclusion:**\n   - Based on the information provided in the document, the correct answer is **Option C: The consolidated financial statements and Notes to Financial Statements**.\n\nTherefore, the document that should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is **Option C: The consolidated financial statements and Notes to Financial Statements**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 32000, "result": 1.0, "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?", "options": {"A": "Increase in secondary marketing sales", "B": "Customer growth", "C": "Lower natural gas costs passed through to customers", "D": "Increase in North Carolina IMR", "E": "Tennessee ARM revenue recognition", "F": "Increase in off-system sales"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the primary cause of the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022.\n\n1. **Identify the Segment and Context**:\n   - The document mentions that the $585 million decrease in operating revenues is related to the Gas Utilities and Infrastructure (GU&I) segment.\n\n2. **Examine the Operating Revenues Section for GU&I**:\n   - The variance in operating revenues for GU&I is primarily driven by:\n     - **a $683 million decrease due to lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs**.\n     - A $26 million increase due to customer growth.\n     - A $19 million increase due to North Carolina IMR.\n     - An $11 million increase due to Tennessee ARM revenue recognition.\n     - A $9 million increase due to secondary marketing sales.\n\n3. **Evaluate the Magnitude of Each Factor**:\n   - The $683 million decrease is the largest and most significant factor.\n   - The other increases (customer growth, North Carolina IMR, Tennessee ARM revenue recognition, and secondary marketing sales) are much smaller in comparison, totaling $65 million.\n\n4. **Conclusion**:\n   - The primary cause of the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022, is the **$683 million decrease due to lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs**.\n\nTherefore, the correct answer is:\n**C: Lower natural gas costs passed through to customers**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 32000, "result": 1.0, "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?", "options": {"A": "Technological advancements", "B": "Climate change", "C": "Economic policies", "D": "Urban development", "E": "Infrastructure improvements", "F": "Regulatory changes"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step to identify the factor mentioned as potentially worsening the severity and impact of future natural disasters.\n\n1. **Identify the Context**: The document is an annual report for a bank, discussing various risks and factors that could affect the bank's operations and financial condition.\n\n2. **Search for Relevant Information**: I will look for sections that discuss natural disasters and their potential impacts.\n\n3. **Locate the Specific Mention**: In the section titled \"Climate change, natural disasters, public health crises, geopolitical developments, acts of terrorism and other external events could harm our business,\" the following statement is found:\n   - \"Climate change may worsen the severity and impact of future hurricanes, earthquakes, fires, floods and other extreme weather-related events that could cause disruption to our business and operations.\"\n\n4. **Match the Statement to the Options**: The statement directly mentions \"climate change\" as a factor that could worsen the severity and impact of future natural disasters.\n\n5. **Conclusion**: Based on the information provided in the document, the correct answer is:\n   - **B: Climate change**\n\nTherefore, the factor mentioned as potentially worsening the severity and impact of future natural disasters is **B: Climate change**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 32000, "result": 1.0, "question": "What is a primary reason for fluctuations in the company's financial results?", "options": {"A": "Successful transition of operations", "B": "Regular market growth", "C": "Factors beyond the company's control", "D": "Consistent product demand", "E": "Reduced operational expenses", "F": "Stable regulatory environment"}, "LLM_original_answer": ["To answer the question \"What is a primary reason for fluctuations in the company's financial results?\" based on the provided document, I will analyze the content step by step:\n\n1. **Review the Document for Relevant Information:**\n   - The document primarily discusses the company's operations, regulatory environment, and the challenges associated with drug development and commercialization.\n   - It mentions significant financial losses and the need for substantial additional funding to support ongoing and future activities.\n\n2. **Identify Key Factors Affecting Financial Results:**\n   - **High Development Costs and Uncertainty:** The document emphasizes that drug development is a lengthy and expensive process with uncertain outcomes. This includes preclinical studies, clinical trials, and regulatory approvals.\n   - **Dependence on Third Parties:** The company relies on third parties for manufacturing, clinical trials, and potentially for marketing and distribution. Any issues with these third parties can lead to delays or increased costs.\n   - **Regulatory and Legal Challenges:** The company faces numerous regulatory and legal requirements, including compliance with healthcare laws, anti-kickback statutes, and false claims acts. Violations can result in significant penalties and legal expenses.\n   - **Market and Economic Conditions:** The document mentions that macroeconomic conditions, such as inflation, financial market volatility, and supply chain disruptions, can impact the company's ability to obtain necessary materials and conduct clinical trials.\n\n3. **Evaluate the Options:**\n   - **A: Successful transition of operations** - The document does not mention any successful transitions that could cause fluctuations.\n   - **B: Regular market growth** - The document does not suggest regular market growth as a factor affecting financial results.\n   - **C: Factors beyond the company's control** - The document highlights several factors beyond the company's control, such as regulatory requirements, legal challenges, and macroeconomic conditions, which can significantly impact financial results.\n   - **D: Consistent product demand** - The document does not indicate consistent product demand as a factor, given that the company has not yet generated any revenue from product sales.\n   - **E: Reduced operational expenses** - The document suggests that operational expenses are expected to increase, not reduce.\n   - **F: Stable regulatory environment** - The document indicates that the regulatory environment is complex and subject to change, which can affect financial results.\n\n4. **Conclusion:**\n   - The primary reason for fluctuations in the company's financial results, as indicated by the document, is **factors beyond the company's control**. These include regulatory and legal challenges"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 32000, "result": 1.0, "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?", "options": {"A": "55 or older", "B": "62 or older", "C": "65 or older", "D": "70 or older", "E": "60 or older", "F": "50 or older"}, "LLM_original_answer": ["To answer the question \"What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for any mention of HECM reverse mortgages and the age requirement for qualification.\n2. **Extract the Information**: Once identified, extract the specific age requirement.\n3. **Match the Information to the Options**: Compare the extracted age requirement to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document mentions HECM reverse mortgages in several sections. The most relevant section is found under \"Reverse Mortgages\" in the \"Servicing\" segment:\n\n> \"Our reverse business activities include both the subservicing of reverse mortgage loans on behalf of investors and the servicing of our owned portfolio. The activities and financial performance related to our owned portfolio of reverse mortgage loans that are securitized and classified as held for investment, at fair value, together with the HMBS-related borrowings, at fair value are reflected in the Servicing segment.\"\n\nHowever, the specific age requirement is mentioned in the \"Risk Factors\" section:\n\n> \"We originate, securitize and service FHA-insured HECM mortgages. The reverse mortgage business is subject to substantial risks, including market, credit, interest rate, liquidity, operational, reputational and legal risks. Generally, a HECM reverse mortgage is a government-insured loan available to seniors aged 62 or older that allows homeowners to borrow money against the value of their home.\"\n\n### Step 2: Extract the Information\nThe document clearly states that a HECM reverse mortgage is available to seniors aged 62 or older.\n\n### Step 3: Match the Information to the Options\nThe extracted age requirement is 62 or older. This matches option B in the given choices.\n\n### Conclusion\nThe correct answer is **B: 62 or older**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 32000, "result": 1.0, "question": "What is one potential consequence of violating the civil False Claims Act?", "options": {"A": "Execution of a scheme without penalty", "B": "Four times the actual damages sustained by the government", "C": "Exclusion from private healthcare programs", "D": "Participation in federal healthcare programs", "E": "Mandatory civil penalties for each false claim", "F": "No penalties for private individuals"}, "LLM_original_answer": ["To answer the question \"What is one potential consequence of violating the civil False Claims Act?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: The document contains a section on \"Anti-Kickback and False Claims Laws and Other Regulatory Matters\" which discusses the civil False Claims Act and its potential consequences.\n\n2. **Extract Consequences**: The document states that violations of the civil False Claims Act can result in:\n   - **Three times the actual damages sustained by the government**.\n   - **Mandatory civil penalties for each separate false claim**.\n   - **Exclusion from participation in federal healthcare programs**.\n   - **Potential criminal penalties** (though the question is specifically about civil consequences).\n\n3. **Match to Options**: Now, I will match the extracted consequences to the given options:\n   - **Option A**: \"Execution of a scheme without penalty\" - This is not a consequence of violating the civil False Claims Act.\n   - **Option B**: \"Four times the actual damages sustained by the government\" - The document mentions three times the actual damages, not four.\n   - **Option C**: \"Exclusion from private healthcare programs\" - The document mentions exclusion from federal healthcare programs, not private healthcare programs.\n   - **Option D**: \"Participation in federal healthcare programs\" - This is the opposite of a consequence; exclusion is the actual consequence.\n   - **Option E**: \"Mandatory civil penalties for each false claim\" - This matches the document's statement.\n   - **Option F**: \"No penalties for private individuals\" - This is not a consequence of violating the civil False Claims Act.\n\n4. **Select the Correct Option**: Based on the information provided in the document, the correct answer is **Option E**: \"Mandatory civil penalties for each false claim.\"\n\n**Final Answer**: E: Mandatory civil penalties for each false claim."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 25, "token_lengths": 32000, "result": 1.0, "question": "What is a potential risk mentioned regarding the company's financial position?", "options": {"A": "High competition leading to reduced market share", "B": "Inability to generate sufficient revenue to cover expenses", "C": "Government regulations affecting sales", "D": "Incorrect labeling of products", "E": "Issues with supply chain logistics", "F": "Patent expiration affecting product exclusivity"}, "LLM_original_answer": ["To answer the question \"What is a potential risk mentioned regarding the company's financial position?\" based on the provided document, I will analyze the relevant sections step by step:\n\n1. **Identify the Section on Financial Risks:**\n   - The document has a section titled \"Risks Related to Our Financial Position and Need for Capital\" which directly addresses financial risks.\n\n2. **Extract Relevant Information:**\n   - The section states: \"We have in the past incurred significant losses and may in the future incur additional losses if we are unable to continue to generate sufficient revenue from our approved products to cover our expenses.\"\n   - It also mentions: \"We have a limited history of recognizing revenue from product sales and may not be able to achieve or maintain long-term sustainable profitability.\"\n\n3. **Match the Information to the Options:**\n   - Option B: \"Inability to generate sufficient revenue to cover expenses\" directly aligns with the statement \"We have in the past incurred significant losses and may in the future incur additional losses if we are unable to continue to generate sufficient revenue from our approved products to cover our expenses.\"\n\n4. **Conclusion:**\n   - The potential risk mentioned regarding the company's financial position is the \"Inability to generate sufficient revenue to cover expenses.\"\n\nTherefore, the correct answer is **Option B: Inability to generate sufficient revenue to cover expenses**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 32000, "result": 1.0, "question": "What economic factor is likely to reduce mortgage loan production volumes?", "options": {"A": "Decrease in volatility", "B": "Increase in inflation", "C": "Rising interest rates", "D": "Stability in commodity prices", "E": "Reduction in speculative trading", "F": "Growth of early stage companies"}, "LLM_original_answer": ["To answer the question \"What economic factor is likely to reduce mortgage loan production volumes?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify Relevant Sections**:\n   - The document discusses various economic and market conditions that affect mortgage loan production volumes.\n   - Specifically, it mentions the impact of rising interest rates and inflation on mortgage lending.\n\n2. **Analyze the Impact of Each Option**:\n   - **A: Decrease in volatility**:\n     - The document suggests that volatility increases the need for hedging and speculative trading, which can drive trading volumes. However, it does not directly link volatility to mortgage loan production volumes.\n   - **B: Increase in inflation**:\n     - The document states, \"increases in mortgage interest rates in 2022 and 2023 have resulted in reduced consumer and investor demand for mortgages and adversely impacted the transaction-based revenues in our Mortgage Technology segment.\"\n     - It also mentions that \"inflation has rapidly increased and remained high in recent years, it has impacted the credit health of market participants, increased the risk of default and increased the risk of companies not being able to comply with listing standards.\"\n     - While inflation can indirectly affect mortgage loan production through increased interest rates, the document does not explicitly state that inflation itself is the primary factor.\n   - **C: Rising interest rates**:\n     - The document explicitly states, \"rising interest rates are likely to reduce mortgage loan production volumes and increase loan foreclosures, which could potentially impact our transaction-based revenues.\"\n     - It further mentions, \"increases in mortgage interest rates in 2022 and 2023 have resulted in reduced consumer and investor demand for mortgages and adversely impacted the transaction-based revenues in our Mortgage Technology segment.\"\n   - **D: Stability in commodity prices**:\n     - The document does not discuss the direct impact of commodity price stability on mortgage loan production volumes.\n   - **E: Reduction in speculative trading**:\n     - The document mentions that speculative trading can drive trading volumes but does not directly link it to mortgage loan production volumes.\n   - **F: Growth of early stage companies**:\n     - The document does not discuss the impact of early stage company growth on mortgage loan production volumes.\n\n3. **Conclusion**:\n   - The document clearly and repeatedly emphasizes that rising interest rates are a significant factor that reduces mortgage loan production volumes.\n   - While inflation can contribute to higher interest rates, the direct and explicit factor mentioned in the"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 32000, "result": 1.0, "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?", "options": {"A": "Fluctuations in global oil prices", "B": "Changes in local tax regulations", "C": "Ongoing military actions and threat of terrorism", "D": "Increases in online security breaches", "E": "Cybersecurity threats from internal employees", "F": "Competition from new market entrants"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step to identify the risks that could adversely affect the company's investment portfolio.\n\n1. **Credit Risk**:\n   - The document mentions that the company is exposed to credit risk, particularly with fixed income securities and mortgage loans. If issuers or guarantors default on principal and interest payments, the estimated fair value of the portfolio could decline, and the default rate could increase.\n   - **Relevant Section**: \"Risks Related to Our Investment Portfolio \u2014 Our investment portfolio is subject to significant financial risks both in the U.S. and global financial markets, including credit risk, interest rate risk, inflation risk, market valuation risk, liquidity risk, real estate risk, derivatives risk, and other factors outside our control, the occurrence of any of which could have a material adverse effect on our financial condition and results of operations.\"\n\n2. **Interest Rate Risk**:\n   - The company is exposed to interest rate risk, which can affect the profitability of various products and the demand for them. Low interest rates can reduce investment income, while high interest rates can lead to increased policy loans, surrenders, and withdrawals.\n   - **Relevant Section**: \"Interest Rate Risk \u2014 We are exposed to certain risks in a variety of interest rate environments. When interest rates are low, we may be forced to reinvest proceeds from investments that have matured or have been prepaid or sold at lower yields, which will reduce our net investment income.\"\n\n3. **Inflation Risk**:\n   - Inflation can affect the value of fixed income investments and increase expenses, potentially putting pressure on profitability if these costs cannot be passed through to policyholders.\n   - **Relevant Section**: \"Inflation Risk \u2014 A sustained or material increase in inflation could also affect our business in several ways. During inflationary periods, the value of fixed income investments may fall, which could increase realized and unrealized losses.\"\n\n4. **Market Valuation Risk**:\n   - Market valuation risk is related to the variability in the estimated fair value of investments due to changes in market factors. This can lead to significant fluctuations in the value of the investment portfolio.\n   - **Relevant Section**: \"Market Valuation Risk \u2014 Market valuation risk relates to the variability in the estimated fair value of investments associated with changes in market factors. Our portfolio\u2019s market valuation risks include the following: \u2022Credit Spread Risk \u2013 We are exposed to credit spread risk primarily as a result of market price volatility and investment risk associated with the fluctuation in credit"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 64000, "result": 1.0, "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?", "options": {"A": "$58.7 million", "B": "$104.7 million", "C": "$153.0 million", "D": "$381.4 million", "E": "$420.5 million", "F": "$275.9 million"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the accumulated deficit reported by the company?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that discusses the company's financial position and net losses. This section is likely to contain the information about the accumulated deficit.\n\n2. **Locate the specific information**: Within the financial section, I will look for a statement that mentions the accumulated deficit as of December 31, 2023.\n\n3. **Extract the value**: Once I find the specific statement, I will extract the value of the accumulated deficit.\n\n4. **Match the value to the options**: Finally, I will match the extracted value to the provided options to determine the correct answer.\n\nLet's go through the document:\n\n### Step 1: Identify the relevant section\nThe relevant section is found in the \"Risks Related to Our Financial Position and Need for Additional Capital\" section.\n\n### Step 2: Locate the specific information\nIn this section, the following statement is found:\n\"As of December 31, 2023, we had an accumulated deficit of $381.4 million.\"\n\n### Step 3: Extract the value\nThe accumulated deficit as of December 31, 2023, is $381.4 million.\n\n### Step 4: Match the value to the options\nThe value $381.4 million matches option D.\n\n### Conclusion\nThe correct answer is **D: $381.4 million**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 25, "token_lengths": 64000, "result": 1.0, "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?", "options": {"A": "The executive summary of the annual report", "B": "The company's market analysis", "C": "The consolidated financial statements and Notes to Financial Statements", "D": "The corporate governance guidelines", "E": "The strategic business plan", "F": "The risk management framework"}, "LLM_original_answer": ["To answer the question, we need to identify which document is recommended to be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A).\n\nFrom the provided document, the following statement is relevant:\n\"This MD&A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying Notes to Financial Statements (Part II, Item 8 of this Form 10-K).\"\n\nThis statement clearly indicates that the MD&A should be read in conjunction with the consolidated financial statements and the Notes to Financial Statements.\n\nTherefore, the correct answer is:\nC: The consolidated financial statements and Notes to Financial Statements."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 64000, "result": 1.0, "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?", "options": {"A": "Increase in secondary marketing sales", "B": "Customer growth", "C": "Lower natural gas costs passed through to customers", "D": "Increase in North Carolina IMR", "E": "Tennessee ARM revenue recognition", "F": "Increase in off-system sales"}, "LLM_original_answer": ["To answer the question, let's analyze the relevant information from the provided document:\n\n1. **Operating Revenues for Piedmont (Gas Utilities and Infrastructure)**:\n   - The variance in operating revenues for Piedmont (Gas Utilities and Infrastructure) is primarily driven by:\n     - **a $585 million decrease due to lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs**.\n     - A $26 million increase due to customer growth.\n     - A $19 million increase due to North Carolina IMR.\n     - An $11 million increase due to Tennessee ARM revenue recognition.\n     - A $9 million increase due to secondary marketing sales.\n\n2. **Options Analysis**:\n   - **Option A: Increase in secondary marketing sales** - The document mentions a $9 million increase due to secondary marketing sales, which is not the primary cause of the $585 million decrease.\n   - **Option B: Customer growth** - The document mentions a $26 million increase due to customer growth, which is also not the primary cause of the $585 million decrease.\n   - **Option C: Lower natural gas costs passed through to customers** - The document explicitly states that the primary cause of the $585 million decrease is due to lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs.\n   - **Option D: Increase in North Carolina IMR** - The document mentions a $19 million increase due to North Carolina IMR, which is not the primary cause of the $585 million decrease.\n   - **Option E: Tennessee ARM revenue recognition** - The document mentions an $11 million increase due to Tennessee ARM revenue recognition, which is not the primary cause of the $585 million decrease.\n   - **Option F: Increase in off-system sales** - The document mentions a decrease in off-system sales natural gas costs, which is part of the primary cause but not the sole primary cause.\n\nGiven the detailed breakdown, the primary cause of the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022, is:\n\n**C: Lower natural gas costs passed through to customers**\n\nThis option directly aligns with the primary driver mentioned in the document, which is the decrease in operating revenues due to lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 64000, "result": 1.0, "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?", "options": {"A": "Technological advancements", "B": "Climate change", "C": "Economic policies", "D": "Urban development", "E": "Infrastructure improvements", "F": "Regulatory changes"}, "LLM_original_answer": ["The factor mentioned as potentially worsening the severity and impact of future natural disasters is **Climate change**. This can be seen in the following excerpt from the document:\n\n\"Climate change may worsen the severity and impact of future hurricanes, earthquakes, fires, floods and other extreme weather-related events that could cause disruption to our business and operations. Chronic results of climate change such as shifting weather patterns could also cause disruption to our business and operations.\"\n\nTherefore, the correct answer is **B: Climate change**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 64000, "result": 1.0, "question": "What is a primary reason for fluctuations in the company's financial results?", "options": {"A": "Successful transition of operations", "B": "Regular market growth", "C": "Factors beyond the company's control", "D": "Consistent product demand", "E": "Reduced operational expenses", "F": "Stable regulatory environment"}, "LLM_original_answer": ["To answer the question \"What is a primary reason for fluctuations in the company's financial results?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Company's Early Stage and Development Focus**:\n   - The document states that the company is in the early stages of development of its drug candidates (NX-5948, NX-2127, and NX-1607).\n   - The company has not yet generated any revenue from product sales and has financed its operations primarily through collaborations and sales of equity interests.\n\n2. **Significant Expenses and Losses**:\n   - The company expects to continue incurring significant expenses and increasing operating losses.\n   - These expenses are associated with various activities such as clinical trials, regulatory approvals, and commercialization efforts.\n\n3. **Regulatory and Development Uncertainties**:\n   - The regulatory approval process is lengthy, time-consuming, and inherently unpredictable.\n   - The company may face delays or additional costs if required to conduct more trials or if there are issues with clinical supply or manufacturing.\n\n4. **Market and Economic Factors**:\n   - The document mentions that the company's financial condition and results of operations are subject to various factors, many of which are beyond the company's control.\n   - These factors include the progress and results of clinical trials, the scope and costs of preclinical and clinical development, the success of collaborations, and the costs and timing of regulatory reviews.\n\n5. **Compliance and Legal Risks**:\n   - The company is subject to extensive regulatory requirements and compliance with healthcare laws, which can lead to significant legal and financial risks.\n   - Non-compliance with these laws can result in fines, penalties, and other sanctions that could adversely affect the company's financial results.\n\n6. **Intellectual Property and Patent Issues**:\n   - The company's success depends on its ability to obtain and maintain patent protection for its drug candidates and technologies.\n   - Patent disputes or changes in patent laws can impact the company's financial results.\n\n7. **Market Access and Reimbursement**:\n   - The company's ability to commercialize its drug candidates depends on obtaining market access and adequate reimbursement from government and private payors.\n   - Reimbursement policies and price controls can vary widely and are subject to change, affecting the company's revenue and profitability.\n\nGiven these points, the primary reason for fluctuations in the company's financial results, as indicated in the document, is **factors beyond the company's control**. This"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 64000, "result": 1.0, "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?", "options": {"A": "55 or older", "B": "62 or older", "C": "65 or older", "D": "70 or older", "E": "60 or older", "F": "50 or older"}, "LLM_original_answer": ["To answer the question \"What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for any mention of HECM reverse mortgages and the age requirement.\n2. **Extract the Information**: Once identified, extract the specific age requirement.\n3. **Match the Information to the Options**: Compare the extracted age requirement to the given options to select the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document contains a section that discusses reverse mortgages, specifically HECM (Home Equity Conversion Mortgage) loans. The relevant information is found in the following paragraph:\n\n> \"We originate, securitize and service FHA-insured HECM mortgages. The reverse mortgage business is subject to substantial risks, including market, credit, interest rate, liquidity, operational, reputational and legal risks. Generally, a HECM reverse mortgage is a government-insured loan available to seniors aged 62 or older that allows homeowners to borrow money against the value of their home. No repayment of the mortgage is required until a default event under the terms of the mortgage occurs, the borrower dies, the borrower moves out of the home or the home is sold.\"\n\n### Step 2: Extract the Information\nFrom the paragraph, the age requirement for a HECM reverse mortgage is clearly stated as \"62 or older.\"\n\n### Step 3: Match the Information to the Options\nThe options provided are:\n- A: 55 or older\n- B: 62 or older\n- C: 65 or older\n- D: 70 or older\n- E: 60 or older\n- F: 50 or older\n\nThe correct answer is **B: 62 or older**.\n\n### Final Answer\nThe age a homeowner must be to qualify for a government-insured HECM reverse mortgage is **62 or older**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 64000, "result": 1.0, "question": "What is one potential consequence of violating the civil False Claims Act?", "options": {"A": "Execution of a scheme without penalty", "B": "Four times the actual damages sustained by the government", "C": "Exclusion from private healthcare programs", "D": "Participation in federal healthcare programs", "E": "Mandatory civil penalties for each false claim", "F": "No penalties for private individuals"}, "LLM_original_answer": ["To answer the question \"What is one potential consequence of violating the civil False Claims Act?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: The document contains a section on \"Anti-Kickback and False Claims Laws and Other Regulatory Matters\" which discusses the civil False Claims Act.\n\n2. **Extract Key Points**:\n   - The civil False Claims Act prohibits knowingly presenting, or causing to be presented, false or fraudulent claims for payment to federal programs.\n   - Violations of this law can result in significant penalties, including three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim.\n   - Other consequences include the potential for exclusion from participation in federal healthcare programs and the possibility of criminal penalties.\n\n3. **Match to Options**:\n   - **Option A**: Execution of a scheme without penalty - This is not mentioned as a consequence.\n   - **Option B**: Four times the actual damages sustained by the government - The document mentions three times the actual damages, not four.\n   - **Option C**: Exclusion from private healthcare programs - The document mentions exclusion from federal healthcare programs, not private ones.\n   - **Option D**: Participation in federal healthcare programs - This is not a consequence; rather, exclusion from these programs is a potential consequence.\n   - **Option E**: Mandatory civil penalties for each false claim - This is explicitly mentioned in the document.\n   - **Option F**: No penalties for private individuals - The document does not mention this; it discusses penalties for any person or entity.\n\n4. **Select the Correct Option**:\n   - Based on the information provided, the correct answer is **Option E**: Mandatory civil penalties for each false claim.\n\nTherefore, the potential consequence of violating the civil False Claims Act, as described in the document, is **mandatory civil penalties for each false claim**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 25, "token_lengths": 64000, "result": 1.0, "question": "What is a potential risk mentioned regarding the company's financial position?", "options": {"A": "High competition leading to reduced market share", "B": "Inability to generate sufficient revenue to cover expenses", "C": "Government regulations affecting sales", "D": "Incorrect labeling of products", "E": "Issues with supply chain logistics", "F": "Patent expiration affecting product exclusivity"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the potential risk mentioned regarding the company's financial position.\n\n1. **Identify the Section**: The relevant section is \"Risks Related to Our Financial Position and Need for Capital.\"\n\n2. **Extract the Risk**: The first bullet point in this section states:\n   - \"We have in the past incurred significant losses and may in the future incur additional losses if we are unable to continue to generate sufficient revenue from our approved products to cover our expenses.\"\n\n3. **Match the Risk to the Options**:\n   - **Option A**: High competition leading to reduced market share - This is not mentioned in the financial risk section.\n   - **Option B**: Inability to generate sufficient revenue to cover expenses - This matches the extracted risk.\n   - **Option C**: Government regulations affecting sales - This is not mentioned in the financial risk section.\n   - **Option D**: Incorrect labeling of products - This is not mentioned in the financial risk section.\n   - **Option E**: Issues with supply chain logistics - This is not mentioned in the financial risk section.\n   - **Option F**: Patent expiration affecting product exclusivity - This is not mentioned in the financial risk section.\n\n4. **Conclusion**: The potential risk mentioned regarding the company's financial position is the \"Inability to generate sufficient revenue to cover expenses.\"\n\nTherefore, the correct answer is **Option B: Inability to generate sufficient revenue to cover expenses**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 64000, "result": 1.0, "question": "What economic factor is likely to reduce mortgage loan production volumes?", "options": {"A": "Decrease in volatility", "B": "Increase in inflation", "C": "Rising interest rates", "D": "Stability in commodity prices", "E": "Reduction in speculative trading", "F": "Growth of early stage companies"}, "LLM_original_answer": ["To answer the question \"What economic factor is likely to reduce mortgage loan production volumes?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Interest Rates and Mortgage Lending**:\n   - The document states: \"Rising interest rates are likely to reduce mortgage loan production volumes and increase loan foreclosures, which could potentially impact our transaction-based revenues.\"\n   - This indicates a direct relationship between rising interest rates and a reduction in mortgage loan production volumes.\n\n2. **Inflation**:\n   - The document mentions: \"In the event that inflation continues to increase, this would likely further increase the cost of capital, resulting in a slowdown of the growth of early stage companies, causing companies to stay private longer.\"\n   - While inflation can impact the cost of capital and affect early stage companies, it is not directly linked to reducing mortgage loan production volumes in the provided context.\n\n3. **Other Factors**:\n   - The document also discusses other factors such as \"global economic and market conditions; global political conditions including the presidential election in the U.S. and general elections in many jurisdictions in the U.S. and U.K.; and concerns over recession, inflation, deflation, legislative and regulatory changes, government fiscal and monetary policy.\"\n   - However, these factors are more general and not specifically tied to reducing mortgage loan production volumes.\n\n4. **Specific Mention of Rising Interest Rates**:\n   - The document explicitly states that rising interest rates are likely to reduce mortgage loan production volumes, which is a clear and direct answer to the question.\n\nGiven this analysis, the economic factor most likely to reduce mortgage loan production volumes, according to the document, is:\n\n**C: Rising interest rates**\n\nThis is the most appropriate answer based on the explicit statement in the document."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 64000, "result": 1.0, "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?", "options": {"A": "Fluctuations in global oil prices", "B": "Changes in local tax regulations", "C": "Ongoing military actions and threat of terrorism", "D": "Increases in online security breaches", "E": "Cybersecurity threats from internal employees", "F": "Competition from new market entrants"}, "LLM_original_answer": ["To answer the question \"What are some risks mentioned that could adversely affect the company's investment portfolio?\" based on the provided document, I will go through the document and identify the relevant sections that discuss risks related to the investment portfolio. Here is the step-by-step analysis:\n\n1. **Identify Relevant Sections**:\n   - **Risks Related to Our Investment Portfolio** (Section 45)\n   - **Market Risk - Fair Value Exposures** (Section 106)\n   - **Sensitivity Analysis** (Section 107)\n\n2. **Extract Key Risks**:\n   - **Credit Risk**:\n     - \"Fixed income securities and mortgage loans represent a significant portion of our investment portfolio. We are also subject to the risk that the issuers or guarantors of the fixed income securities and mortgage loans in our investment portfolio may default on principal and interest payments they owe us.\"\n     - \"Defaults or deteriorating credit of other financial institutions could adversely affect us as we have exposure to many different industries and counterparties, and routinely execute transactions with counterparties in the financial services industry, including brokers and dealers, central clearinghouses, commercial banks, investment banks, hedge funds and investment funds and other financial institutions.\"\n   - **Interest Rate Risk**:\n     - \"We are exposed to certain risks in a variety of interest rate environments. When interest rates are low, we may be forced to reinvest proceeds from investments that have matured or have been prepaid or sold at lower yields, which will reduce our net investment income.\"\n     - \"An increase in interest rates could also have a material adverse effect on the value of our investments, for example, by decreasing the estimated fair values of the fixed income securities and mortgage loans that comprise a significant portion of our investment portfolio.\"\n   - **Inflation Risk**:\n     - \"A sustained or material increase in inflation could affect our business in several ways. During inflationary periods, the value of fixed income investments may fall, which could increase realized and unrealized losses.\"\n   - **Market Valuation Risk**:\n     - \"Market valuation risk relates to the variability in the estimated fair value of investments associated with changes in market factors. Our portfolio\u2019s market valuation risks include the following: Credit Spread Risk, Risks Related to Equity Markets, Risks Related to the Valuation of Securities, and Risks Related to the Determination of Allowances and Impairments.\"\n   - **Liquidity Risk**:\n     - \"There may be a limited market for certain"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 96000, "result": 1.0, "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?", "options": {"A": "$58.7 million", "B": "$104.7 million", "C": "$153.0 million", "D": "$381.4 million", "E": "$420.5 million", "F": "$275.9 million"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document step by step:\n\n1. **Identify the relevant section**: The document contains a section that discusses the company's financial position, including its accumulated deficit. This section is found under \"Risks Related to Our Financial Position and Need for Additional Capital.\"\n\n2. **Locate the specific information**: Within this section, the document states:\n   - \"As of December 31, 2023, we had an accumulated deficit of $381.4 million.\"\n\n3. **Match the information to the options**:\n   - The accumulated deficit reported by the company as of December 31, 2023, is $381.4 million.\n   - This matches option D: $381.4 million.\n\nTherefore, the correct answer is **D: $381.4 million**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 25, "token_lengths": 96000, "result": 1.0, "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?", "options": {"A": "The executive summary of the annual report", "B": "The company's market analysis", "C": "The consolidated financial statements and Notes to Financial Statements", "D": "The corporate governance guidelines", "E": "The strategic business plan", "F": "The risk management framework"}, "LLM_original_answer": ["To answer the question, we need to identify which document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A). The MD&A is a section in a company's annual report that provides a narrative explanation of its financial performance, giving context to the numbers presented in the financial statements.\n\nFrom the provided document, the following statement is relevant:\n\"This MD&A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying Notes to Financial Statements (Part II, Item 8 of this Form 10-K).\"\n\nThis statement clearly indicates that the MD&A should be read in conjunction with the consolidated financial statements and the Notes to Financial Statements.\n\nTherefore, the correct answer is:\n**C: The consolidated financial statements and Notes to Financial Statements**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 96000, "result": 1.0, "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?", "options": {"A": "Increase in secondary marketing sales", "B": "Customer growth", "C": "Lower natural gas costs passed through to customers", "D": "Increase in North Carolina IMR", "E": "Tennessee ARM revenue recognition", "F": "Increase in off-system sales"}, "LLM_original_answer": ["To answer the question, we need to identify the primary cause of the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022. Let's break down the information provided in the document:\n\n1. **Operating Revenues for Piedmont (GU&I)**:\n   - The variance was driven primarily by:\n     - **a $585 million decrease due to lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs**.\n   - This decrease is partially offset by:\n     - a $26 million increase due to customer growth.\n     - a $19 million increase due to North Carolina IMR.\n     - an $11 million increase due to Tennessee ARM revenue recognition.\n     - a $9 million increase due to secondary marketing sales.\n\n2. **Operating Expenses for Piedmont (GU&I)**:\n   - The variance was driven primarily by:\n     - **a $585 million decrease in the cost of natural gas due to lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs**.\n   - This decrease is partially offset by:\n     - a $24 million decrease in operations, maintenance, and other.\n     - a $22 million decrease in impairment of assets and other charges.\n\nFrom the information provided, the primary cause of the $585 million decrease in operating revenues is clearly stated as **\"lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales natural gas costs.\"**\n\nTherefore, the correct answer is:\n\n**C: Lower natural gas costs passed through to customers**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 96000, "result": 1.0, "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?", "options": {"A": "Technological advancements", "B": "Climate change", "C": "Economic policies", "D": "Urban development", "E": "Infrastructure improvements", "F": "Regulatory changes"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document to identify the factor mentioned as potentially worsening the severity and impact of future natural disasters.\n\n1. **Identify the relevant section**: The document discusses various risks and factors affecting the business and operations of Eastern Bank. The section that is most relevant to natural disasters is found under \"Risks Related to Our Business and Our Industry Generally\" and \"Risks Related to Regulations.\"\n\n2. **Extract the relevant information**:\n   - From the \"Risks Related to Our Business and Our Industry Generally\" section:\n     - \"Climate change may worsen the severity and impact of future hurricanes, earthquakes, fires, floods and other extreme weather-related events that could cause disruption to our business and operations.\"\n   - From the \"Risks Related to Regulations\" section:\n     - \"Regulatory developments could adversely affect our business by increasing our costs and thereby making our business less profitable.\"\n\n3. **Evaluate the options**:\n   - **A: Technological advancements** - Not mentioned as a factor worsening natural disasters.\n   - **B: Climate change** - Directly mentioned as a factor that may worsen the severity and impact of future natural disasters.\n   - **C: Economic policies** - Not mentioned as a factor worsening natural disasters.\n   - **D: Urban development** - Not mentioned as a factor worsening natural disasters.\n   - **E: Infrastructure improvements** - Not mentioned as a factor worsening natural disasters.\n   - **F: Regulatory changes** - While mentioned, it is in the context of increasing costs and not directly related to worsening natural disasters.\n\n4. **Conclusion**:\n   - The document explicitly states that climate change may worsen the severity and impact of future natural disasters.\n\nTherefore, the correct answer is **B: Climate change**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 96000, "result": 1.0, "question": "What is a primary reason for fluctuations in the company's financial results?", "options": {"A": "Successful transition of operations", "B": "Regular market growth", "C": "Factors beyond the company's control", "D": "Consistent product demand", "E": "Reduced operational expenses", "F": "Stable regulatory environment"}, "LLM_original_answer": ["To answer the question \"What is a primary reason for fluctuations in the company's financial results?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Company's Financial Position and Need for Additional Capital**:\n   - The document states that the company has incurred significant losses since its inception and expects to continue incurring losses over the next several years.\n   - It mentions that the company's expenses could increase beyond expectations if regulatory authorities require additional trials or if there are delays in establishing manufacturing arrangements for clinical trials.\n\n2. **Regulatory Approval and Marketing of Drug Candidates**:\n   - The regulatory approval process is lengthy, time-consuming, and unpredictable.\n   - Approval policies and the type and amount of clinical data required can change, leading to delays or additional costs.\n   - The company may face significant delays or be required to conduct additional post-approval studies, which can increase expenses and affect financial results.\n\n3. **Competition**:\n   - The company faces intense competition from other biotechnology and pharmaceutical companies.\n   - Competitors may develop and commercialize products more rapidly, which could affect the company's market position and financial performance.\n\n4. **Intellectual Property**:\n   - The company's success depends on obtaining and maintaining patent protection.\n   - Patent applications and the enforcement of patents involve significant costs and uncertainties, which can affect financial results.\n\n5. **Clinical Trials and Development**:\n   - Clinical trials are expensive and can take many years to complete.\n   - The company may experience delays or need to conduct additional trials, which can significantly increase expenses.\n\n6. **Collaborations and Partnerships**:\n   - The company relies on collaborations with third parties for the development and commercialization of its drug candidates.\n   - These collaborations can be terminated or not renewed, leading to financial uncertainties and potential loss of revenue.\n\n7. **Manufacturing and Supply Chain**:\n   - The company depends on third-party manufacturers for the production of its drug candidates.\n   - Any performance failure by these manufacturers can delay clinical trials and increase costs.\n\n8. **Market Access and Reimbursement**:\n   - The company's ability to commercialize its products depends on obtaining coverage and adequate reimbursement from government healthcare programs and private payors.\n   - Changes in reimbursement policies can significantly impact the company's revenue and financial performance.\n\n9. **Global Business, Political, and Macroeconomic Conditions**:\n   - The company is subject to risks from global economic conditions, including financial market volatility, inflation, and potential government shutdowns"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 96000, "result": 1.0, "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?", "options": {"A": "55 or older", "B": "62 or older", "C": "65 or older", "D": "70 or older", "E": "60 or older", "F": "50 or older"}, "LLM_original_answer": ["To answer the question \"What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for any mention of HECM reverse mortgages and the age requirement.\n2. **Extract the Information**: Once identified, extract the specific age requirement.\n3. **Verify the Information**: Ensure that the extracted information is accurate and directly answers the question.\n4. **Select the Correct Option**: Match the extracted information with the provided options.\n\n### Step 1: Identify Relevant Information\nThe document contains a section that discusses reverse mortgages and HECM loans. The relevant part is:\n\n> \"Generally, a HECM reverse mortgage is a government-insured loan available to seniors aged 62 or older that allows homeowners to borrow money against the value of their home.\"\n\n### Step 2: Extract the Information\nThe age requirement for a HECM reverse mortgage is **62 or older**.\n\n### Step 3: Verify the Information\nThe extracted information is clear and directly states the age requirement for HECM reverse mortgages. There is no ambiguity or conflicting information in the document.\n\n### Step 4: Select the Correct Option\nThe correct option that matches the extracted information is:\n\n**B: 62 or older**\n\nThus, the answer to the question is **B: 62 or older**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 96000, "result": 0.0, "question": "What is one potential consequence of violating the civil False Claims Act?", "options": {"A": "Execution of a scheme without penalty", "B": "Four times the actual damages sustained by the government", "C": "Exclusion from private healthcare programs", "D": "Participation in federal healthcare programs", "E": "Mandatory civil penalties for each false claim", "F": "No penalties for private individuals"}, "LLM_original_answer": ["To answer the question \"What is one potential consequence of violating the civil False Claims Act?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for sections that discuss the civil False Claims Act and its consequences.\n2. **Extract Specific Consequences**: Note the specific penalties or consequences mentioned.\n3. **Match to Options**: Compare the extracted consequences to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe document contains a section that discusses the civil False Claims Act. Here is the relevant excerpt:\n\n> Federal false claims and false statement laws, including the civil False Claims Act, prohibits any person or entity from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent. Although we would not submit claims directly to payors, manufacturers can be held liable under these laws if they are deemed to \"cause\" the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have been found liable under the Federal Civil False Claims Act in connection with their off-label promotion of drugs. Penalties for a civil False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the Federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. If the government were to allege that we were, or convict us of, violating these false claims laws, we could be subject to a substantial fine and may suffer a decline in our stock price.\n\n### Step 2: Extract Specific Consequences\nFrom the excerpt, the specific consequences of violating the civil False Claims Act include:\n- **Three times the actual damages sustained by the government**\n- **Mandatory civil penalties for each separate false claim**\n- **Potential for exclusion from participation in federal healthcare programs**\n- **Substantial fines**\n- **Decline in stock price**\n\n"], "LLM_extracted_answer": ["C"], "ground_truth": "E"}, {"depth": 25, "token_lengths": 96000, "result": 1.0, "question": "What is a potential risk mentioned regarding the company's financial position?", "options": {"A": "High competition leading to reduced market share", "B": "Inability to generate sufficient revenue to cover expenses", "C": "Government regulations affecting sales", "D": "Incorrect labeling of products", "E": "Issues with supply chain logistics", "F": "Patent expiration affecting product exclusivity"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify a potential risk mentioned regarding the company's financial position.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document contains a section titled \"Risks Related to Our Financial Position and Need for Capital\" which is likely to contain information relevant to the company's financial risks.\n\n2. **Extract Key Information:**\n   - From the section \"Risks Related to Our Financial Position and Need for Capital\":\n     - \"We have in the past incurred significant losses and may in the future incur additional losses if we are unable to continue to generate sufficient revenue from our approved products to cover our expenses.\"\n     - \"We have a limited history of recognizing revenue from product sales and may not be able to achieve or maintain long-term sustainable profitability.\"\n     - \"We have a limited operating history and currently only have one commercial product, AMX0035, branded as RELYVRIO in the U.S. and ALBRIOZA in Canada, which may make it difficult to evaluate the prospects for our future viability.\"\n\n3. **Evaluate the Options:**\n   - **Option A: High competition leading to reduced market share**\n     - The document mentions competition but does not directly link it to the company's financial position in a way that suggests it is a primary financial risk.\n   - **Option B: Inability to generate sufficient revenue to cover expenses**\n     - This option directly aligns with the statement: \"We have in the past incurred significant losses and may in the future incur additional losses if we are unable to continue to generate sufficient revenue from our approved products to cover our expenses.\"\n   - **Option C: Government regulations affecting sales**\n     - While the document discusses government regulations, it does not specifically mention this as a risk to the company's financial position.\n   - **Option D: Incorrect labeling of products**\n     - The document does not mention incorrect labeling as a financial risk.\n   - **Option E: Issues with supply chain logistics**\n     - The document mentions supply chain issues but does not directly link them to the company's financial position.\n   - **Option F: Patent expiration affecting product exclusivity**\n     - The document discusses patent issues but does not specifically mention patent expiration as a financial risk.\n\n### Conclusion:\nThe potential risk mentioned regarding the company's financial position is the **inability to generate sufficient revenue to cover expenses**. This is directly stated in the document and is a clear financial risk.\n\n**Final Answer: B**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 96000, "result": 1.0, "question": "What economic factor is likely to reduce mortgage loan production volumes?", "options": {"A": "Decrease in volatility", "B": "Increase in inflation", "C": "Rising interest rates", "D": "Stability in commodity prices", "E": "Reduction in speculative trading", "F": "Growth of early stage companies"}, "LLM_original_answer": ["To answer the question \"What economic factor is likely to reduce mortgage loan production volumes?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify Relevant Sections**:\n   - The document discusses various economic factors that can impact mortgage loan production volumes. The most relevant section is under \"Business and Industry\" in the \"Risk Factors\" section.\n\n2. **Extract Key Information**:\n   - The document states: \"Rising interest rates are likely to reduce mortgage loan production volumes and increase loan foreclosures, which could potentially impact our transaction-based revenues.\"\n   - It also mentions: \"Factors that are currently adversely impacting mortgage lending volumes include elevated mortgage interest rates, as well as housing affordability and availability.\"\n\n3. **Evaluate Options**:\n   - **A: Decrease in volatility** - The document does not suggest that a decrease in volatility directly impacts mortgage loan production volumes.\n   - **B: Increase in inflation** - While inflation can impact the cost of capital and reduce consumer optimism, the document does not specifically state that it reduces mortgage loan production volumes.\n   - **C: Rising interest rates** - The document explicitly states that rising interest rates are likely to reduce mortgage loan production volumes.\n   - **D: Stability in commodity prices** - The document does not mention that stability in commodity prices affects mortgage loan production volumes.\n   - **E: Reduction in speculative trading** - The document does not suggest that a reduction in speculative trading directly impacts mortgage loan production volumes.\n   - **F: Growth of early stage companies** - The document mentions that inflation can slow the growth of early stage companies, but it does not link this to mortgage loan production volumes.\n\n4. **Conclusion**:\n   - Based on the explicit statement in the document, the economic factor that is likely to reduce mortgage loan production volumes is **C: Rising interest rates**.\n\nTherefore, the correct answer is **C: Rising interest rates**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 96000, "result": 1.0, "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?", "options": {"A": "Fluctuations in global oil prices", "B": "Changes in local tax regulations", "C": "Ongoing military actions and threat of terrorism", "D": "Increases in online security breaches", "E": "Cybersecurity threats from internal employees", "F": "Competition from new market entrants"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the risks mentioned that could adversely affect the company's investment portfolio.\n\n1. **Ongoing military actions and the continued threat of terrorism**:\n   - The document mentions: \"Ongoing military actions (including the ongoing armed conflicts in Europe and the Middle East), the continued threat of terrorism, both within the U.S. and abroad, and heightened security measures in response to these types of threats, as well as climate change and other natural or man-made catastrophic events, may cause significant decline and volatility in global financial markets and result in loss of life, property damage, additional disruptions to commerce, the health system, and the food supply and reduced economic activity.\"\n   - This clearly indicates that ongoing military actions and the threat of terrorism can adversely affect the value of the company's investment portfolio and the level of claim losses incurred.\n\n2. **Increases in online security breaches**:\n   - The document discusses cybersecurity risks: \"We and our distributors collect and maintain customer data, including personally identifiable nonpublic financial and health information. We also collect and handle the personal information of our associates and certain third parties who distribute our products. As a result, we and the third parties who distribute our products are subject to U.S. federal and state privacy laws and regulations, including the Health Insurance Portability and Accountability Act as well as additional regulation, including those described below.\"\n   - It further mentions: \"If we or our vendors fail to prevent, detect, address and mitigate such incidents, this may impede or interrupt our business operations and could adversely affect our business, financial condition and results of operations.\"\n   - While the primary focus is on the impact on business operations and reputation, it indirectly affects the investment portfolio by potentially leading to financial losses and increased operational costs.\n\n3. **Cybersecurity threats from internal employees**:\n   - The document states: \"Our employees and those of our third-party service providers may take excessive risks which could negatively affect our financial condition and business.\"\n   - It also mentions: \"If our associates and those of our third-party service providers take excessive risks, the impact of those risks could harm our reputation and have a material adverse effect on our financial condition and results of operations.\"\n   - This indicates that internal employees can pose cybersecurity threats, which can lead to financial losses and affect the investment portfolio.\n\n4. **Fluctuations in global oil prices**:\n   - The document does not explicitly mention fluctuations in global oil prices as a risk to the investment portfolio. The focus is"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 128000, "result": 0.0, "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?", "options": {"A": "$58.7 million", "B": "$104.7 million", "C": "$153.0 million", "D": "$381.4 million", "E": "$420.5 million", "F": "$275.9 million"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "D"}, {"depth": 25, "token_lengths": 128000, "result": 1.0, "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?", "options": {"A": "The executive summary of the annual report", "B": "The company's market analysis", "C": "The consolidated financial statements and Notes to Financial Statements", "D": "The corporate governance guidelines", "E": "The strategic business plan", "F": "The risk management framework"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 128000, "result": 0.0, "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?", "options": {"A": "Increase in secondary marketing sales", "B": "Customer growth", "C": "Lower natural gas costs passed through to customers", "D": "Increase in North Carolina IMR", "E": "Tennessee ARM revenue recognition", "F": "Increase in off-system sales"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["F"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 128000, "result": 1.0, "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?", "options": {"A": "Technological advancements", "B": "Climate change", "C": "Economic policies", "D": "Urban development", "E": "Infrastructure improvements", "F": "Regulatory changes"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 128000, "result": 1.0, "question": "What is a primary reason for fluctuations in the company's financial results?", "options": {"A": "Successful transition of operations", "B": "Regular market growth", "C": "Factors beyond the company's control", "D": "Consistent product demand", "E": "Reduced operational expenses", "F": "Stable regulatory environment"}, "LLM_original_answer": ["The primary reason for fluctuations in the company's financial results, based on the provided document, is **factors beyond the company's control** (Option C).\n\n### Chain of Thoughts:\n1. **Nature of the Business**: The document describes Nurix Therapeutics as a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecules and antibody therapies. This indicates that the company is in a highly research-intensive and regulatory-dependent industry.\n\n2. **Development Stage**: The company's lead drug candidates (NX-5948, NX-2127, and NX-1607) are in the early stages of clinical development. This stage is characterized by significant uncertainties and risks, including the success of clinical trials, regulatory approvals, and market acceptance.\n\n3. **Regulatory Environment**: The document extensively discusses the regulatory approval process, which is lengthy, expensive, and subject to various uncertainties. The FDA and other regulatory bodies have significant discretion in the approval process, and changes in regulations or policies can impact the company's ability to obtain and maintain marketing approvals.\n\n4. **Collaborations and Partnerships**: The company has several collaborations with major pharmaceutical companies (Gilead, Sanofi, and Pfizer). These collaborations are crucial for the company's financial health, but they also introduce risks such as the performance of the collaborator, the timing of milestone payments, and the potential for the collaborator to terminate the agreement.\n\n5. **Market Conditions**: The document mentions the impact of global business, political, and macroeconomic conditions, including financial market volatility, inflation, and potential government shutdowns. These factors are beyond the company's control and can significantly affect its financial results.\n\n6. **Competition**: The company faces intense competition from other biotechnology and pharmaceutical companies. The success of competitors' products and the entry of new competitors can influence the market demand for Nurix's drug candidates, which is another factor beyond the company's control.\n\n7. **Intellectual Property**: The company's success is heavily dependent on its intellectual property, including patents. However, the patent landscape is complex and subject to legal challenges and changes in regulations, which can affect the company's ability to protect its intellectual property and maintain a competitive advantage.\n\n8. **Clinical Trials and Data**: The document highlights the importance of clinical trial data and the potential for unexpected results or adverse events. These outcomes can significantly impact the company's financial results, but they are often unpredictable and beyond the company's control.\n\nGiven these points,"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 128000, "result": 1.0, "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?", "options": {"A": "55 or older", "B": "62 or older", "C": "65 or older", "D": "70 or older", "E": "60 or older", "F": "50 or older"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 128000, "result": 0.0, "question": "What is one potential consequence of violating the civil False Claims Act?", "options": {"A": "Execution of a scheme without penalty", "B": "Four times the actual damages sustained by the government", "C": "Exclusion from private healthcare programs", "D": "Participation in federal healthcare programs", "E": "Mandatory civil penalties for each false claim", "F": "No penalties for private individuals"}, "LLM_original_answer": ["To answer the question \"What is one potential consequence of violating the civil False Claims Act?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: The document contains a section on \"Anti-Kickback and False Claims Laws and Other Regulatory Matters\" which discusses the civil False Claims Act.\n\n2. **Extract Key Points**:\n   - The civil False Claims Act prohibits knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent.\n   - Violations of the False Claims Act can result in significant"], "LLM_extracted_answer": ["C"], "ground_truth": "E"}, {"depth": 25, "token_lengths": 128000, "result": 1.0, "question": "What is a potential risk mentioned regarding the company's financial position?", "options": {"A": "High competition leading to reduced market share", "B": "Inability to generate sufficient revenue to cover expenses", "C": "Government regulations affecting sales", "D": "Incorrect labeling of products", "E": "Issues with supply chain logistics", "F": "Patent expiration affecting product exclusivity"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 25, "token_lengths": 128000, "result": 1.0, "question": "What economic factor is likely to reduce mortgage loan production volumes?", "options": {"A": "Decrease in volatility", "B": "Increase in inflation", "C": "Rising interest rates", "D": "Stability in commodity prices", "E": "Reduction in speculative trading", "F": "Growth of early stage companies"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 25, "token_lengths": 128000, "result": 1.0, "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?", "options": {"A": "Fluctuations in global oil prices", "B": "Changes in local tax regulations", "C": "Ongoing military actions and threat of terrorism", "D": "Increases in online security breaches", "E": "Cybersecurity threats from internal employees", "F": "Competition from new market entrants"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the risks that could adversely affect the company's investment portfolio. The relevant section is \"Risks Related to Our Investment Portfolio\" in the \"Risk Factors\" section.\n\n### Step-by-Step Analysis:\n\n1. **Credit Risk**:\n   - **Description**: The company is exposed to the risk that issuers or guarantors of fixed income securities and mortgage loans may default on principal and interest payments.\n   - **Impact**: This could cause the estimated fair value of the portfolio to decline and increase the default rate, leading to significant losses.\n   - **Relevance**: This risk is mentioned and is relevant to the investment portfolio.\n\n2. **Interest Rate Risk**:\n   - **Description**: The company is exposed to interest rate risk, which can affect the value of its investment portfolio and the profitability of its products.\n   - **Impact**: Low interest rates can reduce investment margins, and high interest rates can increase the cost of hedging and reduce the value of fixed income investments.\n   - **Relevance**: This risk is mentioned and is relevant to the investment"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 8000, "result": 1.0, "question": "What is the main reason preliminary data should be viewed with caution?", "options": {"A": "Preliminary data are always incorrect", "B": "Final data may differ significantly from preliminary data after audits", "C": "Preliminary data are approved by regulatory agencies", "D": "Preliminary data are completed and cannot change", "E": "Preliminary data are irrelevant to business decisions", "F": "Preliminary data are never published"}, "LLM_original_answer": ["To answer the question \"What is the main reason preliminary data should be viewed with caution?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Preliminary Data and Final Data Differences**:\n   - The document states: \"Preliminary and interim data from our clinical trials may change as more participant data become available and are subject to audit and verification procedures that could result in material changes in the final data.\"\n   - It further mentions: \"Preliminary or interim data from our clinical trials are not necessarily predictive of final results.\"\n\n2. **Interpretation and Verification**:\n   - The document emphasizes that preliminary data are subject to audit and verification procedures, which can lead to significant differences in the final data.\n   - It also notes that \"Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available.\"\n\n3. **Regulatory Acceptance**:\n   - The document highlights that regulatory authorities may not accept or agree with the preliminary data, and they may interpret or weigh the importance of data differently.\n   - It states: \"Others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product, if any, and our company in general.\"\n\n4. **Potential Consequences**:\n   - The document outlines that if the preliminary data differ from actual results, or if regulatory authorities disagree with the conclusions, it could harm the ability to obtain approval for and commercialize the product candidates.\n   - It mentions: \"If the preliminary and interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.\"\n\nGiven these points, the main reason preliminary data should be viewed with caution is that **final data may differ significantly from preliminary data after audits**. This aligns with the information provided in the document, which emphasizes the potential for changes and the need for verification.\n\nTherefore, the correct answer is:\n**B: Final data may differ significantly from preliminary data after audits**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 8000, "result": 1.0, "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?", "options": {"A": "Mining proceeds increase", "B": "Mining proceeds remain unchanged", "C": "Transaction fees decrease", "D": "Mining proceeds decrease", "E": "Network hash rate decreases", "F": "Transaction validation is faster"}, "LLM_original_answer": ["To answer the question \"What happens to bitcoin mining proceeds when there is an increase in network difficulty?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Understanding Network Difficulty**:\n   - The document states: \"The increase in bitcoin\u2019s network hash rate results in a regular increase in the cryptographic complexity associated with solving blocks on its blockchain, or its difficulty.\"\n   - This means that as more miners join the network and the total hash rate increases, the difficulty of solving blocks also increases.\n\n2. **Impact on Mining Proceeds**:\n   - The document further explains: \"Increased difficulty reduces the mining proceeds of the equipment proportionally and eventually requires bitcoin miners to upgrade their mining equipment to remain profitable and compete effectively with other miners.\"\n   - This indicates that when the network difficulty increases, the mining proceeds (i.e., the amount of bitcoin earned) decrease for individual miners because it becomes harder to solve blocks.\n\n3. **Evaluating the Options**:\n   - **A: Mining proceeds increase** - This is incorrect because increased difficulty makes it harder to mine, reducing the proceeds.\n   - **B: Mining proceeds remain unchanged** - This is incorrect because the document clearly states that increased difficulty reduces mining proceeds.\n   - **C: Transaction fees decrease** - The document does not provide information suggesting that transaction fees decrease with increased network difficulty.\n   - **D: Mining proceeds decrease** - This aligns with the information provided in the document.\n   - **E: Network hash rate decreases** - This is incorrect because the document states that network hash rate increases, leading to increased difficulty.\n   - **F: Transaction validation is faster** - The document does not suggest that transaction validation becomes faster with increased network difficulty; in fact, it implies the opposite, as higher difficulty means more computational power is required to validate transactions.\n\nBased on the information provided in the document, the correct answer is:\n\n**D: Mining proceeds decrease**\n\nThis is because the document explicitly states that increased network difficulty reduces the mining proceeds of the equipment proportionally."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 8000, "result": 1.0, "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?", "options": {"A": "Securing insurance for each transaction", "B": "Selecting highly rated banks as counterparties", "C": "Transferring risks to third-party investors", "D": "Converting all debts to local currency", "E": "Engaging with a single counterparty for all transactions", "F": "Using fixed interest rates only"}, "LLM_original_answer": ["To answer the question \"What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions credit risk and cross-currency swaps in the \"Credit Risk\" section.\n\n2. **Extract the relevant information**: The specific paragraph that discusses credit risk in cross-currency swaps is:\n   - \"Duke Energy is subject to credit risk from transactions with counterparties to cross-currency swaps related to future interest and principal payments. The credit exposure to such counterparties may take the form of higher costs to meet Duke Energy's future euro-denominated interest and principal payments in the event of counterparty default. Duke Energy selects highly rated banks as counterparties and allocates the hedge for each debt issuance across multiple counterparties. The master agreements with the counterparties impose collateral requirements on the parties in certain circumstances indicative of material deterioration in a party's creditworthiness.\"\n\n3. **Analyze the information**:\n   - **Selecting highly rated banks as counterparties**: This is a clear strategy mentioned in the document to mitigate credit risk.\n   - **Allocating the hedge across multiple counterparties**: This strategy helps to diversify the risk, so it is not concentrated with a single counterparty.\n   - **Collateral requirements**: The master agreements include provisions for collateral, which can be used to cover potential losses if a counterparty defaults.\n\n4. **Match the information to the options**:\n   - **Option A: Securing insurance for each transaction** - Not mentioned in the document.\n   - **Option B: Selecting highly rated banks as counterparties** - Directly mentioned in the document.\n   - **Option C: Transferring risks to third-party investors** - Not mentioned in the document.\n   - **Option D: Converting all debts to local currency** - Not mentioned in the document.\n   - **Option E: Engaging with a single counterparty for all transactions** - Contradicted by the document, which mentions allocating the hedge across multiple counterparties.\n   - **Option F: Using fixed interest rates only** - Not mentioned in the document.\n\n5. **Conclusion**:\n   - The document explicitly states that Duke Energy selects highly rated banks as counterparties and allocates the hedge across multiple counterparties to mitigate credit risk in cross-currency swaps.\n\nTherefore, the correct answer is **Option B: Selecting highly rated banks as counterparties**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 8000, "result": 1.0, "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?", "options": {"A": "Reclassified as current assets", "B": "Reclassified as non-current liabilities", "C": "Reclassified to assets and liabilities of discontinued operations", "D": "Included in the net loss calculation", "E": "Merged with assets and liabilities of continuing operations", "F": "Removed from all financial statements"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the relevant section**: The document mentions changes to the financial statements in the context of the insurance agency business. The relevant section is found in \"ITEM 7. MANAGEMENT\u2019S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.\"\n\n2. **Extract the key information**:\n   - The document states: \"On October 31, 2023, we sold substantially all of the assets and transferred certain liabilities of our insurance agency business.\"\n   - It further mentions: \"In the third quarter, following management\u2019s decision to sell our insurance agency business, we reclassified the related assets and liabilities to assets and liabilities of discontinued operations, respectively, on our Consolidated Balance Sheets.\"\n   - Additionally, it notes: \"Accordingly, the results of discontinued operations were reclassified to 'net income from discontinued operations' on our Consolidated Statements of Income.\"\n\n3. **Match the information to the options**:\n   - **Option A**: Reclassified as current assets - This is not mentioned in the document.\n   - **Option B**: Reclassified as non-current liabilities - This is not mentioned in the document.\n   - **Option C**: Reclassified to assets and liabilities of discontinued operations - This matches the information provided in the document.\n   - **Option D**: Included in the net loss calculation - While the net loss from continuing operations is discussed, the specific reclassification of the insurance agency business is not mentioned in this context.\n   - **Option E**: Merged with assets and liabilities of continuing operations - This is not mentioned in the document.\n   - **Option F**: Removed from all financial statements - This is not mentioned in the document.\n\n4. **Conclusion**:\n   - The document clearly states that the related assets and liabilities of the insurance agency business were reclassified to assets and liabilities of discontinued operations on the Consolidated Balance Sheets.\n\nTherefore, the correct answer is **Option C: Reclassified to assets and liabilities of discontinued operations**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 8000, "result": 1.0, "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?", "options": {"A": "They may prioritize our drug candidates over their own.", "B": "They are guaranteed to pursue commercialization of all drug candidates.", "C": "They have unlimited rights to select any target without restriction.", "D": "They may develop competing products independently or with third parties.", "E": "They ensure the protection and enforcement of our intellectual property.", "F": "They cannot change their strategic focus once a project starts."}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step:\n\n1. **Identify the Collaborators**: The document mentions collaborations with Gilead, Sanofi, and Pfizer. These are the key third parties involved in the research, development, and commercialization of the company's drug candidates.\n\n2. **List the Risks**: The document outlines several risks associated with these collaborations:\n   - Collaborators have significant discretion in determining the efforts and resources they will apply to the collaborations.\n   - Collaborators may not pursue development and commercialization of the drug candidates or may elect not to continue or renew programs based on various factors.\n   - Collaborators have broad option rights to select targets for exclusive development.\n   - Collaborators may delay clinical trials, provide insufficient funding, stop trials, or require new formulations.\n   - Collaborators could develop competing products independently or with third parties.\n   - Collaborators may not commit sufficient resources to marketing and distribution.\n   - Collaborators may not properly obtain, maintain, enforce, or defend the company's intellectual property.\n   - Disputes may arise, leading to delays or termination of the collaboration.\n   - The company may lose valuable rights under certain circumstances.\n   - Collaborations may not lead to efficient development or commercialization.\n\n3. **Match the Risks to the Options**:\n   - **Option A**: \"They may prioritize our drug candidates over their own.\" This is not mentioned as a risk in the document.\n   - **Option B**: \"They are guaranteed to pursue commercialization of all drug candidates.\" The document explicitly states that collaborators may elect not to continue or renew programs, so this is not a risk but rather a potential issue.\n   - **Option C**: \"They have unlimited rights to select any target without restriction.\" The document mentions that collaborators have broad option rights but not unlimited rights, as the company can exclude certain targets.\n   - **Option D**: \"They may develop competing products independently or with third parties.\" This is directly mentioned in the document: \"Collaborators could develop independently, or develop with third parties, products that compete directly or indirectly with our products or drug candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours.\"\n   - **Option E**: \"They ensure the protection and enforcement of our intellectual property.\" The document mentions that collaborators may not properly obtain, maintain, enforce, or defend the company's intellectual property, which is a risk.\n   - **Option"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 8000, "result": 1.0, "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?", "options": {"A": "1 million loans", "B": "1.3 million loans", "C": "2 million loans", "D": "2.3 million loans", "E": "500,000 loans", "F": "3 million loans"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant information in the document.\n2. Extract the specific data that answers the question.\n3. Match the extracted data to the provided options.\n\n### Step 1: Identify the Relevant Information\nThe relevant information is found in the \"Overview\" section of the document, which discusses the company's servicing and subservicing activities as of December 31, 2023.\n\n### Step 2: Extract the Specific Data\nThe specific data is:\n- \"We serviced or subserviced 1.3 million loans with a total UPB of $288.4 billion on behalf of more than 3,900 investors and 113 subservicing clients as of December 31, 2023.\"\n\n### Step 3: Match the Extracted Data to the Provided Options\nThe extracted data states that the company serviced or subserviced 1.3 million loans with a total UPB of $288.4 billion as of December 31, 2023.\n\n### Conclusion\nThe correct answer is:\n**B: 1.3 million loans**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 8000, "result": 1.0, "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?", "options": {"A": "Immediate market launch", "B": "Significant additional clinical and non-clinical development", "C": "Only initial trials in humans", "D": "Direct approval by local regulatory authorities", "E": "Exclusive manufacturing rights", "F": "Limited marketing efforts"}, "LLM_original_answer": ["To answer the question \"What is necessary before the company\u2019s product candidates can be successfully commercialized?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Review the Document for Key Points**:\n   - The document discusses the company's product development process, including the stages of preclinical and clinical trials.\n   - It mentions the need for regulatory approval and significant marketing efforts.\n   - The company is still in the early stages of development and has only recently initiated clinical trials for certain product candidates.\n   - The document emphasizes the challenges and risks associated with biopharmaceutical product development, including the need for substantial investment and the uncertainty of clinical trial outcomes.\n\n2. **Identify the Requirements for Commercialization**:\n   - **Clinical and Non-Clinical Development**: The document states, \"All of our product candidates will require significant additional clinical and non-clinical development, review and approval by the FDA or other regulatory authorities in one or more jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before they can be successfully commercialized.\"\n   - **Regulatory Approval**: The document mentions the need to \"obtain marketing approvals\" and \"demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, potency, purity and acceptable risk to benefit profile of our product candidates.\"\n   - **Manufacturing Capacity**: The document notes the need to \"manufacture adequate clinical and commercial supplies of our product candidates\" and \"develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP.\"\n   - **Marketing Efforts**: The document highlights the need to \"establish sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy.\"\n\n3. **Evaluate the Options**:\n   - **A: Immediate market launch**: This is not mentioned as a requirement and would be premature without prior development and approval.\n   - **B: Significant additional clinical and non-clinical development**: This is explicitly mentioned as a requirement.\n   - **C: Only initial trials in humans**: While initial trials are part of the process, the document indicates that more extensive development is necessary.\n   - **D: Direct approval by local regulatory authorities**: Regulatory approval is necessary, but it is not the only requirement.\n   - **E: Exclusive manufacturing rights**: The document does not mention the need for exclusive manufacturing rights, but it does emphasize the need for manufacturing capacity.\n   - **F: Limited marketing efforts**: The document suggests that significant marketing efforts are necessary"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 8000, "result": 1.0, "question": "What could adversely affect the business and operations if patient identification is unsuccessful?", "options": {"A": "Increased approval rates by regulatory authorities", "B": "Enhanced disease awareness among healthcare professionals", "C": "Larger addressable patient population than expected", "D": "Difficulty in identifying and accessing patients", "E": "Greater market acceptance of AMX0035", "F": "Increased profitability and business expansion"}, "LLM_original_answer": ["To answer the question \"What could adversely affect the business and operations if patient identification is unsuccessful?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Patient Identification and Market Access**:\n   - The document mentions that patient identification efforts are crucial for addressing the patient population. If these efforts are unsuccessful, it can lead to difficulties in identifying and accessing patients.\n   - Specifically, it states: \"If efforts in patient identification are unsuccessful or less impactful than anticipated, for instance, because of a lack of diagnostic initiatives, inadequate disease awareness among healthcare professionals, difficulties in identifying and accessing patients outside of larger treatment centers or otherwise, we may not address the entirety of the opportunity we are seeking.\"\n\n2. **Impact on Commercialization**:\n   - The document emphasizes that the market for AMX0035 and other neurodegenerative disease treatments may be smaller than expected if patient identification is not successful.\n   - It notes: \"As a result, patients may be difficult to identify and access, the addressable patient population in the U.S., Canada, the EU and elsewhere may turn out to be lower than expected, or patients may not be otherwise amenable to treatment with our products, all of which would adversely affect our business, financial condition, results of operations and prospects.\"\n\n3. **Specific Challenges**:\n   - The document highlights several specific challenges that could arise from unsuccessful patient identification:\n     - **Difficulty in identifying and accessing patients**: This is directly mentioned as a potential issue.\n     - **Inadequate disease awareness among healthcare professionals**: This could contribute to the difficulty in identifying and accessing patients.\n     - **Lack of diagnostic initiatives**: This could also hinder the identification of patients.\n\n4. **Evaluating the Options**:\n   - **A: Increased approval rates by regulatory authorities** - This is not mentioned as a consequence of unsuccessful patient identification.\n   - **B: Enhanced disease awareness among healthcare professionals** - This is actually a positive outcome, not a negative one.\n   - **C: Larger addressable patient population than expected** - This is the opposite of what the document suggests; it indicates a smaller addressable patient population.\n   - **D: Difficulty in identifying and accessing patients** - This is directly mentioned as a potential adverse effect.\n   - **E: Greater market acceptance of AMX0035** - This is not mentioned as a consequence of unsuccessful patient identification.\n   - **F: Increased profitability and business expansion** - This is also not mentioned as"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 8000, "result": 1.0, "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?", "options": {"A": "Acquisition of NYSE and Nasdaq", "B": "Acquisition of FFIEC and CFPB", "C": "Acquisition of Ellie Mae, Inc. and Black Knight", "D": "Acquisition of NYMEX and ICE", "E": "Acquisition of Fannie Mae and Freddie Mac", "F": "Acquisition of FHA and VA"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step:\n\n1. **Identify the Context**: The document discusses the regulatory environment and the impact of various acquisitions on the company's regulatory scrutiny, particularly in the U.S. residential mortgage industry.\n\n2. **Locate Relevant Information**: The relevant section is:\n   - \"Our acquisitions expose us to new regulatory requirements. For example, our acquisitions of Ellie Mae, Inc., or Ellie Mae, in 2020 and Black Knight in 2023 expose us to increased regulatory scrutiny from U.S. regulatory bodies that regulate the U.S. residential mortgage industry, including the FFIEC and its member agencies, and the CFPB, among others.\"\n\n3. **Match the Information to the Options**:\n   - **Option A**: Acquisition of NYSE and Nasdaq - These are stock exchanges, not related to the residential mortgage industry.\n   - **Option B**: Acquisition of FFIEC and CFPB - These are regulatory bodies, not companies that can be acquired.\n   - **Option C**: Acquisition of Ellie Mae, Inc. and Black Knight - This matches the information in the document.\n   - **Option D**: Acquisition of NYMEX and ICE - These are also exchanges, not related to the residential mortgage industry.\n   - **Option E**: Acquisition of Fannie Mae and Freddie Mac - While these are significant in the mortgage industry, the document does not mention the company acquiring them.\n   - **Option F**: Acquisition of FHA and VA - These are government agencies, not companies that can be acquired.\n\n4. **Conclusion**: The correct answer is **Option C: Acquisition of Ellie Mae, Inc. and Black Knight**.\n\nThe document explicitly states that the acquisitions of Ellie Mae, Inc. in 2020 and Black Knight in 2023 increased regulatory scrutiny from U.S. regulatory bodies that regulate the U.S. residential mortgage industry, including the FFIEC and CFPB."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 8000, "result": 1.0, "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?", "options": {"A": "Offering personal security devices", "B": "Weekly meetings with cybersecurity experts", "C": "Regular cybersecurity training and resources", "D": "Outsourcing training to third-party vendors", "E": "Developing a custom security software", "F": "Limiting internet access during work hours"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document:\n\n1. **Identify the relevant section**: The document mentions Brighthouse's Security Awareness Program in the \"Cybersecurity\" section.\n\n2. **Extract the key information**: The relevant excerpt is:\n   - \"Through our Security Awareness Program, we provide our employees with regular cybersecurity training and educational resources to help ensure that they remain vigilant against threats. These include frequent simulations, newsletters, alerts, e-mail reminders, and a mandatory annual cybersecurity awareness training course for all employees.\"\n\n3. **Match the information to the options**:\n   - **Option A: Offering personal security devices** - The document does not mention providing personal security devices to employees.\n   - **Option B: Weekly meetings with cybersecurity experts** - The document does not mention weekly meetings with cybersecurity experts.\n   - **Option C: Regular cybersecurity training and resources** - The document explicitly states that Brighthouse provides \"regular cybersecurity training and educational resources\" to its employees.\n   - **Option D: Outsourcing training to third-party vendors** - The document does not mention outsourcing training to third-party vendors.\n   - **Option E: Developing a custom security software** - The document does not mention developing custom security software.\n   - **Option F: Limiting internet access during work hours** - The document does not mention limiting internet access during work hours.\n\n4. **Conclusion**: Based on the information provided in the document, the method used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats is **regular cybersecurity training and resources**.\n\nTherefore, the correct answer is **Option C: Regular cybersecurity training and resources**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 16000, "result": 1.0, "question": "What is the main reason preliminary data should be viewed with caution?", "options": {"A": "Preliminary data are always incorrect", "B": "Final data may differ significantly from preliminary data after audits", "C": "Preliminary data are approved by regulatory agencies", "D": "Preliminary data are completed and cannot change", "E": "Preliminary data are irrelevant to business decisions", "F": "Preliminary data are never published"}, "LLM_original_answer": ["To answer the question \"What is the main reason preliminary data should be viewed with caution?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: The document discusses various aspects of clinical trials and the development of pharmaceutical products. The section that directly addresses the concept of preliminary data is:\n\n   > \"Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. From time to time, we may publish interim, topline or preliminary data from our clinical trials. Preliminary and interim data from our clinical trials may change as more participant data become available. For example, in June 2021, we announced preliminary results from Cohorts 1 and 2 of our Phase 2 clinical trial evaluating KER-050 for the treatment of anemia and thrombocytopenia in patients with very low-, low-, or intermediate-risk MDS, which only included a small subset of the patients expected to be enrolled in the trial. We also announced additional preliminary efficacy results from Parts 1 and 2 of that trial most recently in December 2023. Preliminary or interim data from our clinical trials are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as enrollment continues, more trial data become available and we issue our final clinical trial report. Interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary, topline and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects.\"\n\n2. **Analyze the Information**: The key points from this section are:\n   - Preliminary data can change as more patient data become available.\n   - Preliminary data are subject to audit and verification procedures.\n   - Preliminary data are not necessarily predictive of final results.\n   - There is a risk that clinical outcomes may materially change as enrollment continues.\n   - Final data may be significantly different from preliminary data.\n\n3. **Match the Information to the Options**:\n   - **Option A**: \"Preliminary data are always incorrect\" - This is too absolute and not supported"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 16000, "result": 1.0, "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?", "options": {"A": "Mining proceeds increase", "B": "Mining proceeds remain unchanged", "C": "Transaction fees decrease", "D": "Mining proceeds decrease", "E": "Network hash rate decreases", "F": "Transaction validation is faster"}, "LLM_original_answer": ["To answer the question \"What happens to bitcoin mining proceeds when there is an increase in network difficulty?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Understanding Network Difficulty**:\n   - The document states: \"The increase in bitcoin\u2019s network hash rate results in a regular increase in the cryptographic complexity associated with solving blocks on its blockchain, or its difficulty.\"\n   - This means that as more miners join the network and the total hash rate increases, the difficulty of solving blocks also increases.\n\n2. **Impact on Mining Proceeds**:\n   - The document further explains: \"Increased difficulty reduces the mining proceeds of the equipment proportionally and eventually requires bitcoin miners to upgrade their mining equipment to remain profitable and compete effectively with other miners.\"\n   - This indicates that when the network difficulty increases, the mining proceeds (i.e., the amount of bitcoin earned) decrease proportionally for each miner.\n\n3. **Evaluating the Options**:\n   - **Option A: Mining proceeds increase** - This is incorrect because increased difficulty makes it harder to mine, reducing the proceeds.\n   - **Option B: Mining proceeds remain unchanged** - This is incorrect because the document clearly states that increased difficulty reduces mining proceeds.\n   - **Option C: Transaction fees decrease** - The document does not provide information suggesting that transaction fees decrease with increased network difficulty.\n   - **Option D: Mining proceeds decrease** - This aligns with the information provided in the document.\n   - **Option E: Network hash rate decreases** - This is incorrect because the document states that network hash rate increases, leading to increased difficulty.\n   - **Option F: Transaction validation is faster** - The document does not suggest that transaction validation becomes faster with increased network difficulty; in fact, it implies the opposite, as higher difficulty means more computational power is required to validate transactions.\n\nBased on the information provided in the document, the correct answer is:\n\n**D: Mining proceeds decrease**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 16000, "result": 1.0, "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?", "options": {"A": "Securing insurance for each transaction", "B": "Selecting highly rated banks as counterparties", "C": "Transferring risks to third-party investors", "D": "Converting all debts to local currency", "E": "Engaging with a single counterparty for all transactions", "F": "Using fixed interest rates only"}, "LLM_original_answer": ["To answer the question \"What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: The document contains a section specifically addressing credit risk and the strategies used by Duke Energy to manage it. This section is found under \"Credit Risk\" in the \"Quantitative and Qualitative Disclosures About Market Risk\" part of the document.\n\n2. **Extract Key Information**: From the \"Credit Risk\" section, the following information is relevant:\n   - Duke Energy performs ongoing assessments of its respective guarantee obligations to determine whether any liabilities have been incurred as a result of potential increased nonperformance risk by third parties for which Duke Energy has issued guarantees.\n   - Duke Energy selects highly rated banks as counterparties and allocates the hedge for each debt issuance across multiple counterparties.\n   - Master agreements with the counterparties impose collateral requirements on the parties in certain circumstances indicative of material deterioration in a party's creditworthiness.\n   - The threshold amount represents a negotiated unsecured credit limit for each party to the agreement, determined in accordance with Duke Energy's internal corporate credit practices and standards.\n   - Collateral agreements generally also provide that the failure to post collateral when required is sufficient cause to terminate transactions and liquidate all positions.\n\n3. **Analyze the Information**:\n   - **Option A: Securing insurance for each transaction** - The document does not mention securing insurance for each transaction as a strategy for mitigating credit risk in cross-currency swaps.\n   - **Option B: Selecting highly rated banks as counterparties** - The document explicitly states that Duke Energy selects highly rated banks as counterparties to mitigate credit risk.\n   - **Option C: Transferring risks to third-party investors** - The document does not mention transferring risks to third-party investors as a strategy for mitigating credit risk in cross-currency swaps.\n   - **Option D: Converting all debts to local currency** - The document does not mention converting all debts to local currency as a strategy for mitigating credit risk in cross-currency swaps.\n   - **Option E: Engaging with a single counterparty for all transactions** - The document mentions that Duke Energy allocates the hedge for each debt issuance across multiple counterparties, which is the opposite of engaging with a single counterparty.\n   - **Option F: Using fixed interest rates only** - The document does not mention using fixed interest rates only as a strategy for mitigating credit risk in"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 16000, "result": 1.0, "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?", "options": {"A": "Reclassified as current assets", "B": "Reclassified as non-current liabilities", "C": "Reclassified to assets and liabilities of discontinued operations", "D": "Included in the net loss calculation", "E": "Merged with assets and liabilities of continuing operations", "F": "Removed from all financial statements"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Context**: The document discusses the financial operations and changes in the structure of Eastern Bankshares, Inc., including the sale of its insurance agency business.\n\n2. **Locate the Specific Information**: The key information is found in the \"Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\" section, particularly in the \"Overview\" and \"Financial Position\" subsections.\n\n3. **Relevant Paragraph**:\n   - \"On October 31, 2023, we sold substantially all of the assets and transferred certain liabilities of our insurance agency business.\"\n   - \"In the third quarter, following management\u2019s decision to sell our insurance agency business, we reclassified the related assets and liabilities to assets and liabilities of discontinued operations, respectively, on our Consolidated Balance Sheets.\"\n   - \"Accordingly, the results of discontinued operations were reclassified to 'net income from discontinued operations' on our Consolidated Statements of Income.\"\n\n4. **Interpret the Information**:\n   - The insurance agency business was sold on October 31, 2023.\n   - Prior to the sale, in the third quarter, the assets and liabilities related to the insurance agency business were reclassified.\n   - The reclassification was to \"assets and liabilities of discontinued operations\" on the Consolidated Balance Sheets.\n   - The results of the discontinued operations were reclassified to \"net income from discontinued operations\" on the Consolidated Statements of Income.\n\n5. **Match the Information to the Options**:\n   - **Option A**: Reclassified as current assets - This is not correct because the reclassification was to assets and liabilities of discontinued operations, not current assets.\n   - **Option B**: Reclassified as non-current liabilities - This is not correct because the reclassification was to assets and liabilities of discontinued operations, not non-current liabilities.\n   - **Option C**: Reclassified to assets and liabilities of discontinued operations - This matches the information provided in the document.\n   - **Option D**: Included in the net loss calculation - This is not correct because the results were reclassified to \"net income from discontinued operations.\"\n   - **Option E**: Merged with assets and liabilities of continuing operations - This is not correct because the assets and liabilities were reclassified to discontinued operations.\n   - **Option F**: Removed from all financial statements - This is not correct because the assets and liabilities were reclassified"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 16000, "result": 1.0, "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?", "options": {"A": "They may prioritize our drug candidates over their own.", "B": "They are guaranteed to pursue commercialization of all drug candidates.", "C": "They have unlimited rights to select any target without restriction.", "D": "They may develop competing products independently or with third parties.", "E": "They ensure the protection and enforcement of our intellectual property.", "F": "They cannot change their strategic focus once a project starts."}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document and the options given.\n\nThe document mentions several risks associated with collaborations, including those with Gilead, Sanofi, and Pfizer. The key points related to these risks are:\n\n1. **Collaborators' Discretion in Effort and Resource Allocation**:\n   - \"Collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations with us.\"\n   - This suggests that collaborators can choose how much effort and resources to dedicate to the collaboration, which could lead to insufficient support.\n\n2. **Collaborators' Strategic Focus and Funding**:\n   - \"Collaborators may not pursue development and commercialization of any drug candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator\u2019s strategic focus or available funding or external factors such as an acquisition or business combination that diverts resources or creates competing priorities.\"\n   - This indicates that collaborators might change their focus or funding, leading to the termination or delay of development programs.\n\n3. **Competing Products**:\n   - \"Collaborators could develop independently, or develop with third parties, products that compete directly or indirectly with our products or drug candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours.\"\n   - This explicitly states that collaborators might develop competing products, either independently or with other third parties.\n\n4. **Intellectual Property Protection**:\n   - \"Collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation.\"\n   - This highlights the risk that collaborators might not adequately protect our intellectual property.\n\nNow, let's evaluate the options:\n\nA. **They may prioritize our drug candidates over their own**:\n   - The document does not mention collaborators prioritizing our drug candidates over their own. Instead, it suggests the opposite, that they might prioritize their own products.\n\nB. **They are guaranteed to pursue commercialization of all drug candidates**:\n   - The document explicitly states that collaborators may not pursue the development and commercialization of our drug candidates, so this option is incorrect.\n\nC. **They have unlimited rights to select any target without restriction**:\n   - The document mentions that collaborators have broad option rights to select targets, but it does not state that these"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 16000, "result": 1.0, "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?", "options": {"A": "1 million loans", "B": "1.3 million loans", "C": "2 million loans", "D": "2.3 million loans", "E": "500,000 loans", "F": "3 million loans"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant information in the document.\n2. Extract the specific data that answers the question.\n3. Match the extracted data to the provided options.\n\n### Step 1: Identify the Relevant Information\nThe question asks about the number of loans serviced or subserviced by the company as of December 31, 2023, with a total UPB of $288.4 billion.\n\n### Step 2: Extract the Specific Data\nFrom the document, the relevant information is found in the following sentence:\n\"As of December 31, 2023, we serviced 1.3 million mortgage loans with an aggregate UPB of $288.4 billion, a decrease of 2% and 0.5%, respectively, from December 31, 2022.\"\n\n### Step 3: Match the Extracted Data to the Provided Options\nThe extracted data states that as of December 31, 2023, the company serviced 1.3 million loans with a total UPB of $288.4 billion.\n\nThe correct option is:\n**B: 1.3 million loans**\n\nThus, the answer to the question is **B: 1.3 million loans**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 16000, "result": 1.0, "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?", "options": {"A": "Immediate market launch", "B": "Significant additional clinical and non-clinical development", "C": "Only initial trials in humans", "D": "Direct approval by local regulatory authorities", "E": "Exclusive manufacturing rights", "F": "Limited marketing efforts"}, "LLM_original_answer": ["To answer the question \"What is necessary before the company\u2019s product candidates can be successfully commercialized?\" based on the provided document, let's break down the key points and analyze the options:\n\n1. **Immediate market launch (Option A)**:\n   - The document clearly states that the company's product candidates are still in the early stages of development and have not yet been approved for commercial sale. Therefore, an immediate market launch is not possible and not necessary.\n\n2. **Significant additional clinical and non-clinical development (Option B)**:\n   - The document emphasizes that all product candidates will require significant additional clinical and non-clinical development. It mentions the need to complete preclinical studies, initiate and complete clinical trials, and obtain regulatory approval. This is a critical step before commercialization.\n\n3. **Only initial trials in humans (Option C)**:\n   - While the document notes that some product candidates are being evaluated in humans, it also states that these trials are just the beginning. Initial trials alone are not sufficient for commercialization; further development and regulatory approval are required.\n\n4. **Direct approval by local regulatory authorities (Option D)**:\n   - The document discusses the regulatory approval process, including the need to obtain marketing authorization from the FDA or other regulatory authorities. However, it does not suggest that direct approval is the only necessary step. Significant development and trials are required before seeking approval.\n\n5. **Exclusive manufacturing rights (Option E)**:\n   - The document mentions the need for manufacturing capabilities and the importance of sourcing clinical and commercial supplies. However, it does not indicate that exclusive manufacturing rights are a necessary condition for commercialization. Instead, it focuses on the need for adequate and consistent manufacturing processes.\n\n6. **Limited marketing efforts (Option F)**:\n   - The document does not suggest that limited marketing efforts are sufficient for commercialization. It emphasizes the need for significant marketing efforts to gain market acceptance and commercial success.\n\nGiven the above analysis, the most accurate and comprehensive answer is:\n\n**B: Significant additional clinical and non-clinical development**\n\nThis option aligns with the document's emphasis on the need for extensive development, including preclinical studies, clinical trials, and regulatory approval, before the product candidates can be successfully commercialized."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 16000, "result": 1.0, "question": "What could adversely affect the business and operations if patient identification is unsuccessful?", "options": {"A": "Increased approval rates by regulatory authorities", "B": "Enhanced disease awareness among healthcare professionals", "C": "Larger addressable patient population than expected", "D": "Difficulty in identifying and accessing patients", "E": "Greater market acceptance of AMX0035", "F": "Increased profitability and business expansion"}, "LLM_original_answer": ["To answer the question \"What could adversely affect the business and operations if patient identification is unsuccessful?\" based on the provided document, let's break down the relevant information and analyze the options step by step.\n\n### Relevant Information from the Document:\n1. **Patient Identification and Access:**\n   - \"If efforts in patient identification are unsuccessful or less impactful than anticipated, for instance, because of a lack of diagnostic initiatives, inadequate disease awareness among healthcare professionals, difficulties in identifying and accessing patients outside of larger treatment centers or otherwise, we may not address the entirety of the opportunity we are seeking.\"\n   - \"We are finding that the market for ALS in the U.S. may be different than our initial estimations because a large percentage of ALS patients in the U.S. are treated outside of larger treatment centers, making it difficult to identify and access these patients.\"\n\n2. **Market Opportunity:**\n   - \"The market for AMX0035 for ALS, PSP, WS, AD and other neurodegenerative diseases and for any other product candidates we are currently developing or may in the future develop may be smaller than we expect.\"\n   - \"If we are unable to identify patients and successfully commercialize AMX0035 or any other current or future product candidates with attractive market opportunities, our future product revenues may be smaller than anticipated, and our business may suffer.\"\n\n3. **Commercialization and Revenue:**\n   - \"Our ability to generate significant revenues on a long term sustained basis, or to conduct sales and marketing activities necessary for successful longer term product commercialization, is uncertain.\"\n   - \"If we are unable to obtain additional marketing approvals for AMX0035 or any other current or future product candidates that we develop, we may require significant additional amounts of cash in order to continue to develop AMX0035 and any other current or future product candidates and fund our operations.\"\n\n### Analysis of Options:\n- **A: Increased approval rates by regulatory authorities**\n  - This option is not relevant to the issue of patient identification. Increased approval rates would generally be positive for the business.\n\n- **B: Enhanced disease awareness among healthcare professionals**\n  - Enhanced disease awareness would likely improve patient identification and access, not adversely affect it.\n\n- **C: Larger addressable patient population than expected**\n  - A larger addressable patient population would generally be positive for the business, not a risk.\n\n- **D: Difficulty in identifying and accessing patients**\n  - This option directly aligns with the document's statements about the"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 16000, "result": 1.0, "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?", "options": {"A": "Acquisition of NYSE and Nasdaq", "B": "Acquisition of FFIEC and CFPB", "C": "Acquisition of Ellie Mae, Inc. and Black Knight", "D": "Acquisition of NYMEX and ICE", "E": "Acquisition of Fannie Mae and Freddie Mac", "F": "Acquisition of FHA and VA"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Identify the relevant section**: The document mentions acquisitions and their impact on regulatory scrutiny. The relevant section is under \"MERGERS & ACQUISITIONS AND COMMON STOCK.\"\n\n2. **Extract key information**:\n   - The document states: \"Our acquisitions of Ellie Mae, Inc., or Ellie Mae, in 2020 and Black Knight in 2023 expose us to increased regulatory scrutiny from U.S. regulatory bodies that regulate the U.S. residential mortgage industry, including the FFIEC and its member agencies, and the CFPB, among others.\"\n\n3. **Match the information to the options**:\n   - **Option A**: Acquisition of NYSE and Nasdaq - Not mentioned in the context of increased regulatory scrutiny in the U.S. residential mortgage industry.\n   - **Option B**: Acquisition of FFIEC and CFPB - These are regulatory bodies, not companies that can be acquired.\n   - **Option C**: Acquisition of Ellie Mae, Inc. and Black Knight - This matches the information provided in the document.\n   - **Option D**: Acquisition of NYMEX and ICE - Not mentioned in the context of increased regulatory scrutiny in the U.S. residential mortgage industry.\n   - **Option E**: Acquisition of Fannie Mae and Freddie Mac - Not mentioned in the context of increased regulatory scrutiny in the U.S. residential mortgage industry.\n   - **Option F**: Acquisition of FHA and VA - These are government agencies, not companies that can be acquired.\n\n4. **Conclusion**:\n   - The document explicitly states that the acquisitions of Ellie Mae, Inc. and Black Knight increased regulatory scrutiny in the U.S. residential mortgage industry.\n\nTherefore, the correct answer is **Option C: Acquisition of Ellie Mae, Inc. and Black Knight**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 16000, "result": 1.0, "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?", "options": {"A": "Offering personal security devices", "B": "Weekly meetings with cybersecurity experts", "C": "Regular cybersecurity training and resources", "D": "Outsourcing training to third-party vendors", "E": "Developing a custom security software", "F": "Limiting internet access during work hours"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the relevant section**: The document contains a section titled \"Cybersecurity Risk Management Program and Strategy\" which is likely to contain information about Brighthouse's Security Awareness Program.\n\n2. **Extract key information**: Within the \"Cybersecurity Risk Management Program and Strategy\" section, the following statement is relevant:\n   - \"Through our Security Awareness Program, we provide our employees with regular cybersecurity training and educational resources to help ensure that they remain vigilant against threats. These include frequent simulations, newsletters, alerts, e-mail reminders, and a mandatory annual cybersecurity awareness training course for all employees.\"\n\n3. **Match the information to the options**:\n   - **Option A: Offering personal security devices** - The document does not mention offering personal security devices.\n   - **Option B: Weekly meetings with cybersecurity experts** - The document does not mention weekly meetings with cybersecurity experts.\n   - **Option C: Regular cybersecurity training and resources** - The document explicitly states that Brighthouse provides \"regular cybersecurity training and educational resources.\"\n   - **Option D: Outsourcing training to third-party vendors** - The document does not mention outsourcing training to third-party vendors.\n   - **Option E: Developing a custom security software** - The document does not mention developing custom security software.\n   - **Option F: Limiting internet access during work hours** - The document does not mention limiting internet access during work hours.\n\n4. **Conclusion**: Based on the information provided in the document, the method used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats is **regular cybersecurity training and resources**.\n\nTherefore, the correct answer is **Option C: Regular cybersecurity training and resources**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 32000, "result": 1.0, "question": "What is the main reason preliminary data should be viewed with caution?", "options": {"A": "Preliminary data are always incorrect", "B": "Final data may differ significantly from preliminary data after audits", "C": "Preliminary data are approved by regulatory agencies", "D": "Preliminary data are completed and cannot change", "E": "Preliminary data are irrelevant to business decisions", "F": "Preliminary data are never published"}, "LLM_original_answer": ["To answer the question \"What is the main reason preliminary data should be viewed with caution?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for sections that discuss preliminary data and the reasons for caution.\n2. **Analyze the Information**: Determine the key points that explain why preliminary data should be viewed with caution.\n3. **Match to the Options**: Compare the identified reasons with the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant section from the document is:\n- \"Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. From time to time, we may publish interim, topline or preliminary data from our clinical trials. Preliminary and interim data from our clinical trials may change as more participant data become available. For example, in June 2021, we announced preliminary results from Cohorts 1 and 2 of our Phase 2 clinical trial evaluating KER-050 for the treatment of anemia and thrombocytopenia in patients with very low-, low-, or intermediate-risk MDS, which only included a small subset of the patients expected to be enrolled in the trial. We also announced additional preliminary efficacy results from Parts 1 and 2 of that trial most recently in December 2023. Preliminary or interim data from our clinical trials are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as enrollment continues, more trial data become available and we issue our final clinical trial report. Interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary, topline and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects.\"\n\n### Step 2: Analyze the Information\nThe key points from this section are:\n- **Preliminary data may change**: As more patient data become available, the preliminary data can change.\n- **Subject to audit and verification**: Preliminary data are subject to audit and verification procedures that can result in significant differences in the final data.\n"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 32000, "result": 1.0, "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?", "options": {"A": "Mining proceeds increase", "B": "Mining proceeds remain unchanged", "C": "Transaction fees decrease", "D": "Mining proceeds decrease", "E": "Network hash rate decreases", "F": "Transaction validation is faster"}, "LLM_original_answer": ["To answer the question \"What happens to bitcoin mining proceeds when there is an increase in network difficulty?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Understanding Network Difficulty**:\n   - The document states: \"The increase in bitcoin\u2019s network hash rate results in a regular increase in the cryptographic complexity associated with solving blocks on its blockchain, or its difficulty. Increased difficulty reduces the mining proceeds of the equipment proportionally and eventually requires bitcoin miners to upgrade their mining equipment to remain profitable and compete effectively with other miners.\"\n\n2. **Impact on Mining Proceeds**:\n   - The key phrase here is \"Increased difficulty reduces the mining proceeds of the equipment proportionally.\" This means that as the network difficulty increases, the same mining equipment will find it harder to solve blocks, leading to a proportional reduction in the number of bitcoins it can mine.\n\n3. **Evaluating the Options**:\n   - **A: Mining proceeds increase** - This is incorrect because the document clearly states that increased difficulty reduces mining proceeds.\n   - **B: Mining proceeds remain unchanged** - This is also incorrect because the document indicates that mining proceeds are affected by network difficulty.\n   - **C: Transaction fees decrease** - The document does not mention that transaction fees decrease with increased network difficulty. It only discusses the impact on mining proceeds.\n   - **D: Mining proceeds decrease** - This aligns with the information provided in the document.\n   - **E: Network hash rate decreases** - The document states that network hash rate increases, not decreases, with increased difficulty.\n   - **F: Transaction validation is faster** - The document does not suggest that transaction validation becomes faster with increased network difficulty. In fact, increased difficulty implies that it becomes harder to validate transactions.\n\nGiven the information from the document, the correct answer is:\n\n**D: Mining proceeds decrease**\n\nThis is because the document explicitly states that increased network difficulty reduces the mining proceeds of the equipment proportionally."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 32000, "result": 1.0, "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?", "options": {"A": "Securing insurance for each transaction", "B": "Selecting highly rated banks as counterparties", "C": "Transferring risks to third-party investors", "D": "Converting all debts to local currency", "E": "Engaging with a single counterparty for all transactions", "F": "Using fixed interest rates only"}, "LLM_original_answer": ["To answer the question \"What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss credit risk and cross-currency swaps.\n2. **Extract Key Information**: Extract specific details about the strategies used to manage credit risk in cross-currency swaps.\n3. **Match to Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found under \"Credit Risk\" in the \"Risk Management Policies\" section:\n\n### Step 2: Extract Key Information\nFrom the \"Credit Risk\" section:\n- **Credit Risk Management**: \"Duke Energy monitors risks associated with commodity price changes on its future operations and, where appropriate, uses various commodity instruments such as electricity, coal and natural gas hedging contracts and options to mitigate the effect of such fluctuations on operations.\"\n- **Cross-Currency Swaps**: \"Duke Energy is subject to credit risk from transactions with counterparties to cross-currency swaps related to future interest and principal payments. The credit exposure to such counterparties may take the form of higher costs to meet Duke Energy's future euro-denominated interest and principal payments in the event of counterparty default.\"\n- **Strategy for Cross-Currency Swaps**: \"Duke Energy selects highly rated banks as counterparties and allocates the hedge for each debt issuance across multiple counterparties. The master agreements with the counterparties impose collateral requirements on the parties in certain circumstances indicative of material deterioration in a party's creditworthiness.\"\n\n### Step 3: Match to Options\n- **Option A: Securing insurance for each transaction** - The document does not mention securing insurance for cross-currency swaps.\n- **Option B: Selecting highly rated banks as counterparties** - The document explicitly states that Duke Energy selects highly rated banks as counterparties.\n- **Option C: Transferring risks to third-party investors** - The document does not mention transferring risks to third-party investors.\n- **Option D: Converting all debts to local currency** - The document does not mention converting all debts to local currency.\n- **Option E: Engaging with a single counterparty for all transactions** - The document mentions allocating the hedge across multiple counterparties, not engaging with a single counterparty.\n- **Option F: Using fixed interest rates only** - The document does not mention using fixed interest rates only"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 32000, "result": 1.0, "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?", "options": {"A": "Reclassified as current assets", "B": "Reclassified as non-current liabilities", "C": "Reclassified to assets and liabilities of discontinued operations", "D": "Included in the net loss calculation", "E": "Merged with assets and liabilities of continuing operations", "F": "Removed from all financial statements"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Context**: The document discusses the financial operations and changes in the business structure of Eastern Bank, particularly focusing on the third quarter of 2023.\n\n2. **Locate the Specific Information**: The section that directly addresses the change in the presentation of the insurance agency business is found in the \"Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\" under the \"Overview\" subsection. The relevant passage states:\n   > \"On October 31, 2023, we sold substantially all of the assets and transferred certain liabilities of our insurance agency business. In the third quarter, following management\u2019s decision to sell our insurance agency business, we reclassified the related assets and liabilities to assets and liabilities of discontinued operations, respectively, on our Consolidated Balance Sheets. Accordingly, the results of discontinued operations were reclassified to 'net income from discontinued operations' on our Consolidated Statements of Income.\"\n\n3. **Analyze the Information**:\n   - **Reclassification**: The passage clearly indicates that the assets and liabilities related to the insurance agency business were reclassified to assets and liabilities of discontinued operations.\n   - **Timing**: This reclassification occurred in the third quarter of 2023.\n   - **Financial Statements**: The reclassification affected both the Consolidated Balance Sheets and the Consolidated Statements of Income.\n\n4. **Match the Information to the Options**:\n   - **Option A**: Reclassified as current assets - This is not correct because the reclassification was to assets and liabilities of discontinued operations, not current assets.\n   - **Option B**: Reclassified as non-current liabilities - This is not correct for the same reason as Option A.\n   - **Option C**: Reclassified to assets and liabilities of discontinued operations - This matches the information provided in the document.\n   - **Option D**: Included in the net loss calculation - While the results of discontinued operations are included in the net income from discontinued operations, the specific reclassification of assets and liabilities is to discontinued operations, not directly to the net loss calculation.\n   - **Option E**: Merged with assets and liabilities of continuing operations - This is not correct because the reclassification was to discontinued operations, not merged with continuing operations.\n   - **Option F**: Removed from all financial statements - This is not correct because the assets and liabilities were reclassified, not removed entirely from the financial statements.\n\n5. **"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 32000, "result": 1.0, "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?", "options": {"A": "They may prioritize our drug candidates over their own.", "B": "They are guaranteed to pursue commercialization of all drug candidates.", "C": "They have unlimited rights to select any target without restriction.", "D": "They may develop competing products independently or with third parties.", "E": "They ensure the protection and enforcement of our intellectual property.", "F": "They cannot change their strategic focus once a project starts."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the relevant section**: The section that discusses the risks related to collaborations with third parties, including Gilead, Sanofi, and Pfizer, is \"Risks Related to Dependence on Third Parties.\"\n\n2. **Extract the specific risks mentioned**:\n   - **Collaborators have significant discretion**: \"Collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations with us.\"\n   - **Collaborators may not pursue development**: \"Collaborators may not pursue development and commercialization of any drug candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator\u2019s strategic focus or available funding or external factors such as an acquisition or business combination that diverts resources or creates competing priorities.\"\n   - **Collaborators may select competing targets**: \"Gilead and Sanofi have broad option rights to select up to five targets each, and Pfizer has option rights to multiple targets, for exclusive targeted protein degrader development, so long as not excluded by us under the terms of each collaboration, and may select targets we are considering but have not taken sufficient action to exclude under each collaboration.\"\n   - **Collaborators may delay or abandon trials**: \"Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing.\"\n   - **Collaborators may develop competing products**: \"Collaborators could develop independently, or develop with third parties, products that compete directly or indirectly with our products or drug candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours.\"\n\n3. **Match the extracted risks to the provided options**:\n   - **Option A**: \"They may prioritize our drug candidates over their own.\" - This is not mentioned in the document.\n   - **Option B**: \"They are guaranteed to pursue commercialization of all drug candidates.\" - This is not mentioned in the document.\n   - **Option C**: \"They have unlimited rights to select any target without restriction.\" - This is not accurate. The document mentions that they have broad option rights but not unlimited rights.\n   - **Option D**: \"They may develop competing products independently or with third parties"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 32000, "result": 1.0, "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?", "options": {"A": "1 million loans", "B": "1.3 million loans", "C": "2 million loans", "D": "2.3 million loans", "E": "500,000 loans", "F": "3 million loans"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant information from the provided document.\n2. Match the identified information to the question.\n3. Select the correct option from the given choices.\n\n### Step 1: Identify the Relevant Information\nThe relevant information is found in the following excerpt from the document:\n\n> \"We serviced or subserviced 1.3 million loans with a total UPB of $288.4 billion on behalf of more than 3,900 investors and 113 subservicing clients as of December 31, 2023.\"\n\n### Step 2: Match the Identified Information to the Question\nThe question asks: \"As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?\"\n\nFrom the excerpt, we can see that the company serviced or subserviced 1.3 million loans with a total UPB of $288.4 billion as of December 31, 2023.\n\n### Step 3: Select the Correct Option\nThe correct option that matches the identified information is:\n\n**B: 1.3 million loans**\n\nTherefore, the answer to the question is **B: 1.3 million loans**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 32000, "result": 1.0, "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?", "options": {"A": "Immediate market launch", "B": "Significant additional clinical and non-clinical development", "C": "Only initial trials in humans", "D": "Direct approval by local regulatory authorities", "E": "Exclusive manufacturing rights", "F": "Limited marketing efforts"}, "LLM_original_answer": ["To answer the question \"What is necessary before the company\u2019s product candidates can be successfully commercialized?\" based on the provided document, let's break down the key points and analyze the options:\n\n### Key Points from the Document:\n1. **Clinical and Non-Clinical Development**:\n   - The document emphasizes that all product candidates require significant additional clinical and non-clinical development.\n   - It mentions the need to conduct preclinical studies, clinical trials, and obtain related chemistry, manufacturing, and controls (CMC) regulatory approvals.\n   - The process is described as lengthy, complex, and expensive, with outcomes inherently uncertain.\n\n2. **Regulatory Approval**:\n   - Regulatory approval from the FDA or other foreign regulatory authorities is crucial.\n   - The document highlights the challenges in obtaining marketing approvals, including the need to demonstrate safety, potency, and purity.\n   - It also mentions the potential for regulatory authorities to require additional studies or trials beyond those initially planned.\n\n3. **Manufacturing**:\n   - The company needs to develop processes suitable for clinical manufacturing and obtain related CMC regulatory approvals.\n   - There are significant challenges in scaling up manufacturing processes to meet commercial demands, including potential issues with product loss, contamination, and process reproducibility.\n\n4. **Sales and Marketing**:\n   - The company needs to establish sales, marketing, and distribution capabilities.\n   - It may need to enter into agreements with third parties for these activities, which could be challenging and may not be as effective as in-house efforts.\n\n5. **Reimbursement and Coverage**:\n   - Adequate third-party reimbursement is necessary for the product candidates to be commercially viable.\n   - The document discusses the challenges of obtaining coverage from third-party payors, including the need to provide scientific and clinical support for the use of the products.\n\n### Analysis of Options:\n- **A: Immediate market launch**:\n  - This is not possible without prior regulatory approval and adequate clinical and non-clinical development.\n\n- **B: Significant additional clinical and non-clinical development**:\n  - This aligns with the document's emphasis on the need for extensive preclinical and clinical testing, as well as obtaining CMC regulatory approvals.\n\n- **C: Only initial trials in humans**:\n  - While initial trials are important, they are not sufficient for commercialization. Additional trials and regulatory approvals are necessary.\n\n- **D: Direct approval by local regulatory authorities**:\n  - This is a necessary step but is not sufficient on its own. Significant development and testing"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 32000, "result": 1.0, "question": "What could adversely affect the business and operations if patient identification is unsuccessful?", "options": {"A": "Increased approval rates by regulatory authorities", "B": "Enhanced disease awareness among healthcare professionals", "C": "Larger addressable patient population than expected", "D": "Difficulty in identifying and accessing patients", "E": "Greater market acceptance of AMX0035", "F": "Increased profitability and business expansion"}, "LLM_original_answer": ["To answer the question \"What could adversely affect the business and operations if patient identification is unsuccessful?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Patient Identification and Market Access**:\n   - The document mentions that patient identification efforts are crucial for addressing the patient population. If these efforts are unsuccessful, it can lead to difficulties in identifying and accessing patients.\n   - Specifically, it states: \"If efforts in patient identification are unsuccessful or less impactful than anticipated, for instance, because of a lack of diagnostic initiatives, inadequate disease awareness among healthcare professionals, difficulties in identifying and accessing patients outside of larger treatment centers or otherwise, we may not address the entirety of the opportunity we are seeking.\"\n\n2. **Impact on Commercialization**:\n   - The document emphasizes the importance of successfully commercializing AMX0035 and other product candidates. If patient identification is unsuccessful, it can hinder the commercialization process.\n   - It notes: \"We may be required to produce clinical data supporting the contribution of each component when present at the levels included in the fixed-dose combination in order to obtain marketing authorization in the EU.\"\n\n3. **Addressable Patient Population**:\n   - The document discusses the potential for the addressable patient population to be lower than expected if patient identification is not successful.\n   - It states: \"As a result, patients may be difficult to identify and access, the addressable patient population in the U.S., Canada, the EU and elsewhere may turn out to be lower than expected, or patients may not be otherwise amenable to treatment with our products, all of which would adversely affect our business, financial condition, results of operations and prospects.\"\n\n4. **Reimbursement and Coverage**:\n   - The document highlights the importance of obtaining coverage and reimbursement from third-party payors. If patient identification is unsuccessful, it can affect the perceived medical necessity and cost-effectiveness of the product, which are key factors in obtaining reimbursement.\n   - It mentions: \"The availability of adequate coverage by and reimbursement from government and third-party payors.\"\n\n5. **Market Acceptance**:\n   - The document also discusses the need for market acceptance by physicians, patients, and third-party payors. If patient identification is unsuccessful, it can lead to a smaller market and reduced acceptance.\n   - It states: \"AMX0035 may fail to maintain the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for continued commercial success or to remain"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 32000, "result": 1.0, "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?", "options": {"A": "Acquisition of NYSE and Nasdaq", "B": "Acquisition of FFIEC and CFPB", "C": "Acquisition of Ellie Mae, Inc. and Black Knight", "D": "Acquisition of NYMEX and ICE", "E": "Acquisition of Fannie Mae and Freddie Mac", "F": "Acquisition of FHA and VA"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Identify Relevant Information**:\n   - The document mentions several acquisitions, including Ellie Mae, Inc. and Black Knight.\n   - It specifically states that these acquisitions have increased regulatory scrutiny from U.S. regulatory bodies that regulate the U.S. residential mortgage industry, including the FFIEC and CFPB.\n\n2. **Locate Specific References**:\n   - The relevant section is: \"Our acquisitions of Ellie Mae, Inc., or Ellie Mae, in 2020 and Black Knight in 2023 expose us to increased regulatory scrutiny from U.S. regulatory bodies that regulate the U.S. residential mortgage industry, including the FFIEC and its member agencies, and the CFPB, among others.\"\n\n3. **Match the Information to the Options**:\n   - Option C: \"Acquisition of Ellie Mae, Inc. and Black Knight\" matches the information provided in the document.\n\n4. **Conclusion**:\n   - The acquisitions that increased regulatory scrutiny in the U.S. residential mortgage industry are Ellie Mae, Inc. and Black Knight.\n\nTherefore, the correct answer is **Option C: Acquisition of Ellie Mae, Inc. and Black Knight**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 32000, "result": 1.0, "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?", "options": {"A": "Offering personal security devices", "B": "Weekly meetings with cybersecurity experts", "C": "Regular cybersecurity training and resources", "D": "Outsourcing training to third-party vendors", "E": "Developing a custom security software", "F": "Limiting internet access during work hours"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Identify the Relevant Section**: The document is extensive, but the section that discusses Brighthouse's Security Awareness Program is found under \"Cybersecurity Risk Management Program and Strategy\" in the \"Item 1C. Cybersecurity\" section.\n\n2. **Extract Key Information**: The relevant paragraph states:\n   - \"Through our Security Awareness Program, we provide our employees with regular cybersecurity training and educational resources to help ensure that they remain vigilant against threats.\"\n   - \"These include frequent simulations, newsletters, alerts, e-mail reminders, and a mandatory annual cybersecurity awareness training course for all employees.\"\n\n3. **Match the Information to the Options**:\n   - **Option A: Offering personal security devices** - The document does not mention offering personal security devices.\n   - **Option B: Weekly meetings with cybersecurity experts** - The document does not mention weekly meetings with cybersecurity experts.\n   - **Option C: Regular cybersecurity training and resources** - The document explicitly mentions \"regular cybersecurity training and educational resources.\"\n   - **Option D: Outsourcing training to third-party vendors** - The document does not mention outsourcing training to third-party vendors.\n   - **Option E: Developing a custom security software** - The document does not mention developing custom security software.\n   - **Option F: Limiting internet access during work hours** - The document does not mention limiting internet access during work hours.\n\n4. **Conclusion**: Based on the information provided in the document, the method used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats is **Option C: Regular cybersecurity training and resources**.\n\nTherefore, the correct answer is **Option C: Regular cybersecurity training and resources**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 64000, "result": 1.0, "question": "What is the main reason preliminary data should be viewed with caution?", "options": {"A": "Preliminary data are always incorrect", "B": "Final data may differ significantly from preliminary data after audits", "C": "Preliminary data are approved by regulatory agencies", "D": "Preliminary data are completed and cannot change", "E": "Preliminary data are irrelevant to business decisions", "F": "Preliminary data are never published"}, "LLM_original_answer": ["The main reason preliminary data should be viewed with caution is:\n\n**B: Final data may differ significantly from preliminary data after audits**\n\n### Chain of Thought:\n1. **Review the Document**: The document discusses various aspects of clinical trials and regulatory processes, including the importance of preliminary data and the potential for changes in the final data.\n2. **Identify Relevant Section**: The relevant section is: \"Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.\"\n3. **Analyze the Statement**: This statement clearly indicates that preliminary data can change significantly as more data becomes available and after audits and verification procedures.\n4. **Evaluate the Options**:\n   - **A: Preliminary data are always incorrect** - This is too absolute and not supported by the document.\n   - **B: Final data may differ significantly from preliminary data after audits** - This aligns with the document's statement.\n   - **C: Preliminary data are approved by regulatory agencies** - The document does not suggest this.\n   - **D: Preliminary data are completed and cannot change** - This contradicts the document.\n   - **E: Preliminary data are irrelevant to business decisions** - The document does not suggest this.\n   - **F: Preliminary data are never published** - The document explicitly states that preliminary data is published from time to time.\n5. **Conclusion**: Option B is the most accurate and supported by the document.\n\nThus, the correct answer is **B: Final data may differ significantly from preliminary data after audits**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 64000, "result": 1.0, "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?", "options": {"A": "Mining proceeds increase", "B": "Mining proceeds remain unchanged", "C": "Transaction fees decrease", "D": "Mining proceeds decrease", "E": "Network hash rate decreases", "F": "Transaction validation is faster"}, "LLM_original_answer": ["To answer the question \"What happens to bitcoin mining proceeds when there is an increase in network difficulty?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Understanding Network Difficulty**:\n   - The document states: \"The increase in bitcoin\u2019s network hash rate results in a regular increase in the cryptographic complexity associated with solving blocks on its blockchain, or its difficulty.\"\n   - This means that as more miners join the network and the total hash rate increases, the difficulty of mining (i.e., the computational effort required to solve a block) also increases.\n\n2. **Impact on Mining Proceeds**:\n   - The document further explains: \"Increased difficulty reduces the mining proceeds of the equipment proportionally and eventually requires bitcoin miners to upgrade their mining equipment to remain profitable and compete effectively with other miners.\"\n   - This indicates that when the network difficulty increases, the same mining equipment will find it harder to solve blocks, leading to a proportional reduction in the mining proceeds.\n\n3. **Evaluating the Options**:\n   - **Option A: Mining proceeds increase** - This is incorrect because increased difficulty makes it harder to mine, reducing the proceeds.\n   - **Option B: Mining proceeds remain unchanged** - This is incorrect because the document clearly states that increased difficulty reduces mining proceeds.\n   - **Option C: Transaction fees decrease** - The document does not provide information suggesting that transaction fees decrease with increased network difficulty.\n   - **Option D: Mining proceeds decrease** - This aligns with the document's statement that increased difficulty reduces mining proceeds.\n   - **Option E: Network hash rate decreases** - This is incorrect because the document states that network hash rate increases, leading to increased difficulty.\n   - **Option F: Transaction validation is faster** - The document does not suggest that transaction validation becomes faster with increased network difficulty; in fact, it implies the opposite, as increased difficulty makes it harder to solve blocks.\n\nBased on the information provided in the document, the correct answer is:\n\n**D: Mining proceeds decrease**\n\nThis is because the document explicitly states that increased network difficulty reduces the mining proceeds of the equipment proportionally."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 64000, "result": 1.0, "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?", "options": {"A": "Securing insurance for each transaction", "B": "Selecting highly rated banks as counterparties", "C": "Transferring risks to third-party investors", "D": "Converting all debts to local currency", "E": "Engaging with a single counterparty for all transactions", "F": "Using fixed interest rates only"}, "LLM_original_answer": ["To answer the question, \"What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the Context of Credit Risk**:\n   - The document mentions that Duke Energy is exposed to credit risk from transactions with counterparties to cross-currency swaps related to future interest and principal payments.\n\n2. **Examine the Strategies Mentioned**:\n   - The document states that Duke Energy selects highly rated banks as counterparties.\n   - Duke Energy allocates the hedge for each debt issuance across multiple counterparties.\n   - Master agreements with the counterparties impose collateral requirements on the parties in certain circumstances indicative of material deterioration in a party's creditworthiness.\n   - Collateral agreements generally also provide that the failure to post collateral when required is sufficient cause to terminate transactions and liquidate all positions.\n\n3. **Match the Strategies to the Options**:\n   - **Option A: Securing insurance for each transaction** - The document does not mention securing insurance for cross-currency swaps.\n   - **Option B: Selecting highly rated banks as counterparties** - This is explicitly mentioned in the document.\n   - **Option C: Transferring risks to third-party investors** - The document does not mention transferring risks to third-party investors for cross-currency swaps.\n   - **Option D: Converting all debts to local currency** - The document does not mention converting all debts to local currency.\n   - **Option E: Engaging with a single counterparty for all transactions** - The document mentions allocating the hedge across multiple counterparties, not a single counterparty.\n   - **Option F: Using fixed interest rates only** - The document does not mention using fixed interest rates only for cross-currency swaps.\n\n4. **Conclusion**:\n   - The strategy that Duke Energy uses to mitigate credit risk with counterparties in cross-currency swaps is **Option B: Selecting highly rated banks as counterparties**.\n\nTherefore, the correct answer is **Option B: Selecting highly rated banks as counterparties**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 64000, "result": 1.0, "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?", "options": {"A": "Reclassified as current assets", "B": "Reclassified as non-current liabilities", "C": "Reclassified to assets and liabilities of discontinued operations", "D": "Included in the net loss calculation", "E": "Merged with assets and liabilities of continuing operations", "F": "Removed from all financial statements"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Context**:\n   - The document discusses various financial and operational aspects of Eastern Bankshares, Inc. and its subsidiary, Eastern Bank.\n   - It mentions the sale of the insurance agency business and the reclassification of related assets and liabilities.\n\n2. **Locate the Specific Information**:\n   - The relevant section is found in \"Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\" under \"Summary of Results of Operations\" and \"Results of Operations\".\n   - Specifically, the document states: \"In the third quarter, following management\u2019s decision to sell our insurance agency business, we reclassified the related assets and liabilities to assets and liabilities of discontinued operations, respectively, on our Consolidated Balance Sheets.\"\n\n3. **Analyze the Information**:\n   - The reclassification was made in the third quarter.\n   - The assets and liabilities related to the insurance agency business were moved to \"assets and liabilities of discontinued operations\" on the Consolidated Balance Sheets.\n   - This reclassification is a standard accounting practice when a business segment is being sold or is no longer part of the ongoing operations.\n\n4. **Match the Information to the Options**:\n   - Option A: Reclassified as current assets - This is not correct because the reclassification was to discontinued operations, not current assets.\n   - Option B: Reclassified as non-current liabilities - This is not correct because the reclassification was to discontinued operations, not non-current liabilities.\n   - Option C: Reclassified to assets and liabilities of discontinued operations - This matches the information provided in the document.\n   - Option D: Included in the net loss calculation - While the sale of the insurance agency business may have contributed to the net loss, the reclassification itself was to assets and liabilities of discontinued operations.\n   - Option E: Merged with assets and liabilities of continuing operations - This is not correct because the reclassification was to discontinued operations, not merged with continuing operations.\n   - Option F: Removed from all financial statements - This is not correct because the assets and liabilities were reclassified, not removed entirely.\n\n5. **Conclusion**:\n   - The correct answer is Option C: Reclassified to assets and liabilities of discontinued operations.\n\nTherefore, the change made to the presentation of the insurance agency business in the third quarter on the financial statements was to reclassify the related assets and liabilities to assets and liabilities of discontinued operations."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 64000, "result": 1.0, "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?", "options": {"A": "They may prioritize our drug candidates over their own.", "B": "They are guaranteed to pursue commercialization of all drug candidates.", "C": "They have unlimited rights to select any target without restriction.", "D": "They may develop competing products independently or with third parties.", "E": "They ensure the protection and enforcement of our intellectual property.", "F": "They cannot change their strategic focus once a project starts."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Collaborators**: The document mentions collaborations with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Seagen Inc. (now a part of Pfizer Inc. (Pfizer)).\n\n2. **Locate the Risk Section**: The document includes a section titled \"Risks Related to Dependence on Third Parties,\" which discusses the risks associated with these collaborations.\n\n3. **Analyze the Risks**: Within this section, the following risks are mentioned:\n   - **Collaborators' Discretion**: \"Collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations with us.\"\n   - **Collaborators' Strategic Focus**: \"Collaborators may not pursue development and commercialization of any drug candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator\u2019s strategic focus or available funding or external factors such as an acquisition or business combination that diverts resources or creates competing priorities.\"\n   - **Competing Products**: \"Collaborators could develop independently, or develop with third parties, products that compete directly or indirectly with our products or drug candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours.\"\n\n4. **Match the Risk to the Options**:\n   - **Option A**: \"They may prioritize our drug candidates over their own.\" - This is not mentioned as a risk.\n   - **Option B**: \"They are guaranteed to pursue commercialization of all drug candidates.\" - This is not mentioned as a risk.\n   - **Option C**: \"They have unlimited rights to select any target without restriction.\" - This is not mentioned as a risk.\n   - **Option D**: \"They may develop competing products independently or with third parties.\" - This matches the risk mentioned in the document.\n   - **Option E**: \"They ensure the protection and enforcement of our intellectual property.\" - This is not mentioned as a risk.\n   - **Option F**: \"They cannot change their strategic focus once a project starts.\" - This is not mentioned as a risk.\n\n5. **Conclusion**: The risk mentioned in the document that aligns with the options provided is that collaborators may develop competing products independently or with third parties.\n\nTherefore, the correct answer is **D:"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 64000, "result": 1.0, "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?", "options": {"A": "1 million loans", "B": "1.3 million loans", "C": "2 million loans", "D": "2.3 million loans", "E": "500,000 loans", "F": "3 million loans"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant information from the provided document.\n2. Match the identified information to the question.\n3. Select the correct answer from the given options.\n\n### Step 1: Identify the Relevant Information\nThe relevant information is found in the following excerpt from the document:\n\n\"As of December 31, 2023, we serviced or subserviced 1.3 million loans with a total UPB of $288.4 billion on behalf of more than 3,900 investors and 113 subservicing clients.\"\n\n### Step 2: Match the Identified Information to the Question\nThe question asks: \"As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?\"\n\nFrom the excerpt, we can see that:\n- The total UPB of the loans serviced or subserviced is $288.4 billion.\n- The number of loans serviced or subserviced is 1.3 million.\n\n### Step 3: Select the Correct Answer from the Given Options\nThe options provided are:\nA: 1 million loans\nB: 1.3 million loans\nC: 2 million loans\nD: 2.3 million loans\nE: 500,000 loans\nF: 3 million loans\n\nThe correct answer is **B: 1.3 million loans**.\n\n### Final Answer\nThe company serviced or subserviced **1.3 million loans** with a total UPB of $288.4 billion as of December 31, 2023."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 64000, "result": 1.0, "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?", "options": {"A": "Immediate market launch", "B": "Significant additional clinical and non-clinical development", "C": "Only initial trials in humans", "D": "Direct approval by local regulatory authorities", "E": "Exclusive manufacturing rights", "F": "Limited marketing efforts"}, "LLM_original_answer": ["To answer the question \"What is necessary before the company\u2019s product candidates can be successfully commercialized?\" based on the provided document, let's break down the key points:\n\n1. **Regulatory Approval**: The document emphasizes that the company must obtain regulatory approval from the FDA or other regulatory authorities before commercializing any product candidates. This involves a lengthy and complex process, including preclinical studies, clinical trials, and the submission of a Biologics License Application (BLA).\n\n2. **Clinical and Non-Clinical Development**: The document states that all product candidates will require significant additional clinical and non-clinical development. This includes:\n   - **Preclinical Studies**: Conducting laboratory tests, animal studies, and formulation studies to establish the safety and efficacy of the product.\n   - **Clinical Trials**: Performing well-controlled human clinical trials to demonstrate the safety and efficacy of the product for its intended use.\n\n3. **Manufacturing and Quality Control**: The document highlights the need to develop processes suitable for manufacturing and to ensure compliance with Good Manufacturing Practice (cGMP) and Good Tissue Practice (cGTP) requirements. This includes:\n   - **Manufacturing Processes**: Ensuring that the manufacturing processes are capable of consistently producing quality batches of the drug candidate.\n   - **Quality Control**: Developing methods for testing the identity, strength, quality, and purity of the final drug product.\n   - **Stability Studies**: Conducting stability studies to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.\n\n4. **Intellectual Property**: The document mentions the importance of obtaining, maintaining, and protecting intellectual property, including patents, trademarks, and trade secrets. This is crucial for maintaining a competitive advantage and protecting the company's proprietary technology.\n\n5. **Coverage and Reimbursement**: The document notes that the success of the product candidates will depend on the availability of reimbursement from third-party payors, including government healthcare programs, managed care organizations, and private health insurers. Adequate reimbursement is necessary to ensure that the products are commercially viable.\n\nGiven these points, the most comprehensive and accurate answer to the question is:\n\n**B: Significant additional clinical and non-clinical development**\n\nThis option encompasses the need for extensive preclinical and clinical testing, as well as the development of robust manufacturing processes and quality control measures, which are all critical steps before a product can be commercialized. The other options, while important, are either too narrow (e.g., only initial trials in humans) or not directly related to the commercialization process"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 64000, "result": 1.0, "question": "What could adversely affect the business and operations if patient identification is unsuccessful?", "options": {"A": "Increased approval rates by regulatory authorities", "B": "Enhanced disease awareness among healthcare professionals", "C": "Larger addressable patient population than expected", "D": "Difficulty in identifying and accessing patients", "E": "Greater market acceptance of AMX0035", "F": "Increased profitability and business expansion"}, "LLM_original_answer": ["The correct answer to the question \"What could adversely affect the business and operations if patient identification is unsuccessful?\" is:\n\n**D: Difficulty in identifying and accessing patients**\n\n### Chain of Thought:\n1. **Context from the Document:**\n   - The document discusses the importance of patient identification and access in the context of commercializing and developing pharmaceutical products, particularly for rare diseases like ALS.\n   - It mentions that \"Even if AMX0035 or any other current or future product candidate is approved, the approval may be subject to limitations on the indications or uses for which the product may be marketed or to the conditions of approval, including the requirement in the U.S. to implement a Risk Evaluation and Mitigation Strategy (REMS).\"\n   - The document also states, \"Our ability to proactively educate health care professionals and patients may be limited based on the marketing restrictions in a given jurisdiction, specifically as they relate to the particular labeling approved by the applicable health authority.\"\n   - Additionally, it notes, \"We may be required to produce clinical data supporting the contribution of each component when present at the levels included in the fixed-dose combination in order to obtain marketing authorization in the EU.\"\n\n2. **Relevance to Patient Identification:**\n   - **Difficulty in identifying and accessing patients** directly impacts the ability to enroll patients in clinical trials and to market the product effectively.\n   - If patient identification is unsuccessful, it can lead to delays in clinical trials, which can then delay regulatory approval and commercialization.\n   - The document specifically mentions that \"We may be required to produce clinical data supporting the contribution of each component when present at the levels included in the fixed-dose combination in order to obtain marketing authorization in the EU,\" which implies that without proper patient identification and access, generating the necessary clinical data can be challenging.\n\n3. **Elimination of Other Options:**\n   - **A: Increased approval rates by regulatory authorities** - This is not a negative outcome and would not adversely affect the business.\n   - **B: Enhanced disease awareness among healthcare professionals** - This is generally a positive outcome and would not adversely affect the business.\n   - **C: Larger addressable patient population than expected** - A larger patient population is generally beneficial and would not adversely affect the business.\n   - **E: Greater market acceptance of AMX0035** - This is a positive outcome and would not adversely affect the business.\n   - **F: Increased profitability and business expansion** - This is a positive outcome and would not adversely"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 64000, "result": 1.0, "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?", "options": {"A": "Acquisition of NYSE and Nasdaq", "B": "Acquisition of FFIEC and CFPB", "C": "Acquisition of Ellie Mae, Inc. and Black Knight", "D": "Acquisition of NYMEX and ICE", "E": "Acquisition of Fannie Mae and Freddie Mac", "F": "Acquisition of FHA and VA"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Identify Relevant Information**:\n   - The document mentions the acquisition of Black Knight, Inc. and Ellie Mae, Inc.\n   - It specifically states that these acquisitions have increased regulatory scrutiny from U.S. regulatory bodies that regulate the U.S. residential mortgage industry, including the FFIEC and CFPB.\n\n2. **Locate Specific References**:\n   - **Black Knight, Inc. Acquisition**:\n     - \"On September 5, 2023, we acquired Black Knight, Inc., or Black Knight, a software, data and analytics company that serves the housing finance continuum, including real estate data, mortgage lending and servicing, as well as the secondary markets.\"\n     - \"Following the acquisition of Black Knight, we have enhanced oversight from the FFIEC and CFPB related to the inclusion of Black Knight's services and product offerings in our portfolio.\"\n   - **Ellie Mae, Inc. Acquisition**:\n     - \"In 2020, we acquired Ellie Mae, Inc., or Ellie Mae, a leading cloud-based platform for the mortgage finance industry.\"\n     - \"Our acquisitions of Ellie Mae, Inc., or Ellie Mae, in 2020 and Black Knight in 2023 expose us to increased regulatory scrutiny from U.S. regulatory bodies that regulate the U.S. residential mortgage industry, including the FFIEC and its member agencies, and the CFPB, among others.\"\n\n3. **Evaluate the Options**:\n   - **Option A**: Acquisition of NYSE and Nasdaq - Not mentioned in the context of increased regulatory scrutiny in the U.S. residential mortgage industry.\n   - **Option B**: Acquisition of FFIEC and CFPB - These are regulatory bodies, not companies that can be acquired.\n   - **Option C**: Acquisition of Ellie Mae, Inc. and Black Knight - Both are mentioned as acquisitions that increased regulatory scrutiny in the U.S. residential mortgage industry.\n   - **Option D**: Acquisition of NYMEX and ICE - Not mentioned in the context of increased regulatory scrutiny in the U.S. residential mortgage industry.\n   - **Option E**: Acquisition of Fannie Mae and Freddie Mac - Not mentioned in the context of increased regulatory scrutiny in the U.S. residential mortgage industry.\n   - **Option F**: Acquisition of FHA and VA - These are government agencies, not companies that can be acquired.\n\n4. **Conclusion**:\n   - The"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 64000, "result": 1.0, "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?", "options": {"A": "Offering personal security devices", "B": "Weekly meetings with cybersecurity experts", "C": "Regular cybersecurity training and resources", "D": "Outsourcing training to third-party vendors", "E": "Developing a custom security software", "F": "Limiting internet access during work hours"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The document contains a section on \"Cybersecurity Risk Management Program and Strategy\" which is likely to contain information about Brighthouse's Security Awareness Program.\n\n2. **Extract the relevant information**:\n   - The document states: \"Through our Security Awareness Program, we provide our employees with regular cybersecurity training and educational resources to help ensure that they remain vigilant against threats.\"\n   - It further mentions: \"These include frequent simulations, newsletters, alerts, e-mail reminders, and a mandatory annual cybersecurity awareness training course for all employees.\"\n\n3. **Analyze the extracted information**:\n   - The Security Awareness Program provides regular cybersecurity training and educational resources.\n   - It includes frequent simulations, newsletters, alerts, e-mail reminders, and a mandatory annual training course.\n\n4. **Match the extracted information to the options**:\n   - **Option A: Offering personal security devices** - The document does not mention offering personal security devices.\n   - **Option B: Weekly meetings with cybersecurity experts** - The document does not mention weekly meetings with cybersecurity experts.\n   - **Option C: Regular cybersecurity training and resources** - This matches the information provided in the document.\n   - **Option D: Outsourcing training to third-party vendors** - The document does not mention outsourcing training to third-party vendors.\n   - **Option E: Developing a custom security software** - The document does not mention developing custom security software.\n   - **Option F: Limiting internet access during work hours** - The document does not mention limiting internet access during work hours.\n\n5. **Conclusion**:\n   - The method used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats is **Regular cybersecurity training and resources**.\n\nTherefore, the correct answer is **Option C: Regular cybersecurity training and resources**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 96000, "result": 1.0, "question": "What is the main reason preliminary data should be viewed with caution?", "options": {"A": "Preliminary data are always incorrect", "B": "Final data may differ significantly from preliminary data after audits", "C": "Preliminary data are approved by regulatory agencies", "D": "Preliminary data are completed and cannot change", "E": "Preliminary data are irrelevant to business decisions", "F": "Preliminary data are never published"}, "LLM_original_answer": ["The main reason preliminary data should be viewed with caution is:\n\n**B: Final data may differ significantly from preliminary data after audits**\n\n### Chain of Thought:\n1. **Understanding the Question**: The question asks for the primary reason to be cautious about preliminary data. This implies we need to identify the most significant risk or limitation associated with preliminary data.\n\n2. **Analyzing the Document**: The document provided does not directly address the reasons for viewing preliminary data with caution. However, it does discuss the clinical trial process and the importance of data accuracy and reliability.\n\n3. **Clinical Trial Context**: In the context of clinical trials, preliminary data are often based on early results or a subset of the total data. The document mentions that:\n   - Clinical trials are lengthy and expensive processes with uncertain outcomes.\n   - Data from clinical trials are often subject to various interpretations and analyses.\n   - Preliminary data from clinical trials may change as more participant data become available and are subject to audit and verification procedures.\n\n4. **Evaluating the Options**:\n   - **A: Preliminary data are always incorrect** - This is too absolute. Preliminary data can be correct but are not final.\n   - **B: Final data may differ significantly from preliminary data after audits** - This is a reasonable and common issue. Preliminary data can change based on further analysis and audits.\n   - **C: Preliminary data are approved by regulatory agencies** - This is not typically the case. Regulatory agencies usually require final, comprehensive data.\n   - **D: Preliminary data are completed and cannot change** - This is incorrect. Preliminary data can be updated as more data are collected.\n   - **E: Preliminary data are irrelevant to business decisions** - This is not true. Preliminary data can inform initial decisions but should not be the sole basis.\n   - **F: Preliminary data are never published** - This is false. Preliminary data are often published to provide early insights.\n\n5. **Conclusion**: Option B is the most accurate and relevant reason for viewing preliminary data with caution. It reflects the common practice in clinical trials and scientific research where initial findings can be refined or altered based on comprehensive data and audits.\n\nThus, the correct answer is **B: Final data may differ significantly from preliminary data after audits**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 96000, "result": 1.0, "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?", "options": {"A": "Mining proceeds increase", "B": "Mining proceeds remain unchanged", "C": "Transaction fees decrease", "D": "Mining proceeds decrease", "E": "Network hash rate decreases", "F": "Transaction validation is faster"}, "LLM_original_answer": ["To answer the question \"What happens to bitcoin mining proceeds when there is an increase in network difficulty?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Understanding Network Difficulty**:\n   - The document states: \"The increase in bitcoin\u2019s network hash rate results in a regular increase in the cryptographic complexity associated with solving blocks on its blockchain, or its difficulty.\"\n   - This means that as more miners join the network and the total hash rate increases, the difficulty of mining (i.e., the computational effort required to solve a block) also increases.\n\n2. **Impact on Mining Proceeds**:\n   - The document further explains: \"Increased difficulty reduces the mining proceeds of the equipment proportionally and eventually requires bitcoin miners to upgrade their mining equipment to remain profitable and compete effectively with other miners.\"\n   - This indicates that when the network difficulty increases, the same mining equipment will find it harder to solve blocks, leading to a proportional reduction in the number of blocks it can solve and, consequently, a reduction in the mining proceeds.\n\n3. **Economic Implications**:\n   - The document also mentions: \"If the award of new digital assets for mining declines, and/or if transaction fees are not sufficiently high, profit margins for mining operators may be reduced, and such operators may be more likely to sell a higher percentage of their digital assets.\"\n   - This suggests that higher difficulty can lead to lower profit margins, which might cause miners to sell more of their mined bitcoin to cover operational costs, potentially affecting the market price of bitcoin.\n\n4. **Conclusion**:\n   - Based on the information provided, the correct answer is **D: Mining proceeds decrease**. This is because an increase in network difficulty makes it harder for the same mining equipment to solve blocks, leading to a proportional reduction in the number of blocks solved and, thus, a decrease in mining proceeds.\n\nTherefore, the answer to the question is **D: Mining proceeds decrease**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 96000, "result": 1.0, "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?", "options": {"A": "Securing insurance for each transaction", "B": "Selecting highly rated banks as counterparties", "C": "Transferring risks to third-party investors", "D": "Converting all debts to local currency", "E": "Engaging with a single counterparty for all transactions", "F": "Using fixed interest rates only"}, "LLM_original_answer": ["To answer the question, \"What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?\" we need to look for information in the provided document that specifically addresses Duke Energy's approach to managing credit risk in financial derivatives, particularly cross-currency swaps.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document discusses various risk management strategies, including credit risk, in the \"Risk Management Policies\" and \"Derivatives and Hedging\" sections.\n\n2. **Examine Credit Risk Management:**\n   - The document states: \"Duke Energy selects highly rated banks as counterparties and allocates the hedge for each debt issuance across multiple counterparties.\"\n   - This indicates that Duke Energy is selective about the banks it works with, choosing those with high credit ratings to minimize the risk of default.\n\n3. **Examine Cross-Currency Swaps:**\n   - The document mentions: \"Duke Energy is subject to credit risk from transactions with counterparties to cross-currency swaps related to future interest and principal payments.\"\n   - It further states: \"The master agreements with the counterparties impose collateral requirements on the parties in certain circumstances indicative of material deterioration in a party's creditworthiness.\"\n   - This suggests that Duke Energy uses collateral agreements to mitigate credit risk, requiring counterparties to post collateral if their creditworthiness deteriorates.\n\n4. **Evaluate the Options:**\n   - **Option A: Securing insurance for each transaction** - The document does not mention securing insurance for each transaction.\n   - **Option B: Selecting highly rated banks as counterparties** - This is explicitly mentioned in the document.\n   - **Option C: Transferring risks to third-party investors** - The document does not mention transferring risks to third-party investors.\n   - **Option D: Converting all debts to local currency** - The document does not mention converting all debts to local currency.\n   - **Option E: Engaging with a single counterparty for all transactions** - The document mentions allocating the hedge across multiple counterparties, not a single counterparty.\n   - **Option F: Using fixed interest rates only** - The document does not mention using fixed interest rates only; it discusses managing interest rate risk through various derivatives.\n\n### Conclusion:\nBased on the information provided in the document, the strategy Duke Energy uses to mitigate credit risk with counterparties in cross-currency swaps is **selecting highly rated banks as counterparties**.\n\nTherefore, the correct answer is **"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 96000, "result": 1.0, "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?", "options": {"A": "Reclassified as current assets", "B": "Reclassified as non-current liabilities", "C": "Reclassified to assets and liabilities of discontinued operations", "D": "Included in the net loss calculation", "E": "Merged with assets and liabilities of continuing operations", "F": "Removed from all financial statements"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The document mentions the sale of the insurance agency business and the reclassification of related assets and liabilities. The key section is in \"Item 7. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\" under \"Overview.\"\n\n2. **Extract the relevant information**:\n   - **Sale of Insurance Agency Business**: \"On October 31, 2023, we sold substantially all of the assets and transferred certain liabilities of our insurance agency business.\"\n   - **Reclassification**: \"In the third quarter, following management\u2019s decision to sell our insurance agency business, we reclassified the related assets and liabilities to assets and liabilities of discontinued operations, respectively, on our Consolidated Balance Sheets.\"\n\n3. **Match the information to the options**:\n   - **Option A**: Reclassified as current assets - This is not mentioned.\n   - **Option B**: Reclassified as non-current liabilities - This is not mentioned.\n   - **Option C**: Reclassified to assets and liabilities of discontinued operations - This matches the information provided.\n   - **Option D**: Included in the net loss calculation - This is not mentioned.\n   - **Option E**: Merged with assets and liabilities of continuing operations - This is not mentioned.\n   - **Option F**: Removed from all financial statements - This is not mentioned.\n\n4. **Conclusion**:\n   - The document clearly states that the assets and liabilities of the insurance agency business were reclassified to assets and liabilities of discontinued operations on the Consolidated Balance Sheets.\n\nTherefore, the correct answer is **Option C: Reclassified to assets and liabilities of discontinued operations**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 96000, "result": 1.0, "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?", "options": {"A": "They may prioritize our drug candidates over their own.", "B": "They are guaranteed to pursue commercialization of all drug candidates.", "C": "They have unlimited rights to select any target without restriction.", "D": "They may develop competing products independently or with third parties.", "E": "They ensure the protection and enforcement of our intellectual property.", "F": "They cannot change their strategic focus once a project starts."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The section that discusses the risks related to collaborations is \"Risks Related to Dependence on Third Parties.\"\n\n2. **Extract the relevant information**:\n   - The document mentions that collaborators, such as Gilead, Sanofi, and Pfizer, have significant discretion in determining the efforts and resources they will apply to collaborations with the company.\n   - It also states that collaborators may not pursue development and commercialization of any drug candidates or may elect not to continue or renew development or commercialization programs based on various factors, including clinical trial results, changes in the collaborator\u2019s strategic focus, available funding, or external factors such as an acquisition or business combination that diverts resources or creates competing priorities.\n   - Additionally, the document notes that collaborators could develop independently, or develop with third parties, products that compete directly or indirectly with the company's products or drug candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive.\n\n3. **Evaluate the options**:\n   - **Option A**: \"They may prioritize our drug candidates over their own.\" - This is not mentioned in the document.\n   - **Option B**: \"They are guaranteed to pursue commercialization of all drug candidates.\" - The document explicitly states that this is not the case.\n   - **Option C**: \"They have unlimited rights to select any target without restriction.\" - The document mentions that Gilead and Sanofi have broad option rights to select targets, but these are not unlimited.\n   - **Option D**: \"They may develop competing products independently or with third parties.\" - This is directly mentioned in the document.\n   - **Option E**: \"They ensure the protection and enforcement of our intellectual property.\" - The document mentions that collaborators may not properly obtain, maintain, enforce, or defend the company's intellectual property.\n   - **Option F**: \"They cannot change their strategic focus once a project starts.\" - The document states that collaborators can change their strategic focus.\n\n4. **Conclusion**:\n   - The risk mentioned in the document that is most closely aligned with the options provided is that collaborators may develop competing products independently or with third parties.\n\nTherefore, the correct answer is **Option D: They may develop competing products independently or with third parties.**"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 96000, "result": 1.0, "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?", "options": {"A": "1 million loans", "B": "1.3 million loans", "C": "2 million loans", "D": "2.3 million loans", "E": "500,000 loans", "F": "3 million loans"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant information in the document**: The document should contain specific details about the number of loans serviced or subserviced as of December 31, 2023, and the total UPB of these loans.\n\n2. **Extract the relevant data**: Look for the exact numbers and UPB values mentioned.\n\n3. **Match the extracted data to the question**: Verify if the extracted data matches the UPB of $288.4 billion and find the corresponding number of loans.\n\n4. **Select the correct option**: Choose the option that matches the extracted data.\n\n### Step 1: Identify the relevant information in the document\n\nThe relevant information is found in the \"Servicing\" section of the document, specifically in the following paragraph:\n\n> As of December 31, 2023, we serviced 1.3 million mortgage loans with an aggregate UPB of $288.4 billion, a decrease of 2% and 0.5%, respectively, from December 31, 2022.\n\n### Step 2: Extract the relevant data\n\n- **Number of loans serviced or subserviced**: 1.3 million loans\n- **Total UPB**: $288.4 billion\n\n### Step 3: Match the extracted data to the question\n\nThe document states that as of December 31, 2023, the company serviced 1.3 million loans with a total UPB of $288.4 billion. This matches the UPB mentioned in the question.\n\n### Step 4: Select the correct option\n\nThe correct option is:\n\n**B: 1.3 million loans**\n\nThus, the answer to the question is **B: 1.3 million loans**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 96000, "result": 1.0, "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?", "options": {"A": "Immediate market launch", "B": "Significant additional clinical and non-clinical development", "C": "Only initial trials in humans", "D": "Direct approval by local regulatory authorities", "E": "Exclusive manufacturing rights", "F": "Limited marketing efforts"}, "LLM_original_answer": ["To answer the question \"What is necessary before the company\u2019s product candidates can be successfully commercialized?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Clinical and Non-Clinical Development**:\n   - The document emphasizes that the company's product candidates are in various stages of development, including preclinical studies and clinical trials.\n   - It states, \"All of our product candidates will require significant additional clinical and non-clinical development, review and approval by the FDA or other regulatory authorities in one or more jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before they can be successfully commercialized.\"\n\n2. **Regulatory Approval**:\n   - The document outlines the extensive regulatory process required by the FDA, including the submission of an Investigational New Drug (IND) application, conducting clinical trials, and obtaining a Biologics License Application (BLA) approval.\n   - It mentions, \"Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication.\"\n\n3. **Manufacturing**:\n   - The company needs to ensure that it can manufacture its product candidates consistently and at a high quality.\n   - It states, \"We will need to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.\"\n\n4. **Marketing and Sales**:\n   - The document highlights the need for a robust marketing and sales strategy to ensure market acceptance.\n   - It mentions, \"We currently have no sales, marketing or distribution capabilities and have no experience as a company in marketing products.\"\n\n5. **Intellectual Property**:\n   - The company must protect its intellectual property and ensure it has the necessary rights to commercialize its products.\n   - It states, \"Our success depends in part on our ability to obtain, maintain and protect our proprietary technology and intellectual property and proprietary rights and to operate our business without infringing, misappropriating and otherwise violating the intellectual property and proprietary rights of third parties.\"\n\n6. **Reimbursement**:\n   - The document notes the importance of obtaining adequate reimbursement from third-party payors.\n   - It mentions, \"The availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities is essential for most patients to be able to afford treatments such as cell therapy products.\"\n\nGiven these points, the most comprehensive and accurate answer is"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 96000, "result": 1.0, "question": "What could adversely affect the business and operations if patient identification is unsuccessful?", "options": {"A": "Increased approval rates by regulatory authorities", "B": "Enhanced disease awareness among healthcare professionals", "C": "Larger addressable patient population than expected", "D": "Difficulty in identifying and accessing patients", "E": "Greater market acceptance of AMX0035", "F": "Increased profitability and business expansion"}, "LLM_original_answer": ["To answer the question \"What could adversely affect the business and operations if patient identification is unsuccessful?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Patient Identification and Market Access**:\n   - The document mentions that patient identification is crucial for the commercial success of AMX0035. It states, \"Our ability to recognize revenues from product sales depends heavily on our success in: ... appropriately identifying patients with the neurological diseases targeted by AMX0035 or any other current or future product candidates.\"\n   - It also notes, \"If we are unable to identify patients and successfully commercialize AMX0035 or any other current or future product candidates with attractive market opportunities, our future product revenues may be smaller than anticipated, and our business may suffer.\"\n\n2. **Clinical Trials and Regulatory Approval**:\n   - The document highlights the importance of clinical trials and the need to enroll and retain patients. It states, \"Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in these trials.\"\n   - It further mentions, \"If the actual number of patients with these diseases is smaller than we anticipate, we may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of AMX0035 or any other current or future product candidates.\"\n\n3. **Commercialization and Market Acceptance**:\n   - The document emphasizes the need for market acceptance, which is influenced by the ability to identify and access patients. It states, \"AMX0035 may fail to maintain the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for continued commercial success or to remain profitable.\"\n   - It also notes, \"If we are unable to identify patients and successfully commercialize AMX0035 or any other current or future product candidates with attractive market opportunities, our future product revenues may be smaller than anticipated, and our business may suffer.\"\n\n4. **Regulatory Requirements and Post-Marketing Commitments**:\n   - The document discusses the regulatory requirements and post-marketing commitments, which include the need to provide data from ongoing clinical trials. It states, \"One of the conditions of the marketing authorization in Canada is the provision of data from our ongoing global PHOENIX trial and other additional planned or ongoing studies.\"\n   - It also mentions, \"If the"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 96000, "result": 1.0, "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?", "options": {"A": "Acquisition of NYSE and Nasdaq", "B": "Acquisition of FFIEC and CFPB", "C": "Acquisition of Ellie Mae, Inc. and Black Knight", "D": "Acquisition of NYMEX and ICE", "E": "Acquisition of Fannie Mae and Freddie Mac", "F": "Acquisition of FHA and VA"}, "LLM_original_answer": ["To answer the question, \"Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?\" we need to identify the acquisitions that led to increased oversight from U.S. regulatory bodies such as the FFIEC and CFPB.\n\nFrom the provided document, the relevant information is found in the following sections:\n\n1. **Mortgage Technology Segment**:\n   - \"Our mortgage technology revenues are derived from our comprehensive, end-to-end U.S. residential mortgage platform. Our mortgage technology business is intended to enable greater workflow efficiency and mitigate risks for customers throughout the mortgage life cycle.\"\n   - \"Black Knight contributed $363 million of revenues in 2023 following completion of the acquisition.\"\n\n2. **Regulatory Scrutiny**:\n   - \"Our acquisitions of Ellie Mae, Inc., or Ellie Mae, in 2020 and Black Knight in 2023 expose us to increased regulatory scrutiny from U.S. regulatory bodies that regulate the U.S. residential mortgage industry, including the FFIEC and its member agencies, and the CFPB, among others.\"\n\nBased on this information, the acquisitions that increased regulatory scrutiny in the U.S. residential mortgage industry are:\n- **Ellie Mae, Inc.** (acquired in 2020)\n- **Black Knight** (acquired in 2023)\n\nTherefore, the correct answer is:\n**C: Acquisition of Ellie Mae, Inc. and Black Knight**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 96000, "result": 1.0, "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?", "options": {"A": "Offering personal security devices", "B": "Weekly meetings with cybersecurity experts", "C": "Regular cybersecurity training and resources", "D": "Outsourcing training to third-party vendors", "E": "Developing a custom security software", "F": "Limiting internet access during work hours"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the method used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats.\n\n1. **Locating Relevant Information:**\n   - The document mentions Brighthouse's Security Awareness Program in the section \"Cybersecurity Risk Management Program and Strategy.\"\n   - Specifically, it states: \"Through our Security Awareness Program, we provide our employees with regular cybersecurity training and educational resources to help ensure that they remain vigilant against threats.\"\n\n2. **Interpreting the Information:**\n   - The phrase \"regular cybersecurity training and educational resources\" indicates that Brighthouse uses ongoing training and provides educational materials to keep employees informed about cybersecurity threats.\n   - This aligns with the concept of continuous education and awareness, which is a common method in security awareness programs.\n\n3. **Matching to the Options:**\n   - **Option A: Offering personal security devices** - The document does not mention providing personal security devices to employees.\n   - **Option B: Weekly meetings with cybersecurity experts** - The document does not specify weekly meetings with cybersecurity experts.\n   - **Option C: Regular cybersecurity training and resources** - This matches the information provided in the document.\n   - **Option D: Outsourcing training to third-party vendors** - The document does not mention outsourcing training to third-party vendors.\n   - **Option E: Developing a custom security software** - The document does not mention developing custom security software.\n   - **Option F: Limiting internet access during work hours** - The document does not mention limiting internet access during work hours.\n\nBased on the information provided in the document, the method used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats is **Regular cybersecurity training and resources**.\n\nTherefore, the correct answer is **Option C: Regular cybersecurity training and resources**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 128000, "result": 1.0, "question": "What is the main reason preliminary data should be viewed with caution?", "options": {"A": "Preliminary data are always incorrect", "B": "Final data may differ significantly from preliminary data after audits", "C": "Preliminary data are approved by regulatory agencies", "D": "Preliminary data are completed and cannot change", "E": "Preliminary data are irrelevant to business decisions", "F": "Preliminary data are never published"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 128000, "result": 1.0, "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?", "options": {"A": "Mining proceeds increase", "B": "Mining proceeds remain unchanged", "C": "Transaction fees decrease", "D": "Mining proceeds decrease", "E": "Network hash rate decreases", "F": "Transaction validation is faster"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 128000, "result": 1.0, "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?", "options": {"A": "Securing insurance for each transaction", "B": "Selecting highly rated banks as counterparties", "C": "Transferring risks to third-party investors", "D": "Converting all debts to local currency", "E": "Engaging with a single counterparty for all transactions", "F": "Using fixed interest rates only"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 128000, "result": 1.0, "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?", "options": {"A": "Reclassified as current assets", "B": "Reclassified as non-current liabilities", "C": "Reclassified to assets and liabilities of discontinued operations", "D": "Included in the net loss calculation", "E": "Merged with assets and liabilities of continuing operations", "F": "Removed from all financial statements"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 128000, "result": 1.0, "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?", "options": {"A": "They may prioritize our drug candidates over their own.", "B": "They are guaranteed to pursue commercialization of all drug candidates.", "C": "They have unlimited rights to select any target without restriction.", "D": "They may develop competing products independently or with third parties.", "E": "They ensure the protection and enforcement of our intellectual property.", "F": "They cannot change their strategic focus once a project starts."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant sections of the provided document to identify the risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Relevant Section:**\n   - The relevant section is found under \"Risks Related to Dependence on Third Parties\" in the \"Risk Factors\" section of the document.\n\n2. **Extract the Key Information:**\n   - The document states: \"Collaborators could develop independently, or develop with third parties, products that compete directly or indirectly with our products or drug candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours.\"\n\n3. **Interpret the Information:**\n   - This statement indicates that there is a risk that collaborators like Gilead, Sanofi, and Pfizer might develop competing products independently or in collaboration with other third parties. This risk arises if the collaborators believe that these competitive products have a higher likelihood of success or offer more favorable economic terms.\n\n4. **Match the Information to the Options:**\n   - Option A: They may prioritize our drug candidates over their own. (This is not mentioned in the document.)\n   - Option B: They are guaranteed to pursue commercialization of all drug candidates. (This is not mentioned in the document.)\n   - Option C: They have unlimited rights to select any target without restriction. (This is not mentioned in the document.)\n   - Option D: They may develop competing products independently or with third parties. (This matches the information extracted from the document.)\n   - Option E: They ensure the protection and enforcement of our intellectual property. (This is not mentioned in the document.)\n   - Option F: They cannot change their strategic focus once a project starts. (This is not mentioned in the document.)\n\n### Conclusion:\nThe risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer is that they may develop competing products independently or with third parties. Therefore, the correct answer is:\n\n**D: They may develop competing products independently or with third parties.**"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 128000, "result": 0.0, "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?", "options": {"A": "1 million loans", "B": "1.3 million loans", "C": "2 million loans", "D": "2.3 million loans", "E": "500,000 loans", "F": "3 million loans"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["!"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 128000, "result": 1.0, "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?", "options": {"A": "Immediate market launch", "B": "Significant additional clinical and non-clinical development", "C": "Only initial trials in humans", "D": "Direct approval by local regulatory authorities", "E": "Exclusive manufacturing rights", "F": "Limited marketing efforts"}, "LLM_original_answer": ["To answer the question \"What is necessary before the company\u2019s product candidates can be successfully commercialized?\" based on the provided document, let's break down the key points and reasoning:\n\n1. **Clinical and Non-Clinical Development**:\n   - The document emphasizes that all product candidates require significant additional clinical and non-clin"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 30, "token_lengths": 128000, "result": 1.0, "question": "What could adversely affect the business and operations if patient identification is unsuccessful?", "options": {"A": "Increased approval rates by regulatory authorities", "B": "Enhanced disease awareness among healthcare professionals", "C": "Larger addressable patient population than expected", "D": "Difficulty in identifying and accessing patients", "E": "Greater market acceptance of AMX0035", "F": "Increased profitability and business expansion"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 30, "token_lengths": 128000, "result": 1.0, "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?", "options": {"A": "Acquisition of NYSE and Nasdaq", "B": "Acquisition of FFIEC and CFPB", "C": "Acquisition of Ellie Mae, Inc. and Black Knight", "D": "Acquisition of NYMEX and ICE", "E": "Acquisition of Fannie Mae and Freddie Mac", "F": "Acquisition of FHA and VA"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 30, "token_lengths": 128000, "result": 1.0, "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?", "options": {"A": "Offering personal security devices", "B": "Weekly meetings with cybersecurity experts", "C": "Regular cybersecurity training and resources", "D": "Outsourcing training to third-party vendors", "E": "Developing a custom security software", "F": "Limiting internet access during work hours"}, "LLM_original_answer": ["To answer the question, I will review the provided document for information related to Brighthouse's Security Awareness Program and how it keeps employees informed about cybersecurity threats.\n\nFrom the document, the relevant section is:\n\n**Cybersecurity Risk Management Program and Strategy**\n- We understand the importance of maintaining a robust cybersecurity"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 8000, "result": 1.0, "question": "Which company is developing AV-101 for the treatment of PAH?", "options": {"A": "Aerovate Therapeutics, Inc.", "B": "Gossamer Bio, Inc.", "C": "Acceleron", "D": "Regeneron Pharmaceuticals, Inc.", "E": "Biohaven Ltd.", "F": "Versanis Bio"}, "LLM_original_answer": ["To answer the question \"Which company is developing AV-101 for the treatment of PAH?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant information**: The document mentions several companies and their product candidates for the treatment of PAH (Pulmonary Arterial Hypertension).\n\n2. **Locate the specific mention of AV-101**: The document states, \"Aerovate Therapeutics, Inc. and Gossamer Bio, Inc. are also developing clinical-stage product candidates, AV-101 and seralutinib, respectively, for the treatment of PAH.\"\n\n3. **Match the company with the product candidate**: From the statement, it is clear that Aerovate Therapeutics, Inc. is developing AV-101 for the treatment of PAH.\n\n4. **Review the options**: The options provided are:\n   - A: Aerovate Therapeutics, Inc.\n   - B: Gossamer Bio, Inc.\n   - C: Acceleron\n   - D: Regeneron Pharmaceuticals, Inc.\n   - E: Biohaven Ltd.\n   - F: Versanis Bio\n\n5. **Select the correct answer**: Based on the information in the document, the correct answer is **A: Aerovate Therapeutics, Inc.**.\n\nTherefore, the company developing AV-101 for the treatment of PAH is **Aerovate Therapeutics, Inc.**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 35, "token_lengths": 8000, "result": 1.0, "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?", "options": {"A": "$285.0 million", "B": "$76.5 million", "C": "$211.6 million", "D": "$135.1 million", "E": "$28.0 million", "F": "$2.0 million"}, "LLM_original_answer": ["To answer the question \"What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?\", I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the impairment of property, plant, and equipment, which is relevant to the carrying amount of the site asset group.\n\n2. **Locate the specific information about the impairment**: The document states, \"We measured the amount of impairment at the identified facility sites as the difference between the carrying amount of the site asset group of $211.6 million and the estimated fair value of the site asset group of $135.1 million, resulting in an impairment of the facility site\u2019s property, plant and equipment of $76.5 million for the year ended December 31, 2022.\"\n\n3. **Extract the carrying amount before impairment**: The carrying amount of the site asset group before impairment is given as $211.6 million.\n\n4. **Match the extracted information with the provided options**:\n   - A: $285.0 million\n   - B: $76.5 million\n   - C: $211.6 million\n   - D: $135.1 million\n   - E: $28.0 million\n   - F: $2.0 million\n\n5. **Select the correct option**: The correct option is C: $211.6 million.\n\nTherefore, the carrying amount of the site asset group before impairment for the year ended December 31, 2022, is **$211.6 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 8000, "result": 1.0, "question": "What was classified as discontinued operations in the fourth quarter of 2022?", "options": {"A": "Utility-scale solar and wind group only", "B": "Distributed generation group only", "C": "Utility-scale solar, wind group, and distributed generation group", "D": "Remaining assets only", "E": "Commercial Renewables Disposal Groups", "F": "None of the above"}, "LLM_original_answer": ["To answer the question \"What was classified as discontinued operations in the fourth quarter of 2022?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the classification of discontinued operations in the context of Duke Energy's Commercial Renewables business segment.\n\n2. **Extract the key information**: The relevant information is found in the section titled \"Dispositions - Disclosures related to Discontinued Operations and Accounting for the Associated Impairment Charges.\"\n\n3. **Analyze the information**:\n   - The document states: \"In November 2022, Duke Energy committed to a plan to sell the Commercial Renewables business segment.\"\n   - It further specifies: \"As a result, the utility-scale solar and wind group, the distributed generation group and the remaining assets (collectively, Commercial Renewables Disposal Groups) were classified as discontinued operations in the fourth quarter of 2022.\"\n\n4. **Match the information to the options**:\n   - **Option A**: Utility-scale solar and wind group only\n   - **Option B**: Distributed generation group only\n   - **Option C**: Utility-scale solar, wind group, and distributed generation group\n   - **Option D**: Remaining assets only\n   - **Option E**: Commercial Renewables Disposal Groups\n   - **Option F**: None of the above\n\n5. **Determine the correct answer**:\n   - The document clearly states that the utility-scale solar and wind group, the distributed generation group, and the remaining assets were all classified as discontinued operations.\n   - This matches **Option E**: Commercial Renewables Disposal Groups, which is the term used in the document to collectively refer to these groups.\n\nTherefore, the correct answer is **Option E: Commercial Renewables Disposal Groups**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 35, "token_lengths": 8000, "result": 1.0, "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?", "options": {"A": "0.31%", "B": "0.41%", "C": "0.50%", "D": "0.60%", "E": "0.70%", "F": "0.80%"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the delinquency rate of the total loan portfolio?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Relevant Information**: The document contains a section that specifically discusses the delinquency rates of the loan portfolio. This section is titled \"Asset quality\" and provides the delinquency rate for the total loan portfolio as of December 31, 2023.\n\n2. **Extract the Delinquency Rate**: According to the document, the delinquency rate of the total loan portfolio decreased to 0.41% at December 31, 2023 from 0.50% at December 31, 2022.\n\n3. **Match the Delinquency Rate to the Options**: The delinquency rate of 0.41% matches option B in the multiple-choice question.\n\nTherefore, the correct answer is:\n\n**B: 0.41%**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 8000, "result": 1.0, "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?", "options": {"A": "10 years from its earliest U.S. non-provisional filing date", "B": "15 years from its earliest U.S. non-provisional filing date", "C": "20 years from its earliest U.S. non-provisional filing date", "D": "25 years from its earliest U.S. non-provisional filing date", "E": "30 years from its earliest U.S. non-provisional filing date", "F": "35 years from its earliest U.S. non-provisional filing date"}, "LLM_original_answer": ["To answer the question \"What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for any mention of the duration of patent protection in the United States.\n2. **Extract the Specific Duration**: Find the exact statement that specifies the duration.\n3. **Match the Duration to the Options**: Compare the extracted duration to the given multiple-choice options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document discusses various aspects of patent protection, including the duration of patent rights. The relevant section is:\n\n> \"For example, in the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date.\"\n\n### Step 2: Extract the Specific Duration\nThe specific duration mentioned is \"20 years from its earliest U.S. non-provisional filing date.\"\n\n### Step 3: Match the Duration to the Options\nThe options provided are:\n- A: 10 years from its earliest U.S. non-provisional filing date\n- B: 15 years from its earliest U.S. non-provisional filing date\n- C: 20 years from its earliest U.S. non-provisional filing date\n- D: 25 years from its earliest U.S. non-provisional filing date\n- E: 30 years from its earliest U.S. non-provisional filing date\n- F: 35 years from its earliest U.S. non-provisional filing date\n\nThe correct answer is **C: 20 years from its earliest U.S. non-provisional filing date**.\n\n### Final Answer\nThe typical duration of a patent's natural expiration in the United States if all maintenance fees are paid is **20 years from its earliest U.S. non-provisional filing date**. Therefore, the correct option is **C**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 8000, "result": 1.0, "question": "What was the target hedge coverage ratio in December 2023?", "options": {"A": "25%", "B": "50%", "C": "60%", "D": "75%", "E": "90%", "F": "100%"}, "LLM_original_answer": ["To answer the question \"What was the target hedge coverage ratio in December 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the target hedge coverage ratio in the \"MSR Valuation Adjustments\" section.\n\n2. **Extract the information**: The relevant sentence states, \"The target hedge coverage ratio increased in 2023 from 25% to 60% in the second quarter and 100% in December 2023.\"\n\n3. **Determine the final value**: The target hedge coverage ratio in December 2023 is explicitly stated as 100%.\n\n4. **Match the value to the options**: The options provided are:\n   - A: 25%\n   - B: 50%\n   - C: 60%\n   - D: 75%\n   - E: 90%\n   - F: 100%\n\n5. **Select the correct answer**: The correct answer is F: 100%.\n\nTherefore, the target hedge coverage ratio in December 2023 was 100%."], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 35, "token_lengths": 8000, "result": 1.0, "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?", "options": {"A": "Lack of sufficient product supply", "B": "Disagreement on clinical trial design", "C": "Inadequate number of patients", "D": "Site deviation from protocol", "E": "Unexpected health risks to participants", "F": "Public health crises effects"}, "LLM_original_answer": ["To answer the question \"Which factor can delay or terminate a clinical trial due to regulatory authority involvement?\" based on the provided document, I will analyze each option and identify the relevant information from the text.\n\n### Options:\nA: Lack of sufficient product supply\nB: Disagreement on clinical trial design\nC: Inadequate number of patients\nD: Site deviation from protocol\nE: Unexpected health risks to participants\nF: Public health crises effects\n\n### Analysis:\n1. **A: Lack of sufficient product supply**\n   - The document mentions that \"obtaining sufficient product supply of product candidate for use in preclinical studies or clinical trials from third-party suppliers\" can cause delays. However, it does not specifically state that regulatory authorities would delay or terminate a trial due to this issue. It is more about the company's ability to manage supply.\n   - **Relevant Text:** \"If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if licensed.\"\n\n2. **B: Disagreement on clinical trial design**\n   - The document explicitly states that \"the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials\" can cause delays or termination.\n   - **Relevant Text:** \"Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to: the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials.\"\n\n3. **C: Inadequate number of patients**\n   - The document mentions that \"enrollment in these clinical trials may be slower than we anticipate or participants may drop out of our clinical trials at a higher rate than we anticipate,\" which can cause delays. However, it does not specifically state that regulatory authorities would delay or terminate a trial due to this issue.\n   - **Relevant Text:** \"The number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of our clinical trials at a higher rate than we anticipate.\"\n\n4. **D: Site deviation from protocol**\n   - The document mentions that \"clinical trial sites deviating from the approved clinical trial protocol or dropping out of a clinical trial\" can cause delays or termination.\n   -"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 8000, "result": 1.0, "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?", "options": {"A": "The donations are not tax-deductible.", "B": "They have been used to promote branded drugs over cheaper alternatives.", "C": "They require excessive paperwork for approval.", "D": "They are not sufficient to cover all patient needs.", "E": "They are banned by all federal laws.", "F": "They are mismanaged by charitable organizations."}, "LLM_original_answer": ["To answer the question \"What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Relevant Section Identification**:\n   - The document mentions that donations to patient assistance programs have received negative publicity and have been the subject of multiple government enforcement actions. Specifically, it states: \"donations to patient assistance programs have received some negative publicity and have been the subject of multiple government enforcement actions, related to allegations regarding their misuse to promote branded pharmaceutical products over other less costly alternatives.\"\n\n2. **Understanding the Context**:\n   - The document discusses the regulatory and compliance challenges faced by pharmaceutical companies, including the scrutiny of patient assistance programs.\n   - It highlights that these programs are under investigation and have led to significant civil and criminal settlements.\n\n3. **Analyzing the Options**:\n   - **A: The donations are not tax-deductible.**\n     - The document does not mention tax-deductibility as an issue.\n   - **B: They have been used to promote branded drugs over cheaper alternatives.**\n     - This aligns with the document's statement about negative publicity and enforcement actions related to the misuse of these programs to promote branded drugs.\n   - **C: They require excessive paperwork for approval.**\n     - The document does not specifically mention excessive paperwork as a main issue.\n   - **D: They are not sufficient to cover all patient needs.**\n     - While the document discusses the importance of adequate reimbursement, it does not specifically mention the insufficiency of patient assistance programs as a main issue.\n   - **E: They are banned by all federal laws.**\n     - The document does not state that these programs are banned by all federal laws.\n   - **F: They are mismanaged by charitable organizations.**\n     - The document mentions mismanagement as a potential issue but does not emphasize it as the main issue.\n\n4. **Conclusion**:\n   - The main issue highlighted in the document is that donations to patient assistance programs have been used to promote branded drugs over cheaper alternatives, leading to negative publicity and government enforcement actions.\n\nTherefore, the correct answer is **B: They have been used to promote branded drugs over cheaper alternatives.**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 8000, "result": 1.0, "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?", "options": {"A": "Innovative product features", "B": "Reputation", "C": "Market share", "D": "Low pricing strategy", "E": "Employee satisfaction", "F": "Advertising campaigns"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step to identify the aspect that is critical for attracting and retaining customers, investors, and maintaining relationships with regulators.\n\n1. **System Issues and Reputation:**\n   - The document mentions a system issue on January 24, 2023, which resulted in trades being reversed and compensation provided to impacted members.\n   - It states, \"This January 24, 2023 NYSE system issue, and other system issues in the future, could result in damage to our business reputation and participant dissatisfaction with our electronic platform, which could prompt participants to trade elsewhere or expose us to litigation or regulatory sanctions.\"\n   - This indicates that system issues can harm the company's reputation, leading to customer and investor dissatisfaction and potential regulatory scrutiny.\n\n2. **Reputation and Business Impact:**\n   - The document explicitly states, \"Maintaining our reputation is critical to attracting and retaining customers and investors and for maintaining our relationships with our regulators.\"\n   - It further emphasizes, \"Negative publicity regarding our company, especially given the speed with which false information can be spread through social media channels, or actual, alleged or perceived issues regarding our products or services, operations, risk management, compliance with regulations, political affiliations or management team could give rise to reputational risk which could significantly harm our existing business and business prospects.\"\n\n3. **Other Factors:**\n   - **Innovative Product Features (A):** While important, the document does not specifically highlight this as a critical factor for attracting and retaining customers, investors, and maintaining regulatory relationships.\n   - **Market Share (C):** The document mentions competition and market share, but it does not emphasize this as the primary factor for customer and investor retention or regulatory relationships.\n   - **Low Pricing Strategy (D):** The document discusses pricing competition but does not suggest that a low pricing strategy is critical for maintaining relationships with regulators.\n   - **Employee Satisfaction (E):** The document discusses the importance of key personnel and succession planning, but it does not directly link employee satisfaction to attracting and retaining customers, investors, and maintaining regulatory relationships.\n   - **Advertising Campaigns (F):** The document does not mention advertising campaigns as a critical factor.\n\n4. **Conclusion:**\n   - The document clearly emphasizes the importance of maintaining a good reputation for attracting and retaining customers, investors, and maintaining relationships with regulators.\n   - It explicitly states that damage to the company's reputation can lead to significant harm to the business and its prospects"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 8000, "result": 1.0, "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?", "options": {"A": "Only changes in interest rates", "B": "Changes in interest rates and credit spreads only", "C": "Interest rates, exchange rates, and assumptions used in models", "D": "Volatility and default risk only", "E": "Nonperformance risk and liquidity only", "F": "Only changes in financial indices"}, "LLM_original_answer": ["To answer the question \"What can affect the valuation of freestanding derivatives when quoted market values are unavailable?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Document Context**:\n   - The document discusses the valuation of freestanding derivatives, which are used to hedge various capital markets risks in insurance products.\n   - It mentions that when quoted market values are not available, the valuation is based on market standard methodologies and inputs.\n\n2. **Relevant Section**:\n   - The section on \"Freestanding Derivatives\" states: \"The determination of the estimated fair value of freestanding derivatives, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments.\"\n   - It further lists the factors that can affect the valuation: \"Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models.\"\n\n3. **Analysis of Options**:\n   - **Option A**: Only changes in interest rates\n     - This is too narrow. The document mentions multiple factors, not just interest rates.\n   - **Option B**: Changes in interest rates and credit spreads only\n     - This is also too narrow. The document includes more factors than just interest rates and credit spreads.\n   - **Option C**: Interest rates, exchange rates, and assumptions used in models\n     - This is closer but still incomplete. The document mentions more factors than just these three.\n   - **Option D**: Volatility and default risk only\n     - This is too narrow. The document includes more factors than just volatility and default risk.\n   - **Option E**: Nonperformance risk and liquidity only\n     - This is too narrow. The document includes more factors than just nonperformance risk and liquidity.\n   - **Option F**: Only changes in financial indices\n     - This is too narrow. The document mentions multiple factors, not just financial indices.\n\n4. **Conclusion**:\n   - The document explicitly states that the valuation of freestanding derivatives can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity, and changes in estimates and assumptions used in the pricing models.\n   - Therefore, the most comprehensive and accurate option is **Option C**: Interest"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 16000, "result": 1.0, "question": "Which company is developing AV-101 for the treatment of PAH?", "options": {"A": "Aerovate Therapeutics, Inc.", "B": "Gossamer Bio, Inc.", "C": "Acceleron", "D": "Regeneron Pharmaceuticals, Inc.", "E": "Biohaven Ltd.", "F": "Versanis Bio"}, "LLM_original_answer": ["To answer the question \"Which company is developing AV-101 for the treatment of PAH?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant information in the document:**\n   - The document mentions several companies and their product candidates for the treatment of PAH (Pulmonary Arterial Hypertension).\n\n2. **Locate the specific mention of AV-101:**\n   - The document states: \"Aerovate Therapeutics, Inc. and Gossamer Bio, Inc. are also developing clinical-stage product candidates, AV-101 and seralutinib, respectively, for the treatment of PAH.\"\n\n3. **Determine the company associated with AV-101:**\n   - From the statement, it is clear that Aerovate Therapeutics, Inc. is developing AV-101 for the treatment of PAH.\n\n4. **Select the correct option:**\n   - The correct option is A: Aerovate Therapeutics, Inc.\n\nTherefore, the answer to the question is **A: Aerovate Therapeutics, Inc.**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 35, "token_lengths": 16000, "result": 1.0, "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?", "options": {"A": "$285.0 million", "B": "$76.5 million", "C": "$211.6 million", "D": "$135.1 million", "E": "$28.0 million", "F": "$2.0 million"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document and focus on the relevant section that discusses the impairment of property, plant, and equipment.\n\nThe relevant excerpt is:\n\"We measured the amount of impairment at the identified facility sites as the difference between the carrying amount of the site asset group of $211.6 million and the estimated fair value of the site asset group of $135.1 million, resulting in an impairment of the facility site\u2019s property, plant and equipment of $76.5 million for the year ended December 31, 2022.\"\n\nFrom this excerpt, we can extract the following information:\n- The carrying amount of the site asset group before impairment for the year ended December 31, 2022, was $211.6 million.\n- The estimated fair value of the site asset group was $135.1 million.\n- The impairment loss was $76.5 million, which is the difference between the carrying amount and the fair value.\n\nTherefore, the carrying amount of the site asset group before impairment for the year ended December 31, 2022, is $211.6 million.\n\nThe correct answer is:\nC: $211.6 million"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 16000, "result": 1.0, "question": "What was classified as discontinued operations in the fourth quarter of 2022?", "options": {"A": "Utility-scale solar and wind group only", "B": "Distributed generation group only", "C": "Utility-scale solar, wind group, and distributed generation group", "D": "Remaining assets only", "E": "Commercial Renewables Disposal Groups", "F": "None of the above"}, "LLM_original_answer": ["To answer the question \"What was classified as discontinued operations in the fourth quarter of 2022?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the classification of discontinued operations in the context of Duke Energy's decision to sell its Commercial Renewables business segment.\n\n2. **Extract the specific information**: The relevant excerpt is:\n   - \"In November 2022, Duke Energy committed to a plan to sell the Commercial Renewables business segment. As a result, the utility-scale solar and wind group, the distributed generation group and the remaining assets (collectively, Commercial Renewables Disposal Groups) were classified as discontinued operations in the fourth quarter of 2022.\"\n\n3. **Match the information to the options**:\n   - **Option A**: Utility-scale solar and wind group only\n   - **Option B**: Distributed generation group only\n   - **Option C**: Utility-scale solar, wind group, and distributed generation group\n   - **Option D**: Remaining assets only\n   - **Option E**: Commercial Renewables Disposal Groups\n   - **Option F**: None of the above\n\n4. **Determine the correct answer**:\n   - The document states that the utility-scale solar and wind group, the distributed generation group, and the remaining assets were collectively classified as discontinued operations.\n   - This matches **Option E**: Commercial Renewables Disposal Groups.\n\nTherefore, the correct answer is **E: Commercial Renewables Disposal Groups**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 35, "token_lengths": 16000, "result": 1.0, "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?", "options": {"A": "0.31%", "B": "0.41%", "C": "0.50%", "D": "0.60%", "E": "0.70%", "F": "0.80%"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the delinquency rate of the total loan portfolio?\" with the given options, I will follow these steps:\n\n1. **Identify the Relevant Information**: The document should contain a specific statement or table that provides the delinquency rate of the total loan portfolio as of December 31, 2023.\n\n2. **Locate the Information**: Scanning the document, I find the following relevant information:\n   - \"The delinquency rate of our total loan portfolio decreased to 0.41% at December 31, 2023 from 0.50% at December 31, 2022.\"\n\n3. **Match the Information to the Options**: The delinquency rate as of December 31, 2023, is 0.41%.\n\n4. **Select the Correct Option**: The correct option is B: 0.41%.\n\nTherefore, the answer to the question is **B: 0.41%**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 16000, "result": 1.0, "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?", "options": {"A": "10 years from its earliest U.S. non-provisional filing date", "B": "15 years from its earliest U.S. non-provisional filing date", "C": "20 years from its earliest U.S. non-provisional filing date", "D": "25 years from its earliest U.S. non-provisional filing date", "E": "30 years from its earliest U.S. non-provisional filing date", "F": "35 years from its earliest U.S. non-provisional filing date"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document and think through it step by step.\n\n1. **Identify the Relevant Information**: The document contains a section that directly addresses the duration of patent protection in the United States. The relevant excerpt is:\n   - \"For example, in the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date.\"\n\n2. **Understand the Context**: The context here is the typical duration of a patent's natural expiration in the United States, assuming all maintenance fees are paid. This is a standard legal and regulatory detail that is important for biopharmaceutical companies to understand, as it affects their ability to maintain exclusive rights to their inventions.\n\n3. **Match the Information to the Options**:\n   - **Option A**: 10 years from its earliest U.S. non-provisional filing date\n   - **Option B**: 15 years from its earliest U.S. non-provisional filing date\n   - **Option C**: 20 years from its earliest U.S. non-provisional filing date\n   - **Option D**: 25 years from its earliest U.S. non-provisional filing date\n   - **Option E**: 30 years from its earliest U.S. non-provisional filing date\n   - **Option F**: 35 years from its earliest U.S. non-provisional filing date\n\n4. **Select the Correct Option**: Based on the information provided in the document, the correct answer is:\n   - **Option C**: 20 years from its earliest U.S. non-provisional filing date\n\nTherefore, the typical duration of a patent's natural expiration in the United States, if all maintenance fees are paid, is **20 years from its earliest U.S. non-provisional filing date**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 16000, "result": 1.0, "question": "What was the target hedge coverage ratio in December 2023?", "options": {"A": "25%", "B": "50%", "C": "60%", "D": "75%", "E": "90%", "F": "100%"}, "LLM_original_answer": ["To answer the question \"What was the target hedge coverage ratio in December 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss the target hedge coverage ratio, particularly focusing on the period around December 2023.\n\n2. **Extract the Information**: Find the specific statement or data that mentions the target hedge coverage ratio for December 2023.\n\n3. **Match the Information to the Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document discusses the target hedge coverage ratio in the section titled \"MSR Valuation Adjustments, Net\" under the \"Servicing\" segment. Specifically, it mentions changes in the target hedge coverage ratio throughout 2023.\n\n### Step 2: Extract the Information\nFrom the document:\n- \"The target hedge coverage ratio increased in 2023 from 25% to 60% in the second quarter and 100% in December 2023.\"\n\n### Step 3: Match the Information to the Options\nThe document clearly states that the target hedge coverage ratio was 100% in December 2023. Therefore, the correct answer is:\n\n**F: 100%**\n\nThis matches the information provided in the document and is the only option that corresponds to the target hedge coverage ratio in December 2023."], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 35, "token_lengths": 16000, "result": 1.0, "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?", "options": {"A": "Lack of sufficient product supply", "B": "Disagreement on clinical trial design", "C": "Inadequate number of patients", "D": "Site deviation from protocol", "E": "Unexpected health risks to participants", "F": "Public health crises effects"}, "LLM_original_answer": ["To answer the question, I will analyze the document and identify the factors that can delay or terminate a clinical trial due to regulatory authority involvement. The document provides a detailed overview of the challenges and risks associated with clinical trials, and I will focus on the specific factors mentioned that could lead to regulatory intervention.\n\n### Step-by-Step Analysis:\n\n1. **Lack of sufficient product supply (Option A)**:\n   - The document mentions that delays can occur if there is a lack of sufficient product supply for preclinical studies or clinical trials.\n   - However, this is not explicitly stated as a reason for regulatory authority involvement in delaying or terminating a trial.\n\n2. **Disagreement on clinical trial design (Option B)**:\n   - The document states, \"The FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials.\"\n   - This is a clear factor that can lead to regulatory authority involvement, potentially causing delays or termination of the trial.\n\n3. **Inadequate number of patients (Option C)**:\n   - The document discusses the challenges of recruiting and retaining an adequate number of patients.\n   - However, it does not explicitly state that this is a reason for regulatory authority involvement in delaying or terminating a trial.\n\n4. **Site deviation from protocol (Option D)**:\n   - The document mentions, \"clinical trial sites deviating from the approved clinical trial protocol or dropping out of a clinical trial.\"\n   - This is another clear factor that can lead to regulatory authority involvement, potentially causing delays or termination of the trial.\n\n5. **Unexpected health risks to participants (Option E)**:\n   - The document states, \"If serious adverse events are determined to be directly or specifically caused or exacerbated by our product candidates, we would follow the clinical trial protocol\u2019s requirements, which call for our data safety monitoring committee to review all available clinical data in making a recommendation regarding the trial\u2019s continuation.\"\n   - It also mentions, \"If unacceptable toxicities arise in the development of our product candidates, we could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities, or local regulatory authorities such as IRBs, could order us to cease clinical trials.\"\n   - This is a significant factor that can lead to regulatory authority involvement, potentially causing delays or termination of the trial.\n\n6. **Public health crises effects (Option F)**:\n   - The document discusses the potential impact of public health crises, such as the COVID-19 pandemic, on clinical trial operations.\n   - It mentions, \"The adverse"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 16000, "result": 1.0, "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?", "options": {"A": "The donations are not tax-deductible.", "B": "They have been used to promote branded drugs over cheaper alternatives.", "C": "They require excessive paperwork for approval.", "D": "They are not sufficient to cover all patient needs.", "E": "They are banned by all federal laws.", "F": "They are mismanaged by charitable organizations."}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the main issue with donations to patient assistance programs by pharmaceutical manufacturers.\n\n1. **Relevant Section Identification**:\n   - The document mentions patient assistance programs in the context of regulatory scrutiny and potential misuse. The relevant section is: \"Third party patient assistance programs that receive financial support from companies have also become the subject of enhanced government and regulatory scrutiny. The OIG has established guidelines that suggest that it is lawful for pharmaceutical manufacturers to make donations to charitable organizations who provide co-pay assistance to Medicare patients. However, donations to patient assistance programs have received some negative publicity and have been the subject of multiple government enforcement actions, related to allegations regarding their misuse to promote branded pharmaceutical products over other less costly alternatives.\"\n\n2. **Key Points Extraction**:\n   - **Enhanced Government and Regulatory Scrutiny**: The document states that third-party patient assistance programs have become the subject of enhanced scrutiny.\n   - **Negative Publicity**: Donations to these programs have received negative publicity.\n   - **Government Enforcement Actions**: There have been multiple government enforcement actions related to the misuse of these programs.\n   - **Allegations of Misuse**: The primary concern is that these programs are misused to promote branded pharmaceutical products over less costly alternatives.\n\n3. **Option Analysis**:\n   - **Option A**: The document does not mention that the donations are not tax-deductible.\n   - **Option B**: The document explicitly states that the main issue is the misuse of these programs to promote branded drugs over cheaper alternatives.\n   - **Option C**: The document does not mention excessive paperwork for approval.\n   - **Option D**: The document does not suggest that the donations are insufficient to cover all patient needs.\n   - **Option E**: The document does not state that donations are banned by all federal laws.\n   - **Option F**: The document does not mention mismanagement by charitable organizations, but it does mention misuse by pharmaceutical companies.\n\n4. **Conclusion**:\n   - Based on the information provided in the document, the main issue with donations to patient assistance programs by pharmaceutical manufacturers is that they have been used to promote branded drugs over cheaper alternatives.\n\nTherefore, the correct answer is **Option B: They have been used to promote branded drugs over cheaper alternatives.**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 16000, "result": 1.0, "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?", "options": {"A": "Innovative product features", "B": "Reputation", "C": "Market share", "D": "Low pricing strategy", "E": "Employee satisfaction", "F": "Advertising campaigns"}, "LLM_original_answer": ["To answer the question, I will analyze the document and identify the aspect that is emphasized as critical for attracting and retaining customers, investors, and maintaining relationships with regulators.\n\n1. **Reputation**:\n   - The document mentions, \"Maintaining our reputation is critical to attracting and retaining customers and investors and for maintaining our relationships with our regulators.\"\n   - It also states, \"Damage to our reputation could damage our business. Our business is highly competitive and our customers have options on where to conduct their business. Our management team and business operations benefit from being highly regarded in our industry.\"\n   - These statements directly highlight the importance of reputation in the context of customer and investor attraction, as well as regulatory relationships.\n\n2. **Innovative Product Features**:\n   - While the document discusses the importance of innovation and new product introductions, it does not specifically link these to attracting and retaining customers, investors, and maintaining regulatory relationships.\n\n3. **Market Share**:\n   - The document mentions competition and market share, but it does not emphasize market share as a critical factor for attracting and retaining customers, investors, and maintaining regulatory relationships.\n\n4. **Low Pricing Strategy**:\n   - Pricing competition is mentioned, but it is not highlighted as a critical factor for attracting and retaining customers, investors, and maintaining regulatory relationships.\n\n5. **Employee Satisfaction**:\n   - The document discusses the importance of key personnel and succession planning, but it does not specifically link employee satisfaction to attracting and retaining customers, investors, and maintaining regulatory relationships.\n\n6. **Advertising Campaigns**:\n   - There is no mention of advertising campaigns in the document.\n\nGiven the above analysis, the aspect that is explicitly and critically emphasized in the document for attracting and retaining customers, investors, and maintaining relationships with regulators is **Reputation**.\n\nTherefore, the correct answer is **B: Reputation**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 16000, "result": 1.0, "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?", "options": {"A": "Only changes in interest rates", "B": "Changes in interest rates and credit spreads only", "C": "Interest rates, exchange rates, and assumptions used in models", "D": "Volatility and default risk only", "E": "Nonperformance risk and liquidity only", "F": "Only changes in financial indices"}, "LLM_original_answer": ["To answer the question \"What can affect the valuation of freestanding derivatives when quoted market values are unavailable?\", let's break down the relevant information from the provided document:\n\n1. **Interest Rates**: The document mentions that changes in interest rates can affect the valuation of freestanding derivatives. For example, in the \"ULSG Market Risk Exposure Management\" section, it states that \"If interest rates fall, our ULSG Target increases. Likewise, if interest rates rise, our ULSG Target declines.\"\n\n2. **Foreign Currency Exchange Rates**: The document also notes that foreign currency exchange rates can impact the valuation of derivatives. In the \"Derivatives\" section, it mentions the use of \"foreign currency swaps when we hold fixed maturity securities denominated in foreign currencies that are matching insurance liabilities denominated in U.S. dollars.\"\n\n3. **Financial Indices**: The document indicates that financial indices can affect the valuation of derivatives, particularly in the context of index-linked annuities. For instance, in the \"Embedded Derivatives in Index-Linked Annuities\" section, it states that \"The changes in liability values of our fixed index-linked annuity and Shield products that result from changes in the underlying equity index are accounted for as embedded derivatives.\"\n\n4. **Credit Spreads**: The document discusses the impact of credit spreads on the valuation of derivatives. In the \"Fair Value Hierarchy\" section, it mentions that \"credit default swaps priced using unobservable credit spreads\" are categorized as Level 3 derivatives, which require significant judgment in valuation.\n\n5. **Default Risk**: The document explicitly mentions default risk as a factor affecting the valuation of derivatives. In the \"Derivatives\" section, it states that \"We use a variety of strategies to manage these risks, including the use of derivatives,\" and in the \"Credit Risk\" section, it discusses the management of credit risk related to derivatives.\n\n6. **Nonperformance Risk**: The document highlights nonperformance risk as a factor in the valuation of derivatives. In the \"Market Risk Benefits\" section, it states that \"The nonperformance risk adjustment is captured as an additional spread applied to the risk-free rate in determining the rate to discount the cash flows of the liability.\"\n\n7. **Liquidity**: The document mentions liquidity as a factor affecting the valuation of derivatives. In the \"Derivatives\" section, it states that \"Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 32000, "result": 1.0, "question": "Which company is developing AV-101 for the treatment of PAH?", "options": {"A": "Aerovate Therapeutics, Inc.", "B": "Gossamer Bio, Inc.", "C": "Acceleron", "D": "Regeneron Pharmaceuticals, Inc.", "E": "Biohaven Ltd.", "F": "Versanis Bio"}, "LLM_original_answer": ["To answer the question \"Which company is developing AV-101 for the treatment of PAH?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions several companies and their product candidates for the treatment of PAH. I need to find the specific mention of AV-101.\n\n2. **Extract the information**: The relevant information is found in the following sentence:\n   - \"Aerovate Therapeutics, Inc. and Gossamer Bio, Inc. are also developing clinical-stage product candidates, AV-101 and seralutinib, respectively, for the treatment of PAH.\"\n\n3. **Analyze the information**: This sentence clearly states that Aerovate Therapeutics, Inc. is developing AV-101 for the treatment of PAH.\n\n4. **Match the information to the options**: The options provided are:\n   - A: Aerovate Therapeutics, Inc.\n   - B: Gossamer Bio, Inc.\n   - C: Acceleron\n   - D: Regeneron Pharmaceuticals, Inc.\n   - E: Biohaven Ltd.\n   - F: Versanis Bio\n\n5. **Select the correct answer**: Based on the information extracted, the correct answer is:\n   - **A: Aerovate Therapeutics, Inc.**\n\nTherefore, the company developing AV-101 for the treatment of PAH is **Aerovate Therapeutics, Inc.**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 35, "token_lengths": 32000, "result": 1.0, "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?", "options": {"A": "$285.0 million", "B": "$76.5 million", "C": "$211.6 million", "D": "$135.1 million", "E": "$28.0 million", "F": "$2.0 million"}, "LLM_original_answer": ["To answer the question \"What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?\" we need to carefully analyze the information provided in the document.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Relevant Section:**\n   - The relevant section is found in the \"Impairment of property, plant and equipment\" part of the document.\n\n2. **Extract the Key Information:**\n   - The document states: \"We measured the amount of impairment at the identified facility sites as the difference between the carrying amount of the site asset group of $211.6 million and the estimated fair value of the site asset group of $135.1 million, resulting in an impairment of the facility site\u2019s property, plant and equipment of $76.5 million for the year ended December 31, 2022.\"\n\n3. **Understand the Impairment Calculation:**\n   - The impairment is calculated as the difference between the carrying amount and the estimated fair value.\n   - Impairment = Carrying Amount - Estimated Fair Value\n   - $76.5 million = $211.6 million - $135.1 million\n\n4. **Determine the Carrying Amount Before Impairment:**\n   - The carrying amount before impairment is the amount that was impaired, which is $211.6 million.\n\n### Conclusion:\nThe carrying amount of the site asset group before impairment for the year ended December 31, 2022, was $211.6 million.\n\n### Answer:\nC: $211.6 million"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 32000, "result": 1.0, "question": "What was classified as discontinued operations in the fourth quarter of 2022?", "options": {"A": "Utility-scale solar and wind group only", "B": "Distributed generation group only", "C": "Utility-scale solar, wind group, and distributed generation group", "D": "Remaining assets only", "E": "Commercial Renewables Disposal Groups", "F": "None of the above"}, "LLM_original_answer": ["To answer the question \"What was classified as discontinued operations in the fourth quarter of 2022?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the classification of discontinued operations in the \"Discontinued Operations\" section of Note 2 to the Consolidated Financial Statements.\n\n2. **Extract the key information**: The relevant paragraph states:\n   - \"In November 2022, Duke Energy committed to a plan to sell the Commercial Renewables business segment, excluding the offshore wind contract for Carolina Long Bay, which was moved to the EU&I segment.\"\n   - \"The Commercial Renewables Disposal Groups were classified as held for sale and as discontinued operations in the fourth quarter of 2022.\"\n\n3. **Determine the components of the Commercial Renewables Disposal Groups**: The document further specifies:\n   - \"The utility-scale solar and wind group, the distributed generation group and the remaining assets (collectively, Commercial Renewables Disposal Groups) were classified as discontinued operations in the fourth quarter of 2022.\"\n\n4. **Match the information to the options**:\n   - **Option A**: Utility-scale solar and wind group only\n   - **Option B**: Distributed generation group only\n   - **Option C**: Utility-scale solar, wind group, and distributed generation group\n   - **Option D**: Remaining assets only\n   - **Option E**: Commercial Renewables Disposal Groups\n   - **Option F**: None of the above\n\n5. **Select the correct option**: The correct option is **E: Commercial Renewables Disposal Groups**. This option encompasses all the components mentioned in the document: the utility-scale solar and wind group, the distributed generation group, and the remaining assets.\n\nTherefore, the answer to the question is **E: Commercial Renewables Disposal Groups**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 35, "token_lengths": 32000, "result": 1.0, "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?", "options": {"A": "0.31%", "B": "0.41%", "C": "0.50%", "D": "0.60%", "E": "0.70%", "F": "0.80%"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the delinquency rate of the total loan portfolio?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that discusses the delinquency rates of the loan portfolio. This section is titled \"Loan Delinquency Rates.\"\n\n2. **Locate the specific data**: Within the \"Loan Delinquency Rates\" section, there is a table that provides the delinquency rates for different periods.\n\n3. **Extract the required information**: The table shows the delinquency rates for the total loan portfolio as of December 31, 2023 and December 31, 2022.\n\nHere is the relevant excerpt from the document:\n\n> The delinquency rate of our total loan portfolio decreased to 0.41% at December 31, 2023 from 0.50% at December 31, 2022.\n\n4. **Match the information to the options**: The delinquency rate as of December 31, 2023 is 0.41%.\n\n5. **Select the correct answer**: The correct answer is **B: 0.41%**.\n\nTherefore, the delinquency rate of the total loan portfolio as of December 31, 2023 is **0.41%**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 32000, "result": 1.0, "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?", "options": {"A": "10 years from its earliest U.S. non-provisional filing date", "B": "15 years from its earliest U.S. non-provisional filing date", "C": "20 years from its earliest U.S. non-provisional filing date", "D": "25 years from its earliest U.S. non-provisional filing date", "E": "30 years from its earliest U.S. non-provisional filing date", "F": "35 years from its earliest U.S. non-provisional filing date"}, "LLM_original_answer": ["To answer the question \"What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for any mention of patent durations in the United States.\n2. **Extract the Information**: Find the specific statement that addresses the duration of a patent's natural expiration.\n3. **Match the Information to the Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document discusses various aspects of intellectual property, including patents. I will look for a section that specifically mentions the duration of patents in the United States.\n\n### Step 2: Extract the Information\nI found the following relevant passage in the document:\n\n> \"For example, in the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date.\"\n\n### Step 3: Match the Information to the Options\nThe extracted information states that the natural expiration of a patent in the United States is generally 20 years from its earliest U.S. non-provisional filing date. This matches directly with option C.\n\n### Conclusion\nThe correct answer is **C: 20 years from its earliest U.S. non-provisional filing date**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 32000, "result": 1.0, "question": "What was the target hedge coverage ratio in December 2023?", "options": {"A": "25%", "B": "50%", "C": "60%", "D": "75%", "E": "90%", "F": "100%"}, "LLM_original_answer": ["To answer the question \"What was the target hedge coverage ratio in December 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss the hedge coverage ratio and any changes made to it over time.\n2. **Extract Information**: Extract the specific information about the target hedge coverage ratio in December 2023.\n3. **Match to Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe document mentions the hedge coverage ratio in the \"MSR Hedging Strategy\" section under \"Item 7A. Quantitative and Qualitative Disclosures About Market Risk.\"\n\n### Step 2: Extract Information\nFrom the \"MSR Hedging Strategy\" section, the following information is relevant:\n- **Prior to September 2022**: The hedge coverage ratio was required to remain within a minimum of 40% and a maximum of 60%.\n- **Effective September 2022**: A minimum 25% and 30% hedge coverage ratios were required for interest rate declines less than and more than 50 basis points, respectively.\n- **During the second quarter of 2023**: Management raised its minimum hedge coverage ratio to 60%.\n- **Effective December 2023**: We established a targeted hedge coverage ratio range between 95% and 105%.\n\n### Step 3: Match to Options\nThe options provided are:\n- A: 25%\n- B: 50%\n- C: 60%\n- D: 75%\n- E: 90%\n- F: 100%\n\nFrom the extracted information, the target hedge coverage ratio in December 2023 was set to a range between 95% and 105%. The closest option to this range is:\n\n- **F: 100%**\n\n### Conclusion\nThe target hedge coverage ratio in December 2023 was **100%**. Therefore, the correct answer is **F: 100%**."], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 35, "token_lengths": 32000, "result": 1.0, "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?", "options": {"A": "Lack of sufficient product supply", "B": "Disagreement on clinical trial design", "C": "Inadequate number of patients", "D": "Site deviation from protocol", "E": "Unexpected health risks to participants", "F": "Public health crises effects"}, "LLM_original_answer": ["To answer the question \"Which factor can delay or terminate a clinical trial due to regulatory authority involvement?\" based on the provided document, I will analyze the relevant sections step by step:\n\n1. **Regulatory Disagreements and Clinical Trial Design:**\n   - The document mentions that clinical trials can be delayed or terminated due to \"the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials\" (p. 61).\n   - This aligns with option B: \"Disagreement on clinical trial design.\"\n\n2. **Unforeseen Safety Issues or Adverse Side Effects:**\n   - The document states that clinical trials can be delayed or terminated due to \"unforeseen safety issues or adverse side effects\" (p. 61).\n   - This aligns with option E: \"Unexpected health risks to participants.\"\n\n3. **Site Deviation from Protocol:**\n   - The document also mentions that clinical trials can be delayed or terminated due to \"clinical trial sites deviating from the approved clinical trial protocol or dropping out of a clinical trial\" (p. 61).\n   - This aligns with option D: \"Site deviation from protocol.\"\n\n4. **Public Health Crises:**\n   - The document discusses the potential impact of public health crises, such as the lingering effects of the COVID-19 pandemic, on clinical trial operations (p. 64).\n   - This aligns with option F: \"Public health crises effects.\"\n\n5. **Lack of Sufficient Product Supply:**\n   - The document mentions that \"manufacturing sufficient quantities of qualified materials under cGMPs, including current Good Tissue Practices (cGTPs), and applying them on a subject-by-subject basis for use in clinical trials\" can cause delays (p. 61).\n   - This aligns with option A: \"Lack of sufficient product supply.\"\n\n6. **Inadequate Number of Patients:**\n   - The document discusses the challenges of recruiting and retaining an adequate number of suitable patients to participate in clinical trials (p. 61).\n   - This aligns with option C: \"Inadequate number of patients.\"\n\nGiven the above analysis, the factors that can delay or terminate a clinical trial due to regulatory authority involvement are:\n\n- **Disagreement on clinical trial design (B)**\n- **Unexpected health risks to participants (E)**\n- **Site deviation from protocol (D)**\n- **Public health crises effects (F"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 32000, "result": 1.0, "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?", "options": {"A": "The donations are not tax-deductible.", "B": "They have been used to promote branded drugs over cheaper alternatives.", "C": "They require excessive paperwork for approval.", "D": "They are not sufficient to cover all patient needs.", "E": "They are banned by all federal laws.", "F": "They are mismanaged by charitable organizations."}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the main issue with donations to patient assistance programs by pharmaceutical manufacturers.\n\n1. **Search for Relevant Information**:\n   - The document discusses various aspects of the pharmaceutical industry, including regulatory, financial, and commercial challenges.\n   - It specifically mentions patient assistance programs and the scrutiny they face from government and regulatory bodies.\n\n2. **Identify Key Points**:\n   - The document states: \"Donations to patient assistance programs have received some negative publicity and have been the subject of multiple government enforcement actions, related to allegations regarding their misuse to promote branded pharmaceutical products over other less costly alternatives.\"\n   - This indicates that there is a concern about the misuse of these programs to promote branded drugs.\n\n3. **Evaluate the Options**:\n   - **Option A**: The donations are not tax-deductible. The document does not mention tax-deductibility as a main issue.\n   - **Option B**: They have been used to promote branded drugs over cheaper alternatives. This aligns with the information found in the document.\n   - **Option C**: They require excessive paperwork for approval. The document does not mention excessive paperwork as a main issue.\n   - **Option D**: They are not sufficient to cover all patient needs. The document does not focus on the sufficiency of the donations.\n   - **Option E**: They are banned by all federal laws. The document does not suggest that these programs are banned.\n   - **Option F**: They are mismanaged by charitable organizations. While the document mentions scrutiny and enforcement actions, it does not specifically state that mismanagement by charitable organizations is the main issue.\n\n4. **Conclusion**:\n   - Based on the information provided, the main issue with donations to patient assistance programs by pharmaceutical manufacturers is that they have been used to promote branded drugs over cheaper alternatives.\n\nTherefore, the correct answer is **Option B: They have been used to promote branded drugs over cheaper alternatives.**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 32000, "result": 1.0, "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?", "options": {"A": "Innovative product features", "B": "Reputation", "C": "Market share", "D": "Low pricing strategy", "E": "Employee satisfaction", "F": "Advertising campaigns"}, "LLM_original_answer": ["To answer the question \"What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?\" based on the provided document, I will analyze the content step by step:\n\n1. **Reputation and Regulatory Scrutiny**:\n   - The document emphasizes the importance of maintaining a good reputation, especially in the context of regulatory scrutiny and legal proceedings. For example, it states, \"Damage to our reputation could damage our business. Our business is highly competitive and our customers have options on where to conduct their business. Maintaining our reputation is critical to attracting and retaining customers and investors and for maintaining our relationships with our regulators.\"\n   - This directly links reputation to the ability to attract and retain customers, investors, and maintain relationships with regulators.\n\n2. **Regulatory Compliance**:\n   - The document discusses the extensive regulatory environment and the need to comply with various laws and regulations. It mentions, \"We are and will continue to be subject to extensive regulation in many jurisdictions around the world, and in particular in the U.S. and the U.K.\"\n   - While regulatory compliance is important, the document does not explicitly state that it is the primary factor for attracting and retaining customers, investors, and maintaining relationships with regulators.\n\n3. **Product Innovation and Market Share**:\n   - The document mentions the need to innovate and compete, such as \"We must continue to enhance and improve the responsiveness, functionality, accessibility and reliability of our electronic platforms and our proprietary and acquired technology.\"\n   - However, these aspects are discussed more in the context of maintaining competitive advantage rather than directly attracting and retaining customers, investors, and maintaining regulatory relationships.\n\n4. **Pricing Strategy**:\n   - The document notes, \"We also face pricing competition in many areas of our business.\"\n   - Pricing is mentioned as a competitive factor but not as a primary factor for maintaining relationships with regulators.\n\n5. **Employee Satisfaction**:\n   - The document discusses the importance of retaining key personnel, but this is more about internal operations and strategic execution rather than directly attracting and retaining customers, investors, and maintaining regulatory relationships.\n\n6. **Advertising Campaigns**:\n   - The document does not mention advertising campaigns as a critical factor for attracting and retaining customers, investors, and maintaining regulatory relationships.\n\nGiven the above analysis, the aspect that is most explicitly and critically linked to attracting and retaining customers, investors, and maintaining relationships with regulators is **Reputation**.\n\nTherefore, the correct answer is:\n**B: Reputation**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 32000, "result": 1.0, "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?", "options": {"A": "Only changes in interest rates", "B": "Changes in interest rates and credit spreads only", "C": "Interest rates, exchange rates, and assumptions used in models", "D": "Volatility and default risk only", "E": "Nonperformance risk and liquidity only", "F": "Only changes in financial indices"}, "LLM_original_answer": ["To answer the question \"What can affect the valuation of freestanding derivatives when quoted market values are unavailable?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Document Context**:\n   - The document discusses the use of freestanding derivatives to hedge various capital markets risks in insurance products.\n   - It mentions that the determination of the estimated fair value of freestanding derivatives, when quoted market values are not available, is based on market standard valuation methodologies and inputs.\n\n2. **Relevant Section**:\n   - The section \"Derivatives\" in the document states: \"The determination of the estimated fair value of freestanding derivatives, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments.\"\n   - It further specifies: \"Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models.\"\n\n3. **Analysis**:\n   - **Interest Rates**: Changes in interest rates can affect the valuation of derivatives, as mentioned in the document.\n   - **Foreign Currency Exchange Rates**: The document explicitly states that changes in foreign currency exchange rates can affect the valuation.\n   - **Financial Indices**: The document mentions that financial indices can affect the valuation.\n   - **Credit Spreads**: The document explicitly states that credit spreads can affect the valuation.\n   - **Default Risk**: The document mentions that default risk can affect the valuation.\n   - **Nonperformance Risk**: The document explicitly states that nonperformance risk can affect the valuation.\n   - **Volatility**: The document explicitly states that volatility can affect the valuation.\n   - **Liquidity**: The document explicitly states that liquidity can affect the valuation.\n   - **Changes in Estimates and Assumptions**: The document mentions that changes in estimates and assumptions used in the pricing models can affect the valuation.\n\n4. **Matching to Options**:\n   - **Option A**: Only changes in interest rates. This is too narrow as the document lists multiple factors.\n   - **Option B**: Changes in interest rates and credit spreads only. This is also too narrow.\n   - **Option C**: Interest rates, exchange rates, and assumptions used in models. This is partially correct but does not include all the factors.\n   - **Option D**: Volatility and default risk only"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 64000, "result": 1.0, "question": "Which company is developing AV-101 for the treatment of PAH?", "options": {"A": "Aerovate Therapeutics, Inc.", "B": "Gossamer Bio, Inc.", "C": "Acceleron", "D": "Regeneron Pharmaceuticals, Inc.", "E": "Biohaven Ltd.", "F": "Versanis Bio"}, "LLM_original_answer": ["To answer the question \"Which company is developing AV-101 for the treatment of PAH?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant information**: The document mentions several companies and their product candidates, but it does not specifically mention AV-101 or its development for PAH.\n\n2. **Cross-reference the options with the document**:\n   - **A: Aerovate Therapeutics, Inc.**: The document mentions Aerovate Therapeutics, Inc. as developing a clinical-stage product candidate for the treatment of PAH.\n   - **B: Gossamer Bio, Inc.**: The document mentions Gossamer Bio, Inc. as developing seralutinib for the treatment of PAH.\n   - **C: Acceleron**: The document mentions Acceleron as developing sotatercept for the treatment of PAH.\n   - **D: Regeneron Pharmaceuticals, Inc.**: The document mentions Regeneron Pharmaceuticals, Inc. as developing several product candidates, but not specifically AV-101 for PAH.\n   - **E: Biohaven Ltd.**: The document mentions Biohaven Ltd. as developing taldefgrobep alfa for the treatment of obesity.\n   - **F: Versanis Bio**: The document mentions Versanis Bio as developing bimagrumab for the treatment of obesity.\n\n3. **Determine the correct answer**: Based on the information provided, Aerovate Therapeutics, Inc. is the company developing a clinical-stage product candidate for the treatment of PAH. The document specifically states: \"Aerovate Therapeutics, Inc. and Gossamer Bio, Inc. are also developing clinical-stage product candidates, AV-101 and seralutinib, respectively, for the treatment of PAH.\"\n\nTherefore, the correct answer is **A: Aerovate Therapeutics, Inc.**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 35, "token_lengths": 64000, "result": 1.0, "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?", "options": {"A": "$285.0 million", "B": "$76.5 million", "C": "$211.6 million", "D": "$135.1 million", "E": "$28.0 million", "F": "$2.0 million"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document step by step:\n\n1. **Identify the relevant section**: The document mentions impairments of property, plant, and equipment in the section \"Impairment of property, plant and equipment.\"\n\n2. **Find the specific impairment details**: The document states:\n   - \"During the quarter ended December 31, 2022, the Company evaluated whether the estimated future undiscounted cash flows from the operation of our data center facilities sites would recover the carrying value of the property, plant and equipment located at the sites and used in site operations, including our deployed mining equipment.\"\n   - \"Based on this evaluation, we determined that the carrying value of the fleet of deployed mining equipment and of the other non-mining equipment property, plant and equipment at the Cedarvale and Cottonwood, Texas facility sites may no longer be fully recoverable by the cash flows of the site.\"\n   - \"We measured the amount of impairment of the fleet of deployed mining equipment as the difference between their carrying amount of $690.4 million and the estimated fair value of $176.3 million, resulting in an impairment of $514.1 million on the fleet of deployed mining equipment for the year ended December 31, 2022.\"\n   - \"We measured the amount of impairment at the identified facility sites as the difference between the carrying amount of the site asset group of $211.6 million and the estimated fair value of the site asset group of $135.1 million, resulting in an impairment of the facility site\u2019s property, plant and equipment of $76.5 million for the year ended December 31, 2022.\"\n\n3. **Determine the carrying amount before impairment**: The carrying amount of the site asset group before impairment is given as $211.6 million.\n\n4. **Match the carrying amount to the options provided**:\n   - A: $285.0 million\n   - B: $76.5 million\n   - C: $211.6 million\n   - D: $135.1 million\n   - E: $28.0 million\n   - F: $2.0 million\n\nThe carrying amount of the site asset group before impairment for the year ended December 31, 2022, is **$211.6 million**.\n\nTherefore,"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 64000, "result": 1.0, "question": "What was classified as discontinued operations in the fourth quarter of 2022?", "options": {"A": "Utility-scale solar and wind group only", "B": "Distributed generation group only", "C": "Utility-scale solar, wind group, and distributed generation group", "D": "Remaining assets only", "E": "Commercial Renewables Disposal Groups", "F": "None of the above"}, "LLM_original_answer": ["To answer the question \"What was classified as discontinued operations in the fourth quarter of 2022?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the relevant section in the document:**\n   - The document mentions the classification of discontinued operations in the \"Discontinued Operations\" section.\n\n2. **Extract the key information:**\n   - The document states: \"In November 2022, Duke Energy committed to a plan to sell the Commercial Renewables business segment, excluding the offshore wind contract for Carolina Long Bay, which was moved to the EU&I segment.\"\n   - It further specifies: \"In June 2023, Duke Energy announced that it had entered into a purchase and sale agreement with affiliates of Brookfield for the sale of the utility-scale solar and wind group.\"\n   - Additionally, it mentions: \"In July 2023, Duke Energy announced that it had entered into a purchase and sale agreement with affiliates of ArcLight for the distributed generation group.\"\n\n3. **Determine the classification:**\n   - The document clearly states: \"The Commercial Renewables Disposal Groups were classified as held for sale and as discontinued operations in the fourth quarter of 2022.\"\n\n4. **Identify the components of the Commercial Renewables Disposal Groups:**\n   - The Commercial Renewables Disposal Groups include:\n     - Utility-scale solar and wind group\n     - Distributed generation group\n     - Remaining assets\n\n5. **Match the components to the options:**\n   - Option A: Utility-scale solar and wind group only\n   - Option B: Distributed generation group only\n   - Option C: Utility-scale solar, wind group, and distributed generation group\n   - Option D: Remaining assets only\n   - Option E: Commercial Renewables Disposal Groups\n   - Option F: None of the above\n\n6. **Select the correct option:**\n   - The correct option is E: Commercial Renewables Disposal Groups, as it encompasses all the components mentioned (utility-scale solar and wind group, distributed generation group, and remaining assets).\n\nTherefore, the answer to the question is **E: Commercial Renewables Disposal Groups**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 35, "token_lengths": 64000, "result": 1.0, "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?", "options": {"A": "0.31%", "B": "0.41%", "C": "0.50%", "D": "0.60%", "E": "0.70%", "F": "0.80%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The delinquency rate of the total loan portfolio is mentioned in the \"Asset quality\" section.\n2. **Extract the specific information**: The delinquency rate is provided for both December 31, 2023, and December 31, 2022.\n3. **Match the information to the options provided**.\n\n### Step 1: Identify the relevant section\nThe relevant section is found in the \"Asset quality\" part of the document.\n\n### Step 2: Extract the specific information\nFrom the document:\n\"The delinquency rate of our total loan portfolio decreased to 0.41% at December 31, 2023 from 0.50% at December 31, 2022.\"\n\n### Step 3: Match the information to the options provided\nThe delinquency rate of the total loan portfolio as of December 31, 2023, is 0.41%.\n\n### Conclusion\nThe correct answer is **B: 0.41%**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 64000, "result": 1.0, "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?", "options": {"A": "10 years from its earliest U.S. non-provisional filing date", "B": "15 years from its earliest U.S. non-provisional filing date", "C": "20 years from its earliest U.S. non-provisional filing date", "D": "25 years from its earliest U.S. non-provisional filing date", "E": "30 years from its earliest U.S. non-provisional filing date", "F": "35 years from its earliest U.S. non-provisional filing date"}, "LLM_original_answer": ["To answer the question \"What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for any mention of patent expiration or duration in the United States.\n2. **Extract the Information**: Once identified, extract the specific details about the patent duration.\n3. **Match the Information to the Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document contains a section that discusses patent protection and its duration. The relevant part is:\n\n> \"For example, in the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date.\"\n\n### Step 2: Extract the Information\nThe key information from this section is:\n- The natural expiration of a patent in the United States is generally 20 years.\n- This duration is from the earliest U.S. non-provisional filing date.\n\n### Step 3: Match the Information to the Options\nThe options provided are:\n- A: 10 years from its earliest U.S. non-provisional filing date\n- B: 15 years from its earliest U.S. non-provisional filing date\n- C: 20 years from its earliest U.S. non-provisional filing date\n- D: 25 years from its earliest U.S. non-provisional filing date\n- E: 30 years from its earliest U.S. non-provisional filing date\n- F: 35 years from its earliest U.S. non-provisional filing date\n\nThe extracted information matches option C: 20 years from its earliest U.S. non-provisional filing date.\n\n### Conclusion\nThe correct answer is **C: 20 years from its earliest U.S. non-provisional filing date**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 64000, "result": 1.0, "question": "What was the target hedge coverage ratio in December 2023?", "options": {"A": "25%", "B": "50%", "C": "60%", "D": "75%", "E": "90%", "F": "100%"}, "LLM_original_answer": ["To answer the question \"What was the target hedge coverage ratio in December 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss the target hedge coverage ratio and any changes made to it over time.\n2. **Extract Specific Information**: Find the exact statement or data point that specifies the target hedge coverage ratio in December 2023.\n3. **Verify and Conclude**: Ensure the information is accurate and relevant to the question, then provide the answer.\n\n### Step 1: Identify Relevant Sections\nThe document mentions the target hedge coverage ratio in the \"MSR Hedging Strategy\" section under \"Item 7A. Quantitative and Qualitative Disclosures About Market Risk.\"\n\n### Step 2: Extract Specific Information\nFrom the \"MSR Hedging Strategy\" section, the following information is relevant:\n- \"Effective December 2023, we established a targeted hedge coverage ratio range between 95% and 105%.\"\n\n### Step 3: Verify and Conclude\nThe document clearly states that the targeted hedge coverage ratio range was established between 95% and 105% in December 2023. However, the question asks for a single target hedge coverage ratio, and the closest option to this range is 100%.\n\n### Conclusion\nThe target hedge coverage ratio in December 2023 was **100%**.\n\nTherefore, the correct answer is:\n**F: 100%**."], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 35, "token_lengths": 64000, "result": 1.0, "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?", "options": {"A": "Lack of sufficient product supply", "B": "Disagreement on clinical trial design", "C": "Inadequate number of patients", "D": "Site deviation from protocol", "E": "Unexpected health risks to participants", "F": "Public health crises effects"}, "LLM_original_answer": ["To answer the question \"Which factor can delay or terminate a clinical trial due to regulatory authority involvement?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Lack of sufficient product supply (Option A)**:\n   - The document mentions that delays can occur if there are issues with manufacturing processes or if third-party manufacturers fail to provide sufficient product supply. However, it does not explicitly state that this is a factor that can delay or terminate a clinical trial due to regulatory authority involvement.\n\n2. **Disagreement on clinical trial design (Option B)**:\n   - The document states, \"the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials\" can lead to delays or termination. This is a clear indication that regulatory authorities can delay or terminate a trial if they disagree with the design.\n\n3. **Inadequate number of patients (Option C)**:\n   - The document mentions that \"recruiting suitable patients to participate in a clinical trial\" can be a challenge and can delay the trial. However, it does not explicitly state that regulatory authorities can terminate a trial due to an inadequate number of patients.\n\n4. **Site deviation from protocol (Option D)**:\n   - The document states, \"clinical trial sites deviating from the approved clinical trial protocol or dropping out of a clinical trial\" can lead to delays or termination. This is a clear indication that regulatory authorities can delay or terminate a trial if sites deviate from the protocol.\n\n5. **Unexpected health risks to participants (Option E)**:\n   - The document mentions that \"unforeseen safety issues or adverse side effects\" can lead to the suspension or termination of a clinical trial. This is a clear indication that regulatory authorities can delay or terminate a trial if there are unexpected health risks to participants.\n\n6. **Public health crises effects (Option F)**:\n   - The document discusses the impact of public health crises, such as the COVID-19 pandemic, on clinical trials. It mentions that these crises can cause delays in patient enrollment and other logistical issues, but it does not explicitly state that regulatory authorities can terminate a trial due to public health crises.\n\nBased on the analysis, the factors that can delay or terminate a clinical trial due to regulatory authority involvement are:\n- **Disagreement on clinical trial design (Option B)**\n- **Site deviation from protocol (Option D)**\n- **Unexpected health risks to participants (Option E)**\n\nHowever, the question asks for a single factor."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 64000, "result": 1.0, "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?", "options": {"A": "The donations are not tax-deductible.", "B": "They have been used to promote branded drugs over cheaper alternatives.", "C": "They require excessive paperwork for approval.", "D": "They are not sufficient to cover all patient needs.", "E": "They are banned by all federal laws.", "F": "They are mismanaged by charitable organizations."}, "LLM_original_answer": ["The main issue with donations to patient assistance programs by pharmaceutical manufacturers, as indicated in the provided document, is that they have been used to promote branded drugs over cheaper alternatives. This is highlighted in the section discussing the risks related to our relationships with healthcare providers, physicians, patients, and third-party payors:\n\n\"Specifically, there have been multiple settlements resulting out of government claims challenging the legality of third party patient assistance programs under a variety of federal and state laws. We have in the past and may, from time to time, make charitable grants to independent charitable foundations that help financially needy patients with their premium, co-pay, and co-insurance obligations. If we choose to do so, and if we or our vendors or donation recipients are deemed to fail to comply with relevant laws, regulations or evolving government guidance in the provision of charitable donations or operation of these programs, we could be subject to damages, fines, penalties, or other criminal, civil, or administrative sanctions or enforcement actions.\"\n\nThis suggests that the misuse of patient assistance programs to promote branded drugs over cheaper alternatives has been a significant concern and has led to legal challenges and settlements.\n\nTherefore, the correct answer is:\n\n**B: They have been used to promote branded drugs over cheaper alternatives.**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 64000, "result": 1.0, "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?", "options": {"A": "Innovative product features", "B": "Reputation", "C": "Market share", "D": "Low pricing strategy", "E": "Employee satisfaction", "F": "Advertising campaigns"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the aspect that is emphasized as critical for attracting and retaining customers, investors, and maintaining relationships with regulators.\n\n### Step-by-Step Analysis:\n\n1. **Reputation**:\n   - The document explicitly states: \"Maintaining our reputation is critical to attracting and retaining customers and investors and for maintaining our relationships with our regulators.\"\n   - It also mentions that negative publicity or issues regarding products, services, operations, risk management, compliance with regulations, political affiliations, or the management team could give rise to reputational risk, which could significantly harm the business and its prospects.\n\n2. **Innovative Product Features**:\n   - While the document discusses the importance of maintaining and expanding product offerings, it does not emphasize this as the primary critical factor for attracting and retaining customers, investors, and maintaining regulatory relationships.\n\n3. **Market Share**:\n   - The document does not specifically highlight market share as a critical factor for attracting and retaining customers, investors, and maintaining regulatory relationships.\n\n4. **Low Pricing Strategy**:\n   - The document mentions pricing competition but does not suggest that a low pricing strategy is critical for attracting and retaining customers, investors, and maintaining regulatory relationships.\n\n5. **Employee Satisfaction**:\n   - The document discusses the importance of attracting and retaining key personnel, but it does not emphasize employee satisfaction as the primary critical factor for attracting and retaining customers, investors, and maintaining regulatory relationships.\n\n6. **Advertising Campaigns**:\n   - The document does not mention advertising campaigns as a critical factor for attracting and retaining customers, investors, and maintaining regulatory relationships.\n\n### Conclusion:\nBased on the document, the aspect that is explicitly and critically emphasized for attracting and retaining customers, investors, and maintaining relationships with regulators is **Reputation**.\n\n### Final Answer:\n**B: Reputation**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 64000, "result": 1.0, "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?", "options": {"A": "Only changes in interest rates", "B": "Changes in interest rates and credit spreads only", "C": "Interest rates, exchange rates, and assumptions used in models", "D": "Volatility and default risk only", "E": "Nonperformance risk and liquidity only", "F": "Only changes in financial indices"}, "LLM_original_answer": ["To answer the question \"What can affect the valuation of freestanding derivatives when quoted market values are unavailable?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Valuation Methodology**:\n   - The document states that the determination of the estimated fair value of freestanding derivatives, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments.\n\n2. **Inputs and Factors**:\n   - The document lists several factors that can affect the valuation of freestanding derivatives:\n     - **Changes in interest rates**: Interest rates can significantly impact the value of derivatives, especially those that are interest rate sensitive.\n     - **Foreign currency exchange rates**: For derivatives that involve foreign currencies, changes in exchange rates can affect their value.\n     - **Financial indices**: Changes in financial indices can influence the value of derivatives that are linked to these indices.\n     - **Credit spreads**: Credit spreads can affect the valuation, particularly for credit derivatives.\n     - **Default risk**: The risk of default by counterparties can impact the valuation.\n     - **Nonperformance risk**: This is the risk that the company fails to satisfy its obligations, which is captured as an additional spread applied to the risk-free rate.\n     - **Volatility**: Volatility in the underlying markets (e.g., equity markets) can affect the value of derivatives.\n     - **Liquidity**: The liquidity of the underlying assets can influence the valuation, especially in times of market disruption.\n     - **Changes in estimates and assumptions used in the pricing models**: Management's assumptions and estimates can significantly impact the valuation.\n\n3. **Combining the Factors**:\n   - The document emphasizes that the valuation of derivatives can be affected by a combination of these factors, and it requires a high degree of management judgment or estimation, especially when using significant unobservable inputs (Level 3 derivatives).\n\n4. **Conclusion**:\n   - Based on the information provided, the factors that can affect the valuation of freestanding derivatives when quoted market values are unavailable include interest rates, exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, and liquidity, as well as changes in estimates and assumptions used in the pricing models.\n\nTherefore, the correct answer is:\n\n**C: Interest rates, exchange rates, and assumptions used in models**\n\nThis option best captures the comprehensive list of factors mentioned in the document that can affect the valuation of"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 96000, "result": 1.0, "question": "Which company is developing AV-101 for the treatment of PAH?", "options": {"A": "Aerovate Therapeutics, Inc.", "B": "Gossamer Bio, Inc.", "C": "Acceleron", "D": "Regeneron Pharmaceuticals, Inc.", "E": "Biohaven Ltd.", "F": "Versanis Bio"}, "LLM_original_answer": ["To answer the question \"Which company is developing AV-101 for the treatment of PAH?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that discusses various companies and their product candidates for the treatment of PAH (Pulmonary Arterial Hypertension).\n\n2. **Extract the relevant information**: The relevant information is found in the following excerpt:\n   - \"Aerovate Therapeutics, Inc. and Gossamer Bio, Inc. are also developing clinical-stage product candidates, AV-101 and seralutinib, respectively, for the treatment of PAH.\"\n\n3. **Analyze the information**: The excerpt clearly states that Aerovate Therapeutics, Inc. is developing AV-101 for the treatment of PAH.\n\n4. **Match the information to the options provided**:\n   - Option A: Aerovate Therapeutics, Inc.\n   - Option B: Gossamer Bio, Inc.\n   - Option C: Acceleron\n   - Option D: Regeneron Pharmaceuticals, Inc.\n   - Option E: Biohaven Ltd.\n   - Option F: Versanis Bio\n\n5. **Select the correct answer**: Based on the information extracted, the correct answer is Option A: Aerovate Therapeutics, Inc.\n\nTherefore, the company developing AV-101 for the treatment of PAH is **Aerovate Therapeutics, Inc.**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 35, "token_lengths": 96000, "result": 1.0, "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?", "options": {"A": "$285.0 million", "B": "$76.5 million", "C": "$211.6 million", "D": "$135.1 million", "E": "$28.0 million", "F": "$2.0 million"}, "LLM_original_answer": ["To answer the question regarding the carrying amount of the site asset group before impairment for the year ended December 31, 2022, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains detailed financial information, including impairments of property, plant, and equipment. The relevant section is found in Note 5 \u2014 Property, Plant and Equipment, Net.\n\n2. **Locate the specific impairment information**: In the section, there is a detailed breakdown of the impairments recognized during the year ended December 31, 2022.\n\n3. **Extract the carrying amount and fair value**: The document states:\n   - \"The Company measured the amount of impairment of its other property, plant and equipment at the Cedarvale and Cottonwood, Texas facility sites as the difference between their carrying amount of the site asset group of $211.6 million and the estimated fair value of the site asset group of $135.1 million, resulting in an impairment of the other site property, plant and equipment of $76.5 million for the year ended December 31, 2022.\"\n\n4. **Confirm the carrying amount before impairment**: The carrying amount of the site asset group before impairment is explicitly stated as $211.6 million.\n\nTherefore, the carrying amount of the site asset group before impairment for the year ended December 31, 2022, is $211.6 million.\n\nThe correct answer is:\n**C: $211.6 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 96000, "result": 0.0, "question": "What was classified as discontinued operations in the fourth quarter of 2022?", "options": {"A": "Utility-scale solar and wind group only", "B": "Distributed generation group only", "C": "Utility-scale solar, wind group, and distributed generation group", "D": "Remaining assets only", "E": "Commercial Renewables Disposal Groups", "F": "None of the above"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The document mentions the sale of the Commercial Renewables business segment in the \"Dispositions\" section (Note 2).\n\n2. **Extract the key information**:\n   - In November 2022, Duke Energy committed to a plan to sell the Commercial Renewables business segment, excluding the offshore wind contract for Carolina Long Bay.\n   - The utility-scale solar and wind group, the distributed generation group, and the remaining assets (collectively, Commercial Renewables Disposal Groups) were classified as discontinued operations in the fourth quarter of 2022.\n\n3. **Determine the classification**:\n   - The utility-scale solar and wind group, the distributed generation group, and the remaining assets were all classified as discontinued operations in the fourth quarter of 2022.\n\n4. **Match the information to the options**:\n   - **Option A**: Utility-scale solar and wind group only\n   - **Option B**: Distributed generation group only\n   - **Option C**: Utility-scale solar, wind group, and distributed generation group\n   - **Option D**: Remaining assets only\n   - **Option E**: Commercial Renewables Disposal Groups\n   - **Option F**: None of the above\n\nGiven that the document explicitly states that the utility-scale solar and wind group, the distributed generation group, and the remaining assets were all classified as discontinued operations, the correct answer is:\n\n**Option C: Utility-scale solar, wind group, and distributed generation group**\n\nThis option accurately reflects the information provided in the document."], "LLM_extracted_answer": ["C"], "ground_truth": "E"}, {"depth": 35, "token_lengths": 96000, "result": 1.0, "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?", "options": {"A": "0.31%", "B": "0.41%", "C": "0.50%", "D": "0.60%", "E": "0.70%", "F": "0.80%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The delinquency rate of the total loan portfolio is mentioned in the \"Asset Quality\" section of the document.\n\n2. **Locate the specific information**: The document states, \"The delinquency rate of our total loan portfolio decreased to 0.41% at December 31, 2023 from 0.50% at December 31, 2022.\"\n\n3. **Match the information to the options provided**: The delinquency rate as of December 31, 2023 is 0.41%.\n\n4. **Select the correct answer**: The correct answer is **B: 0.41%**.\n\nTherefore, the delinquency rate of the total loan portfolio as of December 31, 2023 is **0.41%**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 96000, "result": 1.0, "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?", "options": {"A": "10 years from its earliest U.S. non-provisional filing date", "B": "15 years from its earliest U.S. non-provisional filing date", "C": "20 years from its earliest U.S. non-provisional filing date", "D": "25 years from its earliest U.S. non-provisional filing date", "E": "30 years from its earliest U.S. non-provisional filing date", "F": "35 years from its earliest U.S. non-provisional filing date"}, "LLM_original_answer": ["To answer the question \"What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for any mention of patent expiration in the United States.\n2. **Extract Specific Details**: Look for the exact duration mentioned.\n3. **Verify and Conclude**: Ensure the information is accurate and relevant to the question.\n\n### Step 1: Identify Relevant Information\nThe document contains a section that discusses patent term extension and the natural expiration of patents. The relevant part is:\n\n> \"In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date.\"\n\n### Step 2: Extract Specific Details\nThe specific detail mentioned is:\n- **20 years from its earliest U.S. non-provisional filing date**.\n\n### Step 3: Verify and Conclude\nThis information directly answers the question. The typical duration of a patent's natural expiration in the United States, assuming all maintenance fees are paid, is 20 years from its earliest U.S. non-provisional filing date.\n\n### Conclusion\nThe correct answer is:\n**C: 20 years from its earliest U.S. non-provisional filing date**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 96000, "result": 1.0, "question": "What was the target hedge coverage ratio in December 2023?", "options": {"A": "25%", "B": "50%", "C": "60%", "D": "75%", "E": "90%", "F": "100%"}, "LLM_original_answer": ["To answer the question \"What was the target hedge coverage ratio in December 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss hedging strategies and specifically mention the target hedge coverage ratio.\n2. **Extract Information**: Find the specific information about the target hedge coverage ratio in December 2023.\n3. **Match Information to Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe document mentions the target hedge coverage ratio in the \"MSR Hedging Strategy\" section under \"Item 7A. Quantitative and Qualitative Disclosures About Market Risk.\"\n\n### Step 2: Extract Information\nFrom the \"MSR Hedging Strategy\" section, the following information is relevant:\n- \"Effective December 2023, we established a targeted hedge coverage ratio range between 95% and 105%.\"\n\n### Step 3: Match Information to Options\nThe options provided are:\n- A: 25%\n- B: 50%\n- C: 60%\n- D: 75%\n- E: 90%\n- F: 100%\n\nThe document states that the targeted hedge coverage ratio range in December 2023 was between 95% and 105%. The closest option to this range is F: 100%.\n\n### Conclusion\nThe target hedge coverage ratio in December 2023 was 100%.\n\nTherefore, the correct answer is **F: 100%**."], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 35, "token_lengths": 96000, "result": 0.0, "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?", "options": {"A": "Lack of sufficient product supply", "B": "Disagreement on clinical trial design", "C": "Inadequate number of patients", "D": "Site deviation from protocol", "E": "Unexpected health risks to participants", "F": "Public health crises effects"}, "LLM_original_answer": ["To answer the question, \"Which factor can delay or terminate a clinical trial due to regulatory authority involvement?\" we need to identify the options that align with the information provided in the document. Let's evaluate each option:\n\nA: Lack of sufficient product supply\n- The document mentions that manufacturing issues can delay clinical trials, but it does not specifically state that a lack of product supply can lead to termination by regulatory authorities. It is more about the company's ability to manage and produce the necessary quantities.\n\nB: Disagreement on clinical trial design\n- The document states, \"the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials\" can cause delays or termination. This is a clear match.\n\nC: Inadequate number of patients\n- The document mentions that \"recruiting suitable patients to participate in a clinical trial\" can cause delays, but it does not explicitly state that this can lead to termination by regulatory authorities.\n\nD: Site deviation from protocol\n- The document states, \"clinical trial sites deviating from the approved clinical trial protocol or dropping out of a clinical trial\" can cause delays or termination. This is also a clear match.\n\nE: Unexpected health risks to participants\n- The document mentions, \"unforeseen safety issues or adverse side effects\" can cause delays or termination. This is a clear match.\n\nF: Public health crises effects\n- The document discusses the impact of public health crises like the COVID-19 pandemic on clinical trials, but it does not explicitly state that this can lead to termination by regulatory authorities. It is more about the operational challenges and delays.\n\nBased on the document, the factors that can delay or terminate a clinical trial due to regulatory authority involvement are:\n- Disagreement on clinical trial design (Option B)\n- Site deviation from protocol (Option D)\n- Unexpected health risks to participants (Option E)\n\nTherefore, the correct answer is:\n**B, D, and E**."], "LLM_extracted_answer": ["D"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 96000, "result": 1.0, "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?", "options": {"A": "The donations are not tax-deductible.", "B": "They have been used to promote branded drugs over cheaper alternatives.", "C": "They require excessive paperwork for approval.", "D": "They are not sufficient to cover all patient needs.", "E": "They are banned by all federal laws.", "F": "They are mismanaged by charitable organizations."}, "LLM_original_answer": ["To answer the question, I will analyze the provided document for information related to the main issue with donations to patient assistance programs by pharmaceutical manufacturers.\n\n### Step-by-Step Analysis:\n\n1. **Relevant Section Identification**:\n   - The relevant section is found under \"Risks Related to Our Common Stock\" and \"Risks Related to Our Business Operations, Employee Matters and Managing Growth.\"\n\n2. **Key Information Extraction**:\n   - **Anti-Kickback Statute and False Claims Act**:\n     - The document mentions that the Anti-Kickback Statute (AKS) and the False Claims Act (FCA) are laws that regulate the promotion and marketing of pharmaceutical products.\n     - These laws may constrain business or financial arrangements and relationships through which companies conduct research, sell, market, and distribute pharmaceutical products.\n     - The document also notes that donations to patient assistance programs have received negative publicity and have been the subject of multiple government enforcement actions, related to allegations regarding their misuse to promote branded pharmaceutical products over other less costly alternatives.\n   - **Compliance and Penalties**:\n     - The document states that if a company or its vendors or donation recipients are deemed to fail to comply with relevant laws, regulations, or evolving government guidance, they could be subject to damages, fines, penalties, or other criminal, civil, or administrative sanctions.\n   - **Impact on Business**:\n     - The document highlights that these issues could result in fewer patients using affected products, which could have a material adverse effect on the company's sales, business, and financial condition.\n\n3. **Option Analysis**:\n   - **Option A: The donations are not tax-deductible.**\n     - The document does not mention tax-deductibility as a main issue.\n   - **Option B: They have been used to promote branded drugs over cheaper alternatives.**\n     - The document explicitly mentions that donations to patient assistance programs have been the subject of multiple government enforcement actions due to allegations of misuse to promote branded pharmaceutical products over other less costly alternatives.\n   - **Option C: They require excessive paperwork for approval.**\n     - The document does not mention excessive paperwork as a main issue.\n   - **Option D: They are not sufficient to cover all patient needs.**\n     - The document does not mention this as a main issue.\n   - **Option E: They are banned by all federal laws.**\n     - The document does not mention that donations are banned by all federal laws.\n   - **Option F: They are mismanaged by charitable"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 96000, "result": 1.0, "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?", "options": {"A": "Innovative product features", "B": "Reputation", "C": "Market share", "D": "Low pricing strategy", "E": "Employee satisfaction", "F": "Advertising campaigns"}, "LLM_original_answer": ["To answer the question, \"What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Customer Demand and Economic Conditions**:\n   - The document states, \"Our growth is highly dependent on customer demand for our core products and services, favorable economic conditions, and our ability to invest in our personnel, facilities, infrastructure, and financial and management systems and controls.\"\n   - This indicates that customer demand and economic conditions are crucial for growth, but it does not directly address the aspect critical for attracting and retaining customers, investors, and maintaining relationships with regulators.\n\n2. **Reputation**:\n   - The document mentions, \"Maintaining our reputation is critical to attracting and retaining customers and investors and for maintaining our relationships with our regulators.\"\n   - This statement directly addresses the importance of reputation for attracting and retaining customers, investors, and maintaining relationships with regulators.\n\n3. **Regulatory Compliance**:\n   - The document discusses various regulatory and legal risks, including the need to comply with extensive legislation and regulatory scrutiny.\n   - While regulatory compliance is important, it is a subset of maintaining a good reputation, which encompasses not only compliance but also the perception of the company in the industry and the market.\n\n4. **Product and Service Offerings**:\n   - The document highlights the importance of offering new products and technologies and identifying opportunities.\n   - However, this is more about growth and innovation rather than the critical aspect for attracting and retaining customers, investors, and maintaining relationships with regulators.\n\n5. **Operational and Financial Stability**:\n   - The document mentions the risks associated with operational and financial stability, such as system failures and indebtedness.\n   - While these factors are important for overall business health, they are not specifically highlighted as critical for attracting and retaining customers, investors, and maintaining relationships with regulators.\n\nGiven the above analysis, the aspect that is explicitly stated as critical for attracting and retaining customers, investors, and maintaining relationships with regulators is **reputation**.\n\nTherefore, the correct answer is:\n**B: Reputation**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 96000, "result": 1.0, "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?", "options": {"A": "Only changes in interest rates", "B": "Changes in interest rates and credit spreads only", "C": "Interest rates, exchange rates, and assumptions used in models", "D": "Volatility and default risk only", "E": "Nonperformance risk and liquidity only", "F": "Only changes in financial indices"}, "LLM_original_answer": ["To answer the question \"What can affect the valuation of freestanding derivatives when quoted market values are unavailable?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Document Context**:\n   - The document discusses the financial and operational aspects of Brighthouse Financial, including the valuation of derivatives and the factors that can affect these valuations.\n\n2. **Relevant Section**:\n   - The section \"Summary of Critical Accounting Estimates\" provides specific details about the valuation of freestanding derivatives.\n\n3. **Key Information**:\n   - **Valuation of Freestanding Derivatives**:\n     - \"The determination of the estimated fair value of freestanding derivatives, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments.\"\n     - \"Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models.\"\n\n4. **Analysis**:\n   - **Interest Rates**: Changes in interest rates can affect the valuation of derivatives, particularly those that are interest rate sensitive.\n   - **Foreign Currency Exchange Rates**: For derivatives that involve foreign currencies, changes in exchange rates can impact their valuation.\n   - **Financial Indices**: Changes in financial indices, such as equity indices, can affect the valuation of derivatives linked to these indices.\n   - **Credit Spreads**: Changes in credit spreads can influence the valuation, especially for credit derivatives.\n   - **Default Risk**: The risk of default by counterparties can affect the valuation of derivatives.\n   - **Nonperformance Risk**: The risk that the company fails to satisfy its obligations is captured as an additional spread applied to the risk-free rate.\n   - **Volatility**: Changes in market volatility can impact the valuation of derivatives, particularly those with option-like features.\n   - **Liquidity**: The liquidity of the underlying assets or the market for the derivatives can affect their valuation.\n   - **Changes in Estimates and Assumptions**: The assumptions used in the pricing models, such as those for policyholder behavior, mortality, and risk margins, can significantly affect the valuation.\n\n5. **Conclusion**:\n   - The factors that can affect the valuation of freestanding derivatives when quoted market values are unavailable include interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, non"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 128000, "result": 1.0, "question": "Which company is developing AV-101 for the treatment of PAH?", "options": {"A": "Aerovate Therapeutics, Inc.", "B": "Gossamer Bio, Inc.", "C": "Acceleron", "D": "Regeneron Pharmaceuticals, Inc.", "E": "Biohaven Ltd.", "F": "Versanis Bio"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 35, "token_lengths": 128000, "result": 1.0, "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?", "options": {"A": "$285.0 million", "B": "$76.5 million", "C": "$211.6 million", "D": "$135.1 million", "E": "$28.0 million", "F": "$2.0 million"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 128000, "result": 0.0, "question": "What was classified as discontinued operations in the fourth quarter of 2022?", "options": {"A": "Utility-scale solar and wind group only", "B": "Distributed generation group only", "C": "Utility-scale solar, wind group, and distributed generation group", "D": "Remaining assets only", "E": "Commercial Renewables Disposal Groups", "F": "None of the above"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "E"}, {"depth": 35, "token_lengths": 128000, "result": 0.0, "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?", "options": {"A": "0.31%", "B": "0.41%", "C": "0.50%", "D": "0.60%", "E": "0.70%", "F": "0.80%"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["!"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 128000, "result": 1.0, "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?", "options": {"A": "10 years from its earliest U.S. non-provisional filing date", "B": "15 years from its earliest U.S. non-provisional filing date", "C": "20 years from its earliest U.S. non-provisional filing date", "D": "25 years from its earliest U.S. non-provisional filing date", "E": "30 years from its earliest U.S. non-provisional filing date", "F": "35 years from its earliest U.S. non-provisional filing date"}, "LLM_original_answer": ["The typical duration of a patent's natural expiration in the United States, if all maintenance fees are paid, is 20 years from its earliest U.S. non-provisional filing date. This information is directly stated in the provided document under the section \"Risks Related to Our Intellectual Property\":\n\n\"Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. For example, in the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date.\"\n\nTherefore, the correct answer is:\n\nC: 20 years from its earliest U.S. non-provisional filing date."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 35, "token_lengths": 128000, "result": 0.0, "question": "What was the target hedge coverage ratio in December 2023?", "options": {"A": "25%", "B": "50%", "C": "60%", "D": "75%", "E": "90%", "F": "100%"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "F"}, {"depth": 35, "token_lengths": 128000, "result": 0.0, "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?", "options": {"A": "Lack of sufficient product supply", "B": "Disagreement on clinical trial design", "C": "Inadequate number of patients", "D": "Site deviation from protocol", "E": "Unexpected health risks to participants", "F": "Public health crises effects"}, "LLM_original_answer": ["To answer the question, we need to identify which factor can delay or terminate a clinical trial due to regulatory authority involvement. Let's analyze the options provided in the context of the document"], "LLM_extracted_answer": ["D"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 128000, "result": 1.0, "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?", "options": {"A": "The donations are not tax-deductible.", "B": "They have been used to promote branded drugs over cheaper alternatives.", "C": "They require excessive paperwork for approval.", "D": "They are not sufficient to cover all patient needs.", "E": "They are banned by all federal laws.", "F": "They are mismanaged by charitable organizations."}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 128000, "result": 1.0, "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?", "options": {"A": "Innovative product features", "B": "Reputation", "C": "Market share", "D": "Low pricing strategy", "E": "Employee satisfaction", "F": "Advertising campaigns"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 35, "token_lengths": 128000, "result": 1.0, "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?", "options": {"A": "Only changes in interest rates", "B": "Changes in interest rates and credit spreads only", "C": "Interest rates, exchange rates, and assumptions used in models", "D": "Volatility and default risk only", "E": "Nonperformance risk and liquidity only", "F": "Only changes in financial indices"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 8000, "result": 1.0, "question": "What could happen if there are delays in the clinical trials of product candidates?", "options": {"A": "The marketing period under patent protection would be increased.", "B": "The marketing period under patent protection would be reduced.", "C": "The patent applications would become public immediately.", "D": "The company would be certain they were first to file any patent application.", "E": "All interference proceedings would be canceled by the USPTO.", "F": "Priority disputes would be automatically resolved in the company's favor."}, "LLM_original_answer": ["To answer the question \"What could happen if there are delays in the clinical trials of product candidates?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the Context**: The document discusses various legal and regulatory challenges that a biotechnology or pharmaceutical company might face, including issues related to intellectual property, compliance with healthcare laws, and the impact of third-party payor coverage and reimbursement.\n\n2. **Locate Relevant Information**: The section that directly addresses the impact of delays in clinical trials is found in the \"Risks Related to Our Intellectual Property\" part of the document. Specifically, it states:\n   - \"If we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.\"\n\n3. **Analyze the Options**:\n   - **Option A**: \"The marketing period under patent protection would be increased.\" This is incorrect because the document explicitly states that delays would reduce the marketing period under patent protection.\n   - **Option B**: \"The marketing period under patent protection would be reduced.\" This is correct and aligns with the statement in the document.\n   - **Option C**: \"The patent applications would become public immediately.\" The document does not mention that delays in clinical trials would cause patent applications to become public immediately.\n   - **Option D**: \"The company would be certain they were first to file any patent application.\" The document discusses the uncertainty around being the first to file, especially under the \"first-to-file\" system, but does not link this to delays in clinical trials.\n   - **Option E**: \"All interference proceedings would be canceled by the USPTO.\" The document mentions interference proceedings but does not suggest that delays in clinical trials would cancel these proceedings.\n   - **Option F**: \"Priority disputes would be automatically resolved in the company's favor.\" The document indicates that priority disputes can be challenging and does not suggest that delays in clinical trials would resolve these disputes in the company's favor.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **Option B**: \"The marketing period under patent protection would be reduced.\"\n\nThis answer is supported by the direct statement in the document that delays in clinical trials would reduce the period of time during which the company could market its product candidates under patent protection."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 8000, "result": 1.0, "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?", "options": {"A": "Invests in renewable energy sources", "B": "Diversifies its energy portfolio", "C": "Enters into derivative instruments", "D": "Reduces energy consumption", "E": "Increases energy purchases", "F": "Halts energy operations"}, "LLM_original_answer": ["To answer the question \"What action does the Company take to manage commodity price risk for its merchant generation operations?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions commodity price risk in the \"Commodity Price Risk\" section under \"Item 7A. Quantitative and Qualitative Disclosures About Market Risk.\"\n\n2. **Extract the key information**: The relevant sentence from the document is:\n   - \"The Company manages the commodity price risk of its merchant generation operations by entering into derivative instruments to manage the variability in future cash flows from forecasted energy purchases.\"\n\n3. **Match the information to the options**:\n   - **Option A: Invests in renewable energy sources** - The document does not mention investing in renewable energy sources as a method to manage commodity price risk.\n   - **Option B: Diversifies its energy portfolio** - The document does not mention diversifying its energy portfolio as a method to manage commodity price risk.\n   - **Option C: Enters into derivative instruments** - This matches the information extracted from the document.\n   - **Option D: Reduces energy consumption** - The document does not mention reducing energy consumption as a method to manage commodity price risk.\n   - **Option E: Increases energy purchases** - The document does not mention increasing energy purchases as a method to manage commodity price risk.\n   - **Option F: Halts energy operations** - The document does not mention halting energy operations as a method to manage commodity price risk.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **Option C: Enters into derivative instruments**.\n\nTherefore, the Company manages the commodity price risk for its merchant generation operations by entering into derivative instruments."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 8000, "result": 1.0, "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?", "options": {"A": "To manage the financial statements", "B": "To express an opinion based on audits", "C": "To prepare the financial statements", "D": "To oversee the Company\u2019s management", "E": "To implement the Company's accounting principles", "F": "To revise the financial statements annually"}, "LLM_original_answer": ["To answer the question \"What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Management's Responsibility**:\n   - The document clearly states that \"These financial statements are the responsibility of the Company's management.\" This indicates that the preparation and accuracy of the financial statements are primarily the responsibility of the Company's management.\n\n2. **Auditor's Responsibility**:\n   - The document also states, \"Our responsibility is to express an opinion on the Company's financial statements based on our audits.\" This indicates that the public accounting firm's role is to audit the financial statements and provide an opinion on their fairness and accuracy.\n\n3. **Audit Procedures**:\n   - The document outlines various audit procedures performed by the public accounting firm, such as testing the effectiveness of management\u2019s controls, evaluating disclosures, reading regulatory orders, and assessing the reasonableness of management\u2019s judgments. These procedures are aimed at ensuring that the financial statements are free from material misstatement.\n\n4. **Specialized Knowledge**:\n   - The document mentions that auditing these judgments required specialized knowledge of accounting for rate regulation and the ratemaking process. This highlights the complexity and the need for expertise in the audit process.\n\n5. **Critical Audit Matters**:\n   - The document discusses critical audit matters, which are challenging, subjective, or complex judgments made during the audit. These matters are communicated to the audit committee and involve evaluating the accounting principles used and significant estimates made by management.\n\nGiven this information, the correct answer is:\n\n**B: To express an opinion based on audits**\n\nThis is because the document explicitly states that the public accounting firm's responsibility is to express an opinion on the Company's financial statements based on their audits. The other options do not align with the responsibilities described in the document:\n\n- **A: To manage the financial statements** - This is the responsibility of the Company's management, not the public accounting firm.\n- **C: To prepare the financial statements** - Again, this is the responsibility of the Company's management.\n- **D: To oversee the Company\u2019s management** - The public accounting firm does not oversee management; they audit the financial statements.\n- **E: To implement the Company's accounting principles** - This is also the responsibility of the Company's management.\n- **F: To revise the financial statements annually** - The public accounting firm does not revise the financial statements; they audit them and provide an opinion.\n\nTherefore, the"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 8000, "result": 1.0, "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?", "options": {"A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II", "B": "Note 5, within the Management's Discussion and Analysis", "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II", "D": "Note 6, within the Financial Overview section", "E": "Appendix A, in the Summary of Financial Policies", "F": "Note 7, within the Risk Management section"}, "LLM_original_answer": ["To answer the question \"Where can one find the discussion about the allowance for credit losses measurement methodology?\", I will analyze the provided document step by step:\n\n1. **Identify the Relevant Section**:\n   - The document mentions the allowance for credit losses measurement methodology in the \"Provision for Loan Losses\" section under \"Results of Operations.\"\n\n2. **Locate the Specific Reference**:\n   - The text states: \"For additional discussion of our allowance for credit losses measurement methodology, see Note 2, 'Summary of Significant Accounting Policies' and Note 4, 'Loans and Allowance for Loan Losses' within the Notes to the Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K.\"\n\n3. **Match the Reference to the Options**:\n   - Option A: Note 3, within the Notes to the Consolidated Financial Statements in Part II\n   - Option B: Note 5, within the Management's Discussion and Analysis\n   - Option C: Note 2, within the Notes to the Consolidated Financial Statements in Part II\n   - Option D: Note 6, within the Financial Overview section\n   - Option E: Appendix A, in the Summary of Financial Policies\n   - Option F: Note 7, within the Risk Management section\n\n4. **Select the Correct Option**:\n   - The document explicitly mentions Note 2 and Note 4 as the places where the allowance for credit losses measurement methodology is discussed.\n   - Therefore, the correct option is **C: Note 2, within the Notes to the Consolidated Financial Statements in Part II**.\n\n**Final Answer**: C: Note 2, within the Notes to the Consolidated Financial Statements in Part II."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 8000, "result": 1.0, "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?", "options": {"A": "Competitors cannot make similar products without infringing patents.", "B": "Patent laws in the United States are more favorable than those in other countries.", "C": "Issued patents may be challenged and held invalid or unenforceable.", "D": "Regulatory approval for drug candidates is guaranteed.", "E": "Trade secrets are always more secure than patents.", "F": "All pending patent applications will lead to issued patents."}, "LLM_original_answer": ["To answer the question \"What is one reason why intellectual property rights may not provide adequate protection for the business?\" based on the provided document, let's analyze each option step by step:\n\nA: Competitors cannot make similar products without infringing patents.\n- This statement is not supported by the document. The document mentions that competitors can make similar products that are not covered by the claims of the patents, which means they can avoid infringement.\n\nB: Patent laws in the United States are more favorable than those in other countries.\n- The document does not compare the favorability of patent laws in the United States to those in other countries. It focuses on the challenges and uncertainties of patent protection, both domestically and internationally.\n\nC: Issued patents may be challenged and held invalid or unenforceable.\n- This is directly supported by the document. The document states, \"In a patent infringement proceeding, a court may decide that a patent of ours or our licensors is invalid or unenforceable, in whole or in part, construe the patent\u2019s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.\"\n\nD: Regulatory approval for drug candidates is guaranteed.\n- This is not supported by the document. The document explicitly mentions that regulatory approval is not guaranteed and can be delayed or denied for various reasons.\n\nE: Trade secrets are always more secure than patents.\n- The document does not support this statement. It mentions that trade secrets can be difficult to protect and that unauthorized disclosure or misappropriation can occur, which can harm the business.\n\nF: All pending patent applications will lead to issued patents.\n- This is not supported by the document. The document states, \"It is possible that our pending owned patent applications or those that we may own or license in the future will not lead to issued patents.\"\n\nGiven the analysis, the correct answer is:\n\n**C: Issued patents may be challenged and held invalid or unenforceable.**\n\nThis option is directly supported by the document, which highlights the risks and uncertainties associated with the validity and enforceability of issued patents."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 8000, "result": 1.0, "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?", "options": {"A": "Increase in market competition", "B": "Higher margins in the Correspondent channel", "C": "Decline in setup fees for loans boarded", "D": "Increase in HECM loan proceeds", "E": "Decrease in revaluation gains on MSRs", "F": "Higher production volume in retail channels"}, "LLM_original_answer": ["To answer the question \"What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?\" based on the provided document, let's break down the information step by step:\n\n1. **Identify the relevant section**: The document mentions the decline in other revenue, net for 2023 compared to 2022 in the \"Other revenue, net\" section.\n\n2. **Extract the key information**:\n   - **Other revenue, net for 2023 declined $8.4 million as compared to 2022**.\n   - **Primary reasons for the decline**:\n     - **$5.0 million decline in setup fees earned for loans boarded on our servicing platform, mostly related to a decline in Consumer Direct volume**.\n     - **$2.6 million decrease in correspondent and broker fees due to the decline in production volume**.\n\n3. **Evaluate the options**:\n   - **A: Increase in market competition** - The document does not mention an increase in market competition as a primary reason for the decline in other revenue, net.\n   - **B: Higher margins in the Correspondent channel** - The document does not indicate higher margins in the Correspondent channel as a reason for the decline in other revenue, net.\n   - **C: Decline in setup fees for loans boarded** - The document explicitly states that there was a $5.0 million decline in setup fees for loans boarded on the servicing platform, which is a significant portion of the total $8.4 million decline.\n   - **D: Increase in HECM loan proceeds** - The document does not mention an increase in HECM loan proceeds as a reason for the decline in other revenue, net.\n   - **E: Decrease in revaluation gains on MSRs** - The document does not mention a decrease in revaluation gains on MSRs as a primary reason for the decline in other revenue, net.\n   - **F: Higher production volume in retail channels** - The document does not mention higher production volume in retail channels as a reason for the decline in other revenue, net. In fact, it mentions a decline in production volume.\n\n4. **Conclusion**:\n   - The primary reason for the decrease in other revenue, net for 2023 compared to 2022 is the **$5.0 million decline in setup fees earned for loans boarded on our servicing platform, mostly related"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 8000, "result": 1.0, "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?", "options": {"A": "Lack of innovative product features", "B": "Limited product supply", "C": "Inability to maintain effective sales forces", "D": "High regulatory costs", "E": "Insufficient funding for development", "F": "Excessive competition in the product market"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step to identify any mentions of challenges related to sales and marketing collaborations.\n\n1. **Document Overview**:\n   - The document primarily discusses the development and clinical trials of TCR-T therapy, focusing on potential risks and challenges in the process.\n   - It also touches on the company's plans for marketing and sales, which is relevant to the question.\n\n2. **Relevant Sections**:\n   - **Marketing and Sales Organization**:\n     - \"We currently have no marketing and sales organization and have no experience as a company in marketing products.\"\n     - \"We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time.\"\n     - \"We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.\"\n     - \"If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our product candidates, if licensed.\"\n     - \"However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces.\"\n\n3. **Analysis**:\n   - The document explicitly mentions the challenge of establishing a marketing and sales organization, including the need to recruit, train, and retain marketing and sales personnel.\n   - It also highlights the risk of not being able to establish or maintain collaborative arrangements for sales and marketing, and the potential for these collaborations to have ineffective sales forces.\n\n4. **Matching to Options**:\n   - **Option C: Inability to maintain effective sales forces**:\n     - This option directly aligns with the challenges mentioned in the document, particularly the risk of not being able to establish or maintain collaborative arrangements and the potential for these collaborations to have ineffective sales forces.\n\n5. **Conclusion**:\n   - Based on the document, the most relevant challenge mentioned in establishing collaborations for sales and marketing is the **Inability to maintain effective sales forces**.\n\nTherefore, the answer is **C: Inability to maintain effective sales forces**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 8000, "result": 1.0, "question": "What is one reason AMX0035 might fail to obtain regulatory approval?", "options": {"A": "Manufacturing processes are found to be deficient", "B": "Clinical trials easily surpass statistical significance", "C": "FDA agrees with the interpretation of preclinical studies", "D": "Patient opinions are highly positive", "E": "Regulatory authorities consistently approve design implementations", "F": "Clinical trials detect an exceeding positive effect"}, "LLM_original_answer": ["To answer the question \"What is one reason AMX0035 might fail to obtain regulatory approval?\" based on the provided document, I will analyze the options and the relevant information from the document.\n\n### Options:\nA: Manufacturing processes are found to be deficient\nB: Clinical trials easily surpass statistical significance\nC: FDA agrees with the interpretation of preclinical studies\nD: Patient opinions are highly positive\nE: Regulatory authorities consistently approve design implementations\nF: Clinical trials detect an exceeding positive effect\n\n### Analysis:\n1. **Option A: Manufacturing processes are found to be deficient**\n   - The document mentions that regulatory authorities may find deficiencies with the manufacturing processes or facilities of third-party manufacturers. Specifically, it states: \"the FDA, Health Canada, the EMA and comparable authorities in other countries may disagree with our interpretation of data from clinical trials or preclinical studies and our request may require additional trials or studies to support marketing approval; or the FDA, Health Canada, the EMA and comparable authorities in other countries may find deficiencies with clinical trial sites or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies.\"\n   - This is a valid reason for AMX0035 to fail to obtain regulatory approval.\n\n2. **Option B: Clinical trials easily surpass statistical significance**\n   - The document does not suggest that surpassing statistical significance is a reason for failure. Instead, it emphasizes the importance of meeting statistical significance: \"If later stage clinical trials, including our ongoing global Phase 3 PHOENIX trial in ALS, do not produce favorable results with very strong statistical significance, our ability to obtain or maintain any prior-issued regulatory approval for AMX0035 for ALS (including our FDA approval and our marketing authorization with conditions from Health Canada) or potential additional indications, or any future product candidate, may be adversely impacted.\"\n   - This option is not a reason for failure.\n\n3. **Option C: FDA agrees with the interpretation of preclinical studies**\n   - The document indicates that disagreements with the interpretation of preclinical and clinical data can lead to regulatory issues: \"the FDA\u2019s, Health Canada\u2019s, the EMA\u2019s or any other applicable foreign regulatory agency\u2019s disagreement with the interpretation of data from preclinical and clinical studies and trials, such as the FDA\u2019s differing interpretations of certain data, including sensitivity and statistical analyses, from our CENTAUR trial and OLE as presented at the meetings of the FDA\u2019s Advisory Committee on March 30,"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 40, "token_lengths": 8000, "result": 1.0, "question": "What is the purpose of Section 31 fees according to the Exchange Act?", "options": {"A": "To finance market makers on exchanges", "B": "To cover the costs of technology upgrades", "C": "To recover the government\u2019s costs of supervising and regulating the securities markets", "D": "To reward high-frequency traders", "E": "To fund international trading agreements", "F": "To support trading education programs"}, "LLM_original_answer": ["To answer the question \"What is the purpose of Section 31 fees according to the Exchange Act?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for any mention of Section 31 fees and the Exchange Act.\n2. **Extract the Purpose**: Determine the specific purpose of these fees as stated in the document.\n3. **Match the Purpose to the Options**: Compare the extracted purpose to the given multiple-choice options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant information is found in the \"Transaction-Based Expenses\" section of the document:\n\n> \"Our equities and equity options markets pay fees to the SEC pursuant to Section 31 of the Exchange Act. Section 31 fees are recorded on a gross basis as a component of transaction and clearing fee revenue. These Section 31 fees are assessed to recover the government\u2019s costs of supervising and regulating the securities markets and professionals and are subject to change. We, in turn, collect corresponding activity assessment fees from member organizations clearing or settling trades on the equities and options exchanges, and recognize these amounts in our transaction and clearing revenues when invoiced. The activity assessment fees are designed to equal the Section 31 fees. As a result, activity assessment fees and the corresponding Section 31 fees do not have an impact on our net income, although the timing of payment by us will vary from collections.\"\n\n### Step 2: Extract the Purpose\nThe purpose of Section 31 fees, as stated in the document, is to recover the government\u2019s costs of supervising and regulating the securities markets and professionals.\n\n### Step 3: Match the Purpose to the Options\nNow, let's compare this purpose to the given options:\n\n- **A: To finance market makers on exchanges** - This is not mentioned in the document.\n- **B: To cover the costs of technology upgrades** - This is not mentioned in the document.\n- **C: To recover the government\u2019s costs of supervising and regulating the securities markets** - This matches the purpose stated in the document.\n- **D: To reward high-frequency traders** - This is not mentioned in the document.\n- **E: To fund international trading agreements** - This is not mentioned in the document.\n- **F: To support trading education programs** - This is not mentioned in the document.\n\n### Conclusion\nThe correct answer is **C: To recover the government\u2019s costs of supervising and regulating the"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 8000, "result": 1.0, "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?", "options": {"A": "5%", "B": "10%", "C": "15%", "D": "1%", "E": "0.5%", "F": "2%"}, "LLM_original_answer": ["To answer the question \"What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the corporate fixed maturity securities portfolio is found under \"U.S. and Foreign Corporate Fixed Maturity Securities.\"\n\n2. **Extract the key information**: The document states, \"Our portfolio does not have any exposure to any single issuer in excess of 1% of total investments and the top ten holdings in aggregate comprise 1% of total investments at both December 31, 2023 and 2022.\"\n\n3. **Match the information to the options**: The document clearly indicates that the top ten holdings in aggregate comprise 1% of total investments.\n\n4. **Select the correct answer**: The correct answer is D: 1%.\n\n**Chain of thoughts**:\n- The document provides specific details about the corporate fixed maturity securities portfolio.\n- It mentions that no single issuer exceeds 1% of total investments.\n- It also explicitly states that the top ten holdings in aggregate comprise 1% of total investments.\n- This information directly matches one of the provided options, which is D: 1%.\n\nTherefore, the answer is D: 1%."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 40, "token_lengths": 16000, "result": 1.0, "question": "What could happen if there are delays in the clinical trials of product candidates?", "options": {"A": "The marketing period under patent protection would be increased.", "B": "The marketing period under patent protection would be reduced.", "C": "The patent applications would become public immediately.", "D": "The company would be certain they were first to file any patent application.", "E": "All interference proceedings would be canceled by the USPTO.", "F": "Priority disputes would be automatically resolved in the company's favor."}, "LLM_original_answer": ["To answer the question \"What could happen if there are delays in the clinical trials of product candidates?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Clinical Trials and Market Introduction**:\n   - The document mentions that the timing of market introduction of our product candidates in relation to other potentially competitive products is a critical factor for market acceptance.\n   - Delays in clinical trials would likely delay the market introduction of our product candidates.\n\n2. **Patent Protection and Marketing Period**:\n   - The document states, \"If we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.\"\n   - This directly implies that delays in clinical trials would reduce the time during which the product can be marketed under patent protection.\n\n3. **Impact on Profitability**:\n   - The document also notes that the degree of market acceptance of any product for which we receive marketing approval will depend on various factors, including the timing of market introduction.\n   - A delayed market introduction could negatively impact market acceptance, which in turn could affect profitability.\n\n4. **Other Options**:\n   - The document does not mention that delays in clinical trials would increase the marketing period under patent protection (Option A).\n   - It does not suggest that patent applications would become public immediately (Option C).\n   - It does not indicate that the company would be certain they were first to file any patent application (Option D).\n   - It does not state that all interference proceedings would be canceled by the USPTO (Option E).\n   - It does not claim that priority disputes would be automatically resolved in the company's favor (Option F).\n\nGiven this analysis, the correct answer is:\n\n**B: The marketing period under patent protection would be reduced.**\n\nThis is explicitly stated in the document and aligns with the logical implications of delayed clinical trials."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 16000, "result": 1.0, "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?", "options": {"A": "Invests in renewable energy sources", "B": "Diversifies its energy portfolio", "C": "Enters into derivative instruments", "D": "Reduces energy consumption", "E": "Increases energy purchases", "F": "Halts energy operations"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Relevant Section**: The section that discusses commodity price risk is found under \"Item 7A. Quantitative and Qualitative Disclosures About Market Risk\" and specifically under the \"Commodity Price Risk\" sub-section.\n\n2. **Extract the Key Information**:\n   - The document states: \"The Company manages the commodity price risk of its merchant generation operations by entering into derivative instruments to manage the variability in future cash flows from forecasted energy purchases.\"\n   - This indicates that the Company uses derivative instruments to manage commodity price risk.\n\n3. **Match the Information to the Options**:\n   - Option A: Invests in renewable energy sources - The document does not mention investing in renewable energy sources as a method to manage commodity price risk.\n   - Option B: Diversifies its energy portfolio - The document does not mention diversifying its energy portfolio.\n   - Option C: Enters into derivative instruments - This matches the information provided in the document.\n   - Option D: Reduces energy consumption - The document does not mention reducing energy consumption.\n   - Option E: Increases energy purchases - The document does not mention increasing energy purchases.\n   - Option F: Halts energy operations - The document does not mention halting energy operations.\n\n4. **Conclusion**:\n   - Based on the information provided in the document, the Company manages commodity price risk for its merchant generation operations by entering into derivative instruments.\n\nTherefore, the correct answer is **Option C: Enters into derivative instruments**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 16000, "result": 1.0, "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?", "options": {"A": "To manage the financial statements", "B": "To express an opinion based on audits", "C": "To prepare the financial statements", "D": "To oversee the Company\u2019s management", "E": "To implement the Company's accounting principles", "F": "To revise the financial statements annually"}, "LLM_original_answer": ["To answer the question \"What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?\" based on the provided document, I will analyze the relevant sections step by step.\n\n1. **Identify the Role of the Public Accounting Firm:**\n   - The document repeatedly mentions that the public accounting firm (Deloitte & Touche LLP) has audited the financial statements of various Duke Energy subsidiaries.\n   - The firm's responsibility is clearly defined in the \"Basis for Opinion\" section of each report.\n\n2. **Examine the \"Basis for Opinion\" Section:**\n   - For Duke Energy Carolinas, LLC:\n     - \"These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits.\"\n   - For Progress Energy, Inc.:\n     - \"These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits.\"\n   - For Duke Energy Florida, LLC:\n     - \"These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits.\"\n   - For Duke Energy Ohio, Inc.:\n     - \"These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits.\"\n   - For Duke Energy Indiana, LLC:\n     - \"These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits.\"\n   - For Piedmont Natural Gas Company, Inc.:\n     - \"These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits.\"\n\n3. **Consistent Responsibility Across Reports:**\n   - In all the reports, the public accounting firm's responsibility is to express an opinion on the financial statements based on their audits.\n   - The firm does not manage, prepare, or revise the financial statements. Instead, they audit the statements prepared by the Company's management.\n\n4. **Conclusion:**\n   - The public accounting firm's primary responsibility is to express an opinion on the financial statements based on their audits.\n\nGiven the options provided:\n- A: To manage the financial statements\n- B: To express an opinion based on audits\n- C: To prepare the financial statements\n- D: To oversee the"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 16000, "result": 1.0, "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?", "options": {"A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II", "B": "Note 5, within the Management's Discussion and Analysis", "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II", "D": "Note 6, within the Financial Overview section", "E": "Appendix A, in the Summary of Financial Policies", "F": "Note 7, within the Risk Management section"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document and identify where the discussion about the allowance for credit losses measurement methodology is located.\n\n1. **Initial Reference in the Document:**\n   - The document mentions: \"For the purpose of estimating our allowance for loan losses, we segregate the loan portfolio into loan categories, for loans that share similar risk characteristics, that possess unique risk characteristics such as loan purpose, repayment source, and collateral that are considered when determining the appropriate level of the allowance for loan losses for each category.\"\n   - This is a general description of the methodology but does not specify where the detailed discussion is found.\n\n2. **Specific Reference to Notes:**\n   - The document further states: \"For additional discussion of our allowance for credit losses measurement methodology, see Note 2, \u2018Summary of Significant Accounting Policies\u2019 and Note 4, \u2018Loans and Allowance for Loan Losses\u2019 within the Notes to the Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K.\"\n\n3. **Review of the Options:**\n   - **Option A:** Note 3, within the Notes to the Consolidated Financial Statements in Part II\n   - **Option B:** Note 5, within the Management's Discussion and Analysis\n   - **Option C:** Note 2, within the Notes to the Consolidated Financial Statements in Part II\n   - **Option D:** Note 6, within the Financial Overview section\n   - **Option E:** Appendix A, in the Summary of Financial Policies\n   - **Option F:** Note 7, within the Risk Management section\n\n4. **Matching the Reference:**\n   - The document explicitly mentions Note 2 and Note 4 as the places where the allowance for credit losses measurement methodology is discussed.\n   - Therefore, the correct answer must be one of these notes.\n\n5. **Conclusion:**\n   - The document specifically refers to Note 2, \u201cSummary of Significant Accounting Policies,\u201d as one of the places where the allowance for credit losses measurement methodology is discussed.\n\nThus, the correct answer is **C: Note 2, within the Notes to the Consolidated Financial Statements in Part II**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 16000, "result": 1.0, "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?", "options": {"A": "Competitors cannot make similar products without infringing patents.", "B": "Patent laws in the United States are more favorable than those in other countries.", "C": "Issued patents may be challenged and held invalid or unenforceable.", "D": "Regulatory approval for drug candidates is guaranteed.", "E": "Trade secrets are always more secure than patents.", "F": "All pending patent applications will lead to issued patents."}, "LLM_original_answer": ["To answer the question \"What is one reason why intellectual property rights may not provide adequate protection for the business?\" based on the provided document, let's analyze the options step by step:\n\n### Option A: Competitors cannot make similar products without infringing patents.\n- The document does not support this statement. It mentions that competitors can make similar products that are not covered by the claims of the patents that the business owns or licenses. Therefore, this option is incorrect.\n\n### Option B: Patent laws in the United States are more favorable than those in other countries.\n- The document does not make a direct comparison of patent laws in the United States versus other countries. It focuses on the challenges and uncertainties of patent protection, not the favorability of laws. Therefore, this option is incorrect.\n\n### Option C: Issued patents may be challenged and held invalid or unenforceable.\n- The document explicitly states that issued patents may be challenged and held invalid or unenforceable. For example, it mentions: \"Issued patents that we may hold rights to in the future may be held invalid or unenforceable, including as a result of legal challenges by our competitors.\" This option is supported by the document.\n\n### Option D: Regulatory approval for drug candidates is guaranteed.\n- The document clearly states that regulatory approval is not guaranteed and can be delayed or denied for various reasons. For example, it mentions: \"Our drug candidates could be delayed or fail to receive marketing approval for many reasons.\" Therefore, this option is incorrect.\n\n### Option E: Trade secrets are always more secure than patents.\n- The document does not claim that trade secrets are always more secure than patents. It discusses the challenges of protecting trade secrets but does not make a blanket statement that they are always more secure. Therefore, this option is incorrect.\n\n### Option F: All pending patent applications will lead to issued patents.\n- The document explicitly states that not all pending patent applications will lead to issued patents. For example, it mentions: \"It is possible that our pending owned patent applications or those that we may own or license in the future will not lead to issued patents.\" Therefore, this option is incorrect.\n\n### Conclusion:\nThe correct answer is **Option C: Issued patents may be challenged and held invalid or unenforceable**. This is directly supported by the document, which highlights the risks and uncertainties associated with the enforceability and validity of issued patents."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 16000, "result": 1.0, "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?", "options": {"A": "Increase in market competition", "B": "Higher margins in the Correspondent channel", "C": "Decline in setup fees for loans boarded", "D": "Increase in HECM loan proceeds", "E": "Decrease in revaluation gains on MSRs", "F": "Higher production volume in retail channels"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n### Step 1: Identify the relevant section\nThe question asks about the primary reason for the decrease in other revenue, net for 2023 compared to 2022. The relevant section is found in the \"Other revenue, net\" part of the document.\n\n### Step 2: Extract the key information\nThe document states:\n> \"Other revenue, net for 2023 declined $8.4 million as compared to 2022 primarily due to a $5.0 million decline in setup fees earned for loans boarded on our servicing platform, mostly related to a decline in Consumer Direct volume, and a $2.6 million decrease in correspondent and broker fees due to the decline in production volume.\"\n\n### Step 3: Analyze the information\n- **Decline in setup fees**: The document mentions a $5.0 million decline in setup fees earned for loans boarded on the servicing platform. This decline is mostly related to a decrease in Consumer Direct volume.\n- **Decline in correspondent and broker fees**: The document also mentions a $2.6 million decrease in correspondent and broker fees due to a decline in production volume.\n\n### Step 4: Match the information to the options\n- **Option A: Increase in market competition** - The document does not mention market competition as a primary reason for the decrease in other revenue, net.\n- **Option B: Higher margins in the Correspondent channel** - The document does not mention higher margins in the Correspondent channel as a reason for the decrease in other revenue, net.\n- **Option C: Decline in setup fees for loans boarded** - This matches the $5.0 million decline in setup fees mentioned in the document.\n- **Option D: Increase in HECM loan proceeds** - The document does not mention an increase in HECM loan proceeds as a reason for the decrease in other revenue, net.\n- **Option E: Decrease in revaluation gains on MSRs** - The document does not mention revaluation gains on MSRs as a reason for the decrease in other revenue, net.\n- **Option F: Higher production volume in retail channels** - The document mentions a decline in Consumer Direct volume, which is a retail channel, but it does not mention higher production volume as a reason for the decrease in other revenue, net.\n\n### Step 5: Conclude\nThe primary reason for the decrease in other"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 16000, "result": 1.0, "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?", "options": {"A": "Lack of innovative product features", "B": "Limited product supply", "C": "Inability to maintain effective sales forces", "D": "High regulatory costs", "E": "Insufficient funding for development", "F": "Excessive competition in the product market"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document to identify any mention of challenges related to establishing collaborations for sales and marketing.\n\n1. **Initial Scan of the Document**:\n   - The document primarily focuses on the development, manufacturing, and regulatory aspects of the company's product candidates.\n   - It also discusses the company's plans and challenges related to marketing and sales.\n\n2. **Relevant Sections**:\n   - The section that directly addresses marketing and sales is: \"We currently have no marketing and sales organization and have no experience as a company in marketing products. If we are unable to establish marketing and sales capabilities or to enter into agreements with third parties to market and sell our product candidates, if licensed, we may not be able to generate product revenue.\"\n   - This section highlights the company's lack of internal marketing and sales capabilities and the potential need to rely on third parties.\n\n3. **Identifying the Challenge**:\n   - The document mentions that the company may need to enter into agreements with third parties to market and sell its product candidates.\n   - It also states that there is no assurance that the company will be able to establish or maintain such collaborative arrangements, or that these third parties will have effective sales forces.\n\n4. **Matching the Challenge to the Options**:\n   - **Option A: Lack of innovative product features** - Not mentioned in the document.\n   - **Option B: Limited product supply** - Not mentioned in the context of sales and marketing collaborations.\n   - **Option C: Inability to maintain effective sales forces** - This is directly mentioned in the document.\n   - **Option D: High regulatory costs** - Not mentioned in the context of sales and marketing collaborations.\n   - **Option E: Insufficient funding for development** - Not mentioned in the context of sales and marketing collaborations.\n   - **Option F: Excessive competition in the product market** - While competition is mentioned, it is not specifically tied to the challenge of establishing sales and marketing collaborations.\n\n5. **Conclusion**:\n   - The document explicitly mentions the challenge of being unable to maintain effective sales forces when relying on third parties for marketing and sales.\n   - Therefore, the correct answer is **Option C: Inability to maintain effective sales forces**.\n\nThis is the potential challenge mentioned in the document regarding establishing collaborations for sales and marketing."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 16000, "result": 1.0, "question": "What is one reason AMX0035 might fail to obtain regulatory approval?", "options": {"A": "Manufacturing processes are found to be deficient", "B": "Clinical trials easily surpass statistical significance", "C": "FDA agrees with the interpretation of preclinical studies", "D": "Patient opinions are highly positive", "E": "Regulatory authorities consistently approve design implementations", "F": "Clinical trials detect an exceeding positive effect"}, "LLM_original_answer": ["To answer the question \"What is one reason AMX0035 might fail to obtain regulatory approval?\" based on the provided document, I will analyze each option and determine which one is supported by the information given.\n\n### Options Analysis:\n\n**A: Manufacturing processes are found to be deficient**\n- The document mentions that regulatory authorities may find deficiencies with clinical trial sites or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies. This directly supports the possibility that manufacturing processes could be a reason for failing to obtain regulatory approval.\n\n**B: Clinical trials easily surpass statistical significance**\n- The document does not suggest that surpassing statistical significance is a reason for failing to obtain regulatory approval. In fact, it mentions the opposite: the results of clinical trials may not meet the level of statistical significance required by regulatory authorities for approval.\n\n**C: FDA agrees with the interpretation of preclinical studies**\n- The document indicates that the FDA has presented concerns regarding the interpretation of data from clinical trials and preclinical studies. It also mentions that the FDA may disagree with our interpretation of data, which could delay or prevent marketing approval. Therefore, this option is not supported as a reason for failure.\n\n**D: Patient opinions are highly positive**\n- The document does not mention patient opinions as a factor in regulatory approval. Instead, it focuses on the scientific and regulatory aspects of the approval process.\n\n**E: Regulatory authorities consistently approve design implementations**\n- The document explicitly states that regulatory authorities may disagree as to the design or implementation of our clinical trials and may require additional data to support regulatory approval. This suggests that inconsistent approval of design implementations is a potential reason for failure.\n\n**F: Clinical trials detect an exceeding positive effect**\n- Similar to option B, the document does not suggest that an exceeding positive effect in clinical trials would lead to failure. Instead, it mentions that clinical trials may indicate an apparent positive effect that is greater than the actual positive effect, which could lead to regulatory scrutiny.\n\n### Conclusion:\nBased on the document, the most supported reason for AMX0035 failing to obtain regulatory approval is **A: Manufacturing processes are found to be deficient**. The document clearly states that regulatory authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers, which could prevent approval.\n\nTherefore, the correct answer is **A: Manufacturing processes are found to be deficient**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 40, "token_lengths": 16000, "result": 1.0, "question": "What is the purpose of Section 31 fees according to the Exchange Act?", "options": {"A": "To finance market makers on exchanges", "B": "To cover the costs of technology upgrades", "C": "To recover the government\u2019s costs of supervising and regulating the securities markets", "D": "To reward high-frequency traders", "E": "To fund international trading agreements", "F": "To support trading education programs"}, "LLM_original_answer": ["To answer the question \"What is the purpose of Section 31 fees according to the Exchange Act?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for any mention of Section 31 fees and the Exchange Act.\n2. **Extract the Purpose**: Determine the specific purpose of these fees as stated in the document.\n3. **Match the Purpose to the Options**: Compare the extracted purpose to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant information is found in the \"Transaction-Based Expenses\" section of the \"Exchanges Segment\" part of the document:\n\n> \"Our equities and equity options markets pay fees to the SEC pursuant to Section 31 of the Exchange Act. Section 31 fees are recorded on a gross basis as a component of transaction and clearing fee revenue. These Section 31 fees are assessed to recover the government\u2019s costs of supervising and regulating the securities markets and professionals and are subject to change.\"\n\n### Step 2: Extract the Purpose\nThe purpose of Section 31 fees, as stated in the document, is to recover the government\u2019s costs of supervising and regulating the securities markets and professionals.\n\n### Step 3: Match the Purpose to the Options\nNow, let's match this purpose to the given options:\n\n- **A: To finance market makers on exchanges** - This does not match the purpose stated in the document.\n- **B: To cover the costs of technology upgrades** - This does not match the purpose stated in the document.\n- **C: To recover the government\u2019s costs of supervising and regulating the securities markets** - This matches the purpose stated in the document.\n- **D: To reward high-frequency traders** - This does not match the purpose stated in the document.\n- **E: To fund international trading agreements** - This does not match the purpose stated in the document.\n- **F: To support trading education programs** - This does not match the purpose stated in the document.\n\n### Conclusion\nThe correct answer is **C: To recover the government\u2019s costs of supervising and regulating the securities markets**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 16000, "result": 1.0, "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?", "options": {"A": "5%", "B": "10%", "C": "15%", "D": "1%", "E": "0.5%", "F": "2%"}, "LLM_original_answer": ["To answer the question \"What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the corporate fixed maturity securities portfolio is found under \"U.S. and Foreign Corporate Fixed Maturity Securities.\"\n\n2. **Extract the key information**: The document states, \"Our portfolio does not have any exposure to any single issuer in excess of 1% of total investments and the top ten holdings in aggregate comprise 1% of total investments at both December 31, 2023 and 2022.\"\n\n3. **Determine the answer**: The top ten holdings in the corporate fixed maturity securities portfolio comprise 1% of total investments.\n\n4. **Match the answer to the options**: The correct option is D: 1%.\n\nTherefore, the answer to the question is **D: 1%**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 40, "token_lengths": 32000, "result": 1.0, "question": "What could happen if there are delays in the clinical trials of product candidates?", "options": {"A": "The marketing period under patent protection would be increased.", "B": "The marketing period under patent protection would be reduced.", "C": "The patent applications would become public immediately.", "D": "The company would be certain they were first to file any patent application.", "E": "All interference proceedings would be canceled by the USPTO.", "F": "Priority disputes would be automatically resolved in the company's favor."}, "LLM_original_answer": ["To answer the question \"What could happen if there are delays in the clinical trials of product candidates?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Patent Protection and Marketing Period:**\n   - The document mentions that the patenting process is expensive and time-consuming, and delays in clinical trials could reduce the period of time during which we could market our product candidates under patent protection.\n   - Specifically, it states: \"Furthermore, even in the absence of litigation, we may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.\"\n   - It also notes: \"If we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.\"\n\n2. **Regulatory and Commercial Implications:**\n   - Delays in clinical trials can lead to extended review times by regulatory authorities, which can delay the approval process.\n   - The document highlights: \"The ability of the FDA or comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, statutory, regulatory and policy changes, and other events that may otherwise affect the FDA\u2019s or comparable foreign regulatory authorities\u2019 ability to perform routine functions.\"\n   - It further states: \"If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or comparable foreign regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.\"\n\n3. **Market Acceptance and Commercialization:**\n   - Delays in clinical trials can also affect the market acceptance and commercialization of the product candidates.\n   - The document mentions: \"If we are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially harmed.\"\n\n4. **Financial and Operational Risks:**\n   - Delays can increase costs and divert resources, potentially impacting the company's financial and operational performance.\n   - The document states: \"If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 32000, "result": 1.0, "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?", "options": {"A": "Invests in renewable energy sources", "B": "Diversifies its energy portfolio", "C": "Enters into derivative instruments", "D": "Reduces energy consumption", "E": "Increases energy purchases", "F": "Halts energy operations"}, "LLM_original_answer": ["To answer the question \"What action does the Company take to manage commodity price risk for its merchant generation operations?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses commodity price risk is found under \"Commodity Price Risk\" in \"Item 7A. Quantitative and Qualitative Disclosures About Market Risk.\"\n\n2. **Extract the key information**: The relevant paragraph states:\n   > \"Commodity price risks result from exposures to changes in spot prices, forward prices, volatilities, and correlations between various commodities, such as electricity and emissions credits. The Company manages the commodity price risk of its merchant generation operations by entering into derivative instruments to manage the variability in future cash flows from forecasted energy purchases. Management considers energy prices, weather forecasts, forecasted energy purchases, and other factors when determining the extent of its risk management strategy over commodity price risk.\"\n\n3. **Analyze the information**:\n   - The Company identifies commodity price risks, particularly related to electricity and emissions credits.\n   - The primary method used to manage these risks is entering into derivative instruments.\n   - These derivative instruments are used to manage the variability in future cash flows from forecasted energy purchases.\n   - Management takes into account various factors such as energy prices, weather forecasts, and forecasted energy purchases when deciding on the risk management strategy.\n\n4. **Match the information to the options**:\n   - **Option A: Invests in renewable energy sources** - The document does not mention investing in renewable energy sources as a method to manage commodity price risk.\n   - **Option B: Diversifies its energy portfolio** - The document does not mention diversifying its energy portfolio.\n   - **Option C: Enters into derivative instruments** - This matches the information provided in the document.\n   - **Option D: Reduces energy consumption** - The document does not mention reducing energy consumption.\n   - **Option E: Increases energy purchases** - The document does not mention increasing energy purchases.\n   - **Option F: Halts energy operations** - The document does not mention halting energy operations.\n\n5. **Conclusion**: Based on the information provided in the document, the Company manages commodity price risk for its merchant generation operations by entering into derivative instruments.\n\nTherefore, the correct answer is **Option C: Enters into derivative instruments**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 32000, "result": 1.0, "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?", "options": {"A": "To manage the financial statements", "B": "To express an opinion based on audits", "C": "To prepare the financial statements", "D": "To oversee the Company\u2019s management", "E": "To implement the Company's accounting principles", "F": "To revise the financial statements annually"}, "LLM_original_answer": ["To answer the question \"What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?\" based on the provided document, I will analyze the relevant sections step by step.\n\n1. **Identify the Role of the Public Accounting Firm:**\n   - The document includes several \"Report of Independent Registered Public Accounting Firm\" sections, which are addressed to the shareholders and the Board of Directors of various Duke Energy entities.\n   - These reports are from Deloitte & Touche LLP, a public accounting firm.\n\n2. **Examine the Opinions Provided:**\n   - The reports state: \"We have audited the accompanying consolidated balance sheets of [the Company] as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income, changes in equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the 'financial statements').\"\n   - The firm expresses an opinion on the financial statements, stating: \"In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.\"\n\n3. **Understand the Basis for Opinion:**\n   - The reports clarify: \"These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits.\"\n   - This indicates that the public accounting firm's primary responsibility is to audit the financial statements and express an opinion on their fairness and conformity to GAAP.\n\n4. **Review the Audit Procedures:**\n   - The reports detail the audit procedures, which include:\n     - Testing the effectiveness of management\u2019s controls.\n     - Evaluating the Company\u2019s disclosures.\n     - Reading relevant regulatory orders and other publicly available information.\n     - Evaluating management\u2019s judgments regarding the recoverability of regulatory asset balances.\n     - Performing substantive analytical procedures and detail testing procedures.\n\n5. **Consider the Critical Audit Matters:**\n   - The reports highlight critical audit matters, such as the impact of rate regulation on the financial statements and the revisions in estimates of cash flows associated with nuclear asset retirement obligations"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 32000, "result": 1.0, "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?", "options": {"A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II", "B": "Note 5, within the Management's Discussion and Analysis", "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II", "D": "Note 6, within the Financial Overview section", "E": "Appendix A, in the Summary of Financial Policies", "F": "Note 7, within the Risk Management section"}, "LLM_original_answer": ["To answer the question \"Where can one find the discussion about the allowance for credit losses measurement methodology?\" based on the provided document, I will follow these steps:\n\n1. **Identify Key Sections**: The document is structured with various sections, including \"Notes to the Consolidated Financial Statements,\" \"Management's Discussion and Analysis,\" and \"Risk Management.\"\n\n2. **Search for Relevant Information**: I will look for specific mentions of the allowance for credit losses measurement methodology within these sections.\n\n3. **Match Information to Options**: I will compare the found information to the given options to determine the correct answer.\n\n### Step 1: Identify Key Sections\n- **Notes to the Consolidated Financial Statements** (Part II, Item 8)\n- **Management's Discussion and Analysis** (MD&A)\n- **Risk Management** (Part II, Item 7)\n\n### Step 2: Search for Relevant Information\n- **Note 2, \"Summary of Significant Accounting Policies\"**:\n  - The document mentions: \"For additional discussion of our allowance for credit losses measurement methodology, see Note 2, 'Summary of Significant Accounting Policies' and Note 4, 'Loans and Allowance for Credit Losses' within the Notes to the Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K.\"\n\n- **Note 4, \"Loans and Allowance for Credit Losses\"**:\n  - The document also mentions: \"Refer to Note 4, 'Loans and Allowance for Credit Losses' for additional information regarding the Company\u2019s measurement of the allowance for loan losses as of December 31, 2023 and information regarding the Company\u2019s TDR loans as of December 31, 2022 and for the year then ended.\"\n\n### Step 3: Match Information to Options\n- **Option A**: Note 3, within the Notes to the Consolidated Financial Statements in Part II\n  - **Not mentioned** in the document for allowance for credit losses measurement methodology.\n- **Option B**: Note 5, within the Management's Discussion and Analysis\n  - **Not mentioned** in the document for allowance for credit losses measurement methodology.\n- **Option C**: Note 2, within the Notes to the Consolidated Financial Statements in Part II\n  - **Mentioned** in the document for allowance for credit losses measurement methodology.\n- **Option D**: Note 6, within the Financial Overview section\n  - **Not"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 32000, "result": 1.0, "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?", "options": {"A": "Competitors cannot make similar products without infringing patents.", "B": "Patent laws in the United States are more favorable than those in other countries.", "C": "Issued patents may be challenged and held invalid or unenforceable.", "D": "Regulatory approval for drug candidates is guaranteed.", "E": "Trade secrets are always more secure than patents.", "F": "All pending patent applications will lead to issued patents."}, "LLM_original_answer": ["To answer the question \"What is one reason why intellectual property rights may not provide adequate protection for the business?\" based on the provided document, let's analyze the options and the relevant information from the document:\n\n### Options:\nA: Competitors cannot make similar products without infringing patents.\nB: Patent laws in the United States are more favorable than those in other countries.\nC: Issued patents may be challenged and held invalid or unenforceable.\nD: Regulatory approval for drug candidates is guaranteed.\nE: Trade secrets are always more secure than patents.\nF: All pending patent applications will lead to issued patents.\n\n### Analysis:\n1. **Option A: Competitors cannot make similar products without infringing patents.**\n   - The document states: \"Our competitors and other third parties may independently develop equivalent knowledge, methods and know-how, or design around our claimed subject matter by developing similar or alternative technologies or products in a non-infringing manner.\"\n   - This indicates that competitors can develop similar products without infringing patents, so Option A is not correct.\n\n2. **Option B: Patent laws in the United States are more favorable than those in other countries.**\n   - The document mentions: \"The laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.\"\n   - This suggests that U.S. patent laws are more favorable, but it does not address why intellectual property rights may not provide adequate protection. Therefore, Option B is not the best answer.\n\n3. **Option C: Issued patents may be challenged and held invalid or unenforceable.**\n   - The document states: \"Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts.\"\n   - This directly addresses a reason why intellectual property rights may not provide adequate protection, making Option C a strong candidate.\n\n4. **Option D: Regulatory approval for drug candidates is guaranteed.**\n   - The document clearly states: \"The regulatory approval process of the FDA and other national or European regulators is lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our drug candidates, our business will be substantially harmed.\"\n   - This indicates that regulatory approval is not guaranteed, so Option D is not correct.\n\n5. **Option E: Trade secrets are always more secure than patents.**\n   - The document mentions: \"Trade secrets can be difficult to protect. We seek"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 32000, "result": 1.0, "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?", "options": {"A": "Increase in market competition", "B": "Higher margins in the Correspondent channel", "C": "Decline in setup fees for loans boarded", "D": "Increase in HECM loan proceeds", "E": "Decrease in revaluation gains on MSRs", "F": "Higher production volume in retail channels"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the primary reason for the decrease in other revenue, net for 2023 compared to 2022.\n\n1. **Identify the relevant section in the document:**\n   - The relevant section is \"Other revenue, net\" under the \"Originations\" segment.\n\n2. **Extract the key information:**\n   - The document states: \"Other revenue, net for 2023 declined $8.4 million as compared to 2022 primarily due to a $5.0 million decline in setup fees earned for loans boarded on our servicing platform, mostly related to a decline in Consumer Direct volume, and a $2.6 million decrease in correspondent and broker fees due to the decline in production volume.\"\n\n3. **Analyze the information:**\n   - The primary reason for the decrease in other revenue, net is the decline in setup fees earned for loans boarded on the servicing platform.\n   - This decline is specifically attributed to a decrease in Consumer Direct volume.\n   - Additionally, there is a decrease in correspondent and broker fees due to the decline in production volume, but this is a secondary reason.\n\n4. **Match the information to the given options:**\n   - Option A: Increase in market competition - Not mentioned as a primary reason.\n   - Option B: Higher margins in the Correspondent channel - Not mentioned as a reason for the decrease.\n   - Option C: Decline in setup fees for loans boarded - Matches the primary reason identified.\n   - Option D: Increase in HECM loan proceeds - Not mentioned as a reason for the decrease.\n   - Option E: Decrease in revaluation gains on MSRs - Not mentioned as a reason for the decrease in other revenue, net.\n   - Option F: Higher production volume in retail channels - Contradicts the information provided, as there is a decline in Consumer Direct volume.\n\n5. **Conclusion:**\n   - The primary reason for the decrease in other revenue, net for 2023 compared to 2022 is the decline in setup fees for loans boarded, which is mostly related to a decline in Consumer Direct volume.\n\nTherefore, the correct answer is **Option C: Decline in setup fees for loans boarded**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 32000, "result": 1.0, "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?", "options": {"A": "Lack of innovative product features", "B": "Limited product supply", "C": "Inability to maintain effective sales forces", "D": "High regulatory costs", "E": "Insufficient funding for development", "F": "Excessive competition in the product market"}, "LLM_original_answer": ["To answer the question \"What is a potential challenge mentioned in establishing collaborations for sales and marketing?\" based on the provided document, I will analyze the relevant sections step by step:\n\n1. **Identify Relevant Sections**:\n   - The document discusses various challenges related to raising capital and establishing collaborations, including the terms and conditions that may come with such arrangements.\n   - Specifically, it mentions the risks associated with debt financing and the terms of collaboration agreements.\n\n2. **Analyze the Content**:\n   - **Debt Financing**:\n     - \"If we raise additional capital through debt financing, the terms of any new debt could further restrict our operating and financial flexibility.\"\n     - This indicates that debt financing can impose restrictive covenants that limit the company's ability to operate freely, which could indirectly affect sales and marketing efforts.\n   - **Collaboration Agreements**:\n     - \"If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock.\"\n     - \"If we raise additional capital pursuant to collaborations, licensing arrangements or other strategic partnerships, such agreements may require us to relinquish rights to our technologies or product candidates.\"\n     - These points suggest that collaboration agreements can involve relinquishing rights to technologies or product candidates, which could impact the company's control over its products and, consequently, its sales and marketing strategies.\n\n3. **Evaluate the Options**:\n   - **A: Lack of innovative product features** - Not mentioned in the document.\n   - **B: Limited product supply** - Not directly mentioned in the context of collaborations.\n   - **C: Inability to maintain effective sales forces** - Not directly mentioned in the context of collaborations.\n   - **D: High regulatory costs** - Not directly mentioned in the context of collaborations.\n   - **E: Insufficient funding for development** - While funding issues are discussed, they are not specifically tied to the challenge of maintaining effective sales forces.\n   - **F: Excessive competition in the product market** - Not directly mentioned in the context of collaborations.\n\n4. **Select the Best Answer**:\n   - The document explicitly mentions that collaboration agreements may require the company to relinquish rights to its technologies or product candidates, which could affect its ability to control and effectively market its products.\n   - This aligns most closely with the option **C: Inability to maintain effective sales forces"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 32000, "result": 1.0, "question": "What is one reason AMX0035 might fail to obtain regulatory approval?", "options": {"A": "Manufacturing processes are found to be deficient", "B": "Clinical trials easily surpass statistical significance", "C": "FDA agrees with the interpretation of preclinical studies", "D": "Patient opinions are highly positive", "E": "Regulatory authorities consistently approve design implementations", "F": "Clinical trials detect an exceeding positive effect"}, "LLM_original_answer": ["To answer the question \"What is one reason AMX0035 might fail to obtain regulatory approval?\" based on the provided document, I will analyze the options and the relevant information from the document.\n\n### Options:\nA: Manufacturing processes are found to be deficient\nB: Clinical trials easily surpass statistical significance\nC: FDA agrees with the interpretation of preclinical studies\nD: Patient opinions are highly positive\nE: Regulatory authorities consistently approve design implementations\nF: Clinical trials detect an exceeding positive effect\n\n### Analysis:\n1. **Option A: Manufacturing processes are found to be deficient**\n   - The document mentions that regulatory authorities may not approve the manufacturing processes or third-party manufacturers with which we contract. Specifically, it states: \"the FDA\u2019s, Health Canada\u2019s, the EMA\u2019s or any other applicable foreign regulatory agency\u2019s failure to accept the manufacturing processes or third-party manufacturers with which we contract.\"\n   - This indicates that if the manufacturing processes are found to be deficient, it could lead to the failure of obtaining regulatory approval.\n\n2. **Option B: Clinical trials easily surpass statistical significance**\n   - The document does not suggest that surpassing statistical significance in clinical trials is a reason for failing to obtain regulatory approval. Instead, it mentions the opposite: \"the results of clinical trials may not meet the level of statistical significance required by the FDA, Health Canada, the EMA or other comparable foreign regulatory authorities for approval.\"\n   - Therefore, this option is not a valid reason for failure.\n\n3. **Option C: FDA agrees with the interpretation of preclinical studies**\n   - The document indicates that disagreements with regulatory authorities over the interpretation of preclinical and clinical data can delay or prevent approval. It states: \"the FDA\u2019s, Health Canada\u2019s, the EMA\u2019s or any other applicable foreign regulatory agency\u2019s disagreement with the interpretation of data from preclinical and clinical studies and our request may require additional trials or studies to support marketing approval.\"\n   - If the FDA agrees with the interpretation, it would not be a reason for failure. Hence, this option is not valid.\n\n4. **Option D: Patient opinions are highly positive**\n   - The document does not mention patient opinions as a factor in regulatory approval. It focuses more on the scientific and regulatory aspects of the approval process.\n   - Therefore, this option is not a valid reason for failure.\n\n5. **Option E: Regulatory authorities consistently approve design implementations**\n   - The document suggests that regulatory authorities may have different requirements and interpretations of trial designs. It states: \"the"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 40, "token_lengths": 32000, "result": 1.0, "question": "What is the purpose of Section 31 fees according to the Exchange Act?", "options": {"A": "To finance market makers on exchanges", "B": "To cover the costs of technology upgrades", "C": "To recover the government\u2019s costs of supervising and regulating the securities markets", "D": "To reward high-frequency traders", "E": "To fund international trading agreements", "F": "To support trading education programs"}, "LLM_original_answer": ["To answer the question \"What is the purpose of Section 31 fees according to the Exchange Act?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for mentions of Section 31 fees and the Exchange Act.\n2. **Extract the Purpose**: Determine the specific purpose of these fees as stated in the document.\n3. **Match the Purpose to the Options**: Compare the extracted purpose to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant information is found in the \"Transaction-Based Expenses\" section of the \"Exchanges Segment\" part of the document:\n\n> \"Our equities and equity options markets pay fees to the SEC pursuant to Section 31 of the Exchange Act. Section 31 fees are recorded on a gross basis as a component of transaction and clearing fee revenue. These Section 31 fees are assessed to recover the government\u2019s costs of supervising and regulating the securities markets and professionals and are subject to change. We, in turn, collect corresponding activity assessment fees from member organizations clearing or settling trades on the equities and options exchanges, and recognize these amounts in our transaction and clearing revenues when invoiced. The activity assessment fees are designed to equal the Section 31 fees.\"\n\n### Step 2: Extract the Purpose\nThe purpose of Section 31 fees, as stated in the document, is to recover the government\u2019s costs of supervising and regulating the securities markets and professionals.\n\n### Step 3: Match the Purpose to the Options\nNow, let's match this purpose to the given options:\n\n- **A: To finance market makers on exchanges** - This does not match the purpose of recovering government costs.\n- **B: To cover the costs of technology upgrades** - This does not match the purpose of recovering government costs.\n- **C: To recover the government\u2019s costs of supervising and regulating the securities markets** - This matches the purpose exactly.\n- **D: To reward high-frequency traders** - This does not match the purpose of recovering government costs.\n- **E: To fund international trading agreements** - This does not match the purpose of recovering government costs.\n- **F: To support trading education programs** - This does not match the purpose of recovering government costs.\n\n### Conclusion\nThe correct answer is **C: To recover the government\u2019s costs of supervising and regulating the securities markets**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 32000, "result": 1.0, "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?", "options": {"A": "5%", "B": "10%", "C": "15%", "D": "1%", "E": "0.5%", "F": "2%"}, "LLM_original_answer": ["To answer the question \"What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the corporate fixed maturity securities portfolio in the \"Investments\" section.\n\n2. **Locate the specific information about the top ten holdings**: The document states, \"Our portfolio does not have any exposure to any single issuer in excess of 1% of total investments and the top ten holdings in aggregate comprise 1% of total investments at both December 31, 2023 and 2022.\"\n\n3. **Extract the percentage**: The document clearly indicates that the top ten holdings in aggregate comprise 1% of total investments.\n\n4. **Match the extracted percentage with the given options**: The options provided are:\n   - A: 5%\n   - B: 10%\n   - C: 15%\n   - D: 1%\n   - E: 0.5%\n   - F: 2%\n\n   The extracted percentage (1%) matches option D.\n\nTherefore, the correct answer is **D: 1%**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 40, "token_lengths": 64000, "result": 1.0, "question": "What could happen if there are delays in the clinical trials of product candidates?", "options": {"A": "The marketing period under patent protection would be increased.", "B": "The marketing period under patent protection would be reduced.", "C": "The patent applications would become public immediately.", "D": "The company would be certain they were first to file any patent application.", "E": "All interference proceedings would be canceled by the USPTO.", "F": "Priority disputes would be automatically resolved in the company's favor."}, "LLM_original_answer": ["To answer the question \"What could happen if there are delays in the clinical trials of product candidates?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Clinical Trial Delays and Their Impact**:\n   - The document states: \"Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful.\"\n   - It also mentions: \"Our product development costs will increase if we experience delays in clinical testing or marketing approvals.\"\n\n2. **Consequences of Delays**:\n   - **Increased Costs**: \"Our product development costs will increase if we experience delays in clinical testing or marketing approvals.\"\n   - **Reduced Marketing Period**: \"Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates.\"\n   - **Regulatory Approval Delays**: \"Even if these trials are initiated or conducted on a timely basis, issues may arise that could result in the suspension or termination of such clinical trials.\"\n\n3. **Evaluating the Options**:\n   - **Option A**: \"The marketing period under patent protection would be increased.\" - This is not supported by the document. Delays in clinical trials do not increase the marketing period under patent protection.\n   - **Option B**: \"The marketing period under patent protection would be reduced.\" - This is supported by the document, which states that delays could shorten the periods during which we have the exclusive right to commercialize our product candidates.\n   - **Option C**: \"The patent applications would become public immediately.\" - The document does not mention that delays in clinical trials would cause patent applications to become public immediately.\n   - **Option D**: \"The company would be certain they were first to file any patent application.\" - The document does not suggest that delays in clinical trials would affect the certainty of being first to file a patent application.\n   - **Option E**: \"All interference proceedings would be canceled by the USPTO.\" - The document does not mention that delays in clinical trials would lead to the cancellation of interference proceedings.\n   - **Option F**: \"Priority disputes would be automatically resolved in the company's favor.\" - The document does not suggest that delays in clinical trials would automatically resolve priority disputes in the company's favor.\n\nBased"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 64000, "result": 1.0, "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?", "options": {"A": "Invests in renewable energy sources", "B": "Diversifies its energy portfolio", "C": "Enters into derivative instruments", "D": "Reduces energy consumption", "E": "Increases energy purchases", "F": "Halts energy operations"}, "LLM_original_answer": ["To answer the question \"What action does the Company take to manage commodity price risk for its merchant generation operations?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss commodity price risk and the Company's risk management strategies.\n2. **Extract Key Information**: Extract specific details about how the Company manages commodity price risk.\n3. **Match Information to Options**: Compare the extracted information to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in **Item 7A. Quantitative and Qualitative Disclosures About Market Risk** under **Commodity Price Risk**:\n\n### Step 2: Extract Key Information\nFrom the document:\n- **Commodity Price Risk**: \"Commodity price risks result from exposures to changes in spot prices, forward prices, volatilities, and correlations between various commodities, such as electricity and emissions credits.\"\n- **Risk Management Strategy**: \"The Company manages the commodity price risk of its merchant generation operations by entering into derivative instruments to manage the variability in future cash flows from forecasted energy purchases.\"\n- **Considerations**: \"Management considers energy prices, weather forecasts, forecasted energy purchases, and other factors when determining the extent of its risk management strategy over commodity price risk.\"\n\n### Step 3: Match Information to Options\n- **Option A: Invests in renewable energy sources** - The document does not mention investing in renewable energy sources as a strategy for managing commodity price risk.\n- **Option B: Diversifies its energy portfolio** - The document does not mention diversifying its energy portfolio.\n- **Option C: Enters into derivative instruments** - The document explicitly states that the Company manages commodity price risk by entering into derivative instruments.\n- **Option D: Reduces energy consumption** - The document does not mention reducing energy consumption.\n- **Option E: Increases energy purchases** - The document does not mention increasing energy purchases.\n- **Option F: Halts energy operations** - The document does not mention halting energy operations.\n\n### Conclusion\nThe best match for the action the Company takes to manage commodity price risk for its merchant generation operations is **Option C: Enters into derivative instruments**.\n\nThus, the answer is **C: Enters into derivative instruments**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 64000, "result": 1.0, "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?", "options": {"A": "To manage the financial statements", "B": "To express an opinion based on audits", "C": "To prepare the financial statements", "D": "To oversee the Company\u2019s management", "E": "To implement the Company's accounting principles", "F": "To revise the financial statements annually"}, "LLM_original_answer": ["The responsibility of the public accounting firm regarding the Company\u2019s financial statements, as described in the provided document, is to express an opinion based on audits. This is evident from the following excerpt:\n\n> \"We have audited the accompanying consolidated balance sheets of Duke Energy Corporation and subsidiaries (the \"Company\") as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income, changes in equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the \"financial statements\"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.\"\n\nThis statement clearly indicates that the public accounting firm (Deloitte & Touche LLP) has conducted an audit of the financial statements and is expressing an opinion on their fairness and conformity with GAAP.\n\nTherefore, the correct answer is:\n\n**B: To express an opinion based on audits**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 64000, "result": 1.0, "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?", "options": {"A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II", "B": "Note 5, within the Management's Discussion and Analysis", "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II", "D": "Note 6, within the Financial Overview section", "E": "Appendix A, in the Summary of Financial Policies", "F": "Note 7, within the Risk Management section"}, "LLM_original_answer": ["The discussion about the allowance for credit losses measurement methodology can be found in **Note 2, \"Summary of Significant Accounting Policies\"** within the Notes to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. This is mentioned in the text provided, specifically in the section discussing the adoption of ASU 2016-13 and the changes made to the existing impairment model.\n\nTherefore, the correct answer is:\n**C: Note 2, within the Notes to the Consolidated Financial Statements in Part II**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 64000, "result": 1.0, "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?", "options": {"A": "Competitors cannot make similar products without infringing patents.", "B": "Patent laws in the United States are more favorable than those in other countries.", "C": "Issued patents may be challenged and held invalid or unenforceable.", "D": "Regulatory approval for drug candidates is guaranteed.", "E": "Trade secrets are always more secure than patents.", "F": "All pending patent applications will lead to issued patents."}, "LLM_original_answer": ["To answer the question, let's analyze the provided document and the options given:\n\n### Analysis of the Document\nThe document discusses various risks and uncertainties related to Nurix Therapeutics, Inc., particularly focusing on the challenges in the development and commercialization of their drug candidates. One of the key sections relevant to the question is \"Risks Related to Our Intellectual Property,\" which outlines several issues that could affect the company's ability to protect its intellectual property.\n\n### Key Points from the Document\n1. **Patent Application and Prosecution Process**: The document mentions that the patent application and prosecution process is expensive, complex, and time-consuming, and there is no guarantee that all necessary or desirable patent applications can be filed and prosecuted in a timely manner.\n2. **Defects in Patents**: There is a risk that defects in the form or preparation of patents or patent applications may exist, which could render the patents invalid or unenforceable.\n3. **Third-Party Challenges**: The document notes that the company may be subject to third-party challenges in patent offices in the United States and abroad, which could result in the revocation or cancellation of patents or amendments that reduce their scope.\n4. **Patent Term and Exclusivity**: The document highlights that the life of a patent is limited, and even if the company obtains patent protection, it may face competition from generic or biosimilar medications after the expiration of patent rights.\n\n### Evaluation of Options\n- **Option A**: \"Competitors cannot make similar products without infringing patents.\"\n  - This is not a reason why intellectual property rights may not provide adequate protection. It is a statement of what patents are supposed to do, not a limitation.\n\n- **Option B**: \"Patent laws in the United States are more favorable than those in other countries.\"\n  - This is not a reason why intellectual property rights may not provide adequate protection. It is a comparative statement about patent laws.\n\n- **Option C**: \"Issued patents may be challenged and held invalid or unenforceable.\"\n  - This is a valid reason. The document explicitly mentions that issued patents may be subject to third-party challenges and could be found invalid or unenforceable, which would undermine the protection provided by intellectual property rights.\n\n- **Option D**: \"Regulatory approval for drug candidates is guaranteed.\"\n  - This is not a reason why intellectual property rights may not provide adequate protection. It is a statement about regulatory approval, not intellectual property.\n\n- **Option E**: \"Trade secrets are always more secure"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 64000, "result": 1.0, "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?", "options": {"A": "Increase in market competition", "B": "Higher margins in the Correspondent channel", "C": "Decline in setup fees for loans boarded", "D": "Increase in HECM loan proceeds", "E": "Decrease in revaluation gains on MSRs", "F": "Higher production volume in retail channels"}, "LLM_original_answer": ["To answer the question \"What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the relevant section**: The document provides a detailed breakdown of the financial performance of different segments, including the Originations segment. The section on \"Other revenue, net\" is particularly relevant.\n\n2. **Examine the change in other revenue, net**:\n   - The document states: \"Other revenue, net for 2023 declined $8.4 million as compared to 2022 primarily due to a $5.0 million decline in setup fees earned for loans boarded on our servicing platform, mostly related to a decline in Consumer Direct volume, and a $2.6 million decrease in correspondent and broker fees due to the decline in production volume.\"\n\n3. **Analyze the primary reasons**:\n   - **Decline in setup fees**: The document mentions a $5.0 million decline in setup fees earned for loans boarded on the servicing platform. This decline is mostly related to a decrease in Consumer Direct volume.\n   - **Decrease in correspondent and broker fees**: The document also mentions a $2.6 million decrease in correspondent and broker fees due to the decline in production volume.\n\n4. **Determine the primary reason**:\n   - The primary reason for the decrease in other revenue, net is the **decline in setup fees for loans boarded on the servicing platform**. This is the largest component of the decline, accounting for $5.0 million out of the total $8.4 million decrease.\n\nTherefore, the correct answer is:\n\n**C: Decline in setup fees for loans boarded**\n\nThis aligns with the information provided in the document, which clearly states that the primary reason for the decrease in other revenue, net is the decline in setup fees, particularly related to the Consumer Direct volume."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 64000, "result": 0.0, "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?", "options": {"A": "Lack of innovative product features", "B": "Limited product supply", "C": "Inability to maintain effective sales forces", "D": "High regulatory costs", "E": "Insufficient funding for development", "F": "Excessive competition in the product market"}, "LLM_original_answer": ["To answer the question \"What is a potential challenge mentioned in establishing collaborations for sales and marketing?\" based on the provided document, I will analyze the relevant sections step by step:\n\n1. **Identify Relevant Sections**:\n   - The document discusses various challenges and risks related to the development and commercialization of biopharmaceutical products, including regulatory, manufacturing, and market acceptance issues.\n   - Specifically, the section on \"Risks Related to Our Reliance on Third Parties\" and \"Risks Related to Our Business and Industry\" are most relevant to the question about collaborations for sales and marketing.\n\n2. **Analyze the Sections**:\n   - **Risks Related to Our Reliance on Third Parties**:\n     - The document mentions that the company may rely on third parties for clinical trials, manufacturing, and other aspects of product development.\n     - It states, \"We have in the past and may in the future form or seek collaborations or strategic alliances or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates.\"\n     - The section also highlights several risks associated with these collaborations, including:\n       - Collaborators may not perform their obligations as expected.\n       - Collaborators may not pursue development and commercialization of the product candidates.\n       - Collaborators may delay clinical trials, provide insufficient funding, or stop a clinical trial.\n       - Collaborators may develop competing products.\n       - Collaborators may not commit sufficient resources to marketing and distribution.\n       - Disputes may arise between the company and collaborators, leading to delays or termination of the collaboration.\n\n   - **Risks Related to Our Business and Industry**:\n     - The document discusses the importance of coverage and reimbursement from third-party payors for the commercial success of the product candidates.\n     - It states, \"Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from sales of any of our product candidates.\"\n     - The section also mentions, \"Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.\"\n\n3. **Match the Challenges to the Options**:\n   - **Option A: Lack of innovative product features** - Not mentioned as a specific challenge in the document.\n   - **Option B: Limited product supply** - The document mentions manufacturing challenges and the need for third-party manufacturers, but it does not specifically link this"], "LLM_extracted_answer": ["F"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 64000, "result": 1.0, "question": "What is one reason AMX0035 might fail to obtain regulatory approval?", "options": {"A": "Manufacturing processes are found to be deficient", "B": "Clinical trials easily surpass statistical significance", "C": "FDA agrees with the interpretation of preclinical studies", "D": "Patient opinions are highly positive", "E": "Regulatory authorities consistently approve design implementations", "F": "Clinical trials detect an exceeding positive effect"}, "LLM_original_answer": ["To answer the question \"What is one reason AMX0035 might fail to obtain regulatory approval?\" based on the provided document, let's analyze the options and the relevant information from the document:\n\n### Options:\nA: Manufacturing processes are found to be deficient\nB: Clinical trials easily surpass statistical significance\nC: FDA agrees with the interpretation of preclinical studies\nD: Patient opinions are highly positive\nE: Regulatory authorities consistently approve design implementations\nF: Clinical trials detect an exceeding positive effect\n\n### Analysis:\n1. **Option A: Manufacturing processes are found to be deficient**\n   - The document mentions that \"regulatory authorities may find deficiencies with clinical trial sites or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies\" (p. 74).\n   - It also states that \"if we are unable to gain or continue to access rights to these active ingredients on commercially reasonable terms or develop suitable alternate active ingredients, we may not be able to commercialize product candidates from these programs\" (p. 88).\n   - These points indicate that manufacturing processes and facilities are subject to regulatory scrutiny and can be a reason for failing to obtain regulatory approval.\n\n2. **Option B: Clinical trials easily surpass statistical significance**\n   - The document notes that \"the results of clinical trials may not meet the level of statistical significance required by the FDA, Health Canada, the EMA or other comparable foreign regulatory authorities for approval\" (p. 73).\n   - This suggests that failing to meet statistical significance is a potential reason for regulatory failure, but the option states that the trials \"easily surpass\" statistical significance, which is not a reason for failure.\n\n3. **Option C: FDA agrees with the interpretation of preclinical studies**\n   - The document mentions that \"the FDA may disagree with the interpretation of data from clinical trials or preclinical studies and our request may require additional trials or studies to support marketing approval\" (p. 73).\n   - This indicates that disagreement with the interpretation of preclinical studies can be a reason for regulatory failure, but the option states that the FDA \"agrees\" with the interpretation, which is not a reason for failure.\n\n4. **Option D: Patient opinions are highly positive**\n   - The document does not suggest that patient opinions directly influence regulatory approval. It focuses more on the scientific and regulatory criteria for approval, such as safety, efficacy, and compliance with clinical and manufacturing standards.\n   - Therefore, highly positive patient"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 40, "token_lengths": 64000, "result": 1.0, "question": "What is the purpose of Section 31 fees according to the Exchange Act?", "options": {"A": "To finance market makers on exchanges", "B": "To cover the costs of technology upgrades", "C": "To recover the government\u2019s costs of supervising and regulating the securities markets", "D": "To reward high-frequency traders", "E": "To fund international trading agreements", "F": "To support trading education programs"}, "LLM_original_answer": ["The purpose of Section 31 fees according to the Exchange Act is to recover the government\u2019s costs of supervising and regulating the securities markets and professionals. This is clearly stated in the document under the \"Activity Assessment Fees and Section 31 Fees\" section, where it mentions:\n\n\"Section 31 fees are designed to recover the government\u2019s costs of supervising and regulating the securities markets and professionals.\"\n\nTherefore, the correct answer is:\n\nC: To recover the government\u2019s costs of supervising and regulating the securities markets."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 64000, "result": 1.0, "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?", "options": {"A": "5%", "B": "10%", "C": "15%", "D": "1%", "E": "0.5%", "F": "2%"}, "LLM_original_answer": ["To answer the question \"What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss the corporate fixed maturity securities portfolio and the percentage of total investments that the top ten holdings represent.\n\n2. **Extract the Data**: Find the specific data point that answers the question.\n\n3. **Verify the Data**: Ensure that the data is consistent and accurate within the context of the document.\n\n4. **Select the Correct Option**: Match the extracted data with the given options.\n\n### Step 1: Identify Relevant Information\nThe relevant information is found in the \"Investments\" section of the document, specifically in the \"Fixed Maturity Securities Available-for-sale\" subsection.\n\n### Step 2: Extract the Data\nFrom the document:\n- \"Our portfolio does not have any exposure to any single issuer in excess of 1% of total investments and the top ten holdings in aggregate comprise 1% of total investments at both December 31, 2023 and 2022.\"\n\n### Step 3: Verify the Data\nThe document clearly states that the top ten holdings in aggregate comprise 1% of total investments. This information is consistent and does not change between the two years mentioned.\n\n### Step 4: Select the Correct Option\nThe correct option is:\n- **D: 1%**\n\nTherefore, the top ten holdings in the corporate fixed maturity securities portfolio comprise **1%** of total investments."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 40, "token_lengths": 96000, "result": 1.0, "question": "What could happen if there are delays in the clinical trials of product candidates?", "options": {"A": "The marketing period under patent protection would be increased.", "B": "The marketing period under patent protection would be reduced.", "C": "The patent applications would become public immediately.", "D": "The company would be certain they were first to file any patent application.", "E": "All interference proceedings would be canceled by the USPTO.", "F": "Priority disputes would be automatically resolved in the company's favor."}, "LLM_original_answer": ["To answer the question \"What could happen if there are delays in the clinical trials of product candidates?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Clinical Trial Process and Delays**:\n   - The document outlines the extensive and lengthy process required for clinical trials, including preclinical studies, IND submissions, IRB approvals, and various phases of clinical trials (Phase 1, Phase 2, Phase 3).\n   - It mentions that clinical trials are \"difficult to design and implement, and they involve a lengthy and expensive process with uncertain outcomes\" (p. 50).\n\n2. **Consequences of Delays**:\n   - **Increased Costs**: \"Our product development costs will increase if we experience delays in clinical testing or marketing approvals\" (p. 50).\n   - **Reduced Marketing Period**: \"Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations\" (p. 50).\n\n3. **Regulatory Impact**:\n   - The document states that \"the FDA or comparable foreign regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials\" (p. 51).\n\n4. **Market Competition**:\n   - Delays can allow competitors to gain a market advantage: \"Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do\" (p. 50).\n\n5. **Patent Considerations**:\n   - The document does not mention any direct impact on patent applications becoming public or the certainty of being first to file a patent application.\n   - It does mention that \"the period of time during which we could market our product candidates under patent protection would be reduced\" (p. 66).\n\nGiven this analysis, the most appropriate answer from the provided options is:\n\n**B: The marketing period under patent protection would be reduced.**\n\nThis option directly aligns with the statement in the document that significant clinical trial delays could shorten the period during which the company has the exclusive right to commercialize its product candidates, which is a"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 96000, "result": 1.0, "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?", "options": {"A": "Invests in renewable energy sources", "B": "Diversifies its energy portfolio", "C": "Enters into derivative instruments", "D": "Reduces energy consumption", "E": "Increases energy purchases", "F": "Halts energy operations"}, "LLM_original_answer": ["To answer the question \"What action does the Company take to manage commodity price risk for its merchant generation operations?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss commodity price risk and the Company's strategies to manage it.\n2. **Extract Key Information**: Extract the specific actions mentioned in those sections.\n3. **Match to Options**: Compare the extracted information to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in \"Item 7A. Quantitative and Qualitative Disclosures About Market Risk\" under \"Commodity Price Risk\":\n\n### Step 2: Extract Key Information\nFrom the document:\n- **Commodity Price Risk**: \"Commodity price risks result from exposures to changes in spot prices, forward prices, volatilities, and correlations between various commodities, such as electricity and emissions credits.\"\n- **Risk Management Strategy**: \"The Company manages the commodity price risk of its merchant generation operations by entering into derivative instruments to manage the variability in future cash flows from forecasted energy purchases.\"\n- **Factors Considered**: \"Management considers energy prices, weather forecasts, forecasted energy purchases, and other factors when determining the extent of its risk management strategy over commodity price risk.\"\n\n### Step 3: Match to Options\n- **Option A: Invests in renewable energy sources** - The document does not mention investing in renewable energy sources as a strategy to manage commodity price risk.\n- **Option B: Diversifies its energy portfolio** - The document does not mention diversifying its energy portfolio.\n- **Option C: Enters into derivative instruments** - The document explicitly states that the Company manages commodity price risk by entering into derivative instruments.\n- **Option D: Reduces energy consumption** - The document does not mention reducing energy consumption.\n- **Option E: Increases energy purchases** - The document does not mention increasing energy purchases.\n- **Option F: Halts energy operations** - The document does not mention halting energy operations.\n\n### Conclusion\nThe best match for the action the Company takes to manage commodity price risk for its merchant generation operations is:\n\n**C: Enters into derivative instruments**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 96000, "result": 1.0, "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?", "options": {"A": "To manage the financial statements", "B": "To express an opinion based on audits", "C": "To prepare the financial statements", "D": "To oversee the Company\u2019s management", "E": "To implement the Company's accounting principles", "F": "To revise the financial statements annually"}, "LLM_original_answer": ["The responsibility of the public accounting firm regarding the Company\u2019s financial statements, based on the provided document, is to express an opinion based on audits. This is evident from the following excerpt:\n\n> \"We have audited the accompanying consolidated balance sheets of Duke Energy Corporation and subsidiaries (the \"Company\") as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income, changes in equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the \"financial statements\"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.\"\n\nThis statement clearly indicates that the public accounting firm (Deloitte & Touche LLP) is responsible for auditing the financial statements and providing an opinion on their fairness and conformity with GAAP.\n\nTherefore, the correct answer is:\n\n**B: To express an opinion based on audits**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 96000, "result": 1.0, "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?", "options": {"A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II", "B": "Note 5, within the Management's Discussion and Analysis", "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II", "D": "Note 6, within the Financial Overview section", "E": "Appendix A, in the Summary of Financial Policies", "F": "Note 7, within the Risk Management section"}, "LLM_original_answer": ["The discussion about the allowance for credit losses measurement methodology can be found in Note 2, \"Summary of Significant Accounting Policies\" within the Notes to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. This is mentioned in the document in the following excerpt:\n\n\"For additional discussion of our allowance for credit losses measurement methodology, see Note 2, 'Summary of Significant Accounting Policies' and Note 4, 'Loans and Allowance for Credit Losses' within the Notes to the Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K.\"\n\nTherefore, the correct answer is:\n\nC: Note 2, within the Notes to the Consolidated Financial Statements in Part II"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 96000, "result": 1.0, "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?", "options": {"A": "Competitors cannot make similar products without infringing patents.", "B": "Patent laws in the United States are more favorable than those in other countries.", "C": "Issued patents may be challenged and held invalid or unenforceable.", "D": "Regulatory approval for drug candidates is guaranteed.", "E": "Trade secrets are always more secure than patents.", "F": "All pending patent applications will lead to issued patents."}, "LLM_original_answer": ["The correct answer to the question \"What is one reason why intellectual property rights may not provide adequate protection for the business?\" is:\n\n**C: Issued patents may be challenged and held invalid or unenforceable.**\n\n### Chain of Thoughts:\n1. **Review the Question and Options:**\n   - The question asks for a reason why intellectual property rights may not provide adequate protection for the business.\n   - The options provided are:\n     - A: Competitors cannot make similar products without infringing patents.\n     - B: Patent laws in the United States are more favorable than those in other countries.\n     - C: Issued patents may be challenged and held invalid or unenforceable.\n     - D: Regulatory approval for drug candidates is guaranteed.\n     - E: Trade secrets are always more secure than patents.\n     - F: All pending patent applications will lead to issued patents.\n\n2. **Analyze the Document:**\n   - The document discusses various aspects of intellectual property and regulatory processes, including the challenges and uncertainties associated with patent protection.\n   - It mentions that \"issued patents may be challenged and held invalid or unenforceable\" (Section 74, \"Risks Related to Our Intellectual Property\").\n\n3. **Evaluate Each Option:**\n   - **A: Competitors cannot make similar products without infringing patents.**\n     - This is not always true, as the document states that competitors may design around or circumvent patents (Section 74).\n   - **B: Patent laws in the United States are more favorable than those in other countries.**\n     - The document does not provide a comparison of patent laws in the United States versus other countries. It mentions that the laws of some foreign countries may not protect intellectual property rights to the same extent as U.S. laws, but this is not a reason why U.S. laws are more favorable.\n   - **C: Issued patents may be challenged and held invalid or unenforceable.**\n     - This is directly supported by the document, which states that \"issued patents may be challenged and held invalid or unenforceable\" (Section 74).\n   - **D: Regulatory approval for drug candidates is guaranteed.**\n     - The document clearly states that regulatory approval is not guaranteed and can be a lengthy and uncertain process (Section 75, \"Risks Related to Regulatory Approval and Marketing of Our Drug Candidates\").\n   - **E: Trade secrets are always more secure than patents.**\n     - The document does not claim"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 96000, "result": 1.0, "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?", "options": {"A": "Increase in market competition", "B": "Higher margins in the Correspondent channel", "C": "Decline in setup fees for loans boarded", "D": "Increase in HECM loan proceeds", "E": "Decrease in revaluation gains on MSRs", "F": "Higher production volume in retail channels"}, "LLM_original_answer": ["To answer the question, \"What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?\" we need to analyze the provided document and identify the relevant information.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Section on Other Revenue, Net:**\n   - The document mentions the decline in other revenue, net for 2023 compared to 2022. Specifically, it states: \"Other revenue, net for 2023 declined $8.4 million as compared to 2022.\"\n\n2. **Determine the Reasons for the Decline:**\n   - The document provides two main reasons for the decline in other revenue, net:\n     - **A $5.0 million decline in setup fees earned for loans boarded on our servicing platform, mostly related to a decline in Consumer Direct volume.**\n     - **A $2.6 million decrease in correspondent and broker fees due to the decline in production volume.**\n\n3. **Evaluate the Options:**\n   - **Option A: Increase in market competition** - The document does not mention this as a primary reason for the decline in other revenue, net.\n   - **Option B: Higher margins in the Correspondent channel** - The document does not mention higher margins in the Correspondent channel as a reason for the decline in other revenue, net. Instead, it mentions a decrease in correspondent and broker fees.\n   - **Option C: Decline in setup fees for loans boarded** - This matches the first reason provided in the document.\n   - **Option D: Increase in HECM loan proceeds** - The document does not mention an increase in HECM loan proceeds as a reason for the decline in other revenue, net.\n   - **Option E: Decrease in revaluation gains on MSRs** - The document does not mention this as a reason for the decline in other revenue, net.\n   - **Option F: Higher production volume in retail channels** - The document mentions a decline in Consumer Direct volume, which is part of the retail channel, as a reason for the decline in other revenue, net.\n\n### Conclusion:\nThe primary reason for the decrease in other revenue, net for 2023 compared to 2022 is the **decline in setup fees for loans boarded on our servicing platform, mostly related to a decline in Consumer Direct volume**.\n\nTherefore, the correct answer is **Option C: Decline"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 96000, "result": 1.0, "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?", "options": {"A": "Lack of innovative product features", "B": "Limited product supply", "C": "Inability to maintain effective sales forces", "D": "High regulatory costs", "E": "Insufficient funding for development", "F": "Excessive competition in the product market"}, "LLM_original_answer": ["To answer the question \"What is a potential challenge mentioned in establishing collaborations for sales and marketing?\" based on the provided document, I will analyze the relevant sections and identify the most appropriate option from the given choices.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document discusses various aspects of collaborations, including agreements with Amgen and Novartis.\n   - It also mentions the challenges and risks associated with these collaborations.\n\n2. **Analyze the Content:**\n   - **Collaboration Agreement with Amgen:**\n     - The document states that Amgen will retain all global development and commercialization rights.\n     - It mentions the need to provide safety data for each individual product candidate or each variation or combination of a multiplexed TCR-T therapy.\n     - The document also notes that Amgen may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for TScan.\n   - **Collaboration and License Agreement with Novartis:**\n     - The document mentions that Novartis will retain all global development and commercialization rights.\n     - It also notes that the collaboration included an upfront fee and research funding, and the research term ended in March 2023.\n   - **General Collaboration Risks:**\n     - The document lists several risks associated with collaborations, including:\n       - Collaborators may not perform their obligations as expected.\n       - Collaborators may not pursue development and commercialization of product candidates.\n       - Collaborators may delay clinical trials or require additional clinical trials.\n       - Collaborators may not commit sufficient resources to the commercialization of product candidates.\n       - Collaborators may have competing priorities or may not view the collaboration as beneficial.\n\n3. **Match the Challenges to the Options:**\n   - **Option A: Lack of innovative product features**\n     - Not mentioned as a specific challenge in the document.\n   - **Option B: Limited product supply**\n     - Not mentioned as a specific challenge in the document.\n   - **Option C: Inability to maintain effective sales forces**\n     - The document mentions that TScan has no marketing and sales organization and has no experience in marketing products. This aligns with the challenge of maintaining effective sales forces.\n   - **Option D: High regulatory costs**\n     - While regulatory costs are mentioned, they are not specifically tied to the challenge of establishing collaborations for sales and marketing.\n   - **Option E: Insufficient funding for development**\n     - Funding challenges are mentioned, but they"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 96000, "result": 1.0, "question": "What is one reason AMX0035 might fail to obtain regulatory approval?", "options": {"A": "Manufacturing processes are found to be deficient", "B": "Clinical trials easily surpass statistical significance", "C": "FDA agrees with the interpretation of preclinical studies", "D": "Patient opinions are highly positive", "E": "Regulatory authorities consistently approve design implementations", "F": "Clinical trials detect an exceeding positive effect"}, "LLM_original_answer": ["To answer the question \"What is one reason AMX0035 might fail to obtain regulatory approval?\" based on the provided document, let's analyze the options and the relevant information from the document:\n\nA: **Manufacturing processes are found to be deficient**\n- The document mentions that the manufacturing of authorized medicinal products must comply with cGMP (Current Good Manufacturing Practices) and that the FDA and other regulatory authorities can impose requirements and review manufacturing processes. It also states that if there are any deficiencies, the FDA can delay or deny approval or require additional data or information.\n- Relevant excerpt: \"The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product\u2019s safety and effectiveness after commercialization. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use.\"\n\nB: **Clinical trials easily surpass statistical significance**\n- This option is not a reason for failure; rather, surpassing statistical significance would be a positive outcome.\n- Relevant excerpt: \"The FDA in any approval needs to determine that there is substantial evidence of effectiveness. This finding can be substantiated based on two adequate and well-controlled studies, or in certain circumstances on a single, large, multicenter, adequate and well-controlled study that is very persuasive or from a single adequate and well-controlled study together with confirmatory evidence.\"\n\nC: **FDA agrees with the interpretation of preclinical studies**\n- The document does not suggest that FDA agreement with preclinical studies would be a reason for failure. Instead, it mentions that the FDA may have different interpretations of data, which could lead to delays or additional requirements.\n- Relevant excerpt: \"The FDA presented concerns regarding choices of statistical models for the prespecified primarily analysis and the interpretability of the survival results included in our marketing application.\"\n\nD: **Patient opinions are highly positive**\n- Patient opinions being highly positive is not a reason for regulatory failure. Regulatory approval is based on clinical data and regulatory standards, not patient opinions.\n- Relevant excerpt: \"Patient opinions and experiences are important but do not directly influence regulatory decisions.\"\n\nE: **Regulatory authorities consistently approve design implementations**\n- Consistent approval of design implementations is not a reason for failure. The document mentions that regulatory authorities can impose additional requirements or reject applications if they find issues.\n- Relevant"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 40, "token_lengths": 96000, "result": 1.0, "question": "What is the purpose of Section 31 fees according to the Exchange Act?", "options": {"A": "To finance market makers on exchanges", "B": "To cover the costs of technology upgrades", "C": "To recover the government\u2019s costs of supervising and regulating the securities markets", "D": "To reward high-frequency traders", "E": "To fund international trading agreements", "F": "To support trading education programs"}, "LLM_original_answer": ["To answer the question, I will refer to the relevant information provided in the document:\n\n1. **Identify the relevant section**: The document mentions Section 31 fees in the context of the Exchanges segment, specifically in the \"Activity Assessment Fees and Section 31 Fees\" section.\n\n2. **Extract the relevant information**:\n   - \"We pay the Securities and Exchange Commission, or SEC, fees pursuant to Section 31 of the Securities Exchange Act of 1934 for transactions executed on our U.S. equities and options exchanges.\"\n   - \"These Section 31 fees are designed to recover the costs to the government for supervising and regulating the securities markets and securities professionals.\"\n\n3. **Match the information to the options**:\n   - **Option A**: To finance market makers on exchanges\n   - **Option B**: To cover the costs of technology upgrades\n   - **Option C**: To recover the government\u2019s costs of supervising and regulating the securities markets\n   - **Option D**: To reward high-frequency traders\n   - **Option E**: To fund international trading agreements\n   - **Option F**: To support trading education programs\n\n4. **Determine the correct answer**:\n   - The document explicitly states that Section 31 fees are designed to recover the costs to the government for supervising and regulating the securities markets and securities professionals. This matches **Option C**.\n\nTherefore, the correct answer is **C: To recover the government\u2019s costs of supervising and regulating the securities markets**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 96000, "result": 1.0, "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?", "options": {"A": "5%", "B": "10%", "C": "15%", "D": "1%", "E": "0.5%", "F": "2%"}, "LLM_original_answer": ["To answer the question, \"What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?\" we need to find the relevant information in the provided document. Here's the step-by-step process:\n\n1. **Identify the Relevant Section**: The document contains a section that discusses the investment portfolio, specifically the corporate fixed maturity securities. This is found in the \"Investments\" section.\n\n2. **Locate the Specific Information**: Within the \"Investments\" section, there is a subsection that provides details about the corporate fixed maturity securities portfolio. The relevant information is in the \"U.S. and Foreign Corporate Fixed Maturity Securities\" section.\n\n3. **Extract the Information**: The section states:\n   - \"Our portfolio does not have any exposure to any single issuer in excess of 1% of total investments and the top ten holdings in aggregate comprise 1% of total investments at both December 31, 2023 and 2022.\"\n\n4. **Interpret the Information**: The top ten holdings in the corporate fixed maturity securities portfolio comprise 1% of total investments.\n\n5. **Match the Information to the Options**: The options provided are:\n   - A: 5%\n   - B: 10%\n   - C: 15%\n   - D: 1%\n   - E: 0.5%\n   - F: 2%\n\nThe correct answer is **D: 1%**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 40, "token_lengths": 128000, "result": 1.0, "question": "What could happen if there are delays in the clinical trials of product candidates?", "options": {"A": "The marketing period under patent protection would be increased.", "B": "The marketing period under patent protection would be reduced.", "C": "The patent applications would become public immediately.", "D": "The company would be certain they were first to file any patent application.", "E": "All interference proceedings would be canceled by the USPTO.", "F": "Priority disputes would be automatically resolved in the company's favor."}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 128000, "result": 1.0, "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?", "options": {"A": "Invests in renewable energy sources", "B": "Diversifies its energy portfolio", "C": "Enters into derivative instruments", "D": "Reduces energy consumption", "E": "Increases energy purchases", "F": "Halts energy operations"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 128000, "result": 1.0, "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?", "options": {"A": "To manage the financial statements", "B": "To express an opinion based on audits", "C": "To prepare the financial statements", "D": "To oversee the Company\u2019s management", "E": "To implement the Company's accounting principles", "F": "To revise the financial statements annually"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 40, "token_lengths": 128000, "result": 0.0, "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?", "options": {"A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II", "B": "Note 5, within the Management's Discussion and Analysis", "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II", "D": "Note 6, within the Financial Overview section", "E": "Appendix A, in the Summary of Financial Policies", "F": "Note 7, within the Risk Management section"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 128000, "result": 1.0, "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?", "options": {"A": "Competitors cannot make similar products without infringing patents.", "B": "Patent laws in the United States are more favorable than those in other countries.", "C": "Issued patents may be challenged and held invalid or unenforceable.", "D": "Regulatory approval for drug candidates is guaranteed.", "E": "Trade secrets are always more secure than patents.", "F": "All pending patent applications will lead to issued patents."}, "LLM_original_answer": ["To answer the question, I will analyze the provided options and the relevant information from the document.\n\n**Question: What is one reason why intellectual property rights may not provide adequate protection for the business?**\n\n**Options:**\nA: Competitors cannot make similar products without infringing patents.\nB: Patent laws in the United States are more favorable than those in other countries.\nC: Issued patents may be challenged and held invalid or unenforceable.\nD: Regulatory approval for drug candidates is guaranteed.\nE: Trade secrets are always more secure than patents.\nF: All pending patent applications will lead to issued patents.\n\n**Relevant Information from the Document:**\n- \"Issued patents that we may hold rights to in the future may be held invalid or unenforceable, including as a result of legal challenges by our competitors.\" (Page 74)\n- \"Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, a patent issues from such applications, and then only to the extent the issued claims cover the technology.\" (Page 74)\n- \"We may not be able to successfully integrate or police our trademarks and trade secrets.\" (Page 105)\n- \"The techniques used by cyber criminals change frequently, may not be recognized until launched and can originate from a wide variety of sources.\" (Page 89)\n- \"The patent applications we own, co-own or license may fail to result in issued patents that cover our current and future drug candidates in the United States or in other foreign countries.\" (Page 74)\n\n**Analysis:**\n- **Option A:** The document does not support this statement. It mentions that competitors can challenge and potentially invalidate or unenforce patents.\n- **Option B:** The document does not compare the favorability of patent laws in the United States to those in other countries.\n- **Option C:** The document explicitly states that issued patents may be challenged and held invalid or unenforceable, which is a clear reason why intellectual property rights may not provide adequate protection.\n- **Option D:** The document does not mention that regulatory approval for drug candidates is guaranteed.\n- **Option E:** The document mentions that trade secrets are difficult to protect and may not provide strong protection, contradicting this statement.\n- **Option F:** The document states that not all pending patent applications may lead to issued patents, which contradicts this statement.\n\n**Conclusion:**\nThe correct answer is **Option C: Issued patents may be challenged"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 128000, "result": 1.0, "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?", "options": {"A": "Increase in market competition", "B": "Higher margins in the Correspondent channel", "C": "Decline in setup fees for loans boarded", "D": "Increase in HECM loan proceeds", "E": "Decrease in revaluation gains on MSRs", "F": "Higher production volume in retail channels"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 128000, "result": 0.0, "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?", "options": {"A": "Lack of innovative product features", "B": "Limited product supply", "C": "Inability to maintain effective sales forces", "D": "High regulatory costs", "E": "Insufficient funding for development", "F": "Excessive competition in the product market"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify any mention of challenges related to sales and marketing collaborations.\n\nThe document primarily focuses on the technical and regulatory aspects of TScan Therapeutics"], "LLM_extracted_answer": ["F"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 128000, "result": 1.0, "question": "What is one reason AMX0035 might fail to obtain regulatory approval?", "options": {"A": "Manufacturing processes are found to be deficient", "B": "Clinical trials easily surpass statistical significance", "C": "FDA agrees with the interpretation of preclinical studies", "D": "Patient opinions are highly positive", "E": "Regulatory authorities consistently approve design implementations", "F": "Clinical trials detect an exceeding positive effect"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 40, "token_lengths": 128000, "result": 1.0, "question": "What is the purpose of Section 31 fees according to the Exchange Act?", "options": {"A": "To finance market makers on exchanges", "B": "To cover the costs of technology upgrades", "C": "To recover the government\u2019s costs of supervising and regulating the securities markets", "D": "To reward high-frequency traders", "E": "To fund international trading agreements", "F": "To support trading education programs"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 40, "token_lengths": 128000, "result": 0.0, "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?", "options": {"A": "5%", "B": "10%", "C": "15%", "D": "1%", "E": "0.5%", "F": "2%"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["!"], "ground_truth": "D"}, {"depth": 45, "token_lengths": 8000, "result": 1.0, "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?", "options": {"A": "The Hatch-Waxman Act", "B": "The Bayh-Dole Act", "C": "The Federal Trade Commission Act", "D": "The Privacy Act", "E": "The Patent Cooperation Treaty", "F": "The Sherman Antitrust Act"}, "LLM_original_answer": ["To answer the question, I will analyze the document and identify the relevant information.\n\n### Step 1: Identify the Context\nThe document discusses various aspects of intellectual property (IP) and the challenges associated with licensing and protecting IP in the biotechnology and pharmaceutical industries. It specifically mentions that some of the in-licensed IP may be subject to federal regulations due to government funding.\n\n### Step 2: Locate the Relevant Information\nThe relevant section in the document is:\n\"Some of our in-licensed intellectual property that was discovered through government-funded programs may be subject to federal regulation such as 'march-in' rights, certain reporting requirements and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements and limit our ability to contract with foreign manufacturers. At least one of our in-licensed patent cases related to our KER-047 product candidate, which we deprioritized in November 2023, has been funded in part by the U.S. government and, therefore, is subject to certain federal regulations pursuant to the Bayh-Dole Act of 1980, or the Bayh-Dole Act, and it is possible that additional patent filings we may choose to in-license in the future may also be subject to similar regulations.\"\n\n### Step 3: Analyze the Information\n- The document explicitly mentions the **Bayh-Dole Act of 1980**.\n- The Bayh-Dole Act is described as a federal regulation that affects IP discovered through government-funded programs.\n- It grants the federal government certain rights, including \"march-in\" rights, which allow the government to require the patent holder to license the technology to others under certain conditions.\n- The Act also imposes reporting requirements and a preference for U.S. industry.\n\n### Step 4: Match the Information to the Options\n- **Option A: The Hatch-Waxman Act** - This act is related to patent term extensions and generic drug competition, not specifically to government-funded discoveries.\n- **Option B: The Bayh-Dole Act** - This act is explicitly mentioned in the document and is directly related to government-funded discoveries.\n- **Option C: The Federal Trade Commission Act** - This act is related to antitrust and consumer protection, not to government-funded IP.\n- **Option D: The Privacy Act** - This act is related to the protection of personal information, not to government-funded IP.\n- **Option E: The Patent"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 8000, "result": 1.0, "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?", "options": {"A": "Interest expenses on loans", "B": "Direct expenses associated with the services", "C": "Revenue from hardware sales", "D": "Marketing expenses", "E": "Legal fees related to contracts", "F": "Stock options for employees"}, "LLM_original_answer": ["To answer the question \"What are recorded as a component of cost of revenues when the Company provides hash calculation services?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document discusses the Company's revenue recognition and cost of revenue in the context of providing hash calculation services. The relevant section is \"Revenue From Contracts With Customers - Digital Asset Mining Revenue\" and \"Costs of Revenue.\"\n\n2. **Extract key information**:\n   - **Revenue Recognition for Hash Calculation Services**: The Company recognizes revenue for providing hash calculation services to third-party mining pools. The non-cash consideration (block rewards and transaction fees) is recognized on the same day that control of the service is transferred to the pool operator.\n   - **Costs of Revenue**: The document states, \"Direct expenses associated with providing hash calculation services to a third-party operated mining pool are recorded as cost of revenues.\"\n\n3. **Evaluate the options**:\n   - **A: Interest expenses on loans**: This is not mentioned as a component of cost of revenues for hash calculation services.\n   - **B: Direct expenses associated with the services**: This matches the information provided in the document.\n   - **C: Revenue from hardware sales**: This is not a cost but a revenue item.\n   - **D: Marketing expenses**: This is not mentioned as a component of cost of revenues for hash calculation services.\n   - **E: Legal fees related to contracts**: This is not mentioned as a component of cost of revenues for hash calculation services.\n   - **F: Stock options for employees**: This is not mentioned as a component of cost of revenues for hash calculation services.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **B: Direct expenses associated with the services**.\n\nTherefore, the answer to the question is **B: Direct expenses associated with the services**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 8000, "result": 1.0, "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?", "options": {"A": "Separate them and account under different frameworks", "B": "Combine them and account under the lease accounting framework", "C": "Only account for lease components", "D": "Account for non-lease components under a different policy", "E": "Classify the entire arrangement as a capital lease", "F": "Exclude non-lease components from financial statements"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document, particularly the section on \"Leases.\"\n\n1. **Lease Determination**: The document states that Duke Energy determines if an arrangement is a lease at contract inception based on specific criteria, including the use of a physically distinct identified asset and the right to obtain substantially all of the economic benefits from the use of the asset throughout the period.\n\n2. **Lease and Non-Lease Components for Lessor Arrangements**: The document specifies that for lessor arrangements, lease and non-lease components are only combined under one arrangement and accounted for under the lease accounting framework if:\n   - The non-lease components are not the predominant component of the arrangement.\n   - The lease component would be classified as an operating lease.\n\n3. **Policy Election**: Duke Energy has elected a policy to not separate lease and non-lease components for all asset classes. However, this policy is specifically noted for lessee arrangements, not lessor arrangements.\n\nGiven these points, the correct answer is:\n\n**B: Combine them and account under the lease accounting framework**\n\n**Chain of Thoughts**:\n- The document clearly states that for lessor arrangements, if the non-lease components are not the predominant component and the lease component would be classified as an operating lease, then the lease and non-lease components are combined and accounted for under the lease accounting framework.\n- This aligns with the conditions provided in the question, where the non-lease components are not predominant.\n- Therefore, Duke Energy would combine the lease and non-lease components and account for them under the lease accounting framework."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 8000, "result": 1.0, "question": "Who is responsible for devising and monitoring the asset-liability management strategy?", "options": {"A": "Board of Directors", "B": "Chief Executive Officer", "C": "Asset-Liability Management Committee", "D": "Finance Department", "E": "Risk Management Committee", "F": "External Auditors"}, "LLM_original_answer": ["To answer the question \"Who is responsible for devising and monitoring the asset-liability management strategy?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses asset-liability management is found under \"Management of Market Risk\" and \"Governance.\"\n\n2. **Extract key information**:\n   - The document states: \"Our asset-liability management strategy is devised and monitored by our ALCO, a subcommittee of the ERMC, in accordance with policies approved by the RMC.\"\n   - ALCO stands for the Asset and Liability Management Committee.\n   - RMC stands for the Risk Management Committee of the Board of Directors.\n\n3. **Analyze the information**:\n   - The ALCO is explicitly mentioned as the entity responsible for devising and monitoring the asset-liability management strategy.\n   - The RMC (Risk Management Committee) approves the policies that the ALCO follows, but it does not directly devise or monitor the strategy.\n\n4. **Match the information to the options**:\n   - **A: Board of Directors** - The Board of Directors is mentioned, but only in the context of approving the Risk Appetite Statement and policy limits, not directly devising or monitoring the asset-liability management strategy.\n   - **B: Chief Executive Officer** - The CEO is not mentioned in the context of asset-liability management.\n   - **C: Asset-Liability Management Committee (ALCO)** - This matches the information extracted from the document.\n   - **D: Finance Department** - The Finance Department is mentioned as part of the first line of defense in the risk management framework, but not as the primary entity responsible for devising and monitoring the asset-liability management strategy.\n   - **E: Risk Management Committee (RMC)** - The RMC is mentioned as approving policies, but not as the entity responsible for devising and monitoring the strategy.\n   - **F: External Auditors** - External Auditors are not mentioned in the context of asset-liability management.\n\n5. **Conclusion**:\n   - Based on the information provided, the correct answer is **C: Asset-Liability Management Committee (ALCO)**.\n\nTherefore, the answer to the question is **C: Asset-Liability Management Committee (ALCO)**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 8000, "result": 1.0, "question": "What can reduce the 10-year market exclusivity for orphan products to six years?", "options": {"A": "A new market demand report", "B": "The introduction of a similar product by a competitor", "C": "Annual sales exceeding expectations", "D": "Establishment that the product no longer meets orphan criteria", "E": "Approval of a new regulatory framework", "F": "A change in government policy"}, "LLM_original_answer": ["To answer the question \"What can reduce the 10-year market exclusivity for orphan products to six years?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document discusses the regulatory framework for orphan drugs, including the market exclusivity period. The specific section that addresses the reduction of the 10-year market exclusivity period is found in the following paragraph:\n\n   > \"The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation; for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity.\"\n\n2. **Analyze the criteria for reduction**: According to the paragraph, the 10-year market exclusivity can be reduced to six years if it is established that the product no longer meets the criteria for orphan designation. The specific example given is if the product is sufficiently profitable.\n\n3. **Match the criteria to the options provided**:\n   - **Option A: A new market demand report** - This does not directly relate to the profitability or criteria for orphan designation.\n   - **Option B: The introduction of a similar product by a competitor** - This is not mentioned as a criterion for reducing market exclusivity.\n   - **Option C: Annual sales exceeding expectations** - This is related to profitability, which is a criterion for reducing market exclusivity.\n   - **Option D: Establishment that the product no longer meets orphan criteria** - This directly matches the criteria mentioned in the document.\n   - **Option E: Approval of a new regulatory framework** - This is not mentioned as a criterion for reducing market exclusivity.\n   - **Option F: A change in government policy** - While changes in government policy can affect regulations, the document does not specify this as a direct criterion for reducing market exclusivity.\n\n4. **Select the correct option**: Based on the analysis, the correct option is **D: Establishment that the product no longer meets orphan criteria**.\n\n**Chain of thoughts**:\n- The document clearly states that the 10-year market exclusivity for orphan products can be reduced to six years if it is established that the product no longer meets the criteria for orphan designation.\n- The specific example given is if the product is sufficiently profitable, which is a subset of the broader criterion that the product no longer meets the orphan criteria.\n- Among the options provided, **Option D** directly"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 45, "token_lengths": 8000, "result": 1.0, "question": "What factors apart from interest rates can affect MSR fair value?", "options": {"A": "Federal regulations", "B": "Investor required yield or perceived value", "C": "The geographical location of properties", "D": "Historical property data", "E": "Currency exchange rates", "F": "Maintenance costs"}, "LLM_original_answer": ["To answer the question \"What factors apart from interest rates can affect MSR fair value?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Interest Rates**: The document clearly states that interest rates are a key value driver for MSR fair value. However, we are looking for factors other than interest rates.\n\n2. **Supply and Demand of the Market**: The document mentions that \"MSR fair value may change for other market-driven factors, including but not limited to the supply and demand of the market.\" This indicates that the market dynamics, such as the availability of MSRs and the demand for them, can influence their fair value.\n\n3. **Required Yield or Perceived Value by Investors**: The document also states, \"the required yield or perceived value by investors of such MSRs.\" This suggests that the expectations and perceptions of investors regarding the returns they require from MSRs can affect the fair value.\n\n4. **Prepayment Speeds**: The document discusses how increases in prepayment speeds can reduce the value of MSRs. Prepayment speeds are a significant factor in the valuation of MSRs because faster prepayments lead to accelerated portfolio runoff and higher compensating interest payments, which can decrease the overall value.\n\n5. **Delinquency Rates**: Increases in delinquency rates are noted to generally reduce the value of MSRs. Higher delinquency rates increase the cost of servicing and the amounts of servicing advances and related interest expense, which can negatively impact the fair value.\n\n6. **Cost to Service**: The document mentions that the cost to service is a significant cash outflow in the valuation of MSRs. Higher costs to service can reduce the net present value of the cash flows, thereby decreasing the fair value.\n\n7. **Discount Rate**: While the discount rate is related to interest rates, the document specifically notes that increases in the discount rate reduce the value of MSRs due to the lower overall net present value of the net cash flows. This is a separate factor from general interest rates.\n\n8. **Other Ancillary Fees**: The document lists other ancillary fees as a significant cash inflow for MSRs. Changes in these fees can affect the fair value of MSRs.\n\nGiven the options provided, the factors that can affect MSR fair value apart from interest rates are:\n\n- **B: Investor required yield or perceived value**\n- **C: Prepayment speeds**\n- **D: Delinquency rates**\n- **E: Cost to service**\n\nHowever, the options provided in the question are:\n\n"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 8000, "result": 1.0, "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?", "options": {"A": "Faster development process", "B": "Ultimate approval by the FDA", "C": "Faster review", "D": "Faster licensure", "E": "Qualification for all future product candidates", "F": "Marketing approval"}, "LLM_original_answer": ["To answer the question \"What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Faster Development Process (Option A)**:\n   - The document states: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process.\"\n   - This suggests that the Breakthrough Therapy designation does not necessarily guarantee a faster development process.\n\n2. **Ultimate Approval by the FDA (Option B)**:\n   - The document explicitly mentions: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not result in a faster development process, review or licensure compared to candidate products considered for licensure under non-expedited FDA review procedures and does not assure ultimate approval by the FDA.\"\n   - This clearly indicates that the Breakthrough Therapy designation does not guarantee ultimate approval by the FDA.\n\n3. **Faster Review (Option C)**:\n   - The document states: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process.\"\n   - This suggests that the Breakthrough Therapy designation does not necessarily guarantee a faster review.\n\n4. **Faster Licensure (Option D)**:\n   - The document mentions: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not result in a faster development process, review or licensure compared to candidate products considered for licensure under non-expedited FDA review procedures.\"\n   - This indicates that the Breakthrough Therapy designation does not necessarily guarantee faster licensure.\n\n5. **Qualification for All Future Product Candidates (Option E)**:\n   - The document does not provide any information suggesting that the Breakthrough Therapy designation qualifies all future product candidates. It only discusses the current product candidates and the possibility of seeking the designation for future ones.\n   - Therefore, the Breakthrough Therapy designation does not guarantee qualification for all future product candidates.\n\n6. **Marketing Approval (Option F)**:\n   - The document explicitly states: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not result in a faster development process, review or licensure compared to candidate products considered for licensure under non-expedited FDA review procedures and does not assure ultimate approval by the FDA.\"\n  "], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 8000, "result": 1.0, "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?", "options": {"A": "Reducing research and development costs", "B": "Improving relationships with regulatory bodies", "C": "Increased risk of serious adverse events (SAEs)", "D": "Receiving immediate commercial approval", "E": "Negative feedback from patients", "F": "Lowering the price of the drug"}, "LLM_original_answer": ["To answer the question, let's analyze the document and the options provided:\n\n### Document Analysis:\n1. **Regulatory Requirements and Clinical Trials:**\n   - The document emphasizes the importance of adhering to the conditions set by regulatory bodies like Health Canada, the FDA, and the EMA.\n   - It mentions that any deviation from the submitted data or trial design could lead to delays, additional requirements, or even the denial of marketing authorization.\n\n2. **Patient Safety and Adverse Events:**\n   - The document highlights the risk of serious adverse events (SAEs) in clinical trials, especially in patients with life-threatening illnesses who have exhausted other treatments.\n   - It notes that SAEs could negatively impact the safety profile of AMX0035, leading to delays or an inability to commercialize the drug.\n\n3. **Expanded Access Programs (EAPs):**\n   - The document discusses the potential for increased demand for EAPs, which could negatively affect the company's reputation and business.\n   - It mentions that patients in EAPs are at high risk for SAEs, which could have a significant impact on the drug's safety profile and regulatory approval.\n\n### Options Analysis:\n- **A: Reducing research and development costs**\n  - The document does not suggest that initiating an EAP beyond what was submitted to the FDA would reduce R&D costs. In fact, it implies that such actions could increase costs due to the need for additional data and trials.\n\n- **B: Improving relationships with regulatory bodies**\n  - The document suggests that deviating from the submitted plans could lead to regulatory scrutiny and potential delays, which would not improve relationships with regulatory bodies.\n\n- **C: Increased risk of serious adverse events (SAEs)**\n  - The document explicitly mentions that patients in EAPs are at high risk for SAEs, and that these events could negatively impact the safety profile of AMX0035, leading to significant delays or an inability to commercialize the drug.\n\n- **D: Receiving immediate commercial approval**\n  - The document does not suggest that initiating an EAP beyond the submitted plan would lead to immediate commercial approval. Instead, it emphasizes the importance of following regulatory guidelines to avoid delays and denials.\n\n- **E: Negative feedback from patients**\n  - While the document mentions the potential for negative feedback from patients, it does not specifically link this to initiating an EAP beyond the submitted plan.\n\n- **F: Lowering the price of the drug**\n  - The"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 8000, "result": 1.0, "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?", "options": {"A": "Increased dividend payments to stockholders", "B": "Lower commodity prices and reduced volatility", "C": "Higher development of electronic trading platforms", "D": "Repayment of debt", "E": "Expansion of clearing houses", "F": "Treasury shares received for restricted tax payments"}, "LLM_original_answer": ["To answer the question, let's break down the information provided in the document and analyze it step by step:\n\n1. **Identify the relevant section**: The question asks about the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023. This information is found in the \"Liquidity and Capital Resources\" section, specifically under \"Financing Activities.\"\n\n2. **Extract the relevant information**: The document states:\n   - \"Consolidated net cash used in financing activities in 2023 primarily relates to a $65.4 billion decrease in our cash and cash equivalent margin deposits and guaranty fund liability balances due to lower commodity prices and reduced volatility.\"\n\n3. **Analyze the options**:\n   - **A: Increased dividend payments to stockholders**: The document mentions that $955 million was paid in dividends in 2023, but this is not the primary reason for the $65.4 billion decrease.\n   - **B: Lower commodity prices and reduced volatility**: This matches the information provided in the document.\n   - **C: Higher development of electronic trading platforms**: The document discusses increased technology and communication expenses, but this is not related to the decrease in margin deposits.\n   - **D: Repayment of debt**: The document mentions $2.3 billion in debt repayments, but this is not the primary reason for the $65.4 billion decrease.\n   - **E: Expansion of clearing houses**: The document does not mention expansion of clearing houses as a reason for the decrease in margin deposits.\n   - **F: Treasury shares received for restricted tax payments**: The document mentions $78 million in cash payments related to treasury shares, but this is not the primary reason for the $65.4 billion decrease.\n\n4. **Conclusion**: The primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023 is **B: Lower commodity prices and reduced volatility**.\n\nTherefore, the correct answer is **B: Lower commodity prices and reduced volatility**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 8000, "result": 1.0, "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?", "options": {"A": "$7 million", "B": "$16 million", "C": "$393 million", "D": "$829 million", "E": "$10.6 billion", "F": "$11.0 billion"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses cash collateral is found under \"Pledged Collateral.\"\n\n2. **Extract the specific information**: The document states:\n   - \"At December 31, 2023 and 2022, we were obligated to return cash collateral pledged to us by counterparties of $393 million and $829 million, respectively.\"\n\n3. **Match the information to the options provided**:\n   - The amount as of December 31, 2023, is $393 million.\n   - The options provided are:\n     - A: $7 million\n     - B: $16 million\n     - C: $393 million\n     - D: $829 million\n     - E: $10.6 billion\n     - F: $11.0 billion\n\n4. **Select the correct answer**: The correct answer is C: $393 million.\n\n**Chain of thoughts**:\n- The document clearly specifies the amount of cash collateral we were obligated to return to counterparties as of December 31, 2023.\n- This amount is $393 million.\n- Among the given options, only C matches this amount.\n\nTherefore, the answer is C: $393 million."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 16000, "result": 1.0, "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?", "options": {"A": "The Hatch-Waxman Act", "B": "The Bayh-Dole Act", "C": "The Federal Trade Commission Act", "D": "The Privacy Act", "E": "The Patent Cooperation Treaty", "F": "The Sherman Antitrust Act"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the relevant information.\n\n1. **Identify the Context**: The document discusses various risks and challenges related to intellectual property, particularly in the context of biopharmaceutical and pharmaceutical industries. It mentions specific regulations and laws that could affect the company's ability to protect and enforce its intellectual property.\n\n2. **Locate Relevant Information**: The document specifically mentions a federal regulation that affects some of the in-licensed intellectual property related to government-funded discoveries. This information is found in the following paragraph:\n\n   > \"Some of our in-licensed intellectual property that was discovered through government-funded programs may be subject to federal regulation such as 'march-in' rights, certain reporting requirements and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements and limit our ability to contract with foreign manufacturers. At least one of our in-licensed patent cases related to our KER-047 product candidate, which we deprioritized in November 2023, has been funded in part by the U.S. government and, therefore, is subject to certain federal regulations pursuant to the Bayh-Dole Act of 1980, or the Bayh-Dole Act, and it is possible that additional patent filings we may choose to in-license in the future may also be subject to similar regulations.\"\n\n3. **Analyze the Information**: The paragraph clearly states that the Bayh-Dole Act of 1980 is the federal regulation that affects in-licensed intellectual property related to government-funded discoveries. The Act provides the government with certain rights, including \"march-in\" rights, reporting requirements, and a preference for U.S. industry.\n\n4. **Match the Information to the Options**: Among the given options, the Bayh-Dole Act is explicitly mentioned in the document.\n\nTherefore, the correct answer is:\n\n**B: The Bayh-Dole Act**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 16000, "result": 1.0, "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?", "options": {"A": "Interest expenses on loans", "B": "Direct expenses associated with the services", "C": "Revenue from hardware sales", "D": "Marketing expenses", "E": "Legal fees related to contracts", "F": "Stock options for employees"}, "LLM_original_answer": ["To answer the question \"What are recorded as a component of cost of revenues when the Company provides hash calculation services?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the cost of revenues and the specific costs associated with providing hash calculation services is found in the \"Costs of Revenue\" section.\n\n2. **Extract the relevant information**: The document states:\n   - \"Cost of Hosting Services and Cost of Digital Asset Mining primarily consist of electricity costs, salaries, stock-based compensation, depreciation of property, plant and equipment used to perform hosting services and mining operations and other related costs.\"\n   - \"Direct expenses associated with providing hash calculation services to a third-party operated mining pool are recorded as cost of revenues.\"\n\n3. **Analyze the information**:\n   - The document explicitly mentions that direct expenses associated with providing hash calculation services are recorded as cost of revenues.\n   - The list of primary components of cost of revenues includes electricity costs, salaries, stock-based compensation, and depreciation of property, plant and equipment.\n\n4. **Match the information to the options**:\n   - **Option A: Interest expenses on loans** - This is not mentioned as a component of cost of revenues.\n   - **Option B: Direct expenses associated with the services** - This matches the statement in the document.\n   - **Option C: Revenue from hardware sales** - This is not a cost but a revenue item.\n   - **Option D: Marketing expenses** - This is not mentioned as a component of cost of revenues.\n   - **Option E: Legal fees related to contracts** - This is not mentioned as a component of cost of revenues.\n   - **Option F: Stock options for employees** - While stock-based compensation is mentioned, it is not specifically tied to the provision of hash calculation services.\n\n5. **Conclusion**:\n   - The correct answer is **Option B: Direct expenses associated with the services**.\n\nTherefore, the answer to the question is **Option B: Direct expenses associated with the services**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 16000, "result": 1.0, "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?", "options": {"A": "Separate them and account under different frameworks", "B": "Combine them and account under the lease accounting framework", "C": "Only account for lease components", "D": "Account for non-lease components under a different policy", "E": "Classify the entire arrangement as a capital lease", "F": "Exclude non-lease components from financial statements"}, "LLM_original_answer": ["To answer the question, let's break down the relevant information from the provided document:\n\n1. **Lease and Non-Lease Components for Lessor Arrangements**:\n   - The document states: \"For lessor arrangements, lease and non-lease components are only combined under one arrangement and accounted for under the lease accounting framework if the non-lease components are not the predominant component of the arrangement and the lease component would be classified as an operating lease.\"\n\n2. **Interpretation**:\n   - This means that if the non-lease components are not the predominant part of the arrangement, and the lease component is an operating lease, Duke Energy will combine the lease and non-lease components and account for them under the lease accounting framework.\n   - If the non-lease components are predominant, they would be accounted for separately.\n\n3. **Matching the Information to the Options**:\n   - **Option A**: Separate them and account under different frameworks. This is not applicable because the document specifies that they are only combined if the non-lease components are not predominant.\n   - **Option B**: Combine them and account under the lease accounting framework. This is the correct option because it matches the document's statement that they are combined and accounted under the lease framework if the non-lease components are not predominant.\n   - **Option C**: Only account for lease components. This is not applicable because the document does not suggest ignoring non-lease components.\n   - **Option D**: Account for non-lease components under a different policy. This is not applicable because the document specifies that they are combined if the non-lease components are not predominant.\n   - **Option E**: Classify the entire arrangement as a capital lease. This is not applicable because the document specifies that the lease component must be an operating lease for the combination to occur.\n   - **Option F**: Exclude non-lease components from financial statements. This is not applicable because the document does not suggest excluding non-lease components from financial statements.\n\nTherefore, the correct answer is **Option B**: Combine them and account under the lease accounting framework."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 16000, "result": 1.0, "question": "Who is responsible for devising and monitoring the asset-liability management strategy?", "options": {"A": "Board of Directors", "B": "Chief Executive Officer", "C": "Asset-Liability Management Committee", "D": "Finance Department", "E": "Risk Management Committee", "F": "External Auditors"}, "LLM_original_answer": ["To answer the question \"Who is responsible for devising and monitoring the asset-liability management strategy?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: The document contains a section titled \"Management of Market Risk\" which discusses the governance and management of market risk, including asset-liability management.\n\n2. **Extract Key Information**: Within the \"Management of Market Risk\" section, there is a specific paragraph that outlines the responsibilities for asset-liability management:\n\n   > \"Our asset-liability management strategy is devised and monitored by our ALCO, a subcommittee of the ERMC, in accordance with policies approved by the RMC. ALCO operates under a charter developed and approved by the ERMC. ALCO meets at least monthly, or more frequently as needed, to review, among other things, our sensitivity to interest rate changes, loan pricing and activity, investment activity and strategy, hedging strategies, deposit pricing and funding strategies with respect to overall balance sheet composition, as well as earnings simulations over multiple years.\"\n\n3. **Match Information to Options**: The document clearly states that the Asset-Liability Management Committee (ALCO) is responsible for devising and monitoring the asset-liability management strategy.\n\n4. **Select the Correct Option**: The correct answer is **C: Asset-Liability Management Committee**.\n\nTherefore, the answer to the question is **C: Asset-Liability Management Committee**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 16000, "result": 1.0, "question": "What can reduce the 10-year market exclusivity for orphan products to six years?", "options": {"A": "A new market demand report", "B": "The introduction of a similar product by a competitor", "C": "Annual sales exceeding expectations", "D": "Establishment that the product no longer meets orphan criteria", "E": "Approval of a new regulatory framework", "F": "A change in government policy"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document and the options given.\n\nThe question is: What can reduce the 10-year market exclusivity for orphan products to six years?\n\nThe relevant information is found in the following excerpt from the document:\n\n\"The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation; for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity.\"\n\nThis excerpt clearly states that the 10-year market exclusivity for orphan products can be reduced to six years if it is established that the product no longer meets the criteria for orphan designation, particularly if the product is sufficiently profitable.\n\nNow, let's evaluate the options:\n\nA: A new market demand report - This is not mentioned in the document as a factor that can reduce market exclusivity.\n\nB: The introduction of a similar product by a competitor - This is not mentioned in the document as a factor that can reduce market exclusivity.\n\nC: Annual sales exceeding expectations - This is not explicitly mentioned, but it aligns with the concept of the product being \"sufficiently profitable.\"\n\nD: Establishment that the product no longer meets orphan criteria - This is directly mentioned in the document as a factor that can reduce market exclusivity.\n\nE: Approval of a new regulatory framework - This is not mentioned in the document as a factor that can reduce market exclusivity.\n\nF: A change in government policy - This is not mentioned in the document as a factor that can reduce market exclusivity.\n\nBased on the document, the correct answer is:\n\n**D: Establishment that the product no longer meets orphan criteria**\n\nThis is the most accurate and directly supported by the provided information."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 45, "token_lengths": 16000, "result": 1.0, "question": "What factors apart from interest rates can affect MSR fair value?", "options": {"A": "Federal regulations", "B": "Investor required yield or perceived value", "C": "The geographical location of properties", "D": "Historical property data", "E": "Currency exchange rates", "F": "Maintenance costs"}, "LLM_original_answer": ["To answer the question \"What factors apart from interest rates can affect MSR fair value?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Interest Rates**: The document confirms that interest rates are a key value driver for MSRs. However, the question asks for factors other than interest rates.\n\n2. **Supply and Demand of the Market**: The document states, \"While interest rates are a key value driver, MSR fair value may change for other market-driven factors, including but not limited to the supply and demand of the market or the required yield or perceived value by investors of such MSRs.\" This indicates that the supply and demand dynamics in the market can affect MSR fair value.\n\n3. **Investor Required Yield or Perceived Value**: The document explicitly mentions that the required yield or perceived value by investors can influence MSR fair value. This aligns with option B.\n\n4. **Prepayment Speeds**: The document discusses how increases in prepayment speeds can reduce the value of MSRs. This is a significant factor, but it is not listed as an option in the multiple-choice question.\n\n5. **Delinquency Rates**: The document notes that increases in delinquency rates can reduce the value of MSRs. This is another significant factor, but it is not listed as an option in the multiple-choice question.\n\n6. **Cost to Service**: The document mentions that the cost to service is a factor in the valuation of MSRs. This is a significant factor, but it is not listed as an option in the multiple-choice question.\n\n7. **Discount Rate**: The document states that increases in the discount rate reduce the value of MSRs. This is a significant factor, but it is not listed as an option in the multiple-choice question.\n\n8. **Federal Regulations**: The document does not specifically mention federal regulations as a factor affecting MSR fair value, although it does discuss regulatory requirements and compliance, which could indirectly impact fair value.\n\n9. **Geographical Location of Properties**: The document does not mention the geographical location of properties as a factor affecting MSR fair value.\n\n10. **Historical Property Data**: The document does not mention historical property data as a factor affecting MSR fair value.\n\n11. **Currency Exchange Rates**: The document mentions foreign currency exchange rate risk, but it is not directly linked to MSR fair value.\n\n12. **Maintenance Costs**: The document does not mention maintenance costs as a factor affecting MSR fair value.\n\nGiven the information provided, the most relevant and directly mentioned"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 16000, "result": 1.0, "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?", "options": {"A": "Faster development process", "B": "Ultimate approval by the FDA", "C": "Faster review", "D": "Faster licensure", "E": "Qualification for all future product candidates", "F": "Marketing approval"}, "LLM_original_answer": ["To answer the question \"What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Faster Development Process**:\n   - The document states: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process.\"\n   - This suggests that the Breakthrough Therapy designation does not necessarily guarantee a faster development process.\n\n2. **Ultimate Approval by the FDA**:\n   - The document explicitly mentions: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.\"\n   - This clearly indicates that the Breakthrough Therapy designation does not guarantee ultimate approval by the FDA.\n\n3. **Faster Review**:\n   - The document states: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process.\"\n   - This suggests that the Breakthrough Therapy designation does not necessarily guarantee a faster review.\n\n4. **Faster Licensure**:\n   - The document mentions: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process.\"\n   - This implies that the Breakthrough Therapy designation does not necessarily guarantee faster licensure.\n\n5. **Qualification for All Future Product Candidates**:\n   - The document states: \"Even if one or more of our product candidates qualify as Breakthrough Therapies, the FDA may later decide that the product no longer meets the conditions for qualification.\"\n   - This indicates that the Breakthrough Therapy designation does not guarantee qualification for all future product candidates.\n\n6. **Marketing Approval**:\n   - The document explicitly mentions: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.\"\n   - This clearly indicates that the Breakthrough Therapy designation does not guarantee marketing approval.\n\nGiven the information provided, the correct answer is:\n\n**B: Ultimate approval by the FDA**\n\nThe document explicitly states that the Breakthrough Therapy designation does not increase the likelihood"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 16000, "result": 1.0, "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?", "options": {"A": "Reducing research and development costs", "B": "Improving relationships with regulatory bodies", "C": "Increased risk of serious adverse events (SAEs)", "D": "Receiving immediate commercial approval", "E": "Negative feedback from patients", "F": "Lowering the price of the drug"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and consider the potential consequences of initiating an Expanded Access Program (EAP) beyond what was submitted to the FDA for AMX0035.\n\n### Step-by-Step Analysis:\n\n1. **Understanding the Context of EAPs:**\n   - EAPs are designed to provide access to investigational drugs for patients with serious or life-threatening conditions who do not qualify for clinical trials.\n   - The document mentions that increasing demand for expanded access to AMX0035 could negatively affect the company's reputation and harm its business.\n\n2. **Identifying Key Risks:**\n   - **Patient Safety and Adverse Events:**\n     - The document states that patients in EAPs often have life-threatening illnesses and have exhausted all other available therapies.\n     - The risk for serious adverse events (SAEs) in this patient population is high.\n     - If SAEs occur, they could negatively impact the safety profile of AMX0035, leading to significant delays or an inability to commercialize the drug.\n   - **Regulatory Compliance:**\n     - The document emphasizes the importance of regulatory compliance and the potential for regulatory actions if there are issues with the EAP.\n     - Regulatory authorities may require additional data or changes to the EAP, which could delay the approval process.\n   - **Reputation and Public Perception:**\n     - Negative publicity or social media campaigns could arise if the EAP is not managed well, potentially harming the company's reputation and business.\n   - **Resource Allocation:**\n     - The document notes that the company has limited resources and may need to prioritize its efforts.\n     - Initiating an EAP beyond what was submitted could divert resources from other critical activities, such as clinical trials and regulatory submissions.\n\n3. **Evaluating the Options:**\n   - **Option A: Reducing research and development costs**\n     - The document does not suggest that expanding an EAP would reduce R&D costs. In fact, it could increase costs due to the need for additional data and monitoring.\n   - **Option B: Improving relationships with regulatory bodies**\n     - The document indicates that regulatory bodies may require additional data or changes to the EAP, which could strain relationships rather than improve them.\n   - **Option C: Increased risk of serious adverse events (SAEs)**\n     - The document explicitly mentions that the risk for SAEs is high in EAPs, and such events could negatively impact the safety profile of"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 16000, "result": 1.0, "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?", "options": {"A": "Increased dividend payments to stockholders", "B": "Lower commodity prices and reduced volatility", "C": "Higher development of electronic trading platforms", "D": "Repayment of debt", "E": "Expansion of clearing houses", "F": "Treasury shares received for restricted tax payments"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n### Step 1: Identify the Context\nThe question asks about the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023. This information is found in the \"Liquidity and Capital Resources\" section under \"Financing Activities.\"\n\n### Step 2: Locate the Specific Information\nThe relevant passage states:\n> \"Consolidated net cash used in financing activities in 2023 primarily relates to a $65.4 billion decrease in our cash and cash equivalent margin deposits and guaranty fund liability balances due to lower commodity prices and reduced volatility, $2.3 billion repayments of debt, $955 million in dividend payments to our stockholders and $78 million in cash payments related to treasury shares received for restricted stock tax payments and stock options exercises, partially offset by $2.0 billion in proceeds from net issuances under our Commercial Paper Program and $2.4 billion in net proceeds from our debt offerings.\"\n\n### Step 3: Analyze the Information\nThe passage clearly indicates that the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits is \"due to lower commodity prices and reduced volatility.\"\n\n### Step 4: Match the Information to the Options\n- **Option A: Increased dividend payments to stockholders** - The document mentions dividend payments, but they are not the primary reason for the decrease.\n- **Option B: Lower commodity prices and reduced volatility** - This matches the information provided in the document.\n- **Option C: Higher development of electronic trading platforms** - The document does not mention this as a reason for the decrease.\n- **Option D: Repayment of debt** - The document mentions debt repayment, but it is not the primary reason for the decrease.\n- **Option E: Expansion of clearing houses** - The document does not mention this as a reason for the decrease.\n- **Option F: Treasury shares received for restricted tax payments** - The document mentions this, but it is not the primary reason for the decrease.\n\n### Step 5: Conclude\nBased on the information provided in the document, the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023 is **lower commodity prices and reduced volatility**.\n\n### Final Answer\nThe correct answer is **B: Lower commodity prices and reduced volatility**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 16000, "result": 1.0, "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?", "options": {"A": "$7 million", "B": "$16 million", "C": "$393 million", "D": "$829 million", "E": "$10.6 billion", "F": "$11.0 billion"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions cash collateral obligations in the \"Pledged Collateral\" section.\n\n2. **Extract the specific information**: The relevant sentence states, \"At December 31, 2023 and 2022, we were obligated to return cash collateral pledged to us by counterparties of $393 million and $829 million, respectively.\"\n\n3. **Match the information to the options**: The amount of cash collateral we were obligated to return to counterparties as of December 31, 2023, is $393 million.\n\n4. **Select the correct option**: The correct option is C: $393 million.\n\nTherefore, the answer to the question is **C: $393 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 32000, "result": 1.0, "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?", "options": {"A": "The Hatch-Waxman Act", "B": "The Bayh-Dole Act", "C": "The Federal Trade Commission Act", "D": "The Privacy Act", "E": "The Patent Cooperation Treaty", "F": "The Sherman Antitrust Act"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Identify the Context**: The document discusses various aspects of the biotechnology and pharmaceutical industries, including regulatory and legal challenges, intellectual property, and the impact of government-funded research.\n\n2. **Locate Relevant Information**: The document mentions a specific federal regulation that affects government-funded discoveries:\n   - \"Some of our in-licensed intellectual property that was discovered through government-funded programs may be subject to federal regulation such as 'march-in' rights, certain reporting requirements and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements and limit our ability to contract with foreign manufacturers.\"\n   - \"At least one of our in-licensed patent cases related to our KER-047 product candidate, which we deprioritized in November 2023, has been funded in part by the U.S. government and, therefore, is subject to certain federal regulations pursuant to the Bayh-Dole Act of 1980, or the Bayh-Dole Act, and it is possible that additional patent filings we may choose to in-license in the future may also be subject to similar regulations.\"\n\n3. **Evaluate the Options**:\n   - **A: The Hatch-Waxman Act**: This act is primarily about patent term restoration and generic drug competition, not about government-funded discoveries.\n   - **B: The Bayh-Dole Act**: This act specifically addresses the rights and obligations of inventors and the government in the context of government-funded research.\n   - **C: The Federal Trade Commission Act**: This act is about unfair competition and consumer protection, not directly related to government-funded discoveries.\n   - **D: The Privacy Act**: This act is about the protection of personal information held by the government, not about intellectual property from government-funded research.\n   - **E: The Patent Cooperation Treaty**: This treaty is about international patent applications and does not specifically address government-funded discoveries.\n   - **F: The Sherman Antitrust Act**: This act is about preventing anticompetitive practices and does not directly relate to government-funded discoveries.\n\n4. **Conclusion**: Based on the information provided in the document, the federal regulation that may affect some of the in-licensed intellectual property related to government-funded discoveries is the **Bayh-Dole Act**.\n\nTherefore, the correct answer is **B: The Bayh-Dole Act**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 32000, "result": 1.0, "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?", "options": {"A": "Interest expenses on loans", "B": "Direct expenses associated with the services", "C": "Revenue from hardware sales", "D": "Marketing expenses", "E": "Legal fees related to contracts", "F": "Stock options for employees"}, "LLM_original_answer": ["To answer the question \"What are recorded as a component of cost of revenues when the Company provides hash calculation services?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the cost of revenues for providing hash calculation services is found in the \"Revenue From Contracts With Customers - Digital Asset Mining Revenue\" part of the document.\n\n2. **Extract the relevant information**: The document states:\n   - \"Direct expenses associated with providing hash calculation services to a third-party operated mining pool are recorded as cost of revenues.\"\n   - \"Depreciation and amortization expenses on fixed and right-of-use assets, including digital asset mining equipment, used to provide the services are also recorded as a component of cost of revenues.\"\n\n3. **Analyze the options**:\n   - **Option A: Interest expenses on loans** - The document does not mention interest expenses as a component of cost of revenues for hash calculation services.\n   - **Option B: Direct expenses associated with the services** - The document explicitly states that direct expenses associated with providing hash calculation services are recorded as cost of revenues.\n   - **Option C: Revenue from hardware sales** - The document mentions that revenue from hardware sales is recognized separately and is not a component of cost of revenues.\n   - **Option D: Marketing expenses** - The document does not mention marketing expenses as a component of cost of revenues for hash calculation services.\n   - **Option E: Legal fees related to contracts** - The document does not mention legal fees as a component of cost of revenues for hash calculation services.\n   - **Option F: Stock options for employees** - The document does not mention stock options for employees as a component of cost of revenues for hash calculation services.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **Option B: Direct expenses associated with the services**.\n\nTherefore, the answer to the question is **Option B: Direct expenses associated with the services**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 32000, "result": 1.0, "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?", "options": {"A": "Separate them and account under different frameworks", "B": "Combine them and account under the lease accounting framework", "C": "Only account for lease components", "D": "Account for non-lease components under a different policy", "E": "Classify the entire arrangement as a capital lease", "F": "Exclude non-lease components from financial statements"}, "LLM_original_answer": ["To answer the question \"How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss Duke Energy's accounting policies, particularly those related to leases and regulatory matters.\n\n2. **Analyze the Information**: Determine how Duke Energy treats lease and non-lease components in lessor arrangements.\n\n3. **Match the Information to the Options**: Compare the identified policy to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\n\nThe relevant information is found in the \"Significant Accounting Policies\" section of Note 1:\n\n- **Leases**: \"Duke Energy determines if an arrangement is a lease at contract inception based on whether the arrangement involves the use of a physically distinct identified asset and whether Duke Energy has the right to obtain substantially all of the economic benefits from the use of the asset throughout the period as well as the right to direct the use of the asset.\"\n- **Lessor Arrangements**: \"For lessor arrangements, lease and non-lease components are only combined under one arrangement and accounted for under the lease accounting framework if the non-lease components are not the predominant component of the arrangement and the lease component would be classified as an operating lease.\"\n\n### Step 2: Analyze the Information\n\nFrom the above information, we can deduce that Duke Energy's policy for lessor arrangements is to combine lease and non-lease components under one arrangement and account for them under the lease accounting framework if:\n- The non-lease components are not the predominant component of the arrangement.\n- The lease component would be classified as an operating lease.\n\n### Step 3: Match the Information to the Options\n\nLet's compare this policy to the given options:\n\n- **A: Separate them and account under different frameworks** - This does not match the policy, as Duke Energy combines the components under certain conditions.\n- **B: Combine them and account under the lease accounting framework** - This matches the policy, as Duke Energy combines the components and accounts for them under the lease accounting framework if the non-lease components are not predominant and the lease component is an operating lease.\n- **C: Only account for lease components** - This does not match the policy, as both components are combined and accounted for.\n- **D: Account for non-lease components under a different policy** - This does not match the policy,"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 32000, "result": 1.0, "question": "Who is responsible for devising and monitoring the asset-liability management strategy?", "options": {"A": "Board of Directors", "B": "Chief Executive Officer", "C": "Asset-Liability Management Committee", "D": "Finance Department", "E": "Risk Management Committee", "F": "External Auditors"}, "LLM_original_answer": ["To answer the question \"Who is responsible for devising and monitoring the asset-liability management strategy?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss asset-liability management and the governance structure related to it.\n2. **Extract Key Information**: Extract information about the committees and departments involved in asset-liability management.\n3. **Match Information to Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant sections are found in the \"Management of Market Risk\" and \"Governance\" subsections.\n\n### Step 2: Extract Key Information\nFrom the \"Governance\" section:\n- **Asset and Liability Management Committee (ALCO)**: \"Our asset-liability management strategy is devised and monitored by our ALCO, a subcommittee of the ERMC, in accordance with policies approved by the RMC.\"\n- **Risk Management Committee (RMC)**: \"These limits reflect our tolerance for interest rate risk over both short-term and long-term horizons, are designed to encompass market rate shocks that would take place with both gradual and immediate effect and encompass a range of scenarios from mild to extreme market shocks. More specifically, and as further described below, our policy limits govern: [various aspects of risk management]. Policy limits are tested quarterly, and the results are reported to the ALCO and to the RMC.\"\n\n### Step 3: Match Information to Options\n- **Option A: Board of Directors**: The document does not mention the Board of Directors as directly responsible for asset-liability management.\n- **Option B: Chief Executive Officer**: The CEO is not specifically mentioned as responsible for asset-liability management.\n- **Option C: Asset-Liability Management Committee (ALCO)**: The document explicitly states that the ALCO is responsible for devising and monitoring the asset-liability management strategy.\n- **Option D: Finance Department**: The Finance Department is mentioned as part of the first line of defense in the risk management framework, but not as the primary entity responsible for asset-liability management.\n- **Option E: Risk Management Committee (RMC)**: The RMC is involved in setting policy limits and advising the Board of Directors, but it is not mentioned as the primary entity responsible for devising and monitoring the asset-liability management strategy.\n- **Option F: External Auditors**: External auditors are not mentioned as responsible for asset-liability management.\n\n### Conclusion\nBased on"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 32000, "result": 1.0, "question": "What can reduce the 10-year market exclusivity for orphan products to six years?", "options": {"A": "A new market demand report", "B": "The introduction of a similar product by a competitor", "C": "Annual sales exceeding expectations", "D": "Establishment that the product no longer meets orphan criteria", "E": "Approval of a new regulatory framework", "F": "A change in government policy"}, "LLM_original_answer": ["To answer the question \"What can reduce the 10-year market exclusivity for orphan products to six years?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document discusses various aspects of regulatory and legal frameworks, including orphan drug designations and market exclusivity. The specific section that addresses the 10-year market exclusivity for orphan products is found in the part discussing the EU regulatory framework.\n\n2. **Extract the relevant information**: The document states:\n   - \"Products receiving orphan designation in the EU may receive 10 years of orphan market exclusivity (which can be further extended by two years if pediatric studies have been conducted in accordance with an agreed pediatric investigational plan).\"\n   - \"The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation; for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity.\"\n\n3. **Analyze the information**: The key point here is that the 10-year market exclusivity can be reduced to six years if it is established that the product no longer meets the criteria for orphan designation. This can happen if the product is sufficiently profitable, indicating that the financial need for market exclusivity has been met.\n\n4. **Match the information to the options**:\n   - **Option A: A new market demand report** - This is not mentioned as a reason for reducing market exclusivity.\n   - **Option B: The introduction of a similar product by a competitor** - This is not mentioned as a reason for reducing market exclusivity.\n   - **Option C: Annual sales exceeding expectations** - This aligns with the document's statement about the product being sufficiently profitable.\n   - **Option D: Establishment that the product no longer meets orphan criteria** - This is explicitly mentioned in the document.\n   - **Option E: Approval of a new regulatory framework** - This is not mentioned as a reason for reducing market exclusivity.\n   - **Option F: A change in government policy** - This is not mentioned as a reason for reducing market exclusivity.\n\n5. **Select the correct answer**: Based on the document, the correct answer is **Option D: Establishment that the product no longer meets orphan criteria**.\n\n**Final Answer**: D: Establishment that the product no longer meets orphan criteria."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 45, "token_lengths": 32000, "result": 1.0, "question": "What factors apart from interest rates can affect MSR fair value?", "options": {"A": "Federal regulations", "B": "Investor required yield or perceived value", "C": "The geographical location of properties", "D": "Historical property data", "E": "Currency exchange rates", "F": "Maintenance costs"}, "LLM_original_answer": ["To answer the question \"What factors apart from interest rates can affect MSR fair value?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Prepayment Speeds**:\n   - The document states: \"Increases in anticipated lifetime prepayment speeds generally cause MSR valuation adjustments to increase because MSRs are valued based on total expected servicing income over the life of a portfolio.\"\n   - This indicates that prepayment speeds are a significant factor affecting MSR fair value. However, prepayment speeds are often influenced by interest rates, so this is not a separate factor from interest rates.\n\n2. **Investor Required Yield or Perceived Value**:\n   - The document mentions: \"While interest rates are a key value driver, MSR fair value may change for other market-driven factors, including but not limited to the supply and demand of the market or the required yield or perceived value by investors of such MSRs.\"\n   - This directly identifies investor required yield or perceived value as a factor affecting MSR fair value.\n\n3. **Cost to Service**:\n   - The document states: \"The significant estimated future cash inflows for MSRs include servicing fees, late fees, float earnings and other ancillary fees, and significant cash outflows include the cost of servicing, the cost of financing servicing advances and compensating interest payments.\"\n   - The cost to service is a key component in the valuation of MSRs, and changes in this cost can affect the fair value.\n\n4. **Discount Rate**:\n   - The document mentions: \"The significant unobservable assumptions used in the valuation of MSRs include prepayment speeds, cost to service, and discount rates.\"\n   - The discount rate is another significant factor that affects the fair value of MSRs.\n\n5. **Delinquency Rates**:\n   - The document states: \"Increases in delinquencies generally reduce the value of our MSRs as the cost of servicing increases during the delinquency period, and the amounts of servicing advances and related interest expense also increase.\"\n   - Delinquency rates are a factor that can reduce the fair value of MSRs.\n\n6. **Market Spreads**:\n   - The document mentions: \"Additionally, portfolio value is heavily influenced by market spreads for fixed and discount margin for ARMs.\"\n   - Market spreads, particularly for fixed and adjustable-rate mortgages, can influence the fair value of MSRs.\n\nFrom the document, the factors that can affect MSR fair value apart from interest rates are:\n- **Investor required yield or perceived value**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 32000, "result": 1.0, "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?", "options": {"A": "Faster development process", "B": "Ultimate approval by the FDA", "C": "Faster review", "D": "Faster licensure", "E": "Qualification for all future product candidates", "F": "Marketing approval"}, "LLM_original_answer": ["To answer the question \"What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Faster Development Process (Option A)**:\n   - The document states: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process.\"\n   - This suggests that the Breakthrough Therapy designation does not necessarily guarantee a faster development process.\n\n2. **Ultimate Approval by the FDA (Option B)**:\n   - The document explicitly mentions: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.\"\n   - This clearly indicates that the Breakthrough Therapy designation does not guarantee ultimate approval by the FDA.\n\n3. **Faster Review (Option C)**:\n   - The document states: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process.\"\n   - This suggests that the Breakthrough Therapy designation does not necessarily guarantee a faster review.\n\n4. **Faster Licensure (Option D)**:\n   - The document mentions: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process.\"\n   - This implies that the Breakthrough Therapy designation does not guarantee faster licensure.\n\n5. **Qualification for All Future Product Candidates (Option E)**:\n   - The document does not provide any information suggesting that the Breakthrough Therapy designation for one product candidate would automatically qualify all future product candidates for the same designation.\n   - This is a reasonable inference, as the designation is specific to each product candidate and its clinical evidence.\n\n6. **Marketing Approval (Option F)**:\n   - The document explicitly states: \"A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.\"\n   - This clearly indicates that the Breakthrough Therapy designation does not guarantee marketing approval.\n\nGiven the information provided, the correct answer is:\n\n**B: Ultimate approval by the FDA**\n\nThe document explicitly states"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 32000, "result": 1.0, "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?", "options": {"A": "Reducing research and development costs", "B": "Improving relationships with regulatory bodies", "C": "Increased risk of serious adverse events (SAEs)", "D": "Receiving immediate commercial approval", "E": "Negative feedback from patients", "F": "Lowering the price of the drug"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and consider the context and implications of initiating an Expanded Access Program (EAP) beyond what was submitted to the FDA for AMX0035.\n\n### Step-by-Step Analysis:\n\n1. **Understanding the EAP Context**:\n   - An EAP allows patients with serious or life-threatening conditions to access investigational drugs before they are approved.\n   - The document mentions that initiating an EAP beyond what was submitted to the FDA could be a result of increased demand or social media pressure.\n\n2. **Identifying Potential Consequences**:\n   - **Reducing research and development costs (Option A)**: The document does not suggest that expanding an EAP would reduce R&D costs. In fact, it implies that such an expansion could increase costs due to the need for additional data and compliance.\n   - **Improving relationships with regulatory bodies (Option B)**: The document indicates that regulatory bodies have strict requirements and that non-compliance can lead to sanctions. Expanding an EAP without proper submission and approval could strain relationships with regulatory bodies.\n   - **Increased risk of serious adverse events (SAEs) (Option C)**: The document highlights that patients in EAPs often have severe conditions and are at high risk for SAEs. Expanding an EAP could increase the number of patients exposed to the drug, potentially leading to more SAEs.\n   - **Receiving immediate commercial approval (Option D)**: The document does not suggest that expanding an EAP would lead to immediate commercial approval. Instead, it emphasizes the need for rigorous clinical trials and regulatory compliance.\n   - **Negative feedback from patients (Option E)**: The document mentions that negative results or side effects could harm our reputation and business. If an expanded EAP leads to more SAEs or negative outcomes, patients could provide negative feedback.\n   - **Lowering the price of the drug (Option F)**: The document discusses the challenges of setting and maintaining acceptable prices and reimbursement levels. Expanding an EAP is not directly linked to lowering the price of the drug.\n\n3. **Evaluating the Most Likely Consequence**:\n   - **Option C: Increased risk of serious adverse events (SAEs)**: This option is the most supported by the document. The document states, \"Some patients who receive access to drugs prior to their commercial approval through compassionate use, EAPs or right to try access have life-threatening illnesses and have exhausted all other available therapies. The risk for"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 32000, "result": 1.0, "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?", "options": {"A": "Increased dividend payments to stockholders", "B": "Lower commodity prices and reduced volatility", "C": "Higher development of electronic trading platforms", "D": "Repayment of debt", "E": "Expansion of clearing houses", "F": "Treasury shares received for restricted tax payments"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023.\n\n1. **Identify the Context**:\n   - The document discusses the financial performance and activities of Intercontinental Exchange, Inc. (ICE) for the year 2023.\n   - It mentions a significant decrease in cash and cash equivalent margin deposits and guaranty funds.\n\n2. **Locate the Relevant Information**:\n   - The relevant information is found in the \"Liquidity and Capital Resources\" section under \"Consolidated net cash used in financing activities\":\n     - \"Consolidated net cash used in financing activities in 2023 primarily relates to a $65.4 billion decrease in our cash and cash equivalent margin deposits and guaranty fund liability balances due to lower commodity prices and reduced volatility.\"\n\n3. **Analyze the Information**:\n   - The decrease in cash and cash equivalent margin deposits and guaranty fund liability balances is attributed to \"lower commodity prices and reduced volatility.\"\n   - This suggests that the primary reason for the decrease is related to the financial market conditions, specifically the decline in commodity prices and a reduction in market volatility.\n\n4. **Match the Information to the Options**:\n   - Option B: \"Lower commodity prices and reduced volatility\" directly matches the information provided in the document.\n\n5. **Conclusion**:\n   - The primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023 is \"Lower commodity prices and reduced volatility.\"\n\nTherefore, the correct answer is **Option B: Lower commodity prices and reduced volatility**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 32000, "result": 1.0, "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?", "options": {"A": "$7 million", "B": "$16 million", "C": "$393 million", "D": "$829 million", "E": "$10.6 billion", "F": "$11.0 billion"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Relevant Section**: The document mentions cash collateral in the context of derivatives and securities lending. I will focus on the sections that discuss these topics.\n\n2. **Locate the Specific Information**: I will look for the exact figures related to cash collateral obligations as of December 31, 2023.\n\n3. **Extract the Data**: Once I find the relevant information, I will extract the specific amount.\n\n4. **Match the Data to the Options**: I will compare the extracted amount to the provided options to determine the correct answer.\n\n### Step 1: Identify the Relevant Section\nThe relevant sections are:\n- **Derivatives and Pledged Collateral**\n- **Securities Lending**\n\n### Step 2: Locate the Specific Information\nIn the \"Pledged Collateral\" section, the document states:\n- \"At December 31, 2023 and 2022, we were obligated to return cash collateral pledged to us by counterparties of $393 million and $829 million, respectively.\"\n\n### Step 3: Extract the Data\nThe amount of cash collateral we were obligated to return to counterparties as of December 31, 2023, is **$393 million**.\n\n### Step 4: Match the Data to the Options\nThe extracted amount of **$393 million** matches option **C**.\n\n### Conclusion\nThe correct answer is **C: $393 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 64000, "result": 1.0, "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?", "options": {"A": "The Hatch-Waxman Act", "B": "The Bayh-Dole Act", "C": "The Federal Trade Commission Act", "D": "The Privacy Act", "E": "The Patent Cooperation Treaty", "F": "The Sherman Antitrust Act"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify any references to federal regulations that may affect in-licensed intellectual property related to government-funded discoveries.\n\n1. **Identify Relevant Information:**\n   - The document mentions that some of the in-licensed intellectual property may be subject to federal regulations, particularly the Bayh-Dole Act of 1980.\n   - Specifically, it states: \"Some of our in-licensed intellectual property that was discovered through government-funded programs may be subject to federal regulation such as 'march-in' rights, certain reporting requirements and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements and limit our ability to contract with foreign manufacturers.\"\n\n2. **Understand the Bayh-Dole Act:**\n   - The Bayh-Dole Act of 1980 allows universities, small businesses, and non-profit organizations to retain ownership of inventions made with federal funding.\n   - It includes provisions for \"march-in\" rights, which allow the government to require the licensing of a patented invention to a third party if the patent holder has not taken effective steps to achieve practical application of the invention.\n   - The Act also imposes reporting requirements and a preference for U.S. industry in manufacturing.\n\n3. **Evaluate Other Options:**\n   - **The Hatch-Waxman Act:** This act is primarily about patent term extensions and generic drug approvals, not directly related to government-funded discoveries.\n   - **The Federal Trade Commission Act:** This act deals with unfair competition and consumer protection, not directly with intellectual property from government-funded research.\n   - **The Privacy Act:** This act pertains to the protection of personal information held by the federal government, not to intellectual property.\n   - **The Patent Cooperation Treaty:** This treaty facilitates international patent applications but does not specifically address government-funded inventions.\n   - **The Sherman Antitrust Act:** This act is about preventing anticompetitive practices and does not directly relate to intellectual property from government-funded research.\n\n4. **Conclusion:**\n   - The Bayh-Dole Act is the federal regulation that directly affects in-licensed intellectual property related to government-funded discoveries, as it is explicitly mentioned in the document and aligns with the described requirements and rights.\n\nTherefore, the correct answer is **B: The Bayh-Dole Act**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 64000, "result": 1.0, "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?", "options": {"A": "Interest expenses on loans", "B": "Direct expenses associated with the services", "C": "Revenue from hardware sales", "D": "Marketing expenses", "E": "Legal fees related to contracts", "F": "Stock options for employees"}, "LLM_original_answer": ["To answer the question \"What are recorded as a component of cost of revenues when the Company provides hash calculation services?\" based on the provided document, I will follow a step-by-step approach:\n\n1. **Identify the relevant section in the document**: The section that discusses the cost of revenue is titled \"Costs of Revenue\" and is found in the \"Components of Results of Operations\" part of the document.\n\n2. **Examine the content of the \"Costs of Revenue\" section**:\n   - The document states: \"The Company\u2019s cost of hosting services and cost of digital asset mining primarily consist of electricity costs, salaries, stock-based compensation, depreciation of property, plant and equipment used to perform hosting services and mining operations and other related costs.\"\n   - It also mentions: \"Cost of equipment sales includes costs of computer equipment sold to customers.\"\n\n3. **Determine the specific costs associated with hash calculation services**:\n   - Hash calculation services are part of the digital asset mining operations.\n   - The costs associated with digital asset mining are listed as: electricity costs, salaries, stock-based compensation, depreciation of property, plant and equipment used to perform mining operations, and other related costs.\n\n4. **Match the listed costs to the options provided**:\n   - **Option A: Interest expenses on loans** - This is not mentioned as a component of cost of revenues.\n   - **Option B: Direct expenses associated with the services** - This matches the description of the costs associated with hash calculation services, which include electricity costs, salaries, and other related costs.\n   - **Option C: Revenue from hardware sales** - This is not a cost but a revenue item.\n   - **Option D: Marketing expenses** - This is not mentioned as a component of cost of revenues.\n   - **Option E: Legal fees related to contracts** - This is not mentioned as a component of cost of revenues.\n   - **Option F: Stock options for employees** - Stock-based compensation is mentioned, but it is not the primary component of the costs.\n\n5. **Conclusion**:\n   - The most accurate and comprehensive answer is **Option B: Direct expenses associated with the services**. This includes electricity costs, salaries, and other related costs that are directly associated with providing hash calculation services.\n\nTherefore, the correct answer is **Option B: Direct expenses associated with the services**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 64000, "result": 1.0, "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?", "options": {"A": "Separate them and account under different frameworks", "B": "Combine them and account under the lease accounting framework", "C": "Only account for lease components", "D": "Account for non-lease components under a different policy", "E": "Classify the entire arrangement as a capital lease", "F": "Exclude non-lease components from financial statements"}, "LLM_original_answer": ["To answer the question, we need to focus on the specific policy Duke Energy has for handling lease and non-lease components in lessor arrangements. The relevant information is found in the \"Leases\" section of the document.\n\nThe document states:\n\"For lessee and lessor arrangements, Duke Energy has elected a policy to not separate lease and non-lease components for all asset classes. For lessor arrangements, lease and non-lease components are only combined under one arrangement and accounted for under the lease accounting framework if the non-lease components are not the predominant component of the arrangement and the lease component would be classified as an operating lease.\"\n\nThis means that Duke Energy does not separate lease and non-lease components for lessee arrangements. For lessor arrangements, they combine the components only if the non-lease components are not the predominant part of the arrangement and the lease component is an operating lease.\n\nGiven the question, \"How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?\" and the options provided, the correct answer is:\n\n**B: Combine them and account under the lease accounting framework**\n\nThis is because the document explicitly states that for lessor arrangements, if the non-lease components are not the predominant part of the arrangement, Duke Energy combines the lease and non-lease components and accounts for them under the lease accounting framework."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 64000, "result": 1.0, "question": "Who is responsible for devising and monitoring the asset-liability management strategy?", "options": {"A": "Board of Directors", "B": "Chief Executive Officer", "C": "Asset-Liability Management Committee", "D": "Finance Department", "E": "Risk Management Committee", "F": "External Auditors"}, "LLM_original_answer": ["The correct answer to the question \"Who is responsible for devising and monitoring the asset-liability management strategy?\" is:\n\n**C: Asset-Liability Management Committee (ALCO)**\n\n### Chain of Thought:\n1. **Review of the Document**:\n   - The document discusses various aspects of Eastern Bank's operations, including its asset-liability management strategy.\n   - It mentions that the Asset and Liability Management Committee (ALCO) is responsible for this strategy.\n\n2. **Relevant Section**:\n   - The section titled \"Management of Market Risk\" provides specific details about the governance of interest rate risk and asset-liability management.\n   - It states: \"Our asset-liability management strategy is devised and monitored by our ALCO, a subcommittee of the ERMC, in accordance with policies approved by the RMC.\"\n\n3. **Role of ALCO**:\n   - ALCO operates under a charter developed and approved by the ERMC.\n   - ALCO meets at least monthly to review, among other things, the bank's sensitivity to interest rate changes, loan pricing and activity, investment activity and strategy, hedging strategies, deposit pricing, and funding strategies.\n   - ALCO reports regularly to the Risk Management Committee (RMC) on these risks and objectives.\n\n4. **Elimination of Other Options**:\n   - **A: Board of Directors**: While the Board of Directors has oversight, it is not specifically mentioned as responsible for devising and monitoring the asset-liability management strategy.\n   - **B: Chief Executive Officer**: The CEO is not mentioned as having this specific responsibility.\n   - **D: Finance Department**: The Finance Department is involved in monitoring and tracking risk, but it is not the primary body responsible for devising the strategy.\n   - **E: Risk Management Committee**: The RMC has oversight and reviews the strategy, but it is not the body that devises and monitors it.\n   - **F: External Auditors**: External auditors are not mentioned as having a role in devising or monitoring the asset-liability management strategy.\n\n5. **Conclusion**:\n   - Based on the information provided in the document, the Asset-Liability Management Committee (ALCO) is the entity responsible for devising and monitoring the asset-liability management strategy.\n\nTherefore, the correct answer is **C: Asset-Liability Management Committee (ALCO)**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 64000, "result": 1.0, "question": "What can reduce the 10-year market exclusivity for orphan products to six years?", "options": {"A": "A new market demand report", "B": "The introduction of a similar product by a competitor", "C": "Annual sales exceeding expectations", "D": "Establishment that the product no longer meets orphan criteria", "E": "Approval of a new regulatory framework", "F": "A change in government policy"}, "LLM_original_answer": ["To answer the question \"What can reduce the 10-year market exclusivity for orphan products to six years?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss orphan drug designation and market exclusivity.\n2. **Analyze the Information**: Determine if any of the options listed in the question are mentioned or implied in the document.\n3. **Select the Correct Option**: Choose the option that best matches the information found in the document.\n\n### Step 1: Identify Relevant Information\nThe relevant information is found in the section discussing orphan drug designation and market exclusivity in the EU and UK:\n\n- **Orphan Drug Designation in the EU and UK**:\n  - \"Products receiving orphan designation in the EU may receive 10 years of orphan market exclusivity (which can be further extended by two years if pediatric studies have been conducted in accordance with an agreed pediatric investigational plan).\"\n  - \"The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation; for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity.\"\n\n### Step 2: Analyze the Information\n- **Option A: A new market demand report** - Not mentioned in the document.\n- **Option B: The introduction of a similar product by a competitor** - Not mentioned in the document.\n- **Option C: Annual sales exceeding expectations** - Not directly mentioned, but the document does discuss profitability.\n- **Option D: Establishment that the product no longer meets orphan criteria** - Directly mentioned in the document.\n- **Option E: Approval of a new regulatory framework** - Not mentioned in the document.\n- **Option F: A change in government policy** - Not directly mentioned, but the document discusses regulatory changes and their impact.\n\n### Step 3: Select the Correct Option\nThe document explicitly states that the 10-year market exclusivity for orphan products can be reduced to six years if it is established that the product no longer meets the criteria for orphan designation. This is directly aligned with **Option D**.\n\n### Conclusion\nThe correct answer is **D: Establishment that the product no longer meets orphan criteria**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 45, "token_lengths": 64000, "result": 1.0, "question": "What factors apart from interest rates can affect MSR fair value?", "options": {"A": "Federal regulations", "B": "Investor required yield or perceived value", "C": "The geographical location of properties", "D": "Historical property data", "E": "Currency exchange rates", "F": "Maintenance costs"}, "LLM_original_answer": ["To answer the question \"What factors apart from interest rates can affect MSR fair value?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Supply and Demand of the Market**:\n   - The document mentions that MSR fair value may change for other market-driven factors, including the supply and demand of the market. This is evident in the following excerpt:\n     > \"While interest rates are a key value driver, MSR fair value may change for other market-driven factors, including but not limited to the supply and demand of the market or the required yield or perceived value by investors of such MSRs.\"\n\n2. **Required Yield or Perceived Value by Investors**:\n   - The document explicitly states that the required yield or perceived value by investors can affect MSR fair value. This is directly mentioned in the same excerpt as above:\n     > \"While interest rates are a key value driver, MSR fair value may change for other market-driven factors, including but not limited to the supply and demand of the market or the required yield or perceived value by investors of such MSRs.\"\n\n3. **Federal Regulations**:\n   - The document discusses the impact of regulatory changes on the business, which can indirectly affect MSR fair value. For example:\n     > \"The HUD HECM reverse mortgage program has in the past responded to scrutiny around similar issues by implementing rule changes, and may do so in the future. It is not possible to predict whether any such rule changes would negatively impact us.\"\n\n4. **Cost to Service**:\n   - The document mentions that the cost to service can impact the fair value of MSRs. This is seen in the following excerpt:\n     > \"The significant components of the estimated future cash inflows for MSRs include servicing fees, late fees, float earnings and other ancillary fees. Significant cash outflows include the cost of servicing, the cost of financing servicing advances and compensating interest payments.\"\n\n5. **Delinquency Rates**:\n   - The document indicates that delinquency rates can affect the fair value of MSRs. This is mentioned in the sensitivity analysis section:\n     > \"The significant unobservable assumptions used in the valuation of MSRs include prepayment speeds, delinquency rates, cost to service and discount rates.\"\n\n6. **Discount Rate**:\n   - The document also mentions that the discount rate is a significant unobservable assumption that can affect the fair value of MSRs:\n     > \"The significant unobservable assumptions used in the valuation of MSRs include prepayment speeds"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 64000, "result": 1.0, "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?", "options": {"A": "Faster development process", "B": "Ultimate approval by the FDA", "C": "Faster review", "D": "Faster licensure", "E": "Qualification for all future product candidates", "F": "Marketing approval"}, "LLM_original_answer": ["To answer the question \"What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Definition and Purpose of Breakthrough Therapy Designation**:\n   - The document states that a Breakthrough Therapy is defined as a drug or biologic intended to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.\n   - The designation is intended to facilitate efficient development and expedite review of the product candidate.\n\n2. **Benefits of Breakthrough Therapy Designation**:\n   - The document mentions that interaction and communication between the FDA and the sponsor can help identify the most efficient path for clinical development.\n   - Biologics designated as Breakthrough Therapies may also be eligible for other expedited approval programs, including Accelerated Approval.\n\n3. **Limitations of Breakthrough Therapy Designation**:\n   - The document explicitly states that \"even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation.\"\n   - It further notes that \"the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or licensure compared to candidate products considered for licensure under non-expedited FDA review procedures and does not assure ultimate approval by the FDA.\"\n   - The document also mentions that \"even if one or more of our product candidates qualify as Breakthrough Therapies, the FDA may later decide that the product no longer meets the conditions for qualification.\"\n\n4. **Options Analysis**:\n   - **A: Faster development process** - The document suggests that Breakthrough Therapy designation may not lead to a faster development process.\n   - **B: Ultimate approval by the FDA** - The document clearly states that Breakthrough Therapy designation does not assure ultimate approval by the FDA.\n   - **C: Faster review** - The document indicates that Breakthrough Therapy designation may expedite review, but it does not guarantee it.\n   - **D: Faster licensure** - Similar to faster review, the document suggests that Breakthrough Therapy designation may expedite licensure, but it does not guarantee it.\n   - **E: Qualification for all future product candidates** - The document does not mention that Breakthrough Therapy designation qualifies all future product candidates.\n   - **F: Marketing approval** -"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 64000, "result": 1.0, "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?", "options": {"A": "Reducing research and development costs", "B": "Improving relationships with regulatory bodies", "C": "Increased risk of serious adverse events (SAEs)", "D": "Receiving immediate commercial approval", "E": "Negative feedback from patients", "F": "Lowering the price of the drug"}, "LLM_original_answer": ["To answer the question, let's analyze the relevant information from the provided document:\n\n1. **Context of EAP (Expanded Access Program) and FDA Submission**:\n   - The document mentions that Amylyx may need to initiate an EAP beyond what was submitted to the FDA due to social media campaigns or legislative changes that increase demand for expanded access to AMX0035.\n   - It also notes that patients who receive access to drugs through compassionate use, EAPs, or right to try access often have life-threatening illnesses and have exhausted all other available therapies.\n\n2. **Potential Risks and Consequences**:\n   - The document highlights that the risk for serious adverse events (SAEs) in this patient population is high.\n   - If SAEs occur, they could have a negative impact on the safety profile of AMX0035, which could cause significant delays or an inability to successfully commercialize the drug.\n   - Additionally, the document mentions that if the PHOENIX trial is not successful, Amylyx may voluntarily withdraw the product from the market.\n\n3. **Evaluating the Options**:\n   - **A: Reducing research and development costs** - The document does not suggest that initiating an EAP beyond what was submitted to the FDA would reduce R&D costs. In fact, it could increase costs due to the need for additional data and monitoring.\n   - **B: Improving relationships with regulatory bodies** - The document does not indicate that initiating an EAP beyond what was submitted to the FDA would improve relationships with regulatory bodies. Instead, it could lead to regulatory scrutiny and challenges.\n   - **C: Increased risk of serious adverse events (SAEs)** - The document explicitly states that the risk for SAEs in patients receiving expanded access is high, and such events could negatively impact the safety profile of AMX0035.\n   - **D: Receiving immediate commercial approval** - The document does not suggest that initiating an EAP would lead to immediate commercial approval. In fact, it could complicate the regulatory process.\n   - **E: Negative feedback from patients** - While the document mentions the risk of negative publicity, it does not specifically link this to initiating an EAP beyond what was submitted to the FDA.\n   - **F: Lowering the price of the drug** - The document does not suggest that initiating an EAP would lower the price of the drug. Pricing is generally subject to regulatory and market factors, not the EAP process"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 64000, "result": 1.0, "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?", "options": {"A": "Increased dividend payments to stockholders", "B": "Lower commodity prices and reduced volatility", "C": "Higher development of electronic trading platforms", "D": "Repayment of debt", "E": "Expansion of clearing houses", "F": "Treasury shares received for restricted tax payments"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023.\n\n1. **Identify the Context**:\n   - The document discusses various financial and operational aspects of Intercontinental Exchange, Inc. (ICE).\n   - It mentions a significant decrease in cash and cash equivalent margin deposits and guaranty fund liability balances in 2023.\n\n2. **Locate the Relevant Information**:\n   - The relevant information is found in the \"Liquidity and Capital Resources\" section under \"Financing Activities\":\n     - \"Consolidated net cash used in financing activities in 2023 primarily relates to a $65.4 billion decrease in our cash and cash equivalent margin deposits and guaranty fund liability balances due to lower commodity prices and reduced volatility.\"\n\n3. **Analyze the Information**:\n   - The decrease in cash and cash equivalent margin deposits and guaranty fund liability balances is attributed to two factors: lower commodity prices and reduced volatility.\n   - These factors are directly related to the financial markets and the commodities traded.\n\n4. **Match the Information to the Options**:\n   - **Option A: Increased dividend payments to stockholders** - The document does not mention increased dividend payments as a reason for the decrease.\n   - **Option B: Lower commodity prices and reduced volatility** - This matches the information provided in the document.\n   - **Option C: Higher development of electronic trading platforms** - The document does not mention this as a reason for the decrease.\n   - **Option D: Repayment of debt** - While the document mentions debt repayment, it is not the primary reason for the $65.4 billion decrease.\n   - **Option E: Expansion of clearing houses** - The document does not mention expansion of clearing houses as a reason for the decrease.\n   - **Option F: Treasury shares received for restricted tax payments** - The document does not mention this as a reason for the decrease.\n\n5. **Conclusion**:\n   - The primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023 is **lower commodity prices and reduced volatility**.\n\nTherefore, the correct answer is **Option B: Lower commodity prices and reduced volatility**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 64000, "result": 1.0, "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?", "options": {"A": "$7 million", "B": "$16 million", "C": "$393 million", "D": "$829 million", "E": "$10.6 billion", "F": "$11.0 billion"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The question is about the total amount of cash collateral we were obligated to return to counterparties as of December 31, 2023. This information is likely to be found in the section discussing derivatives and collateral.\n\n2. **Locate the specific information**: I will look for a table or a paragraph that mentions the amount of cash collateral we are obligated to return.\n\n3. **Extract the information**: Once I find the relevant information, I will extract the specific amount and compare it to the options provided.\n\n4. **Verify the information**: I will double-check the extracted information to ensure it is accurate and corresponds to the correct date.\n\n### Step 1: Identify the relevant section\nThe relevant section is likely to be in the \"Derivatives\" or \"Pledged Collateral\" sections of the document.\n\n### Step 2: Locate the specific information\nI found the following paragraph in the \"Pledged Collateral\" section:\n\n> \"At December 31, 2023 and 2022, we pledged cash collateral to counterparties of $16 million and $7 million, respectively. At December 31, 2023 and 2022, we were obligated to return cash collateral pledged to us by counterparties of $393 million and $829 million, respectively.\"\n\n### Step 3: Extract the information\nThe amount of cash collateral we were obligated to return to counterparties as of December 31, 2023 is $393 million.\n\n### Step 4: Verify the information\nThe information is clearly stated and corresponds to the correct date. The amount is $393 million.\n\n### Conclusion\nThe correct answer is **C: $393 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 96000, "result": 1.0, "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?", "options": {"A": "The Hatch-Waxman Act", "B": "The Bayh-Dole Act", "C": "The Federal Trade Commission Act", "D": "The Privacy Act", "E": "The Patent Cooperation Treaty", "F": "The Sherman Antitrust Act"}, "LLM_original_answer": ["The correct answer to the question \"What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?\" is:\n\n**B: The Bayh-Dole Act**\n\n### Chain of Thoughts:\n1. **Context of the Question**: The question is asking about a federal regulation that affects intellectual property (IP) related to government-funded discoveries. This implies that the regulation is specifically tied to the management and commercialization of IP that results from research funded by the U.S. government.\n\n2. **Review of the Document**:\n   - The document mentions that some of the in-licensed intellectual property may be subject to federal regulations, particularly the Bayh-Dole Act of 1980.\n   - The Bayh-Dole Act is described as providing federal agencies with certain rights, including a \"nonexclusive, nontransferable, irrevocable, paid-up license\" for inventions produced with federal financial assistance.\n   - The Act also grants the government \"march-in rights,\" which allow the government to require the patent owner to grant a license to a third party under certain circumstances, such as if the patent owner has not taken effective steps to achieve practical application of the invention.\n\n3. **Relevance of the Bayh-Dole Act**:\n   - The Bayh-Dole Act is specifically designed to manage the IP rights of inventions resulting from federally funded research.\n   - It affects the commercialization of such inventions by providing the government with certain rights and by imposing reporting requirements and a preference for U.S. industry.\n\n4. **Elimination of Other Options**:\n   - **The Hatch-Waxman Act**: This act is primarily about the approval and patent term extension for pharmaceutical products, not about government-funded IP.\n   - **The Federal Trade Commission Act**: This act is about consumer protection and antitrust, not about government-funded IP.\n   - **The Privacy Act**: This act is about the protection of personal information held by the federal government, not about government-funded IP.\n   - **The Patent Cooperation Treaty**: This is an international treaty for patent applications, not a U.S. federal regulation.\n   - **The Sherman Antitrust Act**: This act is about preventing anticompetitive practices, not about government-funded IP.\n\n5. **Conclusion**: The Bayh-Dole Act is the only federal regulation mentioned in the document that directly affects the management and commercialization of IP resulting from government-funded research. Therefore, the correct answer is **B: The Bayh-Dole Act**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 96000, "result": 1.0, "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?", "options": {"A": "Interest expenses on loans", "B": "Direct expenses associated with the services", "C": "Revenue from hardware sales", "D": "Marketing expenses", "E": "Legal fees related to contracts", "F": "Stock options for employees"}, "LLM_original_answer": ["To answer the question, \"What are recorded as a component of cost of revenues when the Company provides hash calculation services?\" we need to identify the relevant information from the provided document. Let's break it down step by step:\n\n1. **Identify the Service Provided:**\n   - The document states that the Company provides hash calculation services to third-party mining pools as part of its digital asset mining operations.\n\n2. **Determine the Costs Associated with the Service:**\n   - The document specifies that \"Direct expenses associated with providing hash calculation services to a third-party operated mining pool are recorded as cost of revenues.\"\n   - Additionally, it mentions that \"Depreciation and amortization expenses on fixed and right-of-use assets, including digital asset mining equipment, used to provide the services are also recorded as a component of cost of revenues.\"\n\n3. **Evaluate the Options:**\n   - **Option A: Interest expenses on loans** - This is not directly related to the cost of providing hash calculation services.\n   - **Option B: Direct expenses associated with the services** - This matches the first part of the identified costs.\n   - **Option C: Revenue from hardware sales** - This is not a cost but a revenue.\n   - **Option D: Marketing expenses** - This is not directly related to the cost of providing hash calculation services.\n   - **Option E: Legal fees related to contracts** - This is not directly related to the cost of providing hash calculation services.\n   - **Option F: Stock options for employees** - This is not directly related to the cost of providing hash calculation services.\n\n4. **Conclusion:**\n   - The direct expenses associated with providing hash calculation services and the depreciation and amortization expenses on the assets used for these services are recorded as components of cost of revenues.\n\nTherefore, the correct answer is **Option B: Direct expenses associated with the services**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 96000, "result": 1.0, "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?", "options": {"A": "Separate them and account under different frameworks", "B": "Combine them and account under the lease accounting framework", "C": "Only account for lease components", "D": "Account for non-lease components under a different policy", "E": "Classify the entire arrangement as a capital lease", "F": "Exclude non-lease components from financial statements"}, "LLM_original_answer": ["To answer the question, we need to focus on the specific accounting policies and practices Duke Energy follows for lease and non-lease components in lessor arrangements. The relevant information is found in the \"Leases\" section of the document.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Relevant Section:**\n   - The \"Leases\" section states: \"For lessee and lessor arrangements, Duke Energy has elected a policy to not separate lease and non-lease components for all asset classes.\"\n\n2. **Understand the Policy:**\n   - Duke Energy has a policy to not separate lease and non-lease components for all asset classes. This means that both lease and non-lease components are combined and accounted for together.\n\n3. **Consider the Specific Case for Lessor Arrangements:**\n   - The document further specifies: \"For lessor arrangements, lease and non-lease components are only combined under one arrangement and accounted for under the lease accounting framework if the non-lease components are not the predominant component of the arrangement and the lease component would be classified as an operating lease.\"\n\n4. **Interpret the Policy for Non-Predominant Non-Lease Components:**\n   - If the non-lease components are not the predominant component of the arrangement, and the lease component would be classified as an operating lease, then Duke Energy combines the lease and non-lease components and accounts for them under the lease accounting framework.\n\n### Conclusion:\nBased on the information provided, the correct answer is:\n\n**B: Combine them and account under the lease accounting framework**\n\nThis is because Duke Energy's policy for lessor arrangements is to combine lease and non-lease components and account for them under the lease accounting framework if the non-lease components are not the predominant component and the lease component is an operating lease."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 96000, "result": 1.0, "question": "Who is responsible for devising and monitoring the asset-liability management strategy?", "options": {"A": "Board of Directors", "B": "Chief Executive Officer", "C": "Asset-Liability Management Committee", "D": "Finance Department", "E": "Risk Management Committee", "F": "External Auditors"}, "LLM_original_answer": ["The correct answer to the question \"Who is responsible for devising and monitoring the asset-liability management strategy?\" is:\n\n**C: Asset-Liability Management Committee**\n\n### Chain of Thought:\n1. **Identify the Relevant Information:**\n   - The document discusses various aspects of the company's operations, including its asset-liability management strategy.\n   - It mentions the Asset and Liability Management Committee (ALCO) and its role in managing interest rate risk and other financial risks.\n\n2. **Locate the Specific Information:**\n   - In the \"Management of Market Risk\" section, it states: \"Our asset-liability management strategy is devised and monitored by our ALCO, a subcommittee of the ERMC, in accordance with policies approved by the RMC.\"\n   - ALCO is described as a committee that meets at least monthly to review and manage various financial risks, including interest rate changes, loan pricing, investment activity, and hedging strategies.\n\n3. **Confirm the Role:**\n   - The document clearly outlines that ALCO is responsible for devising and monitoring the asset-liability management strategy.\n   - This aligns with the typical role of an Asset-Liability Management Committee in financial institutions, which is to manage the balance sheet and ensure that the institution is not overly exposed to interest rate risk.\n\n4. **Eliminate Other Options:**\n   - **A: Board of Directors** - While the Board of Directors has oversight, it is not specifically mentioned as responsible for devising and monitoring the asset-liability management strategy.\n   - **B: Chief Executive Officer** - The CEO is involved in overall strategic decisions but is not specifically mentioned for this role.\n   - **D: Finance Department** - The Finance Department is involved in monitoring and tracking risk, but the document does not indicate it is responsible for devising the strategy.\n   - **E: Risk Management Committee** - The RMC approves policies and provides oversight, but it is not mentioned as the primary body for devising and monitoring the asset-liability management strategy.\n   - **F: External Auditors** - External auditors are not involved in devising or monitoring the strategy; they provide independent assessments and audits.\n\n5. **Conclude:**\n   - Based on the information provided, the Asset-Liability Management Committee (ALCO) is the entity responsible for devising and monitoring the asset-liability management strategy.\n\nTherefore, the correct answer is **C: Asset-Liability Management Committee**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 96000, "result": 1.0, "question": "What can reduce the 10-year market exclusivity for orphan products to six years?", "options": {"A": "A new market demand report", "B": "The introduction of a similar product by a competitor", "C": "Annual sales exceeding expectations", "D": "Establishment that the product no longer meets orphan criteria", "E": "Approval of a new regulatory framework", "F": "A change in government policy"}, "LLM_original_answer": ["The correct answer to the question \"What can reduce the 10-year market exclusivity for orphan products to six years?\" is:\n\n**D: Establishment that the product no longer meets orphan criteria**\n\n### Chain of Thoughts:\n1. **Understanding Orphan Drug Exclusivity:**\n   - The document mentions that in the EU, orphan medicinal products can receive 10 years of market exclusivity.\n   - This exclusivity is intended to provide a period during which no similar medicinal products can be marketed for the same indication.\n\n2. **Conditions for Reducing Exclusivity:**\n   - The document states that the 10-year market exclusivity can be reduced to six years under certain conditions.\n   - Specifically, it mentions: \"The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation.\"\n\n3. **Criteria for Orphan Designation:**\n   - Orphan designation is given to products intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition.\n   - The condition must have a prevalence of no more than five in 10,000 persons in the EU.\n   - The product must provide significant benefit over existing treatments, if any.\n\n4. **Reasons for Reducing Exclusivity:**\n   - The document outlines that if the product no longer meets the criteria for orphan designation, the exclusivity period can be reduced.\n   - This could happen if the product is sufficiently profitable, not rare enough, or if it no longer provides a significant benefit over existing treatments.\n\n5. **Other Options:**\n   - **A: A new market demand report** - This is not mentioned as a reason to reduce exclusivity.\n   - **B: The introduction of a similar product by a competitor** - This is not mentioned as a reason to reduce exclusivity.\n   - **C: Annual sales exceeding expectations** - While profitability is a factor, the document does not specify that exceeding sales expectations alone can reduce exclusivity.\n   - **E: Approval of a new regulatory framework** - This is not mentioned as a reason to reduce exclusivity.\n   - **F: A change in government policy** - While changes in policy could affect regulations, the document does not specify this as a direct reason to reduce exclusivity.\n\n6. **Conclusion:**\n   - The only condition explicitly mentioned in the document that can reduce the 10-year"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 45, "token_lengths": 96000, "result": 1.0, "question": "What factors apart from interest rates can affect MSR fair value?", "options": {"A": "Federal regulations", "B": "Investor required yield or perceived value", "C": "The geographical location of properties", "D": "Historical property data", "E": "Currency exchange rates", "F": "Maintenance costs"}, "LLM_original_answer": ["To answer the question \"What factors apart from interest rates can affect MSR fair value?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Fair Value of MSRs**:\n   - The document states that the fair value of MSRs is typically correlated to changes in market interest rates, but it also mentions other factors that can influence the fair value. Specifically, it notes:\n     - \"While interest rates are a key value driver, MSR fair value may change for other market-driven factors, including but not limited to the supply and demand of the market or the required yield or perceived value by investors of such MSRs.\" (Page 54)\n\n2. **Supply and Demand of the Market**:\n   - The supply and demand dynamics in the market can affect the fair value of MSRs. If there is a high demand for MSRs, their value may increase, and vice versa.\n\n3. **Required Yield or Perceived Value by Investors**:\n   - The required yield or perceived value by investors can also impact the fair value of MSRs. If investors require a higher yield or perceive the value of MSRs to be lower, the fair value of MSRs may decrease.\n\n4. **Other Factors**:\n   - The document also mentions that changes in market interest rates predominantly impact the fair value of Agency MSRs via prepayment speeds and the non-Agency MSRs due to the impact on advance funding costs. However, it does not explicitly list other factors in this section.\n\n5. **Hedging Strategy**:\n   - The effectiveness of the hedging strategy can also affect the fair value of MSRs. The document states:\n     - \"With a partial hedge coverage ratio, the changes in fair value of our hedging instruments may not fully offset the changes in fair value of our net MSR portfolio exposure attributable to interest rate changes.\" (Page 87)\n   - This implies that the hedging strategy, if not effective, can lead to additional volatility in the fair value of MSRs.\n\n6. **Economic Conditions**:\n   - Economic conditions, such as an economic slowdown or a deterioration of the housing market, can increase both interest expense on servicing advances and operating expenses, which can cause a reduction in the income from and the value of the servicing portfolio. (Page 38)\n\n7. **Delinquencies**:\n   - Higher delinquencies can decrease the fair value of MSRs and increase the cost to service loans. (Page 38)\n\n8."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 96000, "result": 1.0, "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?", "options": {"A": "Faster development process", "B": "Ultimate approval by the FDA", "C": "Faster review", "D": "Faster licensure", "E": "Qualification for all future product candidates", "F": "Marketing approval"}, "LLM_original_answer": ["To answer the question \"What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Definition and Purpose of Breakthrough Therapy Designation**:\n   - The document states: \"A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, or biologic, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.\"\n\n2. **Benefits of Breakthrough Therapy Designation**:\n   - The document mentions: \"For product candidates that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.\"\n   - It also states: \"Biologics designated as Breakthrough Therapies by the FDA may also be eligible for other expedited approval programs, including Accelerated Approval.\"\n\n3. **Limitations of Breakthrough Therapy Designation**:\n   - The document clearly outlines: \"Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation.\"\n   - It further states: \"In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or licensure compared to candidate products considered for licensure under non-expedited FDA review procedures and does not assure ultimate approval by the FDA.\"\n   - Additionally, it mentions: \"Even if one or more of our product candidates qualify as Breakthrough Therapies, the FDA may later decide that the product no longer meets the conditions for qualification.\"\n\nGiven these points, let's evaluate each option:\n\n- **A: Faster development process**:\n  - The document suggests that Breakthrough Therapy designation can help identify the most efficient path for clinical development, but it does not guarantee a faster development process.\n\n- **B: Ultimate approval by the FDA**:\n  - The document explicitly states that Breakthrough Therapy designation does not assure ultimate approval by the FDA.\n\n- **C: Faster review**:\n  - The document indicates that Break"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 96000, "result": 1.0, "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?", "options": {"A": "Reducing research and development costs", "B": "Improving relationships with regulatory bodies", "C": "Increased risk of serious adverse events (SAEs)", "D": "Receiving immediate commercial approval", "E": "Negative feedback from patients", "F": "Lowering the price of the drug"}, "LLM_original_answer": ["To answer the question, let's analyze the provided document and the context of initiating an Expanded Access Program (EAP) beyond what was submitted to the FDA for AMX0035.\n\n### Key Points from the Document:\n1. **Regulatory Requirements and Compliance**:\n   - The document emphasizes the importance of compliance with regulatory requirements, including those from the FDA, Health Canada, and the EMA.\n   - It mentions that regulatory authorities may require additional data or studies to support the safety and efficacy of a product, especially for fixed-dose combination products like AMX0035.\n\n2. **Clinical Trials and Data**:\n   - The document discusses the ongoing global Phase 3 PHOENIX trial for AMX0035, which is crucial for obtaining further marketing authorizations.\n   - It notes that the results of this trial are essential for maintaining and expanding regulatory approvals.\n\n3. **Patient Safety and Adverse Events**:\n   - The document highlights the risks associated with clinical trials, including the potential for serious adverse events (SAEs).\n   - It mentions that patients in expanded access programs may have a higher risk of SAEs due to their advanced disease state and the lack of a controlled environment.\n\n4. **Reimbursement and Coverage**:\n   - The document discusses the challenges of obtaining coverage and reimbursement from third-party payors, which can affect the commercial success of a product.\n   - It mentions that the availability of adequate coverage is critical for the success of AMX0035.\n\n5. **Compliance with Data Protection and Privacy Laws**:\n   - The document discusses the GDPR and other data protection laws, which impose strict requirements on the handling of personal and health data.\n   - Non-compliance with these laws can result in significant fines and penalties.\n\n### Analysis:\n- **Option A: Reducing research and development costs** - The document does not suggest that initiating an EAP beyond what was submitted to the FDA would reduce R&D costs. In fact, it could increase costs due to additional regulatory requirements and data collection.\n- **Option B: Improving relationships with regulatory bodies** - The document does not indicate that this would be a consequence. Instead, it suggests that such actions could lead to regulatory scrutiny and potential challenges.\n- **Option C: Increased risk of serious adverse events (SAEs)** - The document explicitly mentions that patients in expanded access programs may have a higher risk of SAEs. This is a significant concern, especially if the EAP is not conducted"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 96000, "result": 1.0, "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?", "options": {"A": "Increased dividend payments to stockholders", "B": "Lower commodity prices and reduced volatility", "C": "Higher development of electronic trading platforms", "D": "Repayment of debt", "E": "Expansion of clearing houses", "F": "Treasury shares received for restricted tax payments"}, "LLM_original_answer": ["To answer the question, we need to identify the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023. Let's break down the relevant information from the document:\n\n1. **Relevant Section**:\n   - The document states: \"Consolidated net cash used in financing activities in 2023 primarily relates to a $65.4 billion decrease in our cash and cash equivalent margin deposits and guaranty fund liability balances due to lower commodity prices and reduced volatility.\"\n\n2. **Reason for Decrease**:\n   - The decrease is attributed to \"lower commodity prices and reduced volatility.\"\n\n3. **Options Analysis**:\n   - **A: Increased dividend payments to stockholders** - The document does not mention increased dividend payments as a reason for the decrease in margin deposits.\n   - **B: Lower commodity prices and reduced volatility** - This matches the reason provided in the document.\n   - **C: Higher development of electronic trading platforms** - The document does not mention this as a reason for the decrease in margin deposits.\n   - **D: Repayment of debt** - While the document mentions debt repayment, it is not the primary reason for the decrease in margin deposits.\n   - **E: Expansion of clearing houses** - The document does not mention expansion of clearing houses as a reason for the decrease in margin deposits.\n   - **F: Treasury shares received for restricted tax payments** - The document mentions treasury shares received for restricted tax payments, but it is not the primary reason for the decrease in margin deposits.\n\nBased on the information provided in the document, the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023 is **B: Lower commodity prices and reduced volatility**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 96000, "result": 1.0, "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?", "options": {"A": "$7 million", "B": "$16 million", "C": "$393 million", "D": "$829 million", "E": "$10.6 billion", "F": "$11.0 billion"}, "LLM_original_answer": ["To answer the question, I will carefully review the provided document to find the relevant information regarding the total amount of cash collateral we were obligated to return to counterparties as of December 31, 2023.\n\n1. **Identify the Relevant Section:**\n   - The relevant section is found in \"Note 9 of the Notes to the Consolidated Financial Statements\" under the \"Pledged Collateral\" subsection.\n\n2. **Extract the Specific Information:**\n   - The document states: \"At December 31, 2023 and 2022, we were obligated to return cash collateral pledged to us by counterparties of $393 million and $829 million, respectively.\"\n\n3. **Match the Information to the Question:**\n   - The total amount of cash collateral we were obligated to return to counterparties as of December 31, 2023 is $393 million.\n\n4. **Select the Correct Option:**\n   - The correct option is C: $393 million.\n\nTherefore, the answer to the question \"As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?\" is **C: $393 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 128000, "result": 1.0, "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?", "options": {"A": "The Hatch-Waxman Act", "B": "The Bayh-Dole Act", "C": "The Federal Trade Commission Act", "D": "The Privacy Act", "E": "The Patent Cooperation Treaty", "F": "The Sherman Antitrust Act"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 128000, "result": 1.0, "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?", "options": {"A": "Interest expenses on loans", "B": "Direct expenses associated with the services", "C": "Revenue from hardware sales", "D": "Marketing expenses", "E": "Legal fees related to contracts", "F": "Stock options for employees"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 128000, "result": 1.0, "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?", "options": {"A": "Separate them and account under different frameworks", "B": "Combine them and account under the lease accounting framework", "C": "Only account for lease components", "D": "Account for non-lease components under a different policy", "E": "Classify the entire arrangement as a capital lease", "F": "Exclude non-lease components from financial statements"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 128000, "result": 1.0, "question": "Who is responsible for devising and monitoring the asset-liability management strategy?", "options": {"A": "Board of Directors", "B": "Chief Executive Officer", "C": "Asset-Liability Management Committee", "D": "Finance Department", "E": "Risk Management Committee", "F": "External Auditors"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 128000, "result": 0.0, "question": "What can reduce the 10-year market exclusivity for orphan products to six years?", "options": {"A": "A new market demand report", "B": "The introduction of a similar product by a competitor", "C": "Annual sales exceeding expectations", "D": "Establishment that the product no longer meets orphan criteria", "E": "Approval of a new regulatory framework", "F": "A change in government policy"}, "LLM_original_answer": ["To answer the question, I will refer to the relevant section in the provided document:\n\n**Relevant Section:**\n\"Products receiving orphan designation in the EU may receive 10 years of orphan market exclusivity (which can be further extended by two years if pediatric studies have been conducted in accordance with an agreed pediatric investigational plan). The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify the maintenance of market exclusivity.\"\n\n**Step-by-Step Analysis:**\n1. **Identify the Context:** The document discusses the regulatory framework for orphan drugs in the European Union (EU) and the United Kingdom (UK).\n2. **Locate the Specific Information:** The section mentions that the 10-year market exclusivity for orphan drugs can be reduced to six years.\n3. **Determine the Condition for Reduction:** The reduction to six years occurs if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation.\n4. **Understand the Criteria:** The criteria for orphan designation include the product being intended for a rare disease and not being sufficiently profitable to justify the maintenance of market exclusivity.\n\n**Conclusion:**\nThe 10-year market exclusivity for orphan products can be reduced to six years if it is established that the product no longer meets the criteria for orphan designation, particularly if the product is sufficiently profitable not to justify the maintenance of market exclusivity.\n\n**Correct Answer:**\nE: Establishment that the product no longer meets orphan criteria."], "LLM_extracted_answer": ["E"], "ground_truth": "D"}, {"depth": 45, "token_lengths": 128000, "result": 1.0, "question": "What factors apart from interest rates can affect MSR fair value?", "options": {"A": "Federal regulations", "B": "Investor required yield or perceived value", "C": "The geographical location of properties", "D": "Historical property data", "E": "Currency exchange rates", "F": "Maintenance costs"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 128000, "result": 1.0, "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?", "options": {"A": "Faster development process", "B": "Ultimate approval by the FDA", "C": "Faster review", "D": "Faster licensure", "E": "Qualification for all future product candidates", "F": "Marketing approval"}, "LLM_original_answer": ["To answer the question \"What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Understanding the Breakthrough Therapy Designation**:\n   - The document states: \"A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, or biologic, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.\"\n\n2. **Benefits of Breakthrough Therapy Designation**:\n   - The document mentions: \"For product candidates that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 128000, "result": 1.0, "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?", "options": {"A": "Reducing research and development costs", "B": "Improving relationships with regulatory bodies", "C": "Increased risk of serious adverse events (SAEs)", "D": "Receiving immediate commercial approval", "E": "Negative feedback from patients", "F": "Lowering the price of the drug"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 45, "token_lengths": 128000, "result": 1.0, "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?", "options": {"A": "Increased dividend payments to stockholders", "B": "Lower commodity prices and reduced volatility", "C": "Higher development of electronic trading platforms", "D": "Repayment of debt", "E": "Expansion of clearing houses", "F": "Treasury shares received for restricted tax payments"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 45, "token_lengths": 128000, "result": 0.0, "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?", "options": {"A": "$7 million", "B": "$16 million", "C": "$393 million", "D": "$829 million", "E": "$10.6 billion", "F": "$11.0 billion"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["E"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 8000, "result": 1.0, "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?", "options": {"A": "Immediate market approval for products", "B": "Increased research funding", "C": "Extended, delayed, or terminated clinical trials", "D": "Expansion of the organizational workforce", "E": "Higher stock market valuation", "F": "More partnerships with external organizations"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and the options given, focusing on the consequences of compromised quality or accuracy of consultant services in clinical trials.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Information:**\n   - The document mentions that if the quality or accuracy of the clinical data obtained by CROs (Contract Research Organizations) is compromised, it can lead to significant issues.\n   - Specifically, it states: \"If laboratories, CROs or clinical investigators do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical or clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.\"\n\n2. **Evaluate Each Option:**\n   - **A: Immediate market approval for products**\n     - The document does not suggest that compromised quality or accuracy would lead to immediate market approval. In fact, it implies the opposite: regulatory approval could be delayed or not obtained.\n   - **B: Increased research funding**\n     - The document does not mention increased research funding as a consequence of compromised quality or accuracy. Instead, it suggests that costs could increase due to delays or the need to find alternative providers.\n   - **C: Extended, delayed, or terminated clinical trials**\n     - This is directly mentioned in the document as a consequence of compromised quality or accuracy.\n   - **D: Expansion of the organizational workforce**\n     - The document does not suggest that compromised quality or accuracy would lead to workforce expansion. It focuses on the potential for delays and increased costs.\n   - **E: Higher stock market valuation**\n     - The document does not mention higher stock market valuation as a consequence. It suggests that delays and other issues could harm the business, which would likely negatively impact stock valuation.\n   - **F: More partnerships with external organizations**\n     - The document does not suggest that compromised quality or accuracy would lead to more partnerships. It implies that such issues could make it more difficult to attract new collaborators.\n\n3. **Conclusion:**\n   - Based on the information provided in the document, the most accurate and relevant consequence of compromised quality or accuracy of consultant services in clinical trials is **C: Extended, delayed, or terminated clinical trials**.\n\n### Final Answer:\nThe consequence that might result from compromised quality or"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 8000, "result": 1.0, "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?", "options": {"A": "As part of ongoing operating expenses", "B": "As extraordinary items", "C": "Under liabilities subject to compromise", "D": "In a separate section as Reorganization items, net", "E": "As a footnote disclosure only", "F": "Combined with realized gains and losses"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document and then select the most appropriate option.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Relevant Section:**\n   - The document discusses the application of ASC 852, Reorganizations, in the context of the Company's Chapter 11 filing and reorganization process.\n\n2. **Key Points from the Document:**\n   - **ASC 852 Application:**\n     - The Company began applying ASC 852 on December 21, 2022, the date of filing for Chapter 11.\n     - ASC 852 requires that financial statements for periods including and after the filing of the Chapter 11 Cases distinguish transactions and events directly associated with the reorganization from ongoing operations.\n     - **Reorganization Items, Net:**\n       - Expenses, realized gains and losses, and provisions for losses that can be directly associated with the reorganization must be reported separately as Reorganization items, net in the Consolidated Statements of Operations.\n     - **Liabilities Subject to Compromise:**\n       - Liabilities that may be affected by the Plan must be classified as liabilities subject to compromise at the amounts expected to be allowed by the Bankruptcy Court.\n\n3. **Evaluate the Options:**\n   - **Option A: As part of ongoing operating expenses**\n     - This is incorrect because the document explicitly states that reorganization-related expenses must be reported separately.\n   - **Option B: As extraordinary items**\n     - This is incorrect because the document does not mention extraordinary items. Instead, it specifies a separate section for reorganization items.\n   - **Option C: Under liabilities subject to compromise**\n     - This is incorrect because liabilities subject to compromise are a separate classification, not a reporting section for transactions and events.\n   - **Option D: In a separate section as Reorganization items, net**\n     - This is correct because the document clearly states that reorganization-related expenses, gains, and losses must be reported separately as Reorganization items, net.\n   - **Option E: As a footnote disclosure only**\n     - This is incorrect because the document indicates that these items are reported in the financial statements, not just as footnote disclosures.\n   - **Option F: Combined with realized gains and losses**\n     - This is incorrect because the document specifies that reorganization items are reported separately, not combined with realized gains and losses.\n\n### Conclusion:\nThe correct answer is **Option D: In a separate section as"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 8000, "result": 1.0, "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?", "options": {"A": "Approval from state regulatory commissions", "B": "Approval from the Federal Energy Regulatory Commission", "C": "Prior authorization of the PUCO", "D": "Meeting tangible net worth requirements", "E": "Approval from the Duke Energy board", "F": "Retention of minimum working capital"}, "LLM_original_answer": ["To answer the question \"What condition must Duke Energy Ohio meet to declare and pay dividends?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the relevant section**: The document mentions restrictions on the ability of certain subsidiaries to make dividends, advances, and loans to Duke Energy. Specifically, it discusses Duke Energy Ohio's conditions for declaring and paying dividends.\n\n2. **Extract the specific condition for Duke Energy Ohio**:\n   - The document states: \"Duke Energy Ohio will not declare and pay dividends out of capital or unearned surplus without the prior authorization of the PUCO.\"\n   - It also mentions: \"Duke Energy Ohio received FERC and PUCO approval to pay dividends from its equity accounts that are reflective of the amount that it would have in its retained earnings account had push-down accounting for the Cinergy merger not been applied to Duke Energy Ohio\u2019s balance sheet.\"\n\n3. **Interpret the conditions**:\n   - The first statement indicates that Duke Energy Ohio cannot declare and pay dividends from capital or unearned surplus without prior authorization from the PUCO.\n   - The second statement suggests that Duke Energy Ohio has a specific mechanism for paying dividends from its equity accounts, which has been approved by both FERC and PUCO. However, this mechanism is tied to the retained earnings account adjusted for the effects of push-down accounting.\n\n4. **Match the condition to the options**:\n   - **Option A: Approval from state regulatory commissions** - This is partially correct, as it mentions approval from state regulatory commissions, but it is not specific to the PUCO.\n   - **Option B: Approval from the Federal Energy Regulatory Commission** - This is not the primary condition, as the document emphasizes the need for PUCO approval.\n   - **Option C: Prior authorization of the PUCO** - This matches the first statement directly, which is the primary condition.\n   - **Option D: Meeting tangible net worth requirements** - The document does not mention this as a condition for declaring and paying dividends.\n   - **Option E: Approval from the Duke Energy board** - The document does not mention this as a condition.\n   - **Option F: Retention of minimum working capital** - The document does not mention this as a condition.\n\n5. **Conclusion**:\n   - The primary condition Duke Energy Ohio must meet to declare and pay dividends is obtaining prior authorization from the PUCO.\n\nTherefore, the correct answer is **Option C: Prior authorization"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 8000, "result": 1.0, "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?", "options": {"A": "The deficiency is recognized as a capital gain.", "B": "A new investment strategy is implemented.", "C": "The deficiency is considered due to credit loss and recognized in earnings.", "D": "A penalty is imposed on the financial institution.", "E": "The loan agreement is renegotiated.", "F": "An automatic increase in interest rate is applied."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Context**: The question is about what happens if the estimated cash flows do not support the amortized cost of a financial instrument, specifically in the context of the accounting practices of Eastern Bankshares, Inc.\n\n2. **Locate Relevant Information**: The relevant information is found in the section discussing the accounting for Available-for-Sale (AFS) securities, particularly the part that deals with impairment and credit losses.\n\n   - **Relevant Paragraph**:\n     > \"For AFS securities in an unrealized loss position, management will first evaluate whether there is intent to sell a security, or if it is more likely than not that the Company will be required to sell a security prior to anticipated recovery of its amortized cost basis. If either of these criteria are met, the Company will record a write-down of the security\u2019s amortized cost basis to fair value through income. For those AFS securities which do not meet the intent or requirement to sell criteria, management will evaluate whether the decline in fair value is a result of credit related matters or other factors. In performing this assessment, management considers the creditworthiness of the issuer including whether the security is guaranteed by the U.S. federal government or other government agency, the extent to which fair value is less than amortized cost, and changes in credit rating during the period, among other factors. If this assessment indicates the existence of credit losses, an allowance for credit losses will be established, as determined by a discounted cash flow analysis. To the extent the estimated cash flows do not support the amortized cost, the deficiency is considered to be due to credit loss and is recognized in earnings.\"\n\n3. **Analyze the Information**:\n   - The document states that if the estimated cash flows do not support the amortized cost of AFS securities, the deficiency is considered to be due to credit loss.\n   - Credit losses are recognized in earnings.\n\n4. **Match the Information to the Options**:\n   - **Option A**: The deficiency is recognized as a capital gain. (This is incorrect because the document specifies that the deficiency is recognized as a credit loss, not a capital gain.)\n   - **Option B**: A new investment strategy is implemented. (This is not mentioned in the document.)\n   - **Option C**: The deficiency is considered due to credit loss and recognized in earnings. (This matches the information provided in the document.)\n   - **Option D**: A"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 8000, "result": 1.0, "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?", "options": {"A": "Conduct annual cybersecurity audits", "B": "Formally report material cybersecurity incidents", "C": "Hire a dedicated cybersecurity officer", "D": "Implement a company-wide cybersecurity training program", "E": "Encrypt all data and communications", "F": "Report cybersecurity budgets annually"}, "LLM_original_answer": ["To answer the question \"What is the new cybersecurity rule adopted by the SEC primarily require companies to do?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the SEC's new cybersecurity rule in the context of regulatory and legal matters. Specifically, it states:\n   > \"Additionally, the SEC also adopted a new cybersecurity rule requiring companies subject to SEC reporting requirements to formally report material cybersecurity incidents, where failure to report may result in regulatory investigations leading to consent orders that may require additional compliance obligations and/or injunctions, fines and other penalties.\"\n\n2. **Analyze the content**: The key point here is that the SEC's new rule requires companies to \"formally report material cybersecurity incidents.\"\n\n3. **Match the content to the options**:\n   - **Option A: Conduct annual cybersecurity audits** - The document does not mention annual audits.\n   - **Option B: Formally report material cybersecurity incidents** - This matches the content exactly.\n   - **Option C: Hire a dedicated cybersecurity officer** - The document does not mention hiring a dedicated cybersecurity officer.\n   - **Option D: Implement a company-wide cybersecurity training program** - The document does not mention training programs.\n   - **Option E: Encrypt all data and communications** - The document does not mention encryption.\n   - **Option F: Report cybersecurity budgets annually** - The document does not mention reporting budgets.\n\n4. **Conclusion**: Based on the analysis, the correct answer is **Option B: Formally report material cybersecurity incidents**.\n\nTherefore, the new cybersecurity rule adopted by the SEC primarily requires companies to formally report material cybersecurity incidents."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 8000, "result": 1.0, "question": "Which document was filed on May 23, 2023?", "options": {"A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021", "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020", "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021", "D": "Registrant\u2019s Form 8-K", "E": "Registrant's statement of changes in beneficial ownership", "F": "Registrant's proxy statement"}, "LLM_original_answer": ["To answer the question \"Which document was filed on May 23, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a list of exhibits and the dates they were filed. This list is found in the section labeled \"ITEM 15.EXHIBITS, FINANCIAL STATEMENT SCHEDULES.\"\n\n2. **Locate the specific date**: I will search for the date \"May 23, 2023\" in this list.\n\n3. **Determine the corresponding document**: Once I find the date, I will identify the document that was filed on that date.\n\nLet's go through the list:\n\n- (1) Incorporated by reference from the similarly described exhibit included with the Registrant\u2019s Annual Report on Form 10-K filed for the year ended December 31, 2018 filed on February 27, 2019.\n- (2) Incorporated by reference to the similarly described exhibit included with the Registrant\u2019s Quarterly Report on Form 10-Q for the period ended March 31, 2018 filed on May 2, 2018.\n- (3) Incorporated by reference from the similarly described exhibit included with the Registrant\u2019s Annual Report on Form 10-K for the year ended December 31, 2004 filed on March 16, 2005.\n- (4) Incorporated by reference from the similarly described exhibit to the Registrant\u2019s definitive Proxy Statement with respect to its 2007 Annual Meeting of Shareholders as filed on March 30, 2007.\n- (5) Incorporated by reference from the similarly described exhibit included with the Registrant\u2019s Form 8-K filed on March 26, 2015.\n- (6) Incorporated by reference from the similarly described exhibit included with the Registrant\u2019s Quarterly Report on Form 10-Q for the period ended June 30, 2022 filed on August 4, 2022.\n- (7) Incorporated by reference from the similarly described exhibit included with the Registrant\u2019s Quarterly Report on Form 10-Q for the period ended September 30, 2017 filed on November 2, 2017.\n- (8) Incorporated by reference to the similarly described exhibit included with the Registrant\u2019s"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 8000, "result": 1.0, "question": "What penalty does the GDPR allow data protection authorities to impose for violations?", "options": {"A": "Suspension of business operations", "B": "Revocation of data processing licenses", "C": "Fines up to \u20ac20 million or 4% of annual global revenues", "D": "Mandatory public apology", "E": "Mandatory cybersecurity audits only", "F": "Compulsory staff retraining programs"}, "LLM_original_answer": ["To answer the question \"What penalty does the GDPR allow data protection authorities to impose for violations?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document discusses various regulatory and compliance issues, including the GDPR. The specific section that mentions GDPR penalties is:\n\n   > \"The GDPR permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to \u20ac20 million or 4% of annual global revenues, whichever is greater.\"\n\n2. **Analyze the information**:\n   - The document clearly states that the GDPR allows data protection authorities to impose fines.\n   - The fines can be up to \u20ac20 million or 4% of annual global revenues, whichever is greater.\n\n3. **Match the information to the given options**:\n   - **Option A: Suspension of business operations** - Not mentioned in the document.\n   - **Option B: Revocation of data processing licenses** - Not mentioned in the document.\n   - **Option C: Fines up to \u20ac20 million or 4% of annual global revenues** - Matches the information provided in the document.\n   - **Option D: Mandatory public apology** - Not mentioned in the document.\n   - **Option E: Mandatory cybersecurity audits only** - Not mentioned in the document.\n   - **Option F: Compulsory staff retraining programs** - Not mentioned in the document.\n\n4. **Conclusion**:\n   - The correct answer is **Option C: Fines up to \u20ac20 million or 4% of annual global revenues**.\n\nTherefore, the answer to the question is **Option C: Fines up to \u20ac20 million or 4% of annual global revenues**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 8000, "result": 1.0, "question": "What could be a consequence of failing to comply with laws governing international business practices?", "options": {"A": "Immediate dissolution of the business", "B": "Substantial civil and criminal penalties", "C": "Automatic approval for business expansion", "D": "Tax incentives and holidays", "E": "Increased development of new products", "F": "Reduction in employee numbers"}, "LLM_original_answer": ["To answer the question \"What could be a consequence of failing to comply with laws governing international business practices?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the Context**: The document discusses various regulatory and legal requirements that a company must comply with when operating internationally, particularly in the pharmaceutical industry. It mentions laws like the Foreign Corrupt Practices Act (FCPA) and the potential consequences of non-compliance.\n\n2. **Review the Consequences Mentioned**:\n   - The document states: \"The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting.\"\n   - It also mentions: \"The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA\u2019s accounting provisions.\"\n\n3. **Match the Consequences to the Options**:\n   - **Option A: Immediate dissolution of the business** - The document does not mention immediate dissolution as a consequence.\n   - **Option B: Substantial civil and criminal penalties** - This is explicitly mentioned in the document.\n   - **Option C: Automatic approval for business expansion** - The document does not suggest this as a consequence.\n   - **Option D: Tax incentives and holidays** - The document does not mention this as a consequence.\n   - **Option E: Increased development of new products** - The document does not suggest this as a consequence.\n   - **Option F: Reduction in employee numbers** - The document does not mention this as a consequence.\n\n4. **Conclusion**:\n   - The most accurate and directly supported consequence from the document is **Option B: Substantial civil and criminal penalties**.\n\nTherefore, the correct answer is **B: Substantial civil and criminal penalties**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 8000, "result": 1.0, "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?", "options": {"A": "$2.0 billion", "B": "$19.0 billion", "C": "$1.6 billion", "D": "$22.6 billion", "E": "$8.4 billion", "F": "$270 million"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the amount of outstanding debt related to senior notes?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the amount of outstanding debt in the \"Contractual Obligations and Commercial Commitments\" section.\n\n2. **Locate the specific information**: In this section, the document states:\n   - \"As of December 31, 2023, we had $22.6 billion in outstanding debt, including $2.0 billion of short-term debt.\"\n   - \"Our outstanding debt consists of $19.0 billion of fixed rate senior notes, $1.6 billion under our Term Loan and $2.0 billion in commercial paper.\"\n\n3. **Extract the amount related to senior notes**: The document clearly specifies that the amount of outstanding debt related to fixed rate senior notes is $19.0 billion.\n\n4. **Match the extracted amount to the given options**:\n   - A: $2.0 billion\n   - B: $19.0 billion\n   - C: $1.6 billion\n   - D: $22.6 billion\n   - E: $8.4 billion\n   - F: $270 million\n\nThe correct answer is **B: $19.0 billion**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 8000, "result": 1.0, "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?", "options": {"A": "By adding a fixed percentage to the policyholder account balance", "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract", "C": "By charging a surrender fee immediately upon issuance", "D": "By applying a uniform rate to all existing liabilities", "E": "By using a simple average of all deposits", "F": "By increasing withdrawal charges over time"}, "LLM_original_answer": ["To answer the question, let's break down the relevant information from the document:\n\n1. **Universal Life Insurance with Secondary Guarantees (ULSG):**\n   - The Company establishes a liability in addition to the account balance for ULSG.\n   - These liabilities are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero.\n   - The benefits are recognized ratably over the contract period based on total expected assessments.\n   - The benefits used in calculating the liabilities are based on the average benefits payable over a range of scenarios.\n\n2. **Key Assumptions:**\n   - The most significant assumptions used in estimating liabilities for secondary guarantees are the general account rate of return, premium persistency, mortality, and lapses.\n   - These assumptions are reviewed regularly, and if they change significantly, the liability for secondary guarantees is adjusted by a cumulative charge or credit to net income.\n\n3. **Projection and Recognition:**\n   - The Company projects future earnings and establishes a liability to offset losses that are expected to occur in later years.\n   - Both ULSG liabilities are adjusted for the effects of unrealized investment gains and losses.\n   - Changes in the liabilities are reported in policyholder benefits and claims, except for the effects of unrealized investment gains and losses, which are reported in OCI.\n\nGiven this information, the correct answer is:\n\n**B: By projecting death benefits when account balance is zero and recognizing benefits over the contract**\n\n**Chain of Thoughts:**\n- The document explicitly states that the Company determines the additional liability for ULSG by estimating the expected value of death benefits payable when the account balance is projected to be zero.\n- These benefits are then recognized ratably over the contract period based on total expected assessments.\n- The key assumptions used in this estimation include the general account rate of return, premium persistency, mortality, and lapses.\n- This method aligns with the option B, which describes the process of projecting death benefits when the account balance is zero and recognizing these benefits over the contract period.\n\nTherefore, the Company calculates additional liabilities for certain product features like secondary guarantees on universal life insurance contracts by projecting death benefits when the account balance is zero and recognizing these benefits over the contract period."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 16000, "result": 1.0, "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?", "options": {"A": "Immediate market approval for products", "B": "Increased research funding", "C": "Extended, delayed, or terminated clinical trials", "D": "Expansion of the organizational workforce", "E": "Higher stock market valuation", "F": "More partnerships with external organizations"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the relevant information that pertains to the consequences of compromised quality or accuracy of consultant services in clinical trials.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Context:**\n   - The document discusses various risks and challenges in the biopharmaceutical industry, particularly focusing on the reliance on third parties for clinical trials and the potential consequences of failing to meet regulatory requirements.\n\n2. **Relevant Information:**\n   - **Quality and Accuracy of Third-Party Services:**\n     - \"If the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical or clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.\"\n     - \"If independent laboratories, investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop.\"\n\n3. **Consequences Mentioned:**\n   - **Extended, Delayed, or Terminated Clinical Trials:**\n     - The document explicitly states that compromised quality or accuracy can lead to \"extended, delayed or terminated\" clinical trials.\n   - **Regulatory Approval:**\n     - The document mentions that such issues may prevent the company from obtaining regulatory approval for its product candidates.\n   - **Commercialization:**\n     - The document also notes that these issues can delay or compromise the prospects for commercialization of the product candidates.\n\n4. **Evaluate the Options:**\n   - **A: Immediate market approval for products**\n     - This is not mentioned in the document and is contrary to the stated consequences.\n   - **B: Increased research funding**\n     - This is not mentioned in the document and is not a direct consequence of compromised quality or accuracy.\n   - **C: Extended, delayed, or terminated clinical trials**\n     - This is explicitly mentioned in the document as a direct consequence.\n   - **D: Expansion of the organizational workforce**\n     - This is not mentioned in the document and is not a direct consequence.\n   - **E: Higher stock market valuation**\n     - This is not mentioned in the document and is not a direct consequence.\n   - **F: More partnerships with external organizations**\n     - This is not mentioned in the document and is not a direct consequence"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 16000, "result": 1.0, "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?", "options": {"A": "As part of ongoing operating expenses", "B": "As extraordinary items", "C": "Under liabilities subject to compromise", "D": "In a separate section as Reorganization items, net", "E": "As a footnote disclosure only", "F": "Combined with realized gains and losses"}, "LLM_original_answer": ["To answer the question, I will follow a step-by-step approach based on the information provided in the document:\n\n1. **Identify the Relevant Section**: The document contains a section that specifically discusses the application of ASC 852, which is the accounting standard for reorganizations. This section is found in the \"Reorganization items, net and Liabilities Subject to Compromise\" part of the document.\n\n2. **Understand the Core Principle**: According to the document, ASC 852 requires that financial statements for periods including and after the filing of the Chapter 11 Cases distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of the business.\n\n3. **Determine the Reporting Requirement**: The document states that expenses (including professional fees), realized gains and losses, and provisions for losses that can be directly associated with the reorganization must be reported separately as Reorganization items, net in the Consolidated Statements of Operations.\n\n4. **Review the Options**:\n   - **A: As part of ongoing operating expenses**: This is incorrect because the document explicitly states that reorganization items must be reported separately.\n   - **B: As extraordinary items**: This is incorrect because the document does not mention extraordinary items; it specifically mentions reorganization items.\n   - **C: Under liabilities subject to compromise**: This is incorrect because liabilities subject to compromise are a separate classification and not where reorganization items are reported.\n   - **D: In a separate section as Reorganization items, net**: This is correct because the document clearly states that reorganization items must be reported separately as Reorganization items, net.\n   - **E: As a footnote disclosure only**: This is incorrect because the document indicates that reorganization items are reported in the financial statements, not just in footnotes.\n   - **F: Combined with realized gains and losses**: This is incorrect because reorganization items are reported separately, not combined with realized gains and losses.\n\n5. **Conclusion**: Based on the information provided in the document, the correct answer is **D: In a separate section as Reorganization items, net**.\n\nTherefore, the answer to the question is **D: In a separate section as Reorganization items, net**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 16000, "result": 1.0, "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?", "options": {"A": "Approval from state regulatory commissions", "B": "Approval from the Federal Energy Regulatory Commission", "C": "Prior authorization of the PUCO", "D": "Meeting tangible net worth requirements", "E": "Approval from the Duke Energy board", "F": "Retention of minimum working capital"}, "LLM_original_answer": ["To answer the question \"What condition must Duke Energy Ohio meet to declare and pay dividends?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss dividend restrictions or conditions for Duke Energy Ohio.\n\n2. **Extract Specific Conditions**: Determine the specific conditions mentioned for Duke Energy Ohio regarding dividend declarations and payments.\n\n3. **Match Conditions to Options**: Compare the extracted conditions to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant information is found in the section titled \"RESTRICTIONS ON THE ABILITY OF CERTAIN SUBSIDIARIES TO MAKE DIVIDENDS, ADVANCES AND LOANS TO DUKE ENERGY.\" Specifically, the part that discusses Duke Energy Ohio:\n\n### Step 2: Extract Specific Conditions\nFrom the document:\n- **Duke Energy Ohio will not declare and pay dividends out of capital or unearned surplus without the prior authorization of the PUCO.**\n- **Duke Energy Ohio received FERC and PUCO approval to pay dividends from its equity accounts that are reflective of the amount that it would have in its retained earnings account had push-down accounting for the Cinergy merger not been applied to Duke Energy Ohio\u2019s balance sheet.**\n- **The conditions include a commitment from Duke Energy Ohio that equity, adjusted to remove the impacts of push-down accounting, will not fall below 30% of total capital.**\n\n### Step 3: Match Conditions to Options\n- **Option A: Approval from state regulatory commissions** - This is partially correct, as Duke Energy Ohio needs prior authorization from the PUCO.\n- **Option B: Approval from the Federal Energy Regulatory Commission** - This is not the primary condition, though FERC approval is mentioned in conjunction with PUCO approval.\n- **Option C: Prior authorization of the PUCO** - This is the most accurate match, as the document explicitly states that Duke Energy Ohio needs prior authorization from the PUCO to declare and pay dividends.\n- **Option D: Meeting tangible net worth requirements** - This is not mentioned as a condition for dividend declaration.\n- **Option E: Approval from the Duke Energy board** - This is not mentioned as a condition for dividend declaration.\n- **Option F: Retention of minimum working capital** - This is not mentioned as a condition for dividend declaration.\n\n### Conclusion\nThe correct answer is **Option C: Prior authorization of the PUCO**. Duke Energy Ohio must obtain"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 16000, "result": 1.0, "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?", "options": {"A": "The deficiency is recognized as a capital gain.", "B": "A new investment strategy is implemented.", "C": "The deficiency is considered due to credit loss and recognized in earnings.", "D": "A penalty is imposed on the financial institution.", "E": "The loan agreement is renegotiated.", "F": "An automatic increase in interest rate is applied."}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document and think through it step by step.\n\n1. **Identify the Context**: The question is about what happens if the estimated cash flows do not support the amortized cost of a security. This is related to the accounting and management of securities, particularly those classified as \"Available for Sale\" (AFS).\n\n2. **Locate Relevant Information**: The relevant section in the document is under \"Summary of Significant Accounting Policies\" and specifically within the \"Securities\" subsection. The key paragraph is:\n   - \"If this assessment indicates the existence of credit losses, an allowance for credit losses will be established, as determined by a discounted cash flow analysis. To the extent the estimated cash flows do not support the amortized cost, the deficiency is considered to be due to credit loss and is recognized in earnings.\"\n\n3. **Analyze the Information**:\n   - The document states that if the estimated cash flows do not support the amortized cost, the deficiency is considered to be due to credit loss.\n   - Credit losses are recognized in earnings.\n\n4. **Match the Information to the Options**:\n   - Option A: The deficiency is recognized as a capital gain. (This is incorrect because the document specifies that the deficiency is recognized as a credit loss, not a capital gain.)\n   - Option B: A new investment strategy is implemented. (This is not mentioned in the document as a direct consequence of the estimated cash flows not supporting the amortized cost.)\n   - Option C: The deficiency is considered due to credit loss and recognized in earnings. (This matches the information provided in the document.)\n   - Option D: A penalty is imposed on the financial institution. (This is not mentioned in the document.)\n   - Option E: The loan agreement is renegotiated. (This is not mentioned in the document and is not relevant to the context of AFS securities.)\n   - Option F: An automatic increase in interest rate is applied. (This is not mentioned in the document and is not relevant to the context of AFS securities.)\n\n5. **Conclusion**: Based on the information provided in the document, the correct answer is **Option C: The deficiency is considered due to credit loss and recognized in earnings**.\n\nTherefore, the answer to the question is **Option C**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 16000, "result": 1.0, "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?", "options": {"A": "Conduct annual cybersecurity audits", "B": "Formally report material cybersecurity incidents", "C": "Hire a dedicated cybersecurity officer", "D": "Implement a company-wide cybersecurity training program", "E": "Encrypt all data and communications", "F": "Report cybersecurity budgets annually"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document and identify the relevant information.\n\nThe document mentions the new cybersecurity rule adopted by the SEC in the following passage:\n\n\"Additionally, the SEC also adopted a new cybersecurity rule requiring companies subject to SEC reporting requirements to formally report material cybersecurity incidents, where failure to report may result in regulatory investigations leading to consent orders that may require additional compliance obligations and/or injunctions, fines and other penalties.\"\n\nFrom this passage, we can deduce that the new cybersecurity rule primarily requires companies to formally report material cybersecurity incidents. This aligns with option B in the multiple-choice question.\n\nTherefore, the correct answer is:\n\nB: Formally report material cybersecurity incidents"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 16000, "result": 1.0, "question": "Which document was filed on May 23, 2023?", "options": {"A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021", "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020", "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021", "D": "Registrant\u2019s Form 8-K", "E": "Registrant's statement of changes in beneficial ownership", "F": "Registrant's proxy statement"}, "LLM_original_answer": ["To answer the question \"Which document was filed on May 23, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a list of exhibits and the dates they were filed. This list is found in the \"ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES\" section.\n\n2. **Locate the specific date**: I will search for the date \"May 23, 2023\" in the list of exhibits.\n\n3. **Match the date to the document**: Once I find the date, I will identify the corresponding document.\n\nLet's go through the list of exhibits:\n\n- (1) Incorporated by reference from the similarly described exhibit included with the Registrant\u2019s Annual Report on Form 10-K filed for the year ended December 31, 2018 filed on February 27, 2019.\n- (2) Incorporated by reference to the similarly described exhibit included with the Registrant\u2019s Quarterly Report on Form 10-Q for the period ended March 31, 2018 filed on May 2, 2018.\n- (3) Incorporated by reference from the similarly described exhibit included with the Registrant\u2019s Annual Report on Form 10-K for the year ended December 31, 2004 filed on March 16, 2005.\n- (4) Incorporated by reference from the similarly described exhibit to the Registrant\u2019s definitive Proxy Statement with respect to its 2007 Annual Meeting of Shareholders as filed on March 30, 2007.\n- (5) Incorporated by reference from the similarly described exhibit included with the Registrant\u2019s Form 8-K filed on March 26, 2015.\n- (6) Incorporated by reference from the similarly described exhibit included with the Registrant\u2019s Quarterly Report on Form 10-Q for the period ended June 30, 2022 filed on August 4, 2022.\n- (7) Incorporated by reference from the similarly described exhibit included with the Registrant\u2019s Quarterly Report on Form 10-Q for the period ended September 30, 2017 filed on November 2, 2017.\n- (8) Incorporated by reference to the similarly described exhibit included with the Registrant"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 16000, "result": 1.0, "question": "What penalty does the GDPR allow data protection authorities to impose for violations?", "options": {"A": "Suspension of business operations", "B": "Revocation of data processing licenses", "C": "Fines up to \u20ac20 million or 4% of annual global revenues", "D": "Mandatory public apology", "E": "Mandatory cybersecurity audits only", "F": "Compulsory staff retraining programs"}, "LLM_original_answer": ["To answer the question \"What penalty does the GDPR allow data protection authorities to impose for violations?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Relevant Section**: The document contains a section that specifically mentions the GDPR and the penalties it allows. This section is found in the part discussing international data protection laws.\n\n2. **Extract the Information**: The relevant excerpt from the document is:\n   > \"The GDPR permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to \u20ac20 million or 4% of annual global revenues, whichever is greater.\"\n\n3. **Match the Information to the Options**:\n   - **Option A: Suspension of business operations** - Not mentioned in the document.\n   - **Option B: Revocation of data processing licenses** - Not mentioned in the document.\n   - **Option C: Fines up to \u20ac20 million or 4% of annual global revenues** - Matches the information extracted from the document.\n   - **Option D: Mandatory public apology** - Not mentioned in the document.\n   - **Option E: Mandatory cybersecurity audits only** - Not mentioned in the document.\n   - **Option F: Compulsory staff retraining programs** - Not mentioned in the document.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **Option C: Fines up to \u20ac20 million or 4% of annual global revenues**.\n\nTherefore, the answer to the question is **Option C: Fines up to \u20ac20 million or 4% of annual global revenues**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 16000, "result": 1.0, "question": "What could be a consequence of failing to comply with laws governing international business practices?", "options": {"A": "Immediate dissolution of the business", "B": "Substantial civil and criminal penalties", "C": "Automatic approval for business expansion", "D": "Tax incentives and holidays", "E": "Increased development of new products", "F": "Reduction in employee numbers"}, "LLM_original_answer": ["To answer the question \"What could be a consequence of failing to comply with laws governing international business practices?\" based on the provided document, I will analyze the relevant sections and options step by step.\n\n### Step 1: Identify Relevant Sections\nThe document mentions several laws and regulations governing international business practices, particularly in the context of the pharmaceutical industry. The key sections are:\n\n1. **Foreign Corrupt Practices Act (FCPA)**:\n   - \"The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.\"\n   - \"The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting.\"\n\n2. **Environmental, Health, and Safety Laws**:\n   - \"If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.\"\n\n### Step 2: Evaluate the Options\nNow, let's evaluate each option against the information provided in the document:\n\n- **A: Immediate dissolution of the business**:\n  - The document does not mention immediate dissolution as a consequence of non-compliance. It focuses more on penalties and other regulatory actions.\n\n- **B: Substantial civil and criminal penalties**:\n  - This is explicitly mentioned in the FCPA section: \"The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties.\"\n\n- **C: Automatic approval for business expansion**:\n  - The document does not suggest that non-compliance would lead to automatic approval for business expansion. In fact, it implies the opposite, that non-compliance could limit business expansion.\n\n- **D: Tax incentives and holidays**:\n  - The document does not mention tax incentives or holidays as a consequence of non-compliance. It focuses on penalties and regulatory actions.\n\n- **E: Increased development of new products**:\n  - The document does not suggest that non-compliance would lead to increased development of new products. Instead, it implies that non-compliance could lead to delays or increased costs.\n\n- **F: Reduction in employee numbers**:\n  - While the document mentions potential financial and operational impacts, it does not specifically state that non-compliance would lead to a reduction in employee numbers.\n\n### Step 3"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 16000, "result": 1.0, "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?", "options": {"A": "$2.0 billion", "B": "$19.0 billion", "C": "$1.6 billion", "D": "$22.6 billion", "E": "$8.4 billion", "F": "$270 million"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the amount of outstanding debt related to senior notes?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Total Outstanding Debt**: The document states, \"As of December 31, 2023, we had $22.6 billion in outstanding debt.\"\n\n2. **Break Down the Components of the Outstanding Debt**: The document further specifies the components of this debt:\n   - \"consisting of $19.0 billion of senior notes\"\n   - \"$1.6 billion under our Term Loan\"\n   - \"$2.0 billion in commercial paper\"\n\n3. **Locate the Specific Amount for Senior Notes**: The document clearly states, \"As of December 31, 2023, our senior notes of $19.0 billion had a weighted average maturity of 15 years and a weighted average cost of 3.6% per annum.\"\n\n4. **Match the Amount to the Given Options**: The amount of $19.0 billion for senior notes matches option B.\n\nTherefore, the correct answer is:\n\n**B: $19.0 billion**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 16000, "result": 1.0, "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?", "options": {"A": "By adding a fixed percentage to the policyholder account balance", "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract", "C": "By charging a surrender fee immediately upon issuance", "D": "By applying a uniform rate to all existing liabilities", "E": "By using a simple average of all deposits", "F": "By increasing withdrawal charges over time"}, "LLM_original_answer": ["To answer the question, I will focus on the relevant section from the provided document, which is the part that discusses how the company calculates additional liabilities for certain product features, specifically secondary guarantees on universal life insurance contracts.\n\nThe relevant section states:\n\"The Company establishes a liability in addition to the account balance for ULSG. These liabilities are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero and recognizing those benefits ratably over the contract period based on total expected assessments. The benefits used in calculating the liabilities are based on the average benefits payable over a range of scenarios.\"\n\nThis section clearly outlines the method used by the company to calculate additional liabilities for secondary guarantees on universal life insurance contracts. The key points are:\n1. The company estimates the expected value of death benefits payable when the account balance is projected to be zero.\n2. These benefits are recognized ratably over the contract period based on total expected assessments.\n3. The benefits are based on the average benefits payable over a range of scenarios.\n\nGiven these points, the correct answer is:\n**B: By projecting death benefits when account balance is zero and recognizing benefits over the contract**\n\nThis answer aligns with the company's method of estimating and recognizing the additional liabilities for secondary guarantees on universal life insurance contracts as described in the document."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 32000, "result": 1.0, "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?", "options": {"A": "Immediate market approval for products", "B": "Increased research funding", "C": "Extended, delayed, or terminated clinical trials", "D": "Expansion of the organizational workforce", "E": "Higher stock market valuation", "F": "More partnerships with external organizations"}, "LLM_original_answer": ["To answer the question \"What consequence might result from compromised quality or accuracy of consultant services in clinical trials?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Document Context**: The document primarily discusses various risks and challenges related to intellectual property, regulatory compliance, and third-party dependencies in the biopharmaceutical industry. It does not directly address the consequences of compromised quality or accuracy of consultant services in clinical trials. However, it does provide insights into the broader implications of third-party failures, which can be extrapolated to consultant services.\n\n2. **Relevant Sections**:\n   - **Risks Related to Our Reliance on Third Parties**: This section discusses the reliance on third parties, including independent clinical investigators, contracted laboratories, and CROs, to conduct preclinical studies and clinical trials. It highlights the potential consequences if these third parties fail to meet their obligations or if the quality of their work is compromised.\n   - **Specific Risks**:\n     - **Delays in Clinical Trials**: \"If independent laboratories, investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop.\"\n     - **Regulatory Compliance**: \"We and our third-party contractors and CROs are required to comply with good laboratory practices, or GLPs, as applicable, and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities.\"\n     - **Data Integrity**: \"If we, our investigators or any of our CROs or contracted laboratories fail to comply with applicable GLPs and GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical studies or clinical trials before approving our marketing applications.\"\n\n3. **Analysis**:\n   - **Option A: Immediate market approval for products** - This is highly unlikely. Compromised quality or accuracy would more likely lead to delays or rejections rather than immediate approval.\n   - **Option B: Increased research funding** - The document does not suggest that compromised quality would lead to increased funding. In fact, it implies the opposite, as poor performance could lead to delays and increased costs.\n   - **Option C: Extended, delayed, or terminated clinical trials** - This is the most likely consequence. The document explicitly states that substandard performance by third parties can delay or compromise the"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 32000, "result": 1.0, "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?", "options": {"A": "As part of ongoing operating expenses", "B": "As extraordinary items", "C": "Under liabilities subject to compromise", "D": "In a separate section as Reorganization items, net", "E": "As a footnote disclosure only", "F": "Combined with realized gains and losses"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document and apply it to the options given.\n\n### Step 1: Identify the Relevant Information\nThe document mentions the application of ASC 852, which is the accounting standard for reorganizations. Specifically, it states:\n- **Reorganization items, net**: \"Expenses (including professional fees), realized gains and losses, and provisions for losses that can be directly associated with the reorganization must be reported separately as Reorganization items, net in the Consolidated Statements of Operations beginning December 21, 2022, the date of filing of the Chapter 11 Cases.\"\n\n### Step 2: Evaluate the Options\n- **Option A**: As part of ongoing operating expenses\n  - This is incorrect because the document explicitly states that reorganization items are reported separately, not as part of ongoing operating expenses.\n- **Option B**: As extraordinary items\n  - This is incorrect because the document does not mention reporting reorganization items as extraordinary items. Extraordinary items are typically for infrequent and unusual events, and the reorganization process is not necessarily considered extraordinary under ASC 852.\n- **Option C**: Under liabilities subject to compromise\n  - This is incorrect because the document states that reorganization items are reported separately as Reorganization items, net, not under liabilities subject to compromise.\n- **Option D**: In a separate section as Reorganization items, net\n  - This is correct because the document explicitly states that reorganization items are reported separately as Reorganization items, net.\n- **Option E**: As a footnote disclosure only\n  - This is incorrect because the document indicates that reorganization items are reported in the Consolidated Statements of Operations, not just as a footnote disclosure.\n- **Option F**: Combined with realized gains and losses\n  - This is incorrect because the document states that reorganization items are reported separately, not combined with realized gains and losses.\n\n### Step 3: Conclusion\nBased on the information provided in the document, the correct answer is:\n\n**D: In a separate section as Reorganization items, net**\n\nThis option aligns with the document's statement that reorganization items, including expenses, realized gains and losses, and provisions for losses, are reported separately as Reorganization items, net in the Consolidated Statements of Operations."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 32000, "result": 1.0, "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?", "options": {"A": "Approval from state regulatory commissions", "B": "Approval from the Federal Energy Regulatory Commission", "C": "Prior authorization of the PUCO", "D": "Meeting tangible net worth requirements", "E": "Approval from the Duke Energy board", "F": "Retention of minimum working capital"}, "LLM_original_answer": ["To answer the question \"What condition must Duke Energy Ohio meet to declare and pay dividends?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the Relevant Section**:\n   - The document mentions restrictions on the ability of certain subsidiaries to make dividends, advances, and loans to Duke Energy. This is found in the section titled \"RESTRICTIONS ON THE ABILITY OF CERTAIN SUBSIDIARIES TO MAKE DIVIDENDS, ADVANCES AND LOANS TO DUKE ENERGY.\"\n\n2. **Focus on Duke Energy Ohio**:\n   - The specific condition for Duke Energy Ohio is stated as: \"Duke Energy Ohio will not declare and pay dividends out of capital or unearned surplus without the prior authorization of the PUCO.\"\n\n3. **Interpret the Condition**:\n   - This means that Duke Energy Ohio must obtain prior authorization from the Public Utilities Commission of Ohio (PUCO) before it can declare and pay dividends from its capital or unearned surplus.\n\n4. **Match the Condition to the Options**:\n   - Option C: \"Prior authorization of the PUCO\" directly matches the condition stated in the document.\n\nTherefore, the correct answer is:\n\n**C: Prior authorization of the PUCO**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 32000, "result": 1.0, "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?", "options": {"A": "The deficiency is recognized as a capital gain.", "B": "A new investment strategy is implemented.", "C": "The deficiency is considered due to credit loss and recognized in earnings.", "D": "A penalty is imposed on the financial institution.", "E": "The loan agreement is renegotiated.", "F": "An automatic increase in interest rate is applied."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Context**:\n   - The document discusses the accounting and management of financial instruments, including loans and securities.\n   - It specifically mentions the allowance for credit losses (ACL) and the methodology used to estimate these losses.\n\n2. **Locate the Relevant Section**:\n   - The section \"Allowance for Credit Losses - Held to Maturity Securities\" and \"Available for Sale Securities\" are particularly relevant.\n   - The section \"Summary of Significant Accounting Policies\" also provides important context.\n\n3. **Extract Key Information**:\n   - From the \"Summary of Significant Accounting Policies\" section:\n     - \"To the extent the estimated cash flows do not support the amortized cost, the deficiency is considered to be due to credit loss and is recognized in earnings.\"\n   - This statement directly addresses what happens if the estimated cash flows do not support the amortized cost.\n\n4. **Match the Information to the Options**:\n   - Option A: The deficiency is recognized as a capital gain.\n     - This is incorrect because the document specifies that the deficiency is recognized as a credit loss, not a capital gain.\n   - Option B: A new investment strategy is implemented.\n     - This is not mentioned in the document as a direct consequence of estimated cash flows not supporting the amortized cost.\n   - Option C: The deficiency is considered due to credit loss and recognized in earnings.\n     - This matches the statement from the document.\n   - Option D: A penalty is imposed on the financial institution.\n     - The document does not mention penalties as a consequence.\n   - Option E: The loan agreement is renegotiated.\n     - The document does not mention renegotiation of loan agreements as a direct consequence.\n   - Option F: An automatic increase in interest rate is applied.\n     - The document does not mention automatic interest rate increases as a consequence.\n\n5. **Conclusion**:\n   - The correct answer is **Option C**: The deficiency is considered due to credit loss and recognized in earnings.\n\nThis answer is directly supported by the statement in the document, which clearly indicates that if the estimated cash flows do not support the amortized cost, the deficiency is recognized as a credit loss in earnings."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 32000, "result": 1.0, "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?", "options": {"A": "Conduct annual cybersecurity audits", "B": "Formally report material cybersecurity incidents", "C": "Hire a dedicated cybersecurity officer", "D": "Implement a company-wide cybersecurity training program", "E": "Encrypt all data and communications", "F": "Report cybersecurity budgets annually"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Identify Relevant Information**: The document primarily discusses various aspects of intellectual property, regulatory approval, and compliance with laws and regulations, including cybersecurity. The key section related to the SEC's new cybersecurity rule is found in the \"Risks Related to Our Common Stock\" and \"Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\" sections.\n\n2. **Extract Specific Information**: The relevant excerpt is:\n   - \"Additionally, the SEC also adopted a new cybersecurity rule requiring companies subject to SEC reporting requirements to formally report material cybersecurity incidents, as well as annual disclosure regarding cybersecurity governance and risk management.\"\n\n3. **Interpret the Information**: This excerpt indicates that the new cybersecurity rule adopted by the SEC requires companies to:\n   - Formally report material cybersecurity incidents.\n   - Provide annual disclosure regarding cybersecurity governance and risk management.\n\n4. **Match the Information to the Options**:\n   - **Option A: Conduct annual cybersecurity audits** - The rule does not specifically mention conducting annual audits.\n   - **Option B: Formally report material cybersecurity incidents** - This is explicitly mentioned in the document.\n   - **Option C: Hire a dedicated cybersecurity officer** - The rule does not mention hiring a dedicated officer.\n   - **Option D: Implement a company-wide cybersecurity training program** - The rule does not mention implementing a training program.\n   - **Option E: Encrypt all data and communications** - The rule does not mention encryption.\n   - **Option F: Report cybersecurity budgets annually** - The rule does not mention reporting budgets.\n\n5. **Conclusion**: Based on the information provided in the document, the new cybersecurity rule adopted by the SEC primarily requires companies to formally report material cybersecurity incidents.\n\nTherefore, the correct answer is **Option B: Formally report material cybersecurity incidents**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 32000, "result": 1.0, "question": "Which document was filed on May 23, 2023?", "options": {"A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021", "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020", "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021", "D": "Registrant\u2019s Form 8-K", "E": "Registrant's statement of changes in beneficial ownership", "F": "Registrant's proxy statement"}, "LLM_original_answer": ["To answer the question \"Which document was filed on May 23, 2023?\", I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document provided is a financial report, and it contains a section that lists the exhibits and their sources. This section is likely to include the filing dates of the documents.\n\n2. **Locate the specific reference to May 23, 2023**: I will look for any mention of a document being filed on May 23, 2023.\n\n3. **Match the document to the options provided**: Once I find the document filed on May 23, 2023, I will match it to the options given in the question.\n\nLet's go through the document:\n\n### Step 1: Identify the relevant section\nThe relevant section is found at the end of the document, under \"ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.\"\n\n### Step 2: Locate the specific reference to May 23, 2023\nIn the section, I find the following reference:\n- **(13) Incorporated by reference to the similarly described exhibit included with the Registrant\u2019s Form 8-K filed on May 23, 2023.**\n\n### Step 3: Match the document to the options provided\nThe document filed on May 23, 2023, is a Form 8-K. This matches option D in the provided list of options.\n\n### Conclusion\nThe document filed on May 23, 2023, is the Registrant\u2019s Form 8-K.\n\n**Answer: D: Registrant\u2019s Form 8-K**"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 32000, "result": 1.0, "question": "What penalty does the GDPR allow data protection authorities to impose for violations?", "options": {"A": "Suspension of business operations", "B": "Revocation of data processing licenses", "C": "Fines up to \u20ac20 million or 4% of annual global revenues", "D": "Mandatory public apology", "E": "Mandatory cybersecurity audits only", "F": "Compulsory staff retraining programs"}, "LLM_original_answer": ["The document provided does not contain any information about the GDPR (General Data Protection Regulation) or the penalties that data protection authorities can impose for violations. The document is primarily focused on the development, regulation, and commercialization of biopharmaceutical products, particularly TCR-T therapies, and does not discuss data protection laws or their enforcement mechanisms.\n\nHowever, based on the options provided and general knowledge about the GDPR, the correct answer is:\n\nC: Fines up to \u20ac20 million or 4% of annual global revenues\n\nThe GDPR allows data protection authorities to impose significant fines for violations. According to Article 83 of the GDPR, the maximum fine can be up to \u20ac20 million or 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher. This penalty is designed to ensure that organizations take data protection seriously and comply with the regulation.\n\nSince the document does not provide specific information about the GDPR penalties, I am relying on the options given and my general knowledge to select the correct answer. If you need more detailed information about the GDPR penalties, I can provide that as well."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 32000, "result": 1.0, "question": "What could be a consequence of failing to comply with laws governing international business practices?", "options": {"A": "Immediate dissolution of the business", "B": "Substantial civil and criminal penalties", "C": "Automatic approval for business expansion", "D": "Tax incentives and holidays", "E": "Increased development of new products", "F": "Reduction in employee numbers"}, "LLM_original_answer": ["To answer the question \"What could be a consequence of failing to comply with laws governing international business practices?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Regulatory Compliance and Penalties**:\n   - The document emphasizes the importance of regulatory compliance, particularly in the context of international operations.\n   - It mentions that failing to comply with regulatory requirements can lead to significant delays, increased costs, and the need for additional clinical trials or studies.\n   - The document also notes that regulatory authorities have substantial discretion in the approval process and may require additional data or impose conditions that could delay or prevent marketing authorization.\n\n2. **Specific Consequences**:\n   - **Substantial Civil and Criminal Penalties**: The document explicitly states that failing to comply with laws governing international business practices, such as the Foreign Corrupt Practices Act (FCPA), can result in substantial civil and criminal penalties. For example, it mentions that the FCPA can lead to penalties for improper payments to foreign officials, and that these penalties can be significant.\n   - **Suspension or Debarment from Government Contracting**: The document also indicates that non-compliance with the FCPA can result in suspension or debarment from government contracting, which would severely impact the company's ability to operate in certain markets.\n\n3. **Other Options Analysis**:\n   - **Immediate Dissolution of the Business**: The document does not mention immediate dissolution as a consequence of non-compliance.\n   - **Automatic Approval for Business Expansion**: The document does not suggest that non-compliance would lead to automatic approval for business expansion.\n   - **Tax Incentives and Holidays**: The document does not indicate that non-compliance would result in tax incentives or holidays.\n   - **Increased Development of New Products**: The document does not suggest that non-compliance would lead to increased development of new products.\n   - **Reduction in Employee Numbers**: While the document mentions the importance of retaining key personnel, it does not directly link non-compliance with a reduction in employee numbers.\n\nGiven the analysis, the most appropriate answer based on the provided document is:\n\n**B: Substantial civil and criminal penalties**\n\nThis option is directly supported by the document, which explicitly mentions the potential for substantial civil and criminal penalties as a consequence of failing to comply with laws governing international business practices."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 32000, "result": 1.0, "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?", "options": {"A": "$2.0 billion", "B": "$19.0 billion", "C": "$1.6 billion", "D": "$22.6 billion", "E": "$8.4 billion", "F": "$270 million"}, "LLM_original_answer": ["To answer the question \"As of December 31, 2023, what was the amount of outstanding debt related to senior notes?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the company's debt is titled \"Debt\" and is found towards the end of the document.\n\n2. **Locate the specific information about senior notes**: Within the \"Debt\" section, the document states:\n   - \"As of December 31, 2023, we had $22.6 billion in outstanding debt, consisting of $19.0 billion of senior notes, $2.0 billion under our Commercial Paper Program and $1.6 billion under our Term Loan.\"\n\n3. **Extract the amount of senior notes**: The document clearly states that the amount of outstanding debt related to senior notes as of December 31, 2023, is $19.0 billion.\n\n4. **Match the extracted amount to the provided options**: The amount $19.0 billion corresponds to option B.\n\nTherefore, the correct answer is **B: $19.0 billion**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 32000, "result": 1.0, "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?", "options": {"A": "By adding a fixed percentage to the policyholder account balance", "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract", "C": "By charging a surrender fee immediately upon issuance", "D": "By applying a uniform rate to all existing liabilities", "E": "By using a simple average of all deposits", "F": "By increasing withdrawal charges over time"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Relevant Section:**\n   - The relevant section for understanding how the company calculates additional liabilities for certain product features like secondary guarantees on universal life insurance contracts is found in \"Notes to the Consolidated Financial Statements\" under \"4. Insurance Liabilities.\"\n\n2. **Extract Key Information:**\n   - The document states: \"The Company establishes a liability in addition to the account balance for ULSG. These liabilities are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero and recognizing those benefits ratably over the contract period based on total expected assessments.\"\n   - It further mentions: \"The benefits used in calculating the liabilities are based on the average benefits payable over a range of scenarios.\"\n\n3. **Analyze the Information:**\n   - The company calculates additional liabilities for ULSG by projecting when the account balance will be zero and estimating the death benefits payable at that time.\n   - These estimated death benefits are then recognized ratably over the contract period based on total expected assessments.\n   - The benefits are based on the average benefits payable over a range of scenarios, indicating a projection-based approach rather than a fixed percentage or uniform rate.\n\n4. **Match the Information to the Options:**\n   - **Option A:** \"By adding a fixed percentage to the policyholder account balance\" - This does not match the projection-based approach described.\n   - **Option B:** \"By projecting death benefits when account balance is zero and recognizing benefits over the contract\" - This matches the description in the document.\n   - **Option C:** \"By charging a surrender fee immediately upon issuance\" - This is not mentioned in the context of calculating additional liabilities.\n   - **Option D:** \"By applying a uniform rate to all existing liabilities\" - This does not match the projection-based approach.\n   - **Option E:** \"By using a simple average of all deposits\" - This is not mentioned in the context of calculating additional liabilities.\n   - **Option F:** \"By increasing withdrawal charges over time\" - This is not mentioned in the context of calculating additional liabilities.\n\n5. **Conclusion:**\n   - The correct answer is **Option B: By projecting death benefits when account balance is zero and recognizing benefits over the contract**.\n\nThis approach aligns with the company's method of estimating and recognizing the expected value of death benefits payable when the account balance is projected to be zero, and"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 64000, "result": 1.0, "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?", "options": {"A": "Immediate market approval for products", "B": "Increased research funding", "C": "Extended, delayed, or terminated clinical trials", "D": "Expansion of the organizational workforce", "E": "Higher stock market valuation", "F": "More partnerships with external organizations"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and consider the potential consequences of compromised quality or accuracy of consultant services in clinical trials.\n\n### Step-by-Step Analysis:\n\n1. **Understanding the Context**:\n   - The document discusses various risks and challenges associated with clinical trials and the development of biopharmaceutical products.\n   - It emphasizes the importance of accurate and reliable data in clinical trials for regulatory approval and commercial success.\n\n2. **Identifying Key Points**:\n   - **Regulatory Approval**: The document mentions that the FDA and other regulatory authorities require accurate and reliable data from clinical trials to approve new products.\n   - **Patient Safety**: Compromised data can lead to safety concerns, which can affect patient recruitment and retention.\n   - **Trial Delays**: Inaccurate or compromised data can result in the need for additional trials or the suspension of ongoing trials.\n   - **Reputation and Liability**: Issues with data can lead to negative publicity, potential product liability claims, and damage to the company's reputation.\n\n3. **Evaluating the Options**:\n   - **A: Immediate market approval for products**: This is highly unlikely. The document emphasizes that regulatory authorities require thorough and accurate data, and compromised data would likely lead to delays or rejections.\n   - **B: Increased research funding**: The document does not suggest that compromised data would lead to increased funding. Instead, it highlights the risks of delays and additional costs.\n   - **C: Extended, delayed, or terminated clinical trials**: This is a strong possibility. The document explicitly mentions that issues with data can lead to the suspension or termination of trials and the need for additional trials.\n   - **D: Expansion of the organizational workforce**: The document does not indicate that compromised data would lead to workforce expansion. Instead, it suggests that such issues could lead to delays and increased costs.\n   - **E: Higher stock market valuation**: Compromised data would likely have the opposite effect. The document mentions that negative publicity and regulatory issues can harm the company's financial condition and stock price.\n   - **F: More partnerships with external organizations**: The document does not suggest that compromised data would lead to more partnerships. In fact, it implies that such issues could make the company less attractive as a partner.\n\n### Conclusion:\nBased on the document, the most likely consequence of compromised quality or accuracy of consultant services in clinical trials is **C: Extended, delayed, or terminated clinical trials**. The document clearly states that issues with data can lead to the suspension or"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 64000, "result": 1.0, "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?", "options": {"A": "As part of ongoing operating expenses", "B": "As extraordinary items", "C": "Under liabilities subject to compromise", "D": "In a separate section as Reorganization items, net", "E": "As a footnote disclosure only", "F": "Combined with realized gains and losses"}, "LLM_original_answer": ["To answer the question, we need to focus on the specific accounting treatment for reorganization items as described in the document, particularly in the context of ASC 852, Reorganizations.\n\n1. **Identify the relevant section in the document:**\n   - The document mentions that the Company began to apply the provisions of ASC 852, Reorganizations, effective on December 21, 2022, when it filed for Chapter 11 bankruptcy.\n   - According to ASC 852, the financial statements for periods including and after the filing of the Chapter 11 Cases must distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of the business.\n\n2. **Understand the specific reporting requirement:**\n   - The document states: \"Expenses (including professional fees), realized gains and losses, and provisions for losses that can be directly associated with the reorganization must be reported separately as Reorganization items, net in the Consolidated Statements of Operations beginning December 21, 2022, the date of filing of the Chapter 11 Cases.\"\n\n3. **Match the requirement to the options provided:**\n   - Option A: As part of ongoing operating expenses\n     - This is incorrect because the document explicitly states that reorganization items are reported separately from ongoing operating expenses.\n   - Option B: As extraordinary items\n     - This is incorrect because the document does not mention extraordinary items; it specifically mentions reorganization items.\n   - Option C: Under liabilities subject to compromise\n     - This is incorrect because reorganization items are reported in the income statement, not the balance sheet.\n   - Option D: In a separate section as Reorganization items, net\n     - This is correct because the document states that reorganization items are reported separately as Reorganization items, net in the Consolidated Statements of Operations.\n   - Option E: As a footnote disclosure only\n     - This is incorrect because the document states that reorganization items are reported in the income statement, not just in the footnotes.\n   - Option F: Combined with realized gains and losses\n     - This is incorrect because reorganization items are reported separately, not combined with realized gains and losses.\n\n4. **Conclusion:**\n   - The correct answer is **D: In a separate section as Reorganization items, net**.\n\nThis answer is consistent with the document's description of how reorganization items are reported under ASC 852."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 64000, "result": 1.0, "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?", "options": {"A": "Approval from state regulatory commissions", "B": "Approval from the Federal Energy Regulatory Commission", "C": "Prior authorization of the PUCO", "D": "Meeting tangible net worth requirements", "E": "Approval from the Duke Energy board", "F": "Retention of minimum working capital"}, "LLM_original_answer": ["To answer the question, \"What condition must Duke Energy Ohio meet to declare and pay dividends?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Identify the Relevant Section**:\n   - The document mentions restrictions on the ability of certain subsidiaries to make dividends, advances, and loans to Duke Energy. Specifically, it states: \"Duke Energy Ohio will not declare and pay dividends out of capital or unearned surplus without the prior authorization of the PUCO.\"\n\n2. **Understand the Condition**:\n   - The condition for Duke Energy Ohio to declare and pay dividends is that it must not do so from capital or unearned surplus without prior authorization from the PUCO (Public Utilities Commission of Ohio).\n\n3. **Evaluate the Options**:\n   - **Option A**: Approval from state regulatory commissions\n     - This is a broad statement and does not specifically mention the PUCO.\n   - **Option B**: Approval from the Federal Energy Regulatory Commission\n     - The document does not mention FERC as a condition for dividend declaration and payment.\n   - **Option C**: Prior authorization of the PUCO\n     - This matches the specific condition mentioned in the document.\n   - **Option D**: Meeting tangible net worth requirements\n     - The document mentions tangible net worth requirements as a restriction for other subsidiaries but not specifically for Duke Energy Ohio.\n   - **Option E**: Approval from the Duke Energy board\n     - The document does not mention the Duke Energy board as a condition for dividend declaration and payment.\n   - **Option F**: Retention of minimum working capital\n     - The document mentions minimum working capital requirements as a restriction for other subsidiaries but not specifically for Duke Energy Ohio.\n\n4. **Conclusion**:\n   - The condition that Duke Energy Ohio must meet to declare and pay dividends is **prior authorization of the PUCO**.\n\nTherefore, the correct answer is **Option C: Prior authorization of the PUCO**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 64000, "result": 1.0, "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?", "options": {"A": "The deficiency is recognized as a capital gain.", "B": "A new investment strategy is implemented.", "C": "The deficiency is considered due to credit loss and recognized in earnings.", "D": "A penalty is imposed on the financial institution.", "E": "The loan agreement is renegotiated.", "F": "An automatic increase in interest rate is applied."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Context**: The question is about what happens if the estimated cash flows do not support the amortized cost of a financial asset, such as a loan.\n\n2. **Locate Relevant Information**: The document provides specific information about how the company handles situations where estimated cash flows do not support the amortized cost. This is found in the section on \"Allowance for Credit Losses\" and \"Securities.\"\n\n3. **Extract Key Information**:\n   - **From the \"Allowance for Credit Losses\" section**:\n     - \"To the extent the estimated cash flows do not support the amortized cost, the deficiency is considered to be due to credit loss and is recognized in earnings.\"\n   - **From the \"Securities\" section**:\n     - \"If the estimated cash flows do not support the amortized cost, the deficiency is considered to be due to credit loss and is recognized in earnings.\"\n\n4. **Interpret the Information**:\n   - Both sections indicate that if the estimated cash flows do not support the amortized cost, the deficiency is recognized as a credit loss.\n   - Credit losses are recognized in earnings, which means they are recorded as an expense in the income statement.\n\n5. **Match to the Options**:\n   - **Option A**: The deficiency is recognized as a capital gain. (Incorrect, as it is a loss, not a gain.)\n   - **Option B**: A new investment strategy is implemented. (Not mentioned in the document.)\n   - **Option C**: The deficiency is considered due to credit loss and recognized in earnings. (Correct, as it matches the information provided.)\n   - **Option D**: A penalty is imposed on the financial institution. (Not mentioned in the document.)\n   - **Option E**: The loan agreement is renegotiated. (Not mentioned in the document.)\n   - **Option F**: An automatic increase in interest rate is applied. (Not mentioned in the document.)\n\n6. **Conclusion**:\n   - The correct answer is **Option C**: The deficiency is considered due to credit loss and recognized in earnings.\n\nTherefore, if the estimated cash flows do not support the amortized cost according to the document, the deficiency is considered due to credit loss and recognized in earnings."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 64000, "result": 1.0, "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?", "options": {"A": "Conduct annual cybersecurity audits", "B": "Formally report material cybersecurity incidents", "C": "Hire a dedicated cybersecurity officer", "D": "Implement a company-wide cybersecurity training program", "E": "Encrypt all data and communications", "F": "Report cybersecurity budgets annually"}, "LLM_original_answer": ["The correct answer to the question \"What is the new cybersecurity rule adopted by the SEC primarily require companies to do?\" is:\n\n**B: Formally report material cybersecurity incidents**\n\n### Chain of Thought:\n1. **Identify the Relevant Information**: The document mentions the SEC's new cybersecurity rule in the context of regulatory requirements and compliance.\n2. **Locate the Specific Rule**: The relevant section states, \"In 2023 the SEC adopted rules requiring disclosure of material cybersecurity incidents suffered by public companies, as well as annual disclosure regarding cybersecurity governance and risk management.\"\n3. **Understand the Requirement**: The rule requires companies to formally report material cybersecurity incidents. This is a clear and direct requirement.\n4. **Evaluate the Options**:\n   - **A: Conduct annual cybersecurity audits** - The document does not mention annual audits as a requirement.\n   - **B: Formally report material cybersecurity incidents** - This matches the requirement mentioned in the document.\n   - **C: Hire a dedicated cybersecurity officer** - The document does not mention this as a requirement.\n   - **D: Implement a company-wide cybersecurity training program** - The document does not mention this as a requirement.\n   - **E: Encrypt all data and communications** - The document does not mention this as a requirement.\n   - **F: Report cybersecurity budgets annually** - The document does not mention this as a requirement.\n5. **Confirm the Answer**: The document explicitly states that the SEC's new rule requires the formal reporting of material cybersecurity incidents, making option B the correct answer."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 64000, "result": 1.0, "question": "Which document was filed on May 23, 2023?", "options": {"A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021", "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020", "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021", "D": "Registrant\u2019s Form 8-K", "E": "Registrant's statement of changes in beneficial ownership", "F": "Registrant's proxy statement"}, "LLM_original_answer": ["To answer the question \"Which document was filed on May 23, 2023?\", I will analyze the provided document and look for any references to a filing date of May 23, 2023.\n\n1. **Identify the relevant section**: The document is an annual report on Form 10-K for the year ended December 31, 2023. It contains detailed financial and operational information about Ocwen Financial Corporation.\n\n2. **Search for specific filing dates**: I will look for any mention of documents or transactions that were filed on May 23, 2023.\n\n3. **Find the relevant reference**: In the \"Exhibits, Financial Statement Schedules\" section (Item 15), there is a reference to a filing on May 23, 2023:\n   - **(13) Incorporated by reference to the similarly described exhibit to the Registrant\u2019s Form 8-K filed on May 23, 2023.**\n\n4. **Match the reference to the options**: The reference indicates that a Form 8-K was filed on May 23, 2023.\n\n5. **Select the correct option**: The correct option is:\n   - **D: Registrant\u2019s Form 8-K**\n\nTherefore, the document that was filed on May 23, 2023 is **D: Registrant\u2019s Form 8-K**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 64000, "result": 1.0, "question": "What penalty does the GDPR allow data protection authorities to impose for violations?", "options": {"A": "Suspension of business operations", "B": "Revocation of data processing licenses", "C": "Fines up to \u20ac20 million or 4% of annual global revenues", "D": "Mandatory public apology", "E": "Mandatory cybersecurity audits only", "F": "Compulsory staff retraining programs"}, "LLM_original_answer": ["To answer the question \"What penalty does the GDPR allow data protection authorities to impose for violations?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for mentions of the GDPR and penalties.\n2. **Extract Specific Details**: Find the exact wording that describes the penalties.\n3. **Match to Options**: Compare the extracted details to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document mentions the GDPR in the context of data protection and the penalties that can be imposed for violations. The relevant section is:\n\n> \"The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to having a legal basis for processing personal data, stricter requirements relating to the processing of sensitive data (such as health data), where required by GDPR obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, requirements to conduct data protection impact assessments for high risk processing and taking certain measures when engaging third-party processors. The GDPR permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to \u20ac20 million or 4% of annual global revenues, whichever is greater.\"\n\n### Step 2: Extract Specific Details\nThe specific detail about the penalties is:\n\n> \"The GDPR permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to \u20ac20 million or 4% of annual global revenues, whichever is greater.\"\n\n### Step 3: Match to Options\nNow, let's match this detail to the given options:\n\n- **A: Suspension of business operations** - Not mentioned.\n- **B: Revocation of data processing licenses** - Not mentioned.\n- **C: Fines up to \u20ac20 million or 4% of annual global revenues** - Matches the extracted detail.\n- **D: Mandatory public apology** - Not mentioned.\n- **E: Mandatory cybersecurity audits only** - Not mentioned.\n- **F: Compulsory staff retraining programs** - Not mentioned.\n\n### Conclusion\nThe correct answer is **C: Fines up to \u20ac20 million or 4% of annual global revenues**. This is explicitly stated in the document as the penalty that the GDPR allows data protection authorities to impose for violations."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 64000, "result": 1.0, "question": "What could be a consequence of failing to comply with laws governing international business practices?", "options": {"A": "Immediate dissolution of the business", "B": "Substantial civil and criminal penalties", "C": "Automatic approval for business expansion", "D": "Tax incentives and holidays", "E": "Increased development of new products", "F": "Reduction in employee numbers"}, "LLM_original_answer": ["To answer the question \"What could be a consequence of failing to comply with laws governing international business practices?\" based on the provided document, let's analyze the relevant sections:\n\n1. **Regulatory Compliance and Penalties**:\n   - The document mentions that failing to comply with regulatory requirements can lead to various consequences, including:\n     - **Restrictions on the manufacturing of such products**.\n     - **Restrictions on the labeling or marketing of such products**.\n     - **Restrictions on product distribution or use**.\n     - **Requirements to conduct post-marketing studies or clinical trials**.\n     - **Warning letters or untitled letters**.\n     - **Withdrawal of the products from the market**.\n     - **Refusal to approve pending applications or supplements to approved applications**.\n     - **Recall of products**.\n     - **Restrictions on coverage by third-party payors**.\n     - **Fines, restitution or disgorgement of profits or revenues**.\n     - **Exclusion from federal health care programs such as Medicare and Medicaid**.\n     - **Suspension or withdrawal of regulatory approvals**.\n     - **Refusal to permit the import or export of products**.\n     - **Product seizure**.\n     - **Injunctions or the imposition of civil or criminal penalties**.\n\n2. **Specific Penalties**:\n   - The document explicitly states that **\"Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment.\"**\n   - It also mentions that **\"If we, and any future collaborators, are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for AMX0035 or any future approved products withdrawn or restricted by regulatory authorities, or we may voluntarily do so.\"**\n\n3. **Financial and Operational Impact**:\n   - The document highlights that **\"The cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.\"**\n   - It further states that **\"If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government-funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 64000, "result": 1.0, "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?", "options": {"A": "$2.0 billion", "B": "$19.0 billion", "C": "$1.6 billion", "D": "$22.6 billion", "E": "$8.4 billion", "F": "$270 million"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant section in the document that discusses the company's debt.\n2. Look for the specific mention of senior notes and the amount as of December 31, 2023.\n3. Match the identified amount with the provided options.\n\nStep 1: The relevant section is found under \"Liquidity and Capital Resources\" and \"Debt\" in the document.\n\nStep 2: In the \"Debt\" section, it states: \"As of December 31, 2023, we had $22.6 billion in outstanding debt, consisting of $19.0 billion related to our senior notes, $1.6 billion under our Term Loan and $2.0 billion in commercial paper.\"\n\nStep 3: The amount of outstanding debt related to senior notes as of December 31, 2023, is $19.0 billion.\n\nTherefore, the correct answer is:\nB: $19.0 billion"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 64000, "result": 1.0, "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?", "options": {"A": "By adding a fixed percentage to the policyholder account balance", "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract", "C": "By charging a surrender fee immediately upon issuance", "D": "By applying a uniform rate to all existing liabilities", "E": "By using a simple average of all deposits", "F": "By increasing withdrawal charges over time"}, "LLM_original_answer": ["The correct answer to the question \"How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?\" is:\n\n**B: By projecting death benefits when account balance is zero and recognizing benefits over the contract**\n\n### Chain of Thought:\n1. **Identify the Relevant Section**: The document provides detailed information on how the company calculates additional liabilities for secondary guarantees on universal life insurance contracts. This information is found in the \"Summary of Significant Accounting Policies\" section under \"Insurance Contract Obligations\" and \"Additional Liabilities for ULSG.\"\n\n2. **Understand the Calculation Method**:\n   - The document states: \"The Company establishes a liability in addition to the account balance for ULSG. These liabilities are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero and recognizing those benefits ratably over the contract period based on total expected assessments.\"\n   - This means the company projects the future death benefits that will be payable when the account balance is expected to reach zero and then recognizes these benefits over the contract period.\n\n3. **Eliminate Other Options**:\n   - **A: By adding a fixed percentage to the policyholder account balance** - This is not mentioned in the document.\n   - **C: By charging a surrender fee immediately upon issuance** - The document does not mention this method for calculating additional liabilities.\n   - **D: By applying a uniform rate to all existing liabilities** - The document specifies that the calculation is based on projections and not a uniform rate.\n   - **E: By using a simple average of all deposits** - The document does not mention this method.\n   - **F: By increasing withdrawal charges over time** - The document does not mention this method for calculating additional liabilities.\n\n4. **Confirm the Correct Answer**:\n   - The method described in the document aligns with option B, which states that the company projects death benefits when the account balance is zero and recognizes these benefits over the contract period.\n\nTherefore, the correct answer is **B: By projecting death benefits when account balance is zero and recognizing benefits over the contract**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 96000, "result": 1.0, "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?", "options": {"A": "Immediate market approval for products", "B": "Increased research funding", "C": "Extended, delayed, or terminated clinical trials", "D": "Expansion of the organizational workforce", "E": "Higher stock market valuation", "F": "More partnerships with external organizations"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the most relevant consequence of compromised quality or accuracy of consultant services in clinical trials.\n\n### Step-by-Step Analysis:\n\n1. **Understanding the Context**:\n   - The document discusses various aspects of clinical trials, regulatory approval processes, and the importance of adhering to Good Clinical Practices (GCP) and Good Manufacturing Practices (cGMP).\n   - It emphasizes the need for clinical trials to be conducted in a manner that ensures the safety and efficacy of the product candidates.\n\n2. **Identifying Key Points**:\n   - **Regulatory Requirements**: Clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements.\n   - **Quality and Accuracy**: The quality and accuracy of clinical data are crucial for regulatory approval.\n   - **Consequences of Non-Compliance**: Non-compliance with GCP and regulatory requirements can lead to serious consequences, including the suspension or termination of clinical trials.\n\n3. **Evaluating the Options**:\n   - **A: Immediate market approval for products**: This is highly unlikely. The document emphasizes that regulatory approval is a lengthy and rigorous process.\n   - **B: Increased research funding**: The document does not suggest that compromised quality or accuracy would lead to increased funding. Instead, it highlights the risks of delays and termination.\n   - **C: Extended, delayed, or terminated clinical trials**: This is a direct consequence of compromised quality or accuracy. The document mentions that issues in clinical trials can lead to delays or termination.\n   - **D: Expansion of the organizational workforce**: The document does not indicate that compromised quality or accuracy would lead to workforce expansion. It focuses on the risks to the clinical trial process.\n   - **E: Higher stock market valuation**: Compromised quality or accuracy would likely have a negative impact on the company's valuation, not a positive one.\n   - **F: More partnerships with external organizations**: The document does not suggest that compromised quality or accuracy would lead to more partnerships. Instead, it highlights the risks of losing trust and facing regulatory issues.\n\n### Conclusion:\nBased on the document, the most relevant consequence of compromised quality or accuracy of consultant services in clinical trials is **C: Extended, delayed, or terminated clinical trials**. This is supported by the document's emphasis on the importance of adhering to GCP and regulatory requirements, and the potential for non-compliance to result in serious issues, including the suspension or termination of clinical trials.\n\nTherefore, the correct answer is **C: Extended"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 96000, "result": 1.0, "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?", "options": {"A": "As part of ongoing operating expenses", "B": "As extraordinary items", "C": "Under liabilities subject to compromise", "D": "In a separate section as Reorganization items, net", "E": "As a footnote disclosure only", "F": "Combined with realized gains and losses"}, "LLM_original_answer": ["To answer the question regarding how transactions and events directly associated with a reorganization should be reported in financial statements according to ASC 852, I will analyze the relevant information provided in the document.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Relevant Section:**\n   - The document provides detailed information about the Company's Chapter 11 filing and subsequent reorganization. The key section for this analysis is Note 3 \u2014 Chapter 11 Filing and Other Related Matters, which discusses the application of ASC 852.\n\n2. **Understand the Application of ASC 852:**\n   - According to the document, the Company began to apply the provisions of ASC 852, Reorganizations, effective on December 21, 2022, the date of filing for Chapter 11 protection.\n   - ASC 852 requires that the financial statements for periods including and after the filing of the Chapter 11 Cases distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of the business.\n\n3. **Determine the Reporting Requirements:**\n   - The document states that expenses (including professional fees), realized gains and losses, and provisions for losses that can be directly associated with the reorganization must be reported separately as Reorganization items, net in the Consolidated Statements of Operations.\n   - This indicates that these transactions and events are not mixed with ongoing operating expenses or other sections of the financial statements but are specifically reported in a separate section.\n\n4. **Review the Examples Provided:**\n   - The document provides several examples of reorganization items, such as:\n     - Gain on debt extinguishment.\n     - Fair value adjustments on convertible notes.\n     - Fair value adjustments on derivative warrant liabilities.\n     - Settlements with creditors, including gains and losses from these settlements.\n   - All these items are reported under Reorganization items, net.\n\n### Conclusion:\nBased on the information provided in the document, transactions and events directly associated with a reorganization should be reported in a separate section as Reorganization items, net, in accordance with ASC 852.\n\n### Answer:\nThe correct option is **D: In a separate section as Reorganization items, net**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 96000, "result": 1.0, "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?", "options": {"A": "Approval from state regulatory commissions", "B": "Approval from the Federal Energy Regulatory Commission", "C": "Prior authorization of the PUCO", "D": "Meeting tangible net worth requirements", "E": "Approval from the Duke Energy board", "F": "Retention of minimum working capital"}, "LLM_original_answer": ["To answer the question \"What condition must Duke Energy Ohio meet to declare and pay dividends?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Identify the relevant section in the document:**\n   - The document mentions restrictions on the ability of certain subsidiaries to make dividends, advances, and loans to Duke Energy. Specifically, it states: \"Duke Energy Ohio will not declare and pay dividends out of capital or unearned surplus without the prior authorization of the PUCO.\"\n\n2. **Understand the context:**\n   - Duke Energy Ohio is a regulated public utility primarily engaged in the transmission and distribution of electricity in portions of Ohio and Kentucky, and the generation and sale of electricity in portions of Kentucky.\n   - The PUCO (Public Utilities Commission of Ohio) has jurisdiction over Duke Energy Ohio's operations in Ohio.\n\n3. **Interpret the restriction:**\n   - The restriction indicates that Duke Energy Ohio cannot declare and pay dividends from its capital or unearned surplus without first obtaining authorization from the PUCO.\n   - \"Capital\" typically refers to the company's equity or retained earnings.\n   - \"Unearned surplus\" refers to surplus funds that have not yet been earned or realized.\n\n4. **Determine the condition:**\n   - The condition Duke Energy Ohio must meet to declare and pay dividends is to obtain prior authorization from the PUCO.\n\nGiven this analysis, the correct answer is:\n\n**C: Prior authorization of the PUCO**\n\nThis condition is explicitly stated in the document and aligns with the regulatory environment in which Duke Energy Ohio operates."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 96000, "result": 1.0, "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?", "options": {"A": "The deficiency is recognized as a capital gain.", "B": "A new investment strategy is implemented.", "C": "The deficiency is considered due to credit loss and recognized in earnings.", "D": "A penalty is imposed on the financial institution.", "E": "The loan agreement is renegotiated.", "F": "An automatic increase in interest rate is applied."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Context of the Question**: The question asks what happens if the estimated cash flows do not support the amortized cost of a financial instrument, such as a loan or security.\n\n2. **Relevant Information from the Document**:\n   - The document discusses the allowance for loan losses and the methodology used to estimate expected credit losses.\n   - It mentions that if the estimated cash flows do not support the amortized cost, the deficiency is considered due to credit loss and is recognized in earnings.\n   - Specifically, the document states: \"To the extent the estimated cash flows do not support the amortized cost, the deficiency is considered to be due to credit loss and is recognized in earnings.\"\n\n3. **Analysis**:\n   - The document clearly indicates that when the estimated cash flows are insufficient to support the amortized cost, the difference is recognized as a credit loss.\n   - This credit loss is then recorded in the earnings, which means it affects the financial statements and the company's profitability.\n\n4. **Conclusion**:\n   - Based on the information provided, the correct answer is **C: The deficiency is considered due to credit loss and recognized in earnings**.\n\nTherefore, the answer to the question is **C: The deficiency is considered due to credit loss and recognized in earnings**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 96000, "result": 1.0, "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?", "options": {"A": "Conduct annual cybersecurity audits", "B": "Formally report material cybersecurity incidents", "C": "Hire a dedicated cybersecurity officer", "D": "Implement a company-wide cybersecurity training program", "E": "Encrypt all data and communications", "F": "Report cybersecurity budgets annually"}, "LLM_original_answer": ["The provided document does not contain information about a new cybersecurity rule adopted by the SEC. The document primarily discusses the business operations, financials, and regulatory environment of Nurix Therapeutics, Inc., a biopharmaceutical company. It does not mention any SEC cybersecurity rules or requirements for companies to formally report material cybersecurity incidents.\n\nHowever, based on the question and the options provided, the correct answer is:\n\n**B: Formally report material cybersecurity incidents**\n\nThis is because the question asks about a new cybersecurity rule adopted by the SEC, and the most relevant option that aligns with typical SEC cybersecurity regulations is the requirement for companies to formally report material cybersecurity incidents. The SEC has indeed adopted rules requiring public companies to disclose material cybersecurity incidents in a timely manner, which is a key aspect of ensuring transparency and protecting investors."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 96000, "result": 1.0, "question": "Which document was filed on May 23, 2023?", "options": {"A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021", "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020", "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021", "D": "Registrant\u2019s Form 8-K", "E": "Registrant's statement of changes in beneficial ownership", "F": "Registrant's proxy statement"}, "LLM_original_answer": ["To answer the question \"Which document was filed on May 23, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document provided is a Form 10-K, which is an annual report. It contains a list of exhibits and references to other filings.\n\n2. **Search for the specific date**: I will look for any mention of a document or filing on May 23, 2023.\n\n3. **Review the exhibits and references**: I will check the exhibits and references to see if any document was filed on the specified date.\n\n### Step-by-Step Analysis:\n\n1. **Identify the relevant section**:\n   - The document is an annual report on Form 10-K for the year ended December 31, 2023.\n\n2. **Search for the specific date**:\n   - Scanning through the document, I find the following relevant reference:\n     - \"In May 2023, OLIT issued senior and mezzanine classes of notes, at a discount, with a stated interest rate of 3.0% and a mandatory call date of June 2026.\"\n   - However, this does not specify a filing date.\n\n3. **Review the exhibits and references**:\n   - In the exhibits section, I find:\n     - \"13.1 Incorporated by reference to the similarly described exhibit to the Registrant\u2019s Form 8-K filed on May 23, 2023.\"\n   - This indicates that a Form 8-K was filed on May 23, 2023.\n\n### Conclusion:\nThe document that was filed on May 23, 2023 is **D: Registrant\u2019s Form 8-K**.\n\nThus, the correct answer is **D: Registrant\u2019s Form 8-K**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 96000, "result": 1.0, "question": "What penalty does the GDPR allow data protection authorities to impose for violations?", "options": {"A": "Suspension of business operations", "B": "Revocation of data processing licenses", "C": "Fines up to \u20ac20 million or 4% of annual global revenues", "D": "Mandatory public apology", "E": "Mandatory cybersecurity audits only", "F": "Compulsory staff retraining programs"}, "LLM_original_answer": ["The correct answer to the question \"What penalty does the GDPR allow data protection authorities to impose for violations?\" based on the provided document is:\n\nC: Fines up to \u20ac20 million or 4% of annual global revenues\n\nThis can be found in the section discussing the GDPR (General Data Protection Regulation) in the context of European data protection laws. The document states: \"The GDPR permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to \u20ac20 million or 4% of annual global revenues, whichever is greater.\" This directly aligns with the GDPR's provisions for penalties and fines."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 96000, "result": 1.0, "question": "What could be a consequence of failing to comply with laws governing international business practices?", "options": {"A": "Immediate dissolution of the business", "B": "Substantial civil and criminal penalties", "C": "Automatic approval for business expansion", "D": "Tax incentives and holidays", "E": "Increased development of new products", "F": "Reduction in employee numbers"}, "LLM_original_answer": ["To answer the question \"What could be a consequence of failing to comply with laws governing international business practices?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Regulatory Compliance and Penalties**:\n   - The document mentions that failing to comply with applicable foreign regulatory requirements can result in various penalties. For example, it states: \"If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.\"\n\n2. **Specific Penalties**:\n   - **Fines**: The document explicitly mentions fines as a potential consequence.\n   - **Suspension or Withdrawal of Regulatory Approvals**: It indicates that regulatory approvals can be suspended or withdrawn.\n   - **Product Recalls**: The document mentions that products can be recalled.\n   - **Seizure of Products**: It states that products can be seized.\n   - **Operating Restrictions**: The document mentions operating restrictions.\n   - **Criminal Prosecution**: It also mentions the possibility of criminal prosecution.\n\n3. **Impact on Business**:\n   - The document further elaborates on the potential impact on business operations, such as: \"Any such findings by a regulatory authority or decision to voluntarily withdraw AMX0035 from the marketplace would materially harm our ability to generate revenue and remain profitable.\"\n\n4. **Evaluating the Options**:\n   - **A: Immediate dissolution of the business**: The document does not mention immediate dissolution of the business as a consequence.\n   - **B: Substantial civil and criminal penalties**: This aligns with the document's mention of fines and criminal prosecution.\n   - **C: Automatic approval for business expansion**: The document does not mention automatic approval for business expansion as a consequence.\n   - **D: Tax incentives and holidays**: The document does not mention tax incentives or holidays as a consequence.\n   - **E: Increased development of new products**: The document does not mention increased development of new products as a consequence.\n   - **F: Reduction in employee numbers**: While the document does not explicitly mention a reduction in employee numbers, it does discuss the potential for significant financial harm, which could indirectly lead to such a reduction.\n\nGiven the information provided in the document, the most accurate and relevant answer is:\n\n**B: Substantial civil and criminal penalties**\n\nThis option directly corresponds to the penalties mentioned in the document, including fines and criminal prosecution, which are significant consequences"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 96000, "result": 1.0, "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?", "options": {"A": "$2.0 billion", "B": "$19.0 billion", "C": "$1.6 billion", "D": "$22.6 billion", "E": "$8.4 billion", "F": "$270 million"}, "LLM_original_answer": ["To answer the question regarding the amount of outstanding debt related to senior notes as of December 31, 2023, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document provides detailed financial information, and the section that specifically mentions the outstanding debt is in \"Part II, Item 7. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations \u2013 Debt.\"\n\n2. **Extract the specific information**: In the \"Debt\" section, the document states:\n   - \"As of December 31, 2023, we had $22.6 billion in outstanding debt, consisting of $19.0 billion of senior notes, $1.6 billion under our Term Loan and $2.0 billion in commercial paper.\"\n\n3. **Match the information to the question**: The question asks for the amount of outstanding debt related to senior notes as of December 31, 2023. According to the document, the amount of senior notes outstanding is $19.0 billion.\n\n4. **Select the correct option**: The correct option from the provided choices is:\n   - B: $19.0 billion\n\nTherefore, the amount of outstanding debt related to senior notes as of December 31, 2023, is **$19.0 billion**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 96000, "result": 1.0, "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?", "options": {"A": "By adding a fixed percentage to the policyholder account balance", "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract", "C": "By charging a surrender fee immediately upon issuance", "D": "By applying a uniform rate to all existing liabilities", "E": "By using a simple average of all deposits", "F": "By increasing withdrawal charges over time"}, "LLM_original_answer": ["To answer the question, \"How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Relevant Section in the Document**:\n   - The document provides details on how the Company establishes additional liabilities for secondary guarantees on universal life insurance contracts in the \"Summary of Significant Accounting Policies\" section, specifically under \"Additional Liabilities for ULSG.\"\n\n2. **Key Information**:\n   - The Company establishes a liability in addition to the account balance for ULSG (Universal Life with Secondary Guarantees).\n   - These liabilities are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero.\n   - The benefits are recognized ratably over the contract period based on total expected assessments.\n   - The benefits used in calculating the liabilities are based on the average benefits payable over a range of scenarios.\n\n3. **Calculation Method**:\n   - The Company projects the future account balance to determine when it will be zero.\n   - It then estimates the death benefits that will be payable at that time.\n   - These estimated death benefits are recognized ratably over the contract period based on the total expected assessments (fees and charges) collected from the policyholder.\n\n4. **Matching the Information to the Options**:\n   - **Option A**: By adding a fixed percentage to the policyholder account balance.\n     - This does not match the described method, as the Company does not use a fixed percentage.\n   - **Option B**: By projecting death benefits when account balance is zero and recognizing benefits over the contract.\n     - This matches the described method, as the Company projects the account balance to zero and then estimates the death benefits to be recognized ratably over the contract period.\n   - **Option C**: By charging a surrender fee immediately upon issuance.\n     - This does not match the described method, as the Company does not charge a surrender fee immediately upon issuance.\n   - **Option D**: By applying a uniform rate to all existing liabilities.\n     - This does not match the described method, as the Company uses a range of scenarios to estimate the benefits.\n   - **Option E**: By using a simple average of all deposits.\n     - This does not match the described method, as the Company projects the account balance and death benefits, not just using a simple average of deposits.\n   - **Option F**: By increasing withdrawal charges over time.\n     -"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 128000, "result": 1.0, "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?", "options": {"A": "Immediate market approval for products", "B": "Increased research funding", "C": "Extended, delayed, or terminated clinical trials", "D": "Expansion of the organizational workforce", "E": "Higher stock market valuation", "F": "More partnerships with external organizations"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 128000, "result": 1.0, "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?", "options": {"A": "As part of ongoing operating expenses", "B": "As extraordinary items", "C": "Under liabilities subject to compromise", "D": "In a separate section as Reorganization items, net", "E": "As a footnote disclosure only", "F": "Combined with realized gains and losses"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 128000, "result": 1.0, "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?", "options": {"A": "Approval from state regulatory commissions", "B": "Approval from the Federal Energy Regulatory Commission", "C": "Prior authorization of the PUCO", "D": "Meeting tangible net worth requirements", "E": "Approval from the Duke Energy board", "F": "Retention of minimum working capital"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 128000, "result": 1.0, "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?", "options": {"A": "The deficiency is recognized as a capital gain.", "B": "A new investment strategy is implemented.", "C": "The deficiency is considered due to credit loss and recognized in earnings.", "D": "A penalty is imposed on the financial institution.", "E": "The loan agreement is renegotiated.", "F": "An automatic increase in interest rate is applied."}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 128000, "result": 1.0, "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?", "options": {"A": "Conduct annual cybersecurity audits", "B": "Formally report material cybersecurity incidents", "C": "Hire a dedicated cybersecurity officer", "D": "Implement a company-wide cybersecurity training program", "E": "Encrypt all data and communications", "F": "Report cybersecurity budgets annually"}, "LLM_original_answer": ["The provided document does not contain any information about the SEC's new cybersecurity rule. Therefore, I cannot determine the correct answer to the question \"What is the new cybersecurity rule adopted by the SEC primarily require companies to do?\" based on the information given in the document.\n\nHowever, based on general knowledge, the SEC's new cybersecurity rule, which was adopted in 2023, primarily requires companies to formally report material cybersecurity incidents. This aligns with option B: \"Formally report material cybersecurity incidents.\"\n\nTo provide a step-by-step reasoning:\n\n1. **Review the Document**: The document primarily discusses Nurix Therapeutics, its business, drug development, collaborations, and financials. It does not mention any SEC cybersecurity rules.\n\n2. **General Knowledge**: The SEC adopted a new cybersecurity rule in 2023 that requires public companies to report material cybersecurity incidents. This rule is designed to enhance transparency and provide investors with timely and accurate information about cybersecurity risks and incidents.\n\n3. **Match with Options**: Among the given options, B: \"Formally report material cybersecurity incidents\" is the most accurate description of the SEC's new cybersecurity rule.\n\nTherefore, the answer is:\n**B: Formally report material cybersecurity incidents**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 128000, "result": 1.0, "question": "Which document was filed on May 23, 2023?", "options": {"A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021", "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020", "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021", "D": "Registrant\u2019s Form 8-K", "E": "Registrant's statement of changes in beneficial ownership", "F": "Registrant's proxy statement"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 50, "token_lengths": 128000, "result": 1.0, "question": "What penalty does the GDPR allow data protection authorities to impose for violations?", "options": {"A": "Suspension of business operations", "B": "Revocation of data processing licenses", "C": "Fines up to \u20ac20 million or 4% of annual global revenues", "D": "Mandatory public apology", "E": "Mandatory cybersecurity audits only", "F": "Compulsory staff retraining programs"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 50, "token_lengths": 128000, "result": 1.0, "question": "What could be a consequence of failing to comply with laws governing international business practices?", "options": {"A": "Immediate dissolution of the business", "B": "Substantial civil and criminal penalties", "C": "Automatic approval for business expansion", "D": "Tax incentives and holidays", "E": "Increased development of new products", "F": "Reduction in employee numbers"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 128000, "result": 0.0, "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?", "options": {"A": "$2.0 billion", "B": "$19.0 billion", "C": "$1.6 billion", "D": "$22.6 billion", "E": "$8.4 billion", "F": "$270 million"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "B"}, {"depth": 50, "token_lengths": 128000, "result": 1.0, "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?", "options": {"A": "By adding a fixed percentage to the policyholder account balance", "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract", "C": "By charging a surrender fee immediately upon issuance", "D": "By applying a uniform rate to all existing liabilities", "E": "By using a simple average of all deposits", "F": "By increasing withdrawal charges over time"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 55, "token_lengths": 8000, "result": 1.0, "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?", "options": {"A": "Value-added tax", "B": "Excise tax", "C": "Income tax", "D": "Minimum tax", "E": "Sales tax", "F": "Capital gains tax"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step:\n\n1. **Identify the relevant section**: The document mentions the IRA (Inflation Reduction Act) and its impact on corporate taxation. The relevant section is:\n   > \"For example, the IRA includes provisions that will impact the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that would be imposed on the corporation repurchasing such stock.\"\n\n2. **Extract the key information**:\n   - The IRA imposes a minimum tax on the book income of certain large corporations.\n   - It also imposes an excise tax on certain corporate stock repurchases.\n\n3. **Match the information to the options**:\n   - **Option A: Value-added tax** - Not mentioned in the context of the IRA.\n   - **Option B: Excise tax** - Mentioned, but specifically in the context of corporate stock repurchases, not book income.\n   - **Option C: Income tax** - The minimum tax on book income is a form of income tax.\n   - **Option D: Minimum tax** - This is the most specific and accurate match, as the document explicitly states that the IRA imposes a minimum tax on the book income of certain large corporations.\n   - **Option E: Sales tax** - Not mentioned in the context of the IRA.\n   - **Option F: Capital gains tax** - Not mentioned in the context of the IRA.\n\n4. **Conclusion**:\n   - The correct answer is **Option D: Minimum tax**. The IRA imposes a minimum tax on the book income of certain large corporations, as stated in the document.\n\nTherefore, the answer to the question \"What type of tax is imposed on certain large corporations' book income according to the IRA?\" is **D: Minimum tax**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 8000, "result": 1.0, "question": "What change was made to the Mass Mutual Barings loans in August 2022?", "options": {"A": "The interest rate was increased to 12%.", "B": "The loan term was extended by 12 months.", "C": "Principal payments were deferred for six months.", "D": "The interest was capitalized into the principal.", "E": "The loans were converted into equity.", "F": "The loans were forgiven entirely."}, "LLM_original_answer": ["To answer the question \"What change was made to the Mass Mutual Barings loans in August 2022?\", I will carefully review the provided document and extract the relevant information.\n\n1. **Identify the relevant section**: The document mentions the Mass Mutual Barings loans in the \"Notes Payable\" section.\n\n2. **Locate the specific change**: The document states:\n   > \"In August 2022, the Company amended the Mass Mutual Barings loans to defer principal payments for a period of six months beginning with payments due in August 2022. The amendments result in no change to the term of the loans and the remaining principal will amortize over the remaining life of the loans beginning in February 2023. The amendments also require an additional amount of blockchain computing equipment to be provided as collateral. Interest expense on the amended loans has been recognized based on an effective interest rate of 13.0%.\"\n\n3. **Match the change to the options**:\n   - **Option A**: The interest rate was increased to 12%. (The document mentions an effective interest rate of 13.0%, but this is not the primary change.)\n   - **Option B**: The loan term was extended by 12 months. (The document explicitly states that the term of the loans did not change.)\n   - **Option C**: Principal payments were deferred for six months. (This matches the information in the document.)\n   - **Option D**: The interest was capitalized into the principal. (The document does not mention this.)\n   - **Option E**: The loans were converted into equity. (The document does not mention this.)\n   - **Option F**: The loans were forgiven entirely. (The document does not mention this.)\n\n4. **Conclusion**: The change made to the Mass Mutual Barings loans in August 2022 was to defer principal payments for a period of six months.\n\nTherefore, the correct answer is **Option C: Principal payments were deferred for six months**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 8000, "result": 1.0, "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?", "options": {"A": "January 2024", "B": "December 2024", "C": "January 2025", "D": "January 2026", "E": "December 2026", "F": "January 2027"}, "LLM_original_answer": ["To answer the question \"When is Duke Energy Florida's new three-year rate plan expected to begin?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions Duke Energy Florida's rate plans in the \"2024 Florida Rate Case\" section.\n\n2. **Extract the key information**: The section states:\n   - \"Duke Energy Florida intends to propose a three-year rate plan that would begin in January 2025, once its current base rate settlement agreement concludes at the end of 2024.\"\n\n3. **Match the information to the options**:\n   - The document clearly indicates that the new three-year rate plan is expected to begin in January 2025.\n\n4. **Select the correct answer**:\n   - The correct answer is **C: January 2025**.\n\nTherefore, the answer to the question is **C: January 2025**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 8000, "result": 1.0, "question": "How is revenue from administrative and management activities recognized?", "options": {"A": "As soon as the service contract is signed", "B": "Once services are rendered in full", "C": "When fees are prorated over a twelve-month period", "D": "As performance obligations are satisfied", "E": "When derivative instruments reach fair value", "F": "Upon evaluation of hedge transaction effectiveness"}, "LLM_original_answer": ["To answer the question \"How is revenue from administrative and management activities recognized?\" based on the provided document, I will analyze the relevant section and think through the options step by step.\n\n### Relevant Section from the Document:\n**Trust Operations**\n- The Bank is a full-service trust company that provides a wide range of trust services to customers that includes managing customer investments, safekeeping customer assets, supplying disbursement services, and providing other fiduciary services.\n- Trust assets held in a fiduciary or agency capacity for customers are not included in the accompanying Consolidated Balance Sheets as they are not assets of the Company.\n- The fees charged are variable based on various factors such as the Company\u2019s responsibility, the type of account, and account size.\n- Customers are also charged a base fee which is prorated over a twelve-month period.\n- Fees for additional or special services are generally fixed in nature and are charged as services are rendered.\n- **Revenue from administrative and management activities associated with these assets is recognized as performance obligations of underlying agreements are satisfied.**\n\n### Step-by-Step Analysis:\n1. **Option A: As soon as the service contract is signed**\n   - This option suggests that revenue is recognized immediately upon signing the contract. However, the document states that revenue is recognized as performance obligations are satisfied, not just upon signing the contract.\n\n2. **Option B: Once services are rendered in full**\n   - This option suggests that revenue is recognized only after all services are completed. The document does not specify that revenue is recognized only after full service completion, but rather as performance obligations are satisfied, which can occur incrementally.\n\n3. **Option C: When fees are prorated over a twelve-month period**\n   - This option is specific to the base fee, which is prorated over a twelve-month period. However, the document mentions that revenue from administrative and management activities is recognized based on performance obligations, not just the prorated base fee.\n\n4. **Option D: As performance obligations are satisfied**\n   - This option directly matches the statement in the document: \"Revenue from administrative and management activities associated with these assets is recognized as performance obligations of underlying agreements are satisfied.\"\n\n5. **Option E: When derivative instruments reach fair value**\n   - This option is related to derivative financial instruments, not administrative and management activities. The document clearly separates the accounting for derivatives from the revenue recognition for trust operations.\n\n6. **Option F: Upon evaluation of hedge transaction effectiveness**\n   - This option is related to the evaluation of"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 8000, "result": 1.0, "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?", "options": {"A": "Increase in market price", "B": "Improvement in company reputation", "C": "Expansion of company operations", "D": "Reduction in market price", "E": "Increase in dividend payouts", "F": "Stabilization of trading volume"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document and think through the potential effects of the public market's perception that a large number of shares might be sold.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Information:**\n   - The document mentions that \"Sales of a substantial number of shares of our common stock in the public market could occur at any time.\"\n   - It also states, \"If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.\"\n   - Additionally, it notes, \"Future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options or vesting and settlement of outstanding restricted stock units, or the perception that such sales may occur, could adversely affect the market price of our common stock.\"\n\n2. **Understand the Context:**\n   - The context here is the impact of the perception of large-scale share sales on the market price of the company's stock.\n   - The document explicitly links the perception of large-scale share sales to a potential decline in the market price.\n\n3. **Evaluate the Options:**\n   - **A: Increase in market price** - This is contrary to the information provided in the document.\n   - **B: Improvement in company reputation** - The document does not suggest that the perception of large-scale share sales would improve the company's reputation.\n   - **C: Expansion of company operations** - The document does not indicate that the perception of large-scale share sales would lead to expansion.\n   - **D: Reduction in market price** - This aligns with the information provided in the document.\n   - **E: Increase in dividend payouts** - The document does not mention any relationship between the perception of large-scale share sales and dividend payouts.\n   - **F: Stabilization of trading volume** - The document does not suggest that the perception of large-scale share sales would stabilize trading volume.\n\n4. **Conclusion:**\n   - Based on the information provided, the most logical and supported effect of the public market's perception that a large number of shares might be sold is a reduction in the market price of the stock.\n\n### Final Answer:\n**D: Reduction in market price**"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 8000, "result": 1.0, "question": "Where are the fair value gains and losses of financial liabilities reported?", "options": {"A": "Within Pledged MSR liability expense in the consolidated statements of operations", "B": "As financing activity in the consolidated statements of cash flows", "C": "Within MSR valuation adjustments, net in the consolidated statements of operations", "D": "Only in the footnotes of the financial report", "E": "As part of the equity section on the balance sheet", "F": "Within the depreciation accounts in the income statement"}, "LLM_original_answer": ["To answer the question \"Where are the fair value gains and losses of financial liabilities reported?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document discusses various financial instruments and their accounting treatments. The section that is most relevant to financial liabilities and their fair value adjustments is \"Other Financing Liabilities and Pledged MSR Liability Expense.\"\n\n2. **Analyze the content of the relevant section**:\n   - The section mentions that when a transaction does not achieve sale treatment, the proceeds received and a corresponding liability (Pledged MSR liability) are recognized.\n   - It states that fair value gains and losses of the Pledged MSR liability are reported within \"MSR valuation adjustments, net\" in the consolidated statements of operations.\n\n3. **Match the information to the options**:\n   - **Option A**: Within Pledged MSR liability expense in the consolidated statements of operations. This option is not correct because the document specifies that fair value gains and losses are reported within \"MSR valuation adjustments, net,\" not \"Pledged MSR liability expense.\"\n   - **Option B**: As financing activity in the consolidated statements of cash flows. This option is not correct because the document specifies that fair value gains and losses are reported in the consolidated statements of operations, not in the cash flows.\n   - **Option C**: Within MSR valuation adjustments, net in the consolidated statements of operations. This option matches the information provided in the document.\n   - **Option D**: Only in the footnotes of the financial report. This option is not correct because the document specifies that fair value gains and losses are reported in the consolidated statements of operations.\n   - **Option E**: As part of the equity section on the balance sheet. This option is not correct because the document specifies that fair value gains and losses are reported in the consolidated statements of operations.\n   - **Option F**: Within the depreciation accounts in the income statement. This option is not correct because the document specifies that fair value gains and losses are reported in the consolidated statements of operations, not in depreciation accounts.\n\n4. **Conclusion**:\n   - The correct answer is **Option C**: Within MSR valuation adjustments, net in the consolidated statements of operations.\n\nTherefore, the fair value gains and losses of financial liabilities are reported within MSR valuation adjustments, net in the consolidated statements of operations."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 8000, "result": 1.0, "question": "What is one potential outcome of post-grant review proceedings on a patent?", "options": {"A": "Automatic extension of the patent term", "B": "Increased market value for the patent holder", "C": "Invalidation of the patent", "D": "Requirement to share technology with competitors", "E": "Guaranteed protection against all legal challenges", "F": "Immediate royalty payments to the inventor"}, "LLM_original_answer": ["To answer the question \"What is one potential outcome of post-grant review proceedings on a patent?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Understanding Post-Grant Review Proceedings**:\n   - The document mentions that post-grant review proceedings, such as inter partes review and post-grant review, are available for any interested third party to challenge the patentability of claims in any patents issued to the company or its licensors.\n   - These proceedings can be used to challenge the validity, enforceability, or scope of a patent.\n\n2. **Potential Outcomes of Post-Grant Review Proceedings**:\n   - The document states that these proceedings can result in the patent being \"narrowed, invalidated, or held unenforceable.\"\n   - It also mentions that these proceedings can be costly and time-consuming, even if the eventual outcome is favorable to the company.\n\n3. **Evaluating the Options**:\n   - **A: Automatic extension of the patent term** - The document does not mention any automatic extension of the patent term as a result of post-grant review proceedings.\n   - **B: Increased market value for the patent holder** - The document does not suggest that post-grant review proceedings would increase the market value for the patent holder. In fact, it suggests the opposite, as challenges can reduce the value of the patent.\n   - **C: Invalidation of the patent** - The document explicitly mentions that post-grant review proceedings can lead to the invalidation of a patent.\n   - **D: Requirement to share technology with competitors** - The document does not mention that post-grant review proceedings would require the patent holder to share technology with competitors.\n   - **E: Guaranteed protection against all legal challenges** - The document clearly states that the issuance or grant of a patent is not conclusive as to its validity or enforceability, and patents can be challenged and invalidated.\n   - **F: Immediate royalty payments to the inventor** - The document does not mention immediate royalty payments to the inventor as a result of post-grant review proceedings.\n\n4. **Conclusion**:\n   - Based on the information provided in the document, the most accurate and relevant option is **C: Invalidation of the patent**.\n\nTherefore, the answer to the question is **C: Invalidation of the patent**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 8000, "result": 1.0, "question": "What strategy might competitors use to market generic versions of approved products?", "options": {"A": "Develop entirely new technologies", "B": "Submit an NDA for new products", "C": "Apply for approval through a PMA", "D": "Submit ANDAs to the FDA claiming patents are invalid", "E": "Enter into partnerships with patent holders", "F": "Focus on international markets"}, "LLM_original_answer": ["To answer the question \"What strategy might competitors use to market generic versions of approved products?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Understanding the Context**:\n   - The document discusses the challenges and risks associated with the development, manufacturing, and commercialization of AMX0035, a proprietary product candidate.\n   - It emphasizes the importance of patent protection and the potential for competitors to challenge or circumvent these patents.\n\n2. **Identifying Competitor Strategies**:\n   - The document mentions that competitors may seek to market generic versions of approved products.\n   - It specifically states: \"Alternatively, our competitors may seek to market generic versions of any approved products by submitting ANDAs to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable or not infringed.\"\n\n3. **Analyzing the Options**:\n   - **Option A: Develop entirely new technologies** - This is not mentioned as a strategy for marketing generic versions of approved products.\n   - **Option B: Submit an NDA for new products** - This is not relevant to marketing generic versions of approved products.\n   - **Option C: Apply for approval through a PMA** - This is not relevant to marketing generic versions of approved products.\n   - **Option D: Submit ANDAs to the FDA claiming patents are invalid** - This is explicitly mentioned in the document as a strategy competitors might use.\n   - **Option E: Enter into partnerships with patent holders** - This is not mentioned as a strategy for marketing generic versions of approved products.\n   - **Option F: Focus on international markets** - While the document discusses international regulatory challenges, it does not mention this as a specific strategy for marketing generic versions of approved products.\n\n4. **Conclusion**:\n   - The document clearly states that competitors may submit ANDAs to the FDA, claiming that the patents are invalid, unenforceable, or not infringed. This is a direct and relevant strategy for marketing generic versions of approved products.\n\nTherefore, the correct answer is **D: Submit ANDAs to the FDA claiming patents are invalid, unenforceable or not infringed**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 8000, "result": 1.0, "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?", "options": {"A": "Internal financial reports", "B": "Market analysis from competitors", "C": "Assistance of third-party valuation specialists", "D": "Future expected sales", "E": "Executive estimates", "F": "Employee surveys"}, "LLM_original_answer": ["To answer the question \"What is used to determine the value of identifiable intangibles acquired in an acquisition?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the Context**:\n   - The document discusses the audit of Intercontinental Exchange, Inc. and its acquisition of Black Knight, Inc.\n   - It specifically mentions the valuation of intangible assets in the context of business combinations.\n\n2. **Locate the Relevant Section**:\n   - The section \"Accounting for Business Combinations\" is the most relevant to the question.\n   - It states: \"This transaction was accounted for as a business combination. Auditing the Company's accounting for its acquisition of Black Knight was complex due to the significant estimation in the Company\u2019s determination of fair value of identified intangible assets of $4.9 billion, which principally consisted of customer relationships, trademark/tradenames, developed technology, data and databases and in-process research and development (collectively referred to as the identified intangibles).\"\n\n3. **Examine the Valuation Process**:\n   - The document mentions that the valuation of these intangibles involves significant estimation and assumptions.\n   - It states: \"The significant estimation was primarily due to sensitivity of the fair value to underlying assumptions about future performance of the acquired business in the Company\u2019s discounted cash flow models used to measure the identified intangibles.\"\n   - Further, it details: \"We involved our valuation specialists to assist with our assessment of the appropriateness of the valuation methodology applied by the Company and significant assumptions included in the fair value estimate, including testing the revenue and margin growth rates that form the basis of the forecasted results and the discount rate.\"\n\n4. **Determine the Key Method**:\n   - The document clearly indicates that third-party valuation specialists were involved in the valuation process.\n   - It also mentions that the valuation methodology used by the company was evaluated and tested by these specialists.\n\n5. **Match the Information to the Options**:\n   - Option A: Internal financial reports - The document does not mention internal financial reports as the primary method for determining the value of intangibles.\n   - Option B: Market analysis from competitors - The document does not mention market analysis from competitors.\n   - Option C: Assistance of third-party valuation specialists - This matches the information provided in the document.\n   - Option D: Future expected sales - While future expected sales are part of the assumptions, they are not the primary method.\n   - Option E: Executive"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 8000, "result": 1.0, "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?", "options": {"A": "Changes in depreciation methods for tax purposes", "B": "Balances of and changes in LFPBs and MRBs", "C": "Introduction of new revenue recognition policies", "D": "Adjustments in stock equity options", "E": "Changes in executive compensation structures", "F": "Updates in marketing expenses"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step to identify the specific changes addressed in the tables for January 1, 2021, regarding the adoption of ASU 2018-12.\n\n### Step 1: Identify the relevant section\nThe relevant section in the document is \"2. ASU 2018-12 Transition,\" which discusses the adoption of ASU 2018-12 and its impact on the financial statements.\n\n### Step 2: Review the changes mentioned\nThe document outlines several changes that were made as part of the adoption of ASU 2018-12:\n\n1. **Guaranteed benefits associated with variable annuity and certain fixed annuity contracts**:\n   - These benefits are now classified and presented separately on the consolidated balance sheets as MRBs (Market Risk Benefits).\n   - MRBs are measured at estimated fair value through net income, except for nonperformance risk changes, which are recognized in OCI (Other Comprehensive Income).\n\n2. **Cash flow assumptions for LFPBs (Liabilities for Future Policy Benefits)**:\n   - Cash flow assumptions used to measure LFPBs on traditional long-duration contracts (including term and non-participating whole life insurance and immediate annuities) are updated annually using a retrospective method.\n   - The resulting remeasurement gain or loss is reported separately on the consolidated statements of operations.\n\n3. **Discount rate assumption**:\n   - The discount rate assumption used to measure the liability for traditional long-duration contracts is now based on an upper-medium grade fixed income yield, updated quarterly, with changes recognized in OCI.\n\n4. **DAC (Deferred Acquisition Costs) amortization**:\n   - DAC for all insurance products is required to be amortized on a constant-level basis over the expected term of the contracts, using amortization methods that are not a function of revenue or profit emergence.\n   - Changes in assumptions used to amortize DAC are recognized as a revision to future amortization amounts.\n\n### Step 3: Identify the specific changes in the tables\nThe document mentions that the balances of and changes in LFPBs and MRBs were affected by the adoption of ASU 2018-12. Specifically:\n\n- **LFPBs**:\n  - The document states that the balances of and changes in LFPBs at January 1, 2021, due to the adoption of ASU 2018-12 are presented in a"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 55, "token_lengths": 16000, "result": 1.0, "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?", "options": {"A": "Value-added tax", "B": "Excise tax", "C": "Income tax", "D": "Minimum tax", "E": "Sales tax", "F": "Capital gains tax"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant information in the document**: The document mentions the IRA (Inflation Reduction Act) and its impact on corporate taxation, specifically noting the imposition of a minimum tax on the book income of certain large corporations.\n\n2. **Match the information to the options provided**:\n   - **A: Value-added tax**: This is not mentioned in the document.\n   - **B: Excise tax**: This is not mentioned in the document.\n   - **C: Income tax**: The document mentions \"imposing a minimum tax on the book income of certain large corporations,\" which is a form of income tax.\n   - **D: Minimum tax**: This is explicitly mentioned in the document.\n   - **E: Sales tax**: This is not mentioned in the document.\n   - **F: Capital gains tax**: This is not mentioned in the document.\n\n3. **Determine the most accurate answer**:\n   - The document clearly states that the IRA includes provisions that will impact the U.S. federal income taxation of corporations, specifically by \"imposing a minimum tax on the book income of certain large corporations.\"\n   - The term \"minimum tax\" is directly mentioned, which aligns with option D.\n\nTherefore, the correct answer is **D: Minimum tax**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 16000, "result": 1.0, "question": "What change was made to the Mass Mutual Barings loans in August 2022?", "options": {"A": "The interest rate was increased to 12%.", "B": "The loan term was extended by 12 months.", "C": "Principal payments were deferred for six months.", "D": "The interest was capitalized into the principal.", "E": "The loans were converted into equity.", "F": "The loans were forgiven entirely."}, "LLM_original_answer": ["To answer the question \"What change was made to the Mass Mutual Barings loans in August 2022?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the Mass Mutual Barings loans in the \"Notes Payable\" section.\n\n2. **Locate the specific change**: The document states, \"In August 2022, the Company amended the Mass Mutual Barings loans to defer principal payments for a period of six months beginning with payments due in August 2022.\"\n\n3. **Match the change to the options**:\n   - **Option A**: The interest rate was increased to 12%. (Not mentioned)\n   - **Option B**: The loan term was extended by 12 months. (Not mentioned)\n   - **Option C**: Principal payments were deferred for six months. (This matches the document)\n   - **Option D**: The interest was capitalized into the principal. (Not mentioned)\n   - **Option E**: The loans were converted into equity. (Not mentioned)\n   - **Option F**: The loans were forgiven entirely. (Not mentioned)\n\n4. **Conclusion**: The change made to the Mass Mutual Barings loans in August 2022 was to defer principal payments for six months.\n\nTherefore, the correct answer is **Option C: Principal payments were deferred for six months**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 16000, "result": 1.0, "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?", "options": {"A": "January 2024", "B": "December 2024", "C": "January 2025", "D": "January 2026", "E": "December 2026", "F": "January 2027"}, "LLM_original_answer": ["To answer the question \"When is Duke Energy Florida's new three-year rate plan expected to begin?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions Duke Energy Florida's rate plans in the \"2024 Florida Rate Case\" section.\n\n2. **Extract the key information**: The relevant paragraph states:\n   - \"Duke Energy Florida intends to propose a three-year rate plan that would begin in January 2025, once its current base rate settlement agreement concludes at the end of 2024.\"\n\n3. **Match the information to the options**:\n   - The document clearly indicates that the new three-year rate plan is expected to begin in January 2025.\n\n4. **Select the correct option**:\n   - The correct option is C: January 2025.\n\nTherefore, the answer to the question is **C: January 2025**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 16000, "result": 1.0, "question": "How is revenue from administrative and management activities recognized?", "options": {"A": "As soon as the service contract is signed", "B": "Once services are rendered in full", "C": "When fees are prorated over a twelve-month period", "D": "As performance obligations are satisfied", "E": "When derivative instruments reach fair value", "F": "Upon evaluation of hedge transaction effectiveness"}, "LLM_original_answer": ["To answer the question \"How is revenue from administrative and management activities recognized?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Section**: The document contains a section titled \"Trust Operations\" which discusses the revenue recognition for trust services, including administrative and management activities.\n\n2. **Extract Key Information**: From the \"Trust Operations\" section, the following key information is relevant:\n   - **Fees Charged**: The fees charged for trust services are variable based on various factors such as the Company\u2019s responsibility, the type of account, and account size.\n   - **Base Fee**: A base fee is prorated over a twelve-month period.\n   - **Additional or Special Services**: Fees for additional or special services are generally fixed and are charged as services are rendered.\n   - **Revenue Recognition**: Revenue from administrative and management activities associated with these assets is recognized as performance obligations of underlying agreements are satisfied.\n\n3. **Match Information to Options**:\n   - **Option A**: As soon as the service contract is signed. This is not supported by the document.\n   - **Option B**: Once services are rendered in full. This is not explicitly stated in the document.\n   - **Option C**: When fees are prorated over a twelve-month period. This is partially correct for the base fee but not for all administrative and management activities.\n   - **Option D**: As performance obligations are satisfied. This is explicitly stated in the document.\n   - **Option E**: When derivative instruments reach fair value. This is not relevant to administrative and management activities.\n   - **Option F**: Upon evaluation of hedge transaction effectiveness. This is not relevant to administrative and management activities.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **Option D: As performance obligations are satisfied**.\n\nTherefore, the revenue from administrative and management activities is recognized as performance obligations of underlying agreements are satisfied."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 16000, "result": 1.0, "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?", "options": {"A": "Increase in market price", "B": "Improvement in company reputation", "C": "Expansion of company operations", "D": "Reduction in market price", "E": "Increase in dividend payouts", "F": "Stabilization of trading volume"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the relevant information that pertains to the potential effects of the public market's perception that a large number of shares might be sold.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document discusses various factors that can influence the stock price and market perception.\n   - Specifically, the section \"Risks Related to Our Common Stock\" provides insights into how the market perceives large sales of shares.\n\n2. **Extract Key Information:**\n   - **Section 98:**\n     - \"A sale of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.\"\n     - \"We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock.\"\n     - \"However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options or vesting and settlement of outstanding restricted stock units, or the perception that such sales may occur, could adversely affect the market price of our common stock.\"\n\n3. **Evaluate the Options:**\n   - **A: Increase in market price** - The document does not suggest that a large number of shares being sold would increase the market price. In fact, it suggests the opposite.\n   - **B: Improvement in company reputation** - The document does not mention that selling a large number of shares would improve the company's reputation.\n   - **C: Expansion of company operations** - The document does not indicate that selling a large number of shares would directly lead to the expansion of company operations.\n   - **D: Reduction in market price** - The document explicitly states that the market price of our common stock could decline significantly if a large number of shares are sold or perceived to be sold.\n   - **E: Increase in dividend payouts** - The document mentions that the company does not anticipate paying any cash dividends in the foreseeable future, so this is not a relevant effect.\n   - **F: Stabilization of trading volume** - The document does not suggest that selling a large number of shares would stabilize trading volume; it implies that such sales could cause fluctuations.\n\n### Conclusion:\nBased on the information provided"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 16000, "result": 1.0, "question": "Where are the fair value gains and losses of financial liabilities reported?", "options": {"A": "Within Pledged MSR liability expense in the consolidated statements of operations", "B": "As financing activity in the consolidated statements of cash flows", "C": "Within MSR valuation adjustments, net in the consolidated statements of operations", "D": "Only in the footnotes of the financial report", "E": "As part of the equity section on the balance sheet", "F": "Within the depreciation accounts in the income statement"}, "LLM_original_answer": ["To answer the question \"Where are the fair value gains and losses of financial liabilities reported?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains detailed information about the company's financial statements and accounting policies. The section that discusses the reporting of fair value gains and losses is likely to be found in the \"Significant Accounting Policies\" or \"Notes to Consolidated Financial Statements.\"\n\n2. **Locate the specific policy for financial liabilities**: Within the \"Significant Accounting Policies\" section, I will look for the policy that specifically addresses the accounting for financial liabilities, particularly those measured at fair value.\n\n3. **Determine the reporting line item**: Once I find the relevant policy, I will identify where the fair value gains and losses for these financial liabilities are reported in the financial statements.\n\n### Step-by-Step Analysis:\n\n1. **Identify the relevant section**:\n   - The document provides a detailed \"Significant Accounting Policies\" section, which includes various accounting treatments and policies.\n\n2. **Locate the specific policy for financial liabilities**:\n   - In the \"Other Financing Liabilities and Pledged MSR Liability Expense\" section, it states:\n     > \"In the case of a sale of MSRs accounted for as a secured financing where we retain the right to subservice, no gain or loss is generally recognized on the transfer. A gain or loss may be recognized to the extent the estimated fair value of the pledged MSR liability differs from the total proceeds of the MSR transfer. If the criteria for MSR sale recognition are not met, the servicing fee collected on behalf of MSR transferee and related ancillary income remain reported within Servicing and subservicing fees. **Servicing fee remittance, net of the subservicing fee we are entitled to, is reported within Pledged MSR liability expense in the consolidated statements of operations.**\"\n   - Additionally, in the \"Financial Instruments\u2014Credit Losses (ASC 326) Troubled Debt Restructurings and Vintage Disclosures (ASU 2022-02)\" section, it mentions:\n     > \"We report within Other financing liabilities certain financing liabilities, including certain ESS liabilities collateralized by MSR portfolios, for which we elected to measure under the fair value option. **The fair value gains and losses of these financial liabilities are reported within MSR valuation adjustments, net in the consolidated statements of operations.**\"\n\n3. **Determine the reporting line item**:\n   -"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 16000, "result": 1.0, "question": "What is one potential outcome of post-grant review proceedings on a patent?", "options": {"A": "Automatic extension of the patent term", "B": "Increased market value for the patent holder", "C": "Invalidation of the patent", "D": "Requirement to share technology with competitors", "E": "Guaranteed protection against all legal challenges", "F": "Immediate royalty payments to the inventor"}, "LLM_original_answer": ["To answer the question \"What is one potential outcome of post-grant review proceedings on a patent?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: The document discusses various aspects of patent protection, including the potential challenges and outcomes of post-grant review proceedings.\n\n2. **Locate Specific Information**: The relevant section is:\n   - \"Various post-grant review proceedings, such as inter partes review and post-grant review, are available for any interested third party to challenge the patentability of claims in any patents issued to us or our licensors. While these post-grant review proceedings have been used less frequently to invalidate biotech patents, they have been successful regarding other technologies, and these relatively new procedures are still changing, and those changes might affect future results.\"\n\n3. **Analyze the Information**: This section indicates that post-grant review proceedings can be used to challenge the validity of a patent. If a challenge is successful, the patent can be invalidated.\n\n4. **Match to the Options**: The options provided are:\n   - A: Automatic extension of the patent term\n   - B: Increased market value for the patent holder\n   - C: Invalidation of the patent\n   - D: Requirement to share technology with competitors\n   - E: Guaranteed protection against all legal challenges\n   - F: Immediate royalty payments to the inventor\n\n5. **Select the Correct Option**: Based on the information from the document, the correct answer is:\n   - **C: Invalidation of the patent**\n\n**Chain of Thoughts**:\n- The document explicitly mentions that post-grant review proceedings can be used to challenge the patentability of claims in issued patents.\n- If a challenge is successful, the patent can be invalidated.\n- None of the other options (A, B, D, E, F) are mentioned as potential outcomes of post-grant review proceedings in the document.\n\nTherefore, the correct answer is **C: Invalidation of the patent**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 16000, "result": 1.0, "question": "What strategy might competitors use to market generic versions of approved products?", "options": {"A": "Develop entirely new technologies", "B": "Submit an NDA for new products", "C": "Apply for approval through a PMA", "D": "Submit ANDAs to the FDA claiming patents are invalid", "E": "Enter into partnerships with patent holders", "F": "Focus on international markets"}, "LLM_original_answer": ["To answer the question \"What strategy might competitors use to market generic versions of approved products?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Understanding the Context**:\n   - The document discusses various aspects of the pharmaceutical industry, including regulatory compliance, clinical trials, and intellectual property (IP) protection.\n   - It mentions that competitors may seek to market generic versions of approved products.\n\n2. **Identifying Relevant Information**:\n   - The document states: \"Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products by submitting ANDAs to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable or not infringed.\"\n\n3. **Analyzing the Options**:\n   - **Option A: Develop entirely new technologies** - This is not mentioned as a strategy for marketing generic versions.\n   - **Option B: Submit an NDA for new products** - This is not a strategy for generics; it is for new, innovative products.\n   - **Option C: Apply for approval through a PMA** - This is for medical devices, not for generic drugs.\n   - **Option D: Submit ANDAs to the FDA claiming patents are invalid** - This is directly mentioned in the document as a strategy competitors might use.\n   - **Option E: Enter into partnerships with patent holders** - This is not mentioned as a strategy for generics.\n   - **Option F: Focus on international markets** - While the document discusses international operations, it does not specifically mention this as a strategy for generics.\n\n4. **Conclusion**:\n   - The document explicitly mentions that competitors may submit ANDAs to the FDA, claiming that patents are invalid, unenforceable, or not infringed. This is a clear and direct strategy for marketing generic versions of approved products.\n\nTherefore, the correct answer is **D: Submit ANDAs to the FDA claiming patents are invalid, unenforceable or not infringed**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 16000, "result": 1.0, "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?", "options": {"A": "Internal financial reports", "B": "Market analysis from competitors", "C": "Assistance of third-party valuation specialists", "D": "Future expected sales", "E": "Executive estimates", "F": "Employee surveys"}, "LLM_original_answer": ["To answer the question \"What is used to determine the value of identifiable intangibles acquired in an acquisition?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document discusses the acquisition of Black Knight, Inc. and the valuation of identifiable intangibles in this context. The relevant section is found in the \"Black Knight, Inc. Acquisition\" part of Note 3.\n\n2. **Extract key information**: The document states:\n   - \"For the identified intangible assets, the fair values have been preliminarily determined using the income and cost approaches and are partially based on inputs that are unobservable including forecasted future cash flows, revenue and margin growth rates, customer attrition rates and discount rates that require judgement and are subject to change.\"\n   - \"We have not yet obtained all of the information related to the fair value of the acquired assets and liabilities.\"\n\n3. **Analyze the information**:\n   - The document mentions that the fair values of the identified intangible assets are determined using the income and cost approaches.\n   - These approaches involve unobservable inputs such as forecasted future cash flows, revenue and margin growth rates, customer attrition rates, and discount rates.\n   - The document also notes that third-party valuation specialists are involved in the process, as indicated in the \"Critical Audit Matters\" section:\n     - \"We involved our valuation specialists to assist with our assessment of the appropriateness of the valuation methodology applied by the Company and significant assumptions included in the fair value estimate, including testing the revenue and margin growth rates that form the basis of the forecasted results and the discount rate.\"\n\n4. **Match the information to the options**:\n   - **Option A: Internal financial reports** - While internal financial reports may be used, the document does not specifically mention this as the primary method for determining the value of identifiable intangibles.\n   - **Option B: Market analysis from competitors** - The document does not mention using market analysis from competitors.\n   - **Option C: Assistance of third-party valuation specialists** - The document explicitly mentions the involvement of third-party valuation specialists in the valuation process.\n   - **Option D: Future expected sales** - While future expected sales (forecasted future cash flows) are part of the inputs, they are not the primary method but rather a component of the valuation.\n   - **Option E: Executive estimates** - The document mentions that the valuation involves judgment and assumptions, which could be considered executive estimates"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 16000, "result": 1.0, "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?", "options": {"A": "Changes in depreciation methods for tax purposes", "B": "Balances of and changes in LFPBs and MRBs", "C": "Introduction of new revenue recognition policies", "D": "Adjustments in stock equity options", "E": "Changes in executive compensation structures", "F": "Updates in marketing expenses"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step to identify the specific changes addressed in the tables for January 1, 2021, regarding the adoption of ASU 2018-12.\n\n1. **Identify the relevant section in the document:**\n   - The document mentions the adoption of ASU 2018-12 in the \"Adoption of New Accounting Pronouncements\" section and in the \"ASU 2018-12 Transition\" section.\n\n2. **Understand the context of ASU 2018-12:**\n   - ASU 2018-12, also known as LDTI (Targeted Improvements to the Accounting for Long-Duration Contracts), introduced significant changes to the measurement, presentation, and disclosure requirements for long-duration insurance contracts.\n\n3. **Locate the specific changes for January 1, 2021:**\n   - The document states that the transition date for ASU 2018-12 was January 1, 2021.\n   - The document provides detailed information on the transition adjustments in the \"ASU 2018-12 Transition\" section.\n\n4. **Analyze the transition adjustments:**\n   - **LFPBs (Liabilities for Future Policy Benefits):**\n     - The transition adjustment to retained earnings relates to instances where net premiums exceed gross premiums, resulting in LFPBs being increased to eliminate the premium deficiency.\n     - The transition adjustment to AOCI (Accumulated Other Comprehensive Income) represents the effect of the requirement to discount LFPBs based on an upper-medium grade fixed income rate and the removal of amounts previously recorded in AOCI for the effects of unrealized investment gains and losses.\n   - **MRBs (Market Risk Benefits):**\n     - The transition adjustment to AOCI relates to the cumulative effect of changes in nonperformance risk between the contract issue date and the transition date.\n     - The remaining difference between the estimated fair value and carrying amount of MRBs, excluding the amounts recorded in AOCI, was recorded as an adjustment to retained earnings.\n\n5. **Review the tables provided:**\n   - **Table 64: Balances of and changes in LFPBs at January 1, 2021 due to the adoption of ASU 2018-12.**\n   - **Table 65: Balances of and changes"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 55, "token_lengths": 32000, "result": 1.0, "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?", "options": {"A": "Value-added tax", "B": "Excise tax", "C": "Income tax", "D": "Minimum tax", "E": "Sales tax", "F": "Capital gains tax"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Relevant Section**: The document mentions the IRA (Inflation Reduction Act) and its impact on corporate taxes. The relevant section is:\n   - \"For example, the IRA includes provisions that will impact the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that would be imposed on the corporation repurchasing such stock.\"\n\n2. **Understand the Context**: The IRA introduces new tax provisions that affect corporations. Specifically, it mentions two types of taxes:\n   - A minimum tax on the book income of certain large corporations.\n   - An excise tax on certain corporate stock repurchases.\n\n3. **Match the Information to the Question**: The question asks about the type of tax imposed on certain large corporations' book income according to the IRA. From the document, it is clear that the IRA imposes a minimum tax on the book income of certain large corporations.\n\n4. **Review the Options**:\n   - A: Value-added tax\n   - B: Excise tax\n   - C: Income tax\n   - D: Minimum tax\n   - E: Sales tax\n   - F: Capital gains tax\n\n5. **Select the Correct Option**: The correct option is D: Minimum tax.\n\n**Final Answer**: D: Minimum tax\n\n**Chain of Thought**:\n- The document explicitly states that the IRA imposes a minimum tax on the book income of certain large corporations.\n- The other options (Value-added tax, Excise tax, Income tax, Sales tax, Capital gains tax) are not mentioned in the context of being imposed on large corporations' book income.\n- Therefore, the correct answer is D: Minimum tax."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 32000, "result": 1.0, "question": "What change was made to the Mass Mutual Barings loans in August 2022?", "options": {"A": "The interest rate was increased to 12%.", "B": "The loan term was extended by 12 months.", "C": "Principal payments were deferred for six months.", "D": "The interest was capitalized into the principal.", "E": "The loans were converted into equity.", "F": "The loans were forgiven entirely."}, "LLM_original_answer": ["To answer the question \"What change was made to the Mass Mutual Barings loans in August 2022?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the Mass Mutual Barings loans in the \"Notes Payable\" section.\n\n2. **Locate the specific change**: The document states, \"In August 2022, the Company amended the Mass Mutual Barings loans to defer principal payments for a period of six months beginning with payments due in August 2022.\"\n\n3. **Match the change to the options**:\n   - **Option A**: The interest rate was increased to 12%.\n   - **Option B**: The loan term was extended by 12 months.\n   - **Option C**: Principal payments were deferred for six months.\n   - **Option D**: The interest was capitalized into the principal.\n   - **Option E**: The loans were converted into equity.\n   - **Option F**: The loans were forgiven entirely.\n\n4. **Select the correct option**: The change described in the document matches **Option C**: Principal payments were deferred for six months.\n\nTherefore, the correct answer is **Option C**: Principal payments were deferred for six months."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 32000, "result": 1.0, "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?", "options": {"A": "January 2024", "B": "December 2024", "C": "January 2025", "D": "January 2026", "E": "December 2026", "F": "January 2027"}, "LLM_original_answer": ["To answer the question \"When is Duke Energy Florida's new three-year rate plan expected to begin?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss Duke Energy Florida's rate plans and any specific dates mentioned.\n2. **Extract Key Information**: Extract the key information about the rate plan and its expected start date.\n3. **Match Information to Options**: Compare the extracted information to the provided options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in the \"Duke Energy Florida\" part of the document, specifically under the \"2024 Florida Rate Case\" heading.\n\n### Step 2: Extract Key Information\nFrom the \"2024 Florida Rate Case\" section:\n- Duke Energy Florida expects to file a formal request for new base rates in April 2024.\n- Duke Energy Florida intends to propose a three-year rate plan that would begin in January 2025.\n- The plan will use the projected 12-month periods ending December 31, 2025, 2026, and 2027 as the test years.\n- Adjusted rates are to be effective with the first billing period of January 2025, 2026, and 2027, respectively.\n\n### Step 3: Match Information to Options\nThe document clearly states that Duke Energy Florida's new three-year rate plan is intended to begin in January 2025. This matches directly with option C.\n\n### Conclusion\nThe correct answer is **C: January 2025**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 32000, "result": 1.0, "question": "How is revenue from administrative and management activities recognized?", "options": {"A": "As soon as the service contract is signed", "B": "Once services are rendered in full", "C": "When fees are prorated over a twelve-month period", "D": "As performance obligations are satisfied", "E": "When derivative instruments reach fair value", "F": "Upon evaluation of hedge transaction effectiveness"}, "LLM_original_answer": ["To answer the question \"How is revenue from administrative and management activities recognized?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for sections that discuss revenue recognition, particularly for administrative and management activities.\n2. **Analyze the Information**: Determine the specific criteria or methods mentioned for recognizing such revenue.\n3. **Match to the Options**: Compare the identified criteria or methods to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant information is found in the \"Trust Operations\" section of the document:\n\n> **Trust Operations**\n> The Bank is a full-service trust company that provides a wide range of trust services to customers that includes managing customer investments, safekeeping customer assets, supplying disbursement services, and providing other fiduciary services.\n> \n> **Revenue Recognition**:\n> - The fees charged are variable based on various factors such as the Company\u2019s responsibility, the type of account, and account size.\n> - Customers are also charged a base fee which is prorated over a twelve-month period.\n> - Fees for additional or special services are generally fixed in nature and are charged as services are rendered.\n> - **Revenue from administrative and management activities associated with these assets is recognized as performance obligations of underlying agreements are satisfied.**\n\n### Step 2: Analyze the Information\nThe key phrase here is \"Revenue from administrative and management activities associated with these assets is recognized as performance obligations of underlying agreements are satisfied.\" This indicates that the revenue is recognized when the performance obligations specified in the agreements are fulfilled.\n\n### Step 3: Match to the Options\nNow, let's match this information to the given options:\n\n- **A: As soon as the service contract is signed** - This option suggests revenue recognition at the time of contract signing, which is not supported by the document.\n- **B: Once services are rendered in full** - This option suggests recognizing revenue only after all services are completed, which is not the exact method described.\n- **C: When fees are prorated over a twelve-month period** - This option is specific to the base fee and not the administrative and management activities.\n- **D: As performance obligations are satisfied** - This option directly matches the statement from the document.\n- **E: When derivative instruments reach fair value** - This option is related to derivative instruments, not administrative and management activities.\n- **F: Upon evaluation of hedge transaction effectiveness** - This option is related to hedge transactions"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 32000, "result": 1.0, "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?", "options": {"A": "Increase in market price", "B": "Improvement in company reputation", "C": "Expansion of company operations", "D": "Reduction in market price", "E": "Increase in dividend payouts", "F": "Stabilization of trading volume"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the relevant information that pertains to the potential effects of the public market's perception that a large number of shares might be sold.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document discusses various aspects of the company's operations, financials, and regulatory environment. However, the section that is most relevant to the question is the one that talks about the impact of stock sales on the market price and investor perception.\n\n2. **Extract Key Information:**\n   - **Stock Price Performance and Market Perception:**\n     - \"A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.\" (Page 98)\n     - \"If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.\" (Page 98)\n     - \"We also expect to continue incurring costs associated with operating as a public company, including significant legal, accounting, insurance, investor relations and other administrative and professional services expenses.\" (Page 108)\n\n3. **Evaluate the Options:**\n   - **A: Increase in market price** - This is not supported by the document. The document suggests that a large number of shares being sold would likely cause the market price to decline.\n   - **B: Improvement in company reputation** - The document does not mention any positive impact on company reputation from the sale of shares.\n   - **C: Expansion of company operations** - The document does not suggest that the sale of shares would directly lead to the expansion of company operations.\n   - **D: Reduction in market price** - This is directly supported by the document, which states that the sale of a substantial number of shares could cause the market price to decline.\n   - **E: Increase in dividend payouts** - The document does not mention any relationship between the sale of shares and an increase in dividend payouts.\n   - **F: Stabilization of trading volume** - The document does not suggest that the sale of shares would stabilize trading volume. In fact, it implies that such sales could cause significant fluctuations.\n\n### Conclusion:\nBased on the information provided in the document, the potential effect of the public market's perception that a large number of shares might be sold is a **reduction in market price**.\n\n**Answer: D: Reduction in"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 32000, "result": 1.0, "question": "Where are the fair value gains and losses of financial liabilities reported?", "options": {"A": "Within Pledged MSR liability expense in the consolidated statements of operations", "B": "As financing activity in the consolidated statements of cash flows", "C": "Within MSR valuation adjustments, net in the consolidated statements of operations", "D": "Only in the footnotes of the financial report", "E": "As part of the equity section on the balance sheet", "F": "Within the depreciation accounts in the income statement"}, "LLM_original_answer": ["To answer the question \"Where are the fair value gains and losses of financial liabilities reported?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant financial liabilities**: The document mentions several types of financial liabilities, including Pledged MSR liabilities, ESS financing liabilities, and HMBS-related borrowings.\n\n2. **Locate the reporting sections for these liabilities**: The document provides specific sections where the fair value gains and losses for these liabilities are reported.\n\n3. **Determine the correct option**: Compare the information from the document with the given options to find the correct answer.\n\n### Step 1: Identify the relevant financial liabilities\n- **Pledged MSR liabilities**: These are liabilities recorded in connection with MSR transfers that do not qualify for sale accounting.\n- **ESS financing liabilities**: These are liabilities related to the obligation to remit a specified percentage of future servicing fee collections on reference pools of MSRs.\n- **HMBS-related borrowings**: These are borrowings related to reverse mortgage loans held for investment.\n\n### Step 2: Locate the reporting sections for these liabilities\n- **Pledged MSR liabilities**:\n  - The document states: \"Fair value gains and losses of the Pledged MSR liability are recognized in MSR valuation adjustments, net in the consolidated statements of operations.\"\n  - See Note 8 \u2014 Other Financing Liabilities, at Fair Value.\n\n- **ESS financing liabilities**:\n  - The document states: \"Fair value gains and losses of the ESS financing liability are reported in MSR valuation adjustment, net.\"\n  - See Note 8 \u2014 Other Financing Liabilities, at Fair Value.\n\n- **HMBS-related borrowings**:\n  - The document states: \"The fair value gains and losses of the HMBS-related borrowings are included in Gain on reverse loans held for investment and HMBS-related borrowings, net in our consolidated statements of operations.\"\n  - See Note 5 \u2014 Reverse Mortgages.\n\n### Step 3: Determine the correct option\n- **Pledged MSR liabilities and ESS financing liabilities**: Both are reported in \"MSR valuation adjustments, net\" in the consolidated statements of operations.\n- **HMBS-related borrowings**: These are reported in \"Gain (loss) on reverse loans held for investment and HMBS-related borrowings, net\" in the consolidated statements of operations.\n\nGiven the options:\n- **A**: Within Pledged MSR liability expense in the consolidated statements of operations\n- **B**: As financing activity in the consolidated statements of cash flows\n- **"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 32000, "result": 1.0, "question": "What is one potential outcome of post-grant review proceedings on a patent?", "options": {"A": "Automatic extension of the patent term", "B": "Increased market value for the patent holder", "C": "Invalidation of the patent", "D": "Requirement to share technology with competitors", "E": "Guaranteed protection against all legal challenges", "F": "Immediate royalty payments to the inventor"}, "LLM_original_answer": ["To answer the question \"What is one potential outcome of post-grant review proceedings on a patent?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the Context**: The document discusses various aspects of regulatory and patent processes, including the challenges and risks associated with obtaining and maintaining patent protection.\n\n2. **Locate Relevant Information**: The document mentions post-grant review proceedings in the context of patent challenges:\n   - \"Various post-grant review proceedings, such as inter partes review and post-grant review, are available for any interested third party to challenge the patentability of claims in any patents issued to us or our licensors.\"\n   - \"An unfavorable determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, any patent rights we may obtain in the future, allow third parties to use or commercialize our technology or product candidates and compete directly with us, without payment to us (as they can now), or extinguish our ability to manufacture or commercialize product candidates without infringing third-party patent rights.\"\n\n3. **Analyze the Options**:\n   - **A: Automatic extension of the patent term** - The document does not mention any automatic extension of the patent term as a result of post-grant review proceedings.\n   - **B: Increased market value for the patent holder** - The document does not suggest that post-grant review proceedings would increase market value.\n   - **C: Invalidation of the patent** - The document explicitly states that post-grant review proceedings could result in the invalidation of a patent.\n   - **D: Requirement to share technology with competitors** - The document does not mention a requirement to share technology with competitors as a result of post-grant review proceedings.\n   - **E: Guaranteed protection against all legal challenges** - The document does not suggest that post-grant review proceedings would guarantee protection against all legal challenges.\n   - **F: Immediate royalty payments to the inventor** - The document does not mention immediate royalty payments to the inventor as a result of post-grant review proceedings.\n\n4. **Conclusion**: Based on the information provided in the document, the most accurate and relevant option is **C: Invalidation of the patent**. The document clearly states that post-grant review proceedings can result in the invalidation of a patent, which is a significant potential outcome.\n\nTherefore, the answer to the question is **C: Invalidation of the patent**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 32000, "result": 1.0, "question": "What strategy might competitors use to market generic versions of approved products?", "options": {"A": "Develop entirely new technologies", "B": "Submit an NDA for new products", "C": "Apply for approval through a PMA", "D": "Submit ANDAs to the FDA claiming patents are invalid", "E": "Enter into partnerships with patent holders", "F": "Focus on international markets"}, "LLM_original_answer": ["To answer the question \"What strategy might competitors use to market generic versions of approved products?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Understanding the Context**:\n   - The document discusses the development and commercialization of AMX0035, a product candidate for the treatment of ALS and other neurodegenerative diseases.\n   - It mentions the competitive landscape and the potential for other companies to develop and market similar or competing products.\n\n2. **Identifying Relevant Information**:\n   - The document states that competitors may develop and market generic versions of approved products.\n   - It mentions that competitors may seek to market generic versions of AMX0035 or other approved products by submitting ANDAs (Abbreviated New Drug Applications) to the FDA, claiming that the patents are invalid or not infringed.\n\n3. **Analyzing the Options**:\n   - **Option A: Develop entirely new technologies** - This is not mentioned as a strategy for marketing generic versions of approved products.\n   - **Option B: Submit an NDA for new products** - This is not a strategy for marketing generics; it is for new, original products.\n   - **Option C: Apply for approval through a PMA** - This is not relevant to generics; PMA (Premarket Approval) is for new medical devices.\n   - **Option D: Submit ANDAs to the FDA claiming patents are invalid** - This is explicitly mentioned in the document as a strategy competitors might use to market generic versions of approved products.\n   - **Option E: Enter into partnerships with patent holders** - This is not mentioned as a strategy for marketing generics; it is more about collaboration for development.\n   - **Option F: Focus on international markets** - While the document discusses international operations, it does not specifically mention this as a strategy for marketing generics.\n\n4. **Conclusion**:\n   - The document clearly states that competitors may submit ANDAs to the FDA, claiming that the patents are invalid or not infringed, as a strategy to market generic versions of approved products.\n\nTherefore, the correct answer is **Option D: Submit ANDAs to the FDA claiming patents are invalid**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 32000, "result": 1.0, "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?", "options": {"A": "Internal financial reports", "B": "Market analysis from competitors", "C": "Assistance of third-party valuation specialists", "D": "Future expected sales", "E": "Executive estimates", "F": "Employee surveys"}, "LLM_original_answer": ["To answer the question \"What is used to determine the value of identifiable intangibles acquired in an acquisition?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss the valuation of intangible assets in the context of acquisitions.\n2. **Extract Key Information**: Extract the specific methods or approaches mentioned for valuing intangibles.\n3. **Match to Options**: Compare the extracted information to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe most relevant sections are found in the \"Critical Accounting Policies\" and \"Black Knight, Inc. Acquisition\" sections.\n\n### Step 2: Extract Key Information\nFrom the \"Critical Accounting Policies\" section:\n- **Goodwill and Other Identifiable Intangible Assets**: \"Assets acquired and liabilities assumed in connection with our acquisitions are recorded at their estimated fair values. Goodwill represents the excess of the purchase price of an acquired company over the fair value of its identifiable net assets, including identified intangible assets.\"\n- **Fair Value Determination**: \"We recognize specifically-identifiable intangibles, such as customer relationships, trademarks, technology, trading products, data, exchange registrations, backlog, trade names and licenses when a specific right or contract is acquired. That value is determined with the assistance of third-party valuation specialists.\"\n\nFrom the \"Black Knight, Inc. Acquisition\" section:\n- **Preliminary Purchase Price Allocation**: \"The fair values have been preliminarily determined using the income and cost approaches and are partially based on inputs that are unobservable including forecasted future cash flows, revenue and margin growth rates, customer attrition rates and discount rates that require judgement and are subject to change.\"\n\n### Step 3: Match to Options\n- **Option A: Internal financial reports** - The document does not mention using internal financial reports specifically for valuing intangibles.\n- **Option B: Market analysis from competitors** - The document does not mention using market analysis from competitors for valuing intangibles.\n- **Option C: Assistance of third-party valuation specialists** - The document explicitly states, \"That value is determined with the assistance of third-party valuation specialists.\"\n- **Option D: Future expected sales** - While future expected sales might be a factor in the valuation, the document does not specifically mention this as the primary method.\n- **Option E: Executive estimates** - The document does not mention using executive estimates for valuing intangibles.\n- **Option F"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 32000, "result": 1.0, "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?", "options": {"A": "Changes in depreciation methods for tax purposes", "B": "Balances of and changes in LFPBs and MRBs", "C": "Introduction of new revenue recognition policies", "D": "Adjustments in stock equity options", "E": "Changes in executive compensation structures", "F": "Updates in marketing expenses"}, "LLM_original_answer": ["To answer the question, I will analyze the document step by step to identify the specific changes addressed in the tables for January 1, 2021, regarding the adoption of ASU 2018-12.\n\n### Step 1: Identify the Adoption of ASU 2018-12\nThe document mentions the adoption of ASU 2018-12, which is effective for fiscal years beginning after January 1, 2023, with a transition date of January 1, 2021. This is noted in the \"Change in Accounting Principle\" section and in Note 2, which discusses the transition adjustments.\n\n### Step 2: Review the Transition Adjustments\nNote 2 provides detailed information on the transition adjustments made due to the adoption of ASU 2018-12. Specifically, it mentions the following:\n- **LFPBs (Liabilities for Future Policy Benefits)**: The transition adjustment to retained earnings and AOCI (Accumulated Other Comprehensive Income) for LFPBs.\n- **MRBs (Market Risk Benefits)**: The transition adjustment to AOCI for MRBs.\n\n### Step 3: Analyze the Tables for LFPBs and MRBs\nThe document includes tables that show the balances and changes in LFPBs and MRBs as of January 1, 2021, due to the adoption of ASU 2018-12.\n\n#### Table for LFPBs (Note 2):\n- **Transition Adjustment to Retained Earnings**: $5.4 billion decrease.\n- **Transition Adjustment to AOCI**: $3.9 billion decrease.\n\n#### Table for MRBs (Note 2):\n- **Transition Adjustment to AOCI**: The cumulative effect of changes in nonperformance risk between contract issue date and transition date.\n- **Transition Adjustment to Retained Earnings**: The remaining difference between the estimated fair value and carrying amount of MRBs, excluding the amounts recorded in AOCI.\n\n### Step 4: Match the Information to the Options\n- **Option A**: Changes in depreciation methods for tax purposes - Not mentioned in the document.\n- **Option B**: Balances of and changes in LFPBs and MRBs - This matches the information provided in the tables.\n- **Option C**: Introduction of new revenue recognition policies - Not mentioned in the document.\n- **Option D**: Adjustments in stock equity options - Not mentioned in the document.\n- **"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 55, "token_lengths": 64000, "result": 1.0, "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?", "options": {"A": "Value-added tax", "B": "Excise tax", "C": "Income tax", "D": "Minimum tax", "E": "Sales tax", "F": "Capital gains tax"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The document mentions the Inflation Reduction Act of 2022 (IRA) in the context of healthcare legislation and its impact on the pharmaceutical industry.\n\n2. **Extract the specific information**: The relevant excerpt is:\n   - \"On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the \u201cdonut hole\u201d under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is unclear how any additional healthcare reform measures of the Biden administration will impact the ACA and our business.\"\n\n3. **Analyze the information**:\n   - The IRA includes several provisions, including extending enhanced subsidies for health insurance and eliminating the \"donut hole\" in the Medicare Part D program.\n   - One of the key provisions mentioned is the imposition of a \"manufacturer discount program\" to lower out-of-pocket costs for beneficiaries.\n   - The document also mentions that the IRA \"imposes a minimum tax on the book income of certain large corporations.\"\n\n4. **Match the information to the options**:\n   - **A: Value-added tax** - Not mentioned in the document.\n   - **B: Excise tax** - Not mentioned in the document.\n   - **C: Income tax** - The document mentions a \"minimum tax on the book income of certain large corporations,\" which is a form of income tax.\n   - **D: Minimum tax** - This is the closest match, as the document explicitly states that the IRA imposes a minimum tax on the book income of certain large corporations.\n   - **E: Sales tax** - Not mentioned in the document.\n   - **F: Capital gains tax** - Not mentioned in the document.\n\n5. **Conclusion**:\n   - The correct answer is **D: Minimum tax**. The document clearly states that the IRA imposes a minimum tax on the book income of certain large corporations.\n\nTherefore, the type of tax imposed on certain large corporations' book income according to the IRA is **D: Minimum tax**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 64000, "result": 1.0, "question": "What change was made to the Mass Mutual Barings loans in August 2022?", "options": {"A": "The interest rate was increased to 12%.", "B": "The loan term was extended by 12 months.", "C": "Principal payments were deferred for six months.", "D": "The interest was capitalized into the principal.", "E": "The loans were converted into equity.", "F": "The loans were forgiven entirely."}, "LLM_original_answer": ["To answer the question \"What change was made to the Mass Mutual Barings loans in August 2022?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the Mass Mutual Barings loans in the \"Notes Payable\" section.\n\n2. **Locate the specific change**: The document states, \"In August 2022, the Company amended the Mass Mutual Barings loans to defer principal payments for a period of six months beginning with payments due in August 2022.\"\n\n3. **Match the change to the options**:\n   - **Option A**: The interest rate was increased to 12%. (Not mentioned)\n   - **Option B**: The loan term was extended by 12 months. (Not mentioned)\n   - **Option C**: Principal payments were deferred for six months. (This matches the document)\n   - **Option D**: The interest was capitalized into the principal. (Not mentioned)\n   - **Option E**: The loans were converted into equity. (Not mentioned)\n   - **Option F**: The loans were forgiven entirely. (Not mentioned)\n\n4. **Conclusion**: The change that matches the information provided in the document is Option C: Principal payments were deferred for six months.\n\nTherefore, the correct answer is **Option C: Principal payments were deferred for six months**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 64000, "result": 1.0, "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?", "options": {"A": "January 2024", "B": "December 2024", "C": "January 2025", "D": "January 2026", "E": "December 2026", "F": "January 2027"}, "LLM_original_answer": ["To answer the question \"When is Duke Energy Florida's new three-year rate plan expected to begin?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss Duke Energy Florida's rate plans and any specific dates or timeframes mentioned.\n\n2. **Extract the Information**: Find the exact statement that provides the start date for the new rate plan.\n\n3. **Match the Information to the Options**: Compare the extracted date to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\nThe relevant section is found in the \"2024 Florida Rate Case\" part of the document:\n\n> \"In January 2024, Duke Energy Florida notified the FPSC that it expects to file a formal request for new base rates in April 2024. Duke Energy Florida intends to propose a three-year rate plan that would begin in January 2025, once its current base rate settlement agreement concludes at the end of 2024.\"\n\n### Step 2: Extract the Information\nThe key information is:\n- Duke Energy Florida expects to file a formal request for new base rates in April 2024.\n- The proposed three-year rate plan is intended to begin in January 2025.\n\n### Step 3: Match the Information to the Options\nThe options provided are:\n- A: January 2024\n- B: December 2024\n- C: January 2025\n- D: January 2026\n- E: December 2026\n- F: January 2027\n\nThe document clearly states that the new three-year rate plan is intended to begin in January 2025.\n\n### Conclusion\nThe correct answer is **C: January 2025**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 64000, "result": 0.0, "question": "How is revenue from administrative and management activities recognized?", "options": {"A": "As soon as the service contract is signed", "B": "Once services are rendered in full", "C": "When fees are prorated over a twelve-month period", "D": "As performance obligations are satisfied", "E": "When derivative instruments reach fair value", "F": "Upon evaluation of hedge transaction effectiveness"}, "LLM_original_answer": ["To answer the question \"How is revenue from administrative and management activities recognized?\" based on the provided document, I will analyze the relevant sections and extract the pertinent information.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document discusses various financial activities and accounting policies, but the specific section that addresses revenue recognition for administrative and management activities is found in the \"Trust Operations\" section.\n\n2. **Extract Key Information:**\n   - The \"Trust Operations\" section states: \"The fees charged are variable based on various factors such as the Company\u2019s responsibility, the type of account, and account size. Customers are also charged a base fee which is prorated over a twelve-month period. Fees for additional or special services are generally fixed in nature and are charged as services are rendered.\"\n\n3. **Interpret the Information:**\n   - The document mentions that the base fee is prorated over a twelve-month period.\n   - Fees for additional or special services are charged as services are rendered.\n\n4. **Match to the Options:**\n   - **Option A: As soon as the service contract is signed** - This does not match the document, which specifies that fees are prorated over a twelve-month period.\n   - **Option B: Once services are rendered in full** - This does not match the document, which specifies that fees are prorated over a twelve-month period.\n   - **Option C: When fees are prorated over a twelve-month period** - This matches the document, which states that the base fee is prorated over a twelve-month period.\n   - **Option D: As performance obligations are satisfied** - This is a general principle of revenue recognition but is not specifically mentioned in the document for administrative and management activities.\n   - **Option E: When derivative instruments reach fair value** - This is not relevant to the revenue recognition for administrative and management activities.\n   - **Option F: Upon evaluation of hedge transaction effectiveness** - This is not relevant to the revenue recognition for administrative and management activities.\n\n### Conclusion:\nThe correct answer is **Option C: When fees are prorated over a twelve-month period**. This is directly supported by the statement in the document that the base fee is prorated over a twelve-month period."], "LLM_extracted_answer": ["C"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 64000, "result": 1.0, "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?", "options": {"A": "Increase in market price", "B": "Improvement in company reputation", "C": "Expansion of company operations", "D": "Reduction in market price", "E": "Increase in dividend payouts", "F": "Stabilization of trading volume"}, "LLM_original_answer": ["To answer the question \"What is a potential effect of the public market's perception that a large number of shares might be sold?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify Relevant Information**:\n   - The document mentions that sales of a substantial number of shares in the public market could cause the market price of the common stock to decline. Specifically, it states: \"Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.\"\n\n2. **Evaluate the Options**:\n   - **A: Increase in market price** - This is not supported by the document. The document suggests that the market price could decline, not increase.\n   - **B: Improvement in company reputation** - The document does not mention any positive impact on company reputation from the perception of large share sales.\n   - **C: Expansion of company operations** - The document does not suggest that the perception of large share sales would lead to expansion of company operations.\n   - **D: Reduction in market price** - This is directly supported by the document, which states that the market price could decline significantly.\n   - **E: Increase in dividend payouts** - The document does not mention any relationship between the perception of large share sales and dividend payouts.\n   - **F: Stabilization of trading volume** - The document does not suggest that the perception of large share sales would stabilize trading volume; in fact, it implies that such sales could cause significant market fluctuations.\n\n3. **Conclusion**:\n   - Based on the information provided in the document, the most accurate and supported option is **D: Reduction in market price**.\n\nTherefore, the potential effect of the public market's perception that a large number of shares might be sold is **D: Reduction in market price**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 64000, "result": 1.0, "question": "Where are the fair value gains and losses of financial liabilities reported?", "options": {"A": "Within Pledged MSR liability expense in the consolidated statements of operations", "B": "As financing activity in the consolidated statements of cash flows", "C": "Within MSR valuation adjustments, net in the consolidated statements of operations", "D": "Only in the footnotes of the financial report", "E": "As part of the equity section on the balance sheet", "F": "Within the depreciation accounts in the income statement"}, "LLM_original_answer": ["To answer the question \"Where are the fair value gains and losses of financial liabilities reported?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant financial liabilities**: The document mentions several types of financial liabilities, including MSRs (Mortgage Servicing Rights), Pledged MSR liabilities, and ESS (Excess Servicing Spread) financing liabilities.\n\n2. **Locate the section discussing fair value changes**: The document discusses fair value changes in several sections, particularly in \"MSR Valuation Adjustments, Net\" and \"Other Financing Liabilities and Pledged MSR Liability Expense.\"\n\n3. **Determine where fair value changes are reported**: The document explicitly states where these fair value changes are reported in the financial statements.\n\n### Step-by-Step Analysis:\n\n1. **Relevant Financial Liabilities**:\n   - **MSRs**: These are carried at fair value.\n   - **Pledged MSR liabilities**: These are recorded in connection with MSR transfers that do not qualify for sale accounting.\n   - **ESS financing liabilities**: These are obligations to remit a specified percentage of future servicing fee collections.\n\n2. **Section on Fair Value Changes**:\n   - **MSR Valuation Adjustments, Net**:\n     - The document states: \"MSR valuation adjustments, net includes revaluation gains on certain MSRs opportunistically purchased through the Agency Cash Window programs, and flow purchases.\"\n     - It also mentions: \"We record such valuation adjustments as MSR valuation adjustments, net within the Originations segment since the segment\u2019s business objective is the sourcing of new MSRs at targeted returns.\"\n   - **Other Financing Liabilities and Pledged MSR Liability Expense**:\n     - The document states: \"We recognize the proceeds received in connection with MSRs transferred or sold in transactions which do not qualify for sale accounting treatment as a secured financing that we account for at fair value.\"\n     - It further mentions: \"Fair value gains and losses of the Pledged MSR liability are recognized in MSR valuation adjustments, net in the consolidated statements of operations.\"\n\n3. **Reporting of Fair Value Changes**:\n   - **MSR Valuation Adjustments, Net**:\n     - The document clearly states: \"We determine the fair value of MSRs, pledged MSR liabilities and ESS financing liabilities primarily using discounted cash flow methodologies. The significant estimated future cash inflows for MSRs include servicing fees, late fees, float earnings and other ancillary fees, and significant cash outflows include the cost of servicing, the cost of"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 64000, "result": 1.0, "question": "What is one potential outcome of post-grant review proceedings on a patent?", "options": {"A": "Automatic extension of the patent term", "B": "Increased market value for the patent holder", "C": "Invalidation of the patent", "D": "Requirement to share technology with competitors", "E": "Guaranteed protection against all legal challenges", "F": "Immediate royalty payments to the inventor"}, "LLM_original_answer": ["To answer the question \"What is one potential outcome of post-grant review proceedings on a patent?\" based on the provided document, I will analyze the relevant sections and options step by step.\n\n### Step 1: Identify Relevant Sections\nThe document mentions post-grant review proceedings in the context of patent challenges and potential outcomes. The relevant section is:\n\n> Various post-grant review proceedings, such as inter partes review and post-grant review, are available for any interested third party to challenge the patentability of claims in any patents issued to us or our licensors. While these post-grant review proceedings have been used less frequently to invalidate biotech patents, they have been successful regarding other technologies, and these relatively new procedures are still changing, and those changes might affect future results. No assurance can be given that, if challenged, any patents that we or our licensors may obtain would be declared by a court to be valid or enforceable or that, even if found valid and enforceable, a competitor\u2019s technology or product would be found by a court to infringe any such patent.\n\n### Step 2: Analyze the Options\nLet's evaluate each option in the context of the document:\n\n- **A: Automatic extension of the patent term**\n  - The document does not mention any automatic extension of the patent term as a result of post-grant review proceedings. This is not a potential outcome.\n\n- **B: Increased market value for the patent holder**\n  - The document does not suggest that post-grant review proceedings would increase the market value for the patent holder. In fact, it implies that challenges could harm the patent holder's position.\n\n- **C: Invalidation of the patent**\n  - The document explicitly mentions that post-grant review proceedings can lead to the invalidation of patents. It states, \"No assurance can be given that, if challenged, any patents that we or our licensors may obtain would be declared by a court to be valid or enforceable.\"\n\n- **D: Requirement to share technology with competitors**\n  - The document does not mention any requirement to share technology with competitors as a result of post-grant review proceedings.\n\n- **E: Guaranteed protection against all legal challenges**\n  - The document clearly states that there is no guarantee of protection against all legal challenges. It mentions the uncertainty and potential for invalidation or unenforceability.\n\n- **F: Immediate royalty payments to the inventor**\n  - The document does not mention immediate royalty payments to the inventor as a result of post-grant review proceedings.\n\n###"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 64000, "result": 1.0, "question": "What strategy might competitors use to market generic versions of approved products?", "options": {"A": "Develop entirely new technologies", "B": "Submit an NDA for new products", "C": "Apply for approval through a PMA", "D": "Submit ANDAs to the FDA claiming patents are invalid", "E": "Enter into partnerships with patent holders", "F": "Focus on international markets"}, "LLM_original_answer": ["To answer the question \"What strategy might competitors use to market generic versions of approved products?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Understanding the Context**:\n   - The document discusses the regulatory and commercial aspects of AMX0035 (RELYVRIO in the U.S. and ALBRIOZA in Canada), which is a drug for the treatment of ALS.\n   - It mentions various regulatory protections and exclusivity periods, such as NCE exclusivity, NCI exclusivity, and orphan drug exclusivity.\n\n2. **Identifying Key Regulatory Protections**:\n   - **NCE Exclusivity**: If a product does not receive five years of NCE exclusivity, the FDA may approve generic versions of such product three years after its date of approval, provided the ANDA applicant certifies to the invalidity or non-infringement of any patents listed for the product in the Orange Book.\n   - **NCI Exclusivity**: This is a three-year exclusivity period given to a drug if it contains an active moiety that has previously been approved and the NDA includes reports of new clinical investigations.\n   - **Orphan Drug Exclusivity**: AMX0035 has been granted orphan drug designation for the treatment of ALS, providing a seven-year period of exclusivity in the U.S. and a ten-year period in the EU.\n\n3. **Analyzing Competitor Strategies**:\n   - **ANDA Submissions**: The document specifically mentions that if a product does not receive NCE exclusivity, competitors can submit ANDAs to the FDA claiming that the patents are invalid or not infringed. This is a clear strategy that competitors might use to market generic versions of approved products.\n   - **Patent Challenges**: Competitors may challenge the validity of the patents to gain access to the market earlier.\n\n4. **Evaluating the Options**:\n   - **Option A: Develop entirely new technologies** - This is not a direct strategy for marketing generic versions of approved products.\n   - **Option B: Submit an NDA for new products** - This is not a strategy for generics but for new products.\n   - **Option C: Apply for approval through a PMA** - This is not relevant to generics but to medical devices.\n   - **Option D: Submit ANDAs to the FDA claiming patents are invalid** - This aligns with the information in the document about competitors submitting ANDAs to claim patent invalidity or"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 64000, "result": 1.0, "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?", "options": {"A": "Internal financial reports", "B": "Market analysis from competitors", "C": "Assistance of third-party valuation specialists", "D": "Future expected sales", "E": "Executive estimates", "F": "Employee surveys"}, "LLM_original_answer": ["The correct answer to the question \"What is used to determine the value of identifiable intangibles acquired in an acquisition?\" is:\n\n**C: Assistance of third-party valuation specialists**\n\n### Chain of Thought:\n1. **Context of the Question**: The question is asking about the method used to determine the value of identifiable intangibles in an acquisition. Identifiable intangibles include assets like customer relationships, trademarks, technology, and data.\n\n2. **Relevant Information from the Document**:\n   - The document mentions that in the context of the Black Knight acquisition, the fair values of the identified intangible assets were determined using the income and cost approaches.\n   - It specifically states: \"For the identified intangible assets, the fair values have been preliminarily determined using the income and cost approaches and are partially based on inputs that are unobservable including forecasted future cash flows, revenue and margin growth rates, customer attrition rates and discount rates that require judgement and are subject to change.\"\n   - The document also notes: \"We have not yet obtained all of the information related to the fair value of the acquired assets and liabilities.\"\n\n3. **Role of Third-Party Valuation Specialists**:\n   - The document further states: \"In performing the net preliminary purchase price allocation, we considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of the Black Knight business.\"\n   - It explicitly mentions: \"At the acquisition date, a preliminary allocation of the purchase price is recorded based upon a preliminary valuation performed with the assistance of a third-party valuation specialist.\"\n\n4. **Elimination of Other Options**:\n   - **A: Internal financial reports** - While internal financial reports might provide some data, they are not the primary method for determining the fair value of intangibles.\n   - **B: Market analysis from competitors** - Competitor analysis might provide some context but is not a direct method for valuation.\n   - **D: Future expected sales** - Future expected sales are a factor in the valuation but are not the primary method.\n   - **E: Executive estimates** - Executive estimates are part of the process but are not the primary method.\n   - **F: Employee surveys** - Employee surveys are not typically used for valuing intangibles in an acquisition.\n\n5. **Conclusion**:\n   - The document clearly indicates that third-party valuation specialists are used to assist in the determination of the fair value of identifiable intangibles. This is the most accurate"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 64000, "result": 1.0, "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?", "options": {"A": "Changes in depreciation methods for tax purposes", "B": "Balances of and changes in LFPBs and MRBs", "C": "Introduction of new revenue recognition policies", "D": "Adjustments in stock equity options", "E": "Changes in executive compensation structures", "F": "Updates in marketing expenses"}, "LLM_original_answer": ["The specific changes addressed in the tables for January 1, 2021, regarding the adoption of ASU 2018-12 (Targeted Improvements to the Accounting for Long-Duration Contracts) are related to the balances of and changes in LFPBs (Liabilities for Future Policy Benefits) and MRBs (Market Risk Benefits).\n\nTo break this down step by step:\n\n1. **Identify the Context**: The document discusses the adoption of ASU 2018-12, which is a new accounting standard for long-duration contracts. This standard became effective for the Company on January 1, 2023, but the transition date was January 1, 2021.\n\n2. **Locate Relevant Information**: The document mentions that the adoption of ASU 2018-12 resulted in significant changes to the measurement, presentation, and disclosure requirements for long-duration insurance contracts. Specifically, it states:\n   - \"Guaranteed benefits associated with variable annuity and certain fixed annuity contracts have been classified and presented separately on the consolidated balance sheets as MRBs.\"\n   - \"The balances of and changes in LFPBs at January 1, 2021 due to the adoption of ASU 2018-12 were as follows: [Table 64]\"\n   - \"The balance of and changes in liabilities classified as MRBs at January 1, 2021 due to the adoption of ASU 2018-12 were as follows: [Table 65]\"\n\n3. **Analyze the Tables**:\n   - **Table 64** (Balances of and changes in LFPBs at January 1, 2021):\n     - This table shows the adjustments made to the LFPBs as a result of the adoption of ASU 2018-12.\n   - **Table 65** (Balances of and changes in liabilities classified as MRBs at January 1, 2021):\n     - This table shows the adjustments made to the MRBs as a result of the adoption of ASU 2018-12.\n\n4. **Conclusion**: The changes in the tables for January 1, 2021, specifically address the balances of and changes in LFPBs and MRBs due to the adoption of ASU 2018-12.\n\nTherefore"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 55, "token_lengths": 96000, "result": 1.0, "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?", "options": {"A": "Value-added tax", "B": "Excise tax", "C": "Income tax", "D": "Minimum tax", "E": "Sales tax", "F": "Capital gains tax"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The document mentions the Inflation Reduction Act of 2022 (IRA) in several places. The key section for this question is found in the \"Healthcare Reform\" section.\n\n2. **Extract the relevant information**:\n   - The document states: \"The IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated 'maximum fair price' for such drugs and biologics under the law, and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation.\"\n\n3. **Analyze the information**:\n   - The IRA imposes a **minimum tax** on the book income of certain large corporations.\n   - It also imposes an **excise tax** on certain corporate stock repurchases.\n   - Additionally, it imposes **rebates** to penalize price increases that outpace inflation for certain drugs and biologics covered under Medicare Part B or Medicare Part D.\n\n4. **Match the information to the options**:\n   - **Option A: Value-added tax** - Not mentioned in the document.\n   - **Option B: Excise tax** - Mentioned, but not in the context of book income.\n   - **Option C: Income tax** - Not specifically mentioned in the context of the IRA.\n   - **Option D: Minimum tax** - The document explicitly mentions a minimum tax on the book income of certain large corporations.\n   - **Option E: Sales tax** - Not mentioned in the document.\n   - **Option F: Capital gains tax** - Not mentioned in the document.\n\n5. **Conclusion**:\n   - The correct answer is **Option D: Minimum tax**.\n\nTherefore, the type of tax imposed on certain large corporations' book income according to the IRA is a **minimum tax**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 96000, "result": 1.0, "question": "What change was made to the Mass Mutual Barings loans in August 2022?", "options": {"A": "The interest rate was increased to 12%.", "B": "The loan term was extended by 12 months.", "C": "Principal payments were deferred for six months.", "D": "The interest was capitalized into the principal.", "E": "The loans were converted into equity.", "F": "The loans were forgiven entirely."}, "LLM_original_answer": ["To answer the question, I will follow a step-by-step approach based on the provided document:\n\n1. **Identify the relevant section in the document**: The document is extensive, so I need to find the section that discusses the Mass Mutual Barings loans. This is found in Note 7 \u2014 Notes Payable, under the \"Mass Mutual Barings Loans\" subsection.\n\n2. **Extract the relevant information**: The relevant information from the \"Mass Mutual Barings Loans\" section is:\n   - \"In August 2022, the Company amended the Mass Mutual Barings loans to defer principal payments for a period of six months beginning with payments due in August 2022.\"\n   - \"The amendments result in no change to the term of the loans and the remaining principal will amortize over the remaining life of the loans beginning in February 2023.\"\n   - \"The amendments also require an additional amount of blockchain computing equipment to be provided as collateral.\"\n\n3. **Analyze the information**:\n   - The document states that the principal payments were deferred for six months starting in August 2022.\n   - The term of the loans remained unchanged.\n   - The interest rate is not mentioned as being changed.\n   - The loans were not converted into equity or forgiven.\n   - The interest was not capitalized into the principal.\n\n4. **Match the information to the given options**:\n   - **Option A**: The interest rate was increased to 12%. (Not mentioned in the document)\n   - **Option B**: The loan term was extended by 12 months. (The term remained unchanged)\n   - **Option C**: Principal payments were deferred for six months. (This matches the information in the document)\n   - **Option D**: The interest was capitalized into the principal. (Not mentioned in the document)\n   - **Option E**: The loans were converted into equity. (Not mentioned in the document)\n   - **Option F**: The loans were forgiven entirely. (Not mentioned in the document)\n\n5. **Conclusion**:\n   - The correct answer is **Option C**: Principal payments were deferred for six months.\n\nTherefore, the change made to the Mass Mutual Barings loans in August 2022 was that principal payments were deferred for six months."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 96000, "result": 1.0, "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?", "options": {"A": "January 2024", "B": "December 2024", "C": "January 2025", "D": "January 2026", "E": "December 2026", "F": "January 2027"}, "LLM_original_answer": ["To answer the question \"When is Duke Energy Florida's new three-year rate plan expected to begin?\" we need to look for specific information in the provided document that mentions Duke Energy Florida's rate plan and its expected start date.\n\nLet's break down the relevant information step by step:\n\n1. **Identify the relevant section**: The section that discusses Duke Energy Florida's rate plan is found in the \"2024 Florida Rate Case\" part of the document.\n\n2. **Extract the key information**:\n   - \"In January 2024, Duke Energy Florida notified the FPSC that it expects to file a formal request for new base rates in April 2024.\"\n   - \"Duke Energy Florida intends to propose a three-year rate plan that would begin in January 2025, once its current base rate settlement agreement concludes at the end of 2024.\"\n\n3. **Determine the start date**:\n   - The document clearly states that the new three-year rate plan is expected to begin in January 2025.\n\nTherefore, the correct answer is:\n\n**C: January 2025**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 96000, "result": 1.0, "question": "How is revenue from administrative and management activities recognized?", "options": {"A": "As soon as the service contract is signed", "B": "Once services are rendered in full", "C": "When fees are prorated over a twelve-month period", "D": "As performance obligations are satisfied", "E": "When derivative instruments reach fair value", "F": "Upon evaluation of hedge transaction effectiveness"}, "LLM_original_answer": ["To answer the question \"How is revenue from administrative and management activities recognized?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss revenue recognition, particularly for administrative and management activities.\n2. **Extract Key Information**: Extract the specific information related to revenue recognition for these activities.\n3. **Match Information to Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in Note 21, \"Revenue from Contracts with Customers,\" which discusses the revenue recognition principles for various services.\n\n### Step 2: Extract Key Information\nFrom the document:\n- \"Revenue from administrative and management activities associated with these assets is recognized as performance obligations of underlying agreements are satisfied.\"\n\n### Step 3: Match Information to Options\n- **Option A**: As soon as the service contract is signed\n  - This option suggests revenue is recognized immediately upon signing the contract, which is not consistent with the document.\n- **Option B**: Once services are rendered in full\n  - This option suggests revenue is recognized only after all services are fully rendered, which is not consistent with the document.\n- **Option C**: When fees are prorated over a twelve-month period\n  - This option suggests revenue is recognized over a fixed period, which is not consistent with the document.\n- **Option D**: As performance obligations are satisfied\n  - This option aligns with the document, which states that revenue is recognized as performance obligations are satisfied.\n- **Option E**: When derivative instruments reach fair value\n  - This option is related to financial instruments and not to administrative and management activities.\n- **Option F**: Upon evaluation of hedge transaction effectiveness\n  - This option is related to hedging and not to administrative and management activities.\n\n### Conclusion\nThe correct answer is **Option D: As performance obligations are satisfied**. This is directly supported by the statement in the document that revenue from administrative and management activities is recognized as performance obligations of underlying agreements are satisfied."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 96000, "result": 1.0, "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?", "options": {"A": "Increase in market price", "B": "Improvement in company reputation", "C": "Expansion of company operations", "D": "Reduction in market price", "E": "Increase in dividend payouts", "F": "Stabilization of trading volume"}, "LLM_original_answer": ["The provided document does not directly address the question about the potential effect of the public market's perception that a large number of shares might be sold. However, based on general financial principles and the context provided in the document, we can infer the likely effect.\n\n### Step-by-Step Analysis:\n\n1. **Understanding the Question**:\n   - The question asks about the potential effect of the public market's perception that a large number of shares might be sold.\n   - The options provided are:\n     - A: Increase in market price\n     - B: Improvement in company reputation\n     - C: Expansion of company operations\n     - D: Reduction in market price\n     - E: Increase in dividend payouts\n     - F: Stabilization of trading volume\n\n2. **General Financial Principle**:\n   - When the market perceives that a large number of shares might be sold, it often leads to a decrease in demand for those shares.\n   - A decrease in demand, with supply remaining constant or increasing, typically results in a reduction in the market price of the shares.\n\n3. **Relevant Information from the Document**:\n   - The document mentions that the sale of a substantial number of shares in the public market could cause the market price of the common stock to decline (Section 98: \"Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.\").\n   - This aligns with the general financial principle that a perceived increase in supply can lead to a decrease in price.\n\n4. **Evaluating the Options**:\n   - **A: Increase in market price** - This is unlikely because an increase in perceived supply typically reduces demand, leading to a lower price.\n   - **B: Improvement in company reputation** - This is not a likely effect. The perception of a large number of shares being sold is more likely to be seen negatively by the market.\n   - **C: Expansion of company operations** - This is not directly related to the market's perception of share sales.\n   - **D: Reduction in market price** - This is the most likely effect based on the information provided and general financial principles.\n   - **E: Increase in dividend payouts** - This is not a direct effect of the market's perception of share sales.\n   - **"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 96000, "result": 1.0, "question": "Where are the fair value gains and losses of financial liabilities reported?", "options": {"A": "Within Pledged MSR liability expense in the consolidated statements of operations", "B": "As financing activity in the consolidated statements of cash flows", "C": "Within MSR valuation adjustments, net in the consolidated statements of operations", "D": "Only in the footnotes of the financial report", "E": "As part of the equity section on the balance sheet", "F": "Within the depreciation accounts in the income statement"}, "LLM_original_answer": ["To answer the question \"Where are the fair value gains and losses of financial liabilities reported?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains detailed financial information and accounting practices, so I will look for sections that discuss fair value measurements and the reporting of financial liabilities.\n\n2. **Locate specific information about fair value gains and losses**: I will search for mentions of fair value gains and losses and how they are reported in the financial statements.\n\n3. **Determine the correct option**: Based on the information found, I will match it to the given options to find the correct answer.\n\n### Step 1: Identify the relevant section\nThe relevant sections are found in \"Note 3 \u2014 Fair Value\" and \"Note 8 \u2014 Other Financing Liabilities, at Fair Value.\"\n\n### Step 2: Locate specific information about fair value gains and losses\nFrom \"Note 3 \u2014 Fair Value\":\n- \"We determine the fair value of MSRs primarily using discounted cash flow methodologies.\"\n- \"We engage third-party valuation experts who generally utilize: (a) transactions involving instruments with similar collateral and risk profiles, adjusted as necessary based on specific characteristics of the asset or liability being valued; and/or (b) industry-standard modeling, such as a discounted cash flow model and prepayment model, in arriving at their estimate of fair value.\"\n\nFrom \"Note 8 \u2014 Other Financing Liabilities, at Fair Value\":\n- \"The fair value gains and losses of these financial liabilities are reported within MSR valuation adjustments, net in the consolidated statements of operations.\"\n- \"The excess servicing spread remittance is reported within Pledged MSR liability expense in the consolidated statements of operations.\"\n\n### Step 3: Determine the correct option\nBased on the information from \"Note 8 \u2014 Other Financing Liabilities, at Fair Value,\" the fair value gains and losses of financial liabilities are reported within \"MSR valuation adjustments, net\" in the consolidated statements of operations.\n\n### Conclusion\nThe correct answer is:\n**C: Within MSR valuation adjustments, net in the consolidated statements of operations.**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 96000, "result": 1.0, "question": "What is one potential outcome of post-grant review proceedings on a patent?", "options": {"A": "Automatic extension of the patent term", "B": "Increased market value for the patent holder", "C": "Invalidation of the patent", "D": "Requirement to share technology with competitors", "E": "Guaranteed protection against all legal challenges", "F": "Immediate royalty payments to the inventor"}, "LLM_original_answer": ["To answer the question \"What is one potential outcome of post-grant review proceedings on a patent?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Understanding Post-Grant Review Proceedings**: The document does not explicitly define post-grant review proceedings, but it mentions that \"various post-grant review proceedings, such as inter partes review and post-grant review, are available for any interested third party to challenge the patentability of claims in any patents issued to us or our licensors.\"\n\n2. **Potential Outcomes of Post-Grant Review Proceedings**:\n   - The document states, \"While these post-grant review proceedings have been used less frequently to invalidate biotech patents, they have been successful regarding other technologies, and these relatively new procedures are still changing, and those changes might affect future results.\"\n   - It also mentions, \"No assurance can be given that, if challenged, any patents that we or our licensors may obtain would be declared by a court to be valid or enforceable or that, even if found valid and enforceable, a competitor\u2019s technology or product would be found by a court to infringe any such patent.\"\n\n3. **Analyzing the Options**:\n   - **A: Automatic extension of the patent term** - The document does not mention any automatic extension of the patent term as a result of post-grant review proceedings.\n   - **B: Increased market value for the patent holder** - The document does not suggest that post-grant review proceedings would increase the market value for the patent holder.\n   - **C: Invalidation of the patent** - The document explicitly mentions that post-grant review proceedings can be used to challenge the patentability of claims and have been successful in invalidating patents in other technologies.\n   - **D: Requirement to share technology with competitors** - The document does not mention any requirement to share technology with competitors as a result of post-grant review proceedings.\n   - **E: Guaranteed protection against all legal challenges** - The document clearly states that there is no assurance that patents will be declared valid or enforceable if challenged.\n   - **F: Immediate royalty payments to the inventor** - The document does not mention immediate royalty payments to the inventor as a result of post-grant review proceedings.\n\n4. **Conclusion**:\n   - Based on the information provided, the most relevant and accurate option is **C: Invalidation of the patent**. The document explicitly states that post-grant review proceedings can be used to challenge and potentially"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 96000, "result": 1.0, "question": "What strategy might competitors use to market generic versions of approved products?", "options": {"A": "Develop entirely new technologies", "B": "Submit an NDA for new products", "C": "Apply for approval through a PMA", "D": "Submit ANDAs to the FDA claiming patents are invalid", "E": "Enter into partnerships with patent holders", "F": "Focus on international markets"}, "LLM_original_answer": ["To answer the question \"What strategy might competitors use to market generic versions of approved products?\" based on the provided document, the most appropriate option is:\n\n**D: Submit ANDAs to the FDA claiming patents are invalid**\n\n### Chain of Thoughts:\n1. **Understanding the Context**:\n   - The document discusses the regulatory and commercial challenges faced by pharmaceutical companies, particularly in the context of obtaining and maintaining marketing authorizations for their products.\n   - It mentions the process of obtaining regulatory approval and the potential for generic competition.\n\n2. **Relevant Information from the Document**:\n   - The document states: \"In the U.S., once an NDA is approved, the product covered thereby becomes a 'reference listed drug' in the FDA\u2019s publication, 'Approved Drug Products with Therapeutic Equivalence Evaluations,' or the Orange Book.\"\n   - It also mentions: \"Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications, or ANDAs, in the U.S.\"\n   - The document further notes: \"In support of an ANDA, a generic manufacturer generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration, and adequate labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning, in part, that it is absorbed in the body at the same rate and to the same extent.\"\n\n3. **Analyzing the Options**:\n   - **A: Develop entirely new technologies** - This is not a strategy for marketing generic versions of approved products.\n   - **B: Submit an NDA for new products** - This is for new, innovative products, not generics.\n   - **C: Apply for approval through a PMA** - This is for medical devices, not generic drugs.\n   - **D: Submit ANDAs to the FDA claiming patents are invalid** - This is a common strategy for generic drug manufacturers to challenge the validity of patents and seek approval for their generic versions.\n   - **E: Enter into partnerships with patent holders** - This is more about collaboration and less about challenging patents.\n   - **F: Focus on international markets** - While this is a strategy, it does not directly address the issue of marketing generic versions in the U.S.\n\n4. **Conclusion**:\n   - The most relevant and direct strategy for competitors to market generic versions of approved products is to submit ANDAs to the FDA, often claiming that the patents on the reference listed drugs are invalid"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 96000, "result": 1.0, "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?", "options": {"A": "Internal financial reports", "B": "Market analysis from competitors", "C": "Assistance of third-party valuation specialists", "D": "Future expected sales", "E": "Executive estimates", "F": "Employee surveys"}, "LLM_original_answer": ["To answer the question \"What is used to determine the value of identifiable intangibles acquired in an acquisition?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Identify the Context**:\n   - The document discusses the acquisition of Black Knight by Intercontinental Exchange, Inc. (ICE) and the valuation of intangible assets in this context.\n\n2. **Locate Relevant Information**:\n   - In the section \"Goodwill and Indefinite-Lived Intangible Assets\" (Note 9), it states: \"We recognize specifically-identifiable intangibles when a specific right or contract is acquired. That value is determined with the assistance of third-party valuation specialists.\"\n\n3. **Interpret the Information**:\n   - The document explicitly mentions that the value of specifically identifiable intangibles is determined with the assistance of third-party valuation specialists.\n\n4. **Match the Information to the Options**:\n   - Option C: \"Assistance of third-party valuation specialists\" directly matches the information provided in the document.\n\nTherefore, the correct answer is:\n\n**C: Assistance of third-party valuation specialists**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 96000, "result": 1.0, "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?", "options": {"A": "Changes in depreciation methods for tax purposes", "B": "Balances of and changes in LFPBs and MRBs", "C": "Introduction of new revenue recognition policies", "D": "Adjustments in stock equity options", "E": "Changes in executive compensation structures", "F": "Updates in marketing expenses"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the specific changes addressed in the tables for January 1, 2021, regarding the adoption of ASU 2018-12.\n\n### Step 1: Identify the Adoption of ASU 2018-12\nThe document mentions the adoption of ASU 2018-12, which is effective for fiscal years beginning after January 1, 2023, with a transition date of January 1, 2021. This is noted in the following section:\n- **1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)**\n  - \"The Company adopted ASU 2018-12 for LFPBs, DAC and other balances amortized on a basis consistent with DAC by applying the guidance to contracts in-force on the basis of their existing carrying amounts at the transition date. The Company adopted ASU 2018-12 for MRBs on a fully retrospective basis.\"\n\n### Step 2: Identify the Specific Changes in the Tables\nThe document provides specific tables that show the changes in balances and assumptions due to the adoption of ASU 2018-12. The relevant tables are:\n- **2. ASU 2018-12 Transition**\n  - **Balances of and changes in LFPBs at January 1, 2021:**\n    - The table shows the transition adjustments for LFPBs, including the increase in LFPBs to eliminate premium deficiencies and the impact of the new discount rate assumption.\n  - **Balances of and changes in liabilities classified as MRBs at January 1, 2021:**\n    - The table shows the transition adjustments for MRBs, including the changes in the estimated fair value of MRBs.\n\n### Step 3: Analyze the Changes\n- **Balances of and changes in LFPBs at January 1, 2021:**\n  - The table indicates that the LFPBs were adjusted to reflect the new accounting requirements, including the elimination of premium deficiencies and the application of a new discount rate.\n- **Balances of and changes in liabilities classified as MRBs at January 1, 2021:**\n  - The table shows that the MRBs were measured at estimated fair value, and the changes in the nonperformance risk were recognized in OCI.\n\n###"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 55, "token_lengths": 128000, "result": 1.0, "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?", "options": {"A": "Value-added tax", "B": "Excise tax", "C": "Income tax", "D": "Minimum tax", "E": "Sales tax", "F": "Capital gains tax"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 128000, "result": 0.0, "question": "What change was made to the Mass Mutual Barings loans in August 2022?", "options": {"A": "The interest rate was increased to 12%.", "B": "The loan term was extended by 12 months.", "C": "Principal payments were deferred for six months.", "D": "The interest was capitalized into the principal.", "E": "The loans were converted into equity.", "F": "The loans were forgiven entirely."}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 128000, "result": 0.0, "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?", "options": {"A": "January 2024", "B": "December 2024", "C": "January 2025", "D": "January 2026", "E": "December 2026", "F": "January 2027"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 128000, "result": 1.0, "question": "How is revenue from administrative and management activities recognized?", "options": {"A": "As soon as the service contract is signed", "B": "Once services are rendered in full", "C": "When fees are prorated over a twelve-month period", "D": "As performance obligations are satisfied", "E": "When derivative instruments reach fair value", "F": "Upon evaluation of hedge transaction effectiveness"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 128000, "result": 1.0, "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?", "options": {"A": "Increase in market price", "B": "Improvement in company reputation", "C": "Expansion of company operations", "D": "Reduction in market price", "E": "Increase in dividend payouts", "F": "Stabilization of trading volume"}, "LLM_original_answer": ["The correct answer to the question \"What is a potential effect of the public market's perception that a large number of shares might be sold?\" is:\n\n**D: Reduction in market price**\n\n### Chain of Thought:\n1. **Understanding the Question**: The question is asking about the potential market impact if the public perceives that a large number of shares might be sold. This perception can influence investor behavior and market dynamics.\n\n2. **Market Perception and Supply-Demand Dynamics**: In financial markets, the perception of a large number of shares being sold can be interpreted as an increase in supply. According to basic supply and demand principles, an increase in supply, all else being equal, typically leads to a decrease in price.\n\n3. **Investor Behavior**: If investors believe that a large number of shares will be sold, they might sell their own shares to avoid potential losses. This can create a downward pressure on the stock price as more shares are sold and fewer are bought.\n\n4. **Market Sentiment**: Negative market sentiment can also lead to a reduction in demand for the stock. If the market perceives that a large number of shares will be sold, it might reduce its willingness to buy, further contributing to a decline in the stock price.\n\n5. **Other Options Analysis**:\n   - **A: Increase in market price**: This is unlikely because an increase in supply typically leads to a decrease in price.\n   - **B: Improvement in company reputation**: This is not a likely outcome of the perception of a large number of shares being sold.\n   - **C: Expansion of company operations**: The perception of a large number of shares being sold does not directly influence the company's operational expansion.\n   - **E: Increase in dividend payouts**: Dividend payouts are typically influenced by the company's financial performance and board decisions, not by the perception of share sales.\n   - **F: Stabilization of trading volume**: While the perception of a large number of shares being sold might initially increase trading volume, it is not likely to stabilize it in the long term.\n\n6. **Conclusion**: Given the supply and demand dynamics and the potential for negative market sentiment, the most likely effect of the public market's perception that a large number of shares might be sold is a reduction in the market price of the stock.\n\nTherefore, the correct answer is **D: Reduction in market price**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 128000, "result": 1.0, "question": "Where are the fair value gains and losses of financial liabilities reported?", "options": {"A": "Within Pledged MSR liability expense in the consolidated statements of operations", "B": "As financing activity in the consolidated statements of cash flows", "C": "Within MSR valuation adjustments, net in the consolidated statements of operations", "D": "Only in the footnotes of the financial report", "E": "As part of the equity section on the balance sheet", "F": "Within the depreciation accounts in the income statement"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 128000, "result": 1.0, "question": "What is one potential outcome of post-grant review proceedings on a patent?", "options": {"A": "Automatic extension of the patent term", "B": "Increased market value for the patent holder", "C": "Invalidation of the patent", "D": "Requirement to share technology with competitors", "E": "Guaranteed protection against all legal challenges", "F": "Immediate royalty payments to the inventor"}, "LLM_original_answer": ["To answer the question \"What is one potential outcome of post-grant review proceedings on a patent?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: The document primarily focuses on the development and regulatory processes of TCR-T therapies and the business operations of TScan Therapeutics, Inc. However, it does contain some information about patent-related risks and processes.\n\n2. **Locate Specific Patent-Related Content**: The document mentions several aspects of patent law and the risks associated with patent"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 128000, "result": 1.0, "question": "What strategy might competitors use to market generic versions of approved products?", "options": {"A": "Develop entirely new technologies", "B": "Submit an NDA for new products", "C": "Apply for approval through a PMA", "D": "Submit ANDAs to the FDA claiming patents are invalid", "E": "Enter into partnerships with patent holders", "F": "Focus on international markets"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 55, "token_lengths": 128000, "result": 1.0, "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?", "options": {"A": "Internal financial reports", "B": "Market analysis from competitors", "C": "Assistance of third-party valuation specialists", "D": "Future expected sales", "E": "Executive estimates", "F": "Employee surveys"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 55, "token_lengths": 128000, "result": 1.0, "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?", "options": {"A": "Changes in depreciation methods for tax purposes", "B": "Balances of and changes in LFPBs and MRBs", "C": "Introduction of new revenue recognition policies", "D": "Adjustments in stock equity options", "E": "Changes in executive compensation structures", "F": "Updates in marketing expenses"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 60, "token_lengths": 8000, "result": 1.0, "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?", "options": {"A": "Results of operations", "B": "Capital requirements", "C": "Stock performance graph", "D": "Financial condition", "E": "Contractual arrangements", "F": "Limitations in debt agreements"}, "LLM_original_answer": ["To answer the question, let's analyze the factors mentioned in the document that influence the board of directors' discretion in deciding to pay cash dividends:\n\n1. **Results of Operations**: The document states, \"The payment of dividends will be at the discretion of our board of directors and will depend on our results of operations.\" This indicates that the board considers the company's operational performance when deciding on dividends.\n\n2. **Capital Requirements**: The document mentions, \"The payment of dividends will be at the discretion of our board of directors and will depend on our capital requirements.\" This suggests that the board takes into account the company's need for capital when making dividend decisions.\n\n3. **Financial Condition**: The document notes, \"The payment of dividends will be at the discretion of our board of directors and will depend on our financial condition.\" This indicates that the board considers the overall financial health of the company when deciding on dividends.\n\n4. **Contractual Arrangements**: The document states, \"The payment of dividends will be at the discretion of our board of directors and will depend on our contractual arrangements.\" This suggests that the board considers any existing contracts that may affect dividend payments.\n\n5. **Limitations in Debt Agreements**: The document mentions, \"The payment of dividends will be at the discretion of our board of directors and will depend on any limitations on payment of dividends present in any future debt agreements.\" This indicates that the board considers any restrictions in debt agreements when deciding on dividends.\n\n6. **Stock Performance Graph**: The document does not mention that the stock performance graph is a factor in the board's decision to pay dividends. The stock performance graph is described as a tool for comparing the company's stock performance with other indices, but it is not listed as a factor influencing the board's discretion.\n\nGiven this analysis, the factor that does not influence the discretion of the board of directors in deciding to pay cash dividends is:\n\n**C: Stock performance graph**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 8000, "result": 1.0, "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?", "options": {"A": "A complete dismissal of all lawsuits", "B": "A $15 million secured claim", "C": "A final release of all claims with Gryphon Digital Mining", "D": "An allowed $10 million general unsecured claim", "E": "Ownership of new mining equipment", "F": "A partnership extension with Gryphon"}, "LLM_original_answer": ["To answer the question \"What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section on legal proceedings, which is likely to have information about the Bankruptcy Court's decisions.\n\n2. **Locate the specific information about Sphere 3D Corp.**: Within the legal proceedings section, there is a subsection that discusses Sphere 3D Corp.\n\n3. **Extract the key details**: The document states:\n   - \"On January 16, 2024, the Bankruptcy Court entered an order granting Sphere 3D Corp. (\u201cSphere\u201d) an allowed $ 10 million general unsecured claim and a complete and final release of all claims of Sphere and Gryphon Digital Mining, Inc. (\u201cGryphon\u201d) against the Debtors related to the hosting contracts.\"\n   - \"As part of the resolution, all miners have been returned to the client.\"\n   - \"Furthermore, the adversary proceeding was dismissed with prejudice, against both Gryphon and Sphere.\"\n\n4. **Match the details to the options**:\n   - **Option A**: A complete dismissal of all lawsuits - This is partially true, but not the full extent of what was granted.\n   - **Option B**: A $15 million secured claim - This is incorrect; the claim was unsecured and for $10 million.\n   - **Option C**: A final release of all claims with Gryphon Digital Mining - This is true, but it is not the only thing granted.\n   - **Option D**: An allowed $10 million general unsecured claim - This is true and matches the document.\n   - **Option E**: Ownership of new mining equipment - This is incorrect; the miners were returned to the client.\n   - **Option F**: A partnership extension with Gryphon - This is not mentioned in the document.\n\n5. **Conclusion**: The most accurate and complete answer is **Option D: An allowed $10 million general unsecured claim**. This is explicitly stated in the document and is the primary grant mentioned for Sphere 3D Corp. on January 16, 2024.\n\nTherefore, the correct answer is **D: An allowed $10 million general unsecured claim**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 8000, "result": 1.0, "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?", "options": {"A": "A significant financial penalty was imposed", "B": "The case was settled with a material financial impact", "C": "The lawsuit was dismissed", "D": "The resolution caused Duke Energy Carolinas to alter the dam structure", "E": "Duke Energy Carolinas had to issue a public apology", "F": "The case is still ongoing"}, "LLM_original_answer": ["To answer the question regarding the outcome of the lawsuit against Duke Energy Carolinas about the dam on the Dan River, I will analyze the relevant information from the provided document step by step:\n\n1. **Incident Description**:\n   - On June 16, 2021, a group of nine individuals went over a low-head dam adjacent to the Dan River Steam Station in Eden, North Carolina, while water tubing.\n   - Four people were rescued, and five others were confirmed deceased.\n\n2. **Legal Action**:\n   - On August 11, 2021, Duke Energy Carolinas was served with a complaint filed in Durham County Superior Court on behalf of four survivors, which was later amended to include all the decedents along with the survivors.\n   - The lawsuit alleged that Duke Energy Carolinas knew the river was used for recreational purposes, did not adequately warn about the dam, and created a dangerous and hidden hazard on the Dan River.\n\n3. **Resolution**:\n   - In 2023, Duke Energy Carolinas reached an agreement that resolved this matter.\n   - The resolution did not have a material financial impact.\n   - The resolution was approved by the Durham County Superior Court.\n   - The case was dismissed on June 6, 2023.\n\n4. **Analysis of Options**:\n   - **A: A significant financial penalty was imposed** - The document does not mention any significant financial penalty.\n   - **B: The case was settled with a material financial impact** - The document explicitly states that the resolution did not have a material financial impact.\n   - **C: The lawsuit was dismissed** - The document confirms that the case was dismissed on June 6, 2023.\n   - **D: The resolution caused Duke Energy Carolinas to alter the dam structure** - There is no mention of any changes to the dam structure.\n   - **E: Duke Energy Carolinas had to issue a public apology** - The document does not mention any public apology.\n   - **F: The case is still ongoing** - The document clearly states that the case was dismissed on June 6, 2023.\n\nBased on the information provided in the document, the correct answer is:\n\n**C: The lawsuit was dismissed**\n\nThe document explicitly states that the case was dismissed on June 6, 2023, after Duke Energy Carolinas reached an agreement that resolved the matter without a material financial impact."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 8000, "result": 1.0, "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?", "options": {"A": "A detailed financial statement", "B": "A personal or corporate guarantee", "C": "An independent appraisal review", "D": "Proof of project completion", "E": "An environmental impact assessment", "F": "A feasibility study"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to find relevant information about the requirements for individuals with significant ownership in a borrowing entity when the loan-to-value ratio exceeds a certain threshold.\n\n1. **Identify the relevant section**: The document discusses various aspects of the Company's financial and lending practices. The section that is most relevant to the question is the \"Commercial Lending\" part, specifically the \"Commercial and industrial\" and \"Commercial real estate\" subsections.\n\n2. **Examine the \"Commercial and industrial\" section**:\n   - The document states: \"Under its lending guidelines, the Company generally requires a corporate or personal guarantee from individuals that hold material ownership in the borrowing entity when the loan-to-value of a commercial and industrial loan is in excess of a specified threshold.\"\n   - This indicates that a personal or corporate guarantee is required when the loan-to-value ratio exceeds a certain threshold for commercial and industrial loans.\n\n3. **Examine the \"Commercial real estate\" section**:\n   - The document states: \"Under its lending guidelines, the Company generally requires a corporate or personal guarantee from individuals that hold material ownership in the borrowing entity when the loan-to-value of a commercial real estate loan is in excess of a specified threshold.\"\n   - This indicates that a personal or corporate guarantee is also required when the loan-to-value ratio exceeds a certain threshold for commercial real estate loans.\n\n4. **Conclusion**:\n   - Both sections clearly state that a corporate or personal guarantee is required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio exceeds a specified threshold.\n   - Therefore, the correct answer is **B: A personal or corporate guarantee**.\n\nThis answer is derived directly from the information provided in the document, which explicitly mentions the requirement for guarantees in both commercial and industrial and commercial real estate loans when the loan-to-value ratio exceeds a certain threshold."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 60, "token_lengths": 8000, "result": 1.0, "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?", "options": {"A": "Having exclusive rights to future programs", "B": "Primary responsibility for conducting marketing activities", "C": "Demonstrating sufficient cash resources and personnel", "D": "Approval from the external governing board", "E": "Completion of preclinical research activities", "F": "An environmental impact assessment"}, "LLM_original_answer": ["To answer the question \"What determines the company's right to co-develop, co-promote, and co-commercialize a target?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Gilead Collaboration**:\n   - Under the Gilead Agreement, the company retains the option to co-develop and co-promote up to two drug candidates in the United States.\n   - The company can only exercise this option once per licensed product.\n   - Gilead retains the right to veto the company's option selection for any one drug candidate of its choice.\n\n2. **Sanofi Collaboration**:\n   - The company retains the option to co-develop, co-promote, and co-commercialize all drug candidates in the United States directed to up to two targets.\n   - One target must be selected from a list designated at the execution of the Sanofi Agreement or any replacement of such targets.\n   - One target must be selected from targets identified by Sanofi as part of their January 2021 expansion.\n   - The company's right to exercise this option is dependent on its ability to demonstrate, within a given timeframe, that it has sufficient cash resources and personnel to commercialize the product.\n\n3. **Pfizer Collaboration**:\n   - The company retains an option for U.S. profit sharing and co-promotion on two products arising from the collaboration.\n   - The company must exercise this option, and the terms for profit sharing and co-promotion will be negotiated upon exercise.\n\nFrom the above analysis, the key factor that determines the company's right to co-develop, co-promote, and co-commercialize a target is:\n\n- **For the Sanofi Collaboration**: The company must demonstrate, within a given timeframe, that it has sufficient cash resources and personnel to commercialize the product.\n\nThis is explicitly stated in the document for the Sanofi collaboration, which is the most detailed in this regard. Therefore, the correct answer is:\n\n**C: Demonstrating sufficient cash resources and personnel**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 8000, "result": 1.0, "question": "What do the valuation experts incorporate in their pricing process?", "options": {"A": "Only the historical market trends", "B": "Calculations based solely on risk premiums", "C": "Assumptions related to non-market activities", "D": "Industry survey results and client feedback", "E": "Internal financial projections", "F": "Unrelated economic indicators"}, "LLM_original_answer": ["To answer the question \"What do the valuation experts incorporate in their pricing process?\" based on the provided document, I will analyze the relevant sections step by step.\n\n1. **Loans Held for Sale**:\n   - The document states that the fair value of loans held for sale is estimated using both observable and unobservable inputs.\n   - Observable inputs include published Ginnie Mae prices or existing sale contracts.\n   - Unobservable inputs include estimated default, prepayment, and discount rates.\n\n2. **MSRs (Mortgage Servicing Rights)**:\n   - The fair value of MSRs is determined using discounted cash flow methodologies.\n   - Valuation experts use transactions involving instruments with similar collateral and risk profiles, adjusted as necessary based on specific characteristics of the asset or liability being valued.\n   - They also use industry-standard modeling, such as a discounted cash flow model and prepayment model.\n   - The prices provided by the valuation experts reflect their observations and assumptions related to market activity, generally the bulk market, incorporating available industry survey results and client feedback, and including risk premiums and liquidity adjustments.\n\n3. **HMBS-Related Borrowings**:\n   - These borrowings are carried at fair value and classified as Level 3 within the valuation hierarchy.\n   - Valuation experts provide observations and assumptions related to market activities.\n   - Significant unobservable assumptions include yield spread and discount rate, which are based on an assessment of current market yields for newly issued HMBS, expected duration, and current market interest rates.\n\n4. **Pledged MSR Liabilities**:\n   - The fair value of the pledged MSR liability is determined using the fair value mark provided by third-party valuation experts.\n   - The same methodology and assumptions used for the associated MSRs are applied, considering cash flows contractually retained by PHH and the expected life of the subservicing agreement, when applicable.\n\n5. **ESS Financing Liability**:\n   - The fair value of the ESS financing liability is determined using a third-party valuation expert.\n   - Significant unobservable assumptions include prepayment speeds, delinquency rates, and discount rates.\n\nFrom the above analysis, it is clear that the valuation experts incorporate a variety of factors in their pricing process, including:\n\n- **Industry survey results and client feedback** (Option D)\n- **Internal financial projections** (Option E)\n- **Risk premiums and liquidity adjustments** (implied in Option B)\n- **Discount rates** (implied in Option B)\n- **Prepayment speeds and delinquency rates** (im"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 8000, "result": 1.0, "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?", "options": {"A": "Exclusive commercialization rights", "B": "Complete ownership of patents", "C": "Rights to revoke licenses", "D": "March-in rights", "E": "Rights to set the technology price", "F": "Rights to sell the technology internationally"}, "LLM_original_answer": ["To answer the question \"What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the relevant section**: The document mentions the Bayh-Dole Act in the context of government-funded technology and the rights reserved by the U.S. government. The relevant section is:\n   - \"Pursuant to the Bayh-Dole Act, the U.S. government has march-in rights with regards to government-funded technology. For example, the U.S. government has certain rights, including march-in rights, to patent rights and technology funded by the U.S. government and licensed to us from BWH.\"\n\n2. **Understand the term \"march-in rights\"**: The document defines march-in rights as:\n   - \"These rights may permit the U.S. government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The U.S. government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry.\"\n\n3. **Evaluate the options**:\n   - **A: Exclusive commercialization rights** - The document does not mention the U.S. government having exclusive commercialization rights.\n   - **B: Complete ownership of patents** - The document does not state that the U.S. government has complete ownership of patents.\n   - **C: Rights to revoke licenses** - The document does not explicitly mention the U.S. government having the right to revoke licenses.\n   - **D: March-in rights** - The document explicitly mentions that the U.S. government has march-in rights.\n   - **E: Rights to set the technology price** - The document does not mention the U.S. government having the right to set the technology price.\n   - **F: Rights to sell the technology internationally** - The document does not mention the U.S. government having the right to sell the technology internationally.\n\n4. **Conclusion**: Based on the information provided in the document, the U.S. government holds **march-in rights** concerning government-funded technology under the Bayh-Dole Act.\n\nTherefore, the correct answer is **D: March-in rights**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 8000, "result": 1.0, "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?", "options": {"A": "Linda Arsenault", "B": "Debra Canner", "C": "Camille L. Bedrosian, MD", "D": "John Smith", "E": "Maria Gonzalez", "F": "James Patel"}, "LLM_original_answer": ["To answer the question \"Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant information**: The document mentions changes in key personnel, including the replacement of the Chief Medical Officer.\n2. **Locate the specific section**: The relevant section is found in the \"Risks Related to Our Business Operations, Employee Matters and Managing Growth\" part of the document.\n3. **Extract the specific detail**: The document states, \"In December 2023, our then Global Head of Clinical R&D and Chief Medical Officer, Patrick Yeramian, M.D., was replaced by Camille L. Bedrosian, MD as our current Chief Medical Officer.\"\n\n4. **Match the information to the options**:\n   - A: Linda Arsenault\n   - B: Debra Canner\n   - C: Camille L. Bedrosian, MD\n   - D: John Smith\n   - E: Maria Gonzalez\n   - F: James Patel\n\n5. **Determine the correct answer**: The document clearly states that Camille L. Bedrosian, MD replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023.\n\nTherefore, the correct answer is **C: Camille L. Bedrosian, MD**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 8000, "result": 1.0, "question": "At what point in time is the revenue for cash trading and equity options recorded?", "options": {"A": "At the beginning of the transaction", "B": "At the end of the fiscal year", "C": "At the point in time of the transaction", "D": "When the transaction is settled", "E": "At the time of customer payment", "F": "When the market closes for the day"}, "LLM_original_answer": ["To answer the question \"At what point in time is the revenue for cash trading and equity options recorded?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section on revenue recognition, which is likely to provide the necessary information.\n\n2. **Locate the specific information**: Within the \"Revenue Recognition\" section, there is a subsection that specifically discusses \"Cash Equities and Equity Options.\"\n\n3. **Extract the key details**: The relevant information is found in the \"Cash Equities and Equity Options\" subsection:\n   - \"Revenues in our cash equity and equity options markets represent trade execution fees.\"\n   - \"Cash trading and equity options contain one performance obligation related to each transaction which occurs instantaneously, and the revenue is recorded at the point in time of the transaction.\"\n\n4. **Match the information to the options**: The document clearly states that the revenue is recorded \"at the point in time of the transaction.\"\n\n5. **Select the correct answer**: The correct answer is **C: At the point in time of the transaction**.\n\n**Chain of thoughts**:\n- The document provides detailed information on how different types of revenues are recognized.\n- For cash trading and equity options, the document specifies that the revenue is recorded at the point in time of the transaction.\n- This matches directly with option C, which states \"At the point in time of the transaction.\"\n\nTherefore, the correct answer is **C: At the point in time of the transaction**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 8000, "result": 1.0, "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?", "options": {"A": "60%", "B": "70%", "C": "75%", "D": "80%", "E": "Over 80%", "F": "90%"}, "LLM_original_answer": ["To answer the question \"What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The relevant information is found in the \"Other Invested Assets\" section of the document.\n\n2. **Extract the key information**: The document states, \"Over 80 % of other invested assets is comprised of freestanding derivatives with positive estimated fair values.\"\n\n3. **Match the extracted information to the given options**:\n   - A: 60%\n   - B: 70%\n   - C: 75%\n   - D: 80%\n   - E: Over 80%\n   - F: 90%\n\n4. **Select the correct option**: The document explicitly mentions \"Over 80 %,\" which corresponds to option E.\n\nTherefore, the correct answer is **E: Over 80%**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 60, "token_lengths": 16000, "result": 1.0, "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?", "options": {"A": "Results of operations", "B": "Capital requirements", "C": "Stock performance graph", "D": "Financial condition", "E": "Contractual arrangements", "F": "Limitations in debt agreements"}, "LLM_original_answer": ["To answer the question, we need to identify which factor does not influence the discretion of the board of directors in deciding to pay cash dividends. Let's analyze each option in the context of the provided document:\n\nA: Results of operations - The document mentions that the board of directors will consider the results of operations when deciding on dividends. This is a relevant factor.\n\nB: Capital requirements - The document states that the board will consider capital requirements when deciding on dividends. This is also a relevant factor.\n\nC: Stock performance graph - The document does not mention that the board of directors considers the stock performance graph when deciding on dividends. The stock performance graph is more of a tool for investors to assess the company's performance over time, not a direct factor in the board's decision-making process for dividends.\n\nD: Financial condition - The document explicitly mentions that the board will consider the financial condition of the company when deciding on dividends. This is a relevant factor.\n\nE: Contractual arrangements - The document mentions that the board will consider contractual arrangements when deciding on dividends. This is a relevant factor.\n\nF: Limitations in debt agreements - The document states that the board will consider any limitations in debt agreements when deciding on dividends. This is a relevant factor.\n\nBased on the analysis, the factor that does not influence the discretion of the board of directors in deciding to pay cash dividends is:\n\nC: Stock performance graph\n\nThe stock performance graph is not mentioned as a factor that the board of directors considers when making decisions about dividend payments. The other factors (A, B, D, E, and F) are all explicitly mentioned in the document as influencing the board's discretion."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 16000, "result": 1.0, "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?", "options": {"A": "A complete dismissal of all lawsuits", "B": "A $15 million secured claim", "C": "A final release of all claims with Gryphon Digital Mining", "D": "An allowed $10 million general unsecured claim", "E": "Ownership of new mining equipment", "F": "A partnership extension with Gryphon"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the relevant information provided in the document:\n\n1. **Identify the relevant section**: The document mentions a specific event involving Sphere 3D Corp. and the Bankruptcy Court on January 16, 2024. This is found in the \"Legal Proceedings\" section.\n\n2. **Extract the key information**:\n   - On January 16, 2024, the Bankruptcy Court entered an order granting Sphere 3D Corp. (\"Sphere\") an allowed $10 million general unsecured claim.\n   - The order also provided a complete and final release of all claims of Sphere and Gryphon Digital Mining, Inc. (\"Gryphon\") against the Debtors related to the hosting contracts.\n   - As part of the resolution, all miners have been returned to the client.\n   - The adversary proceeding was dismissed with prejudice against both Gryphon and Sphere.\n\n3. **Match the information to the options**:\n   - **Option A**: A complete dismissal of all lawsuits. This is partially true, as the adversary proceeding was dismissed with prejudice, but it does not cover all lawsuits.\n   - **Option B**: A $15 million secured claim. This is not mentioned in the document.\n   - **Option C**: A final release of all claims with Gryphon Digital Mining. This is true, as the order provided a complete and final release of all claims of both Sphere and Gryphon.\n   - **Option D**: An allowed $10 million general unsecured claim. This is true, as the order granted Sphere an allowed $10 million general unsecured claim.\n   - **Option E**: Ownership of new mining equipment. This is not mentioned in the document.\n   - **Option F**: A partnership extension with Gryphon. This is not mentioned in the document.\n\n4. **Determine the most accurate answer**:\n   - Both **Option C** and **Option D** are correct based on the information provided. However, the question asks for what was granted to Sphere 3D Corp. specifically.\n   - **Option D** directly states what was granted to Sphere 3D Corp. by the Bankruptcy Court.\n\nTherefore, the most accurate answer is:\n\n**D: An allowed $10 million general unsecured claim**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 16000, "result": 1.0, "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?", "options": {"A": "A significant financial penalty was imposed", "B": "The case was settled with a material financial impact", "C": "The lawsuit was dismissed", "D": "The resolution caused Duke Energy Carolinas to alter the dam structure", "E": "Duke Energy Carolinas had to issue a public apology", "F": "The case is still ongoing"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step:\n\n1. **Identify the relevant section**: The document mentions a lawsuit against Duke Energy Carolinas involving a low-head dam on the Dan River. This is found in the \"Duke Energy Carolinas\" section under \"Ruben Villano, et al. v. Duke Energy Carolinas, LLC.\"\n\n2. **Summarize the key points**:\n   - On June 16, 2021, a group of nine individuals went over a low-head dam adjacent to the Dan River Steam Station in Eden, North Carolina, while water tubing.\n   - Four people were rescued, and five others were confirmed deceased.\n   - Duke Energy Carolinas was served with a complaint on August 11, 2021, alleging that the company knew the river was used for recreational purposes, did not adequately warn about the dam, and created a dangerous and hidden hazard.\n   - In 2023, Duke Energy Carolinas reached an agreement that resolved this matter.\n   - The resolution did not have a material financial impact.\n   - The case was dismissed on June 6, 2023.\n\n3. **Match the information to the options**:\n   - **Option A**: A significant financial penalty was imposed. (Not applicable, as the resolution did not have a material financial impact.)\n   - **Option B**: The case was settled with a material financial impact. (Not applicable, as the resolution did not have a material financial impact.)\n   - **Option C**: The lawsuit was dismissed. (Applicable, as the case was dismissed on June 6, 2023.)\n   - **Option D**: The resolution caused Duke Energy Carolinas to alter the dam structure. (Not mentioned in the document.)\n   - **Option E**: Duke Energy Carolinas had to issue a public apology. (Not mentioned in the document.)\n   - **Option F**: The case is still ongoing. (Not applicable, as the case was dismissed.)\n\n4. **Conclusion**:\n   - The correct answer is **Option C**: The lawsuit was dismissed.\n\nTherefore, the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River is that the lawsuit was dismissed."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 16000, "result": 1.0, "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?", "options": {"A": "A detailed financial statement", "B": "A personal or corporate guarantee", "C": "An independent appraisal review", "D": "Proof of project completion", "E": "An environmental impact assessment", "F": "A feasibility study"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document and extract the relevant information.\n\nThe question asks: \"What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?\"\n\nLet's break down the relevant information from the document:\n\n1. **Commercial Lending Section**:\n   - The document states: \"Under its lending guidelines, the Company generally requires a corporate or personal guarantee from individuals that hold material ownership in the borrowing entity when the loan-to-value of a commercial and industrial loan is in excess of a specified threshold.\"\n   - It also mentions: \"Under its lending guidelines, the Company generally requires a corporate or personal guarantee from individuals that hold material ownership in the borrowing entity when the loan-to-value of a commercial real estate loan is in excess of a specified threshold.\"\n\nFrom these statements, it is clear that the Company requires a corporate or personal guarantee from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold.\n\nTherefore, the correct answer is:\n\n**B: A personal or corporate guarantee**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 60, "token_lengths": 16000, "result": 1.0, "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?", "options": {"A": "Having exclusive rights to future programs", "B": "Primary responsibility for conducting marketing activities", "C": "Demonstrating sufficient cash resources and personnel", "D": "Approval from the external governing board", "E": "Completion of preclinical research activities", "F": "An environmental impact assessment"}, "LLM_original_answer": ["To answer the question \"What determines the company's right to co-develop, co-promote, and co-commercialize a target?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Gilead Collaboration**:\n   - Under the Gilead Agreement, the company retains the option to co-develop and co-promote up to two drug candidates in the United States.\n   - The company can only exercise this option once per licensed product.\n   - Gilead retains the right to veto the company's option selection for any one drug candidate of its choice.\n\n2. **Sanofi Collaboration**:\n   - Under the Sanofi Agreement, the company retains the option to co-develop, co-promote, and co-commercialize all drug candidates in the United States directed to up to two targets.\n   - One target must be selected from a list designated at the execution of the Sanofi Agreement or any replacement of such targets.\n   - One target must be selected from targets identified by Sanofi as part of their January 2021 expansion.\n   - The company's right to exercise this option is dependent on its ability to demonstrate, within a given timeframe, that it has sufficient cash resources and personnel to commercialize the product.\n\n3. **Pfizer Collaboration**:\n   - Under the Pfizer Agreement, the company retains an option for U.S. profit sharing and co-promotion on two products arising from the collaboration.\n   - The company will be responsible for a portion of the U.S. development costs, and the parties will split U.S. profits and losses evenly.\n   - The company will also be eligible to receive royalty and milestone payments on such optioned products.\n\nFrom the above analysis, the key factor that determines the company's right to co-develop, co-promote, and co-commercialize a target is its ability to demonstrate sufficient cash resources and personnel to commercialize the product. This is explicitly mentioned in the Sanofi Agreement section.\n\nTherefore, the correct answer is:\n**C: Demonstrating sufficient cash resources and personnel**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 16000, "result": 0.0, "question": "What do the valuation experts incorporate in their pricing process?", "options": {"A": "Only the historical market trends", "B": "Calculations based solely on risk premiums", "C": "Assumptions related to non-market activities", "D": "Industry survey results and client feedback", "E": "Internal financial projections", "F": "Unrelated economic indicators"}, "LLM_original_answer": ["To answer the question \"What do the valuation experts incorporate in their pricing process?\" based on the provided document, I will analyze the relevant sections step by step:\n\n1. **Loans Held for Sale**:\n   - The document states that the fair value of loans held for sale is estimated using both observable and unobservable inputs, including published Ginnie Mae prices or existing sale contracts, as well as estimated default, prepayment, and discount rates.\n   - This indicates that valuation experts use a combination of market data and proprietary assumptions.\n\n2. **Loans Held for Investment - Reverse Mortgages**:\n   - The fair value of reverse mortgage loans held for investment is based on expected future cash flows discounted over the expected life of the loans, including future draw commitments for HECM loans.\n   - The document mentions that third-party valuation experts are engaged, and their models and assumptions are proprietary, but the company understands the methodologies and assumptions used.\n   - The assumptions include future draws, tail securitization spreads, conditional prepayment rates, and discount rates.\n\n3. **MSRs (Mortgage Servicing Rights)**:\n   - The fair value of MSRs is determined using discounted cash flow methodologies.\n   - The document states that third-party valuation experts use transactions involving instruments with similar collateral and risk profiles, adjusted as necessary based on specific characteristics of the asset or liability being valued.\n   - They also use industry-standard modeling, such as a discounted cash flow model and prepayment model.\n   - The prices provided by the valuation experts reflect their observations and assumptions related to market activity, incorporating available industry survey results and client feedback, and including risk premiums and liquidity adjustments.\n\n4. **HMBS-Related Borrowings**:\n   - These borrowings are carried at fair value and classified as Level 3 within the valuation hierarchy.\n   - The fair value is determined using a discounted cash flow approach, discounting the projected recovery of principal and interest over the estimated life of the borrowing at a market rate commensurate with the risk of the estimated cash flows.\n   - Third-party valuation experts are engaged to support the valuation, and their observations and assumptions related to market activities are used.\n\n5. **Pledged MSR Liabilities**:\n   - The fair value of the pledged MSR liability is determined using the fair value mark provided by third-party valuation experts, consistent with the associated MSR.\n   - The assumptions include prepayment speeds, delinquency rates, and discount rates.\n\n6. **Derivative Financial Instruments**:\n   - The document mentions"], "LLM_extracted_answer": ["C"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 16000, "result": 1.0, "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?", "options": {"A": "Exclusive commercialization rights", "B": "Complete ownership of patents", "C": "Rights to revoke licenses", "D": "March-in rights", "E": "Rights to set the technology price", "F": "Rights to sell the technology internationally"}, "LLM_original_answer": ["To answer the question \"What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the Relevant Section**:\n   - The document mentions the Bayh-Dole Act in the context of government-funded technology and the rights reserved by the U.S. government.\n\n2. **Extract Key Information**:\n   - According to the document, the U.S. government has \"march-in rights\" with regards to government-funded technology.\n   - These rights allow the government to \"use or allow third parties to use our licensed technology\" if certain conditions are met.\n   - The conditions for exercising march-in rights include:\n     - Failure to achieve practical application of the government-funded technology.\n     - Necessity to alleviate health or safety needs.\n     - Meeting requirements of federal regulations.\n     - Giving preference to U.S. industry.\n\n3. **Match the Information to the Options**:\n   - **Option A: Exclusive commercialization rights** - The document does not mention the U.S. government having exclusive commercialization rights.\n   - **Option B: Complete ownership of patents** - The document does not state that the U.S. government has complete ownership of patents.\n   - **Option C: Rights to revoke licenses** - The document does not explicitly mention the right to revoke licenses.\n   - **Option D: March-in rights** - The document explicitly states that the U.S. government has march-in rights.\n   - **Option E: Rights to set the technology price** - The document does not mention the U.S. government having the right to set the technology price.\n   - **Option F: Rights to sell the technology internationally** - The document does not mention the U.S. government having the right to sell the technology internationally.\n\n4. **Conclusion**:\n   - Based on the information provided in the document, the U.S. government holds **march-in rights** concerning government-funded technology under the Bayh-Dole Act.\n\nTherefore, the correct answer is **D: March-in rights**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 16000, "result": 1.0, "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?", "options": {"A": "Linda Arsenault", "B": "Debra Canner", "C": "Camille L. Bedrosian, MD", "D": "John Smith", "E": "Maria Gonzalez", "F": "James Patel"}, "LLM_original_answer": ["To answer the question \"Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that discusses changes in key personnel, which is likely to include information about the replacement of the Chief Medical Officer.\n\n2. **Locate the specific information**: Scanning the document, I find the following relevant sentence:\n   - \"In December 2023, our then Global Head of Clinical R&D and Chief Medical Officer, Patrick Yeramian, M.D., was replaced by Camille L. Bedrosian, MD as our current Chief Medical Officer.\"\n\n3. **Extract the answer**: From the sentence, it is clear that Camille L. Bedrosian, MD replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023.\n\n4. **Match the answer to the options**: The correct answer, Camille L. Bedrosian, MD, corresponds to option C.\n\nTherefore, the answer to the question is:\n\n**C: Camille L. Bedrosian, MD**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 16000, "result": 1.0, "question": "At what point in time is the revenue for cash trading and equity options recorded?", "options": {"A": "At the beginning of the transaction", "B": "At the end of the fiscal year", "C": "At the point in time of the transaction", "D": "When the transaction is settled", "E": "At the time of customer payment", "F": "When the market closes for the day"}, "LLM_original_answer": ["To answer the question \"At what point in time is the revenue for cash trading and equity options recorded?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Relevant Section**: The document contains a section titled \"Revenue Recognition\" which is likely to contain the information needed to answer the question.\n\n2. **Locate the Specific Information**: Within the \"Revenue Recognition\" section, there is a subsection that specifically discusses \"Cash Equities and Equity Options.\"\n\n3. **Extract the Information**: The relevant information is found in the \"Cash Equities and Equity Options\" subsection:\n   - \"Revenues in our cash equity and equity options markets represent trade execution fees.\"\n   - \"Cash trading and equity options contain one performance obligation related to each transaction which occurs instantaneously, and the revenue is recorded at the point in time of the transaction.\"\n\n4. **Match the Information to the Options**: The document clearly states that revenue for cash trading and equity options is recorded \"at the point in time of the transaction.\"\n\n5. **Select the Correct Option**: The correct option that matches this information is:\n   - **C: At the point in time of the transaction**\n\nTherefore, the revenue for cash trading and equity options is recorded at the point in time of the transaction."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 16000, "result": 1.0, "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?", "options": {"A": "60%", "B": "70%", "C": "75%", "D": "80%", "E": "Over 80%", "F": "90%"}, "LLM_original_answer": ["To answer the question \"What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant information**: The document states, \"Over 80 % of other invested assets is comprised of freestanding derivatives with positive estimated fair values.\"\n\n2. **Match the information to the options**: The statement \"Over 80%\" directly corresponds to one of the options provided.\n\n3. **Select the correct option**: The correct option is E: Over 80%.\n\nTherefore, the answer to the question is **E: Over 80%**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 60, "token_lengths": 32000, "result": 1.0, "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?", "options": {"A": "Results of operations", "B": "Capital requirements", "C": "Stock performance graph", "D": "Financial condition", "E": "Contractual arrangements", "F": "Limitations in debt agreements"}, "LLM_original_answer": ["To answer the question, we need to identify which factor does not influence the discretion of the board of directors in deciding to pay cash dividends. Let's analyze each option in the context of the provided document:\n\n1. **Results of operations (A)**: The document mentions that the company has incurred significant operating losses and does not expect to generate revenue from product sales in the foreseeable future. This suggests that the results of operations are a critical factor in the board's decision to pay dividends.\n\n2. **Capital requirements (B)**: The document discusses the need for substantial additional funding to support ongoing and future activities, including clinical trials and commercialization efforts. This indicates that capital requirements are a significant factor in the board's decision to pay dividends.\n\n3. **Stock performance graph (C)**: The document does not mention stock performance graphs as a factor influencing the board's decision to pay dividends. Instead, it focuses on the company's financial condition, operational results, and capital needs.\n\n4. **Financial condition (D)**: The document explicitly states that the company's financial condition is a key factor in the board's decision to pay dividends. It mentions the company's accumulated deficit and the need to retain funds for development and expansion.\n\n5. **Contractual arrangements (E)**: The document discusses various contractual arrangements, such as licensing agreements and collaboration agreements, which can impact the company's financial condition and, by extension, the decision to pay dividends.\n\n6. **Limitations in debt agreements (F)**: The document mentions that the company may be subject to limitations in debt agreements, which could restrict the payment of dividends.\n\nGiven this analysis, the factor that does not influence the discretion of the board of directors in deciding to pay cash dividends is:\n\n**C: Stock performance graph**\n\nThe document does not provide any information suggesting that stock performance graphs are a factor in the board's decision-making process regarding dividend payments. The focus is on financial condition, capital requirements, and other operational and contractual factors."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 32000, "result": 0.0, "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?", "options": {"A": "A complete dismissal of all lawsuits", "B": "A $15 million secured claim", "C": "A final release of all claims with Gryphon Digital Mining", "D": "An allowed $10 million general unsecured claim", "E": "Ownership of new mining equipment", "F": "A partnership extension with Gryphon"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant section in the document that discusses the Bankruptcy Court's actions on January 16, 2024.\n2. Determine what was granted to Sphere 3D Corp. on that date.\n3. Match the information found in the document to the provided options.\n\n### Step 1: Identify the Relevant Section\nThe relevant section is found in the \"Chapter 11 Filing and Other Related Matters\" part of the document, specifically under the \"Sphere 3D Corp. and Gryphon Settlement\" subsection:\n\n> **Sphere 3D Corp. and Gryphon Settlement**\n> On January 16, 2024, the Bankruptcy Court entered an order (the \u201cCore-Sphere-Gryphon Order\u201d), granting Sphere 3D Corp (\u201cSphere\u201d) an allowed $ 10 million general unsecured claim and a complete and final release of all claims of Sphere and Gryphon Digital Mining, Inc. (\u201cGryphon\u201d) against the Debtors related to the hosting contracts. As part of the resolution, all miners have been returned to the client. Furthermore, the adversary proceeding was dismissed with prejudice, against both Gryphon and Sphere. The satisfaction of the settlement resulted in a gain of $ 23.3 million recorded to Reorganization items, net in the Consolidated Statements of Operations for the year ended December 31, 2023.\n\n### Step 2: Determine What Was Granted to Sphere 3D Corp.\nFrom the relevant section, we can see that the Bankruptcy Court granted Sphere 3D Corp.:\n- An allowed $10 million general unsecured claim.\n- A complete and final release of all claims of Sphere and Gryphon Digital Mining, Inc. against the Debtors related to the hosting contracts.\n\n### Step 3: Match the Information to the Provided Options\n- **Option A: A complete dismissal of all lawsuits** - This is partially correct, as the adversary proceeding was dismissed with prejudice, but it does not cover all lawsuits.\n- **Option B: A $15 million secured claim** - This is incorrect, as the claim was unsecured and for $10 million.\n- **Option C: A final release of all claims with Gryphon Digital Mining** - This is correct, as the order granted a complete and final release of all claims of Sphere and Gryphon against the Debtors.\n- **Option D: An allowed $10 million general un"], "LLM_extracted_answer": ["C"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 32000, "result": 1.0, "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?", "options": {"A": "A significant financial penalty was imposed", "B": "The case was settled with a material financial impact", "C": "The lawsuit was dismissed", "D": "The resolution caused Duke Energy Carolinas to alter the dam structure", "E": "Duke Energy Carolinas had to issue a public apology", "F": "The case is still ongoing"}, "LLM_original_answer": ["To answer the question \"What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions a specific lawsuit involving Duke Energy Carolinas and a low-head dam on the Dan River. This information is found in the \"Duke Energy Carolinas\" section under \"Litigation\".\n\n2. **Extract the key details**:\n   - **Incident**: On June 16, 2021, a group of nine individuals went over a low-head dam adjacent to the Dan River Steam Station in Eden, North Carolina, while water tubing. Four people were rescued, and five others were confirmed deceased.\n   - **Lawsuit**: On August 11, 2021, Duke Energy Carolinas was served with a complaint filed in Durham County Superior Court on behalf of four survivors, which was later amended to include all the decedents and survivors.\n   - **Allegations**: The lawsuit alleged that Duke Energy Carolinas knew the river was used for recreational purposes, did not adequately warn about the dam, and created a dangerous and hidden hazard on the Dan River.\n   - **Resolution**: In 2023, Duke Energy Carolinas reached an agreement that resolved this matter. The resolution did not have a material financial impact and was approved by the Durham County Superior Court. The case was dismissed on June 6, 2023.\n\n3. **Match the details to the options**:\n   - **Option A**: A significant financial penalty was imposed. (Not applicable, as the resolution did not have a material financial impact.)\n   - **Option B**: The case was settled with a material financial impact. (Not applicable, as the resolution did not have a material financial impact.)\n   - **Option C**: The lawsuit was dismissed. (Applicable, as the case was dismissed on June 6, 2023.)\n   - **Option D**: The resolution caused Duke Energy Carolinas to alter the dam structure. (Not mentioned in the document.)\n   - **Option E**: Duke Energy Carolinas had to issue a public apology. (Not mentioned in the document.)\n   - **Option F**: The case is still ongoing. (Not applicable, as the case was dismissed.)\n\n4. **Conclusion**: Based on the information provided, the correct answer is **Option C: The lawsuit was dismissed**.\n\nThe document"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 32000, "result": 1.0, "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?", "options": {"A": "A detailed financial statement", "B": "A personal or corporate guarantee", "C": "An independent appraisal review", "D": "Proof of project completion", "E": "An environmental impact assessment", "F": "A feasibility study"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document.\n\nThe question asks: \"What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?\"\n\nThe relevant section from the document is:\n\n> Under its lending guidelines, the Company generally requires a corporate or personal guarantee from individuals that hold material ownership in the borrowing entity when the loan-to-value of a commercial and industrial loan is in excess of a specified threshold.\n\nThis statement indicates that when the loan-to-value ratio of a commercial and industrial loan exceeds a certain threshold, the Company typically requires a corporate or personal guarantee from individuals with significant ownership in the borrowing entity.\n\nHowever, the question specifically asks about commercial real estate loans, not commercial and industrial loans. To find the answer, I will look for a similar statement related to commercial real estate loans:\n\n> Under its lending guidelines, the Company generally requires a corporate or personal guarantee from individuals that hold material ownership in the borrowing entity when the loan-to-value of a commercial real estate loan is in excess of a specified threshold.\n\nThis statement directly addresses the requirement for commercial real estate loans. It confirms that when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold, the Company typically requires a corporate or personal guarantee from individuals with significant ownership in the borrowing entity.\n\nTherefore, the correct answer is:\n\n**B: A personal or corporate guarantee**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 60, "token_lengths": 32000, "result": 1.0, "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?", "options": {"A": "Having exclusive rights to future programs", "B": "Primary responsibility for conducting marketing activities", "C": "Demonstrating sufficient cash resources and personnel", "D": "Approval from the external governing board", "E": "Completion of preclinical research activities", "F": "An environmental impact assessment"}, "LLM_original_answer": ["To answer the question \"What determines the company's right to co-develop, co-promote, and co-commercialize a target?\" based on the provided document, I will analyze the relevant sections step by step.\n\n1. **Identify Relevant Sections:**\n   - The document mentions the company's rights to co-develop, co-promote, and co-commercialize drug candidates in the context of collaboration agreements with Gilead, Sanofi, and Pfizer.\n   - Specifically, the Sanofi Agreement is detailed in a way that directly addresses the criteria for exercising these rights.\n\n2. **Analyze the Sanofi Agreement:**\n   - **Sanofi Agreement (Page 107):**\n     - \"Our right to exercise our option to co-develop, co-promote and co-commercialize a given target is dependent on our ability to demonstrate, within a given timeframe, that we have sufficient cash resources and personnel to commercialize the product.\"\n     - This statement clearly indicates that the company's right to co-develop, co-promote, and co-commercialize a target is contingent on demonstrating sufficient cash resources and personnel.\n\n3. **Evaluate Other Options:**\n   - **Option A: Having exclusive rights to future programs**\n     - The document does not mention that exclusive rights to future programs determine the company's right to co-develop, co-promote, and co-commercialize a target.\n   - **Option B: Primary responsibility for conducting marketing activities**\n     - The document does not state that primary responsibility for conducting marketing activities is a determining factor.\n   - **Option C: Demonstrating sufficient cash resources and personnel**\n     - This is explicitly mentioned in the Sanofi Agreement section.\n   - **Option D: Approval from the external governing board**\n     - The document does not mention that approval from an external governing board is a determining factor.\n   - **Option E: Completion of preclinical research activities**\n     - While the company is responsible for preclinical research activities, the document does not state that the completion of these activities alone determines the right to co-develop, co-promote, and co-commercialize a target.\n   - **Option F: An environmental impact assessment**\n     - The document does not mention that an environmental impact assessment is a determining factor.\n\n4. **Conclusion:**\n   - Based on the explicit statement in the Sanofi Agreement section, the company's right to co-develop, co-promote, and co-commercialize a target is determined by demonstrating sufficient cash resources and personnel.\n\nTherefore, the correct answer is **C: Demonstrating"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 32000, "result": 1.0, "question": "What do the valuation experts incorporate in their pricing process?", "options": {"A": "Only the historical market trends", "B": "Calculations based solely on risk premiums", "C": "Assumptions related to non-market activities", "D": "Industry survey results and client feedback", "E": "Internal financial projections", "F": "Unrelated economic indicators"}, "LLM_original_answer": ["To answer the question \"What do the valuation experts incorporate in their pricing process?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Mortgage Servicing Rights (MSRs) Valuation**:\n   - The document states that the fair value of MSRs is determined using discounted cash flow methodologies.\n   - The significant components of the estimated future cash inflows for MSRs include servicing fees, late fees, float earnings, and other ancillary fees.\n   - Significant cash outflows include the cost of servicing, the cost of financing servicing advances, and compensating interest payments.\n   - The document mentions that third-party valuation experts use transactions involving instruments with similar collateral and risk profiles, adjusted as necessary based on specific characteristics of the asset or liability being valued.\n   - Industry-standard modeling, such as a discounted cash flow model and prepayment model, is also used.\n   - The prices provided by the valuation experts reflect their observations and assumptions related to market activity, incorporating available industry survey results and client feedback, and including risk premiums and liquidity adjustments.\n\n2. **Reverse Mortgage Loans Valuation**:\n   - The fair value of reverse mortgage loans is based on the expected future cash flows discounted over the expected life of the loans at a rate commensurate with the risk of the estimated cash flows, including future draw commitments for HECM loans.\n   - Inputs of the discounted cash flows include future draws, tail securitization spreads, conditional prepayment rates (including voluntary and involuntary prepayments), and discount rates.\n\n3. **General Valuation Process**:\n   - The document emphasizes that the fair value is estimated using a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs.\n   - Observable inputs are based on market data obtained from independent sources.\n   - Unobservable inputs are based on the reporting entity\u2019s own assumptions about the assumptions market participants would use, developed based on the best information available.\n\n4. **Specific Assumptions and Inputs**:\n   - Prepayment speeds\n   - Cost to service\n   - Discount rates\n   - Delinquency rates\n   - Future draw commitments\n   - Tail securitization spreads\n   - Risk premiums\n   - Liquidity adjustments\n\nGiven the above information, the valuation experts incorporate a variety of factors in their pricing process, including market data, industry survey results, client feedback, and specific assumptions about prepayment speeds, cost to service, and discount rates. Therefore, the most comprehensive and"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 32000, "result": 1.0, "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?", "options": {"A": "Exclusive commercialization rights", "B": "Complete ownership of patents", "C": "Rights to revoke licenses", "D": "March-in rights", "E": "Rights to set the technology price", "F": "Rights to sell the technology internationally"}, "LLM_original_answer": ["To answer the question \"What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for mentions of the Bayh-Dole Act and the rights associated with government-funded technology.\n2. **Analyze the Information**: Determine which specific rights are mentioned.\n3. **Match to the Options**: Compare the identified rights to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant information is found in the following excerpt:\n\n> Pursuant to the Bayh-Dole Act, the U.S. government has march-in rights with regards to government-funded technology. For example, the U.S. government has certain rights, including march-in rights, to patent rights and technology funded by the U.S. government and licensed to us from BWH. When new technologies are developed with government funding, in order to secure ownership of such patent rights, the recipient of such funding is required to comply with certain government regulations, including timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such inventions. Any failure to timely elect title to such inventions may provide the U.S. government with the right to, at any time, take title to such inventions. Additionally, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention or to have others use the invention on its behalf. If the government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. These rights may permit the U.S. government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The U.S. government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the U.S.\n\n### Step 2: Analyze the Information\nFrom the excerpt, the U.S. government has the following rights concerning government-funded technology under the Bayh-Dole Act:\n- **March-in rights**: The government can exercise these rights if it determines that"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 32000, "result": 1.0, "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?", "options": {"A": "Linda Arsenault", "B": "Debra Canner", "C": "Camille L. Bedrosian, MD", "D": "John Smith", "E": "Maria Gonzalez", "F": "James Patel"}, "LLM_original_answer": ["To answer the question \"Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?\", I will follow these steps:\n\n1. **Identify the relevant information in the document:**\n   - The document states: \"In December 2023, our then Global Head of Clinical R&D and Chief Medical Officer, Patrick Yeramian, M.D., was replaced by Camille L. Bedrosian, MD as our current Chief Medical Officer.\"\n\n2. **Match the information to the options provided:**\n   - Option A: Linda Arsenault\n   - Option B: Debra Canner\n   - Option C: Camille L. Bedrosian, MD\n   - Option D: John Smith\n   - Option E: Maria Gonzalez\n   - Option F: James Patel\n\n3. **Select the correct answer:**\n   - The document clearly indicates that Camille L. Bedrosian, MD replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023.\n\nTherefore, the correct answer is **Option C: Camille L. Bedrosian, MD**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 32000, "result": 1.0, "question": "At what point in time is the revenue for cash trading and equity options recorded?", "options": {"A": "At the beginning of the transaction", "B": "At the end of the fiscal year", "C": "At the point in time of the transaction", "D": "When the transaction is settled", "E": "At the time of customer payment", "F": "When the market closes for the day"}, "LLM_original_answer": ["To answer the question \"At what point in time is the revenue for cash trading and equity options recorded?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section on revenue recognition, which is likely to provide the necessary information.\n\n2. **Locate the specific information**: Within the revenue recognition section, I will look for details related to cash trading and equity options.\n\n3. **Extract the relevant information**: I will extract the specific details that answer the question.\n\n4. **Formulate the answer**: Based on the extracted information, I will determine the correct option from the given choices.\n\n### Step 1: Identify the relevant section\nThe relevant section is found in \"5. Revenue Recognition\" of the document.\n\n### Step 2: Locate the specific information\nIn the \"5. Revenue Recognition\" section, there is a subsection that specifically discusses \"Cash Equities and Equity Options\" revenues.\n\n### Step 3: Extract the relevant information\nThe document states:\n- **Cash Equities and Equity Options**: \"Revenues in our cash equity and equity options markets represent trade execution fees. Cash trading and equity options contain one performance obligation related to each transaction which occurs instantaneously, and the revenue is recorded at the point in time of the transaction.\"\n\n### Step 4: Formulate the answer\nBased on the extracted information, the revenue for cash trading and equity options is recorded at the point in time of the transaction.\n\nTherefore, the correct answer is:\n**C: At the point in time of the transaction**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 32000, "result": 1.0, "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?", "options": {"A": "60%", "B": "70%", "C": "75%", "D": "80%", "E": "Over 80%", "F": "90%"}, "LLM_original_answer": ["To answer the question \"What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The relevant information is found in the \"Other Invested Assets\" section of the document.\n\n2. **Extract the key information**: The document states:\n   - \"Other invested assets consist principally of freestanding derivatives with positive estimated fair values which are described in \u2018\u2014 Derivatives\u2019 below.\"\n   - \"Over 80 % of other invested assets is comprised of freestanding derivatives with positive estimated fair values.\"\n\n3. **Match the extracted information to the options**: The document explicitly states that over 80% of other invested assets is comprised of freestanding derivatives with positive estimated fair values.\n\n4. **Select the correct option**: The correct option that matches the information provided in the document is:\n   - **E: Over 80%**\n\nTherefore, the answer to the question is **E: Over 80%**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 60, "token_lengths": 64000, "result": 1.0, "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?", "options": {"A": "Results of operations", "B": "Capital requirements", "C": "Stock performance graph", "D": "Financial condition", "E": "Contractual arrangements", "F": "Limitations in debt agreements"}, "LLM_original_answer": ["To answer the question, we need to identify which factor does not influence the discretion of the board of directors in deciding to pay cash dividends. The provided document does not directly address the factors influencing the board's decision to pay dividends. However, we can infer from the context and general business knowledge that the factors listed in the options are typically considered by boards when making such decisions.\n\nLet's analyze each option:\n\nA: Results of operations - This is a critical factor. Boards often consider the company's financial performance and profitability when deciding on dividends.\n\nB: Capital requirements - Boards need to consider the company's future capital needs, such as investments in research and development, to ensure the company's long-term growth and stability.\n\nC: Stock performance graph - This is less directly related to the board's decision. While stock performance can influence investor expectations and the company's overall financial health, it is not a primary factor in the decision to pay dividends.\n\nD: Financial condition - This is a key factor. The company's overall financial health and liquidity are crucial in determining whether it can afford to pay dividends.\n\nE: Contractual arrangements - Boards must consider any contractual obligations that may restrict the payment of dividends, such as agreements with creditors or investors.\n\nF: Limitations in debt agreements - Similar to contractual arrangements, limitations in debt agreements can directly impact the board's ability to pay dividends.\n\nGiven this analysis, the factor that does not directly influence the board's discretion in deciding to pay cash dividends is:\n\nC: Stock performance graph\n\nThe stock performance graph, while important for investor relations and overall company valuation, is not a primary factor in the board's decision-making process for dividend payments. The board's primary focus is on the company's financial performance, capital needs, financial condition, and any legal or contractual restrictions."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 64000, "result": 1.0, "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?", "options": {"A": "A complete dismissal of all lawsuits", "B": "A $15 million secured claim", "C": "A final release of all claims with Gryphon Digital Mining", "D": "An allowed $10 million general unsecured claim", "E": "Ownership of new mining equipment", "F": "A partnership extension with Gryphon"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step:\n\n1. **Identify the relevant section**: The document contains a section titled \"Sphere 3D Corp. and Gryphon Settlement\" which is likely to contain the information about what was granted to Sphere 3D Corp. by the Bankruptcy Court.\n\n2. **Extract the relevant information**:\n   - On January 16, 2024, the Bankruptcy Court entered an order (the \u201cCore-Sphere-Gryphon Order\u201d).\n   - The order granted Sphere 3D Corp. (\u201cSphere\u201d) an allowed $10 million general unsecured claim.\n   - The order also provided a complete and final release of all claims of Sphere and Gryphon Digital Mining, Inc. (\u201cGryphon\u201d) against the Debtors related to the hosting contracts.\n   - As part of the resolution, all miners have been returned to the client.\n   - Furthermore, the adversary proceeding was dismissed with prejudice, against both Gryphon and Sphere.\n\n3. **Match the information to the options**:\n   - **Option A**: A complete dismissal of all lawsuits - This is partially correct as the adversary proceeding was dismissed with prejudice.\n   - **Option B**: A $15 million secured claim - This is incorrect as the claim was unsecured.\n   - **Option C**: A final release of all claims with Gryphon Digital Mining - This is correct as the order provided a complete and final release of all claims.\n   - **Option D**: An allowed $10 million general unsecured claim - This is correct as the order granted Sphere an allowed $10 million general unsecured claim.\n   - **Option E**: Ownership of new mining equipment - This is incorrect as the miners were returned to the client.\n   - **Option F**: A partnership extension with Gryphon - This is incorrect as the order did not mention any partnership extension.\n\n4. **Determine the most accurate answer**:\n   - The most accurate answer is **Option D**: An allowed $10 million general unsecured claim, as it directly matches the information provided in the document.\n\nTherefore, the correct answer is **D: An allowed $10 million general unsecured claim**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 64000, "result": 1.0, "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?", "options": {"A": "A significant financial penalty was imposed", "B": "The case was settled with a material financial impact", "C": "The lawsuit was dismissed", "D": "The resolution caused Duke Energy Carolinas to alter the dam structure", "E": "Duke Energy Carolinas had to issue a public apology", "F": "The case is still ongoing"}, "LLM_original_answer": ["To answer the question regarding the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River, I will analyze the relevant information provided in the document:\n\n1. **Identify the relevant section**: The relevant section is found under \"LITIGATION\" in the document, specifically the part that discusses the lawsuit involving the low-head dam on the Dan River.\n\n2. **Extract the key information**:\n   - **Case Details**: On June 16, 2021, a group of nine individuals went over a low-head dam adjacent to the Dan River Steam Station in Eden, North Carolina, while water tubing. Four people were rescued, and five others were confirmed deceased.\n   - **Lawsuit Filed**: On August 11, 2021, Duke Energy Carolinas was served with a complaint filed in Durham County Superior Court on behalf of four survivors, which was later amended to include all the decedents and survivors.\n   - **Allegations**: The lawsuit alleged that Duke Energy Carolinas knew the river was used for recreational purposes, did not adequately warn about the dam, and created a dangerous and hidden hazard on the Dan River.\n   - **Resolution**: In 2023, Duke Energy Carolinas reached an agreement that resolved this matter. The resolution did not have a material financial impact and was approved by the Durham County Superior Court.\n   - **Case Dismissal**: The case was dismissed on June 6, 2023.\n\n3. **Evaluate the options**:\n   - **A: A significant financial penalty was imposed** - This is not correct because the resolution did not have a material financial impact.\n   - **B: The case was settled with a material financial impact** - This is not correct because the resolution did not have a material financial impact.\n   - **C: The lawsuit was dismissed** - This is correct because the case was dismissed on June 6, 2023.\n   - **D: The resolution caused Duke Energy Carolinas to alter the dam structure** - This is not mentioned in the document.\n   - **E: Duke Energy Carolinas had to issue a public apology** - This is not mentioned in the document.\n   - **F: The case is still ongoing** - This is incorrect because the case was dismissed.\n\n4. **Conclusion**:\n   - The correct answer is **C: The lawsuit was dismissed**.\n\nThe document clearly states that the case was dismissed on June 6,"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 64000, "result": 1.0, "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?", "options": {"A": "A detailed financial statement", "B": "A personal or corporate guarantee", "C": "An independent appraisal review", "D": "Proof of project completion", "E": "An environmental impact assessment", "F": "A feasibility study"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to find relevant information.\n\n### Step 1: Identify the Context\nThe question is about what is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value (LTV) ratio of a commercial real estate loan exceeds a certain threshold.\n\n### Step 2: Locate Relevant Information\nI will look for sections that discuss commercial real estate loans and the requirements for significant ownership.\n\n#### Key Sections:\n1. **Commercial Real Estate Portfolio**:\n   - \"The increase in such loan balances was primarily due to management\u2019s active focus on originating loans collateralized by industrial/warehouse and multi-family property types, which are included in the commercial real estate investment loan category, due to management\u2019s belief that the credit performance of such loans has a stable outlook.\"\n\n2. **Loan to Value Ratio (LTV)**:\n   - \"We generally require an LTV of 80% or less on new CRE loan originations. Certain CRE loans with LTVs greater than 80% may have additional collateral pledged which is not included in the computation of the amounts stated.\"\n\n3. **Credit Quality and Risk Management**:\n   - \"For the commercial portfolio, which includes our commercial and industrial, commercial real estate, commercial construction and business banking loans, we monitor credit quality using a risk rating scale, which assigns a risk-grade to each borrower based on a number of quantitative and qualitative factors associated with a commercial loan transaction.\"\n   - \"Key factors include: industry and market conditions, position within the industry, earnings trends, operating cash flow, asset/liability values, debt capacity, guarantor strength, management and controls, financial reporting, collateral and other considerations.\"\n\n4. **Guarantor Strength**:\n   - \"Under its lending guidelines, the Company generally requires a corporate or personal guarantee from individuals that hold material ownership in the borrowing entity when the loan-to-value of a commercial and industrial loan is in excess of a specified threshold.\"\n   - \"Under its lending guidelines, the Company generally requires a corporate or personal guarantee from individuals that hold material ownership in the borrowing entity when the loan-to-value of a commercial real estate loan is in excess of a specified threshold.\"\n\n### Step 3: Synthesize the Information\nFrom the document, it is clear that when the LTV ratio of a commercial real estate loan exceeds a certain threshold (80% in this case), the company generally requires additional collateral or a personal or corporate guarantee from individuals with significant ownership in the borrowing"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 60, "token_lengths": 64000, "result": 1.0, "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?", "options": {"A": "Having exclusive rights to future programs", "B": "Primary responsibility for conducting marketing activities", "C": "Demonstrating sufficient cash resources and personnel", "D": "Approval from the external governing board", "E": "Completion of preclinical research activities", "F": "An environmental impact assessment"}, "LLM_original_answer": ["To answer the question \"What determines the company's right to co-develop, co-promote, and co-commercialize a target?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the Context**: The document discusses various collaborations and agreements the company has with other biopharmaceutical companies, such as Gilead, Sanofi, and Pfizer. These collaborations involve the discovery, development, and commercialization of drug candidates.\n\n2. **Examine the Specific Agreements**:\n   - **Gilead Agreement**:\n     - Gilead has the option to license drug candidates directed to up to five targets.\n     - The company retains the option to co-develop and co-promote up to two drug candidates in the United States.\n     - The company can only exercise this option once per licensed product.\n     - Gilead retains the right to veto the company\u2019s option selection for any one drug candidate of its choice.\n   - **Sanofi Agreement**:\n     - Sanofi has exclusive rights and is responsible for the clinical development, commercialization, and manufacture of drug candidates.\n     - The company retains the option to co-develop, co-promote, and co-commercialize all drug candidates in the United States directed to up to two targets.\n     - The company\u2019s right to exercise this option is dependent on its ability to demonstrate, within a given timeframe, that it has sufficient cash resources and personnel to commercialize the product.\n   - **Pfizer Agreement**:\n     - Pfizer has the option to obtain exclusive licenses to develop and commercialize certain degraders.\n     - The company retains an option for U.S. profit sharing and co-promotion on two products arising from the collaboration.\n\n3. **Determine the Key Factor**:\n   - For the Sanofi Agreement, the document explicitly states: \"The Company\u2019s right to exercise its option to co-develop, co-promote and co-commercialize a given target is dependent on its ability to demonstrate, within a given timeframe, that it has sufficient cash resources and personnel to commercialize the product.\"\n\n4. **Match the Key Factor to the Options**:\n   - **Option A**: Having exclusive rights to future programs\n     - This is not mentioned as a determining factor for co-development, co-promotion, and co-commercialization.\n   - **Option B**: Primary responsibility for conducting marketing activities\n     - This is not mentioned as a determining factor for co-development, co-promotion, and co-commercialization.\n   -"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 64000, "result": 1.0, "question": "What do the valuation experts incorporate in their pricing process?", "options": {"A": "Only the historical market trends", "B": "Calculations based solely on risk premiums", "C": "Assumptions related to non-market activities", "D": "Industry survey results and client feedback", "E": "Internal financial projections", "F": "Unrelated economic indicators"}, "LLM_original_answer": ["To answer the question \"What do the valuation experts incorporate in their pricing process?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Valuation of MSRs and Other Financing Liabilities, at Fair Value**:\n   - The document states: \"We engage third-party valuation experts who generally utilize: (a) transactions involving instruments with similar collateral and risk profiles, adjusted as necessary based on specific characteristics of the asset or liability being valued; and/or (b) industry-standard modeling, such as a discounted cash flow model and a prepayment model, in arriving at their estimate of fair value.\"\n   - It further mentions: \"The prices provided by the valuation experts reflect their observations and assumptions related to market activity, generally the bulk market, incorporating available industry survey results and client feedback, and including risk premiums and liquidity adjustments.\"\n\n2. **Fair Value - Mortgage Servicing Rights**:\n   - The document provides: \"The significant components of the estimated future cash inflows for MSRs include servicing fees, late fees, float earnings and other ancillary fees. Significant cash outflows include the cost of servicing, the cost of financing servicing advances and compensating interest payments.\"\n\n3. **Fair Value \u2013 Loans Held for Investment**:\n   - The document states: \"The fair value of reverse mortgage loans held for investment and HMBS-related borrowings is based primarily on discounted cash flow methodologies. Inputs to the discounted cash flows of these assets include future draws and tail securitization spreads, conditional prepayment rate (including voluntary and involuntary prepayments) and discount rate.\"\n\n4. **Fair Value of Pledged MSR Liability**:\n   - The document mentions: \"The fair value of the Pledged MSR liability is determined using the fair value mark provided by third-party valuation experts, consistent with the associated MSR, using the same methodology and assumptions, while considering cash flows contractually retained by PHH and expected life of subservicing agreement, when applicable.\"\n\nFrom these points, we can conclude that the valuation experts incorporate the following in their pricing process:\n\n- **Transactions involving instruments with similar collateral and risk profiles, adjusted as necessary based on specific characteristics of the asset or liability being valued**.\n- **Industry-standard modeling, such as a discounted cash flow model and a prepayment model**.\n- **Observations and assumptions related to market activity, generally the bulk market**.\n- **Available industry survey results and client feedback**.\n- **Risk premiums and liquidity adjustments**.\n- **Future draws and tail secur"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 64000, "result": 1.0, "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?", "options": {"A": "Exclusive commercialization rights", "B": "Complete ownership of patents", "C": "Rights to revoke licenses", "D": "March-in rights", "E": "Rights to set the technology price", "F": "Rights to sell the technology internationally"}, "LLM_original_answer": ["To answer the question \"What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for mentions of the Bayh-Dole Act and any related government rights.\n2. **Analyze the Information**: Determine which specific rights are mentioned.\n3. **Match to Options**: Compare the identified rights to the given options to find the best match.\n\n### Step 1: Identify Relevant Information\nThe relevant information is found in the following excerpt from the document:\n\n> \"Certain of our in-licensed patent rights may be subject to a reservation of rights by one or more third parties. Pursuant to the Bayh-Dole Act, the U.S. government has march-in rights with regards to government-funded technology. For example, the U.S. government has certain rights, including march-in rights, to patent rights and technology funded by the U.S. government and licensed to us from BWH. When new technologies are developed with government funding, in order to secure ownership of such patent rights, the recipient of such funding is required to comply with certain government regulations, including timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such inventions. Any failure to timely elect title to such inventions may provide the U.S. government with the right to, at any time, take title to such inventions. Additionally, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention or to have others use the invention on its behalf. If the government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. These rights may permit the U.S. government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The U.S. government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the U.S. Any exercise by the government of any of the foregoing rights could harm our competitive position, business, financial condition, results of operations, and prospects"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 64000, "result": 1.0, "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?", "options": {"A": "Linda Arsenault", "B": "Debra Canner", "C": "Camille L. Bedrosian, MD", "D": "John Smith", "E": "Maria Gonzalez", "F": "James Patel"}, "LLM_original_answer": ["To answer the question \"Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that discusses changes in key personnel, which is likely to include information about the replacement of the Chief Medical Officer.\n\n2. **Locate the specific information**: I will look for a sentence or paragraph that mentions Patrick Yeramian, M.D., and the person who replaced him.\n\n3. **Extract the answer**: Once I find the relevant information, I will extract the name of the person who replaced Patrick Yeramian, M.D.\n\n4. **Verify the answer**: I will double-check the extracted information to ensure it is accurate and matches the question.\n\nLet's go through the document:\n\n### Step 1: Identify the relevant section\nThe relevant section is found in the \"Risks Related to Our Business Operations, Employee Matters and Managing Growth\" section, which discusses changes in key personnel.\n\n### Step 2: Locate the specific information\nThe specific information is found in the following paragraph:\n\n> \"In December 2023, our then Global Head of Clinical R&D and Chief Medical Officer, Patrick Yeramian, M.D., was replaced by Camille L. Bedrosian, MD as our current Chief Medical Officer.\"\n\n### Step 3: Extract the answer\nThe person who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023 is **Camille L. Bedrosian, MD**.\n\n### Step 4: Verify the answer\nThe extracted information is clear and directly answers the question. The document states that Camille L. Bedrosian, MD, replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023.\n\n### Final Answer\nThe correct answer is **C: Camille L. Bedrosian, MD**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 64000, "result": 1.0, "question": "At what point in time is the revenue for cash trading and equity options recorded?", "options": {"A": "At the beginning of the transaction", "B": "At the end of the fiscal year", "C": "At the point in time of the transaction", "D": "When the transaction is settled", "E": "At the time of customer payment", "F": "When the market closes for the day"}, "LLM_original_answer": ["To answer the question \"At what point in time is the revenue for cash trading and equity options recorded?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss revenue recognition, particularly for cash trading and equity options.\n2. **Extract Key Information**: Extract the specific details about when revenue is recognized for these types of transactions.\n3. **Match Information to Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant section for revenue recognition is found in **Note 5: Revenue Recognition**. Specifically, the part that discusses **Exchanges Revenues** and **Cash Equities and Equity Options**.\n\n### Step 2: Extract Key Information\nFrom the document:\n- **Exchanges Revenues**:\n  - **Futures and Options**: \"Revenues in our futures and options trading businesses primarily represent fees charged for the performance obligations of derivatives trading and clearing. Derivatives trading and clearing fees contain two performance obligations: (1) trade execution/clearing novation and (2) risk management of open interest. While we allocate the transaction price between these two performance obligations, since they generally are satisfied almost simultaneously, there is no significant deferral of revenue.\"\n  - **Cash Equities and Equity Options**: \"Revenues in our cash equity and equity options markets represent trade execution fees. Cash trading and equity options contain one performance obligation related to each transaction which occurs instantaneously, and the revenue is recorded at the point in time of the transaction.\"\n\n### Step 3: Match Information to Options\n- **Futures and Options**: The revenue is recognized almost simultaneously with the performance obligations, but there is no significant deferral.\n- **Cash Equities and Equity Options**: The revenue is recorded at the point in time of the transaction.\n\nGiven the options:\n- A: At the beginning of the transaction\n- B: At the end of the fiscal year\n- C: At the point in time of the transaction\n- D: When the transaction is settled\n- E: At the time of customer payment\n- F: When the market closes for the day\n\nThe correct answer is **C: At the point in time of the transaction**.\n\n### Final Answer\nThe revenue for cash trading and equity options is recorded at the point in time of the transaction."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 64000, "result": 1.0, "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?", "options": {"A": "60%", "B": "70%", "C": "75%", "D": "80%", "E": "Over 80%", "F": "90%"}, "LLM_original_answer": ["To answer the question \"What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The relevant information is found in the \"Other Invested Assets\" section of Note 9 of the Notes to the Consolidated Financial Statements.\n\n2. **Extract the key information**:\n   - The document states: \"Over 80 % of other invested assets is comprised of freestanding derivatives with positive estimated fair values.\"\n\n3. **Match the extracted information to the options**:\n   - The statement \"Over 80%\" directly corresponds to option E: \"Over 80%\".\n\n4. **Conclusion**:\n   - The correct answer is E: Over 80%.\n\nThus, the percentage of other invested assets that is comprised of freestanding derivatives with positive estimated fair values is **Over 80%**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 60, "token_lengths": 96000, "result": 1.0, "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?", "options": {"A": "Results of operations", "B": "Capital requirements", "C": "Stock performance graph", "D": "Financial condition", "E": "Contractual arrangements", "F": "Limitations in debt agreements"}, "LLM_original_answer": ["To answer the question, we need to identify which factor among the given options does not influence the discretion of the board of directors in deciding to pay cash dividends. Let's analyze each option in the context of the provided document:\n\nA: Results of operations - The document mentions that the company's financial performance and results of operations are critical factors in its business. Poor results of operations could negatively impact the company's ability to pay dividends.\n\nB: Capital requirements - The document discusses the significant capital requirements for the company's operations, including clinical trials and product development. High capital requirements could limit the company's ability to pay dividends.\n\nC: Stock performance graph - The document does not mention stock performance graphs as a factor influencing the board's decision to pay dividends. The focus is more on financial and operational metrics.\n\nD: Financial condition - The document emphasizes the importance of the company's financial condition, including cash and cash equivalents, in determining its ability to fund operations and potential dividends.\n\nE: Contractual arrangements - The document mentions various contractual arrangements, such as license agreements and collaboration agreements, which could impose financial obligations or restrictions that affect the company's ability to pay dividends.\n\nF: Limitations in debt agreements - The document discusses the potential for debt agreements to include limitations or covenants that could restrict the company's ability to pay dividends.\n\nGiven this analysis, the factor that does not influence the discretion of the board of directors in deciding to pay cash dividends is:\n\nC: Stock performance graph\n\nThe document does not indicate that stock performance graphs are a factor considered by the board in making dividend decisions. The focus is on financial and operational metrics, capital requirements, and contractual obligations."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 96000, "result": 0.0, "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?", "options": {"A": "A complete dismissal of all lawsuits", "B": "A $15 million secured claim", "C": "A final release of all claims with Gryphon Digital Mining", "D": "An allowed $10 million general unsecured claim", "E": "Ownership of new mining equipment", "F": "A partnership extension with Gryphon"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The document contains a section titled \"Sphere 3D Corp. and Gryphon Settlement\" which is directly related to the question.\n\n2. **Extract the key information**:\n   - On January 16, 2024, the Bankruptcy Court entered an order (the \"Core-Sphere-Gryphon Order\").\n   - The order granted Sphere 3D Corp. (\"Sphere\") an allowed $10 million general unsecured claim.\n   - The order also provided a complete and final release of all claims of Sphere and Gryphon Digital Mining, Inc. (\"Gryphon\") against the Debtors related to the hosting contracts.\n   - As part of the resolution, all miners have been returned to the client.\n   - Furthermore, the adversary proceeding was dismissed with prejudice, against both Gryphon and Sphere.\n\n3. **Match the information to the options**:\n   - **Option A**: A complete dismissal of all lawsuits. This is partially true, as the adversary proceeding was dismissed with prejudice, but it does not cover all lawsuits.\n   - **Option B**: A $15 million secured claim. This is not true, as the claim was $10 million and general unsecured, not secured.\n   - **Option C**: A final release of all claims with Gryphon Digital Mining. This is true, as the order provided a complete and final release of all claims of Sphere and Gryphon against the Debtors.\n   - **Option D**: An allowed $10 million general unsecured claim. This is true, as the order granted Sphere an allowed $10 million general unsecured claim.\n   - **Option E**: Ownership of new mining equipment. This is not true, as the miners were returned to the client.\n   - **Option F**: A partnership extension with Gryphon. This is not mentioned in the document.\n\n4. **Determine the correct answer**:\n   - The correct answer is **Option C: A final release of all claims with Gryphon Digital Mining**. This is explicitly stated in the document and matches the information provided.\n\nTherefore, the answer to the question \"What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?\" is **Option C: A final release of all claims with Gryphon Digital Mining**."], "LLM_extracted_answer": ["C"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 96000, "result": 1.0, "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?", "options": {"A": "A significant financial penalty was imposed", "B": "The case was settled with a material financial impact", "C": "The lawsuit was dismissed", "D": "The resolution caused Duke Energy Carolinas to alter the dam structure", "E": "Duke Energy Carolinas had to issue a public apology", "F": "The case is still ongoing"}, "LLM_original_answer": ["To answer the question regarding the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River, I will analyze the relevant information provided in the document:\n\n1. **Identify the Relevant Section**:\n   - The relevant section is found in Note 5, \"Commitments and Contingencies,\" under the \"Litigation\" subsection.\n\n2. **Extract the Key Information**:\n   - The document states: \"On June 16, 2021, a group of nine individuals went over a low-head dam adjacent to the Dan River Steam Station in Eden, North Carolina, while water tubing. Emergency personnel rescued four people and five others were confirmed deceased.\"\n   - It further mentions: \"In 2023, Duke Energy Carolinas reached an agreement that resolved this matter. The resolution, which did not have a material financial impact, was approved by the Durham County Superior Court. The case was dismissed on June 6, 2023.\"\n\n3. **Analyze the Information**:\n   - The lawsuit was resolved through an agreement.\n   - The resolution did not have a material financial impact.\n   - The case was dismissed on June 6, 2023.\n\n4. **Match the Information to the Options**:\n   - **Option A**: A significant financial penalty was imposed. (Not applicable, as the resolution did not have a material financial impact.)\n   - **Option B**: The case was settled with a material financial impact. (Not applicable, as the resolution did not have a material financial impact.)\n   - **Option C**: The lawsuit was dismissed. (Applicable, as the case was dismissed on June 6, 2023.)\n   - **Option D**: The resolution caused Duke Energy Carolinas to alter the dam structure. (Not mentioned in the document.)\n   - **Option E**: Duke Energy Carolinas had to issue a public apology. (Not mentioned in the document.)\n   - **Option F**: The case is still ongoing. (Not applicable, as the case was dismissed.)\n\n5. **Conclusion**:\n   - The correct answer is **Option C**: The lawsuit was dismissed.\n\nTherefore, the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River is that the case was dismissed."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 96000, "result": 1.0, "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?", "options": {"A": "A detailed financial statement", "B": "A personal or corporate guarantee", "C": "An independent appraisal review", "D": "Proof of project completion", "E": "An environmental impact assessment", "F": "A feasibility study"}, "LLM_original_answer": ["To answer the question, \"What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?\" we need to look for information in the provided document that discusses the requirements for significant owners in the context of commercial real estate loans and loan-to-value (LTV) ratios.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document discusses various aspects of loans, including commercial real estate loans and the requirements for loan guarantees.\n   - The section \"Loans\" in Note 4, \"Loans and Allowance for Credit Losses,\" provides details on the Company's lending policies and practices.\n\n2. **Examine Commercial Real Estate Loan Policies:**\n   - The document states: \"Under its lending guidelines, the Company generally requires a corporate or personal guarantee from individuals that hold material ownership in the borrowing entity when the loan-to-value of a commercial real estate loan is in excess of a specified threshold.\"\n\n3. **Understand the Context:**\n   - This statement directly addresses the requirement for significant owners to provide guarantees when the LTV ratio exceeds a certain threshold.\n   - The term \"material ownership\" is used, which typically refers to significant ownership in the borrowing entity.\n\n4. **Match the Information to the Options:**\n   - **Option A: A detailed financial statement** - The document does not mention detailed financial statements as a requirement for significant owners when the LTV ratio exceeds a threshold.\n   - **Option B: A personal or corporate guarantee** - This matches the statement in the document.\n   - **Option C: An independent appraisal review** - While appraisals are mentioned in the document, they are not specifically required from significant owners when the LTV ratio exceeds a threshold.\n   - **Option D: Proof of project completion** - The document does not mention this as a requirement.\n   - **Option E: An environmental impact assessment** - This is not mentioned as a requirement for significant owners.\n   - **Option F: A feasibility study** - The document does not mention this as a requirement.\n\n### Conclusion:\nBased on the information provided in the document, the correct answer is:\n\n**B: A personal or corporate guarantee**\n\nThis is explicitly stated in the document as a requirement for individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a specified threshold."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 60, "token_lengths": 96000, "result": 1.0, "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?", "options": {"A": "Having exclusive rights to future programs", "B": "Primary responsibility for conducting marketing activities", "C": "Demonstrating sufficient cash resources and personnel", "D": "Approval from the external governing board", "E": "Completion of preclinical research activities", "F": "An environmental impact assessment"}, "LLM_original_answer": ["To answer the question \"What determines the company's right to co-develop, co-promote, and co-commercialize a target?\" based on the provided document, let's analyze the relevant sections:\n\n1. **Gilead Collaboration**:\n   - Under the Gilead Agreement, Gilead has the option to license drug candidates directed to up to five targets resulting from the collaboration.\n   - The company retains the option to co-develop and co-promote, under a profit share structure, up to two drug candidates in the United States, provided that the company may only exercise such option once per licensed product and Gilead retains the right to veto the company\u2019s option selection for any one drug candidate of its choice.\n\n2. **Sanofi Collaboration**:\n   - Sanofi has exclusive rights and is responsible for the clinical development, commercialization, and manufacture of drug candidates resulting from the collaboration.\n   - The company retains the option to co-develop, co-promote, and co-commercialize all drug candidates in the United States directed to up to two targets.\n   - The company\u2019s right to exercise its option to co-develop, co-promote, and co-commercialize a given target is dependent on its ability to demonstrate, within a given timeframe, that it has sufficient cash resources and personnel to commercialize the product.\n\n3. **Pfizer Collaboration**:\n   - Pfizer has the option to obtain exclusive licenses to develop and commercialize certain degraders.\n   - The company retains an option for U.S. profit sharing and co-promotion on two products arising from the collaboration.\n\nFrom the above sections, it is clear that the company's right to co-develop, co-promote, and co-commercialize a target is primarily determined by its ability to demonstrate sufficient cash resources and personnel to commercialize the product. This is explicitly stated in the Sanofi collaboration section.\n\nTherefore, the correct answer is:\n**C: Demonstrating sufficient cash resources and personnel**\n\nThis option aligns with the specific requirement mentioned in the document for the Sanofi collaboration, which is a key part of the company's strategy for co-development and co-commercialization."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 96000, "result": 1.0, "question": "What do the valuation experts incorporate in their pricing process?", "options": {"A": "Only the historical market trends", "B": "Calculations based solely on risk premiums", "C": "Assumptions related to non-market activities", "D": "Industry survey results and client feedback", "E": "Internal financial projections", "F": "Unrelated economic indicators"}, "LLM_original_answer": ["To answer the question \"What do the valuation experts incorporate in their pricing process?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the relevant section in the document:**\n   - The document discusses the valuation of MSRs (Mortgage Servicing Rights) and other financial instruments in several sections, particularly in \"Valuation of MSRs and Other Financing Liabilities, at Fair Value\" under Note 7 and Note 8.\n\n2. **Extract the key information:**\n   - The document states: \"To assist in the determination of fair value, we engage third-party valuation experts who generally utilize: (a) transactions involving instruments with similar collateral and risk profiles, adjusted as necessary based on specific characteristics of the asset or liability being valued; and/or (b) industry-standard modeling, such as a discounted cash flow model and a prepayment model, in arriving at their estimate of fair value.\"\n   - It further mentions: \"The prices provided by the valuation experts reflect their observations and assumptions related to market activity, generally the bulk market, incorporating available industry survey results and client feedback, and including risk premiums and liquidity adjustments.\"\n\n3. **Analyze the information:**\n   - **Transactions involving similar instruments:** Valuation experts consider transactions involving instruments with similar collateral and risk profiles, adjusting for specific characteristics of the asset or liability being valued.\n   - **Industry-standard modeling:** They use models such as discounted cash flow and prepayment models.\n   - **Market activity observations:** The prices reflect observations and assumptions related to market activity, particularly the bulk market.\n   - **Industry survey results and client feedback:** They incorporate available industry survey results and client feedback.\n   - **Risk premiums and liquidity adjustments:** They include risk premiums and liquidity adjustments in their valuations.\n\n4. **Match the information to the provided options:**\n   - **Option A:** Only the historical market trends - This is not accurate as the document mentions more than just historical trends.\n   - **Option B:** Calculations based solely on risk premiums - This is not accurate as the document mentions multiple factors, not just risk premiums.\n   - **Option C:** Assumptions related to non-market activities - This is not accurate as the document focuses on market activities.\n   - **Option D:** Industry survey results and client feedback - This is accurate as the document explicitly mentions incorporating these.\n   - **Option E:** Internal financial projections - This is not explicitly mentioned in the document.\n   - **Option F:** Unrelated"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 96000, "result": 1.0, "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?", "options": {"A": "Exclusive commercialization rights", "B": "Complete ownership of patents", "C": "Rights to revoke licenses", "D": "March-in rights", "E": "Rights to set the technology price", "F": "Rights to sell the technology internationally"}, "LLM_original_answer": ["The correct answer to the question \"What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?\" based on the provided document is:\n\n**D: March-in rights**\n\n### Chain of Thought:\n1. **Identify the Relevant Section**: The document mentions the Bayh-Dole Act in the context of government-funded technology and the rights the U.S. government holds.\n2. **Locate the Specific Information**: The relevant information is found in the section titled \"Risks Related to Manufacturing\" under the sub-section \"Certain of our in-licensed patent rights are, and our future owned and in-licensed patent rights may be, subject to a reservation of rights by one or more third parties, including government march-in rights with regards to certain patents, that may limit our ability to exclude third parties from commercializing product candidates similar or identical to ours.\"\n3. **Extract the Key Points**:\n   - The U.S. government has certain rights, including march-in rights, to patent rights and technology funded by the U.S. government.\n   - These rights are applicable to patents and technology licensed to the company from institutions like BWH (Brigham and Women's Hospital).\n4. **Understand the Implications**:\n   - March-in rights allow the U.S. government to require the patent holder to license the technology to a third party if certain conditions are met.\n   - These conditions include the failure to achieve practical application of the technology, the need to alleviate health or safety needs, meeting federal regulations, or giving preference to U.S. industry.\n5. **Match the Information to the Options**:\n   - **A: Exclusive commercialization rights** - The document does not mention the U.S. government having exclusive commercialization rights.\n   - **B: Complete ownership of patents** - The document does not state that the U.S. government has complete ownership of patents.\n   - **C: Rights to revoke licenses** - The document does not mention the U.S. government having the right to revoke licenses.\n   - **D: March-in rights** - This matches the information provided in the document.\n   - **E: Rights to set the technology price** - The document does not mention the U.S. government having the right to set the technology price.\n   - **F: Rights to sell the technology internationally** - The document does not mention the U.S. government having the right to sell the technology internationally.\n\nTherefore, the U.S. government holds **March-in rights** concerning"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 96000, "result": 1.0, "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?", "options": {"A": "Linda Arsenault", "B": "Debra Canner", "C": "Camille L. Bedrosian, MD", "D": "John Smith", "E": "Maria Gonzalez", "F": "James Patel"}, "LLM_original_answer": ["To answer the question \"Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant information**: The document mentions changes in executive positions, including the replacement of the Chief Medical Officer.\n\n2. **Locate the specific information**: The relevant section is found in the \"Risks Related to Our Business Operations, Employee Matters and Managing Growth\" part of the document.\n\n3. **Extract the information**: The document states:\n   > \"In December 2023, our then Global Head of Clinical R&D and Chief Medical Officer, Patrick Yeramian, M.D., was replaced by Camille L. Bedrosian, MD as our current Chief Medical Officer.\"\n\n4. **Match the information to the options**: The options provided are:\n   - A: Linda Arsenault\n   - B: Debra Canner\n   - C: Camille L. Bedrosian, MD\n   - D: John Smith\n   - E: Maria Gonzalez\n   - F: James Patel\n\n5. **Select the correct answer**: The document clearly states that Camille L. Bedrosian, MD replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023.\n\nTherefore, the correct answer is:\n**C: Camille L. Bedrosian, MD**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 96000, "result": 1.0, "question": "At what point in time is the revenue for cash trading and equity options recorded?", "options": {"A": "At the beginning of the transaction", "B": "At the end of the fiscal year", "C": "At the point in time of the transaction", "D": "When the transaction is settled", "E": "At the time of customer payment", "F": "When the market closes for the day"}, "LLM_original_answer": ["The correct answer to the question \"At what point in time is the revenue for cash trading and equity options recorded?\" is:\n\n**C: At the point in time of the transaction**\n\n### Chain of Thoughts:\n1. **Identify the Relevant Section**: The document provides detailed information about revenue recognition, particularly in the \"Revenue Recognition\" section (Note 5).\n\n2. **Examine the Specific Revenue Recognition Policies**:\n   - For **Cash Equities and Equity Options**, the document states: \"Revenues in our cash equity and equity options markets represent trade execution fees. Cash trading and equity options contain one performance obligation related to each transaction which occurs instantaneously, and the revenue is recorded at the point in time of the transaction.\"\n\n3. **Understand the Performance Obligation**:\n   - The performance obligation for cash trading and equity options is the execution of the trade, which occurs instantaneously.\n\n4. **Conclusion**:\n   - Since the performance obligation is satisfied at the point in time of the transaction, the revenue is recorded at that same point in time.\n\nThus, the revenue for cash trading and equity options is recorded at the point in time of the transaction."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 96000, "result": 1.0, "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?", "options": {"A": "60%", "B": "70%", "C": "75%", "D": "80%", "E": "Over 80%", "F": "90%"}, "LLM_original_answer": ["To answer the question \"What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The relevant information is found in the \"Other Invested Assets\" section of Note 9 of the Notes to the Consolidated Financial Statements.\n\n2. **Extract the key information**:\n   - The document states: \"Over 80% of other invested assets is comprised of freestanding derivatives with positive estimated fair values which are described in '\u2014 Derivatives' below.\"\n\n3. **Interpret the information**:\n   - The statement directly indicates that over 80% of other invested assets are freestanding derivatives with positive estimated fair values.\n\n4. **Match the information to the given options**:\n   - The options provided are:\n     - A: 60%\n     - B: 70%\n     - C: 75%\n     - D: 80%\n     - E: Over 80%\n     - F: 90%\n\n5. **Select the correct option**:\n   - The correct option is E: Over 80%.\n\nTherefore, the answer to the question is **E: Over 80%**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 60, "token_lengths": 128000, "result": 1.0, "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?", "options": {"A": "Results of operations", "B": "Capital requirements", "C": "Stock performance graph", "D": "Financial condition", "E": "Contractual arrangements", "F": "Limitations in debt agreements"}, "LLM_original_answer": ["To answer the question, we need to identify which factor does not influence the discretion of the board of directors in deciding to pay cash dividends. The factors listed in the options are:\n\nA: Results of operations\nB: Capital requirements\nC: Stock performance graph\nD: Financial condition\nE: Contractual arrangements\nF: Limitations in debt agreements\n\nFrom the provided document, we can infer the following:\n\n1. **Results of operations (A)**: The document discusses the importance of financial performance and the impact of losses and expenses on the company's ability to operate and develop products. This suggests that the results of operations are a significant factor in the board's decision to pay dividends.\n\n2. **Capital requirements (B)**: The document mentions the need for substantial additional funding to support ongoing and future activities, including clinical trials and commercialization. This indicates that capital requirements are a critical factor in the board's decision-making process.\n\n3. **Stock performance graph (C)**: The document does not mention stock performance graphs as a factor influencing the board's decision to pay dividends. Instead, it focuses on financial performance, regulatory compliance, and operational needs.\n\n4. **Financial condition (D)**: The document emphasizes the importance of the company's financial condition, including cash and cash equivalents, accumulated deficit"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 128000, "result": 1.0, "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?", "options": {"A": "A complete dismissal of all lawsuits", "B": "A $15 million secured claim", "C": "A final release of all claims with Gryphon Digital Mining", "D": "An allowed $10 million general unsecured claim", "E": "Ownership of new mining equipment", "F": "A partnership extension with Gryphon"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 128000, "result": 0.0, "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?", "options": {"A": "A significant financial penalty was imposed", "B": "The case was settled with a material financial impact", "C": "The lawsuit was dismissed", "D": "The resolution caused Duke Energy Carolinas to alter the dam structure", "E": "Duke Energy Carolinas had to issue a public apology", "F": "The case is still ongoing"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 128000, "result": 1.0, "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?", "options": {"A": "A detailed financial statement", "B": "A personal or corporate guarantee", "C": "An independent appraisal review", "D": "Proof of project completion", "E": "An environmental impact assessment", "F": "A feasibility study"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 60, "token_lengths": 128000, "result": 1.0, "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?", "options": {"A": "Having exclusive rights to future programs", "B": "Primary responsibility for conducting marketing activities", "C": "Demonstrating sufficient cash resources and personnel", "D": "Approval from the external governing board", "E": "Completion of preclinical research activities", "F": "An environmental impact assessment"}, "LLM_original_answer": ["To answer the question \"What determines the company's right to co-develop, co-promote, and co-commercialize a target?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Pfizer Agreement (Sanofi and Pfizer Collaborations)**:\n   - The document mentions that under the Sanofi Agreement, the company retains the option to co-develop, co-promote, and co-commercialize up to two targets in the United States. The company's right to exercise this option is dependent on its ability to demonstrate, within a given timeframe, that it has sufficient cash resources and personnel to commercialize the product.\n   - Similarly, under the Pfizer Agreement, the company retains an option for U.S. profit sharing and co-promotion on two products arising from the collaboration. The terms for these options are not explicitly detailed, but the general principle of demonstrating sufficient resources and personnel is likely to apply.\n\n2. **Revenue Recognition and Performance Obligations**:\n   - The document discusses the revenue recognition process for these collaborations, which involves evaluating the transaction price and the performance obligations. The company's ability to satisfy these performance obligations is crucial for maintaining its rights under the agreements.\n\n3. **General Business and Financial Considerations**:\n   - The company's financial health and ability to meet the financial and operational requirements of the collaborations are critical. This includes maintaining sufficient cash resources and personnel to support the development and commercialization of the products.\n\nGiven these points, the most relevant option from the provided choices is:\n\n**C: Demonstrating sufficient cash resources and personnel**\n\nThis option aligns with the document's emphasis on the company's need to demonstrate its ability to meet financial and operational requirements to retain its rights to co-develop, co-promote, and co-commercialize targets under the Sanofi and Pfizer collaborations."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 128000, "result": 1.0, "question": "What do the valuation experts incorporate in their pricing process?", "options": {"A": "Only the historical market trends", "B": "Calculations based solely on risk premiums", "C": "Assumptions related to non-market activities", "D": "Industry survey results and client feedback", "E": "Internal financial projections", "F": "Unrelated economic indicators"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 128000, "result": 1.0, "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?", "options": {"A": "Exclusive commercialization rights", "B": "Complete ownership of patents", "C": "Rights to revoke licenses", "D": "March-in rights", "E": "Rights to set the technology price", "F": "Rights to sell the technology internationally"}, "LLM_original_answer": ["The correct answer to the question \"What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?\" is:\n\n**D: March-in rights**\n\n### Chain of Thought:\n1. **Context of the Bayh-Dole Act**: The Bayh-D"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 60, "token_lengths": 128000, "result": 1.0, "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?", "options": {"A": "Linda Arsenault", "B": "Debra Canner", "C": "Camille L. Bedrosian, MD", "D": "John Smith", "E": "Maria Gonzalez", "F": "James Patel"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 128000, "result": 1.0, "question": "At what point in time is the revenue for cash trading and equity options recorded?", "options": {"A": "At the beginning of the transaction", "B": "At the end of the fiscal year", "C": "At the point in time of the transaction", "D": "When the transaction is settled", "E": "At the time of customer payment", "F": "When the market closes for the day"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 60, "token_lengths": 128000, "result": 0.0, "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?", "options": {"A": "60%", "B": "70%", "C": "75%", "D": "80%", "E": "Over 80%", "F": "90%"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "E"}, {"depth": 65, "token_lengths": 8000, "result": 1.0, "question": "What action might the company be forced to take if they cannot secure additional funding?", "options": {"A": "Expand marketing efforts", "B": "Open new research facilities", "C": "Increase staff salaries", "D": "Delay, reduce, or eliminate some research and development programs", "E": "Acquire other companies", "F": "Launch new products immediately"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step:\n\n1. **Funding Requirements**: The document states that the company will need substantial additional funding to support its operating activities, including advancing product candidates through clinical development, seeking regulatory approval, and preparing for commercialization. This indicates that the company's operations are heavily dependent on securing additional funding.\n\n2. **Current Financial Position**: As of December 31, 2023, the company had cash and cash equivalents of $331.1 million. Additionally, the company received net proceeds of approximately $151.0 million from a public offering in January 2024, which together are expected to fund operations into 2027. However, the document also mentions that adequate funding may not be available on acceptable terms, or at all.\n\n3. **Consequences of Inadequate Funding**: The document explicitly states that if the company is unable to obtain funding, it will be forced to delay, reduce, or eliminate some or all of its research and development programs, product portfolio expansion, or commercialization efforts. This could adversely affect the company's business prospects, or it may be unable to continue operations.\n\n4. **Economic Uncertainty**: The document highlights several economic uncertainties, including rising inflation, higher interest rates, and the risk of recession, which could make it more difficult to obtain traditional financing. These factors could further exacerbate the company's financial challenges.\n\n5. **Impact on Operations**: The document emphasizes that the company's ability to continue its operations and advance its product candidates is contingent on securing additional funding. Without it, the company would face significant operational constraints.\n\nGiven these points, the action that the company might be forced to take if it cannot secure additional funding is:\n\n**D: Delay, reduce, or eliminate some research and development programs**\n\nThis option directly aligns with the statement in the document that the company will be forced to delay, reduce, or eliminate some or all of its research and development programs if it cannot obtain the necessary funding. The other options (A, B, C, E, F) are not mentioned as potential actions in the event of a funding shortfall."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 8000, "result": 1.0, "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?", "options": {"A": "December 31, 2023", "B": "January 4, 2024", "C": "November 20, 2023", "D": "December 15, 2023", "E": "January 10, 2024", "F": "December 1, 2023"}, "LLM_original_answer": ["To answer the question \"On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the pre-payment of the Replacement DIP Facility in the \"Subsequent Events\" section (Note 17).\n\n2. **Locate the specific information**: In the \"Payoff of DIP\" subsection, it states:\n   - \"On January 4, 2024, the Company pre-paid the outstanding balance of $ 4.5 million on the Replacement DIP Facility provided by B. Riley Financial, the Company\u2019s DIP lender.\"\n\n3. **Match the date with the options provided**:\n   - The date mentioned in the document is January 4, 2024.\n\n4. **Select the correct option**:\n   - The correct option is B: January 4, 2024.\n\nTherefore, the answer to the question is **B: January 4, 2024**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 8000, "result": 0.0, "question": "Which entity sells certain trade receivables to CRC?", "options": {"A": "Duke Energy Ohio", "B": "CRC", "C": "Duke Energy Indiana", "D": "Subsidiary Registrants", "E": "Intercompany", "F": "Duke Energy"}, "LLM_original_answer": ["To answer the question \"Which entity sells certain trade receivables to CRC?\", I will analyze the provided document step by step:\n\n1. **Identify the relevant section**: The document mentions the sale of trade receivables in the \"Related Party Transactions\" section.\n\n2. **Extract the relevant information**: The specific paragraph states:\n   - \"As discussed in Note 18, certain trade receivables have been sold by Duke Energy Ohio and Duke Energy Indiana to CRC, an affiliate formed by a subsidiary of Duke Energy.\"\n\n3. **Determine the entities involved**:\n   - Duke Energy Ohio\n   - Duke Energy Indiana\n   - CRC (an affiliate formed by a subsidiary of Duke Energy)\n\n4. **Match the entities to the options**:\n   - Option A: Duke Energy Ohio\n   - Option B: CRC\n   - Option C: Duke Energy Indiana\n   - Option D: Subsidiary Registrants\n   - Option E: Intercompany\n   - Option F: Duke Energy\n\n5. **Select the correct answer**:\n   - The document clearly states that Duke Energy Ohio and Duke Energy Indiana sell certain trade receivables to CRC.\n   - Therefore, the correct answer is either Option A (Duke Energy Ohio) or Option C (Duke Energy Indiana).\n\nSince the question asks for a single entity, and both Duke Energy Ohio and Duke Energy Indiana are mentioned, we need to choose the most specific entity from the options provided. Both entities are listed, but the question asks for a single entity.\n\n**Final Answer**: The correct answer is **Option C: Duke Energy Indiana**. However, it's important to note that Duke Energy Ohio is also mentioned as selling trade receivables to CRC. If the question allows for multiple correct answers, both A and C would be correct. Given the options and the typical format of multiple-choice questions, the most specific and singular answer is Duke Energy Indiana."], "LLM_extracted_answer": ["C"], "ground_truth": "A"}, {"depth": 65, "token_lengths": 8000, "result": 0.0, "question": "What was the collateral value of commercial real estate loans at December 31, 2023?", "options": {"A": "$1.4 billion", "B": "$1.5 billion", "C": "$1.2 billion", "D": "$2.9 billion", "E": "$2.0 billion", "F": "$5.9 million"}, "LLM_original_answer": ["To answer the question \"What was the collateral value of commercial real estate loans at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for specific mentions of collateral values for commercial real estate loans as of December 31, 2023.\n\n2. **Extract the Data**: Find the exact value mentioned in the document.\n\n3. **Match the Value to the Options**: Compare the extracted value to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document contains a section that discusses the collateral values for different types of loans. Specifically, it mentions commercial real estate loans in the following paragraph:\n\n> \"For commercial real estate loans, the Company relies primarily upon third-party valuation information from certified appraisers and values are generally based upon recent appraisals of the underlying collateral, brokers\u2019 opinions based upon recent sales of comparable properties, estimated equipment auction or liquidation values, income capitalization, or a combination of income capitalization and comparable sales. As of December 31, 2023 and December 31, 2022, the Company had collateral-dependent commercial loans totaling $ 30.7 million and $ 16.2 million, respectively.\"\n\n### Step 2: Extract the Data\nThe document states that the collateral-dependent commercial loans as of December 31, 2023 totaled $ 30.7 million. However, this value is for all collateral-dependent commercial loans, not specifically for commercial real estate loans.\n\n### Step 3: Match the Value to the Options\nThe options provided are:\n- A: $1.4 billion\n- B: $1.5 billion\n- C: $1.2 billion\n- D: $2.9 billion\n- E: $2.0 billion\n- F: $5.9 million\n\nThe document does not provide a specific value for the collateral of commercial real estate loans alone. However, it does mention the collateral value of commercial real estate loans in the context of borrowed funds and the Federal Reserve Discount Window:\n\n> \"At December 31, 2023 and 2022, the Company had available and unused borrowing capacity of approximately $ 775.9 million and $ 538.9 million, respectively, at the Federal Reserve Discount Window. At December 31, 202"], "LLM_extracted_answer": ["F"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 8000, "result": 1.0, "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?", "options": {"A": "The company is a subsidiary", "B": "The company operates in multiple countries", "C": "The company is a smaller reporting company", "D": "The company has financial statements in Item 8", "E": "The company issued new stock options", "F": "The company had a significant loss"}, "LLM_original_answer": ["The correct answer is **C: The company is a smaller reporting company**.\n\n### Chain of Thoughts:\n1. **Review the Question and Options:**\n   - The question asks why Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk.\n   - The options provided are:\n     - A: The company is a subsidiary\n     - B: The company operates in multiple countries\n     - C: The company is a smaller reporting company\n     - D: The company has financial statements in Item 8\n     - E: The company issued new stock options\n     - F: The company had a significant loss\n\n2. **Identify Relevant Information in the Document:**\n   - The document states: \"As a \u2018smaller reporting company\u2019 as defined by Item 10 of Regulation S-K, we are not required to provide this information.\"\n   - This statement is found in the section titled \"Item 7A. Quantitative and Qualitative Disclosures About Market Risk.\"\n\n3. **Analyze the Information:**\n   - The statement directly indicates that Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk because it is classified as a \"smaller reporting company\" under Item 10 of Regulation S-K.\n   - None of the other options (A, B, D, E, F) are mentioned in the document as reasons for not providing the required disclosures.\n\n4. **Conclusion:**\n   - The reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk is that it is a smaller reporting company, as explicitly stated in the document.\n\nTherefore, the correct answer is **C: The company is a smaller reporting company**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 8000, "result": 1.0, "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?", "options": {"A": "Ocwen must renegotiate terms with MAV.", "B": "Ocwen can sell to a third party on more favorable terms.", "C": "Ocwen can sell to a third party on no more favorable terms.", "D": "Ocwen must wait until May 2, 2025 to sell.", "E": "Ocwen can sell immediately without restrictions.", "F": "Ocwen must consult PHH before selling."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document, particularly focusing on the section that discusses the relationship between Ocwen and MAV regarding the sale of MSRs.\n\n### Relevant Information:\n1. **Right of First Offer**:\n   - Ocwen and its affiliates must first offer GSE MSRs that meet the \"buy-box\" criteria to MAV before initiating a sale process with a third party.\n   - If MAV does not accept Ocwen\u2019s offer, Ocwen may sell the MSRs to a third party on terms no more favorable to the purchaser than those offered to MAV.\n   - The price at which Ocwen and its affiliates will offer MSRs to MAV is based on the valuation of an independent third-party.\n\n### Analysis:\n- The document clearly states that if MAV does not accept Ocwen\u2019s offer, Ocwen may sell the MSRs to a third party, but the terms must not be more favorable to the purchaser than those offered to MAV.\n- This condition is explicitly mentioned in the \"Right of First Offer\" section.\n\n### Conclusion:\nThe correct answer is **C: Ocwen can sell to a third party on no more favorable terms**.\n\nThis answer is directly supported by the document, which specifies that Ocwen must sell the MSRs to a third party on terms no more favorable than those offered to MAV if MAV does not accept the offer."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 8000, "result": 1.0, "question": "What is the effect of stockholders acting together in this company?", "options": {"A": "Increased stock value", "B": "Reduction in company expenses", "C": "Significant influence over stockholder approvals", "D": "Improved employee satisfaction", "E": "Higher dividend payouts", "F": "Faster company growth"}, "LLM_original_answer": ["To answer the question \"What is the effect of stockholders acting together in this company?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Stockholder Influence on Corporate Matters**:\n   - The document mentions that as of March 1, 2024, the executive officers, directors, and entities affiliated with them beneficially owned approximately 32% of the outstanding voting stock and approximately 38% of the outstanding common stock.\n   - This concentration of ownership gives these stockholders significant influence over all matters that require stockholder approval, including the election of directors and approval of significant corporate transactions.\n\n2. **Potential Outcomes of Stockholder Influence**:\n   - **Election of Directors**: The document states that these stockholders, acting together, can influence the election of directors. This is further reinforced by the nominating agreement with the BBA Funds, which ensures that one of their designated individuals is included in the slate of nominees for director elections.\n   - **Approval of Significant Corporate Transactions**: The document also mentions that these stockholders can influence the approval of significant corporate transactions, which could include mergers, acquisitions, or other strategic partnerships.\n\n3. **Impact on the Company**:\n   - **Significant Influence Over Stockholder Approvals**: The document explicitly states that these stockholders, acting together, have significant influence over stockholder approvals. This aligns directly with option C.\n\n4. **Other Options Analysis**:\n   - **A: Increased stock value**: The document does not provide direct evidence that stockholders acting together will increase stock value. While their influence could potentially lead to decisions that benefit the company, this is not a guaranteed outcome.\n   - **B: Reduction in company expenses**: The document does not suggest that stockholders acting together will reduce company expenses. In fact, it mentions that strategic partnerships and collaborations can increase expenses.\n   - **D: Improved employee satisfaction**: The document does not discuss the impact of stockholder actions on employee satisfaction.\n   - **E: Higher dividend payouts**: The document does not mention any direct link between stockholder actions and higher dividend payouts.\n   - **F: Faster company growth**: While stockholder influence could potentially lead to faster growth through strategic decisions, the document does not provide specific evidence for this.\n\nGiven the analysis, the most accurate and directly supported answer from the document is:\n\n**C: Significant influence over stockholder approvals**\n\nThis option is explicitly mentioned in the document and is a clear effect of stockholders acting together"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 8000, "result": 0.0, "question": "What potential issue could result in increased costs for the company related to AMX0035 development?", "options": {"A": "Increased clinical trial participant costs", "B": "Loss of clinical trial data", "C": "Increased manufacturing costs", "D": "Rising costs of raw materials", "E": "Higher insurance premiums", "F": "Decreased research funding"}, "LLM_original_answer": ["To answer the question \"What potential issue could result in increased costs for the company related to AMX0035 development?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Increased clinical trial participant costs (Option A)**:\n   - The document mentions that a pandemic, epidemic, or outbreak of an infectious disease could cause difficulties or additional costs in enrolling patients in future clinical trials.\n   - Specifically, it states: \"Any negative impact any future pandemic or similar disruption has on patient enrollment or treatment, or the development of AMX0035 and any other current or future product candidates, could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize AMX0035 and any other current or future product candidates, if approved, increase our operating expenses, which could have a material adverse effect on our financial results.\"\n   - This suggests that increased costs in enrolling patients could be a significant issue.\n\n2. **Loss of clinical trial data (Option B)**:\n   - The document discusses the risk of losing clinical trial data, particularly in the context of cyber-attacks or data breaches.\n   - It states: \"For example, the loss of clinical trial data from completed, ongoing or future clinical trials for AMX0035 or any of our future product candidates could result in delays in our development and regulatory approval efforts and significantly increase our costs to recover or reproduce the data.\"\n   - This indicates that the loss of clinical trial data could lead to increased costs.\n\n3. **Increased manufacturing costs (Option C)**:\n   - The document does not explicitly mention increased manufacturing costs as a direct result of AMX0035 development. However, it does discuss the broader context of financial and operational challenges.\n   - It mentions: \"If we or any of the third parties with whom we engage were to experience business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business and our results of operations and financial conditions.\"\n   - While this could indirectly affect manufacturing costs, it is not as directly linked as the other options.\n\n4. **Rising costs of raw materials (Option D)**:\n   - The document does not specifically mention rising costs of raw materials. It focuses more on broader financial and operational risks.\n   - However, it does discuss the impact of global macroeconomic factors, which could include"], "LLM_extracted_answer": ["A"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 8000, "result": 1.0, "question": "How were the 2020 Senior Notes paid off?", "options": {"A": "With company savings", "B": "Through new equity issuance", "C": "By selling company assets", "D": "With net proceeds from the offering of the May 2020 Notes", "E": "By obtaining a bank loan", "F": "Through a government grant"}, "LLM_original_answer": ["To answer the question \"How were the 2020 Senior Notes paid off?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the 2020 Senior Notes in the \"Senior Notes Issued in May 2020\" section.\n\n2. **Extract the key information**: According to the document, the 2020 Senior Notes were issued in May 2020, and the net proceeds from this offering were used for general corporate purposes, including to fund the redemption of the $1.25 billion aggregate principal amount of 2.75% senior notes due December 2020, which were redeemed in accordance with their terms on June 25, 2020.\n\n3. **Match the information to the options**:\n   - **A: With company savings**: The document does not mention using company savings to pay off the 2020 Senior Notes.\n   - **B: Through new equity issuance**: The document does not mention using new equity issuance to pay off the 2020 Senior Notes.\n   - **C: By selling company assets**: The document does not mention selling company assets to pay off the 2020 Senior Notes.\n   - **D: With net proceeds from the offering of the May 2020 Notes**: The document explicitly states that the net proceeds from the May 2020 Notes were used to fund the redemption of the 2020 Senior Notes.\n   - **E: By obtaining a bank loan**: The document does not mention using a bank loan to pay off the 2020 Senior Notes.\n   - **F: Through a government grant**: The document does not mention using a government grant to pay off the 2020 Senior Notes.\n\n4. **Conclusion**: Based on the information provided in the document, the 2020 Senior Notes were paid off with net proceeds from the offering of the May 2020 Notes.\n\nTherefore, the correct answer is **D: With net proceeds from the offering of the May 2020 Notes**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 8000, "result": 1.0, "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?", "options": {"A": "The base lapse rate is increased.", "B": "The base lapse rate is reduced.", "C": "The base lapse rate remains unchanged.", "D": "The base lapse rate is doubled.", "E": "The base lapse rate is halved.", "F": "The base lapse rate is eliminated entirely."}, "LLM_original_answer": ["To answer the question, I need to focus on the information provided in the document about how the base lapse rate is affected when the guaranteed amount exceeds the account value for variable annuity guarantees.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Section:**\n   - The relevant section is found in the \"Fair Value\" section, specifically under \"Lapse Rate Assumptions\" for variable annuity guarantees.\n\n2. **Extract Key Information:**\n   - The document states: \"For variable annuity guarantees, a dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in-the-money contracts are less likely to lapse.\"\n\n3. **Interpret the Information:**\n   - When the guaranteed amount exceeds the account value, the base lapse rate is reduced. This is because policyholders are less likely to surrender their contracts when they are \"in-the-money\" (i.e., the guaranteed amount is higher than the account value).\n\n4. **Match with Options:**\n   - Option A: The base lapse rate is increased.\n   - Option B: The base lapse rate is reduced.\n   - Option C: The base lapse rate remains unchanged.\n   - Option D: The base lapse rate is doubled.\n   - Option E: The base lapse rate is halved.\n   - Option F: The base lapse rate is eliminated entirely.\n\n### Conclusion:\nBased on the information provided in the document, the correct answer is:\n\n**B: The base lapse rate is reduced.**\n\nThis is because the document explicitly states that the base lapse rate is reduced when the guaranteed amount exceeds the account value, as in-the-money contracts are less likely to lapse."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 16000, "result": 1.0, "question": "What action might the company be forced to take if they cannot secure additional funding?", "options": {"A": "Expand marketing efforts", "B": "Open new research facilities", "C": "Increase staff salaries", "D": "Delay, reduce, or eliminate some research and development programs", "E": "Acquire other companies", "F": "Launch new products immediately"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step:\n\n1. **Company's Financial Situation**:\n   - The company has incurred significant operating losses since its inception in 2015.\n   - As of December 31, 2023, the company had an accumulated deficit of $381.4 million.\n   - The company's primary uses of cash are to fund operating expenses, particularly research and development expenditures.\n   - The company does not have any products approved for sale and does not expect to generate revenue from product sales unless and until it successfully completes development and obtains regulatory approval for one or more of its product candidates.\n\n2. **Funding Requirements**:\n   - The company expects its expenses to increase substantially as it advances preclinical activities and clinical trials of its product candidates.\n   - Additional costs are associated with operating as a public company, including legal, accounting, investor relations, and other expenses.\n   - The company's future funding requirements will depend on various factors, including the progress and timing of clinical trials, regulatory approvals, and the need for additional preclinical studies.\n\n3. **Current Funding**:\n   - As of December 31, 2023, the company had cash and cash equivalents of $331.1 million.\n   - In January 2024, the company received an additional $151.0 million from a public offering of common stock.\n   - The company believes that its existing cash and cash equivalents will be sufficient to fund its projected liquidity requirements for at least the next 12 months.\n\n4. **Risks and Uncertainties**:\n   - The company faces numerous risks and uncertainties associated with the development of its product candidates.\n   - If the company is unable to obtain additional funding, it could be forced to delay, reduce, or eliminate some or all of its research and development programs and clinical development efforts.\n   - Public health crises, bank failures, geopolitical tensions, and resulting global economic slowdowns could disrupt the company's ability to access additional capital.\n\n5. **Conclusion**:\n   - Given the company's significant operating losses, the need for substantial future funding, and the risks associated with not securing additional funding, the most likely action the company would be forced to take if it cannot secure additional funding is to delay, reduce, or eliminate some or all of its research and development programs and clinical development efforts.\n\nTherefore, the correct answer is:\n\n**D: Delay, reduce,"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 16000, "result": 1.0, "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?", "options": {"A": "December 31, 2023", "B": "January 4, 2024", "C": "November 20, 2023", "D": "December 15, 2023", "E": "January 10, 2024", "F": "December 1, 2023"}, "LLM_original_answer": ["To answer the question \"On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the pre-payment of the Replacement DIP Facility in the \"Subsequent Events\" section, specifically under the \"Payoff of DIP\" subsection.\n\n2. **Locate the specific date**: In the \"Payoff of DIP\" subsection, the document states:\n   > \"On January 4, 2024, the Company pre-paid the outstanding balance of $ 4.5 million on the Replacement DIP Facility provided by B. Riley Financial, the Company\u2019s DIP lender.\"\n\n3. **Match the date to the options**: The date mentioned in the document is January 4, 2024.\n\n4. **Select the correct option**: The correct option that matches this date is:\n   > B: January 4, 2024\n\nTherefore, the answer to the question is **B: January 4, 2024**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 16000, "result": 0.0, "question": "Which entity sells certain trade receivables to CRC?", "options": {"A": "Duke Energy Ohio", "B": "CRC", "C": "Duke Energy Indiana", "D": "Subsidiary Registrants", "E": "Intercompany", "F": "Duke Energy"}, "LLM_original_answer": ["To answer the question \"Which entity sells certain trade receivables to CRC?\", let's break down the relevant information from the document step by step:\n\n1. **Identify CRC**: CRC is described as a bankruptcy remote, special purpose entity indirectly owned by Duke Energy. It buys certain accounts receivable from Duke Energy Ohio and Duke Energy Indiana.\n\n2. **Receivables Financing \u2013 CRC**:\n   - CRC buys certain accounts receivable arising from the sale of electricity, natural gas, and related services from Duke Energy Ohio and Duke Energy Indiana.\n   - Duke Energy Ohio and Duke Energy Indiana sell these receivables to CRC.\n\n3. **Sale of Receivables**:\n   - The document states: \"On a revolving basis, CRC buys certain accounts receivable arising from the sale of electricity, natural gas and related services from Duke Energy Ohio and Duke Energy Indiana.\"\n   - This indicates that Duke Energy Ohio and Duke Energy Indiana are the entities that sell receivables to CRC.\n\n4. **Options Analysis**:\n   - **A: Duke Energy Ohio** - This entity is mentioned as selling receivables to CRC.\n   - **B: CRC** - CRC is the entity buying the receivables, not selling them.\n   - **C: Duke Energy Indiana** - This entity is also mentioned as selling receivables to CRC.\n   - **D: Subsidiary Registrants** - This is a broader term and does not specifically identify the entities that sell receivables to CRC.\n   - **E: Intercompany** - This term is used in a different context and does not refer to the sale of receivables to CRC.\n   - **F: Duke Energy** - Duke Energy is the parent company and does not directly sell receivables to CRC; it is the parent of the entities that do.\n\n5. **Conclusion**:\n   - Both Duke Energy Ohio and Duke Energy Indiana sell certain trade receivables to CRC.\n\nGiven the options provided, the correct answer is:\n\n**C: Duke Energy Indiana**\n\nHowever, since Duke Energy Ohio is also mentioned, if the question allows for multiple correct answers, both **A: Duke Energy Ohio** and **C: Duke Energy Indiana** would be correct. If only one answer is required, **C: Duke Energy Indiana** is the most specific and directly mentioned in the context of the sale to CRC."], "LLM_extracted_answer": ["C"], "ground_truth": "A"}, {"depth": 65, "token_lengths": 16000, "result": 1.0, "question": "What was the collateral value of commercial real estate loans at December 31, 2023?", "options": {"A": "$1.4 billion", "B": "$1.5 billion", "C": "$1.2 billion", "D": "$2.9 billion", "E": "$2.0 billion", "F": "$5.9 million"}, "LLM_original_answer": ["To answer the question \"What was the collateral value of commercial real estate loans at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss commercial real estate loans and their collateral values.\n2. **Extract Specific Information**: Find the specific collateral value for commercial real estate loans as of December 31, 2023.\n3. **Match with Options**: Compare the extracted information with the given options to select the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe document contains a section on \"Borrowed Funds\" which includes information about the collateral value of loans. Specifically, it mentions the collateral value of loans pledged to secure advances from the FHLBB (Federal Home Loan Bank of Boston).\n\n### Step 2: Extract Specific Information\nFrom the \"Borrowed Funds\" section, we find the following relevant information:\n- **Collateral Value of Commercial Real Estate Loans**: \"The collateral value of residential real estate and commercial real estate loans securing these advances was $ 1.4 billion and $ 1.5 billion, respectively, at December 31, 2023, and $ 1.5 billion and $ 1.2 billion, respectively, at December 31, 2022.\"\n\n### Step 3: Match with Options\nThe collateral value of commercial real estate loans as of December 31, 2023, is $1.5 billion.\n\n### Conclusion\nThe correct answer is **B: $1.5 billion**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 16000, "result": 1.0, "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?", "options": {"A": "The company is a subsidiary", "B": "The company operates in multiple countries", "C": "The company is a smaller reporting company", "D": "The company has financial statements in Item 8", "E": "The company issued new stock options", "F": "The company had a significant loss"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the relevant section**: The key information is found in Item 7A. Quantitative and Qualitative Disclosures About Market Risk.\n\n2. **Extract the relevant statement**: The document states, \"As a \u2018smaller reporting company\u2019 as defined by Item 10 of Regulation S-K, we are not required to provide this information.\"\n\n3. **Match the statement to the options**:\n   - **Option A**: The company is a subsidiary. This is not mentioned in the document.\n   - **Option B**: The company operates in multiple countries. This is not mentioned in the document.\n   - **Option C**: The company is a smaller reporting company. This matches the statement in the document.\n   - **Option D**: The company has financial statements in Item 8. While the company does have financial statements in Item 8, this is not the reason given for not providing market risk disclosures.\n   - **Option E**: The company issued new stock options. This is mentioned in the document but is not the reason for not providing market risk disclosures.\n   - **Option F**: The company had a significant loss. While the company has incurred significant losses, this is not the reason given for not providing market risk disclosures.\n\n4. **Conclusion**: The reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk is that the company is a smaller reporting company as defined by Item 10 of Regulation S-K.\n\nTherefore, the correct answer is **C: The company is a smaller reporting company**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 16000, "result": 1.0, "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?", "options": {"A": "Ocwen must renegotiate terms with MAV.", "B": "Ocwen can sell to a third party on more favorable terms.", "C": "Ocwen can sell to a third party on no more favorable terms.", "D": "Ocwen must wait until May 2, 2025 to sell.", "E": "Ocwen can sell immediately without restrictions.", "F": "Ocwen must consult PHH before selling."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The key information is found in the \"Right of First Offer\" section under \"Note 12 \u2014 Investment in Equity Method Investee and Related Party Transactions.\"\n\n2. **Extract the condition**: The section states:\n   - \"If MAV does not accept Ocwen\u2019s offer, Ocwen may sell the MSRs to a third party on terms no more favorable to the purchaser than those offered to MAV.\"\n\n3. **Match the condition to the options**:\n   - **Option A**: Ocwen must renegotiate terms with MAV. (Not mentioned in the document)\n   - **Option B**: Ocwen can sell to a third party on more favorable terms. (Contradicts the document)\n   - **Option C**: Ocwen can sell to a third party on no more favorable terms. (Matches the document)\n   - **Option D**: Ocwen must wait until May 2, 2025 to sell. (Not mentioned in the document)\n   - **Option E**: Ocwen can sell immediately without restrictions. (Contradicts the document)\n   - **Option F**: Ocwen must consult PHH before selling. (Not mentioned in the document)\n\n4. **Conclusion**: The condition specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs is that Ocwen can sell to a third party on terms no more favorable to the purchaser than those offered to MAV.\n\nTherefore, the correct answer is **Option C: Ocwen can sell to a third party on no more favorable terms.**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 16000, "result": 1.0, "question": "What is the effect of stockholders acting together in this company?", "options": {"A": "Increased stock value", "B": "Reduction in company expenses", "C": "Significant influence over stockholder approvals", "D": "Improved employee satisfaction", "E": "Higher dividend payouts", "F": "Faster company growth"}, "LLM_original_answer": ["To answer the question \"What is the effect of stockholders acting together in this company?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify Relevant Information:**\n   - The document mentions that as of March 1, 2024, the company's executive officers, directors, and entities affiliated with them beneficially owned approximately 32% of the outstanding voting stock and approximately 38% of the outstanding common stock.\n   - It states that these stockholders, acting together, have significant influence over all matters that require stockholder approval, including the election of directors and approval of significant corporate transactions.\n\n2. **Analyze the Information:**\n   - **Significant Influence Over Stockholder Approvals:** The document explicitly states that these stockholders, when acting together, have significant influence over stockholder approvals. This means they can impact decisions such as the election of directors, approval of significant corporate transactions, and other important corporate matters.\n\n3. **Evaluate the Options:**\n   - **A: Increased stock value** - The document does not provide information suggesting that stockholders acting together directly increases stock value.\n   - **B: Reduction in company expenses** - There is no mention of stockholders acting together to reduce company expenses.\n   - **C: Significant influence over stockholder approvals** - This is directly supported by the document.\n   - **D: Improved employee satisfaction** - The document does not discuss the impact of stockholders on employee satisfaction.\n   - **E: Higher dividend payouts** - The document does not mention stockholders acting together to increase dividend payouts.\n   - **F: Faster company growth** - The document does not provide information suggesting that stockholders acting together directly leads to faster company growth.\n\n4. **Conclusion:**\n   - Based on the information provided in the document, the correct answer is **C: Significant influence over stockholder approvals**.\n\nTherefore, the effect of stockholders acting together in this company is **C: Significant influence over stockholder approvals**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 16000, "result": 0.0, "question": "What potential issue could result in increased costs for the company related to AMX0035 development?", "options": {"A": "Increased clinical trial participant costs", "B": "Loss of clinical trial data", "C": "Increased manufacturing costs", "D": "Rising costs of raw materials", "E": "Higher insurance premiums", "F": "Decreased research funding"}, "LLM_original_answer": ["To answer the question, I will analyze the document and identify the potential issues that could result in increased costs for the company related to AMX0035 development.\n\n### Step-by-Step Analysis:\n\n1. **Intellectual Property Risks:**\n   - The document mentions that there may be third-party patents or patent applications that could affect the commercialization of AMX0035.\n   - If AMX0035 is found to infringe on third-party patents, the company could face:\n     - **Legal Costs:** Substantial costs for defending against patent infringement claims.\n     - **Licensing Costs:** If a license is required to continue development, the company may have to pay significant royalties or grant cross-licenses.\n     - **Development Delays:** Potential delays in development or commercialization if the company is forced to cease operations or modify its processes.\n\n2. **Supply Chain and Manufacturing Risks:**\n   - The document notes that global macroeconomic conditions, including conflicts and high inflation, could disrupt the supply chain.\n   - This could lead to:\n     - **Increased Manufacturing Costs:** Disruptions in the supply chain could result in higher costs for raw materials and packaging.\n     - **Cost Inflation:** The company may experience cost inflation for manufacturing and transportation.\n\n3. **Clinical Trial Risks:**\n   - The document mentions the possibility of delays or interruptions in clinical trials due to various factors, including pandemics or other disruptions.\n   - This could result in:\n     - **Increased Clinical Trial Participant Costs:** If clinical trials are delayed, the company may incur additional costs to retain participants or restart trials.\n     - **Data Loss:** While not directly mentioned as a cost, the loss of clinical trial data could lead to significant additional expenses to reproduce or recover the data.\n\n4. **Regulatory and Compliance Risks:**\n   - The company is required to comply with various regulations, including those related to financial reporting and corporate governance.\n   - This could lead to:\n     - **Increased Compliance Costs:** Significant legal, accounting, and other expenses to meet reporting and compliance requirements.\n\n5. **Employee and Management Risks:**\n   - The document highlights the importance of retaining key personnel and the potential for increased costs if key employees leave.\n   - This could result in:\n     - **Increased Recruitment and Training Costs:** Costs associated with hiring and training new employees to replace those who leave.\n\n### Matching to the Options:\n\n- **A: Increased clinical trial participant costs** - This is a potential issue mentioned in the"], "LLM_extracted_answer": ["A"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 16000, "result": 1.0, "question": "How were the 2020 Senior Notes paid off?", "options": {"A": "With company savings", "B": "Through new equity issuance", "C": "By selling company assets", "D": "With net proceeds from the offering of the May 2020 Notes", "E": "By obtaining a bank loan", "F": "Through a government grant"}, "LLM_original_answer": ["To answer the question \"How were the 2020 Senior Notes paid off?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section titled \"Senior Notes Issued in May 2020\" which discusses the issuance and use of the proceeds from the May 2020 Notes.\n\n2. **Extract the relevant information**: The section states:\n   - \"On May 26, 2020, we issued $ 2.5 billion in aggregate principal amount of new senior notes comprised of $ 1.25 billion in aggregate principal amount of 2.10 % senior notes due in 2030 and $ 1.25 billion in aggregate principal amount of 3.00 % senior notes due in 2050 (collectively, the May 2020 Notes).\"\n   - \"We used the net proceeds of the May 2020 Notes for general corporate purposes, including to fund the redemption of our $ 1.25 billion aggregate principal amount of 2.75 % senior notes due December 2020, or the 2020 Senior Notes, which were redeemed in accordance with their terms on June 25, 2020, and to pay down a portion of our commercial paper outstanding.\"\n\n3. **Analyze the information**:\n   - The document clearly states that the net proceeds from the May 2020 Notes were used to fund the redemption of the 2020 Senior Notes.\n   - The 2020 Senior Notes were redeemed on June 25, 2020, using the net proceeds from the May 2020 Notes.\n\n4. **Match the information to the options**:\n   - Option A: With company savings - The document does not mention using company savings to pay off the 2020 Senior Notes.\n   - Option B: Through new equity issuance - The document does not mention using new equity issuance to pay off the 2020 Senior Notes.\n   - Option C: By selling company assets - The document does not mention selling company assets to pay off the 2020 Senior Notes.\n   - Option D: With net proceeds from the offering of the May 2020 Notes - The document explicitly states that the net proceeds from the May 2020"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 16000, "result": 1.0, "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?", "options": {"A": "The base lapse rate is increased.", "B": "The base lapse rate is reduced.", "C": "The base lapse rate remains unchanged.", "D": "The base lapse rate is doubled.", "E": "The base lapse rate is halved.", "F": "The base lapse rate is eliminated entirely."}, "LLM_original_answer": ["To answer the question, I need to focus on the information provided in the document that pertains to variable annuity guarantees and how the base lapse rate is affected when the guaranteed amount exceeds the account value.\n\n1. **Relevant Information from the Document:**\n   - The document mentions that for variable annuity guarantees, a dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value. Specifically, it states: \"For variable annuity guarantees, a dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in-the-money contracts are less likely to lapse.\"\n\n2. **Understanding the Base Lapse Rate:**\n   - The base lapse rate is the expected rate at which policyholders will terminate their contracts before the maturity date.\n   - When the guaranteed amount exceeds the account value, the policyholder is \"in-the-money,\" meaning they have a financial incentive to keep the contract because the guarantee is worth more than the current account value.\n\n3. **Effect of the Guaranteed Amount Exceeding the Account Value:**\n   - The document explicitly states that the base lapse rate is reduced in such cases. This is because policyholders are less likely to lapse their contracts when they are in-the-money, as they benefit from the higher guaranteed amount.\n\n4. **Conclusion:**\n   - Based on the information provided, the correct answer is that the base lapse rate is reduced when the guaranteed amount exceeds the account value.\n\nTherefore, the answer is **B: The base lapse rate is reduced.**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 32000, "result": 1.0, "question": "What action might the company be forced to take if they cannot secure additional funding?", "options": {"A": "Expand marketing efforts", "B": "Open new research facilities", "C": "Increase staff salaries", "D": "Delay, reduce, or eliminate some research and development programs", "E": "Acquire other companies", "F": "Launch new products immediately"}, "LLM_original_answer": ["To answer the question \"What action might the company be forced to take if they cannot secure additional funding?\" based on the provided document, I will analyze the relevant sections step by step:\n\n1. **Financial Situation and Funding Needs**:\n   - The document states: \"We will need substantial additional funding to support our operating activities as we advance our product candidates through clinical development, seek regulatory approval and prepare for and, if any of our product candidates are approved, proceed to commercialization.\"\n   - It also mentions: \"If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs and clinical development efforts, which would adversely affect our business prospects, or we may be unable to continue operations.\"\n\n2. **Options for Action**:\n   - The document does not explicitly list all possible actions, but it does provide a clear indication of what might happen if funding is not secured.\n   - Specifically, it states: \"If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs and clinical development efforts.\"\n\n3. **Matching to the Options**:\n   - **Option A: Expand marketing efforts** - The document does not suggest expanding marketing efforts as a response to a lack of funding.\n   - **Option B: Open new research facilities** - The document does not suggest opening new research facilities as a response to a lack of funding.\n   - **Option C: Increase staff salaries** - The document does not suggest increasing staff salaries as a response to a lack of funding.\n   - **Option D: Delay, reduce, or eliminate some research and development programs** - This directly matches the statement in the document: \"If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs and clinical development efforts.\"\n   - **Option E: Acquire other companies** - The document does not suggest acquiring other companies as a response to a lack of funding.\n   - **Option F: Launch new products immediately** - The document does not suggest launching new products immediately as a response to a lack of funding. In fact, it emphasizes the need for regulatory approval and clinical development, which require significant funding.\n\n4. **Conclusion**:\n   - Based on the document, the most appropriate action the company might be forced to take if they cannot secure additional funding is to delay, reduce, or eliminate some research and development programs.\n\nTherefore, the correct"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 32000, "result": 1.0, "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?", "options": {"A": "December 31, 2023", "B": "January 4, 2024", "C": "November 20, 2023", "D": "December 15, 2023", "E": "January 10, 2024", "F": "December 1, 2023"}, "LLM_original_answer": ["To answer the question \"On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the pre-payment of the Replacement DIP Facility in the \"Subsequent Events\" section (Note 17).\n\n2. **Locate the specific information**: In Note 17, the document states:\n   > \"Payoff of DIP On January 4, 2024, the Company pre-paid the outstanding balance of $ 4.5 million on the Replacement DIP Facility provided by B. Riley Financial, the Company\u2019s DIP lender. The $ 4.5 million payment included exit fees of approximately $ 0.2 million. The Replacement DIP was terminated on the Effective Date.\"\n\n3. **Extract the date**: The date mentioned for the pre-payment is January 4, 2024.\n\n4. **Match the date with the options**: The date January 4, 2024, corresponds to option B.\n\nTherefore, the correct answer is:\n**B: January 4, 2024**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 32000, "result": 0.0, "question": "Which entity sells certain trade receivables to CRC?", "options": {"A": "Duke Energy Ohio", "B": "CRC", "C": "Duke Energy Indiana", "D": "Subsidiary Registrants", "E": "Intercompany", "F": "Duke Energy"}, "LLM_original_answer": ["To answer the question \"Which entity sells certain trade receivables to CRC?\", let's break down the information step by step:\n\n1. **Identify CRC**: CRC is mentioned as a special purpose entity indirectly owned by Duke Energy. It is used to buy certain accounts receivable from Duke Energy Ohio and Duke Energy Indiana.\n\n2. **Receivables Financing \u2013 CRC**:\n   - CRC buys certain accounts receivable arising from the sale of electricity, natural gas, and related services from Duke Energy Ohio and Duke Energy Indiana.\n   - Duke Energy Ohio and Duke Energy Indiana sell, on a revolving basis, nearly all of their retail accounts receivable, including receivables for unbilled revenues, to CRC.\n\n3. **Specific Mention in the Document**:\n   - The document explicitly states: \"Duke Energy Ohio and Duke Energy Indiana sell, on a revolving basis, nearly all of their retail accounts receivable, including receivables for unbilled revenues, to an affiliate, CRC, and account for the transfers of receivables as sales.\"\n\n4. **Conclusion**:\n   - Based on the information provided, both Duke Energy Ohio and Duke Energy Indiana sell certain trade receivables to CRC.\n\nGiven the options provided:\n- A: Duke Energy Ohio\n- B: CRC\n- C: Duke Energy Indiana\n- D: Subsidiary Registrants\n- E: Intercompany\n- F: Duke Energy\n\nThe correct answer is **C: Duke Energy Indiana**. However, it is also true that Duke Energy Ohio sells receivables to CRC. Since the question asks for a single entity, and both options A and C are correct, the most specific and directly mentioned entity in the context of the question is **C: Duke Energy Indiana**. \n\nTherefore, the answer is **C: Duke Energy Indiana**."], "LLM_extracted_answer": ["C"], "ground_truth": "A"}, {"depth": 65, "token_lengths": 32000, "result": 1.0, "question": "What was the collateral value of commercial real estate loans at December 31, 2023?", "options": {"A": "$1.4 billion", "B": "$1.5 billion", "C": "$1.2 billion", "D": "$2.9 billion", "E": "$2.0 billion", "F": "$5.9 million"}, "LLM_original_answer": ["To answer the question \"What was the collateral value of commercial real estate loans at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss commercial real estate loans and their collateral values.\n2. **Extract Specific Information**: Find the specific collateral values mentioned for commercial real estate loans.\n3. **Match the Information to the Question**: Ensure the information is for the correct date (December 31, 2023).\n\n### Step 1: Identify Relevant Sections\nThe document contains a section on \"Loans Pledged as Collateral\" which might be relevant. Additionally, the \"Credit Quality\" section provides details on the collateral for commercial real estate loans.\n\n### Step 2: Extract Specific Information\nFrom the \"Loans Pledged as Collateral\" section:\n- The carrying value of loans pledged to secure advances from the FHLBB were $4.6 billion and $3.9 billion at December 31, 2023 and 2022, respectively.\n- The balance of funds borrowed from the FHLBB were $17.7 million and $704.1 million at December 31, 2023 and 2022, respectively.\n- The carrying value of loans pledged to secure advances from the Federal Reserve Bank (FRB) was $1.1 billion at both December 31, 2023 and 2022, respectively.\n\nFrom the \"Credit Quality\" section:\n- For commercial real estate loans, the primary repayment sources include operating income generated by the real estate, permanent debt refinancing, sale of the real estate, and, secondarily, liquidation of the collateral.\n- The collateral values are established by independent third-party appraisals and evaluations.\n\n### Step 3: Match the Information to the Question\nThe document does not explicitly state the collateral value of commercial real estate loans as of December 31, 2023. However, it does provide the carrying value of loans pledged as collateral to the FHLBB and FRB. The most relevant information is:\n\n- **FHLBB**: The collateral value of residential real estate and commercial real estate loans securing these advances was $1.4 billion and $1.5 billion, respectively, at December 31, 2023.\n- **FRB**: The carrying value of loans pledged to"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 32000, "result": 1.0, "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?", "options": {"A": "The company is a subsidiary", "B": "The company operates in multiple countries", "C": "The company is a smaller reporting company", "D": "The company has financial statements in Item 8", "E": "The company issued new stock options", "F": "The company had a significant loss"}, "LLM_original_answer": ["The correct answer is **C: The company is a smaller reporting company**.\n\n### Chain of Thoughts:\n1. **Review the Question and Options:**\n   - The question asks why Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk.\n   - The options provided are:\n     - A: The company is a subsidiary\n     - B: The company operates in multiple countries\n     - C: The company is a smaller reporting company\n     - D: The company has financial statements in Item 8\n     - E: The company issued new stock options\n     - F: The company had a significant loss\n\n2. **Identify Relevant Information in the Document:**\n   - The document states: \"As a \u2018smaller reporting company\u2019 as defined by Item 10 of Regulation S-K, we are not required to provide this information.\"\n   - This statement is found in **Item 7A. Quantitative and Qualitative Disclosures About Market Risk**.\n\n3. **Evaluate Each Option:**\n   - **A: The company is a subsidiary** - The document does not mention that Nurix Therapeutics, Inc. is a subsidiary of another company.\n   - **B: The company operates in multiple countries** - While the company has collaborations with international partners, this is not the reason given for the exemption.\n   - **C: The company is a smaller reporting company** - This matches the statement in the document.\n   - **D: The company has financial statements in Item 8** - Having financial statements in Item 8 is a requirement for all public companies, not a reason for exemption from market risk disclosures.\n   - **E: The company issued new stock options** - Issuing stock options is mentioned in the document but is not the reason for the exemption.\n   - **F: The company had a significant loss** - While the company has incurred significant losses, this is not the reason given for the exemption.\n\n4. **Conclusion:**\n   - The document explicitly states that Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk because it is a smaller reporting company. Therefore, the correct answer is **C: The company is a smaller reporting company**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 32000, "result": 1.0, "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?", "options": {"A": "Ocwen must renegotiate terms with MAV.", "B": "Ocwen can sell to a third party on more favorable terms.", "C": "Ocwen can sell to a third party on no more favorable terms.", "D": "Ocwen must wait until May 2, 2025 to sell.", "E": "Ocwen can sell immediately without restrictions.", "F": "Ocwen must consult PHH before selling."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document, focusing on the conditions specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Relevant Section:**\n   - The relevant section is found in **Note 12 \u2014 Investment in Equity Method Investee and Related Party Transactions**, specifically under the **Right of First Offer** subsection.\n\n2. **Extract Key Information:**\n   - **Right of First Offer:** Until the earlier of (i) the time that MAV has been fully funded and (ii) May 3, 2025 (subject to one annual extension by mutual agreement), if Ocwen seeks to sell any GSE MSRs that meet the buy-box, Ocwen must first offer such MSRs to MAV before initiating a sale process with a third party.\n   - **Condition if MAV Does Not Accept:** If MAV does not accept Ocwen\u2019s offer, Ocwen may sell the MSRs to a third party on terms no more favorable to the purchaser than those offered to MAV.\n\n3. **Evaluate the Options:**\n   - **Option A:** Ocwen must renegotiate terms with MAV.\n     - The document does not mention renegotiation as a condition.\n   - **Option B:** Ocwen can sell to a third party on more favorable terms.\n     - The document explicitly states that Ocwen cannot sell on more favorable terms.\n   - **Option C:** Ocwen can sell to a third party on no more favorable terms.\n     - This aligns with the document\u2019s statement.\n   - **Option D:** Ocwen must wait until May 2, 2025 to sell.\n     - The document specifies May 3, 2025, but also mentions the possibility of an annual extension.\n   - **Option E:** Ocwen can sell immediately without restrictions.\n     - The document clearly states that Ocwen must first offer the MSRs to MAV.\n   - **Option F:** Ocwen must consult PHH before selling.\n     - The document does not mention consulting PHH as a condition.\n\n### Conclusion:\nBased on the information provided in the document, the correct answer is:\n\n**C: Ocwen can sell to a third party on no more favorable terms.**\n\nThis is explicitly stated in the document under the **Right of First Offer** section, which specifies that if MAV does not accept Ocwen\u2019s offer, Ocwen may sell the MSRs to a third"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 32000, "result": 1.0, "question": "What is the effect of stockholders acting together in this company?", "options": {"A": "Increased stock value", "B": "Reduction in company expenses", "C": "Significant influence over stockholder approvals", "D": "Improved employee satisfaction", "E": "Higher dividend payouts", "F": "Faster company growth"}, "LLM_original_answer": ["To answer the question \"What is the effect of stockholders acting together in this company?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Stockholder Influence and Corporate Governance**:\n   - The document mentions that the company's executive officers, directors, and entities affiliated with them beneficially own approximately 32% of the outstanding voting stock and 38% of the outstanding common stock.\n   - This concentration of ownership gives these stockholders significant influence over all matters that require stockholder approval, including the election of directors and approval of significant corporate transactions.\n\n2. **Impact on Corporate Decisions**:\n   - The significant influence of these stockholders means that they can affect major corporate decisions, such as mergers, tender offers, and proxy contests.\n   - This influence can delay or prevent changes in control that other stockholders might view as beneficial.\n\n3. **Effect on Stock Price and Market Perception**:\n   - The document notes that the concentration of stock ownership can affect the trading price of the company's common stock.\n   - If these stockholders act together to influence corporate matters, it could lead to market perceptions that affect the stock price, either positively or negatively.\n\n4. **Strategic Alliances and Collaborations**:\n   - The company has entered into significant collaborations and licensing agreements, such as those with Novartis and Amgen.\n   - Stockholders acting together could influence the company's ability to form or maintain these strategic alliances, which are crucial for the company's development and commercialization efforts.\n\n5. **Intellectual Property and Patent Protection**:\n   - The company's success is heavily dependent on its intellectual property, particularly patents.\n   - Stockholders acting together could influence decisions related to the protection and enforcement of these patents, which are critical for maintaining a competitive advantage.\n\n6. **Financial and Operational Flexibility**:\n   - The document mentions that the company has a loan agreement with K2HV, which includes certain registration rights and other provisions.\n   - Stockholders acting together could affect the company's financial flexibility and the terms of any additional financing or strategic transactions.\n\nGiven these points, the most relevant option from the provided choices is:\n\n**C: Significant influence over stockholder approvals**\n\nThis option directly aligns with the information in the document, which emphasizes the significant influence that a concentrated group of stockholders can have over corporate matters requiring stockholder approval. This influence can affect major decisions, market perceptions, and the company's strategic alliances and intellectual property protection.\n\nTherefore,"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 32000, "result": 0.0, "question": "What potential issue could result in increased costs for the company related to AMX0035 development?", "options": {"A": "Increased clinical trial participant costs", "B": "Loss of clinical trial data", "C": "Increased manufacturing costs", "D": "Rising costs of raw materials", "E": "Higher insurance premiums", "F": "Decreased research funding"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the potential issues that could result in increased costs for the company related to AMX0035 development.\n\n### Step 1: Identify Key Sections\nThe document contains several sections that discuss the development and commercialization of AMX0035. The most relevant sections are:\n- **Collaboration Risks**\n- **Manufacturing Risks**\n- **Regulatory and Compliance Risks**\n- **Intellectual Property Risks**\n- **Economic and Geopolitical Risks**\n\n### Step 2: Analyze Each Section for Cost-Related Issues\n\n#### **Collaboration Risks**\n- **Increased clinical trial participant costs**: The document mentions that collaborators may delay clinical trials, provide insufficient funding, or stop a clinical trial, which could lead to increased costs. However, it does not specifically mention increased participant costs.\n- **Loss of clinical trial data**: The document notes that the loss of clinical trial data could result in delays and the need to repeat or conduct new clinical trials, which would increase costs.\n- **Increased manufacturing costs**: The document discusses the reliance on third-party manufacturers and the risks associated with this, including the possibility of increased costs if these manufacturers fail to meet expectations or if there are supply chain disruptions.\n- **Rising costs of raw materials**: The document mentions the risk of disruptions in the supply chain, which could lead to increased costs for raw materials.\n- **Higher insurance premiums**: The document does not specifically mention higher insurance premiums as a potential issue.\n- **Decreased research funding**: The document discusses the risk of collaborators not providing sufficient funding, which could indirectly lead to decreased research funding.\n\n#### **Manufacturing Risks**\n- **Increased manufacturing costs**: The document explicitly states that the use of third parties to manufacture AMX0035 in compliance with cGMP may increase the risk of not having sufficient cGMP-compliant quantities of AMX0035 or necessary quantities of such materials on time or at an acceptable cost.\n- **Rising costs of raw materials**: The document mentions the risk of supply chain disruptions, which could lead to increased costs for raw materials.\n\n#### **Regulatory and Compliance Risks**\n- **Increased manufacturing costs**: The document notes that if third-party manufacturers fail to comply with regulatory requirements, the company may face additional costs and delays in obtaining regulatory approval.\n- **Rising costs of raw materials**: The document mentions the risk of supply chain disruptions, which could lead to"], "LLM_extracted_answer": ["C"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 32000, "result": 1.0, "question": "How were the 2020 Senior Notes paid off?", "options": {"A": "With company savings", "B": "Through new equity issuance", "C": "By selling company assets", "D": "With net proceeds from the offering of the May 2020 Notes", "E": "By obtaining a bank loan", "F": "Through a government grant"}, "LLM_original_answer": ["To answer the question \"How were the 2020 Senior Notes paid off?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section on debt, which is likely to have information about the 2020 Senior Notes.\n\n2. **Locate the specific information about the 2020 Senior Notes**: Within the \"Debt\" section, there is a subsection titled \"Senior Notes Issued in May 2020\" that provides details about the 2020 Senior Notes.\n\n3. **Extract the information about the redemption of the 2020 Senior Notes**: The document states that the 2020 Senior Notes were redeemed in June 2020.\n\n4. **Determine the source of funds for the redemption**: The document specifies that the net proceeds from the offering of the May 2020 Notes were used to fund the redemption of the 2020 Senior Notes.\n\nHere is the relevant excerpt from the document:\n\n> **Senior Notes Issued in May 2020**: On May 26, 2020, we issued $ 2.5 billion in aggregate principal amount of new senior notes comprised of $ 1.25 billion in aggregate principal amount of 2.10 % senior notes due in 2030 and $ 1.25 billion in aggregate principal amount of 3.00 % senior notes due in 2050 (collectively, the May 2020 Notes). We used the net proceeds of the May 2020 Notes for general corporate purposes, including to fund the redemption of our $ 1.25 billion aggregate principal amount of 2.75 % senior notes due December 2020, or the 2020 Senior Notes, which were redeemed in accordance with their terms on June 25, 2020, and to pay down a portion of our commercial paper outstanding. We incurred debt issuance costs of $ 23 million relating to the issuance of the May 2020 Notes and these costs are presented in the accompanying consolidated balance sheet as a deduction from the carrying amount of the related debt liability and will be amortized over the remaining term of each note series.\n\nBased on this information, the 2020 Senior Notes were paid off using the net proceeds from the offering"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 32000, "result": 1.0, "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?", "options": {"A": "The base lapse rate is increased.", "B": "The base lapse rate is reduced.", "C": "The base lapse rate remains unchanged.", "D": "The base lapse rate is doubled.", "E": "The base lapse rate is halved.", "F": "The base lapse rate is eliminated entirely."}, "LLM_original_answer": ["To answer the question \"How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss variable annuity guarantees and lapse rates.\n2. **Extract Key Information**: Extract information about how the base lapse rate is affected when the guaranteed amount exceeds the account value.\n3. **Analyze the Information**: Determine the correct answer based on the extracted information.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in the \"Fair Value\" section, specifically under the \"Lapse Rate\" subsection:\n\n### Step 2: Extract Key Information\nFrom the document:\n- **Lapse Rate**: \"For variable annuity guarantees, a dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in-the-money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies.\"\n\n### Step 3: Analyze the Information\n- The document states that the base lapse rate is **reduced** when the guaranteed amount exceeds the account value.\n- This is because in-the-money contracts (where the guaranteed amount is greater than the account value) are less likely to lapse.\n\n### Conclusion\nBased on the information provided in the document, the correct answer is:\n\n**B: The base lapse rate is reduced.**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 64000, "result": 1.0, "question": "What action might the company be forced to take if they cannot secure additional funding?", "options": {"A": "Expand marketing efforts", "B": "Open new research facilities", "C": "Increase staff salaries", "D": "Delay, reduce, or eliminate some research and development programs", "E": "Acquire other companies", "F": "Launch new products immediately"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the most relevant information that aligns with the options given.\n\nThe document discusses various aspects of the company's operations, including the importance of securing funding for the development and commercialization of its product candidates. Specifically, it mentions:\n\n1. **Funding and Capital Requirements**:\n   - \"We will need to grow the size of our organization, and we may experience difficulties in managing this growth.\"\n   - \"We will not generate any revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our product candidates.\"\n   - \"We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates.\"\n   - \"If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs and clinical development efforts, which would adversely affect our business prospects, or we may be unable to continue operations.\"\n\n2. **Impact of Funding Shortages**:\n   - \"If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or comparable foreign regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.\"\n   - \"If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved.\"\n\n3. **Research and Development Programs**:\n   - \"We are required to use commercially reasonable efforts to develop and commercialize licensed products and processes, and must achieve certain required diligence milestones.\"\n   - \"If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs and clinical development efforts, which would adversely affect our business prospects, or we may be unable to continue operations.\"\n\nGiven these points, the most relevant action the company might be forced to take if they cannot secure additional funding is:\n\n**D: Delay, reduce, or eliminate some research and development programs**\n\nThis option directly aligns with the document's emphasis on the need for funding to support ongoing and future research and development activities, and the potential consequences of a lack of funding,"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 64000, "result": 1.0, "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?", "options": {"A": "December 31, 2023", "B": "January 4, 2024", "C": "November 20, 2023", "D": "December 15, 2023", "E": "January 10, 2024", "F": "December 1, 2023"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant information**: The document mentions the pre-payment of the outstanding balance on the Replacement DIP Facility.\n2. **Locate the specific date**: The document states, \"On January 4, 2024, the Company pre-paid the outstanding balance of $ 4.5 million on the Replacement DIP Facility provided by B. Riley Financial, the Company\u2019s DIP lender.\"\n3. **Match the date with the options provided**: The date mentioned in the document is January 4, 2024.\n\nBased on the information provided in the document, the correct answer is:\n\n**B: January 4, 2024**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 64000, "result": 0.0, "question": "Which entity sells certain trade receivables to CRC?", "options": {"A": "Duke Energy Ohio", "B": "CRC", "C": "Duke Energy Indiana", "D": "Subsidiary Registrants", "E": "Intercompany", "F": "Duke Energy"}, "LLM_original_answer": ["To answer the question \"Which entity sells certain trade receivables to CRC?\", let's analyze the relevant information from the provided document:\n\n1. **Identify CRC**: CRC is mentioned as a \"bankruptcy remote, special purpose entity indirectly owned by Duke Energy\" that buys certain accounts receivable from Duke Energy Ohio and Duke Energy Indiana.\n\n2. **Relevant Section**: The section that provides the most direct information is \"Receivables Financing \u2013 CRC\" under \"18.VARIABLE INTEREST ENTITIES\". It states:\n   - \"CRC buys certain accounts receivable arising from the sale of electricity, natural gas and related services from Duke Energy Ohio and Duke Energy Indiana.\"\n\n3. **Entities Involved**: The entities involved in selling receivables to CRC are Duke Energy Ohio and Duke Energy Indiana.\n\n4. **Conclusion**: Based on the information provided, the entities that sell certain trade receivables to CRC are Duke Energy Ohio and Duke Energy Indiana.\n\nGiven the options provided:\n- A: Duke Energy Ohio\n- B: CRC\n- C: Duke Energy Indiana\n- D: Subsidiary Registrants\n- E: Intercompany\n- F: Duke Energy\n\nThe correct answer is **C: Duke Energy Indiana** and **A: Duke Energy Ohio**. Since the question asks for a single entity, and both Duke Energy Ohio and Duke Energy Indiana are mentioned, the most appropriate single answer from the given options is **C: Duke Energy Indiana**.\n\nHowever, if the question allows for multiple correct answers, both **A: Duke Energy Ohio** and **C: Duke Energy Indiana** would be correct. Given the typical format of multiple-choice questions, the most precise single answer is:\n\n**C: Duke Energy Indiana**."], "LLM_extracted_answer": ["C"], "ground_truth": "A"}, {"depth": 65, "token_lengths": 64000, "result": 1.0, "question": "What was the collateral value of commercial real estate loans at December 31, 2023?", "options": {"A": "$1.4 billion", "B": "$1.5 billion", "C": "$1.2 billion", "D": "$2.9 billion", "E": "$2.0 billion", "F": "$5.9 million"}, "LLM_original_answer": ["To answer the question \"What was the collateral value of commercial real estate loans at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss commercial real estate loans and their collateral values.\n2. **Extract Specific Data**: Find the specific collateral value mentioned for commercial real estate loans.\n3. **Match with Options**: Compare the extracted data with the given options to select the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document contains a section that discusses the collateral value of loans securing advances from the FHLBB and the Federal Reserve Bank. This section is particularly relevant because it provides specific collateral values for different types of loans.\n\n### Step 2: Extract Specific Data\nFrom the document, the relevant information is found in the \"Borrowed Funds\" section:\n\n- **FHLB Advances**:\n  - \"At December 31, 2023 and 2022, advances from the FHLBB were secured by stock in the FHLBB, residential real estate loans and commercial real estate loans.\"\n  - \"The collateral value of residential real estate and commercial real estate loans securing these advances was $1.4 billion and $1.5 billion, respectively, at December 31, 2023, and $1.5 billion and $1.2 billion, respectively, at December 31, 2022.\"\n\n### Step 3: Match with Options\nThe collateral value of commercial real estate loans securing FHLB advances at December 31, 2023, is $1.5 billion.\n\n### Conclusion\nThe correct answer is **B: $1.5 billion**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 64000, "result": 1.0, "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?", "options": {"A": "The company is a subsidiary", "B": "The company operates in multiple countries", "C": "The company is a smaller reporting company", "D": "The company has financial statements in Item 8", "E": "The company issued new stock options", "F": "The company had a significant loss"}, "LLM_original_answer": ["The correct answer is C: The company is a smaller reporting company.\n\n**Chain of Thought:**\n\n1. **Review the Question and Options:**\n   - The question asks why Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk.\n   - The options provided are:\n     - A: The company is a subsidiary\n     - B: The company operates in multiple countries\n     - C: The company is a smaller reporting company\n     - D: The company has financial statements in Item 8\n     - E: The company issued new stock options\n     - F: The company had a significant loss\n\n2. **Identify Relevant Information in the Document:**\n   - The document states: \"As a \u2018smaller reporting company\u2019 as defined by Item 10 of Regulation S-K, we are not required to provide this information.\"\n   - This statement is found in Item 7A. Quantitative and Qualitative Disclosures About Market Risk.\n\n3. **Evaluate Each Option:**\n   - **A: The company is a subsidiary** - The document does not mention that Nurix Therapeutics, Inc. is a subsidiary of another company.\n   - **B: The company operates in multiple countries** - While the company may have international operations, this is not the reason given for the exemption.\n   - **C: The company is a smaller reporting company** - This matches the statement in the document.\n   - **D: The company has financial statements in Item 8** - Having financial statements in Item 8 is a requirement for all public companies, but it does not exempt a company from market risk disclosures.\n   - **E: The company issued new stock options** - Issuing stock options is mentioned in the document, but it is not the reason for the exemption.\n   - **F: The company had a significant loss** - While the company has incurred significant losses, this is not the reason given for the exemption.\n\n4. **Conclusion:**\n   - The document explicitly states that Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk because it is a smaller reporting company.\n   - Therefore, the correct answer is C: The company is a smaller reporting company."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 64000, "result": 1.0, "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?", "options": {"A": "Ocwen must renegotiate terms with MAV.", "B": "Ocwen can sell to a third party on more favorable terms.", "C": "Ocwen can sell to a third party on no more favorable terms.", "D": "Ocwen must wait until May 2, 2025 to sell.", "E": "Ocwen can sell immediately without restrictions.", "F": "Ocwen must consult PHH before selling."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the Relevant Section:**\n   - The relevant section is found in Note 12 \u2014 Investment in Equity Method Investee and Related Party Transactions, specifically under the \"Right of First Offer\" subsection.\n\n2. **Extract the Key Information:**\n   - The document states: \"If MAV does not accept Ocwen\u2019s offer, Ocwen may sell the MSRs to a third party on terms no more favorable to the purchaser than those offered to MAV.\"\n\n3. **Interpret the Information:**\n   - This means that if MAV (Mortgage Asset Vehicle) does not accept Ocwen\u2019s offer to sell the MSRs, Ocwen is allowed to sell the MSRs to a third party. However, the terms of the sale to the third party must not be more favorable to the third party than the terms offered to MAV.\n\n4. **Match the Information to the Options:**\n   - Option B: \"Ocwen can sell to a third party on more favorable terms.\"\n   - Option C: \"Ocwen can sell to a third party on no more favorable terms.\"\n   - The document explicitly states that Ocwen can sell to a third party but not on more favorable terms than those offered to MAV.\n\n5. **Conclusion:**\n   - The correct answer is **Option C: Ocwen can sell to a third party on no more favorable terms.**\n\nThis step-by-step analysis ensures that the answer is directly derived from the provided document and accurately reflects the condition specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 64000, "result": 1.0, "question": "What is the effect of stockholders acting together in this company?", "options": {"A": "Increased stock value", "B": "Reduction in company expenses", "C": "Significant influence over stockholder approvals", "D": "Improved employee satisfaction", "E": "Higher dividend payouts", "F": "Faster company growth"}, "LLM_original_answer": ["The provided document does not contain information directly related to the effect of stockholders acting together in the company. However, based on the context and the options provided, the most relevant answer can be inferred from the following excerpt:\n\n**\"As of March 1, 2024, our executive officers, directors, and entities affiliated with such persons beneficially owned, in the aggregate, approximately 32% of our outstanding voting stock and approximately 38% of our outstanding common stock. As a result, these stockholders, acting together, have significant influence over all matters that require approval by our stockholders, including the election of directors and approval of significant corporate transactions.\"**\n\nThis excerpt suggests that stockholders acting together can have a significant influence over stockholder approvals, which is a key aspect of corporate governance and decision-making.\n\nTherefore, the most appropriate answer is:\n\n**C: Significant influence over stockholder approvals**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 64000, "result": 0.0, "question": "What potential issue could result in increased costs for the company related to AMX0035 development?", "options": {"A": "Increased clinical trial participant costs", "B": "Loss of clinical trial data", "C": "Increased manufacturing costs", "D": "Rising costs of raw materials", "E": "Higher insurance premiums", "F": "Decreased research funding"}, "LLM_original_answer": ["To answer the question \"What potential issue could result in increased costs for the company related to AMX0035 development?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Data Protection and Regulatory Compliance:**\n   - The document discusses the potential for increased compliance costs due to changes in data protection laws and regulations, particularly in the UK and EU. This could lead to additional legal risk, uncertainty, complexity, and cost in handling European personal data.\n   - **Relevant Option:** This aligns with option **E: Higher insurance premiums**. While the document does not explicitly mention insurance premiums, increased legal and regulatory compliance costs often lead to higher insurance premiums to cover the increased risks.\n\n2. **Clinical Trial Participant Costs:**\n   - The document mentions that clinical trials are expensive and can take many years to complete. It also notes that patient enrollment and retention are significant factors in the timing and cost of clinical trials.\n   - **Relevant Option:** This aligns with option **A: Increased clinical trial participant costs**. The document highlights the challenges in enrolling and retaining patients, which can increase the costs associated with clinical trials.\n\n3. **Manufacturing Costs:**\n   - The document discusses the reliance on third-party manufacturers for the production of AMX0035 and the potential for increased costs if these manufacturers fail to meet regulatory requirements or if there are delays in production.\n   - **Relevant Option:** This aligns with option **C: Increased manufacturing costs**. The document mentions the risk of increased costs and delays if third-party manufacturers do not perform as expected.\n\n4. **Rising Costs of Raw Materials:**\n   - The document notes that the company has committed approximately $195.0 million under agreements related to raw material purchases and manufacturing services, which are expected to be paid through 2028.\n   - **Relevant Option:** This aligns with option **D: Rising costs of raw materials**. The document indicates that the company is exposed to the risk of increased costs for raw materials and manufacturing services.\n\n5. **Research Funding:**\n   - The document does not mention any specific issues related to decreased research funding. It focuses more on the costs and challenges of clinical trials and regulatory compliance.\n   - **Relevant Option:** This does not align with option **F: Decreased research funding**.\n\n6. **Loss of Clinical Trial Data:**\n   - The document mentions the risk of data breaches and the importance of protecting clinical"], "LLM_extracted_answer": ["A"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 64000, "result": 1.0, "question": "How were the 2020 Senior Notes paid off?", "options": {"A": "With company savings", "B": "Through new equity issuance", "C": "By selling company assets", "D": "With net proceeds from the offering of the May 2020 Notes", "E": "By obtaining a bank loan", "F": "Through a government grant"}, "LLM_original_answer": ["To answer the question \"How were the 2020 Senior Notes paid off?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the 2020 Senior Notes in the \"Debt\" section, specifically under \"Senior Notes Issued in May 2020.\"\n\n2. **Extract the relevant information**: The relevant paragraph states:\n   - \"On May 26, 2020, we issued $2.5 billion in aggregate principal amount of new senior notes comprised of $1.25 billion in aggregate principal amount of 2.10% senior notes due in 2030 and $1.25 billion in aggregate principal amount of 3.00% senior notes due in 2050 (collectively, the May 2020 Notes).\"\n   - \"We used the net proceeds of the May 2020 Notes for general corporate purposes, including to fund the redemption of our $1.25 billion aggregate principal amount of 2.75% senior notes due December 2020, or the 2020 Senior Notes, which were redeemed in accordance with their terms on June 25, 2020, and to pay down a portion of our commercial paper outstanding.\"\n\n3. **Analyze the information**:\n   - The document clearly states that the net proceeds from the May 2020 Notes were used to fund the redemption of the 2020 Senior Notes.\n   - The 2020 Senior Notes were redeemed on June 25, 2020.\n\n4. **Match the information to the given options**:\n   - **Option A: With company savings** - The document does not mention using company savings to pay off the 2020 Senior Notes.\n   - **Option B: Through new equity issuance** - The document does not mention issuing new equity to pay off the 2020 Senior Notes.\n   - **Option C: By selling company assets** - The document does not mention selling company assets to pay off the 2020 Senior Notes.\n   - **Option D: With net proceeds from the offering of the May 2020 Notes** - The document explicitly states that the net proceeds from the May 2020 Notes were used to fund the redemption of the 202"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 64000, "result": 1.0, "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?", "options": {"A": "The base lapse rate is increased.", "B": "The base lapse rate is reduced.", "C": "The base lapse rate remains unchanged.", "D": "The base lapse rate is doubled.", "E": "The base lapse rate is halved.", "F": "The base lapse rate is eliminated entirely."}, "LLM_original_answer": ["To answer the question, we need to focus on the information provided in the document that pertains to the behavior of policyholders and the assumptions used in the valuation of liabilities for variable annuity guarantees. The key points from the document are:\n\n1. **Policyholder Behavior Assumptions**: The document mentions that the Company updates assumptions regarding policyholder behavior, including lapses, for its variable annuity business. This is done to reflect changes in the expected behavior of policyholders, which can impact the valuation of liabilities and the performance of the guarantees.\n\n2. **Dynamic Lapse Function**: Specifically, the document states, \"For variable annuity guarantees, a dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in-the-money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies.\"\n\nFrom these points, we can deduce the following:\n\n- **Base Lapse Rate**: The base lapse rate is the assumed rate at which policyholders will terminate their contracts.\n- **Guaranteed Amount Exceeding Account Value**: When the guaranteed amount exceeds the account value, the document indicates that the base lapse rate is reduced. This is because policyholders are less likely to lapse their contracts when they are \"in-the-money,\" meaning the guaranteed benefits are more valuable than the current account value.\n\nGiven this information, the correct answer to the question \"How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?\" is:\n\n**B: The base lapse rate is reduced.**\n\nThis aligns with the dynamic lapse function described in the document, which reduces the base lapse rate when the guaranteed amount is greater than the account value."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 96000, "result": 1.0, "question": "What action might the company be forced to take if they cannot secure additional funding?", "options": {"A": "Expand marketing efforts", "B": "Open new research facilities", "C": "Increase staff salaries", "D": "Delay, reduce, or eliminate some research and development programs", "E": "Acquire other companies", "F": "Launch new products immediately"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and extract relevant information to determine the most appropriate action the company might be forced to take if they cannot secure additional funding.\n\n### Key Points from the Document:\n1. **Financial Situation**:\n   - The company has incurred significant losses since its inception and expects to continue incurring losses.\n   - The company has a limited operating history and no products approved for commercial sale.\n   - The company has substantial research and development expenses and needs additional funding to continue its operations.\n\n2. **Funding Requirements**:\n   - The company will need substantial additional funding to complete the development and commercialization of its product candidates.\n   - Failure to obtain this necessary capital when needed may force the company to delay, reduce, or eliminate certain of its product development or research operations.\n\n3. **Current Funding**:\n   - As of December 31, 2023, the company had $331.1 million in cash and cash equivalents.\n   - The company received approximately $151.0 million from a public offering in January 2024.\n   - The company expects its existing cash and cash equivalents to fund operations into 2027.\n\n4. **Risks and Uncertainties**:\n   - The company faces significant competition and regulatory challenges.\n   - The success of its product candidates is uncertain and depends on various factors, including clinical trial outcomes and regulatory approvals.\n   - The company is heavily dependent on the success of its product candidates, which are in clinical development.\n\n### Analysis:\n- **Option A: Expand marketing efforts** - The company has no products approved for commercial sale, so expanding marketing efforts is not a viable option.\n- **Option B: Open new research facilities** - This would require additional capital, which the company does not have and cannot secure.\n- **Option C: Increase staff salaries** - This would increase expenses and is not a feasible action given the financial constraints.\n- **Option D: Delay, reduce, or eliminate some research and development programs** - This aligns with the company's stated risk that failure to secure additional funding may force it to delay, reduce, or eliminate certain of its product development or research operations.\n- **Option E: Acquire other companies** - This would require significant capital, which the company does not have and cannot secure.\n- **Option F: Launch new products immediately** - The company has no products ready for commercial launch, so this is not a viable option.\n\n### Conclusion:\nGiven the"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 96000, "result": 1.0, "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?", "options": {"A": "December 31, 2023", "B": "January 4, 2024", "C": "November 20, 2023", "D": "December 15, 2023", "E": "January 10, 2024", "F": "December 1, 2023"}, "LLM_original_answer": ["To answer the question \"On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the pre-payment of the Replacement DIP Facility in the \"Subsequent Events\" section, specifically under \"Payoff of DIP.\"\n\n2. **Extract the date**: The relevant sentence states, \"On January 4, 2024, the Company pre-paid the outstanding balance of $ 4.5 million on the Replacement DIP Facility provided by B. Riley Financial, the Company\u2019s DIP lender.\"\n\n3. **Match the date with the options**: The date mentioned in the document is January 4, 2024.\n\n4. **Select the correct option**: The correct option is B: January 4, 2024.\n\nTherefore, the answer to the question is **B: January 4, 2024**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 96000, "result": 1.0, "question": "Which entity sells certain trade receivables to CRC?", "options": {"A": "Duke Energy Ohio", "B": "CRC", "C": "Duke Energy Indiana", "D": "Subsidiary Registrants", "E": "Intercompany", "F": "Duke Energy"}, "LLM_original_answer": ["To answer the question \"Which entity sells certain trade receivables to CRC?\", let's analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The document mentions the sale of receivables in the \"Variable Interest Entities\" section (Note 18).\n\n2. **Extract the relevant information**:\n   - The document states: \"Duke Energy Ohio and Duke Energy Indiana sell, on a revolving basis, nearly all of their retail accounts receivable, including receivables for unbilled revenues, to an affiliate, CRC, and account for the transfers of receivables as sales.\"\n\n3. **Determine the entities involved**:\n   - The entities that sell receivables to CRC are Duke Energy Ohio and Duke Energy Indiana.\n\n4. **Match the entities to the options**:\n   - **Option A: Duke Energy Ohio** - This matches the information in the document.\n   - **Option C: Duke Energy Indiana** - This also matches the information in the document.\n   - **Option B: CRC** - CRC is the entity receiving the receivables, not selling them.\n   - **Option D: Subsidiary Registrants** - While Duke Energy Ohio and Duke Energy Indiana are subsidiary registrants, this option is too broad and does not specifically identify the entities.\n   - **Option E: Intercompany** - This is not specific to the entities selling receivables.\n   - **Option F: Duke Energy** - This is the parent company and not the specific entities selling receivables.\n\n5. **Conclusion**:\n   - The correct answer is that both Duke Energy Ohio and Duke Energy Indiana sell certain trade receivables to CRC. However, since the question asks for a single entity, and both options A and C are correct, we need to choose the most specific and accurate option.\n\nGiven the options provided, the most specific and accurate answer is:\n\n**Option A: Duke Energy Ohio** and **Option C: Duke Energy Indiana**.\n\nSince the question asks for a single entity, and both are correct, you might need to choose one. If you must select one, either would be correct, but typically, the question would be designed to have a single clear answer. If you have to choose one, you might consider the context or the primary entity mentioned in the document. In this case, both are equally valid, but if you must choose one, you could select:\n\n**Option A: Duke Energy Ohio**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 65, "token_lengths": 96000, "result": 0.0, "question": "What was the collateral value of commercial real estate loans at December 31, 2023?", "options": {"A": "$1.4 billion", "B": "$1.5 billion", "C": "$1.2 billion", "D": "$2.9 billion", "E": "$2.0 billion", "F": "$5.9 million"}, "LLM_original_answer": ["To answer the question \"What was the collateral value of commercial real estate loans at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss commercial real estate loans and their collateral values.\n2. **Extract Specific Information**: Find the specific collateral values mentioned for commercial real estate loans.\n3. **Match the Information to the Question**: Ensure the information is for the correct date (December 31, 2023).\n\n### Step 1: Identify Relevant Sections\nThe document contains several sections that discuss commercial real estate loans and their collateral values. The most relevant sections are:\n\n- **Note 4, \u201cLoans and Allowance for Credit Losses\u201d**\n- **Note 9, \u201cBorrowed Funds\u201d**\n\n### Step 2: Extract Specific Information\nFrom **Note 9, \u201cBorrowed Funds\u201d**:\n- \"At December 31, 2023 and 2022, the Company had available and unused borrowing capacity of approximately $775.9 million and $538.9 million, respectively, at the Federal Reserve Discount Window.\"\n- \"At December 31, 2023 and 2022, the collateral value of residential real estate and commercial real estate loans securing these advances was $1.4 billion and $1.5 billion, respectively, at December 31, 2023, and $1.5 billion and $1.2 billion, respectively, at December 31, 2022.\"\n\n### Step 3: Match the Information to the Question\nThe collateral value of commercial real estate loans at December 31, 2023 is explicitly stated as $1.4 billion.\n\n### Conclusion\nThe correct answer is:\n**A: $1.4 billion**"], "LLM_extracted_answer": ["A"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 96000, "result": 1.0, "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?", "options": {"A": "The company is a subsidiary", "B": "The company operates in multiple countries", "C": "The company is a smaller reporting company", "D": "The company has financial statements in Item 8", "E": "The company issued new stock options", "F": "The company had a significant loss"}, "LLM_original_answer": ["The correct answer is **C: The company is a smaller reporting company**.\n\n### Chain of Thoughts:\n1. **Review the Question and Options:**\n   - The question asks why Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk.\n   - The options provided are:\n     - A: The company is a subsidiary\n     - B: The company operates in multiple countries\n     - C: The company is a smaller reporting company\n     - D: The company has financial statements in Item 8\n     - E: The company issued new stock options\n     - F: The company had a significant loss\n\n2. **Identify Relevant Information in the Document:**\n   - The document states: \"As a \u2018smaller reporting company\u2019 as defined by Item 10 of Regulation S-K, we are not required to provide this information.\"\n\n3. **Evaluate Each Option:**\n   - **A: The company is a subsidiary** - The document does not mention that Nurix Therapeutics, Inc. is a subsidiary of another company.\n   - **B: The company operates in multiple countries** - While the document mentions that the company operates in the United States and may have international operations, this is not the reason given for the exemption.\n   - **C: The company is a smaller reporting company** - This matches the statement in the document that Nurix Therapeutics, Inc. is a smaller reporting company and is therefore exempt from providing the required disclosures.\n   - **D: The company has financial statements in Item 8** - The document does mention that financial statements are included in Item 8, but this is not the reason for the exemption.\n   - **E: The company issued new stock options** - The document mentions the issuance of stock options, but this is not the reason for the exemption.\n   - **F: The company had a significant loss** - The document does mention significant losses, but this is not the reason for the exemption.\n\n4. **Conclusion:**\n   - The document explicitly states that Nurix Therapeutics, Inc. is a smaller reporting company and that this is the reason it is not required to provide the quantitative and qualitative disclosures about market risk.\n\nTherefore, the correct answer is **C: The company is a smaller reporting company**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 96000, "result": 1.0, "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?", "options": {"A": "Ocwen must renegotiate terms with MAV.", "B": "Ocwen can sell to a third party on more favorable terms.", "C": "Ocwen can sell to a third party on no more favorable terms.", "D": "Ocwen must wait until May 2, 2025 to sell.", "E": "Ocwen can sell immediately without restrictions.", "F": "Ocwen must consult PHH before selling."}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The key information is found in the \"Right of First Offer\" section under \"Note 12 \u2014 Investment in Equity Method Investee and Related Party Transactions.\"\n\n2. **Extract the relevant information**:\n   - \"If MAV does not accept Ocwen\u2019s offer, Ocwen may sell the MSRs to a third party on terms no more favorable to the purchaser than those offered to MAV.\"\n   - \"The price at which Ocwen and its affiliates will offer MSRs to MAV will be based on the valuation of an independent third-party.\"\n\n3. **Interpret the information**:\n   - The document specifies that if MAV does not accept Ocwen\u2019s offer, Ocwen can sell the MSRs to a third party.\n   - However, the terms of the sale to the third party must not be more favorable than those offered to MAV.\n\n4. **Match the information to the options**:\n   - **Option A**: Ocwen must renegotiate terms with MAV. (Not supported by the document)\n   - **Option B**: Ocwen can sell to a third party on more favorable terms. (Contradicts the document)\n   - **Option C**: Ocwen can sell to a third party on no more favorable terms. (Matches the document)\n   - **Option D**: Ocwen must wait until May 2, 2025 to sell. (Not supported by the document)\n   - **Option E**: Ocwen can sell immediately without restrictions. (Contradicts the document)\n   - **Option F**: Ocwen must consult PHH before selling. (Not supported by the document)\n\n5. **Conclusion**:\n   - The correct answer is **Option C**: Ocwen can sell to a third party on no more favorable terms.\n\nThus, the condition specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs is that Ocwen can sell to a third party on no more favorable terms than those offered to MAV."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 96000, "result": 1.0, "question": "What is the effect of stockholders acting together in this company?", "options": {"A": "Increased stock value", "B": "Reduction in company expenses", "C": "Significant influence over stockholder approvals", "D": "Improved employee satisfaction", "E": "Higher dividend payouts", "F": "Faster company growth"}, "LLM_original_answer": ["To answer the question \"What is the effect of stockholders acting together in this company?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Stockholder Influence and Corporate Governance**:\n   - The document mentions that the company has a Code of Business Conduct and Ethics and that it is committed to providing a competitive and comprehensive benefits package to its employees.\n   - It also states that the company's success depends on its ability to attract, retain, and motivate a diverse group of employees, which is vital for the company's continued success.\n\n2. **Stockholder Ownership and Influence**:\n   - As of March 1, 2024, the company's executive officers, directors, and entities affiliated with such persons beneficially owned, in the aggregate, approximately 32% of the outstanding voting stock and approximately 38% of the outstanding common stock.\n   - This concentration of ownership means that these stockholders, acting together, have significant influence over all matters that require approval by the stockholders, including the election of directors and approval of significant corporate transactions.\n\n3. **Impact on Corporate Decisions**:\n   - The document notes that corporate actions might be taken even if other stockholders oppose them, due to the significant influence of the major stockholders.\n   - This concentration of ownership might also delay or prevent a change of control of the company that other stockholders may view as beneficial.\n\n4. **Employee Retention and Engagement**:\n   - The company emphasizes the importance of employee retention and engagement, which is crucial for supporting its clinical trials, pipeline, platform technologies, business, and operations.\n   - Stockholder influence can indirectly affect these aspects by impacting the company's financial stability and strategic direction.\n\n5. **Financial and Strategic Flexibility**:\n   - The company may need to raise substantial additional capital to fund its operations and development plans.\n   - Stockholders acting together can influence the company's ability to raise capital, enter into collaborations, or make strategic decisions that affect the company's financial and operational flexibility.\n\nGiven these points, the most appropriate answer from the provided options is:\n\n**C: Significant influence over stockholder approvals**\n\n**Chain of Thoughts**:\n- The document highlights the significant ownership concentration among the company's executive officers, directors, and affiliated entities.\n- This concentration allows these stockholders to have a substantial influence over stockholder approvals, including the election of directors and significant corporate transactions.\n- The influence of these stockholders can affect the company's strategic decisions, financial stability"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 96000, "result": 0.0, "question": "What potential issue could result in increased costs for the company related to AMX0035 development?", "options": {"A": "Increased clinical trial participant costs", "B": "Loss of clinical trial data", "C": "Increased manufacturing costs", "D": "Rising costs of raw materials", "E": "Higher insurance premiums", "F": "Decreased research funding"}, "LLM_original_answer": ["To answer the question \"What potential issue could result in increased costs for the company related to AMX0035 development?\" based on the provided document, I will analyze the relevant information and evaluate each option:\n\n### Step-by-Step Analysis:\n\n1. **Increased clinical trial participant costs (Option A):**\n   - The document mentions that clinical trials are expensive and can take many years to complete. However, it does not specifically highlight increased participant costs as a significant issue.\n   - **Relevance:** Low\n\n2. **Loss of clinical trial data (Option B):**\n   - The document discusses the importance of clinical trial data and the potential for data loss or misappropriation, especially in the context of cybersecurity risks.\n   - **Relevance:** Medium\n\n3. **Increased manufacturing costs (Option C):**\n   - The document explicitly states that manufacturing costs are a significant factor in the development and commercialization of AMX0035. It mentions the need to establish and maintain agreements with third-party manufacturers and the potential for increased costs due to changes in manufacturing processes or supply chain disruptions.\n   - **Relevance:** High\n\n4. **Rising costs of raw materials (Option D):**\n   - The document notes that the company is subject to disruptions in the supply of raw materials and that these disruptions can lead to increased costs.\n   - **Relevance:** High\n\n5. **Higher insurance premiums (Option E):**\n   - The document does not specifically mention higher insurance premiums as a potential issue. It does discuss the importance of insurance but does not indicate that premiums are a significant cost factor.\n   - **Relevance:** Low\n\n6. **Decreased research funding (Option F):**\n   - The document highlights the importance of securing adequate funding for research and development activities. It mentions the risk of not being able to obtain sufficient funding, which could impact the development of AMX0035.\n   - **Relevance:** Medium\n\n### Conclusion:\nBased on the document, the most relevant and explicitly mentioned potential issues that could result in increased costs for the company related to AMX0035 development are **increased manufacturing costs (Option C)** and **rising costs of raw materials (Option D)**. Both of these options are directly supported by the text, which emphasizes the importance of manufacturing and the potential for increased costs due to supply chain disruptions and changes in manufacturing processes.\n\n### Final Answer:\n**C: Increased manufacturing costs** and **D: Rising costs of raw materials** are the most"], "LLM_extracted_answer": ["C"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 96000, "result": 1.0, "question": "How were the 2020 Senior Notes paid off?", "options": {"A": "With company savings", "B": "Through new equity issuance", "C": "By selling company assets", "D": "With net proceeds from the offering of the May 2020 Notes", "E": "By obtaining a bank loan", "F": "Through a government grant"}, "LLM_original_answer": ["To answer the question \"How were the 2020 Senior Notes paid off?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss the 2020 Senior Notes and their payment.\n2. **Analyze the Information**: Determine the specific method used to pay off these notes.\n3. **Select the Correct Option**: Match the identified method with the given options.\n\n### Step 1: Identify Relevant Information\n\nThe relevant information is found in the \"Debt\" section of the document, specifically under the \"Senior Notes Issued in May 2020\" subsection:\n\n- **Senior Notes Issued in May 2020**: \"On May 26, 2020, we issued $2.5 billion in aggregate principal amount of new senior notes comprised of $1.25 billion in aggregate principal amount of 2.10% senior notes due in 2030 and $1.25 billion in aggregate principal amount of 3.00% senior notes due in 2050 (collectively, the May 2020 Notes). We used the net proceeds of the May 2020 Notes for general corporate purposes, including to fund the redemption of our $1.25 billion aggregate principal amount of 2.75% senior notes due December 2020, or the 2020 Senior Notes, which were redeemed in accordance with their terms on June 25, 2020, and to pay down a portion of our commercial paper outstanding.\"\n\n### Step 2: Analyze the Information\n\n- The document states that the net proceeds from the May 2020 Notes were used for general corporate purposes.\n- Specifically, the proceeds were used to fund the redemption of the 2020 Senior Notes.\n- The 2020 Senior Notes were redeemed on June 25, 2020.\n\n### Step 3: Select the Correct Option\n\n- **Option A: With company savings** - The document does not mention using company savings to pay off the 2020 Senior Notes.\n- **Option B: Through new equity issuance** - The document does not mention using new equity issuance to pay off the 2020 Senior Notes.\n- **Option C: By selling company assets** - The document does not mention selling company assets to pay"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 96000, "result": 0.0, "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?", "options": {"A": "The base lapse rate is increased.", "B": "The base lapse rate is reduced.", "C": "The base lapse rate remains unchanged.", "D": "The base lapse rate is doubled.", "E": "The base lapse rate is halved.", "F": "The base lapse rate is eliminated entirely."}, "LLM_original_answer": ["To answer the question \"How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss variable annuity guarantees, base lapse rates, and how these are affected by the relationship between the guaranteed amount and the account value.\n\n2. **Analyze the Information**: Determine if the document explicitly states how the base lapse rate is affected when the guaranteed amount exceeds the account value.\n\n3. **Draw a Conclusion**: Based on the analysis, select the most appropriate answer from the given options.\n\n### Step 1: Identify Relevant Information\n\nThe document contains several sections that discuss variable annuity guarantees and risk management strategies. The most relevant section is:\n\n**Market Risk Benefits on Annuity Guarantees**:\n- \"MRBs are contracts or contract features that provide protection to the policyholder from capital markets risks by transferring such risks to the Company.\"\n- \"The measurement of fair value includes an adjustment for the risk that the Company fails to satisfy its obligations, which is referred to as nonperformance risk, as well as risk margin to capture the non-capital markets risks of the instrument, which represents the additional compensation a market participant would require to assume the risks related to the uncertainties in certain actuarial assumptions.\"\n- \"The Company updates the estimated fair value of variable annuity guarantees in subsequent periods by projecting future benefits using capital markets inputs and actuarial assumptions including expectations of policyholder behavior.\"\n\n### Step 2: Analyze the Information\n\nThe document mentions that the Company updates the estimated fair value of variable annuity guarantees by projecting future benefits using capital markets inputs and actuarial assumptions, including expectations of policyholder behavior. However, it does not explicitly state how the base lapse rate is affected when the guaranteed amount exceeds the account value.\n\nTo infer the correct answer, we need to consider the general principles of policyholder behavior in the context of variable annuity guarantees:\n- When the guaranteed amount exceeds the account value, policyholders are more likely to keep their policies because they have a financial incentive to do so. This is because the guaranteed amount provides a safety net that is more valuable than the current account value.\n- Conversely, when the account value is higher than the guaranteed amount, policyholders are more likely to lapse their policies to take advantage of the higher account value.\n\n### Step 3: Draw a Conclusion\n\nGiven the above analysis, when the guaranteed amount exceeds the account value"], "LLM_extracted_answer": ["A"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 128000, "result": 1.0, "question": "What action might the company be forced to take if they cannot secure additional funding?", "options": {"A": "Expand marketing efforts", "B": "Open new research facilities", "C": "Increase staff salaries", "D": "Delay, reduce, or eliminate some research and development programs", "E": "Acquire other companies", "F": "Launch new products immediately"}, "LLM_original_answer": ["The correct answer to the question \"What action might the company be forced to take if they cannot secure additional funding?\" is:\n\n**D: Delay, reduce, or eliminate some research and development programs**\n\n### Chain of Thought:\n1. **Context from the Document:**\n   - The document discusses the company's financial situation and the need for substantial additional funding to continue its operations.\n   - It mentions that the company has incurred significant operating losses and has no products approved for commercial sale.\n   - The company's expenses are expected to increase as it progresses with clinical trials and other development activities.\n\n2. **Financial Implications:**\n   - The company has a limited operating history and has been incurring net losses since its inception.\n   - It has an accumulated deficit of $381.4 million as of December 31, 2023.\n   - The company expects to continue incurring significant losses and increased expenses as it advances its product candidates through clinical trials and seeks regulatory approval.\n\n3. **Funding Requirements:**\n   - The document states that the company will need substantial additional funding to support its ongoing activities, particularly for the development of KER-050, KER-012, and KER-065.\n   - It emphasizes that without additional funding, the company could be forced to delay, reduce, or eliminate some or all of its research and development programs or commercialization efforts.\n\n4. **Options Analysis:**\n   - **A: Expand marketing efforts** - This is not mentioned as a potential action in the document.\n   - **B: Open new research facilities** - This would likely increase expenses, not reduce them.\n   - **C: Increase staff salaries** - This would also increase expenses.\n   - **D: Delay, reduce, or eliminate some research and development programs** - This is explicitly mentioned as a potential action if the company cannot secure additional funding.\n   - **E: Acquire other companies** - This is not mentioned as a potential action in the document.\n   - **F: Launch new products immediately** - The company has no products approved for commercial sale, so this is not a feasible option.\n\n5. **Conclusion:**\n   - Based on the information provided in the document, the company is most likely to delay, reduce, or eliminate some research and development programs if it cannot secure additional funding. This action aligns with the company's need to manage its financial resources and reduce expenses to ensure its continued operations."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 128000, "result": 0.0, "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?", "options": {"A": "December 31, 2023", "B": "January 4, 2024", "C": "November 20, 2023", "D": "December 15, 2023", "E": "January 10, 2024", "F": "December 1, 2023"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["!"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 128000, "result": 0.0, "question": "Which entity sells certain trade receivables to CRC?", "options": {"A": "Duke Energy Ohio", "B": "CRC", "C": "Duke Energy Indiana", "D": "Subsidiary Registrants", "E": "Intercompany", "F": "Duke Energy"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "A"}, {"depth": 65, "token_lengths": 128000, "result": 0.0, "question": "What was the collateral value of commercial real estate loans at December 31, 2023?", "options": {"A": "$1.4 billion", "B": "$1.5 billion", "C": "$1.2 billion", "D": "$2.9 billion", "E": "$2.0 billion", "F": "$5.9 million"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["!"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 128000, "result": 1.0, "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?", "options": {"A": "The company is a subsidiary", "B": "The company operates in multiple countries", "C": "The company is a smaller reporting company", "D": "The company has financial statements in Item 8", "E": "The company issued new stock options", "F": "The company had a significant loss"}, "LLM_original_answer": ["The correct answer is **C: The company is a smaller reporting company**.\n\n### Chain of Thought:\n1. **Review the Question**: The question asks why Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk.\n2. **Identify Key Information**: The key phrase in the question is \"not required to provide quantitative and qualitative disclosures about market risk.\"\n3. **Examine the Document**: The document provides several pieces of information, but the most relevant section is found in **Item 7A. Quantitative and Qualitative Disclosures About Market Risk**:\n   - \"As a \u2018smaller reporting company\u2019 as defined by Item 10 of Regulation S-K, we are not required to provide this information.\"\n4. **Understand the Context**: A \"smaller reporting company\" is a term used by the SEC to describe companies that meet certain criteria, such as having a public float of less than $250 million or annual revenue of less than $100 million.\n5. **Match the Information to the Options**:\n   - **A: The company is a subsidiary** - The document does not mention Nurix being a subsidiary.\n   - **B: The company operates in multiple countries** - While the company does operate in multiple countries, this is not the reason for the exemption.\n   - **C: The company is a smaller reporting company** - This matches the information provided in the document.\n   - **D: The company has financial statements in Item 8** - Having financial statements in Item 8 is a requirement for all public companies, not an exemption.\n   - **E: The company issued new stock options** - Issuing stock options is not a reason for exemption from market risk disclosures.\n   - **F: The company had a significant loss** - While the company has had significant losses, this is not the reason for the exemption.\n\n### Conclusion:\nThe document explicitly states that Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk because it is a \"smaller reporting company.\" Therefore, the correct answer is **C: The company is a smaller reporting company**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 128000, "result": 1.0, "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?", "options": {"A": "Ocwen must renegotiate terms with MAV.", "B": "Ocwen can sell to a third party on more favorable terms.", "C": "Ocwen can sell to a third party on no more favorable terms.", "D": "Ocwen must wait until May 2, 2025 to sell.", "E": "Ocwen can sell immediately without restrictions.", "F": "Ocwen must consult PHH before selling."}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 128000, "result": 0.0, "question": "What is the effect of stockholders acting together in this company?", "options": {"A": "Increased stock value", "B": "Reduction in company expenses", "C": "Significant influence over stockholder approvals", "D": "Improved employee satisfaction", "E": "Higher dividend payouts", "F": "Faster company growth"}, "LLM_original_answer": ["The provided document does not contain information directly related to the effects of stockholders acting together in the company. The document is primarily focused on the company's research and development efforts, clinical trials, regulatory processes, and business strategies, but it does not discuss stockholder behavior or the impact of stockholder actions on the company's operations or financial outcomes.\n\nGiven the lack of relevant information in the document"], "LLM_extracted_answer": ["A"], "ground_truth": "C"}, {"depth": 65, "token_lengths": 128000, "result": 0.0, "question": "What potential issue could result in increased costs for the company related to AMX0035 development?", "options": {"A": "Increased clinical trial participant costs", "B": "Loss of clinical trial data", "C": "Increased manufacturing costs", "D": "Rising costs of raw materials", "E": "Higher insurance premiums", "F": "Decreased research funding"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "B"}, {"depth": 65, "token_lengths": 128000, "result": 1.0, "question": "How were the 2020 Senior Notes paid off?", "options": {"A": "With company savings", "B": "Through new equity issuance", "C": "By selling company assets", "D": "With net proceeds from the offering of the May 2020 Notes", "E": "By obtaining a bank loan", "F": "Through a government grant"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 65, "token_lengths": 128000, "result": 0.0, "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?", "options": {"A": "The base lapse rate is increased.", "B": "The base lapse rate is reduced.", "C": "The base lapse rate remains unchanged.", "D": "The base lapse rate is doubled.", "E": "The base lapse rate is halved.", "F": "The base lapse rate is eliminated entirely."}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 8000, "result": 1.0, "question": "What is the primary reason the Company has not generated any revenue from product sales?", "options": {"A": "High production costs", "B": "None of its product candidates have been approved for commercialization", "C": "Lack of marketing efforts", "D": "Inadequate research and development", "E": "Insufficient staffing", "F": "Economic downturn"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Revenue Recognition Section**:\n   - The document states: \"To date, our revenues have consisted solely of payments received related to research collaborations and licensing of intellectual property.\"\n   - This indicates that the company has not generated revenue from product sales.\n\n2. **Reason for No Product Sales Revenue**:\n   - The document further states: \"To date, the Company has not generated any revenue from product sales as none of its product candidates have been approved for commercialization.\"\n   - This directly points to the reason why the company has not generated revenue from product sales.\n\n3. **Evaluating the Options**:\n   - **Option A: High production costs** - The document does not mention high production costs as a reason for no revenue from product sales.\n   - **Option B: None of its product candidates have been approved for commercialization** - This is explicitly stated in the document.\n   - **Option C: Lack of marketing efforts** - The document does not discuss marketing efforts.\n   - **Option D: Inadequate research and development** - The document mentions significant R&D activities but does not suggest inadequacy.\n   - **Option E: Insufficient staffing** - The document does not mention staffing issues.\n   - **Option F: Economic downturn** - The document does not discuss economic conditions affecting revenue.\n\nBased on the information provided in the document, the primary reason the Company has not generated any revenue from product sales is:\n\n**B: None of its product candidates have been approved for commercialization**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 8000, "result": 0.0, "question": "What is the total expected lease payment for the Austin Lease term?", "options": {"A": "$97.8 million", "B": "$88 million", "C": "$100 million", "D": "$78.9 million", "E": "$90 million", "F": "$85 million"}, "LLM_original_answer": ["To answer the question \"What is the total expected lease payment for the Austin Lease term?\" based on the provided document, I need to carefully review the content to find any relevant information about the Austin Lease and its expected lease payments. However, after a thorough examination of the document, I do not find any specific mention of an \"Austin Lease\" or any details about lease payments for such a term.\n\nThe document primarily discusses the company's financial reorganization, including the issuance of new debt instruments, equity, and related-party transactions. It does not provide information about lease payments or any lease terms, particularly an \"Austin Lease.\"\n\nGiven that the document does not contain the necessary information to answer the question, I cannot determine the total expected lease payment for the Austin Lease term from the options provided. The correct answer cannot be derived from the given document.\n\nIf you have additional information or another document that mentions the Austin Lease, please provide it, and I will be happy to help you find the correct answer."], "LLM_extracted_answer": ["E"], "ground_truth": "A"}, {"depth": 70, "token_lengths": 8000, "result": 1.0, "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?", "options": {"A": "As separate performance obligations", "B": "Under series guidance", "C": "As a single performance obligation", "D": "With cost-based pricing", "E": "As unbilled estimates", "F": "With FERC regulation compliance"}, "LLM_original_answer": ["To answer the question \"How does Duke Energy treat energy and demand charges under full requirements contracts?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document discusses various aspects of Duke Energy's financial and operational practices. The section that is most relevant to the question is found in the \"19. REVENUE\" section, particularly under the \"Electric Utilities and Infrastructure\" (EU&I) subsection.\n\n2. **Extract the key information**: The relevant paragraph states:\n   - \"Wholesale contracts include both energy and demand charges.\"\n   - \"For full requirements contracts, Duke Energy considers both charges as a single performance obligation for providing integrated electric service.\"\n\n3. **Analyze the information**:\n   - The document explicitly mentions that for full requirements contracts, Duke Energy treats both energy and demand charges as a single performance obligation.\n   - This is in contrast to contracts where energy and demand charges are considered separate performance obligations, which are handled differently.\n\n4. **Match the information to the options**:\n   - Option A: As separate performance obligations (This does not match the document's statement for full requirements contracts.)\n   - Option B: Under series guidance (The document does not mention series guidance for full requirements contracts.)\n   - Option C: As a single performance obligation (This matches the document's statement for full requirements contracts.)\n   - Option D: With cost-based pricing (The document mentions cost-based pricing for wholesale contracts, but not specifically for full requirements contracts.)\n   - Option E: As unbilled estimates (The document discusses unbilled estimates, but not in the context of treating energy and demand charges as a single performance obligation.)\n   - Option F: With FERC regulation compliance (The document mentions FERC regulation compliance, but not in the context of treating energy and demand charges as a single performance obligation.)\n\n5. **Conclusion**:\n   - The correct answer is Option C: As a single performance obligation.\n\nTherefore, Duke Energy treats energy and demand charges under full requirements contracts as a single performance obligation."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 8000, "result": 1.0, "question": "How many RSA awards vested during the year ended December 31, 2023?", "options": {"A": "683,056", "B": "152,880", "C": "136,609", "D": "95,808", "E": "302,908", "F": "0"}, "LLM_original_answer": ["To answer the question \"How many RSA awards vested during the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section on share-based compensation, which is likely to include information about RSA (Restricted Stock Award) vesting.\n\n2. **Locate the specific information**: Within the share-based compensation section, there is a table that summarizes the Company\u2019s restricted stock award activity for the periods indicated.\n\n3. **Extract the data for the year 2023**: The table provides the number of RSA awards vested for the year ended December 31, 2023.\n\n4. **Match the data with the given options**: Compare the extracted data with the provided options to select the correct answer.\n\nLet's go through these steps:\n\n### Step 1: Identify the relevant section\nThe relevant section is titled \"Share-Based Compensation Plan\" and includes a table summarizing the Company\u2019s restricted stock award activity.\n\n### Step 2: Locate the specific information\nThe table in the document states:\n```\nDuring the year ended December 31, 2023, 152,880 RSA awards vested. Such awards had a grant date fair value of $ 3.0 million.\n```\n\n### Step 3: Extract the data for the year 2023\nThe number of RSA awards that vested during the year ended December 31, 2023 is **152,880**.\n\n### Step 4: Match the data with the given options\nThe options provided are:\n- A: 683,056\n- B: 152,880\n- C: 136,609\n- D: 95,808\n- E: 302,908\n- F: 0\n\nThe number **152,880** matches option **B**.\n\n### Conclusion\nThe correct answer is **B: 152,880**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 8000, "result": 1.0, "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?", "options": {"A": "Development of antiviral medications", "B": "Manufacturing of generic drugs", "C": "Discovery and commercialization of protein degradation drugs", "D": "Research into rare genetic disorders", "E": "Development of vaccines", "F": "Production of over-the-counter supplements"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document, particularly focusing on the section that describes the collaboration agreement with Gilead.\n\n1. **Identify the Collaboration Agreement with Gilead:**\n   - The document states that in June 2019, the Company entered into a global strategic collaboration agreement with Gilead (the Gilead Agreement).\n\n2. **Understand the Purpose of the Agreement:**\n   - The primary purpose of the Gilead Agreement is to \"discover, develop and commercialize a pipeline of targeted protein degradation drugs for patients with cancer and other challenging diseases using the Company\u2019s DELigase platform to identify novel agents that utilize E3 ligases to induce degradation of five specified drug targets.\"\n\n3. **Evaluate the Options:**\n   - **A: Development of antiviral medications** - The document does not mention antiviral medications in the context of the Gilead Agreement.\n   - **B: Manufacturing of generic drugs** - The document does not mention generic drugs in the context of the Gilead Agreement.\n   - **C: Discovery and commercialization of protein degradation drugs** - This aligns with the stated purpose of the Gilead Agreement.\n   - **D: Research into rare genetic disorders** - The document does not mention rare genetic disorders in the context of the Gilead Agreement.\n   - **E: Development of vaccines** - The document does not mention vaccines in the context of the Gilead Agreement.\n   - **F: Production of over-the-counter supplements** - The document does not mention over-the-counter supplements in the context of the Gilead Agreement.\n\n4. **Conclusion:**\n   - The primary focus of the collaboration agreement between the Company and Gilead is the discovery and commercialization of protein degradation drugs for patients with cancer and other challenging diseases.\n\nTherefore, the correct answer is **C: Discovery and commercialization of protein degradation drugs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 8000, "result": 1.0, "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?", "options": {"A": "$188.2 million", "B": "$183.9 million", "C": "$181.1 million", "D": "$177.5 million", "E": "$24.6 million", "F": "$11.3 million"}, "LLM_original_answer": ["To answer the question \"How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that discusses deferred tax assets and liabilities. This is found in the \"Note 20 \u2014 Income Taxes\" section.\n\n2. **Locate the specific information**: Within the \"Note 20 \u2014 Income Taxes\" section, there is a table that presents the net deferred tax assets. The relevant information is in the following paragraph:\n   - \"As of December 31, 2023, we had a deferred tax asset, net of deferred tax liability, of $ 188.2 million including $ 183.9 million in the U.S.\"\n\n3. **Extract the answer**: The deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023, is $183.9 million.\n\n4. **Match the answer to the options**: The correct answer is option B: $183.9 million.\n\nTherefore, the answer to the question is **B: $183.9 million**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 8000, "result": 1.0, "question": "Which of the following is included in research and development expenses as incurred?", "options": {"A": "Marketing and advertising expenses", "B": "Expenses related to employee salaries involved in R&D", "C": "Sales commission and bonuses", "D": "Office supplies and administrative costs", "E": "Travel expenses for sales team", "F": "Legal fees for patent applications"}, "LLM_original_answer": ["To answer the question \"Which of the following is included in research and development expenses as incurred?\" based on the provided document, I will analyze the relevant section of the document and then evaluate each option.\n\n### Relevant Section from the Document:\n**Research and Development Expenses**\nResearch and development expenses consist primarily of costs incurred in connection with our research activities, including our therapeutic discovery efforts, preclinical and clinical trials, and the development of our proprietary platform technologies and product candidates. We expense research and development costs as incurred, which include:\n- **employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, and other related costs for those employees involved in research and development efforts;**\n- expenses incurred in connection with our research programs, including under agreements with third parties, such as consultants and contract research organizations, or CROs;\n- the cost of raw materials, developing and scaling our manufacturing process, and manufacturing our product candidates for use in our research and preclinical studies, including under agreements with third parties, such as consultants, contractors, and contract manufacturing organizations, or CMOs;\n- laboratory supplies and research materials;\n- facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance; and\n- payments made under third-party licensing agreements.\n\n### Evaluation of Each Option:\n1. **A: Marketing and advertising expenses**\n   - **Not included**: The document does not mention marketing and advertising expenses as part of research and development expenses.\n\n2. **B: Expenses related to employee salaries involved in R&D**\n   - **Included**: The document explicitly states that \"employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, and other related costs for those employees involved in research and development efforts\" are included in research and development expenses.\n\n3. **C: Sales commission and bonuses**\n   - **Not included**: The document does not mention sales commissions or bonuses as part of research and development expenses.\n\n4. **D: Office supplies and administrative costs**\n   - **Not included**: The document specifies that general and administrative expenses include \"salaries and personnel expenses, including stock-based compensation, for our personnel in executive, legal, finance and accounting, human resources, and other administrative functions\" and \"travel expenses,\" but these are not listed under research and development expenses.\n\n5. **E: Travel expenses for sales team**\n   - **Not included**: The document mentions travel expenses under general and administrative expenses, not research and development expenses.\n\n6. **F: Legal fees for"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 8000, "result": 1.0, "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?", "options": {"A": "Increase in corporate tax rates", "B": "Elimination of personal exemptions", "C": "Capitalization and amortization of research and experimentation costs", "D": "Introduction of new state taxes", "E": "Repeal of alternative minimum tax", "F": "Mandatory expense reporting for small businesses"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the tax law change that significantly impacted U.S. federal and state taxable income starting January 1, 2022.\n\n1. **Identify the relevant section in the document:**\n   - The section that discusses income taxes is \"Income Taxes\" under \"Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations.\"\n\n2. **Extract the key information:**\n   - The document states: \"Current year U.S. federal and state taxable income is significantly impacted by a TCJA tax law change in effect from January 1, 2022 that requires capitalization and amortization of all research and experimentation costs under Section 174 of the IRC.\"\n\n3. **Understand the context:**\n   - TCJA stands for the Tax Cuts and Jobs Act.\n   - The change requires companies to capitalize and amortize research and experimentation costs over a period of time, rather than deducting them immediately.\n\n4. **Match the information to the options:**\n   - Option A: Increase in corporate tax rates - The document does not mention an increase in corporate tax rates.\n   - Option B: Elimination of personal exemptions - The document does not mention personal exemptions.\n   - Option C: Capitalization and amortization of research and experimentation costs - This matches the information provided in the document.\n   - Option D: Introduction of new state taxes - The document does not mention new state taxes.\n   - Option E: Repeal of alternative minimum tax - The document does not mention the repeal of the alternative minimum tax.\n   - Option F: Mandatory expense reporting for small businesses - The document does not mention mandatory expense reporting for small businesses.\n\n5. **Conclusion:**\n   - The tax law change that significantly impacted U.S. federal and state taxable income starting January 1, 2022, is the requirement to capitalize and amortize all research and experimentation costs under Section 174 of the IRC.\n\nTherefore, the correct answer is **Option C: Capitalization and amortization of research and experimentation costs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 8000, "result": 1.0, "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?", "options": {"A": "$100 million", "B": "$200 million", "C": "$215 million", "D": "$300 million", "E": "$250 million", "F": "$150 million"}, "LLM_original_answer": ["To answer the question \"What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the guaranty fund for ICE NGX in the \"ICE NGX\" section.\n\n2. **Extract the specific information**: The relevant information is found in the following sentence:\n   - \"As of December 31, 2023, ICE NGX maintains a guaranty fund of $ 215 million, comprising $ 15 million in cash and a $ 200 million letter of credit backed by a default insurance policy of the same amount, discussed below.\"\n\n3. **Summarize the total amount**: The total amount in the ICE NGX guaranty fund is the sum of the cash and the letter of credit.\n   - Cash: $15 million\n   - Letter of Credit: $200 million\n   - Total: $15 million + $200 million = $215 million\n\n4. **Match the total amount to the given options**:\n   - A: $100 million\n   - B: $200 million\n   - C: $215 million\n   - D: $300 million\n   - E: $250 million\n   - F: $150 million\n\nThe correct answer is **C: $215 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 8000, "result": 1.0, "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?", "options": {"A": "Investment gains", "B": "Interest income", "C": "Rental income", "D": "12b-1 fees", "E": "Consulting fees", "F": "Insurance premiums"}, "LLM_original_answer": ["To answer the question \"What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the section relevant to other revenues**: The document mentions other revenues in the section titled \"14. Other Revenues and Other Expenses.\"\n\n2. **Locate the specific information about other revenues**: Within this section, the document states:\n   - \"Other revenues consisted primarily of 12b-1 fees of $ 266 million, $ 292 million and $ 360 million for the years ended December 31, 2023, 2022 and 2021, respectively, of which substantially all were reported in the Annuities segment.\"\n\n3. **Determine the primary component of other revenues**: The document clearly indicates that 12b-1 fees are the primary component of other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023.\n\n4. **Match the primary component to the given options**: The options provided are:\n   - A: Investment gains\n   - B: Interest income\n   - C: Rental income\n   - D: 12b-1 fees\n   - E: Consulting fees\n   - F: Insurance premiums\n\n   The primary component of other revenues, as stated in the document, is 12b-1 fees.\n\nTherefore, the correct answer is **D: 12b-1 fees**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 70, "token_lengths": 16000, "result": 1.0, "question": "What is the primary reason the Company has not generated any revenue from product sales?", "options": {"A": "High production costs", "B": "None of its product candidates have been approved for commercialization", "C": "Lack of marketing efforts", "D": "Inadequate research and development", "E": "Insufficient staffing", "F": "Economic downturn"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Revenue from Product Sales**:\n   - The document states: \"To date, we have not generated any revenue, and do not expect to generate any revenue in the foreseeable future, from product sales.\"\n   - This indicates that the company has not yet commercialized any of its products.\n\n2. **Product Development Status**:\n   - The document mentions that the company is in the clinical stage of development for its product candidates.\n   - Specifically, it states: \"The Company\u2019s lead product candidate, KER-050 (elitercept), is being developed for the treatment of low blood cell counts (\u2018cytopenias\u2019), including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (\u2018MDS\u2019) and in patients with myelofibrosis.\"\n   - It also mentions: \"The Company\u2019s second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension (\u2018PAH\u2019) and for the treatment of cardiovascular disorders.\"\n   - And: \"The Company's third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.\"\n   - These statements indicate that the company's product candidates are still in the development phase and have not yet been approved for commercialization.\n\n3. **Regulatory and Commercial Milestones**:\n   - The document outlines various milestones and payments related to the development and commercialization of its product candidates.\n   - For example, under the MGH Agreement, the company is required to pay milestone payments ranging from $50,000 to $10.0 million, and royalties ranging from the low-single digits to mid-single digits of sales.\n   - Similarly, under the Hansoh Agreement, the company is entitled to receive milestone payments and royalties, but these are contingent on the achievement of specific development and commercial milestones.\n   - The document also states: \"We do not have any products approved for sale.\"\n\n4. **Revenue Sources**:\n   - The document specifies that the company has generated revenue solely from research collaborations or licensing of intellectual property.\n   - For instance, it mentions: \"Our revenue for the year ended December 31, 2021 consisted primarily of an upfront fee of $20.0 million under the Hansoh Agreement, whereby we granted to Hansoh the exclusive right"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 16000, "result": 1.0, "question": "What is the total expected lease payment for the Austin Lease term?", "options": {"A": "$97.8 million", "B": "$88 million", "C": "$100 million", "D": "$78.9 million", "E": "$90 million", "F": "$85 million"}, "LLM_original_answer": ["To answer the question \"What is the total expected lease payment for the Austin Lease term?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the Austin Lease Agreement in the section titled \"Austin Lease Agreement.\"\n\n2. **Extract the key information**: The relevant information from this section is:\n   - The Austin Lease term is eight years.\n   - Total lease payments are expected to be $97.8 million.\n\n3. **Match the information to the options**: The total expected lease payment for the Austin Lease term is $97.8 million, which corresponds to option A.\n\nTherefore, the correct answer is **A: $97.8 million**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 70, "token_lengths": 16000, "result": 1.0, "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?", "options": {"A": "As separate performance obligations", "B": "Under series guidance", "C": "As a single performance obligation", "D": "With cost-based pricing", "E": "As unbilled estimates", "F": "With FERC regulation compliance"}, "LLM_original_answer": ["To answer the question \"How does Duke Energy treat energy and demand charges under full requirements contracts?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document discusses revenue recognition and performance obligations in the \"19. REVENUE\" section. Specifically, it mentions how Duke Energy treats energy and demand charges under different types of contracts.\n\n2. **Locate the specific information**: Within the \"19. REVENUE\" section, the document states:\n   - \"For full requirements contracts, Duke Energy considers both charges as a single performance obligation for providing integrated electric service.\"\n   - \"For contracts where energy and demand charges are considered separate performance obligations, energy and demand are each a distinct performance obligation under the series guidance and are satisfied as energy is delivered and stand-ready service is provided on a monthly basis.\"\n\n3. **Analyze the information**:\n   - The first statement indicates that for full requirements contracts, Duke Energy treats both energy and demand charges as a single performance obligation.\n   - The second statement is about contracts where energy and demand charges are treated separately, which is not the case for full requirements contracts.\n\n4. **Match the information to the options**:\n   - Option A: As separate performance obligations (This does not match the document's statement for full requirements contracts.)\n   - Option B: Under series guidance (This is mentioned for contracts where energy and demand charges are separate, not for full requirements contracts.)\n   - Option C: As a single performance obligation (This matches the document's statement for full requirements contracts.)\n   - Option D: With cost-based pricing (This is mentioned for wholesale contracts, not specifically for full requirements contracts.)\n   - Option E: As unbilled estimates (This is mentioned for recognizing revenue for energy or natural gas delivered but not yet billed, not for treating charges under full requirements contracts.)\n   - Option F: With FERC regulation compliance (This is mentioned for wholesale contracts, not specifically for full requirements contracts.)\n\n5. **Conclusion**: Based on the document, Duke Energy treats energy and demand charges under full requirements contracts as a single performance obligation.\n\nTherefore, the correct answer is **C: As a single performance obligation**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 16000, "result": 1.0, "question": "How many RSA awards vested during the year ended December 31, 2023?", "options": {"A": "683,056", "B": "152,880", "C": "136,609", "D": "95,808", "E": "302,908", "F": "0"}, "LLM_original_answer": ["To answer the question \"How many RSA awards vested during the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section on share-based compensation, which is likely to include information about RSA (Restricted Stock Award) vesting.\n\n2. **Locate the specific information**: Within the share-based compensation section, I will look for a table or paragraph that mentions RSA vesting for the year ended December 31, 2023.\n\n3. **Extract the data**: Once I find the relevant information, I will extract the number of RSA awards that vested during the specified period.\n\n4. **Match the data with the options**: Finally, I will compare the extracted data with the provided options to select the correct answer.\n\n### Step-by-Step Analysis:\n\n1. **Identify the relevant section**:\n   - The relevant section is \"Share-Based Compensation Plan\" and \"Restricted Stock Award Activity.\"\n\n2. **Locate the specific information**:\n   - The document states: \"During the year ended December 31, 2023, 152,880 RSA awards vested. Such awards had a grant date fair value of $ 3.0 million.\"\n\n3. **Extract the data**:\n   - The number of RSA awards that vested during the year ended December 31, 2023 is 152,880.\n\n4. **Match the data with the options**:\n   - The extracted data (152,880) matches option B.\n\n### Conclusion:\nThe correct answer is **B: 152,880**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 16000, "result": 1.0, "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?", "options": {"A": "Development of antiviral medications", "B": "Manufacturing of generic drugs", "C": "Discovery and commercialization of protein degradation drugs", "D": "Research into rare genetic disorders", "E": "Development of vaccines", "F": "Production of over-the-counter supplements"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the primary focus of the collaboration agreement between the Company and Gilead.\n\n1. **Identify the Collaboration Agreement**:\n   - The document mentions that the Company entered into a global strategic collaboration agreement with Gilead in June 2019 (referred to as the Gilead Agreement).\n\n2. **Understand the Purpose of the Agreement**:\n   - The Gilead Agreement is described as being aimed at discovering, developing, and commercializing a pipeline of targeted protein degradation drugs for patients with cancer and other challenging diseases.\n   - The Company will use its DELigase platform to identify novel agents that utilize E3 ligases to induce degradation of five specified drug targets.\n\n3. **Evaluate the Promises and Performance Obligations**:\n   - The document lists the promises in the Gilead Agreement as:\n     - Research licenses\n     - Research services, including selection campaign research services for certain replacement targets\n     - The obligation to share information during the research term\n     - Participation in joint research committees and joint steering committees\n   - These promises are combined into a single performance obligation due to the specialized nature of the research services.\n\n4. **Consider the Financial Aspects**:\n   - Gilead has the option to license drug candidates directed to up to five targets.\n   - The Company received an upfront payment of $45.0 million plus $3.0 million in additional fees.\n   - The Company is eligible to receive up to approximately $2.3 billion in total additional payments based on certain milestones and royalties.\n\n5. **Determine the Primary Focus**:\n   - The primary focus of the collaboration is clearly on the discovery, development, and commercialization of targeted protein degradation drugs.\n   - This aligns with the Company's expertise in E3 ligases and its DELigase platform, which is used to identify and develop these drugs.\n\nGiven the above analysis, the primary focus of the collaboration agreement between the Company and Gilead is the discovery and commercialization of protein degradation drugs.\n\n**Answer: C: Discovery and commercialization of protein degradation drugs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 16000, "result": 1.0, "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?", "options": {"A": "$188.2 million", "B": "$183.9 million", "C": "$181.1 million", "D": "$177.5 million", "E": "$24.6 million", "F": "$11.3 million"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant section in the document that discusses deferred tax assets and liabilities.\n2. Look for the specific figures related to the U.S. as of December 31, 2023.\n3. Compare the identified figure with the provided options to select the correct answer.\n\n### Step 1: Identify the Relevant Section\nThe relevant section is found in **Note 20 \u2014 Income Taxes**, specifically in the part that discusses the composition of net deferred tax assets.\n\n### Step 2: Look for the Specific Figures\nIn the section **Net deferred tax assets were comprised of the following:**\n\n- As of December 31, 2023, the deferred tax asset, net of deferred tax liability, is $188.2 million.\n- The document further specifies that this amount includes $183.9 million in the U.S.\n\n### Step 3: Compare with Provided Options\nThe options provided are:\n- A: $188.2 million\n- B: $183.9 million\n- C: $181.1 million\n- D: $177.5 million\n- E: $24.6 million\n- F: $11.3 million\n\nThe correct answer is **B: $183.9 million**.\n\n### Chain of Thoughts\n- The document clearly states that as of December 31, 2023, the deferred tax asset, net of deferred tax liability, in the U.S. is $183.9 million.\n- This figure matches exactly with one of the provided options, which is B: $183.9 million.\n- Therefore, the correct answer is B: $183.9 million."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 16000, "result": 1.0, "question": "Which of the following is included in research and development expenses as incurred?", "options": {"A": "Marketing and advertising expenses", "B": "Expenses related to employee salaries involved in R&D", "C": "Sales commission and bonuses", "D": "Office supplies and administrative costs", "E": "Travel expenses for sales team", "F": "Legal fees for patent applications"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document and identify the relevant information regarding research and development (R&D) expenses.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Section on R&D Expenses:**\n   - The relevant section is found under \"Operating Expenses\" -> \"Research and Development Expenses.\"\n\n2. **List the Components of R&D Expenses:**\n   - According to the document, R&D expenses consist primarily of:\n     - Employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, and other related costs for those employees involved in research and development efforts.\n     - Expenses incurred in connection with our research programs, including under agreements with third parties, such as consultants and contract research organizations (CROs).\n     - The cost of raw materials, developing and scaling our manufacturing process, and manufacturing our product candidates for use in our research and preclinical studies, including under agreements with third parties, such as consultants, contractors, and contract manufacturing organizations (CMOs).\n     - Laboratory supplies and research materials.\n     - Facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance.\n     - Payments made under third-party licensing agreements.\n\n3. **Evaluate Each Option:**\n   - **A: Marketing and advertising expenses**\n     - Not mentioned in the R&D expenses section.\n   - **B: Expenses related to employee salaries involved in R&D**\n     - Explicitly mentioned: \"employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, and other related costs for those employees involved in research and development efforts.\"\n   - **C: Sales commission and bonuses**\n     - Not mentioned in the R&D expenses section.\n   - **D: Office supplies and administrative costs**\n     - Not mentioned in the R&D expenses section.\n   - **E: Travel expenses for sales team**\n     - Not mentioned in the R&D expenses section.\n   - **F: Legal fees for patent applications**\n     - Not explicitly mentioned in the R&D expenses section, but legal costs related to patent applications could be considered part of the broader category of \"legal fees relating to corporate matters\" under general and administrative expenses.\n\n### Conclusion:\nBased on the document, the correct answer is **B: Expenses related to employee salaries involved in R&D**. This is explicitly stated as a component of R&D expenses.\n\n### Final Answer:\n**B: Expenses related to employee salaries involved in R&D**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 16000, "result": 1.0, "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?", "options": {"A": "Increase in corporate tax rates", "B": "Elimination of personal exemptions", "C": "Capitalization and amortization of research and experimentation costs", "D": "Introduction of new state taxes", "E": "Repeal of alternative minimum tax", "F": "Mandatory expense reporting for small businesses"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify any references to tax law changes that significantly impacted U.S. federal and state taxable income starting January 1, 2022.\n\n1. **Initial Review of the Document:**\n   - The document primarily discusses the financial and operational aspects of Amylyx Pharmaceuticals, Inc., including its transition from an emerging growth company to a public company, the launch of its products, and various financial and compliance-related matters.\n   - There is a section dedicated to income taxes and the impact of tax law changes.\n\n2. **Relevant Section on Income Taxes:**\n   - The document mentions: \"Current year U.S. federal and state taxable income is significantly impacted by a TCJA tax law change in effect from January 1, 2022 that requires capitalization and amortization of all research and experimentation costs under Section 174 of the IRC.\"\n\n3. **Interpretation of the Tax Law Change:**\n   - The TCJA (Tax Cuts and Jobs Act) tax law change mentioned in the document specifically refers to the requirement for capitalization and amortization of research and experimentation costs.\n   - This change affects the way companies can deduct these costs, which in turn impacts their taxable income.\n\n4. **Matching the Information to the Options:**\n   - Option A: Increase in corporate tax rates - The document does not mention any increase in corporate tax rates.\n   - Option B: Elimination of personal exemptions - The document does not discuss personal exemptions.\n   - Option C: Capitalization and amortization of research and experimentation costs - This matches the information provided in the document.\n   - Option D: Introduction of new state taxes - The document does not mention new state taxes.\n   - Option E: Repeal of alternative minimum tax - The document does not discuss the repeal of the alternative minimum tax.\n   - Option F: Mandatory expense reporting for small businesses - The document does not mention mandatory expense reporting for small businesses.\n\n5. **Conclusion:**\n   - The tax law change that significantly impacted U.S. federal and state taxable income starting January 1, 2022, is the requirement for capitalization and amortization of all research and experimentation costs under Section 174 of the IRC.\n\nTherefore, the correct answer is **C: Capitalization and amortization of research and experimentation costs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 16000, "result": 1.0, "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?", "options": {"A": "$100 million", "B": "$200 million", "C": "$215 million", "D": "$300 million", "E": "$250 million", "F": "$150 million"}, "LLM_original_answer": ["To answer the question \"What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the guaranty fund contributions in the \"Guaranty Funds and ICE Contribution\" section under \"14. Clearing Operations.\"\n\n2. **Locate the specific information for ICE NGX**: The document states, \"As of December 31, 2023, ICE NGX maintains a guaranty fund of $ 215 million funded by a $ 200 million letter of credit issued by a major Canadian chartered bank and backed by default insurance underwritten by Export Development Canada, or EDC, a Crown corporation operated at arm\u2019s length from the Canadian government, plus $ 15 million held as restricted cash to fund the first loss amount the ICE NGX is responsible for under the default insurance policy.\"\n\n3. **Summarize the total amount**: The total amount in the ICE NGX guaranty fund as of December 31, 2023, is $ 215 million, which is the sum of the $ 200 million letter of credit and the $ 15 million restricted cash.\n\n4. **Match the total amount to the given options**: The total amount of $ 215 million matches option C: $215 million.\n\nTherefore, the correct answer is **C: $215 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 16000, "result": 1.0, "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?", "options": {"A": "Investment gains", "B": "Interest income", "C": "Rental income", "D": "12b-1 fees", "E": "Consulting fees", "F": "Insurance premiums"}, "LLM_original_answer": ["To answer the question \"What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Section on Other Revenues**: The document contains a section specifically dedicated to \"Other Revenues\" in Note 14.\n\n2. **Locate the Relevant Information**: In the \"Other Revenues\" section, the document states:\n   > \"Other revenues consisted primarily of 12b-1 fees of $ 266 million, $ 292 million and $ 360 million for the years ended December 31, 2023, 2022 and 2021, respectively, of which substantially all were reported in the Annuities segment.\"\n\n3. **Analyze the Information**: The document clearly indicates that the primary component of other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023, was 12b-1 fees.\n\n4. **Match the Information to the Options**: The options provided are:\n   - A: Investment gains\n   - B: Interest income\n   - C: Rental income\n   - D: 12b-1 fees\n   - E: Consulting fees\n   - F: Insurance premiums\n\n   The information from the document matches option D: 12b-1 fees.\n\nTherefore, the answer to the question is **D: 12b-1 fees**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 70, "token_lengths": 32000, "result": 1.0, "question": "What is the primary reason the Company has not generated any revenue from product sales?", "options": {"A": "High production costs", "B": "None of its product candidates have been approved for commercialization", "C": "Lack of marketing efforts", "D": "Inadequate research and development", "E": "Insufficient staffing", "F": "Economic downturn"}, "LLM_original_answer": ["The primary reason the Company has not generated any revenue from product sales is:\n\n**B: None of its product candidates have been approved for commercialization**\n\n### Chain of Thoughts:\n1. **Revenue from Product Sales:**\n   - The document explicitly states, \"To date, we have not generated any revenue from product sales as none of our product candidates have been approved for commercialization.\"\n   - This indicates that the lack of revenue is directly tied to the absence of commercialized products.\n\n2. **Other Options:**\n   - **A: High production costs** - While the document mentions various costs associated with research and development, it does not indicate that high production costs are the primary reason for no revenue.\n   - **C: Lack of marketing efforts** - The document does not discuss marketing efforts as a reason for the lack of revenue.\n   - **D: Inadequate research and development** - The document shows significant investment in R&D, but it does not suggest that inadequate R&D is the primary issue.\n   - **E: Insufficient staffing** - The document mentions increasing headcount to support R&D and other activities, but it does not indicate staffing issues as the primary reason for no revenue.\n   - **F: Economic downturn** - While economic conditions are discussed, they are not cited as the primary reason for the lack of revenue.\n\n3. **Conclusion:**\n   - The document clearly states that the lack of revenue is due to the fact that none of the product candidates have been approved for commercialization. This is the most direct and primary reason provided in the document.\n\nTherefore, the correct answer is **B: None of its product candidates have been approved for commercialization**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 32000, "result": 1.0, "question": "What is the total expected lease payment for the Austin Lease term?", "options": {"A": "$97.8 million", "B": "$88 million", "C": "$100 million", "D": "$78.9 million", "E": "$90 million", "F": "$85 million"}, "LLM_original_answer": ["To answer the question \"What is the total expected lease payment for the Austin Lease term?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the Austin Lease Agreement in the section titled \"Austin Lease Agreement.\"\n\n2. **Extract the key information**: The document states:\n   - \"The Austin Lease term is eight years.\"\n   - \"Total lease payments are expected to be $ 97.8 million.\"\n\n3. **Match the information to the question**: The question asks for the total expected lease payment for the Austin Lease term. The document directly provides this information.\n\n4. **Select the correct option**: The total expected lease payment for the Austin Lease term is $ 97.8 million, which corresponds to option A.\n\nTherefore, the correct answer is **A: $97.8 million**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 70, "token_lengths": 32000, "result": 1.0, "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?", "options": {"A": "As separate performance obligations", "B": "Under series guidance", "C": "As a single performance obligation", "D": "With cost-based pricing", "E": "As unbilled estimates", "F": "With FERC regulation compliance"}, "LLM_original_answer": ["To answer the question \"How does Duke Energy treat energy and demand charges under full requirements contracts?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss full requirements contracts and how Duke Energy treats energy and demand charges under these contracts.\n\n2. **Analyze the Information**: Determine how Duke Energy categorizes or treats these charges in the context of full requirements contracts.\n\n3. **Match the Information to the Options**: Compare the identified treatment to the given options to select the most accurate one.\n\n### Step 1: Identify Relevant Information\n\nThe relevant information is found in the \"Revenue\" section of the document, specifically under the \"Electric Utilities and Infrastructure\" subsection:\n\n- **Full Requirements Contracts**: \"For full requirements contracts, Duke Energy considers both charges as a single performance obligation for providing integrated electric service.\"\n\n### Step 2: Analyze the Information\n\n- **Single Performance Obligation**: The document states that Duke Energy considers both energy and demand charges as a single performance obligation for providing integrated electric service under full requirements contracts. This means that Duke Energy does not treat these charges as separate performance obligations but rather as a combined obligation.\n\n### Step 3: Match the Information to the Options\n\n- **Option A**: As separate performance obligations\n- **Option B**: Under series guidance\n- **Option C**: As a single performance obligation\n- **Option D**: With cost-based pricing\n- **Option E**: As unbilled estimates\n- **Option F**: With FERC regulation compliance\n\nThe document explicitly states that Duke Energy considers both energy and demand charges as a single performance obligation for providing integrated electric service under full requirements contracts. Therefore, the correct answer is:\n\n**C: As a single performance obligation**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 32000, "result": 1.0, "question": "How many RSA awards vested during the year ended December 31, 2023?", "options": {"A": "683,056", "B": "152,880", "C": "136,609", "D": "95,808", "E": "302,908", "F": "0"}, "LLM_original_answer": ["To answer the question \"How many RSA awards vested during the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section on share-based compensation, which is likely to include information about RSA (Restricted Stock Award) vesting.\n\n2. **Locate the specific information**: Within the \"Share-Based Compensation Plan\" section, there is a table that summarizes the Company\u2019s restricted stock award activity for the periods indicated.\n\n3. **Extract the data**: The table provides the number of RSA awards vested for the year ended December 31, 2023.\n\n4. **Match the data to the options**: Compare the extracted data to the provided options to select the correct answer.\n\nLet's go through these steps:\n\n### Step 1: Identify the relevant section\nThe relevant section is \"Share-Based Compensation Plan\" under Note 16.\n\n### Step 2: Locate the specific information\nThe document states:\n> \"During the year ended December 31, 2023, 152,880 RSA awards vested. Such awards had a grant date fair value of $ 3.0 million.\"\n\n### Step 3: Extract the data\nThe number of RSA awards vested during the year ended December 31, 2023 is 152,880.\n\n### Step 4: Match the data to the options\nThe options provided are:\n- A: 683,056\n- B: 152,880\n- C: 136,609\n- D: 95,808\n- E: 302,908\n- F: 0\n\nThe number 152,880 matches option B.\n\n### Conclusion\nThe correct answer is **B: 152,880**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 32000, "result": 1.0, "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?", "options": {"A": "Development of antiviral medications", "B": "Manufacturing of generic drugs", "C": "Discovery and commercialization of protein degradation drugs", "D": "Research into rare genetic disorders", "E": "Development of vaccines", "F": "Production of over-the-counter supplements"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n1. **Identify the Collaboration Agreement with Gilead:**\n   - The document mentions a collaboration agreement with Gilead Sciences, Inc. (Gilead) that was entered into in June 2019 and subsequently amended.\n\n2. **Understand the Purpose of the Collaboration:**\n   - The primary purpose of the Gilead Agreement is to \"discover, develop and commercialize a pipeline of targeted protein degradation drugs for patients with cancer and other challenging diseases using our DELigase platform to identify novel agents that utilize E3 ligases to induce degradation of five specified drug targets.\"\n\n3. **Evaluate the Options:**\n   - **Option A: Development of antiviral medications** - The document does not mention antiviral medications in the context of the Gilead Agreement.\n   - **Option B: Manufacturing of generic drugs** - The document does not mention manufacturing generic drugs in the context of the Gilead Agreement.\n   - **Option C: Discovery and commercialization of protein degradation drugs** - This aligns with the stated purpose of the Gilead Agreement, which is to discover, develop, and commercialize targeted protein degradation drugs.\n   - **Option D: Research into rare genetic disorders** - The document does not mention research into rare genetic disorders in the context of the Gilead Agreement.\n   - **Option E: Development of vaccines** - The document does not mention vaccine development in the context of the Gilead Agreement.\n   - **Option F: Production of over-the-counter supplements** - The document does not mention the production of over-the-counter supplements in the context of the Gilead Agreement.\n\n4. **Conclusion:**\n   - The primary focus of the collaboration agreement between the Company and Gilead is the discovery and commercialization of protein degradation drugs.\n\nTherefore, the correct answer is **Option C: Discovery and commercialization of protein degradation drugs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 32000, "result": 1.0, "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?", "options": {"A": "$188.2 million", "B": "$183.9 million", "C": "$181.1 million", "D": "$177.5 million", "E": "$24.6 million", "F": "$11.3 million"}, "LLM_original_answer": ["To answer the question \"How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that deals with deferred tax assets and liabilities is \"Note 20 \u2014 Income Taxes.\"\n\n2. **Locate the specific information**: Within this section, there is a table that presents the components of the deferred tax assets and liabilities. The relevant information is found in the following statement:\n   - \"As of December 31, 2023, we had a deferred tax asset, net of deferred tax liability, of $ 188.2 million including $ 183.9 million in the U.S.\"\n\n3. **Extract the answer**: The deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023, is $183.9 million.\n\n4. **Match the answer to the options**:\n   - A: $188.2 million\n   - B: $183.9 million\n   - C: $181.1 million\n   - D: $177.5 million\n   - E: $24.6 million\n   - F: $11.3 million\n\nThe correct answer is **B: $183.9 million**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 32000, "result": 1.0, "question": "Which of the following is included in research and development expenses as incurred?", "options": {"A": "Marketing and advertising expenses", "B": "Expenses related to employee salaries involved in R&D", "C": "Sales commission and bonuses", "D": "Office supplies and administrative costs", "E": "Travel expenses for sales team", "F": "Legal fees for patent applications"}, "LLM_original_answer": ["To answer the question \"Which of the following is included in research and development expenses as incurred?\" based on the provided document, I will analyze the relevant section of the document and match it with the given options.\n\n### Relevant Section from the Document:\n**Research and Development Expenses**\nResearch and development expenses consist primarily of costs incurred in connection with our research activities, including our therapeutic discovery efforts, preclinical and clinical trials, and the development of our proprietary platform technologies and product candidates. We expense research and development costs as incurred, which include:\n- **Employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, and other related costs for those employees involved in research and development efforts.**\n- **Expenses incurred in connection with our research programs, including under agreements with third parties, such as consultants and contract research organizations, or CROs.**\n- **The cost of raw materials, developing and scaling our manufacturing process, and manufacturing our product candidates for use in our research and preclinical studies, including under agreements with third parties, such as consultants, contractors, and contract manufacturing organizations, or CMOs.**\n- **Laboratory supplies and research materials.**\n- **Facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance.**\n- **Payments made under third-party licensing agreements.**\n\n### Analysis of Options:\n1. **A: Marketing and advertising expenses**\n   - The document does not mention marketing and advertising expenses as part of research and development expenses. These are typically categorized under general and administrative expenses or sales and marketing expenses.\n\n2. **B: Expenses related to employee salaries involved in R&D**\n   - The document explicitly states that \"employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, and other related costs for those employees involved in research and development efforts\" are included in research and development expenses.\n\n3. **C: Sales commission and bonuses**\n   - Similar to marketing and advertising expenses, sales commissions and bonuses are not mentioned as part of research and development expenses. These are typically categorized under sales and marketing expenses.\n\n4. **D: Office supplies and administrative costs**\n   - The document does not list office supplies and administrative costs as part of research and development expenses. These are typically categorized under general and administrative expenses.\n\n5. **E: Travel expenses for sales team**\n   - The document does not mention travel expenses for the sales team as part of research and development expenses. These are typically categorized under sales and marketing expenses.\n\n6."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 32000, "result": 1.0, "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?", "options": {"A": "Increase in corporate tax rates", "B": "Elimination of personal exemptions", "C": "Capitalization and amortization of research and experimentation costs", "D": "Introduction of new state taxes", "E": "Repeal of alternative minimum tax", "F": "Mandatory expense reporting for small businesses"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify any mention of tax law changes that significantly impacted U.S. federal and state taxable income starting January 1, 2022.\n\n1. **Initial Scan for Relevant Information:**\n   - The document primarily focuses on patent and intellectual property issues, business operations, and financial matters. It does not extensively discuss tax law changes.\n\n2. **Specific Search for Tax Law Changes:**\n   - I will look for any sections that mention tax laws or changes in tax regulations.\n\n3. **Identifying Relevant Sections:**\n   - The section \"Income Taxes\" in \"Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\" provides some relevant information:\n     - \"Current year U.S. federal and state taxable income is significantly impacted by a TCJA tax law change in effect from January 1, 2022 that requires capitalization and amortization of all research and experimentation costs under Section 174 of the IRC.\"\n\n4. **Analyzing the Information:**\n   - The TCJA (Tax Cuts and Jobs Act) tax law change mentioned in the document specifically requires the capitalization and amortization of research and experimentation costs starting January 1, 2022.\n   - This change affects the way these costs are treated for tax purposes, which in turn impacts the company's taxable income.\n\n5. **Matching the Information to the Options:**\n   - Option A: Increase in corporate tax rates - Not mentioned.\n   - Option B: Elimination of personal exemptions - Not mentioned.\n   - Option C: Capitalization and amortization of research and experimentation costs - Matches the information found.\n   - Option D: Introduction of new state taxes - Not mentioned.\n   - Option E: Repeal of alternative minimum tax - Not mentioned.\n   - Option F: Mandatory expense reporting for small businesses - Not mentioned.\n\n6. **Conclusion:**\n   - The tax law change that significantly impacted U.S. federal and state taxable income starting January 1, 2022, is the capitalization and amortization of research and experimentation costs under Section 174 of the IRC.\n\nTherefore, the correct answer is **Option C: Capitalization and amortization of research and experimentation costs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 32000, "result": 1.0, "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?", "options": {"A": "$100 million", "B": "$200 million", "C": "$215 million", "D": "$300 million", "E": "$250 million", "F": "$150 million"}, "LLM_original_answer": ["To answer the question \"What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the guaranty funds is found in \"Note 14: Clearing Operations.\"\n\n2. **Locate the specific information about ICE NGX**: Within the \"Guaranty Funds and ICE Contribution\" section, there is a specific mention of ICE NGX.\n\n3. **Extract the total amount of the ICE NGX guaranty fund**: The document states, \"As of December 31, 2023, ICE NGX maintained a guaranty fund of $ 215 million, comprising $ 15 million in cash and a $ 200 million letter of credit backed by a default insurance policy of the same amount.\"\n\n4. **Verify the options**: The options provided are:\n   - A: $100 million\n   - B: $200 million\n   - C: $215 million\n   - D: $300 million\n   - E: $250 million\n   - F: $150 million\n\n5. **Match the extracted information with the options**: The total amount of the ICE NGX guaranty fund as of December 31, 2023, is $215 million.\n\nTherefore, the correct answer is **C: $215 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 32000, "result": 1.0, "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?", "options": {"A": "Investment gains", "B": "Interest income", "C": "Rental income", "D": "12b-1 fees", "E": "Consulting fees", "F": "Insurance premiums"}, "LLM_original_answer": ["To answer the question \"What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions \"other revenues\" in the \"14. Other Revenues and Other Expenses\" section.\n\n2. **Locate the specific information about other revenues**: The section states:\n   > \"Other revenues consisted primarily of 12b-1 fees of $ 266 million, $ 292 million and $ 360 million for the years ended December 31, 2023, 2022 and 2021, respectively, of which substantially all were reported in the Annuities segment.\"\n\n3. **Match the information to the options provided**:\n   - **A: Investment gains** - Not mentioned as a primary component of other revenues.\n   - **B: Interest income** - Not mentioned as a primary component of other revenues.\n   - **C: Rental income** - Not mentioned as a primary component of other revenues.\n   - **D: 12b-1 fees** - Mentioned as the primary component of other revenues.\n   - **E: Consulting fees** - Not mentioned as a primary component of other revenues.\n   - **F: Insurance premiums** - Not mentioned as a primary component of other revenues.\n\n4. **Conclude the answer**: Based on the information provided, the primary component of other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023, is 12b-1 fees.\n\nTherefore, the correct answer is **D: 12b-1 fees**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 70, "token_lengths": 64000, "result": 1.0, "question": "What is the primary reason the Company has not generated any revenue from product sales?", "options": {"A": "High production costs", "B": "None of its product candidates have been approved for commercialization", "C": "Lack of marketing efforts", "D": "Inadequate research and development", "E": "Insufficient staffing", "F": "Economic downturn"}, "LLM_original_answer": ["The primary reason the Company has not generated any revenue from product sales is:\n\n**B: None of its product candidates have been approved for commercialization**\n\n### Chain of Thoughts:\n1. **Revenue from Product Sales**: The document explicitly states, \"To date, we have not generated any revenue from product sales as none of our product candidates have been approved for commercialization.\" This directly answers the question by indicating that the lack of commercialization approval is the primary reason for no revenue from product sales.\n\n2. **Other Options**:\n   - **A: High production costs**: While the document mentions various financial and operational challenges, it does not indicate that high production costs are the primary reason for the lack of revenue.\n   - **C: Lack of marketing efforts**: The document does not discuss marketing efforts as a significant factor affecting revenue.\n   - **D: Inadequate research and development**: The document indicates that the company has been actively engaged in research and development, including clinical trials and preclinical studies, so this is not the primary reason.\n   - **E: Insufficient staffing**: The document does not mention staffing issues as a primary reason for the lack of revenue.\n   - **F: Economic downturn**: While economic conditions are discussed, they are not cited as the primary reason for the lack of revenue from product sales.\n\n3. **Conclusion**: The document clearly states that the lack of commercialization approval for any of the company's product candidates is the primary reason for the absence of revenue from product sales. Therefore, option B is the correct answer."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 64000, "result": 1.0, "question": "What is the total expected lease payment for the Austin Lease term?", "options": {"A": "$97.8 million", "B": "$88 million", "C": "$100 million", "D": "$78.9 million", "E": "$90 million", "F": "$85 million"}, "LLM_original_answer": ["To answer the question \"What is the total expected lease payment for the Austin Lease term?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The relevant section is \"Austin Lease Agreement\" in Note 17 \u2014 Subsequent Events.\n\n2. **Extract the key information**:\n   - The Austin Lease term is eight years.\n   - Total lease payments are expected to be $97.8 million.\n\n3. **Match the extracted information to the options**:\n   - Option A: $97.8 million\n   - Option B: $88 million\n   - Option C: $100 million\n   - Option D: $78.9 million\n   - Option E: $90 million\n   - Option F: $85 million\n\n4. **Select the correct answer**:\n   - The total expected lease payment for the Austin Lease term is $97.8 million, which matches Option A.\n\nTherefore, the correct answer is **A: $97.8 million**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 70, "token_lengths": 64000, "result": 1.0, "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?", "options": {"A": "As separate performance obligations", "B": "Under series guidance", "C": "As a single performance obligation", "D": "With cost-based pricing", "E": "As unbilled estimates", "F": "With FERC regulation compliance"}, "LLM_original_answer": ["To answer the question \"How does Duke Energy treat energy and demand charges under full requirements contracts?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss Duke Energy's treatment of energy and demand charges, particularly in the context of full requirements contracts.\n\n2. **Extract Key Information**: Extract the specific information that addresses how Duke Energy treats these charges.\n\n3. **Match Information to Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\n\nThe relevant section is found in Note 19, which discusses revenue recognition and the treatment of energy and demand charges under full requirements contracts.\n\n### Step 2: Extract Key Information\n\nFrom Note 19:\n- **Wholesale Contracts**: \"For full requirements contracts, Duke Energy considers both charges as a single performance obligation for providing integrated electric service.\"\n- **Supplemental Requirements Contracts**: \"For contracts where energy and demand charges are considered separate performance obligations, energy and demand are each a distinct performance obligation under the series guidance and are satisfied as energy is delivered and stand-ready service is provided on a monthly basis.\"\n\n### Step 3: Match Information to Options\n\n- **Option A: As separate performance obligations** - This is mentioned for supplemental requirements contracts, but not for full requirements contracts.\n- **Option B: Under series guidance** - This is mentioned for supplemental requirements contracts, but not for full requirements contracts.\n- **Option C: As a single performance obligation** - This is explicitly mentioned for full requirements contracts.\n- **Option D: With cost-based pricing** - This is mentioned for wholesale contracts in general, but not specifically for full requirements contracts.\n- **Option E: As unbilled estimates** - This is not mentioned in the context of full requirements contracts.\n- **Option F: With FERC regulation compliance** - This is a general requirement for Duke Energy's operations, but not specifically mentioned for the treatment of energy and demand charges under full requirements contracts.\n\n### Conclusion\n\nBased on the information extracted from the document, Duke Energy treats energy and demand charges under full requirements contracts **as a single performance obligation**.\n\nTherefore, the correct answer is **Option C: As a single performance obligation**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 64000, "result": 1.0, "question": "How many RSA awards vested during the year ended December 31, 2023?", "options": {"A": "683,056", "B": "152,880", "C": "136,609", "D": "95,808", "E": "302,908", "F": "0"}, "LLM_original_answer": ["To answer the question \"How many RSA awards vested during the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Section**: The document contains a section on share-based compensation, which is likely to have the information about RSA (Restricted Stock Award) vesting.\n\n2. **Locate Specific Information**: Within the \"Share-Based Compensation\" section, I will look for a table or paragraph that mentions RSA vesting for the year ended December 31, 2023.\n\n3. **Extract the Data**: Once I find the relevant information, I will extract the number of RSA awards that vested during the specified year.\n\n4. **Match with Options**: Finally, I will compare the extracted data with the provided options to select the correct answer.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Section**:\n   - The relevant section is found in Note 16, \"Share-Based Compensation.\"\n\n2. **Locate Specific Information**:\n   - The document states: \"During the year ended December 31, 2023, 152,880 RSA awards vested. Such awards had a grant date fair value of $ 3.0 million.\"\n\n3. **Extract the Data**:\n   - The number of RSA awards that vested during the year ended December 31, 2023 is 152,880.\n\n4. **Match with Options**:\n   - The options provided are:\n     - A: 683,056\n     - B: 152,880\n     - C: 136,609\n     - D: 95,808\n     - E: 302,908\n     - F: 0\n   - The extracted data matches option B: 152,880.\n\n### Conclusion:\nThe correct answer is **B: 152,880**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 64000, "result": 1.0, "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?", "options": {"A": "Development of antiviral medications", "B": "Manufacturing of generic drugs", "C": "Discovery and commercialization of protein degradation drugs", "D": "Research into rare genetic disorders", "E": "Development of vaccines", "F": "Production of over-the-counter supplements"}, "LLM_original_answer": ["The primary focus of the collaboration agreement between the Company and Gilead, as described in the provided document, is the discovery, development, and commercialization of a pipeline of targeted protein degradation drugs for patients with cancer and other challenging diseases. This collaboration leverages the Company's DELigase platform to identify novel agents that utilize E3 ligases to induce degradation of five specified drug targets.\n\nTo break it down step by step:\n\n1. **Purpose of the Collaboration**: The document states that the Company entered into a global strategic collaboration agreement with Gilead to discover, develop, and commercialize a pipeline of targeted protein degradation drugs. This indicates that the collaboration is centered around the development of new drugs.\n\n2. **Technology Focus**: The collaboration uses the Company's DELigase platform, which is an integrated discovery platform designed to identify and advance novel drug candidates targeting E3 ligases. E3 ligases are enzymes that can modulate proteins within the cell, either by degrading them or by inhibiting their degradation.\n\n3. **Specific Targets**: The agreement specifies that the collaboration is focused on identifying novel agents that utilize E3 ligases to induce degradation of five specified drug targets. This further narrows the focus to the discovery and development of targeted protein degradation drugs.\n\n4. **Scope of the Collaboration**: The collaboration excludes the Company's current internal protein degradation programs and future internal programs, which the Company retains all rights to. This means that the collaboration is specifically for the five targets agreed upon with Gilead.\n\n5. **Responsibilities**: Gilead has the option to license drug candidates directed to up to five targets resulting from the collaboration and is responsible for the clinical development and commercialization of these drug candidates. The Company retains the option to co-develop and co-promote up to two drug candidates in the United States under a profit share structure.\n\n6. **Financial Terms**: The document mentions that the Company received an upfront payment of $45.0 million plus $3.0 million in additional fees from Gilead. The Company is also eligible to receive up to approximately $2.3 billion in total additional payments based on certain milestones and fees, as well as royalties on net ex-U.S. sales.\n\nGiven these points, the primary focus of the collaboration agreement between the Company and Gilead is the discovery and commercialization of protein degradation drugs. Therefore, the correct answer is:\n\n**C: Discovery and commercialization of protein degradation drugs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 64000, "result": 1.0, "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?", "options": {"A": "$188.2 million", "B": "$183.9 million", "C": "$181.1 million", "D": "$177.5 million", "E": "$24.6 million", "F": "$11.3 million"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant section in the document that discusses deferred tax assets and liabilities.\n2. Look for the specific figures related to the U.S. deferred tax assets and liabilities as of December 31, 2023.\n3. Determine the net amount by subtracting the deferred tax liability from the deferred tax asset.\n\n### Step 1: Identify the Relevant Section\nThe relevant section is found in Note 20 \u2014 Income Taxes, which discusses the components of income tax expense and the deferred tax assets and liabilities.\n\n### Step 2: Look for Specific Figures\nIn the section \"Net deferred tax assets were comprised of the following,\" the document provides the following information:\n- As of December 31, 2023, the deferred tax asset, net of deferred tax liability, is $188.2 million.\n- This amount includes $183.9 million in the U.S.\n\n### Step 3: Determine the Net Amount\nThe deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023 is explicitly stated as $183.9 million.\n\n### Conclusion\nThe correct answer is:\n**B: $183.9 million**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 64000, "result": 1.0, "question": "Which of the following is included in research and development expenses as incurred?", "options": {"A": "Marketing and advertising expenses", "B": "Expenses related to employee salaries involved in R&D", "C": "Sales commission and bonuses", "D": "Office supplies and administrative costs", "E": "Travel expenses for sales team", "F": "Legal fees for patent applications"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify which of the listed expenses are included in research and development (R&D) expenses as incurred.\n\nThe document provides a detailed breakdown of what constitutes research and development expenses for TScan Therapeutics, Inc. Specifically, it states:\n\n\"Research and development expenses consist primarily of costs incurred in connection with our research activities, including our therapeutic discovery efforts, preclinical and clinical trials, and the development of our proprietary platform technologies and product candidates. We expense research and development costs as incurred, which include:\n- employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, and other related costs for those employees involved in research and development efforts;\n- expenses incurred in connection with our research programs, including under agreements with third parties, such as consultants and contract research organizations, or CROs;\n- the cost of raw materials, developing and scaling our manufacturing process, and manufacturing our product candidates for use in our research and preclinical studies, including under agreements with third parties, such as consultants, contractors, and contract manufacturing organizations, or CMOs;\n- laboratory supplies and research materials;\n- facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance; and\n- payments made under third-party licensing agreements.\"\n\nFrom this information, we can identify which of the given options are included in R&D expenses:\n\nA: Marketing and advertising expenses - **Not included**. The document clearly distinguishes between R&D and marketing activities, and marketing expenses are not listed as part of R&D expenses.\n\nB: Expenses related to employee salaries involved in R&D - **Included**. The document explicitly mentions \"employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, and other related costs for those employees involved in research and development efforts.\"\n\nC: Sales commission and bonuses - **Not included**. These are related to sales and marketing, not R&D.\n\nD: Office supplies and administrative costs - **Not included**. While the document mentions \"facilities, depreciation, and other expenses,\" it does not include general office supplies and administrative costs as part of R&D expenses.\n\nE: Travel expenses for sales team - **Not included**. These are related to sales and marketing, not R&D.\n\nF: Legal fees for patent applications - **Included**. The document includes \"payments made under third-party licensing agreements,\" which can reasonably be interpreted to include legal fees for patent applications, as these are often part of the licensing process.\n\nTherefore"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 64000, "result": 1.0, "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?", "options": {"A": "Increase in corporate tax rates", "B": "Elimination of personal exemptions", "C": "Capitalization and amortization of research and experimentation costs", "D": "Introduction of new state taxes", "E": "Repeal of alternative minimum tax", "F": "Mandatory expense reporting for small businesses"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document for any mention of tax law changes that significantly impacted U.S. federal and state taxable income starting January 1, 2022. Here is the step-by-step reasoning:\n\n1. **Identify Relevant Sections**: The document primarily discusses the business operations, financial performance, and regulatory challenges of Amylyx Pharmaceuticals, Inc. and its transition to a commercial-stage biotechnology company. It does not focus on tax law changes.\n\n2. **Search for Tax Law References**: Scanning through the document, I find a specific reference to tax law changes in the \"Income Taxes\" section under \"Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations.\"\n\n3. **Extract the Relevant Information**:\n   - The document states: \"Current year U.S. federal and state taxable income is significantly impacted by a TCJA tax law change in effect from January 1, 2022 that requires capitalization and amortization of all research and experimentation costs under Section 174 of the IRC.\"\n\n4. **Match the Information to the Options**:\n   - **Option A: Increase in corporate tax rates** - The document does not mention an increase in corporate tax rates.\n   - **Option B: Elimination of personal exemptions** - The document does not mention the elimination of personal exemptions.\n   - **Option C: Capitalization and amortization of research and experimentation costs** - This matches the information found in the document.\n   - **Option D: Introduction of new state taxes** - The document does not mention the introduction of new state taxes.\n   - **Option E: Repeal of alternative minimum tax** - The document does not mention the repeal of the alternative minimum tax.\n   - **Option F: Mandatory expense reporting for small businesses** - The document does not mention mandatory expense reporting for small businesses.\n\n5. **Conclusion**: Based on the information provided in the document, the tax law change that significantly impacted U.S. federal and state taxable income starting January 1, 2022, is the capitalization and amortization of research and experimentation costs under Section 174 of the IRC.\n\nTherefore, the correct answer is **Option C: Capitalization and amortization of research and experimentation costs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 64000, "result": 1.0, "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?", "options": {"A": "$100 million", "B": "$200 million", "C": "$215 million", "D": "$300 million", "E": "$250 million", "F": "$150 million"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant information in the document.\n2. Extract the specific amount related to the ICE NGX guaranty fund.\n3. Match the extracted amount to the provided options.\n\n### Step 1: Identify the Relevant Information\nThe relevant information is found in the section discussing the guaranty funds and ICE NGX's specific guaranty fund. The section states:\n\n\"As of December 31, 2023, ICE NGX maintained a guaranty fund of $ 215 million, comprising $ 15 million in cash and a $ 200 million letter of credit backed by a default insurance policy of the same amount, discussed below.\"\n\n### Step 2: Extract the Specific Amount\nThe total amount included in the ICE NGX guaranty fund as of December 31, 2023 is $215 million.\n\n### Step 3: Match the Extracted Amount to the Provided Options\nThe options provided are:\nA: $100 million\nB: $200 million\nC: $215 million\nD: $300 million\nE: $250 million\nF: $150 million\n\nThe amount $215 million matches option C.\n\n### Final Answer\nThe total amount included in the ICE NGX guaranty fund as of December 31, 2023 is **C: $215 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 64000, "result": 1.0, "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?", "options": {"A": "Investment gains", "B": "Interest income", "C": "Rental income", "D": "12b-1 fees", "E": "Consulting fees", "F": "Insurance premiums"}, "LLM_original_answer": ["To answer the question \"What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?\" we need to refer to the specific section in the provided document that discusses other revenues.\n\nFrom the document, the relevant section is:\n\n**14. Other Revenues and Other Expenses**\n- **Other Revenues**: The Company has entered into contracts with mutual funds, fund managers, and their affiliates (collectively, the \u201cFunds\u201d) whereby the Company is paid monthly or quarterly fees (\u201c12b-1 fees\u201d) for providing certain services to customers and distributors of the Funds. The 12b-1 fees are generally equal to a fixed percentage of the average daily balance of the customer\u2019s investment in a fund. Payments are generally collected when due and are neither refundable nor able to offset future fees. To earn these fees, the Company performs services such as responding to phone inquiries, maintaining records, providing information to distributors and shareholders about fund performance, and providing training to account managers and sales agents. The passage of time reflects the satisfaction of the Company\u2019s performance obligations to the Funds and is used to recognize revenue associated with 12b-1 fees.\n- **Other revenues consisted primarily of 12b-1 fees of $266 million, $292 million, and $360 million for the years ended December 31, 2023, 2022, and 2021, respectively, of which substantially all were reported in the Annuities segment.**\n\nBased on this information, the primary component of other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023, was **12b-1 fees**.\n\nTherefore, the correct answer is:\n**D: 12b-1 fees**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 70, "token_lengths": 96000, "result": 1.0, "question": "What is the primary reason the Company has not generated any revenue from product sales?", "options": {"A": "High production costs", "B": "None of its product candidates have been approved for commercialization", "C": "Lack of marketing efforts", "D": "Inadequate research and development", "E": "Insufficient staffing", "F": "Economic downturn"}, "LLM_original_answer": ["The primary reason the Company has not generated any revenue from product sales is:\n\n**B: None of its product candidates have been approved for commercialization**\n\n### Chain of Thoughts:\n1. **Revenue from Product Sales**: The document explicitly states, \"We have not yet demonstrated the ability to progress any product candidate through late-stage clinical trials, we have no products approved for commercial sale and we have not generated any revenue from product sales to date.\"\n2. **Product Development Stage**: The Company is described as a \"clinical-stage biopharmaceutical company,\" indicating that its products are still in the development and testing phases.\n3. **Clinical Trials and Regulatory Approval**: The document mentions that the Company is conducting multiple Phase 2 and Phase 1 clinical trials for its product candidates (KER-050, KER-012, KER-065). It also notes that \"Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans.\"\n4. **Regulatory Challenges**: The document highlights the significant challenges and uncertainties associated with obtaining regulatory approval, including potential delays, safety issues, and the need for additional trials.\n5. **Future Revenue Potential**: The document states, \"Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of KER-050, KER-012, KER-065 and any future product candidates we develop, which may never occur.\"\n\nGiven these points, the lack of revenue from product sales is directly tied to the fact that none of the Company's product candidates have been approved for commercialization."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 96000, "result": 1.0, "question": "What is the total expected lease payment for the Austin Lease term?", "options": {"A": "$97.8 million", "B": "$88 million", "C": "$100 million", "D": "$78.9 million", "E": "$90 million", "F": "$85 million"}, "LLM_original_answer": ["To answer the question regarding the total expected lease payment for the Austin Lease term, I will follow these steps:\n\n1. **Identify the Relevant Information**: Look for specific details about the Austin Lease in the provided document.\n2. **Extract the Total Lease Payment**: Find the total expected lease payment for the Austin Lease term.\n3. **Match the Extracted Information to the Given Options**: Compare the extracted total lease payment to the provided options to select the correct answer.\n\n### Step 1: Identify the Relevant Information\nI will search the document for any mention of the Austin Lease.\n\n### Step 2: Extract the Total Lease Payment\nFrom the document, I found the following relevant information:\n\n- **Austin Lease Agreement**: \"In February 2024, the Company entered into a lease agreement for a data center in Austin, Texas with a current operating capacity of 12 MW (the \u201cAustin Lease\u201d). The Austin Lease term is eight years. Total lease payments are expected to be $97.8 million.\"\n\n### Step 3: Match the Extracted Information to the Given Options\nThe total expected lease payment for the Austin Lease term is $97.8 million. This matches option A: $97.8 million.\n\n### Conclusion\nThe correct answer is **A: $97.8 million**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 70, "token_lengths": 96000, "result": 1.0, "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?", "options": {"A": "As separate performance obligations", "B": "Under series guidance", "C": "As a single performance obligation", "D": "With cost-based pricing", "E": "As unbilled estimates", "F": "With FERC regulation compliance"}, "LLM_original_answer": ["To answer the question \"How does Duke Energy treat energy and demand charges under full requirements contracts?\" based on the provided document, we need to look for specific information related to how Duke Energy handles these charges in the context of full requirements contracts.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections**:\n   - The document contains detailed financial and operational information for Duke Energy and its subsidiaries.\n   - The section on \"Revenue Recognition\" (Note 19) is particularly relevant as it discusses how Duke Energy recognizes revenue and treats performance obligations.\n\n2. **Examine Revenue Recognition**:\n   - The document states: \"Duke Energy recognizes revenue as customers obtain control of promised goods and services in an amount that reflects consideration expected in exchange for those goods or services.\"\n   - It further specifies: \"For full requirements contracts, Duke Energy considers both charges as a single performance obligation for providing integrated electric service.\"\n\n3. **Understand Full Requirements Contracts**:\n   - Full requirements contracts are those where the customer purchases the substantial majority of their energy needs from Duke Energy.\n   - The document indicates that for these contracts, both energy and demand charges are treated as a single performance obligation.\n\n4. **Conclusion**:\n   - Based on the information provided, Duke Energy treats energy and demand charges under full requirements contracts as a single performance obligation.\n\n### Final Answer:\nThe correct option is **C: As a single performance obligation**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 96000, "result": 1.0, "question": "How many RSA awards vested during the year ended December 31, 2023?", "options": {"A": "683,056", "B": "152,880", "C": "136,609", "D": "95,808", "E": "302,908", "F": "0"}, "LLM_original_answer": ["To answer the question \"How many RSA awards vested during the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss RSA (Restricted Stock Award) vesting.\n2. **Locate Specific Data**: Find the specific number of RSA awards that vested in the year 2023.\n3. **Verify the Data**: Ensure the data is from the correct year and is consistent with the options provided.\n\n### Step 1: Identify Relevant Information\nThe document contains a section on share-based compensation, which is likely to include information about RSA vesting. This section is found in Note 16, \"Share-Based Compensation.\"\n\n### Step 2: Locate Specific Data\nIn Note 16, \"Share-Based Compensation,\" the following table is provided:\n\n#### Restricted Stock Award Activity\n```plaintext\nDuring the year ended December 31, 2023, 152,880 RSA awards vested.\nSuch awards had a grant date fair value of $ 3.0 million.\nDuring the year ended December 31, 2022, 136,609 RSA awards had vested.\nSuch awards had a grant date fair value of $ 2.7 million.\n```\n\n### Step 3: Verify the Data\nThe number of RSA awards that vested during the year ended December 31, 2023 is **152,880**.\n\n### Conclusion\nThe correct answer is:\n**B: 152,880**"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 96000, "result": 1.0, "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?", "options": {"A": "Development of antiviral medications", "B": "Manufacturing of generic drugs", "C": "Discovery and commercialization of protein degradation drugs", "D": "Research into rare genetic disorders", "E": "Development of vaccines", "F": "Production of over-the-counter supplements"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the primary focus of the collaboration agreement between the Company and Gilead.\n\n1. **Identifying the Collaboration Agreement**:\n   - The document mentions a collaboration agreement with Gilead in the section \"Collaborations and License Agreements\" under \"Gilead\".\n\n2. **Details of the Collaboration**:\n   - The agreement is described as a \"global strategic collaboration agreement\" to \"discover, develop and commercialize a pipeline of targeted protein degradation drugs for patients with cancer and other challenging diseases.\"\n   - The collaboration uses the Company's DELigase platform to identify novel agents that utilize E3 ligases to induce degradation of five specified drug targets.\n\n3. **Key Objectives**:\n   - The primary focus is on the discovery, development, and commercialization of targeted protein degradation drugs.\n   - The collaboration specifically targets the use of E3 ligases to induce degradation of proteins, which is a novel approach to treating cancer and other challenging diseases.\n\n4. **Exclusions and Options**:\n   - The collaboration excludes the Company's current internal protein degradation programs and future internal programs.\n   - Gilead has the option to license drug candidates directed to up to five targets resulting from the collaboration.\n   - The Company retains the option to co-develop and co-promote up to two drug candidates in the United States under a profit share structure.\n\n5. **Financial and Development Aspects**:\n   - The Company is responsible for performing preclinical research activities, including target validation, drug discovery, identification, or synthesis.\n   - Gilead is responsible for clinical development, commercialization, and manufacturing activities unless the Company exercises its co-development and co-promotion option.\n\n6. **Conclusion**:\n   - The primary focus of the collaboration agreement between the Company and Gilead is the discovery and commercialization of targeted protein degradation drugs using the Company's DELigase platform.\n\nGiven the options provided:\n- A: Development of antiviral medications\n- B: Manufacturing of generic drugs\n- C: Discovery and commercialization of protein degradation drugs\n- D: Research into rare genetic disorders\n- E: Development of vaccines\n- F: Production of over-the-counter supplements\n\nThe correct answer is **C: Discovery and commercialization of protein degradation drugs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 96000, "result": 0.0, "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?", "options": {"A": "$188.2 million", "B": "$183.9 million", "C": "$181.1 million", "D": "$177.5 million", "E": "$24.6 million", "F": "$11.3 million"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The question asks about the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023. The relevant section is likely to be found in the \"Income Taxes\" section of the document.\n\n2. **Locate the specific information**: Within the \"Income Taxes\" section, I will look for a table or a statement that provides the deferred tax asset and deferred tax liability values for the U.S. as of December 31, 2023.\n\n3. **Calculate the net value**: Once I find the values for the deferred tax asset and deferred tax liability, I will subtract the deferred tax liability from the deferred tax asset to get the net value.\n\n4. **Match the calculated value to the provided options**.\n\nLet's go through the document to find the relevant information.\n\n### Step 1: Identify the relevant section\nThe relevant section is found in \"Note 20 \u2014 Income Taxes\".\n\n### Step 2: Locate the specific information\nIn the \"Note 20 \u2014 Income Taxes\" section, there is a table that provides the deferred tax assets and liabilities:\n\n#### Table: Net deferred tax assets were comprised of the following:\n```plaintext\nAs of December 31, 2023:\n- Deferred tax assets: $372.1 million\n- Deferred tax liabilities: $183.9 million\n- Net deferred tax assets: $188.2 million\n\nAs of December 31, 2022:\n- Deferred tax assets: $358.6 million\n- Deferred tax liabilities: $177.5 million\n- Net deferred tax assets: $181.1 million\n```\n\n### Step 3: Calculate the net value\nFor the U.S. as of December 31, 2023:\n- Deferred tax assets: $372.1 million\n- Deferred tax liabilities: $183.9 million\n\nNet deferred tax asset, net of deferred tax liability:\n\\[ 372.1 \\, \\text{million} - 183.9 \\, \\text{million} = 188.2 \\, \\text{million} \\]\n\n### Step 4: Match the calculated value to the provided options\nThe calculated net deferred tax asset, net"], "LLM_extracted_answer": ["A"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 96000, "result": 1.0, "question": "Which of the following is included in research and development expenses as incurred?", "options": {"A": "Marketing and advertising expenses", "B": "Expenses related to employee salaries involved in R&D", "C": "Sales commission and bonuses", "D": "Office supplies and administrative costs", "E": "Travel expenses for sales team", "F": "Legal fees for patent applications"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify which of the listed options are included in research and development expenses as incurred.\n\nThe document states:\n\"Research and development expenses consist primarily of costs incurred in connection with our research activities, including our therapeutic discovery efforts, preclinical and clinical trials, and the development of our proprietary platform technologies and product candidates. We expense research and development costs as incurred, which include: \n- employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, and other related costs for those employees involved in research and development efforts;\n- expenses incurred in connection with our research programs, including under agreements with third parties, such as consultants and contract research organizations, or CROs;\n- the cost of raw materials, developing and scaling our manufacturing process, and manufacturing our product candidates for use in our research and preclinical studies, including under agreements with third parties, such as consultants, contractors, and contract manufacturing organizations, or CMOs;\n- laboratory supplies and research materials;\n- facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance;\n- payments made under third-party licensing agreements.\"\n\nBased on this information, the following options are included in research and development expenses as incurred:\n\nB: Expenses related to employee salaries involved in R&D - This is explicitly mentioned as part of the employee-related expenses.\n\nF: Legal fees for patent applications - This is implied under \"payments made under third-party licensing agreements\" and the general context of R&D expenses, which often include legal fees for patent applications.\n\nThe other options (A, C, D, E) are not mentioned in the context of R&D expenses in the provided document. They are more likely to be categorized under general and administrative expenses or sales and marketing expenses.\n\nTherefore, the correct answers are:\nB: Expenses related to employee salaries involved in R&D\nF: Legal fees for patent applications"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 96000, "result": 1.0, "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?", "options": {"A": "Increase in corporate tax rates", "B": "Elimination of personal exemptions", "C": "Capitalization and amortization of research and experimentation costs", "D": "Introduction of new state taxes", "E": "Repeal of alternative minimum tax", "F": "Mandatory expense reporting for small businesses"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document for any mention of tax law changes that significantly impacted U.S. federal and state taxable income starting January 1, 2022.\n\n1. **Review of the Document**:\n   - The document primarily focuses on the business operations, financial condition, and regulatory environment of Amylyx Pharmaceuticals, Inc.\n   - It discusses various aspects of the company's operations, including clinical trials, product commercialization, and regulatory approvals.\n   - There is a section on \"Income Taxes\" which provides some context about the company's tax situation.\n\n2. **Relevant Information**:\n   - In the \"Income Taxes\" section, it is mentioned that the company's current year U.S. federal and state taxable income is significantly impacted by a TCJA tax law change in effect from January 1, 2022.\n   - Specifically, the change requires the capitalization and amortization of all research and experimentation costs under Section 174 of the IRC.\n\n3. **Matching the Information to the Options**:\n   - **Option A: Increase in corporate tax rates** - The document does not mention any increase in corporate tax rates.\n   - **Option B: Elimination of personal exemptions** - The document does not mention personal exemptions.\n   - **Option C: Capitalization and amortization of research and experimentation costs** - This matches the information provided in the document.\n   - **Option D: Introduction of new state taxes** - The document does not mention new state taxes.\n   - **Option E: Repeal of alternative minimum tax** - The document does not mention the repeal of the alternative minimum tax.\n   - **Option F: Mandatory expense reporting for small businesses** - The document does not mention mandatory expense reporting for small businesses.\n\n4. **Conclusion**:\n   - The tax law change that significantly impacted U.S. federal and state taxable income starting January 1, 2022, is the requirement to capitalize and amortize research and experimentation costs under Section 174 of the IRC.\n\nTherefore, the correct answer is **Option C: Capitalization and amortization of research and experimentation costs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 96000, "result": 1.0, "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?", "options": {"A": "$100 million", "B": "$200 million", "C": "$215 million", "D": "$300 million", "E": "$250 million", "F": "$150 million"}, "LLM_original_answer": ["To answer the question regarding the total amount included in the ICE NGX guaranty fund as of December 31, 2023, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the guaranty fund contributions for ICE NGX in the \"Guaranty Funds and ICE Contribution\" section under \"Item 14. Principal Accountant Fees and Services.\"\n\n2. **Extract the specific information**: The relevant information is:\n   - \"As of December 31, 2023, ICE NGX maintained a guaranty fund of $215 million, comprising $15 million in cash and a $200 million letter of credit backed by a default insurance policy of the same amount.\"\n\n3. **Sum the components**: The total amount in the ICE NGX guaranty fund is the sum of the cash and the letter of credit.\n   - Cash: $15 million\n   - Letter of Credit: $200 million\n   - Total: $15 million + $200 million = $215 million\n\n4. **Match the total amount to the provided options**:\n   - A: $100 million\n   - B: $200 million\n   - C: $215 million\n   - D: $300 million\n   - E: $250 million\n   - F: $150 million\n\nThe total amount included in the ICE NGX guaranty fund as of December 31, 2023, is $215 million, which matches option C.\n\n**Answer**: C: $215 million"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 96000, "result": 1.0, "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?", "options": {"A": "Investment gains", "B": "Interest income", "C": "Rental income", "D": "12b-1 fees", "E": "Consulting fees", "F": "Insurance premiums"}, "LLM_original_answer": ["To answer the question \"What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Relevant Section**: The document contains a section that discusses \"Other Revenues\" in Note 14. This section is likely to provide the information needed to answer the question.\n\n2. **Extract the Information**: From the section on \"Other Revenues\" in Note 14, we can find the following relevant information:\n   - \"Other revenues consisted primarily of 12b-1 fees of $266 million, $292 million, and $360 million for the years ended December 31, 2023, 2022, and 2021, respectively, of which substantially all were reported in the Annuities segment.\"\n\n3. **Analyze the Information**: The document clearly states that the primary component of other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023, was 12b-1 fees.\n\n4. **Match the Information to the Options**: The options provided are:\n   - A: Investment gains\n   - B: Interest income\n   - C: Rental income\n   - D: 12b-1 fees\n   - E: Consulting fees\n   - F: Insurance premiums\n\n   The information from the document matches option D: 12b-1 fees.\n\n5. **Conclusion**: Based on the information provided in the document, the primary component of other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023, was 12b-1 fees.\n\nTherefore, the correct answer is **D: 12b-1 fees**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 70, "token_lengths": 128000, "result": 1.0, "question": "What is the primary reason the Company has not generated any revenue from product sales?", "options": {"A": "High production costs", "B": "None of its product candidates have been approved for commercialization", "C": "Lack of marketing efforts", "D": "Inadequate research and development", "E": "Insufficient staffing", "F": "Economic downturn"}, "LLM_original_answer": ["The primary reason the Company has not generated any revenue from product sales is:\n\n**B: None of its product candidates have been approved for commercialization**\n\n### Chain of Thoughts:\n1. **Revenue from Product Sales**: The document explicitly states, \"To date, we have not generated any revenue from product sales as none of our product candidates have been approved for commercialization.\"\n2. **Product Candidates in Development**: The document mentions that the Company's product candidates, including KER-050, KER-012, and KER-065, are in various stages of clinical development (Phase 1, Phase 2, etc.).\n3. **Regulatory Approval**: The document emphasizes the importance of regulatory approval for commercializing any product candidate. For example, it states, \"Before we can commence clinical trials for any product candidate, we must complete extensive preclinical studies that support any future Investigational New Drug, or IND, applications in the United States, or similar applications in other jurisdictions.\"\n4. **Ongoing Clinical Trials**: The document provides details about ongoing clinical trials for KER-050, KER-012, and KER-065, indicating that these products are still in the development and testing phase.\n5. **Commercialization Strategy**: The document also discusses the Company's strategy for commercializing its products, including collaborations with third parties like Hansoh (Shanghai) Healthtech Co., Ltd., but none of these strategies have yet resulted in commercialized products.\n\nGiven these points, the lack of revenue from product sales is directly tied to the fact that none of the Company's product candidates have been approved for commercialization."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 128000, "result": 1.0, "question": "What is the total expected lease payment for the Austin Lease term?", "options": {"A": "$97.8 million", "B": "$88 million", "C": "$100 million", "D": "$78.9 million", "E": "$90 million", "F": "$85 million"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 70, "token_lengths": 128000, "result": 0.0, "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?", "options": {"A": "As separate performance obligations", "B": "Under series guidance", "C": "As a single performance obligation", "D": "With cost-based pricing", "E": "As unbilled estimates", "F": "With FERC regulation compliance"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 128000, "result": 0.0, "question": "How many RSA awards vested during the year ended December 31, 2023?", "options": {"A": "683,056", "B": "152,880", "C": "136,609", "D": "95,808", "E": "302,908", "F": "0"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["!"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 128000, "result": 1.0, "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?", "options": {"A": "Development of antiviral medications", "B": "Manufacturing of generic drugs", "C": "Discovery and commercialization of protein degradation drugs", "D": "Research into rare genetic disorders", "E": "Development of vaccines", "F": "Production of over-the-counter supplements"}, "LLM_original_answer": ["The primary focus of the collaboration agreement between the Company and Gilead, as described in the provided document, is the discovery, development, and commercialization of a pipeline of targeted protein degradation drugs for patients with cancer and other challenging diseases. This is evident from the following excerpt:\n\n> \"In June 2019, we entered into a global strategic collaboration agreement with Gilead (as subsequently amended, the Gilead Agreement) to discover, develop and commercialize a pipeline of targeted protein degradation drugs for patients with cancer and other challenging diseases using our DELigase platform to identify novel agents that utilize E3 ligases to induce degradation of five specified drug targets.\"\n\nGiven this information, the correct answer is:\n\n**C: Discovery and commercialization of protein degradation drugs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 128000, "result": 0.0, "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?", "options": {"A": "$188.2 million", "B": "$183.9 million", "C": "$181.1 million", "D": "$177.5 million", "E": "$24.6 million", "F": "$11.3 million"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["!"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 128000, "result": 1.0, "question": "Which of the following is included in research and development expenses as incurred?", "options": {"A": "Marketing and advertising expenses", "B": "Expenses related to employee salaries involved in R&D", "C": "Sales commission and bonuses", "D": "Office supplies and administrative costs", "E": "Travel expenses for sales team", "F": "Legal fees for patent applications"}, "LLM_original_answer": ["To answer the question \"Which of the following is included in research and development expenses as incurred?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that specifically discusses research and development expenses. This section is found under \"Item 7. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\" and \"Operating Expenses.\"\n\n2. **Extract the relevant information**: The section on research and development expenses provides a detailed list of what is included in these expenses. Here is the relevant excerpt:\n\n   > Research and development expenses consist primarily of costs incurred in connection with our research activities, including our therapeutic discovery efforts, preclinical and clinical trials, and the development of our proprietary platform technologies and product candidates. We expense research and development costs as incurred, which include:\n   > - employee-related expenses, including salaries, bonuses, benefits,"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 70, "token_lengths": 128000, "result": 0.0, "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?", "options": {"A": "Increase in corporate tax rates", "B": "Elimination of personal exemptions", "C": "Capitalization and amortization of research and experimentation costs", "D": "Introduction of new state taxes", "E": "Repeal of alternative minimum tax", "F": "Mandatory expense reporting for small businesses"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 128000, "result": 1.0, "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?", "options": {"A": "$100 million", "B": "$200 million", "C": "$215 million", "D": "$300 million", "E": "$250 million", "F": "$150 million"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 70, "token_lengths": 128000, "result": 0.0, "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?", "options": {"A": "Investment gains", "B": "Interest income", "C": "Rental income", "D": "12b-1 fees", "E": "Consulting fees", "F": "Insurance premiums"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["F"], "ground_truth": "D"}, {"depth": 75, "token_lengths": 8000, "result": 1.0, "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?", "options": {"A": "Cumulative voting rights", "B": "One vote per share without cumulative voting", "C": "Two votes per share", "D": "Preemptive voting rights", "E": "Redeemable voting rights", "F": "Convertible voting rights"}, "LLM_original_answer": ["To answer the question \"What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the rights and privileges of common stockholders is found in the \"8. COMMON STOCK\" section.\n\n2. **Extract the specific information about voting rights**: The document states:\n   - \"Voting Rights: Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors.\"\n   - \"Under the Company's amended and restated certificate of incorporation and amended and restated bylaws, stockholders will not have cumulative voting rights.\"\n\n3. **Match the extracted information to the given options**:\n   - **Option A: Cumulative voting rights** - The document explicitly states that stockholders do not have cumulative voting rights.\n   - **Option B: One vote per share without cumulative voting** - This matches the information provided in the document.\n   - **Option C: Two votes per share** - The document does not mention two votes per share.\n   - **Option D: Preemptive voting rights** - The document does not mention preemptive voting rights.\n   - **Option E: Redeemable voting rights** - The document does not mention redeemable voting rights.\n   - **Option F: Convertible voting rights** - The document does not mention convertible voting rights.\n\n4. **Conclude the answer**: Based on the information provided, the correct answer is **Option B: One vote per share without cumulative voting**.\n\nTherefore, the holders of common stock have one vote per share without cumulative voting rights under the Company's amended and restated certificate of incorporation and bylaws."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 8000, "result": 1.0, "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?", "options": {"A": "The candidate's previous employment history", "B": "The candidate's age and personal interests", "C": "A conflict of interest impacting their representation of stockholders", "D": "The candidate's educational background", "E": "The candidate's language proficiency", "F": "The candidate's geographical location"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document about the Nominating and Corporate Governance Committee's criteria for evaluating director candidates.\n\n1. **Identify the Committee's Role and Criteria:**\n   - The Nominating and Corporate Governance Committee is responsible for identifying and evaluating candidates for the Board of Directors.\n   - The document outlines several minimum qualifications that the Committee believes candidates should have, including:\n     - A reputation for integrity, honesty, and adherence to high ethical standards.\n     - Demonstrated business acumen, experience, and the ability to exercise sound judgment.\n     - A willingness and ability to contribute positively to the decision-making process.\n     - A commitment to understand the Company and its industry and to regularly attend and participate in meetings.\n     - The interest and ability to understand the sometimes conflicting interests of the various constituencies of the Company, including stockholders, employees, customers, governmental units, creditors, and the general public.\n     - The ability to serve for at least three years before reaching the age of 75.\n     - Not having, nor appearing to have, a conflict of interest that would impair the candidate\u2019s ability to represent the interests of all the Company\u2019s stockholders and to fulfill the responsibilities of a director.\n\n2. **Evaluate the Options:**\n   - **Option A: The candidate's previous employment history**\n     - The document does not explicitly mention previous employment history as a primary concern. While it is likely considered, it is not listed as a specific qualification concern.\n   - **Option B: The candidate's age and personal interests**\n     - The document mentions the ability to serve for at least three years before reaching the age of 75, but it does not mention personal interests as a concern.\n   - **Option C: A conflict of interest impacting their representation of stockholders**\n     - The document explicitly states that the Committee believes candidates should not have, nor appear to have, a conflict of interest that would impair their ability to represent the interests of all the Company\u2019s stockholders.\n   - **Option D: The candidate's educational background**\n     - The document does not list educational background as a specific qualification concern, although it is mentioned for individual directors.\n   - **Option E: The candidate's language proficiency**\n     - The document does not mention language proficiency as a qualification concern.\n   - **Option F: The candidate's geographical location**\n     - The document does not mention geographical location as a qualification concern.\n\n3. **Conclusion:**\n   - Based on the information"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 8000, "result": 1.0, "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?", "options": {"A": "9.00%", "B": "7.50%", "C": "8.50%", "D": "6.00%", "E": "7.00%", "F": "5.50%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant section in the document that discusses the long-term rate of return assumptions for pension and 401(h) account assets.\n2. Extract the specific information related to the RCBP (Duke Energy Retirement Cash Balance Plan) pension and RCBP 401(h) account assets.\n3. Match the extracted information with the provided options.\n\n### Step 1: Identify the Relevant Section\nThe relevant section is found in the \"PLAN ASSETS\" part of the document, specifically under the \"Description and Allocations\" subsection.\n\n### Step 2: Extract the Specific Information\nThe document states:\n\"As of December 31, 2023, Duke Energy assumes qualified pension and other post-retirement plan assets will generate a long-term rate of return of 8.50% for the RCBP pension and RCBP 401(h) account assets and 7.00% for the DELPP pension and DELPP 401(h) account assets.\"\n\n### Step 3: Match the Extracted Information with the Provided Options\nThe long-term rate of return for the RCBP pension and RCBP 401(h) account assets is 8.50%.\n\n### Conclusion\nThe correct answer is **C: 8.50%**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 8000, "result": 1.0, "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?", "options": {"A": "2020", "B": "2021", "C": "2022", "D": "2023", "E": "2024", "F": "2025"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document and analyze it step by step.\n\n### Step 1: Identify the relevant information\nThe key information needed to answer the question is found in the section titled \"22 Other Comprehensive Income.\" Specifically, the paragraph that discusses the total original gain of $41.2 million, net of tax, becoming fully accreted into income.\n\n### Step 2: Extract the specific details\nThe relevant sentence states:\n\"The total original gain of $ 41.2 million, net of tax, became fully accreted into income during the year ended December 31, 2023.\"\n\n### Step 3: Match the information to the options\nThe options provided are:\n- A: 2020\n- B: 2021\n- C: 2022\n- D: 2023\n- E: 2024\n- F: 2025\n\n### Step 4: Determine the correct answer\nThe document clearly states that the total original gain of $41.2 million, net of tax, became fully accreted into income during the year ended December 31, 2023. This matches directly with option D.\n\n### Conclusion\nThe correct answer is **D: 2023**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 75, "token_lengths": 8000, "result": 1.0, "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?", "options": {"A": "No less than 120% of fair value per share", "B": "No less than 80% of fair value per share", "C": "No less than 110% of fair value per share", "D": "No less than 100% of fair value per share", "E": "Fixed amount regardless of fair value", "F": "No specific requirement"}, "LLM_original_answer": ["To answer the question \"What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section on stock-based compensation, which is likely to include information about stock options and their requirements.\n\n2. **Locate the specific requirement**: Within the stock-based compensation section, I will look for the specific requirement regarding the exercise price for incentive stock options granted to employees who own more than 10% of the voting power.\n\n3. **Extract the information**: Once I find the relevant information, I will extract it and match it to the provided options.\n\n### Step-by-Step Analysis:\n\n1. **Identify the relevant section**:\n   - The relevant section is found under \"8. Stock-Based Compensation\" and specifically within the \"Equity Incentive Plans\" subsection.\n\n2. **Locate the specific requirement**:\n   - The document states: \"In the case of an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10 % of the total combined voting power of all classes of stock, the exercise price shall be no less than 110 % of the fair value per share on the date of grant, and the award shall expire five years from the date of grant.\"\n\n3. **Extract the information**:\n   - The exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power is \"no less than 110% of the fair value per share on the date of grant.\"\n\n### Matching to the Provided Options:\n- **Option A**: No less than 120% of fair value per share\n- **Option B**: No less than 80% of fair value per share\n- **Option C**: No less than 110% of fair value per share\n- **Option D**: No less than 100% of fair value per share\n- **Option E**: Fixed amount regardless of fair value\n- **Option F**: No specific requirement\n\nThe correct answer is **Option C: No less than 110% of fair value per share**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 8000, "result": 1.0, "question": "What was the required minimum net worth for PHH at December 31, 2023?", "options": {"A": "$350 million", "B": "$420.5 million", "C": "$448.3 million", "D": "$480 million", "E": "$500 million", "F": "$525.7 million"}, "LLM_original_answer": ["To answer the question \"What was the required minimum net worth for PHH at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss PHH's financial requirements, particularly those related to net worth.\n\n2. **Locate the Specific Requirement**: Find the exact statement that specifies the required minimum net worth for PHH as of December 31, 2023.\n\n3. **Match the Requirement to the Options**: Compare the identified minimum net worth requirement to the given options to select the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document mentions regulatory requirements and financial eligibility criteria for PHH. The relevant section is found in Note 24 \u2014 Regulatory Requirements.\n\n### Step 2: Locate the Specific Requirement\nIn the section discussing PHH's minimum financial eligibility requirements, the document states:\n> \"Under the applicable formula, the required minimum net worth was $ 448.3 million at December 31, 2023.\"\n\n### Step 3: Match the Requirement to the Options\nThe options provided are:\n- A: $350 million\n- B: $420.5 million\n- C: $448.3 million\n- D: $480 million\n- E: $500 million\n- F: $525.7 million\n\nThe required minimum net worth for PHH at December 31, 2023, is explicitly stated as $448.3 million.\n\n### Conclusion\nThe correct answer is **C: $448.3 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 8000, "result": 1.0, "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?", "options": {"A": "NYSE governance rules", "B": "SEC disclosure guidelines", "C": "Nasdaq governance rules", "D": "International Business Standards", "E": "U.S. Financial Regulations", "F": "Federal Trade Commission rules"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document:\n\n1. **Identify the relevant section**: The document mentions the adoption of a Code of Business Conduct and Ethics in the section titled \"Item 10. Directors, Executive Officers and Corporate Governance.\"\n\n2. **Extract the specific requirement**: The relevant sentence states, \"We have adopted a Code of Business Conduct and Ethics for all of our directors, officers and employees as required by Nasdaq governance rules and as defined by applicable SEC rules.\"\n\n3. **Match the requirement to the options**:\n   - **Option A: NYSE governance rules** - The document does not mention NYSE governance rules.\n   - **Option B: SEC disclosure guidelines** - The document mentions \"applicable SEC rules,\" but this is in addition to Nasdaq governance rules, not as the primary requirement.\n   - **Option C: Nasdaq governance rules** - The document explicitly states that the Code of Business Conduct and Ethics is required by Nasdaq governance rules.\n   - **Option D: International Business Standards** - The document does not mention international business standards.\n   - **Option E: U.S. Financial Regulations** - While U.S. financial regulations might be relevant in a broader context, the specific requirement is attributed to Nasdaq governance rules.\n   - **Option F: Federal Trade Commission rules** - The document does not mention Federal Trade Commission rules.\n\n4. **Conclusion**: Based on the information provided, the governance rule that requires a Code of Business Conduct and Ethics for directors, officers, and employees is **Nasdaq governance rules**.\n\nTherefore, the correct answer is **C: Nasdaq governance rules**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 8000, "result": 1.0, "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?", "options": {"A": "The Chief Financial Officer", "B": "Independent registered public accounting firm", "C": "The undersigned, duly authorized person", "D": "The Secretary of the Board", "E": "The company's legal department", "F": "The external auditor"}, "LLM_original_answer": ["To answer the question \"Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the signing of the report in the \"SIGNATURES\" section.\n\n2. **Examine the content of the \"SIGNATURES\" section**:\n   - The section states: \"Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.\"\n   - This indicates that the report is signed by the \"undersigned, duly authorized person.\"\n\n3. **Match the information to the given options**:\n   - Option A: The Chief Financial Officer\n   - Option B: Independent registered public accounting firm\n   - Option C: The undersigned, duly authorized person\n   - Option D: The Secretary of the Board\n   - Option E: The company's legal department\n   - Option F: The external auditor\n\n4. **Select the correct option**:\n   - The correct option is C: The undersigned, duly authorized person.\n\nTherefore, the answer to the question is **C: The undersigned, duly authorized person**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 8000, "result": 1.0, "question": "Where can information about the 2024 election of directors be found?", "options": {"A": "In the company\u2019s financial statements", "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders", "C": "In the General Instruction G(3) of Form 10-K", "D": "Under the 'Executive Officers' section of the report", "E": "In the company's quarterly earnings report", "F": "In the 'Delinquent Section 16(a) Reports' section"}, "LLM_original_answer": ["To answer the question \"Where can information about the 2024 election of directors be found?\" based on the provided document, I will analyze the options step by step:\n\n1. **Option A: In the company\u2019s financial statements**\n   - The document does not mention any information about the election of directors in the financial statements. Financial statements typically focus on financial data and performance, not on corporate governance or elections.\n\n2. **Option B: In the Proxy Statement for the 2024 Annual Meeting of Stockholders**\n   - The document explicitly states: \"Information relating to our Board of Directors set forth under the caption \u2018Proposal 1 \u2014 Election of Directors \u2014 Nominees for Election as Directors at the 2024 Annual Meeting\u2019 in our Proxy Statement for our 2024 Annual Meeting of Stockholders, or the 2024 Proxy Statement, is incorporated herein by reference.\"\n   - This indicates that the information about the 2024 election of directors is found in the Proxy Statement for the 2024 Annual Meeting of Stockholders.\n\n3. **Option C: In the General Instruction G(3) of Form 10-K**\n   - The document mentions that information relating to executive officers is provided under General Instruction G(3) of Form 10-K, but it does not mention anything about the election of directors in this section.\n\n4. **Option D: Under the 'Executive Officers' section of the report**\n   - The document provides information about executive officers in the \"Executive Officers\" section, but it does not include information about the election of directors.\n\n5. **Option E: In the company's quarterly earnings report**\n   - The document does not mention any information about the election of directors in the quarterly earnings report. Quarterly earnings reports typically focus on financial performance over a specific quarter.\n\n6. **Option F: In the 'Delinquent Section 16(a) Reports' section**\n   - The document states that information regarding compliance by directors and executive officers with the reporting requirements of Section 16(a) of the Exchange Act is found in the 2024 Proxy Statement under the caption \"Delinquent Section 16(a) Reports.\" This section is related to compliance and reporting, not the election of directors.\n\nBased on the analysis, the correct answer is:\n\n**B: In the Proxy Statement for the 2024 Annual Meeting of Stockholders**\n\nThis is where the document explicitly directs readers to find information"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 8000, "result": 1.0, "question": "What framework did the Company use to establish criteria for internal control over financial reporting?", "options": {"A": "SOX Compliance Framework", "B": "ISO 9001 Standards", "C": "Internal Control \u2014 Integrated Framework (2013)", "D": "GAAP Standards", "E": "FASB Guidelines", "F": "IFRS Regulations"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document step by step.\n\n1. **Identify the Relevant Section**: The section that discusses the internal control over financial reporting is found in \"Item 9A. Controls and Procedures\" and \"Management\u2019s Annual Report on Internal Control Over Financial Reporting.\"\n\n2. **Extract the Key Information**:\n   - In \"Management\u2019s Annual Report on Internal Control Over Financial Reporting,\" it states: \"Management has completed an assessment of the effectiveness of the Company\u2019s internal control over financial reporting as of December 31, 2023. In making the assessment, management used the criteria set forth in 'Internal Control - Integrated Framework' promulgated by the Committee of Sponsoring Organizations of the Treadway Commission.\"\n   - The attestation report by Deloitte & Touche LLP also mentions: \"We have audited the internal control over financial reporting of Brighthouse Financial, Inc. and subsidiaries (the 'Company') as of December 31, 2023, based on criteria established in Internal Control \u2014 Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).\"\n\n3. **Match the Information to the Options**:\n   - The document explicitly mentions the use of the \"Internal Control - Integrated Framework\" promulgated by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).\n   - The 2013 version of this framework is specifically referenced in the attestation report.\n\n4. **Select the Correct Option**:\n   - The correct option is **C: Internal Control \u2014 Integrated Framework (2013)**.\n\nTherefore, the framework that the Company used to establish criteria for internal control over financial reporting is **C: Internal Control \u2014 Integrated Framework (2013)**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 16000, "result": 1.0, "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?", "options": {"A": "Cumulative voting rights", "B": "One vote per share without cumulative voting", "C": "Two votes per share", "D": "Preemptive voting rights", "E": "Redeemable voting rights", "F": "Convertible voting rights"}, "LLM_original_answer": ["To answer the question regarding the voting rights of holders of common stock under the Company's amended and restated certificate of incorporation and bylaws, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the rights and privileges of common stockholders is found in \"ITEM 8.COMMON STOCK.\"\n\n2. **Extract the specific information about voting rights**: The relevant excerpt from the document is:\n   - \"Voting Rights: Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under the Company's amended and restated certificate of incorporation and amended and restated bylaws, stockholders will not have cumulative voting rights.\"\n\n3. **Analyze the information**:\n   - The document states that each holder of common stock is entitled to one vote per share.\n   - It also explicitly mentions that stockholders will not have cumulative voting rights.\n\n4. **Match the information to the provided options**:\n   - **Option A: Cumulative voting rights** - This is explicitly stated as not being applicable.\n   - **Option B: One vote per share without cumulative voting** - This matches the information provided in the document.\n   - **Option C: Two votes per share** - This is not mentioned in the document.\n   - **Option D: Preemptive voting rights** - This is not mentioned in the document.\n   - **Option E: Redeemable voting rights** - This is not mentioned in the document.\n   - **Option F: Convertible voting rights** - This is not mentioned in the document.\n\n5. **Conclude the answer**:\n   - Based on the information provided in the document, the correct answer is **Option B: One vote per share without cumulative voting**.\n\nTherefore, the voting rights of holders of common stock under the Company's amended and restated certificate of incorporation and bylaws are **Option B: One vote per share without cumulative voting**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 16000, "result": 1.0, "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?", "options": {"A": "The candidate's previous employment history", "B": "The candidate's age and personal interests", "C": "A conflict of interest impacting their representation of stockholders", "D": "The candidate's educational background", "E": "The candidate's language proficiency", "F": "The candidate's geographical location"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the relevant section of the provided document, which is the part describing the Nominating and Corporate Governance Committee's responsibilities and criteria for evaluating director candidates.\n\nThe relevant section states:\n\"The Nominating and Corporate Governance Committee also believes that candidates for director should not have, nor appear to have, a conflict of interest that would impair the candidate\u2019s ability to represent the interests of all the Company\u2019s stockholders and to fulfill the responsibilities of a director.\"\n\nThis statement directly addresses the committee's concern regarding conflicts of interest that could affect a candidate's ability to represent the stockholders' interests effectively.\n\nLet's review the options provided:\nA: The candidate's previous employment history\nB: The candidate's age and personal interests\nC: A conflict of interest impacting their representation of stockholders\nD: The candidate's educational background\nE: The candidate's language proficiency\nF: The candidate's geographical location\n\nThe correct answer is clearly **C: A conflict of interest impacting their representation of stockholders**. This is the specific concern mentioned in the document regarding the qualifications of director candidates. The other options, while they might be relevant in other contexts, are not explicitly mentioned as concerns of the Nominating and Corporate Governance Committee in the provided document."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 16000, "result": 1.0, "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?", "options": {"A": "9.00%", "B": "7.50%", "C": "8.50%", "D": "6.00%", "E": "7.00%", "F": "5.50%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant section in the document that discusses the long-term rate of return assumptions for pension and 401(h) account assets.\n2. Extract the specific information related to the RCBP (Retirement Cash Balance Plan) pension and RCBP 401(h) account assets.\n3. Match the extracted information to the provided options.\n\n### Step 1: Identify the Relevant Section\nThe relevant section is found in the \"Assumptions Used for Pension Benefits Accounting\" part of the document.\n\n### Step 2: Extract the Specific Information\nFrom the document, the following information is provided:\n- \"As of December 31, 2023, Duke Energy assumes qualified pension and other post-retirement plan assets will generate a long-term rate of return of 8.50% for the RCBP pension and RCBP 401(h) account assets and 7.00% for the DELPP pension and DELPP 401(h) account assets.\"\n\n### Step 3: Match the Extracted Information to the Provided Options\nThe long-term rate of return for the RCBP pension and RCBP 401(h) account assets is 8.50%.\n\n### Conclusion\nThe correct answer is:\n**C: 8.50%**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 16000, "result": 1.0, "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?", "options": {"A": "2020", "B": "2021", "C": "2022", "D": "2023", "E": "2024", "F": "2025"}, "LLM_original_answer": ["To answer the question, I will follow the information provided in the document and analyze it step by step.\n\n1. **Identify the relevant information**: The question asks about the year when the total original gain of $41.2 million, net of tax, became fully accreted into income. This information is found in the \"Other Comprehensive Income\" section of the document.\n\n2. **Locate the specific statement**: In the \"Other Comprehensive Income\" section, the document states:\n   - \"The total original gain of $ 41.2 million, net of tax, became fully accreted into income during the year ended December 31, 2023.\"\n\n3. **Verify the context**: The document also provides additional context:\n   - \"The balance of this gain had amortized to less than $ 0.1 million, and $ 7.4 million, net of tax, at December 31, 2022 and December 31, 2021, respectively.\"\n\n4. **Conclusion**: Based on the specific statement and the context provided, the total original gain of $41.2 million, net of tax, became fully accreted into income during the year ended December 31, 2023.\n\nTherefore, the correct answer is **D: 2023**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 75, "token_lengths": 16000, "result": 1.0, "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?", "options": {"A": "No less than 120% of fair value per share", "B": "No less than 80% of fair value per share", "C": "No less than 110% of fair value per share", "D": "No less than 100% of fair value per share", "E": "Fixed amount regardless of fair value", "F": "No specific requirement"}, "LLM_original_answer": ["To answer the question \"What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section on stock-based compensation, which is likely to include information about stock options and their requirements.\n\n2. **Locate the specific information**: Within the \"Stock-Based Compensation\" section, there is a subsection titled \"Equity Incentive Plans\" that discusses the terms of stock options.\n\n3. **Extract the relevant details**: The document states:\n   > \"In the case of an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10 % of the total combined voting power of all classes of stock, the exercise price shall be no less than 110 % of the fair value per share on the date of grant, and the award shall expire five years from the date of grant.\"\n\n4. **Match the information to the options**: The requirement for the exercise price of incentive stock options granted to an employee owning over 10% of voting power is \"no less than 110% of the fair value per share.\"\n\n5. **Select the correct answer**: The correct answer is **C: No less than 110% of fair value per share**.\n\nTherefore, the answer to the question is **C: No less than 110% of fair value per share**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 16000, "result": 1.0, "question": "What was the required minimum net worth for PHH at December 31, 2023?", "options": {"A": "$350 million", "B": "$420.5 million", "C": "$448.3 million", "D": "$480 million", "E": "$500 million", "F": "$525.7 million"}, "LLM_original_answer": ["To answer the question \"What was the required minimum net worth for PHH at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss financial requirements, particularly those related to PHH's net worth.\n\n2. **Extract Specific Information**: Find the exact statement that mentions the required minimum net worth for PHH as of December 31, 2023.\n\n3. **Match the Information to the Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in Note 24 \u2014 Regulatory Requirements, which discusses the financial eligibility requirements for PHH.\n\n### Step 2: Extract Specific Information\nFrom the document:\n> \"PHH\u2019s minimum financial eligibility requirements for GSE seller/servicers and Ginnie Mae issuers were updated by the GSEs and Ginnie Mae effective September 30, 2023, including the following:\"\n\n> \"Under the applicable formula, the required minimum net worth was **$ 448.3 million** at December 31, 2023.\"\n\n### Step 3: Match the Information to the Options\nThe required minimum net worth for PHH at December 31, 2023, is **$ 448.3 million**.\n\n### Conclusion\nThe correct answer is **C: $448.3 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 16000, "result": 1.0, "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?", "options": {"A": "NYSE governance rules", "B": "SEC disclosure guidelines", "C": "Nasdaq governance rules", "D": "International Business Standards", "E": "U.S. Financial Regulations", "F": "Federal Trade Commission rules"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the relevant governance rule that requires a Code of Business Conduct and Ethics for directors, officers, and employees.\n\n1. **Identify the relevant section in the document:**\n   - The document mentions the Code of Business Conduct and Ethics in the section titled \"Item 10. Directors, Executive Officers and Corporate Governance.\"\n\n2. **Extract the relevant information:**\n   - The specific statement is: \"We have adopted a Code of Business Conduct and Ethics for all of our directors, officers and employees as required by Nasdaq governance rules and as defined by applicable SEC rules.\"\n\n3. **Determine the governance rule:**\n   - The document explicitly states that the Code of Business Conduct and Ethics is required by Nasdaq governance rules and applicable SEC rules.\n\n4. **Match the information to the given options:**\n   - Option A: NYSE governance rules (not mentioned in the document)\n   - Option B: SEC disclosure guidelines (mentioned but not as the primary requirement)\n   - Option C: Nasdaq governance rules (explicitly mentioned as the requirement)\n   - Option D: International Business Standards (not mentioned in the document)\n   - Option E: U.S. Financial Regulations (not specifically mentioned in the context of the Code)\n   - Option F: Federal Trade Commission rules (not mentioned in the document)\n\n5. **Conclusion:**\n   - The governance rule that requires a Code of Business Conduct and Ethics for directors, officers, and employees is the Nasdaq governance rules.\n\nTherefore, the correct answer is **C: Nasdaq governance rules**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 16000, "result": 1.0, "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?", "options": {"A": "The Chief Financial Officer", "B": "Independent registered public accounting firm", "C": "The undersigned, duly authorized person", "D": "The Secretary of the Board", "E": "The company's legal department", "F": "The external auditor"}, "LLM_original_answer": ["To answer the question \"Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document includes a section titled \"SIGNATURES\" which is likely to contain information about who signs the report.\n\n2. **Examine the SIGNATURES section**: The SIGNATURES section states:\n   ```\n   Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.\n   ```\n   This indicates that the report is signed by the \"undersigned, thereunto duly authorized.\"\n\n3. **Determine the meaning of \"undersigned, thereunto duly authorized\"**: The term \"undersigned, thereunto duly authorized\" typically refers to a person who has been officially designated or authorized by the company to sign the report. This person is often a senior executive or an officer of the company.\n\n4. **Review the options provided**:\n   - A: The Chief Financial Officer\n   - B: Independent registered public accounting firm\n   - C: The undersigned, duly authorized person\n   - D: The Secretary of the Board\n   - E: The company's legal department\n   - F: The external auditor\n\n5. **Match the identified section with the options**:\n   - The document explicitly states that the report is signed by the \"undersigned, thereunto duly authorized.\"\n   - This matches directly with option C: \"The undersigned, duly authorized person.\"\n\nTherefore, the correct answer is:\n\n**C: The undersigned, duly authorized person**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 16000, "result": 1.0, "question": "Where can information about the 2024 election of directors be found?", "options": {"A": "In the company\u2019s financial statements", "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders", "C": "In the General Instruction G(3) of Form 10-K", "D": "Under the 'Executive Officers' section of the report", "E": "In the company's quarterly earnings report", "F": "In the 'Delinquent Section 16(a) Reports' section"}, "LLM_original_answer": ["To answer the question \"Where can information about the 2024 election of directors be found?\" based on the provided document, I will go through the options step by step:\n\nA: In the company\u2019s financial statements\n- The document does not mention any information about the election of directors in the financial statements. Financial statements typically focus on financial data and performance, not corporate governance or elections.\n\nB: In the Proxy Statement for the 2024 Annual Meeting of Stockholders\n- The document explicitly states: \"Information relating to our Board of Directors set forth under the caption \u2018Proposal 1 \u2014 Election of Directors \u2014 Nominees for Election as Directors at the 2024 Annual Meeting\u2019 in our Proxy Statement for our 2024 Annual Meeting of Stockholders, or the 2024 Proxy Statement, is incorporated herein by reference.\" This indicates that the information about the 2024 election of directors is found in the Proxy Statement for the 2024 Annual Meeting of Stockholders.\n\nC: In the General Instruction G(3) of Form 10-K\n- The document mentions that information about executive officers is provided under General Instruction G(3) of Form 10-K, but it does not mention anything about the election of directors in this section.\n\nD: Under the 'Executive Officers' section of the report\n- The document provides information about executive officers in the \"Executive Officers\" section, but it does not mention the election of directors here.\n\nE: In the company's quarterly earnings report\n- The document does not mention any information about the election of directors in the quarterly earnings report. Quarterly earnings reports typically focus on financial performance over the quarter.\n\nF: In the 'Delinquent Section 16(a) Reports' section\n- The document states that information regarding compliance by directors and executive officers with the reporting requirements of Section 16(a) of the Exchange Act is found in the \"Delinquent Section 16(a) Reports\" section of the 2024 Proxy Statement. This section is about compliance with reporting requirements, not the election of directors.\n\nBased on the above analysis, the correct answer is:\n\n**B: In the Proxy Statement for the 2024 Annual Meeting of Stockholders**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 16000, "result": 1.0, "question": "What framework did the Company use to establish criteria for internal control over financial reporting?", "options": {"A": "SOX Compliance Framework", "B": "ISO 9001 Standards", "C": "Internal Control \u2014 Integrated Framework (2013)", "D": "GAAP Standards", "E": "FASB Guidelines", "F": "IFRS Regulations"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the framework used by the Company for establishing criteria for internal control over financial reporting.\n\n1. **Identify Relevant Sections**:\n   - The document includes a section on \"Management\u2019s Annual Report on Internal Control Over Financial Reporting\" and an \"Attestation Report of the Company\u2019s Registered Public Accounting Firm.\"\n\n2. **Examine Management\u2019s Annual Report**:\n   - The section states: \"Management of Brighthouse Financial, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of control procedures.\"\n   - It further mentions: \"Management has completed an assessment of the effectiveness of the Company\u2019s internal control over financial reporting as of December 31, 2023. In making the assessment, management used the criteria set forth in 'Internal Control - Integrated Framework' promulgated by the Committee of Sponsoring Organizations of the Treadway Commission.\"\n\n3. **Examine Attestation Report**:\n   - The attestation report by Deloitte & Touche LLP states: \"We have audited the internal control over financial reporting of Brighthouse Financial, Inc. and subsidiaries (the 'Company') as of December 31, 2023, based on criteria established in Internal Control \u2014 Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).\"\n   - It also mentions: \"In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control \u2014 Integrated Framework (2013) issued by COSO.\"\n\n4. **Conclusion**:\n   - Both the management report and the attestation report explicitly state that the criteria used for assessing the effectiveness of internal control over financial reporting are based on the \"Internal Control \u2014 Integrated Framework (2013)\" issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).\n\nTherefore, the correct answer is:\n**C: Internal Control \u2014 Integrated Framework (2013)**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 32000, "result": 1.0, "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?", "options": {"A": "Cumulative voting rights", "B": "One vote per share without cumulative voting", "C": "Two votes per share", "D": "Preemptive voting rights", "E": "Redeemable voting rights", "F": "Convertible voting rights"}, "LLM_original_answer": ["To answer the question regarding the voting rights of holders of common stock under the Company's amended and restated certificate of incorporation and bylaws, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The relevant section is found in the \"Common Stock\" part of the document, specifically under the \"Voting Rights\" subsection.\n\n2. **Extract the key information**: The document states:\n   - \"Voting Rights: Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors.\"\n   - \"Under the Company's amended and restated certificate of incorporation and amended and restated bylaws, stockholders will not have cumulative voting rights.\"\n\n3. **Match the extracted information to the options provided**:\n   - **Option A: Cumulative voting rights** - The document explicitly states that stockholders will not have cumulative voting rights.\n   - **Option B: One vote per share without cumulative voting** - This matches the information provided in the document.\n   - **Option C: Two votes per share** - The document does not mention two votes per share.\n   - **Option D: Preemptive voting rights** - The document does not mention preemptive voting rights.\n   - **Option E: Redeemable voting rights** - The document does not mention redeemable voting rights.\n   - **Option F: Convertible voting rights** - The document does not mention convertible voting rights.\n\n4. **Conclude the answer**: Based on the information provided in the document, the correct answer is **Option B: One vote per share without cumulative voting**.\n\nTherefore, the holders of common stock have one vote per share without cumulative voting rights under the Company's amended and restated certificate of incorporation and bylaws."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 32000, "result": 1.0, "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?", "options": {"A": "The candidate's previous employment history", "B": "The candidate's age and personal interests", "C": "A conflict of interest impacting their representation of stockholders", "D": "The candidate's educational background", "E": "The candidate's language proficiency", "F": "The candidate's geographical location"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document about the Nominating and Corporate Governance Committee and its criteria for evaluating director candidates.\n\nThe document states:\n\"The Nominating and Corporate Governance Committee also believes that candidates for director should not have, nor appear to have, a conflict of interest that would impair the candidate\u2019s ability to represent the interests of all the Company\u2019s stockholders and to fulfill the responsibilities of a director.\"\n\nThis statement directly addresses the committee's concern regarding conflicts of interest that could affect a candidate's ability to represent stockholders effectively.\n\nNow, let's evaluate the options:\n\nA: The candidate's previous employment history - The document does not mention this as a specific concern of the committee.\nB: The candidate's age and personal interests - The document does not mention this as a specific concern of the committee.\nC: A conflict of interest impacting their representation of stockholders - This is explicitly mentioned in the document.\nD: The candidate's educational background - The document does not mention this as a specific concern of the committee.\nE: The candidate's language proficiency - The document does not mention this as a specific concern of the committee.\nF: The candidate's geographical location - The document does not mention this as a specific concern of the committee.\n\nBased on the information provided in the document, the correct answer is:\n\nC: A conflict of interest impacting their representation of stockholders."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 32000, "result": 1.0, "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?", "options": {"A": "9.00%", "B": "7.50%", "C": "8.50%", "D": "6.00%", "E": "7.00%", "F": "5.50%"}, "LLM_original_answer": ["To answer the question \"What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section on \"Employee Benefit Plans\" which includes information about pension plans and other post-retirement benefits.\n\n2. **Locate the specific information**: Within the \"Employee Benefit Plans\" section, there is a subsection titled \"Assumptions Used for Pension Benefits Accounting\" and another titled \"Assumptions Used for Other Post-Retirement Benefits Accounting.\"\n\n3. **Find the long-term rate of return assumption**: In the \"Assumptions Used for Pension Benefits Accounting\" section, there is a statement that reads:\n   - \"As of December 31, 2023, Duke Energy assumes qualified pension and other post-retirement plan assets will generate a long-term rate of return of 8.50% for the RCBP pension and RCBP 401(h) account assets and 7.00% for the DELPP pension and DELPP 401(h) account assets.\"\n\n4. **Match the information to the question**: The question asks specifically about the RCBP pension and RCBP 401(h) account assets. According to the document, the long-term rate of return assumed for these assets is 8.50%.\n\n5. **Select the correct option**: The correct option from the given choices is C: 8.50%.\n\nTherefore, the long-term rate of return that Duke Energy assumes for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023, is **8.50%**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 32000, "result": 1.0, "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?", "options": {"A": "2020", "B": "2021", "C": "2022", "D": "2023", "E": "2024", "F": "2025"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant information in the document.\n2. Determine the year when the gain became fully accreted into income.\n3. Select the correct option from the provided choices.\n\n### Step 1: Identify the Relevant Information\nThe relevant information is found in the section titled \"22. Other Comprehensive Income.\" Specifically, the following statement is key:\n- \"The total original gain of $ 41.2 million, net of tax, became fully accreted into income during the year ended December 31, 2023.\"\n\n### Step 2: Determine the Year\nThe statement clearly indicates that the total original gain of $41.2 million, net of tax, became fully accreted into income during the year ended December 31, 2023.\n\n### Step 3: Select the Correct Option\nThe correct option is:\n- D: 2023\n\nThus, the answer to the question is **D: 2023**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 75, "token_lengths": 32000, "result": 1.0, "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?", "options": {"A": "No less than 120% of fair value per share", "B": "No less than 80% of fair value per share", "C": "No less than 110% of fair value per share", "D": "No less than 100% of fair value per share", "E": "Fixed amount regardless of fair value", "F": "No specific requirement"}, "LLM_original_answer": ["To answer the question \"What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for sections that discuss stock options, particularly those related to employees owning more than 10% of the voting power.\n\n2. **Extract Specific Details**: Look for specific details about the exercise price requirements for such stock options.\n\n3. **Match the Information to the Options**: Compare the extracted information to the given multiple-choice options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\nThe relevant information is found in the \"Stock-Based Compensation\" section of the document, specifically under the \"Equity Incentive Plans\" subsection.\n\n### Step 2: Extract Specific Details\nThe document states:\n\"In the case of an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the total combined voting power of all classes of stock, the exercise price shall be no less than 110% of the fair value per share on the date of grant, and the award shall expire five years from the date of grant.\"\n\n### Step 3: Match the Information to the Options\nThe extracted information directly matches option C: \"No less than 110% of fair value per share.\"\n\n### Conclusion\nThe correct answer is **C: No less than 110% of fair value per share**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 32000, "result": 1.0, "question": "What was the required minimum net worth for PHH at December 31, 2023?", "options": {"A": "$350 million", "B": "$420.5 million", "C": "$448.3 million", "D": "$480 million", "E": "$500 million", "F": "$525.7 million"}, "LLM_original_answer": ["To answer the question \"What was the required minimum net worth for PHH at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss financial requirements, particularly those related to net worth.\n\n2. **Locate Specific Net Worth Requirements**: Find the specific net worth requirement for PHH as of December 31, 2023.\n\n3. **Match the Requirement to the Options**: Compare the identified net worth requirement to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document mentions financial covenants and regulatory requirements in several sections. The most relevant section is likely to be found in \"Note 24 \u2014 Regulatory Requirements,\" as it discusses the financial eligibility requirements for PHH.\n\n### Step 2: Locate Specific Net Worth Requirements\nIn the \"Note 24 \u2014 Regulatory Requirements\" section, the following information is provided:\n- **PHH\u2019s minimum financial eligibility requirements for GSE seller/servicers and Ginnie Mae issuers were updated by the GSEs and Ginnie Mae effective September 30, 2023.**\n- **The most restrictive of the various net worth and liquidity requirements for licensing and seller/servicer obligations referenced above are mostly based on the UPB of assets serviced by PHH.**\n- **Under the applicable formula, the required minimum net worth was $ 448.3 million at December 31, 2023.**\n- **PHH\u2019s adjusted net worth was $ 517.8 million at December 31, 2023.**\n\n### Step 3: Match the Requirement to the Options\nThe required minimum net worth for PHH at December 31, 2023, is explicitly stated as $ 448.3 million.\n\n### Conclusion\nThe correct answer is:\n**C: $448.3 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 32000, "result": 1.0, "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?", "options": {"A": "NYSE governance rules", "B": "SEC disclosure guidelines", "C": "Nasdaq governance rules", "D": "International Business Standards", "E": "U.S. Financial Regulations", "F": "Federal Trade Commission rules"}, "LLM_original_answer": ["The correct answer is **C: Nasdaq governance rules**.\n\n### Chain of Thought:\n1. **Identify the Requirement**: The question asks for the governance rule that requires a Code of Business Conduct and Ethics for directors, officers, and employees.\n2. **Review the Document**: The document mentions the adoption of a Code of Business Conduct and Ethics in the context of corporate governance.\n3. **Relevant Section**: The relevant section is found in **Item 10. Directors, Executive Officers and Corporate Governance**.\n4. **Specific Mention**: The document states, \"We have adopted a Code of Business Conduct and Ethics for all of our directors, officers and employees as required by Nasdaq governance rules and as defined by applicable SEC rules.\"\n5. **Conclusion**: The Nasdaq governance rules are explicitly mentioned as the requirement for adopting the Code of Business Conduct and Ethics.\n\nThus, the correct answer is **C: Nasdaq governance rules**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 32000, "result": 1.0, "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?", "options": {"A": "The Chief Financial Officer", "B": "Independent registered public accounting firm", "C": "The undersigned, duly authorized person", "D": "The Secretary of the Board", "E": "The company's legal department", "F": "The external auditor"}, "LLM_original_answer": ["To answer the question \"Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss the signing of the report and the roles of individuals involved in the process.\n\n2. **Analyze the Content**: Examine the content to determine who is specifically mentioned as being responsible for signing the report.\n\n3. **Match with Options**: Compare the identified individuals or roles with the given options to find the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in the \"SIGNATURES\" part of the document, specifically:\n\n> **Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.**\n\n### Step 2: Analyze the Content\nThe section states that the report is signed on behalf of the Registrant by the \"undersigned, thereunto duly authorized.\" This indicates that the person signing the report is someone who has been authorized to do so by the company.\n\n### Step 3: Match with Options\nThe options provided are:\n- A: The Chief Financial Officer\n- B: Independent registered public accounting firm\n- C: The undersigned, duly authorized person\n- D: The Secretary of the Board\n- E: The company's legal department\n- F: The external auditor\n\nThe phrase \"the undersigned, thereunto duly authorized\" directly matches with option C: \"The undersigned, duly authorized person.\"\n\n### Conclusion\nThe correct answer is **C: The undersigned, duly authorized person**. This is explicitly stated in the document as the person responsible for signing the report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 32000, "result": 1.0, "question": "Where can information about the 2024 election of directors be found?", "options": {"A": "In the company\u2019s financial statements", "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders", "C": "In the General Instruction G(3) of Form 10-K", "D": "Under the 'Executive Officers' section of the report", "E": "In the company's quarterly earnings report", "F": "In the 'Delinquent Section 16(a) Reports' section"}, "LLM_original_answer": ["To answer the question \"Where can information about the 2024 election of directors be found?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that mention the election of directors or the 2024 Annual Meeting of Stockholders.\n2. **Check for Specific References**: Within these sections, check for specific references to the 2024 election of directors.\n3. **Evaluate the Options**: Compare the identified references to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe document mentions the election of directors and the 2024 Annual Meeting of Stockholders in the following sections:\n- **ITEM 10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE**\n\n### Step 2: Check for Specific References\nIn **ITEM 10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE**, the following relevant information is provided:\n- \"Information relating to our Board of Directors set forth under the caption \u2018Proposal 1 \u2014 Election of Directors \u2014 Nominees for Election as Directors at the 2024 Annual Meeting\u2019 in our Proxy Statement for our 2024 Annual Meeting of Stockholders, or the 2024 Proxy Statement, is incorporated herein by reference.\"\n\n### Step 3: Evaluate the Options\n- **Option A: In the company\u2019s financial statements** - The document does not mention that information about the election of directors is found in the financial statements.\n- **Option B: In the Proxy Statement for the 2024 Annual Meeting of Stockholders** - The document explicitly states that information about the election of directors is found in the Proxy Statement for the 2024 Annual Meeting of Stockholders.\n- **Option C: In the General Instruction G(3) of Form 10-K** - The document does not mention that information about the election of directors is found in General Instruction G(3) of Form 10-K.\n- **Option D: Under the 'Executive Officers' section of the report** - The document mentions the 'Executive Officers' section but does not indicate that it contains information about the election of directors.\n- **Option E: In the company's quarterly earnings report** - The document does not mention that information about the election of directors is found in the quarterly earnings report.\n- **Option F: In the 'Delinquent Section"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 32000, "result": 1.0, "question": "What framework did the Company use to establish criteria for internal control over financial reporting?", "options": {"A": "SOX Compliance Framework", "B": "ISO 9001 Standards", "C": "Internal Control \u2014 Integrated Framework (2013)", "D": "GAAP Standards", "E": "FASB Guidelines", "F": "IFRS Regulations"}, "LLM_original_answer": ["To answer the question \"What framework did the Company use to establish criteria for internal control over financial reporting?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss internal control over financial reporting.\n2. **Extract Key Information**: Extract the specific information about the framework used.\n3. **Match to Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in \"Item 9A. Controls and Procedures\" and \"Management\u2019s Annual Report on Internal Control Over Financial Reporting.\"\n\n### Step 2: Extract Key Information\nFrom the document:\n- **Management\u2019s Annual Report on Internal Control Over Financial Reporting**:\n  - \"Management of Brighthouse Financial, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting.\"\n  - \"In making the assessment, management used the criteria set forth in 'Internal Control - Integrated Framework' promulgated by the Committee of Sponsoring Organizations of the Treadway Commission.\"\n  - \"Based upon the assessment performed under that framework, management has maintained and concluded that the Company\u2019s internal control over financial reporting was effective as of December 31, 2023.\"\n\n- **Attestation Report of the Company\u2019s Registered Public Accounting Firm**:\n  - \"We have audited the internal control over financial reporting of Brighthouse Financial, Inc. and subsidiaries (the 'Company') as of December 31, 2023, based on criteria established in Internal Control \u2014 Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).\"\n\n### Step 3: Match to Options\nThe document explicitly mentions that the Company used the criteria set forth in \"Internal Control - Integrated Framework\" promulgated by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The 2013 version of this framework is specifically referenced in the attestation report.\n\n### Conclusion\nThe correct answer is:\n**C: Internal Control \u2014 Integrated Framework (2013)**\n\nThis framework is used by the Company to establish criteria for internal control over financial reporting, as clearly stated in both the management's annual report and the attestation report by the independent registered public accounting firm."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 64000, "result": 1.0, "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?", "options": {"A": "Cumulative voting rights", "B": "One vote per share without cumulative voting", "C": "Two votes per share", "D": "Preemptive voting rights", "E": "Redeemable voting rights", "F": "Convertible voting rights"}, "LLM_original_answer": ["Based on the provided document, the voting rights of holders of common stock under the Company's amended and restated certificate of incorporation and bylaws are as follows:\n\n- **Voting Rights**: Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors.\n- **Cumulative Voting**: The document explicitly states that stockholders will not have cumulative voting rights.\n\nGiven this information, the correct answer to the question \"What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?\" is:\n\n**B: One vote per share without cumulative voting**\n\nThis is supported by the following excerpt from the document:\n\n> \"Voting Rights: Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under the Company's amended and restated certificate of incorporation and amended and restated bylaws, stockholders will not have cumulative voting rights.\"\n\nThis clearly indicates that each share of common stock carries one vote, and cumulative voting is not allowed."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 64000, "result": 1.0, "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?", "options": {"A": "The candidate's previous employment history", "B": "The candidate's age and personal interests", "C": "A conflict of interest impacting their representation of stockholders", "D": "The candidate's educational background", "E": "The candidate's language proficiency", "F": "The candidate's geographical location"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Context and Committee Role**:\n   - The document mentions the Nominating and Corporate Governance Committee, which is responsible for identifying and evaluating candidates for director positions.\n   - The committee's role includes ensuring that the candidates meet certain qualifications and do not have conflicts of interest that could impair their ability to represent the stockholders effectively.\n\n2. **Qualification Concerns**:\n   - The document states: \"The Nominating and Corporate Governance Committee believes that candidates for director should have certain minimum qualifications, including a reputation for integrity, honesty and adherence to high ethical standards; demonstrated business acumen, experience and the ability to exercise sound judgements in matters that relate to the current and long-term objectives of the Company and a willingness and ability to contribute positively to the decision-making process of the Company.\"\n   - Additionally, it mentions: \"The Nominating and Corporate Governance Committee also believes that candidates for director should not have, nor appear to have, a conflict of interest that would impair the candidate\u2019s ability to represent the interests of all the Company\u2019s stockholders and to fulfill the responsibilities of a director.\"\n\n3. **Conflict of Interest**:\n   - The document specifically highlights the concern about conflicts of interest: \"The Nominating and Corporate Governance Committee also believes that candidates for director should not have, nor appear to have, a conflict of interest that would impair the candidate\u2019s ability to represent the interests of all the Company\u2019s stockholders and to fulfill the responsibilities of a director.\"\n\nGiven this information, the Nominating and Corporate Governance Committee's primary qualification concern regarding candidates for director is:\n\n**C: A conflict of interest impacting their representation of stockholders.**\n\nThis is explicitly stated in the document and aligns with the committee's responsibility to ensure that directors can act in the best interests of all stockholders without any impairing conflicts."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 64000, "result": 0.0, "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?", "options": {"A": "9.00%", "B": "7.50%", "C": "8.50%", "D": "6.00%", "E": "7.00%", "F": "5.50%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the long-term rate of return for pension and 401(h) account assets is likely to be found in the \"Employee Benefit Plans\" section, particularly under \"Defined Benefit Retirement Plans.\"\n\n2. **Locate the specific information**: Within the \"Defined Benefit Retirement Plans\" section, I will look for details about the RCBP (Retirement Cash Balance Plan) and the RCBP 401(h) account assets.\n\n3. **Extract the long-term rate of return**: Once I find the relevant information, I will extract the long-term rate of return assumed for these assets.\n\n4. **Match the extracted rate to the provided options**: Finally, I will compare the extracted rate to the options provided to determine the correct answer.\n\n### Step 1: Identify the relevant section\nThe relevant section is found in \"23. EMPLOYEE BENEFIT PLANS\" under \"DEFINED BENEFIT RETIREMENT PLANS.\"\n\n### Step 2: Locate the specific information\nIn the \"DEFINED BENEFIT RETIREMENT PLANS\" section, I find the following relevant information:\n\n> **Assumptions Used for Pension Benefits Accounting**\n>\n> The discount rate used to determine the current year pension obligation and following year\u2019s pension expense is based on a bond selection-settlement portfolio approach. This approach develops a discount rate by selecting a portfolio of high-quality corporate bonds that generate sufficient cash flow to provide for projected benefit payments of the plan. The selected bond portfolio is derived from a universe of non-callable corporate bonds rated Aa quality or higher. After the bond portfolio is selected, a single interest rate is determined that equates the present value of the plan\u2019s projected benefit payments discounted at this rate with the market value of the bonds selected.\n>\n> **The RCBP contains a mostly active participant population while the DELPP contains a mostly inactive participant population. The average remaining service period for RCBP participants is nine years and the average life expectancy of DELPP participants is 15 years.**\n>\n> **Unrecognized net actuarial gains/losses and prior service credit are amortized over 12 years for Duke Energy and Duke Energy Florida, 14 years for Duke Energy Ohio, 13 years for Duke Energy Indiana, 11 years for Duke Energy Carolinas, Progress Energy and Duke Energy Progress and nine years for Piedmont.**\n>\n>"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 64000, "result": 1.0, "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?", "options": {"A": "2020", "B": "2021", "C": "2022", "D": "2023", "E": "2024", "F": "2025"}, "LLM_original_answer": ["To answer the question, we need to identify when the total original gain of $41.2 million, net of tax, became fully accreted into income. Let's break down the relevant information from the document:\n\n1. **Relevant Statement**: \"The total original gain of $41.2 million, net of tax, became fully accreted into income during the year ended December 31, 2023.\"\n\n2. **Context**: This statement is found in the section discussing the fair value of assets and liabilities, specifically in the context of other comprehensive income (loss).\n\n3. **Interpretation**: The phrase \"became fully accreted into income\" means that the entire amount of the gain was recognized in the income statement during the specified year. The year mentioned is 2023.\n\nGiven this information, the correct answer is:\n\n**D: 2023**"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 75, "token_lengths": 64000, "result": 1.0, "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?", "options": {"A": "No less than 120% of fair value per share", "B": "No less than 80% of fair value per share", "C": "No less than 110% of fair value per share", "D": "No less than 100% of fair value per share", "E": "Fixed amount regardless of fair value", "F": "No specific requirement"}, "LLM_original_answer": ["The provided document does not contain information about the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power. However, based on the information typically found in such contexts, the correct answer is:\n\nC: No less than 110% of fair value per share\n\nThis is derived from the following excerpt in the document:\n\n\"In the case of an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the total combined voting power of all classes of stock, the exercise price shall be no less than 110% of the fair value per share on the date of grant, and the award shall expire five years from the date of grant.\"\n\nThis clearly states that for an employee owning more than 10% of the voting power, the exercise price for an incentive stock option must be no less than 110% of the fair value per share."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 64000, "result": 1.0, "question": "What was the required minimum net worth for PHH at December 31, 2023?", "options": {"A": "$350 million", "B": "$420.5 million", "C": "$448.3 million", "D": "$480 million", "E": "$500 million", "F": "$525.7 million"}, "LLM_original_answer": ["To answer the question regarding the required minimum net worth for PHH at December 31, 2023, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for specific mentions of PHH's minimum net worth requirements in the document.\n2. **Locate the Exact Value**: Find the exact value of the minimum net worth requirement for PHH as of December 31, 2023.\n3. **Match the Value to the Options**: Compare the identified value to the provided options to select the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document contains a section that discusses the financial requirements for PHH, including net worth and liquidity. This section is likely to contain the required minimum net worth for PHH.\n\n### Step 2: Locate the Exact Value\nIn the document, under the \"Covenants\" section, there is a specific mention of the minimum net worth requirement for PHH:\n\n> \"The most restrictive consolidated net worth requirement contained in our debt agreements with borrowings outstanding at December 31, 2023, excluding additional Agency minimum requirements, is a minimum of $ 275.0 million and $ 300.0 million tangible net worth for Ocwen and PHH, respectively.\"\n\nHowever, this is not the final answer. We need to check if there are any other mentions of PHH's minimum net worth requirements, especially in the context of regulatory requirements.\n\nIn the \"Regulatory Requirements\" section, there is another relevant piece of information:\n\n> \"The most restrictive of the various net worth and liquidity requirements for licensing and seller/servicer obligations referenced above are mostly based on the UPB of assets serviced by PHH. Under the applicable formula, the required minimum net worth was $ 448.3 million at December 31, 2023.\"\n\n### Step 3: Match the Value to the Options\nThe required minimum net worth for PHH at December 31, 2023, as stated in the document, is $448.3 million.\n\n### Conclusion\nThe correct answer is:\n**C: $448.3 million**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 64000, "result": 1.0, "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?", "options": {"A": "NYSE governance rules", "B": "SEC disclosure guidelines", "C": "Nasdaq governance rules", "D": "International Business Standards", "E": "U.S. Financial Regulations", "F": "Federal Trade Commission rules"}, "LLM_original_answer": ["The correct answer is **C: Nasdaq governance rules**.\n\n### Chain of Thought:\n1. **Identify the Requirement**: The question asks for the governance rule that requires a Code of Business Conduct and Ethics for directors, officers, and employees.\n2. **Review the Document**: The document mentions, \"We have adopted a Code of Business Conduct and Ethics for all of our directors, officers and employees as required by Nasdaq governance rules and as defined by applicable SEC rules.\"\n3. **Match the Requirement**: The document explicitly states that the Code of Business Conduct and Ethics is required by Nasdaq governance rules.\n4. **Consider Other Options**: The other options (NYSE governance rules, SEC disclosure guidelines, International Business Standards, U.S. Financial Regulations, Federal Trade Commission rules) are not mentioned in the document as requiring the Code of Business Conduct and Ethics.\n5. **Conclusion**: Based on the information provided in the document, the correct answer is C: Nasdaq governance rules."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 64000, "result": 1.0, "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?", "options": {"A": "The Chief Financial Officer", "B": "Independent registered public accounting firm", "C": "The undersigned, duly authorized person", "D": "The Secretary of the Board", "E": "The company's legal department", "F": "The external auditor"}, "LLM_original_answer": ["The correct answer to the question \"Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?\" is:\n\n**C: The undersigned, duly authorized person**\n\n### Chain of Thought:\n1. **Context of the Question**: The question is asking about the person responsible for signing the report on behalf of the registrant, which is a requirement under the Securities Exchange Act of 1934.\n\n2. **Review of the Document**: The document provided is extensive and covers various aspects of Amylyx Pharmaceuticals, Inc., including its business, financial condition, and regulatory compliance. However, it does not explicitly state who is responsible for signing the report on behalf of the registrant.\n\n3. **Relevant Section in the Document**: The closest relevant section is found in the \"SIGNATURES\" part of the document, which states:\n   - \"Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.\"\n\n4. **Interpretation**: The phrase \"the undersigned, thereunto duly authorized\" indicates that the person signing the report is someone who has been officially authorized to do so on behalf of the registrant. This is a standard legal phrase used in such contexts to denote a person who has the authority to sign the document.\n\n5. **Conclusion**: Based on the standard legal language used in the document, the person responsible for signing the report on behalf of the registrant is \"the undersigned, duly authorized person.\"\n\n### Elimination of Other Options:\n- **A: The Chief Financial Officer**: While the CFO is often involved in financial reporting, the document does not specify that the CFO is the one responsible for signing the report.\n- **B: Independent registered public accounting firm**: The accounting firm is responsible for auditing and providing an opinion on the financial statements, not for signing the report on behalf of the registrant.\n- **D: The Secretary of the Board**: The document does not mention the Secretary of the Board as the person responsible for signing the report.\n- **E: The company's legal department**: The legal department may provide legal advice and review, but the document does not specify that they are responsible for signing the report.\n- **F: The external auditor**: Similar to the independent registered public accounting firm, the"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 64000, "result": 1.0, "question": "Where can information about the 2024 election of directors be found?", "options": {"A": "In the company\u2019s financial statements", "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders", "C": "In the General Instruction G(3) of Form 10-K", "D": "Under the 'Executive Officers' section of the report", "E": "In the company's quarterly earnings report", "F": "In the 'Delinquent Section 16(a) Reports' section"}, "LLM_original_answer": ["The correct answer is **B: In the Proxy Statement for the 2024 Annual Meeting of Stockholders**.\n\n### Chain of Thought:\n1. **Review the Question**: The question asks where information about the 2024 election of directors can be found.\n2. **Identify Key Information**: The document mentions that information about the election of directors is typically found in the Proxy Statement for the Annual Meeting of Stockholders.\n3. **Locate Relevant Section**: In the document, under **Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE**, it states:\n   - \"Information relating to our Board of Directors set forth under the caption \u2018Proposal 1 \u2014 Election of Directors \u2014 Nominees for Election as Directors at the 2024 Annual Meeting\u2019 in our Proxy Statement for our 2024 Annual Meeting of Stockholders, or the 2024 Proxy Statement, is incorporated herein by reference.\"\n4. **Confirm the Answer**: This clearly indicates that the information about the 2024 election of directors is found in the Proxy Statement for the 2024 Annual Meeting of Stockholders.\n\nTherefore, the correct answer is **B: In the Proxy Statement for the 2024 Annual Meeting of Stockholders**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 64000, "result": 1.0, "question": "What framework did the Company use to establish criteria for internal control over financial reporting?", "options": {"A": "SOX Compliance Framework", "B": "ISO 9001 Standards", "C": "Internal Control \u2014 Integrated Framework (2013)", "D": "GAAP Standards", "E": "FASB Guidelines", "F": "IFRS Regulations"}, "LLM_original_answer": ["The correct answer is **C: Internal Control \u2014 Integrated Framework (2013)**.\n\n### Chain of Thought:\n1. **Identify the Context**: The question is asking about the framework used by the company to establish criteria for internal control over financial reporting.\n2. **Locate Relevant Information**: The document mentions the internal control framework in the section titled \"Item 8. Financial Statements and Supplementary Data\" and \"Item 9A. Controls and Procedures.\"\n3. **Extract Specific Information**:\n   - In the \"Report of Independent Registered Public Accounting Firm\" section, it states: \"We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company\u2019s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control \u2014 Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.\"\n   - In the \"Management\u2019s Annual Report on Internal Control Over Financial Reporting\" section, it states: \"Management has completed an assessment of the effectiveness of the Company\u2019s internal control over financial reporting as of December 31, 2023. In making the assessment, management used the criteria set forth in 'Internal Control - Integrated Framework' promulgated by the Committee of Sponsoring Organizations of the Treadway Commission.\"\n4. **Confirm the Framework**: Both sections clearly indicate that the company used the \"Internal Control \u2014 Integrated Framework (2013)\" issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) to establish criteria for internal control over financial reporting.\n5. **Match with Options**: The option that matches this information is C: Internal Control \u2014 Integrated Framework (2013).\n\nTherefore, the company used the **Internal Control \u2014 Integrated Framework (2013)** to establish criteria for internal control over financial reporting."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 96000, "result": 1.0, "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?", "options": {"A": "Cumulative voting rights", "B": "One vote per share without cumulative voting", "C": "Two votes per share", "D": "Preemptive voting rights", "E": "Redeemable voting rights", "F": "Convertible voting rights"}, "LLM_original_answer": ["Based on the provided document, the correct answer to the question \"What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?\" is:\n\n**B: One vote per share without cumulative voting**\n\n### Chain of Thought:\n1. **Document Review**: The document provided does not contain detailed information about the voting rights of common stockholders. However, it does mention the voting rights in a specific section.\n   \n2. **Relevant Section**: The relevant section is found in the \"Available Information\" part of the document, specifically under the \"Rights and Preferences\" of the holders of common stock.\n\n3. **Voting Rights Statement**: The document states: \"Voting Rights: Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under the Company's amended and restated certificate of incorporation and amended and restated bylaws, stockholders will not have cumulative voting rights.\"\n\n4. **Interpretation**:\n   - **One Vote per Share**: The document clearly states that each holder of common stock is entitled to one vote for each share.\n   - **No Cumulative Voting**: The document explicitly mentions that stockholders will not have cumulative voting rights.\n\n5. **Conclusion**: Given the information provided, the correct answer is that holders of common stock have one vote per share without cumulative voting.\n\nThus, the answer is **B: One vote per share without cumulative voting**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 96000, "result": 1.0, "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?", "options": {"A": "The candidate's previous employment history", "B": "The candidate's age and personal interests", "C": "A conflict of interest impacting their representation of stockholders", "D": "The candidate's educational background", "E": "The candidate's language proficiency", "F": "The candidate's geographical location"}, "LLM_original_answer": ["The correct answer to the question \"What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?\" is:\n\n**C: A conflict of interest impacting their representation of stockholders**\n\n### Chain of Thought:\n1. **Review the Document**: The document provides detailed information about the company, its operations, and governance structure, including the role and responsibilities of the Nominating and Corporate Governance Committee.\n2. **Identify Relevant Section**: The section that discusses the Nominating and Corporate Governance Committee is found under \"Item 13. Certain Relationships and Related Transactions, and Director Independence.\"\n3. **Extract Key Information**: The document states, \"The Nominating and Corporate Governance Committee also believes that candidates for director should not have, nor appear to have, a conflict of interest that would impair the candidate\u2019s ability to represent the interests of all the Company\u2019s stockholders and to fulfill the responsibilities of a director.\"\n4. **Match to Options**: This statement directly aligns with option C, which mentions a conflict of interest impacting their representation of stockholders.\n5. **Eliminate Other Options**:\n   - **A: The candidate's previous employment history** - The document does not mention this as a primary concern.\n   - **B: The candidate's age and personal interests** - The document does not mention age or personal interests as concerns.\n   - **D: The candidate's educational background** - The document does not mention educational background as a primary concern.\n   - **E: The candidate's language proficiency** - The document does not mention language proficiency as a concern.\n   - **F: The candidate's geographical location** - The document does not mention geographical location as a concern.\n\nTherefore, the Nominating and Corporate Governance Committee is primarily concerned with ensuring that director candidates do not have a conflict of interest that would impair their ability to represent the interests of all stockholders."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 96000, "result": 1.0, "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?", "options": {"A": "9.00%", "B": "7.50%", "C": "8.50%", "D": "6.00%", "E": "7.00%", "F": "5.50%"}, "LLM_original_answer": ["To answer the question regarding the long-term rate of return Duke Energy assumes for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023, I will follow these steps:\n\n1. **Identify the Relevant Section**: The document contains a section that discusses the assumptions used for pension benefits accounting, which is likely to include the long-term rate of return for the RCBP pension and RCBP 401(h) account assets.\n\n2. **Locate the Specific Information**: Within the \"Assumptions Used for Pension Benefits Accounting\" section, I will look for the specific rate of return mentioned for the RCBP pension and RCBP 401(h) account assets.\n\n3. **Verify the Date**: Ensure that the information is current as of December 31, 2023.\n\nLet's go through the document to find the relevant information:\n\n### Step 1: Identify the Relevant Section\nThe relevant section is found in \"Assumptions Used for Pension Benefits Accounting\" under \"Employee Benefit Plans\" (Note 23).\n\n### Step 2: Locate the Specific Information\nIn the \"Assumptions Used for Pension Benefits Accounting\" section, the following information is provided:\n- \"As of December 31, 2023, Duke Energy assumes qualified pension and other post-retirement plan assets will generate a long-term rate of return of 8.50% for the RCBP pension and RCBP 401(h) account assets and 7.00% for the DELPP pension and DELPP 401(h) account assets.\"\n\n### Step 3: Verify the Date\nThe information is explicitly stated as of December 31, 2023, which matches the date in the question.\n\n### Conclusion\nThe long-term rate of return Duke Energy assumes for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023, is 8.50%.\n\nTherefore, the correct answer is:\n**C: 8.50%**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 96000, "result": 1.0, "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?", "options": {"A": "2020", "B": "2021", "C": "2022", "D": "2023", "E": "2024", "F": "2025"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The document mentions the total original gain of $41.2 million, net of tax, in the \"Other Comprehensive Income\" section (Note 22).\n\n2. **Extract the key information**:\n   - The total original gain of $41.2 million, net of tax, became fully accreted into income during the year ended December 31, 2023.\n   - The balance of this gain had amortized to less than $0.1 million, and $7.4 million, net of tax, at December 31, 2022 and December 31, 2021, respectively.\n\n3. **Determine the year**:\n   - The document explicitly states that the total original gain of $41.2 million, net of tax, became fully accreted into income during the year ended December 31, 2023.\n\nBased on this information, the correct answer is:\n\n**D: 2023**"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 75, "token_lengths": 96000, "result": 1.0, "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?", "options": {"A": "No less than 120% of fair value per share", "B": "No less than 80% of fair value per share", "C": "No less than 110% of fair value per share", "D": "No less than 100% of fair value per share", "E": "Fixed amount regardless of fair value", "F": "No specific requirement"}, "LLM_original_answer": ["The provided document does not contain information about the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power. However, based on the information provided in the document, we can infer the correct answer from the section on stock-based compensation, which states:\n\n\"In the case of an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the total combined voting power of all classes of stock, the exercise price shall be no less than 110% of the fair value per share on the date of grant, and the award shall expire five years from the date of grant.\"\n\nGiven this information, the correct answer is:\n\nC: No less than 110% of fair value per share\n\nThis is the specific requirement for the exercise price of incentive stock options granted to employees who own more than 10% of the voting power."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 96000, "result": 1.0, "question": "What was the required minimum net worth for PHH at December 31, 2023?", "options": {"A": "$350 million", "B": "$420.5 million", "C": "$448.3 million", "D": "$480 million", "E": "$500 million", "F": "$525.7 million"}, "LLM_original_answer": ["To answer the question \"What was the required minimum net worth for PHH at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss financial requirements, particularly those related to PHH and the end of 2023.\n\n2. **Locate Specific Requirement**: Find the specific mention of the required minimum net worth for PHH as of December 31, 2023.\n\n3. **Verify the Information**: Ensure that the information is accurate and directly pertains to the required minimum net worth for PHH.\n\n### Step 1: Identify Relevant Information\nThe document contains a section under \"Note 24 \u2014 Regulatory Requirements\" that discusses the financial eligibility requirements for PHH as a GSE seller/servicer and Ginnie Mae issuer.\n\n### Step 2: Locate Specific Requirement\nIn the \"Note 24 \u2014 Regulatory Requirements\" section, the following table is provided:\n\n```plaintext\nPHH\u2019s minimum financial eligibility requirements for GSE seller/servicers and Ginnie Mae issuers were updated by the GSEs and Ginnie Mae effective September 30, 2023, including the following:\n##table 133##\nF-65\n```\n\nThis table includes the required minimum net worth for PHH. The relevant entry is:\n\n- **Required Minimum Net Worth**: $448.3 million\n\n### Step 3: Verify the Information\nThe document clearly states that the required minimum net worth for PHH as of December 31, 2023, was $448.3 million. This information is consistent with the regulatory requirements mentioned in the document.\n\n### Conclusion\nThe required minimum net worth for PHH at December 31, 2023, was **$448.3 million**.\n\nTherefore, the correct answer is:\n**C: $448.3 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 96000, "result": 1.0, "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?", "options": {"A": "NYSE governance rules", "B": "SEC disclosure guidelines", "C": "Nasdaq governance rules", "D": "International Business Standards", "E": "U.S. Financial Regulations", "F": "Federal Trade Commission rules"}, "LLM_original_answer": ["The correct answer is **C: Nasdaq governance rules**.\n\n### Chain of Thoughts:\n1. **Identify the Requirement**: The question asks for the governance rule that requires a Code of Business Conduct and Ethics for directors, officers, and employees.\n2. **Review the Document**: The document mentions that the company has adopted a Code of Business Conduct and Ethics for all of its directors, officers, and employees.\n3. **Find the Source**: The document specifically states, \"We have adopted a Code of Business Conduct and Ethics for all of our directors, officers and employees as required by Nasdaq governance rules and as defined by applicable SEC rules.\"\n4. **Match the Source to the Options**: Among the given options, only **C: Nasdaq governance rules** is mentioned as the source requiring the Code of Business Conduct and Ethics.\n5. **Confirm the Answer**: The document clearly indicates that the requirement is from Nasdaq governance rules, making it the correct answer.\n\nThus, the governance rule that requires a Code of Business Conduct and Ethics for directors, officers, and employees is **C: Nasdaq governance rules**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 96000, "result": 1.0, "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?", "options": {"A": "The Chief Financial Officer", "B": "Independent registered public accounting firm", "C": "The undersigned, duly authorized person", "D": "The Secretary of the Board", "E": "The company's legal department", "F": "The external auditor"}, "LLM_original_answer": ["The correct answer to the question \"Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?\" is:\n\n**C: The undersigned, duly authorized person**\n\n### Chain of Thought:\n1. **Review of the Document**:\n   - The document provided is an annual report for Amylyx Pharmaceuticals, Inc.\n   - It includes a section where the report is signed on behalf of the Registrant.\n\n2. **Relevant Section**:\n   - The relevant section is found at the end of the document, specifically in the \"SIGNATURES\" section.\n   - The section states: \"Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.\"\n\n3. **Interpretation**:\n   - The phrase \"the undersigned, thereunto duly authorized\" indicates that the person signing the report is authorized to do so on behalf of the Registrant.\n   - This aligns with the general requirement under the Securities Exchange Act of 1934 that a report must be signed by a person who is duly authorized to represent the company.\n\n4. **Options Analysis**:\n   - **A: The Chief Financial Officer** - While the CFO is often involved in financial reporting, the document does not specify that the CFO is the only person authorized to sign the report.\n   - **B: Independent registered public accounting firm** - The accounting firm audits the financial statements but does not sign the report on behalf of the Registrant.\n   - **C: The undersigned, duly authorized person** - This matches the language used in the document.\n   - **D: The Secretary of the Board** - The document does not mention the Secretary of the Board as the person signing the report.\n   - **E: The company's legal department** - The legal department may be involved in preparing the report, but the document does not specify that they sign it.\n   - **F: The external auditor** - Similar to the independent registered public accounting firm, the external auditor audits the financial statements but does not sign the report.\n\n5. **Conclusion**:\n   - Based on the language in the document and the options provided, the correct answer is **C: The undersigned, duly authorized person**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 96000, "result": 1.0, "question": "Where can information about the 2024 election of directors be found?", "options": {"A": "In the company\u2019s financial statements", "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders", "C": "In the General Instruction G(3) of Form 10-K", "D": "Under the 'Executive Officers' section of the report", "E": "In the company's quarterly earnings report", "F": "In the 'Delinquent Section 16(a) Reports' section"}, "LLM_original_answer": ["To answer the question \"Where can information about the 2024 election of directors be found?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that mention the election of directors or the 2024 Annual Meeting of Stockholders.\n2. **Check for Specific References**: Within those sections, check for specific references to the 2024 Proxy Statement or any other document that might contain the relevant information.\n3. **Review the Document Structure**: Ensure that the identified section is the most appropriate and relevant to the question.\n\n### Step 1: Identify Relevant Sections\n- **Item 10. Directors, Executive Officers and Corporate Governance**: This section is likely to contain information about the election of directors.\n- **Item 16. Form 10-K Summary**: This section might provide a summary or reference to where the detailed information can be found.\n\n### Step 2: Check for Specific References\n- **Item 10. Directors, Executive Officers and Corporate Governance**:\n  - The document states: \"Information relating to our Board of Directors set forth under the caption \u2018Proposal 1 \u2014 Election of Directors \u2014 Nominees for Election as Directors at the 2024 Annual Meeting\u2019 in our Proxy Statement for our 2024 Annual Meeting of Stockholders, or the 2024 Proxy Statement, is incorporated herein by reference.\"\n\n### Step 3: Review the Document Structure\n- The reference in Item 10 is clear and specific, indicating that the detailed information about the 2024 election of directors is found in the 2024 Proxy Statement.\n\n### Conclusion\nThe correct answer is:\n**B: In the Proxy Statement for the 2024 Annual Meeting of Stockholders**\n\nThis is because the document explicitly states that the information about the election of directors for the 2024 Annual Meeting is found in the 2024 Proxy Statement."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 96000, "result": 1.0, "question": "What framework did the Company use to establish criteria for internal control over financial reporting?", "options": {"A": "SOX Compliance Framework", "B": "ISO 9001 Standards", "C": "Internal Control \u2014 Integrated Framework (2013)", "D": "GAAP Standards", "E": "FASB Guidelines", "F": "IFRS Regulations"}, "LLM_original_answer": ["To answer the question, \"What framework did the Company use to establish criteria for internal control over financial reporting?\" we need to identify the relevant information from the provided document. Here's the step-by-step reasoning:\n\n1. **Identify the Company**: The document is about Brighthouse Financial, Inc. and its subsidiaries.\n\n2. **Locate Information on Internal Control**: We need to find sections that discuss the internal control over financial reporting. This information is typically found in the \"Controls and Procedures\" or \"Management\u2019s Annual Report on Internal Control Over Financial Reporting\" sections.\n\n3. **Relevant Section**: The relevant section is found in \"Item 9A. Controls and Procedures\" and \"Management\u2019s Annual Report on Internal Control Over Financial Reporting\" in \"Item 9B. Other Information.\"\n\n4. **Extract the Framework Information**:\n   - From \"Item 9A. Controls and Procedures\":\n     - \"Management, with the participation of the Chief Executive Officer and the Chief Financial Officer, has evaluated the effectiveness of the design and operation of the Company\u2019s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report.\"\n   - From \"Management\u2019s Annual Report on Internal Control Over Financial Reporting\":\n     - \"Management of Brighthouse Financial, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of control procedures. The objectives of internal control include providing management with reasonable, but not absolute, assurance that assets are safeguarded against loss from unauthorized use or disposition, and that transactions are executed in accordance with management\u2019s authorization and recorded properly to permit the preparation of consolidated financial statements in conformity with GAAP.\"\n     - \"Management has completed an assessment of the effectiveness of the Company\u2019s internal control over financial reporting as of December 31, 2023. In making the assessment, management used the criteria set forth in 'Internal Control - Integrated Framework' promulgated by the Committee of Sponsoring Organizations of the Treadway Commission.\"\n\n5. **Determine the Framework**:\n   - The document explicitly states that the criteria used for the assessment of internal control over financial reporting are set forth in \"Internal Control - Integrated Framework\" promulgated by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).\n\n6."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 128000, "result": 1.0, "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?", "options": {"A": "Cumulative voting rights", "B": "One vote per share without cumulative voting", "C": "Two votes per share", "D": "Preemptive voting rights", "E": "Redeemable voting rights", "F": "Convertible voting rights"}, "LLM_original_answer": ["The correct answer to the question \"What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?\" is:\n\n**B: One vote per share without cumulative voting**\n\n### Chain of Thought:\n1. **Identify the Relevant Information**: The document provides a summary of the rights and privileges of the holders of common stock as of December 31, 2023.\n2. **Locate the Specific Voting Rights Information**: The relevant section states: \"Voting Rights: Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors.\"\n3. **Understand the Voting Rights**: This statement clearly indicates that each share of common stock carries one vote.\n4. **Check for Cumulative Voting**: The document also mentions: \"Under the Company's amended and restated certificate of incorporation and amended and restated bylaws, stockholders will not have cumulative voting rights.\"\n5. **Conclusion**: Combining these two pieces of information, it is clear that holders of common stock have one vote per share without cumulative voting.\n\nThus, the correct answer is **B: One vote per share without cumulative voting**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 128000, "result": 1.0, "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?", "options": {"A": "The candidate's previous employment history", "B": "The candidate's age and personal interests", "C": "A conflict of interest impacting their representation of stockholders", "D": "The candidate's educational background", "E": "The candidate's language proficiency", "F": "The candidate's geographical location"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 128000, "result": 0.0, "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?", "options": {"A": "9.00%", "B": "7.50%", "C": "8.50%", "D": "6.00%", "E": "7.00%", "F": "5.50%"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 128000, "result": 0.0, "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?", "options": {"A": "2020", "B": "2021", "C": "2022", "D": "2023", "E": "2024", "F": "2025"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["!"], "ground_truth": "D"}, {"depth": 75, "token_lengths": 128000, "result": 1.0, "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?", "options": {"A": "No less than 120% of fair value per share", "B": "No less than 80% of fair value per share", "C": "No less than 110% of fair value per share", "D": "No less than 100% of fair value per share", "E": "Fixed amount regardless of fair value", "F": "No specific requirement"}, "LLM_original_answer": ["The provided document does not contain information about the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power. However, based on general knowledge and the options provided, the correct answer is:\n\n**C: No less than 110% of fair value per share**\n\nThis is a common requirement for incentive stock options (ISOs) granted to employees who own more than 10% of the voting power of the company. The exercise price for such options must be at least 110% of the fair market value of the stock on the date of grant to comply with IRS regulations. This higher requirement is intended to prevent potential abuse and ensure that the options are granted at a fair price."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 128000, "result": 0.0, "question": "What was the required minimum net worth for PHH at December 31, 2023?", "options": {"A": "$350 million", "B": "$420.5 million", "C": "$448.3 million", "D": "$480 million", "E": "$500 million", "F": "$525.7 million"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 128000, "result": 1.0, "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?", "options": {"A": "NYSE governance rules", "B": "SEC disclosure guidelines", "C": "Nasdaq governance rules", "D": "International Business Standards", "E": "U.S. Financial Regulations", "F": "Federal Trade Commission rules"}, "LLM_original_answer": ["The correct answer to the question \"What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?\" is:\n\n**A: NYSE governance rules**\n\n### Chain of Thoughts:\n1. **Context of the Question**: The question is asking about a governance rule that mandates a Code of Business Conduct and Ethics for directors, officers, and employees.\n2. **Review of the Document**: The document provided is extensive and covers various aspects of TScan Therapeutics, Inc., including its business, financials, and regulatory environment. However, it also includes a section on governance.\n3. **Relevant Section**: In the \"Governance\" section, it states: \"We have adopted a Code of Business Conduct and Ethics for all of our directors, officers and employees as required by Nasdaq governance rules and as defined by applicable SEC rules.\"\n4. **Analysis"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 128000, "result": 1.0, "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?", "options": {"A": "The Chief Financial Officer", "B": "Independent registered public accounting firm", "C": "The undersigned, duly authorized person", "D": "The Secretary of the Board", "E": "The company's legal department", "F": "The external auditor"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 75, "token_lengths": 128000, "result": 1.0, "question": "Where can information about the 2024 election of directors be found?", "options": {"A": "In the company\u2019s financial statements", "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders", "C": "In the General Instruction G(3) of Form 10-K", "D": "Under the 'Executive Officers' section of the report", "E": "In the company's quarterly earnings report", "F": "In the 'Delinquent Section 16(a) Reports' section"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 75, "token_lengths": 128000, "result": 1.0, "question": "What framework did the Company use to establish criteria for internal control over financial reporting?", "options": {"A": "SOX Compliance Framework", "B": "ISO 9001 Standards", "C": "Internal Control \u2014 Integrated Framework (2013)", "D": "GAAP Standards", "E": "FASB Guidelines", "F": "IFRS Regulations"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 8000, "result": 1.0, "question": "What happens if the lender makes a margin call and the borrower cannot fund it?", "options": {"A": "The borrower can delay payment without consequences", "B": "The lender must forgive the outstanding debt", "C": "The lender is contractually allowed to liquidate MSRs", "D": "The borrower must immediately pay off all outstanding debts", "E": "The lender cannot take any action", "F": "The borrower can negotiate new terms"}, "LLM_original_answer": ["To answer the question \"What happens if the lender makes a margin call and the borrower cannot fund it?\" based on the provided document, I will analyze the relevant sections step by step.\n\n1. **Understanding Margin Calls**:\n   - The document mentions that repurchase agreements and loan and security agreements include margin call provisions. These provisions require the borrower to maintain borrowings at a specified percentage of the fair value of the assets pledged to secure the borrowings.\n   - If the fair value of the pledged assets decreases, the lender may issue a margin call, requiring the borrower to either provide additional collateral or repay a portion of the borrowings.\n\n2. **Consequences of Not Funding a Margin Call**:\n   - The document explicitly states: \"We are exposed to loss in the event a lender makes a margin call to us and we are unable to fund the margin call. In such a circumstance, the lender is contractually allowed to liquidate the assets securing the repurchase agreement and pursue repayment from us for any balance not satisfied through the sale of the collateral.\"\n   - This statement is repeated in the context of both repurchase agreements and loan and security agreements, indicating that the consequences are consistent across these types of financing.\n\n3. **Evaluating the Options**:\n   - **Option A**: The borrower can delay payment without consequences. This is not supported by the document, as it clearly states that the lender can take action if the margin call is not funded.\n   - **Option B**: The lender must forgive the outstanding debt. This is not supported by the document, as there is no mention of the lender being required to forgive the debt.\n   - **Option C**: The lender is contractually allowed to liquidate MSRs. This is supported by the document, which states that the lender can liquidate the assets securing the repurchase agreement or the MSRs securing the loan and security agreements.\n   - **Option D**: The borrower must immediately pay off all outstanding debts. This is not explicitly stated in the document. The document only mentions that the borrower must fund the margin call, not necessarily pay off all outstanding debts.\n   - **Option E**: The lender cannot take any action. This is contradicted by the document, which states that the lender can liquidate the assets and pursue repayment.\n   - **Option F**: The borrower can negotiate new terms. This is not supported by the document, as it does not mention the possibility of negotiating new terms in the event of a margin call.\n\nBased on the analysis, the correct answer"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 8000, "result": 1.0, "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?", "options": {"A": "$6.81", "B": "$0.01", "C": "$8.72", "D": "$10.00", "E": "$5.50", "F": "$7.50"}, "LLM_original_answer": ["To answer the question \"What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that specifically mentions the exercise price for Tranche 1 Warrants. This section is found in the \"Outstanding Equity Awards at Fiscal Year-End of 2023\" part of the document.\n\n2. **Extract the information**: The relevant sentence from the document is:\n   - \"Includes shares issuable upon the exercise of Tranche 1 Warrants, which entitle the holder to purchase one share of Core Common Stock at an exercise price of $6.81 per share.\"\n\n3. **Match the information to the options**: The exercise price mentioned in the document is $6.81 per share.\n\n4. **Select the correct answer**: The correct answer is option A: $6.81.\n\nTherefore, the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock is **$6.81**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 80, "token_lengths": 8000, "result": 1.0, "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?", "options": {"A": "Duke Energy Carolinas, LLC", "B": "Duke Energy Progress, LLC", "C": "Progress Energy, Inc.", "D": "Piedmont Natural Gas Company, Inc.", "E": "Duke Energy Florida, LLC", "F": "All of the above"}, "LLM_original_answer": ["To answer the question, we need to identify which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities. Let's break down the information provided in the document:\n\n1. **Duke Energy Corporation Master Retirement Trust**:\n   - The document discusses the Duke Energy Corporation Master Retirement Trust, which is a trust that manages retirement assets for Duke Energy and its subsidiaries.\n   - It mentions that the assets of the trust are allocated to various subsidiaries, including Duke Energy Carolinas, Progress Energy, Duke Energy Progress, Duke Energy Florida, Duke Energy Ohio, Duke Energy Indiana, and Piedmont.\n\n2. **Subsidiary Registrants**:\n   - The document refers to \"Subsidiary Registrants\" multiple times, which include Duke Energy Carolinas, Progress Energy, Duke Energy Progress, Duke Energy Florida, Duke Energy Ohio, Duke Energy Indiana, and Piedmont.\n   - These subsidiaries are allocated a proportionate share of the assets from the Duke Energy Corporation Master Retirement Trust.\n\n3. **Consolidated Financial Statements**:\n   - The document does not explicitly state which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities.\n   - However, it is implied that the consolidated financial statements of Duke Energy Corporation, the parent company, would include the financial information of all its subsidiaries, including the statement of comprehensive income.\n\n4. **Options Analysis**:\n   - **Option A: Duke Energy Carolinas, LLC** - This is a subsidiary of Duke Energy Corporation.\n   - **Option B: Duke Energy Progress, LLC** - This is also a subsidiary of Duke Energy Corporation.\n   - **Option C: Progress Energy, Inc.** - This is a subsidiary of Duke Energy Corporation.\n   - **Option D: Piedmont Natural Gas Company, Inc.** - This is a subsidiary of Duke Energy Corporation.\n   - **Option E: Duke Energy Florida, LLC** - This is a subsidiary of Duke Energy Corporation.\n   - **Option F: All of the above** - This option suggests that all the listed subsidiaries are included in the consolidated financial statements.\n\nGiven that the document discusses the allocation of assets to various subsidiaries and the management of these assets by the Duke Energy Corporation Master Retirement Trust, it is reasonable to conclude that the consolidated financial statements of Duke Energy Corporation, the parent company, would include the financial information of all its subsidiaries, including the statement of comprehensive income.\n\nTherefore, the correct answer is:\n\n**F: All of the above**\n\nThis is because the consolidated financial statements of Duke"], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 8000, "result": 1.0, "question": "What type of businesses does Business Markets and Other primarily serve?", "options": {"A": "Public Sector and Enterprise", "B": "Businesses that meet Enterprise requirements", "C": "Businesses that meet Public Sector requirements", "D": "Businesses not meeting Enterprise and Public Sector requirements", "E": "Only IoT companies", "F": "Only conferencing service providers"}, "LLM_original_answer": ["To answer the question \"What type of businesses does Business Markets and Other primarily serve?\" based on the provided document, I will analyze the relevant section:\n\n### Relevant Section:\n**Business Markets and Other**\n- **Offers wireless services and equipment, conferencing services, tailored voice and networking products, Fios services, advanced voice solutions, and security services to businesses that ordinarily do not meet the requirements to be categorized as Enterprise and Public Sector, as described above.**\n- **Includes solutions that support mobile resource management.**\n- **In 2023, Business Markets and Other revenues were $12.7 billion, representing approximately 42% of Business\u2019s total revenues.**\n- **Provides fixed connectivity solutions comparable to the residential fixed services provided by Consumer, as well as business services and connectivity similar to the products and services offered by Global Enterprise, in each case with features and pricing designed to address the needs of small and medium businesses.**\n\n### Analysis:\n1. **Primary Customers**:\n   - The document explicitly states that Business Markets and Other serves \"businesses that ordinarily do not meet the requirements to be categorized as Enterprise and Public Sector.\"\n   - This indicates that the primary customers are businesses that are not large enough to be considered Enterprise or do not have the specific requirements of the Public Sector.\n\n2. **Types of Services**:\n   - The services offered include wireless services and equipment, conferencing services, tailored voice and networking products, Fios services, advanced voice solutions, and security services.\n   - These services are designed to meet the needs of small and medium businesses.\n\n3. **Comparison to Other Segments**:\n   - The document mentions that the services provided by Business Markets and Other are similar to those offered by the Consumer segment but tailored for business needs.\n   - It also mentions that the services are similar to those offered by Global Enterprise, but again, designed for smaller businesses.\n\n### Conclusion:\nBased on the analysis, the type of businesses that Business Markets and Other primarily serves are those that do not meet the requirements to be categorized as Enterprise and Public Sector. This aligns with the description of small and medium businesses.\n\n### Answer:\nThe correct option is **D: Businesses not meeting Enterprise and Public Sector requirements**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 80, "token_lengths": 8000, "result": 1.0, "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?", "options": {"A": "Product quality and reliability", "B": "Technological capabilities", "C": "Marketing strategies", "D": "Cost-effectiveness", "E": "Industry experience", "F": "Vendor financing"}, "LLM_original_answer": ["To answer the question, I will carefully review the competitive factors mentioned in the document and compare them with the options provided.\n\n### Step 1: Identify the Competitive Factors Mentioned in the Document\nThe document states:\n> \"Competitive factors in these markets include product quality and reliability, technological capabilities, cost-effectiveness and industry experience.\"\n\n### Step 2: List the Options and Compare\nLet's list the options and see which ones are mentioned in the document:\n- **A: Product quality and reliability** - Mentioned.\n- **B: Technological capabilities** - Mentioned.\n- **C: Marketing strategies** - Not mentioned.\n- **D: Cost-effectiveness** - Mentioned.\n- **E: Industry experience** - Mentioned.\n- **F: Vendor financing** - Not mentioned.\n\n### Step 3: Determine the Factor Not Mentioned\nFrom the comparison, the factors that are not mentioned in the document are:\n- **C: Marketing strategies**\n- **F: Vendor financing**\n\n### Step 4: Select the Correct Answer\nSince the question asks for the factor that is NOT mentioned, and both \"Marketing strategies\" and \"Vendor financing\" are not mentioned, we need to choose the one that is listed as an option.\n\nThe correct answer is:\n- **C: Marketing strategies**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 8000, "result": 1.0, "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?", "options": {"A": "$20.7 million UPB (154 loans)", "B": "$66.7 million UPB (71 loans)", "C": "$20.7 million UPB (354 loans)", "D": "$66.7 million UPB (154 loans)", "E": "$66.7 million UPB (71 loans)", "F": "$20.7 million UPB (71 loans)"}, "LLM_original_answer": ["To answer the question \"What is the total outstanding representation and warranty repurchase demands at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the outstanding representation and warranty repurchase demands in the \"Loan Put-Back and Related Contingencies\" section.\n\n2. **Extract the specific information**: The relevant sentence states, \"At December 31, 2023 and 2022, we had outstanding representation and warranty repurchase demands of $ 20.7 million UPB ( 71 loans) and $ 66.7 million UPB ( 354 loans), respectively.\"\n\n3. **Match the information to the options**:\n   - The total outstanding representation and warranty repurchase demands at December 31, 2023 are $20.7 million UPB (71 loans).\n   - The options provided are:\n     - A: $20.7 million UPB (154 loans)\n     - B: $66.7 million UPB (71 loans)\n     - C: $20.7 million UPB (354 loans)\n     - D: $66.7 million UPB (154 loans)\n     - E: $66.7 million UPB (71 loans)\n     - F: $20.7 million UPB (71 loans)\n\n4. **Select the correct option**: The correct option is F: $20.7 million UPB (71 loans).\n\nTherefore, the answer to the question is **F: $20.7 million UPB (71 loans)**."], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 8000, "result": 1.0, "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?", "options": {"A": "Kansas City and Sioux City", "B": "Des Moines and Minneapolis", "C": "Springfield and St. Louis", "D": "Northwest Arkansas and Eastern Iowa", "E": "Sioux City and Des Moines", "F": "Rural markets in Missouri and Kansas"}, "LLM_original_answer": ["To answer the question \"Where are the two largest deposit concentrations of the Company located as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Company**: The document mentions that the company in question is Great Southern Bancorp, Inc., which operates through Great Southern Bank.\n\n2. **Locate Deposit Information**: The document provides specific deposit information for different states and market areas as of December 31, 2023.\n\n3. **Extract Relevant Data**:\n   - **Missouri**: Total deposits of $3.48 billion.\n     - **Springfield, Missouri**: $1.95 billion.\n     - **St. Louis, Missouri**: $588 million.\n   - **Iowa**: Total deposits of $696 million.\n     - **Sioux City, Iowa**: Not specified.\n     - **Des Moines, Iowa**: Not specified.\n     - **Eastern Iowa (Quad Cities)**: Not specified.\n   - **Kansas**: Total deposits of $339 million.\n   - **Minnesota**: Total deposits of $149 million.\n   - **Nebraska**: Total deposits of $22 million.\n   - **Arkansas**: Total deposits of $34 million.\n\n4. **Determine the Two Largest Concentrations**:\n   - The largest concentration is in **Springfield, Missouri** with $1.95 billion.\n   - The second largest concentration is in **St. Louis, Missouri** with $588 million.\n\n5. **Match with Provided Options**:\n   - **Option A**: Kansas City and Sioux City\n   - **Option B**: Des Moines and Minneapolis\n   - **Option C**: Springfield and St. Louis\n   - **Option D**: Northwest Arkansas and Eastern Iowa\n   - **Option E**: Sioux City and Des Moines\n   - **Option F**: Rural markets in Missouri and Kansas\n\nBased on the data extracted from the document, the two largest deposit concentrations are in **Springfield, Missouri** and **St. Louis, Missouri**.\n\nTherefore, the correct answer is **Option C: Springfield and St. Louis**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 8000, "result": 1.0, "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?", "options": {"A": "Two directors", "B": "Three directors", "C": "Four directors", "D": "Five directors", "E": "Six directors", "F": "Seven directors"}, "LLM_original_answer": ["To answer the question \"How many directors are in each class of the QTI Holdings Board following the Effective Time?\", I will analyze the relevant information provided in the document.\n\n1. **Identify the relevant section**: The document mentions the composition of the QTI Holdings Board in the section discussing the business combination and the Effective Time.\n\n2. **Extract the key information**:\n   - The document states: \"Following the Effective Time, the board of directors of QT Imaging Holdings (the \u201cQTI Holdings Board\u201d) consists of seven directors classified in three classes, the initial members of which (the \u201cInitial Post-Closing QTI Holdings Directors\u201d) consisted of three individuals identified by GigCapital5 who will serve either in Class I, Class II or Class III, and included the chairman of the QTI Holdings Board, and three individuals identified by QT Imaging who will serve either in Class I, Class II or Class III, and one more board seat was filled by the GigCapital5 Board prior to Closing.\"\n\n3. **Determine the number of directors in each class**:\n   - The QTI Holdings Board consists of seven directors.\n   - These seven directors are classified into three classes.\n   - Three individuals are identified by GigCapital5 and will serve in Class I, Class II, or Class III.\n   - Three individuals are identified by QT Imaging and will serve in Class I, Class II, or Class III.\n   - One more board seat was filled by the GigCapital5 Board prior to Closing.\n\n4. **Calculate the distribution**:\n   - Since there are seven directors and three classes, and the document does not specify that any class has more or fewer directors than the others, we can assume that the directors are distributed as evenly as possible among the three classes.\n   - Dividing seven directors by three classes gives us approximately 2.33 directors per class. However, since the number of directors must be a whole number, the distribution must be 2 directors in two classes and 3 directors in one class.\n\n5. **Conclusion**:\n   - The document does not explicitly state the exact distribution of directors among the classes, but it implies that the distribution is as even as possible.\n   - Given the options provided, the most reasonable and consistent answer is that one class has 3 directors, and the other two classes have 2 directors each.\n\nTherefore, the correct answer is **B: Three directors**. This is the only option that fits the distribution of seven directors across three classes."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 80, "token_lengths": 8000, "result": 1.0, "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?", "options": {"A": "RMB0.8 million", "B": "RMB1.0 million", "C": "RMB1.3 million", "D": "RMB1.5 million", "E": "RMB1.8 million", "F": "RMB2.0 million"}, "LLM_original_answer": ["To answer the question \"What is the average capital spending for a new Pizza Hut restaurant unit in 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document contains a section that discusses the average capital spending for new restaurant units. This section is found under \"Expansion Management.\"\n\n2. **Extract the specific information**: The relevant sentence from the \"Expansion Management\" section states:\n   - \"As we are opening more smaller format stores and actively managing costs, the average capital spending for each new KFC and Pizza Hut restaurant unit in 2023 was approximately RMB1.5 million and 1.3 million, respectively.\"\n\n3. **Determine the average capital spending for Pizza Hut**: According to the extracted information, the average capital spending for a new Pizza Hut restaurant unit in 2023 was approximately RMB1.3 million.\n\n4. **Match the information to the given options**:\n   - A: RMB0.8 million\n   - B: RMB1.0 million\n   - C: RMB1.3 million\n   - D: RMB1.5 million\n   - E: RMB1.8 million\n   - F: RMB2.0 million\n\n5. **Select the correct option**: The correct option that matches the average capital spending for a new Pizza Hut restaurant unit in 2023 is C: RMB1.3 million.\n\nTherefore, the answer to the question is **C: RMB1.3 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 8000, "result": 1.0, "question": "What is a potential consequence of failing to effectively manage company growth?", "options": {"A": "Improved financial condition", "B": "Enhanced employee morale", "C": "Improved forecasting accuracy", "D": "Adverse effects on business operations", "E": "Increased employee retention", "F": "Greater operational efficiency"}, "LLM_original_answer": ["To answer the question \"What is a potential consequence of failing to effectively manage company growth?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Growth and Expansion**:\n   - The document mentions that the company has expanded its product portfolio, now offering 37 free and 135 paid products across 11 primary customer-facing brands.\n   - The company has also grown its team to 79 editors and analysts, and has a total of 584 employees as of December 31, 2023.\n\n2. **Challenges of Growth**:\n   - The document explicitly states, \"If we fail to effectively manage our growth, our efficiency, ability to meet our forecasts, and employee morale, productivity, and retention could suffer, and our business, results of operations, and financial condition could be adversely affected.\"\n\n3. **Specific Consequences**:\n   - **Efficiency**: The company's ability to operate efficiently could be compromised.\n   - **Forecasting Accuracy**: The company's ability to meet its forecasts could be negatively impacted.\n   - **Employee Morale, Productivity, and Retention**: These could all suffer, leading to potential issues with maintaining a skilled and motivated workforce.\n   - **Business Operations**: The overall business operations could be adversely affected.\n\n4. **Evaluating the Options**:\n   - **A: Improved financial condition** - This is not a potential consequence of failing to manage growth effectively; it is the opposite.\n   - **B: Enhanced employee morale** - This is also not a potential consequence of failing to manage growth effectively; it is the opposite.\n   - **C: Improved forecasting accuracy** - This is not a potential consequence of failing to manage growth effectively; it is the opposite.\n   - **D: Adverse effects on business operations** - This aligns with the document's statement about the potential adverse effects on business operations.\n   - **E: Increased employee retention** - This is not a potential consequence of failing to manage growth effectively; it is the opposite.\n   - **F: Greater operational efficiency** - This is not a potential consequence of failing to manage growth effectively; it is the opposite.\n\nGiven the analysis, the correct answer is:\n\n**D: Adverse effects on business operations**\n\nThis option directly corresponds to the potential negative impacts mentioned in the document, such as reduced efficiency, difficulty in meeting forecasts, and issues with employee morale, productivity, and retention, all of which can lead"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 80, "token_lengths": 16000, "result": 1.0, "question": "What happens if the lender makes a margin call and the borrower cannot fund it?", "options": {"A": "The borrower can delay payment without consequences", "B": "The lender must forgive the outstanding debt", "C": "The lender is contractually allowed to liquidate MSRs", "D": "The borrower must immediately pay off all outstanding debts", "E": "The lender cannot take any action", "F": "The borrower can negotiate new terms"}, "LLM_original_answer": ["The document provided does not contain specific information about what happens if a lender makes a margin call and the borrower cannot fund it. However, based on the general information provided in the \"Financing\" section, particularly under \"Sales of assets under agreements to repurchase\" and \"Loan and security agreements,\" we can infer the following:\n\n1. **Margin Call Provisions**: The repurchase agreements and loan and security agreements typically contain margin call provisions. These provisions require the borrower to maintain a specified percentage of the fair value of the assets pledged to secure the borrowings.\n\n2. **Consequences of Not Funding a Margin Call**: If the borrower is unable to fund a margin call, the lender is contractually allowed to liquidate the assets securing the repurchase agreement or the loan and security agreement. The lender can then pursue repayment from the borrower for any balance not satisfied through the sale of the collateral.\n\nGiven this information, the correct answer to the question \"What happens if the lender makes a margin call and the borrower cannot fund it?\" is:\n\n**C: The lender is contractually allowed to liquidate MSRs**\n\nThis is the most accurate option based on the information provided in the document. The lender has the contractual right to liquidate the assets (including MSRs) securing the borrowings if the borrower cannot meet the margin call."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 16000, "result": 1.0, "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?", "options": {"A": "$6.81", "B": "$0.01", "C": "$8.72", "D": "$10.00", "E": "$5.50", "F": "$7.50"}, "LLM_original_answer": ["To answer the question \"What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that discusses the ownership of the company's common stock, including information about Tranche 1 Warrants and Tranche 2 Warrants.\n\n2. **Locate the specific information about Tranche 1 Warrants**: In the \"Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters\" section, there is a note that provides the exercise price for Tranche 1 Warrants.\n\n3. **Extract the exercise price**: The note states, \"Includes shares issuable upon the exercise of Tranche 1 Warrants, which entitle the holder to purchase one share of Core Common Stock at an exercise price of $6.81 per share.\"\n\n4. **Match the extracted information with the given options**: The exercise price of $6.81 per share matches option A.\n\nTherefore, the correct answer is:\n\n**A: $6.81**"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 80, "token_lengths": 16000, "result": 1.0, "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?", "options": {"A": "Duke Energy Carolinas, LLC", "B": "Duke Energy Progress, LLC", "C": "Progress Energy, Inc.", "D": "Piedmont Natural Gas Company, Inc.", "E": "Duke Energy Florida, LLC", "F": "All of the above"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step:\n\n1. **Identify the Context**: The question asks which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities.\n\n2. **Review the Document**: The document provides detailed financial and operational information about Duke Energy and its subsidiaries. It includes sections on revenue recognition, severance benefits, stock-based compensation, and other financial statements.\n\n3. **Locate Relevant Information**: The document lists the consolidated financial statements for various Duke Energy entities. Specifically, it mentions the following entities and their financial statements:\n   - **Duke Energy Corporation**: Includes Consolidated Statements of Operations and Comprehensive Income.\n   - **Duke Energy Carolinas, LLC**: Includes Consolidated Statements of Operations and Comprehensive Income.\n   - **Progress Energy, Inc.**: Includes Consolidated Statements of Operations and Comprehensive Income.\n   - **Duke Energy Progress, LLC**: Includes Consolidated Statements of Operations and Comprehensive Income.\n   - **Duke Energy Florida, LLC**: Includes Consolidated Statements of Operations and Comprehensive Income.\n   - **Duke Energy Ohio, Inc.**: Includes Consolidated Statements of Operations and Comprehensive Income.\n   - **Duke Energy Indiana, LLC**: Includes Consolidated Statements of Operations and Comprehensive Income.\n   - **Piedmont Natural Gas Company, Inc.**: Includes Consolidated Statements of Operations and Comprehensive Income.\n\n4. **Evaluate the Options**:\n   - **Option A: Duke Energy Carolinas, LLC**: The document confirms that Duke Energy Carolinas, LLC includes a statement of comprehensive income.\n   - **Option B: Duke Energy Progress, LLC**: The document confirms that Duke Energy Progress, LLC includes a statement of comprehensive income.\n   - **Option C: Progress Energy, Inc.**: The document confirms that Progress Energy, Inc. includes a statement of comprehensive income.\n   - **Option D: Piedmont Natural Gas Company, Inc.**: The document confirms that Piedmont Natural Gas Company, Inc. includes a statement of comprehensive income.\n   - **Option E: Duke Energy Florida, LLC**: The document confirms that Duke Energy Florida, LLC includes a statement of comprehensive income.\n   - **Option F: All of the above**: Since all the listed entities (A, B, C, D, E) are confirmed to include a statement of comprehensive income, this option is correct.\n\n5. **Conclusion**: Based on the information provided in the document, the correct answer is **F: All of the above**. Each of the listed Duke Energy entities"], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 16000, "result": 1.0, "question": "What type of businesses does Business Markets and Other primarily serve?", "options": {"A": "Public Sector and Enterprise", "B": "Businesses that meet Enterprise requirements", "C": "Businesses that meet Public Sector requirements", "D": "Businesses not meeting Enterprise and Public Sector requirements", "E": "Only IoT companies", "F": "Only conferencing service providers"}, "LLM_original_answer": ["To answer the question \"What type of businesses does Business Markets and Other primarily serve?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the Business Markets and Other segment is found in the \"Verizon Business Group\" part of the document.\n\n2. **Extract the key information**: The document states:\n   - \"Business Markets and Other offers wireless services and equipment, conferencing services, tailored voice and networking products, Fios services, advanced voice solutions and security services to businesses that ordinarily do not meet the requirements to be categorized as Enterprise and Public Sector, as described above.\"\n\n3. **Interpret the information**: The key phrase here is \"businesses that ordinarily do not meet the requirements to be categorized as Enterprise and Public Sector.\" This indicates that Business Markets and Other serves businesses that are not large enough or do not have the specific requirements to be considered part of the Enterprise and Public Sector segment.\n\n4. **Match the information to the options**:\n   - **Option A**: Public Sector and Enterprise - This is incorrect because the document explicitly states that Business Markets and Other serves businesses that do not meet the requirements for Enterprise and Public Sector.\n   - **Option B**: Businesses that meet Enterprise requirements - This is incorrect for the same reason as Option A.\n   - **Option C**: Businesses that meet Public Sector requirements - This is incorrect for the same reason as Option A.\n   - **Option D**: Businesses not meeting Enterprise and Public Sector requirements - This matches the information provided in the document.\n   - **Option E**: Only IoT companies - The document does not specify that Business Markets and Other serves only IoT companies.\n   - **Option F**: Only conferencing service providers - The document mentions conferencing services but does not specify that Business Markets and Other serves only conferencing service providers.\n\n5. **Conclusion**: Based on the information extracted and interpreted, the correct answer is **Option D: Businesses not meeting Enterprise and Public Sector requirements**.\n\nTherefore, the type of businesses that Business Markets and Other primarily serves are those that do not meet the requirements to be categorized as Enterprise and Public Sector."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 80, "token_lengths": 16000, "result": 1.0, "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?", "options": {"A": "Product quality and reliability", "B": "Technological capabilities", "C": "Marketing strategies", "D": "Cost-effectiveness", "E": "Industry experience", "F": "Vendor financing"}, "LLM_original_answer": ["To answer the question, I will carefully review the competitive factors mentioned in the document and identify which of the given options is not listed.\n\nThe document states:\n\"Competitive factors in these markets include product quality and reliability, technological capabilities, cost-effectiveness and industry experience.\"\n\nLet's break down the options and compare them to the factors mentioned in the document:\n\nA: Product quality and reliability - **Mentioned** in the document.\nB: Technological capabilities - **Mentioned** in the document.\nC: Marketing strategies - **Not mentioned** in the document.\nD: Cost-effectiveness - **Mentioned** in the document.\nE: Industry experience - **Mentioned** in the document.\nF: Vendor financing - **Not mentioned** in the document, but the document does discuss financing in the context of customer contracts and payment terms.\n\nFrom the above analysis, the factors mentioned in the document are:\n- Product quality and reliability\n- Technological capabilities\n- Cost-effectiveness\n- Industry experience\n\nThe factors not mentioned in the document are:\n- Marketing strategies\n- Vendor financing\n\nSince the question asks for the factor that is **NOT** mentioned as a competitive factor, the correct answer is:\n\n**C: Marketing strategies**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 16000, "result": 1.0, "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?", "options": {"A": "$20.7 million UPB (154 loans)", "B": "$66.7 million UPB (71 loans)", "C": "$20.7 million UPB (354 loans)", "D": "$66.7 million UPB (154 loans)", "E": "$66.7 million UPB (71 loans)", "F": "$20.7 million UPB (71 loans)"}, "LLM_original_answer": ["To answer the question \"What is the total outstanding representation and warranty repurchase demands at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses representation and warranty repurchase demands is found in the \"Loan Put-Back and Related Contingencies\" part of the document.\n\n2. **Extract the specific information**: The document states:\n   > \"At December 31, 2023 and 2022, we had outstanding representation and warranty repurchase demands of $ 20.7 million UPB ( 71 loans) and $ 66.7 million UPB ( 354 loans), respectively.\"\n\n3. **Match the information to the options**:\n   - Option A: $20.7 million UPB (154 loans)\n   - Option B: $66.7 million UPB (71 loans)\n   - Option C: $20.7 million UPB (354 loans)\n   - Option D: $66.7 million UPB (154 loans)\n   - Option E: $66.7 million UPB (71 loans)\n   - Option F: $20.7 million UPB (71 loans)\n\n4. **Select the correct option**: The correct information from the document is \"$ 20.7 million UPB ( 71 loans)\" for December 31, 2023.\n\nTherefore, the correct answer is **Option F: $20.7 million UPB (71 loans)**."], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 16000, "result": 0.0, "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?", "options": {"A": "Kansas City and Sioux City", "B": "Des Moines and Minneapolis", "C": "Springfield and St. Louis", "D": "Northwest Arkansas and Eastern Iowa", "E": "Sioux City and Des Moines", "F": "Rural markets in Missouri and Kansas"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the company in question.\n2. Look for information regarding the company's deposit concentrations.\n3. Match the information with the provided options.\n\n### Step 1: Identify the Company\nThe company in question is Great Southern Bancorp, Inc. (Bancorp), which is the parent of Great Southern Bank (the Bank).\n\n### Step 2: Look for Information Regarding Deposit Concentrations\nFrom the document, the relevant information is found in the \"Market Areas\" section:\n\n- **Springfield, Missouri**: $1.95 billion in deposits.\n- **St. Louis, Missouri**: $588 million in deposits.\n- **Kansas City, Missouri**: Not specified, but mentioned as a significant market.\n- **Sioux City, Iowa**: Not specified, but mentioned as a significant market.\n- **Des Moines, Iowa**: Not specified, but mentioned as a significant market.\n- **Northwest Arkansas**: Not specified, but mentioned as a significant market.\n- **Minneapolis, Minnesota**: Not specified, but mentioned as a significant market.\n- **Eastern Iowa (Quad Cities)**: Not specified, but mentioned as a significant market.\n- **Rural markets in Missouri and Kansas**: Deposits in Missouri and Kansas are specified as $3.48 billion and $339 million, respectively, but these are not broken down into rural markets.\n\n### Step 3: Match the Information with the Provided Options\nThe two largest deposit concentrations are:\n- **Springfield, Missouri**: $1.95 billion\n- **St. Louis, Missouri**: $588 million\n\nThese amounts are significantly larger than the deposits in other mentioned markets. Therefore, the correct answer is:\n\n**E: Sioux City and Des Moines**\n\nHowever, this option is incorrect based on the provided data. The correct answer should be:\n\n**B: Des Moines and Minneapolis**\n\nBut since the document does not specify the exact deposit amounts for Sioux City, Des Moines, and Minneapolis, and the two largest concentrations are clearly in Springfield and St. Louis, the correct answer based on the provided data is:\n\n**F: Rural markets in Missouri and Kansas**\n\nHowever, this option is not the correct answer because the two largest concentrations are in Springfield and St. Louis, not in rural markets.\n\n### Conclusion\nThe correct answer is:\n\n**E: Sioux City and Des Moines**\n\nBut this is not accurate based on the provided data. The correct answer should be:\n\n**B:"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 16000, "result": 1.0, "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?", "options": {"A": "Two directors", "B": "Three directors", "C": "Four directors", "D": "Five directors", "E": "Six directors", "F": "Seven directors"}, "LLM_original_answer": ["To answer the question \"How many directors are in each class of the QTI Holdings Board following the Effective Time?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the composition of the board of directors in the section titled \"Following the Effective Time, the board of directors of QT Imaging Holdings (the \u201cQTI Holdings Board\u201d) consists of seven directors classified in three classes.\"\n\n2. **Understand the board structure**: The document states that the board consists of seven directors, and these directors are classified into three classes.\n\n3. **Determine the number of directors per class**: Since there are seven directors and they are classified into three classes, we need to determine how these directors are distributed among the classes. The document does not explicitly state the number of directors in each class, but it does provide some information about the initial members:\n   - Three individuals identified by GigCapital5 will serve in Class I, Class II, or Class III.\n   - Three individuals identified by QT Imaging will serve in Class I, Class II, or Class III.\n   - One more board seat was filled by the GigCapital5 Board prior to Closing.\n\n4. **Calculate the distribution**: Given that there are seven directors and they are divided into three classes, the most logical distribution would be:\n   - Class I: 2 directors\n   - Class II: 2 directors\n   - Class III: 3 directors\n\nHowever, the document does not specify the exact distribution, but it does indicate that the board is classified into three classes with a total of seven directors.\n\n5. **Select the closest option**: The options provided are:\n   - A: Two directors\n   - B: Three directors\n   - C: Four directors\n   - D: Five directors\n   - E: Six directors\n   - F: Seven directors\n\nSince the document does not specify the exact number of directors in each class, but it does mention that the board is classified into three classes with a total of seven directors, the closest and most reasonable option is:\n\n**B: Three directors**\n\nThis is because it is the most balanced and logical distribution given the total number of directors and the classes mentioned. However, it is important to note that the document does not explicitly state the number of directors in each class, so this is an inference based on the information provided."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 80, "token_lengths": 16000, "result": 1.0, "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?", "options": {"A": "RMB0.8 million", "B": "RMB1.0 million", "C": "RMB1.3 million", "D": "RMB1.5 million", "E": "RMB1.8 million", "F": "RMB2.0 million"}, "LLM_original_answer": ["To answer the question \"What is the average capital spending for a new Pizza Hut restaurant unit in 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions capital spending for new restaurant units in the \"Expansion Management\" section.\n\n2. **Extract the specific information**: The relevant sentence states, \"As we are opening more smaller format stores and actively managing costs, the average capital spending for each new KFC and Pizza Hut restaurant unit in 2023 was approximately RMB1.5 million and 1.3 million, respectively.\"\n\n3. **Determine the answer**: The average capital spending for a new Pizza Hut restaurant unit in 2023 is RMB1.3 million.\n\n4. **Match the answer to the options**: The correct option is C: RMB1.3 million.\n\nTherefore, the answer to the question is **C: RMB1.3 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 16000, "result": 1.0, "question": "What is a potential consequence of failing to effectively manage company growth?", "options": {"A": "Improved financial condition", "B": "Enhanced employee morale", "C": "Improved forecasting accuracy", "D": "Adverse effects on business operations", "E": "Increased employee retention", "F": "Greater operational efficiency"}, "LLM_original_answer": ["To answer the question \"What is a potential consequence of failing to effectively manage company growth?\" based on the provided document, I will analyze the relevant sections and extract the key points that address the issue of growth management and its potential consequences.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document discusses the challenges and risks associated with managing growth, particularly in the context of a company that has expanded significantly over the years.\n   - Key sections include \"Our Growth Strategy,\" \"Risks Related to Our Business and Industry,\" and \"Failure to maintain and protect our reputation for trustworthiness and independence may harm our business.\"\n\n2. **Extract Key Points:**\n   - **Operational Challenges:**\n     - \"The growth and expansion of our business creates significant challenges for our management, operational, and financial resources.\"\n     - \"To effectively manage our growth, we must continue to improve our operational, financial, and management processes and systems and to effectively expand, train, and manage our employee base.\"\n   - **System and Control Adequacy:**\n     - \"In the event of growth of our operations or the number of our third-party relationships, our information technology systems and our internal controls and procedures may not be adequate to support our operations.\"\n   - **Employee Morale and Retention:**\n     - \"Our future success depends on attracting, developing, and retaining capable management, editors, and other key personnel.\"\n     - \"If our organization experiences growth or we are required to implement more complex organizational management structures, we may find it increasingly difficult to maintain the benefits of our corporate culture, including our ability to quickly develop and launch new and innovative products and solutions.\"\n   - **Financial Impact:**\n     - \"If we fail to effectively manage our growth, our efficiency, ability to meet our forecasts, and employee morale, productivity, and retention could suffer, and our business, results of operations, and financial condition could be adversely affected.\"\n\n3. **Evaluate Options:**\n   - **A: Improved financial condition** - This is not a potential consequence of failing to manage growth effectively; it is the opposite.\n   - **B: Enhanced employee morale** - This is also not a potential consequence of failing to manage growth effectively; it is the opposite.\n   - **C: Improved forecasting accuracy** - This is not a potential consequence of failing to manage growth effectively; it is the opposite.\n   - **D: Adverse effects on business operations** - This aligns with the document's discussion of"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 80, "token_lengths": 32000, "result": 1.0, "question": "What happens if the lender makes a margin call and the borrower cannot fund it?", "options": {"A": "The borrower can delay payment without consequences", "B": "The lender must forgive the outstanding debt", "C": "The lender is contractually allowed to liquidate MSRs", "D": "The borrower must immediately pay off all outstanding debts", "E": "The lender cannot take any action", "F": "The borrower can negotiate new terms"}, "LLM_original_answer": ["To answer the question \"What happens if the lender makes a margin call and the borrower cannot fund it?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: The document discusses the financial operations and risks of Keros Therapeutics, Inc., but it also includes a section on financing and margin calls, which is relevant to the question.\n\n2. **Locate the Specific Section**: The relevant section is found under \"Financing\" and \"Debt\" in the document. Specifically, the part that discusses margin calls in repurchase agreements and loan and security agreements.\n\n3. **Extract Key Points**:\n   - **Repurchase Agreements**: \"The repurchase agreements generally contain margin provisions that require us to maintain our borrowings at a specified percentage of the fair value of the assets pledged to secure the borrowings. As a result, we are subject to margin calls during the period the repurchase agreements are outstanding and, therefore, may be required to repay a portion of the borrowings before the respective repurchase agreements mature if the fair value (as determined by the applicable lender) of the assets securing those repurchase agreements decreases.\"\n   - **Consequences of Margin Calls**: \"We are exposed to loss in the event a lender makes a margin call to us and we are unable to fund the margin call. In such a circumstance, the lender is contractually allowed to liquidate the assets securing the repurchase agreement and pursue repayment from us for any balance not satisfied through the sale of the collateral.\"\n\n4. **Analyze the Information**:\n   - The document clearly states that if a borrower cannot fund a margin call, the lender is contractually allowed to liquidate the assets securing the repurchase agreement.\n   - The lender can also pursue repayment from the borrower for any balance not satisfied through the liquidation of the collateral.\n\n5. **Match to the Options**:\n   - **Option A**: The borrower can delay payment without consequences. (Not supported by the document)\n   - **Option B**: The lender must forgive the outstanding debt. (Not supported by the document)\n   - **Option C**: The lender is contractually allowed to liquidate MSRs. (Supported by the document)\n   - **Option D**: The borrower must immediately pay off all outstanding debts. (Not explicitly supported, but the lender can pursue repayment)\n   - **Option E**: The lender cannot take any action. (Not supported by the document)\n   - **Option F**: The borrower can negotiate new terms."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 32000, "result": 1.0, "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?", "options": {"A": "$6.81", "B": "$0.01", "C": "$8.72", "D": "$10.00", "E": "$5.50", "F": "$7.50"}, "LLM_original_answer": ["To answer the question \"What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that specifically discusses the Warrants issued as part of the Plan of Reorganization. This section is titled \"Warrant Agreement.\"\n\n2. **Locate the specific information about Tranche 1 Warrants**: Within the \"Warrant Agreement\" section, there is a detailed description of the Tranche 1 Warrants.\n\n3. **Extract the exercise price**: The document states, \"Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the 'Tranche 1 Exercise Price').\"\n\n4. **Verify the options**: The options provided are:\n   - A: $6.81\n   - B: $0.01\n   - C: $8.72\n   - D: $10.00\n   - E: $5.50\n   - F: $7.50\n\n5. **Match the extracted information with the options**: The exercise price of $6.81 per share for Tranche 1 Warrants matches option A.\n\nTherefore, the correct answer is **A: $6.81**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 80, "token_lengths": 32000, "result": 1.0, "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?", "options": {"A": "Duke Energy Carolinas, LLC", "B": "Duke Energy Progress, LLC", "C": "Progress Energy, Inc.", "D": "Piedmont Natural Gas Company, Inc.", "E": "Duke Energy Florida, LLC", "F": "All of the above"}, "LLM_original_answer": ["To answer the question, we need to identify which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities. Let's break down the information from the document:\n\n1. **Duke Energy Corporation**:\n   - The document mentions that Duke Energy Corporation has consolidated financial statements that include a statement of comprehensive income. This is evident from the section that lists the consolidated financial statements of Duke Energy Corporation, which includes \"Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2023, 2022 and 2021.\"\n\n2. **Duke Energy Carolinas, LLC**:\n   - The document also mentions that Duke Energy Carolinas, LLC has consolidated financial statements that include a statement of comprehensive income. This is seen in the section listing the consolidated financial statements of Duke Energy Carolinas, LLC, which includes \"Consolidated Statements of Operations and Comprehensive Income for the Years Ended December 31, 2023, 2022 and 2021.\"\n\n3. **Progress Energy, Inc.**:\n   - Progress Energy, Inc. is listed as having consolidated financial statements that include a statement of comprehensive income. This is mentioned in the section listing the consolidated financial statements of Progress Energy, Inc., which includes \"Consolidated Statements of Operations and Comprehensive Income for the Years Ended December 31, 2023, 2022 and 2021.\"\n\n4. **Duke Energy Progress, LLC**:\n   - Duke Energy Progress, LLC is also listed as having consolidated financial statements that include a statement of comprehensive income. This is mentioned in the section listing the consolidated financial statements of Duke Energy Progress, LLC, which includes \"Consolidated Statements of Operations and Comprehensive Income for the Years Ended December 31, 2023, 2022 and 2021.\"\n\n5. **Duke Energy Florida, LLC**:\n   - Duke Energy Florida, LLC is listed as having consolidated financial statements that include a statement of comprehensive income. This is mentioned in the section listing the consolidated financial statements of Duke Energy Florida, LLC, which includes \"Consolidated Statements of Operations and Comprehensive Income for the Years Ended December 31, 2023, 2022 and 2021.\"\n\n6. **Piedmont Natural Gas Company, Inc.**:\n   - Piedmont Natural Gas Company, Inc. is listed as having"], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 32000, "result": 1.0, "question": "What type of businesses does Business Markets and Other primarily serve?", "options": {"A": "Public Sector and Enterprise", "B": "Businesses that meet Enterprise requirements", "C": "Businesses that meet Public Sector requirements", "D": "Businesses not meeting Enterprise and Public Sector requirements", "E": "Only IoT companies", "F": "Only conferencing service providers"}, "LLM_original_answer": ["To answer the question \"What type of businesses does Business Markets and Other primarily serve?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the Business Markets and Other segment is found in the \"Verizon Business Group\" part of the document.\n\n2. **Extract the key information**: The document states:\n   - \"Business Markets and Other offers wireless services and equipment, conferencing services, tailored voice and networking products, Fios services, advanced voice solutions and security services to businesses that ordinarily do not meet the requirements to be categorized as Enterprise and Public Sector, as described above.\"\n   - \"In the Business Markets and Other category, customer purchasing behaviors and preferences continue to evolve. Solution speed and simplicity are becoming key differentiators for customers who are seeking full life-cycle offers that simplify the process of starting, running and growing their businesses.\"\n\n3. **Analyze the extracted information**:\n   - The segment serves businesses that do not meet the criteria for the Enterprise and Public Sector category.\n   - These businesses are typically small and medium-sized businesses, as they are described as seeking solutions that simplify the process of starting, running, and growing their businesses.\n\n4. **Match the information to the given options**:\n   - **Option A: Public Sector and Enterprise** - This is not correct, as the segment serves businesses that do not meet the requirements for these categories.\n   - **Option B: Businesses that meet Enterprise requirements** - This is not correct, as the segment serves businesses that do not meet these requirements.\n   - **Option C: Businesses that meet Public Sector requirements** - This is not correct, as the segment serves businesses that do not meet these requirements.\n   - **Option D: Businesses not meeting Enterprise and Public Sector requirements** - This matches the description in the document.\n   - **Option E: Only IoT companies** - This is not correct, as the segment serves a broader range of businesses, not just IoT companies.\n   - **Option F: Only conferencing service providers** - This is not correct, as the segment serves a broader range of businesses, not just conferencing service providers.\n\n5. **Conclude with the correct answer**:\n   - The correct answer is **Option D: Businesses not meeting Enterprise and Public Sector requirements**.\n\nTherefore, the type of businesses that Business Markets and Other primarily serves are those that do not meet the requirements to be categorized as Enterprise and Public Sector."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 80, "token_lengths": 32000, "result": 1.0, "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?", "options": {"A": "Product quality and reliability", "B": "Technological capabilities", "C": "Marketing strategies", "D": "Cost-effectiveness", "E": "Industry experience", "F": "Vendor financing"}, "LLM_original_answer": ["To answer the question, I will analyze the competitive factors mentioned in the document and compare them to the options provided.\n\n### Step 1: Identify the Competitive Factors Mentioned in the Document\nThe document states:\n\"Competitive factors in these markets include product quality and reliability, technological capabilities, cost-effectiveness and industry experience.\"\n\n### Step 2: List the Options Provided\nThe options are:\nA: Product quality and reliability\nB: Technological capabilities\nC: Marketing strategies\nD: Cost-effectiveness\nE: Industry experience\nF: Vendor financing\n\n### Step 3: Compare the Options to the Competitive Factors Mentioned\n- **A: Product quality and reliability** - Mentioned in the document.\n- **B: Technological capabilities** - Mentioned in the document.\n- **C: Marketing strategies** - Not mentioned in the document.\n- **D: Cost-effectiveness** - Mentioned in the document.\n- **E: Industry experience** - Mentioned in the document.\n- **F: Vendor financing** - Not mentioned in the document.\n\n### Step 4: Determine the Factor Not Mentioned\nThe factors not mentioned in the document are:\n- **C: Marketing strategies**\n- **F: Vendor financing**\n\n### Step 5: Select the Correct Answer\nSince the question asks for the factor that is NOT mentioned as a competitive factor, and both \"Marketing strategies\" and \"Vendor financing\" are not mentioned, we need to choose the one that is listed as an option.\n\nThe correct answer is:\n**C: Marketing strategies**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 32000, "result": 1.0, "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?", "options": {"A": "$20.7 million UPB (154 loans)", "B": "$66.7 million UPB (71 loans)", "C": "$20.7 million UPB (354 loans)", "D": "$66.7 million UPB (154 loans)", "E": "$66.7 million UPB (71 loans)", "F": "$20.7 million UPB (71 loans)"}, "LLM_original_answer": ["To answer the question \"What is the total outstanding representation and warranty repurchase demands at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Relevant Section**: The document mentions representation and warranty repurchase demands in Note 26 \u2014 Contingencies, specifically in the section discussing \"Loan Put-Back and Related Contingencies.\"\n\n2. **Extract the Data**: The relevant data is found in the following sentence:\n   - \"At December 31, 2023 and 2022, we had outstanding representation and warranty repurchase demands of $ 20.7 million UPB ( 71 loans) and $ 66.7 million UPB ( 354 loans), respectively.\"\n\n3. **Match the Data to the Options**:\n   - The data for December 31, 2023 is $20.7 million UPB (71 loans).\n\n4. **Select the Correct Option**:\n   - The correct option is **F: $20.7 million UPB (71 loans)**.\n\nTherefore, the total outstanding representation and warranty repurchase demands at December 31, 2023 is **$20.7 million UPB (71 loans)**."], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 32000, "result": 1.0, "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?", "options": {"A": "Kansas City and Sioux City", "B": "Des Moines and Minneapolis", "C": "Springfield and St. Louis", "D": "Northwest Arkansas and Eastern Iowa", "E": "Sioux City and Des Moines", "F": "Rural markets in Missouri and Kansas"}, "LLM_original_answer": ["To answer the question \"Where are the two largest deposit concentrations of the Company located as of December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Company**: The document is about Great Southern Bancorp, Inc. (Bancorp), which is the parent company of Great Southern Bank.\n\n2. **Locate the Relevant Information**: The document provides details about the deposit concentrations of Great Southern Bank as of December 31, 2023.\n\n3. **Extract the Deposit Concentrations**:\n   - **Missouri**: $3.48 billion in deposits, with the two largest concentrations in:\n     - **Springfield, Missouri**: $1.95 billion\n     - **St. Louis, Missouri**: $588 million\n   - **Iowa**: $696 million in deposits\n   - **Kansas**: $339 million in deposits\n   - **Minnesota**: $149 million in deposits\n   - **Nebraska**: $22 million in deposits\n   - **Arkansas**: $34 million in deposits\n\n4. **Determine the Two Largest Concentrations**:\n   - The largest concentration is in **Springfield, Missouri** with $1.95 billion.\n   - The second largest concentration is in **St. Louis, Missouri** with $588 million.\n\n5. **Match the Concentrations to the Given Options**:\n   - **Option A**: Kansas City and Sioux City\n   - **Option B**: Des Moines and Minneapolis\n   - **Option C**: Springfield and St. Louis\n   - **Option D**: Northwest Arkansas and Eastern Iowa\n   - **Option E**: Sioux City and Des Moines\n   - **Option F**: Rural markets in Missouri and Kansas\n\nBased on the information extracted from the document, the two largest deposit concentrations are in **Springfield, Missouri** and **St. Louis, Missouri**.\n\nTherefore, the correct answer is **Option C: Springfield and St. Louis**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 32000, "result": 1.0, "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?", "options": {"A": "Two directors", "B": "Three directors", "C": "Four directors", "D": "Five directors", "E": "Six directors", "F": "Seven directors"}, "LLM_original_answer": ["To answer the question \"How many directors are in each class of the QTI Holdings Board following the Effective Time?\", I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the structure of the board of directors in the section discussing the Business Combination and the Effective Time.\n\n2. **Extract the specific information about the board structure**: The relevant excerpt is:\n   - \"Following the Effective Time, the board of directors of QT Imaging Holdings (the \u201cQTI Holdings Board\u201d) consists of seven directors classified in three classes, the initial members of which (the \u201cInitial Post-Closing QTI Holdings Directors\u201d) consisted of three individuals identified by GigCapital5 who will serve either in Class I, Class II or Class III, and included the chairman of the QTI Holdings Board, and three individuals identified by QT Imaging who will serve either in Class I, Class II or Class III, and one more board seat was filled by the GigCapital5 Board prior to Closing.\"\n\n3. **Determine the number of directors in each class**: The document states that the board consists of seven directors classified into three classes. However, it does not explicitly state how many directors are in each class. To infer this, we need to consider the typical structure of a board divided into three classes. In such a structure, the directors are usually divided as evenly as possible.\n\n4. **Calculate the number of directors per class**: Since there are seven directors and three classes, the most even distribution would be:\n   - Two classes with 2 directors each.\n   - One class with 3 directors.\n\n5. **Match the calculation with the options provided**: The options are:\n   - A: Two directors\n   - B: Three directors\n   - C: Four directors\n   - D: Five directors\n   - E: Six directors\n   - F: Seven directors\n\nGiven the calculation, the correct answer is that two classes have 2 directors each, and one class has 3 directors. However, the question asks for the number of directors in each class, and the options provided do not include a combination of 2 and 3 directors. The closest match to the structure described is:\n\n- **Option A: Two directors** (for two of the classes)\n- **Option B: Three directors** (for one of the classes)\n\nSince the question asks for the number of directors in each class, and the options provided do not include a combination, the most accurate answer based on the document is:\n\n- **"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 80, "token_lengths": 32000, "result": 1.0, "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?", "options": {"A": "RMB0.8 million", "B": "RMB1.0 million", "C": "RMB1.3 million", "D": "RMB1.5 million", "E": "RMB1.8 million", "F": "RMB2.0 million"}, "LLM_original_answer": ["To answer the question \"What is the average capital spending for a new Pizza Hut restaurant unit in 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions capital spending for new restaurant units in the \"Expansion Management\" section.\n\n2. **Extract the specific information**: The document states, \"In 2023, we continued to broaden our offerings by adding some of our restaurant classics. We also developed our own retail brand, Shaofaner, which sells packaged foods through online and offline channels. We intend to continue to capture the opportunity with our capabilities in product innovation, supply chain and online and offline assets. ... In addition, we continuously look for ways to improve the guest experience. We continue to refresh the look of our restaurants and remodel with the latest technology, equipment and infrastructure. Approximately 75% of KFC restaurant units and 85% of Pizza Hut restaurant units as of December 31, 2023 were remodeled or built in the past five years.\"\n\n3. **Find the capital spending data**: The document provides the average capital spending for new KFC and Pizza Hut restaurant units in 2023: \"In 2023, the average capital spending for each new KFC and Pizza Hut restaurant unit was approximately RMB1.5 million and RMB1.3 million, respectively.\"\n\n4. **Match the data to the question**: The question specifically asks about the average capital spending for a new Pizza Hut restaurant unit in 2023. According to the document, the average capital spending for a new Pizza Hut restaurant unit in 2023 was RMB1.3 million.\n\n5. **Select the correct option**: The correct option from the provided choices is C: RMB1.3 million.\n\nTherefore, the answer to the question is **C: RMB1.3 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 32000, "result": 1.0, "question": "What is a potential consequence of failing to effectively manage company growth?", "options": {"A": "Improved financial condition", "B": "Enhanced employee morale", "C": "Improved forecasting accuracy", "D": "Adverse effects on business operations", "E": "Increased employee retention", "F": "Greater operational efficiency"}, "LLM_original_answer": ["To answer the question \"What is a potential consequence of failing to effectively manage company growth?\" based on the provided document, I will analyze the relevant sections and extract the key points that address the issue of growth management and its potential consequences.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document primarily focuses on financial and operational aspects of Brighthouse Financial, Inc. However, there are sections that discuss the challenges and risks associated with growth and expansion.\n\n2. **Extract Key Points:**\n   - **Growth and Expansion Challenges:**\n     - \"The scope and complexity of our business have increased significantly in recent years. The growth and expansion of our business creates significant challenges for our management, operational, and financial resources.\" (Page 14)\n     - \"To effectively manage our growth, we must continue to improve our operational, financial, and management processes and systems and to effectively expand, train, and manage our employee base.\" (Page 14)\n     - \"If our organization experiences growth or we are required to implement more complex organizational management structures, we may find it increasingly difficult to maintain the benefits of our corporate culture, including our ability to quickly develop and launch new and innovative products and solutions.\" (Page 14)\n     - \"Our growth may make it difficult to evaluate our future prospects. Our ability to forecast our future results of operations is subject to a number of uncertainties, including our ability to effectively plan for and model future growth.\" (Page 14)\n     - \"We have encountered in the past, and may encounter in the future, risks and uncertainties frequently experienced by growing companies in rapidly changing industries.\" (Page 14)\n\n3. **Analyze the Consequences:**\n   - **Operational Inefficiencies:**\n     - If the company fails to improve its operational, financial, and management processes, it could lead to inefficiencies and operational issues.\n   - **Employee Morale and Retention:**\n     - The document mentions the importance of maintaining the corporate culture and the difficulty of doing so as the company grows. This suggests that failing to manage growth could negatively impact employee morale and retention.\n   - **Financial Performance:**\n     - The document highlights the challenges in forecasting future results and the potential for increased operating costs and lower profit margins if growth is not managed effectively.\n   - **Customer Satisfaction:**\n     - The ability to quickly develop and launch new products and solutions is crucial for maintaining customer satisfaction and engagement. Failing to manage growth could hinder"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 80, "token_lengths": 64000, "result": 1.0, "question": "What happens if the lender makes a margin call and the borrower cannot fund it?", "options": {"A": "The borrower can delay payment without consequences", "B": "The lender must forgive the outstanding debt", "C": "The lender is contractually allowed to liquidate MSRs", "D": "The borrower must immediately pay off all outstanding debts", "E": "The lender cannot take any action", "F": "The borrower can negotiate new terms"}, "LLM_original_answer": ["The correct answer to the question \"What happens if the lender makes a margin call and the borrower cannot fund it?\" based on the provided document is:\n\n**C: The lender is contractually allowed to liquidate MSRs**\n\n### Chain of Thought:\n1. **Understanding Margin Calls**: A margin call is a demand from a lender for additional funds or collateral to bring the loan balance back to an agreed-upon level. This is common in leveraged investments, such as those involving mortgage-backed securities (MBS) or mortgage servicing rights (MSRs).\n\n2. **Document Context**: The document discusses the company's business, including its investments in MSRs and the risks associated with these investments. It mentions that the company uses repurchase agreements to finance its investments, and these agreements often contain margin provisions.\n\n3. **Relevant Section**: The document states, \"A decrease in the fair value of the pledged collateral can result in a margin call. Any such margin call may require that we liquidate assets at a disadvantageous time or provide that the secured parties may sell the collateral, either of which could result in significant losses to us.\"\n\n4. **Interpretation**: This section clearly indicates that if the borrower (the company) cannot fund a margin call, the lender (the secured party) is contractually allowed to liquidate the pledged assets, which in this case are MSRs.\n\n5. **Elimination of Other Options**:\n   - **A: The borrower can delay payment without consequences** - This is incorrect because the document implies that failing to meet a margin call can lead to significant losses.\n   - **B: The lender must forgive the outstanding debt** - This is not supported by the document.\n   - **D: The borrower must immediately pay off all outstanding debts** - While the borrower might need to provide additional collateral, the document does not suggest immediate full repayment of all debts.\n   - **E: The lender cannot take any action** - This is incorrect because the lender can liquidate the assets.\n   - **F: The borrower can negotiate new terms** - The document does not mention negotiation as an option in the event of a margin call.\n\nTherefore, the correct answer is **C: The lender is contractually allowed to liquidate MSRs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 64000, "result": 1.0, "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?", "options": {"A": "$6.81", "B": "$0.01", "C": "$8.72", "D": "$10.00", "E": "$5.50", "F": "$7.50"}, "LLM_original_answer": ["To answer the question \"What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document contains a section that discusses the warrants issued as part of the Plan of Reorganization. This section is found in Note 17 \u2014 Subsequent Events, specifically in the Warrant Agreement subsection.\n\n2. **Locate the specific information about Tranche 1 Warrants**: In the Warrant Agreement section, the document states:\n   - \"Pursuant to the Warrant Agreement, the Company was authorized to issue (i) an aggregate of 98,313,313 warrants, each exercisable for one share of New Common Stock at an exercise price of $ 6.81 per share (the \u201cTranche 1 Warrants\u201d) and (ii) an aggregate of 81,927,898 warrants, each exercisable for one share of New Common Stock at an exercise price of $ 0.01 per share (the \u201cTranche 2 Warrants\u201d and, together with the Tranche 1 Warrants, the \u201cWarrants\u201d).\"\n\n3. **Extract the exercise price for Tranche 1 Warrants**: From the above statement, it is clear that the exercise price for Tranche 1 Warrants is $6.81 per share.\n\n4. **Verify the options**: The options provided are:\n   - A: $6.81\n   - B: $0.01\n   - C: $8.72\n   - D: $10.00\n   - E: $5.50\n   - F: $7.50\n\n5. **Select the correct answer**: The correct answer is A: $6.81.\n\nTherefore, the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock is **$6.81**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 80, "token_lengths": 64000, "result": 1.0, "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?", "options": {"A": "Duke Energy Carolinas, LLC", "B": "Duke Energy Progress, LLC", "C": "Progress Energy, Inc.", "D": "Piedmont Natural Gas Company, Inc.", "E": "Duke Energy Florida, LLC", "F": "All of the above"}, "LLM_original_answer": ["To answer the question, we need to identify which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities. Let's break down the information from the document:\n\n1. **Duke Energy Corporation**:\n   - The document mentions that Duke Energy and its subsidiaries file a consolidated federal income tax return and other state and foreign jurisdictional returns.\n   - It also states that the Duke Energy Registrants' consolidated financial statements include a statement of comprehensive income.\n\n2. **Duke Energy Carolinas, LLC**:\n   - The document provides detailed financial information for Duke Energy Carolinas, including its consolidated statements of operations and comprehensive income.\n\n3. **Duke Energy Progress, LLC**:\n   - Similar to Duke Energy Carolinas, the document provides detailed financial information for Duke Energy Progress, including its consolidated statements of operations and comprehensive income.\n\n4. **Progress Energy, Inc.**:\n   - The document includes consolidated financial statements for Progress Energy, which would include a statement of comprehensive income.\n\n5. **Piedmont Natural Gas Company, Inc.**:\n   - The document provides detailed financial information for Piedmont, including its consolidated statements of operations and comprehensive income.\n\n6. **Duke Energy Florida, LLC**:\n   - The document includes detailed financial information for Duke Energy Florida, including its consolidated statements of operations and comprehensive income.\n\nGiven this information, all of the listed entities (Duke Energy Carolinas, LLC, Duke Energy Progress, LLC, Progress Energy, Inc., Piedmont Natural Gas Company, Inc., and Duke Energy Florida, LLC) are part of Duke Energy's consolidated financial statements, which include a statement of comprehensive income.\n\nTherefore, the correct answer is:\n\n**F: All of the above**."], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 64000, "result": 1.0, "question": "What type of businesses does Business Markets and Other primarily serve?", "options": {"A": "Public Sector and Enterprise", "B": "Businesses that meet Enterprise requirements", "C": "Businesses that meet Public Sector requirements", "D": "Businesses not meeting Enterprise and Public Sector requirements", "E": "Only IoT companies", "F": "Only conferencing service providers"}, "LLM_original_answer": ["To answer the question \"What type of businesses does Business Markets and Other primarily serve?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the Relevant Section**:\n   - The relevant section is found in the \"Verizon Business Group\" part of the document, specifically under the \"Business Markets and Other\" category.\n\n2. **Extract Key Information**:\n   - The document states: \"Business Markets and Other offers wireless services and equipment, conferencing services, tailored voice and networking products, Fios services, advanced voice solutions and security services to businesses that ordinarily do not meet the requirements to be categorized as Enterprise and Public Sector, as described above.\"\n\n3. **Interpret the Information**:\n   - The key phrase here is \"businesses that ordinarily do not meet the requirements to be categorized as Enterprise and Public Sector.\"\n   - This implies that Business Markets and Other serves businesses that are smaller or have different requirements compared to those served by the Enterprise and Public Sector segment.\n\n4. **Match the Information to the Options**:\n   - Option A: Public Sector and Enterprise - This is not correct because the document explicitly states that Business Markets and Other serves businesses that do not meet the requirements for Enterprise and Public Sector.\n   - Option B: Businesses that meet Enterprise requirements - This is not correct for the same reason as above.\n   - Option C: Businesses that meet Public Sector requirements - This is also not correct for the same reason as above.\n   - Option D: Businesses not meeting Enterprise and Public Sector requirements - This matches the information provided in the document.\n   - Option E: Only IoT companies - The document does not specify that Business Markets and Other serves only IoT companies.\n   - Option F: Only conferencing service providers - The document mentions conferencing services but does not specify that Business Markets and Other serves only conferencing service providers.\n\n5. **Conclusion**:\n   - The correct answer is Option D: Businesses not meeting Enterprise and Public Sector requirements.\n\nTherefore, the type of businesses that Business Markets and Other primarily serves are those that do not meet the requirements to be categorized as Enterprise and Public Sector."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 80, "token_lengths": 64000, "result": 1.0, "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?", "options": {"A": "Product quality and reliability", "B": "Technological capabilities", "C": "Marketing strategies", "D": "Cost-effectiveness", "E": "Industry experience", "F": "Vendor financing"}, "LLM_original_answer": ["To answer the question, I will analyze the document to identify the competitive factors mentioned and then determine which of the provided options is not mentioned.\n\n### Competitive Factors Mentioned in the Document:\n1. **Product Quality and Reliability**: The document discusses the importance of product quality and reliability, especially in the context of regulatory approvals and the trust that customers place in the company's products.\n2. **Technological Capabilities**: The document emphasizes the company's technological capabilities, including the development of AI, biometrics, and other advanced technologies.\n3. **Cost-Effectiveness**: The document mentions the cost-effectiveness of generic drugs and the potential impact of cost on the company's market position.\n4. **Industry Experience**: The document highlights the company's extensive experience and expertise in the biopharmaceutical industry, particularly in E3 ligases and drug discovery.\n5. **Marketing Strategies**: The document does not explicitly mention marketing strategies as a competitive factor. However, it does discuss the importance of market acceptance and demand for the company's drug candidates, which can be related to marketing efforts.\n\n### Options Analysis:\n- **A: Product quality and reliability** - Mentioned.\n- **B: Technological capabilities** - Mentioned.\n- **C: Marketing strategies** - Not explicitly mentioned.\n- **D: Cost-effectiveness** - Mentioned.\n- **E: Industry experience** - Mentioned.\n- **F: Vendor financing** - The document mentions the potential risks and challenges related to vendor financing, but it does not discuss vendor financing as a competitive factor.\n\n### Conclusion:\nThe factor that is **NOT** mentioned as a competitive factor in the markets where the company operates is **C: Marketing strategies**.\n\nTherefore, the correct answer is **C: Marketing strategies**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 64000, "result": 1.0, "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?", "options": {"A": "$20.7 million UPB (154 loans)", "B": "$66.7 million UPB (71 loans)", "C": "$20.7 million UPB (354 loans)", "D": "$66.7 million UPB (154 loans)", "E": "$66.7 million UPB (71 loans)", "F": "$20.7 million UPB (71 loans)"}, "LLM_original_answer": ["To answer the question \"What is the total outstanding representation and warranty repurchase demands at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Relevant Section**: The document contains a section that discusses representation and warranty repurchase demands. This section is found in Note 26 \u2014 Contingencies.\n\n2. **Extract the Specific Information**: Within Note 26, the document states:\n   > \"At December 31, 2023 and 2022, we had outstanding representation and warranty repurchase demands of $ 20.7 million UPB ( 71 loans) and $ 66.7 million UPB ( 354 loans), respectively.\"\n\n3. **Match the Information to the Options**: The information provided in the document matches the following option:\n   - **Option A**: $20.7 million UPB (154 loans)\n   - **Option B**: $66.7 million UPB (71 loans)\n   - **Option C**: $20.7 million UPB (354 loans)\n   - **Option D**: $66.7 million UPB (154 loans)\n   - **Option E**: $66.7 million UPB (71 loans)\n   - **Option F**: $20.7 million UPB (71 loans)\n\n4. **Select the Correct Option**: The correct option that matches the information from the document is:\n   - **Option F**: $20.7 million UPB (71 loans)\n\nTherefore, the total outstanding representation and warranty repurchase demands at December 31, 2023 is **$20.7 million UPB (71 loans)**."], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 64000, "result": 1.0, "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?", "options": {"A": "Kansas City and Sioux City", "B": "Des Moines and Minneapolis", "C": "Springfield and St. Louis", "D": "Northwest Arkansas and Eastern Iowa", "E": "Sioux City and Des Moines", "F": "Rural markets in Missouri and Kansas"}, "LLM_original_answer": ["The document provided does not contain specific information about the largest deposit concentrations of the Company as of December 31, 2023, in the format or context that directly answers the question. However, based on the information given, we can infer the answer from the following excerpt:\n\n\"Great Southern\u2019s largest concentrations of deposits and loans are in the Springfield, Missouri, and St. Louis, market areas.\"\n\nThis statement indicates that the two largest deposit concentrations of the Company are in Springfield, Missouri, and St. Louis, Missouri.\n\nTherefore, the correct answer is:\n\n**C: Springfield and St. Louis**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 64000, "result": 1.0, "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?", "options": {"A": "Two directors", "B": "Three directors", "C": "Four directors", "D": "Five directors", "E": "Six directors", "F": "Seven directors"}, "LLM_original_answer": ["To answer the question \"How many directors are in each class of the QTI Holdings Board following the Effective Time?\", I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the structure of the QTI Holdings Board following the Effective Time in the \"Business Combination\" section.\n\n2. **Extract the specific information**: The relevant excerpt is:\n   - \"Following the Effective Time, the board of directors of QT Imaging Holdings (the \u201cQTI Holdings Board\u201d) consists of seven directors classified in three classes, the initial members of which (the \u201cInitial Post-Closing QTI Holdings Directors\u201d) consisted of three individuals identified by GigCapital5 who will serve either in Class I, Class II or Class III, and included the chairman of the QTI Holdings Board, and three individuals identified by QT Imaging who will serve either in Class I, Class II or Class III, and one more board seat was filled by the GigCapital5 Board prior to Closing.\"\n\n3. **Analyze the information**:\n   - The QTI Holdings Board consists of seven directors.\n   - These seven directors are classified into three classes.\n   - The initial members of the board were identified by GigCapital5 and QT Imaging, with three individuals from each side, and one additional seat filled by the GigCapital5 Board.\n\n4. **Determine the number of directors per class**:\n   - Since there are seven directors and three classes, the directors are distributed among these classes.\n   - The document does not explicitly state the number of directors in each class, but it implies that the distribution is such that each class has a similar number of directors, with one class having an additional director to make the total seven.\n\n5. **Calculate the distribution**:\n   - If each class had an equal number of directors, there would be 7 / 3 \u2248 2.33 directors per class, which is not possible since the number of directors must be a whole number.\n   - Therefore, two classes must have 2 directors each, and one class must have 3 directors to make the total seven.\n\n6. **Select the correct option**:\n   - The correct answer is that two classes have 2 directors each, and one class has 3 directors.\n   - The options provided are:\n     - A: Two directors\n     - B: Three directors\n     - C: Four directors\n     - D: Five directors\n     - E: Six directors\n     - F: Seven directors\n\nGiven the distribution"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 80, "token_lengths": 64000, "result": 1.0, "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?", "options": {"A": "RMB0.8 million", "B": "RMB1.0 million", "C": "RMB1.3 million", "D": "RMB1.5 million", "E": "RMB1.8 million", "F": "RMB2.0 million"}, "LLM_original_answer": ["To answer the question regarding the average capital spending for a new Pizza Hut restaurant unit in 2023, I will follow these steps:\n\n1. **Identify the Relevant Information**: Look for specific mentions of capital spending for new Pizza Hut units in the provided document.\n2. **Extract the Data**: Find the exact figures or statements that provide the capital spending amounts.\n3. **Calculate the Average**: If multiple figures are provided, calculate the average. If a single figure is provided, that will be the answer.\n\n### Step 1: Identify the Relevant Information\nThe document contains a section that discusses the capital spending for new restaurant units. Specifically, it mentions the average capital spending for KFC and Pizza Hut units in 2023.\n\n### Step 2: Extract the Data\nThe relevant excerpt is:\n- \"As of December 31, 2023, the average capital spending for each new KFC and Pizza Hut restaurant unit in 2023 was approximately RMB1.5 million and RMB1.3 million, respectively.\"\n\n### Step 3: Calculate the Average\nThe document directly provides the average capital spending for a new Pizza Hut restaurant unit in 2023 as RMB1.3 million.\n\n### Conclusion\nThe average capital spending for a new Pizza Hut restaurant unit in 2023 is **RMB1.3 million**.\n\nTherefore, the correct answer is:\n**C: RMB1.3 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 64000, "result": 1.0, "question": "What is a potential consequence of failing to effectively manage company growth?", "options": {"A": "Improved financial condition", "B": "Enhanced employee morale", "C": "Improved forecasting accuracy", "D": "Adverse effects on business operations", "E": "Increased employee retention", "F": "Greater operational efficiency"}, "LLM_original_answer": ["To answer the question \"What is a potential consequence of failing to effectively manage company growth?\" based on the provided document, let's analyze the relevant sections:\n\n1. **Growth and Expansion Challenges**:\n   - The document mentions that the growth and expansion of the business create significant challenges for management, operational, and financial resources. Specifically, it states: \"The growth and expansion of our business creates significant challenges for our management, operational, and financial resources.\"\n   - It also notes that the scope and complexity of the business have increased significantly, which can strain existing systems and processes: \"The scope and complexity of our business have increased significantly in recent years.\"\n\n2. **Operational and Financial Impact**:\n   - The document highlights that if the company fails to manage its growth effectively, it could lead to significant operating inefficiencies and adversely affect its growth and profitability: \"In the event of growth of our operations or the number of our third-party relationships, our information technology systems and our internal controls and procedures may not be adequate to support our operations.\"\n   - It further states: \"If our organization experiences growth or we are required to implement more complex organizational management structures, we may find it increasingly difficult to maintain the benefits of our corporate culture, including our ability to quickly develop and launch new and innovative products and solutions.\"\n\n3. **Employee Morale and Retention**:\n   - The document suggests that growth can affect employee morale and retention: \"Our growth may make it difficult to evaluate our future prospects. Our ability to forecast our future results of operations is subject to a number of uncertainties, including our ability to effectively plan for and model future growth.\"\n   - It also mentions the importance of retaining key personnel: \"Our future success depends on attracting, developing, and retaining capable management, editors, and other key personnel.\"\n\n4. **Financial Forecasts and Models**:\n   - The document emphasizes the need for accurate forecasting and modeling, which can be impacted by growth: \"Our ability to forecast our future results of operations is subject to a number of uncertainties, including our ability to effectively plan for and model future growth.\"\n\nGiven these points, the most appropriate answer from the provided options is:\n\n**D: Adverse effects on business operations**\n\nThis option aligns with the document's emphasis on the potential for significant operating inefficiencies and the strain on management, operational, and financial resources if growth is not effectively managed. The document clearly indicates that failing to manage growth could negatively impact the company's operations, which is a direct and significant consequence."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 80, "token_lengths": 96000, "result": 1.0, "question": "What happens if the lender makes a margin call and the borrower cannot fund it?", "options": {"A": "The borrower can delay payment without consequences", "B": "The lender must forgive the outstanding debt", "C": "The lender is contractually allowed to liquidate MSRs", "D": "The borrower must immediately pay off all outstanding debts", "E": "The lender cannot take any action", "F": "The borrower can negotiate new terms"}, "LLM_original_answer": ["The correct answer to the question \"What happens if the lender makes a margin call and the borrower cannot fund it?\" based on the provided document is:\n\n**C: The lender is contractually allowed to liquidate MSRs**\n\nHere's the step-by-step reasoning:\n\n1. **Identify the Context**: The document discusses the risks and operations of a specialty finance company that invests in mortgage-related assets, including mortgage servicing rights (MSRs).\n\n2. **Locate Relevant Information**: The document mentions the risk associated with margin calls in the context of financing MSRs and other mortgage-related assets. Specifically, it states:\n   - \"A decrease in the fair value of the pledged collateral can result in a margin call. Any such margin call may require that we liquidate assets at a disadvantageous time or provide that the secured parties may sell the collateral, either of which could result in significant losses to us.\"\n   - \"Each of the secured financing arrangements pursuant to which we finance MSRs is further subject to the terms of an acknowledgement agreement with Fannie Mae, Freddie Mac or Ginnie Mae, as applicable, pursuant to which our and the secured parties\u2019 rights are subordinate in all respects to the rights of the applicable Agency.\"\n\n3. **Analyze the Options**:\n   - **A: The borrower can delay payment without consequences** - This is incorrect because the document clearly states that the borrower must either liquidate assets or provide additional collateral.\n   - **B: The lender must forgive the outstanding debt** - This is incorrect because the document does not mention forgiveness of debt as an option.\n   - **C: The lender is contractually allowed to liquidate MSRs** - This is correct because the document explicitly states that the lender may require the borrower to liquidate assets or sell the collateral.\n   - **D: The borrower must immediately pay off all outstanding debts** - This is incorrect because the document mentions the option to liquidate assets or provide additional collateral, not immediate full repayment.\n   - **E: The lender cannot take any action** - This is incorrect because the document clearly states that the lender can take action.\n   - **F: The borrower can negotiate new terms** - This is not mentioned in the document as a specific response to a margin call.\n\n4. **Conclusion**: Based on the information provided, the correct answer is **C: The lender is contractually allowed to liquidate MSRs**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 96000, "result": 1.0, "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?", "options": {"A": "$6.81", "B": "$0.01", "C": "$8.72", "D": "$10.00", "E": "$5.50", "F": "$7.50"}, "LLM_original_answer": ["To answer the question regarding the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock, I will follow these steps:\n\n1. **Identify the Relevant Information**: The document should contain specific details about the Tranche 1 Warrants, including the exercise price.\n\n2. **Locate the Information**: I will search the document for sections that discuss the Tranche 1 Warrants.\n\n3. **Extract the Exercise Price**: Once I find the relevant section, I will extract the exercise price per share for the Tranche 1 Warrants.\n\n4. **Match the Exercise Price to the Options**: Finally, I will match the extracted exercise price to the provided options.\n\n### Step 1: Identify the Relevant Information\nThe relevant information will be the exercise price for the Tranche 1 Warrants.\n\n### Step 2: Locate the Information\nI will search the document for sections that discuss the Tranche 1 Warrants.\n\n### Step 3: Extract the Exercise Price\nFrom the document, I found the following relevant information:\n\n> **Warrant Agreement**\n> On the Effective Date and pursuant to the Plan of Reorganization and the Confirmation Order, the Company entered into a warrant agreement dated as January 23, 2024, (the \u201cWarrant Agreement\u201d) among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company (collectively, in such capacity, the \u201cWarrant Agent\u201d).\n> \n> Pursuant to the Warrant Agreement, the Company was authorized to issue (i) an aggregate of 98,313,313 warrants, each exercisable for one share of New Common Stock at an exercise price of $6.81 per share (the \u201cTranche 1 Warrants\u201d) and (ii) an aggregate of 81,927,898 warrants, each exercisable for one share of New Common Stock at an exercise price of $0.01 per share (the \u201cTranche 2 Warrants\u201d and, together with the Tranche 1 Warrants, the \u201cWarrants\u201d).\n\n### Step 4: Match the Exercise Price to the Options\nThe exercise price for the Tranche 1 Warrants is $6.81 per share.\n\n### Conclusion\nThe correct answer is:\n**A: $6.81**"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 80, "token_lengths": 96000, "result": 1.0, "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?", "options": {"A": "Duke Energy Carolinas, LLC", "B": "Duke Energy Progress, LLC", "C": "Progress Energy, Inc.", "D": "Piedmont Natural Gas Company, Inc.", "E": "Duke Energy Florida, LLC", "F": "All of the above"}, "LLM_original_answer": ["To answer the question, we need to identify which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities. Let's analyze the provided document step by step:\n\n1. **Duke Energy Corporation**:\n   - The document states: \"We have audited the accompanying consolidated balance sheets of Duke Energy Corporation and subsidiaries (the \"Company\") as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income, changes in equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the \"financial statements\").\"\n   - This indicates that Duke Energy Corporation's consolidated financial statements include a statement of comprehensive income.\n\n2. **Duke Energy Carolinas, LLC**:\n   - The document states: \"We have audited the accompanying consolidated balance sheets of Duke Energy Carolinas, LLC and subsidiaries (the \"Company\") as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive income, changes in equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the \"financial statements\").\"\n   - This indicates that Duke Energy Carolinas, LLC's consolidated financial statements include a statement of comprehensive income.\n\n3. **Progress Energy, Inc.**:\n   - The document states: \"We have audited the accompanying consolidated balance sheets of Progress Energy, Inc. and subsidiaries (the \"Company\") as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive income, changes in equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the \"financial statements\").\"\n   - This indicates that Progress Energy, Inc.'s consolidated financial statements include a statement of comprehensive income.\n\n4. **Duke Energy Progress, LLC**:\n   - The document states: \"We have audited the accompanying consolidated balance sheets of Duke Energy Progress, LLC and subsidiaries (the \"Company\") as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive income, changes in equity, and cash"], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 96000, "result": 1.0, "question": "What type of businesses does Business Markets and Other primarily serve?", "options": {"A": "Public Sector and Enterprise", "B": "Businesses that meet Enterprise requirements", "C": "Businesses that meet Public Sector requirements", "D": "Businesses not meeting Enterprise and Public Sector requirements", "E": "Only IoT companies", "F": "Only conferencing service providers"}, "LLM_original_answer": ["To answer the question \"What type of businesses does Business Markets and Other primarily serve?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that provides information about the Business Markets and Other segment is found in the \"Verizon Business Group\" part of the document.\n\n2. **Extract the relevant information**: The document states:\n   - \"Business Markets and Other offers wireless services and equipment, conferencing services, tailored voice and networking products, Fios services, advanced voice solutions and security services to businesses that ordinarily do not meet the requirements to be categorized as Enterprise and Public Sector, as described above.\"\n\n3. **Interpret the information**: The key phrase here is \"businesses that ordinarily do not meet the requirements to be categorized as Enterprise and Public Sector.\" This indicates that the Business Markets and Other segment serves businesses that are smaller or have different requirements compared to those served by the Enterprise and Public Sector segment.\n\n4. **Match the information to the given options**:\n   - **A: Public Sector and Enterprise** - This option is not correct because the Business Markets and Other segment serves businesses that do not meet the requirements for Enterprise and Public Sector.\n   - **B: Businesses that meet Enterprise requirements** - This option is not correct for the same reason.\n   - **C: Businesses that meet Public Sector requirements** - This option is also not correct.\n   - **D: Businesses not meeting Enterprise and Public Sector requirements** - This option matches the information provided in the document.\n   - **E: Only IoT companies** - The document does not specify that the segment serves only IoT companies.\n   - **F: Only conferencing service providers** - The document mentions conferencing services but does not specify that the segment serves only conferencing service providers.\n\n5. **Conclude with the correct answer**: Based on the information extracted and interpreted, the correct answer is **D: Businesses not meeting Enterprise and Public Sector requirements**.\n\nTherefore, the type of businesses that Business Markets and Other primarily serves is **D: Businesses not meeting Enterprise and Public Sector requirements**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 80, "token_lengths": 96000, "result": 1.0, "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?", "options": {"A": "Product quality and reliability", "B": "Technological capabilities", "C": "Marketing strategies", "D": "Cost-effectiveness", "E": "Industry experience", "F": "Vendor financing"}, "LLM_original_answer": ["To answer the question, I will analyze the competitive factors mentioned in the provided document and identify which one is not mentioned.\n\n### Analysis of Competitive Factors in the Document:\n1. **Product Quality and Reliability**: The document mentions the importance of product quality and reliability, especially in the context of mission-critical communications and the need for products to be reliable and meet high standards.\n2. **Technological Capabilities**: The document emphasizes the importance of technological capabilities, including the development of new technologies and the integration of AI and other advanced features.\n3. **Marketing Strategies**: The document does not explicitly mention marketing strategies as a competitive factor. It focuses more on the technical and regulatory aspects of the business.\n4. **Cost-effectiveness**: The document discusses the cost-effectiveness of products and services, including the potential for increased costs due to supply chain issues and the need to manage costs in large, multi-year contracts.\n5. **Industry Experience**: The document highlights the importance of industry experience, particularly in the context of the company's long-standing reputation and the experience of its senior management.\n6. **Vendor Financing**: The document mentions the risk of providing vendor financing to customers, especially in response to financial challenges surrounding state and local governments.\n\n### Conclusion:\nThe competitive factor that is **NOT** mentioned in the document is **Marketing Strategies** (Option C).\n\nTherefore, the correct answer is:\n**C: Marketing strategies**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 96000, "result": 1.0, "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?", "options": {"A": "$20.7 million UPB (154 loans)", "B": "$66.7 million UPB (71 loans)", "C": "$20.7 million UPB (354 loans)", "D": "$66.7 million UPB (154 loans)", "E": "$66.7 million UPB (71 loans)", "F": "$20.7 million UPB (71 loans)"}, "LLM_original_answer": ["To answer the question \"What is the total outstanding representation and warranty repurchase demands at December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss representation and warranty repurchase demands.\n2. **Extract Specific Data**: Find the specific data for the year 2023.\n3. **Compare with Options**: Match the extracted data with the given options to find the correct answer.\n\n### Step 1: Identify Relevant Information\nThe relevant information is found in Note 26 \u2014 Contingencies, specifically in the section discussing representation and warranty repurchase demands.\n\n### Step 2: Extract Specific Data\nFrom the document:\n- \"At December 31, 2023 and 2022, we had outstanding representation and warranty repurchase demands of $20.7 million UPB (71 loans) and $66.7 million UPB (354 loans), respectively.\"\n\n### Step 3: Compare with Options\nThe extracted data matches the following option:\n- **A: $20.7 million UPB (154 loans)**\n- **B: $66.7 million UPB (71 loans)**\n- **C: $20.7 million UPB (354 loans)**\n- **D: $66.7 million UPB (154 loans)**\n- **E: $66.7 million UPB (71 loans)**\n- **F: $20.7 million UPB (71 loans)**\n\nThe correct data is:\n- **$20.7 million UPB (71 loans)**\n\n### Final Answer\nThe total outstanding representation and warranty repurchase demands at December 31, 2023 is **$20.7 million UPB (71 loans)**. Therefore, the correct option is **F: $20.7 million UPB (71 loans)**."], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 96000, "result": 1.0, "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?", "options": {"A": "Kansas City and Sioux City", "B": "Des Moines and Minneapolis", "C": "Springfield and St. Louis", "D": "Northwest Arkansas and Eastern Iowa", "E": "Sioux City and Des Moines", "F": "Rural markets in Missouri and Kansas"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document to find the relevant information about the Company's deposit concentrations as of December 31, 2023.\n\n1. **Identify the relevant section in the document:**\n   - The relevant information is found in the \"Market Areas\" section of the document.\n\n2. **Extract the specific information:**\n   - The document states: \"Great Southern\u2019s largest concentrations of deposits and loans are in the Springfield, Missouri, and St. Louis, market areas.\"\n   - It further provides detailed deposit figures: \"At December 31, 2023, the Company had deposits in Missouri of $3.48 billion, which included its two largest deposit concentrations, in the Springfield and St. Louis areas, with $1.95 billion and $588 million, respectively.\"\n\n3. **Match the information to the options:**\n   - The two largest deposit concentrations are in Springfield and St. Louis.\n   - The options provided are:\n     - A: Kansas City and Sioux City\n     - B: Des Moines and Minneapolis\n     - C: Springfield and St. Louis\n     - D: Northwest Arkansas and Eastern Iowa\n     - E: Sioux City and Des Moines\n     - F: Rural markets in Missouri and Kansas\n\n4. **Select the correct option:**\n   - The correct option is C: Springfield and St. Louis.\n\nTherefore, the two largest deposit concentrations of the Company as of December 31, 2023, are located in Springfield and St. Louis."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 96000, "result": 1.0, "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?", "options": {"A": "Two directors", "B": "Three directors", "C": "Four directors", "D": "Five directors", "E": "Six directors", "F": "Seven directors"}, "LLM_original_answer": ["To answer the question \"How many directors are in each class of the QTI Holdings Board following the Effective Time?\", I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the structure of the QTI Holdings Board following the Effective Time in the \"Business Combination\" section.\n\n2. **Extract the specific information about the board structure**: The relevant excerpt is:\n   - \"Following the Effective Time, the board of directors of QT Imaging Holdings (the \u201cQTI Holdings Board\u201d) consists of seven directors classified in three classes, the initial members of which (the \u201cInitial Post-Closing QTI Holdings Directors\u201d) consisted of three individuals identified by GigCapital5 who will serve either in Class I, Class II or Class III, and included the chairman of the QTI Holdings Board, and three individuals identified by QT Imaging who will serve either in Class I, Class II or Class III, and one more board seat was filled by the GigCapital5 Board prior to Closing.\"\n\n3. **Determine the number of directors in each class**: The document states that the QTI Holdings Board consists of seven directors classified into three classes. It also specifies that:\n   - Three individuals were identified by GigCapital5 to serve in Class I, Class II, or Class III.\n   - Three individuals were identified by QT Imaging to serve in Class I, Class II, or Class III.\n   - One more board seat was filled by the GigCapital5 Board.\n\n4. **Calculate the number of directors per class**: Since there are seven directors and three classes, and the document does not specify an unequal distribution, we can assume that the directors are evenly distributed among the three classes. Therefore, each class would have:\n   - \\( \\frac{7 \\text{ directors}}{3 \\text{ classes}} \\approx 2.33 \\text{ directors per class} \\)\n\nHowever, since the number of directors must be a whole number, and the document does not specify an uneven distribution, the most logical and common practice is to have an equal number of directors in each class, with the remaining director being assigned to one of the classes. Given the typical structure, it is reasonable to assume that two classes have 2 directors each, and one class has 3 directors.\n\n5. **Match the calculated number to the provided options**:\n   - A: Two directors\n   - B: Three directors\n   - C: Four directors\n   - D: Five directors\n   - E: Six directors"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 80, "token_lengths": 96000, "result": 1.0, "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?", "options": {"A": "RMB0.8 million", "B": "RMB1.0 million", "C": "RMB1.3 million", "D": "RMB1.5 million", "E": "RMB1.8 million", "F": "RMB2.0 million"}, "LLM_original_answer": ["To answer the question \"What is the average capital spending for a new Pizza Hut restaurant unit in 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for specific mentions of capital spending for new Pizza Hut restaurant units in 2023.\n2. **Extract the Data**: Find the exact figure or range mentioned.\n3. **Verify the Data**: Ensure the data is from the correct year and context.\n4. **Select the Correct Option**: Match the extracted data with the provided options.\n\n### Step 1: Identify Relevant Information\nThe document contains a section that discusses the capital spending for new restaurant units. Specifically, it mentions the average capital spending for KFC and Pizza Hut restaurant units in 2023.\n\n### Step 2: Extract the Data\nThe relevant excerpt is:\n- \"As of December 31, 2023, the average capital spending for each new KFC and Pizza Hut restaurant unit in 2023 was approximately RMB1.5 million and 1.3 million, respectively.\"\n\n### Step 3: Verify the Data\n- The data is from the correct year (2023).\n- The context is about the average capital spending for new restaurant units.\n- The specific figure for Pizza Hut is RMB1.3 million.\n\n### Step 4: Select the Correct Option\n- The options provided are:\n  - A: RMB0.8 million\n  - B: RMB1.0 million\n  - C: RMB1.3 million\n  - D: RMB1.5 million\n  - E: RMB1.8 million\n  - F: RMB2.0 million\n\nThe correct option is **C: RMB1.3 million**.\n\n### Final Answer\nThe average capital spending for a new Pizza Hut restaurant unit in 2023 is **RMB1.3 million**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 96000, "result": 1.0, "question": "What is a potential consequence of failing to effectively manage company growth?", "options": {"A": "Improved financial condition", "B": "Enhanced employee morale", "C": "Improved forecasting accuracy", "D": "Adverse effects on business operations", "E": "Increased employee retention", "F": "Greater operational efficiency"}, "LLM_original_answer": ["To answer the question \"What is a potential consequence of failing to effectively manage company growth?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Growth and Expansion Challenges**:\n   - The document mentions that the growth and expansion of the business create significant challenges for management, operational, and financial resources. (See \"Our Growth Strategy\" and \"Risks Related to Our Business and Industry\" sections.)\n\n2. **Operational and Financial Systems**:\n   - As the company grows, the information technology systems and internal controls and procedures may not be adequate to support the operations. (See \"Our Growth Strategy\" and \"Risks Related to Our Business and Industry\" sections.)\n\n3. **Employee Management**:\n   - The company must continue to improve operational, financial, and management processes and systems, and effectively expand, train, and manage its employee base. (See \"Our Growth Strategy\" section.)\n\n4. **Corporate Culture**:\n   - Growth may make it difficult to maintain the benefits of the corporate culture, such as the ability to quickly develop and launch new and innovative products and solutions. (See \"Our Growth Strategy\" section.)\n\n5. **Operational Efficiency**:\n   - If the company fails to manage its growth effectively, it could negatively affect business performance, including efficiency, ability to meet forecasts, and employee morale, productivity, and retention. (See \"Our Growth Strategy\" section.)\n\n6. **Adverse Effects on Business Operations**:\n   - The document explicitly states that failing to manage growth effectively could harm the business, results of operations, and financial condition. (See \"Our Growth Strategy\" section.)\n\nGiven these points, the most appropriate answer from the provided options is:\n\n**D: Adverse effects on business operations**\n\nThis option directly aligns with the document's emphasis on the potential negative impacts on business performance, operational efficiency, and financial condition if growth is not effectively managed."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 80, "token_lengths": 128000, "result": 1.0, "question": "What happens if the lender makes a margin call and the borrower cannot fund it?", "options": {"A": "The borrower can delay payment without consequences", "B": "The lender must forgive the outstanding debt", "C": "The lender is contractually allowed to liquidate MSRs", "D": "The borrower must immediately pay off all outstanding debts", "E": "The lender cannot take any action", "F": "The borrower can negotiate new terms"}, "LLM_original_answer": ["To answer the question \"What happens if the lender makes a margin call and the borrower cannot fund it?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: The document contains specific information about margin calls and the consequences if the borrower cannot fund them.\n\n2. **Extract the Information**: The relevant section from the document is:\n   - \"Interest rate hedging may fail to protect or could adversely affect us. To the extent we do not utilize derivative financial instruments to hedge against changes in fair value of MSRs or the derivatives we use in our hedging activities do not perform as expected, our business, financial condition, liquidity, results of operations and ability to make distributions to our shareholders would be more susceptible to volatility due to changes in the fair value of, or cash flows from, MSRs as interest rates change.\"\n   - \"A decrease in the fair value of the pledged collateral can result in a margin call. Any such margin call may require that we liquidate assets at a disadvantageous time or provide that the secured parties may sell the collateral, either of which could result in significant losses to us.\"\n\n3. **Analyze the Information**: The document indicates that if a margin call is made and the borrower cannot fund it, the lender is contractually allowed to take specific actions:\n   - The borrower may be required to liquidate assets at a disadvantageous time.\n   - The secured parties may sell the collateral.\n\n4. **Match the Information to the Options**:\n   - **Option A**: The borrower can delay payment without consequences. (Not supported by the document)\n   - **Option B**: The lender must forgive the outstanding debt. (Not supported by the document)\n   - **Option C**: The lender is contractually allowed to liquidate MSRs. (Supported by the document)\n   - **Option D**: The borrower must immediately pay off all outstanding debts. (Not explicitly supported by the document)\n   - **Option E**: The lender cannot take any action. (Not supported by the document)\n   - **Option F**: The borrower can negotiate new terms. (Not supported by the document)\n\n5. **Conclusion**: Based on the information provided in the document, the correct answer is **Option C**: The lender is contractually allowed to liquidate MSRs.\n\nTherefore, the answer to the question is **Option C**: The lender is contractually allowed to liquidate MSRs."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 128000, "result": 1.0, "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?", "options": {"A": "$6.81", "B": "$0.01", "C": "$8.72", "D": "$10.00", "E": "$5.50", "F": "$7.50"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 80, "token_lengths": 128000, "result": 1.0, "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?", "options": {"A": "Duke Energy Carolinas, LLC", "B": "Duke Energy Progress, LLC", "C": "Progress Energy, Inc.", "D": "Piedmont Natural Gas Company, Inc.", "E": "Duke Energy Florida, LLC", "F": "All of the above"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 128000, "result": 0.0, "question": "What type of businesses does Business Markets and Other primarily serve?", "options": {"A": "Public Sector and Enterprise", "B": "Businesses that meet Enterprise requirements", "C": "Businesses that meet Public Sector requirements", "D": "Businesses not meeting Enterprise and Public Sector requirements", "E": "Only IoT companies", "F": "Only conferencing service providers"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "D"}, {"depth": 80, "token_lengths": 128000, "result": 0.0, "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?", "options": {"A": "Product quality and reliability", "B": "Technological capabilities", "C": "Marketing strategies", "D": "Cost-effectiveness", "E": "Industry experience", "F": "Vendor financing"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the competitive factors mentioned and then determine which of the given options is not mentioned.\n\n### Competitive Factors Mentioned in the Document:\n1. **Product Quality and Reliability**: The document mentions the importance of product quality and reliability, particularly in the context of LMR communications systems and devices.\n   - \"We believe that public safety agencies and enterprises continue to trust LMR communications systems and devices because they are purpose-built and designed for reliability, availability, security and resiliency to withstand the most challenging conditions.\"\n\n2. **Technological Capabilities**: The document emphasizes the importance of technological capabilities, especially in the development of new products and services.\n   - \"Our strategy is to generate value through our technologies that help meet the changing needs of our customers around the world in protecting people, property and places.\"\n\n3. **Cost-Effectiveness**: The document discusses the need to manage costs and the impact of cost on the business.\n   - \"We may not be able to increase our prices commensurately with our increased costs, which could negatively impact our financial results or financial condition.\"\n\n4. **Industry Experience**: The document highlights the importance of industry experience, particularly in the context of the company's long-standing presence in the market.\n   - \"We are a global leader in public safety and enterprise security, grounded in nearly 100 years of close customer and community collaboration.\"\n\n5. **Marketing Strategies**: The document mentions the importance of marketing and sales strategies, including the use of cloud-based solutions and AI.\n   - \"Our goal is to help remove silos and barriers between people and technologies, so that data unifies, information flows, operations run and collaboration improves to help strengthen safety and security everywhere.\"\n\n### Competitive Factors Not Mentioned in the Document:\n- **Vendor Financing**: The document does not mention vendor financing as a competitive factor. It only mentions that some customers may request vendor financing, but this is not discussed as a competitive factor.\n  - \"Requests by certain of our government and enterprise customers that we provide vendor financing, including in response to financial challenges surrounding state and local governments, which may cause us to retain exposure to the credit quality of our customers who we finance if we are unable to sell these receivables on terms acceptable to us.\"\n\n### Conclusion:\nThe competitive factor that is **NOT** mentioned in the document is **Vendor Financing**.\n\n**Answer: F: Vendor Financing**"], "LLM_extracted_answer": ["F"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 128000, "result": 1.0, "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?", "options": {"A": "$20.7 million UPB (154 loans)", "B": "$66.7 million UPB (71 loans)", "C": "$20.7 million UPB (354 loans)", "D": "$66.7 million UPB (154 loans)", "E": "$66.7 million UPB (71 loans)", "F": "$20.7 million UPB (71 loans)"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["F"], "ground_truth": "F"}, {"depth": 80, "token_lengths": 128000, "result": 1.0, "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?", "options": {"A": "Kansas City and Sioux City", "B": "Des Moines and Minneapolis", "C": "Springfield and St. Louis", "D": "Northwest Arkansas and Eastern Iowa", "E": "Sioux City and Des Moines", "F": "Rural markets in Missouri and Kansas"}, "LLM_original_answer": ["The document provided does not contain information about the largest deposit concentrations of the Company as of December 31, 2023. However, the information is available in the \"Market Areas\" section of the document, which states:\n\n\"Great Southern\u2019s largest concentrations of deposits and loans are in the Springfield, Missouri, and St. Louis, market areas. Besides the Springfield and St. Louis market areas, the Company has deposit and loan concentrations in the following market areas: Kansas City, Missouri; Sioux City, Iowa; Des Moines, Iowa; Northwest Arkansas; Minneapolis; and Eastern Iowa in the area known as the 'Quad Cities.' At December 31, 2023, the Company\u2019s total deposits were $4.7"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 128000, "result": 0.0, "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?", "options": {"A": "Two directors", "B": "Three directors", "C": "Four directors", "D": "Five directors", "E": "Six directors", "F": "Seven directors"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["!"], "ground_truth": "B"}, {"depth": 80, "token_lengths": 128000, "result": 1.0, "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?", "options": {"A": "RMB0.8 million", "B": "RMB1.0 million", "C": "RMB1.3 million", "D": "RMB1.5 million", "E": "RMB1.8 million", "F": "RMB2.0 million"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 80, "token_lengths": 128000, "result": 1.0, "question": "What is a potential consequence of failing to effectively manage company growth?", "options": {"A": "Improved financial condition", "B": "Enhanced employee morale", "C": "Improved forecasting accuracy", "D": "Adverse effects on business operations", "E": "Increased employee retention", "F": "Greater operational efficiency"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 8000, "result": 1.0, "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?", "options": {"A": "Increased interest rates on loans", "B": "Federal pre-emption benefits", "C": "Adverse consequences", "D": "Automatic license renewal", "E": "Exemption from state requirements", "F": "Reduction in documentation requirements"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document and then select the most appropriate option.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Context**:\n   - The document discusses the regulatory and compliance requirements for mortgage loan production and servicing.\n   - It mentions the consequences of failing to comply with these laws, regulations, and rules.\n\n2. **Relevant Information**:\n   - The document states: \"The failure of our correspondent sellers to comply with any applicable laws, regulations and rules may also result in these adverse consequences.\"\n   - It further elaborates on the potential adverse consequences: \"PLS has in place a compliance program designed to assess areas of risk with respect to loans we acquire from such correspondent sellers. However, we may not detect every violation of law and, to the extent any correspondent sellers with which we do business fail to comply with applicable laws or regulations and any of their loans or MSRs become part of our assets, it could subject us, as an assignee or purchaser of the related loans or MSRs, to monetary penalties or other losses.\"\n\n3. **Evaluate the Options**:\n   - **A: Increased interest rates on loans** - The document does not mention increased interest rates as a consequence of non-compliance.\n   - **B: Federal pre-emption benefits** - The document explicitly states that correspondent sellers do not benefit from federal pre-emption of state requirements.\n   - **C: Adverse consequences** - This option aligns with the document's statement about the potential for monetary penalties or other losses.\n   - **D: Automatic license renewal** - The document does not mention automatic license renewal as a consequence of non-compliance.\n   - **E: Exemption from state requirements** - The document states that correspondent sellers must comply with state requirements and do not benefit from federal pre-emption.\n   - **F: Reduction in documentation requirements** - The document does not mention a reduction in documentation requirements as a consequence of non-compliance.\n\n### Conclusion:\nThe most appropriate answer based on the provided document is **C: Adverse consequences**. This option directly corresponds to the potential monetary penalties or other losses that the document mentions as a result of non-compliance with applicable laws, regulations, and rules by correspondent sellers."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 8000, "result": 1.0, "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?", "options": {"A": "Low operational costs", "B": "Exclusive commercial partnerships", "C": "Reduced regulation requirements", "D": "Access to diverse investment opportunities", "E": "Financial strength ratings from multiple agencies", "F": "Priority in claim settlements"}, "LLM_original_answer": ["To answer the question \"What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the relevant section in the document:**\n   - The document mentions Syndicate 3456 in the context of its operations and the benefits it gains from being part of the Lloyd\u2019s market.\n\n2. **Extract the key information:**\n   - The document states: \"Further, by being part of the Lloyd\u2019s market, Syndicate 3456 benefits from the following four Lloyd\u2019s financial strength ratings: \u2018A\u2019 (Excellent) from A.M. Best; AA- (Very Strong) from Fitch Ratings; AA- (Very Strong) from Kroll Bond Rating Agency; and AA- (Very Strong) from Standard & Poor\u2019s.\"\n\n3. **Evaluate the options:**\n   - **A: Low operational costs** - The document does not mention any specific benefits related to low operational costs for Syndicate 3456.\n   - **B: Exclusive commercial partnerships** - The document does not mention exclusive commercial partnerships as a benefit.\n   - **C: Reduced regulation requirements** - The document does not suggest that being part of the Lloyd\u2019s market reduces regulation requirements.\n   - **D: Access to diverse investment opportunities** - The document does not mention access to diverse investment opportunities as a benefit for Syndicate 3456.\n   - **E: Financial strength ratings from multiple agencies** - The document explicitly states that Syndicate 3456 benefits from multiple financial strength ratings from different agencies.\n   - **F: Priority in claim settlements** - The document does not mention any priority in claim settlements as a benefit.\n\n4. **Conclusion:**\n   - Based on the information provided, the benefit that Syndicate 3456 gains from being part of the Lloyd\u2019s market is **E: Financial strength ratings from multiple agencies**.\n\nTherefore, the correct answer is **E: Financial strength ratings from multiple agencies**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 85, "token_lengths": 8000, "result": 1.0, "question": "What is one potential reason for future decline in the company's revenue growth?", "options": {"A": "Decreasing demand for their platform", "B": "Expansion into new markets", "C": "Improved operational efficiency", "D": "Increased revenue from current customers", "E": "Successful marketing strategies", "F": "Increased demand for their services"}, "LLM_original_answer": ["To answer the question \"What is one potential reason for future decline in the company's revenue growth?\" based on the provided document, let's analyze the options and the relevant information from the document:\n\n### Options:\nA: Decreasing demand for their platform\nB: Expansion into new markets\nC: Improved operational efficiency\nD: Increased revenue from current customers\nE: Successful marketing strategies\nF: Increased demand for their services\n\n### Analysis:\n1. **A: Decreasing demand for their platform**\n   - The document mentions that \"slowing demand for our platform\" is one of the factors that could contribute to declines in revenue growth. Specifically, it states: \"Many factors may contribute to declines in our revenue growth rate, including increased competition, slowing demand for our products and services from existing and new customers, increased regulatory burdens domestically or abroad, a failure by us to continue capitalizing on growth opportunities, terminations of existing contracts by our customers, and the maturation of our business, among others.\"\n   - This directly aligns with the option A, making it a strong candidate.\n\n2. **B: Expansion into new markets**\n   - The document does not suggest that expansion into new markets would lead to a decline in revenue growth. Instead, it highlights opportunities for expansion: \"We believe there are significant opportunities to expand our imagery and software analytical services, as well as our professional and engineering service offerings, to a broad set of domestic and international customers.\"\n   - This option is not supported by the document.\n\n3. **C: Improved operational efficiency**\n   - Improved operational efficiency is generally a positive factor that can lead to cost savings and better performance. The document mentions: \"Our constellation differentiates BlackSky from competitors as it is optimized to provide reliable and dynamic hourly monitoring of among the most strategic, high-value locations and assets where we believe approximately 90% of the world's gross domestic product occurs.\"\n   - This option is not a reason for a decline in revenue growth.\n\n4. **D: Increased revenue from current customers**\n   - The document suggests that increased revenue from current customers is a positive factor. It mentions: \"We provide analytic services to the NGA under an up to five-year $60 million contract and have continued to win task orders on a regular basis.\"\n   - This option is not a reason for a decline in revenue growth.\n\n5. **E: Successful marketing strategies**\n   - Successful marketing strategies are generally positive and can lead to increased customer acquisition and revenue. The document does not mention any"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 85, "token_lengths": 8000, "result": 1.0, "question": "What potential impact could unfavorable economic conditions have on the organization?", "options": {"A": "Ease legal constraints on current services", "B": "Increase profits from outdated technologies", "C": "Reduce affordability and demand for products", "D": "Eliminate the need for technological enhancements", "E": "Reduce costs associated with competitive advantages", "F": "Ensure the rapid adoption of new technologies"}, "LLM_original_answer": ["To answer the question \"What potential impact could unfavorable economic conditions have on the organization?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Economic Conditions and Affordability:**\n   - The document states: \"Unfavorable economic conditions, such as a recession or economic slowdown in the U.S. or elsewhere, or inflation in the markets in which we operate, could negatively affect the affordability of and demand for some of our products and services and our cost of doing business.\"\n   - This directly suggests that unfavorable economic conditions could make the organization's products and services less affordable, leading to reduced demand.\n\n2. **Consumer Behavior:**\n   - \"In difficult economic conditions, consumers may seek to reduce discretionary spending by forgoing purchases of our products, electing to use fewer higher margin services, dropping down in price plans or obtaining lower-cost products and services offered by other companies.\"\n   - This indicates that consumers might cut back on spending, particularly on higher-margin services, which could reduce the organization's revenue and profitability.\n\n3. **Business Customer Impact:**\n   - \"Similarly, under these conditions, the business customers that we serve may delay purchasing decisions, delay full implementation of service offerings or reduce their use of services.\"\n   - Business customers might also reduce their spending, delay purchases, or scale back their use of the organization's services, further impacting revenue and demand.\n\n4. **Financial Impact:**\n   - \"Adverse economic conditions may lead to an increased number of our consumer and business customers that are unable to pay for services.\"\n   - This suggests that the organization might face higher levels of non-payment, leading to increased bad debt and reduced cash flow.\n\n5. **Cost Increases:**\n   - \"Over the last two years, as a result of the inflationary environment in the U.S., we experienced increases in our direct costs, including electricity and other energy-related costs for our network operations, and transportation and labor costs, as well as increased interest expenses related to rising interest rates.\"\n   - Inflation and other economic pressures can increase the organization's operational costs, reducing profit margins.\n\n6. **Impact on Business Strategy:**\n   - \"If our new services fail to gain acceptance in the marketplace, or if costs associated with the implementation and introduction of these services materially increase, our ability to retain and attract customers could be adversely affected.\"\n   - Economic conditions can affect the success of new service introductions and the associated costs, which could hinder the organization's ability to implement its business strategy"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 8000, "result": 1.0, "question": "What is a potential consequence of changes in tax legislation and regulations on the company?", "options": {"A": "Increase in the number of employees", "B": "Decrease in production costs", "C": "Reduction in market share", "D": "Increase in the complexity and cost of tax compliance", "E": "Rise in customer satisfaction", "F": "Improved international partnerships"}, "LLM_original_answer": ["To answer the question \"What is a potential consequence of changes in tax legislation and regulations on the company?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify Relevant Information:**\n   - The document mentions that the company is subject to income taxes in the U.S. and numerous foreign tax jurisdictions.\n   - It highlights that changes in tax laws and accounting principles can negatively impact the company's provision for income taxes and cash tax liability.\n   - Specifically, the Tax Cuts and Jobs Act of 2017 required the company to capitalize and amortize research and experimental expenditures over five or fifteen years, which had a materially negative impact on the company's cash tax liability in 2023 and is expected to continue through 2026.\n   - The document also notes that tax audits and changes in tax legislation, regulations, policies, or practices could increase the company's effective tax rates, complexity, burden, and cost of tax compliance, all of which could impact operating results, cash flows, and financial condition.\n\n2. **Evaluate Each Option:**\n   - **A: Increase in the number of employees** - The document does not mention any direct link between tax legislation changes and an increase in the number of employees.\n   - **B: Decrease in production costs** - The document does not suggest that tax changes would lead to a decrease in production costs. In fact, it implies that tax changes could increase costs.\n   - **C: Reduction in market share** - While the document discusses market competition and technological changes, it does not directly link tax legislation changes to a reduction in market share.\n   - **D: Increase in the complexity and cost of tax compliance** - The document explicitly states that changes in tax legislation and regulations could increase the complexity and cost of tax compliance.\n   - **E: Rise in customer satisfaction** - The document does not mention any relationship between tax legislation changes and customer satisfaction.\n   - **F: Improved international partnerships** - The document does not suggest that tax changes would lead to improved international partnerships.\n\n3. **Conclusion:**\n   - Based on the information provided, the most accurate and directly supported option is **D: Increase in the complexity and cost of tax compliance**.\n\nTherefore, the potential consequence of changes in tax legislation and regulations on the company is **D: Increase in the complexity and cost of tax compliance**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 8000, "result": 1.0, "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?", "options": {"A": "Each procedure is paid individually based on its value", "B": "All procedures are paid at a reduced flat rate", "C": "The highest valued code is paid at 100%, and additional procedures are bundled", "D": "Only cataract procedures are paid separately", "E": "The total payment is calculated based on the average of all procedure values", "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n### Step 1: Identify the Context\nThe question is about how additional procedures are paid when performed during the same operative session with a higher valued code, specifically in the HOPD (Hospital Outpatient Department) setting.\n\n### Step 2: Locate Relevant Information\nThe document provides specific information about payment policies in the HOPD setting under Medicare and many private payors. The relevant section is:\n\n> \"In the HOPD setting, Medicare procedures performed using OMNI and SION as well as cataract procedures, are paid under comprehensive ambulatory payment classifications (\"C-APCs\"). In these circumstances, the highest valued code is paid at 100%, with payment for additional procedures performed during the same operative session bundled into the single highest payment rate. Many commercial payors use a similar payment methodology, but payment rules can vary across health plans, particularly across plan types (e.g., HMO, PPO, POS).\"\n\n### Step 3: Interpret the Information\n- **Highest Valued Code**: The highest valued code is paid at 100%.\n- **Additional Procedures**: Payment for additional procedures is bundled into the highest paid procedure.\n\n### Step 4: Match the Information to the Options\n- **Option A**: Each procedure is paid individually based on its value. (This does not match the information provided.)\n- **Option B**: All procedures are paid at a reduced flat rate. (This does not match the information provided.)\n- **Option C**: The highest valued code is paid at 100%, and additional procedures are bundled. (This matches the information provided.)\n- **Option D**: Only cataract procedures are paid separately. (This does not match the information provided.)\n- **Option E**: The total payment is calculated based on the average of all procedure values. (This does not match the information provided.)\n- **Option F**: Procedures with lower valued codes are paid first, followed by the highest valued code. (This does not match the information provided.)\n\n### Step 5: Conclude\nBased on the information provided in the document, the correct answer is:\n\n**C: The highest valued code is paid at 100%, and additional procedures are bundled.**\n\nThis accurately reflects the payment methodology described for procedures performed in the HOPD setting under Medicare and many private payors."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 8000, "result": 1.0, "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?", "options": {"A": "Loan sales", "B": "Deposit accounts", "C": "Advances from the Federal Home Loan Bank", "D": "Loan repayments", "E": "Cash flows from operations", "F": "Scheduled loan payments"}, "LLM_original_answer": ["To answer the question \"What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the sources of funds in a specific section titled \"Sources of Funds.\"\n\n2. **Extract the key information**: The section states, \"Deposit accounts have traditionally been the principal source of the Bank\u2019s funds for use in lending and for other general business purposes.\"\n\n3. **Match the information to the options**:\n   - **A: Loan sales** - The document mentions loan sales as a source of funds, but it is not described as the principal source.\n   - **B: Deposit accounts** - This matches the statement in the document.\n   - **C: Advances from the Federal Home Loan Bank** - The document mentions this as a source of funds, but not as the principal source.\n   - **D: Loan repayments** - The document mentions loan repayments as a source of funds, but not as the principal source.\n   - **E: Cash flows from operations** - The document mentions cash flows from operations as a source of funds, but not as the principal source.\n   - **F: Scheduled loan payments** - The document mentions scheduled loan payments as a relatively stable source of funds, but not as the principal source.\n\n4. **Conclusion**: Based on the information provided in the document, the principal source of the Bank\u2019s funds for lending and other business purposes is **B: Deposit accounts**.\n\nTherefore, the correct answer is **B: Deposit accounts**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 85, "token_lengths": 8000, "result": 1.0, "question": "What could negatively impact the business if key members of the executive management team cannot be retained?", "options": {"A": "An increase in stock market volatility", "B": "A decrease in operational costs", "C": "The implementation of new technologies", "D": "A delay in the business plan and growth strategies", "E": "A shortage of raw materials", "F": "An expansion into new markets"}, "LLM_original_answer": ["To answer the question \"What could negatively impact the business if key members of the executive management team cannot be retained?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Dependency on Key Management**:\n   - The document explicitly states: \"Our ability to implement our business plan depends on the continued services of key members of our senior management.\"\n   - It further emphasizes: \"In particular, and to a critical extent, we are dependent on the continued efforts and services of the members of management named in the 'Management of the Combined Company following the Business Combination' section.\"\n\n2. **Consequences of Losing Key Management**:\n   - The document mentions: \"If we lose the services of such key members of our management team, we would likely be forced to expend significant time and money in the pursuit of replacement individuals, which may result in a delay in the implementation of our business plan and plan of operations.\"\n   - It also notes: \"We may not be able to find satisfactory replacements on terms that would not be unduly expensive or burdensome to us.\"\n\n3. **Impact on Business**:\n   - The document states: \"The loss of members of our management team, or our inability to attract or retain other qualified individuals, could have a material adverse effect on our business, results of operations and financial condition.\"\n\nGiven these points, the most relevant option that aligns with the information provided in the document is:\n\n**D: A delay in the business plan and growth strategies**\n\nThis option directly addresses the potential negative impact of losing key members of the executive management team, as the document explicitly mentions that such a loss could result in a delay in the implementation of the business plan and growth strategies. The other options do not specifically relate to the retention of key management as described in the document."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 8000, "result": 1.0, "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?", "options": {"A": "Cancel the transfer entirely", "B": "Impose a penalty on the transferee", "C": "Treat it as a direct transfer of Chinese interests", "D": "Reduce the applicable tax rate", "E": "Exempt the transfer from taxes", "F": "Require a local business licence"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document step by step.\n\n### Step 1: Identify the Relevant Section\nThe relevant section for this question is found under \"Gains on Indirect Disposal of Equity Interests in Our China Subsidiaries.\" This section discusses the tax implications of indirect transfers of Chinese interests.\n\n### Step 2: Understand the Context\nThe document states:\n- **Bulletin 7** issued by the STA in February 2015 allows the STA to re-characterize an indirect transfer of Chinese interests as a direct transfer if the arrangement lacks a reasonable commercial purpose and is used to avoid Chinese enterprise income tax.\n- The STA may treat such an indirect transfer as a direct transfer of Chinese interests, subjecting the gains to Chinese enterprise income tax.\n- The transferee or other parties obligated to pay for the transfer are required to withhold the applicable taxes, currently at a rate of up to 10% of the capital gain.\n- Both the transferor and the party obligated to withhold taxes may be subject to penalties if the taxes are not paid or withheld.\n\n### Step 3: Evaluate the Options\n- **A: Cancel the transfer entirely** - The document does not mention the STA canceling the transfer.\n- **B: Impose a penalty on the transferee** - The document mentions that the transferee may be subject to penalties if they fail to withhold the taxes.\n- **C: Treat it as a direct transfer of Chinese interests** - The document explicitly states that the STA may treat an indirect transfer as a direct transfer if it lacks a reasonable commercial purpose.\n- **D: Reduce the applicable tax rate** - The document does not mention reducing the tax rate in such cases.\n- **E: Exempt the transfer from taxes** - The document does not mention exempting the transfer from taxes.\n- **F: Require a local business licence** - The document does not mention requiring a local business license in the context of indirect transfers.\n\n### Step 4: Select the Correct Answer\nBased on the information provided, the correct answer is:\n- **C: Treat it as a direct transfer of Chinese interests**\n\n### Chain of Thoughts\n1. The document clearly states that the STA may re-characterize an indirect transfer as a direct transfer if it lacks a reasonable commercial purpose.\n2. This re-characterization is a specific action taken by the STA to ensure that the transfer is subject to Chinese enterprise income tax.\n3. The other options (A, B, D"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 8000, "result": 1.0, "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?", "options": {"A": "Real-time credit card authorization", "B": "Biometric authentication", "C": "Blockchain encryption", "D": "Virtual private networks", "E": "Firewall protection", "F": "Antivirus software"}, "LLM_original_answer": ["To answer the question \"What specific technology do they rely on from third parties to authorize and verify credit card transactions?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the use of third-party technology for processing payments, including credit card transactions.\n\n2. **Extract the specific technology mentioned**: The relevant excerpt is:\n   - \"Additionally, we engage third-party vendors and service providers to store and otherwise process some of our customers\u2019 personal information, and they may be the targets of cyberattacks, malicious software, phishing schemes, and fraud.\"\n   - \"In particular, Paid Subscribers are required to furnish certain information (including name, mailing address, phone number, email address, and credit card information) (collectively \u201cpersonal information\u201d), which we use to administer our services.\"\n   - \"Additionally, we rely on security and authentication technology licensed from third parties to perform real-time credit card authorization and verification, and at times rely on third parties, including technology consulting firms, to help protect our infrastructure from security threats.\"\n\n3. **Match the extracted information to the given options**:\n   - The document explicitly states that they rely on \"security and authentication technology licensed from third parties to perform real-time credit card authorization and verification.\"\n\n4. **Select the correct option**:\n   - The correct option is **A: Real-time credit card authorization**.\n\n**Chain of thoughts**:\n- The document clearly mentions that they use third-party technology for real-time credit card authorization and verification.\n- This matches directly with option A, which is \"Real-time credit card authorization.\"\n- Options B, C, D, E, and F are not mentioned in the context of authorizing and verifying credit card transactions.\n\nTherefore, the answer is **A: Real-time credit card authorization**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 85, "token_lengths": 16000, "result": 1.0, "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?", "options": {"A": "Increased interest rates on loans", "B": "Federal pre-emption benefits", "C": "Adverse consequences", "D": "Automatic license renewal", "E": "Exemption from state requirements", "F": "Reduction in documentation requirements"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to find relevant information about the consequences of not complying with applicable laws, regulations, and rules by correspondent sellers.\n\n1. **Identify the Context**: The document discusses the business operations of a specialty finance company, particularly focusing on its correspondent production activities, which involve purchasing loans from approved mortgage originators and then selling or pooling these loans.\n\n2. **Locate Relevant Information**: The document mentions the regulatory environment and the potential consequences of non-compliance. Specifically, it states:\n   - \"The failure of our correspondent sellers to comply with any applicable laws, regulations and rules may also result in these adverse consequences.\"\n   - \"While we may have contractual rights to seek indemnity or repurchase from certain lenders, if they are unable to fulfill their indemnity or repurchase obligations to us to a material extent, our business, liquidity, financial condition and results of operations could be materially and adversely affected.\"\n\n3. **Interpret the Information**: The document clearly indicates that non-compliance by correspondent sellers can lead to \"adverse consequences\" for the company. These consequences include:\n   - **Material Adverse Effects**: The failure to comply can result in significant financial and operational impacts, such as increased costs, reduced payments by borrowers, and potential lawsuits or governmental actions.\n   - **Reputational Damage**: Non-compliance can harm the company's reputation, which can have long-term negative effects on business relationships and customer trust.\n   - **Monetary Penalties**: The company may be subject to fines or penalties if it acquires or retains loans or MSRs from non-compliant sellers.\n   - **Litigation and Enforcement Actions**: Non-compliance can lead to legal actions, which can be costly and time-consuming.\n\n4. **Match the Information to the Options**:\n   - **Option A: Increased interest rates on loans** - The document does not mention increased interest rates as a direct consequence of non-compliance.\n   - **Option B: Federal pre-emption benefits** - The document explicitly states that the company does not benefit from federal pre-emption of state requirements.\n   - **Option C: Adverse consequences** - This matches the information provided in the document, which states that non-compliance can result in adverse consequences.\n   - **Option D: Automatic license renewal** - The document does not mention automatic license renewal as a consequence of non-compliance.\n   - **Option E: Exemption from state requirements** - The document states that the company does not benefit from federal pre"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 16000, "result": 1.0, "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?", "options": {"A": "Low operational costs", "B": "Exclusive commercial partnerships", "C": "Reduced regulation requirements", "D": "Access to diverse investment opportunities", "E": "Financial strength ratings from multiple agencies", "F": "Priority in claim settlements"}, "LLM_original_answer": ["To answer the question, I need to identify the specific benefits that Syndicate 3456 gains from being part of the Lloyd\u2019s market. The document provides several pieces of information that can help us determine this.\n\n1. **Lloyd\u2019s Financial Strength Ratings**:\n   - The document states that Syndicate 3456 benefits from the following four Lloyd\u2019s financial strength ratings: \u201cA\u201d (Excellent) from A.M. Best; AA- (Very Strong) from Fitch Ratings; AA- (Very Strong) from Kroll Bond Rating Agency; and AA- (Very Strong) from Standard & Poor\u2019s.\n   - These ratings are important because they reflect the financial strength and stability of the syndicate, which can enhance its credibility and attractiveness to clients and brokers.\n\n2. **Access to Global Insurtech Opportunities**:\n   - The document mentions that Syndicate 3456 commenced insurance operations under the Lloyd\u2019s syndicate-in-a-box model, with Greenlight Re as the sole capital provider. This enables the company to capitalize on global insurtech opportunities.\n   - However, this point is more about the operational model and less about a direct benefit from being part of Lloyd\u2019s.\n\n3. **Regulatory Oversight**:\n   - Syndicate 3456 is subject to oversight by Lloyd\u2019s, which includes annual approval of the business plan and maximum underwriting capacity.\n   - This point highlights regulatory requirements rather than benefits.\n\n4. **Credit Risk Management**:\n   - The document notes that Lloyd\u2019s ratings are important for competing and marketing reinsurance products to clients and brokers.\n   - This reinforces the importance of the financial strength ratings in building trust and credibility.\n\nGiven these points, the most relevant benefit for Syndicate 3456 by being part of the Lloyd\u2019s market is the **financial strength ratings from multiple agencies**. These ratings enhance the syndicate's reputation and ability to attract and retain clients and brokers, which is crucial for its success in the reinsurance market.\n\nTherefore, the correct answer is:\n**E: Financial strength ratings from multiple agencies**."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 85, "token_lengths": 16000, "result": 1.0, "question": "What is one potential reason for future decline in the company's revenue growth?", "options": {"A": "Decreasing demand for their platform", "B": "Expansion into new markets", "C": "Improved operational efficiency", "D": "Increased revenue from current customers", "E": "Successful marketing strategies", "F": "Increased demand for their services"}, "LLM_original_answer": ["To answer the question \"What is one potential reason for future decline in the company's revenue growth?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the Company**: The document is about BlackSky Technology Inc., a space-based intelligence company.\n\n2. **Review the Risk Factors**: The document includes a section titled \"Risk Factors\" which lists various potential risks and uncertainties that could affect the company's business, financial condition, and results of operations.\n\n3. **Analyze the Options**:\n   - **A: Decreasing demand for their platform**: This is mentioned in the risk factors section: \"slowing demand for our platform, increased competition, changes to technology, a decrease in the growth of our overall market, or our failure to continue to take advantage of growth opportunities.\"\n   - **B: Expansion into new markets**: This is not mentioned as a risk factor for revenue decline.\n   - **C: Improved operational efficiency**: This is generally a positive factor and is not mentioned as a risk for revenue decline.\n   - **D: Increased revenue from current customers**: This is a positive factor and is not mentioned as a risk for revenue decline.\n   - **E: Successful marketing strategies**: This is a positive factor and is not mentioned as a risk for revenue decline.\n   - **F: Increased demand for their services**: This is a positive factor and is not mentioned as a risk for revenue decline.\n\n4. **Select the Most Relevant Option**:\n   - The document explicitly mentions \"slowing demand for our platform\" as one of the factors that could contribute to declines in revenue growth. This aligns directly with option A.\n\nTherefore, the most appropriate answer based on the provided document is:\n\n**A: Decreasing demand for their platform**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 85, "token_lengths": 16000, "result": 1.0, "question": "What potential impact could unfavorable economic conditions have on the organization?", "options": {"A": "Ease legal constraints on current services", "B": "Increase profits from outdated technologies", "C": "Reduce affordability and demand for products", "D": "Eliminate the need for technological enhancements", "E": "Reduce costs associated with competitive advantages", "F": "Ensure the rapid adoption of new technologies"}, "LLM_original_answer": ["To answer the question \"What potential impact could unfavorable economic conditions have on the organization?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Revenue and Demand Impact**:\n   - The document mentions that \"Unfavorable economic conditions, such as a recession or economic slowdown in the U.S. or elsewhere, or inflation in the markets in which we operate, could negatively affect the affordability of and demand for some of our products and services and our cost of doing business.\"\n   - It further states that \"In difficult economic conditions, consumers may seek to reduce discretionary spending by forgoing purchases of our products, electing to use fewer higher margin services, dropping down in price plans or obtaining lower-cost products and services offered by other companies.\"\n   - Similarly, \"business customers that we serve may delay purchasing decisions, delay full implementation of service offerings or reduce their use of services.\"\n\n2. **Cost of Doing Business**:\n   - The document notes that \"Over the last two years, as a result of the inflationary environment in the U.S., we experienced increases in our direct costs, including electricity and other energy-related costs for our network operations, and transportation and labor costs, as well as increased interest expenses related to rising interest rates.\"\n   - These increased costs could lead to reduced profits if the company cannot pass them on to customers or reduce them through operational efficiencies.\n\n3. **Customer Payment Issues**:\n   - \"Adverse economic conditions may lead to an increased number of our consumer and business customers that are unable to pay for services.\"\n   - This could result in higher bad debt expenses and reduced cash flow, further impacting the financial health of the organization.\n\n4. **Amplification of Other Risks**:\n   - The document also mentions that \"unfavorable economic conditions could also amplify other risk factors discussed in this section, including, but not limited to, our competitive position and margins.\"\n   - This suggests that economic downturns could exacerbate existing competitive pressures and reduce the company's ability to maintain or increase its profit margins.\n\nGiven these points, the most appropriate answer from the provided options is:\n\n**C: Reduce affordability and demand for products**\n\nThis option directly aligns with the document's discussion of how unfavorable economic conditions can lead to reduced consumer and business demand for the company's products and services, as well as increased costs, which can affect the affordability of these products."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 16000, "result": 1.0, "question": "What is a potential consequence of changes in tax legislation and regulations on the company?", "options": {"A": "Increase in the number of employees", "B": "Decrease in production costs", "C": "Reduction in market share", "D": "Increase in the complexity and cost of tax compliance", "E": "Rise in customer satisfaction", "F": "Improved international partnerships"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document step by step to identify the potential consequences of changes in tax legislation and regulations on the company.\n\n1. **Tax Provisions and Changes**:\n   - The document mentions the \"Act\" which includes various tax provisions, such as an excise tax on stock repurchases, expanded tax credits for clean energy incentives, and a corporate alternative minimum tax for large corporations.\n   - Specifically, the Tax Cuts and Jobs Act (TCJA) of 2017 has a provision impacting Section 174 of the IRC, requiring the capitalization and amortization of research and experimental (R&E) expenses over five or fifteen years, depending on the location of the research.\n\n2. **Impact on the Company**:\n   - The document states that the Company does not expect the Act to have a material impact on its financial statements.\n   - However, it also mentions that the change in the TCJA regarding R&E expenses had a materially negative impact on the Company's cash tax liability in 2023, and this impact is expected to continue through 2026 unless the provisions are repealed or deferred by Congress.\n   - The Company recorded a deferred tax asset of $44.3 million pursuant to the provisions of Section 174 of the IRC for the year ended November 30, 2023.\n\n3. **Potential Consequences**:\n   - **Increase in the Complexity and Cost of Tax Compliance (Option D)**: The document explicitly states that the change in the TCJA regarding R&E expenses has had a materially negative impact on the Company's cash tax liability. This suggests that the company has to manage the capitalization and amortization of these expenses, which increases the complexity and cost of tax compliance.\n   - **Increase in the Number of Employees (Option A)**: There is no direct mention of changes in tax legislation leading to an increase in the number of employees.\n   - **Decrease in Production Costs (Option B)**: The document does not suggest that tax changes have led to a decrease in production costs. In fact, the increased tax liability could lead to higher costs.\n   - **Reduction in Market Share (Option C)**: The document does not indicate that tax changes have directly affected market share.\n   - **Rise in Customer Satisfaction (Option E)**: There is no mention of tax changes impacting customer satisfaction.\n   - **Improved International Partnerships (Option F)**: The document does not suggest that"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 16000, "result": 1.0, "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?", "options": {"A": "Each procedure is paid individually based on its value", "B": "All procedures are paid at a reduced flat rate", "C": "The highest valued code is paid at 100%, and additional procedures are bundled", "D": "Only cataract procedures are paid separately", "E": "The total payment is calculated based on the average of all procedure values", "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The question is about how additional procedures are paid in the HOPD (Hospital Outpatient Department) setting when performed during the same operative session with a higher valued code.\n\n2. **Extract the relevant information**: The relevant information is found in the \"Reimbursement\" section, specifically under \"Reimbursement for Uses of the OMNI Surgical System and SION Surgical Instrument.\"\n\n3. **Analyze the information**:\n   - The document states: \"In the HOPD setting, Medicare procedures performed using OMNI and SION as well as cataract procedures, are paid under comprehensive ambulatory payment classifications (C-APCs).\"\n   - It further explains: \"In these circumstances, the highest valued code is paid at 100%, with payment for additional procedures performed during the same operative session bundled into the single highest payment rate.\"\n\n4. **Match the information to the options**:\n   - **Option A**: Each procedure is paid individually based on its value. This is not correct because the document explicitly states that additional procedures are bundled.\n   - **Option B**: All procedures are paid at a reduced flat rate. This is not correct because the document specifies that the highest valued code is paid at 100%.\n   - **Option C**: The highest valued code is paid at 100%, and additional procedures are bundled. This matches the information provided in the document.\n   - **Option D**: Only cataract procedures are paid separately. This is not correct because the document does not specify that cataract procedures are paid separately.\n   - **Option E**: The total payment is calculated based on the average of all procedure values. This is not correct because the document states that the highest valued code is paid at 100% and additional procedures are bundled.\n   - **Option F**: Procedures with lower valued codes are paid first, followed by the highest valued code. This is not correct because the document states that the highest valued code is paid at 100% and additional procedures are bundled.\n\n5. **Conclusion**: Based on the information provided in the document, the correct answer is **Option C**: The highest valued code is paid at 100%, and additional procedures are bundled.\n\nTherefore, the answer to the question is **Option C**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 16000, "result": 1.0, "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?", "options": {"A": "Loan sales", "B": "Deposit accounts", "C": "Advances from the Federal Home Loan Bank", "D": "Loan repayments", "E": "Cash flows from operations", "F": "Scheduled loan payments"}, "LLM_original_answer": ["To answer the question \"What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the sources of funds for the Bank is titled \"Sources of Funds\" and is found towards the end of the document.\n\n2. **Extract the key information**: The relevant paragraph states:\n   > \"Deposit accounts have traditionally been the principal source of the Bank\u2019s funds for use in lending and for other general business purposes. In addition to deposits, the Bank obtains funds through advances from the Federal Home Loan Bank of Des Moines (\u201cFHLBank\u201d) and other borrowings, loan repayments, loan sales, and cash flows generated from operations.\"\n\n3. **Match the information to the options**:\n   - **Option A: Loan sales** - The document mentions loan sales as a source of funds, but it is not the principal source.\n   - **Option B: Deposit accounts** - The document explicitly states that deposit accounts have traditionally been the principal source of the Bank\u2019s funds.\n   - **Option C: Advances from the Federal Home Loan Bank** - The document mentions advances from the FHLBank as a source of funds, but it is not the principal source.\n   - **Option D: Loan repayments** - The document mentions loan repayments as a source of funds, but it is not the principal source.\n   - **Option E: Cash flows from operations** - The document mentions cash flows from operations as a source of funds, but it is not the principal source.\n   - **Option F: Scheduled loan payments** - The document mentions scheduled loan payments as a relatively stable source of funds, but it is not the principal source.\n\n4. **Conclude the answer**: Based on the information provided in the document, the principal source of the Bank\u2019s funds for lending and other business purposes is **deposit accounts**.\n\nTherefore, the correct answer is **Option B: Deposit accounts**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 85, "token_lengths": 16000, "result": 1.0, "question": "What could negatively impact the business if key members of the executive management team cannot be retained?", "options": {"A": "An increase in stock market volatility", "B": "A decrease in operational costs", "C": "The implementation of new technologies", "D": "A delay in the business plan and growth strategies", "E": "A shortage of raw materials", "F": "An expansion into new markets"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the relevant information that pertains to the potential negative impacts of not retaining key members of the executive management team.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document mentions the importance of key personnel in the \"Risks and Uncertainties\" section.\n   - The \"Risks Related to Our Business, Financial Condition, and Need for Additional Capital\" section also discusses the dependency on key members of the management team.\n\n2. **Extract Key Information:**\n   - **Risks and Uncertainties:**\n     - \"The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, ... dependence on key personnel, ... risks associated with the economic challenges caused by global health crises such as the COVID-19 pandemic and economic uncertainty in various global markets caused by geopolitical instability and conflict.\"\n   - **Risks Related to Our Business, Financial Condition, and Need for Additional Capital:**\n     - \"We are highly dependent on key members of our executive management team. Our inability to retain these individuals could impede our business plan and growth strategies, which could have a negative impact on our business and the value of your investment.\"\n     - \"Our ability to implement our business plan depends on the continued services of key members of our senior management. If we lose the services of such key members of our management team, we would likely be forced to expend significant time and money in the pursuit of replacement individuals, which may result in a delay in the implementation of our business plan and plan of operations.\"\n\n3. **Evaluate the Options:**\n   - **A: An increase in stock market volatility**\n     - While stock market volatility can impact a company, it is not directly related to the retention of key management.\n   - **B: A decrease in operational costs**\n     - A decrease in operational costs is generally positive and not a negative impact.\n   - **C: The implementation of new technologies**\n     - Implementing new technologies is a positive step and not a negative impact.\n   - **D: A delay in the business plan and growth strategies**\n     - The document explicitly states that losing key management could result in a delay in the implementation of the business plan and growth strategies.\n   - **E: A shortage of raw materials**\n     - While a shortage of raw materials can negatively impact a business, it is not directly linked to the retention of key management.\n   - **F"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 16000, "result": 1.0, "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?", "options": {"A": "Cancel the transfer entirely", "B": "Impose a penalty on the transferee", "C": "Treat it as a direct transfer of Chinese interests", "D": "Reduce the applicable tax rate", "E": "Exempt the transfer from taxes", "F": "Require a local business licence"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the Relevant Section**: The section that discusses the treatment of indirect transfers of Chinese interests is found under \"Gains on Indirect Disposal of Equity Interests in Our China Subsidiaries.\"\n\n2. **Understand the Context**: According to the document, the State Administration of Taxation (STA) issued Bulletin 7 in February 2015. This bulletin addresses the tax treatment of indirect transfers of Chinese taxable assets, including equity interests in a China resident enterprise.\n\n3. **Key Points from Bulletin 7**:\n   - An indirect transfer of Chinese interests by a non-resident enterprise may be re-characterized and treated as a direct transfer if the arrangement lacks a reasonable commercial purpose and is used to avoid Chinese enterprise income tax.\n   - If the STA determines that the indirect transfer lacks a reasonable commercial purpose, the gains from such a transfer may be subject to Chinese enterprise income tax.\n   - The transferee or other person obligated to pay for the transfer would be responsible for withholding the applicable taxes, currently at a rate of up to 10% of the capital gain.\n   - Both the transferor and the party obligated to withhold the applicable taxes may be subject to penalties if the transferor fails to pay the taxes and the party obligated to withhold the taxes fails to do so.\n\n4. **Evaluate the Options**:\n   - **A: Cancel the transfer entirely** - The document does not mention the STA canceling the transfer.\n   - **B: Impose a penalty on the transferee** - The document states that the transferee may be subject to penalties if they fail to withhold the taxes.\n   - **C: Treat it as a direct transfer of Chinese interests** - The document explicitly states that the STA may treat the indirect transfer as a direct transfer if it lacks a reasonable commercial purpose.\n   - **D: Reduce the applicable tax rate** - The document does not mention reducing the tax rate for such transfers.\n   - **E: Exempt the transfer from taxes** - The document does not mention exempting the transfer from taxes.\n   - **F: Require a local business licence** - The document does not mention requiring a local business license for such transfers.\n\n5. **Conclusion**: Based on the information provided in the document, the most appropriate action that the STA may take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose is to treat it as a direct transfer of Chinese"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 16000, "result": 1.0, "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?", "options": {"A": "Real-time credit card authorization", "B": "Biometric authentication", "C": "Blockchain encryption", "D": "Virtual private networks", "E": "Firewall protection", "F": "Antivirus software"}, "LLM_original_answer": ["To answer the question \"What specific technology do they rely on from third parties to authorize and verify credit card transactions?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses payment processing and the use of third-party technology is found in the \"Risks Related to Legal and Regulatory Matters\" and \"Our Technology\" sections.\n\n2. **Extract the relevant information**: The document states:\n   - \"Additionally, we rely on security and authentication technology licensed from third parties to perform real-time credit card authorization and verification, and at times rely on third parties, including technology consulting firms, to help protect our infrastructure from security threats.\"\n\n3. **Match the extracted information to the options provided**:\n   - **A: Real-time credit card authorization** - This matches the extracted information.\n   - **B: Biometric authentication** - Not mentioned in the document.\n   - **C: Blockchain encryption** - Not mentioned in the document.\n   - **D: Virtual private networks** - Not mentioned in the document.\n   - **E: Firewall protection** - While mentioned in the context of general security measures, it is not specifically linked to credit card authorization and verification.\n   - **F: Antivirus software** - While mentioned in the context of general security measures, it is not specifically linked to credit card authorization and verification.\n\n4. **Conclude the answer**: Based on the information provided in the document, the specific technology they rely on from third parties to authorize and verify credit card transactions is **real-time credit card authorization**.\n\nTherefore, the correct answer is **A: Real-time credit card authorization**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 85, "token_lengths": 32000, "result": 1.0, "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?", "options": {"A": "Increased interest rates on loans", "B": "Federal pre-emption benefits", "C": "Adverse consequences", "D": "Automatic license renewal", "E": "Exemption from state requirements", "F": "Reduction in documentation requirements"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify any information that directly or indirectly relates to the consequences of not complying with applicable laws, regulations, and rules by correspondent sellers.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document primarily discusses the business operations and risks of Keros Therapeutics, Inc., but it also includes a section on PennyMac Mortgage Investment Trust (PMT) and its correspondent production activities. The relevant section for this question is the \"Risks Related to Our Business\" section, particularly the part that discusses regulatory compliance.\n\n2. **Extract Key Information:**\n   - **Regulatory Compliance:**\n     - \"We and PLS must also comply with a number of federal, state and local consumer protection and state foreclosure laws. These statutes apply to loan origination, servicing, debt collection, marketing, use of credit reports, safeguarding of non-public, personally identifiable information about our clients, foreclosure and claims handling, investment of and interest payments on escrow balances and escrow payment features, and mandate certain disclosures and notices to customers.\"\n     - \"The failure of our correspondent sellers to comply with any applicable laws, regulations and rules may also result in these adverse consequences. PLS has in place a compliance program designed to assess areas of risk with respect to loans we acquire from such correspondent sellers. However, we may not detect every violation of law and, to the extent any correspondent sellers with which we do business fail to comply with applicable laws or regulations and any of their loans or MSRs become part of our assets, it could subject us, as an assignee or purchaser of the related loans or MSRs, to monetary penalties or other losses.\"\n     - \"Our failure or the failure of PLS to operate effectively and in compliance with these laws, regulations and rules could subject us to lawsuits or governmental actions, reputational damages, increased costs of doing business, reduced payments by borrowers, modification of the original terms of loans, permanent forgiveness of debt, foreclosure process delays, increased servicing advances, litigation, enforcement actions, and repurchase and indemnification obligations, which could materially and adversely affect our business, financial condition, liquidity and results of operations and our ability to make distributions to our shareholders.\"\n\n3. **Interpret the Information:**\n   - The document clearly states that non-compliance with applicable laws, regulations, and rules by correspondent sellers can result in a variety of adverse consequences. These include:\n     - **Lawsuits or Governmental Actions:** Correspondent"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 32000, "result": 1.0, "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?", "options": {"A": "Low operational costs", "B": "Exclusive commercial partnerships", "C": "Reduced regulation requirements", "D": "Access to diverse investment opportunities", "E": "Financial strength ratings from multiple agencies", "F": "Priority in claim settlements"}, "LLM_original_answer": ["To answer the question, we need to identify a benefit that Syndicate 3456 gains by being part of the Lloyd\u2019s market. Let's review the relevant information from the document:\n\n1. **Syndicate 3456 and Lloyd\u2019s:**\n   - Syndicate 3456 supports innovative, technology-driven insurance partners (insurtechs).\n   - Syndicate 3456 benefits from Lloyd\u2019s strong credit ratings, which include:\n     - \"A\" (Excellent) from A.M. Best\n     - AA- (Very Strong) from Fitch Ratings\n     - AA- (Very Strong) from Kroll Bond Rating Agency\n     - AA- (Very Strong) from Standard & Poor\u2019s\n\n2. **Benefits of Strong Credit Ratings:**\n   - Strong credit ratings are important for competing and marketing reinsurance products to clients and brokers.\n   - These ratings reflect the financial strength, operating performance, and ability to meet obligations of the reinsurance subsidiaries.\n   - A strong rating can enhance the credibility and trustworthiness of the syndicate, making it more attractive to potential clients and partners.\n\n3. **Evaluating the Options:**\n   - **A: Low operational costs** - The document does not mention any specific benefits related to low operational costs for Syndicate 3456.\n   - **B: Exclusive commercial partnerships** - While Syndicate 3456 supports insurtechs, the document does not specify exclusive commercial partnerships.\n   - **C: Reduced regulation requirements** - The document indicates that Syndicate 3456 is subject to oversight by Lloyd\u2019s and regulatory bodies like the PRA and FCA, which suggests that regulation requirements are not reduced.\n   - **D: Access to diverse investment opportunities** - The document does not mention investment opportunities as a benefit of being part of Lloyd\u2019s.\n   - **E: Financial strength ratings from multiple agencies** - The document explicitly states that Syndicate 3456 benefits from the strong credit ratings provided by multiple agencies.\n   - **F: Priority in claim settlements** - The document does not mention any priority in claim settlements as a benefit of being part of Lloyd\u2019s.\n\nGiven the information provided, the most accurate benefit for Syndicate 3456 by being part of the Lloyd\u2019s market is:\n\n**E: Financial strength ratings from multiple agencies**\n\nThis is supported by the document's detailed mention of the strong credit ratings from A.M. Best, Fitch Ratings"], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 85, "token_lengths": 32000, "result": 1.0, "question": "What is one potential reason for future decline in the company's revenue growth?", "options": {"A": "Decreasing demand for their platform", "B": "Expansion into new markets", "C": "Improved operational efficiency", "D": "Increased revenue from current customers", "E": "Successful marketing strategies", "F": "Increased demand for their services"}, "LLM_original_answer": ["To answer the question \"What is one potential reason for future decline in the company's revenue growth?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Company Overview and Market Position**:\n   - BlackSky is a space-based intelligence company that provides real-time imagery and analytics.\n   - The company's primary customers are U.S. defense and intelligence agencies, international governments, and commercial organizations.\n\n2. **Revenue Growth Factors**:\n   - Revenue growth is driven by the demand for high-revisit, high-resolution imagery and advanced analytics.\n   - The company has a strong focus on subscription-based and fixed fee contracts.\n\n3. **Risks and Uncertainties**:\n   - The document lists several risks that could affect the company's revenue growth:\n     - **Increased Competition**: The market for geospatial imaging and analytics is highly competitive, and new entrants or advancements by existing competitors could reduce demand for BlackSky's services.\n     - **Slowing Demand**: The demand for BlackSky's platform could slow down due to various factors such as economic downturns, changes in customer priorities, or technological shifts.\n     - **Regulatory Burdens**: Changes in government regulations or policies could increase the cost of operations or limit the company's ability to win contracts.\n     - **Customer Contract Termination**: Large contracts can be terminated by customers, including for convenience, which could lead to a significant loss of revenue.\n     - **Sales Cycle Length and Unpredictability**: The sales cycle for BlackSky's products and services is long and unpredictable, making it difficult to maintain consistent revenue growth.\n\n4. **Evaluating the Options**:\n   - **A: Decreasing demand for their platform**: This aligns with the risk of slowing demand for BlackSky's services, which is explicitly mentioned in the document.\n   - **B: Expansion into new markets**: The document suggests that this is a growth strategy, not a risk.\n   - **C: Improved operational efficiency**: This is generally a positive factor that could enhance revenue growth, not a risk.\n   - **D: Increased revenue from current customers**: This is a positive factor and part of the company's growth strategy.\n   - **E: Successful marketing strategies**: This is also a positive factor that could boost revenue growth.\n   - **F: Increased demand for their services**: This is a positive factor and not a risk.\n\n5. **Conclusion**:\n   - The most relevant option that aligns with the risks mentioned in the document is **"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 85, "token_lengths": 32000, "result": 1.0, "question": "What potential impact could unfavorable economic conditions have on the organization?", "options": {"A": "Ease legal constraints on current services", "B": "Increase profits from outdated technologies", "C": "Reduce affordability and demand for products", "D": "Eliminate the need for technological enhancements", "E": "Reduce costs associated with competitive advantages", "F": "Ensure the rapid adoption of new technologies"}, "LLM_original_answer": ["To answer the question \"What potential impact could unfavorable economic conditions have on the organization?\" based on the provided document, I will analyze the relevant sections and options step by step.\n\n### Step 1: Identify Relevant Sections\nThe document primarily discusses the financial and operational aspects of a company, including its pension plans, revenue from contracts, and the sale of its insurance agency business. However, the most relevant section for understanding the impact of unfavorable economic conditions is found in the \"Risk Factors\" section, which explicitly mentions economic conditions.\n\n### Step 2: Analyze the \"Risk Factors\" Section\nThe \"Risk Factors\" section states:\n- **Adverse conditions in the U.S. and international economies could impact our results of operations and financial condition.**\n  - \"Unfavorable economic conditions, such as a recession or economic slowdown in the U.S. or elsewhere, or inflation in the markets in which we operate, could negatively affect the affordability of and demand for some of our products and services and our cost of doing business.\"\n  - \"In difficult economic conditions, consumers may seek to reduce discretionary spending by forgoing purchases of our products, electing to use fewer higher margin services, dropping down in price plans or obtaining lower-cost products and services offered by other companies.\"\n  - \"Similarly, under these conditions, the business customers that we serve may delay purchasing decisions, delay full implementation of service offerings or reduce their use of services.\"\n  - \"Adverse economic conditions may lead to an increased number of our consumer and business customers that are unable to pay for services.\"\n\n### Step 3: Evaluate Each Option\n- **A: Ease legal constraints on current services**\n  - The document does not mention any legal constraints being eased due to economic conditions. This option is not supported by the text.\n- **B: Increase profits from outdated technologies**\n  - The document suggests that the company may phase out outdated and unprofitable technologies, but it does not indicate that unfavorable economic conditions would increase profits from them. This option is not supported by the text.\n- **C: Reduce affordability and demand for products**\n  - The document explicitly states that unfavorable economic conditions could negatively affect the affordability and demand for the company's products and services. This option is strongly supported by the text.\n- **D: Eliminate the need for technological enhancements**\n  - The document does not suggest that unfavorable economic conditions would eliminate the need for technological enhancements. Instead, it emphasizes the importance of adapting to new technologies to remain competitive. This option is not supported by the"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 32000, "result": 1.0, "question": "What is a potential consequence of changes in tax legislation and regulations on the company?", "options": {"A": "Increase in the number of employees", "B": "Decrease in production costs", "C": "Reduction in market share", "D": "Increase in the complexity and cost of tax compliance", "E": "Rise in customer satisfaction", "F": "Improved international partnerships"}, "LLM_original_answer": ["To answer the question \"What is a potential consequence of changes in tax legislation and regulations on the company?\" based on the provided document, I will analyze the relevant sections and options step by step.\n\n### Step 1: Identify Relevant Sections\nThe document contains a section on \"Income Taxes\" which is directly related to the question. Here are the key points from that section:\n- The company accounts for income taxes under the asset and liability method.\n- Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases of assets and liabilities.\n- The company has established a valuation allowance against its deferred tax assets due to the uncertainty of realizing future tax benefits.\n- The company has generated net operating losses (NOLs) and research credit carryforwards.\n- The company is subject to continued examination of its income tax returns, and tax authorities may disagree with its tax positions.\n- The U.S. Inflation Reduction Act (IRA) and the Tax Cuts and Jobs Act (TCJA) have introduced changes that affect the company's tax liability and compliance costs.\n\n### Step 2: Evaluate Each Option\n#### A: Increase in the number of employees\n- The document does not mention any direct link between tax legislation changes and an increase in the number of employees.\n- **Conclusion**: This option is not supported by the document.\n\n#### B: Decrease in production costs\n- The document does not indicate that tax legislation changes would directly reduce production costs.\n- **Conclusion**: This option is not supported by the document.\n\n#### C: Reduction in market share\n- The document does not suggest that tax legislation changes would directly affect market share.\n- **Conclusion**: This option is not supported by the document.\n\n#### D: Increase in the complexity and cost of tax compliance\n- The document explicitly mentions that the company is subject to continued examination of its income tax returns and that tax authorities may disagree with its tax positions.\n- The U.S. Inflation Reduction Act (IRA) and the Tax Cuts and Jobs Act (TCJA) have introduced new compliance requirements and changes in tax laws.\n- The company has established a valuation allowance to offset deferred tax assets, indicating a level of uncertainty and complexity in tax matters.\n- **Conclusion**: This option is strongly supported by the document.\n\n#### E: Rise in customer satisfaction\n- The document does not mention any direct link between tax legislation changes and customer satisfaction.\n- **Conclusion**: This option is not supported by the document.\n\n#### F: Improved international partnerships\n- The document does not suggest"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 32000, "result": 1.0, "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?", "options": {"A": "Each procedure is paid individually based on its value", "B": "All procedures are paid at a reduced flat rate", "C": "The highest valued code is paid at 100%, and additional procedures are bundled", "D": "Only cataract procedures are paid separately", "E": "The total payment is calculated based on the average of all procedure values", "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document and then select the most appropriate option.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Relevant Section:**\n   - The relevant section for understanding how additional procedures are paid in the HOPD setting is found in the \"Reimbursement\" section, specifically under \"Reimbursement for Uses of the OMNI Surgical System and SION Surgical Instrument.\"\n\n2. **Extract Key Information:**\n   - The document states: \"In the HOPD setting, Medicare procedures performed using OMNI and SION as well as cataract procedures, are paid under comprehensive ambulatory payment classifications (\"C-APCs\").\"\n   - It further explains: \"In these circumstances, the highest valued code is paid at 100%, with payment for additional procedures performed during the same operative session bundled into the single highest payment rate.\"\n\n3. **Interpret the Information:**\n   - This means that when multiple procedures are performed in the HOPD setting, the highest valued procedure is paid at its full rate.\n   - All other procedures are bundled into the payment for the highest valued procedure, meaning they do not receive separate payments.\n\n4. **Match the Information to the Options:**\n   - **Option A:** Each procedure is paid individually based on its value. (This does not match the information provided.)\n   - **Option B:** All procedures are paid at a reduced flat rate. (This does not match the information provided.)\n   - **Option C:** The highest valued code is paid at 100%, and additional procedures are bundled. (This matches the information provided.)\n   - **Option D:** Only cataract procedures are paid separately. (This does not match the information provided.)\n   - **Option E:** The total payment is calculated based on the average of all procedure values. (This does not match the information provided.)\n   - **Option F:** Procedures with lower valued codes are paid first, followed by the highest valued code. (This does not match the information provided.)\n\n### Conclusion:\nBased on the information provided in the document, the correct answer is:\n\n**C: The highest valued code is paid at 100%, and additional procedures are bundled.**\n\nThis accurately reflects the payment methodology described for the HOPD setting, where the highest valued procedure is paid at its full rate, and all other procedures are bundled into that payment."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 32000, "result": 1.0, "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?", "options": {"A": "Loan sales", "B": "Deposit accounts", "C": "Advances from the Federal Home Loan Bank", "D": "Loan repayments", "E": "Cash flows from operations", "F": "Scheduled loan payments"}, "LLM_original_answer": ["To answer the question \"What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the sources of the Bank's funds is titled \"Sources of Funds\" and is found in the latter part of the document.\n\n2. **Extract the key information**: The relevant paragraph states:\n   > \"Deposit accounts have traditionally been the principal source of the Bank\u2019s funds for use in lending and for other general business purposes. In addition to deposits, the Bank obtains funds through advances from the Federal Home Loan Bank of Des Moines (\u201cFHLBank\u201d) and other borrowings, loan repayments, loan sales, and cash flows generated from operations.\"\n\n3. **Analyze the information**:\n   - The document explicitly states that \"deposit accounts have traditionally been the principal source of the Bank\u2019s funds for use in lending and for other general business purposes.\"\n   - Other sources of funds are mentioned, but they are listed as additional sources, not the principal source.\n\n4. **Match the information to the options**:\n   - **Option A: Loan sales** - Mentioned as an additional source, not the principal source.\n   - **Option B: Deposit accounts** - Matches the statement in the document.\n   - **Option C: Advances from the Federal Home Loan Bank** - Mentioned as an additional source, not the principal source.\n   - **Option D: Loan repayments** - Mentioned as an additional source, not the principal source.\n   - **Option E: Cash flows from operations** - Mentioned as an additional source, not the principal source.\n   - **Option F: Scheduled loan payments** - Not specifically mentioned as a source of funds, and is likely part of the broader category of \"loan repayments.\"\n\n5. **Conclusion**: Based on the information provided in the document, the principal source of the Bank\u2019s funds for lending and other business purposes is **deposit accounts**.\n\nTherefore, the correct answer is **Option B: Deposit accounts**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 85, "token_lengths": 32000, "result": 1.0, "question": "What could negatively impact the business if key members of the executive management team cannot be retained?", "options": {"A": "An increase in stock market volatility", "B": "A decrease in operational costs", "C": "The implementation of new technologies", "D": "A delay in the business plan and growth strategies", "E": "A shortage of raw materials", "F": "An expansion into new markets"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and consider the context and implications of the options given.\n\n### Step-by-Step Analysis:\n\n1. **Understanding the Context:**\n   - The document is an annual report for Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company.\n   - It discusses the company's financial condition, operations, and the risks associated with its business.\n\n2. **Identifying Key Information:**\n   - The company is heavily dependent on its executive management team for implementing its business plan and growth strategies.\n   - The document mentions that the company's ability to execute its business plan depends on the continued services of key members of its senior management.\n   - It also states that the loss of key management members could force the company to expend significant time and money in finding replacements, leading to delays in business operations.\n\n3. **Evaluating the Options:**\n   - **A: An increase in stock market volatility** - While stock market volatility can affect the company's stock price, it is not directly related to the retention of key management.\n   - **B: A decrease in operational costs** - A decrease in operational costs would generally be positive for the business, not negative.\n   - **C: The implementation of new technologies** - Implementing new technologies is a strategic initiative that can enhance the company's competitive position, not negatively impact it.\n   - **D: A delay in the business plan and growth strategies** - This is directly related to the retention of key management. If key members of the executive team cannot be retained, the company may face delays in executing its business plan and growth strategies.\n   - **E: A shortage of raw materials** - While a shortage of raw materials can negatively impact the business, it is not directly linked to the retention of key management.\n   - **F: An expansion into new markets** - Expanding into new markets is a positive strategic move, not a negative impact.\n\n4. **Conclusion:**\n   - The most relevant and directly negative impact on the business if key members of the executive management team cannot be retained is **D: A delay in the business plan and growth strategies**.\n\n### Final Answer:\n**D: A delay in the business plan and growth strategies**\n\n### Chain of Thoughts:\n- The document emphasizes the importance of key management in executing the business plan and growth strategies.\n- Loss of key management members would lead to significant time and money being spent on finding replacements, which could result in delays.\n- The other options, while potentially"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 32000, "result": 1.0, "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?", "options": {"A": "Cancel the transfer entirely", "B": "Impose a penalty on the transferee", "C": "Treat it as a direct transfer of Chinese interests", "D": "Reduce the applicable tax rate", "E": "Exempt the transfer from taxes", "F": "Require a local business licence"}, "LLM_original_answer": ["To answer the question, we need to focus on the section of the document that discusses the tax implications of indirect transfers of Chinese interests. The relevant section is:\n\n**Gains on Indirect Disposal of Equity Interests in Our China Subsidiaries:**\n- In February 2015, the STA issued the STA\u2019s Bulletin on Several Issues of Enterprise Income Tax on Income Arising from Indirect Transfers of Property by Non-resident Enterprises (\u201cBulletin 7\u201d).\n- Pursuant to Bulletin 7, an \u201cindirect transfer\u201d of Chinese taxable assets, including equity interests in a China resident enterprise (\u201cChinese interests\u201d), by a non-resident enterprise, may be re-characterized and treated as a direct transfer of Chinese taxable assets, if such arrangement does not have a reasonable commercial purpose and the transferor avoids payment of Chinese enterprise income tax.\n- Where a non-resident enterprise conducts an \u201cindirect transfer\u201d of Chinese interests by disposing of equity interests in an offshore holding company, the transferor, transferee, and/or the China resident enterprise being indirectly transferred may report such indirect transfer to the relevant Chinese tax authority, which may in turn report upward to the STA.\n- Using general anti-tax avoidance provisions, the STA may treat such indirect transfer as a direct transfer of Chinese interests if the transfer avoids Chinese tax by way of an arrangement without reasonable commercial purpose.\n- As a result, gains derived from such indirect transfer may be subject to Chinese enterprise income tax, and the transferee or other person who is obligated to pay for the transfer would be obligated to withhold the applicable taxes, currently at a rate of up to 10% of the capital gain in the case of an indirect transfer of equity interests in a China resident enterprise.\n\nFrom this information, we can deduce the following:\n\n1. **Identify the Action Taken by the STA:**\n   - The STA may re-characterize an indirect transfer as a direct transfer if the arrangement lacks a reasonable commercial purpose and is used to avoid Chinese enterprise income tax.\n\n2. **Determine the Appropriate Option:**\n   - Option C: Treat it as a direct transfer of Chinese interests.\n   - This option aligns with the STA's action of re-characterizing the indirect transfer as a direct transfer to ensure that the transfer is subject to Chinese enterprise income tax.\n\nTherefore, the correct answer is:\n\n**C: Treat it as a direct transfer of Chinese interests.**\n\nThis action ensures that the transfer is subject to the appropriate tax regulations and prevents tax avoidance."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 32000, "result": 1.0, "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?", "options": {"A": "Real-time credit card authorization", "B": "Biometric authentication", "C": "Blockchain encryption", "D": "Virtual private networks", "E": "Firewall protection", "F": "Antivirus software"}, "LLM_original_answer": ["To answer the question \"What specific technology do they rely on from third parties to authorize and verify credit card transactions?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss payment processing, credit card transactions, or third-party services related to these activities.\n2. **Extract Key Information**: Extract any information that mentions specific technologies used for credit card authorization and verification.\n3. **Match to Options**: Compare the extracted information to the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in the \"Risks Related to Legal and Regulatory Matters\" part of the document, specifically under the \"Our business requires that we securely collect, process, store, transmit, and dispose of confidential information relating to our operations, subscribers, employees, and other third parties\" subsection.\n\n### Step 2: Extract Key Information\nThe document states:\n- \"Additionally, we rely on security and authentication technology licensed from third parties to perform real-time credit card authorization and verification, and at times rely on third parties, including technology consulting firms, to help protect our infrastructure from security threats.\"\n\n### Step 3: Match to Options\nThe key phrase here is \"real-time credit card authorization and verification.\" This directly matches with option A: \"Real-time credit card authorization.\"\n\n### Conclusion\nThe specific technology they rely on from third parties to authorize and verify credit card transactions is **Real-time credit card authorization**.\n\nTherefore, the correct answer is **A: Real-time credit card authorization**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 85, "token_lengths": 64000, "result": 1.0, "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?", "options": {"A": "Increased interest rates on loans", "B": "Federal pre-emption benefits", "C": "Adverse consequences", "D": "Automatic license renewal", "E": "Exemption from state requirements", "F": "Reduction in documentation requirements"}, "LLM_original_answer": ["The correct answer to the question \"What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?\" is:\n\n**C: Adverse consequences**\n\n### Chain of Thought:\n1. **Context of the Question**: The question is asking about the consequences of non-compliance with laws, regulations, and rules by correspondent sellers. Correspondent sellers are entities that sell loans to aggregators like Keros Therapeutics, Inc.\n\n2. **Relevant Information from the Document**:\n   - The document mentions that the failure of correspondent sellers to comply with applicable laws, regulations, and rules could result in adverse consequences.\n   - Specifically, it states: \"The failure of our correspondent sellers to comply with any applicable laws, regulations and rules may also result in these adverse consequences.\"\n\n3. **Understanding \"Adverse Consequences\"**:\n   - Adverse consequences can include a range of negative outcomes such as lawsuits, governmental actions, reputational damages, increased costs of doing business, reduced payments by borrowers, modification of the original terms of loans, permanent forgiveness of debt, foreclosure process delays, increased servicing advances, litigation, enforcement actions, and repurchase and indemnification obligations.\n\n4. **Elimination of Other Options**:\n   - **A: Increased interest rates on loans** - The document does not mention increased interest rates as a direct consequence of non-compliance.\n   - **B: Federal pre-emption benefits** - The document discusses the lack of federal pre-emption benefits, but this is not a consequence of non-compliance.\n   - **D: Automatic license renewal** - The document does not mention automatic license renewal as a consequence of non-compliance.\n   - **E: Exemption from state requirements** - The document discusses the lack of exemption from state requirements, but this is not a consequence of non-compliance.\n   - **F: Reduction in documentation requirements** - The document does not mention a reduction in documentation requirements as a consequence of non-compliance.\n\n5. **Conclusion**: Based on the information provided in the document, the most accurate and comprehensive answer is \"C: Adverse consequences.\""], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 64000, "result": 1.0, "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?", "options": {"A": "Low operational costs", "B": "Exclusive commercial partnerships", "C": "Reduced regulation requirements", "D": "Access to diverse investment opportunities", "E": "Financial strength ratings from multiple agencies", "F": "Priority in claim settlements"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify any information that directly or indirectly relates to the benefits of Syndicate 3456 being part of the Lloyd\u2019s market.\n\n1. **Relevant Information from the Document:**\n   - **Syndicate 3456 and Lloyd\u2019s:**\n     - \"Our Syndicate 3456 supports innovative, technology-driven insurance partners ('insurtechs').\" (Page 143)\n     - \"Further, by being part of the Lloyd\u2019s market, Syndicate 3456 benefits from the following four Lloyd\u2019s financial strength ratings: 'A' (Excellent) from A.M. Best; AA- (Very Strong) from Fitch Ratings; AA- (Very Strong) from Kroll Bond Rating Agency; and AA- (Very Strong) from Standard & Poor\u2019s.\" (Page 150)\n\n2. **Analysis:**\n   - **Innovative Partnerships:**\n     - The document mentions that Syndicate 3456 supports innovative, technology-driven insurance partners (insurtechs). This suggests that being part of the Lloyd\u2019s market provides Syndicate 3456 with access to a diverse range of innovative and technology-driven opportunities.\n   - **Financial Strength Ratings:**\n     - The document explicitly states that Syndicate 3456 benefits from multiple financial strength ratings from reputable agencies like A.M. Best, Fitch Ratings, Kroll Bond Rating Agency, and Standard & Poor\u2019s. These ratings are crucial for building trust and credibility with clients and brokers, which can enhance the syndicate's ability to attract and retain business.\n\n3. **Matching to the Options:**\n   - **Option A: Low operational costs**\n     - The document does not mention any benefits related to low operational costs for Syndicate 3456.\n   - **Option B: Exclusive commercial partnerships**\n     - While the document mentions innovative partnerships, it does not specify that these are exclusive.\n   - **Option C: Reduced regulation requirements**\n     - The document does not indicate any reduction in regulatory requirements. In fact, it mentions that Syndicate 3456 is subject to oversight by Lloyd\u2019s and regulatory requirements from the PRA and FCA.\n   - **Option D: Access to diverse investment opportunities**\n     - The document does not specifically mention investment opportunities for Syndicate 3456.\n   - **Option E: Financial strength ratings from multiple agencies**\n     - The document explicitly"], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 85, "token_lengths": 64000, "result": 1.0, "question": "What is one potential reason for future decline in the company's revenue growth?", "options": {"A": "Decreasing demand for their platform", "B": "Expansion into new markets", "C": "Improved operational efficiency", "D": "Increased revenue from current customers", "E": "Successful marketing strategies", "F": "Increased demand for their services"}, "LLM_original_answer": ["To answer the question \"What is one potential reason for future decline in the company's revenue growth?\" based on the provided document, I will analyze the content and identify relevant information.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Company and Context**:\n   - The document primarily discusses Duke Energy, a utility company with operations in electric and natural gas services.\n\n2. **Review the Document for Revenue-Related Information**:\n   - The document includes detailed financial and regulatory information, but it does not explicitly mention a decline in revenue growth. However, it does provide insights into factors that could affect revenue.\n\n3. **Analyze Regulatory and Market Factors**:\n   - **Regulatory Approvals and Rate Cases**: Duke Energy frequently files for rate increases and has to navigate regulatory approvals. For example, Duke Energy Carolinas and Duke Energy Progress have filed for rate increases, and the outcomes of these cases can significantly impact revenue.\n   - **Environmental and Legal Costs**: The document mentions significant costs related to environmental remediation and legal proceedings, which can affect the company's financial performance and, by extension, its revenue growth.\n   - **Workforce Realignment and Severance**: Duke Energy has been implementing workforce realignment and offering severance benefits, which can lead to short-term financial impacts.\n\n4. **Consider Market and Customer Dynamics**:\n   - **Customer Base and Demand**: The document does not indicate a significant issue with the customer base or demand for services. However, it mentions that the company is transitioning to a fully regulated utility, which could affect its revenue streams.\n   - **Competition and Market Growth**: The document does not explicitly mention increased competition or a decrease in market growth, but it does discuss the company's strategic initiatives and investments in new technologies and markets.\n\n5. **Evaluate the Options**:\n   - **A: Decreasing demand for their platform**: The document does not suggest a decrease in demand for Duke Energy's services. In fact, it mentions ongoing investments and regulatory approvals for rate increases.\n   - **B: Expansion into new markets**: The document discusses expansion into new markets, which is generally seen as a positive factor for revenue growth.\n   - **C: Improved operational efficiency**: Improved operational efficiency is generally a positive factor and would not lead to a decline in revenue growth.\n   - **D: Increased revenue from current customers**: The document mentions efforts to increase revenue from current customers through rate increases and new services.\n   - **E: Successful marketing strategies**: The document does not provide information on marketing strategies"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 85, "token_lengths": 64000, "result": 1.0, "question": "What potential impact could unfavorable economic conditions have on the organization?", "options": {"A": "Ease legal constraints on current services", "B": "Increase profits from outdated technologies", "C": "Reduce affordability and demand for products", "D": "Eliminate the need for technological enhancements", "E": "Reduce costs associated with competitive advantages", "F": "Ensure the rapid adoption of new technologies"}, "LLM_original_answer": ["To answer the question \"What potential impact could unfavorable economic conditions have on the organization?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Economic Conditions and Their Impact on Loan Portfolios:**\n   - The document discusses the allowance for loan losses and the factors that influence it, including economic conditions. Specifically, it mentions that the Company's methodology for determining the allowance for loan losses includes an assessment of factors such as \"trends in economic conditions, loan growth, credit underwriting policy exceptions, regulatory and audit findings, and peer comparisons\" (p. 128).\n   - Unfavorable economic conditions can lead to increased loan delinquencies and charge-offs, which in turn can increase the allowance for loan losses. This is evident from the statement: \"Total charge-offs increased by $10.3 million to $15.1 million during the year ended December 31, 2023 from $4.8 million during the year ended December 31, 2022. The increase was primarily due to charge-offs on non-performing commercial real estate loans collateralized by properties in the office risk category taken in the fourth quarter of 2023\" (p. 127).\n\n2. **Impact on Borrowers' Ability to Repay:**\n   - The document states that the ability and willingness of borrowers to honor their repayment commitments are generally dependent on the level of overall economic activity within the borrowers' geographic areas and real estate values (p. 126).\n   - Unfavorable economic conditions can reduce the ability of borrowers to meet their repayment commitments, leading to more loans being placed on non-accrual status and potentially increasing the number of non-performing loans.\n\n3. **Impact on Consumer and Business Lending:**\n   - For consumer and business loans, the document notes that \"the ability and willingness of commercial real estate, commercial and industrial, and construction loan borrowers to honor their repayment commitments is generally dependent on the health of the real estate economy in the borrowers' geographic areas and the general economy\" (p. 126).\n   - In difficult economic conditions, consumers may reduce discretionary spending, forgo purchases, or opt for lower-cost products and services. Similarly, business customers may delay purchasing decisions, reduce their use of services, or face financial difficulties that affect their ability to pay (p. 186).\n\n4. **Impact on Revenue and Profitability:**\n   -"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 64000, "result": 1.0, "question": "What is a potential consequence of changes in tax legislation and regulations on the company?", "options": {"A": "Increase in the number of employees", "B": "Decrease in production costs", "C": "Reduction in market share", "D": "Increase in the complexity and cost of tax compliance", "E": "Rise in customer satisfaction", "F": "Improved international partnerships"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and consider the potential consequences of changes in tax legislation and regulations on the company.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Information:**\n   - The document mentions that the company is subject to income taxes in the U.S. and numerous foreign tax jurisdictions.\n   - The company's provision for income taxes and cash tax liability may be negatively impacted by changes in tax laws and accounting principles.\n   - The Tax Cuts and Jobs Act (TCJA) of 2017 required the company to capitalize and amortize research and experimental (R&E) expenses over five or fifteen years, which had a materially negative impact on the company's cash tax liability in 2023.\n   - The company is also subject to continued examination of its income tax returns, and tax authorities may disagree with the company's tax positions and assess additional taxes.\n   - Changes in tax laws and regulations in various countries could increase the company's effective tax rates, complexity, burden, and cost of tax compliance.\n\n2. **Evaluate the Options:**\n   - **A: Increase in the number of employees** - The document does not suggest that changes in tax legislation would directly lead to an increase in the number of employees.\n   - **B: Decrease in production costs** - The document does not indicate that tax changes would reduce production costs.\n   - **C: Reduction in market share** - While the document mentions increased competition, it does not directly link tax changes to a reduction in market share.\n   - **D: Increase in the complexity and cost of tax compliance** - The document explicitly states that changes in tax laws and regulations could increase the complexity, burden, and cost of tax compliance.\n   - **E: Rise in customer satisfaction** - The document does not suggest that tax changes would lead to an increase in customer satisfaction.\n   - **F: Improved international partnerships** - The document does not indicate that tax changes would improve international partnerships.\n\n3. **Conclusion:**\n   - Based on the information provided, the most relevant and directly supported consequence of changes in tax legislation and regulations is an increase in the complexity and cost of tax compliance.\n\n### Final Answer:\n**D: Increase in the complexity and cost of tax compliance**\n\n### Chain of Thoughts:\n- The document highlights that the company is subject to income taxes in multiple jurisdictions.\n- It mentions the significant impact of the TCJA on the company's tax liability, specifically the requirement to capitalize and amortize R&E"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 64000, "result": 1.0, "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?", "options": {"A": "Each procedure is paid individually based on its value", "B": "All procedures are paid at a reduced flat rate", "C": "The highest valued code is paid at 100%, and additional procedures are bundled", "D": "Only cataract procedures are paid separately", "E": "The total payment is calculated based on the average of all procedure values", "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"}, "LLM_original_answer": ["The correct answer to the question \"In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?\" is:\n\n**C: The highest valued code is paid at 100%, and additional procedures are bundled**\n\n### Chain of Thought:\n1. **Context of the Question**: The question is asking about the payment methodology for multiple procedures performed in the same operative session in a Hospital Outpatient Department (HOPD) setting, specifically when one of the procedures has a higher value than the others.\n\n2. **Relevant Information from the Document**: The document provides the following relevant information:\n   - \"In the HOPD setting, Medicare procedures performed using OMNI and SION as well as cataract procedures, are paid under comprehensive ambulatory payment classifications (C-APCs).\"\n   - \"In these circumstances, the highest valued code will be paid at 100%, with payment for additional procedures performed during the same operative session bundled into the single highest payment rate.\"\n\n3. **Interpretation**:\n   - The document clearly states that in the HOPD setting, the highest valued code is paid at 100%.\n   - Additional procedures are bundled into the payment for the highest valued code, meaning they are not paid individually but are included in the overall payment for the highest valued procedure.\n\n4. **Conclusion**: Based on the information provided, the correct answer is that the highest valued code is paid at 100%, and additional procedures are bundled into this payment.\n\nTherefore, the answer is **C: The highest valued code is paid at 100%, and additional procedures are bundled**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 64000, "result": 1.0, "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?", "options": {"A": "Loan sales", "B": "Deposit accounts", "C": "Advances from the Federal Home Loan Bank", "D": "Loan repayments", "E": "Cash flows from operations", "F": "Scheduled loan payments"}, "LLM_original_answer": ["The correct answer to the question \"What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?\" is:\n\n**B: Deposit accounts**\n\n### Chain of Thought:\n1. **Review the Document**: The document provides a detailed overview of the Bank's operations, including its sources of funds.\n2. **Identify Relevant Section**: The section titled \"Sources of Funds\" is particularly relevant to this question.\n3. **Extract Key Information**: The document states, \"Deposit accounts have traditionally been the principal source of the Bank\u2019s funds for use in lending and for other general business purposes.\"\n4. **Evaluate Options**: \n   - **A: Loan sales** - The document mentions loan sales but does not indicate they are the principal source of funds.\n   - **B: Deposit accounts** - This matches the statement in the document.\n   - **C: Advances from the Federal Home Loan Bank** - While mentioned as a source, it is not described as the principal source.\n   - **D: Loan repayments** - Loan repayments are a source of funds but not the principal one.\n   - **E: Cash flows from operations** - Cash flows from operations are mentioned but not as the principal source.\n   - **F: Scheduled loan payments** - Similar to loan repayments, these are a source but not the principal one.\n5. **Conclusion**: Based on the document, the principal source of the Bank\u2019s funds for lending and other business purposes is deposit accounts.\n\nThus, the correct answer is **B: Deposit accounts**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 85, "token_lengths": 64000, "result": 1.0, "question": "What could negatively impact the business if key members of the executive management team cannot be retained?", "options": {"A": "An increase in stock market volatility", "B": "A decrease in operational costs", "C": "The implementation of new technologies", "D": "A delay in the business plan and growth strategies", "E": "A shortage of raw materials", "F": "An expansion into new markets"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the relevant information that pertains to the potential negative impacts of not retaining key members of the executive management team.\n\n### Relevant Information from the Document:\n1. **Dependency on Key Personnel:**\n   - \"Our success depends, and will likely continue to depend, upon our ability to hire and retain the services of our current executive officers, principal consultants and others.\"\n   - \"The loss of their services might impede the achievement of our research, development and commercialization objectives.\"\n   - \"Our ability to compete in the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel.\"\n\n2. **Impact on Business Operations:**\n   - \"Replacing executive officers or other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully.\"\n   - \"Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key employees on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.\"\n\n3. **Impact on Development and Commercialization:**\n   - \"Our industry has experienced a high rate of turnover of management personnel in recent years.\"\n   - \"Our ability to develop and commercialize AMX0035 or any other current or future product candidates will be limited if we are unable to continue to attract and retain highly qualified personnel.\"\n\n### Analysis:\n- **Dependency on Key Personnel:** The document emphasizes that the company's success is heavily dependent on the services of its current executive officers and principal consultants. The loss of these individuals could impede the company's ability to achieve its research, development, and commercialization objectives.\n- **Impact on Business Operations:** Replacing key personnel is challenging due to the limited pool of qualified individuals in the biotechnology and pharmaceutical industries. This could lead to delays in hiring and training new employees, which would negatively impact the company's operations.\n- **Impact on Development and Commercialization:** The high rate of turnover in the industry and the intense competition for qualified personnel could limit the company's ability to develop and commercialize its products, including AMX0035.\n\n### Conclusion:\nBased on the information provided in the document, the most relevant option that could negatively impact the business if key members of the executive management team cannot be retained is:\n\n**D: A"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 64000, "result": 1.0, "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?", "options": {"A": "Cancel the transfer entirely", "B": "Impose a penalty on the transferee", "C": "Treat it as a direct transfer of Chinese interests", "D": "Reduce the applicable tax rate", "E": "Exempt the transfer from taxes", "F": "Require a local business licence"}, "LLM_original_answer": ["To answer the question, we need to focus on the section of the document that discusses the Chinese tax authorities' treatment of indirect transfers of equity interests. The relevant section is:\n\n\"In February 2015, the STA issued the STA\u2019s Bulletin on Several Issues of Enterprise Income Tax on Income Arising from Indirect Transfers of Property by Non-resident Enterprises (\u201cBulletin 7\u201d). Pursuant to Bulletin 7, an \u201cindirect transfer\u201d of Chinese taxable assets, including equity interests in a China resident enterprise (\u201cChinese interests\u201d), by a non-resident enterprise, may be re-characterized and treated as a direct transfer of Chinese taxable assets, if such arrangement does not have reasonable commercial purpose and the transferor avoids payment of Chinese enterprise income tax.\"\n\nFrom this, we can deduce that if the STA determines that an indirect transfer of Chinese interests lacks a reasonable commercial purpose, the STA may re-characterize the transfer as a direct transfer of Chinese interests. This re-characterization would subject the transfer to Chinese enterprise income tax.\n\nTherefore, the correct answer is:\n\nC: Treat it as a direct transfer of Chinese interests\n\nThis action aligns with the STA's authority to re-characterize indirect transfers to ensure that they are not used to avoid Chinese tax obligations."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 64000, "result": 1.0, "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?", "options": {"A": "Real-time credit card authorization", "B": "Biometric authentication", "C": "Blockchain encryption", "D": "Virtual private networks", "E": "Firewall protection", "F": "Antivirus software"}, "LLM_original_answer": ["To answer the question \"What specific technology do they rely on from third parties to authorize and verify credit card transactions?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Scan the document for sections that discuss payment processing, credit card transactions, or third-party technology used for financial transactions.\n\n2. **Extract Information**: From the identified sections, extract any information related to third-party technology used for credit card authorization and verification.\n\n3. **Evaluate Options**: Compare the extracted information with the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in the \"Our Technology\" and \"Risks Related to Our Business and Industry\" sections, particularly where they discuss the use of third-party technology for security and payment processing.\n\n### Step 2: Extract Information\nFrom the \"Our Technology\" section:\n- \"We rely on internal systems and third-party technology to perform real-time credit card authorization and verification.\"\n\nFrom the \"Risks Related to Our Business and Industry\" section:\n- \"Additionally, we rely on security and authentication technology licensed from third parties to perform real-time credit card authorization and verification, and at times rely on third parties, including technology consulting firms, to help protect our infrastructure from security threats.\"\n\n### Step 3: Evaluate Options\n- **Option A: Real-time credit card authorization**: This matches the information extracted from the document, which explicitly states that the company relies on third-party technology for real-time credit card authorization and verification.\n- **Option B: Biometric authentication**: The document does not mention biometric authentication.\n- **Option C: Blockchain encryption**: The document does not mention blockchain encryption.\n- **Option D: Virtual private networks**: The document does not mention virtual private networks.\n- **Option E: Firewall protection**: While the document mentions firewalls as part of their security measures, it does not specifically state that they are used for credit card authorization and verification.\n- **Option F: Antivirus software**: The document mentions antivirus software as part of their security measures, but it does not specifically state that they are used for credit card authorization and verification.\n\n### Conclusion\nThe correct answer is **Option A: Real-time credit card authorization**. The document explicitly states that the company relies on third-party technology for real-time credit card authorization and verification."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 85, "token_lengths": 96000, "result": 1.0, "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?", "options": {"A": "Increased interest rates on loans", "B": "Federal pre-emption benefits", "C": "Adverse consequences", "D": "Automatic license renewal", "E": "Exemption from state requirements", "F": "Reduction in documentation requirements"}, "LLM_original_answer": ["The correct answer to the question \"What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?\" is:\n\n**C: Adverse consequences**\n\n### Chain of Thoughts:\n1. **Context from the Document:**\n   - The document discusses the risks and regulations associated with the mortgage and real estate industry, particularly focusing on the activities of correspondent sellers.\n   - It mentions that correspondent sellers must comply with various laws, regulations, and rules, including those related to loan production, servicing, and the protection of personal data.\n\n2. **Relevant Information:**\n   - The document states: \"The failure of our correspondent sellers to comply with any applicable laws, regulations and rules may also result in these adverse consequences.\"\n   - This directly links non-compliance with adverse consequences.\n\n3. **Elimination of Other Options:**\n   - **A: Increased interest rates on loans** - The document does not mention increased interest rates as a direct consequence of non-compliance.\n   - **B: Federal pre-emption benefits** - The document discusses federal pre-emption but not as a benefit of non-compliance.\n   - **D: Automatic license renewal** - The document does not suggest that non-compliance leads to automatic license renewal.\n   - **E: Exemption from state requirements** - The document does not indicate that non-compliance results in exemption from state requirements.\n   - **F: Reduction in documentation requirements** - The document does not mention a reduction in documentation requirements as a consequence of non-compliance.\n\n4. **Conclusion:**\n   - The document explicitly states that non-compliance can lead to adverse consequences, which aligns with option C.\n\nTherefore, the correct answer is **C: Adverse consequences**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 96000, "result": 1.0, "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?", "options": {"A": "Low operational costs", "B": "Exclusive commercial partnerships", "C": "Reduced regulation requirements", "D": "Access to diverse investment opportunities", "E": "Financial strength ratings from multiple agencies", "F": "Priority in claim settlements"}, "LLM_original_answer": ["To answer the question, we need to identify a benefit for Syndicate 3456 by being part of the Lloyd\u2019s market. Let's analyze the provided document for relevant information.\n\n1. **Syndicate 3456 and Lloyd\u2019s:**\n   - The document mentions that Syndicate 3456 is part of the Lloyd\u2019s market.\n   - It states that Syndicate 3456 supports innovative, technology-driven insurance partners (insurtechs).\n\n2. **Lloyd\u2019s Financial Strength Ratings:**\n   - The document highlights that Syndicate 3456 benefits from the strong credit ratings of Lloyd\u2019s.\n   - Specifically, it mentions the following ratings:\n     - A (Excellent) from A.M. Best\n     - AA- (Very Strong) from Fitch Ratings\n     - AA- (Very Strong) from Kroll Bond Rating Agency\n     - AA- (Very Strong) from Standard & Poor\u2019s\n\n3. **Impact of Ratings:**\n   - Strong financial strength ratings are crucial for reinsurers as they provide assurance to clients and brokers about the reinsurer's ability to meet its financial obligations.\n   - These ratings can enhance the credibility and trustworthiness of Syndicate 3456, making it more attractive to potential clients and partners.\n\nGiven this information, the benefit for Syndicate 3456 by being part of the Lloyd\u2019s market is:\n\n**E: Financial strength ratings from multiple agencies**\n\nThis benefit is directly supported by the document, which explicitly mentions the strong financial strength ratings that Syndicate 3456 benefits from due to its association with Lloyd\u2019s. These ratings are important for maintaining trust and credibility in the reinsurance market, which can help Syndicate 3456 attract and retain clients."], "LLM_extracted_answer": ["E"], "ground_truth": "E"}, {"depth": 85, "token_lengths": 96000, "result": 1.0, "question": "What is one potential reason for future decline in the company's revenue growth?", "options": {"A": "Decreasing demand for their platform", "B": "Expansion into new markets", "C": "Improved operational efficiency", "D": "Increased revenue from current customers", "E": "Successful marketing strategies", "F": "Increased demand for their services"}, "LLM_original_answer": ["To answer the question \"What is one potential reason for future decline in the company's revenue growth?\" based on the provided document, I will analyze the content and identify the most relevant option from the given choices.\n\n### Step-by-Step Analysis:\n\n1. **Document Overview**:\n   - The document primarily discusses Duke Energy, a regulated utility company, and its various segments, regulatory matters, and financial statements.\n   - It covers topics such as rate regulation, environmental regulations, and the company's strategies for managing risks and ensuring compliance.\n\n2. **Regulatory and Environmental Risks**:\n   - The document mentions several regulatory and environmental risks that could impact Duke Energy's operations and financial performance.\n   - For example, the company is subject to regulations regarding coal ash and nuclear decommissioning, which could lead to significant costs and potential revenue impacts.\n\n3. **Revenue Recognition and Customer Base**:\n   - Duke Energy recognizes revenue based on the delivery of electricity and natural gas, and the majority of its revenue is from regulated operations.\n   - The company's revenue is influenced by customer demand, which can be affected by economic conditions, regulatory changes, and environmental factors.\n\n4. **Potential Decline in Revenue Growth**:\n   - **Option A: Decreasing demand for their platform** - The document does not specifically mention a platform, but it does discuss the potential for decreasing demand for electricity and natural gas due to economic conditions, regulatory changes, and environmental factors.\n   - **Option B: Expansion into new markets** - The document discusses the company's efforts to expand into new markets, particularly in renewable energy, which is seen as a growth opportunity rather than a risk.\n   - **Option C: Improved operational efficiency** - The document mentions efforts to improve operational efficiency, which is generally seen as a positive factor that could reduce costs and improve profitability, not as a reason for revenue decline.\n   - **Option D: Increased revenue from current customers** - The document does not suggest that increased revenue from current customers is a risk; rather, it is a positive factor.\n   - **Option E: Successful marketing strategies** - Similar to Option D, successful marketing strategies are generally seen as a positive factor that could increase revenue.\n   - **Option F: Increased demand for their services** - The document does not suggest that increased demand is a risk; it is generally seen as a positive factor.\n\n5. **Economic and Regulatory Factors**:\n   - The document highlights the impact of economic conditions on customer demand, particularly in the context of the company"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 85, "token_lengths": 96000, "result": 1.0, "question": "What potential impact could unfavorable economic conditions have on the organization?", "options": {"A": "Ease legal constraints on current services", "B": "Increase profits from outdated technologies", "C": "Reduce affordability and demand for products", "D": "Eliminate the need for technological enhancements", "E": "Reduce costs associated with competitive advantages", "F": "Ensure the rapid adoption of new technologies"}, "LLM_original_answer": ["To answer the question \"What potential impact could unfavorable economic conditions have on the organization?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Economic Conditions and Demand for Products:**\n   - The document mentions that the company's financial performance is influenced by economic conditions, particularly in the context of consumer and business spending.\n   - It states, \"Adverse conditions in the U.S. and international economies could impact our results of operations and financial condition. Unfavorable economic conditions, such as a recession or economic slowdown in the U.S. or elsewhere, or inflation in the markets in which we operate, could negatively affect the affordability of and demand for some of our products and services and our cost of doing business.\"\n\n2. **Consumer Behavior:**\n   - In difficult economic conditions, consumers may reduce discretionary spending, which could affect the company's product sales.\n   - The document notes, \"In difficult economic conditions, consumers may seek to reduce discretionary spending by forgoing purchases of our products, electing to use fewer higher margin services, dropping down in price plans or obtaining lower-cost products and services offered by other companies.\"\n\n3. **Business Customers:**\n   - Similarly, business customers may delay purchasing decisions or reduce their use of services.\n   - The document states, \"Similarly, under these conditions, the business customers that we serve may delay purchasing decisions, delay full implementation of service offerings or reduce their use of services.\"\n\n4. **Impact on Revenues and Earnings:**\n   - These changes in consumer and business behavior can lead to lower revenues and earnings.\n   - The document mentions, \"If we are not able to respond successfully to these competitive challenges, our results of operations and financial condition could be adversely impacted.\"\n\n5. **Credit Losses and Bad Debt:**\n   - Unfavorable economic conditions can also lead to an increase in the number of customers who are unable to pay for services, resulting in higher credit losses and bad debt.\n   - The document notes, \"an increase of $603 million in the provision for credit losses resulting from additional bad debt reserves as collections return to pre-pandemic levels, coupled with an increase in wireless retail postpaid gross additions.\"\n\n6. **Operational Costs:**\n   - The company may also face increased operational costs, such as higher interest expenses due to rising interest rates.\n   - The document states, \"Total interest expense increased during 2023 compared to 2022 primarily as a result of an increase"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 96000, "result": 1.0, "question": "What is a potential consequence of changes in tax legislation and regulations on the company?", "options": {"A": "Increase in the number of employees", "B": "Decrease in production costs", "C": "Reduction in market share", "D": "Increase in the complexity and cost of tax compliance", "E": "Rise in customer satisfaction", "F": "Improved international partnerships"}, "LLM_original_answer": ["To answer the question \"What is a potential consequence of changes in tax legislation and regulations on the company?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Tax Legislation and Compliance**:\n   - The document mentions that the company is subject to income taxes in the U.S. and numerous foreign tax jurisdictions.\n   - It also notes that the company's provision for income taxes and cash tax liability can be negatively impacted by changes in tax laws and accounting principles.\n\n2. **Specific Tax Changes**:\n   - The document highlights the Tax Cuts and Jobs Act (TCJA) of 2017, which significantly reformed the Internal Revenue Code.\n   - One specific change is the requirement for companies to capitalize and amortize research and experimental (R&E) expenses over five years for research performed in the U.S. and 15 years for research performed outside the U.S., starting from tax years beginning on or after January 1, 2022.\n   - This change had a materially negative impact on the company's cash tax liability in 2023, and it is expected to continue to impact the company through 2026.\n\n3. **Impact on Financial Performance**:\n   - The document states that the company's financial performance can be affected by changes in the mix of earnings taxable in jurisdictions with different statutory tax rates.\n   - It also mentions that changes in tax laws and regulations can increase the company's effective tax rates, reduce its tax benefits, and increase the complexity and cost of tax compliance.\n\n4. **Potential Consequences**:\n   - **Increase in the complexity and cost of tax compliance (Option D)**: The document explicitly mentions that changes in tax laws and regulations can increase the complexity and cost of tax compliance. This is a direct consequence of the changes in tax legislation, such as the requirement to capitalize and amortize R&E expenses, which adds to the company's administrative and financial burden.\n\n5. **Other Options**:\n   - **Increase in the number of employees (Option A)**: The document does not suggest that changes in tax legislation would lead to an increase in the number of employees.\n   - **Decrease in production costs (Option B)**: The document does not indicate that tax changes would reduce production costs; in fact, increased compliance costs could lead to higher overall costs.\n   - **Reduction in market share (Option C)**: The document does not link tax changes to a reduction in market share.\n   -"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 96000, "result": 1.0, "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?", "options": {"A": "Each procedure is paid individually based on its value", "B": "All procedures are paid at a reduced flat rate", "C": "The highest valued code is paid at 100%, and additional procedures are bundled", "D": "Only cataract procedures are paid separately", "E": "The total payment is calculated based on the average of all procedure values", "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document, particularly focusing on the sections that discuss the payment and reimbursement policies for procedures performed in the HOPD setting.\n\n### Step-by-Step Analysis:\n\n1. **Reimbursement for Procedures in HOPD Setting:**\n   - The document states: \"In the HOPD setting, Medicare procedures performed using OMNI and SION as well as cataract procedures, are paid under comprehensive ambulatory payment classifications (C-APCs).\"\n   - It further explains: \"In these circumstances, the highest valued code is paid at 100%, with payment for additional procedures performed during the same operative session bundled into the single highest payment rate.\"\n\n2. **Multiple Procedure Payment Reduction Rules:**\n   - The document mentions: \"Many commercial payors use a similar payment methodology, but payment rules can vary across health plans, particularly across plan types (e.g., HMO, PPO, POS).\"\n   - However, for Medicare, the document is clear: \"the highest valued code is paid at 100%, with payment for additional procedures performed during the same operative session bundled into the single highest payment rate.\"\n\n3. **Comparison with ASC Setting:**\n   - The document also provides a comparison with the ASC setting: \"Based on POAG prevalence, we estimate that currently approximately 70% of patients who receive glaucoma treatment are covered by Medicare (fee-for-service and Medicare Advantage plans).\"\n   - It notes that in the ASC setting, \"Multiple procedure payment reduction rules apply. Therefore, when a canaloplasty or goniotomy is performed with cataract surgery on the same patient on the same day, payment of the lower-cost procedure (most commonly the cataract procedure) is reduced by 50%.\"\n\n4. **Conclusion:**\n   - The document explicitly states that in the HOPD setting, the highest valued code is paid at 100%, and additional procedures are bundled into the single highest payment rate.\n   - This means that the highest valued procedure is fully paid, and the additional procedures are not paid individually but are included in the payment for the highest valued procedure.\n\n### Final Answer:\nThe correct answer is **C: The highest valued code is paid at 100%, and additional procedures are bundled**.\n\nThis answer is directly supported by the information provided in the document, which clearly states the payment methodology for procedures performed in the HOPD setting under Medicare."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 96000, "result": 1.0, "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?", "options": {"A": "Loan sales", "B": "Deposit accounts", "C": "Advances from the Federal Home Loan Bank", "D": "Loan repayments", "E": "Cash flows from operations", "F": "Scheduled loan payments"}, "LLM_original_answer": ["The correct answer to the question \"What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?\" is:\n\n**B: Deposit accounts**\n\n### Chain of Thoughts:\n1. **Review the Document**: The document provides detailed information about the Bank's operations, including its sources of funds.\n2. **Identify Relevant Section**: The relevant section is found under \"Sources of Funds\" in the document.\n3. **Extract Key Information**: The document states, \"Deposit accounts have traditionally been the principal source of the Bank\u2019s funds for use in lending and for other general business purposes.\"\n4. **Match with Options**: The statement directly matches with option B: Deposit accounts.\n5. **Confirm Answer**: No other option in the list (A, C, D, E, F) is mentioned as the principal source of funds for the Bank.\n\nThus, the principal source of the Bank\u2019s funds for lending and other business purposes is deposit accounts."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 85, "token_lengths": 96000, "result": 1.0, "question": "What could negatively impact the business if key members of the executive management team cannot be retained?", "options": {"A": "An increase in stock market volatility", "B": "A decrease in operational costs", "C": "The implementation of new technologies", "D": "A delay in the business plan and growth strategies", "E": "A shortage of raw materials", "F": "An expansion into new markets"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the potential impacts of not retaining key members of the executive management team.\n\n### Analysis of the Document\n\n1. **Importance of Key Personnel**:\n   - The document emphasizes the critical role of key members of the executive management team: \"Our success depends, and will likely continue to depend, upon our ability to hire and retain the services of our current executive officers, principal consultants and others\" (p. 103).\n   - It also mentions the recent changes in key personnel: \"In February 2024, our then Chief Human Resource Officer, Debra Canner, was replaced by Linda Arsenault as our current Chief Human Resource Officer. In December 2023, our then Global Head of Clinical R&D and Chief Medical Officer, Patrick Yeramian, M.D., was replaced by Camille L. Bedrosian, MD as our current Chief Medical Officer. Additionally, in December, 2023, our then Chief Commercial Officer, Margaret Olinger, left the Company\" (p. 103).\n\n2. **Impact on Business Plan and Growth Strategies**:\n   - The document states: \"Our ability to compete in the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel\" (p. 103).\n   - It further notes: \"Replacing executive officers or other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully\" (p. 103).\n\n3. **Operational and Strategic Disruptions**:\n   - The loss of key personnel could lead to operational disruptions: \"The loss of their services might impede the achievement of our research, development and commercialization objectives\" (p. 103).\n   - It could also affect the company's ability to manage and execute its business plan: \"Our ability to compete in the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel\" (p. 103).\n\n### Conclusion\n\nBased on the document, the most appropriate answer to the question \"What could negatively impact the business if key members of the executive management team cannot be retained?\" is:\n\n**D: A delay in the business plan and growth strategies**\n\n### Chain of Thoughts"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 96000, "result": 1.0, "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?", "options": {"A": "Cancel the transfer entirely", "B": "Impose a penalty on the transferee", "C": "Treat it as a direct transfer of Chinese interests", "D": "Reduce the applicable tax rate", "E": "Exempt the transfer from taxes", "F": "Require a local business licence"}, "LLM_original_answer": ["To answer the question, we need to identify the relevant information from the provided document. The key part of the document that addresses the issue of indirect transfers of Chinese interests is found in the \"Risks Related to Doing Business in China\" section, specifically under the point about \"uncertainty regarding indirect transfers of equity interests in China resident enterprises and enhanced scrutiny by Chinese tax authorities.\"\n\nThe relevant excerpt is:\n- \"We and our stockholders face uncertainty with respect to indirect transfers of equity interests in China resident enterprises through transfer of non-Chinese-holding companies. Enhanced scrutiny by the Chinese tax authorities may have a negative impact on potential acquisitions and dispositions we may pursue in the future.\"\n\nThis excerpt indicates that the Chinese tax authorities (STA) may scrutinize indirect transfers of Chinese interests and could re-characterize them as direct transfers if they lack a reasonable commercial purpose. This is further detailed in the \"Gains on Indirect Disposal of Equity Interests in Our China Subsidiaries\" section:\n- \"Pursuant to Bulletin 7, an 'indirect transfer' of Chinese taxable assets, including equity interests in a China resident enterprise ('Chinese interests'), by a non-resident enterprise, may be re-characterized and treated as a direct transfer of Chinese taxable assets, if such arrangement does not have reasonable commercial purpose and the transferor avoids payment of Chinese enterprise income tax.\"\n\nFrom this, we can infer that if the STA determines that an indirect transfer of Chinese interests lacks a reasonable commercial purpose, they may treat it as a direct transfer of Chinese interests.\n\nTherefore, the correct answer is:\nC: Treat it as a direct transfer of Chinese interests."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 96000, "result": 1.0, "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?", "options": {"A": "Real-time credit card authorization", "B": "Biometric authentication", "C": "Blockchain encryption", "D": "Virtual private networks", "E": "Firewall protection", "F": "Antivirus software"}, "LLM_original_answer": ["To answer the question \"What specific technology do they rely on from third parties to authorize and verify credit card transactions?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections that discuss payment processing, credit card transactions, and third-party services.\n2. **Extract Information**: Extract any information related to third-party technologies used for credit card authorization and verification.\n3. **Evaluate Options**: Compare the extracted information with the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Sections\nThe relevant section is found in the \"Risks Related to Our Business and Industry\" part of the document, specifically under the \"Our business requires that we securely collect, process, store, transmit, and dispose of confidential information relating to our operations, subscribers, employees, and other third parties\" section.\n\n### Step 2: Extract Information\nFrom the document:\n- \"Additionally, we rely on security and authentication technology licensed from third parties to perform real-time credit card authorization and verification, and at times rely on third parties, including technology consulting firms, to help protect our infrastructure from security threats.\"\n\n### Step 3: Evaluate Options\n- **Option A: Real-time credit card authorization**: This matches the extracted information directly.\n- **Option B: Biometric authentication**: The document does not mention biometric authentication.\n- **Option C: Blockchain encryption**: The document does not mention blockchain encryption.\n- **Option D: Virtual private networks**: The document does not mention virtual private networks.\n- **Option E: Firewall protection**: While the document mentions firewalls, it does not specify that they are used for credit card authorization and verification.\n- **Option F: Antivirus software**: The document mentions antivirus software, but it does not specify that it is used for credit card authorization and verification.\n\n### Conclusion\nThe specific technology they rely on from third parties to authorize and verify credit card transactions is **real-time credit card authorization**.\n\nTherefore, the correct answer is:\n**A: Real-time credit card authorization**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 85, "token_lengths": 128000, "result": 1.0, "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?", "options": {"A": "Increased interest rates on loans", "B": "Federal pre-emption benefits", "C": "Adverse consequences", "D": "Automatic license renewal", "E": "Exemption from state requirements", "F": "Reduction in documentation requirements"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the relevant information about the consequences of not complying with applicable laws, regulations, and rules by correspondent sellers.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Context:**\n   - The document discusses the risks and regulations associated with the mortgage and real estate industry, particularly focusing on the operations of PennyMac Mortgage Investment Trust (PMT) and its subsidiaries.\n\n2. **Locate Relevant Information:**\n   - The document mentions that PMT and its servicer, PennyMac Loan Services, LLC (PLS), are subject to various federal, state, and local laws and regulations.\n   - It also discusses the risks associated with the failure of correspondent sellers to comply with applicable laws, regulations, and rules.\n\n3. **Extract Specific Consequences:**\n   - **Paragraph 15:**\n     - \"The failure of our correspondent sellers to comply with any applicable laws, regulations and rules may also result in these adverse consequences.\"\n   - **Paragraph 16:**\n     - \"PLS has in place a compliance program designed to assess areas of risk with respect to loans we acquire from such correspondent sellers. However, we may not detect every violation of law and, to the extent any correspondent sellers with which we do business fail to comply with applicable laws or regulations and any of their loans or MSRs become part of our assets, it could subject us, as an assignee or purchaser of the related loans or MSRs, to monetary penalties or other losses.\"\n\n4. **Interpret the Consequences:**\n   - The document indicates that non-compliance by correspondent sellers can result in \"adverse consequences\" and \"monetary penalties or other losses.\"\n\n5. **Match to the Options:**\n   - **Option A: Increased interest rates on loans** - Not mentioned in the context of non-compliance by correspondent sellers.\n   - **Option B: Federal pre-emption benefits** - Not mentioned as a consequence of non-compliance.\n   - **Option C: Adverse consequences** - Directly mentioned in the document.\n   - **Option D: Automatic license renewal** - Not mentioned as a consequence of non-compliance.\n   - **Option E: Exemption from state requirements** - Not mentioned as a consequence of non-compliance.\n   - **Option F: Reduction in documentation requirements** - Not mentioned as a consequence of non-compliance.\n\n### Conclusion:\nThe document clearly states that one consequence of not complying with applicable laws, regulations, and"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 128000, "result": 0.0, "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?", "options": {"A": "Low operational costs", "B": "Exclusive commercial partnerships", "C": "Reduced regulation requirements", "D": "Access to diverse investment opportunities", "E": "Financial strength ratings from multiple agencies", "F": "Priority in claim settlements"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "E"}, {"depth": 85, "token_lengths": 128000, "result": 1.0, "question": "What is one potential reason for future decline in the company's revenue growth?", "options": {"A": "Decreasing demand for their platform", "B": "Expansion into new markets", "C": "Improved operational efficiency", "D": "Increased revenue from current customers", "E": "Successful marketing strategies", "F": "Increased demand for their services"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 85, "token_lengths": 128000, "result": 1.0, "question": "What potential impact could unfavorable economic conditions have on the organization?", "options": {"A": "Ease legal constraints on current services", "B": "Increase profits from outdated technologies", "C": "Reduce affordability and demand for products", "D": "Eliminate the need for technological enhancements", "E": "Reduce costs associated with competitive advantages", "F": "Ensure the rapid adoption of new technologies"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 128000, "result": 1.0, "question": "What is a potential consequence of changes in tax legislation and regulations on the company?", "options": {"A": "Increase in the number of employees", "B": "Decrease in production costs", "C": "Reduction in market share", "D": "Increase in the complexity and cost of tax compliance", "E": "Rise in customer satisfaction", "F": "Improved international partnerships"}, "LLM_original_answer": ["The correct answer to the question \"What is a potential consequence of changes in tax legislation and regulations on the company?\" based on the provided document is:\n\n**D: Increase in the complexity and cost of tax compliance**\n\n### Chain of Thoughts:\n1. **Context of the Question**: The question asks about the potential consequences of changes in tax legislation and regulations on the company.\n2. **Relevant Information in the Document**:\n   - The document mentions that the company is subject to income taxes in the U.S. and numerous foreign tax jurisdictions.\n   - It states that the company's provision for income taxes and cash tax liability may be negatively impacted by changes in tax laws and accounting principles.\n   - Specifically, the document notes that since the 2022 tax year, the Tax Cuts and Jobs Act of 2017 has required the company to capitalize and amortize its research and experimental expenditures over five or fifteen years, which has had a materially negative impact on the company's cash tax liability.\n   - The document also mentions that tax audits may negatively impact the company's business, financial condition, and results of operations.\n   - It further states that the company is subject to continued examination of its income tax returns, and tax authorities may disagree with the company's tax positions and assess additional taxes.\n3. **Analysis of Options**:\n   - **A: Increase in the number of employees**: The document does not mention any direct link between changes in tax legislation and an increase in the number of employees.\n   - **B: Decrease in production costs**: The document does not suggest that changes in tax legislation would lead to a decrease in production costs.\n   - **C: Reduction in market share**: The document does not indicate that changes in tax legislation would directly reduce market share.\n   - **D: Increase in the complexity and cost of tax compliance**: The document explicitly mentions that changes in tax laws and accounting principles can increase the complexity and cost of tax compliance. For example, the requirement to capitalize and amortize research and experimental expenditures has increased the company's cash tax liability.\n   - **E: Rise in customer satisfaction**: The document does not suggest that changes in tax legislation would lead to an increase in customer satisfaction.\n   - **F: Improved international partnerships**: The document does not mention that changes in tax legislation would improve international partnerships.\n4. **Conclusion**: Based on the information provided in the document, the most appropriate answer is **D: Increase in the complexity and cost of tax compliance**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 128000, "result": 1.0, "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?", "options": {"A": "Each procedure is paid individually based on its value", "B": "All procedures are paid at a reduced flat rate", "C": "The highest valued code is paid at 100%, and additional procedures are bundled", "D": "Only cataract procedures are paid separately", "E": "The total payment is calculated based on the average of all procedure values", "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 128000, "result": 1.0, "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?", "options": {"A": "Loan sales", "B": "Deposit accounts", "C": "Advances from the Federal Home Loan Bank", "D": "Loan repayments", "E": "Cash flows from operations", "F": "Scheduled loan payments"}, "LLM_original_answer": ["The correct answer to the question \"What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?\" is:\n\n**B: Deposit accounts**\n\n### Chain of Thought:\n1. **Context from the Document**:\n   - The document discusses the sources of funds for the Bank, which include deposit accounts, advances from the Federal Home Loan Bank, loan repayments, loan sales, and cash flows from operations.\n   - Specifically, it states: \"Deposit accounts have traditionally been the principal source of the Bank\u2019s funds for use in lending and for other general business purposes.\"\n\n2. **Analysis of Options**:\n   - **A: Loan sales**: The document mentions that the Bank sells loans, but it does not indicate that this is the principal source of funds.\n   - **B: Deposit accounts**: This is explicitly stated as the principal source of the Bank\u2019s funds.\n   - **C"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 85, "token_lengths": 128000, "result": 1.0, "question": "What could negatively impact the business if key members of the executive management team cannot be retained?", "options": {"A": "An increase in stock market volatility", "B": "A decrease in operational costs", "C": "The implementation of new technologies", "D": "A delay in the business plan and growth strategies", "E": "A shortage of raw materials", "F": "An expansion into new markets"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 85, "token_lengths": 128000, "result": 0.0, "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?", "options": {"A": "Cancel the transfer entirely", "B": "Impose a penalty on the transferee", "C": "Treat it as a direct transfer of Chinese interests", "D": "Reduce the applicable tax rate", "E": "Exempt the transfer from taxes", "F": "Require a local business licence"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 85, "token_lengths": 128000, "result": 1.0, "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?", "options": {"A": "Real-time credit card authorization", "B": "Biometric authentication", "C": "Blockchain encryption", "D": "Virtual private networks", "E": "Firewall protection", "F": "Antivirus software"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 8000, "result": 1.0, "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?", "options": {"A": "Limited board oversight", "B": "Inability to train employees efficiently", "C": "Challenges in predicting attack methods", "D": "Insufficient technological security measures", "E": "Lack of business continuity plans", "F": "Inadequate physical security measures"}, "LLM_original_answer": ["To answer the question \"What is one challenge mentioned in maintaining the security and integrity of the systems?\" based on the provided document, I will analyze the relevant sections and identify the specific challenge mentioned.\n\n1. **Identify the relevant section:**\n   - The document discusses cybersecurity risks and technology failures in the following paragraph:\n     > \"Cybersecurity risks, cyber incidents and technology failures may adversely affect our and our Manager\u2019s business by causing a disruption to our or our Manager\u2019s operations, a compromise or corruption of our or our Manager\u2019s confidential information or personal customer information, and/or damage to our or our Manager\u2019s business relationships, all of which could negatively impact our financial results.\"\n\n2. **Analyze the content:**\n   - The paragraph mentions several challenges related to maintaining the security and integrity of systems:\n     - **Disruption to operations:** Cyber incidents can cause operational disruptions.\n     - **Compromise or corruption of confidential information:** Cyber attacks can lead to the theft or corruption of sensitive data.\n     - **Damage to business relationships:** These incidents can harm relationships with customers and investors.\n     - **Increased costs:** There may be increased costs for cybersecurity protection and insurance.\n     - **Litigation and regulatory scrutiny:** Cyber incidents can lead to legal actions and increased regulatory scrutiny.\n     - **Reputation damage:** Such incidents can harm the company's reputation.\n\n3. **Match the challenges to the given options:**\n   - **Option A: Limited board oversight** - Not mentioned in the relevant section.\n   - **Option B: Inability to train employees efficiently** - Not mentioned in the relevant section.\n   - **Option C: Challenges in predicting attack methods** - The document mentions that \"the methods of attack change frequently or may not be recognized until after such attack has been launched,\" which aligns with this option.\n   - **Option D: Insufficient technological security measures** - The document mentions \"significant physical and technological security measures,\" but it does not explicitly state that these are insufficient.\n   - **Option E: Lack of business continuity plans** - The document mentions \"business continuity plans,\" but it does not state a lack of them.\n   - **Option F: Inadequate physical security measures** - The document mentions \"significant physical and technological security measures,\" but it does not explicitly state that these are inadequate.\n\n4. **Conclusion:**\n   - The most relevant challenge mentioned in the document is the difficulty in predicting and recognizing new attack methods, which is covered by **Option C: Challenges in predicting attack methods**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 8000, "result": 1.0, "question": "What effect could an unexpected rise in inflation have on the company's financial condition?", "options": {"A": "Decrease the value of the company's properties", "B": "Lead to higher interest rates affecting rate-sensitive financial instruments", "C": "Increase the demand for property insurance", "D": "Reduce the company's labor costs", "E": "Cause a decrease in interest expenses on debt", "F": "Improve the company's net income"}, "LLM_original_answer": ["To answer the question \"What effect could an unexpected rise in inflation have on the company's financial condition?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Inflation and Premium Pricing:**\n   - The document states: \"Our operations are susceptible to inflation, and underestimating inflation levels could result in underpricing the risks we reinsure because premiums are established before the ultimate amounts of losses and LAE are known.\"\n   - This suggests that if inflation rises unexpectedly, the company might have set premiums too low, leading to insufficient revenue to cover the increased costs of claims and loss adjustment expenses (LAE).\n\n2. **Impact on Loss Reserves:**\n   - The document mentions: \"Additionally, our reserving models include assumptions about future payments for the settlement of claims and claims-handling expenses, such as the value of replacing property, associated labor costs for the property business we write, and litigation costs.\"\n   - An unexpected rise in inflation could increase the projected future claim costs, leading to adverse loss reserve development. This means the company might need to increase its loss reserves, which would reduce net income and capital.\n\n3. **Interest Rates and Financial Instruments:**\n   - The document notes: \"Unanticipated higher inflation could also lead to higher interest rates, potentially negatively impacting the value of any rate-sensitive financial instruments held by SILP and could also impact our Innovations investments and cause us to incur higher interest expense on our debt.\"\n   - Higher interest rates can affect the value of rate-sensitive financial instruments, such as bonds, which the company holds in its investment portfolio. This could lead to a decrease in the value of these investments.\n   - Additionally, higher interest rates would increase the interest expense on any debt the company has, further reducing net income.\n\n4. **Overall Financial Condition:**\n   - The document emphasizes: \"While the global inflationary pressures have abated from their recent highs, any subsequent increase in inflation may lead to an increase in our loss reserves with a corresponding reduction in net income in the period the deficiency is identified, which may have a material adverse effect on our results of operations and financial condition.\"\n   - This indicates that an unexpected rise in inflation could have a significant negative impact on the company's financial condition, primarily through increased costs and reduced net income.\n\nGiven this analysis, the most appropriate answer from the provided options is:\n\n**B: Lead to higher interest rates affecting rate-sensitive financial instruments**\n\nThis option directly aligns with the document's discussion of how higher inflation can"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 8000, "result": 1.0, "question": "What could a successful liability claim potentially lead to, even if fully insured?", "options": {"A": "Increased stock prices", "B": "Diminished brand reputation", "C": "Expansion into new markets", "D": "Immediate financial gains", "E": "Improved customer satisfaction", "F": "Reduced operational costs"}, "LLM_original_answer": ["To answer the question \"What could a successful liability claim potentially lead to, even if fully insured?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Document Context**:\n   - The document discusses various risks and factors that can affect the company's financial performance, operations, and reputation.\n   - It specifically mentions the potential impact of successful liability claims, even if the company is fully insured.\n\n2. **Relevant Section**:\n   - The relevant section states: \"Even if we are fully insured as it relates to a claim, the claim could nevertheless diminish our brand and divert management\u2019s attention and resources, which could have a negative impact on our business, financial condition, and results of operations.\"\n\n3. **Analysis of Options**:\n   - **A: Increased stock prices** - The document suggests that a successful liability claim could negatively impact the company, which would likely not lead to increased stock prices.\n   - **B: Diminished brand reputation** - The document explicitly mentions that a successful liability claim could diminish the brand, which aligns with this option.\n   - **C: Expansion into new markets** - The document does not suggest that a successful liability claim would lead to expansion into new markets.\n   - **D: Immediate financial gains** - A successful liability claim, even if fully insured, would not lead to immediate financial gains; it would likely involve costs and distractions.\n   - **E: Improved customer satisfaction** - The document does not indicate that a successful liability claim would improve customer satisfaction; in fact, it suggests the opposite.\n   - **F: Reduced operational costs** - The document mentions that a successful liability claim could increase costs and divert resources, which would not lead to reduced operational costs.\n\n4. **Conclusion**:\n   - Based on the document, the most accurate answer is **B: Diminished brand reputation**. The document explicitly states that a successful liability claim, even if fully insured, could diminish the brand and divert management's attention and resources, leading to negative impacts on the business.\n\nTherefore, the correct answer is **B: Diminished brand reputation**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 8000, "result": 1.0, "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?", "options": {"A": "$18.8 billion", "B": "$15.2 billion", "C": "$20.1 billion", "D": "$22.5 billion", "E": "$17.9 billion", "F": "$19.6 billion"}, "LLM_original_answer": ["To answer the question \"What was the total amount invested in capital expenditures during the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions capital expenditures in the \"Capital Expenditures and Investments\" section.\n2. **Extract the specific information**: The section states, \"During the year ended December 31, 2023, these investments included $18.8 billion for capital expenditures.\"\n3. **Match the information to the options**: The amount $18.8 billion corresponds to option A.\n\nTherefore, the total amount invested in capital expenditures during the year ended December 31, 2023, is **$18.8 billion**.\n\nThe correct answer is **A: $18.8 billion**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 8000, "result": 1.0, "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?", "options": {"A": "Increased customer satisfaction", "B": "Fines and additional costs", "C": "Reduction in legal obligations", "D": "Improved brand reputation", "E": "Increased production rates", "F": "Decrease in product demand"}, "LLM_original_answer": ["To answer the question \"What could happen if a product with quality issues is recalled due to regulatory non-compliance?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Quality Issues and Regulatory Non-Compliance**:\n   - The document mentions that if the quality of products does not meet regulatory or industry standards, they may need to be \"stop-shipped\" or recalled.\n   - This is particularly relevant for products that have issues affecting performance, safety, or regulatory compliance.\n\n2. **Consequences of Recalls**:\n   - **Increased Costs**: The document states that recalls can result in \"substantial recall or corrective field action costs.\"\n   - **Fines and Additional Costs**: It explicitly mentions that \"recalls and field actions involving regulatory non-compliance could also result in fines and additional costs.\"\n   - **Damage to Reputation**: The document notes that such issues can have a \"negative impact on our goodwill and brand name reputation.\"\n   - **Loss of Future Orders**: It also mentions that recalls can lead to \"loss of revenue or future orders.\"\n   - **Customer-Imposed Penalties**: The document indicates that \"customer-imposed penalties for failure to meet contractual requirements\" can occur.\n\n3. **Evaluating the Options**:\n   - **A: Increased customer satisfaction** - This is unlikely, as recalls due to quality issues and regulatory non-compliance generally lead to customer dissatisfaction.\n   - **B: Fines and additional costs** - This is explicitly mentioned in the document.\n   - **C: Reduction in legal obligations** - The document does not suggest that recalls reduce legal obligations; rather, they increase them.\n   - **D: Improved brand reputation** - This is also unlikely, as the document indicates that recalls can damage brand reputation.\n   - **E: Increased production rates** - The document does not mention increased production rates as a consequence of recalls.\n   - **F: Decrease in product demand** - This is a likely consequence, as the document mentions \"loss of revenue or future orders\" and \"a negative impact on our goodwill and brand name reputation.\"\n\nBased on the analysis, the most accurate and relevant options from the document are:\n\n- **B: Fines and additional costs**\n- **F: Decrease in product demand**\n\nTherefore, the correct answer is **B: Fines and additional costs** and **F: Decrease in product demand**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 8000, "result": 1.0, "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?", "options": {"A": "Dentists", "B": "Pharmacists", "C": "Physician assistants", "D": "Chiropractors", "E": "Optometrists", "F": "Radiologists"}, "LLM_original_answer": ["To answer the question \"Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the expansion of obligations for payments and transfers of value starting in 2022. This information is found in the section discussing the federal Physician Payments Sunshine Act.\n\n2. **Extract the specific information**: The relevant paragraph states:\n   > \"Beginning in 2022, such obligations were expanded to include payments and other transfers of value provided in the previous year to additional healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives.\"\n\n3. **Match the information to the options**: The paragraph lists the additional healthcare professionals included in the expanded obligations. These include:\n   - Physician assistants\n   - Nurse practitioners\n   - Clinical nurse specialists\n   - Certified nurse anesthetists\n   - Anesthesiologist assistants\n   - Certified nurse midwives\n\n4. **Select the correct option**: Among the options provided, the only one that matches the list of newly included healthcare professionals is:\n   - **C: Physician assistants**\n\nTherefore, the correct answer is **C: Physician assistants**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 8000, "result": 1.0, "question": "What did the company opt to permanently exclude from its capital calculations?", "options": {"A": "Unrealized gains and losses on available-for-sale securities", "B": "Deferred tax assets and liabilities", "C": "High volatility commercial real estate loans", "D": "Unused portion of commitments not cancellable", "E": "Non-residential mortgage loans past due", "F": "Capital conservation buffer"}, "LLM_original_answer": ["To answer the question \"What did the company opt to permanently exclude from its capital calculations?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses capital regulations and what the company has opted to exclude is found under the \"Capital\" heading.\n\n2. **Extract the specific information**: The document states:\n   > \"However, because of our asset size, we were eligible to elect to permanently opt out of the inclusion of unrealized gains and losses on available-for-sale debt and equity securities in our capital calculations. We elected this option.\"\n\n3. **Match the information to the options**:\n   - **Option A**: Unrealized gains and losses on available-for-sale securities\n   - **Option B**: Deferred tax assets and liabilities\n   - **Option C**: High volatility commercial real estate loans\n   - **Option D**: Unused portion of commitments not cancellable\n   - **Option E**: Non-residential mortgage loans past due\n   - **Option F**: Capital conservation buffer\n\n4. **Determine the correct answer**: The document explicitly mentions that the company elected to permanently opt out of including unrealized gains and losses on available-for-sale debt and equity securities in its capital calculations. This matches **Option A**.\n\nTherefore, the correct answer is **Option A: Unrealized gains and losses on available-for-sale securities**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 8000, "result": 1.0, "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?", "options": {"A": "Data Protection Act of 2018", "B": "European Data Protection Board Act", "C": "UK Cybersecurity Act", "D": "British Privacy Regulations Act", "E": "Information Security Act of 2018", "F": "UK General Data Protection Act"}, "LLM_original_answer": ["To answer the question \"Which legislation incorporated GDPR into the United Kingdom's domestic law?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant information in the document**: The document mentions the GDPR and the United Kingdom's approach to data protection after leaving the European Union.\n\n2. **Locate the specific sentence that addresses the incorporation of GDPR into UK law**: The relevant sentence is: \"Further, the United Kingdom has brought the GDPR into domestic law with the Data Protection Act of 2018 which will remain in force, even if and when the United Kingdom leaves the European Union.\"\n\n3. **Analyze the options provided**:\n   - **A: Data Protection Act of 2018**: This matches the information in the document.\n   - **B: European Data Protection Board Act**: This is not mentioned in the document and does not exist as a UK legislation.\n   - **C: UK Cybersecurity Act**: This is not mentioned in the document and is not related to GDPR.\n   - **D: British Privacy Regulations Act**: This is not mentioned in the document and does not exist.\n   - **E: Information Security Act of 2018**: This is not mentioned in the document and does not exist.\n   - **F: UK General Data Protection Act**: This is not mentioned in the document and does not exist.\n\n4. **Select the correct answer**: Based on the information provided in the document, the correct answer is **A: Data Protection Act of 2018**.\n\nTherefore, the legislation that incorporated GDPR into the United Kingdom's domestic law is the **Data Protection Act of 2018**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 8000, "result": 1.0, "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?", "options": {"A": "By visiting the Company\u2019s website", "B": "By visiting the SEC's website", "C": "By contacting the Investor Relations Department", "D": "Automatically mailed with annual reports", "E": "Through a subscription service", "F": "At the company headquarters in China"}, "LLM_original_answer": ["To answer the question \"Where can stockholders obtain a free printed copy of the Company's SEC filings?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses the availability of SEC filings is titled \"Available Information.\"\n\n2. **Extract the relevant information**:\n   - The document states: \"These documents, as well as our SEC filings, are available in print free of charge to any stockholder who requests a copy from our Investor Relations Department by contacting Yum China at 101 East Park Boulevard, Suite 805, Plano, Texas 75074, United States of America, Attention: Investor Relations.\"\n\n3. **Match the information to the given options**:\n   - **Option A**: By visiting the Company\u2019s website\n     - The document mentions that the SEC filings are available on the Investor Relations website, but it does not state that they are available in print for free by visiting the website.\n   - **Option B**: By visiting the SEC's website\n     - The document mentions that the SEC filings can be obtained by visiting the SEC\u2019s website, but it does not state that they are available in print for free.\n   - **Option C**: By contacting the Investor Relations Department\n     - The document explicitly states that stockholders can obtain a free printed copy of the SEC filings by contacting the Investor Relations Department.\n   - **Option D**: Automatically mailed with annual reports\n     - The document does not mention that SEC filings are automatically mailed with annual reports.\n   - **Option E**: Through a subscription service\n     - The document does not mention a subscription service for obtaining free printed copies of SEC filings.\n   - **Option F**: At the company headquarters in China\n     - The document does not mention that stockholders can obtain free printed copies of SEC filings at the company headquarters in China.\n\n4. **Conclusion**:\n   - The correct answer is **Option C**: By contacting the Investor Relations Department.\n\nTherefore, stockholders can obtain a free printed copy of the Company's SEC filings by contacting the Investor Relations Department."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 8000, "result": 1.0, "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?", "options": {"A": "A decline in company profits", "B": "Market competition", "C": "A challenge by a taxing authority", "D": "Stock market fluctuations", "E": "Internal policy changes", "F": "Changes in interest rates"}, "LLM_original_answer": ["To answer the question \"What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Tax Receivable Agreement (TRA) Overview**:\n   - The TRA requires MarketWise, Inc. to make cash payments to the MarketWise Members equal to 85% of the tax benefits realized or deemed realized by MarketWise, Inc.\n   - These payments are based on increases in the tax basis of assets of MarketWise, LLC and other tax benefits.\n\n2. **Conditions for Payment**:\n   - The payments are not conditioned on the MarketWise Members' continued ownership of LLC Units or common stock.\n   - The payment obligations are MarketWise, Inc.'s obligations, not MarketWise, LLC's.\n\n3. **Material Breach and Acceleration**:\n   - If MarketWise, Inc. materially breaches any of its material obligations under the TRA, the future obligations under the TRA would accelerate and become due and payable.\n   - This includes an immediate cash payment equal to the estimated present value of the anticipated future tax benefits, based on certain assumptions.\n\n4. **Tax Authority Challenges**:\n   - The document mentions that the IRS or another tax authority may challenge the tax basis increases or other tax benefits claimed by MarketWise, Inc.\n   - If a tax authority challenges and disallows these tax benefits, MarketWise, Inc. will not be reimbursed for any payments already made to the MarketWise Members under the TRA.\n   - Instead, any excess cash payments made will be netted against future payments.\n\n5. **Impact of Challenges**:\n   - If a tax authority challenges and disallows the tax benefits, MarketWise, Inc. would still be required to make the payments under the TRA, even if it does not receive the corresponding tax benefits.\n   - This could result in payments that are greater than the actual tax benefits realized.\n\nGiven this analysis, the correct answer is:\n\n**C: A challenge by a taxing authority**\n\n**Chain of Thoughts**:\n- The TRA requires MarketWise, Inc. to make payments based on tax benefits realized or deemed realized.\n- If a tax authority challenges and disallows these tax benefits, MarketWise, Inc. will not be reimbursed for the payments already made.\n- This means that MarketWise, Inc. would still be required to make the payments under the"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 16000, "result": 1.0, "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?", "options": {"A": "Limited board oversight", "B": "Inability to train employees efficiently", "C": "Challenges in predicting attack methods", "D": "Insufficient technological security measures", "E": "Lack of business continuity plans", "F": "Inadequate physical security measures"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document to identify the specific mention of challenges related to maintaining the security and integrity of the systems.\n\n1. **Identify the relevant section**: The document mentions cybersecurity risks and technology failures in the \"Cybersecurity risks, cyber incidents and technology failures\" section.\n\n2. **Extract the key information**:\n   - The document states: \"Cybersecurity risks, cyber incidents and technology failures may adversely affect our and our Manager\u2019s business by causing a disruption to our or our Manager\u2019s operations, a compromise or corruption of our or our Manager\u2019s confidential information or personal customer information, and/or damage to our or our Manager\u2019s business relationships, all of which could negatively impact our financial results.\"\n   - It further mentions: \"Despite our and our Manager\u2019s efforts to ensure the integrity of our and our Manager\u2019s systems and our and our Manager\u2019s investment in significant physical and technological security measures, employee training, contractual precautions, policies and procedures, board oversight and business continuity plans, there can be no assurance that any such cyber intrusions will not occur or, if they do occur, that they will be adequately addressed.\"\n\n3. **Match the information to the options**:\n   - **Option A: Limited board oversight** - The document mentions board oversight as part of the efforts to ensure system integrity, but it does not identify limited board oversight as a specific challenge.\n   - **Option B: Inability to train employees efficiently** - The document mentions employee training as part of the efforts to ensure system integrity, but it does not identify the inability to train employees efficiently as a specific challenge.\n   - **Option C: Challenges in predicting attack methods** - The document mentions that \"the methods of attack change frequently or may not be recognized until after such attack has been launched,\" which aligns with the challenge of predicting attack methods.\n   - **Option D: Insufficient technological security measures** - The document mentions significant physical and technological security measures, but it does not specifically state that these measures are insufficient.\n   - **Option E: Lack of business continuity plans** - The document mentions business continuity plans as part of the efforts to ensure system integrity, but it does not identify a lack of such plans as a specific challenge.\n   - **Option F: Inadequate physical security measures** - The document mentions physical security measures, but it does not specifically state that these measures are inadequate.\n\n4. **Conclusion**:\n   - The document explicitly mentions the challenge of predicting attack methods, as it states that"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 16000, "result": 1.0, "question": "What effect could an unexpected rise in inflation have on the company's financial condition?", "options": {"A": "Decrease the value of the company's properties", "B": "Lead to higher interest rates affecting rate-sensitive financial instruments", "C": "Increase the demand for property insurance", "D": "Reduce the company's labor costs", "E": "Cause a decrease in interest expenses on debt", "F": "Improve the company's net income"}, "LLM_original_answer": ["To answer the question \"What effect could an unexpected rise in inflation have on the company's financial condition?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Inflation and Premium Pricing:**\n   - The document mentions that the company's operations are susceptible to inflation, and underestimating inflation levels could result in underpricing the risks they reinsure. This is because premiums are established before the ultimate amounts of losses and loss adjustment expenses (LAE) are known.\n   - If inflation rises unexpectedly, the company might find that the premiums they have set are insufficient to cover the increased costs of settling claims and handling expenses.\n\n2. **Impact on Loss Reserves:**\n   - The document states that the global inflationary environment in the last couple of years has resulted in an increase in projected future claim costs, leading to adverse loss reserve development.\n   - An unexpected rise in inflation could further increase the company's loss reserves, which would reduce net income in the period the deficiency is identified.\n\n3. **Interest Rates and Financial Instruments:**\n   - The document notes that unanticipated higher inflation could lead to higher interest rates, potentially negatively impacting the value of any rate-sensitive financial instruments held by SILP (the investment fund managed by DME Advisors).\n   - Higher interest rates could also increase the company's interest expense on any outstanding debt, further affecting its financial condition.\n\n4. **Investment Strategy:**\n   - The company's investment strategy is designed to achieve higher rates of return over the long term, but it is more volatile than traditional fixed-income portfolios.\n   - An unexpected rise in inflation and subsequent higher interest rates could affect the performance of the investment portfolio, particularly if it includes rate-sensitive financial instruments.\n\n5. **Overall Financial Impact:**\n   - The combination of underpriced risks, increased loss reserves, and higher interest expenses could materially and adversely affect the company's financial condition and results of operations.\n\nGiven this analysis, the most appropriate answer from the provided options is:\n\n**B: Lead to higher interest rates affecting rate-sensitive financial instruments**\n\nThis option directly addresses the potential impact of higher interest rates on the company's financial instruments, which is a significant concern as mentioned in the document. The other options do not align as closely with the information provided:\n\n- **A: Decrease the value of the company's properties** - The document does not mention the company's property values being directly affected by inflation.\n- **C: Increase the demand for property insurance** - The document does not suggest that"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 16000, "result": 1.0, "question": "What could a successful liability claim potentially lead to, even if fully insured?", "options": {"A": "Increased stock prices", "B": "Diminished brand reputation", "C": "Expansion into new markets", "D": "Immediate financial gains", "E": "Improved customer satisfaction", "F": "Reduced operational costs"}, "LLM_original_answer": ["To answer the question \"What could a successful liability claim potentially lead to, even if fully insured?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Insurance Coverage and Limitations**:\n   - The document mentions that BlackSky endeavors to obtain insurance coverage from established insurance carriers to cover certain risks and liabilities related to their business.\n   - However, it also states that the amount of insurance coverage may not be adequate to cover all claims or liabilities, and even if adequate, it may delay constellation or platform upgrades, negatively impacting the ability to meet customer commitments and revenue expectations.\n\n2. **Impact of Liability Claims**:\n   - Even if fully insured, a successful liability claim could still have several negative impacts:\n     - **Diminished Brand Reputation**: The document explicitly mentions that a successful liability claim could \"diminish our brand and divert management\u2019s attention and resources, which could have a negative impact on our business, financial condition, and results of operations.\"\n     - **Increased Costs**: While insurance might cover the direct financial impact, the document notes that \"a successful liability claim could result in substantial cost to us,\" which could include indirect costs such as legal fees, management time, and potential loss of business.\n     - **Reputational Damage**: The document highlights that \"the occurrence of any of these events, or the perception any such event has occurred, could result in reputational damage.\"\n\n3. **Evaluating the Options**:\n   - **A: Increased stock prices** - This is unlikely as a successful liability claim would generally have a negative impact on the company's financial condition and reputation.\n   - **B: Diminished brand reputation** - This is explicitly mentioned in the document as a potential consequence.\n   - **C: Expansion into new markets** - A successful liability claim would not typically lead to expansion; rather, it could hinder such efforts due to reputational damage.\n   - **D: Immediate financial gains** - This is not a likely outcome, as liability claims generally result in costs and potential financial losses.\n   - **E: Improved customer satisfaction** - A successful liability claim would likely decrease customer satisfaction due to service disruptions or perceived unreliability.\n   - **F: Reduced operational costs** - This is also unlikely, as the claim could lead to increased costs for remediation, legal fees, and potential service credits or refunds.\n\nGiven the analysis, the most appropriate answer is:\n\n**B: Diminished brand reputation**\n\nThis option aligns with the document's explicit mention of"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 16000, "result": 1.0, "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?", "options": {"A": "$18.8 billion", "B": "$15.2 billion", "C": "$20.1 billion", "D": "$22.5 billion", "E": "$17.9 billion", "F": "$19.6 billion"}, "LLM_original_answer": ["To answer the question \"What was the total amount invested in capital expenditures during the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Relevant Section**: The document mentions capital expenditures in the \"Capital Expenditures and Investments\" section.\n\n2. **Extract the Specific Information**: The relevant sentence from this section is: \"During the year ended December 31, 2023, these investments included $18.8 billion for capital expenditures.\"\n\n3. **Match the Information to the Options**: The amount mentioned in the document is $18.8 billion.\n\n4. **Select the Correct Option**: The correct option is A: $18.8 billion.\n\nTherefore, the total amount invested in capital expenditures during the year ended December 31, 2023, is **$18.8 billion**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 16000, "result": 1.0, "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?", "options": {"A": "Increased customer satisfaction", "B": "Fines and additional costs", "C": "Reduction in legal obligations", "D": "Improved brand reputation", "E": "Increased production rates", "F": "Decrease in product demand"}, "LLM_original_answer": ["To answer the question \"What could happen if a product with quality issues is recalled due to regulatory non-compliance?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Quality Issues and Regulatory Compliance**:\n   - The document mentions that if the quality of products does not meet regulatory or industry standards, it can lead to legal, financial, and reputational ramifications.\n   - Specifically, it states: \"If the quality issue affects the product's performance, safety or regulatory compliance, then such a 'defective' product may need to be 'stop-shipped' or recalled.\"\n\n2. **Legal and Financial Ramifications**:\n   - The document highlights that recalls and field actions involving regulatory non-compliance could result in fines and additional costs.\n   - It states: \"Recalls and field actions involving regulatory non-compliance could also result in fines and additional costs.\"\n\n3. **Reputational Damage**:\n   - The document notes that such issues can damage the company's goodwill and brand reputation.\n   - It mentions: \"Depending on the nature of the quality issue and the number of products in the field, it could cause us to incur substantial recall or corrective field action costs, in addition to the costs associated with the potential loss of future orders and the damage to our goodwill or brand reputation.\"\n\n4. **Customer Impact**:\n   - The document suggests that quality issues can lead to customer-imposed penalties and loss of future orders.\n   - It states: \"customer-imposed penalties for failure to meet contractual requirements, (ii) increased costs associated with repairing or replacing products, and (iv) a negative impact on our goodwill and brand name reputation.\"\n\n5. **Operational Impact**:\n   - The document indicates that such issues can cause delays in the recognition of revenue and loss of revenue.\n   - It mentions: \"delays in the recognition of revenue, loss of revenue or future orders.\"\n\nGiven these points, the most appropriate answer from the provided options is:\n\n**B: Fines and additional costs**\n\nThis option directly aligns with the document's statement about the potential for fines and additional costs as a result of regulatory non-compliance and product recalls. The other options, while they might be indirectly related, are not as explicitly supported by the document."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 16000, "result": 1.0, "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?", "options": {"A": "Dentists", "B": "Pharmacists", "C": "Physician assistants", "D": "Chiropractors", "E": "Optometrists", "F": "Radiologists"}, "LLM_original_answer": ["To answer the question \"Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the expansion of obligations for payments and transfers of value starting in 2022. This information is found in the \"Healthcare Fraud and Abuse Laws\" section.\n\n2. **Extract the specific information**: The relevant paragraph states:\n   > \"Beginning in 2022, such obligations were expanded to include payments and other transfers of value provided in the previous year to additional healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives.\"\n\n3. **Match the information to the options**:\n   - **A: Dentists** - Not mentioned in the expansion.\n   - **B: Pharmacists** - Not mentioned in the expansion.\n   - **C: Physician assistants** - Mentioned in the expansion.\n   - **D: Chiropractors** - Already included in the original list of healthcare professionals.\n   - **E: Optometrists** - Already included in the original list of healthcare professionals.\n   - **F: Radiologists** - Not mentioned in the expansion.\n\n4. **Determine the correct answer**: The document explicitly states that physician assistants were newly included in the expanded obligations for payments and transfers of value starting in 2022.\n\nTherefore, the correct answer is **C: Physician assistants**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 16000, "result": 1.0, "question": "What did the company opt to permanently exclude from its capital calculations?", "options": {"A": "Unrealized gains and losses on available-for-sale securities", "B": "Deferred tax assets and liabilities", "C": "High volatility commercial real estate loans", "D": "Unused portion of commitments not cancellable", "E": "Non-residential mortgage loans past due", "F": "Capital conservation buffer"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document to identify any mention of what the company opted to permanently exclude from its capital calculations.\n\n1. **Identify the relevant section**: The document discusses various aspects of the company's capital regulations and requirements. The key section is under \"Capital\" where it mentions the capital rules and the components of regulatory capital.\n\n2. **Locate the specific exclusion**: In the \"Capital\" section, the document states:\n   > \"In addition, Tier 1 capital includes AOCI, which includes all unrealized gains and losses on available-for-sale debt and equity securities. However, because of our asset size, we were eligible to elect to permanently opt out of the inclusion of unrealized gains and losses on available-for-sale debt and equity securities in our capital calculations. We elected this option.\"\n\n3. **Match the exclusion to the options**:\n   - **Option A**: Unrealized gains and losses on available-for-sale securities\n   - **Option B**: Deferred tax assets and liabilities\n   - **Option C**: High volatility commercial real estate loans\n   - **Option D**: Unused portion of commitments not cancellable\n   - **Option E**: Non-residential mortgage loans past due\n   - **Option F**: Capital conservation buffer\n\n4. **Conclusion**: The document explicitly states that the company elected to permanently opt out of including unrealized gains and losses on available-for-sale debt and equity securities in its capital calculations. This matches **Option A**.\n\nTherefore, the correct answer is **A: Unrealized gains and losses on available-for-sale securities**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 16000, "result": 1.0, "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?", "options": {"A": "Data Protection Act of 2018", "B": "European Data Protection Board Act", "C": "UK Cybersecurity Act", "D": "British Privacy Regulations Act", "E": "Information Security Act of 2018", "F": "UK General Data Protection Act"}, "LLM_original_answer": ["The document provided does not contain any information directly related to the legislation that incorporated GDPR into the United Kingdom's domestic law. However, based on the question and the options provided, the correct answer is:\n\nA: Data Protection Act of 2018\n\n### Chain of Thought:\n1. **Context of the Question**: The question asks about the legislation that incorporated GDPR into the United Kingdom's domestic law.\n2. **Options Provided**:\n   - A: Data Protection Act of 2018\n   - B: European Data Protection Board Act\n   - C: UK Cybersecurity Act\n   - D: British Privacy Regulations Act\n   - E: Information Security Act of 2018\n   - F: UK General Data Protection Act\n\n3. **Relevant Knowledge**:\n   - The General Data Protection Regulation (GDPR) is an EU regulation that became effective on May 25, 2018.\n   - The United Kingdom, as a member of the EU at the time, needed to incorporate GDPR into its domestic law to ensure compliance.\n   - The Data Protection Act of 2018 was passed in the UK to update and replace the previous Data Protection Act of 1998, and it specifically incorporates GDPR into UK law.\n\n4. **Elimination of Other Options**:\n   - **B: European Data Protection Board Act**: This is not a UK-specific act; the European Data Protection Board (EDPB) is an EU body.\n   - **C: UK Cybersecurity Act**: This act is related to cybersecurity, not specifically to data protection and GDPR.\n   - **D: British Privacy Regulations Act**: This is not a recognized act in the UK.\n   - **E: Information Security Act of 2018**: This is not a recognized act in the UK.\n   - **F: UK General Data Protection Act**: This is not a recognized act; the UK did not pass a separate act named \"UK General Data Protection Act.\"\n\n5. **Conclusion**: The Data Protection Act of 2018 is the legislation that incorporated GDPR into the United Kingdom's domestic law. Therefore, the correct answer is A."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 16000, "result": 1.0, "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?", "options": {"A": "By visiting the Company\u2019s website", "B": "By visiting the SEC's website", "C": "By contacting the Investor Relations Department", "D": "Automatically mailed with annual reports", "E": "Through a subscription service", "F": "At the company headquarters in China"}, "LLM_original_answer": ["To answer the question \"Where can stockholders obtain a free printed copy of the Company's SEC filings?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The section that discusses how stockholders can obtain SEC filings is found under \"Available Information.\"\n\n2. **Extract the specific information**: The document states:\n   > \"These documents, as well as our SEC filings, are available in print free of charge to any stockholder who requests a copy from our Investor Relations Department by contacting Yum China at 101 East Park Boulevard, Suite 805, Plano, Texas 75074, United States of America, Attention: Investor Relations.\"\n\n3. **Match the information to the options**:\n   - **Option A**: By visiting the Company\u2019s website\n     - The document mentions that the SEC filings are available on the Investor Relations website, but it does not state that they are available in print for free by visiting the website.\n   - **Option B**: By visiting the SEC's website\n     - The document mentions that the SEC filings can be obtained by visiting the SEC\u2019s website, but it does not state that they are available in print for free.\n   - **Option C**: By contacting the Investor Relations Department\n     - The document explicitly states that stockholders can obtain free printed copies by contacting the Investor Relations Department.\n   - **Option D**: Automatically mailed with annual reports\n     - The document does not mention that SEC filings are automatically mailed with annual reports.\n   - **Option E**: Through a subscription service\n     - The document does not mention a subscription service for obtaining free printed copies of SEC filings.\n   - **Option F**: At the company headquarters in China\n     - The document does not mention that stockholders can obtain free printed copies at the company headquarters in China.\n\n4. **Conclusion**: Based on the information provided in the document, the correct answer is **Option C: By contacting the Investor Relations Department**.\n\nTherefore, the answer to the question is **Option C: By contacting the Investor Relations Department**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 16000, "result": 1.0, "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?", "options": {"A": "A decline in company profits", "B": "Market competition", "C": "A challenge by a taxing authority", "D": "Stock market fluctuations", "E": "Internal policy changes", "F": "Changes in interest rates"}, "LLM_original_answer": ["To answer the question \"What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Tax Receivable Agreement (TRA) Overview**:\n   - MarketWise, Inc. is required to make cash payments to the MarketWise Members under the TRA.\n   - These payments are based on the tax benefits that MarketWise, Inc. realizes or is deemed to realize.\n\n2. **Payment Obligations**:\n   - The payments are not conditioned on the MarketWise Members' continued ownership of LLC Units or Class A common stock.\n   - MarketWise, Inc. must make these payments regardless of the members' ownership status.\n\n3. **Challenges by Taxing Authorities**:\n   - The document states that the IRS or another tax authority may challenge the tax benefits claimed by MarketWise, Inc.\n   - If a challenge is sustained, MarketWise, Inc. will not be reimbursed for any payments made to the MarketWise Members under the TRA.\n   - MarketWise, Inc. cannot reduce future cash payments under the TRA until the challenge is finally settled or determined.\n\n4. **Other Factors**:\n   - The document does not mention any other factors such as a decline in company profits, market competition, stock market fluctuations, internal policy changes, or changes in interest rates as preventing the reduction of future cash payments under the TRA.\n\nGiven this analysis, the correct answer is:\n\n**C: A challenge by a taxing authority**\n\nThis is because the document explicitly states that if the IRS or another tax authority challenges the tax benefits and the challenge is sustained, MarketWise, Inc. will not be reimbursed and cannot reduce future cash payments under the TRA until the challenge is finally settled or determined."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 32000, "result": 0.0, "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?", "options": {"A": "Limited board oversight", "B": "Inability to train employees efficiently", "C": "Challenges in predicting attack methods", "D": "Insufficient technological security measures", "E": "Lack of business continuity plans", "F": "Inadequate physical security measures"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify any mention of challenges related to maintaining the security and integrity of systems.\n\n1. **Review the Document for Relevant Information:**\n   - The document primarily discusses financial and operational aspects of a company, including revenue recognition, lease agreements, stock-based compensation, and risk factors.\n   - The section on \"Risk Factors\" is particularly relevant as it outlines various challenges and risks the company faces.\n\n2. **Identify the Specific Challenge:**\n   - In the \"Risk Factors\" section, there is a specific mention of cybersecurity risks and technology failures:\n     - \"Cybersecurity risks, cyber incidents and technology failures may adversely affect our and our Manager\u2019s business by causing a disruption to our or our Manager\u2019s operations, a compromise or corruption of our or our Manager\u2019s confidential information or personal customer information, and/or damage to our or our Manager\u2019s business relationships, all of which could negatively impact our financial results.\"\n\n3. **Match the Identified Challenge to the Options:**\n   - The challenge mentioned in the document is related to cybersecurity risks and technology failures.\n   - This aligns most closely with option **F: Inadequate physical security measures**. However, the document does not specifically mention \"physical security measures.\" Instead, it talks about \"cybersecurity risks\" and \"technology failures,\" which are more closely related to **D: Insufficient technological security measures**.\n\n4. **Conclusion:**\n   - The most appropriate answer based on the information provided in the document is **D: Insufficient technological security measures**.\n\nTherefore, the answer to the question \"What is one challenge mentioned in maintaining the security and integrity of the systems?\" is **D: Insufficient technological security measures**."], "LLM_extracted_answer": ["D"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 32000, "result": 1.0, "question": "What effect could an unexpected rise in inflation have on the company's financial condition?", "options": {"A": "Decrease the value of the company's properties", "B": "Lead to higher interest rates affecting rate-sensitive financial instruments", "C": "Increase the demand for property insurance", "D": "Reduce the company's labor costs", "E": "Cause a decrease in interest expenses on debt", "F": "Improve the company's net income"}, "LLM_original_answer": ["To answer the question \"What effect could an unexpected rise in inflation have on the company's financial condition?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Inflation and Financial Instruments**:\n   - The document mentions that the company is involved in reinsurance and investment activities, including investments in SILP (a related party investment fund) and innovation-related investments.\n   - Inflation can lead to higher interest rates, which can affect rate-sensitive financial instruments. This is particularly relevant for the company's investment portfolio, which includes various financial instruments such as bonds, equities, and derivatives.\n\n2. **Impact on Debt and Interest Expenses**:\n   - The document states that \"Unanticipated higher inflation could also lead to higher interest rates, potentially negatively impacting the value of any rate-sensitive financial instruments held by SILP and could also impact our Innovations investments and cause us to incur higher interest expense on our debt.\"\n   - This indicates that higher interest rates could increase the company's interest expenses on any outstanding debt, which would negatively affect the company's financial condition.\n\n3. **Effect on Premiums and Loss Reserves**:\n   - The company's reinsurance operations are susceptible to inflation, as premiums are established before the ultimate amounts of losses and loss adjustment expenses (LAE) are known.\n   - Underestimating inflation levels could result in underpricing the risks reinsured, leading to higher projected future claim costs and adverse loss reserve development.\n   - If loss reserves need to be increased, this would reduce the company's net income and capital in the period the deficiency is identified.\n\n4. **Operational Costs**:\n   - The document notes that \"the value of replacing property, associated labor costs for the property business we write, and litigation costs\" are factors in the company's reserving models.\n   - Higher inflation could increase these costs, potentially leading to higher expenses for the company.\n\n5. **Investment Portfolio**:\n   - The company's investment strategy is designed to achieve higher returns over the long term, but it is more volatile than traditional fixed-income portfolios.\n   - Inflation can erode the value of fixed-income investments, and if the company holds such instruments, their value could decrease.\n\nGiven this analysis, the most relevant and direct effect of an unexpected rise in inflation on the company's financial condition is:\n\n**B: Lead to higher interest rates affecting rate-sensitive financial instruments**\n\nThis option is supported by the document's explicit mention that higher inflation could lead to higher interest rates, which"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 32000, "result": 1.0, "question": "What could a successful liability claim potentially lead to, even if fully insured?", "options": {"A": "Increased stock prices", "B": "Diminished brand reputation", "C": "Expansion into new markets", "D": "Immediate financial gains", "E": "Improved customer satisfaction", "F": "Reduced operational costs"}, "LLM_original_answer": ["To answer the question \"What could a successful liability claim potentially lead to, even if fully insured?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Insurance Coverage and Liability Claims**:\n   - The document mentions that Duke Energy maintains various insurance policies to cover certain risks and liabilities related to its business.\n   - However, it also states that the amount of insurance coverage may not be adequate to cover all claims or liabilities, and even if adequate, it may delay constellation or platform upgrades, which could negatively impact the company's ability to meet customer commitments and revenue expectations.\n\n2. **Impact of Liability Claims**:\n   - **Increased Stock Prices (Option A)**: The document does not suggest that a successful liability claim would lead to increased stock prices. In fact, it implies that such claims could have negative impacts.\n   - **Diminished Brand Reputation (Option B)**: The document explicitly mentions that even if fully insured, a successful liability claim could diminish brand reputation and divert management's attention and resources, which could negatively impact the business.\n   - **Expansion into New Markets (Option C)**: There is no indication in the document that a successful liability claim would lead to expansion into new markets.\n   - **Immediate Financial Gains (Option D)**: The document does not suggest that a successful liability claim would result in immediate financial gains. Instead, it highlights potential costs and negative impacts.\n   - **Improved Customer Satisfaction (Option E)**: The document does not suggest that a successful liability claim would improve customer satisfaction. On the contrary, it could harm customer relationships.\n   - **Reduced Operational Costs (Option F)**: The document does not suggest that a successful liability claim would reduce operational costs. Instead, it could lead to increased costs for remediation, legal fees, and potential business interruptions.\n\n3. **Conclusion**:\n   - The document clearly states that a successful liability claim, even if fully insured, could result in substantial costs, diminish brand reputation, and divert management's attention and resources.\n   - Among the given options, **Option B: Diminished brand reputation** is the most directly supported by the document.\n\nTherefore, the correct answer is **B: Diminished brand reputation**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 32000, "result": 1.0, "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?", "options": {"A": "$18.8 billion", "B": "$15.2 billion", "C": "$20.1 billion", "D": "$22.5 billion", "E": "$17.9 billion", "F": "$19.6 billion"}, "LLM_original_answer": ["To answer the question \"What was the total amount invested in capital expenditures during the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Relevant Information**: Look for any mention of capital expenditures in the document.\n2. **Extract the Specific Amount**: Find the exact amount invested in capital expenditures for the year ended December 31, 2023.\n3. **Match the Amount to the Given Options**: Compare the extracted amount to the provided options to select the correct answer.\n\n### Step 1: Identify the Relevant Information\nThe document mentions capital expenditures in the section titled \"Capital Expenditures and Investments.\" Specifically, it states:\n> \"During the year ended December 31, 2023, these investments included $18.8 billion for capital expenditures.\"\n\n### Step 2: Extract the Specific Amount\nThe specific amount invested in capital expenditures during the year ended December 31, 2023 is $18.8 billion.\n\n### Step 3: Match the Amount to the Given Options\nThe options provided are:\n- A: $18.8 billion\n- B: $15.2 billion\n- C: $20.1 billion\n- D: $22.5 billion\n- E: $17.9 billion\n- F: $19.6 billion\n\nThe amount $18.8 billion matches option A.\n\n### Conclusion\nThe total amount invested in capital expenditures during the year ended December 31, 2023 is **$18.8 billion**. Therefore, the correct answer is **A: $18.8 billion**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 32000, "result": 1.0, "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?", "options": {"A": "Increased customer satisfaction", "B": "Fines and additional costs", "C": "Reduction in legal obligations", "D": "Improved brand reputation", "E": "Increased production rates", "F": "Decrease in product demand"}, "LLM_original_answer": ["To answer the question \"What could happen if a product with quality issues is recalled due to regulatory non-compliance?\" based on the provided document, I will analyze the relevant sections and extract the key points that address the potential consequences of such a recall.\n\n### Step-by-Step Analysis:\n\n1. **Quality Issues and Regulatory Non-Compliance:**\n   - The document mentions that if the quality of products does not meet customer expectations or regulatory or industry standards, it can lead to significant negative impacts. Specifically, it states: \"If the quality of our products does not meet our customers' expectations or regulatory or industry standards, then our sales and operating earnings, and ultimately our reputation, could be negatively impacted.\"\n\n2. **Recall and Field Actions:**\n   - The document notes that quality issues can result in \"stop-shipped\" or recalled products. It states: \"In some cases, if the quality issue affects the product's performance, safety or regulatory compliance, then such a 'defective' product may need to be 'stop-shipped' or recalled.\"\n   - Recalls and field actions can incur substantial costs, including \"recall or corrective field action costs.\"\n\n3. **Legal and Financial Ramifications:**\n   - The document highlights that non-compliance with regulations can lead to legal and financial consequences. It states: \"Recalls and field actions involving regulatory non-compliance could also result in fines and additional costs.\"\n   - Additionally, it mentions: \"We may be required, under certain customer contracts, to pay damages for failed performance that might exceed the revenue that we receive from the contracts.\"\n\n4. **Reputational Damage:**\n   - The document emphasizes the potential for reputational damage: \"Such pre-shipment and post-shipment quality issues can have legal, financial and reputational ramifications, including: (i) delays in the recognition of revenue, loss of revenue or future orders, (ii) customer-imposed penalties for failure to meet contractual requirements, (iii) increased costs associated with repairing or replacing products, and (iv) a negative impact on our goodwill and brand name reputation.\"\n\n5. **Impact on Future Orders:**\n   - The document suggests that quality issues can lead to a reduction in future orders: \"Depending on the nature of the quality issue and the number of products in the field, it could cause us to incur substantial recall or corrective field action costs, in addition to the costs associated with the potential loss of future orders and the damage to our goodwill or brand reputation.\"\n\n### Conclusion:\nBased on"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 32000, "result": 1.0, "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?", "options": {"A": "Dentists", "B": "Pharmacists", "C": "Physician assistants", "D": "Chiropractors", "E": "Optometrists", "F": "Radiologists"}, "LLM_original_answer": ["To answer the question \"Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the expansion of obligations for payments and transfers of value starting in 2022. This information is found in the section discussing the federal Physician Payments Sunshine Act.\n\n2. **Extract the specific information**: The relevant paragraph states:\n   > \"The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children\u2019s Health Insurance Program (\"CHIP\"), with specific exceptions, to report annually to the Centers for Medicare & Medicaid Services (\"CMS\") information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. **Beginning in 2022, such obligations were expanded to include payments and other transfers of value provided in the previous year to additional healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives.**\"\n\n3. **Determine the newly included professionals**: The paragraph clearly states that beginning in 2022, the obligations were expanded to include payments and other transfers of value to \"physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives.\"\n\n4. **Match the information to the options provided**:\n   - A: Dentists (already included)\n   - B: Pharmacists (not mentioned)\n   - C: Physician assistants (newly included)\n   - D: Chiropractors (already included)\n   - E: Optometrists (already included)\n   - F: Radiologists (not mentioned)\n\nBased on the information provided in the document, the correct answer is:\n\n**C: Physician assistants**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 32000, "result": 1.0, "question": "What did the company opt to permanently exclude from its capital calculations?", "options": {"A": "Unrealized gains and losses on available-for-sale securities", "B": "Deferred tax assets and liabilities", "C": "High volatility commercial real estate loans", "D": "Unused portion of commitments not cancellable", "E": "Non-residential mortgage loans past due", "F": "Capital conservation buffer"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify any mention of the company opting to exclude a specific item from its capital calculations. The document is primarily about TScan Therapeutics, Inc., but it also includes a section about Great Southern Bancorp, Inc. Since the question is not specific to TScan, I will focus on the section about Great Southern Bancorp, Inc. to find the relevant information.\n\nIn the \"Capital\" section of the document, there is a relevant statement:\n\n> \"However, because of our asset size, we were eligible to elect to permanently opt out of the inclusion of unrealized gains and losses on available-for-sale debt and equity securities in our capital calculations. We elected this option.\"\n\nThis statement clearly indicates that Great Southern Bancorp, Inc. opted to permanently exclude unrealized gains and losses on available-for-sale securities from its capital calculations.\n\nTherefore, the correct answer is:\n\nA: Unrealized gains and losses on available-for-sale securities\n\nThis is the only option that matches the information provided in the document."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 32000, "result": 1.0, "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?", "options": {"A": "Data Protection Act of 2018", "B": "European Data Protection Board Act", "C": "UK Cybersecurity Act", "D": "British Privacy Regulations Act", "E": "Information Security Act of 2018", "F": "UK General Data Protection Act"}, "LLM_original_answer": ["The correct answer to the question \"Which legislation incorporated GDPR into the United Kingdom's domestic law?\" is:\n\n**A: Data Protection Act of 2018**\n\n### Chain of Thoughts:\n1. **Context of the Question**: The question is asking about the legislation that incorporated the General Data Protection Regulation (GDPR) into the United Kingdom's domestic law.\n2. **Relevant Information in the Document**: The document does not directly discuss the GDPR or the UK's domestic legislation. However, it does mention the Data Protection Act of 2018 in the context of the United Kingdom's data protection laws.\n3. **Extraction of Key Information**:\n   - The document states: \"Further, the United Kingdom has brought the GDPR into domestic law with the Data Protection Act of 2018 which will remain in force, even if and when the United Kingdom leaves the European Union.\"\n4. **Conclusion**: Based on the information provided, the Data Protection Act of 2018 is the legislation that incorporated GDPR into the United Kingdom's domestic law.\n\nTherefore, the correct answer is **A: Data Protection Act of 2018**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 32000, "result": 1.0, "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?", "options": {"A": "By visiting the Company\u2019s website", "B": "By visiting the SEC's website", "C": "By contacting the Investor Relations Department", "D": "Automatically mailed with annual reports", "E": "Through a subscription service", "F": "At the company headquarters in China"}, "LLM_original_answer": ["To answer the question \"Where can stockholders obtain a free printed copy of the Company's SEC filings?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that mention SEC filings and how stockholders can obtain them.\n2. **Analyze the Options**: Compare the identified information with the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\n\nFrom the document, the relevant information is found in the \"Available Information\" section:\n\n> \"The Company makes available through the Investor Relations website its annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after electronically filing such material with the SEC. These reports may also be obtained by visiting the SEC\u2019s website at http://www.sec.gov. The reference to the Company\u2019s website address and the SEC\u2019s website address is for informational purposes only, does not constitute incorporation by reference of the information contained on the websites and should not be considered part of this Form 10-K. These documents, as well as our SEC filings, are available in print free of charge to any stockholder who requests a copy from our Investor Relations Department by contacting Yum China at 101 East Park Boulevard, Suite 805, Plano, Texas 75074, United States of America, Attention: Investor Relations.\"\n\n### Step 2: Analyze the Options\n\n- **Option A: By visiting the Company\u2019s website**\n  - The document mentions that the SEC filings are available on the Investor Relations website, but it does not state that stockholders can obtain a free printed copy by visiting the website.\n\n- **Option B: By visiting the SEC's website**\n  - The document mentions that the SEC filings are available on the SEC\u2019s website, but it does not state that stockholders can obtain a free printed copy by visiting the SEC's website.\n\n- **Option C: By contacting the Investor Relations Department**\n  - The document explicitly states that stockholders can obtain a free printed copy of the SEC filings by contacting the Investor Relations Department at the provided address.\n\n- **Option D: Automatically mailed with annual reports**\n  - The document does not mention that SEC filings are automatically mailed with annual reports.\n\n- **Option E: Through a subscription service**\n "], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 32000, "result": 1.0, "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?", "options": {"A": "A decline in company profits", "B": "Market competition", "C": "A challenge by a taxing authority", "D": "Stock market fluctuations", "E": "Internal policy changes", "F": "Changes in interest rates"}, "LLM_original_answer": ["To answer the question, we need to focus on the specific details provided in the document regarding the Tax Receivable Agreement (TRA) and the factors that could affect the cash payments under this agreement.\n\n1. **Understanding the TRA**: The document states that the Tax Receivables Agreement (TRA) with MetLife provides MetLife with the right to receive future payments from Brighthouse Financial (BHF) equal to 86% of the cash savings BHF realizes from the utilization of certain tax benefits, such as net operating losses, capital losses, and tax basis.\n\n2. **Factors Affecting Cash Payments**:\n   - **Cash Savings**: The payments under the TRA are contingent on the cash savings BHF realizes from tax benefits.\n   - **Tax Benefits**: The document mentions that these tax benefits are subject to the utilization of net operating losses, capital losses, and tax basis.\n\n3. **Potential Challenges**:\n   - **Disputes with Taxing Authorities**: The document notes that BHF is subject to examinations of its income tax returns by the IRS and other tax authorities. If a taxing authority challenges the tax benefits BHF claims, and if these challenges are sustained, BHF may not realize the expected tax savings, which would reduce the cash payments under the TRA.\n\n4. **Other Factors**:\n   - **Company Profits**: The document does not suggest that a decline in company profits directly affects the TRA payments. The payments are based on tax savings, not company profits.\n   - **Market Competition**: The document discusses competition in the market but does not link it to the TRA payments.\n   - **Stock Market Fluctuations**: The document does not mention stock market fluctuations affecting the TRA payments.\n   - **Internal Policy Changes**: The document does not indicate that internal policy changes would prevent BHF from reducing future cash payments under the TRA.\n   - **Changes in Interest Rates**: The document does not mention interest rates affecting the TRA payments.\n\n5. **Conclusion**:\n   - The document explicitly mentions that if a taxing authority challenges the tax benefits BHF claims and these challenges are sustained, BHF may not realize the expected tax savings. This would directly affect the cash payments under the TRA.\n\nTherefore, the correct answer is:\n\n**C: A challenge by a taxing authority**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 64000, "result": 1.0, "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?", "options": {"A": "Limited board oversight", "B": "Inability to train employees efficiently", "C": "Challenges in predicting attack methods", "D": "Insufficient technological security measures", "E": "Lack of business continuity plans", "F": "Inadequate physical security measures"}, "LLM_original_answer": ["To answer the question, I will analyze the document for mentions of challenges related to maintaining the security and integrity of systems. The document discusses various aspects of cybersecurity and data protection, which are directly related to the security and integrity of systems.\n\n1. **Compliance with Evolving Regulations**: The document mentions that the company is subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies, and other obligations related to data privacy and security. This indicates a significant challenge in keeping up with the changing regulatory landscape.\n\n2. **Predicting Attack Methods**: The document states, \"Although we seek to detect and investigate all data security incidents, security incidents and other incidents of unauthorized access to our information technology systems and data can be difficult to detect and any delay in identifying such breaches or incidents may lead to increased harm and legal exposure of the type described above.\" This suggests that predicting and detecting attack methods is a challenge.\n\n3. **Employee Training and Use of Generative AI**: The document notes, \"Additionally, our sensitive information could be leaked, disclosed, or revealed as a result of or in connection with our employee\u2019s, personnel\u2019s, or vendor\u2019s use of generative AI technologies, resulting in adverse consequences.\" This highlights the challenge of ensuring that employees are trained and aware of the risks associated with using new technologies like generative AI.\n\n4. **Technical Security Measures**: The document describes various technical, physical, and organizational measures, processes, standards, and policies designed to manage and mitigate material risks from cybersecurity threats. However, it does not explicitly mention insufficient technological security measures as a challenge.\n\n5. **Business Continuity Plans**: The document mentions maintaining disaster recovery and business continuity plans, but it does not indicate a lack of such plans as a challenge.\n\n6. **Physical Security Measures**: The document discusses physical security measures, but it does not suggest that these are inadequate.\n\nGiven these points, the most relevant challenge mentioned in the document is the difficulty in predicting and detecting attack methods, which is directly related to the option \"Challenges in predicting attack methods.\"\n\nTherefore, the correct answer is:\n**C: Challenges in predicting attack methods**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 64000, "result": 1.0, "question": "What effect could an unexpected rise in inflation have on the company's financial condition?", "options": {"A": "Decrease the value of the company's properties", "B": "Lead to higher interest rates affecting rate-sensitive financial instruments", "C": "Increase the demand for property insurance", "D": "Reduce the company's labor costs", "E": "Cause a decrease in interest expenses on debt", "F": "Improve the company's net income"}, "LLM_original_answer": ["To answer the question \"What effect could an unexpected rise in inflation have on the company's financial condition?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Inflation and Interest Rates**:\n   - The document mentions that the company has various debt instruments, including notes payable and finance leases, which are subject to interest rates.\n   - An unexpected rise in inflation often leads to higher interest rates as central banks attempt to control inflation.\n   - Higher interest rates would increase the cost of borrowing, affecting the company's interest expenses on existing and future debt.\n\n2. **Impact on Debt and Leases**:\n   - The company has significant debt and lease obligations, as detailed in Note 7 and Note 9.\n   - For example, the company has entered into finance lease agreements with Liberty Commercial Finance LLC and MassMutual Barings, which bear interest rates.\n   - If interest rates rise, the company's interest expenses on these debt and lease obligations will increase, potentially leading to higher interest costs and reduced net income.\n\n3. **Inflation and Operating Costs**:\n   - The document discusses the company's operations, including hosting and mining segments, which involve significant operational costs.\n   - Inflation could increase the cost of electricity, labor, and other operational expenses, which are crucial for the company's data center and mining operations.\n   - Higher operating costs could reduce the company's gross profit and net income.\n\n4. **Inflation and Revenue**:\n   - The company's revenue is primarily generated from digital asset mining and hosting services.\n   - While inflation might increase the cost of operations, it does not necessarily increase the revenue from these services, especially if the company is unable to pass on the increased costs to its customers.\n   - This could lead to a squeeze on profit margins.\n\n5. **Inflation and Asset Values**:\n   - The document mentions that the company has significant property, plant, and equipment (PPE) as of December 31, 2023.\n   - Inflation can increase the nominal value of these assets, but it does not necessarily improve the company's financial condition if the increase in asset values is not accompanied by an increase in revenue or cash flow.\n\n6. **Inflation and Warrant and Stock-Based Compensation**:\n   - The company has issued warrants and stock-based compensation to employees and directors.\n   - Inflation could affect the fair value of these instruments, but the document does not provide specific details on how this would impact the company"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 64000, "result": 1.0, "question": "What could a successful liability claim potentially lead to, even if fully insured?", "options": {"A": "Increased stock prices", "B": "Diminished brand reputation", "C": "Expansion into new markets", "D": "Immediate financial gains", "E": "Improved customer satisfaction", "F": "Reduced operational costs"}, "LLM_original_answer": ["To answer the question \"What could a successful liability claim potentially lead to, even if fully insured?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Insurance Coverage and Limitations**:\n   - The document mentions that Duke Energy and its subsidiaries have insurance and reinsurance coverage for various liabilities, including nuclear liability, property damage, and other risks.\n   - However, it also notes that the terms and amounts of insurance and reinsurance available might not be adequate to cover all claims and other expenses incurred. (See \"General Insurance\" and \"Nuclear Insurance\" sections.)\n\n2. **Potential Impact of Liability Claims**:\n   - **Diminished Brand Reputation**: The document states, \"Even if we are fully insured as it relates to a claim, the claim could nevertheless diminish our brand and divert management\u2019s attention and resources, which could have a negative impact on our business, financial condition, and results of operations.\" (See \"Risks Related to Our Operations\" section.)\n   - This indicates that a successful liability claim, even if fully insured, can still harm the company's brand and reputation.\n\n3. **Other Options Analysis**:\n   - **Increased Stock Prices**: The document does not suggest that a liability claim would lead to increased stock prices. In fact, it implies the opposite, as claims can negatively impact financial performance and investor confidence.\n   - **Expansion into New Markets**: There is no indication that a liability claim would facilitate expansion into new markets. Instead, it could divert resources and attention away from such efforts.\n   - **Immediate Financial Gains**: The document suggests that a successful liability claim could result in significant costs and disruptions, not immediate financial gains.\n   - **Improved Customer Satisfaction**: Liability claims are likely to cause dissatisfaction among customers, not improve it.\n   - **Reduced Operational Costs**: The document indicates that liability claims can lead to increased costs, not reduced operational costs.\n\nGiven this analysis, the most appropriate answer is:\n\n**B: Diminished brand reputation**\n\nThis option aligns with the document's statement that a successful liability claim, even if fully insured, can still harm the company's brand and divert management\u2019s attention and resources, leading to a negative impact on the business."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 64000, "result": 1.0, "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?", "options": {"A": "$18.8 billion", "B": "$15.2 billion", "C": "$20.1 billion", "D": "$22.5 billion", "E": "$17.9 billion", "F": "$19.6 billion"}, "LLM_original_answer": ["To answer the question \"What was the total amount invested in capital expenditures during the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify the Relevant Section**: The document mentions capital expenditures in the \"Capital Expenditures and Investments\" section.\n\n2. **Locate the Specific Information**: In the \"Capital Expenditures and Investments\" section, the document states:\n   > \"During the year ended December 31, 2023, these investments included $18.8 billion for capital expenditures.\"\n\n3. **Match the Information to the Options**: The amount mentioned in the document is $18.8 billion.\n\n4. **Select the Correct Option**: The correct option that matches the amount $18.8 billion is:\n   > A: $18.8 billion\n\nTherefore, the total amount invested in capital expenditures during the year ended December 31, 2023 is **$18.8 billion**. The correct answer is **Option A: $18.8 billion**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 64000, "result": 1.0, "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?", "options": {"A": "Increased customer satisfaction", "B": "Fines and additional costs", "C": "Reduction in legal obligations", "D": "Improved brand reputation", "E": "Increased production rates", "F": "Decrease in product demand"}, "LLM_original_answer": ["The correct answer to the question \"What could happen if a product with quality issues is recalled due to regulatory non-compliance?\" based on the provided document is:\n\n**B: Fines and additional costs**\n\n### Chain of Thought:\n1. **Identify the Context**: The document discusses various risks and challenges faced by Motorola Solutions, including those related to product quality and regulatory compliance.\n2. **Locate Relevant Information**: The section \"Risks Related to the Operation of Our Business\" specifically mentions the risks associated with product quality issues and recalls.\n3. **Extract Key Points**:\n   - **Quality Issues**: \"If the quality of our products does not meet our customers' expectations or regulatory or industry standards, then our sales and operating earnings, and ultimately our reputation, could be negatively impacted.\"\n   - **Recalls and Field Actions**: \"Recalls and field actions involving regulatory non-compliance could also result in fines and additional costs.\"\n4. **Analyze the Options**:\n   - **A: Increased customer satisfaction** - This is not a likely outcome of a product recall due to quality issues.\n   - **B: Fines and additional costs** - This aligns with the document's statement about the potential consequences of regulatory non-compliance.\n   - **C: Reduction in legal obligations** - The document does not suggest that a recall would reduce legal obligations; rather, it implies increased legal scrutiny.\n   - **D: Improved brand reputation** - A recall due to quality issues is more likely to harm brand reputation, not improve it.\n   - **E: Increased production rates** - There is no indication that a recall would lead to increased production rates.\n   - **F: Decrease in product demand** - While a recall could potentially decrease product demand, the document specifically mentions fines and additional costs as direct consequences.\n5. **Conclusion**: Based on the information provided in the document, the most accurate and relevant answer is **B: Fines and additional costs**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 64000, "result": 1.0, "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?", "options": {"A": "Dentists", "B": "Pharmacists", "C": "Physician assistants", "D": "Chiropractors", "E": "Optometrists", "F": "Radiologists"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document:\n\n1. **Identify the relevant section**: The relevant section is found in the \"Healthcare Fraud and Abuse Laws\" part of the document, which discusses the expansion of obligations for payments and transfers of value.\n\n2. **Extract the specific information**:\n   - The document states: \"Beginning in 2022, such obligations were expanded to include payments and other transfers of value provided in the previous year to additional healthcare professionals, including **physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives**.\"\n\n3. **Match the information to the options**:\n   - The document explicitly mentions **physician assistants** as one of the newly included healthcare professionals starting in 2022.\n\n4. **Conclusion**:\n   - The correct answer is **C: Physician assistants**.\n\nTherefore, the answer to the question \"Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?\" is **C: Physician assistants**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 64000, "result": 1.0, "question": "What did the company opt to permanently exclude from its capital calculations?", "options": {"A": "Unrealized gains and losses on available-for-sale securities", "B": "Deferred tax assets and liabilities", "C": "High volatility commercial real estate loans", "D": "Unused portion of commitments not cancellable", "E": "Non-residential mortgage loans past due", "F": "Capital conservation buffer"}, "LLM_original_answer": ["The document provided does not contain information directly related to the question about what a company opted to permanently exclude from its capital calculations. However, based on the information given in the \"Capital\" section of the document, we can infer the answer:\n\nIn the \"Capital\" section, it states:\n\"However, because of our asset size, we were eligible to elect to permanently opt out of the inclusion of unrealized gains and losses on available-for-sale debt and equity securities in our capital calculations. We elected this option.\"\n\nThis indicates that the company chose to permanently exclude unrealized gains and losses on available-for-sale securities from its capital calculations.\n\nTherefore, the correct answer is:\nA: Unrealized gains and losses on available-for-sale securities"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 64000, "result": 1.0, "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?", "options": {"A": "Data Protection Act of 2018", "B": "European Data Protection Board Act", "C": "UK Cybersecurity Act", "D": "British Privacy Regulations Act", "E": "Information Security Act of 2018", "F": "UK General Data Protection Act"}, "LLM_original_answer": ["The correct answer to the question \"Which legislation incorporated GDPR into the United Kingdom's domestic law?\" is:\n\nA: Data Protection Act of 2018\n\n### Chain of Thought:\n1. **Context of the Question**: The question is asking about the legislation that incorporated the General Data Protection Regulation (GDPR) into the United Kingdom's domestic law.\n2. **Relevant Information in the Document**: The document mentions the GDPR and the United Kingdom's approach to data protection, specifically noting the Data Protection Act of 2018.\n3. **Key Sentence**: \"Further, the United Kingdom has brought the GDPR into domestic law with the Data Protection Act of 2018 which will remain in force, even if and when the United Kingdom leaves the European Union.\"\n4. **Conclusion**: The Data Protection Act of 2018 is the legislation that incorporated GDPR into the United Kingdom's domestic law.\n\nThus, the correct answer is **A: Data Protection Act of 2018**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 64000, "result": 1.0, "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?", "options": {"A": "By visiting the Company\u2019s website", "B": "By visiting the SEC's website", "C": "By contacting the Investor Relations Department", "D": "Automatically mailed with annual reports", "E": "Through a subscription service", "F": "At the company headquarters in China"}, "LLM_original_answer": ["To answer the question \"Where can stockholders obtain a free printed copy of the Company's SEC filings?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the Company**: The document is about Intercontinental Exchange, Inc. (ICE).\n\n2. **Locate Information on SEC Filings**: The document does not explicitly mention where stockholders can obtain free printed copies of ICE's SEC filings. However, it does provide information on how to access other documents, which might be relevant.\n\n3. **Check for Investor Relations Information**: The document mentions that the Global Code of Business Conduct is available on the company's website under the \"Investor Relations\" section. This suggests that the company might provide similar access for SEC filings.\n\n4. **Review the Document for Specific Instructions**: The document does not provide a specific section or statement about obtaining free printed copies of SEC filings. However, it does mention that the company will furnish any exhibit upon request to the Investor Relations Department.\n\n5. **Consider the Options Provided**:\n   - **Option A**: By visiting the Company\u2019s website\n   - **Option B**: By visiting the SEC's website\n   - **Option C**: By contacting the Investor Relations Department\n   - **Option D**: Automatically mailed with annual reports\n   - **Option E**: Through a subscription service\n   - **Option F**: At the company headquarters in China\n\n6. **Evaluate Each Option**:\n   - **Option A**: The document mentions that the Global Code of Business Conduct is available on the company's website, which suggests that other important documents, including SEC filings, might also be available there.\n   - **Option B**: The document does not mention this, but it is a common practice for stockholders to access SEC filings directly from the SEC's website.\n   - **Option C**: The document states that the company will furnish any exhibit upon request to the Investor Relations Department, which implies that stockholders can contact the Investor Relations Department for other documents, including SEC filings.\n   - **Option D**: The document does not mention that SEC filings are automatically mailed with annual reports.\n   - **Option E**: The document does not mention a subscription service for obtaining SEC filings.\n   - **Option F**: The document does not mention obtaining SEC filings at the company headquarters in China.\n\n7. **Conclusion**: Based on the information provided, the most likely options are **A** (visiting the Company\u2019s website) and **C** (contacting the Investor Relations Department"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 64000, "result": 1.0, "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?", "options": {"A": "A decline in company profits", "B": "Market competition", "C": "A challenge by a taxing authority", "D": "Stock market fluctuations", "E": "Internal policy changes", "F": "Changes in interest rates"}, "LLM_original_answer": ["To answer the question \"What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Tax Receivable Agreement Overview**:\n   - MarketWise, Inc. is party to a Tax Receivable Agreement with the MarketWise Members and MarketWise, LLC.\n   - Under this agreement, MarketWise, Inc. is required to make cash payments to the MarketWise Members equal to 85% of the tax benefits realized or deemed to be realized.\n\n2. **Payment Obligations**:\n   - The payments are based on the tax reporting positions that MarketWise, Inc. determines.\n   - The IRS or another tax authority may challenge the tax benefits claimed by MarketWise, Inc.\n   - If a challenge is sustained, MarketWise, Inc. will not be reimbursed for any payments made to the MarketWise Members under the Tax Receivable Agreement.\n\n3. **Material Breach and Acceleration**:\n   - If MarketWise, Inc. materially breaches any of its material obligations under the Tax Receivable Agreement, certain mergers, asset sales, or changes of control occur, or if MarketWise, Inc. elects an early termination, the future obligations under the Tax Receivable Agreement would accelerate.\n   - This would require MarketWise, Inc. to make an immediate cash payment equal to the estimated present value of the anticipated future tax benefits, based on certain assumptions.\n\n4. **Challenges by Taxing Authorities**:\n   - The document explicitly states that if the IRS or another tax authority challenges the tax benefits claimed by MarketWise, Inc., and a court sustains the challenge, MarketWise, Inc. will not be reimbursed for any payments made to the MarketWise Members.\n   - This means that even if the tax benefits are disallowed, MarketWise, Inc. must still make the payments as per the agreement.\n\nGiven this analysis, the correct answer is:\n\n**C: A challenge by a taxing authority**\n\nThis is because the document clearly indicates that if the IRS or another tax authority challenges the tax benefits and the challenge is sustained, MarketWise, Inc. will not be reimbursed for the payments already made under the Tax Receivable Agreement. This prevents MarketWise, Inc. from reducing future cash payments, as they are still obligated to make the payments based on the original agreement, regardless of the outcome"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 96000, "result": 0.0, "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?", "options": {"A": "Limited board oversight", "B": "Inability to train employees efficiently", "C": "Challenges in predicting attack methods", "D": "Insufficient technological security measures", "E": "Lack of business continuity plans", "F": "Inadequate physical security measures"}, "LLM_original_answer": ["The document provided does not directly mention any of the specific challenges listed in the options regarding maintaining the security and integrity of systems. However, it does discuss several aspects of cybersecurity and data protection that are relevant to the broader context of security and integrity. The closest match to the content of the document is:\n\n**F: Inadequate physical security measures**\n\nThis is inferred from the following section of the document:\n\n> \"Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable.\"\n\nWhile the document does not explicitly state \"inadequate physical security measures,\" it does highlight the potential inadequacy of security measures in protecting sensitive information, which can be interpreted as a challenge in maintaining physical and technological security measures.\n\nHowever, the document also mentions other challenges that could be relevant to maintaining security and integrity, such as:\n\n- **Challenges in predicting attack methods (C)**: The document discusses the evolving nature of cybersecurity threats and the difficulty in detecting and remediating vulnerabilities.\n- **Insufficient technological security measures (D)**: The document mentions the limitations of current security measures and the potential for security incidents to compromise sensitive information.\n\nGiven the context, the most directly relevant challenge mentioned in the document is:\n\n**F: Inadequate physical security measures**\n\nThis is the best match based on the provided options and the content of the document."], "LLM_extracted_answer": ["F"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 96000, "result": 1.0, "question": "What effect could an unexpected rise in inflation have on the company's financial condition?", "options": {"A": "Decrease the value of the company's properties", "B": "Lead to higher interest rates affecting rate-sensitive financial instruments", "C": "Increase the demand for property insurance", "D": "Reduce the company's labor costs", "E": "Cause a decrease in interest expenses on debt", "F": "Improve the company's net income"}, "LLM_original_answer": ["To answer the question \"What effect could an unexpected rise in inflation have on the company's financial condition?\" based on the provided document, let's analyze the options and the relevant information from the document:\n\n### Options:\nA: Decrease the value of the company's properties\nB: Lead to higher interest rates affecting rate-sensitive financial instruments\nC: Increase the demand for property insurance\nD: Reduce the company's labor costs\nE: Cause a decrease in interest expenses on debt\nF: Improve the company's net income\n\n### Analysis:\n1. **Option A: Decrease the value of the company's properties**\n   - The document does not provide specific information about the impact of inflation on the value of the company's properties. However, historically, inflation can sometimes increase the value of real estate and other physical assets due to higher construction and maintenance costs. Therefore, this option is less likely to be correct.\n\n2. **Option B: Lead to higher interest rates affecting rate-sensitive financial instruments**\n   - The document mentions that the company has various debt instruments, including notes payable and finance leases. It also states that the company is subject to interest rate changes. An unexpected rise in inflation often leads to higher interest rates, which would increase the interest expense on these debt instruments. This is a plausible effect and is supported by the document.\n\n3. **Option C: Increase the demand for property insurance**\n   - The document does not discuss the company's involvement in property insurance. The company's primary focus is on digital asset mining and hosting services. Therefore, this option is not relevant to the company's financial condition as described in the document.\n\n4. **Option D: Reduce the company's labor costs**\n   - Inflation typically leads to higher labor costs as wages and salaries tend to increase to keep up with the rising cost of living. The document does not suggest any mechanism by which inflation would reduce labor costs. Therefore, this option is incorrect.\n\n5. **Option E: Cause a decrease in interest expenses on debt**\n   - This is the opposite of what would typically happen. Higher inflation usually leads to higher interest rates, which would increase interest expenses. The document supports this by mentioning the company's debt instruments and the potential for interest rate changes.\n\n6. **Option F: Improve the company's net income**\n   - Inflation can negatively impact net income by increasing operating costs, such as electricity and labor costs, which are significant for the company. The document highlights that the company's costs, including electricity and salaries, are a major component"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 96000, "result": 1.0, "question": "What could a successful liability claim potentially lead to, even if fully insured?", "options": {"A": "Increased stock prices", "B": "Diminished brand reputation", "C": "Expansion into new markets", "D": "Immediate financial gains", "E": "Improved customer satisfaction", "F": "Reduced operational costs"}, "LLM_original_answer": ["To answer the question \"What could a successful liability claim potentially lead to, even if fully insured?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Insurance Coverage and Limitations**:\n   - The document mentions that Duke Energy and its subsidiaries have insurance and reinsurance coverage, but it also notes that the amount of insurance coverage may not be adequate to cover all claims and other expenses. (See Note 5, \"Commitments and Contingencies,\" and Note 17, \"Fair Value Measurements\").\n   - Even if fully insured, the document states that \"Even if we are fully insured as it relates to a claim, the claim could nevertheless diminish our brand and divert management\u2019s attention and resources, which could have a negative impact on our business, financial condition, and results of operations.\" (See Item 1A, \"Risk Factors\").\n\n2. **Brand Reputation**:\n   - The document explicitly mentions that a successful liability claim, even if fully insured, could diminish brand reputation. This is a direct and clear indication that brand reputation can be affected. (See Item 1A, \"Risk Factors\").\n\n3. **Operational Impact**:\n   - The document also notes that such claims could divert management\u2019s attention and resources, which could negatively impact the business. This suggests that operational costs and efficiency could be affected, but it does not directly state that operational costs would be reduced. (See Item 1A, \"Risk Factors\").\n\n4. **Financial Impact**:\n   - The document does not suggest that a successful liability claim would lead to increased stock prices, immediate financial gains, or improved customer satisfaction. Instead, it indicates potential negative impacts on financial condition and results of operations. (See Item 1A, \"Risk Factors\").\n\n5. **Regulatory and Legal Impact**:\n   - The document discusses various regulatory and legal proceedings, but it does not suggest that a successful liability claim would lead to expansion into new markets. (See Note 4, \"Regulatory Matters\").\n\nGiven this analysis, the most appropriate answer is:\n\n**B: Diminished brand reputation**\n\nThis option directly aligns with the information provided in the document, which explicitly states that a successful liability claim, even if fully insured, could diminish brand reputation and divert management\u2019s attention and resources, leading to negative impacts on the business."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 96000, "result": 1.0, "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?", "options": {"A": "$18.8 billion", "B": "$15.2 billion", "C": "$20.1 billion", "D": "$22.5 billion", "E": "$17.9 billion", "F": "$19.6 billion"}, "LLM_original_answer": ["To answer the question \"What was the total amount invested in capital expenditures during the year ended December 31, 2023?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Look for sections in the document that discuss capital expenditures and investments.\n2. **Locate Specific Data**: Find the specific amount mentioned for capital expenditures in the year 2023.\n3. **Verify the Data**: Ensure the data is from the correct year and is not part of a different section or context.\n4. **Match with Options**: Compare the identified amount with the given options to select the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document discusses various financial aspects of the company, including capital expenditures. The relevant section is likely to be found in the \"Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\" or similar sections.\n\n### Step 2: Locate Specific Data\nIn the \"Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\" section, I found the following relevant information:\n\n> **Capital Expenditures and Investments**\n> We continue to invest in our wireless networks, high-speed fiber and other advanced technologies to position ourselves at the center of growth trends for the future. During the year ended December 31, 2023, these investments included $18.8 billion for capital expenditures.\n\n### Step 3: Verify the Data\nThe data is clearly stated for the year ended December 31, 2023, and it is not part of a different section or context. The amount is $18.8 billion.\n\n### Step 4: Match with Options\nThe amount $18.8 billion matches with option A: $18.8 billion.\n\n### Conclusion\nThe total amount invested in capital expenditures during the year ended December 31, 2023 is **$18.8 billion**. Therefore, the correct answer is **A: $18.8 billion**."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 96000, "result": 1.0, "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?", "options": {"A": "Increased customer satisfaction", "B": "Fines and additional costs", "C": "Reduction in legal obligations", "D": "Improved brand reputation", "E": "Increased production rates", "F": "Decrease in product demand"}, "LLM_original_answer": ["To answer the question \"What could happen if a product with quality issues is recalled due to regulatory non-compliance?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Identify the Context**:\n   - The document discusses various risks and challenges faced by biopharmaceutical companies, including Nurix Therapeutics, in the development, commercialization, and marketing of their drug candidates.\n\n2. **Relevant Sections**:\n   - **Product Liability and Recall**:\n     - \"If we are unable to successfully defend ourselves against claims that our drug candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: decreased demand for any drug candidates or products that we may develop; termination of clinical trials; withdrawal of marketing approval, recall, restriction on the approval or a 'black box' warning or contraindication for an approved drug; withdrawal of clinical trial participants; significant costs to defend the related litigation; substantial monetary awards to trial participants or patients; loss of revenue; injury to our reputation and significant negative media attention; reduced resources of our management to pursue our business strategy; and the inability to commercialize any products that we may develop.\"\n   - **Regulatory Approval and Marketing**:\n     - \"If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our drug candidates.\"\n     - \"Even if we are able to commercialize any drug candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.\"\n\n3. **Analyze the Options**:\n   - **A: Increased customer satisfaction** - This is unlikely. A recall due to quality issues would likely decrease customer satisfaction.\n   - **B: Fines and additional costs** - This is highly likely. The document mentions substantial liabilities and costs associated with product recalls and legal claims.\n   - **C: Reduction in legal obligations** - This is not supported by the document. In fact, the document suggests increased legal obligations and costs.\n   - **D: Improved brand reputation** - This is unlikely. The document mentions injury to reputation and significant negative media attention.\n   - **E: Increased production rates** - This is not supported by the document. A recall would likely disrupt production and reduce rates.\n   - **F: Decrease in product demand** - This is highly likely. The document mentions decreased demand for"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 96000, "result": 1.0, "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?", "options": {"A": "Dentists", "B": "Pharmacists", "C": "Physician assistants", "D": "Chiropractors", "E": "Optometrists", "F": "Radiologists"}, "LLM_original_answer": ["The document provided does not contain information directly related to the inclusion of healthcare professionals in the expanded obligations for payments and transfers of value starting in 2022. However, the question can be answered based on the information given in the document about the Physician Payments Sunshine Act and its expansion.\n\nFrom the document:\n\"The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children\u2019s Health Insurance Program (\"CHIP\"), with specific exceptions, to report annually to the Centers for Medicare & Medicaid Services (\"CMS\") information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members.\"\n\n\"Beginning in 2022, such obligations were expanded to include payments and other transfers of value provided in the previous year to additional healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives.\"\n\nBased on this information, the correct answer is:\nC: Physician assistants\n\nThe document explicitly states that the obligations were expanded to include physician assistants, among other healthcare professionals, starting in 2022."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 96000, "result": 1.0, "question": "What did the company opt to permanently exclude from its capital calculations?", "options": {"A": "Unrealized gains and losses on available-for-sale securities", "B": "Deferred tax assets and liabilities", "C": "High volatility commercial real estate loans", "D": "Unused portion of commitments not cancellable", "E": "Non-residential mortgage loans past due", "F": "Capital conservation buffer"}, "LLM_original_answer": ["The document provided does not contain a direct statement about the company opting to permanently exclude any specific item from its capital calculations. However, it does mention that the company has elected to opt out of the inclusion of unrealized gains and losses on available-for-sale securities in its capital calculations. This is stated in the following excerpt:\n\n\"However, because of our asset size, we were eligible to elect to permanently opt out of the inclusion of unrealized gains and losses on available-for-sale debt and equity securities in our capital calculations. We elected this option.\"\n\nGiven this information, the correct answer to the question \"What did the company opt to permanently exclude from its capital calculations?\" is:\n\nA: Unrealized gains and losses on available-for-sale securities\n\nThis is the only option that matches the information provided in the document."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 96000, "result": 1.0, "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?", "options": {"A": "Data Protection Act of 2018", "B": "European Data Protection Board Act", "C": "UK Cybersecurity Act", "D": "British Privacy Regulations Act", "E": "Information Security Act of 2018", "F": "UK General Data Protection Act"}, "LLM_original_answer": ["The correct answer to the question \"Which legislation incorporated GDPR into the United Kingdom's domestic law?\" is:\n\nA: Data Protection Act of 2018\n\n### Chain of Thought:\n1. **Context of the Question**: The question is asking about the specific legislation that incorporated the General Data Protection Regulation (GDPR) into the United Kingdom's domestic law.\n2. **Relevant Information in the Document**: The document mentions the GDPR and the UK's data protection regime, but it does not explicitly state which legislation incorporated GDPR into UK law.\n3. **Knowledge of GDPR and UK Law**: The GDPR is a European Union regulation that was adopted by EU member states. When the UK was still part of the EU, it needed to incorporate the GDPR into its domestic law to ensure compliance.\n4. **Data Protection Act of 2018**: The Data Protection Act of 2018 is the UK legislation that was passed to incorporate the GDPR into UK law. It also includes additional provisions specific to the UK.\n5. **Other Options**:\n   - **B: European Data Protection Board Act**: This is not a UK-specific act; it is an EU body.\n   - **C: UK Cybersecurity Act**: This act is related to cybersecurity, not specifically to data protection.\n   - **D: British Privacy Regulations Act**: This is not a real act; the UK does not have a \"British Privacy Regulations Act.\"\n   - **E: Information Security Act of 2018**: This is not a real act; the UK does not have an \"Information Security Act of 2018.\"\n   - **F: UK General Data Protection Act**: This is not a real act; the UK does not have a \"UK General Data Protection Act.\"\n\nGiven the context and the known legislative history, the Data Protection Act of 2018 is the correct answer."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 96000, "result": 1.0, "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?", "options": {"A": "By visiting the Company\u2019s website", "B": "By visiting the SEC's website", "C": "By contacting the Investor Relations Department", "D": "Automatically mailed with annual reports", "E": "Through a subscription service", "F": "At the company headquarters in China"}, "LLM_original_answer": ["The document provided does not contain specific information about where stockholders can obtain a free printed copy of the Company's SEC filings. However, based on the information in the \"Available Information\" section, it can be inferred that stockholders can obtain a free printed copy of the Company's SEC filings by contacting the Investor Relations Department. This is supported by the following excerpt:\n\n\"The Company makes available through the Investor Relations website its annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after electronically filing such material with the SEC. These reports may also be obtained by visiting the SEC\u2019s website at http://www.sec.gov. The reference to the Company\u2019s website address and the SEC\u2019s website address is for informational purposes only, does not constitute incorporation by reference of the information contained on the websites and should not be considered part of this Form 10-K. These documents, as well as our SEC filings, are available in print free of charge to any stockholder who requests a copy from our Investor Relations Department by contacting Yum China at 101 East Park Boulevard, Suite 805, Plano, Texas 75074, United States of America, Attention: Investor Relations.\"\n\nTherefore, the correct answer is:\n\nC: By contacting the Investor Relations Department\n\nThis is the most direct and supported method for stockholders to obtain a free printed copy of the Company's SEC filings according to the provided document."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 96000, "result": 1.0, "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?", "options": {"A": "A decline in company profits", "B": "Market competition", "C": "A challenge by a taxing authority", "D": "Stock market fluctuations", "E": "Internal policy changes", "F": "Changes in interest rates"}, "LLM_original_answer": ["To answer the question \"What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?\" based on the provided document, let's analyze the relevant sections step by step:\n\n1. **Tax Receivable Agreement (TRA) Overview**:\n   - The TRA requires MarketWise, Inc. to make cash payments to the MarketWise Members in respect of certain tax benefits.\n   - These payments are based on the tax reporting positions that MarketWise, Inc. determines.\n\n2. **Challenges to Tax Benefits**:\n   - The IRS or another tax authority may challenge the tax basis increases or other tax benefits claimed by MarketWise, Inc.\n   - If a challenge is sustained, MarketWise, Inc. will not be reimbursed for any cash payments previously made to the MarketWise Members under the TRA.\n\n3. **Material Breach and Acceleration**:\n   - If MarketWise, Inc. materially breaches any of its material obligations under the TRA, certain mergers, asset sales, or changes of control occur, or if MarketWise, Inc. elects an early termination of the TRA, future obligations under the TRA would accelerate and become due and payable.\n   - This acceleration is based on certain assumptions, including that MarketWise, Inc. would have sufficient taxable income to fully utilize all potential future tax benefits, and that any MarketWise Member with unexchanged LLC Units is deemed to have exchanged them, even if the actual exchange happens later.\n\n4. **No Reimbursement for Disallowed Benefits**:\n   - MarketWise, Inc. will not be reimbursed for any payments made to the MarketWise Members if the tax benefits are subsequently disallowed.\n   - Any excess cash payments made by MarketWise, Inc. to the MarketWise Members will be netted against future cash payments, but this netting may not be immediate or sufficient.\n\n5. **Regulatory and Legal Constraints**:\n   - The TRA payments are not conditioned on the MarketWise Members' continued ownership of LLC Units or Class A common stock.\n   - MarketWise, Inc. must make these payments regardless of the members' ownership status.\n\n6. **Impact of Challenges**:\n   - If a tax authority challenges the tax benefits and the challenge is sustained, MarketWise, Inc. will not be permitted to reduce any future cash payments under the TRA until the challenge is finally settled or determined.\n   - This means that"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 128000, "result": 1.0, "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?", "options": {"A": "Limited board oversight", "B": "Inability to train employees efficiently", "C": "Challenges in predicting attack methods", "D": "Insufficient technological security measures", "E": "Lack of business continuity plans", "F": "Inadequate physical security measures"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the challenge mentioned in maintaining the security and integrity of the systems, particularly focusing on the sections that discuss security and regulatory compliance.\n\n1. **Identifying Relevant Sections**:\n   - The document discusses various aspects of regulatory compliance, intellectual property protection, and the challenges associated with clinical trials and product development.\n   - A specific section that stands out is the one related to cybersecurity and the protection of sensitive information.\n\n2. **Relevant Information**:\n   - **Cybersecurity and Data Protection**:\n     - \"If our internal computer systems, or those used by our contract research organizations, or other contractors or consultants upon which we rely, fail, suffer security incidents, or are or were otherwise compromised, we could experience adverse consequences, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.\"\n     - \"Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely.\"\n     - \"We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks, malicious code, malware, denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, attacks enhanced or facilitated by AI, and other similar threats.\"\n\n3. **Analyzing the Options**:\n   - **A: Limited board oversight** - The document does not mention limited board oversight as a challenge.\n   - **B: Inability to train employees efficiently** - The document does not mention this as a specific challenge.\n   - **C: Challenges in predicting attack methods** - The document mentions evolving threats and the difficulty in predicting and defending against various types of cyber-attacks.\n   - **D: Insufficient technological security measures** - The document discusses the need for robust security measures and the potential for security incidents, but it does not explicitly state that the measures are insufficient.\n   - **E: Lack of business continuity plans** - The document mentions business continuity plans in the context of cybersecurity, but it does not highlight a lack"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 128000, "result": 1.0, "question": "What effect could an unexpected rise in inflation have on the company's financial condition?", "options": {"A": "Decrease the value of the company's properties", "B": "Lead to higher interest rates affecting rate-sensitive financial instruments", "C": "Increase the demand for property insurance", "D": "Reduce the company's labor costs", "E": "Cause a decrease in interest expenses on debt", "F": "Improve the company's net income"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 128000, "result": 1.0, "question": "What could a successful liability claim potentially lead to, even if fully insured?", "options": {"A": "Increased stock prices", "B": "Diminished brand reputation", "C": "Expansion into new markets", "D": "Immediate financial gains", "E": "Improved customer satisfaction", "F": "Reduced operational costs"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 128000, "result": 1.0, "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?", "options": {"A": "$18.8 billion", "B": "$15.2 billion", "C": "$20.1 billion", "D": "$22.5 billion", "E": "$17.9 billion", "F": "$19.6 billion"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 128000, "result": 1.0, "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?", "options": {"A": "Increased customer satisfaction", "B": "Fines and additional costs", "C": "Reduction in legal obligations", "D": "Improved brand reputation", "E": "Increased production rates", "F": "Decrease in product demand"}, "LLM_original_answer": ["To answer the question \"What could happen if a product with quality issues is recalled due to regulatory non-compliance?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Regulatory Non-Compliance and Product Recall**:\n   - The document discusses the stringent regulatory requirements for drug and biological products, including the need for compliance with cGMPs (current Good Manufacturing Practices) and the potential for the FDA to require product recalls if these standards are not met.\n   - It states, \"If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our current or future drug candidates for clinical trials, our ability to obtain marketing approval or our ability to provide supply of our drug candidates for patients, if approved, could be delayed or stopped.\"\n\n2. **Consequences of Non-Compliance**:\n   - The document outlines several potential consequences of non-compliance with regulatory standards:\n     - **Fines and Additional Costs**: \"We may be subject to fines, injunctions or the imposition of civil or criminal penalties.\"\n     - **Restrictions on Marketing or Manufacturing**: \"We may be required to recall the drug, change the way the drug is administered or conduct additional clinical trials.\"\n     - **Withdrawal of Marketing Approvals**: \"The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs.\"\n     - **Product Seizure or Detention**: \"The FDA may seize the drug or biological product.\"\n     - **Refusal to Permit Import or Export**: \"The FDA may refuse to permit the import or export of products.\"\n     - **Refusal to Approve Pending Applications**: \"The FDA may refuse to approve pending NDAs, BLAs or supplements to approved NDAs or BLAs, or suspension or revocation of product license approvals.\"\n     - **Injunctions or Imposition of Civil or Criminal Penalties**: \"The FDA may impose injunctions or the imposition of civil or criminal penalties.\"\n\n3. **Impact on Business**:\n   - The document also mentions the broader impact on the business:\n     - **Increased Costs**: \"The cost of compliance with post-approval regulations may have a negative effect on our business, results of operations, financial condition and prospects.\"\n     - **Reputational Damage**: \"We could be materially and adversely affected and our competitors may be dissuaded from collaborating with us, which could have a material adverse effect on our business, financial condition, results of operations and"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 90, "token_lengths": 128000, "result": 1.0, "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?", "options": {"A": "Dentists", "B": "Pharmacists", "C": "Physician assistants", "D": "Chiropractors", "E": "Optometrists", "F": "Radiologists"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 128000, "result": 1.0, "question": "What did the company opt to permanently exclude from its capital calculations?", "options": {"A": "Unrealized gains and losses on available-for-sale securities", "B": "Deferred tax assets and liabilities", "C": "High volatility commercial real estate loans", "D": "Unused portion of commitments not cancellable", "E": "Non-residential mortgage loans past due", "F": "Capital conservation buffer"}, "LLM_original_answer": ["The document provided does not contain information directly related to the question about what the company opted to permanently exclude from its capital calculations. However, based on the information given in the \"Risks Relating to Regulation\" section, it is mentioned that the company has elected to permanently opt out of including unrealized gains and losses on available-for-sale securities in its capital calculations. This is a specific regulatory option that the company has chosen to take advantage of, which aligns with the option provided in the question.\n\nTherefore, the correct answer is:\n\nA: Unrealized gains and losses on available-for-sale securities\n\nThis exclusion is likely a strategic decision to avoid volatility in the company's regulatory capital due to market fluctuations affecting the value of its available-for-sale securities."], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 128000, "result": 1.0, "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?", "options": {"A": "Data Protection Act of 2018", "B": "European Data Protection Board Act", "C": "UK Cybersecurity Act", "D": "British Privacy Regulations Act", "E": "Information Security Act of 2018", "F": "UK General Data Protection Act"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "A"}, {"depth": 90, "token_lengths": 128000, "result": 1.0, "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?", "options": {"A": "By visiting the Company\u2019s website", "B": "By visiting the SEC's website", "C": "By contacting the Investor Relations Department", "D": "Automatically mailed with annual reports", "E": "Through a subscription service", "F": "At the company headquarters in China"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 90, "token_lengths": 128000, "result": 1.0, "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?", "options": {"A": "A decline in company profits", "B": "Market competition", "C": "A challenge by a taxing authority", "D": "Stock market fluctuations", "E": "Internal policy changes", "F": "Changes in interest rates"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 8000, "result": 1.0, "question": "What is one primary responsibility of PLS in the loan servicing agreement?", "options": {"A": "Issuing new loans to investors", "B": "Collecting principal, interest, and escrow payments", "C": "Providing insurance for loan defaults", "D": "Publishing annual financial reports", "E": "Managing client investments in stock markets", "F": "Developing real estate properties"}, "LLM_original_answer": ["To answer the question \"What is one primary responsibility of PLS in the loan servicing agreement?\" based on the provided document, I will analyze the relevant information step by step:\n\n1. **Identify the Role of PLS**:\n   - The document mentions that PLS (Presumably a loan servicing company) is a subsidiary of PFSI and provides various services under different agreements.\n   - Specifically, under the loan servicing agreement, PLS is responsible for servicing our portfolios of loans and MSRs (Mortgage Servicing Rights).\n\n2. **Determine the Primary Responsibilities**:\n   - The document outlines several responsibilities of PLS under the loan servicing agreement:\n     - **Collecting principal, interest, and escrow payments**: \"PLS\u2019 loan servicing activities include collecting principal, interest and escrow account payments, if any, with respect to loans, as well as managing loss mitigation, which may include, among other things, collection activities, loan workouts, modifications, foreclosures, short sales and sales of REO.\"\n     - **Managing loss mitigation**: This includes collection activities, loan workouts, modifications, foreclosures, short sales, and sales of REO.\n     - **Promptly foreclosing and liquidating real property**: \"Our ability, through PLS, to promptly foreclose upon defaulted loans and liquidate the underlying real property plays a critical role in our valuation of the assets in which we invest and our expected return on those investments.\"\n\n3. **Evaluate the Options**:\n   - **Option A: Issuing new loans to investors** - This is not mentioned as a responsibility of PLS in the document.\n   - **Option B: Collecting principal, interest, and escrow payments** - This is explicitly mentioned as one of the primary responsibilities of PLS.\n   - **Option C: Providing insurance for loan defaults** - The document does not mention PLS providing insurance for loan defaults.\n   - **Option D: Publishing annual financial reports** - This is not mentioned as a responsibility of PLS.\n   - **Option E: Managing client investments in stock markets** - This is not mentioned as a responsibility of PLS.\n   - **Option F: Developing real estate properties** - This is not mentioned as a responsibility of PLS.\n\n4. **Conclusion**:\n   - Based on the information provided, the primary responsibility of PLS in the loan servicing agreement that is explicitly mentioned is **collecting principal, interest, and escrow payments**.\n\nTherefore, the correct answer is **"], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 95, "token_lengths": 8000, "result": 1.0, "question": "What is the role of DME Advisors in relation to SILP?", "options": {"A": "Manage risk management and operational needs", "B": "Serve as SILP's custodian", "C": "Select and manage appropriate investments", "D": "Ensure SILP is widely diversified", "E": "Handle collateral purposes for SILP", "F": "Contribute funds to Greenlight Re and GRIL"}, "LLM_original_answer": ["To answer the question \"What is the role of DME Advisors in relation to SILP?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Role of DME Advisors**:\n   - The document states: \"SILP\u2019s performance depends on the ability of DME Advisors to select and manage appropriate investments.\"\n   - It also mentions: \"DME Advisors acts as the exclusive investment advisor for SILP.\"\n\n2. **Investment Management**:\n   - DME Advisors is responsible for structuring investments in relation to our liquidity needs or liabilities.\n   - The document notes: \"We cannot provide assurance that DME Advisors, on behalf of SILP, will successfully structure investments in relation to our liquidity needs or liabilities.\"\n\n3. **Concentration and Diversification**:\n   - The document highlights that SILP may be concentrated in a few large positions, which could result in material adverse valuation movements.\n   - It also mentions: \"Since SILP may not be widely diversified by security or by industry, it may be subject to more rapid changes in value than would be the case if our investment portfolio were required to maintain a wide diversification among companies, securities industries, and types of securities.\"\n\n4. **Collateral and Operational Needs**:\n   - The document states: \"Apart from funds required for collateral purposes, funds allocated to our Innovations investment strategy, risk management, and other operational needs, we are contractually obligated to use commercially reasonable efforts to cause substantially all investable assets of Greenlight Re and GRIL to be contributed to SILP.\"\n\nFrom these points, we can deduce that DME Advisors' primary role is to select and manage appropriate investments for SILP. While they also consider liquidity needs and risk management, the core function is investment management.\n\nTherefore, the correct answer is:\n**C: Select and manage appropriate investments**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 8000, "result": 1.0, "question": "What can materially and adversely affect the operations due to issues with satellites?", "options": {"A": "High employee turnover in satellite companies", "B": "Changes in customer preferences", "C": "Construction and launch delays for satellites", "D": "Increased competition from other industries", "E": "Innovations in unrelated technology sectors", "F": "A surge in global satellite demand"}, "LLM_original_answer": ["To answer the question \"What can materially and adversely affect the operations due to issues with satellites?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Catastrophic Failure or In-Orbit Failures:**\n   - The document states: \"If one or more of our in-orbit satellites or payloads fail, and we have not obtained insurance coverage or have not obtained sufficient insurance coverage, we could be required to record significant impairment charges for the satellite or payload.\"\n   - This indicates that failures of satellites or payloads can lead to significant financial losses and operational disruptions.\n\n2. **Launch Failures:**\n   - The document mentions: \"If one or more of our uninsured satellites is destroyed during failed launch, or if we have not obtained sufficient insurance for a particular event, we could be required to record significant impairment charges for the satellite or payload.\"\n   - This suggests that launch failures can also result in significant financial and operational impacts.\n\n3. **Insurance Coverage:**\n   - The document notes: \"The amount of insurance coverage that we maintain may not be adequate to cover all claims or liabilities, and even if adequate, may delay constellation or platform upgrades, which would negatively impact our ability to meet customer commitments and revenue expectations.\"\n   - This implies that inadequate insurance coverage can delay necessary upgrades and affect customer commitments and revenue.\n\n4. **Anomalies and Malfunctions:**\n   - The document states: \"Satellites can experience malfunctions, commonly referred to as anomalies, which have occurred and may occur in the future in our satellites. Any single anomaly could materially and adversely affect our ability to utilize the satellite.\"\n   - Anomalies can reduce the expected capacity, commercial operation, and useful life of a satellite, leading to reduced revenue and additional expenses for replacements.\n\n5. **Backup Satellite Capacity:**\n   - The document mentions: \"If a satellite experiences a malfunction, our backup satellite capacity may be insufficient to meet all of our customers\u2019 needs or cause service interruptions, and we may need to potentially blackout or reduce service to certain customers, which would adversely affect our relationships with our customers and result in loss of revenue.\"\n   - This indicates that insufficient backup capacity can lead to service interruptions and loss of revenue.\n\n6. **Operational Life and Performance:**\n   - The document states: \"As satellites near the end of their expected operational lives, we expect the performance of each satellite to decline gradually. We can offer no assurance that satellites will maintain their prescribed orbits or remain operational throughout their expected"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 8000, "result": 1.0, "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?", "options": {"A": "Increase in core data", "B": "Rise in traditional voice communication", "C": "Completion of certain fiber transactions in 2022", "D": "Increase in international traffic", "E": "Growth in network connectivity", "F": "Higher volume of wireless devices sold"}, "LLM_original_answer": ["To answer the question \"What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the performance of the Business segment, which includes the Wholesale customer group.\n\n2. **Locate the specific information about Wholesale revenues**: The document states:\n   - \"Business's total operating revenues decreased during 2023 compared to 2022 as a result of decreases in revenue from each of the three Business customer groups.\"\n   - \"Business's total operating revenues increased during 2022 compared to 2021 as a result of an increase in Business Markets and Other revenue, partially offset by decreases in Enterprise and Public Sector and Wholesale revenues.\"\n\n3. **Analyze the context and possible reasons**: The document does not provide a detailed explanation for the decrease in Wholesale revenues. However, it mentions that the decrease in Business segment revenues in 2023 was due to decreases in revenue from each of the three customer groups, including Wholesale.\n\n4. **Consider the options provided**:\n   - **A: Increase in core data**: The document does not mention an increase in core data as a reason for the decrease in Wholesale revenues.\n   - **B: Rise in traditional voice communication**: The document does not indicate a rise in traditional voice communication as a reason for the decrease in Wholesale revenues.\n   - **C: Completion of certain fiber transactions in 2022**: The document mentions the completion of the accelerated $10 billion capital program related to C-Band spectrum deployment in the second quarter of 2023. However, it also notes that the Business segment's revenues decreased in 2023, which could imply that the completion of significant fiber transactions in 2022 might have contributed to a one-time revenue boost that was not repeated in 2023.\n   - **D: Increase in international traffic**: The document does not mention an increase in international traffic as a reason for the decrease in Wholesale revenues.\n   - **E: Growth in network connectivity**: The document discusses growth in network connectivity, but this is generally seen as a positive factor for revenue, not a negative one.\n   - **F: Higher volume of wireless devices sold**: The document indicates a decrease in the volume of wireless devices sold, which is the opposite of what this option suggests.\n\n5. **Conclusion**: Based"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 8000, "result": 1.0, "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?", "options": {"A": "Broadcast radio communications", "B": "Television broadcasting", "C": "Respond to text, video and data", "D": "Satellite tracking", "E": "Weather forecasting", "F": "Financial transactions processing"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document step by step:\n\n1. **Identify the relevant section**: The document mentions ESInet in the context of the Command Center portfolio, specifically under the \"Next Generation 911 Core Services (NGCS)\" section.\n\n2. **Understand the function of ESInet**: According to the document, ESInet is described as \"an Emergency Service IP Network, which can carry voice, data and multimedia.\"\n\n3. **Determine the capability of ESInet for 911 call takers**: The document states that \"ESInet enables 911 call takers at public safety answering points to respond to text, video and data.\"\n\n4. **Match the capability to the given options**:\n   - **A: Broadcast radio communications** - This is not mentioned as a capability of ESInet.\n   - **B: Television broadcasting** - This is not mentioned as a capability of ESInet.\n   - **C: Respond to text, video and data** - This matches the description provided in the document.\n   - **D: Satellite tracking** - This is not mentioned as a capability of ESInet.\n   - **E: Weather forecasting** - This is not mentioned as a capability of ESInet.\n   - **F: Financial transactions processing** - This is not mentioned as a capability of ESInet.\n\n5. **Conclusion**: The correct answer is **C: Respond to text, video and data**.\n\nTherefore, the capability that the ESInet offers to 911 call takers at public safety answering points is to **respond to text, video and data**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 8000, "result": 1.0, "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?", "options": {"A": "Increase in product sales", "B": "Improvement in clinical trial outcomes", "C": "Negative perception of patient benefits and safety", "D": "Guarantee of FDA approval", "E": "Reduction in training requirements for ECPs", "F": "Expansion of product indications"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and the potential risks associated with ECPs (eyecare professionals) using products inconsistently with labeled indications.\n\n### Step-by-Step Analysis:\n\n1. **Understanding the Context**:\n   - The document discusses the importance of third-party payors (e.g., insurance companies, Medicare) in the commercial success of medical products.\n   - It highlights the risks associated with inadequate or inconsistent reimbursement policies and the impact on product adoption and sales.\n\n2. **Identifying Key Risks**:\n   - **Reimbursement Policies**: Third-party payors often have strict criteria for covering procedures, and deviations from labeled indications can lead to non-coverage or reduced reimbursement.\n   - **Patient Outcomes**: If ECPs use products in a manner inconsistent with labeled indications, patient outcomes may be negative, leading to safety concerns and reduced patient benefits.\n   - **Perception and Adoption**: Negative patient outcomes can lead to a negative perception of the product, which can deter ECPs and patients from using it.\n\n3. **Evaluating the Options**:\n   - **A: Increase in product sales**: This is unlikely because inconsistent use can lead to negative outcomes, which would deter sales.\n   - **B: Improvement in clinical trial outcomes**: This is also unlikely because inconsistent use can lead to variability in outcomes, potentially skewing clinical trial results negatively.\n   - **C: Negative perception of patient benefits and safety**: This is a strong possibility. The document explicitly mentions that negative outcomes can impact the perception of patient benefits and safety, leading to limited adoption.\n   - **D: Guarantee of FDA approval**: This is not a risk but a potential benefit. Inconsistent use does not guarantee FDA approval; it can actually hinder it.\n   - **E: Reduction in training requirements for ECPs**: This is not a risk. Inconsistent use might actually increase the need for training to ensure proper use.\n   - **F: Expansion of product indications**: This is not a risk. Inconsistent use can lead to negative outcomes, which would make it harder to expand product indications.\n\n### Conclusion:\nThe most likely risk if ECPs use products inconsistently with labeled indications is **C: Negative perception of patient benefits and safety**. This is supported by the document, which states that if ECPs utilize products in a manner inconsistent with labeled indications, patient outcomes may be negative, which could negatively impact the perception of patient benefits and safety associated with the products and limit their adoption.\n\n###"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 8000, "result": 1.0, "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?", "options": {"A": "Increase in company market value", "B": "Unintended promotion of products", "C": "Disruption of operations or client operations", "D": "Immediate resolution of security measures", "E": "Enhanced customer relationships", "F": "Unrestricted access to public information"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and consider the potential consequences of a breach or cyber-attack on the computer systems of a financial institution like the one described in the document.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document discusses the importance of computer systems and networks for managing client relationships, processing transactions, and storing confidential information.\n   - It also mentions the risks associated with cyber-attacks and the potential consequences of such events.\n\n2. **Relevant Information:**\n   - **Security Risks and Consequences:**\n     - \"Our operations rely on the secure processing, storage, and transmission of confidential and other information in our computer systems and networks. Although we take protective measures and endeavor to modify them as circumstances warrant, the security of our computer systems, software, and networks may be vulnerable to breaches, unauthorized access, misuse, computer viruses, or other malicious code and cyber-attacks that could have a security impact.\"\n     - \"If one or more of these events occur, this could jeopardize our or our clients\u2019 confidential and other information processed and stored in, and transmitted through, our computer systems and networks, or otherwise cause interruptions or malfunctions in our operations or the operations of our clients or counterparties.\"\n     - \"We may be required to expend significant additional resources to modify our protective measures or to investigate and remediate vulnerabilities or other exposures, and we may be subject to litigation and financial losses that are either not insured against or not fully covered through any insurance maintained by us.\"\n     - \"We could also suffer significant reputational damage.\"\n\n3. **Evaluate Each Option:**\n   - **A: Increase in company market value**\n     - This is highly unlikely. A breach or cyber-attack typically leads to a decrease in market value due to loss of trust and potential financial losses.\n   - **B: Unintended promotion of products**\n     - This is not a plausible consequence of a cyber-attack. Cyber-attacks generally do not promote products but rather cause operational and reputational damage.\n   - **C: Disruption of operations or client operations**\n     - This is a direct and plausible consequence. The document explicitly mentions that cyber-attacks can cause interruptions or malfunctions in operations.\n   - **D: Immediate resolution of security measures**\n     - This is not a realistic outcome. While the company may take immediate steps to address the breach, the resolution process can be lengthy and complex.\n   - **E: Enhanced customer relationships**\n     -"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 8000, "result": 1.0, "question": "What is one intended use of the proceeds from the Business Combination?", "options": {"A": "To invest in new technology development", "B": "To reduce company debt", "C": "To build-up the sales and marketing organization", "D": "To acquire competitor companies", "E": "To expand into international markets", "F": "To increase executive compensation"}, "LLM_original_answer": ["To answer the question \"What is one intended use of the proceeds from the Business Combination?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section**: The document mentions the intended use of proceeds from the Business Combination in a specific paragraph. I will locate this paragraph to extract the relevant information.\n\n2. **Extract the information**: Once I find the paragraph, I will carefully read it to identify the specific use of the proceeds that is mentioned.\n\n3. **Match the information to the options**: I will then compare the extracted information to the given options to determine which one matches the intended use of the proceeds.\n\n### Step 1: Identify the relevant section\nThe relevant section is found in the following paragraph:\n\"We intend to use a portion of the proceeds we receive as a result of the Business Combination to build-up the sales and marketing organization.\"\n\n### Step 2: Extract the information\nThe paragraph clearly states that the proceeds from the Business Combination will be used to \"build-up the sales and marketing organization.\"\n\n### Step 3: Match the information to the options\nThe extracted information directly matches option C: \"To build-up the sales and marketing organization.\"\n\n### Conclusion\nThe intended use of the proceeds from the Business Combination, as stated in the document, is to build-up the sales and marketing organization. Therefore, the correct answer is:\n\n**C: To build-up the sales and marketing organization**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 8000, "result": 0.0, "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?", "options": {"A": "50%", "B": "60%", "C": "65%", "D": "70%", "E": "75%", "F": "80%"}, "LLM_original_answer": ["After carefully reviewing the provided document, I did not find any specific information regarding the percentage of KFC and Pizza Hut's system sales that were attributed to loyalty program members as of year-end 2023. The document primarily focuses on the company's history, key personnel, risk factors, and other operational details, but it does not contain the specific data needed to answer the question.\n\nTherefore, based on the information provided in the document, I cannot determine the correct answer from the given options (A: 50%, B: 60%, C: 65%, D: 70%, E: 75%, F: 80%).\n\nIf you have additional information or another document that contains the relevant data, please provide it, and I will be happy to help you find the correct answer."], "LLM_extracted_answer": ["A"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 8000, "result": 1.0, "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?", "options": {"A": "Classified Board of Directors with staggered, three-year terms", "B": "Issuance of preferred stock to dilute ownership", "C": "Exclusive forum in the Court of Chancery of the State of Delaware", "D": "Prohibition on cumulative voting in the election of directors", "E": "Advance notice procedures for nominating candidates", "F": "Limitation of liability and indemnification of directors and officers"}, "LLM_original_answer": ["To answer the question, I will analyze the document and the options provided to identify which provision is intended to prevent minority stockholders from easily electing director candidates.\n\n### Step-by-Step Analysis:\n\n1. **Option A: Classified Board of Directors with staggered, three-year terms**\n   - The document does not mention anything about a classified board of directors or staggered terms. This option is not supported by the text.\n\n2. **Option B: Issuance of preferred stock to dilute ownership**\n   - The document mentions that the company may issue preferred stock, which could make it difficult for another company to acquire them. However, it does not specifically state that this is to prevent minority stockholders from electing directors. This option is not directly supported by the text.\n\n3. **Option C: Exclusive forum in the Court of Chancery of the State of Delaware**\n   - The document does not mention any exclusive forum provision. This option is not supported by the text.\n\n4. **Option D: Prohibition on cumulative voting in the election of directors**\n   - The document does not explicitly mention cumulative voting. However, it does discuss the concentration of voting power with the MarketWise Members, who control at least 87% of the voting power. This suggests that the voting structure is designed to maintain control, which could imply a prohibition on cumulative voting. This is a strong candidate.\n\n5. **Option E: Advance notice procedures for nominating candidates**\n   - The document does not mention any advance notice procedures for nominating candidates. This option is not supported by the text.\n\n6. **Option F: Limitation of liability and indemnification of directors and officers**\n   - The document mentions the potential for significant legal and regulatory scrutiny and the need to maintain insurance for directors and officers, but it does not specifically state that this is to prevent minority stockholders from electing directors. This option is not directly supported by the text.\n\n### Conclusion:\nThe most relevant provision in the document that could be intended to prevent minority stockholders from easily electing director candidates is the concentration of voting power with the MarketWise Members, who control at least 87% of the voting power. This suggests a voting structure that is designed to maintain control, which could imply a prohibition on cumulative voting.\n\nTherefore, the correct answer is:\n**D: Prohibition on cumulative voting in the election of directors**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 95, "token_lengths": 16000, "result": 1.0, "question": "What is one primary responsibility of PLS in the loan servicing agreement?", "options": {"A": "Issuing new loans to investors", "B": "Collecting principal, interest, and escrow payments", "C": "Providing insurance for loan defaults", "D": "Publishing annual financial reports", "E": "Managing client investments in stock markets", "F": "Developing real estate properties"}, "LLM_original_answer": ["To answer the question \"What is one primary responsibility of PLS in the loan servicing agreement?\" based on the provided document, I will analyze the relevant sections step by step:\n\n1. **Identify the Role of PLS:**\n   - The document mentions that PLS (Presumably a loan servicing entity) is involved in various activities, including loan servicing and mortgage banking services.\n   - PLS is described as providing \"prime and special servicing\" under the loan servicing agreement.\n\n2. **Understand the Servicing Activities:**\n   - The document specifies that PLS' loan servicing activities include:\n     - Collecting principal, interest, and escrow account payments with respect to loans.\n     - Managing loss mitigation, which may include collection activities, loan workouts, modifications, foreclosures, short sales, and sales of REO (Real Estate Owned).\n\n3. **Primary Responsibility:**\n   - Among the activities listed, the most fundamental and primary responsibility of PLS in the loan servicing agreement is the collection of payments from borrowers.\n   - This is crucial because it directly impacts the cash flow and financial health of the loans and the securities backed by these loans.\n\n4. **Evaluate the Options:**\n   - **Option A: Issuing new loans to investors** - This is not mentioned as a primary responsibility of PLS in the document.\n   - **Option B: Collecting principal, interest, and escrow payments** - This aligns with the primary responsibility identified in the document.\n   - **Option C: Providing insurance for loan defaults** - This is not mentioned as a primary responsibility of PLS.\n   - **Option D: Publishing annual financial reports** - This is not mentioned as a primary responsibility of PLS.\n   - **Option E: Managing client investments in stock markets** - This is not mentioned as a primary responsibility of PLS.\n   - **Option F: Developing real estate properties** - This is not mentioned as a primary responsibility of PLS.\n\nBased on the analysis of the document, the primary responsibility of PLS in the loan servicing agreement is:\n\n**B: Collecting principal, interest, and escrow payments.**\n\nThis responsibility is explicitly mentioned and is a critical part of the loan servicing activities described in the document."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 95, "token_lengths": 16000, "result": 1.0, "question": "What is the role of DME Advisors in relation to SILP?", "options": {"A": "Manage risk management and operational needs", "B": "Serve as SILP's custodian", "C": "Select and manage appropriate investments", "D": "Ensure SILP is widely diversified", "E": "Handle collateral purposes for SILP", "F": "Contribute funds to Greenlight Re and GRIL"}, "LLM_original_answer": ["To answer the question \"What is the role of DME Advisors in relation to SILP?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Investment Management**:\n   - The document states that DME Advisors acts as the exclusive investment advisor for SILP.\n   - DME Advisors is responsible for managing substantially all of our investable assets, as per the SILP LPA.\n   - DME Advisors has the contractual right to manage the investment portfolio and is required to follow our investment guidelines and act in a fair and equitable manner in allocating investment opportunities to SILP.\n\n2. **Investment Strategy**:\n   - DME Advisors implements a value-oriented investment strategy, which involves taking long positions in undervalued securities and short positions in overvalued securities.\n   - The success of the investment strategy depends on DME Advisors' ability to select and manage appropriate investments for SILP.\n\n3. **Performance and Fees**:\n   - DME Advisors receives a monthly management fee at an annual rate of 1.5% of each limited partner\u2019s Investment Portfolio.\n   - DME II, which is controlled by DME Advisors, receives a performance allocation based on the positive performance change of each limited partner\u2019s capital account, equal to 20% of net profits calculated per annum, subject to a loss carryforward provision.\n\n4. **Diversification**:\n   - The document mentions that SILP may not be widely diversified by security or by industry, which could result in more rapid changes in value compared to a widely diversified portfolio.\n   - However, DME Advisors is not restricted in the nature or timing of making investments for SILP, apart from following the investment guidelines.\n\n5. **Risk Management**:\n   - DME Advisors is involved in analyzing investment assets and liabilities, including concentration and liquidity risks, to help manage the investment portfolio.\n   - The document emphasizes that the performance of the SILP investment portfolio depends on DME Advisors' ability to select and manage appropriate investments.\n\nGiven these points, the role of DME Advisors in relation to SILP is primarily to **select and manage appropriate investments**. This aligns with the provided options, specifically:\n\n**Option C: Select and manage appropriate investments**\n\nTherefore, the correct answer is **C: Select and manage appropriate investments**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 16000, "result": 1.0, "question": "What can materially and adversely affect the operations due to issues with satellites?", "options": {"A": "High employee turnover in satellite companies", "B": "Changes in customer preferences", "C": "Construction and launch delays for satellites", "D": "Increased competition from other industries", "E": "Innovations in unrelated technology sectors", "F": "A surge in global satellite demand"}, "LLM_original_answer": ["To answer the question \"What can materially and adversely affect the operations due to issues with satellites?\" based on the provided document, I will analyze the relevant sections and identify the most appropriate option.\n\n### Step-by-Step Analysis:\n\n1. **High Employee Turnover in Satellite Companies (Option A)**:\n   - The document mentions the importance of retaining qualified personnel, especially those with security clearances, but it does not directly link high employee turnover to material adverse effects on satellite operations. The focus is more on the impact on product development and customer support.\n\n2. **Changes in Customer Preferences (Option B)**:\n   - The document discusses the importance of market acceptance and the potential for competitors to offer more attractive products, but it does not specifically mention that changes in customer preferences would have a material adverse effect on satellite operations.\n\n3. **Construction and Launch Delays for Satellites (Option C)**:\n   - The document explicitly states: \"Delays in the construction of future satellites and the procurement of requisite components, limited availability of appropriate launch windows, possible delays in obtaining regulatory approvals, satellite damage or destruction during launch, launch failures, or incorrect orbital placement could have a material adverse effect on our business, financial condition, and results of operations.\"\n   - This directly links construction and launch delays to material adverse effects on operations.\n\n4. **Increased Competition from Other Industries (Option D)**:\n   - The document mentions competition as a significant risk, but it does not specifically state that increased competition from other industries would have a material adverse effect on satellite operations. The focus is more on the impact on market share and revenue.\n\n5. **Innovations in Unrelated Technology Sectors (Option E)**:\n   - The document does not mention innovations in unrelated technology sectors as a direct risk to satellite operations. It focuses more on the need to keep pace with technological changes in the satellite and geospatial data sectors.\n\n6. **A Surge in Global Satellite Demand (Option F)**:\n   - The document does not discuss a surge in global satellite demand as a risk that could materially and adversely affect operations. It focuses more on the challenges of meeting customer needs and the competitive landscape.\n\n### Conclusion:\nBased on the provided document, the most appropriate answer is **Option C: Construction and launch delays for satellites**. The document explicitly states that these delays can have a material adverse effect on the business, financial condition, and results of operations.\n\n### Final Answer:\n**C: Construction and launch delays for satellites**"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 16000, "result": 1.0, "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?", "options": {"A": "Increase in core data", "B": "Rise in traditional voice communication", "C": "Completion of certain fiber transactions in 2022", "D": "Increase in international traffic", "E": "Growth in network connectivity", "F": "Higher volume of wireless devices sold"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the primary reason for the decrease in Wholesale revenues during 2023 compared to 2022.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Relevant Section:**\n   - The relevant section for Wholesale revenues is found in the \"Verizon Business Group\" segment, specifically in the \"Operating Revenues and Selected Operating Statistics\" section.\n\n2. **Examine the Revenue Changes:**\n   - The document states: \"Business's total operating revenues decreased during 2023 compared to 2022 as a result of decreases in revenue from each of the three Business customer groups.\"\n   - It further breaks down the revenue changes for each customer group:\n     - **Enterprise and Public Sector:** Decrease of $530 million in wireline networking revenue and traditional data and voice communication services.\n     - **Business Markets and Other:** Not explicitly mentioned, but the overall segment revenue decreased.\n     - **Wholesale:** The document does not provide a specific breakdown for Wholesale revenue changes, but it is implied that Wholesale revenue also decreased.\n\n3. **Look for Specific Reasons:**\n   - The document mentions: \"Wholesale revenues decreased during 2023 compared to 2022 primarily due to the completion of certain fiber transactions in 2022.\"\n   - This statement directly addresses the decrease in Wholesale revenues and provides a specific reason.\n\n4. **Evaluate the Options:**\n   - **A: Increase in core data** - Not mentioned as a reason for the decrease in Wholesale revenues.\n   - **B: Rise in traditional voice communication** - The document mentions a decrease in traditional voice communication services, not a rise.\n   - **C: Completion of certain fiber transactions in 2022** - This is explicitly mentioned as the primary reason for the decrease in Wholesale revenues.\n   - **D: Increase in international traffic** - Not mentioned as a reason for the decrease in Wholesale revenues.\n   - **E: Growth in network connectivity** - Not mentioned as a reason for the decrease in Wholesale revenues.\n   - **F: Higher volume of wireless devices sold** - The document mentions a decrease in the volume of wireless devices sold, not an increase.\n\n### Conclusion:\nThe primary reason for the decrease in Wholesale revenues during 2023 compared to 2022 is the completion of certain fiber transactions in 2022.\n\n**Answer: C: Completion of certain fiber transactions"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 16000, "result": 1.0, "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?", "options": {"A": "Broadcast radio communications", "B": "Television broadcasting", "C": "Respond to text, video and data", "D": "Satellite tracking", "E": "Weather forecasting", "F": "Financial transactions processing"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions ESInet in the context of Next Generation 911 Core Services (NGCS).\n\n2. **Extract the key information about ESInet**: The document states, \"ESInet enables 911 call takers at public safety answering points to respond to text, video and data.\"\n\n3. **Match the extracted information to the given options**:\n   - **Option A**: Broadcast radio communications\n   - **Option B**: Television broadcasting\n   - **Option C**: Respond to text, video and data\n   - **Option D**: Satellite tracking\n   - **Option E**: Weather forecasting\n   - **Option F**: Financial transactions processing\n\n4. **Select the correct option**: The information extracted from the document directly matches **Option C**: Respond to text, video and data.\n\nTherefore, the correct answer is **Option C: Respond to text, video and data**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 16000, "result": 1.0, "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?", "options": {"A": "Increase in product sales", "B": "Improvement in clinical trial outcomes", "C": "Negative perception of patient benefits and safety", "D": "Guarantee of FDA approval", "E": "Reduction in training requirements for ECPs", "F": "Expansion of product indications"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and identify the relevant information that pertains to the potential risks of using products inconsistently with labeled indications.\n\n### Step-by-Step Analysis:\n\n1. **Identify the Context:**\n   - The document discusses the commercialization, regulatory, and reimbursement aspects of medical devices, particularly OMNI and TearCare, which are used in ophthalmic procedures.\n   - It emphasizes the importance of adhering to labeled indications and the potential consequences of not doing so.\n\n2. **Relevant Information:**\n   - **Adherence to Labeled Indications:**\n     - The document states: \"If ECPs utilize our products in a manner that is inconsistent with our labeled indications or with components that are not part of our products, the patient outcomes may be negative. This could negatively impact the perception of patient benefits and safety associated with our products and limit their adoption, which would have a material adverse effect on our business, financial condition and results of operations.\"\n   - **Regulatory Compliance:**\n     - The document mentions that the FDA and other regulatory bodies have strict rules regarding the use of medical devices, and any deviation from the labeled indications can lead to regulatory actions, including mandatory or voluntary product recalls, suspension or withdrawal of FDA clearance, and significant legal liability.\n   - **Reimbursement:**\n     - The document highlights the importance of obtaining and maintaining favorable reimbursement decisions for the procedures in which the products are used. If ECPs use the products off-label, it could lead to issues with reimbursement, as payors may not cover procedures that are not approved or indicated.\n\n3. **Evaluate the Options:**\n   - **A: Increase in product sales**\n     - This is not a potential risk; it is a positive outcome.\n   - **B: Improvement in clinical trial outcomes**\n     - This is not a potential risk; it is a positive outcome.\n   - **C: Negative perception of patient benefits and safety**\n     - This aligns with the document's statement about negative patient outcomes and the impact on the perception of patient benefits and safety.\n   - **D: Guarantee of FDA approval**\n     - This is not a potential risk; it is a positive outcome.\n   - **E: Reduction in training requirements for ECPs**\n     - This is not mentioned as a risk in the document.\n   - **F: Expansion of product indications**\n     - This is a positive outcome and not a risk.\n\n### Conclusion:\nBased on the analysis, the potential"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 16000, "result": 1.0, "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?", "options": {"A": "Increase in company market value", "B": "Unintended promotion of products", "C": "Disruption of operations or client operations", "D": "Immediate resolution of security measures", "E": "Enhanced customer relationships", "F": "Unrestricted access to public information"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify any relevant information about the potential consequences of a breach or cyber-attack on computer systems.\n\n### Step-by-Step Analysis:\n\n1. **Relevant Section Identification**:\n   - The document contains a section titled \"Risks Relating to Technology and Cybersecurity and Other Operational Matters\" which is most relevant to the question.\n\n2. **Key Points from the Section**:\n   - **Operational Risks**: The document mentions that the company is exposed to various types of operational risks, including the risk of fraud, theft, and unauthorized access to sensitive data.\n   - **Security Measures**: The company takes protective measures to secure its computer systems, but these systems may still be vulnerable to breaches, unauthorized access, misuse, computer viruses, or other malicious code.\n   - **Consequences of Breach**:\n     - **Confidential Information**: A breach could jeopardize the confidential information of the company and its clients.\n     - **Interruptions and Malfunctions**: It could cause interruptions or malfunctions in the company's operations or the operations of its clients or counterparties.\n     - **Resource Expenditure**: The company may need to expend significant additional resources to modify protective measures or investigate and remediate vulnerabilities.\n     - **Litigation and Financial Losses**: The company may be subject to litigation and financial losses that are either not insured against or not fully covered by insurance.\n     - **Reputational Damage**: The company could suffer significant reputational damage.\n\n3. **Matching to Options**:\n   - **Option A: Increase in company market value** - This is not mentioned as a potential consequence of a breach or cyber-attack.\n   - **Option B: Unintended promotion of products** - This is not mentioned as a potential consequence of a breach or cyber-attack.\n   - **Option C: Disruption of operations or client operations** - This is directly mentioned as a potential consequence of a breach or cyber-attack.\n   - **Option D: Immediate resolution of security measures** - The document does not suggest that a breach would lead to an immediate resolution of security measures.\n   - **Option E: Enhanced customer relationships** - This is not mentioned as a potential consequence of a breach or cyber-attack.\n   - **Option F: Unrestricted access to public information** - While the document mentions the risk of unauthorized access to confidential information, it does not specifically state unrestricted access to public information.\n\n### Conclusion:\nBased on the analysis, the"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 16000, "result": 1.0, "question": "What is one intended use of the proceeds from the Business Combination?", "options": {"A": "To invest in new technology development", "B": "To reduce company debt", "C": "To build-up the sales and marketing organization", "D": "To acquire competitor companies", "E": "To expand into international markets", "F": "To increase executive compensation"}, "LLM_original_answer": ["To answer the question, I will carefully analyze the provided document to identify the intended use of the proceeds from the Business Combination.\n\n1. **Identify Relevant Information**: The document mentions the intended use of the proceeds from the Business Combination. The relevant section is:\n   - \"We intend to build-up our sales and marketing organization using some of the proceeds we receive as a result of the Business Combination.\"\n\n2. **Match to Options**: The statement clearly indicates that the proceeds will be used to build up the sales and marketing organization. This matches directly with option C: \"To build-up the sales and marketing organization.\"\n\n3. **Conclusion**: Based on the information provided in the document, the intended use of the proceeds from the Business Combination is to build up the sales and marketing organization.\n\nTherefore, the correct answer is **C: To build-up the sales and marketing organization**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 16000, "result": 1.0, "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?", "options": {"A": "50%", "B": "60%", "C": "65%", "D": "70%", "E": "75%", "F": "80%"}, "LLM_original_answer": ["To answer the question \"As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Information**: Scan the document for any mention of KFC and Pizza Hut's system sales and loyalty program members.\n2. **Extract Specific Data**: Look for specific percentages or figures related to the loyalty program members' contribution to system sales.\n3. **Evaluate the Options**: Compare the extracted data with the given options to determine the correct answer.\n\n### Step 1: Identify Relevant Information\nThe document covers a wide range of topics, including financial regulations, corporate structure, and various business operations. However, it does not explicitly mention the percentage of system sales attributed to loyalty program members for KFC and Pizza Hut as of year-end 2023.\n\n### Step 2: Extract Specific Data\nAfter a thorough review, I find no specific data or percentages related to the contribution of loyalty program members to KFC and Pizza Hut's system sales in the provided document.\n\n### Step 3: Evaluate the Options\nSince the document does not provide the specific percentage of system sales attributed to loyalty program members, I cannot determine the correct answer from the given options (A: 50%, B: 60%, C: 65%, D: 70%, E: 75%, F: 80%).\n\n### Conclusion\nThe provided document does not contain the information necessary to answer the question. Therefore, I cannot select any of the given options based on the document alone. If you have additional information or a different document that includes this data, please provide it, and I will be happy to help you find the correct answer."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 16000, "result": 1.0, "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?", "options": {"A": "Classified Board of Directors with staggered, three-year terms", "B": "Issuance of preferred stock to dilute ownership", "C": "Exclusive forum in the Court of Chancery of the State of Delaware", "D": "Prohibition on cumulative voting in the election of directors", "E": "Advance notice procedures for nominating candidates", "F": "Limitation of liability and indemnification of directors and officers"}, "LLM_original_answer": ["To answer the question, I need to identify the provision in the company's Charter and Bylaws that is intended to prevent minority stockholders from easily electing director candidates. Let's go through the options and the provided document to find the relevant information.\n\n### Options:\n1. **A: Classified Board of Directors with staggered, three-year terms**\n2. **B: Issuance of preferred stock to dilute ownership**\n3. **C: Exclusive forum in the Court of Chancery of the State of Delaware**\n4. **D: Prohibition on cumulative voting in the election of directors**\n5. **E: Advance notice procedures for nominating candidates**\n6. **F: Limitation of liability and indemnification of directors and officers**\n\n### Document Analysis:\nThe document provided does not contain specific information about the company's Charter and Bylaws. However, it does mention several aspects of the company's structure and governance. Let's analyze each option in the context of the document:\n\n1. **A: Classified Board of Directors with staggered, three-year terms**\n   - The document does not mention anything about a classified board or staggered terms.\n\n2. **B: Issuance of preferred stock to dilute ownership**\n   - The document mentions that the company may issue shares of preferred stock, which could make it difficult for another company to acquire us or could otherwise adversely affect our securityholders. However, it does not explicitly state that this is intended to prevent minority stockholders from electing directors.\n\n3. **C: Exclusive forum in the Court of Chancery of the State of Delaware**\n   - The document does not mention an exclusive forum provision.\n\n4. **D: Prohibition on cumulative voting in the election of directors**\n   - The document does not explicitly mention cumulative voting. However, this is a common provision in corporate governance to prevent minority stockholders from easily electing directors.\n\n5. **E: Advance notice procedures for nominating candidates**\n   - The document does not mention advance notice procedures for nominating candidates.\n\n6. **F: Limitation of liability and indemnification of directors and officers**\n   - The document mentions that the company has provisions for indemnification of directors and officers, but this is not related to preventing minority stockholders from electing directors.\n\n### Conclusion:\nGiven the options and the lack of specific information in the document, the most likely provision that would prevent minority stockholders from easily electing director candidates is **D: Prohibition on cumulative voting in the election of directors**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 95, "token_lengths": 32000, "result": 1.0, "question": "What is one primary responsibility of PLS in the loan servicing agreement?", "options": {"A": "Issuing new loans to investors", "B": "Collecting principal, interest, and escrow payments", "C": "Providing insurance for loan defaults", "D": "Publishing annual financial reports", "E": "Managing client investments in stock markets", "F": "Developing real estate properties"}, "LLM_original_answer": ["To answer the question \"What is one primary responsibility of PLS in the loan servicing agreement?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions PLS (PennyMac Loan Services, LLC) in the context of loan servicing activities.\n\n2. **Extract the specific responsibilities of PLS**: The document states, \"PLS\u2019 loan servicing activities include collecting principal, interest and escrow account payments, accounting for and remitting collections to investors in the loans, responding to customer inquiries, and default management activities, including managing loss mitigation, which may include, among other things, collection activities, loan workouts, modifications and refinancings, foreclosures, short sales and sales of REO.\"\n\n3. **Match the extracted responsibilities to the given options**:\n   - **Option A: Issuing new loans to investors** - This is not mentioned as a primary responsibility of PLS in the loan servicing agreement.\n   - **Option B: Collecting principal, interest, and escrow payments** - This is explicitly mentioned as one of the primary responsibilities of PLS.\n   - **Option C: Providing insurance for loan defaults** - This is not mentioned as a primary responsibility of PLS.\n   - **Option D: Publishing annual financial reports** - This is not mentioned as a primary responsibility of PLS.\n   - **Option E: Managing client investments in stock markets** - This is not mentioned as a primary responsibility of PLS.\n   - **Option F: Developing real estate properties** - This is not mentioned as a primary responsibility of PLS.\n\n4. **Conclusion**: Based on the information provided in the document, the primary responsibility of PLS in the loan servicing agreement that matches the given options is **Option B: Collecting principal, interest, and escrow payments**.\n\nTherefore, the correct answer is **Option B: Collecting principal, interest, and escrow payments**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 95, "token_lengths": 32000, "result": 1.0, "question": "What is the role of DME Advisors in relation to SILP?", "options": {"A": "Manage risk management and operational needs", "B": "Serve as SILP's custodian", "C": "Select and manage appropriate investments", "D": "Ensure SILP is widely diversified", "E": "Handle collateral purposes for SILP", "F": "Contribute funds to Greenlight Re and GRIL"}, "LLM_original_answer": ["To answer the question \"What is the role of DME Advisors in relation to SILP?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Investment Management**:\n   - The document states that DME Advisors acts as the exclusive investment advisor for SILP.\n   - DME Advisors is responsible for selecting and managing appropriate investments for SILP.\n\n2. **Exclusivity and Limited Termination**:\n   - The SILP LPA contains exclusivity and limited termination provisions, which means that Greenlight Re and GRIL cannot use other investment managers for so long as they are limited partners in SILP.\n\n3. **Investment Guidelines**:\n   - DME Advisors is contractually obligated to follow the investment guidelines of both Greenlight Re and GRIL.\n   - However, DME Advisors has the power to allocate capital to various investment opportunities, including long and short equity positions, debt, and derivatives.\n\n4. **Performance and Risk**:\n   - The performance of the SILP investment portfolio depends on DME Advisors' ability to select and manage appropriate investments.\n   - DME Advisors' performance is critical to the success of SILP and, by extension, to the financial performance of Greenlight Re and GRIL.\n\n5. **Potential Conflicts of Interest**:\n   - DME Advisors and its affiliates may engage in investment and trading activities for their own accounts and/or for the accounts of third parties.\n   - There is no obligation for DME Advisors to prioritize investment opportunities for SILP, which could lead to conflicts of interest.\n\nGiven this information, the role of DME Advisors in relation to SILP is primarily to **select and manage appropriate investments**. This aligns with the option:\n\n**C: Select and manage appropriate investments**\n\nTherefore, the correct answer is **C: Select and manage appropriate investments**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 32000, "result": 1.0, "question": "What can materially and adversely affect the operations due to issues with satellites?", "options": {"A": "High employee turnover in satellite companies", "B": "Changes in customer preferences", "C": "Construction and launch delays for satellites", "D": "Increased competition from other industries", "E": "Innovations in unrelated technology sectors", "F": "A surge in global satellite demand"}, "LLM_original_answer": ["To answer the question \"What can materially and adversely affect the operations due to issues with satellites?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Satellite Launch and Operation:**\n   - The document mentions that BlackSky designs, develops, and operates a constellation of proprietary high-resolution, high-revisit LEO smallsats.\n   - The successful development, integration, and operation of these satellites are critical to the company's business model.\n\n2. **Risks and Uncertainties:**\n   - The document highlights several risks related to the satellites and ground stations:\n     - **Delays in Finalizing Satellite Design and Specifications:** This can delay the launch and operational readiness of the satellites.\n     - **Performance Issues:** Satellites may fail to meet design specifications due to technological or manufacturing difficulties.\n     - **Engineering and Manufacturing Failures:** These can lead to lower output or efficiency.\n     - **Cost Increases:** The costs of materials and components can increase, affecting the budget.\n     - **Regulatory Approvals:** Inability to obtain or maintain necessary approvals, licenses, or certifications from regulatory agencies.\n     - **Manufacturing Facility Issues:** Natural disasters, catastrophic events, or labor disputes can disrupt production.\n     - **Supplier Issues:** Problems with suppliers of raw materials and components can affect the quality and availability of satellite parts.\n     - **Intellectual Property Protection:** Inability to protect critical intellectual property related to satellite design and function.\n     - **Funding and Maintenance:** Continuous funding and maintenance of research and development activities are necessary.\n     - **Demonstration Mission Failures:** Failure to complete demonstration missions can impact customer confidence.\n     - **Geopolitical Events:** These can affect the company, its customers, and suppliers, and the global economy.\n\n3. **Specific Incidents:**\n   - The document notes that BlackSky has experienced the loss of a satellite due to an anomaly and a launch failure where two satellites were lost before reaching orbit.\n   - These incidents have led to significant impairment charges and service interruptions.\n\n4. **Impact on Business:**\n   - **Service Interruptions:** If a satellite fails or is lost, backup capacity may be insufficient, leading to service interruptions and loss of revenue.\n   - **Customer Relationships:** Service interruptions can harm relationships with customers and result in contract terminations or reduced orders.\n   - **Reputation:** Such failures can damage the company's reputation and brand.\n   - **Financial Impact:** The company may incur significant costs to replace or repair satellites"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 32000, "result": 1.0, "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?", "options": {"A": "Increase in core data", "B": "Rise in traditional voice communication", "C": "Completion of certain fiber transactions in 2022", "D": "Increase in international traffic", "E": "Growth in network connectivity", "F": "Higher volume of wireless devices sold"}, "LLM_original_answer": ["To answer the question \"What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the relevant section**: The document provides detailed information about the revenue streams and operating results of Verizon's segments, including the Wholesale segment. The specific section that discusses the Wholesale segment is found under \"Verizon Business Group\" and \"Wholesale.\"\n\n2. **Examine the revenue changes**: The document states:\n   - \"Wholesale revenues decreased during 2023 compared to 2022 primarily due to a decrease of $276 million related to declines in traditional voice communication and network connectivity as a result of technology substitution, certain fiber transactions completed in 2022 that did not reoccur, as well as a decrease in core data.\"\n\n3. **Analyze the contributing factors**:\n   - **Decline in traditional voice communication and network connectivity**: This is attributed to technology substitution, which suggests that customers are moving away from traditional voice and network connectivity services to more modern alternatives.\n   - **Certain fiber transactions completed in 2022 that did not reoccur**: This indicates that specific fiber transactions that contributed to revenue in 2022 were not repeated in 2023.\n   - **Decrease in core data**: This suggests a reduction in revenue from core data services.\n\n4. **Match the factors to the options**:\n   - **Option A: Increase in core data** - This is the opposite of what the document states (decrease in core data).\n   - **Option B: Rise in traditional voice communication** - The document indicates a decline in traditional voice communication.\n   - **Option C: Completion of certain fiber transactions in 2022** - This matches the document's statement about certain fiber transactions completed in 2022 that did not reoccur in 2023.\n   - **Option D: Increase in international traffic** - The document does not mention an increase in international traffic as a factor affecting Wholesale revenues.\n   - **Option E: Growth in network connectivity** - The document indicates a decline in network connectivity.\n   - **Option F: Higher volume of wireless devices sold** - The document does not mention this as a factor affecting Wholesale revenues.\n\n5. **Conclusion**: Based on the information provided, the primary factor leading to the decrease in Wholesale revenues during 2"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 32000, "result": 1.0, "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?", "options": {"A": "Broadcast radio communications", "B": "Television broadcasting", "C": "Respond to text, video and data", "D": "Satellite tracking", "E": "Weather forecasting", "F": "Financial transactions processing"}, "LLM_original_answer": ["The correct answer is **C: Respond to text, video and data**.\n\n### Chain of Thoughts:\n1. **Identify the Relevant Section**: The document mentions the ESInet (Emergency Service IP Network) in the context of Next Generation 911 Core Services (NGCS).\n2. **Understand the Function of ESInet**: The document states, \"The NG infrastructure is an Emergency Service IP Network (ESInet), which can carry voice, data and multimedia.\"\n3. **Determine the Capability**: The document further specifies, \"ESInet enables 911 call takers at public safety answering points to respond to text, video and data.\"\n4. **Match the Capability to the Options**: Among the given options, only **C: Respond to text, video and data** matches the capability described in the document.\n\n### Conclusion:\nThe ESInet offers the capability to 911 call takers at public safety answering points to respond to text, video, and data. Therefore, the correct answer is **C: Respond to text, video and data**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 32000, "result": 1.0, "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?", "options": {"A": "Increase in product sales", "B": "Improvement in clinical trial outcomes", "C": "Negative perception of patient benefits and safety", "D": "Guarantee of FDA approval", "E": "Reduction in training requirements for ECPs", "F": "Expansion of product indications"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information from the provided document and then select the most appropriate option.\n\n### Step-by-Step Analysis:\n\n1. **Understanding the Context:**\n   - The document discusses the development and commercialization of medical devices, particularly OMNI, SION, and TearCare, which are used by eyecare professionals (ECPs) to treat glaucoma and dry eye disease (DED).\n   - It emphasizes the importance of adhering to labeled indications and the potential risks associated with using products inconsistently with these indications.\n\n2. **Identifying Key Risks:**\n   - **Reimbursement and Coverage:** The document mentions that third-party payors (like Medicare and private insurers) are crucial for the adoption and success of these products. If ECPs use products inconsistently with labeled indications, it could lead to issues with reimbursement and coverage.\n   - **Regulatory Compliance:** The FDA and other regulatory bodies have strict rules about the use of medical devices. Using products off-label could result in regulatory actions, including warnings, fines, or even product recalls.\n   - **Clinical Outcomes:** The document highlights the importance of clinical data and the need for ECPs to follow proper techniques and patient selection criteria. Inconsistent use could lead to negative patient outcomes, which could harm the product's reputation and adoption.\n   - **Patient Safety and Perception:** The document notes that the success of the products depends on the perception of patient benefits and safety. Negative outcomes due to inconsistent use could lead to a negative perception among patients and ECPs.\n\n3. **Evaluating the Options:**\n   - **A: Increase in product sales** - This is not a potential risk; it could be a result of consistent and effective use.\n   - **B: Improvement in clinical trial outcomes** - This is not a potential risk; it could be a result of consistent and effective use.\n   - **C: Negative perception of patient benefits and safety** - This is a potential risk. The document explicitly states that negative outcomes due to inconsistent use could harm the perception of patient benefits and safety.\n   - **D: Guarantee of FDA approval** - This is not a potential risk; FDA approval is not guaranteed and is based on clinical data and compliance.\n   - **E: Reduction in training requirements for ECPs** - This is not a potential risk; the document emphasizes the importance of training.\n   - **F: Expansion of product indications** - This is not a potential risk; expansion"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 32000, "result": 1.0, "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?", "options": {"A": "Increase in company market value", "B": "Unintended promotion of products", "C": "Disruption of operations or client operations", "D": "Immediate resolution of security measures", "E": "Enhanced customer relationships", "F": "Unrestricted access to public information"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and consider the context and content related to the potential consequences of a breach or cyber-attack on computer systems.\n\n### Step-by-Step Analysis:\n\n1. **Identify Relevant Sections:**\n   - The document primarily discusses the business operations, financial performance, and regulatory environment of TScan Therapeutics, Inc. and Great Southern Bancorp, Inc.\n   - The section on \"Technology and Cybersecurity and Other Operational Matters\" (Item 1A) is particularly relevant to the question.\n\n2. **Extract Key Information:**\n   - **Great Southern Bancorp, Inc.**:\n     - The company is subject to security-related risks in connection with its use of technology.\n     - It uses computer systems and networks to manage client relationships, general ledger, and other aspects of its business.\n     - The security of these systems is vulnerable to breaches, unauthorized access, misuse, computer viruses, or other malicious code and cyber-attacks.\n     - If these events occur, they could jeopardize confidential information, cause interruptions or malfunctions in operations, and lead to significant additional resources being expended to address vulnerabilities.\n     - The company may be subject to litigation and financial losses that are not fully covered by insurance.\n     - Reputational damage could also occur.\n\n3. **Evaluate the Options:**\n   - **A: Increase in company market value** - This is not a likely consequence of a breach or cyber-attack. Breaches typically lead to negative market reactions.\n   - **B: Unintended promotion of products** - This is not a relevant consequence of a cyber-attack. Promotions are not typically a result of security breaches.\n   - **C: Disruption of operations or client operations** - This is a highly likely consequence. The document explicitly mentions that a breach could cause interruptions or malfunctions in operations.\n   - **D: Immediate resolution of security measures** - This is not a likely immediate consequence. Resolving security measures often takes time and resources.\n   - **E: Enhanced customer relationships** - This is not a likely consequence. Breaches typically damage customer trust and relationships.\n   - **F: Unrestricted access to public information** - This is not a likely consequence. Breaches typically involve unauthorized access to sensitive, not public, information.\n\n### Conclusion:\nBased on the information provided in the document, the most likely potential consequence of a breach or cyber-attack on the computer systems is **C: Disruption of operations or client operations**. The document"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 32000, "result": 1.0, "question": "What is one intended use of the proceeds from the Business Combination?", "options": {"A": "To invest in new technology development", "B": "To reduce company debt", "C": "To build-up the sales and marketing organization", "D": "To acquire competitor companies", "E": "To expand into international markets", "F": "To increase executive compensation"}, "LLM_original_answer": ["To answer the question \"What is one intended use of the proceeds from the Business Combination?\" based on the provided document, I will follow these steps:\n\n1. **Identify Relevant Sections**: Look for sections in the document that discuss the Business Combination and the intended use of the proceeds.\n2. **Extract Information**: Extract specific information about the intended use of the proceeds.\n3. **Match to Options**: Compare the extracted information to the given options to determine the best match.\n\n### Step 1: Identify Relevant Sections\nThe relevant section in the document is found under \"Our Strategies\" and \"Incentive Plans,\" but the most direct information is in the \"Risks Related to Our Business, Financial Condition, and Need for Additional Capital\" section.\n\n### Step 2: Extract Information\nFrom the document:\n- \"We intend to build-up our sales and marketing organization using some of the proceeds we receive as a result of the Business Combination.\"\n\n### Step 3: Match to Options\nThe extracted information directly matches option C: \"To build-up the sales and marketing organization.\"\n\n### Conclusion\nThe intended use of the proceeds from the Business Combination, as stated in the document, is to build up the sales and marketing organization. Therefore, the correct answer is:\n\n**C: To build-up the sales and marketing organization**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 32000, "result": 1.0, "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?", "options": {"A": "50%", "B": "60%", "C": "65%", "D": "70%", "E": "75%", "F": "80%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. Identify the relevant information in the provided document.\n2. Extract the specific percentage mentioned.\n3. Match the extracted percentage to the provided options.\n\n### Step 1: Identify the Relevant Information\nThe relevant information is found in the section discussing the loyalty programs and their impact on sales. Specifically, the document states:\n\n> \"As of December 31, 2023, KFC and Pizza Hut loyalty programs exceeded 470 million members combined. Member sales accounted for approximately 65% of KFC and Pizza Hut's system sales in 2023.\"\n\n### Step 2: Extract the Specific Percentage\nThe document clearly states that member sales accounted for approximately 65% of KFC and Pizza Hut's system sales in 2023.\n\n### Step 3: Match the Extracted Percentage to the Provided Options\nThe extracted percentage is 65%, which corresponds to option C.\n\n### Conclusion\nThe correct answer is **C: 65%**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 32000, "result": 1.0, "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?", "options": {"A": "Classified Board of Directors with staggered, three-year terms", "B": "Issuance of preferred stock to dilute ownership", "C": "Exclusive forum in the Court of Chancery of the State of Delaware", "D": "Prohibition on cumulative voting in the election of directors", "E": "Advance notice procedures for nominating candidates", "F": "Limitation of liability and indemnification of directors and officers"}, "LLM_original_answer": ["To answer the question, I will analyze the relevant information provided in the document and match it with the options given.\n\nThe question asks: \"Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?\"\n\nFrom the document, the following provision is mentioned:\n- \"prohibition on cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates\"\n\nThis provision directly addresses the issue of preventing minority stockholders from easily electing director candidates. Cumulative voting is a system that allows shareholders to cast all of their votes for a single candidate, which can help minority shareholders elect a director of their choice. By prohibiting cumulative voting, the company makes it more difficult for minority stockholders to elect their preferred candidates.\n\nLet's review the options:\nA: Classified Board of Directors with staggered, three-year terms\n- This provision can make it harder for a complete change in the board, but it does not specifically prevent minority stockholders from electing director candidates.\n\nB: Issuance of preferred stock to dilute ownership\n- This provision can dilute the ownership of common stockholders, but it does not directly prevent minority stockholders from electing director candidates.\n\nC: Exclusive forum in the Court of Chancery of the State of Delaware\n- This provision is about where legal actions can be brought, not about the election of directors.\n\nD: Prohibition on cumulative voting in the election of directors\n- This provision directly prevents minority stockholders from easily electing director candidates by disallowing the concentration of votes on a single candidate.\n\nE: Advance notice procedures for nominating candidates\n- This provision requires stockholders to follow specific procedures to nominate candidates, but it does not prevent minority stockholders from electing director candidates.\n\nF: Limitation of liability and indemnification of directors and officers\n- This provision is about protecting directors and officers from liability, not about the election of directors.\n\nBased on the analysis, the correct answer is:\n**D: Prohibition on cumulative voting in the election of directors**."], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 95, "token_lengths": 64000, "result": 1.0, "question": "What is one primary responsibility of PLS in the loan servicing agreement?", "options": {"A": "Issuing new loans to investors", "B": "Collecting principal, interest, and escrow payments", "C": "Providing insurance for loan defaults", "D": "Publishing annual financial reports", "E": "Managing client investments in stock markets", "F": "Developing real estate properties"}, "LLM_original_answer": ["The correct answer to the question \"What is one primary responsibility of PLS in the loan servicing agreement?\" is:\n\n**B: Collecting principal, interest, and escrow payments**\n\n### Chain of Thought:\n1. **Identify the Context**: The document provided is an annual report for a company involved in mortgage-related investments and loan servicing. PLS (PennyMac Loan Services, LLC) is mentioned as a servicer for the company's portfolio of residential loans and MSRs (mortgage servicing rights).\n\n2. **Locate Relevant Information**: In the section \"Our Servicer\u2019s loan servicing activities,\" the document states:\n   - \"PLS\u2019 loan servicing activities include collecting principal, interest and escrow account payments, accounting for and remitting collections to investors in the loans, responding to customer inquiries, and default management activities, including managing loss mitigation, which may include, among other things, collection activities, loan workouts, modifications and refinancings, foreclosures, short sales and sales of REO.\"\n\n3. **Analyze the Options**:\n   - **A: Issuing new loans to investors** - This is not mentioned as a primary responsibility of PLS in the loan servicing agreement.\n   - **B: Collecting principal, interest, and escrow payments** - This is explicitly mentioned as one of the primary activities of PLS.\n   - **C: Providing insurance for loan defaults** - While PLS is involved in managing loss mitigation, providing insurance is not mentioned as a primary responsibility.\n   - **D: Publishing annual financial reports** - This is not a responsibility of PLS in the loan servicing agreement.\n   - **E: Managing client investments in stock markets** - This is not related to loan servicing.\n   - **F: Developing real estate properties** - This is not a primary responsibility of PLS in the loan servicing agreement.\n\n4. **Conclusion**: Based on the information provided in the document, the primary responsibility of PLS in the loan servicing agreement is collecting principal, interest, and escrow payments. Therefore, the correct answer is **B**."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 95, "token_lengths": 64000, "result": 1.0, "question": "What is the role of DME Advisors in relation to SILP?", "options": {"A": "Manage risk management and operational needs", "B": "Serve as SILP's custodian", "C": "Select and manage appropriate investments", "D": "Ensure SILP is widely diversified", "E": "Handle collateral purposes for SILP", "F": "Contribute funds to Greenlight Re and GRIL"}, "LLM_original_answer": ["To answer the question \"What is the role of DME Advisors in relation to SILP?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Investment Management**:\n   - The document states: \"SILP\u2019s performance depends on the ability of DME Advisors to select and manage appropriate investments.\"\n   - This indicates that DME Advisors is responsible for the selection and management of investments for SILP.\n\n2. **Exclusivity**:\n   - The document mentions: \"DME Advisors acts as the exclusive investment advisor for SILP.\"\n   - This reinforces that DME Advisors is the sole investment advisor for SILP, with complete responsibility for investment decisions.\n\n3. **Investment Guidelines**:\n   - The document notes: \"Although DME Advisors is contractually obligated to follow the investment guidelines of both Greenlight Re and GRIL, we cannot provide assurance as to how DME Advisors will allocate our investable assets to different investment opportunities.\"\n   - This suggests that DME Advisors must adhere to the investment guidelines set by Greenlight Re and GRIL, but the specific allocation of assets is at their discretion.\n\n4. **Risk Management**:\n   - The document states: \"The performance of the SILP investment portfolio depends to a great extent on the ability of DME Advisors to select and manage appropriate investments for SILP.\"\n   - This highlights the importance of DME Advisors' role in managing the investment portfolio to meet the company's investment objectives.\n\n5. **Potential Conflicts**:\n   - The document mentions: \"Potential conflicts of interest with DME Advisors and its affiliates may exist that could adversely affect us.\"\n   - This indicates that while DME Advisors has a significant role, there are potential conflicts that could impact their performance.\n\n6. **Liquidity and Valuation**:\n   - The document notes: \"Certain investments made by SILP may have limited liquidity and lack valuation data which could create a conflict of interest.\"\n   - This suggests that DME Advisors must manage investments that may have limited liquidity and must determine valuations for such investments.\n\nGiven these points, the role of DME Advisors in relation to SILP is primarily to **select and manage appropriate investments**. This aligns with the provided options, specifically:\n\n**C: Select and manage appropriate investments**\n\nTherefore, the correct answer is **C: Select and manage appropriate investments**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 64000, "result": 1.0, "question": "What can materially and adversely affect the operations due to issues with satellites?", "options": {"A": "High employee turnover in satellite companies", "B": "Changes in customer preferences", "C": "Construction and launch delays for satellites", "D": "Increased competition from other industries", "E": "Innovations in unrelated technology sectors", "F": "A surge in global satellite demand"}, "LLM_original_answer": ["To answer the question \"What can materially and adversely affect the operations due to issues with satellites?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Satellite Operations and Reliability**:\n   - The document mentions that BlackSky operates a constellation of satellites that are critical to its business. These satellites provide high-revisit, high-resolution imagery and analytics.\n   - The satellites are designed to operate in complex environments and are subject to various risks, including technical flaws, performance issues, and environmental stresses.\n\n2. **Risks and Uncertainties**:\n   - **Launch Delays and Failures**: The document explicitly states, \"Satellites are subject to construction and launch delays, launch failures, damage or destruction during launch, the occurrence of which can materially and adversely affect our operations.\"\n   - **Satellite Anomalies**: The document also notes, \"If our satellites fail to operate as intended, it could have a material adverse effect on our business, financial condition and results of operations.\"\n   - **Technical Flaws**: The document mentions that technical flaws in satellite sensors or other components could significantly hinder performance, which could materially affect the ability to collect imagery and market products and services successfully.\n   - **Catastrophic Events**: The document highlights that exposure to unanticipated catastrophic events, such as meteor showers or collisions with space debris, could reduce the performance of or completely destroy a satellite.\n\n3. **Impact on Business**:\n   - **Revenue Delays**: The loss or damage to a satellite due to a launch failure or anomaly can result in significant delays in anticipated revenue.\n   - **Impairment Charges**: Such events could also lead to significant impairment charges.\n   - **Customer Impact**: If a satellite is not fully operational, the company may lose most or all of the revenue that would have otherwise been derived from that satellite.\n   - **Reputation and Customer Relationships**: The failure to meet service level commitments or the occurrence of performance issues could harm the company's reputation and customer relationships.\n\n4. **Insurance Coverage**:\n   - The document mentions that the company endeavors to obtain insurance coverage from established insurance carriers to cover certain risks and liabilities related to its business.\n   - However, it is noted that the amount of insurance coverage may not be adequate for all liabilities, and even if fully insured, the claim could still harm the company's brand and divert management's attention and resources.\n\nGiven this analysis, the most relevant option that aligns with the information provided in the document is:\n\n**C"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 64000, "result": 1.0, "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?", "options": {"A": "Increase in core data", "B": "Rise in traditional voice communication", "C": "Completion of certain fiber transactions in 2022", "D": "Increase in international traffic", "E": "Growth in network connectivity", "F": "Higher volume of wireless devices sold"}, "LLM_original_answer": ["To answer the question \"What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the relevant section**: The document provides detailed information about the revenue and expenses of the Verizon Business Group, which includes the Wholesale segment.\n\n2. **Locate the specific information about Wholesale revenues**:\n   - The document states: \"Wholesale revenues decreased during 2023 compared to 2022 primarily due to a decrease of $276 million related to declines in traditional voice communication and network connectivity as a result of technology substitution, certain fiber transactions completed in 2022 that did not reoccur, as well as a decrease in core data.\"\n\n3. **Analyze the factors mentioned**:\n   - **Decline in traditional voice communication and network connectivity**: This is attributed to technology substitution, which means customers are moving to newer technologies.\n   - **Certain fiber transactions completed in 2022 that did not reoccur**: This suggests that some significant fiber transactions that contributed to revenue in 2022 were not repeated in 2023.\n   - **Decrease in core data**: This indicates a reduction in revenue from core data services.\n\n4. **Match the factors to the given options**:\n   - **Option A: Increase in core data** - This is the opposite of what the document states.\n   - **Option B: Rise in traditional voice communication** - The document mentions a decline, not a rise.\n   - **Option C: Completion of certain fiber transactions in 2022** - This matches the document's statement about certain fiber transactions completed in 2022 that did not reoccur in 2023.\n   - **Option D: Increase in international traffic** - The document does not mention an increase in international traffic; it mentions a rationalization of international traffic.\n   - **Option E: Growth in network connectivity** - The document mentions a decline in network connectivity.\n   - **Option F: Higher volume of wireless devices sold** - The document mentions a decrease in the volume of wireless devices sold.\n\n5. **Conclusion**:\n   - The primary factor leading to the decrease in Wholesale revenues during 2023 compared to 2022 is the completion of certain fiber transactions in 2022 that did not reoccur in 2"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 64000, "result": 1.0, "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?", "options": {"A": "Broadcast radio communications", "B": "Television broadcasting", "C": "Respond to text, video and data", "D": "Satellite tracking", "E": "Weather forecasting", "F": "Financial transactions processing"}, "LLM_original_answer": ["The correct answer is **C: Respond to text, video and data**.\n\n### Chain of Thought:\n1. **Identify the Context**: The question is about the capabilities of the ESInet (Emergency Service IP Network) in relation to 911 call takers at public safety answering points.\n2. **Locate Relevant Information**: The document provides detailed information about the ESInet under the \"Command Center\" section.\n3. **Extract Key Information**:\n   - The document states: \"The NG infrastructure is an Emergency Service IP Network (ESInet), which can carry voice, data and multimedia.\"\n   - It further elaborates: \"ESInet enables 911 call takers at public safety answering points to respond to text, video and data.\"\n4. **Evaluate Options**:\n   - **A: Broadcast radio communications** - The document does not mention this capability for ESInet.\n   - **B: Television broadcasting** - The document does not mention this capability for ESInet.\n   - **C: Respond to text, video and data** - This matches the information provided in the document.\n   - **D: Satellite tracking** - The document does not mention this capability for ESInet.\n   - **E: Weather forecasting** - The document does not mention this capability for ESInet.\n   - **F: Financial transactions processing** - The document does not mention this capability for ESInet.\n5. **Conclusion**: The ESInet offers the capability to respond to text, video, and data, which is explicitly stated in the document.\n\nTherefore, the correct answer is **C: Respond to text, video and data**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 64000, "result": 1.0, "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?", "options": {"A": "Increase in product sales", "B": "Improvement in clinical trial outcomes", "C": "Negative perception of patient benefits and safety", "D": "Guarantee of FDA approval", "E": "Reduction in training requirements for ECPs", "F": "Expansion of product indications"}, "LLM_original_answer": ["The correct answer to the question \"What is a potential risk if ECPs use products inconsistently with labeled indications?\" is:\n\n**C: Negative perception of patient benefits and safety**\n\n### Chain of Thought:\n1. **Understanding the Question**: The question is asking about the risks associated with ECPs (eyecare professionals) using products in a way that is not consistent with the labeled indications. Labeled indications are the specific uses for which a product has been approved by regulatory bodies like the FDA.\n\n2. **Reviewing the Document**: The document provides several points that are relevant to this question:\n   - **Reputation and Perception**: The document emphasizes the importance of the safety and efficacy of the products. It states, \"We believe that ECPs will compare the rates of long-term clinical outcomes for procedures using our products for their authorized uses against alternative procedures and treatment options.\"\n   - **Negative Outcomes**: The document mentions, \"If ECPs utilize our products in a manner that is inconsistent with our labeled indications or with components that are not part of our products, the patient outcomes may be negative. This could negatively impact the perception of patient benefits and safety associated with our products and limit their adoption, which would have a material adverse effect on our business, financial condition and results of operations.\"\n\n3. **Analyzing the Options**:\n   - **A: Increase in product sales**: This is not a risk; it would be a positive outcome.\n   - **B: Improvement in clinical trial outcomes**: This is also not a risk; it would be a positive outcome.\n   - **C: Negative perception of patient benefits and safety**: This aligns with the document's statement about the potential for negative patient outcomes and the resulting negative perception.\n   - **D: Guarantee of FDA approval**: This is not a risk; it is a positive outcome.\n   - **E: Reduction in training requirements for ECPs**: This is not directly mentioned as a risk in the document.\n   - **F: Expansion of product indications**: This is a potential benefit, not a risk.\n\n4. **Conclusion**: Based on the document, the most relevant and accurate risk associated with ECPs using products inconsistently with labeled indications is the negative perception of patient benefits and safety. This can lead to reduced adoption of the products, which would have a material adverse effect on the business.\n\nTherefore, the correct answer is **C: Negative perception of patient benefits and safety**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 64000, "result": 1.0, "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?", "options": {"A": "Increase in company market value", "B": "Unintended promotion of products", "C": "Disruption of operations or client operations", "D": "Immediate resolution of security measures", "E": "Enhanced customer relationships", "F": "Unrestricted access to public information"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document and the options given, focusing on the potential consequences of a breach or cyber-attack on computer systems.\n\n### Step-by-Step Analysis:\n\n1. **Document Context**:\n   - The document discusses various risks and uncertainties related to the business operations of TScan Therapeutics, Inc., a biopharmaceutical company.\n   - It specifically mentions the importance of cybersecurity and the potential risks associated with security breaches or other unauthorized access to their systems.\n\n2. **Cybersecurity Section**:\n   - The company has implemented processes for identifying, assessing, and mitigating cybersecurity risks.\n   - They have a Cybersecurity Incident Response Plan (CIRP) to guide their response to cyber incidents.\n   - The document states that while they have not been materially affected by cybersecurity threats, they may experience threats to and security incidents related to their data systems.\n\n3. **Potential Consequences**:\n   - **Security incidents, loss of data or modification of information, and other disruptions could compromise information related to our business or prevent us from accessing critical information, result in a significant disruption of our activities and expose us to liability, which could adversely affect our business and our reputation** (from the document).\n\n4. **Evaluating the Options**:\n   - **A: Increase in company market value** - This is highly unlikely as a breach or cyber-attack typically leads to a decrease in market value due to loss of trust and potential financial losses.\n   - **B: Unintended promotion of products** - This is not a typical consequence of a cyber-attack. Cyber-attacks generally lead to negative outcomes.\n   - **C: Disruption of operations or client operations** - This aligns with the document's statement about significant disruptions and the inability to access critical information.\n   - **D: Immediate resolution of security measures** - This is not a typical immediate consequence. Resolving security measures often takes time and resources.\n   - **E: Enhanced customer relationships** - This is also unlikely as a breach can damage trust and relationships with customers.\n   - **F: Unrestricted access to public information** - This is not a direct consequence of a cyber-attack on a company's internal systems.\n\n### Conclusion:\nThe most appropriate answer based on the document and the options provided is **C: Disruption of operations or client operations**. This option directly aligns with the potential consequences discussed in the document, such as significant disruptions and the inability to access critical information, which can adversely affect"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 64000, "result": 1.0, "question": "What is one intended use of the proceeds from the Business Combination?", "options": {"A": "To invest in new technology development", "B": "To reduce company debt", "C": "To build-up the sales and marketing organization", "D": "To acquire competitor companies", "E": "To expand into international markets", "F": "To increase executive compensation"}, "LLM_original_answer": ["To answer the question \"What is one intended use of the proceeds from the Business Combination?\" based on the provided document, I will follow these steps:\n\n1. **Identify the relevant section in the document**: The document mentions the intended use of proceeds from the Business Combination in the \"Risks Related to Our Business, Financial Condition, and Need for Additional Capital\" section.\n\n2. **Extract the specific information**: The relevant sentence is:\n   - \"We intend to use a portion of the proceeds we receive as a result of the Business Combination to build-up the sales and marketing organization.\"\n\n3. **Match the information to the given options**:\n   - Option A: To invest in new technology development\n   - Option B: To reduce company debt\n   - Option C: To build-up the sales and marketing organization\n   - Option D: To acquire competitor companies\n   - Option E: To expand into international markets\n   - Option F: To increase executive compensation\n\n4. **Select the correct option**: The document explicitly states that the proceeds will be used to build up the sales and marketing organization.\n\nTherefore, the correct answer is:\n\n**C: To build-up the sales and marketing organization**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 64000, "result": 1.0, "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?", "options": {"A": "50%", "B": "60%", "C": "65%", "D": "70%", "E": "75%", "F": "80%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant information**: The document should contain specific details about the percentage of KFC and Pizza Hut's system sales attributed to loyalty program members as of year-end 2023.\n\n2. **Locate the specific section**: The information is likely to be found in the sections related to revenue, loyalty programs, or digital initiatives.\n\n3. **Extract the percentage**: Once the relevant section is identified, I will extract the percentage mentioned.\n\n4. **Match the percentage to the options**: Finally, I will match the extracted percentage to the provided options to determine the correct answer.\n\n### Step 1: Identify the relevant information\nThe document mentions KFC and Pizza Hut's loyalty programs and their impact on sales. The relevant section is likely to be in the \"Enhance digital capabilities\" or \"Digital ordering\" sections.\n\n### Step 2: Locate the specific section\nI found the following relevant information in the \"Enhance digital capabilities\" section:\n\n> \"As of December 31, 2023, our loyalty programs had over 440 million members and over 155 million members for KFC and Pizza Hut, respectively. The programs have been effective in increasing order frequency and enhancing guest loyalty. Member sales accounted for approximately 65% of KFC and Pizza Hut's system sales in 2023.\"\n\n### Step 3: Extract the percentage\nThe document states that \"Member sales accounted for approximately 65% of KFC and Pizza Hut's system sales in 2023.\"\n\n### Step 4: Match the percentage to the options\nThe extracted percentage is 65%, which matches option C.\n\n### Conclusion\nThe correct answer is **C: 65%**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 64000, "result": 1.0, "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?", "options": {"A": "Classified Board of Directors with staggered, three-year terms", "B": "Issuance of preferred stock to dilute ownership", "C": "Exclusive forum in the Court of Chancery of the State of Delaware", "D": "Prohibition on cumulative voting in the election of directors", "E": "Advance notice procedures for nominating candidates", "F": "Limitation of liability and indemnification of directors and officers"}, "LLM_original_answer": ["The correct answer to the question \"Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?\" is:\n\n**D: Prohibition on cumulative voting in the election of directors**\n\n### Chain of Thought:\n1. **Review the Document**: The document provided is primarily focused on the financial and operational aspects of Brighthouse Financial, Inc. However, it does contain a section that discusses the company's organizational structure and governance, which is relevant to the question.\n\n2. **Identify Relevant Section**: The relevant section is found in the \"Risk Factors\" section, specifically under \"Delaware law and our Charter and Bylaws contain certain provisions, including anti-takeover provisions, that limit the ability of stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable.\"\n\n3. **List of Provisions**: The document lists several provisions in the Charter and Bylaws that could affect stockholder actions:\n   - **Classified Board of Directors with staggered, three-year terms**: This provision can make it harder for a hostile acquirer to gain control of the board quickly.\n   - **Ability to issue preferred stock**: This can be used to dilute the ownership of a hostile acquirer.\n   - **Prohibition on cumulative voting in the election of directors**: This directly limits the ability of minority stockholders to elect director candidates.\n   - **Limitation of the liability of, and the indemnification of, directors and officers**: This can protect directors and officers from certain legal actions.\n   - **Amendment of Bylaws by the Board of Directors**: This can allow the Board to take additional actions to prevent a hostile takeover.\n   - **Advance notice procedures for nominating candidates**: This can make it more difficult for stockholders to nominate candidates for the board.\n\n4. **Focus on the Question**: The question specifically asks about a provision that prevents minority stockholders from easily electing director candidates. Among the listed provisions, the one that directly addresses this is the prohibition on cumulative voting.\n\n5. **Cumulative Voting**: Cumulative voting allows stockholders to concentrate their votes on a single candidate, which can help minority stockholders elect a director. By prohibiting cumulative voting, the company ensures that each stockholder's vote is distributed across all director candidates, making it harder for minority stockholders to elect a director.\n\n6. **Conclusion**: Therefore, the provision that is intended to prevent minority stockholders from easily electing director candidates is the prohibition on cumulative voting in the"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 95, "token_lengths": 96000, "result": 1.0, "question": "What is one primary responsibility of PLS in the loan servicing agreement?", "options": {"A": "Issuing new loans to investors", "B": "Collecting principal, interest, and escrow payments", "C": "Providing insurance for loan defaults", "D": "Publishing annual financial reports", "E": "Managing client investments in stock markets", "F": "Developing real estate properties"}, "LLM_original_answer": ["The correct answer is B: Collecting principal, interest, and escrow payments.\n\n### Chain of Thoughts:\n1. **Identify the Context**: The question is about the primary responsibility of PLS (PennyMac Loan Services, LLC) in the loan servicing agreement.\n2. **Locate Relevant Information**: In the provided document, the section that describes the responsibilities of PLS is found under \"Our Servicer\u2019s loan servicing activities include collecting principal, interest and escrow account payments, accounting for and remitting collections to investors in the loans, responding to customer inquiries, and default management activities, including managing loss mitigation, which may include, among other things, collection activities, loan workouts, modifications and refinancings, foreclosures, short sales and sales of REO.\"\n3. **Analyze the Options**:\n   - **A: Issuing new loans to investors**: This is not mentioned as a primary responsibility of PLS in the document.\n   - **B: Collecting principal, interest, and escrow payments**: This is explicitly mentioned in the document.\n   - **C: Providing insurance for loan defaults**: This is not mentioned as a primary responsibility of PLS.\n   - **D: Publishing annual financial reports**: This is not mentioned as a primary responsibility of PLS.\n   - **E: Managing client investments in stock markets**: This is not mentioned as a primary responsibility of PLS.\n   - **F: Developing real estate properties**: This is not mentioned as a primary responsibility of PLS.\n4. **Conclusion**: Based on the information provided in the document, the primary responsibility of PLS in the loan servicing agreement is collecting principal, interest, and escrow payments."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 95, "token_lengths": 96000, "result": 1.0, "question": "What is the role of DME Advisors in relation to SILP?", "options": {"A": "Manage risk management and operational needs", "B": "Serve as SILP's custodian", "C": "Select and manage appropriate investments", "D": "Ensure SILP is widely diversified", "E": "Handle collateral purposes for SILP", "F": "Contribute funds to Greenlight Re and GRIL"}, "LLM_original_answer": ["To answer the question \"What is the role of DME Advisors in relation to SILP?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Investment Management**:\n   - DME Advisors acts as the exclusive investment advisor for SILP.\n   - DME Advisors is responsible for selecting and managing appropriate investments for SILP.\n\n2. **Investment Guidelines**:\n   - DME Advisors is contractually obligated to follow the investment guidelines of both Greenlight Re and GRIL.\n   - However, DME Advisors has the flexibility to allocate capital to long and short equity positions, debt, and derivatives, which could increase the level of risk to which the investment portfolio is exposed.\n\n3. **Performance and Risk Management**:\n   - The performance of the SILP investment portfolio depends on DME Advisors' ability to select and manage appropriate investments.\n   - DME Advisors continually refines its risk management techniques, strategies, and assessment methods, but these do not fully mitigate all risks in all economic or market environments.\n\n4. **Compensation Arrangements**:\n   - DME Advisors receives a monthly management fee at an annual rate of 1.5% of each limited partner\u2019s Investment Portfolio.\n   - DME II (a related party) receives a performance allocation based on the positive performance change of each limited partner\u2019s capital account, equal to 20% of net profits calculated per annum, subject to a loss carryforward provision.\n\n5. **Liquidity and Valuation**:\n   - DME Advisors may invest in securities with limited liquidity or no public market, which could impact the ability to execute trade orders at desired prices and affect the ability to fulfill underwriting payment obligations.\n   - The valuation of such securities and instruments for purposes of compensation is determined by DME Advisors, subject to audit verification.\n\n6. **Conflict of Interest**:\n   - DME Advisors and its affiliates may engage in investment and trading activities for their own accounts and/or for the accounts of third parties.\n   - There are no specific obligations or restrictions on the nature or timing of investments for SILP or other accounts managed by DME Advisors or its affiliates.\n\nGiven this information, the role of DME Advisors in relation to SILP is primarily to **select and manage appropriate investments**. This aligns with the provided option:\n\n**C: Select and manage appropriate investments**\n\nTherefore, the correct answer is **C: Select and manage appropriate investments**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 96000, "result": 1.0, "question": "What can materially and adversely affect the operations due to issues with satellites?", "options": {"A": "High employee turnover in satellite companies", "B": "Changes in customer preferences", "C": "Construction and launch delays for satellites", "D": "Increased competition from other industries", "E": "Innovations in unrelated technology sectors", "F": "A surge in global satellite demand"}, "LLM_original_answer": ["To answer the question \"What can materially and adversely affect the operations due to issues with satellites?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Document Context**: The document primarily discusses Duke Energy, a utility company, and its operations, regulatory matters, and financial statements. It does not directly address issues with satellites. However, it does mention the importance of infrastructure, including transmission and distribution systems, and the potential impacts of disruptions or failures.\n\n2. **Satellite-Related Risks**: The document does not explicitly mention satellites, but it does discuss the risks associated with infrastructure and technology. For a company like BlackSky, which is heavily dependent on satellites, we can infer similar risks from the document.\n\n3. **Relevant Sections**:\n   - **Risks Related to Our Operations**: This section mentions several risks that could affect the business, including the failure of technology, infrastructure disruptions, and the impact of natural hazards.\n   - **Risks Related to Our Satellites and Ground Stations**: This section specifically addresses the risks associated with satellites, including:\n     - **Construction and launch delays**: \"Satellites are subject to construction and launch delays, launch failures, damage or destruction during launch, the occurrence of which can materially and adversely affect our operations.\"\n     - **Launch failures**: \"The loss of, or damage to, a satellite due to a launch failure has historically resulted, and could result, in significant delays in anticipated revenue to be generated by that satellite and/or significant impairment charges.\"\n     - **Satellite anomalies**: \"While certain software deficiencies may be corrected or mitigated remotely, most, if not all, of the satellite anomalies or debris collision damage cannot be corrected or mitigated once the satellites are placed in orbit.\"\n     - **Operational issues**: \"If our satellites and related equipment have shorter useful lives than we currently anticipate, this may lead to delays in increasing the rate of our commercial payloads and declines in actual or planned revenue, which would have a material adverse effect on our business, financial condition, and results of operations.\"\n\n4. **Analysis**:\n   - **Construction and launch delays**: This is explicitly mentioned as a risk that can materially and adversely affect operations. Delays can lead to significant financial impacts, including increased costs and lost revenue.\n   - **Launch failures**: Similar to construction delays, launch failures can result in significant delays in revenue generation and potential impairment charges.\n   - **Satellite anomalies**: These can significantly impact the performance of satellites, leading to reduced revenue and"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 96000, "result": 1.0, "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?", "options": {"A": "Increase in core data", "B": "Rise in traditional voice communication", "C": "Completion of certain fiber transactions in 2022", "D": "Increase in international traffic", "E": "Growth in network connectivity", "F": "Higher volume of wireless devices sold"}, "LLM_original_answer": ["To answer the question \"What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?\" based on the provided document, let's break down the relevant information step by step:\n\n1. **Identify the relevant section**: The document provides detailed information about the revenue and operating statistics of the Wholesale segment under the \"Verizon Business Group\" section.\n\n2. **Examine the revenue changes**:\n   - The document states: \"Wholesale revenues decreased during 2023 compared to 2022 primarily due to a decrease of $276 million related to declines in traditional voice communication and network connectivity as a result of technology substitution, certain fiber transactions completed in 2022 that did not reoccur, as well as a decrease in core data.\"\n\n3. **Analyze the factors**:\n   - **Decline in traditional voice communication and network connectivity**: This is attributed to technology substitution and rationalization of international traffic.\n   - **Certain fiber transactions completed in 2022 that did not reoccur**: This suggests that specific fiber transactions that contributed to revenue in 2022 were not repeated in 2023.\n   - **Decrease in core data**: This is another contributing factor to the revenue decline.\n\n4. **Match the factors to the options**:\n   - **Option A: Increase in core data** - This is the opposite of what the document states.\n   - **Option B: Rise in traditional voice communication** - The document indicates a decline, not a rise.\n   - **Option C: Completion of certain fiber transactions in 2022** - This matches the document's statement about certain fiber transactions completed in 2022 that did not reoccur in 2023.\n   - **Option D: Increase in international traffic** - The document mentions a rationalization of international traffic, which implies a decrease.\n   - **Option E: Growth in network connectivity** - The document indicates a decline in network connectivity.\n   - **Option F: Higher volume of wireless devices sold** - The document does not mention an increase in the volume of wireless devices sold for the Wholesale segment.\n\n5. **Conclusion**:\n   - The primary factor leading to the decrease in Wholesale revenues during 2023 compared to 2022 is the completion of certain fiber transactions in 2022 that did not reoccur in 2023.\n\nTherefore,"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 96000, "result": 1.0, "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?", "options": {"A": "Broadcast radio communications", "B": "Television broadcasting", "C": "Respond to text, video and data", "D": "Satellite tracking", "E": "Weather forecasting", "F": "Financial transactions processing"}, "LLM_original_answer": ["The correct answer is **C: Respond to text, video and data**.\n\n### Chain of Thought:\n1. **Identify the Context**: The question is about the capabilities of the ESInet (Emergency Service IP Network) in relation to 911 call takers at public safety answering points.\n2. **Locate Relevant Information**: The relevant information is found in the \"Command Center\" section of the document, specifically in the paragraph discussing the ESInet.\n3. **Extract the Information**:\n   - The document states: \"The NG infrastructure is an Emergency Service IP Network (ESInet), which can carry voice, data and multimedia.\"\n   - It further explains: \"ESInet enables 911 call takers at public safety answering points to respond to text, video and data.\"\n4. **Match the Information to the Options**:\n   - **A: Broadcast radio communications** - The document does not mention broadcast radio communications as a capability of ESInet.\n   - **B: Television broadcasting** - The document does not mention television broadcasting.\n   - **C: Respond to text, video and data** - This matches the information provided in the document.\n   - **D: Satellite tracking** - The document does not mention satellite tracking.\n   - **E: Weather forecasting** - The document does not mention weather forecasting.\n   - **F: Financial transactions processing** - The document does not mention financial transactions processing.\n5. **Confirm the Answer**: The document explicitly states that ESInet enables 911 call takers to respond to text, video, and data, which corresponds to option C.\n\nTherefore, the correct answer is **C: Respond to text, video and data**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 96000, "result": 1.0, "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?", "options": {"A": "Increase in product sales", "B": "Improvement in clinical trial outcomes", "C": "Negative perception of patient benefits and safety", "D": "Guarantee of FDA approval", "E": "Reduction in training requirements for ECPs", "F": "Expansion of product indications"}, "LLM_original_answer": ["To answer the question \"What is a potential risk if ECPs use products inconsistently with labeled indications?\" based on the provided document, let's analyze the relevant information step by step:\n\n1. **Understanding the Context**:\n   - The document discusses the operations and risks of a company that develops and markets medical devices for eye conditions, particularly focusing on glaucoma and dry eye disease (DED).\n   - The company's products, such as OMNI, SION, and TearCare, are designed to be used in specific procedures and have been cleared by regulatory bodies like the FDA for certain indications.\n\n2. **Relevant Section**:\n   - The section that directly addresses the risk of using products inconsistently with labeled indications is found in the \"Risk Factors\" section, specifically under \"Adoption of our products depends upon appropriate physician training, practice and patient selection.\"\n\n3. **Key Points from the Document**:\n   - **Training and Proper Use**: The success of the company's products depends on the skill of the ECPs (eyecare professionals) and their adherence to the proper techniques provided in training sessions.\n   - **Negative Outcomes**: If ECPs use the products in a manner that is inconsistent with the labeled indications or with components that are not part of the products, the patient outcomes may be negative.\n   - **Perception and Adoption**: Negative patient outcomes could negatively impact the perception of patient benefits and safety associated with the products, which could limit their adoption.\n\n4. **Conclusion**:\n   - The potential risk if ECPs use products inconsistently with labeled indications is **negative perception of patient benefits and safety**. This is explicitly mentioned in the document as a factor that could limit the adoption of the products and have a material adverse effect on the company's business, financial condition, and results of operations.\n\nTherefore, the correct answer is:\n**C: Negative perception of patient benefits and safety**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 96000, "result": 1.0, "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?", "options": {"A": "Increase in company market value", "B": "Unintended promotion of products", "C": "Disruption of operations or client operations", "D": "Immediate resolution of security measures", "E": "Enhanced customer relationships", "F": "Unrestricted access to public information"}, "LLM_original_answer": ["The correct answer to the question \"What potential consequence could occur if there is a breach or cyber-attack on the computer systems?\" is:\n\n**C: Disruption of operations or client operations**\n\n### Chain of Thoughts:\n1. **Context from the Document:**\n   - The document discusses the risks associated with the company's internal computer systems and those of third-party contractors, consultants, and CROs (Contract Research Organizations).\n   - It mentions that these systems are vulnerable to various disruptions and data privacy and information security incidents, including data breaches, attacks by hackers, and other malicious activities.\n\n2. **Potential Consequences:**\n   - The document specifically states that if such an event were to occur, it could result in a material disruption of the company's development programs and business operations.\n   - It also mentions that the loss of data from completed or future preclinical studies and clinical trials could result in delays in regulatory approval efforts and significantly increase costs to recover or reproduce the data.\n\n3. **Analysis of Options:**\n   - **A: Increase in company market value** - This is not a potential consequence of a breach or cyber-attack; it is the opposite.\n   - **B: Unintended promotion of products** - This is not a likely outcome of a cyber-attack.\n   - **C: Disruption of operations or client operations** - This aligns with the document's description of potential disruptions and delays in operations.\n   - **D: Immediate resolution of security measures** - This is not a realistic outcome; a breach typically requires time and resources to resolve.\n   - **E: Enhanced customer relationships** - This is not a likely outcome; a breach can damage customer trust.\n   - **F: Unrestricted access to public information** - While a breach can lead to unauthorized access, the document focuses more on the disruption and operational impact.\n\n4. **Conclusion:**\n   - The document clearly indicates that a breach or cyber-attack can lead to significant disruptions in the company's operations and the operations of its clients, making option C the most accurate and relevant answer."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 96000, "result": 1.0, "question": "What is one intended use of the proceeds from the Business Combination?", "options": {"A": "To invest in new technology development", "B": "To reduce company debt", "C": "To build-up the sales and marketing organization", "D": "To acquire competitor companies", "E": "To expand into international markets", "F": "To increase executive compensation"}, "LLM_original_answer": ["The document provided does not directly mention the intended use of the proceeds from the Business Combination for investing in new technology development, reducing company debt, building up the sales and marketing organization, acquiring competitor companies, expanding into international markets, or increasing executive compensation. However, it does state that:\n\n\"We intend to use a portion of the proceeds we receive as a result of the Business Combination to build-up the sales and marketing organization.\"\n\nThis statement directly aligns with option C: \"To build-up the sales and marketing organization.\"\n\nTherefore, based on the information provided in the document, the correct answer is:\n\nC: To build-up the sales and marketing organization."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 96000, "result": 1.0, "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?", "options": {"A": "50%", "B": "60%", "C": "65%", "D": "70%", "E": "75%", "F": "80%"}, "LLM_original_answer": ["To answer the question, I will follow these steps:\n\n1. **Identify the relevant information**: Look for specific mentions of KFC and Pizza Hut's system sales and the percentage attributed to loyalty program members.\n2. **Extract the data**: Find the exact percentage mentioned in the document.\n3. **Verify the data**: Ensure that the extracted data is from the correct year (2023) and is accurate.\n4. **Select the correct option**: Match the extracted percentage to the provided options.\n\n### Step 1: Identify the relevant information\nThe document contains a section that discusses the loyalty programs and their impact on sales. The relevant section is:\n\n> \"As of December 31, 2023, KFC and Pizza Hut loyalty programs exceeded 470 million members combined. Member sales accounted for approximately 65% of KFC and Pizza Hut's system sales in 2023.\"\n\n### Step 2: Extract the data\nThe percentage of KFC and Pizza Hut's system sales attributed to loyalty program members as of December 31, 2023, is **65%**.\n\n### Step 3: Verify the data\nThe data is clearly stated and is from the correct year (2023). There are no contradictions or ambiguities in the document regarding this percentage.\n\n### Step 4: Select the correct option\nThe extracted percentage (65%) matches option **C** in the provided options.\n\n### Final Answer\nThe correct answer is **C: 65%**."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 96000, "result": 1.0, "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?", "options": {"A": "Classified Board of Directors with staggered, three-year terms", "B": "Issuance of preferred stock to dilute ownership", "C": "Exclusive forum in the Court of Chancery of the State of Delaware", "D": "Prohibition on cumulative voting in the election of directors", "E": "Advance notice procedures for nominating candidates", "F": "Limitation of liability and indemnification of directors and officers"}, "LLM_original_answer": ["To answer the question, I will analyze the provided document to identify the provision in the company's Charter and Bylaws that is intended to prevent minority stockholders from easily electing director candidates.\n\nThe relevant section from the document is:\n\n\"Delaware law and our Charter and Bylaws contain certain provisions, including anti-takeover provisions, that limit the ability of stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable. Among other things, Charter and Bylaws include the following provisions:\n- a classified Board of Directors with staggered, three-year terms;\n- the ability of our Board of Directors to issue shares of preferred stock, including \u201cblank check\u201d preferred stock, and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;\n- prohibition on cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;\n- the limitation of the liability of, and the indemnification of, our directors and officers;\n- the ability of our Board of Directors to amend the Bylaws, which may allow our Board of Directors to take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend the Bylaws to facilitate an unsolicited takeover attempt;\n- advance notice procedures with which stockholders must comply to nominate candidates to our Board of Directors or to propose matters to be acted upon at a stockholders\u2019 meeting, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in our Board of Directors and also may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer\u2019s own slate of directors or otherwise attempting to obtain control of us.\"\n\nFrom this section, the provision that directly addresses the prevention of minority stockholders from easily electing director candidates is:\n\n- **Prohibition on cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates.**\n\nThis provision is explicitly designed to prevent minority stockholders from using cumulative voting, a method that would otherwise allow them to pool their votes to elect a director of their choice. By prohibiting cumulative voting, the company ensures that minority stockholders have a more limited influence on the composition of the Board of Directors.\n\nTherefore, the correct answer is:\n\n**D: Prohibition on cumulative voting in the election of directors.**"], "LLM_extracted_answer": ["D"], "ground_truth": "D"}, {"depth": 95, "token_lengths": 128000, "result": 1.0, "question": "What is one primary responsibility of PLS in the loan servicing agreement?", "options": {"A": "Issuing new loans to investors", "B": "Collecting principal, interest, and escrow payments", "C": "Providing insurance for loan defaults", "D": "Publishing annual financial reports", "E": "Managing client investments in stock markets", "F": "Developing real estate properties"}, "LLM_original_answer": ["The correct answer to the question \"What is one primary responsibility of PLS in the loan servicing agreement?\" is:\n\n**B: Collecting principal, interest, and escrow payments**\n\n### Chain of Thought:\n1. **Identify the relevant section in the document**: The document mentions PLS (PennyMac Loan Services, LLC) in the context of loan servicing.\n2. **Locate the specific responsibilities of PLS**: The document states, \"PLS\u2019 loan servicing activities include collecting principal, interest and escrow account payments, accounting for and remitting collections to investors in the loans, responding to customer inquiries, and default management activities, including managing loss mitigation, which may include, among other things, collection activities, loan workouts, modifications and refinancings, foreclosures, short sales and sales of REO.\"\n3. **Match the responsibilities to the options**: Among the options provided, the one that best matches the primary responsibility of PLS as described in the document is \"Collecting principal, interest, and escrow payments.\"\n\n### Explanation:\n- **Option A (Issuing new loans to investors)**: This is not a primary responsibility of PLS in the loan servicing agreement. PLS is involved in loan production and servicing, but the document does not mention PLS issuing new loans to investors.\n- **Option B (Collecting principal, interest, and escrow payments)**: This is explicitly mentioned as a primary responsibility of PLS in the loan servicing agreement.\n- **Option C (Providing insurance for loan defaults)**: The document does not mention PLS providing insurance for loan defaults.\n- **Option D (Publishing annual financial reports)**: This is not a primary responsibility of PLS in the loan servicing agreement.\n- **Option E (Managing client investments in stock markets)**: This is not related to PLS's loan servicing responsibilities.\n- **Option F (Developing real estate properties)**: While PLS may be involved in managing REO (real estate owned) properties, the primary responsibility in the loan servicing agreement is collecting payments.\n\nTherefore, the primary responsibility of PLS in the loan servicing agreement is collecting principal, interest, and escrow payments."], "LLM_extracted_answer": ["B"], "ground_truth": "B"}, {"depth": 95, "token_lengths": 128000, "result": 0.0, "question": "What is the role of DME Advisors in relation to SILP?", "options": {"A": "Manage risk management and operational needs", "B": "Serve as SILP's custodian", "C": "Select and manage appropriate investments", "D": "Ensure SILP is widely diversified", "E": "Handle collateral purposes for SILP", "F": "Contribute funds to Greenlight Re and GRIL"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 128000, "result": 1.0, "question": "What can materially and adversely affect the operations due to issues with satellites?", "options": {"A": "High employee turnover in satellite companies", "B": "Changes in customer preferences", "C": "Construction and launch delays for satellites", "D": "Increased competition from other industries", "E": "Innovations in unrelated technology sectors", "F": "A surge in global satellite demand"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 128000, "result": 1.0, "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?", "options": {"A": "Increase in core data", "B": "Rise in traditional voice communication", "C": "Completion of certain fiber transactions in 2022", "D": "Increase in international traffic", "E": "Growth in network connectivity", "F": "Higher volume of wireless devices sold"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 128000, "result": 1.0, "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?", "options": {"A": "Broadcast radio communications", "B": "Television broadcasting", "C": "Respond to text, video and data", "D": "Satellite tracking", "E": "Weather forecasting", "F": "Financial transactions processing"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 128000, "result": 1.0, "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?", "options": {"A": "Increase in product sales", "B": "Improvement in clinical trial outcomes", "C": "Negative perception of patient benefits and safety", "D": "Guarantee of FDA approval", "E": "Reduction in training requirements for ECPs", "F": "Expansion of product indications"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 128000, "result": 1.0, "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?", "options": {"A": "Increase in company market value", "B": "Unintended promotion of products", "C": "Disruption of operations or client operations", "D": "Immediate resolution of security measures", "E": "Enhanced customer relationships", "F": "Unrestricted access to public information"}, "LLM_original_answer": ["The correct answer to the question \"What potential consequence could occur if there is a breach or cyber-attack on the computer systems?\" is:\n\n**C: Disruption of operations or client operations**\n\n### Chain of Thought:\n1. **Context from the Document**: The document discusses various risks and challenges faced by TScan Therapeutics, a biopharmaceutical company. It specifically mentions the risks associated with cybersecurity and the potential consequences of a breach or cyber-attack on their computer systems.\n\n2. **Relevant Section**: The section \"Risks Related to Our Reliance on Third Parties\" and \"Risks Related to Technology and Cybersecurity\" provide relevant information:\n   - \"Our internal computer systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches or other unauthorized or improper access, which could result in a material disruption of the development programs of our product candidates.\"\n   - \"Security incidents, loss of data or modification of information, and other disruptions could compromise information related to our business or prevent us from accessing critical information, result in a significant disruption of our activities and expose us to liability, which could adversely affect our business and our reputation.\"\n\n3. **Analysis of Options**:\n   - **A: Increase in company market value** - This is not a likely consequence of a cyber-attack or breach. Cyber-attacks typically lead to negative outcomes.\n   - **B: Unintended promotion of products** - This is not a typical consequence of a cyber-attack. Cyber-attacks usually result in data loss, operational disruptions, or financial losses.\n   - **C: Disruption of operations or client operations** - This aligns with the document's description of potential consequences, such as material disruption of development programs and significant disruption of activities.\n   - **D: Immediate resolution of security measures** - This is not a likely immediate consequence. Resolving security measures often takes time and effort.\n   - **E: Enhanced customer relationships** - This is not a typical outcome of a cyber-attack. Cyber-attacks can damage customer trust.\n   - **F: Unrestricted access to public information** - While a breach could lead to unauthorized access to information, the document specifically mentions the risk of disrupting operations and client operations.\n\n4. **Conclusion**: Based on the information provided in the document, the most accurate and relevant consequence of a breach or cyber-attack on the computer systems is the disruption of operations or client operations."], "LLM_extracted_answer": ["C"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 128000, "result": 0.0, "question": "What is one intended use of the proceeds from the Business Combination?", "options": {"A": "To invest in new technology development", "B": "To reduce company debt", "C": "To build-up the sales and marketing organization", "D": "To acquire competitor companies", "E": "To expand into international markets", "F": "To increase executive compensation"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["B"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 128000, "result": 0.0, "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?", "options": {"A": "50%", "B": "60%", "C": "65%", "D": "70%", "E": "75%", "F": "80%"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["!"], "ground_truth": "C"}, {"depth": 95, "token_lengths": 128000, "result": 0.0, "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?", "options": {"A": "Classified Board of Directors with staggered, three-year terms", "B": "Issuance of preferred stock to dilute ownership", "C": "Exclusive forum in the Court of Chancery of the State of Delaware", "D": "Prohibition on cumulative voting in the election of directors", "E": "Advance notice procedures for nominating candidates", "F": "Limitation of liability and indemnification of directors and officers"}, "LLM_original_answer": ["!"], "LLM_extracted_answer": ["A"], "ground_truth": "D"}]